[
  {
    "id": 0,
    "text": "",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1,
    "text": "- oxacalcitriol suppresses secondary hyperparathyroidism without inducing",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        2,
        ""
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2,
    "text": "bone turnover in dogs with renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        2,
        ""
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3,
    "text": "BACKGROUND : Calcitriol therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including hypercalcemia and / or marked suppression of bone turnover , which may lead to adynamic bone disease .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "renal failure"
      ],
      [
        "T1",
        "Disease",
        29,
        33,
        "suppression of bone turnover"
      ],
      [
        "T2",
        "Disease",
        38,
        41,
        "adynamic bone disease"
      ],
      [
        "T3",
        "Chemical",
        2,
        3,
        "Calcitriol"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4,
    "text": "A new vitamin D analogue , 22 - oxacalcitriol ( OCT ) , has been shown to have promising characteristics .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "vitamin D"
      ],
      [
        "T1",
        "Chemical",
        6,
        9,
        "22 - oxacalcitriol"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "OCT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 5,
    "text": "This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        25,
        "impaired renal function"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "OCT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 6,
    "text": "METHODS : Sixty dogs were either nephrectomized ( Nx , N = 38 ) or sham - operated ( Sham , N = 22 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 7,
    "text": "The animals received supplemental phosphate to enhance PTH secretion .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "phosphate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 8,
    "text": "Fourteen weeks after the start of phosphate supplementation , half of the Nx and Sham dogs received doses of OCT ( three times per week ) ; the other half were given vehicle for 60 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "phosphate"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "OCT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 9,
    "text": "Thereafter , the treatment modalities for a subset of animals were crossed over for an additional eight months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 10,
    "text": "Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study , and bone biopsies were done at baseline , 60 weeks after OCT or vehicle treatment , and at the end of the crossover period .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "calcium"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "OCT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 11,
    "text": "RESULTS : In Nx dogs , OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "renal insufficiency"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "OCT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 12,
    "text": "In long - standing secondary hyperparathyroidism , OCT ( 0 . 03 microg / kg ) stabilized serum PTH levels during the first months .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "secondary hyperparathyroidism"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "OCT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 13,
    "text": "Serum PTH levels rose thereafter , but the rise was less pronounced compared with baseline than the rise seen in Nx control .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 14,
    "text": "These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "hypercalcemia"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hyperphosphatemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 15,
    "text": "In animals with normal renal function , OCT induced a transient decrease in serum PTH levels at a dose of 0 . 1 microg / kg , which was not sustained with lowering of the doses .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "OCT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 16,
    "text": "In Nx dogs , OCT reversed abnormal bone formation , such as woven osteoid and fibrosis , but did not significantly alter the level of bone turnover .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "woven osteoid"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "OCT"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 17,
    "text": "In addition , OCT improved mineralization lag time , ( that is , the rate at which osteoid mineralizes ) in both Nx and Sham dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "OCT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 18,
    "text": "CONCLUSIONS : These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "renal insufficiency"
      ],
      [
        "T1",
        "Disease",
        33,
        35,
        "secondary hyperparathyroidism"
      ],
      [
        "T2",
        "Disease",
        40,
        43,
        "low bone turnover"
      ],
      [
        "T3",
        "Disease",
        53,
        56,
        "adynamic bone disease"
      ],
      [
        "T4",
        "Chemical",
        8,
        9,
        "OCT"
      ],
      [
        "T5",
        "Disease",
        16,
        17,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 19,
    "text": "Hypotension , bradycardia , and asystole after high - dose intravenous methylprednisolone in a monitored patient .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypotension"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "bradycardia"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "asystole"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "methylprednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 20,
    "text": "We report a case of hypotension , bradycardia , and asystole after intravenous administration of high - dose methylprednisolone in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "bradycardia"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "asystole"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "methylprednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 21,
    "text": "There was a history of ischemic cardiac disease 9 years earlier .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "cardiac disease"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 22,
    "text": "The patient was admitted with a pulmonary - renal syndrome with hemoptysis , rapidly progressive renal failure , and hypoxemia that required mechanical ventilation in the intensive care unit .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        10,
        "pulmonary - renal syndrome"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "renal failure"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hemoptysis"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "hypoxemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 23,
    "text": "After receiving advanced cardiopulmonary resuscitation , the patient recovered cardiac rhythm .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 24,
    "text": "The ECG showed a junctional rhythm without ventricular arrhythmia .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "ventricular arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 25,
    "text": "This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone ( IVMP ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "sudden death"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "methylprednisolone"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "IVMP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 26,
    "text": "These mechanisms are not well understood because , in most cases , the patients were not monitored at the moment of the event .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 27,
    "text": "Rapid infusion and underlying cardiac disease were important risk factors in the case reported here , and the authors discount ventricular arrhythmia as the main mechanism .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "cardiac disease"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "ventricular arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 28,
    "text": "Worsening of levodopa - induced dyskinesias by motor and mental tasks .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 29,
    "text": "Ten patients who had Parkinson ' s disease with disabling dyskinesia were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose dyskinesia following administration of an effective single dose of apomorphine .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        8,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "dyskinesia"
      ],
      [
        "T2",
        "Disease",
        61,
        62,
        "dyskinesia"
      ],
      [
        "T3",
        "Chemical",
        70,
        71,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 30,
    "text": "Compared with the score at rest ( 1 . 3 + / - 0 . 3 ) , a significant aggravation of the dyskinesia score was observed during speaking aloud ( 5 . 2 + / - 1 . 1 , p < 0 . 05 ) , movements of right ( 4 . 5 + / - 1 . 0 , p < 0 . 05 ) and left ( 3 . 7 + / - 0 . 8 , p < 0 . 05 ) fingers , movements of the neck ( 5 . 1 + / - 1 . 0 , p < 0 . 05 ) , and mental calculation ( 3 . 1 + / - 1 . 0 , p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 31,
    "text": "These results suggest that activation tasks such as \" speaking aloud \" could be used for objective assessment of dyskinesia severity .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 32,
    "text": "Urine N - acetyl - beta - D - glucosaminidase - - a marker of tubular damage ?",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 33,
    "text": "BACKGROUND : Although an indicator of renal tubular dysfunction , an increased urinary N - acetyl - beta - D - glucosaminidase ( NAG ) activity might reflect increased lysosomal activity in renal tubular cells .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "renal tubular dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 34,
    "text": "METHODS : Puromycin aminonucleoside ( PAN ) was administered to Sprague Dawley rats to induce proteinuria .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "Puromycin aminonucleoside"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "PAN"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 35,
    "text": "Total protein , albumin , NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 36,
    "text": "The morphological appearance of the kidneys was examined on days three , four , six , eight and thirty three and the NAG isoenzyme patterns on days zero , four , eight and thirty three .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 37,
    "text": "RESULTS : Following intravenous PAN urine volume and urine NAG activity increased significantly by day two , but returned to normal by day four .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 38,
    "text": "After day four all treated animals exhibited a marked rise in urine albumin , total protein excretion and NAG activity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 39,
    "text": "Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 40,
    "text": "Protein droplets first appeared prominent in tubular cells on day four .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 41,
    "text": "Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets ( day six onwards ) .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 42,
    "text": "CONCLUSIONS : This animal model demonstrates that an increase in lysosomal turnover and hence urine NAG activity , occurs when increased protein is presented to the tubular cells .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 43,
    "text": "Urine NAG activity is thus a measure of altered function in the renal tubules and not simply an indicator of damage .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 44,
    "text": "Cauda equina syndrome after spinal anaesthesia with hyperbaric 5 % lignocaine : a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Cauda equina syndrome"
      ],
      [
        "T1",
        "Disease",
        18,
        21,
        "cauda equina syndrome"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "lignocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 45,
    "text": "Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993 - 1997 .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "cauda equina syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 46,
    "text": "All were associated with spinal anaesthesia using hyperbaric 5 % lignocaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "lignocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 47,
    "text": "Five cases had single - shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 48,
    "text": "The dose of hyperbaric 5 % lignocaine administered ranged from 60 to 120 mg .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "lignocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 49,
    "text": "Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5 % lignocaine .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "neurotoxicity"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "lignocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 50,
    "text": "In the other 3 cases , direct neurotoxicity was also probable , but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 51,
    "text": "All cases sustained permanent neurological deficits .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "neurological deficits"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 52,
    "text": "We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2 % and at a total dose preferably not exceeding 60 mg .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "lignocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 53,
    "text": "Systemic toxicity following administration of sirolimus ( formerly rapamycin ) for psoriasis : association of capillary leak syndrome with apoptosis of lesional lymphocytes .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "capillary leak syndrome"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "sirolimus"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "rapamycin"
      ],
      [
        "T4",
        "Disease",
        11,
        12,
        "psoriasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 54,
    "text": "BACKGROUND : Sirolimus ( formerly rapamycin ) is an immunosuppressive agent that interferes with T - cell activation .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Sirolimus"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "rapamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 55,
    "text": "After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "capillary leak syndrome"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "psoriasis"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "sirolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 56,
    "text": "OBSERVATIONS : A keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "capillary leak syndrome"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "sirolimus"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "sirolimus"
      ],
      [
        "T3",
        "Disease",
        43,
        44,
        "psoriasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 57,
    "text": "Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "psoriasis"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "dexamethasone"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "sirolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 58,
    "text": "CONCLUSIONS : Severe adverse effects of sirolimus include fever , anemia , and capillary leak syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "capillary leak syndrome"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "sirolimus"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "fever"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 59,
    "text": "These symptoms may be the result of drug - induced apoptosis of lesional leukocytes , especially activated T lymphocytes , and possibly release of inflammatory mediators .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 60,
    "text": "Because patients with severe psoriasis may develop capillary leak from various systemic therapies , clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "capillary leak"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "inflammatory diseases"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "psoriasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 61,
    "text": "Effect of lithium maintenance therapy on thyroid and parathyroid function .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 62,
    "text": "OBJECTIVES : To assess changes induced by lithium maintenance therapy on the incidence of thyroid , parathyroid and ion alterations .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 63,
    "text": "These were evaluated with respect to the duration of lithium therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with thyroid disease ) .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        34,
        "thyroid disease"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 64,
    "text": "DESIGN : Prospective study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 65,
    "text": "SETTING : Affective Disorders Clinic at St .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 66,
    "text": "Mary ' s Hospital , Montreal .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 67,
    "text": "PATIENTS : One hundred and one patients ( 28 men and 73 women ) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year ' s to 32 years ' duration .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "bipolar disorder"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 68,
    "text": "The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital ' s out - patient clinics .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "psychiatric"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 69,
    "text": "OUTCOME MEASURES : Laboratory analyses of calcium , magnesium and thyroid - stimulating hormone levels performed before beginning lithium therapy and at biannual follow - up .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "calcium"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "magnesium"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 70,
    "text": "RESULTS : Hypothyroidism developed in 40 patients , excluding 8 patients who were hypothyroid at baseline .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Hypothyroidism"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "hypothyroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 71,
    "text": "All patients having first - degree relatives affected by thyroid illness had accelerated onset of hypothyroidism ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "thyroid illness"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hypothyroidism"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "lithium"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 72,
    "text": "Women over 60 years of age were more often affected by hypothyroidism than women under 60 years of age ( 34 . 6 % versus 31 . 9 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "hypothyroidism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 73,
    "text": "Magnesium levels in patients on lithium treatment were unchanged from baseline levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Magnesium"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 74,
    "text": "After lithium treatment , calcium levels were higher than either baseline levels or control levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "lithium"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 75,
    "text": "Thus , lithium treatment counteracted the decrease in plasma calcium levels associated with aging .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "lithium"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 76,
    "text": "CONCLUSIONS : Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "thyroid illness"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypothyroidism"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "hypercalcemia"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 77,
    "text": "Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cefotetan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 78,
    "text": "Second - and third - generation cephalosporins , especially cefotetan , are increasingly associated with severe , sometimes fatal immune hemolytic anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "cephalosporins"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "cefotetan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 79,
    "text": "We noticed that 10 of our 35 cases of cefotetan - induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "hemolytic anemias"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cefotetan"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "cefotetan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 80,
    "text": "Eight of these cases of severe immune hemolytic anemia are described .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "hemolytic anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 81,
    "text": "Effects of nonsteroidal anti - inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "aneurysmal subarachnoid hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 82,
    "text": "Platelet function is impaired by nonsteroidal anti - inflammatory drugs ( NSAIDs ) with prominent anti - inflammatory properties .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 83,
    "text": "Their safety in patients undergoing intracranial surgery is under debate .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 84,
    "text": "Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "aneurysmal subarachnoid hemorrhage"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "SAH"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "ketoprofen"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "ketoprofen"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "acetaminophen"
      ],
      [
        "T5",
        "Chemical",
        45,
        46,
        "acetaminophen"
      ],
      [
        "T6",
        "Disease",
        58,
        59,
        "aneurysmal"
      ],
      [
        "T7",
        "Disease",
        59,
        60,
        "SAH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 85,
    "text": "Treatment was continued for 3 days postoperatively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 86,
    "text": "Test blood samples were taken before treatment and surgery as well as on the first , third , and fifth postoperative mornings .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 87,
    "text": "Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "platelet aggregation"
      ],
      [
        "T1",
        "Chemical",
        8,
        10,
        "adenosine diphosphate"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "ketoprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 88,
    "text": "Aggregation was lower ( P < . 05 ) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "ketoprofen"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 89,
    "text": "In contrast , maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results ( P < . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "platelet aggregation"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "platelet aggregation"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 90,
    "text": "One patient in the ketoprofen group developed a postoperative intracranial hematoma .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ketoprofen"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hematoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 91,
    "text": "Coagulation ( prothrombin time [ PT ] , activated partial thromboplastin time [ APPT ] , fibrinogen concentration , and antithrombin III [ AT III ] ) was comparable between the two groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 92,
    "text": "Ketoprofen but not acetaminophen impaired platelet function in patients with SAH .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ketoprofen"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "acetaminophen"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "SAH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 93,
    "text": "If ketoprofen is used before surgery on cerebral artery aneurysms , it may pose an additional risk factor for hemorrhage .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "artery aneurysms"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "ketoprofen"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 94,
    "text": "Nitric oxide synthase expression in the course of lead - induced hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Nitric oxide"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "lead"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 95,
    "text": "We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "oxygen"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "NO"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "NO"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "nitrotyrosine"
      ],
      [
        "T4",
        "Chemical",
        33,
        34,
        "lead"
      ],
      [
        "T5",
        "Disease",
        36,
        37,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 96,
    "text": "This study was designed to discern whether the reduction in urinary NOx in lead - induced hypertension is , in part , due to depressed NO synthase ( NOS ) expression .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "lead"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "hypertension"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "NO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 97,
    "text": "Male Sprague - Dawley rats were randomly assigned to a lead - treated group ( given lead acetate , 100 ppm , in drinking water and regular rat chow ) , a group given lead and vitamin E - fortified chow , or a normal control group given either regular food and water or vitamin E - fortified food for 12 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        18,
        "lead acetate"
      ],
      [
        "T1",
        "Chemical",
        36,
        38,
        "vitamin E"
      ],
      [
        "T2",
        "Chemical",
        54,
        56,
        "vitamin E"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "lead"
      ],
      [
        "T4",
        "Chemical",
        34,
        35,
        "lead"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 98,
    "text": "Tail blood pressure , urinary NOx excretion , plasma malondialdehyde ( MDA ) , and endothelial and inducible NOS ( eNOS and iNOS ) isotypes in the aorta and kidney were measured .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "malondialdehyde"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "MDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 99,
    "text": "The lead - treated group exhibited a rise in blood pressure and plasma MDA concentration , a fall in urinary NOx excretion , and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "lead"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "MDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 100,
    "text": "Vitamin E supplementation ameliorated hypertension , lowered plasma MDA concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Vitamin E"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hypertension"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "MDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 101,
    "text": "Vitamin E supplementation had no effect on either blood pressure , plasma MDA , or NOS expression in the control group .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Vitamin E"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "MDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 102,
    "text": "The study also revealed significant inhibition of NOS enzymatic activity by lead in cell - free preparations .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "lead"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 103,
    "text": "In conclusion , lead - induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "lead"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 104,
    "text": "This is , in part , due to ROS - mediated NO inactivation , lead - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "NO"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "lead"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 105,
    "text": "Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Glyceryl trinitrate"
      ],
      [
        "T1",
        "Disease",
        5,
        8,
        "migraine without aura"
      ],
      [
        "T2",
        "Disease",
        11,
        14,
        "migraine with aura"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 106,
    "text": "Migraine with aura and migraine without aura have the same pain phase , thus indicating that migraine with aura and migraine without aura share a common pathway of nociception .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Migraine with aura"
      ],
      [
        "T1",
        "Disease",
        4,
        7,
        "migraine without aura"
      ],
      [
        "T2",
        "Disease",
        16,
        19,
        "migraine with aura"
      ],
      [
        "T3",
        "Disease",
        20,
        23,
        "migraine without aura"
      ],
      [
        "T4",
        "Disease",
        10,
        11,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 107,
    "text": "In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( NO ) is involved in pain mechanisms of migraine without aura .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        23,
        26,
        "migraine without aura"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "NO"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 108,
    "text": "In order to clarify whether the same is true for migraine with aura , in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "migraine with aura"
      ],
      [
        "T1",
        "Chemical",
        27,
        29,
        "glyceryl trinitrate"
      ],
      [
        "T2",
        "Disease",
        49,
        52,
        "migraine with aura"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "headache"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 109,
    "text": "The specific aim was to elucidate whether an aura and / or an attack of migraine without aura could be induced .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "migraine without aura"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 110,
    "text": "Fourteen healthy subjects served as controls .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 111,
    "text": "Aura symptoms were not elicited in any subject .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 112,
    "text": "Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Headache"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "migraineurs"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 113,
    "text": "In the controls , the GTN - induced headache gradually disappeared , whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post - infusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "GTN"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "headache"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "migraineurs"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 114,
    "text": "At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        19,
        "migraine without aura"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "headache"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "migraineurs"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "Headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 115,
    "text": "The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "migraine with aura"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "NO"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 116,
    "text": "Since cortical spreading depression has been shown to liberate NO in animals , this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        32,
        "migraine with aura"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "depression"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "NO"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "depression"
      ],
      [
        "T4",
        "Disease",
        27,
        28,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 117,
    "text": "Rapid reversal of life - threatening diltiazem - induced tetany with calcium chloride .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "calcium chloride"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "diltiazem"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "tetany"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 118,
    "text": "We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "respiratory arrest"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "tetany"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "diltiazem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 119,
    "text": "The administration of calcium chloride rapidly resolved the patient ' s tetany with prompt recovery of respiratory function , averting the need for more aggressive airway management and ventilatory support .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "calcium chloride"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "tetany"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 120,
    "text": "The emergency physician should be aware that life - threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        22,
        "calcium chloride"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "tetany"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "diltiazem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 121,
    "text": "Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD )",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "decreased renal function"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "heart failure"
      ],
      [
        "T2",
        "Disease",
        23,
        26,
        "left ventricular dysfunction"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "angiotensin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 122,
    "text": "BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "congestive heart failure"
      ],
      [
        "T1",
        "Disease",
        26,
        29,
        "decreased renal function"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "angiotensin"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "CHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 123,
    "text": "Little information is available to predict which patients are at highest risk for this complication .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 124,
    "text": "OBJECTIVE : To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin - converting enzyme inhibitor therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "reduction in renal function"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "CHF"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "angiotensin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 125,
    "text": "METHOD : We analyzed data from the Studies of Left Ventricular Dysfunction ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of enalapril for the treatment of CHF .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "Left Ventricular Dysfunction"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "enalapril"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "CHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 126,
    "text": "There were 3379 patients randomly assigned to enalapril with a median follow - up of 974 days and 3379 patients randomly assigned to placebo with a mean follow - up of 967 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "enalapril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 127,
    "text": "Decreased renal function was defined as a rise in serum creatinine > / = 0 . 5 mg / dL ( 44 micromol / L ) from baseline .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Decreased renal function"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 128,
    "text": "We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of hypertension , diabetes , and use of antiplatelet , diuretic , and beta - blocker therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        26,
        "creatinine"
      ],
      [
        "T1",
        "Disease",
        40,
        41,
        "hypertension"
      ],
      [
        "T2",
        "Disease",
        42,
        43,
        "diabetes"
      ],
      [
        "T3",
        "Chemical",
        49,
        50,
        "diuretic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 129,
    "text": "RESULTS : Patients randomly assigned to enalapril had a 33 % greater likelihood of decreased renal function than controls ( P = . 003 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        17,
        "decreased renal function"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "enalapril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 130,
    "text": "By multivariate analysis , in both the placebo and enalapril groups older age , diuretic therapy , and diabetes were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        25,
        "decreased renal function"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "enalapril"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "diuretic"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 131,
    "text": "Older age was associated with a greater risk of developing decreased renal function in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "decreased renal function"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "enalapril"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "enalapril"
      ],
      [
        "T3",
        "Chemical",
        55,
        56,
        "enalapril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 132,
    "text": "Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "decreased renal function"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Diuretic"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "enalapril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 133,
    "text": "Conversely , enalapril had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with diabetes .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "enalapril"
      ],
      [
        "T1",
        "Disease",
        48,
        49,
        "diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 134,
    "text": "A lower risk of renal impairment was seen in both groups with beta - blocker therapy ( RR 0 . 70 , 95 % CI 0 . 57 - 0 . 85 ) and higher baseline ejection fraction ( RR 0 . 93 per 5 % increment , 95 % CI 0 . 91 - 0 . 96 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "renal impairment"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 135,
    "text": "CONCLUSIONS : Enalapril use caused a 33 % increase in the risk of decreased renal function in patients with CHF .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "decreased renal function"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Enalapril"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "CHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 136,
    "text": "Diuretic use and advanced age increased this risk .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Diuretic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 137,
    "text": "Diabetes was associated with an increased risk of renal impairment in all patients with CHF , but this risk was reduced in the enalapril group compared with the placebo group .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "renal impairment"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Diabetes"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "CHF"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "enalapril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 138,
    "text": "beta - Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 139,
    "text": "Hypomania - like syndrome induced by olanzapine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypomania"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 140,
    "text": "We report a female patient with a diagnosis of a not otherwise specified psychotic disorder ( DSM - IV ) who developed hypomania shortly after the introduction of olanzapine treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "psychotic disorder"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "hypomania"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 141,
    "text": "Acetazolamide - induced Gerstmann syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "Gerstmann syndrome"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Acetazolamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 142,
    "text": "Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "renal impairment"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "confusion"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "acetazolamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 143,
    "text": "We report a case of acetazolamide - induced Gerstmann syndrome in a patient with normal renal function , to highlight predisposing factors that are frequently overlooked .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "Gerstmann syndrome"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "acetazolamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 144,
    "text": "Vasopressin in the treatment of milrinone - induced hypotension in severe heart failure .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "heart failure"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Vasopressin"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "milrinone"
      ],
      [
        "T3",
        "Disease",
        8,
        9,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 145,
    "text": "The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "heart failure"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "milrinone"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 146,
    "text": "In patients with decompensated heart failure with hypotension after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "heart failure"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "milrinone"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "vasopressin"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "milrinone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 147,
    "text": "Treatment of tacrolimus - related adverse effects by conversion to cyclosporine in liver transplant recipients .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "tacrolimus"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "cyclosporine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 148,
    "text": "When tacrolimus side effects persist despite dose reduction , conversion to cyclosporine - based immunosuppression ( CyA ) is necessary .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "tacrolimus"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "cyclosporine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 149,
    "text": "We characterized tacrolimus side effects that warranted discontinuation of the drug , and outcomes after conversion .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 150,
    "text": "Of 388 liver recipients who received tacrolimus as primary immunosuppression , 70 required conversion to CyA .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 151,
    "text": "We recorded indication for conversion , whether conversion was early or late after transplantation , tacrolimus dose and trough blood level at conversion , and incidence of rejection after conversion .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 152,
    "text": "Conversion was early in 29 patients ( 41 . 4 % ) and late in 41 ( 58 . 6 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 153,
    "text": "Indications for early conversion were neurotoxicity ( 20 ) , ( insulin - dependent ) diabetes mellitus ( IDDM ) ( 5 ) , nephrotoxicity ( 3 ) , gastrointestinal ( GI ) toxicity ( 6 ) , and cardiomyopathy ( 1 ) , and for late conversion were neurotoxicity ( 15 ) , IDDM ( 12 ) , nephrotoxicity ( 3 ) , GI toxicity ( 5 ) , hepatotoxicity ( 6 ) , post - transplant lmphoproliferate disease ( PTLD ) ( 2 ) , cardiomyopathy ( 1 ) , hemolytic anemia ( 1 ) , and pruritus ( 1 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        17,
        "( insulin - dependent ) diabetes mellitus"
      ],
      [
        "T1",
        "Disease",
        29,
        34,
        "gastrointestinal ( GI ) toxicity"
      ],
      [
        "T2",
        "Disease",
        64,
        66,
        "GI toxicity"
      ],
      [
        "T3",
        "Disease",
        75,
        80,
        "post - transplant lmphoproliferate disease"
      ],
      [
        "T4",
        "Disease",
        92,
        94,
        "hemolytic anemia"
      ],
      [
        "T5",
        "Disease",
        5,
        6,
        "neurotoxicity"
      ],
      [
        "T6",
        "Disease",
        18,
        19,
        "IDDM"
      ],
      [
        "T7",
        "Disease",
        24,
        25,
        "nephrotoxicity"
      ],
      [
        "T8",
        "Disease",
        39,
        40,
        "cardiomyopathy"
      ],
      [
        "T9",
        "Disease",
        49,
        50,
        "neurotoxicity"
      ],
      [
        "T10",
        "Disease",
        54,
        55,
        "IDDM"
      ],
      [
        "T11",
        "Disease",
        59,
        60,
        "nephrotoxicity"
      ],
      [
        "T12",
        "Disease",
        70,
        71,
        "hepatotoxicity"
      ],
      [
        "T13",
        "Disease",
        81,
        82,
        "PTLD"
      ],
      [
        "T14",
        "Disease",
        87,
        88,
        "cardiomyopathy"
      ],
      [
        "T15",
        "Disease",
        99,
        100,
        "pruritus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 154,
    "text": "All early - conversion patients showed improvement / resolution of symptoms .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 155,
    "text": "Among late - conversion patients , 37 ( 90 . 2 % ) had improvement / resolution ; in 4 ( 9 . 8 % ) , adverse effects persisted .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 156,
    "text": "The overall rejection rate was 30 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 157,
    "text": "Sixty - two patients ( 88 . 6 % ) are alive with functioning grafts 686 + / - 362 days ( range , 154 - 1433 days ) after conversion .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 158,
    "text": "When tacrolimus side effects are unresponsive to dose reduction , conversion to CyA can be accomplished safely , with no increased risk of rejection and excellent long - term outcome .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 159,
    "text": "Ocular manifestations of juvenile rheumatoid arthritis .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "juvenile rheumatoid arthritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 160,
    "text": "We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "juvenile rheumatoid arthritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 161,
    "text": "Thirty - six of the 210 patients ( 17 . 2 % ) developed iridocyclitis .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "iridocyclitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 162,
    "text": "Iridocyclitis was seen most frequently in young female patients ( 0 to 4 years ) with the monoarticular or pauciatricular form of the arthritis .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Iridocyclitis"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "arthritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 163,
    "text": "However , 30 % of the patients developed uveitis after 16 years of age .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "uveitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 164,
    "text": "Although 61 % of patients had a noncontributory ocular history on entry , 42 % had active uveitis on entry .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "uveitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 165,
    "text": "Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "uveitis"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "uveitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 166,
    "text": "Forty - four percent of patients with uveitis had one or more identifiable signs or symptoms , such as red eye , ocular pain , decreased visual acuity , or photophobia , in order of decreasing frequency .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "ocular pain"
      ],
      [
        "T1",
        "Disease",
        25,
        28,
        "decreased visual acuity"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "uveitis"
      ],
      [
        "T3",
        "Disease",
        30,
        31,
        "photophobia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 167,
    "text": "Even after early detection and prompt treatment , 41 % of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "uveitis"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "corticosteroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 168,
    "text": "Despite this , there was a dramatic decrease in the 50 % incidence of blinding complications of uveitis cited in earlier studies .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "uveitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 169,
    "text": "Cataract and band keratopathy occurred in only 22 and 13 % of our group , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "band keratopathy"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Cataract"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 170,
    "text": "We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "chloroquine"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "hydroxychloroquine"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "chorioretinopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 171,
    "text": "Systemically administered corticosteroids were used in 75 of 210 cases ; a significant number of posterior subcapsular cataracts was found .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "corticosteroids"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "cataracts"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 172,
    "text": "Typical keratoconjunctivitis sicca developed in three of the uveitis cases .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "keratoconjunctivitis"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "uveitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 173,
    "text": "This association with uveitis and JRA was not noted previously .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "uveitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 174,
    "text": "Surgical treatment of cataracts , band keratopathy , and glaucoma achieved uniformly discouraging results .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "band keratopathy"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "cataracts"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 175,
    "text": "Cyclophosphamide - induced cystitis in freely - moving conscious rats : behavioral approach to a new model of visceral pain .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "visceral pain"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Cyclophosphamide"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 176,
    "text": "PURPOSE : To develop a model of visceral pain in rats using a behavioral approach .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "visceral pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 177,
    "text": "Cyclophosphamide ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce cystitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cyclophosphamide"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "CP"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "acrolein"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 178,
    "text": "MATERIALS AND METHODS : CP was administered at doses of 50 , 100 and 200 mg . / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "CP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 179,
    "text": "i . p . to male rats , and their behavior observed and scored .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 180,
    "text": "The effects of morphine ( 0 . 5 to 4 mg . / kg . i . v . ) on CP - induced behavioral modifications were tested administered alone and after naloxone ( 1 mg . / kg . s . c . ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "CP"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "naloxone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 181,
    "text": "In addition , 90 minutes after CP injection , that is , at the time of administration of morphine , the bladder was removed in some rats for histological examination .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "CP"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 182,
    "text": "Finally , to show that the bladder is essential for the CP - induced behavioral modifications , female rats also received CP at doses of 200 mg . / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "CP"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "CP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 183,
    "text": "i . p . and of 20 mg . by the intravesical route , and acrolein at doses of 0 . 5 mg . by the intravesical route and of 5 mg . / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "acrolein"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 184,
    "text": "i . v . RESULTS : CP dose - relatedly induced marked behavioral modifications in male rats : breathing rate decrease , closing of the eyes and occurrence of specific postures .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "CP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 185,
    "text": "Morphine dose - dependently reversed these behavioral disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "behavioral disorders"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 186,
    "text": "A dose of 0 . 5 mg . / kg . produced a reduction of almost 50 % of the behavioral score induced by CP 200 mg . / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "CP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 187,
    "text": "This effect was completely prevented by pretreatment with naloxone .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "naloxone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 188,
    "text": "At the time of administration of morphine , histological modifications of the bladder wall , such as chorionic and muscle layer edema , were observed .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "morphine"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 189,
    "text": "In female rats , CP 200 mg . / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "CP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 190,
    "text": "i . p . produced the same marked behavioral modifications as those observed in male rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 191,
    "text": "Administered at the dose of 20 mg . intravesically , CP did not produce any behavioral effects , whereas acrolein at 0 . 5 mg . intravesically induced behavioral modifications identical to those under CP 200 mg . / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "CP"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "acrolein"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "CP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 192,
    "text": "i . p . , with the same maximal levels .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 193,
    "text": "Conversely , acrolein 5 mg . / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "acrolein"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 194,
    "text": "i . v . did not produce any behavioral effects at all .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 195,
    "text": "CONCLUSIONS : Overall , these results indicate that this experimental model of CP - induced cystitis may be an interesting new behavioral model of inflammatory visceral pain , allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "visceral pain"
      ],
      [
        "T1",
        "Disease",
        34,
        36,
        "painful syndromes"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "CP"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 196,
    "text": "Prednisolone - induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "muscle dysfunction"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Prednisolone"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "atrophy"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "acetylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 197,
    "text": "Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 198,
    "text": "We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology , and their relationship to changes in muscle size and acetylcholine receptor ( AChR ) expression .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "prednisolone"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "acetylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 199,
    "text": "With institutional approval , 35 Sprague - Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg / kg prednisolone ( P10 group ) , 100 mg / kg prednisolone ( P100 group ) , or an equal volume of saline ( S group ) for 7 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "prednisolone"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "prednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 200,
    "text": "A fourth group of rats was pair fed ( food restricted ) with the P100 rats for 7 days ( FR group ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 201,
    "text": "On Day 8 , the nerve - evoked peak twitch tensions , tetanic tensions , and fatigability , and the dose - response curves of d - tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        28,
        "d - tubocurarine"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "tetanic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 202,
    "text": "Rate of body weight gain was depressed in the P100 , FR , and P10 groups compared with the S group .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 203,
    "text": "Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 204,
    "text": "The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups , however , tension per milligram of muscle mass was greater in the P100 group than in the S group .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "tetanic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 205,
    "text": "The 50 % effective dose of d - tubocurarine ( microg / kg ) in the tibialis muscle was smaller in the P10 ( 33 . 6 + / - 5 . 4 ) than in the S ( 61 . 9 + / - 5 . 0 ) or the P100 ( 71 . 3 + / - 9 . 6 ) groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "d - tubocurarine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 206,
    "text": "AChR expression was less in the P10 group than in the S group .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 207,
    "text": "The evoked tensions correlated with muscle mass ( r ( 2 ) = 0 . 32 , P < 0 . 001 ) , however , not with expression of AChR .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 208,
    "text": "The 50 % effective dose of d - tubocurarine did not correlate with muscle mass or AChR expression .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "d - tubocurarine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 209,
    "text": "Our results suggest that the neuromuscular dysfunction after prednisolone is dose - dependent , and derives primarily from muscle atrophy and derives less so from changes in AChR expression .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "neuromuscular dysfunction"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "muscle atrophy"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "prednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 210,
    "text": "IMPLICATIONS : The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 211,
    "text": "We suggest that the observed effects are dose - dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "muscle atrophy"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "acetylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 212,
    "text": "Apomorphine : an underutilized therapy for Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        10,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 213,
    "text": "Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 214,
    "text": "While powerful antiparkinsonian effects had been observed as early as 1951 , the potential of treating fluctuating Parkinson ' s disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        21,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 215,
    "text": "A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off - periods even in patients with complex on - off motor swings .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "apomorphine"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "levodopa"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 216,
    "text": "Continuous subcutaneous apomorphine infusions can reduce daily off - time by more than 50 % in this group of patients , which appears to be a stronger effect than that generally seen with add - on therapy with oral dopamine agonists or COMT inhibitors .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "apomorphine"
      ],
      [
        "T1",
        "Chemical",
        39,
        40,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 217,
    "text": "Extended follow - up studies of up to 8 years have demonstrated long - term persistence of apomorphine efficacy .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 218,
    "text": "In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa - induced dyskinesias .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "apomorphine"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 219,
    "text": "The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems , whereas sedation and psychiatric complications play a lesser role .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "apomorphine"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "psychiatric"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 220,
    "text": "Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson ' s disease , this approach seems to deserve more widespread clinical use .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 221,
    "text": "Probing peripheral and central cholinergic system responses .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 222,
    "text": "OBJECTIVE : The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer ' s disease , yet correlations between central and peripheral responses have not been properly studied .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        35,
        "Alzheimer ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 223,
    "text": "This study assessed the effect of normal aging on ( 1 ) the tropicamide - induced increase in pupil diameter , and ( 2 ) the reversal of this effect with pilocarpine .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "tropicamide"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 224,
    "text": "Scopolamine was used as a positive control to detect age - dependent changes in central cholinergic functioning in the elderly .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 225,
    "text": "DESIGN : Randomized double - blind controlled trial .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 226,
    "text": "PARTICIPANTS : Ten healthy elderly ( mean age 70 ) and 9 young ( mean age 33 ) volunteers .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 227,
    "text": "INTERVENTIONS : Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 228,
    "text": "The study involved 4 sessions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 229,
    "text": "In 1 session , tropicamide ( 20 microL , 0 . 01 % ) was administered to one eye and placebo to the other .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "tropicamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 230,
    "text": "In another session , tropicamide ( 20 microL , 0 . 01 % ) was administered to both eyes , followed 23 minutes later by the application of pilocarpine ( 20 microL , 0 . 1 % ) to one eye and placebo to the other .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "tropicamide"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 231,
    "text": "All eye drops were given in a randomized order .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 232,
    "text": "In 2 separate sessions , a single dose of scopolamine ( 0 . 5 mg , intravenously ) or placebo was administered , and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 233,
    "text": "OUTCOME MEASURES : Pupil size at time points after administration of tropicamide and pilocarpine ; scopolamine - induced impairment in word recall .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        22,
        "impairment in word recall"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "tropicamide"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "pilocarpine"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 234,
    "text": "RESULTS : There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point ( p > 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "tropicamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 235,
    "text": "The elderly group had a significantly greater pilocarpine - induced net decrease in pupil size 85 , 125 , 165 and 215 minutes after administration , compared with the young group ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 236,
    "text": "Compared with the young group , the elderly group had greater scopolamine - induced impairment in word recall 60 , 90 and 120 minutes after administration ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        18,
        "impairment in word recall"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 237,
    "text": "CONCLUSION : There is an age - related pupillary response to pilocarpine that is not found with tropicamide .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "pilocarpine"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "tropicamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 238,
    "text": "Thus , pilocarpine may be useful to assess variations in central cholinergic function in elderly patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 239,
    "text": "Pain responses in methadone - maintained opioid abusers .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Pain"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 240,
    "text": "Providing pain management for known opioid abusers is a challenging clinical task , in part because little is known about their pain experience and analgesic requirements .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "pain"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 241,
    "text": "This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "opioid addicts"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "pain"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 242,
    "text": "By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) pain was examined , both before and after oral administration of therapeutic doses of common opioid ( hydromorphone 2 mg ) and nonsteroidal anti - inflammatory ( ketorolac 10 mg ) analgesic agents .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        22,
        "pain"
      ],
      [
        "T1",
        "Chemical",
        38,
        39,
        "hydromorphone"
      ],
      [
        "T2",
        "Chemical",
        48,
        49,
        "ketorolac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 243,
    "text": "Results showed that MM individuals were significantly less tolerant of CP pain than control subjects , replicating previous work .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 244,
    "text": "Analgesic effects were significant neither for medication nor group .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 245,
    "text": "These data indicate that MM opioid abusers represent a pain - intolerant subset of clinical patients .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "pain - intolerant"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 246,
    "text": "Their complaints of pain should be evaluated seriously and managed aggressively .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 247,
    "text": "High - dose methylprednisolone may do more harm for spinal cord injury .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "spinal cord injury"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "methylprednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 248,
    "text": "Because of the National Acute Spinal Cord Injury Studies ( NASCIS ) , high - dose methylprednisolone became the standard of care for the acute spinal cord injury .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "Spinal Cord Injury"
      ],
      [
        "T1",
        "Disease",
        25,
        28,
        "spinal cord injury"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "methylprednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 249,
    "text": "In the NASCIS , there was no mention regarding the possibility of acute corticosteroid myopathy that high - dose methylprednisolone may cause .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "corticosteroid"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "myopathy"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "methylprednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 250,
    "text": "The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2 - day period for any clinical condition .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "methylprednisolone"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 251,
    "text": "We hypothesize that it may cause some damage to the muscle of spinal cord injury patients .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "damage to the muscle"
      ],
      [
        "T1",
        "Disease",
        12,
        15,
        "spinal cord injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 252,
    "text": "Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .",
    "labels": [
      [
        "T0",
        "Disease",
        38,
        41,
        "spinal cord injury"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "steroid"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "myopathy"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "steroid"
      ],
      [
        "T4",
        "Disease",
        27,
        28,
        "myopathy"
      ],
      [
        "T5",
        "Chemical",
        34,
        35,
        "methylprednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 253,
    "text": "To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "methylprednisolone"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "corticosteroid"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 254,
    "text": "Conversion to rapamycin immunosuppression in renal transplant recipients : report of an initial experience .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "rapamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 255,
    "text": "BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "RAPA"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "cyclosporine"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "CsA"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "tacrolimus"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "Tac"
      ],
      [
        "T5",
        "Disease",
        27,
        28,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 256,
    "text": "METHODS : Twenty renal transplant recipients were switched to fixed dose rapamycin ( RAPA ) ( 5 mg / day ) 0 to 204 months posttransplant .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "rapamycin"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "RAPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 257,
    "text": "Drug monitoring was not initially used to adjust doses .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 258,
    "text": "The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "facial dysmorphism"
      ],
      [
        "T1",
        "Disease",
        30,
        33,
        "posttransplant lymphoproliferative disorder"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "CsA"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "Tac"
      ],
      [
        "T4",
        "Disease",
        9,
        10,
        "nephrotoxicity"
      ],
      [
        "T5",
        "Chemical",
        15,
        16,
        "CsA"
      ],
      [
        "T6",
        "Chemical",
        17,
        18,
        "Tac"
      ],
      [
        "T7",
        "Disease",
        18,
        19,
        "toxicity"
      ],
      [
        "T8",
        "Disease",
        34,
        35,
        "PTLD"
      ],
      [
        "T9",
        "Disease",
        43,
        44,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 259,
    "text": "Follow - up is 7 to 24 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 260,
    "text": "RESULTS : In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [ 233 + / - 34 to 210 + / - 56 micromol / liter ( P < 0 . 05 ) at 6 months ] .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "nephrotoxicity"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 261,
    "text": "Facial dysmorphism improved in two patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Facial dysmorphism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 262,
    "text": "No relapse of PTLD was observed .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "PTLD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 263,
    "text": "Five patients developed pneumonia ( two Pneumocystis carinii pneumonia , one infectious mononucleosis with polyclonal PTLD lung infiltrate ) and two had bronchiolitis obliterans .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "Pneumocystis carinii pneumonia"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "infectious mononucleosis"
      ],
      [
        "T2",
        "Disease",
        22,
        24,
        "bronchiolitis obliterans"
      ],
      [
        "T3",
        "Disease",
        3,
        4,
        "pneumonia"
      ],
      [
        "T4",
        "Disease",
        15,
        16,
        "PTLD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 264,
    "text": "There were no deaths .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 265,
    "text": "RAPA was discontinued in four patients , because of pneumonia in two , PTLD in one , and oral aphtous ulcers in one .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "aphtous ulcers"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "RAPA"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "pneumonia"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "PTLD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 266,
    "text": "RAPA levels were high ( > 15 ng / ml ) in 7 of 13 ( 54 % ) patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "RAPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 267,
    "text": "CONCLUSIONS : RAPA conversion provides adequate immunosuppression to enable CsA withdrawal .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "RAPA"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "CsA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 268,
    "text": "However , when converting patients to RAPA drug levels should be monitored to avoid over - immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "Pneumocystis carinii pneumonia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "RAPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 269,
    "text": "Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed visual field constriction .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "visual field constriction"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "vigabatrin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 270,
    "text": "PURPOSE : Symptomatic visual field constriction thought to be associated with vigabatrin has been reported .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "visual field constriction"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "vigabatrin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 271,
    "text": "The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed visual field loss , three of whom were reported previously .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        21,
        "visual field loss"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "vigabatrin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 272,
    "text": "Six of the patients were no longer receiving vigabatrin .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "vigabatrin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 273,
    "text": "METHODS : The central and peripheral fields were examined with the Humphrey Visual Field Analyzer .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 274,
    "text": "Full visual electrophysiology , including flash electroretinography ( ERG ) , pattern electroretinography , multifocal ERG using the VERIS system , electro - oculography , and flash and pattern visual evoked potentials , was undertaken .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 275,
    "text": "RESULTS : Seven patients showed marked visual field constriction with some sparing of the temporal visual field .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "visual field constriction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 276,
    "text": "The eighth exhibited concentric constriction .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 277,
    "text": "Most electrophysiological responses were usually just within normal limits ; two patients had subnormal Arden electro - oculography indices ; and one patient showed an abnormally delayed photopic b wave .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 278,
    "text": "However , five patients showed delayed 30 - Hz flicker b waves , and seven patients showed delayed oscillatory potentials .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 279,
    "text": "Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 280,
    "text": "CONCLUSION : Marked visual field constriction appears to be associated with vigabatrin therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "visual field constriction"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "vigabatrin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 281,
    "text": "The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "vigabatrin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 282,
    "text": "Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Myocardial ischemia"
      ],
      [
        "T1",
        "Disease",
        4,
        7,
        "coronary artery spasm"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 283,
    "text": "Dobutamine stress echocardiography ( DSE ) is a useful and safe provocation test for myocardial ischemia .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 284,
    "text": "Until now , the test has been focused only on the organic lesion in the coronary artery , and positive DSE has indicated the presence of significant fixed coronary artery stenosis .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        31,
        "coronary artery stenosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 285,
    "text": "The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "coronary spasm"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 286,
    "text": "We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "coronary spastic angina"
      ],
      [
        "T1",
        "Disease",
        14,
        17,
        "coronary artery stenosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 287,
    "text": "All patients had anginal attacks at rest with ST elevation on the electrocardiogram ( variant angina ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "variant angina"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "anginal"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 288,
    "text": "Coronary spasm was induced by intracoronary injection of acetylcholine , and no fixed coronary artery stenosis was documented on angiograms in all patients .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "coronary artery stenosis"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "acetylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 289,
    "text": "DSE was performed with intravenous dobutamine infusion with an incremental doses of 5 , 10 , 20 , 30 , and 40 microg / kg / min every 5 minutes .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 290,
    "text": "Of the 51 patients , 7 patients showed asynergy with ST elevation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 291,
    "text": "All 7 patients ( 13 . 7 % ) had chest pain during asynergy , and both chest pain and electrocardiographic changes were preceded by asynergy .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "chest pain"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "chest pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 292,
    "text": "These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "coronary spasm"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "coronary spastic angina"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 293,
    "text": "When DSE is performed to evaluate coronary artery disease , not only fixed coronary stenosis , but also coronary spasm should be considered as a genesis of asynergy .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "coronary stenosis"
      ],
      [
        "T2",
        "Disease",
        18,
        20,
        "coronary spasm"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 294,
    "text": "Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine - induced myocardial ischemia .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "metoprolol"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "metoprolol"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 295,
    "text": "STUDY OBJECTIVE : To determine the effect of metoprolol on dobutamine stress testing with technetium - 99m sestamibi single - photon emission computed tomography imaging and ST - segment monitoring , and to assess the impact of intravenous glucagon on metoprolol ' s effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        18,
        "technetium - 99m sestamibi"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "metoprolol"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "dobutamine"
      ],
      [
        "T3",
        "Chemical",
        40,
        41,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 296,
    "text": "DESIGN : Randomized , double - blind , placebo - controlled trial .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 297,
    "text": "SETTING : Community hospital .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 298,
    "text": "PATIENTS : Twenty - two patients with known reversible perfusion defects .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 299,
    "text": "INTERVENTION : Patients underwent dobutamine stress tests per standard protocol .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 300,
    "text": "Before dobutamine was begun , no therapy was given during the first visit , and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "dobutamine"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "metoprolol"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 301,
    "text": "Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats / minute or a total intravenous dose of 20 mg .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Metoprolol"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "predobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 302,
    "text": "MEASUREMENTS AND MAIN RESULTS : Metoprolol reduced maximum heart rate 31 % , summed stress scores 29 % , and summed difference scores 43 % versus control .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "Metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 303,
    "text": "Metoprolol plus glucagon also reduced the maximum heart rate 29 % versus control .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 304,
    "text": "Summed stress and summed difference scores were not significantly reduced , although they were 18 % and 30 % lower , respectively , than control .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 305,
    "text": "No significant differences were found in any parameter between metoprolol and metoprolol - glucagon .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "metoprolol"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 306,
    "text": "CONCLUSION : During dobutamine stress testing , metoprolol attenuates or eliminates evidence of myocardial ischemia .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "dobutamine"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 307,
    "text": "Glucagon 1 mg , although somewhat effective , does not correct this effect to the extent that it can be administered clinically .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 308,
    "text": "Evidence of functional somatotopy in GPi from results of pallidotomy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 309,
    "text": "The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on parkinsonian ' off ' signs and levodopa - induced dyskinesias ( LID ) .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        28,
        "parkinsonian"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        36,
        37,
        "dyskinesias"
      ],
      [
        "T3",
        "Disease",
        38,
        39,
        "LID"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 310,
    "text": "We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in LID .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "levodopa"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        52,
        53,
        "LID"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 311,
    "text": "We also found a highly significant correlation ( P : < 0 . 0001 , r = 0 . 8 ) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs , whereas there was no correlation between the ventral volume and the improvement in parkinsonian ' off ' signs .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        36,
        "LID"
      ],
      [
        "T1",
        "Disease",
        54,
        55,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 312,
    "text": "The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian ' off ' signs .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "dyskinesias"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 313,
    "text": "The differential predictive value of levodopa responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "parkinsonian"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "LID"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "dyskinesias"
      ],
      [
        "T4",
        "Disease",
        29,
        30,
        "parkinsonian"
      ],
      [
        "T5",
        "Disease",
        48,
        49,
        "parkinsonian"
      ],
      [
        "T6",
        "Disease",
        54,
        55,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 314,
    "text": "Whereas cells in a wider area of the GPi may be implicated in parkinsonism , the ventral GPi seems to be crucial for the manifestation of LID .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "parkinsonism"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "LID"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 315,
    "text": "We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias , especially along the dorsoventral trajectory used in pallidotomy .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "parkinsonism"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 316,
    "text": "The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms , and hence could be variable .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 317,
    "text": "Screening for stimulant use in adult emergency department seizure patients .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 318,
    "text": "OBJECTIVE : The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "amphetamine"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 319,
    "text": "METHODS : This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 320,
    "text": "Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme - mediated immunoassay methodology .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "amphetamine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "benzoylecgonine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 321,
    "text": "Plasma samples with benzoylecgonine greater than 150 ng / mL or an amphetamine greater than 500 ng / mL were defined as positive .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "benzoylecgonine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 322,
    "text": "Patient demographics , history of underlying drug or alcohol - related seizure disorder , estimated time from seizure to sample collection , history or suspicion of cocaine or amphetamine abuse , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        30,
        "cocaine or amphetamine abuse"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "alcohol"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "seizure"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 323,
    "text": "RESULTS : Fourteen of 248 ( 5 . 6 % , 95 % CI 2 . 7 % - 8 . 5 % ) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples ( 0 % , 95 % CI 0 - 1 . 2 % ) were positive for amphetamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        33,
        "benzoylecgonine"
      ],
      [
        "T1",
        "Chemical",
        53,
        54,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 324,
    "text": "Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse ( p < 0 . 0005 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        21,
        "cocaine or amphetamine abuse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 325,
    "text": "CONCLUSIONS : During this study period , routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "amphetamines"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 326,
    "text": "As a result , routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "drug abuse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 327,
    "text": "Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "sodium valproate"
      ],
      [
        "T1",
        "Disease",
        6,
        13,
        "syndrome of inappropriate secretion of antidiuretic hormone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 328,
    "text": "We report the case of a 62 - year - old man who was administered sodium valproate ( VPA ) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "sodium valproate"
      ],
      [
        "T1",
        "Disease",
        25,
        32,
        "syndrome of inappropriate secretion of antidiuretic hormone"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "VPA"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "SIADH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 329,
    "text": "He had been taking VPA for treatment of idiopathic generalized tonic - clonic convulsions since he was 56 years old .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        14,
        "tonic - clonic convulsions"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 330,
    "text": "After substituting VPA with zonisamide , the serum sodium level returned to normal .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "VPA"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "zonisamide"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 331,
    "text": "We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long - term administration of VPA .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        23,
        "weakness of the central nervous system"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "SIADH"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 332,
    "text": "Association of nitric oxide production and apoptosis in a model of experimental nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 333,
    "text": "BACKGROUND : In recent studies increased amounts of nitric oxide ( NO ) and apoptosis have been implicated in various pathological conditions in the kidney .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "nitric oxide"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "NO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 334,
    "text": "We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin ( ADR ) .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "nephrotic syndrome"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "NO"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "adriamycin"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "ADR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 335,
    "text": "METHODS : The alteration in the NO pathway was assessed by measuring nitrite levels in serum / urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney ( IPRK ) system .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "NO"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "nitrite"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 336,
    "text": "Rats were stratified into control groups and ADR - induced nephropathy groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "ADR"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 337,
    "text": "These two groups were then divided into : group 1 , animals receiving saline ; and group 2 , animals receiving aminoguanidine ( AG ) which is a specific inhibitor of inducible - NO synthase .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "aminoguanidine"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "AG"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "NO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 338,
    "text": "On day 21 , rats were sacrificed after obtaining material for biochemical analysis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 339,
    "text": "RESULTS : Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "mesangial proliferation"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "tubulointerstitial inflammation"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "ADR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 340,
    "text": "They also had significantly higher levels of proteinuria compared with control and treatment groups ( P < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 341,
    "text": "Urine nitrite levels were significantly increased in the ADR - nephropathy group ( P < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "nitrite"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "ADR"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 342,
    "text": "In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR - nephropathy group .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "phenylephrine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "acetylcholine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "ADR"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 343,
    "text": "Apoptosis was not detected in controls .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 344,
    "text": "However , in the ADR - nephropathy group , numerous apoptotic cells were identified in the tubulointerstitial areas .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ADR"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 345,
    "text": "Double staining revealed numerous interstitial apoptotic cells to stain for ED1 , a marker for monocytes / macrophages .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 346,
    "text": "Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "AG"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "nitrite"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 347,
    "text": "CONCLUSION : We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR - induced nephrosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "NO"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "ADR"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "nephrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 348,
    "text": "Dual effects of melatonin on barbiturate - induced narcosis in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "melatonin"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "barbiturate"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "narcosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 349,
    "text": "Melatonin affects the circadian sleep / wake cycle , but it is not clear whether it may influence drug - induced narcosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Melatonin"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "narcosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 350,
    "text": "Sodium thiopenthal was administered intraperitoneally into male rats pre - treated with melatonin ( 0 . 05 , 0 . 5 , 5 and 50 mg / kg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Sodium thiopenthal"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "melatonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 351,
    "text": "Melatonin pre - treatment affected in a dual manner barbiturate narcosis , however , no dose - effect correlation was found .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Melatonin"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "barbiturate"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "narcosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 352,
    "text": "In particular , low doses reduced the latency to and prolonged the duration of barbiturate narcosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "barbiturate"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "narcosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 353,
    "text": "In contrast , the highest dose of melatonin ( 50 mg / kg ) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis , and a reduction in mortality rate .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "melatonin"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "narcosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 354,
    "text": "Melatonin 0 . 5 and 5 mg / kg influenced the duration but not the latency of ketamine - or diazepam - induced narcosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Melatonin"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "ketamine"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "diazepam"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "narcosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 355,
    "text": "Thus , the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "melatonin"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "narcosis"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "barbiturate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 356,
    "text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "breast cancer"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "cardiotoxicity"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "doxorubicin"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "cyclophosphamide"
      ],
      [
        "T4",
        "Chemical",
        16,
        17,
        "doxorubicin"
      ],
      [
        "T5",
        "Chemical",
        18,
        19,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 357,
    "text": "PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .",
    "labels": [
      [
        "T0",
        "Disease",
        43,
        45,
        "breast cancer"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "Myocet"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "doxorubicin"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "cyclophosphamide"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "doxorubicin"
      ],
      [
        "T5",
        "Disease",
        30,
        31,
        "cardiotoxicity"
      ],
      [
        "T6",
        "Disease",
        46,
        47,
        "MBC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 358,
    "text": "PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "MBC"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "Myocet"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "doxorubicin"
      ],
      [
        "T3",
        "Chemical",
        54,
        55,
        "cyclophosphamide"
      ],
      [
        "T4",
        "Disease",
        67,
        68,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 359,
    "text": "Cardiotoxicity was defined by reductions in left - ventricular ejection fraction , assessed by serial multigated radionuclide angiography scans , or congestive heart failure ( CHF ) .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "congestive heart failure"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Cardiotoxicity"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "CHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 360,
    "text": "Antitumor efficacy was assessed by objective tumor response rates ( World Health Organization criteria ) , time to progression , and survival .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 361,
    "text": "RESULTS : Six percent of MC patients versus 21 % ( including five cases of CHF ) of AC patients developed cardiotoxicity ( P = . 0002 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "CHF"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 362,
    "text": "Median cumulative doxorubicin dose at onset was more than 2 , 220 mg / m ( 2 ) for MC versus 480 mg / m ( 2 ) for AC ( P = . 0001 , hazard ratio , 5 . 04 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 363,
    "text": "MC patients also experienced less grade 4 neutropenia .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 364,
    "text": "Antitumor efficacy of MC versus AC was comparable : objective response rates , 43 % versus 43 % ; median time to progression , 5 . 1 % versus 5 . 5 months ; median time to treatment failure , 4 . 6 versus 4 . 4 months ; and median survival , 19 versus 16 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 365,
    "text": "CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Myocet"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "doxorubicin"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "cardiotoxicity"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "neutropenia"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "cyclophosphamide"
      ],
      [
        "T5",
        "Disease",
        35,
        36,
        "MBC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 366,
    "text": "The role of nitrergic system in lidocaine - induced convulsion in the mouse .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "lidocaine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "convulsion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 367,
    "text": "The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced convulsions .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        13,
        "N - nitro - L - arginine - methyl ester"
      ],
      [
        "T1",
        "Chemical",
        14,
        17,
        "L - NAME"
      ],
      [
        "T2",
        "Chemical",
        19,
        21,
        "nitric oxide"
      ],
      [
        "T3",
        "Chemical",
        27,
        30,
        "L - arginine"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "NO"
      ],
      [
        "T5",
        "Chemical",
        32,
        33,
        "NO"
      ],
      [
        "T6",
        "Chemical",
        38,
        39,
        "lidocaine"
      ],
      [
        "T7",
        "Disease",
        41,
        42,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 368,
    "text": "In the first experiment , four groups of mice received physiological saline ( 0 . 9 % ) , L - arginine ( 300 mg / kg , i . p . ) , L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        22,
        "L - arginine"
      ],
      [
        "T1",
        "Chemical",
        34,
        37,
        "L - NAME"
      ],
      [
        "T2",
        "Chemical",
        49,
        50,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 369,
    "text": "Thirty minutes after these injections , all mice received lidocaine ( 50 mg / kg , i . p . ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 370,
    "text": "In the second experiment , four groups of mice received similar treatment in the first experiment , and 30 min after these injections , all mice received a higher dose of lidocaine ( 80 mg / kg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        32,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 371,
    "text": "L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced convulsions .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "L - NAME"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "diazepam"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "lidocaine"
      ],
      [
        "T3",
        "Disease",
        36,
        37,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 372,
    "text": "In contrast , the L - arginine treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced convulsions significantly .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "L - arginine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "lidocaine"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 373,
    "text": "These results may suggest that NO is a proconvulsant mediator in lidocaine - induced convulsions .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "NO"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "lidocaine"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 374,
    "text": "Erythropoietin restores the anemia - induced reduction in cyclophosphamide cytotoxicity in rat tumors .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "anemia"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "cyclophosphamide"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "cytotoxicity"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "tumors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 375,
    "text": "The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "anemia"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "cytotoxicity"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "cyclophosphamide"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "tumors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 376,
    "text": "Anemia was induced using a single dose of carboplatin ( 50 mg / kg i . v . ) resulting in a long - lasting reduction ( 30 % ) of the hemoglobin concentration .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Anemia"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 377,
    "text": "In a second group , the development of anemia was prevented by rHuEPO ( 1000 IU / kg ) administered s . c . three times / week starting 7 days before carboplatin application .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "anemia"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 378,
    "text": "Four days after carboplatin treatment , tumors ( DS - sarcoma of the rat ) were implanted s . c . onto the hind food dorsum .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "carboplatin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "tumors"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "sarcoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 379,
    "text": "Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "carboplatin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 380,
    "text": "When tumors were treated with a single dose of cyclophosphamide ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the tumors was observed .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "tumors"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cyclophosphamide"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "tumors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 381,
    "text": "In the anemia group , the growth delay was significantly shorter compared with nonanemic controls ( 13 . 3 days versus 8 . 6 days ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 382,
    "text": "In the group where anemia was prevented by rHuEPO treatment , growth delay was comparable with that of nonanemic controls ( 13 . 3 days ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 383,
    "text": "These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "anemia"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "cytotoxicity"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "cyclophosphamide"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "tumors"
      ],
      [
        "T4",
        "Disease",
        18,
        19,
        "anemia"
      ],
      [
        "T5",
        "Chemical",
        37,
        38,
        "oxygen"
      ],
      [
        "T6",
        "Disease",
        40,
        41,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 384,
    "text": "Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "haemorrhagic myocarditis"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 385,
    "text": "Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Haemorrhagic myocarditis"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 386,
    "text": "Echocardiographic identification of the disorder can be made .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 387,
    "text": "We believe that the ultrasound features of this disorder have not been previously reported .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 388,
    "text": "Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 389,
    "text": "BACKGROUND : Atrial tachycardia - induced remodeling promotes the occurrence and maintenance of atrial fibrillation ( AF ) and decreases L - type Ca ( 2 + ) current .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Atrial tachycardia"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "atrial fibrillation"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "AF"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "Ca"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 390,
    "text": "There is also a clinical suggestion that acute L - type Ca ( 2 ) channel blockade can promote AF , consistent with an AF promoting effect of Ca ( 2 + ) channel inhibition .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "Ca"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "AF"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "AF"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "Ca"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 391,
    "text": "METHODS : To evaluate the potential mechanisms of AF promotion by Ca ( 2 + ) channel blockers , we administered verapamil to morphine - chloralose anesthetized dogs .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "AF"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "Ca"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "verapamil"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "morphine"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "chloralose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 392,
    "text": "Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Diltiazem"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "atropine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "nadolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 393,
    "text": "Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "AF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 394,
    "text": "RESULTS : Verapamil caused AF promotion in six dogs , increasing mean duration of AF induced by burst pacing , from 8 + / - 4 s ( mean + / - S . E . ) to 95 + / - 39 s ( P < 0 . 01 vs . control ) at a loading dose of 0 . 1 mg / kg and 228 + / - 101 s ( P < 0 . 0005 vs . control ) at a dose of 0 . 2 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Verapamil"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "AF"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "AF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 395,
    "text": "Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 396,
    "text": "In these experiments , verapamil shortened mean effective refractory period ( ERP ) from 122 + / - 5 to 114 + / - 4 ms ( P < 0 . 02 ) at a cycle length of 300 ms , decreased ERP heterogeneity ( from 15 + / - 1 to 10 + / - 1 % , P < 0 . 05 ) , heterogeneously accelerated atrial conduction and decreased the cycle length of AF ( 94 + / - 4 to 84 + / - 3 ms , P < 0 . 005 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "verapamil"
      ],
      [
        "T1",
        "Disease",
        76,
        77,
        "AF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 397,
    "text": "Diltiazem did not affect ERP , AF cycle length or AF duration , but produced conduction acceleration similar to that caused by verapamil ( n = 5 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Diltiazem"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "AF"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "AF"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 398,
    "text": "In the presence of autonomic blockade , verapamil failed to promote AF and increased , rather than decreasing , refractoriness .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "verapamil"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "AF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 399,
    "text": "Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "verapamil"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "diltiazem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 400,
    "text": "Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "verapamil"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "AF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 401,
    "text": "CONCLUSIONS : Verapamil promotes AF in normal dogs by promoting multiple circuit reentry , an effect dependent on intact autonomic tone and not shared by diltiazem .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Verapamil"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "AF"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "diltiazem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 402,
    "text": "Calcitonin gene - related peptide levels during nitric oxide - induced headache in patients with chronic tension - type headache .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        16,
        20,
        "tension - type headache"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 403,
    "text": "It has been proposed that nitric oxide ( NO ) induced headache in primary headaches may be associated with release of calcitonin gene - related peptide ( CGRP ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "primary headaches"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "NO"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 404,
    "text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate ( GTN ) in 16 patients with chronic tension - type headache and 16 healthy controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        21,
        "glyceryl trinitrate"
      ],
      [
        "T1",
        "Disease",
        29,
        33,
        "tension - type headache"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "headache"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "NO"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 405,
    "text": "The subjects were randomly allocated to receive 0 . 5 microg / kg / min GTN or placebo over 20 min on two headache - free days .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "GTN"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 406,
    "text": "Blood samples were collected at baseline , 10 , 20 and 60 min after start of infusion .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 407,
    "text": "Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "headache"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "GTN"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 408,
    "text": "There was no difference between the area under the CGRP curve ( AUCCGRP ) on GTN vs . placebo day in either patients ( P = 0 . 65 ) or controls ( P = 0 . 48 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 409,
    "text": "The AUCCGRP recorded on the GTN day did not differ between patients and controls ( P = 0 . 36 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 410,
    "text": "Both in patients and controls , CGRP levels changed significantly over time , on both the GTN and placebo days ( P < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 411,
    "text": "The present study indicates that NO - induced immediate headache is not associated with release of CGRP .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "NO"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 412,
    "text": "Fluconazole - induced torsade de pointes .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "torsade de pointes"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Fluconazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 413,
    "text": "OBJECTIVE : To present a case of fluconazole - associated torsade de pointes ( TDP ) and discuss fluconazole ' s role in causing TDP .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "torsade de pointes"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "fluconazole"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "TDP"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "fluconazole"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "TDP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 414,
    "text": "CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .",
    "labels": [
      [
        "T0",
        "Disease",
        38,
        41,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        44,
        47,
        "congestive heart failure"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "TDP"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "fluconazole"
      ],
      [
        "T4",
        "Disease",
        35,
        36,
        "TDP"
      ],
      [
        "T5",
        "Disease",
        42,
        43,
        "cardiomyopathy"
      ],
      [
        "T6",
        "Chemical",
        60,
        61,
        "fluconazole"
      ],
      [
        "T7",
        "Disease",
        62,
        63,
        "TDP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 415,
    "text": "The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "premature ventricular contractions"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "ventricular tachycardia"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "TDP"
      ],
      [
        "T3",
        "Chemical",
        4,
        5,
        "fluconazole"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "NSVT"
      ],
      [
        "T5",
        "Chemical",
        47,
        48,
        "fluconazole"
      ],
      [
        "T6",
        "Disease",
        52,
        53,
        "TDP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 416,
    "text": "The possible mechanism is depression of rapidly activating delayed rectifier potassium currents .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "depression"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 417,
    "text": "In our patient , there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "QT prolongation"
      ],
      [
        "T1",
        "Disease",
        23,
        26,
        "premature ventricular contractions"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "TDP"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "NSVT"
      ],
      [
        "T4",
        "Chemical",
        39,
        40,
        "fluconazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 418,
    "text": "CONCLUSIONS : Clinicians should be aware that fluconazole , even at low doses , may cause prolongation of the QT interval , leading to TDP .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        21,
        "prolongation of the QT interval"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "fluconazole"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "TDP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 419,
    "text": "Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "ventricular arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "fluconazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 420,
    "text": "Cutaneous leucocytoclastic vasculitis associated with oxacillin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Cutaneous leucocytoclastic vasculitis"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "oxacillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 421,
    "text": "A 67 - year - old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia , developed renal failure and diffuse , symmetric , palpable purpuric lesions on his feet .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "Staphylococcus aureus bacteremia"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "renal failure"
      ],
      [
        "T2",
        "Disease",
        30,
        32,
        "purpuric lesions"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "oxacillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 422,
    "text": "Necrotic blisters were noted on his fingers .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Necrotic blisters"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 423,
    "text": "Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "leucocytoclastic vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 424,
    "text": "Oxacillin was discontinued and patient was treated with corticosteroids .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Oxacillin"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "corticosteroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 425,
    "text": "The rash disappeared after three weeks and renal function returned to normal .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "rash"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 426,
    "text": "Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain , arthralgia , and renal involvement .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Leucocytoclastic vasculitis"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "abdominal pain"
      ],
      [
        "T2",
        "Disease",
        19,
        21,
        "renal involvement"
      ],
      [
        "T3",
        "Disease",
        5,
        6,
        "purpura"
      ],
      [
        "T4",
        "Disease",
        16,
        17,
        "arthralgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 427,
    "text": "Etiologic factors or associated disorders include infections , medications , collagen vascular disease and neoplasia .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "collagen vascular disease"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "infections"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "neoplasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 428,
    "text": "However , in half of the cases no etiologic factor is identified .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 429,
    "text": "Usually it is a self - limited disorder , but corticosteroid therapy may be needed in life - threatening cases since early treatment with corticosteroids in severe cases can prevent complications .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "corticosteroid"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "corticosteroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 430,
    "text": "Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "leucocytoclastic vasculitis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Oxacillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 431,
    "text": "The renal pathology in a case of lithium - induced diabetes insipidus .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "diabetes insipidus"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 432,
    "text": "A case of lithium - induced diabetes insipidus is reported .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "diabetes insipidus"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 433,
    "text": "At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 434,
    "text": "It is suggested that these changes represent a specific toxic effect of lithium , reported here for the first time in man .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 435,
    "text": "Cholestatic jaundice associated with the use of metformin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cholestatic jaundice"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 436,
    "text": "We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "cholestatic jaundice"
      ],
      [
        "T1",
        "Chemical",
        14,
        16,
        "metformin hydrochloride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 437,
    "text": "Ultrasound of the liver and abdominal CT were normal .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 438,
    "text": "An ERCP showed normal biliary anatomy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 439,
    "text": "A percutaneous liver biopsy was obtained showing marked cholestasis , with portal edema , ductular proliferation , and acute inflammation .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "cholestasis"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "edema"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 440,
    "text": "Metformin hydrochloride was discontinued , and the patient ' s jaundice resolved slowly over a period of several months .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Metformin hydrochloride"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "jaundice"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 441,
    "text": "Given the onset of his jaundice 2 wk after the initiation of metformin , we believe that this case represents an example of metformin - associated hepatotoxicity , the first such case reported .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "jaundice"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "metformin"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "metformin"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 442,
    "text": "Systemic toxicity and resuscitation in bupivacaine - , levobupivacaine - , or ropivacaine - infused rats .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "levobupivacaine"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "ropivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 443,
    "text": "We compared the systemic toxicity of bupivacaine , levobupivacaine , and ropivacaine in anesthetized rats .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "levobupivacaine"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "ropivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 444,
    "text": "We also compared the ability to resuscitate rats after lethal doses of these local anesthetics .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 445,
    "text": "Bupivacaine , levobupivacaine , or ropivacaine was infused at a rate of 2 mg .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "levobupivacaine"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "ropivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 446,
    "text": "kg ( - 1 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 447,
    "text": "min ( - 1 ) while electrocardiogram , electroencephalogram , and arterial pressure were continuously monitored .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 448,
    "text": "When asystole was recorded , drug infusion was stopped and a resuscitation sequence was begun .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "asystole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 449,
    "text": "Epinephrine 0 . 01 mg / kg was administered at 1 - min intervals while external cardiac compressions were applied .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 450,
    "text": "Resuscitation was considered successful when a systolic arterial pressure > or = 100 mm Hg was achieved within 5 min .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 451,
    "text": "The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "levobupivacaine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ropivacaine"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "seizures"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 452,
    "text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "levobupivacaine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "dysrhythmias"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "asystole"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "ropivacaine"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 453,
    "text": "The number of successful resuscitations did not differ among groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 454,
    "text": "However , a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "epinephrine"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "Ropivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 455,
    "text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "cardiac arrest"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "levobupivacaine"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "ropivacaine"
      ],
      [
        "T4",
        "Chemical",
        15,
        16,
        "bupivacaine"
      ],
      [
        "T5",
        "Chemical",
        24,
        25,
        "ropivacaine"
      ],
      [
        "T6",
        "Chemical",
        40,
        41,
        "bupivacaine"
      ],
      [
        "T7",
        "Chemical",
        42,
        43,
        "levobupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 456,
    "text": "Amphotericin B - induced seizures in a patient with AIDS .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Amphotericin B"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "seizures"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "AIDS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 457,
    "text": "OBJECTIVE : To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        19,
        "amphotericin B"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "seizure"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "AIDS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 458,
    "text": "CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "grand mal seizures"
      ],
      [
        "T1",
        "Chemical",
        22,
        24,
        "amphotericin B"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 459,
    "text": "The patients concurrent medications included didanosine , hydroxyzine , promethazine , hydrocortisone , and prochlorperazine .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "didanosine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "hydroxyzine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "promethazine"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "hydrocortisone"
      ],
      [
        "T4",
        "Chemical",
        14,
        15,
        "prochlorperazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 460,
    "text": "Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "amphotercin B"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "phenytoin"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "lorazepam"
      ],
      [
        "T3",
        "Disease",
        8,
        9,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 461,
    "text": "DISCUSSION : AIDS and cryptococcal meningitis , both of which the patient had , can potentially cause seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "cryptococcal meningitis"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "AIDS"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 462,
    "text": "The patient had a history of alcohol abuse ; alcohol intake as well as withdrawal can also cause seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "alcohol abuse"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "alcohol"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 463,
    "text": "Didanosine also has a potential for inducing seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Didanosine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 464,
    "text": "However , these other potential causes of seizure were ruled out .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 465,
    "text": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "amphotericin B"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "seizures"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "AIDS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 466,
    "text": "CONCLUSIONS : Amphotericin B seems to be the probable cause of the seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "Amphotericin B"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 467,
    "text": "To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "amphotericin B"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 468,
    "text": "Sirolimus and mycophenolate mofetil for calcineurin - free immunosuppression in renal transplant recipients .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "mycophenolate mofetil"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Sirolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 469,
    "text": "Calcineurin inhibitors , such as cyclosporine and tacrolimus , have been available for almost 20 years .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "cyclosporine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 470,
    "text": "Although these drugs are highly effective and represent the mainstay of transplant immunosuppression , they are associated with acute and chronic nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        22,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 471,
    "text": "Acute nephrotoxicity , which occurs in the early period after transplantation , leads to a higher rate of dialysis , and chronic nephrotoxicity may eventually result in graft loss .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "nephrotoxicity"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 472,
    "text": "Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 473,
    "text": "Two recently available immunosuppressive agents , mycophenolate mofetil and sirolimus ( rapamycin ) , have no nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "mycophenolate mofetil"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "sirolimus"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "rapamycin"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 474,
    "text": "The use of these drugs in combination with other agents has led to the development of new paradigms of immunosuppressive therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 475,
    "text": "This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 476,
    "text": "Tolerability of nimesulide and paracetamol in patients with NSAID - induced urticaria / angioedema .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "nimesulide"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "paracetamol"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "NSAID"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "urticaria"
      ],
      [
        "T4",
        "Disease",
        13,
        14,
        "angioedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 477,
    "text": "Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous , respiratory and anaphylactoid reactions induced by nonsteroidal anti - inflammatory drugs ( NSAIDs ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        25,
        "nonsteroidal anti - inflammatory drugs"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "nimesulide"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "paracetamol"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "NSAIDs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 478,
    "text": "In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced urticaria / angioedema .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "nimesulide"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "paracetamol"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "NSAID"
      ],
      [
        "T3",
        "Disease",
        30,
        31,
        "urticaria"
      ],
      [
        "T4",
        "Disease",
        32,
        33,
        "angioedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 479,
    "text": "Furthermore , we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "paracetamol"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "nimesulide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 480,
    "text": "A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID - induced urticaria / angioedema .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "nimesulide"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "paracetamol"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "NSAID"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "urticaria"
      ],
      [
        "T4",
        "Disease",
        27,
        28,
        "angioedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 481,
    "text": "A total of 75 / 829 ( 9 . 4 % ) patients experienced reactions to nimesulide or paracetamol .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "nimesulide"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 482,
    "text": "Of the 715 patients tested with nimesulide 62 ( 8 . 6 % ) showed a positive test , while of 114 subjects submitted to the challenge with paracetamol , 13 ( 9 . 6 % ) did not tolerate this drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "nimesulide"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 483,
    "text": "Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of NSAID - induced urticaria / angioedema or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "urticaria"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "NSAID"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "urticaria"
      ],
      [
        "T3",
        "Disease",
        30,
        31,
        "angioedema"
      ],
      [
        "T4",
        "Disease",
        32,
        33,
        "angioedema"
      ],
      [
        "T5",
        "Disease",
        39,
        40,
        "urticaria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 484,
    "text": "Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria / angioedema caused by NSAIDs .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "nimesulide"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "paracetamol"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "urticaria"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "angioedema"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "NSAIDs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 485,
    "text": "However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and , above all , by a history of NSAID - induced angioedema .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "urticaria"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "NSAID"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "angioedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 486,
    "text": "Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24 - hour heart rate response in patients on treatment for glaucoma .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "timolol"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 487,
    "text": "PURPOSE : Topical beta - blocker treatment is routine therapy in the management of patients with glaucoma .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 488,
    "text": "Therapy results in systemic absorption , however , the degree of reduction of resting and peak heart rate has not been quantified .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 489,
    "text": "DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "timolol"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "timolol"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "timolol"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "timolol"
      ],
      [
        "T4",
        "Disease",
        54,
        55,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 490,
    "text": "METHODS : Forty - three Caucasian patients with primary open - angle glaucoma or ocular hypertension with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "open - angle glaucoma"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "ocular hypertension"
      ],
      [
        "T2",
        "Chemical",
        62,
        63,
        "timolol"
      ],
      [
        "T3",
        "Chemical",
        74,
        75,
        "timolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 491,
    "text": "On the 13th day of each period , heart rate was recorded continuously during a typical , ambulant 24 - hour period .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 492,
    "text": "RESULTS : Both timolol solution and timolol gellan reduced the mean 24 - hour heart rate compared with placebo ( P < or = . 001 ) , and this reduction was most pronounced during the daytime ( - 7 . 5 % change in mean heart rate , - 5 . 7 beats / min ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "timolol"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "timolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 493,
    "text": "Timolol gellan showed a numerically but not significantly smaller reduction in 24 - hour heart rate , compared with timolol solution .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Timolol"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "timolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 494,
    "text": "During the night , the mean 12 - hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution ; the difference between solution and gellan treatments was statistically significant ( P = . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "timolol"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "timolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 495,
    "text": "CONCLUSIONS : Both timolol solution and timolol gellan decrease the mean 24 - hour heart rate compared with placebo .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "timolol"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "timolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 496,
    "text": "This response was most pronounced during the active daytime period .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 497,
    "text": "These data quantify the modest bradycardia associated with ophthalmic beta - blocker therapy in a typical patient population on therapy for glaucoma .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "bradycardia"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 498,
    "text": "Although exercise performance was not assessed in this trial , reductions of this magnitude should not have substantial clinical consequences .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 499,
    "text": "Management strategies for ribavirin - induced hemolytic anemia in the treatment of hepatitis C : clinical and economic implications .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "hepatitis C"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 500,
    "text": "OBJECTIVES : Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with interferon - alpha monotherapy in the treatment of chronic hepatitis C ( CHC ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        29,
        "interferon - alpha"
      ],
      [
        "T1",
        "Disease",
        34,
        37,
        "chronic hepatitis C"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "ribavirin"
      ],
      [
        "T3",
        "Disease",
        38,
        39,
        "CHC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 501,
    "text": "Combination therapy is associated with a clinically important adverse effect : ribavirin - induced hemolytic anemia ( RIHA ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "ribavirin"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "RIHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 502,
    "text": "The objective of this study was to evaluate the direct health - care costs and management of RIHA during treatment of CHC in a clinical trial setting .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "RIHA"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "CHC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 503,
    "text": "METHODS : A systematic literature review was conducted to synthesize information on the incidence and management of RIHA .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "RIHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 504,
    "text": "Decision - analytic techniques were used to estimate the cost of treating RIHA .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "RIHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 505,
    "text": "Uncertainty was evaluated using sensitivity analyses .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 506,
    "text": "RESULTS : RIHA , defined as a reduction in hemoglobin to less than 100 g / L , occurs in approximately 7 % to 9 % of patients treated with combination therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "RIHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 507,
    "text": "The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "RIHA"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 508,
    "text": "We estimated the direct cost of treating clinically significant RIHA to be 170 per patient receiving combination therapy per 48 - week treatment course ( range 68 - 692 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "RIHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 509,
    "text": "The results of the one - way sensitivity analyses ranged from 57 to 317 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 510,
    "text": "In comparison , the cost of 48 weeks of combination therapy is 16 , 459 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 511,
    "text": "CONCLUSIONS : The direct cost of treating clinically significant RIHA is 1 % ( 170 / 16 , 459 ) of drug treatment costs .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "RIHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 512,
    "text": "Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real - world population .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "ribavirin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "RIHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 513,
    "text": "Despite these uncertainties , this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "RIHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 514,
    "text": "Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 515,
    "text": "BACKGROUND : Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        20,
        "acute and chronic pain"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "adenosine"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "adenosine"
      ],
      [
        "T3",
        "Disease",
        42,
        43,
        "hypersensitivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 516,
    "text": "The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical hypersensitivity .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "adenosine"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "capsaicin"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "hypersensitivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 517,
    "text": "METHODS : Following Food and Drug Administration and institutional review board approval and written informed consent , 65 volunteers were studied in two trials : an open - label , dose - escalating trial with intrathecal adenosine doses of 0 . 25 - 2 . 0 mg and a double - blind , placebo - controlled trial of adenosine , 2 mg .",
    "labels": [
      [
        "T0",
        "Chemical",
        36,
        37,
        "adenosine"
      ],
      [
        "T1",
        "Chemical",
        58,
        59,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 518,
    "text": "Cerebrospinal fluid was obtained for pharmacokinetic analysis , and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "mechanical hyperalgesia"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "pain"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "allodynia"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "capsaicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 519,
    "text": "RESULTS : Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "mechanical hyperalgesia"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Adenosine"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "pain"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "allodynia"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "capsaicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 520,
    "text": "In contrast , residence time of adenosine in cerebrospinal fluid was short ( < 4 h ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 521,
    "text": "CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of hypersensitivity , presumed to reflect central sensitization in humans after peripheral capsaicin injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "adenosine"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hypersensitivity"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "capsaicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 522,
    "text": "The long - lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "neuropathic pain"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 523,
    "text": "Delayed - onset heparin - induced thrombocytopenia .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 524,
    "text": "BACKGROUND : Heparin - induced thrombocytopenia presents 5 to 12 days after heparin exposure , with or without arterial or venous thromboemboli .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        22,
        "arterial or venous thromboemboli"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Heparin"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "thrombocytopenia"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 525,
    "text": "Delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 526,
    "text": "OBJECTIVE : To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin - induced thrombocytopenia are delayed .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 527,
    "text": "DESIGN : Retrospective case series .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 528,
    "text": "SETTING : Three large urban hospitals ( with active cardiovascular surgery programs ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 529,
    "text": "PATIENTS : 14 patients seen over a 3 - year period in whom heparin - induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "thromboembolic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 530,
    "text": "MEASUREMENTS : Platelet counts , onset of objectively determined thromboembolism , results of heparin - induced platelet factor 4 antibody tests , and outcomes .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "thromboembolism"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 531,
    "text": "RESULTS : Patients went home after hospitalizations that had included heparin exposure - - in most cases , with no thrombocytopenia recognized - - only to return to the hospital ( median , day 14 ) with thromboembolic complications .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        37,
        38,
        "thromboembolic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 532,
    "text": "Thromboemboli were venous ( 12 patients , 7 with pulmonary emboli ) or arterial ( 4 patients ) or both .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "pulmonary emboli"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Thromboemboli"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 533,
    "text": "Platelet counts were mildly decreased in all but 2 patients on second presentation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 534,
    "text": "On readmission , 11 patients received therapeutic heparin , which worsened the patients ' clinical condition and , in all 11 cases , decreased the platelet count ( mean at readmission , 143 x 10 ( 9 ) cells / L ; mean nadir after heparin re - exposure , 39 x 10 ( 9 ) cells / L ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "heparin"
      ],
      [
        "T1",
        "Chemical",
        45,
        46,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 535,
    "text": "Results of serologic tests for heparin - induced antibodies were positive in all patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 536,
    "text": "Subsequent treatments included alternative anticoagulants ( 11 patients ) , thrombolytic drugs ( 3 patients ) , inferior vena cava filters ( 3 patients ) and , eventually , warfarin ( 11 patients ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        29,
        30,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 537,
    "text": "Three patients died .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 538,
    "text": "CONCLUSIONS : Delayed - onset heparin - induced thrombocytopenia is increasingly being recognized .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 539,
    "text": "To avoid disastrous outcomes , physicians must consider heparin - induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism ; therapy with alternative anticoagulants , not heparin , should be initiated .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "thromboembolism"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 540,
    "text": "Treatment of risperidone - induced hyperprolactinemia with a dopamine agonist in children .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "risperidone"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hyperprolactinemia"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 541,
    "text": "BACKGROUND : Risperidone , a potent antagonist of both serotonergic ( 5HT2A ) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Risperidone"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 542,
    "text": "Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "delayed puberty"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "prolactinomas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 543,
    "text": "These possibilities stress the importance of developing a safe and effective approach to drug - induced hyperprolactinemia in youth .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 544,
    "text": "We report the successful treatment of risperidone - induced hyperprolactinemia with cabergoline in youth .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "risperidone"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hyperprolactinemia"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "cabergoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 545,
    "text": "METHODS : We undertook a retrospective case review of four children with risperidone - induced hyperprolactinemia treated with cabergoline .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "risperidone"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hyperprolactinemia"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "cabergoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 546,
    "text": "RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) bipolar disorder or psychoses , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "Mental Disorders"
      ],
      [
        "T1",
        "Disease",
        23,
        25,
        "bipolar disorder"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "psychoses"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "risperidone"
      ],
      [
        "T4",
        "Chemical",
        59,
        60,
        "cabergoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 547,
    "text": "When serum prolactin levels normalized in all four subjects ( mean 11 . 2 + / - 10 . 9 ng / mL ) , the cabergoline dose was reduced to 1 mg / week in three of four subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "cabergoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 548,
    "text": "The mean duration of therapy with cabergoline was 523 . 5 + / - 129 . 7 days , and the mean duration of therapy with risperidone was 788 . 5 + / - 162 . 5 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "cabergoline"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 549,
    "text": "Cabergoline was well tolerated without adverse effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cabergoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 550,
    "text": "CONCLUSIONS : Cabergoline may be useful for the treatment of risperidone - induced hyperprolactinemia in youth ; however , further research is needed .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Cabergoline"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "risperidone"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 551,
    "text": "Acute cholestatic hepatitis after exposure to isoflurane .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "cholestatic hepatitis"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 552,
    "text": "OBJECTIVE : To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "cholestatic hepatitis"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 553,
    "text": "CASE SUMMARY : A 70 - year - old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "cholestatic hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 554,
    "text": "There was no evidence for viral , autoimmune , or metabolic causes of hepatitis .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 555,
    "text": "No other medications were involved except for dipyrone for analgesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "dipyrone"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "analgesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 556,
    "text": "The alanine aminotransferase was elevated to a peak concentration of 1533 U / L and the serum bilirubin reached a peak of 17 . 0 mg / dL .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "alanine"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "bilirubin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 557,
    "text": "There was slow improvement over 4 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 558,
    "text": "Accidental reexposure by the patient to dipyrone was uneventful .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "dipyrone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 559,
    "text": "DISCUSSION : The clinical and histologic picture of this case resembles halothane hepatitis , which has a significant mortality rate .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "halothane hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 560,
    "text": "CONCLUSIONS : Isoflurane , a common anesthetic agent , can cause severe cholestatic hepatitis .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "cholestatic hepatitis"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 561,
    "text": "Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Torsade de pointes"
      ],
      [
        "T1",
        "Disease",
        13,
        17,
        "left bundle branch block"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "metoclopramide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 562,
    "text": "There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "long QT syndrome"
      ],
      [
        "T1",
        "Disease",
        14,
        17,
        "torsade de pointes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 563,
    "text": "However , the torsadogenic potential of metoclopramide , a commonly used antiemetic and prokinetic drug , has not been reported in the literature , despite its chemical similarity to procainamide .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "metoclopramide"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "procainamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 564,
    "text": "We report on a 92 - year - old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        17,
        "left bundle branch block"
      ],
      [
        "T1",
        "Disease",
        19,
        22,
        "torsade de pointes"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "metoclopramide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 565,
    "text": "This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "torsade de pointes"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "cisapride"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "erythromycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 566,
    "text": "These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 567,
    "text": "This is the first documentation that metoclopramide provokes torsade de pointes clinically .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "torsade de pointes"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "metoclopramide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 568,
    "text": "Metoclopramide should be used cautiously in patients with a risk of torsade de pointes .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "torsade de pointes"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Metoclopramide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 569,
    "text": "Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 570,
    "text": "Dopamine ( DA ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of epileptic seizures arising in the limbic system .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "epileptic seizures"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Dopamine"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 571,
    "text": "Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Excitotoxicity"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 572,
    "text": "In this respect , little is known about the role of DA receptors in the occurrence of epilepsy - induced neuronal cell death .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "DA"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 573,
    "text": "Here we analyze the occurrence of seizures and neurotoxicity in D2R - / - mice treated with the cholinergic agonist pilocarpine .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "seizures"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "neurotoxicity"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 574,
    "text": "We compared these results with those previously obtained with kainic acid ( KA ) , a potent glutamate agonist .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "kainic acid"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "KA"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 575,
    "text": "Importantly , D2R - / - mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "seizures"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 576,
    "text": "However , pilocarpine - induced seizures result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "pilocarpine"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "KA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 577,
    "text": "Thus , the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "seizures"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "glutamate"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "acetylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 578,
    "text": "Moreover , the dopaminergic control of epilepsy - induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "epilepsy"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "neurodegeneration"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 579,
    "text": "Steroid structure and pharmacological properties determine the anti - amnesic effects of pregnenolone sulphate in the passive avoidance task in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "pregnenolone sulphate"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Steroid"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "amnesic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 580,
    "text": "Pregnenolone sulphate ( PREGS ) has generated interest as one of the most potent memory - enhancing neurosteroids to be examined in rodent learning studies , with particular importance in the ageing process .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Pregnenolone sulphate"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "PREGS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 581,
    "text": "The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 582,
    "text": "This hypothesis stems from findings that PREGS is a potent positive modulator of N - methyl - d - aspartate receptors ( NMDARs ) and a negative modulator of gamma - aminobutyric acid ( A ) receptors ( GABA ( A ) Rs ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        20,
        "N - methyl - d - aspartate"
      ],
      [
        "T1",
        "Chemical",
        29,
        33,
        "gamma - aminobutyric acid"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "PREGS"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 583,
    "text": "Moreover , PREGS is able to reverse the amnesic - like effects of NMDAR and GABA ( A ) R ligands .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "PREGS"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "amnesic"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 584,
    "text": "To investigate this hypothesis , the present study in rats examined the memory - altering abilities of structural analogs of PREGS , which differ in their modulation of NMDAR and / or GABA ( A ) R function .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "PREGS"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 585,
    "text": "The analogs tested were : 11 - ketopregnenolone sulphate ( an agent that is inactive at GABA ( A ) Rs and NMDARs ) , epipregnanolone ( [ 3beta - hydroxy - 5beta - pregnan - 20 - one ] sulphate , an inhibitor of both GABA ( A ) Rs and NMDARs ) , and a newly synthesized ( - ) PREGS enantiomer ( which is identical to PREGS in effects on GABA ( A ) Rs and NMDARs ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        9,
        "11 - ketopregnenolone sulphate"
      ],
      [
        "T1",
        "Chemical",
        25,
        41,
        "epipregnanolone ( [ 3beta - hydroxy - 5beta - pregnan - 20 - one ] sulphate"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "GABA"
      ],
      [
        "T3",
        "Chemical",
        46,
        47,
        "GABA"
      ],
      [
        "T4",
        "Chemical",
        62,
        63,
        "PREGS"
      ],
      [
        "T5",
        "Chemical",
        69,
        70,
        "PREGS"
      ],
      [
        "T6",
        "Chemical",
        73,
        74,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 586,
    "text": "The memory - enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine - induced amnesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "PREGS"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "scopolamine"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 587,
    "text": "Both PREGS and its ( - ) enantiomer blocked the effects of scopolamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "PREGS"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 588,
    "text": "The results show that , unlike PREGS , 11 - ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine , suggesting that altering the modulation of NMDA receptors diminishes the memory - enhancing effects of PREGS .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        12,
        "11 - ketopregnenolone sulphate"
      ],
      [
        "T1",
        "Chemical",
        13,
        15,
        "epipregnanolone sulphate"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "PREGS"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "scopolamine"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "NMDA"
      ],
      [
        "T5",
        "Chemical",
        38,
        39,
        "PREGS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 589,
    "text": "Moreover , enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine - induced amnesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "PREGS"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "scopolamine"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 590,
    "text": "These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 591,
    "text": "Activation of poly ( ADP - ribose ) polymerase contributes to development of doxorubicin - induced heart failure .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        8,
        "poly ( ADP - ribose )"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "heart failure"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 592,
    "text": "Activation of the nuclear enzyme poly ( ADP - ribose ) polymerase ( PARP ) by oxidant - mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        11,
        "poly ( ADP - ribose )"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 593,
    "text": "Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin ( DOX ) , a widely used antitumor anthracycline antibiotic .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "doxorubicin"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "DOX"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "anthracycline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 594,
    "text": "Thus , we hypothesized that the activation of PARP may contribute to the DOX - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "DOX"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 595,
    "text": "Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        36,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "PJ34"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 596,
    "text": "PARP - 1 + / + and PARP - 1 - / - mice received a single injection of DOX ( 25 mg / kg i . p ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 597,
    "text": "Five days after DOX administration , left ventricular performance was significantly depressed in PARP - 1 + / + mice , but only to a smaller extent in PARP - 1 - / - ones .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 598,
    "text": "Similar experiments were conducted in BALB / c mice treated with PJ34 or vehicle .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "PJ34"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 599,
    "text": "Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "PJ34"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 600,
    "text": "In addition PJ34 significantly reduced the DOX - induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "PJ34"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "DOX"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "lactate"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "creatine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 601,
    "text": "Thus , PARP activation contributes to the cardiotoxicity of DOX .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 602,
    "text": "PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "cardiac complications"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 603,
    "text": "Spironolactone : is it a novel drug for the prevention of amphotericin B - related hypokalemia in cancer patients ?",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "amphotericin B"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Spironolactone"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "hypokalemia"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 604,
    "text": "OBJECTIVE : Nephrotoxicity is the major adverse effect of amphotericin B ( AmB ) , often limiting administration of full dosage .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "amphotericin B"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "Nephrotoxicity"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "AmB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 605,
    "text": "Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "potassium"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "AmB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 606,
    "text": "Potassium depletion also potentiates the tubular toxicity of AmB .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Potassium"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "AmB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 607,
    "text": "This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "spironolactone"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "potassium"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "hypokalemia"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "neutropenic"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "AmB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 608,
    "text": "METHODS : In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "hematological disorders"
      ],
      [
        "T1",
        "Disease",
        34,
        36,
        "fungal infection"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "AmB"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "AmB"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "spironolactone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 609,
    "text": "RESULTS : Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone ( P = 0 . 0027 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "AmB"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "spironolactone"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "potassium"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "AmB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 610,
    "text": "Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range ( P = 0 . 022 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "AmB"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "spironolactone"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "potassium"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 611,
    "text": "Moreover , urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone ( P = 0 . 040 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "potassium"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "AmB"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "spironolactone"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "AmB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 612,
    "text": "CONCLUSION : This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "spironolactone"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "potassium"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hypokalemia"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "potassium"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "neutropenic"
      ],
      [
        "T5",
        "Chemical",
        23,
        24,
        "AmB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 613,
    "text": "Erectile dysfunction occurs following substantia nigra lesions in the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Erectile dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 614,
    "text": "Erectile function was assessed 6 weeks following uni - and bilateral injections of 6 - hydroxydopamine in the substantia nigra nucleus of the brain .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        16,
        "6 - hydroxydopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 615,
    "text": "Behavioral apomorphine - induced penile erections were reduced ( 5 / 8 ) and increased ( 3 / 8 ) in uni - and bilateral lesioned animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 616,
    "text": "Intracavernous pressures , following electrical stimulation of the cavernous nerve , decreased in lesioned animals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 617,
    "text": "Lesions of the substantia nigra were confirmed by histology .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 618,
    "text": "Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 619,
    "text": "Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "erectile dysfunction"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "erectile dysfunction"
      ],
      [
        "T2",
        "Disease",
        24,
        28,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 620,
    "text": "Nicotine potentiation of morphine - induced catalepsy in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Nicotine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "morphine"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 621,
    "text": "In the present study , effects of nicotine on catalepsy induced by morphine in mice have been investigated .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "nicotine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 622,
    "text": "Morphine but not nicotine induced a dose - dependent catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Morphine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "nicotine"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 623,
    "text": "The response of morphine was potentiated by nicotine .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "nicotine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 624,
    "text": "Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "atropine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "naloxone"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "mecamylamine"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "hexamethonium"
      ],
      [
        "T4",
        "Disease",
        14,
        15,
        "catalepsy"
      ],
      [
        "T5",
        "Chemical",
        20,
        21,
        "morphine"
      ],
      [
        "T6",
        "Chemical",
        22,
        23,
        "nicotine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 625,
    "text": "Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased catalepsy induced by morphine plus nicotine .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "atropine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "hexamethonium"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "naloxone"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "catalepsy"
      ],
      [
        "T4",
        "Chemical",
        14,
        15,
        "morphine"
      ],
      [
        "T5",
        "Chemical",
        16,
        17,
        "nicotine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 626,
    "text": "Intraperitoneal administration of atropine , but not intraperitoneal or intracerebroventricular injection of hexamethonium , decreased the effect of a single dose of morphine .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "atropine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "hexamethonium"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 627,
    "text": "It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "morphine"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "morphine"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "nicotine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 628,
    "text": "Force overflow and levodopa - induced dyskinesias in Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 629,
    "text": "We assessed force coordination of the hand in Parkinson ' s disease and its relationship to motor complications of levodopa therapy , particularly to levodopa - induced dyskinesias ( LID ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "levodopa"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "levodopa"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "dyskinesias"
      ],
      [
        "T4",
        "Disease",
        29,
        30,
        "LID"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 630,
    "text": "We studied two groups of Parkinson ' s disease patients with ( Parkinson ' s disease + LID , n = 23 ) and without levodopa - induced dyskinesias ( Parkinson ' s disease - LID , n = 10 ) , and age - matched healthy controls .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        12,
        16,
        "Parkinson ' s disease"
      ],
      [
        "T2",
        "Disease",
        30,
        34,
        "Parkinson ' s disease"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "LID"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "levodopa"
      ],
      [
        "T5",
        "Disease",
        28,
        29,
        "dyskinesias"
      ],
      [
        "T6",
        "Disease",
        35,
        36,
        "LID"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 631,
    "text": "The motor score of the Unified Parkinson ' s Disease Rating Scale , a dyskinesia score and force in a grip - lift paradigm were assessed ON and OFF levodopa .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        10,
        "Parkinson ' s Disease"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "dyskinesia"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 632,
    "text": "A pathological increase of forces was seen in ON - state in Parkinson ' s disease + LID only .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "LID"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 633,
    "text": "In Parkinson ' s disease + LID , the force involved in pressing down the object before lifting was significantly increased by levodopa ( by 61 % , P < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        5,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "LID"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 634,
    "text": "An overshooting of peak grip force by 51 % ( P < 0 . 05 ) and of static grip force by 45 % ( P < 0 . 01 ) was observed in the ON - compared with the OFF - drug condition .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 635,
    "text": "In contrast , no excessive force was found in Parkinson ' s disease - LID .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "LID"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 636,
    "text": "Peak grip force in ON - state was 140 % ( P < 0 . 05 ) higher in Parkinson ' s disease + LID than in Parkinson ' s disease - LID , while static grip force was increased by 138 % ( P < 0 . 01 ) between groups .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        23,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        27,
        31,
        "Parkinson ' s disease"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "LID"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "LID"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 637,
    "text": "Severity of peak - dose dyskinesias was strongly correlated with grip force in ON - state ( r = 0 . 79 with peak force , P < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 638,
    "text": "No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 639,
    "text": "Force excess was only observed in patients with LID and motor fluctuations .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "LID"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 640,
    "text": "A close relationship was seen between the overshooting of forces and dyskinesias in the ON - drug condition .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 641,
    "text": "We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "LID"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 642,
    "text": "Behavioral effects of MK - 801 on reserpine - treated mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 643,
    "text": "The effects of dizocilpine ( MK - 801 ) , a noncompetitive N - methyl - D - aspartate ( NMDA ) receptor antagonist , were studied on dopamine - related behaviors induced by reserpine treatments .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        12,
        19,
        "N - methyl - D - aspartate"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "dizocilpine"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "NMDA"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "dopamine"
      ],
      [
        "T5",
        "Chemical",
        34,
        35,
        "reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 644,
    "text": "This study focuses on behavioral syndromes that may used as models for Parkinson ' s disease , or tardive dyskinesia , and its response after glutamatergic blockage .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "tardive dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 645,
    "text": "Reserpine ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in orofacial dyskinesia , tongue protrusion and vacuous chewing in mice , which are signs indicative of tardive dyskinesia .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "orofacial dyskinesia"
      ],
      [
        "T1",
        "Disease",
        36,
        38,
        "tardive dyskinesia"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 646,
    "text": "Reserpine also produced tremor and catalepsy , which are signs suggestive of Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Reserpine"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "tremor"
      ],
      [
        "T3",
        "Disease",
        5,
        6,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 647,
    "text": "MK - 801 ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and catalepsy induced by reserpine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "MK - 801"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 648,
    "text": "However , MK - 801 injection produced a significant increase of tremor in reserpine - treated mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "MK - 801"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "tremor"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 649,
    "text": "Reserpine ( 1 mg / kg ) , administered 90 min before the test and followed by apomophine injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce oral dyskinesia in mice .",
    "labels": [
      [
        "T0",
        "Disease",
        36,
        38,
        "oral dyskinesia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Reserpine"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "apomophine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 650,
    "text": "On the other hand , reserpine induced increases in tremor and catalepsy compared to control mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "reserpine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "tremor"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 651,
    "text": "MK - 801 ( 0 . 1 mg / kg ) administration attenuated the catalepsy and tremor induced by reserpine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "MK - 801"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "catalepsy"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "tremor"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 652,
    "text": "Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and catalepsy , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .",
    "labels": [
      [
        "T0",
        "Chemical",
        35,
        38,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "reserpine"
      ],
      [
        "T2",
        "Disease",
        30,
        31,
        "tremor"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "catalepsy"
      ],
      [
        "T4",
        "Chemical",
        56,
        57,
        "reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 653,
    "text": "These results show that reserpine produces different and abnormal movements , which are related to dose and schedule employed and can be considered as parkinsonian - like and tardive dsykinesia signs .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "abnormal movements"
      ],
      [
        "T1",
        "Disease",
        28,
        30,
        "tardive dsykinesia"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "reserpine"
      ],
      [
        "T3",
        "Disease",
        24,
        25,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 654,
    "text": "The glutamatergic blockage produced by NMDA can restore these signs , such as vacuous chewing movements , tongue protrusions , catalepsy and tremor according to the employed model .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "NMDA"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "catalepsy"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "tremor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 655,
    "text": "Risperidone - associated , benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "visual disturbances"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Risperidone"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "schizophrenic"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "LSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 656,
    "text": "Two schizophrenic patients , who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics , were successfully treated with risperidone .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "schizophrenic"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "LSD"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "EPS"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 657,
    "text": "They both reported short episodes of transient visual disturbances , which appeared immediately after starting treatment with risperidone .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "visual disturbances"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 658,
    "text": "This imagery resembled visual disturbances previously experienced as \" flashbacks \" related to prior LSD consumption .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "visual disturbances"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "LSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 659,
    "text": "Risperidone administration was continued and the visual disturbances gradually wore off .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "visual disturbances"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 660,
    "text": "During a six - month follow - up period , there was no recurrence of visual disturbances .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "visual disturbances"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 661,
    "text": "This phenomenon may be interpreted as a benign , short - term and self - limiting side effect which does not contraindicate the use of risperidone or interfere with treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        26,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 662,
    "text": "Conclusions based on two case reports should be taken with appropriate caution .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 663,
    "text": "Topiramate - induced nephrolithiasis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Topiramate"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "nephrolithiasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 664,
    "text": "Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "refractory seizures"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Topiramate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 665,
    "text": "Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "metabolic acidosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 666,
    "text": "In addition , a distal tubular acidification defect may result , thus impairing the normal compensatory drop in urine pH .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 667,
    "text": "These factors can lead to the development of calcium phosphate nephrolithiasis .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "calcium phosphate"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "nephrolithiasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 668,
    "text": "We report the first two cases of topiramate - induced nephrolithiasis in the urologic literature .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "topiramate"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "nephrolithiasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 669,
    "text": "Ketamine in war / tropical surgery ( a final tribute to the racemic mixture ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 670,
    "text": "A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients , aged from 6 weeks to 70 years , undergoing limb and abdominal surgery including caesarian sections and interventions in neonates .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 671,
    "text": "Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air / oxygen only .",
    "labels": [
      [
        "T0",
        "Chemical",
        28,
        29,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 672,
    "text": "After premedication with diazepam , glycopyrrolate and local anaesthesia , and induction with standard doses of ketamine , a maintenance dose of 10 - 20 microg / kg / min of ketamine proved safe and effective .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "diazepam"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "glycopyrrolate"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "ketamine"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 673,
    "text": "Emphasis was placed on bedside clinical monitoring , relying heavily on the heart rate .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 674,
    "text": "Diazepam , unless contraindicated or risky , remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Diazepam"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "ketamine"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "hallucinations"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 675,
    "text": "Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "analgesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 676,
    "text": "An antisialogue was usually unnecessary in operations lasting up to 2 h , glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects , especially in a hot climate .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "glycopyrrolate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 677,
    "text": "Experience in war / tropical settings suggests this technique could be useful in civilian contexts such as outdoor life - saving emergency surgery or in mass casualties where , e . g . amputation and rapid extrication were required .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 678,
    "text": "Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "adenovirus disease"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 679,
    "text": "BACKGROUND : Adenovirus is an important cause of morbidity and mortality in the immunocompromised host .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 680,
    "text": "The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children , where case fatality rates as high as 50 % to 80 % have been reported .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "adenovirus disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 681,
    "text": "There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease , nor are there any prospective randomized , controlled trials of potentially useful anti - adenovirus therapies .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "adenovirus disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 682,
    "text": "Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "adenovirus disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 683,
    "text": "Experience is greatest with intravenous ribavirin and cidofovir .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "ribavirin"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cidofovir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 684,
    "text": "Ribavirin , a guanosine analogue , has broad antiviral activity against both RNA and DNA viruses , including documented activity against adenovirus in vitro .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ribavirin"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "guanosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 685,
    "text": "Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection , and orally in combination with interferon to treat hepatitis C .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        14,
        "respiratory syncytial virus infection"
      ],
      [
        "T1",
        "Disease",
        23,
        25,
        "hepatitis C"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 686,
    "text": "Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        13,
        "infection with hemorrhagic fever viruses"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 687,
    "text": "The most common adverse effect of intravenous ribavirin is reversible mild anemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "ribavirin"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 688,
    "text": "The use of cidofovir in severe adenovirus infection has been limited by adverse effects , the most significant of which is nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "adenovirus infection"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "cidofovir"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 689,
    "text": "OBJECTIVE : We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "adenovirus disease"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 690,
    "text": "DESIGN / METHODS : We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "adenovirus disease"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 691,
    "text": "Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "hemorrhagic cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 692,
    "text": "The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "cidofovir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 693,
    "text": "An additional 3 children developed adenovirus pneumonia ; 2 were neonates , 1 of whom had partial DiGeorge syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "adenovirus pneumonia"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "DiGeorge syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 694,
    "text": "The remaining infant had recently undergone a cardiac transplant .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 695,
    "text": "Intravenous ribavirin was administered on a compassionate - use protocol .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 696,
    "text": "RESULTS : Complete clinical recovery followed later by viral clearance was observed in 2 children : the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "hemorrhagic cystitis"
      ],
      [
        "T1",
        "Disease",
        29,
        31,
        "adenovirus pneumonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 697,
    "text": "The remaining 3 children died of adenovirus disease .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "adenovirus disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 698,
    "text": "Intravenous ribavirin therapy was well tolerated .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 699,
    "text": "Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "progressive renal failure"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "cidofovir"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 700,
    "text": "DISCUSSION : Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease , namely solid - organ and bone marrow transplant recipients , neonates , and children with immunodeficiency .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "adenovirus disease"
      ],
      [
        "T1",
        "Disease",
        37,
        38,
        "immunodeficiency"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 701,
    "text": "Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the infection .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "adenovirus disease"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "ribavirin"
      ],
      [
        "T2",
        "Disease",
        36,
        37,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 702,
    "text": "Early identification , eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "adenovirus disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 703,
    "text": "CONCLUSIONS : Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "adenovirus disease"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 704,
    "text": "The availability of newer rapid diagnostic techniques , such as polymerase chain reaction , may make earlier , more effective treatment of adenovirus infection possible .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "adenovirus infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 705,
    "text": "Given the seriousness and increasing prevalence of adenovirus disease in certain hosts , especially children , a large , multicenter clinical trial of potentially useful anti - adenoviral therapies , such as intravenous ribavirin , is clearly required to demonstrate the most effective and least toxic therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "adenovirus disease"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 706,
    "text": "Delayed asystolic cardiac arrest after diltiazem overdose ; resuscitation with high dose intravenous calcium .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "cardiac arrest"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "asystolic"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "diltiazem"
      ],
      [
        "T3",
        "Disease",
        6,
        7,
        "overdose"
      ],
      [
        "T4",
        "Chemical",
        13,
        14,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 707,
    "text": "A 51 year old man took a mixed overdose including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , isosorbide nitrate , and alcohol .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "overdose"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "diltiazem"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "paracetamol"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "aspirin"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "isosorbide"
      ],
      [
        "T5",
        "Chemical",
        26,
        27,
        "nitrate"
      ],
      [
        "T6",
        "Chemical",
        29,
        30,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 708,
    "text": "He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 709,
    "text": "Eighteen hours after the overdose he had two generalised tonic - clonic seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "tonic - clonic seizures"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 710,
    "text": "The patient remained unresponsive with junctional bradycardia , unrecordable blood pressure , and then became asystolic .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "bradycardia"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "asystolic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 711,
    "text": "He was resuscitated with high dose ( 13 . 5 g ) intravenous calcium and adrenaline ( epinephrine ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "calcium"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "adrenaline"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 712,
    "text": "He required inotropic support and temporary pacing over the next 48 hours .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 713,
    "text": "This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose , particularly with the onset of asystole .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "calcium"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "diltiazem"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "overdose"
      ],
      [
        "T3",
        "Disease",
        24,
        25,
        "asystole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 714,
    "text": "It should be considered early in cases of cardiac arrest after diltiazem overdose .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "cardiac arrest"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "diltiazem"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 715,
    "text": "The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 716,
    "text": "Low - molecular - weight heparin for the treatment of patients with mechanical heart valves .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        6,
        "Low - molecular - weight heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 717,
    "text": "BACKGROUND : The interruption of oral anticoagulant ( OAC ) administration is sometimes indicated in patients with mechanical heart valves , mainly before noncardiac surgery , non - surgical interventions , and pregnancy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 718,
    "text": "Unfractionated heparin ( UH ) is currently the substitute for selected patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Unfractionated heparin"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "UH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 719,
    "text": "Low - molecular - weight heparin ( LMWH ) offers theoretical advantages over UH , but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        6,
        "Low - molecular - weight heparin"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "LMWH"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "UH"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "UH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 720,
    "text": "HYPOTHESIS : The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "LMWH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 721,
    "text": "METHODS : For this paper , the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "LMWH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 722,
    "text": "RESULTS : There were eight series and six case reports .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 723,
    "text": "None of the studies was randomized , and only one was prospective .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 724,
    "text": "Data to establish the thromboembolic risk were incomplete .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "thromboembolic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 725,
    "text": "After excluding case reports , the following groups were constructed : ( a ) short - term administration , after valve insertion ( n = 212 ) ; ( b ) short - term , perioperative ( noncardiac ) / periprocedural ( n = 114 ) ; ( c ) long - term , due to intolerance to OAC ( n = 16 ) ; ( d ) long - term , in pregnancy ( n = 10 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 726,
    "text": "The incidence rate of thromboembolism was 0 . 9 % for all the studies and 0 . 5 , 0 , 20 , and 0 % in groups a , b , c , and d , respectively ; for hemorrhage , the overall rate was 3 . 4 % ( 3 . 8 , 2 . 6 , 10 , and 0 % for the respective groups ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "thromboembolism"
      ],
      [
        "T1",
        "Disease",
        40,
        41,
        "hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 727,
    "text": "CONCLUSIONS : In patients with mechanical heart valves , short - term LMWH therapy compares favorably with UH .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "LMWH"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "UH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 728,
    "text": "Data on mid - and long - term LMWH administration in these patients are sparse .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "LMWH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 729,
    "text": "Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "LMWH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 730,
    "text": "Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cardiac arrest"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "cardiac arrest"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "metoclopramide"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "metoclopramide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 731,
    "text": "We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "metoclopramide"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "asystole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 732,
    "text": "The patient received metoclopramide 10 mg i . v . five times during 48 h .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "metoclopramide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 733,
    "text": "After interviewing the attending nurses and reviewing the written documentation , it is clear that every administration of metoclopramide was immediately ( within s ) followed by asystole .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "metoclopramide"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "asystole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 734,
    "text": "The asystole lasted 15 - 30 s on four occasions , on one occasion it lasted 2 min .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "asystole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 735,
    "text": "The patient received atropine 0 . 5 - 1 mg and chest compressions , before sinus rhythm again took over .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "atropine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 736,
    "text": "We interpret this as episodes of cardiac arrest caused by metoclopramide .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "cardiac arrest"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "metoclopramide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 737,
    "text": "The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 738,
    "text": "Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) in arteritis induced in rats by fenoldopam and theophylline , vasodilators .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "tumor"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "arteritis"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "fenoldopam"
      ],
      [
        "T4",
        "Chemical",
        38,
        39,
        "theophylline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 739,
    "text": "Arteritis induced in rats by vasodilators , fenoldopam and theophylline , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        22,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Arteritis"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "fenoldopam"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "theophylline"
      ],
      [
        "T4",
        "Disease",
        35,
        36,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 740,
    "text": "Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "fenoldopam"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "theophylline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 741,
    "text": "Irrespective of theophylline administration , iNOS antigens were remarkably abundant in ED - 1 - positive cells on day 5 and 8 post - fenoldopam - infusion ( DPI ) ; bFGF antigens were remarkably abundant in ED - 1 - positive cells on 1 and 3 DPI ; TGF - beta1 antigens were observed in ED - 1 - positive cells on and after 5 DPI .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "theophylline"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "fenoldopam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 742,
    "text": "These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen , and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        32,
        "arteritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 743,
    "text": "On the other hand , TGF - beta1 was not considered to have a suppressive effect on iNOS expression in these models .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 744,
    "text": "The striatum as a target for anti - rigor effects of an antagonist of mGluR1 , but not an agonist of group II metabotropic glutamate receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 745,
    "text": "The aim of the present study was to find out whether the metabotropic receptor 1 ( mGluR1 ) and group II mGluRs , localized in the striatum , are involved in antiparkinsonian - like effects in rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 746,
    "text": "Haloperidol ( 1 mg / kg ip ) induced parkinsonian - like muscle rigidity , measured as an increased resistance of a rat ' s hind foot to passive flexion and extension at the ankle joint .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "muscle rigidity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Haloperidol"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 747,
    "text": "( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid ( AIDA ; 0 . 5 - 15 microg / 0 . 5 microl ) , a potent and selective mGluR1 antagonist , or ( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate ( 2R , 4R - APDC ; 7 . 5 - 15 microg / 0 . 5 microl ) , a selective group II agonist , was injected bilaterally into the striatum of haloperidol - treated animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        14,
        "( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid"
      ],
      [
        "T1",
        "Chemical",
        38,
        53,
        "( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate"
      ],
      [
        "T2",
        "Chemical",
        54,
        59,
        "2R , 4R - APDC"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "AIDA"
      ],
      [
        "T4",
        "Chemical",
        86,
        87,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 748,
    "text": "AIDA in doses of 7 . 5 - 15 microg / 0 . 5 microl diminished the haloperidol - induced muscle rigidity .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "muscle rigidity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "AIDA"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 749,
    "text": "In contrast , 2R , 4R - APDC injections were ineffective .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        8,
        "2R , 4R - APDC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 750,
    "text": "The present results may suggest that the blockade of striatal mGluR1 , but not the stimulation of group II mGluRs , may ameliorate parkinsonian muscle rigidity .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "muscle rigidity"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 751,
    "text": "A phase II study of thalidomide in advanced metastatic renal cell carcinoma .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "renal cell carcinoma"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 752,
    "text": "OBJECTIVES : To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "renal cell cancer"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 753,
    "text": "PATIENTS AND METHODS : 29 patients were enrolled on a study of thalidomide using an intra - patient dose escalation schedule .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 754,
    "text": "Patients began thalidomide at 400 mg / d and escalated as tolerated to 1200 mg / d by day 54 .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 755,
    "text": "Fifty - nine per cent of patients had had previous therapy with IL - 2 and 52 % were performance status 2 or 3 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 756,
    "text": "Systemic plasma VEGF165 levels were measured by dual monoclonal ELISA in 8 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 757,
    "text": "RESULTS : 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases ( 4 % ) , one minor response , and 2 patients stable for over 6 months .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "metastases"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 758,
    "text": "Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg / day dose level .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Somnolence"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "constipation"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "toxicities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 759,
    "text": "Systemic plasma VEGF165 levels did not change with therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 760,
    "text": "CONCLUSION : These results are consistent with a low level of activity of thalidomide in renal cell carcinoma .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "renal cell carcinoma"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 761,
    "text": "Administration of doses over 800 mg / day was difficult to achieve in this patient population , however lower doses were practical .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 762,
    "text": "The dose - response relationship , if any , of thalidomide for renal cell carcinoma is unclear .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "renal cell carcinoma"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 763,
    "text": "Can lidocaine reduce succinylcholine induced postoperative myalgia ?",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "postoperative myalgia"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 764,
    "text": "This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine - induced myalgia in patients undergoing general anesthesia for gynecological surgery .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "lidocaine"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "succinylcholine"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 765,
    "text": "One hundred and thirty - five patients were assigned to one of three groups in a prospective , double blind , randomized manner .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 766,
    "text": "Group PS , the control group , received normal saline and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group LS , lidocaine 1 . 5 mg x kg ( - 1 ) and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group PR , normal saline and rocuronium 0 . 6 mg x kg ( - 1 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "succinylcholine"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "succinylcholine"
      ],
      [
        "T3",
        "Chemical",
        56,
        57,
        "rocuronium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 767,
    "text": "Morphine 0 . 1 mg x kg ( - 1 ) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor , ECG and pulse oximetry .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 768,
    "text": "Anesthesia was induced with 5 mg . kg ( - 1 ) thiopental iv . followed by succinylcholine ( Group PS , LS ) or rocuronium ( Group PR ) for tracheal intubation .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "thiopental"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "succinylcholine"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "rocuronium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 769,
    "text": "Following administration of these agents , the presence , and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "fasciculation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 770,
    "text": "The blood pressure and heart rate of each patient were monitored on nine occasions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 771,
    "text": "Twenty - four hours later , any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 772,
    "text": "The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS ( p < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "muscle fasciculation"
      ],
      [
        "T1",
        "Disease",
        23,
        25,
        "muscle fasciculation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 773,
    "text": "At 24 h , the incidence of myalgia was higher in Group PS than in Group LS and PR ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 774,
    "text": "A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "muscle fasciculation"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 775,
    "text": "The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 776,
    "text": "In conclusion , where succinylcholine is used , lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "postoperative myalgia"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "succinylcholine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 777,
    "text": "Reduced sodium channel density , altered voltage dependence of inactivation , and increased susceptibility to seizures in mice lacking sodium channel beta 2 - subunits .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "sodium"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 778,
    "text": "Sodium channel beta - subunits modulate channel gating , assembly , and cell surface expression in heterologous cell systems .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 779,
    "text": "We generated beta2 ( - / - ) mice to investigate the role of beta2 in control of sodium channel density , localization , and function in neurons in vivo .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 780,
    "text": "Measurements of [ ( 3 ) H ] saxitoxin ( STX ) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2 ( - / - ) neurons .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "saxitoxin"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "STX"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 781,
    "text": "The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 782,
    "text": "The integral of the compound action potential in optic nerve was significantly reduced , and the threshold for action potential generation was increased , indicating a reduction in the level of functional plasma membrane sodium channels .",
    "labels": [
      [
        "T0",
        "Chemical",
        34,
        35,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 783,
    "text": "In contrast , the conduction velocity , the number and size of axons in the optic nerve , and the specific localization of Na ( v ) 1 . 6 channels in the nodes of Ranvier were unchanged .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "Na"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 784,
    "text": "beta2 ( - / - ) mice displayed increased susceptibility to seizures , as indicated by reduced latency and threshold for pilocarpine - induced seizures , but seemed normal in other neurological tests .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "seizures"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "pilocarpine"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 785,
    "text": "Our observations show that beta2 - subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 786,
    "text": "Acute liver failure with concurrent bupropion and carbimazole therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute liver failure"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "bupropion"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "carbimazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 787,
    "text": "OBJECTIVE : To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "liver failure"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "bupropion"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "carbimazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 788,
    "text": "CASE SUMMARY : A 41 - year - old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "hyperthyroidism"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "carbimazole"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 789,
    "text": "He received a 10 - day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "bupropion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 790,
    "text": "He developed acute liver failure with rapid deterioration of renal function .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "acute liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 791,
    "text": "Liver biopsy showed evidence of nonspecific drug - induced acute liver injury .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        12,
        "drug - induced acute liver injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 792,
    "text": "His condition was further complicated by sepsis and coagulopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "sepsis"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "coagulopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 793,
    "text": "Death resulted 19 days after the onset of symptoms .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 794,
    "text": "The likelihood that bupropion induced hepatotoxicity in our patient was possible , based on the Naranjo probability scale .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "bupropion"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 795,
    "text": "DISCUSSION : Although there is increasing evidence of hepatotoxicity induced by bupropion , this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        28,
        "acute liver failure"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hepatotoxicity"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "bupropion"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "bupropion"
      ],
      [
        "T4",
        "Chemical",
        38,
        39,
        "carbimazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 796,
    "text": "CONCLUSIONS : Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "acute liver insult"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "bupropion"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "hepatotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 797,
    "text": "Pyeloureteral filling defects associated with systemic anticoagulation : a case report .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 798,
    "text": "The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "pyeloureteritis cystica"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "infection"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 799,
    "text": "A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 800,
    "text": "There is no evidence of antecedent or concurrent infection in this patient .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 801,
    "text": "The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "thrombophlebitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 802,
    "text": "The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "pyeloureteritis cystica"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "submucosal hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 803,
    "text": "Nephrotoxic effects in high - risk patients undergoing angiography .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Nephrotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 804,
    "text": "BACKGROUND : The use of iodinated contrast medium can result in nephropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 805,
    "text": "Whether iso - osmolar contrast medium is less nephrotoxic than low - osmolar contrast medium in high - risk patients is uncertain .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "nephrotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 806,
    "text": "METHODS : We conducted a randomized , double - blind , prospective , multicenter study comparing the nephrotoxic effects of an iso - osmolar , dimeric , nonionic contrast medium , iodixanol , with those of a low - osmolar , nonionic , monomeric contrast medium , iohexol .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "nephrotoxic"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "iodixanol"
      ],
      [
        "T2",
        "Chemical",
        47,
        48,
        "iohexol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 807,
    "text": "The study involved 129 patients with diabetes with serum creatinine concentrations of 1 . 5 to 3 . 5 mg per deciliter who underwent coronary or aortofemoral angiography .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "diabetes"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 808,
    "text": "The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 809,
    "text": "Other end points were an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , an increase of 1 . 0 mg per deciliter or more , and a change in the creatinine concentration from day 0 to day 7 .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "creatinine"
      ],
      [
        "T1",
        "Chemical",
        37,
        38,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 810,
    "text": "RESULTS : The creatinine concentration increased significantly less in patients who received iodixanol .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "creatinine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "iodixanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 811,
    "text": "From day 0 to day 3 , the mean peak increase in creatinine was 0 . 13 mg per deciliter in the iodixanol group and 0 . 55 mg per deciliter in the iohexol group ( P = 0 . 001 ; the increase with iodixanol minus the increase with iohexol , - 0 . 42 mg per deciliter [ 95 percent confidence interval , - 0 . 73 to - 0 . 22 ] ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "creatinine"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "iodixanol"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "iohexol"
      ],
      [
        "T3",
        "Chemical",
        45,
        46,
        "iodixanol"
      ],
      [
        "T4",
        "Chemical",
        50,
        51,
        "iohexol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 812,
    "text": "Two of the 64 patients in the iodixanol group ( 3 percent ) had an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , as compared with 17 of the 65 patients in the iohexol group ( 26 percent ) ( P = 0 . 002 ; odds ratio for such an increase in the iodixanol group , 0 . 09 [ 95 percent confidence interval , 0 . 02 to 0 . 41 ] ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "iodixanol"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "creatinine"
      ],
      [
        "T2",
        "Chemical",
        40,
        41,
        "iohexol"
      ],
      [
        "T3",
        "Chemical",
        61,
        62,
        "iodixanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 813,
    "text": "No patient receiving iodixanol had an increase of 1 . 0 mg per deciliter or more , but 10 patients in the iohexol group ( 15 percent ) did .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "iodixanol"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "iohexol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 814,
    "text": "The mean change in the creatinine concentration from day 0 to day 7 was 0 . 07 mg per deciliter in the iodixanol group and 0 . 24 mg per deciliter in the iohexol group ( P = 0 . 003 ; value in the iodixanol group minus the value in the iohexol group , - 0 . 17 mg per deciliter [ 95 percent confidence interval , - 0 . 34 to - 0 . 07 ] ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "creatinine"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "iodixanol"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "iohexol"
      ],
      [
        "T3",
        "Chemical",
        45,
        46,
        "iodixanol"
      ],
      [
        "T4",
        "Chemical",
        52,
        53,
        "iohexol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 815,
    "text": "CONCLUSIONS : Nephropathy induced by contrast medium may be less likely to develop in high - risk patients when iodixanol is used rather than a low - osmolar , nonionic contrast medium .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Nephropathy"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "iodixanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 816,
    "text": "Protective effect of edaravone against streptomycin - induced vestibulotoxicity in the guinea pig .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "edaravone"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "streptomycin"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "vestibulotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 817,
    "text": "This study investigated alleviation of streptomycin - induced vestibulotoxicity by edaravone in guinea pigs .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "streptomycin"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "vestibulotoxicity"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "edaravone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 818,
    "text": "Edaravone , a free radical scavenger , has potent free radical quenching action and is used in clinical practice to treat cerebral infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "cerebral infarction"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Edaravone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 819,
    "text": "Streptomycin was administered to the inner ear by osmotic pump for 24 h , and edaravone ( n = 8 ) or saline ( n = 6 ) was intraperitoneally injected once a day for 7 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Streptomycin"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "edaravone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 820,
    "text": "We observed horizontal vestibulo - ocular reflex as a marker of postoperative vestibular function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 821,
    "text": "Animals injected with saline showed statistically smaller gains than those injected with edaravone .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "edaravone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 822,
    "text": "These results suggest that edaravone suppresses streptomycin - induced vestibulotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "edaravone"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "streptomycin"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "vestibulotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 823,
    "text": "Levodopa - induced oromandibular dystonia in progressive supranuclear palsy .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "progressive supranuclear palsy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Levodopa"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "dystonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 824,
    "text": "Levodopa - induced dyskinesias have been reported in Parkinson ' s disease and multiple system atrophy .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "multiple system atrophy"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Levodopa"
      ],
      [
        "T3",
        "Disease",
        3,
        4,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 825,
    "text": "Cranial dystonias are rare in patients with progressive supranuclear palsy ( PSP ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "progressive supranuclear palsy"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "dystonias"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "PSP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 826,
    "text": "In this report we describe an unusual case of reversible levodopa - induced Oromandibular dystonia ( OMD ) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP , and discuss the possible underlying pathophysiology .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "Oromandibular dystonia"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "OMD"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "PSP"
      ],
      [
        "T4",
        "Disease",
        36,
        37,
        "PSP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 827,
    "text": "Case report : Dexatrim ( Phenylpropanolamine ) as a cause of myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "Dexatrim"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "Phenylpropanolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 828,
    "text": "Phenylpropanolamine ( PPA ) is a sympathetic amine used in over - the - counter cold remedies and weight - control preparations worldwide .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Phenylpropanolamine"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "PPA"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "amine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 829,
    "text": "Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "hemorrhagic strokes"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 830,
    "text": "Several reports have linked the abuse of PPA with myocardial injury , especially when overdose is involved .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "myocardial injury"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "PPA"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 831,
    "text": "We report here the first case of Dexatrim ( PPA ) - induced myocardial injury in a young woman who was using it at recommended doses for weight control .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "myocardial injury"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "Dexatrim"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "PPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 832,
    "text": "In addition , we review the 7 other cases of PPA related myocardial injury that have been reported so far .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "myocardial injury"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "PPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 833,
    "text": "Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA , even at doses generally considered to be safe .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "PPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 834,
    "text": "Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "systemic lupus erythematosus"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "creatine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 835,
    "text": "We report the clinical and bioptic findings for a 57 - year - old woman with severe chloroquine - induced myopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "chloroquine"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 836,
    "text": "Since 1989 , she had been suffering from systemic lupus erythematosus ( SLE ) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "systemic lupus erythematosus"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "renal involvement"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "SLE"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "azathioprine"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 837,
    "text": "Additional therapy with chloroquine ( CQ ) was started because of arthralgia .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "chloroquine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "CQ"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "arthralgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 838,
    "text": "At the same time , slightly increased creatine kinase ( CK ) levels were noted .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "creatine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 839,
    "text": "Myositis was suspected , and the patient was treated with steroids .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Myositis"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 840,
    "text": "The CK increase persisted , however , and she developed progressive muscular weakness and muscular atrophy .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "muscular weakness"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "muscular atrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 841,
    "text": "Routine controls revealed markedly elevated CK levels of 1 , 700 U / l .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 842,
    "text": "The neurological and electrophysiological findings were not typical of myositis .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "myositis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 843,
    "text": "Thus , muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "polymyositis"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 844,
    "text": "As it revealed chloroquine - induced myopathy , medication was stopped .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "chloroquine"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 845,
    "text": "Discriminating between primary SLE - induced affection of the musculoskeletal system and drug - induced side effects is important for appropriate treatment of SLE patients .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        11,
        "affection of the musculoskeletal system"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "SLE"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "SLE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 846,
    "text": "Seizure associated with sleep deprivation and sustained - release bupropion .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "sleep deprivation"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Seizure"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "bupropion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 847,
    "text": "This case report describes a generalized seizure associated with sustained - release bupropion use and sleep deprivation .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "sleep deprivation"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "seizure"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "bupropion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 848,
    "text": "The subject , a 31 - year - old female smoker , was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained - release bupropion as an active control .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        31,
        "bupropion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 849,
    "text": "After 5 weeks of bupropion use , the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "bupropion"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 850,
    "text": "The patient had no other risk factors for seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 851,
    "text": "We suggest that sleep deprivation may add to the risk of bupropion - associated seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "sleep deprivation"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "bupropion"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 852,
    "text": "Postoperative myalgia after succinylcholine : no evidence for an inflammatory origin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Postoperative myalgia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 853,
    "text": "A common side effect associated with succinylcholine is postoperative myalgia .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "postoperative myalgia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 854,
    "text": "The pathogenesis of this myalgia is still unclear ; inflammation has been suggested but without convincing evidence .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "myalgia"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 855,
    "text": "We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 856,
    "text": "The incidence and severity of succinylcholine - associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine ( n = 32 for each ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "succinylcholine"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "myalgia"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "dexamethasone"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 857,
    "text": "Incidence and severity of myalgia did not differ significantly between the two groups : 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group , and severe myalgia was reported by five patients and three patients , respectively ( not significant ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "myalgia"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "dexamethasone"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "myalgia"
      ],
      [
        "T3",
        "Disease",
        34,
        35,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 858,
    "text": "At 48 h after surgery , 12 patients in both groups still suffered from myalgia ( not significant ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 859,
    "text": "In addition , interleukin - 6 ( IL - 6 ) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 860,
    "text": "We found an increase of IL - 6 for only three patients , but only one patient reported myalgia ; no relationship between myalgia and the increase of IL - 6 was found .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "myalgia"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 861,
    "text": "In conclusion , there is no evidence for an inflammatory origin of succinylcholine - associated myalgia .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "succinylcholine"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 862,
    "text": "IMPLICATIONS : Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine - induced postoperative myalgia .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "postoperative myalgia"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "dexamethasone"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "succinylcholine"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 863,
    "text": "Furthermore , there was no significant relationship between postoperative myalgia and time course of interleukin - 6 concentrations , a marker of inflammation .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "postoperative myalgia"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 864,
    "text": "Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "postoperative myalgia"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "dexamethasone"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 865,
    "text": "Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "lindane"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "lindane"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 866,
    "text": "Oral administration of lindane ( 2 . 5 , 5 , 10 and 15 mg / kg , body weight ) for 5 days was found to produce a dose - dependent increase in the activity of P450 dependent 7 - ethoxyresorufin - O - deethylase ( EROD ) , 7 - pentoxyresorufin - O - dealkylase ( PROD ) and N - nitrosodimethylamine demethylase ( NDMA - d ) in rat brain and liver .",
    "labels": [
      [
        "T0",
        "Chemical",
        61,
        64,
        "N - nitrosodimethylamine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "lindane"
      ],
      [
        "T2",
        "Chemical",
        66,
        67,
        "NDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 867,
    "text": "A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose ( 2 . 5 mg / kg ) of lindane was increased from 5 days to 15 or 21 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        31,
        "lindane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 868,
    "text": "As observed with different doses , the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 869,
    "text": "Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1 / 1A2 , 2B1 / 2B2 and 2E1 isoenzymes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 870,
    "text": "In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD , EROD and NDMA - d are due to the increase in the levels of P450 2B1 / 2B2 , 1A1 / 1A2 and 2E1 isoenzymes , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        29,
        30,
        "NDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 871,
    "text": "Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "3 - methylcholanthrene"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "MC"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "lindane"
      ],
      [
        "T3",
        "Disease",
        35,
        36,
        "convulsions"
      ],
      [
        "T4",
        "Chemical",
        39,
        40,
        "phenobarbital"
      ],
      [
        "T5",
        "Chemical",
        52,
        53,
        "ethanol"
      ],
      [
        "T6",
        "Chemical",
        67,
        68,
        "lindane"
      ],
      [
        "T7",
        "Disease",
        69,
        70,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 872,
    "text": "Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "cobalt chloride"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "lindane"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "convulsions"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "lindane"
      ],
      [
        "T4",
        "Chemical",
        27,
        28,
        "lindane"
      ],
      [
        "T5",
        "Chemical",
        37,
        38,
        "ethanol"
      ],
      [
        "T6",
        "Disease",
        46,
        47,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 873,
    "text": "Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "venous thromboembolism"
      ],
      [
        "T1",
        "Chemical",
        11,
        13,
        "cyproterone acetate"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "ethinylestradiol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 874,
    "text": "OBJECTIVE : To achieve absolute risk estimates of venous thromboembolism ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "venous thromboembolism"
      ],
      [
        "T1",
        "Chemical",
        16,
        18,
        "cyproterone acetate"
      ],
      [
        "T2",
        "Chemical",
        30,
        33,
        "combined oral contraceptives"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "VTE"
      ],
      [
        "T4",
        "Chemical",
        19,
        20,
        "ethinylestradiol"
      ],
      [
        "T5",
        "Chemical",
        21,
        22,
        "CPA"
      ],
      [
        "T6",
        "Chemical",
        23,
        24,
        "EE"
      ],
      [
        "T7",
        "Chemical",
        34,
        35,
        "COCs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 875,
    "text": "METHODS : From the Danish National Register of Patients ( NRP ) , 1996 to 1998 , the records of 1 . 1 million Danish women , ages 15 to 44 years , were searched for evidence of VTE .",
    "labels": [
      [
        "T0",
        "Disease",
        38,
        39,
        "VTE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 876,
    "text": "COC use was ascertained through mailed questionnaires .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "COC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 877,
    "text": "Sales statistics of COCs and CPA / EE were provided through Danish Drug Statistics .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "COCs"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "CPA"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "EE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 878,
    "text": "RESULTS : During the time frame of the study , 330 women were found to have had VTE while on COCs .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "VTE"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "COCs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 879,
    "text": "Of these women , 67 were on levonorgestrel - containing COCs .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "levonorgestrel"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "COCs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 880,
    "text": "Eleven were on CPA / EE .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "CPA"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "EE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 881,
    "text": "The corresponding absolute risk of VTE was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "VTE"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "COCs"
      ],
      [
        "T2",
        "Chemical",
        54,
        55,
        "levonorgestrel"
      ],
      [
        "T3",
        "Chemical",
        57,
        58,
        "COCs"
      ],
      [
        "T4",
        "Chemical",
        83,
        84,
        "CPA"
      ],
      [
        "T5",
        "Chemical",
        85,
        86,
        "EE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 882,
    "text": "CONCLUSION : Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA / EE .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "VTE"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "COCs"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "CPA"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "EE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 883,
    "text": "Comparison of developmental toxicology of aspirin ( acetylsalicylic acid ) in rats using selected dosing paradigms .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "acetylsalicylic acid"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 884,
    "text": "BACKGROUND : Analysis of the literature for nonsteroidal anti - inflammatory drugs ( NSAIDs ) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "developmental anomalies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 885,
    "text": "Aspirin ( acetylsalicylic acid [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces developmental anomalies when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ . Teratology 4 : 15 - 24 , 1971 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "acetylsalicylic acid"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "developmental anomalies"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Aspirin"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "ASA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 886,
    "text": "There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17 .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ASA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 887,
    "text": "Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when ASA is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used .",
    "labels": [
      [
        "T0",
        "Disease",
        55,
        57,
        "gastrointestinal toxicity"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "ASA"
      ],
      [
        "T2",
        "Disease",
        63,
        64,
        "malformations"
      ],
      [
        "T3",
        "Chemical",
        65,
        66,
        "ASA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 888,
    "text": "METHODS : ASA was administered as a single dose on GD 9 ( 0 , 250 , 500 , or 625 mg / kg ) , 10 ( 0 , 500 , 625 , or 750 mg / kg ) , or 11 ( 0 , 500 , 750 , or 1000 mg / kg ) and from GD 6 to GD 17 ( 0 , 50 , 125 , or 250 mg / kg a day ) in the multiple dose study to SD rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "ASA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 889,
    "text": "Animals were killed on GD 21 , and fetuses were examined viscerally .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 890,
    "text": "RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though ASA induces several other low - incidence malformations .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "ventricular septal defects"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "midline defects"
      ],
      [
        "T2",
        "Disease",
        24,
        26,
        "diaphragmatic hernia"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "VSDs"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "MDs"
      ],
      [
        "T5",
        "Disease",
        27,
        28,
        "DH"
      ],
      [
        "T6",
        "Disease",
        30,
        31,
        "MDs"
      ],
      [
        "T7",
        "Disease",
        33,
        34,
        "VSDs"
      ],
      [
        "T8",
        "Disease",
        54,
        55,
        "malformations"
      ],
      [
        "T9",
        "Chemical",
        58,
        59,
        "ASA"
      ],
      [
        "T10",
        "Disease",
        65,
        66,
        "malformations"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 891,
    "text": "In single dose studies , DH , MD , and VSD were induced on GDs 9 and 10 .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "DH"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "MD"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "VSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 892,
    "text": "VSD also was noted following treatment on GD 11 .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "VSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 893,
    "text": "In contrast , DH and MD were noted in the multiple dose study design only in the high - dose group , and VSD was noted across all dose groups .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "DH"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "MD"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "VSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 894,
    "text": "CONCLUSIONS : High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "developmental anomalies"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "VSD"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "hydrocephalus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 895,
    "text": "Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis ( GDs 6 to 17 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "malformations"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ASA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 896,
    "text": "It was also evident that , by titrating the dose to achieve a maximum tolerated dose , malformations that normally occur at low incidence , as reported from previous single dose studies , could also be induced with ASA given at multiple doses .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "malformations"
      ],
      [
        "T1",
        "Chemical",
        38,
        39,
        "ASA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 897,
    "text": "Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids : report of a double - blind multicenter study .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "benzodiazepine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "flumazenil"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 898,
    "text": "The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "Flumazenil"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "Diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 899,
    "text": "The efficacy and safety of a new benzodiazepine antagonist , flumazenil , were assessed in a double - blind multicenter study .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "benzodiazepine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 900,
    "text": "Flumazenil ( mean dose , 0 . 76 mg ) or placebo ( mean dose , 8 . 9 ml ) was administered intravenously to 130 and 67 patients , respectively , who had been given diazepam in conjunction with an opioid ( fentanyl , meperidine , or morphine ) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Flumazenil"
      ],
      [
        "T1",
        "Chemical",
        36,
        37,
        "diazepam"
      ],
      [
        "T2",
        "Chemical",
        43,
        44,
        "fentanyl"
      ],
      [
        "T3",
        "Chemical",
        45,
        46,
        "meperidine"
      ],
      [
        "T4",
        "Chemical",
        48,
        49,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 901,
    "text": "The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 902,
    "text": "After 5 minutes , 80 / 115 ( 70 % ) flumazenil - treated patients , compared with 21 / 63 ( 33 % ) placebo - treated patients , were completely awake and alert , as indicated by a score of 5 on the Observer ' s Assessment of Alertness / Sedation Scale .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 903,
    "text": "Ninety - five percent of patients in each group who attained a score of 5 at the 5 - minute assessment showed no loss of alertness throughout the 180 - minute assessment period .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 904,
    "text": "Flumazenil - treated patients also performed significantly better on the Finger - to - Nose Test and the recall of pictures shown at the 5 - minute assessment .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 905,
    "text": "Flumazenil was well tolerated , with no serious adverse effects reported .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 906,
    "text": "Thirty - nine ( 30 % ) of flumazenil - treated patients , compared with 17 ( 25 % ) of placebo - treated patients had one or more drug - related adverse experiences .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 907,
    "text": "The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection - site pain in the placebo group .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "nausea"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "vomiting"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "flumazenil"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "nausea"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 908,
    "text": "Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Flumazenil"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 909,
    "text": "Methylphenidate - induced obsessive - compulsive symptoms in an elderly man .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "obsessive - compulsive symptoms"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Methylphenidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 910,
    "text": "An 82 - year - old man with treatment - resistant depression and early Alzheimer ' s disease was started on methylphenidate .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "treatment - resistant depression"
      ],
      [
        "T1",
        "Disease",
        14,
        18,
        "Alzheimer ' s disease"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "methylphenidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 911,
    "text": "Significant obsessive - compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        5,
        "obsessive - compulsive behavior"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "methylphenidate"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "fluvoxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 912,
    "text": "The patient had no prior psychiatric history , but he had a sister with obsessive - compulsive disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        18,
        "obsessive - compulsive disorder"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "psychiatric"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 913,
    "text": "It appears that methylphenidate precipitated the patient ' s pathological behavior .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "methylphenidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 914,
    "text": "Ciprofloxacin - induced acute interstitial nephritis and autoimmune hemolytic anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "interstitial nephritis"
      ],
      [
        "T1",
        "Disease",
        7,
        10,
        "autoimmune hemolytic anemia"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Ciprofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 915,
    "text": "Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "interstitial nephritis"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "hemolytic anemia"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Ciprofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 916,
    "text": "The combination of both side effects is extremely rare .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 917,
    "text": "In this report , we describe a case of ciprofloxacin - induced interstitial nephritis and autoimmune hemolytic anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "interstitial nephritis"
      ],
      [
        "T1",
        "Disease",
        15,
        18,
        "autoimmune hemolytic anemia"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "ciprofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 918,
    "text": "Hemolytic anemia improved after stopping the drug and initiation of steroid therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 919,
    "text": "Unfortunately , acute interstitial nephritis was irreversible and the patient developed end - stage renal disease .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "interstitial nephritis"
      ],
      [
        "T1",
        "Disease",
        11,
        16,
        "end - stage renal disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 920,
    "text": "Potential deleterious effect of furosemide in radiocontrast nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "furosemide"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 921,
    "text": "The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "furosemide"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 922,
    "text": "18 patients , referred to a radiocontrast study , considered at risk because of preexisting renal insufficiency , were enrolled in a prospective , randomized , controlled trial , performed at the secondary care center of a 1 , 100 - bed private university hospital .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "renal insufficiency"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 923,
    "text": "In addition to fluids , the treatment group received furosemide ( mean dose 110 mg ) intravenously 30 min prior to the injection of contrast material .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "furosemide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 924,
    "text": "The control group received fluids ( mean 3 liters ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 925,
    "text": "Radiological studies were mostly angiographies performed with both ionic and non - ionic contrast material , at an average dose of 245 ml .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 926,
    "text": "Renal function significantly deteriorated in the group pretreated with furosemide ( p < 0 . 005 by ANOVA ) , with a rise in serum creatinine from 145 + / - 13 to 182 + / - 16 mumol / l at 24 h , while no change occurred in the control group ( from 141 + / - 6 to 142 + / - 7 mumol / l ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Renal function significantly deteriorated"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "furosemide"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 927,
    "text": "Renal failure was associated with weight loss in the furosemide - treated group .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Renal failure"
      ],
      [
        "T1",
        "Disease",
        5,
        7,
        "weight loss"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "furosemide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 928,
    "text": "Furosemide may be deleterious in the prevention of radiocontrast nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Furosemide"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 929,
    "text": "Progestational agents and blood coagulation .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "blood coagulation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 930,
    "text": "VII .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 931,
    "text": "Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors : summary report of a ten - year study .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "oral contraceptive"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "blood coagulation"
      ],
      [
        "T2",
        "Disease",
        0,
        1,
        "Thromboembolic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 932,
    "text": "During a ten - year period , 348 women were studied for a total of 5 , 877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        27,
        "oral contraceptives"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 933,
    "text": "Significant increases in certain factors of the blood coagulation and fibrinolysin systems ( factors I , II , VII , VIII , IX , and X and plasminogen ) were observed in the treated groups .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "blood coagulation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 934,
    "text": "Severe complications developed in four patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 935,
    "text": "All four had an abnormal blood coagulation profile , suggesting \" hypercoagulability \" before initiation of therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "blood coagulation"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hypercoagulability"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 936,
    "text": "Some of these findings represented the most extreme abnormalities seen in the entire group of patients ; some increased further during therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 937,
    "text": "One of these patients developed a myocardial infarction before receiving any medication , shortly after the base - line values were obtained .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "myocardial infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 938,
    "text": "One patient developed retinopathy 19 months after she began therapy , and another developed thrombophlebitis after 27 months of therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "retinopathy"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "thrombophlebitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 939,
    "text": "The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "thrombophlebitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 940,
    "text": "All four patients were of the A or AB blood group .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 941,
    "text": "Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "thromboembolic episodes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 942,
    "text": "It appears from these data that hematologic work - ups may be useful in women who are about to start long - term oral contraceptive therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        25,
        "oral contraceptive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 943,
    "text": "Orthostatic hypotension occurs following alpha 2 - adrenoceptor blockade in chronic prazosin - pretreated conscious spontaneously hypertensive rats .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Orthostatic hypotension"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "prazosin"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 944,
    "text": "1 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 945,
    "text": "Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2 - adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats ( SHR ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "prazosin"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 946,
    "text": "2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 947,
    "text": "Conscious SHR ( male 300 - 350 g ) were subjected to 90 degrees head - up tilts for 60 s following acute administration of prazosin ( 0 . 1 mg kg - 1 i . p . ) or rauwolscine ( 3 mg kg - 1 i . v . ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        26,
        "prazosin"
      ],
      [
        "T1",
        "Chemical",
        40,
        41,
        "rauwolscine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 948,
    "text": "Orthostatic hypotension was determined by the average decrease ( % ) in mean arterial pressure ( MAP femoral ) over the 60 - s tilt period .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Orthostatic hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 949,
    "text": "The basal MAP of conscious SHR was reduced to a similar extent by prazosin ( - 23 % ( - ) - 26 % MAP ) and rauwolscine ( - 16 % ( - ) - 33 % MAP ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "prazosin"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "rauwolscine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 950,
    "text": "However , the head - up tilt induced orthostatic hypotension in the SHR treated with prazosin ( - 16 % MAP , n = 6 ) , but not in the SHR treated with rauwolscine ( less than + 2 % MAP , n = 6 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "orthostatic hypotension"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "prazosin"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "rauwolscine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 951,
    "text": "3 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 952,
    "text": "Conscious SHR were treated for 4 days with prazosin at 2 mg kg - 1 day - 1 i . p . for chronic alpha 1 - adrenoceptor blockade .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "prazosin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 953,
    "text": "MAP in conscious SHR after chronic prazosin treatment was 14 % lower than in the untreated SHR ( n = 8 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "prazosin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 954,
    "text": "Head - up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin ( 0 . 1 mg kg - 1 i . p . ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "orthostatic hypotension"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "prazosin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 955,
    "text": "Conversely , administration of rauwolscine ( 3 mg kg - 1 i . v . ) in chronic prazosin treated SHR decreased the basal MAP by 12 - 31 % ( n = 4 ) , and subsequent tilts induced further drops of MAP by 19 - 23 % in these rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "rauwolscine"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "prazosin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 956,
    "text": "4 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 957,
    "text": "The pressor responses and bradycardia to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        36,
        "Abbott - 53693"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "bradycardia"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "cirazoline"
      ],
      [
        "T3",
        "Chemical",
        51,
        52,
        "noradrenaline"
      ],
      [
        "T4",
        "Chemical",
        78,
        79,
        "prazosin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 958,
    "text": "Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "bradycardia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cirazoline"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "prazosin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 959,
    "text": "On the other hand , the pressor effects of Abbott - 53693 were similar in both groups of SHR , but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "Abbott - 53693"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "bradycardia"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "prazosin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 960,
    "text": "Furthermore , the bradycardia that accompanied the noradrenaline - induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47 - 71 % reduction of the pressor effect in chronic alpha 1 - receptor blocked SHR . ( ABSTRACT TRUNCATED AT 400 WORDS )",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "bradycardia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "noradrenaline"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "prazosin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 961,
    "text": "Hemolytic - uremic syndrome associated with ingestion of quinine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Hemolytic - uremic syndrome"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "quinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 962,
    "text": "Hemolytic - uremic syndrome following quinine ingestion is a newly described phenomenon , with just two previous descriptions of 4 cases in the literature .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Hemolytic - uremic syndrome"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "quinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 963,
    "text": "We describe a 5th case .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 964,
    "text": "The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "quinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 965,
    "text": "Treatment has included use of plasma exchange , prednisone , aspirin , and dipyridamole .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "prednisone"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "aspirin"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "dipyridamole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 966,
    "text": "The patients have all regained some degree of renal function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 967,
    "text": "However , it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 968,
    "text": "Quinine - associated hemolytic - uremic syndrome probably occurs more often than is recognized .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "hemolytic - uremic syndrome"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Quinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 969,
    "text": "It is important to recognize this reaction when it occurs and to avoid further quinine exposure , since the reaction seems to be recurrent .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "quinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 970,
    "text": "Amnestic syndrome associated with propranolol toxicity : a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Amnestic syndrome"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "propranolol"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 971,
    "text": "An elderly woman developed an Alzheimer - like subacute dementia as a result of propranolol toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "Alzheimer"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "dementia"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "propranolol"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 972,
    "text": "Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 973,
    "text": "There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 974,
    "text": "Cefotetan - induced immune hemolytic anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Cefotetan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 975,
    "text": "Immune hemolytic anemia due to a drug - adsorption mechanism has been described primarily in patients receiving penicillins and first - generation cephalosporins .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "penicillins"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "cephalosporins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 976,
    "text": "We describe a patient who developed anemia while receiving intravenous cefotetan .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "anemia"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "cefotetan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 977,
    "text": "Cefotetan - dependent antibodies were detected in the patient ' s serum and in an eluate prepared from his red blood cells .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cefotetan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 978,
    "text": "The eluate also reacted weakly with red blood cells in the absence of cefotetan , suggesting the concomitant formation of warm - reactive autoantibodies .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "cefotetan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 979,
    "text": "These observations , in conjunction with clinical and laboratory evidence of extravascular hemolysis , are consistent with drug - induced hemolytic anemia , possibly involving both drug - adsorption and autoantibody formation mechanisms .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hemolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 980,
    "text": "This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "cephalosporins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 981,
    "text": "Use of dexamethasone with mesna for the prevention of ifosfamide - induced hemorrhagic cystitis .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "hemorrhagic cystitis"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "dexamethasone"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "mesna"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "ifosfamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 982,
    "text": "AIM : Hemorrhagic cystitis ( HC ) is a limiting side - effect of chemotherapy with ifosfamide ( IFS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Hemorrhagic cystitis"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "HC"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "ifosfamide"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "IFS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 983,
    "text": "In the study presented here , we investigated the use of dexamethasone in combination with mesna for the prevention of IFS - induced HC .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "dexamethasone"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "mesna"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "IFS"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "HC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 984,
    "text": "METHODS : Male Wistar rats ( 150 - 200 g ; 6 rats per group ) were treated with saline or mesna 5 min ( i . p . ) before and 2 and 6 h after ( v . o . ) administration of IFS .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "mesna"
      ],
      [
        "T1",
        "Chemical",
        45,
        46,
        "IFS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 985,
    "text": "One , two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "mesna"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "dexamethasone"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "dexamethasone"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 986,
    "text": "Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 987,
    "text": "RESULTS : The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84 . 79 % and 89 . 13 % , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "mesna"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "dexamethasone"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "IFS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 988,
    "text": "In addition , it almost abolished the macroscopic and microscopic alterations induced by IFS .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "IFS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 989,
    "text": "Moreover , the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "dexamethasone"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "mesna"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 990,
    "text": "CONCLUSION : Dexamethasone in combination with mesna was efficient in blocking IFS - induced HC .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Dexamethasone"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "mesna"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "IFS"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "HC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 991,
    "text": "However , the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "mesna"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "mesna"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "dexamethasone"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "HC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 992,
    "text": "All - trans - retinoic acid - induced erythema nodosum in patients with acute promyelocytic leukemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        6,
        "All - trans - retinoic acid"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "erythema nodosum"
      ],
      [
        "T2",
        "Disease",
        13,
        16,
        "acute promyelocytic leukemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 993,
    "text": "Erythema nodosum associated with all - trans - retinoic acid ( ATRA ) for acute promyelocytic leukemia ( APL ) is very rare .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Erythema nodosum"
      ],
      [
        "T1",
        "Chemical",
        4,
        10,
        "all - trans - retinoic acid"
      ],
      [
        "T2",
        "Disease",
        14,
        17,
        "acute promyelocytic leukemia"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "ATRA"
      ],
      [
        "T4",
        "Disease",
        18,
        19,
        "APL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 994,
    "text": "We describe four patients with classic APL who developed erythema nodosum during ATRA therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "erythema nodosum"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "APL"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "ATRA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 995,
    "text": "Fever and subsequent multiple painful erythematous nodules over extremities developed on D11 , D16 , D17 , and D19 , respectively , after ATRA therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "erythematous nodules"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Fever"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "painful"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "ATRA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 996,
    "text": "The skin biopsy taken from each patient was consistent with erythema nodosum .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "erythema nodosum"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 997,
    "text": "All patients received short course of steroids .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 998,
    "text": "Fever subsided rapidly and the skin lesions regressed completely .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Fever"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 999,
    "text": "All patients achieved complete remission without withdrawal of ATRA .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "ATRA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1000,
    "text": "ATRA seemed to be the most possible etiology of erythema nodosum in our patients .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "erythema nodosum"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "ATRA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1001,
    "text": "Short - term use of steroid is very effective in ATRA - induced erythema nodosum .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "erythema nodosum"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "steroid"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "ATRA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1002,
    "text": "Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala - kindled rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "loreclezole"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "valproate"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "clonazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1003,
    "text": "Loreclezole ( 5 mg / kg ) exerted a significant protective action in amygdala - kindled rats , reducing both seizure and afterdischarge durations .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Loreclezole"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1004,
    "text": "The combinations of loreclezole ( 2 . 5 mg / kg ) with valproate , clonazepam , or carbamazepine ( applied at their subprotective doses ) also exhibited antiseizure effect in this test .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "loreclezole"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "valproate"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "clonazepam"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1005,
    "text": "However , only two first combinations occurred to be of pharmacodynamic nature .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1006,
    "text": "Among several chemoconvulsants , bicuculline , N - methyl - D - aspartic acid and BAY k - 8644 ( the opener of L - type calcium channels ) reversed the protective activity of loreclezole alone and its combination with valproate .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        14,
        "N - methyl - D - aspartic acid"
      ],
      [
        "T1",
        "Chemical",
        15,
        19,
        "BAY k - 8644"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "bicuculline"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "calcium"
      ],
      [
        "T4",
        "Chemical",
        34,
        35,
        "loreclezole"
      ],
      [
        "T5",
        "Chemical",
        40,
        41,
        "valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1007,
    "text": "On the other hand , bicuculline , aminophylline and BAY k - 8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        13,
        "BAY k - 8644"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "bicuculline"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "aminophylline"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "loreclezole"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "clonazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1008,
    "text": "The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L - type of calcium channels .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "loreclezole"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1009,
    "text": "Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "doxorubicin"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "nephrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1010,
    "text": "BACKGROUND : Doxorubicin induces a self - perpetuating nephropathy characterized by early glomerular and late - onset tubular lesions in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        19,
        "glomerular and late - onset tubular lesions"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Doxorubicin"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1011,
    "text": "We investigated the potential role of mitochondrial injury in the onset of these lesions .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "mitochondrial injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1012,
    "text": "METHODS : Rats were treated with intravenous doxorubicin ( 1 mg kg ( - 1 ) week ( - 1 ) ) for 7 weeks and were sacrificed either 1 week ( ' short - term ' ) or 30 weeks ( ' long - term ' ) following the last dose .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1013,
    "text": "Additional rats received a single dose either 6 days or 2 h prior to euthanasia .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1014,
    "text": "All rats were killed at 48 weeks of age .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1015,
    "text": "Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Glomerular and tubular injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1016,
    "text": "Finally , we quantified both nuclear and mitochondrial DNA ( mtDNA ) as well as superoxide production and the 4834 base pair ' common ' mtDNA deletion .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "superoxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1017,
    "text": "RESULTS : The ' long - term ' group had significant glomerular and tubular lesions , depressed activities of mtDNA - encoded NADH dehydrogenase and cytochrome - c oxidase ( COX ) and increased citrate synthase activity .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        15,
        "glomerular and tubular lesions"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "citrate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1018,
    "text": "In addition , expression of the mtDNA - encoded COX subunit I was reduced and mtDNA levels were decreased .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1019,
    "text": "In ' short - term ' rats , there were fewer tubular lesions , but similar numbers of glomerular lesions activity .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "tubular lesions"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "glomerular lesions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1020,
    "text": "Among all animals , glomerular and tubular injury were inversely correlated with mtDNA levels , mtDNA - encoded respiratory chain activities and with the expression of the mtDNA - encoded respiratory chain subunit COX - I .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        8,
        "glomerular and tubular injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1021,
    "text": "Injury was positively correlated with superoxide production and the activities of nucleus - encoded mitochondrial or cytoplasmic enzymes .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "superoxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1022,
    "text": "Kidneys from the ' long - term ' group showed more mtDNA deletions than in ' short - term ' animals and these were not observed in the other groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1023,
    "text": "CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of superoxide in doxorubicin - induced renal lesions .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        34,
        "renal lesions"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "superoxide"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1024,
    "text": "A randomized , placebo - controlled , crossover study of ephedrine for SSRI - induced female sexual dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "sexual dysfunction"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "ephedrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1025,
    "text": "The objective of this study was to determine whether ephedrine , an alpha - and beta - adrenergic agonist previously shown to enhance genital blood flow in women , has beneficial effects in reversing antidepressant - induced sexual dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        37,
        39,
        "sexual dysfunction"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "ephedrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1026,
    "text": "Nineteen sexually dysfunctional women receiving either fluoxetine , sertraline , or paroxetine participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of ephedrine ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "sexually dysfunctional"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "fluoxetine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "sertraline"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "paroxetine"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "ephedrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1027,
    "text": "Although there were significant improvements relative to baseline in sexual desire and orgasm intensity / pleasure on 50 mg ephedrine 1 - hr prior to sexual activity , significant improvements in these measures , as well as in sexual arousal and orgasmic ability also were noted with placebo .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "ephedrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1028,
    "text": "These findings highlight the importance of conducting placebo - controlled trials for this condition .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1029,
    "text": "Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition ?",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "breast cancer"
      ],
      [
        "T1",
        "Disease",
        11,
        17,
        "detrimental effect on memory and cognition"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1030,
    "text": "A pilot study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1031,
    "text": "This pilot study examines whether hormone therapy for breast cancer affects cognition .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1032,
    "text": "Patients participating in a randomised trial of anastrozole , tamoxifen alone or combined ( ATAC ) ( n = 94 ) and a group of women without breast cancer ( n = 35 ) completed a battery of neuropsychological measures .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "breast cancer"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "anastrozole"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1033,
    "text": "Compared with the control group , the patients were impaired on a processing speed task ( p = 0 . 032 ) and on a measure of immediate verbal memory ( p = 0 . 026 ) after controlling for the use of hormone replacement therapy in both groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1034,
    "text": "Patient group performance was not significantly related to length of treatment or measures of psychological morbidity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1035,
    "text": "The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1036,
    "text": "Verbal memory may be especially sensitive to changes in oestrogen levels , a finding commonly reported in studies of hormone replacement therapy in healthy women .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "oestrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1037,
    "text": "In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1038,
    "text": "Expression of p300 protects cardiac myocytes from apoptosis in vivo .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1039,
    "text": "Doxorubicin is an anti - tumor agent that represses cardiac - specific gene expression and induces myocardial cell apoptosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Doxorubicin"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1040,
    "text": "Doxorubicin depletes cardiac p300 , a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1041,
    "text": "However , the role of p300 in protection against doxorubicin - induced apoptosis is unknown .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1042,
    "text": "Transgenic mice overexpressing p300 in the heart and wild - type mice were subjected to doxorubicin treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1043,
    "text": "Compared with wild - type mice , transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha - sarcomeric actin .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1044,
    "text": "Doxorubicin induced myocardial cell apoptosis in wild - type mice but not in transgenic mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1045,
    "text": "Expression of p300 increased the cardiac level of bcl - 2 and mdm - 2 , but not that of p53 or other members of the bcl - 2 family .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1046,
    "text": "These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin - induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "heart failure"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1047,
    "text": "Methimazole - induced cholestatic jaundice .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cholestatic jaundice"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Methimazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1048,
    "text": "Methimazole is a widely used and generally well - tolerated antithyroid agent .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Methimazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1049,
    "text": "A 43 - year - old woman had severe jaundice and itching 1 month after receiving methimazole ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of hyperthyroidism .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "jaundice"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "itching"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "methimazole"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "propranolol"
      ],
      [
        "T4",
        "Disease",
        32,
        33,
        "hyperthyroidism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1050,
    "text": "The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "jaundice"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1051,
    "text": "When seen at the emergency department 2 weeks later , she still had severe icterus , pruritus , and hyperbilirubinemia , formed mainly of the conjugated fraction .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "icterus"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "pruritus"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "hyperbilirubinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1052,
    "text": "Methimazole - induced cholestasis was diagnosed , and propranolol therapy was resumed .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Methimazole"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "cholestasis"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1053,
    "text": "Over the following 9 days , the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "bilirubin"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "methimazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1054,
    "text": "In rare cases within the first few weeks of therapy , this drug can cause severe and reversible cholestatic jaundice .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "cholestatic jaundice"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1055,
    "text": "Physicians and patients should be aware of this adverse effect so that , upon occurrence , they can discontinue methimazole therapy and avoid unnecessary invasive procedures .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "methimazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1056,
    "text": "Atrial fibrillation following chemotherapy for stage IIIE diffuse large B - cell gastric lymphoma in a patient with myotonic dystrophy ( Steinert ' s disease ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Atrial fibrillation"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "gastric lymphoma"
      ],
      [
        "T2",
        "Disease",
        18,
        20,
        "myotonic dystrophy"
      ],
      [
        "T3",
        "Disease",
        21,
        25,
        "Steinert ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1057,
    "text": "The authors describe the unusual association between diffuse B - cell gastric lymphoma and myotonic dystrophy , the most common form of adult muscular dystrophy , and sudden atrial fibrillation following one cycle of doxorubicin - based chemotherapy in the same patient .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "gastric lymphoma"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "myotonic dystrophy"
      ],
      [
        "T2",
        "Disease",
        23,
        25,
        "muscular dystrophy"
      ],
      [
        "T3",
        "Disease",
        28,
        30,
        "atrial fibrillation"
      ],
      [
        "T4",
        "Chemical",
        34,
        35,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1058,
    "text": "Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Atrial fibrillation"
      ],
      [
        "T1",
        "Disease",
        4,
        6,
        "cardiac arrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1059,
    "text": "The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "cardiac toxicity"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1060,
    "text": "Hypersensitivity immune reaction as a mechanism for dilevalol - associated hepatitis .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypersensitivity"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "dilevalol"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1061,
    "text": "OBJECTIVE : To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol - induced liver injury .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "liver injury"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "dilevalol"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "dilevalol"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "dilevalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1062,
    "text": "PATIENT : A 58 - year - old woman with a clinical diagnosis of dilevalol - induced liver injury .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "liver injury"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "dilevalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1063,
    "text": "METHODS : Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "dilevalol"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "dilevalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1064,
    "text": "A similar protocol was performed with lymphocytes from a healthy subject .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1065,
    "text": "RESULTS : No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "dilevalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1066,
    "text": "A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "dilevalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1067,
    "text": "No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1068,
    "text": "CONCLUSIONS : The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared dilevalol antigens , suggesting the involvement of an immunologic mechanism in dilevalol - induced liver injury .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        34,
        "liver injury"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "dilevalol"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "dilevalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1069,
    "text": "Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside - induced nephrotic syndrome in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "nephrotic syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1070,
    "text": "Nephrotic syndrome is often accompanied by sodium retention and generalized edema .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Nephrotic syndrome"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "sodium"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1071,
    "text": "However , the molecular basis for the decreased renal sodium excretion remains undefined .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1072,
    "text": "We hypothesized that epithelial Na channel ( ENaC ) subunit dysregulation may be responsible for the increased sodium retention .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "Na"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1073,
    "text": "An experimental group of rats was treated with puromycin aminonucleoside ( PAN ; 180 mg / kg iv ) , whereas the control group received only vehicle .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1074,
    "text": "After 7 days , PAN treatment induced significant proteinuria , hypoalbuminemia , decreased urinary sodium excretion , and extensive ascites .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "PAN"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "proteinuria"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "hypoalbuminemia"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "sodium"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "ascites"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1075,
    "text": "The protein abundance of alpha - ENaC and beta - ENaC was increased in the inner stripe of the outer medulla ( ISOM ) and in the inner medulla ( IM ) but was not altered in the cortex .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1076,
    "text": "gamma - ENaC abundance was increased in the cortex , ISOM , and IM .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1077,
    "text": "Immunoperoxidase brightfield - and laser - scanning confocal fluorescence microscopy demonstrated increased targeting of alpha - ENaC , beta - ENaC , and gamma - ENaC subunits to the apical plasma membrane in the distal convoluted tubule ( DCT2 ) , connecting tubule , and cortical and medullary collecting duct segments .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1078,
    "text": "Immunoelectron microscopy further revealed an increased labeling of alpha - ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN - treated rats , indicating enhanced apical targeting of alpha - ENaC subunits .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1079,
    "text": "In contrast , the protein abundances of Na ( + ) / H ( + ) exchanger type 3 ( NHE3 ) , Na ( + ) - K ( + ) - 2Cl ( - ) cotransporter ( BSC - 1 ) , and thiazide - sensitive Na ( + ) - Cl ( - ) cotransporter ( TSC ) were decreased .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "Na"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "H"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "Na"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "K"
      ],
      [
        "T4",
        "Chemical",
        33,
        34,
        "2Cl"
      ],
      [
        "T5",
        "Chemical",
        45,
        46,
        "thiazide"
      ],
      [
        "T6",
        "Chemical",
        48,
        49,
        "Na"
      ],
      [
        "T7",
        "Chemical",
        53,
        54,
        "Cl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1080,
    "text": "Moreover , the abundance of the alpha ( 1 ) - subunit of the Na - K - ATPase was decreased in the cortex and ISOM , but it remained unchanged in the IM .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "Na"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "K"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1081,
    "text": "In conclusion , the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2 , connecting tubule , and collecting duct are likely to play a role in the sodium retention associated with PAN - induced nephrotic syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        41,
        43,
        "nephrotic syndrome"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "sodium"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1082,
    "text": "The decreased abundance of NHE3 , BSC - 1 , TSC , and Na - K - ATPase may play a compensatory role to promote sodium excretion .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "Na"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "K"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1083,
    "text": "Pallidal stimulation : an alternative to pallidotomy ?",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1084,
    "text": "A resurgence of interest in the surgical treatment of Parkinson ' s disease ( PD ) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985 .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1085,
    "text": "Laitinen ' s procedure improved most symptoms in drug - resistant PD , which engendered wide interest in the neurosurgical community .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1086,
    "text": "Another lesioning procedure , ventrolateral thalamotomy , has become a powerful alternative to stimulate the nucleus ventralis intermedius , producing high long - term success rates and low morbidity rates .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1087,
    "text": "Pallidal stimulation has not met with the same success .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1088,
    "text": "According to the literature pallidotomy improves the \" on \" symptoms of PD , such as dyskinesias , as well as the \" off \" symptoms , such as rigidity , bradykinesia , and on - off fluctuations .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "PD"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "dyskinesias"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "rigidity"
      ],
      [
        "T3",
        "Disease",
        31,
        32,
        "bradykinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1089,
    "text": "Pallidal stimulation improves bradykinesia and rigidity to a minor extent ; however , its strength seems to be in improving levodopa - induced dyskinesias .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "bradykinesia"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "rigidity"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "levodopa"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1090,
    "text": "Stimulation often produces an improvement in the hyper - or dyskinetic upper limbs , but increases the \" freezing \" phenomenon in the lower limbs at the same time .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "hyper - or dyskinetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1091,
    "text": "Considering the small increase in the patient ' s independence , the high costs of bilateral implants , and the difficulty most patients experience in handling the devices , the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1092,
    "text": "Effects of the cyclooxygenase - 2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "valdecoxib"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "thrombotic"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "arthritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1093,
    "text": "There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase ( COX ) - 2 - specific inhibitors than nonselective nonsteroidal antiinflammatory drugs ( NSAIDs ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "thrombotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1094,
    "text": "We evaluated cardiovascular event data for valdecoxib , a new COX - 2 - specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "valdecoxib"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "osteoarthritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1095,
    "text": "The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .",
    "labels": [
      [
        "T0",
        "Disease",
        59,
        61,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "thrombotic"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "thrombotic"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "valdecoxib"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "diclofenac"
      ],
      [
        "T5",
        "Chemical",
        40,
        41,
        "ibuprofen"
      ],
      [
        "T6",
        "Chemical",
        46,
        47,
        "naproxen"
      ],
      [
        "T7",
        "Disease",
        57,
        58,
        "osteoarthritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1096,
    "text": "The incidence rates of events were determined in all patients ( n = 7934 ) and in users of low - dose ( < or = 325 mg daily ) aspirin ( n = 1051 ) and nonusers of aspirin ( n = 6883 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        31,
        "aspirin"
      ],
      [
        "T1",
        "Chemical",
        39,
        40,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1097,
    "text": "Crude and exposure - adjusted incidences of thrombotic events were similar for valdecoxib , NSAIDs , and placebo .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "thrombotic"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "valdecoxib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1098,
    "text": "The risk of serious thrombotic events was also similar for each valdecoxib dose .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "thrombotic"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "valdecoxib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1099,
    "text": "Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin ( placebo , 1 . 4 % vs . 0 % ; valdecoxib , 1 . 7 % vs . 0 . 2 % ; NSAIDs , 1 . 9 % vs . 0 . 5 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Thrombotic"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "aspirin"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "aspirin"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "valdecoxib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1100,
    "text": "The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "aspirin"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "valdecoxib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1101,
    "text": "Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials .",
    "labels": [
      [
        "T0",
        "Disease",
        46,
        48,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "valdecoxib"
      ],
      [
        "T2",
        "Disease",
        35,
        36,
        "thrombotic"
      ],
      [
        "T3",
        "Disease",
        44,
        45,
        "osteoarthritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1102,
    "text": "Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hypertrophic cardiomyopathy"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Hypersensitivity"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "myocarditis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1103,
    "text": "The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "eosinophilic myocarditis"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "hypertrophic cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1104,
    "text": "The 47 - year - old female patient , known to have hypertrophic cardiomyopathy , was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "hypertrophic cardiomyopathy"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "biventricular failure"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1105,
    "text": "On transthoracic echocardiogram , she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "left ventricular dysfunction"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "mitral regurgitation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1106,
    "text": "The recipient ' s heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "hypertrophic cardiomyopathy"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "myocarditis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1107,
    "text": "Myocarditis is rare and eosinophilic myocarditis is rarer .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "eosinophilic myocarditis"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Myocarditis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1108,
    "text": "It is likely that the hypersensitivity ( eosinophilic ) myocarditis was related to dobutamine infusion therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hypersensitivity"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "eosinophilic"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "myocarditis"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1109,
    "text": "Eosinophilic myocarditis has been reported with an incidence of 2 . 4 % to 7 . 2 % in explanted hearts and may be related to multidrug therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Eosinophilic myocarditis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1110,
    "text": "Time trends in warfarin - associated hemorrhage .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "warfarin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1111,
    "text": "The annual incidence of warfarin - related bleeding at Brigham and Women ' s Hospital increased from 0 . 97 / 1 , 000 patient admissions in the first time period ( January 1995 to October 1998 ) to 1 . 19 / 1 , 000 patient admissions in the second time period ( November 1998 to August 2002 ) of this study .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "warfarin"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1112,
    "text": "The proportion of patients with major and intracranial bleeding increased from 20 . 2 % and 1 . 9 % , respectively , in the first time period , to 33 . 3 % and 7 . 8 % , respectively , in the second .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "intracranial bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1113,
    "text": "Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "sexual side effects"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Yohimbine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1114,
    "text": "BACKGROUND : Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "male impotence"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "yohimbine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1115,
    "text": "A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "sexual side effects"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "yohimbine"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "clomipramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1116,
    "text": "This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "sexual side effects"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "yohimbine"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1117,
    "text": "METHOD : Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p . r . n . basis in an open clinical trial .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "obsessive compulsive disorder"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "affective disorders"
      ],
      [
        "T2",
        "Disease",
        19,
        22,
        "sexual side effects"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "trichotillomania"
      ],
      [
        "T4",
        "Disease",
        12,
        13,
        "anxiety"
      ],
      [
        "T5",
        "Chemical",
        25,
        26,
        "serotonin"
      ],
      [
        "T6",
        "Chemical",
        30,
        31,
        "yohimbine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1118,
    "text": "Various doses of yohimbine were used to determine the ideal dose for each patient .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "yohimbine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1119,
    "text": "RESULTS : Five of the six patients experienced improved sexual functioning after taking yohimbine .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "yohimbine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1120,
    "text": "One patient who failed to comply with yohimbine treatment had no therapeutic effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "yohimbine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1121,
    "text": "Side effects of yohimbine included excessive sweating , increased anxiety , and a wound - up feeling in some patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "yohimbine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1122,
    "text": "CONCLUSION : The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "sexual side effects"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "yohimbine"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1123,
    "text": "Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "yohimbine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1124,
    "text": "Hemorrhagic cystitis complicating bone marrow transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hemorrhagic cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1125,
    "text": "Hemorrhagic cystitis is a potentially serious complication of high - dose cyclophosphamide therapy administered before bone marrow transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hemorrhagic cystitis"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1126,
    "text": "As standard practice at our institution , patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1127,
    "text": "In an attempt to obviate the inconvenience of bladder irrigation , we conducted a feasibility trial of uroprophylaxis with mesna , which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        32,
        "hemorrhagic cystitis"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "mesna"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1128,
    "text": "Of 97 patients who received standard prophylaxis , 4 had symptomatic hemorrhagic cystitis .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "hemorrhagic cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1129,
    "text": "In contrast , two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "hemorrhagic cystitis"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1130,
    "text": "Because of this suboptimal result , we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "hemorrhagic cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1131,
    "text": "Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases , with special reference to systemic sclerosis and multiple sclerosis .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "autoimmune diseases"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "systemic sclerosis"
      ],
      [
        "T2",
        "Disease",
        24,
        26,
        "multiple sclerosis"
      ],
      [
        "T3",
        "Disease",
        3,
        4,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1132,
    "text": "Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "autoimmune diseases"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1133,
    "text": "Worldwide , over 650 patients have been transplanted in the context of phase I and II clinical trials .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1134,
    "text": "The results are encouraging enough to begin randomised phase III trials .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1135,
    "text": "However , as predicted , significant transplant - related morbidity and mortality have been observed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1136,
    "text": "This is primarily due to complications related to either the stage of the disease at transplant or due to infections .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1137,
    "text": "The number of deaths related to cardiac toxicity is low .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "cardiac toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1138,
    "text": "However , caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage , for example , systemic sclerosis patients .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "heart damage"
      ],
      [
        "T1",
        "Disease",
        26,
        28,
        "systemic sclerosis"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "cyclophosphamide"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "anthracyclines"
      ],
      [
        "T4",
        "Chemical",
        11,
        12,
        "mitoxantrone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1139,
    "text": "In November 2002 , a meeting was held in Florence , bringing together a number of experts in various fields , including rheumatology , cardiology , neurology , pharmacology and transplantation medicine .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1140,
    "text": "The object of the meeting was to analyse existing data , both published or available , in the European Group for Blood and Marrow Transplantation autoimmune disease database , and to propose a safe approach to such patients .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "autoimmune disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1141,
    "text": "A full cardiological assessment before and during the transplant emerged as the major recommendation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1142,
    "text": "Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes ?",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "vitamin C"
      ],
      [
        "T1",
        "Disease",
        5,
        7,
        "cardiovascular disease"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1143,
    "text": "BACKGROUND : Vitamin C acts as a potent antioxidant ; however , it can also be a prooxidant and glycate protein under certain circumstances in vitro .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "Vitamin C"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1144,
    "text": "These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "vitamin C"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "diabetic"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "atherosclerosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1145,
    "text": "OBJECTIVE : The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "vitamin C"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "cardiovascular disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1146,
    "text": "DESIGN : We studied the relation between vitamin C intake and mortality from total cardiovascular disease ( n = 281 ) , coronary artery disease ( n = 175 ) , and stroke ( n = 57 ) in 1923 postmenopausal women who reported being diabetic at baseline .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "vitamin C"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "cardiovascular disease"
      ],
      [
        "T2",
        "Disease",
        22,
        25,
        "coronary artery disease"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "stroke"
      ],
      [
        "T4",
        "Disease",
        45,
        46,
        "diabetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1147,
    "text": "Diet was assessed with a food - frequency questionnaire at baseline , and subjects initially free of coronary artery disease were prospectively followed for 15 y .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "coronary artery disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1148,
    "text": "RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "cardiovascular disease"
      ],
      [
        "T1",
        "Chemical",
        25,
        27,
        "vitamin E"
      ],
      [
        "T2",
        "Chemical",
        29,
        32,
        "beta - carotene"
      ],
      [
        "T3",
        "Disease",
        39,
        41,
        "cardiovascular disease"
      ],
      [
        "T4",
        "Chemical",
        76,
        78,
        "vitamin C"
      ],
      [
        "T5",
        "Disease",
        12,
        13,
        "diabetes"
      ],
      [
        "T6",
        "Disease",
        18,
        19,
        "diabetes"
      ],
      [
        "T7",
        "Chemical",
        23,
        24,
        "folate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1149,
    "text": "Adjusted relative risks of coronary artery disease were 1 . 0 , 0 . 81 , 0 . 99 , 1 . 26 , and 1 . 91 ( P for trend = 0 . 01 ) and of stroke were 1 . 0 , 0 . 52 , 1 . 23 , 2 . 22 , and 2 . 57 ( P for trend < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        39,
        40,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1150,
    "text": "When dietary and supplemental vitamin C were analyzed separately , only supplemental vitamin C showed a positive association with mortality endpoints .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "vitamin C"
      ],
      [
        "T1",
        "Chemical",
        12,
        14,
        "vitamin C"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1151,
    "text": "Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Vitamin C"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "cardiovascular disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1152,
    "text": "CONCLUSION : A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "vitamin C"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "cardiovascular disease"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1153,
    "text": "Optical coherence tomography can measure axonal loss in patients with ethambutol - induced optic neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1154,
    "text": "PURPOSE : To map and identify the pattern , in vivo , of axonal degeneration in ethambutol - induced optic neuropathy using optical coherence tomography ( OCT ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "axonal degeneration"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "optic neuropathy"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1155,
    "text": "Ethambutol is an antimycobacterial agent often used to treat tuberculosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ethambutol"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "tuberculosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1156,
    "text": "A serious complication of ethambutol is an optic neuropathy that impairs visual acuity , contrast sensitivity , and color vision .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1157,
    "text": "However , early on , when the toxic optic neuropathy is mild and partly reversible , the funduscopic findings are often subtle and easy to miss .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "optic neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1158,
    "text": "METHODS : Three subjects with a history of ethambutol ( EMB ) - induced optic neuropathy of short - , intermediate - , and long - term visual deficits were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "optic neuropathy"
      ],
      [
        "T1",
        "Disease",
        27,
        29,
        "visual deficits"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "ethambutol"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "EMB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1159,
    "text": "In addition , OCT ( OCT 3000 , Humphrey - Zeiss , Dublin , CA ) was performed on both eyes of each subject using the retinal nerve fiber layer ( RNFL ) analysis protocol .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1160,
    "text": "OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1161,
    "text": "RESULTS : The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT , n = 661 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1162,
    "text": "In all subjects with history of EMB - induced optic neuropathy , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate visual deficits , 68 % loss ; patient C , with chronic visual deficits , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "optic neuropathy"
      ],
      [
        "T1",
        "Disease",
        50,
        52,
        "visual deficits"
      ],
      [
        "T2",
        "Disease",
        62,
        64,
        "visual deficits"
      ],
      [
        "T3",
        "Chemical",
        6,
        7,
        "EMB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1163,
    "text": "There was a combined mean loss of 46 % of fibers from the superior , inferior , and nasal quadrants in the ( six ) eyes of all three subjects ( mean average thickness of 55 + / - 29 microm ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1164,
    "text": "In both sets ( four ) of eyes of the subjects with persistent visual deficits ( patients B and C ) , there was an average loss of 79 % of nerve fiber thickness in the temporal quadrant .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "visual deficits"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1165,
    "text": "CONCLUSIONS : The OCT results in these patients with EMB - induced optic neuropathy show considerable loss especially of the temporal fibers .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "EMB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1166,
    "text": "This is consistent with prior histopathological studies that show predominant loss of parvo - cellular axons ( or small - caliber axons ) within the papillo - macular bundle in toxic or hereditary optic neuropathies .",
    "labels": [
      [
        "T0",
        "Disease",
        33,
        35,
        "optic neuropathies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1167,
    "text": "OCT can be a valuable tool in the quantitative analysis of optic neuropathies .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "optic neuropathies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1168,
    "text": "Additionally , in terms of management of EMB - induced optic neuropathy , it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "optic neuropathy"
      ],
      [
        "T1",
        "Disease",
        24,
        26,
        "renal impairment"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "EMB"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1169,
    "text": "Hypoxia in renal disease with proteinuria and / or glomerular hypertension .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "renal disease"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Hypoxia"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "proteinuria"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1170,
    "text": "Despite the increasing need to identify and quantify tissue oxygenation at the cellular level , relatively few methods have been available .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1171,
    "text": "In this study , we developed a new hypoxia - responsive reporter vector using a hypoxia - responsive element of the 5 ' vascular endothelial growth factor untranslated region and generated a novel hypoxia - sensing transgenic rat .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hypoxia"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hypoxia"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "hypoxia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1172,
    "text": "We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "diseased kidney"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hypoxia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1173,
    "text": "With this model , we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside - induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "nephrotic syndrome"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hypoxia"
      ],
      [
        "T3",
        "Disease",
        24,
        25,
        "hypoxia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1174,
    "text": "Expression of the hypoxia - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the puromycin aminonucleoside model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of vascular endothelial growth factor showed a mild decrease , reflecting distinct behaviors of the two genes .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        26,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hypoxia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1175,
    "text": "The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "tubulointerstitial injury"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hypoxia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1176,
    "text": "Finally , we identified the localization of proliferating cell nuclear antigen - positive , ED - 1 - positive , and terminal dUTP nick - end labeled - positive cells in the hypoxic cortical area in the remnant kidney model .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        33,
        "hypoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1177,
    "text": "We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "glomerular diseases"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypoxia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1178,
    "text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "chronic hepatitis C"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "ribavirin"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "hemolysis"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "interferon"
      ],
      [
        "T4",
        "Chemical",
        15,
        16,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1179,
    "text": "BACKGROUND : Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "interferon"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1180,
    "text": "Because of ribavirin - related hemolytic anemia , dose reduction is a common event in this therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1181,
    "text": "In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "ribavirin"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "hemolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1182,
    "text": "METHODS : Thirty - seven of 160 patients who had HCV - genotype 1b , had high virus load , and received 24 - week combination therapy developed anemia with hemoglobin level < 10 g / dl or anemia - related signs during therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        29,
        "anemia"
      ],
      [
        "T1",
        "Disease",
        38,
        39,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1183,
    "text": "After that , these 37 patients were reduced one tablet of ribavirin ( 200 mg ) per day .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1184,
    "text": "After reduction of ribavirin , 27 of 37 patients could continue combination therapy for a total of 24 weeks ( group A ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1185,
    "text": "However , 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their < 8 . 5 g / dl hemoglobin values decreased to or anemia - related severe side effects occurred ( group B ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "ribavirin"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1186,
    "text": "We assessed the final efficacy and safety after reduction of ribavirin in groups A and B .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1187,
    "text": "RESULTS : A sustained virological response ( SVR ) was 29 . 6 % ( 8 / 27 ) in group A and 10 % ( 1 / 10 ) in group B , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1188,
    "text": "A 34 . 4 % ( 12 / 27 ) of SVR + biological response in group A was higher than 10 % ( 1 / 10 ) in group B ( P = 0 . 051 ) , with slight significance .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1189,
    "text": "With respect to hemoglobin level at the time of ribavirin reduction , a rate of continuation of therapy in patients with > or = 10 g / dl hemoglobin was higher than that in patients with < 10 g / dl ( P = 0 . 036 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1190,
    "text": "CONCLUSIONS : Reduction of ribavirin at hemoglobin level > or = 10 g / dl is suitable in terms of efficacy and side effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1191,
    "text": "Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "hyperprolactinemia"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1192,
    "text": "The aim of the study was to examine the influence of hyperprolactinemia , induced by haloperidol ( HAL ) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "hyperprolactinemia"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "haloperidol"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "HAL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1193,
    "text": "The study was performed on sexually mature male rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1194,
    "text": "Serum concentrations of prolactin ( PRL ) and testosterone ( T ) were measured .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "PRL"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "testosterone"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "T"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1195,
    "text": "Tissue sections were evaluated with light and electron microscopy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1196,
    "text": "Immunohistochemical reactions for Anti - Proliferating Cell Nuclear Antigen ( PCNA ) were performed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1197,
    "text": "In rats of the experimental group , the mean concentration of : PRL was more than twice higher , whereas T concentration was almost twice lower than that in the control group .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "PRL"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "T"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1198,
    "text": "Light microscopy visualized the following : hypertrophy and epithelium hyperplasia of the glandular ducts , associated with increased PCNA expression .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hypertrophy"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hyperplasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1199,
    "text": "Electron microscopy revealed changes in columnar epithelial cells , concerning organelles , engaged in protein synthesis and secretion .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1200,
    "text": "Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis : correlation with thallium - 201 single - photon emission tomography .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "coronary stenosis"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "thallium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1201,
    "text": "It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "coronary occlusion"
      ],
      [
        "T1",
        "Disease",
        26,
        28,
        "coronary stenoses"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "hyperemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1202,
    "text": "The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        33,
        "coronary stenosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1203,
    "text": "The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual - perfusion technique and with thallium - 201 single - photon emission tomography ( SPECT ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        28,
        "thallium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1204,
    "text": "During a transient ( 20 - s ) coronary occlusion , a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "coronary occlusion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1205,
    "text": "The perfusion defect correlated significantly with the anatomic area at risk ( r = 0 . 74 ; p less than 0 . 002 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1206,
    "text": "During dipyridamole - induced hyperemia , 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "coronary stenosis"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "dipyridamole"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "hyperemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1207,
    "text": "The four dogs without a perfusion defect had a stenosis that resulted in a mild ( 0 % to 50 % ) reduction in dipyridamole - induced hyperemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "dipyridamole"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "hyperemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1208,
    "text": "The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk ( r = 0 . 61 ; p = 0 . 02 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1209,
    "text": "Thallium - 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole - induced hyperemia ; the size of the perfusion defect correlated with the anatomic area at risk ( r = 0 . 58 ; p less than 0 . 03 ) and with the perfusion defect by contrast echocardiography ( r = 0 . 58 ; p less than 0 . 03 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Thallium"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "dipyridamole"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "hyperemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1210,
    "text": "Thus , myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "coronary stenosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1211,
    "text": "The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium - 201 SPECT .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "thallium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1212,
    "text": "The activation of spinal N - methyl - D - aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        11,
        "N - methyl - D - aspartate"
      ],
      [
        "T1",
        "Disease",
        29,
        32,
        "spinal cord ischemia"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1213,
    "text": "We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        21,
        "N - methyl - d - aspartate"
      ],
      [
        "T1",
        "Disease",
        33,
        35,
        "aortic occlusion"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "NMDA"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1214,
    "text": "Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Spinal cord ischemia"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "aortic occlusion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1215,
    "text": "In a microdialysis study , 10 muL of saline ( group C ; n = 8 ) or 30 mug of morphine ( group M ; n = 8 ) was injected intrathecally ( IT ) 0 . 5 h after reflow , and 30 mug of morphine ( group SM ; n = 8 ) or 10 muL of saline ( group SC ; n = 8 ) was injected IT 0 . 5 h after sham operation .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        47,
        48,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1216,
    "text": "Microdialysis samples were collected preischemia , before IT injection , and at 2 , 4 , 8 , 24 , and 48 h of reperfusion ( after IT injection ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1217,
    "text": "Second , we investigated the effect of IT MK - 801 ( 30 mug ) on the histopathologic changes in the spinal cord after morphine - induced spastic paraparesis .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "MK - 801"
      ],
      [
        "T1",
        "Disease",
        27,
        29,
        "spastic paraparesis"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1218,
    "text": "After IT morphine , the cerebrospinal fluid ( CSF ) glutamate concentration was increased in group M relative to both baseline and group C ( P < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1219,
    "text": "This increase persisted for 8 hrs .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1220,
    "text": "IT MK - 801 significantly reduced the number of dark - stained alpha - motoneurons after morphine - induced spastic paraparesis compared with the saline group .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        4,
        "MK - 801"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "spastic paraparesis"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1221,
    "text": "These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate , which is involved in NMDA receptor activation .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "spastic paraparesis"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "morphine"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "glutamate"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "NMDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1222,
    "text": "We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "spinal cord ischemia"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "neurotoxic"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "NMDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1223,
    "text": "Acute low back pain during intravenous administration of amiodarone : a report of two cases .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "low back pain"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1224,
    "text": "Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent - onset atrial fibrillation ( AF ) and maintenance of sinus rhythm .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "AF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1225,
    "text": "We briefly describe two patients suffering from recent - onset atrial fibrillation , who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Disease",
        18,
        21,
        "low back pain"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1226,
    "text": "Notably , this side effect has not been ever reported in the medical literature .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1227,
    "text": "Clinicians should be aware of this reaction since prompt termination of parenteral administration leads to complete resolution .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1228,
    "text": "Quantitative drug levels in stimulant psychosis : relationship to symptom severity , catecholamines and hyperkinesia .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "psychosis"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "catecholamines"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "hyperkinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1229,
    "text": "To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "psychotic symptoms"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "catecholamines"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "psychiatric"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "amphetamine"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "cocaine"
      ],
      [
        "T5",
        "Disease",
        33,
        34,
        "psychosis"
      ],
      [
        "T6",
        "Chemical",
        50,
        51,
        "catecholamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1230,
    "text": "Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Methamphetamine"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "amphetamine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hyperkinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1231,
    "text": "HVA levels were related to global hyperkinesia but not to psychopathology ratings .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hyperkinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1232,
    "text": "Although many other factors such as sensitization may play a role , intensity of stimulant - induced psychotic symptoms and stereotypies appears to be at least in part dose - related .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "psychotic symptoms"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "stereotypies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1233,
    "text": "Pheochromocytoma unmasked by amisulpride and tiapride .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Pheochromocytoma"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "amisulpride"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "tiapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1234,
    "text": "OBJECTIVE : To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "pheochromocytoma"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "amisulpride"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "tiapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1235,
    "text": "CASE SUMMARY : A 42 - year - old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "hypertension"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "headache"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "vomiting"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "amisulpride"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "tiapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1236,
    "text": "Both drugs were immediately discontinued , and the patient recovered after subsequent nicardipine and verapamil treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "nicardipine"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1237,
    "text": "Abdominal ultrasound showed an adrenal mass , and postoperative histologic examination confirmed the diagnosis of pheochromocytoma .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "pheochromocytoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1238,
    "text": "DISCUSSION : Drug - induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs , but the underlying mechanism is unknown .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "pheochromocytoma"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "benzamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1239,
    "text": "In our case , use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "hypertensive"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "amisulpride"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "tiapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1240,
    "text": "CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and tiapride - induced hypertensive crisis in a patient with pheochromocytoma .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "amisulpride"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "tiapride"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "hypertensive"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "pheochromocytoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1241,
    "text": "Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "tiapride"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "amisulpride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1242,
    "text": "Minor neurological dysfunction , cognitive development , and somatic development at the age of 3 to 7 years after dexamethasone treatment in very - low birth - weight infants .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "neurological dysfunction"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1243,
    "text": "The objective of this study was to assess minor neurological dysfunction , cognitive development , and somatic development after dexamethasone therapy in very - low - birthweight infants .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "neurological dysfunction"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1244,
    "text": "Thirty - three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "dexamethasone"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1245,
    "text": "Data were assessed at the age of 3 - 7 years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1246,
    "text": "Dexamethasone was started between the 7th and the 28th day of life over 7 days with a total dose of 2 . 35 mg / kg / day .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1247,
    "text": "Exclusion criteria were asphyxia , malformations , major surgical interventions , small for gestational age , intraventricular haemorrhage grades III and IV , periventricular leukomalacia , and severe psychomotor retardation .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "periventricular leukomalacia"
      ],
      [
        "T1",
        "Disease",
        28,
        30,
        "psychomotor retardation"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "asphyxia"
      ],
      [
        "T3",
        "Disease",
        5,
        6,
        "malformations"
      ],
      [
        "T4",
        "Disease",
        17,
        18,
        "haemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1248,
    "text": "Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw - a - Man Test .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "neurological dysfunctions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1249,
    "text": "There were no differences in demographic data , growth , and socio - economic status between the two groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1250,
    "text": "Fine motor skills and gross motor function were significantly better in the control group ( p < 0 . 01 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1251,
    "text": "In the Draw - a - Man Test , the control group showed better results ( p < 0 . 001 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1252,
    "text": "There were no differences in development of speech , social development , and the Kaufman Assessment Battery for Children .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1253,
    "text": "After dexamethasone treatment , children showed a higher rate of minor neurological dysfunctions .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "neurological dysfunctions"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1254,
    "text": "Neurological development was affected even without neurological diagnosis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1255,
    "text": "Further long - term follow - up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1256,
    "text": "Valproic acid I : time course of lipid peroxidation biomarkers , liver toxicity , and valproic acid metabolite levels in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Valproic acid"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "liver toxicity"
      ],
      [
        "T2",
        "Chemical",
        15,
        17,
        "valproic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1257,
    "text": "A single dose of valproic acid ( VPA ) , which is a widely used antiepileptic drug , is associated with oxidative stress in rats , as recently demonstrated by elevated levels of 15 - F ( 2t ) - isoprostane ( 15 - F ( 2t ) - IsoP ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "valproic acid"
      ],
      [
        "T1",
        "Chemical",
        33,
        41,
        "15 - F ( 2t ) - isoprostane"
      ],
      [
        "T2",
        "Chemical",
        42,
        50,
        "15 - F ( 2t ) - IsoP"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1258,
    "text": "To determine whether there was a temporal relationship between VPA - associated oxidative stress and hepatotoxicity , adult male Sprague - Dawley rats were treated ip with VPA ( 500 mg / kg ) or 0 . 9 % saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "VPA"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hepatotoxicity"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1259,
    "text": "Oxidative stress was assessed by determining plasma and liver levels of 15 - F ( 2t ) - IsoP , lipid hydroperoxides ( LPO ) , and thiobarbituric acid reactive substances ( TBARs ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        19,
        "15 - F ( 2t ) - IsoP"
      ],
      [
        "T1",
        "Chemical",
        20,
        22,
        "lipid hydroperoxides"
      ],
      [
        "T2",
        "Chemical",
        27,
        31,
        "thiobarbituric acid reactive substances"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "LPO"
      ],
      [
        "T4",
        "Chemical",
        32,
        33,
        "TBARs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1260,
    "text": "Plasma and liver 15 - F ( 2t ) - IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        11,
        "15 - F ( 2t ) - IsoP"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1261,
    "text": "Liver LPO levels were not elevated until day 7 of treatment ( 1 . 8 - fold versus control , p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "LPO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1262,
    "text": "Liver and plasma TBARs were not increased until 14 days ( 2 - fold vs . control , p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "TBARs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1263,
    "text": "Liver toxicity was evaluated based on serum levels of alpha - glutathione S - transferase ( alpha - GST ) and by histology .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Liver toxicity"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "glutathione"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1264,
    "text": "Serum alpha - GST levels were significantly elevated by day 4 , which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule , necrosis , and steatosis throughout the study .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "hepatotoxicity"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "inflammation"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "necrosis"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "steatosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1265,
    "text": "The liver levels of beta - oxidation metabolites of VPA were decreased by day 14 , while the levels of 4 - ene - VPA and ( E ) - 2 , 4 - diene - VPA were not elevated throughout the study .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        25,
        "4 - ene - VPA"
      ],
      [
        "T1",
        "Chemical",
        30,
        37,
        "2 , 4 - diene - VPA"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1266,
    "text": "Overall , these findings indicate that VPA treatment results in oxidative stress , as measured by levels of 15 - F ( 2t ) - IsoP , which precedes the onset of necrosis , steatosis , and elevated levels of serum alpha - GST .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        26,
        "15 - F ( 2t ) - IsoP"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "VPA"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "necrosis"
      ],
      [
        "T3",
        "Disease",
        34,
        35,
        "steatosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1267,
    "text": "Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hepatitis B"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "rubella"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1268,
    "text": "OBJECTIVE : To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "hepatitis B"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "rubella"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1269,
    "text": "METHODS : Data were extracted from 2021 paired mother - infant records for the year 2000 birth cohort in New Hampshire ' s 25 delivery hospitals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1270,
    "text": "Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "hepatitis B"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "hepatitis B"
      ],
      [
        "T2",
        "Disease",
        29,
        31,
        "hepatitis B"
      ],
      [
        "T3",
        "Chemical",
        39,
        43,
        "hepatitis B surface antigen"
      ],
      [
        "T4",
        "Disease",
        13,
        14,
        "rubella"
      ],
      [
        "T5",
        "Disease",
        47,
        48,
        "rubella"
      ],
      [
        "T6",
        "Disease",
        57,
        58,
        "rubella"
      ],
      [
        "T7",
        "Disease",
        60,
        61,
        "rubella"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1271,
    "text": "RESULTS : Prenatal screening rates for hepatitis B ( 98 . 8 % ) and rubella ( 99 . 4 % ) were high .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "hepatitis B"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "rubella"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1272,
    "text": "Hepatitis B vaccine birth dose was administered to 76 . 2 % of all infants .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hepatitis B"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1273,
    "text": "All infants who were born to hepatitis B surface antigen - positive mothers also received hepatitis B immune globulin .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        10,
        "hepatitis B surface antigen"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "hepatitis B"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1274,
    "text": "Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "hepatitis B"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1275,
    "text": "The proportion of infants who were vaccinated in January and February 2000 ( 48 . 5 % and 67 . 5 % , respectively ) was less than any other months , whereas the proportion who were vaccinated in December 2000 ( 88 . 2 % ) was the highest .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1276,
    "text": "Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity ( 9 . 5 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "rubella"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1277,
    "text": "In - hospital postpartum rubella vaccine administration was documented for 75 . 6 % of nonimmune women .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "rubella"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1278,
    "text": "CONCLUSION : This study documents good compliance in New Hampshire ' s birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "hepatitis B"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "rubella"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1279,
    "text": "Succinylcholine - induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "masseter muscle rigidity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1280,
    "text": "Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Masseter muscle rigidity"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "malignant hyperthermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1281,
    "text": "The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "masseter muscle rigidity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1282,
    "text": "Here , we describe a case of severe masseter muscle rigidity ( jaw of steel ) after succinylcholine ( Sch ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "masseter muscle rigidity"
      ],
      [
        "T1",
        "Disease",
        12,
        15,
        "jaw of steel"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "succinylcholine"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "Sch"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1283,
    "text": "Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "malignant hyperthermia"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1284,
    "text": "Dexrazoxane protects against myelosuppression from the DNA cleavage - enhancing drugs etoposide and daunorubicin but not doxorubicin .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dexrazoxane"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "myelosuppression"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "etoposide"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "daunorubicin"
      ],
      [
        "T4",
        "Chemical",
        16,
        17,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1285,
    "text": "PURPOSE : The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and cardiac toxicity limit their use .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        32,
        "cardiac toxicity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "anthracyclines"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "daunorubicin"
      ],
      [
        "T3",
        "Chemical",
        6,
        7,
        "doxorubicin"
      ],
      [
        "T4",
        "Chemical",
        9,
        10,
        "epipodophyllotoxin"
      ],
      [
        "T5",
        "Chemical",
        10,
        11,
        "etoposide"
      ],
      [
        "T6",
        "Disease",
        28,
        29,
        "myelosuppression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1286,
    "text": "Dexrazoxane ( ICRF - 187 ) is recommended for protection against anthracycline - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "ICRF - 187"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Dexrazoxane"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "anthracycline"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1287,
    "text": "EXPERIMENTAL DESIGN : Because of their widespread use , the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "hematologic toxicity"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "dexrazoxane"
      ],
      [
        "T2",
        "Chemical",
        36,
        37,
        "etoposide"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "daunorubicin"
      ],
      [
        "T4",
        "Chemical",
        41,
        42,
        "doxorubicin"
      ],
      [
        "T5",
        "Chemical",
        45,
        46,
        "dexrazoxane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1288,
    "text": "Likewise , in vivo , B6D2F1 mice were treated with etoposide , daunorubicin , and doxorubicin , with or without dexrazoxane over a wide range of doses : posttreatment , a full hematologic evaluation was done .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "etoposide"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "daunorubicin"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "doxorubicin"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "dexrazoxane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1289,
    "text": "RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "weight loss"
      ],
      [
        "T1",
        "Disease",
        34,
        36,
        "weight loss"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "dexrazoxane"
      ],
      [
        "T3",
        "Disease",
        7,
        8,
        "myelosuppression"
      ],
      [
        "T4",
        "Chemical",
        12,
        13,
        "daunorubicin"
      ],
      [
        "T5",
        "Chemical",
        14,
        15,
        "etoposide"
      ],
      [
        "T6",
        "Chemical",
        29,
        30,
        "dexrazoxane"
      ],
      [
        "T7",
        "Disease",
        32,
        33,
        "myelosuppression"
      ],
      [
        "T8",
        "Disease",
        41,
        42,
        "cytotoxicity"
      ],
      [
        "T9",
        "Chemical",
        43,
        44,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1290,
    "text": "CONCLUSION : Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically , the potent antagonism of daunorubicin activity raises concern ; a possible interference with anticancer efficacy certainly would call for renewed attention .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "dexrazoxane"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "doxorubicin"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "daunorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1291,
    "text": "Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "etoposide"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "dexrazoxane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1292,
    "text": "Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "hematologic toxicity"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "metastases"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "dexrazoxane"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "etoposide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1293,
    "text": "If successful , this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1294,
    "text": "Assessment of the onset and persistence of amnesia during procedural sedation with propofol .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "amnesia"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1295,
    "text": "OBJECTIVES : To assess patients ' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol , and correlate their recall with their level of awareness as measured by bispectral index ( BIS ) monitoring .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1296,
    "text": "METHODS : This was a prospective , single - intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28 , 2002 , and October 31 , 2003 .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1297,
    "text": "BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1298,
    "text": "At 1 - minute intervals during the procedural sedation , until the patient regained baseline mental status at the end of the procedure , a word from a standardized list was read aloud , and the patient was asked to immediately repeat the word to the investigator .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1299,
    "text": "The BIS score at the time the word was read and the patient ' s ability to repeat the word were recorded .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1300,
    "text": "After the procedure , the patient was asked to state all of the words from the list that he or she could recall , and to identify the last word recalled from prior to the start of the procedure and the first word recalled from after the procedure was completed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1301,
    "text": "RESULTS : Seventy - five consenting patients were enrolled ; one patient was excluded from data analysis for a protocol violation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1302,
    "text": "No serious adverse events were noted during the procedural sedations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1303,
    "text": "The mean ( + / - standard deviation ) time of data collection was 16 . 4 minutes ( + / - 7 . 1 ; range 5 to 34 minutes ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1304,
    "text": "The mean initial ( preprocedure ) BIS score was 97 . 1 ( + / - 2 . 3 ; range 92 to 99 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1305,
    "text": "The mean lowest BIS score occurring during these procedural sedations was 66 . 9 ( + / - 14 . 4 ; range 33 to 91 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1306,
    "text": "The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77 . 1 ( 95 % CI = 74 . 3 to 80 . 0 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1307,
    "text": "The mean highest BIS score corresponding to the inability to repeat words was 81 . 5 ( 95 % CI = 78 . 1 to 84 . 8 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "inability to repeat words"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1308,
    "text": "The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96 . 7 ( + / - 2 . 4 ; range 84 to 98 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1309,
    "text": "The mean BIS score corresponding to the first word recalled after the procedure was completed was 91 . 2 ( 95 % CI = 88 . 1 to 94 . 3 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1310,
    "text": "All patients recalled at least one word that had been read to them during the protocol .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1311,
    "text": "The mean lowest BIS score for any recalled word was 91 . 5 ( + / - 11 . 1 ; range 79 to 98 ) , and no words were recalled when the corresponding BIS score was less than 90 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1312,
    "text": "CONCLUSIONS : There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1313,
    "text": "Furthermore , patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation , suggestive of retrograde amnesia .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "retrograde amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1314,
    "text": "Amiodarone pulmonary toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "pulmonary toxicity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1315,
    "text": "Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side - effects , the most problematic being pneumonitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "pneumonitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1316,
    "text": "The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell - mediated hypersensitivity pneumonitis .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "pulmonary toxicity"
      ],
      [
        "T1",
        "Disease",
        24,
        26,
        "hypersensitivity pneumonitis"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1317,
    "text": "The clinical and radiographic features of amiodarone - induced pulmonary toxicity are characteristic but nonspecific .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "pulmonary toxicity"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1318,
    "text": "The diagnosis depends on exclusion of other entities , such as heart failure , infection , and malignancy .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "heart failure"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "infection"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "malignancy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1319,
    "text": "While withdrawal of amiodarone leads to clinical improvement in majority of cases , this is not always possible or advisable .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1320,
    "text": "Dose reduction or concomitant steroid therapy may have a role in selected patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1321,
    "text": "Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "kainate"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1322,
    "text": "Amino acids 5 and 7 , two potent and selective competitive GluR5 KA receptor antagonists , exhibited high GluR5 receptor affinity over other glutamate receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "KA"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1323,
    "text": "Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , carrageenan - induced thermal hyperalgesia , and capsaicin - induced mechanical hyperalgesia .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "thermal hyperalgesia"
      ],
      [
        "T1",
        "Disease",
        33,
        35,
        "mechanical hyperalgesia"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "pain"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "formalin"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "carrageenan"
      ],
      [
        "T5",
        "Chemical",
        30,
        31,
        "capsaicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1324,
    "text": "Possible azithromycin - associated hiccups .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "azithromycin"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hiccups"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1325,
    "text": "OBJECTIVE : To report a case of persistent hiccups associated by azithromycin therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hiccups"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "azithromycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1326,
    "text": "CASE SUMMARY : A 76 - year - old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "hiccups"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "azithromycin"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "pharyngitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1327,
    "text": "Hiccups were persistent and exhausting .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hiccups"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1328,
    "text": "Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "azithromycin"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "baclofen"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "hiccups"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1329,
    "text": "No organic cause of hiccups was identified despite extensive investigation .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hiccups"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1330,
    "text": "DISCUSSION : Pharmacotherapeutic agents have been uncommonly associated with hiccups .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "hiccups"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1331,
    "text": "Corticosteroids ( dexamethasone and methylprednisolone ) , benzodiazepines ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "dexamethasone"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "methylprednisolone"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "benzodiazepines"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "midazolam"
      ],
      [
        "T4",
        "Disease",
        32,
        33,
        "hiccups"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1332,
    "text": "Few cases of drug - induced hiccups have been reported related to macrolide antimicrobials .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hiccups"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "macrolide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1333,
    "text": "Using the Naranjo adverse effect reaction probability scale this event could be classified as possible ( score 5 points ) , mostly because of the close temporal sequence , previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups .",
    "labels": [
      [
        "T0",
        "Chemical",
        36,
        37,
        "macrolides"
      ],
      [
        "T1",
        "Disease",
        45,
        46,
        "hiccups"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1334,
    "text": "Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "azithromycin"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hiccups"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1335,
    "text": "CONCLUSIONS : Diagnosis of drug - induced hiccups is difficult and often achieved only by a process of elimination .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "hiccups"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1336,
    "text": "However , macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side - effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "macrolide"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hiccups"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1337,
    "text": "Calcium carbonate toxicity : the updated milk - alkali syndrome ; report of 3 cases and review of the literature .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Calcium carbonate"
      ],
      [
        "T1",
        "Disease",
        6,
        10,
        "milk - alkali syndrome"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1338,
    "text": "OBJECTIVE : To describe 3 patients with calcium carbonate - induced hypercalcemia and gain insights into the cause and management of the milk - alkali syndrome .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "calcium carbonate"
      ],
      [
        "T1",
        "Disease",
        22,
        26,
        "milk - alkali syndrome"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1339,
    "text": "METHODS : We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia ( corrected serum calcium > or = 14 mg / dL ) and review the pertinent literature on milk - alkali syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        39,
        "milk - alkali syndrome"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "hypercalcemia"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1340,
    "text": "RESULTS : The 3 patients had acute renal insufficiency , relative metabolic alkalosis , and low parathyroid hormone ( PTH ) , PTH - related peptide , and 1 , 25 - dihydroxyvitamin D concentrations .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "acute renal insufficiency"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "metabolic alkalosis"
      ],
      [
        "T2",
        "Chemical",
        28,
        34,
        "1 , 25 - dihydroxyvitamin D"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1341,
    "text": "No malignant lesion was found .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1342,
    "text": "Treatment included aggressive hydration and varied amounts of furosemide .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "furosemide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1343,
    "text": "The 2 patients with the higher serum calcium concentrations received pamidronate intravenously ( 60 and 30 mg , respectively ) , which caused severe hypocalcemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "calcium"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "pamidronate"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "hypocalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1344,
    "text": "Of the 3 patients , 2 were ingesting acceptable doses of elemental calcium ( 1 g and 2 g daily , respectively ) in the form of calcium carbonate .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        29,
        "calcium carbonate"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1345,
    "text": "In addition to our highlighted cases , we review the history , classification , pathophysiologic features , and treatment of milk - alkali syndrome and summarize the cases reported from early 1995 to November 2003 .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        24,
        "milk - alkali syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1346,
    "text": "CONCLUSION : Milk - alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        6,
        "Milk - alkali syndrome"
      ],
      [
        "T1",
        "Chemical",
        24,
        26,
        "calcium carbonate"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1347,
    "text": "Treatment with hydration , furosemide , and discontinuation of the calcium and vitamin D source is adequate .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "vitamin D"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "furosemide"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1348,
    "text": "Pamidronate treatment is associated with considerable risk for hypocalcemia , even in cases of initially severe hypercalcemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Pamidronate"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hypocalcemia"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1349,
    "text": "Warfarin - induced leukocytoclastic vasculitis .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "leukocytoclastic vasculitis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1350,
    "text": "Skin reactions associated with oral coumarin - derived anticoagulants are an uncommon occurrence .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "coumarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1351,
    "text": "Leukocytoclastic vasculitis ( LV ) is primarily a cutaneous small vessel vasculitis , though systemic involvement may be encountered .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Leukocytoclastic vasculitis"
      ],
      [
        "T1",
        "Disease",
        8,
        12,
        "cutaneous small vessel vasculitis"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "LV"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1352,
    "text": "We report 4 patients with late - onset LV probably due to warfarin .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "LV"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1353,
    "text": "All 4 patients presented with skin eruptions that developed after receiving warfarin for several years .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "skin eruptions"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1354,
    "text": "The results of skin lesion biopsies were available in 3 patients , confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "skin lesion"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "LV Cutaneous lesions"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1355,
    "text": "In 2 of the 4 patients , rechallenge with warfarin led to recurrence of the lesions .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1356,
    "text": "LV may be a late - onset adverse reaction associated with warfarin therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "LV"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1357,
    "text": "Cocaine - induced brainstem seizures and behavior .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cocaine"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1358,
    "text": "A variety of abnormal sensory / motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical ( electrode implants ) and DC electrical current stimulations and by acute and chronic administration of cocaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        41,
        42,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1359,
    "text": "The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1360,
    "text": "Cocaine ( 40 mg / kg ) was injected subcutaneously for an acute experiment and subsequent 20 mg / kg doses twice daily for 3 days in a chronic study .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1361,
    "text": "Cocaine generated more abnormal behaviors in the brainstem perturbation group , especially the electrically perturbated subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1362,
    "text": "The abnormal behaviors were yawning , retrocollis , hyperactivity , hypersensitivity , \" beating drum \" behavior , squealing , head bobbing , circling , sniffing , abnormal posturing , and facial twitching .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hyperactivity"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypersensitivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1363,
    "text": "Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1364,
    "text": "Hypersensitivity to various auditory , tactile , and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypersensitivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1365,
    "text": "These findings suggest that the brainstem generates and propagates pathological discharges that can be elicited by mechanical and DC electrical perturbation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1366,
    "text": "Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1367,
    "text": "Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1368,
    "text": "rTMS of supplementary motor area modulates therapy - induced dyskinesias in Parkinson disease .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "Parkinson disease"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1369,
    "text": "The neural mechanisms and circuitry involved in levodopa - induced dyskinesia are unclear .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1370,
    "text": "Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced Parkinson disease , the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "Parkinson disease"
      ],
      [
        "T1",
        "Disease",
        41,
        42,
        "dyskinetic"
      ],
      [
        "T2",
        "Chemical",
        46,
        47,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1371,
    "text": "rTMS at 1 Hz was observed to markedly reduce drug - induced dyskinesias , whereas 5 - Hz rTMS induced a slight but not significant increase .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "drug - induced dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1372,
    "text": "Intracavitary chemotherapy ( paclitaxel / carboplatin liquid crystalline cubic phases ) for recurrent glioblastoma - - clinical observations .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "paclitaxel"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "carboplatin"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "glioblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1373,
    "text": "Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "brain tumors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1374,
    "text": "Cubic phases consist of curved biocontinuous lipid bilayers , separating two congruent networks of water channels .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1375,
    "text": "Used as a host for cytotoxic drugs , the gel - like matrix can easily be applied to the walls of a surgical resection cavity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1376,
    "text": "For human glioblastoma recurrences , the feasibility , safety , and short - term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "glioblastoma"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "paclitaxel"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1377,
    "text": "A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re - resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "glioblastoma"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "paclitaxel"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1378,
    "text": "Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema , while the remaining patients received only a total of 15 mg paclitaxel .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "brain edema"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "paclitaxel"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1379,
    "text": "In the latter group , brain edema was markedly reduced and dealt medically .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "brain edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1380,
    "text": "Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe , yet the clinical benefit remains to be examined in a clinical phase II study .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "glioblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1381,
    "text": "Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "idiopathic generalized epilepsies"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Lamotrigine"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "myoclonus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1382,
    "text": "Five patients with idiopathic generalized epilepsies ( IGE ) treated with lamotrigine ( LTG ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "idiopathic generalized epilepsies"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "myoclonic jerks"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "IGE"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "lamotrigine"
      ],
      [
        "T4",
        "Chemical",
        13,
        14,
        "LTG"
      ],
      [
        "T5",
        "Disease",
        25,
        26,
        "MJ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1383,
    "text": "In three patients , LTG exacerbated MJ in a dose - dependent manner with early aggravation during titration .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "LTG"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "MJ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1384,
    "text": "MJ disappeared when LTG dose was decreased by 25 to 50 % .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "MJ"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "LTG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1385,
    "text": "In two patients , LTG exacerbated MJ in a delayed but more severe manner , with myoclonic status that only ceased after LTG withdrawal .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "myoclonic status"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "LTG"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "MJ"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "LTG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1386,
    "text": "Absence of acute cerebral vasoconstriction after cocaine - associated subarachnoid hemorrhage .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "subarachnoid hemorrhage"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1387,
    "text": "INTRODUCTION : Cocaine use has been associated with neurovascular complications , including arterial vasoconstriction and vasculitis .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "neurovascular complications"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Cocaine"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1388,
    "text": "However , there are few studies of angiographic effects of cocaine on human cerebral arteries .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1389,
    "text": "Information on these effects could be obtained from angiograms of patients with cocaine - associated subarachnoid hemorrhage ( SAH ) who underwent angiography shortly after cocaine use .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "subarachnoid hemorrhage"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "cocaine"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "SAH"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1390,
    "text": "METHODS : We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "SAH"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1391,
    "text": "Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "SAH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1392,
    "text": "Qualitative comparisons of small artery changes also were made .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1393,
    "text": "RESULTS : Thirteen patients with positive cocaine toxicology were compared to 26 controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1394,
    "text": "There were no significant differences between groups in the mean diameters of the intradural internal carotid , sphenoidal segment of the middle cerebral , precommunicating segment of the anterior cerebral , or basilar arteries ( p greater than 0 . 05 for all comparisons , unpaired t - tests ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1395,
    "text": "There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery ( p greater than 0 . 05 , unpaired t - tests ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1396,
    "text": "Qualitative assessments showed two arterial irregularities in the distal vasculature in each group .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1397,
    "text": "CONCLUSION : No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "vasculitis"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "aneurysmal"
      ],
      [
        "T2",
        "Disease",
        30,
        31,
        "SAH"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1398,
    "text": "Methamphetamine causes alterations in the MAP kinase - related pathways in the brains of mice that display increased aggressiveness .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Methamphetamine"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "aggressiveness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1399,
    "text": "Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders , and are common in methamphetamine ( METH ) abusers .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Aggressive behaviors"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "psychiatric disorders"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "methamphetamine"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1400,
    "text": "Herein , we report that multiple ( but not single ) injections of METH significantly increased aggressiveness in male CD - 1 mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "METH"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "aggressiveness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1401,
    "text": "This increase in aggressiveness was not secondary to METH - induced hyperactivity .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "aggressiveness"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "METH"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hyperactivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1402,
    "text": "Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase - related pathways after multiple and single METH injections .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1403,
    "text": "There were statistically significant ( p < 0 . 05 ) decreases in MEK1 , Erk2p , GSK3alpha , 14 - 3 - 3e , and MEK7 in the striata of mice after multiple injections of METH .",
    "labels": [
      [
        "T0",
        "Chemical",
        36,
        37,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1404,
    "text": "MEK1 was significantly decreased also after a single injection of METH , but to a much lesser degree than after multiple injections of METH .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "METH"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1405,
    "text": "In the frontal cortex , there was a statistically significant decrease in GSK3alpha after multiple ( but not single ) injections of METH .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1406,
    "text": "These findings suggest that alterations in MAP kinase - related pathways in the prefronto - striatal circuitries might be involved in the manifestation of aggressive behaviors in mice .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "aggressive behaviors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1407,
    "text": "Amisulpride related tic - like symptoms in an adolescent schizophrenic .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        6,
        "tic - like symptoms"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Amisulpride"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "schizophrenic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1408,
    "text": "Tic disorders can be effectively treated by atypical antipsychotics such as risperidone , olanzapine and ziprasidone .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Tic disorders"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "risperidone"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "olanzapine"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "ziprasidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1409,
    "text": "However , there are two case reports that show tic - like symptoms , including motor and phonic variants , occurring during treatment with quetiapine or clozapine .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "tic - like symptoms"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "quetiapine"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "clozapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1410,
    "text": "We present a 15 - year - old girl schizophrenic who developed frequent involuntary eye - blinking movements after 5 months of amisulpride treatment ( 1000 mg per day ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        18,
        "involuntary eye - blinking movements"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "schizophrenic"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "amisulpride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1411,
    "text": "The tic - like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        5,
        "tic - like symptoms"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "amisulpride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1412,
    "text": "However , her psychosis recurred after the dose reduction .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1413,
    "text": "We then placed her on an additional 100 mg per day of quetiapine .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1414,
    "text": "She has been in complete remission under the combined medications for more than one year and maintains a fair role function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1415,
    "text": "No more tic - like symptoms or other side effects have been reported .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        6,
        "tic - like symptoms"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1416,
    "text": "Together with previously reported cases , our patient suggests that tic - like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , clozapine , or amisulpride .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        14,
        "tic - like symptoms"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "quetiapine"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "clozapine"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "amisulpride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1417,
    "text": "Chloroquine related complete heart block with blindness : case report .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "heart block"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Chloroquine"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "blindness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1418,
    "text": "A 27 - year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision , easy fatiguability , dyspnoea , dizziness progressing to syncopal attacks .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        19,
        "deterioration of vision"
      ],
      [
        "T1",
        "Disease",
        28,
        30,
        "syncopal attacks"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "chloroquine"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "fatiguability"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "dyspnoea"
      ],
      [
        "T5",
        "Disease",
        25,
        26,
        "dizziness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1419,
    "text": "Ophthalmological assessment revealed features of chloroquine retinopathy , cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "heart failure"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "heart block"
      ],
      [
        "T2",
        "Disease",
        21,
        25,
        "right bundle branch block"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "chloroquine"
      ],
      [
        "T4",
        "Disease",
        6,
        7,
        "retinopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1420,
    "text": "The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "heart block"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "heart failure"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "chloroquine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1421,
    "text": "She however remains blind .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "blind"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1422,
    "text": "Effects of suprofen on the isolated perfused rat kidney .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "suprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1423,
    "text": "Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects , the mechanism of damage remains unclear .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "suprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1424,
    "text": "The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell - free buffer with or without the addition of 5 mg / dL of uric acid .",
    "labels": [
      [
        "T0",
        "Chemical",
        38,
        40,
        "uric acid"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "nephrotoxic"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "suprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1425,
    "text": "There were no significant differences in renal sodium excretion , oxygen consumption , or urinary flow rates in kidneys perfused with suprofen compared with the drug - free control groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "oxygen"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "suprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1426,
    "text": "In contrast , a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid ; no changes were found with suprofen in the absence of uric acid .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        24,
        "uric acid"
      ],
      [
        "T1",
        "Chemical",
        35,
        37,
        "uric acid"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "suprofen"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "suprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1427,
    "text": "A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen , compared with drug - free controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "uric acid"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "suprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1428,
    "text": "However , the fractional excretion of uric acid was unchanged between the groups over the experimental period .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "uric acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1429,
    "text": "In summary , suprofen causes acute declines in renal function , most likely by directly altering the intrarenal distribution of uric acid .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        10,
        "acute declines in renal function"
      ],
      [
        "T1",
        "Chemical",
        20,
        22,
        "uric acid"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "suprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1430,
    "text": "Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine - induced amnesia in adult male rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "ritanserin"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "scopolamine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1431,
    "text": "The effect of ritanserin ( 5 - HT2 antagonist ) on scopolamine ( muscarinic cholinergic antagonist ) - induced amnesia in Morris water maze ( MWM ) was investigated .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "ritanserin"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "scopolamine"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1432,
    "text": "Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1433,
    "text": "One week later , they received repeatedly vehicles ( saline , DMSO , saline + DMSO ) , scopolamine ( 2 microg / 0 . 5 microl saline / side ; 30 min before training ) , ritanserin ( 2 , 4 and 8 microg / 0 . 5 microl DMSO / side ; 20 min before training ) and scopolamine ( 2 microg / 0 . 5 microl ; 30 min before ritanserin injection ) + ritanserin ( 4 microg / 0 . 5 microl DMSO ) through cannulae each day .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "DMSO"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "DMSO"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "scopolamine"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "ritanserin"
      ],
      [
        "T4",
        "Chemical",
        50,
        51,
        "DMSO"
      ],
      [
        "T5",
        "Chemical",
        60,
        61,
        "scopolamine"
      ],
      [
        "T6",
        "Chemical",
        73,
        74,
        "ritanserin"
      ],
      [
        "T7",
        "Chemical",
        77,
        78,
        "ritanserin"
      ],
      [
        "T8",
        "Chemical",
        86,
        87,
        "DMSO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1434,
    "text": "Animals were tested for four consecutive days ( 4 trial / day ) in MWM during which the position of hidden platform was unchanged .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1435,
    "text": "In the fifth day , the platform was elevated above the water surface in another position to evaluate the function of motor , motivational and visual systems .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1436,
    "text": "The results showed a significant increase in escape latencies and traveled distances to find platform in scopolamine - treated group as compared to saline group .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1437,
    "text": "Ritanserin - treated rats ( 4 microg / 0 . 5 microl / side ) showed a significant decrease in the mentioned parameters as compared to DMSO - treated group .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ritanserin"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "DMSO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1438,
    "text": "However , scopolamine and ritanserin co - administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "scopolamine"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "ritanserin"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1439,
    "text": "Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine - induced amnesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "ritanserin"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "scopolamine"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1440,
    "text": "PTU - associated vasculitis in a girl with Turner Syndrome and Graves ' disease .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "Turner Syndrome"
      ],
      [
        "T1",
        "Disease",
        11,
        14,
        "Graves ' disease"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "PTU"
      ],
      [
        "T3",
        "Disease",
        3,
        4,
        "vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1441,
    "text": "Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes , including infectious and autoimmune processes .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "purpura"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1442,
    "text": "A rare cause , drug - induced vasculitis , may result from the production of antineutrophil cytoplasmic antibodies ( ANCAs ) in response to a medication .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1443,
    "text": "We report a girl with Turner syndrome and Graves ' disease who presented with palpable purpuric lesions .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "Turner syndrome"
      ],
      [
        "T1",
        "Disease",
        8,
        11,
        "Graves ' disease"
      ],
      [
        "T2",
        "Disease",
        15,
        17,
        "purpuric lesions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1444,
    "text": "The diagnosis of propylthiouracil ( PTU ) - associated vasculitis was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "propylthiouracil"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "PTU"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "vasculitis"
      ],
      [
        "T3",
        "Chemical",
        40,
        41,
        "PTU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1445,
    "text": "Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis , a complication described in prior case reports .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hyperthyroidism"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1446,
    "text": "Daidzein activates choline acetyltransferase from MC - IXC cells and improves drug - induced amnesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Daidzein"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "choline"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1447,
    "text": "The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of Alzheimer ' s disease ( AD ) .",
    "labels": [
      [
        "T0",
        "Disease",
        33,
        37,
        "Alzheimer ' s disease"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "choline"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "acetylcholine"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "ACh"
      ],
      [
        "T4",
        "Disease",
        38,
        39,
        "AD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1448,
    "text": "Methanolic extracts from Pueraria thunbergiana exhibited an activation effect ( 46 % ) on ChAT in vitro .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1449,
    "text": "Via the sequential isolation of Pueraria thunbergiana , the active component was ultimately identified as daidzein ( 4 ' , 7 - dihydroxy - isoflavone ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        25,
        "4 ' , 7 - dihydroxy - isoflavone"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "daidzein"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1450,
    "text": "In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine - induced impairments of learning and memory , we conducted a series of in vivo tests .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        20,
        "impairments of learning and memory"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "daidzein"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1451,
    "text": "Administration of daidzein ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse scopolamine - induced amnesia , according to the results of a Y - maze test .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "daidzein"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "scopolamine"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1452,
    "text": "Injections of scopolamine into mice resulted in impaired performance on Y - maze tests ( a 37 % decreases in alternation behavior ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1453,
    "text": "By way of contrast , mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment ( an approximately 12 % - 21 % decrease in alternation behavior ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "daidzein"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1454,
    "text": "These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced amnesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "daidzein"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "acetylcholine"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "scopolamine"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1455,
    "text": "Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "overactive bladder"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "tolterodine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1456,
    "text": "OBJECTIVES : To study the urinary symptoms and quality of life changes in Thai women with overactive bladder ( OAB ) after tolterodine treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "overactive bladder"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "OAB"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "tolterodine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1457,
    "text": "MATERIAL AND METHOD : Thirty women ( aged 30 - 77 years ) diagnosed as having OAB at the Gynecology Clinic , King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "OAB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1458,
    "text": "Tolterodine 2 mg , twice daily was given .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Tolterodine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1459,
    "text": "After 8 weeks treatment , changes in micturition diary variables and tolerability were determined .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1460,
    "text": "Short form 36 ( SF36 ) questionaires ( Thai version ) were given before and after 8 weeks of treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1461,
    "text": "RESULTS : At 8 weeks , all micturition per day decreased from 16 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1462,
    "text": "7 + / - 5 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1463,
    "text": "3 to 6 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1464,
    "text": "7 + / - 2 . 4 times per day .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1465,
    "text": "The number of nocturia episodes decreased from 5 . 4 + / - 4 . 2 to 1 . 1 + / - 1 . 0 times per night .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "nocturia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1466,
    "text": "The most common side effect was dry month in 5 cases ( 16 . 7 % ) with 2 cases reporting a moderate degree and 1 case with severe degree .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "dry month"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1467,
    "text": "Only one case ( 3 . 3 % ) withdrew from the present study due to a severe dry mouth .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "dry mouth"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1468,
    "text": "The SF - 36 scores changed significantly in the domains of physical functioning , role function emotional , social function and mental heath .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1469,
    "text": "CONCLUSION : Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Tolterodine"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "OAB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1470,
    "text": "Remifentanil pretreatment reduces myoclonus after etomidate .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Remifentanil"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "myoclonus"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1471,
    "text": "STUDY OBJECTIVE : The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg / kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "remifentanil"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "myoclonus"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1472,
    "text": "DESIGN : This was a randomized , double - blind study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1473,
    "text": "SETTING : The study was conducted at a university hospital .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1474,
    "text": "PATIENTS : Sixty patients were pretreated in a randomized double - blinded fashion with remifentanil 1 microg / kg or placebo .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "remifentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1475,
    "text": "Two minutes after remifentanil or placebo injection , etomidate 0 . 3 mg / kg was given .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "remifentanil"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1476,
    "text": "MEASUREMENTS : Myoclonus was recorded with a scale of 0 to 3 .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Myoclonus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1477,
    "text": "The grade of sedation ( none , mild , moderate , severe ) , nausea , pruritus , and apnea were recorded after injection of both drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "nausea"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "pruritus"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "apnea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1478,
    "text": "MAIN RESULTS : The incidence of myoclonus was significantly lower in the remifentanil group ( 6 . 7 % ) than in the placebo group ( 70 % ) ( P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "myoclonus"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "remifentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1479,
    "text": "None of the patients experienced sedation , apnea , nausea , or pruritus after injection of both drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "apnea"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "nausea"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "pruritus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1480,
    "text": "In the placebo group , male patients were associated with significantly increased incidence of myoclonus after etomidate administration .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "myoclonus"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1481,
    "text": "CONCLUSION : Pretreatment with remifentanil 1 microg / kg reduced myoclonus after etomidate induction without side effects such as sedation , apnea , nausea , or pruritus .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "remifentanil"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "myoclonus"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "etomidate"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "apnea"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "nausea"
      ],
      [
        "T5",
        "Disease",
        26,
        27,
        "pruritus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1482,
    "text": "Men experience increased incidence of myoclonus than women after etomidate administration .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "myoclonus"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1483,
    "text": "Memory function and serotonin transporter promoter gene polymorphism in ecstasy ( MDMA ) users .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "serotonin"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "ecstasy"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1484,
    "text": "Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT neurotoxic lesions on functions in which 5 - HT is involved , such as cognitive function .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        6,
        "3 , 4 - methylenedioxymethamphetamine"
      ],
      [
        "T1",
        "Chemical",
        19,
        22,
        "5 - HT"
      ],
      [
        "T2",
        "Chemical",
        43,
        46,
        "5 - HT"
      ],
      [
        "T3",
        "Disease",
        46,
        48,
        "neurotoxic lesions"
      ],
      [
        "T4",
        "Chemical",
        52,
        55,
        "5 - HT"
      ],
      [
        "T5",
        "Chemical",
        7,
        8,
        "MDMA"
      ],
      [
        "T6",
        "Chemical",
        9,
        10,
        "ecstasy"
      ],
      [
        "T7",
        "Chemical",
        17,
        18,
        "serotonin"
      ],
      [
        "T8",
        "Chemical",
        40,
        41,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1485,
    "text": "Because 5 - HT transporters play a key element in the regulation of synaptic 5 - HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5 - HT transporter promoter gene region ( 5 - HTTLPR ) when studying the effects of MDMA as well as cognitive functioning .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        4,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        14,
        17,
        "5 - HT"
      ],
      [
        "T2",
        "Chemical",
        34,
        37,
        "5 - HT"
      ],
      [
        "T3",
        "Chemical",
        51,
        52,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1486,
    "text": "The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function , as well as the effects of long - term abstention from MDMA , in subjects genotyped for 5 - HTTLPR .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "MDMA"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1487,
    "text": "A second aim of the study was to determine whether these effects differ for females and males .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1488,
    "text": "Fifteen moderate MDMA users ( < 55 lifetime tablets ) , 22 heavy MDMA + users ( > 55 lifetime tablets ) , 16 ex - MDMA + users ( last tablet > 1 year ago ) and 13 controls were compared on a battery of neuropsychological tests .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "MDMA"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "MDMA"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1489,
    "text": "DNA from peripheral nuclear blood cells was genotyped for 5 - HTTLPR using standard polymerase chain reaction methods . A significant group effect was observed only on memory function tasks ( p = 0 . 04 ) but not on reaction times ( p = 0 . 61 ) or attention / executive functioning ( p = 0 . 59 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1490,
    "text": "Heavy and ex - MDMA + users performed significantly poorer on memory tasks than controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1491,
    "text": "In contrast , no evidence of memory impairment was observed in moderate MDMA users .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "memory impairment"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1492,
    "text": "No significant effect of 5 - HTTLPR or gender was observed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1493,
    "text": "While the use of MDMA in quantities that may be considered \" moderate \" is not associated with impaired memory functioning , heavy use of MDMA use may lead to long lasting memory impairments .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        21,
        "impaired memory functioning"
      ],
      [
        "T1",
        "Disease",
        32,
        34,
        "memory impairments"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "MDMA"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1494,
    "text": "No effect of 5 - HTTLPR or gender on memory function or MDMA use was observed .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1495,
    "text": "Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol - induced myocardial infarction in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "mangiferin"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1496,
    "text": "The current study dealt with the protective role of mangiferin , a polyphenol from Mangifera indica Linn .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "mangiferin"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "polyphenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1497,
    "text": "( Anacardiaceae ) , on isoproterenol ( ISPH ) - induced myocardial infarction ( MI ) in rats through its antioxidative mechanism .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "isoproterenol"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "ISPH"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1498,
    "text": "Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused myocardial damage in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "myocardial damage"
      ],
      [
        "T1",
        "Chemical",
        54,
        56,
        "uric acid"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "ISPH"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "lactate"
      ],
      [
        "T4",
        "Chemical",
        44,
        45,
        "creatine"
      ],
      [
        "T5",
        "Chemical",
        60,
        61,
        "iron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1499,
    "text": "The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( TTC ) test used for macroscopic enzyme mapping assay of the ischemic myocardium .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "triphenyl tetrazolium chloride"
      ],
      [
        "T1",
        "Disease",
        23,
        25,
        "ischemic myocardium"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "mangiferin"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "TTC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1500,
    "text": "The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in MI rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        32,
        "Vitamin C"
      ],
      [
        "T1",
        "Chemical",
        33,
        35,
        "Vitamin E"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "superoxide"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "glutathione"
      ],
      [
        "T4",
        "Chemical",
        15,
        16,
        "glutathione"
      ],
      [
        "T5",
        "Chemical",
        18,
        19,
        "glutathione"
      ],
      [
        "T6",
        "Chemical",
        36,
        37,
        "glutathione"
      ],
      [
        "T7",
        "Disease",
        41,
        42,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1501,
    "text": "Upon pretreatment with mangiferin ( 100 mg / kg body weight suspended in 2 ml of dimethyl sulphoxide ) given intraperitoneally for 28 days to MI rats protected the above - mentioned parameters to fall from the normal levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        18,
        "dimethyl sulphoxide"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "mangiferin"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1502,
    "text": "Activities of heart tissue enzymic antioxidants and serum non - enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH - induced MI rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "mangiferin"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "ISPH"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1503,
    "text": "From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH - induced MI due to its antioxidant potential , which regulated the tissues defense system against cardiac damage .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        33,
        "cardiac damage"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "mangiferin"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "ISPH"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1504,
    "text": "Cardiovascular risk with cyclooxygenase inhibitors : general problem with substance specific differences ?",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "cyclooxygenase inhibitors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1505,
    "text": "Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction , stroke , hypertension and heart failure during treatment with cyclooxygenase inhibitors .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "myocardial infarction"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "heart failure"
      ],
      [
        "T2",
        "Chemical",
        24,
        26,
        "cyclooxygenase inhibitors"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "stroke"
      ],
      [
        "T4",
        "Disease",
        17,
        18,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1506,
    "text": "Adverse cardiovascular effects occurred mainly , but not exclusively , in patients with concomitant risk factors .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1507,
    "text": "Cyclooxygenase inhibitors cause complex changes in renal , vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Cyclooxygenase inhibitors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1508,
    "text": "The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1509,
    "text": "A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance - specific differences , which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin - independent effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "cyclooxygenase inhibitors"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "prostaglandin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1510,
    "text": "Diagnostic markers such as N - terminal pro brain natriuretic peptide ( NT - proBNP ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious cardiovascular toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        11,
        "N - terminal pro brain natriuretic peptide"
      ],
      [
        "T1",
        "Chemical",
        12,
        15,
        "NT - proBNP"
      ],
      [
        "T2",
        "Disease",
        41,
        43,
        "cardiovascular toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1511,
    "text": "Pilocarpine seizures cause age - dependent impairment in auditory location discrimination .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        11,
        "impairment in auditory location discrimination"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Pilocarpine"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1512,
    "text": "Children who have status epilepticus have continuous or rapidly repeating seizures that may be life - threatening and may cause life - long changes in brain and behavior .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1513,
    "text": "The extent to which status epilepticus causes deficits in auditory discrimination is unknown .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        7,
        11,
        "deficits in auditory discrimination"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1514,
    "text": "A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "status epilepticus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1515,
    "text": "Male Sprague - Dawley rats were injected with saline on postnatal day ( P ) 20 , or a convulsant dose of pilocarpine on P20 or P45 .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1516,
    "text": "Pilocarpine on either day induced status epilepticus ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures , whereas P20 rats had no cell loss or spontaneous seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "status epilepticus"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Pilocarpine"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "seizures"
      ],
      [
        "T4",
        "Disease",
        30,
        31,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1517,
    "text": "Mature rats were trained with sound - source location and sound - silence discriminations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1518,
    "text": "Control ( saline P20 ) rats acquired both discriminations immediately .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1519,
    "text": "In status epilepticus ( P20 ) rats , acquisition of the sound - source location discrimination was moderately impaired .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "status epilepticus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1520,
    "text": "Status epilepticus ( P45 ) rats failed to acquire either sound - source location or sound - silence discriminations .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Status epilepticus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1521,
    "text": "Status epilepticus in rat causes an age - dependent , long - term impairment in auditory discrimination .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Status epilepticus"
      ],
      [
        "T1",
        "Disease",
        13,
        17,
        "impairment in auditory discrimination"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1522,
    "text": "This impairment may explain one cause of impaired auditory location discrimination in humans .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "impaired auditory location discrimination"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1523,
    "text": "Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "overactive bladder"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "prostaglandins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1524,
    "text": "PURPOSE : NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "PGs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1525,
    "text": "We investigated changes in urinary NGF and PGs in women with OAB .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "PGs"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "OAB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1526,
    "text": "MATERIALS AND METHODS : The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "OAB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1527,
    "text": "Evaluation included patient history , urinalysis , a voiding diary and urodynamic studies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1528,
    "text": "Urine samples were collected .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1529,
    "text": "NGF , PGE2 , PGF2alpha and PGI2 were measured using enzyme - linked immunosorbent assay and compared between the groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "PGE2"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "PGF2alpha"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "PGI2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1530,
    "text": "In addition , correlations between urinary NGF and PG , and urodynamic parameters in patients with OAB were examined .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "PG"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "OAB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1531,
    "text": "RESULTS : Urinary NGF , PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "PGE2"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "PGF2alpha"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "OAB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1532,
    "text": "However , urinary PGI2 was not different between controls and patients with OAB .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "PGI2"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "OAB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1533,
    "text": "In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "OAB"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "PGE2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1534,
    "text": "Urinary NGF , PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "PGF2alpha"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "PGI2"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "OAB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1535,
    "text": "CONCLUSIONS : NGF and PGs have important roles in the development of OAB symptoms in female patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "PGs"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "OAB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1536,
    "text": "Urinary levels of these factors may be used as markers to evaluate OAB symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "OAB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1537,
    "text": "Definition and management of anemia in patients infected with hepatitis C virus .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        12,
        "infected with hepatitis C virus"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1538,
    "text": "Chronic infection with hepatitis C virus ( HCV ) can progress to cirrhosis , hepatocellular carcinoma , and end - stage liver disease .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        6,
        "Chronic infection with hepatitis C virus"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "hepatocellular carcinoma"
      ],
      [
        "T2",
        "Disease",
        18,
        23,
        "end - stage liver disease"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "cirrhosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1539,
    "text": "The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "HCV infection"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "interferon"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1540,
    "text": "Although this regimen produces sustained virologic responses ( SVRs ) in approximately 50 % of patients , it can be associated with a potentially dose - limiting hemolytic anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "hemolytic anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1541,
    "text": "Hemoglobin concentrations decrease mainly as a result of ribavirin - induced hemolysis , and this anemia can be problematic in patients with HCV infection , especially those who have comorbid renal or cardiovascular disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "HCV infection"
      ],
      [
        "T1",
        "Disease",
        30,
        34,
        "renal or cardiovascular disorders"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "ribavirin"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "hemolysis"
      ],
      [
        "T4",
        "Disease",
        15,
        16,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1542,
    "text": "In general , anemia can increase the risk of morbidity and mortality , and may have negative effects on cerebral function and quality of life .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1543,
    "text": "Although ribavirin - associated anemia can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "ribavirin"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1544,
    "text": "Recombinant human erythropoietin has been used to manage ribavirin - associated anemia but has other potential disadvantages .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "ribavirin"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1545,
    "text": "Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Disease",
        30,
        33,
        "chronic hepatitis C"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Viramidine"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "ribavirin"
      ],
      [
        "T4",
        "Chemical",
        19,
        20,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1546,
    "text": "Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1547,
    "text": "BACKGROUND : More than 3 decades after Jones and Smith ( 1973 ) reported on the devastation caused by alcohol exposure on fetal development , the rates of heavy drinking during pregnancy remain relatively unchanged .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1548,
    "text": "Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1549,
    "text": "This study examined the utility of biometry for detecting alcohol - related fetal growth impairment .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "growth impairment"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1550,
    "text": "METHODS : We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1551,
    "text": "The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1552,
    "text": "Because intensity of alcohol consumption is associated with poorer fetal outcomes , separate analyses were conducted for the heavy ( average of > or = 5 drinks per drinking day ) alcohol consumers .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "alcohol"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1553,
    "text": "Fetal measures from the heavy - exposed fetuses were also compared with measures from a nondrinking group that was representative of normal , uncomplicated pregnancies from our clinics .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1554,
    "text": "Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "drug abuse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1555,
    "text": "RESULTS : Nearly half of the pregnant drinkers abstained after learning of their pregnancies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1556,
    "text": "When women reportedly quit drinking early in their pregnancies , fetal growth measures were not significantly different from a non - alcohol - exposed group , regardless of prior drinking patterns .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1557,
    "text": "Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "reduced cerebellar growth"
      ],
      [
        "T1",
        "Disease",
        17,
        22,
        "decreased cranial to body growth"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1558,
    "text": "Amphetamine abuse was predictive of larger cranial to body growth ratios .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1559,
    "text": "CONCLUSIONS : Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1560,
    "text": "Although the reliance on self - reported drinking is a limitation in this study , these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        34,
        35,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1561,
    "text": "Ethambutol - associated optic neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1562,
    "text": "INTRODUCTION : Ethambutol is used in the treatment of tuberculosis , which is still prevalent in Southeast Asia , and can be associated with permanent visual loss .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "visual loss"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Ethambutol"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "tuberculosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1563,
    "text": "We report 3 cases which presented with bitemporal hemianopia .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "bitemporal hemianopia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1564,
    "text": "CLINICAL PICTURE : Three patients with ethambutol - associated toxic optic neuropathy are described .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1565,
    "text": "All 3 patients had loss of central visual acuity , colour vision ( Ishihara ) and visual field .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        18,
        "loss of central visual acuity , colour vision ( Ishihara ) and visual field"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1566,
    "text": "The visual field loss had a bitemporal flavour , suggesting involvement of the optic chiasm .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "visual field loss"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1567,
    "text": "TREATMENT : Despite stopping ethambutol on diagnosis , visual function continued to deteriorate for a few months .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1568,
    "text": "Subsequent improvement was mild in 2 cases .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1569,
    "text": "In the third case , visual acuity and colour vision normalised but the optic discs were pale .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1570,
    "text": "OUTCOME : All 3 patients had some permanent loss of visual function .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "loss of visual function"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1571,
    "text": "CONCLUSIONS : Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow - up .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "visual loss"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1572,
    "text": "The author postulates that in cases of ethambutol associated chiasmopathy , ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "ethambutol"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1573,
    "text": "Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "paroxetine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "alprazolam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1574,
    "text": "A 74 - year - old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia , loss of appetite , exhaustion , and agitation .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "depressive symptoms"
      ],
      [
        "T1",
        "Disease",
        20,
        23,
        "loss of appetite"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "psychiatric"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "insomnia"
      ],
      [
        "T4",
        "Disease",
        27,
        28,
        "agitation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1575,
    "text": "Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1 . 2 mg alprazolam .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "paroxetine"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "alprazolam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1576,
    "text": "On the 10th day of paroxetine and alprazolam treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe muscle rigidity with tremors .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "psychomotor retardation"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "muscle rigidity"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "paroxetine"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "alprazolam"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "tremors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1577,
    "text": "The patient had a fever ( 38 . 2 degrees C ) , fluctuating blood pressure ( between 165 / 90 and 130 / 70 mg mm Hg ) , and severe extrapyramidal symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        34,
        "extrapyramidal symptoms"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "fever"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1578,
    "text": "Laboratory tests showed an elevation of creatine phosphokinase ( 2218 IU / L ) , aspartate aminotransferase ( 134 IU / L ) , alanine aminotransferase ( 78 IU / L ) , and BUN ( 27 . 9 mg / ml ) levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "creatine"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "aspartate"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "alanine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1579,
    "text": "The patient received bromocriptine and diazepam to treat his symptoms .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "bromocriptine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1580,
    "text": "7 days later , the fever disappeared and the patient ' s serum CPK levels were normalized ( 175 IU / L ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "fever"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1581,
    "text": "This patient presented with symptoms of neuroleptic malignant syndrome ( NMS ) , thus demonstrating that NMS - like symptoms can occur after combined paroxetine and alprazolam treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "NMS"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "NMS"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "paroxetine"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "alprazolam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1582,
    "text": "The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case , indicating a probable relationship between the patient ' s NMS - like adverse symptoms and the combined treatment used in this case .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        26,
        "NMS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1583,
    "text": "The involvement of physiologic and environmental aspects specific to this patient was suspected .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1584,
    "text": "Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration , agitation , malnutrition , and exhaustion .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "NMS"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "depressive"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "dehydration"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "agitation"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "malnutrition"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1585,
    "text": "Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1586,
    "text": "Down - regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local - anesthetics - induced convulsions and the counteraction by co - administration with local anesthetics .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "norepinephrine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "desipramine"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1587,
    "text": "Alterations of norepinephrine transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "norepinephrine"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1588,
    "text": "Daily administration of desipramine , an inhibitor of the NET , for 5 days decreased [ ( 3 ) H ] norepinephrine uptake in the P2 fractions of hippocampus but not cortex , striatum or amygdalae .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "desipramine"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1589,
    "text": "Co - administration of lidocaine , bupivacaine or tricaine with desipramine reversed this effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "lidocaine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "tricaine"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "desipramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1590,
    "text": "Daily treatment of cocaine increased [ ( 3 ) H ] norepinephrine uptake into the hippocampus .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1591,
    "text": "Daily administration of desipramine increased the incidence of appearance of lidocaine - induced convulsions and decreased that of cocaine - induced convulsions .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "desipramine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "lidocaine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "convulsions"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "cocaine"
      ],
      [
        "T4",
        "Disease",
        21,
        22,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1592,
    "text": "Co - administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "lidocaine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "desipramine"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "convulsive"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "lidocaine"
      ],
      [
        "T4",
        "Chemical",
        16,
        17,
        "cocaine"
      ],
      [
        "T5",
        "Chemical",
        22,
        23,
        "desipramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1593,
    "text": "These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine - induced sensitization of lidocaine convulsions .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "desipramine"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "desipramine"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "lidocaine"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1594,
    "text": "Inhibition of Na ( + ) channels by local anesthetics may regulate desipramine - induced down - regulation of NET function .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Na"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "desipramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1595,
    "text": "Repeated administration of cocaine induces up - regulation of hippocampal NET function .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1596,
    "text": "Desipramine - induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Desipramine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "lidocaine"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "seizures"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1597,
    "text": "Atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Atorvastatin"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "dexamethasone"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1598,
    "text": "To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( dex ) - induced hypertension , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "atorvastatin"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "atorva"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "dexamethasone"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "dex"
      ],
      [
        "T4",
        "Disease",
        17,
        18,
        "hypertension"
      ],
      [
        "T5",
        "Chemical",
        28,
        29,
        "atorva"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1599,
    "text": "Dex increased systolic blood pressure ( SBP ) from 109 + / - 1 . 8 to 135 + / - 0 . 6 mmHg and plasma superoxide ( 5711 + / - 284 . 9 saline , 7931 + / - 392 . 8 U / ml dex , P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dex"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "superoxide"
      ],
      [
        "T2",
        "Chemical",
        48,
        49,
        "dex"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1600,
    "text": "In this prevention study , SBP in the atorva + dex group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the dex - only group ( P ' < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "atorva"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "dex"
      ],
      [
        "T2",
        "Chemical",
        40,
        41,
        "dex"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1601,
    "text": "Atorva reversed dex - induced hypertension ( 129 + / - 0 . 6 mmHg , vs . 135 + / - 0 . 6 mmHg P ' < 0 . 05 ) and decreased plasma superoxide ( 7931 + / - 392 . 8 dex , 1187 + / - 441 . 2 atorva + dex , P < 0 . 0001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Atorva"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "dex"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "hypertension"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "superoxide"
      ],
      [
        "T4",
        "Chemical",
        45,
        46,
        "dex"
      ],
      [
        "T5",
        "Chemical",
        54,
        55,
        "atorva"
      ],
      [
        "T6",
        "Chemical",
        56,
        57,
        "dex"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1602,
    "text": "Plasma nitrate / nitrite ( NOx ) was decreased in dex - treated rats compared to saline - treated rats ( 11 . 2 + / - 1 . 08 microm , 15 . 3 + / - 1 . 17 microm , respectively , P < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "nitrate"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "nitrite"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "dex"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1603,
    "text": "Atorva affected neither plasma NOx nor thymus weight .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Atorva"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1604,
    "text": "Thus , atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "atorvastatin"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "dexamethasone"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1605,
    "text": "Peripheral neuropathy caused by high - dose cytosine arabinoside treatment in a patient with acute myeloid leukemia .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Peripheral neuropathy"
      ],
      [
        "T1",
        "Chemical",
        7,
        9,
        "cytosine arabinoside"
      ],
      [
        "T2",
        "Disease",
        14,
        17,
        "acute myeloid leukemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1606,
    "text": "The central nervous system toxicity of high - dose cytosine arabinoside is well recognized , but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "cytosine arabinoside"
      ],
      [
        "T1",
        "Chemical",
        19,
        21,
        "cytosine arabinoside"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "toxicity"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1607,
    "text": "A 49 - year - old Japanese man was diagnosed with acute myeloid leukemia .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "acute myeloid leukemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1608,
    "text": "After he achieved complete remission , he received high - dose cytosine arabinoside treatment ( 2 g / m2 twice a day for 5 days ; total , 20 g / m2 ) as consolidation therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "cytosine arabinoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1609,
    "text": "The first course of high - dose cytosine arabinoside resulted in no unusual symptoms , but on day 21 of the second course of treatment , the patient complained of numbness in his right foot .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "cytosine arabinoside"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "numbness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1610,
    "text": "Electromyogram and nerve - conduction studies showed peripheral neuropathy in both peroneal nerves .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "peripheral neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1611,
    "text": "This neuropathy was gradually resolving ; however , after the patient received allogeneic bone marrow transplantation , the symptoms worsened , with the development of graft - versus - host disease , and the symptoms subsequently responded to methylprednisolone .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        31,
        "graft - versus - host disease"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "neuropathy"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "methylprednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1612,
    "text": "Although the mechanisms of peripheral neuropathy are still unclear , high - dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system , and auto / alloimmunity may play an important role in these mechanisms .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "peripheral neuropathy"
      ],
      [
        "T1",
        "Chemical",
        13,
        15,
        "cytosine arabinoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1613,
    "text": "Effect of alpha - tocopherol and deferoxamine on methamphetamine - induced neurotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "alpha - tocopherol"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "deferoxamine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "methamphetamine"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1614,
    "text": "Methamphetamine ( MA ) - induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Methamphetamine"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "MA"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1615,
    "text": "This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced neurotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "alpha - tocopherol"
      ],
      [
        "T1",
        "Chemical",
        10,
        13,
        "alpha - TC"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "oxygen"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "deferoxamine"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "DFO"
      ],
      [
        "T5",
        "Chemical",
        29,
        30,
        "iron"
      ],
      [
        "T6",
        "Chemical",
        34,
        35,
        "MA"
      ],
      [
        "T7",
        "Disease",
        37,
        38,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1616,
    "text": "Male rats were treated with MA ( 10 mg / kg , every 2 h for four injections ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1617,
    "text": "The rat received either alpha - TC ( 20 mg / kg ) intraperitoneally for 3 days and 30 min prior to MA administration or DFO ( 50 mg / kg ) subcutaneously 30 min before MA administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "alpha - TC"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "MA"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "DFO"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1618,
    "text": "The concentrations of dopamine ( DA ) , serotonin and their metabolites decreased significantly after MA administration , which was inhibited by the alpha - TC and DFO pretreatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        26,
        "alpha - TC"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "dopamine"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "DA"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "serotonin"
      ],
      [
        "T4",
        "Chemical",
        15,
        16,
        "MA"
      ],
      [
        "T5",
        "Chemical",
        27,
        28,
        "DFO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1619,
    "text": "alpha - TC and DFO attenuated the MA - induced hyperthermia as well as the alterations in the locomotor activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "alpha - TC"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "DFO"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "MA"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "hyperthermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1620,
    "text": "The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "glutathione"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1621,
    "text": "These changes were significantly attenuated by alpha - TC and DFO .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "alpha - TC"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "DFO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1622,
    "text": "This suggests that alpha - TC and DFO ameliorate the MA - induced neuronal damage by decreasing the level of oxidative stress .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "alpha - TC"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "neuronal damage"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "DFO"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1623,
    "text": "Blockade of both D - 1 and D - 2 dopamine receptors may induce catalepsy in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "dopamine"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1624,
    "text": "1 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1625,
    "text": "The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "catalepsy"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "dopamine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "dopamine"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1626,
    "text": "2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1627,
    "text": "Dopamine antagonist fluphenazine , D - 1 antagonist SCH 23390 or D - 2 antagonist sulpiride induced catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "SCH 23390"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Dopamine"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "fluphenazine"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "sulpiride"
      ],
      [
        "T4",
        "Disease",
        17,
        18,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1628,
    "text": "The effect of fluphenazine and sulpiride was dose - dependent .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "fluphenazine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "sulpiride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1629,
    "text": "Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "SCH 23390"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "sulpiride"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1630,
    "text": "3 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1631,
    "text": "D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the catalepsy induced by fluphenazine , SCH 23390 or sulpiride .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "SKF 38393"
      ],
      [
        "T1",
        "Chemical",
        19,
        21,
        "SCH 23390"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "quinpirole"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "catalepsy"
      ],
      [
        "T4",
        "Chemical",
        17,
        18,
        "fluphenazine"
      ],
      [
        "T5",
        "Chemical",
        22,
        23,
        "sulpiride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1632,
    "text": "4 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1633,
    "text": "Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "SKF 38393"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "quinpirole"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "catalepsy"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1634,
    "text": "5 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1635,
    "text": "The data may indicate that although D - 2 receptor blockade is involved in catalepsy , the D - 1 receptor may plan a role .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1636,
    "text": "Sustained clinical improvement of a patient with decompensated hepatitis B virus - related cirrhosis after treatment with lamivudine monotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "hepatitis B"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "cirrhosis"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1637,
    "text": "Hepatitis B virus ( HBV ) infection , which causes liver cirrhosis and hepatocellular carcinoma , remains a major health problem in Asian countries .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        7,
        "Hepatitis B virus ( HBV ) infection"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "liver cirrhosis"
      ],
      [
        "T2",
        "Disease",
        13,
        15,
        "hepatocellular carcinoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1638,
    "text": "Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers , although the standard medical therapies have not been established up to now .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1639,
    "text": "In this report , we encountered a patient with decompensated HBV - related cirrhosis who exhibited the dramatic improvements after antiviral therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "cirrhosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1640,
    "text": "The patient was a 50 - year - old woman .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1641,
    "text": "Previous conventional medical treatments were not effective for this patient , thus this patient had been referred to our hospital .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1642,
    "text": "However , the administration of lamivudine , a reverse transcriptase inhibitor , for 23 months dramatically improved her liver severity .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1643,
    "text": "During this period , no drug resistant mutant HBV emerged , and the serum HBV - DNA level was continuously suppressed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1644,
    "text": "These virological responses were also maintained even after the antiviral therapy was discontinued .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1645,
    "text": "Moreover , both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        10,
        "hepatitis B surface antigen and e antigen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1646,
    "text": "The administration of lamivudine to patients with HBV - related cirrhosis , like our present case , should be considered as an initial medical therapeutic option , especially in countries where liver transplantation is not reliably available .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "lamivudine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "cirrhosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1647,
    "text": "Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "ventricular arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "cibenzoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1648,
    "text": "Antiarrhythmic effects of ( + ) - cibenzoline and ( - ) - cibenzoline were examined using two canine ventricular arrhythmia models .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "ventricular arrhythmia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cibenzoline"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "cibenzoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1649,
    "text": "Digitalis arrhythmia , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . ) injection of ouabain in pentobarbital - anesthetized dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Digitalis"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "arrhythmia"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "Na"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "ouabain"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "pentobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1650,
    "text": "Adrenaline arrhythmia , which is suppressed by Ca channel blockers , was induced by adrenaline infusion in halothane - anesthetized dogs .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Adrenaline arrhythmia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "Ca"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "adrenaline"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "halothane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1651,
    "text": "Ten and 5 mg / kg i . v . ( + ) - cibenzoline suppressed digitalis - and adrenaline - induced arrhythmias , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "cibenzoline"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "digitalis"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "adrenaline"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "arrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1652,
    "text": "The minimum effective plasma concentrations of ( + ) - cibenzoline for digitalis - and adrenaline - induced arrhythmias were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "cibenzoline"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "digitalis"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "adrenaline"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "arrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1653,
    "text": "A lower dose of 1 mg / kg i . v . of ( - ) - cibenzoline suppressed the digitalis - induced arrhythmia , whereas 5 mg / kg i . v . was needed to suppress adrenaline - induced arrhythmias .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "cibenzoline"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "digitalis"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "arrhythmia"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "adrenaline"
      ],
      [
        "T4",
        "Disease",
        41,
        42,
        "arrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1654,
    "text": "The minimum effective plasma concentrations of ( - ) - cibenzoline for digitalis - and adrenaline - induced arrhythmia were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "cibenzoline"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "digitalis"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "adrenaline"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1655,
    "text": "The stronger antiarrhythmic effect of ( - ) - cibenzoline indicates that ( - ) - isomer may have an effect nearly 5 - 20 times stronger in suppressing Na channels , but effects of both drugs on Ca channels may be almost equipotent .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "cibenzoline"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "Na"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "Ca"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1656,
    "text": "Passage of mannitol into the brain around gliomas : a potential cause of rebound phenomenon .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "mannitol"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "gliomas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1657,
    "text": "A study on 21 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1658,
    "text": "AIM : Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so - called rebound phenomenon .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "brain edema"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "elevated ICP"
      ],
      [
        "T2",
        "Disease",
        15,
        17,
        "brain tumor"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1659,
    "text": "Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1660,
    "text": "This has only been demonstrated experimentally in animals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1661,
    "text": "As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "brain tumor"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1662,
    "text": "METHODS : Mannitol ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had malignant glioma , seven brain metastases and four meningioma ) about 30 minutes before craniotomy .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "malignant glioma"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Mannitol"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "metastases"
      ],
      [
        "T3",
        "Disease",
        31,
        32,
        "meningioma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1663,
    "text": "During resection , a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "edematous"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1664,
    "text": "Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1665,
    "text": "RESULTS : In most glioma patients , mannitol concentrations in white matter were 2 to 6 times higher than in plasma ( mean 3 . 5 times ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "glioma"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1666,
    "text": "In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "meningioma"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "metastases"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1667,
    "text": "CONCLUSIONS : The results of our study show that even after a single bolus , mannitol may leak through the altered BBB near gliomas , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral edema and promoting rebound of ICP .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "mannitol"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "gliomas"
      ],
      [
        "T2",
        "Disease",
        38,
        39,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1668,
    "text": "Placebo - level incidence of extrapyramidal symptoms ( EPS ) with quetiapine in controlled studies of patients with bipolar mania .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "extrapyramidal symptoms"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "bipolar mania"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "EPS"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1669,
    "text": "OBJECTIVES : To evaluate extrapyramidal symptoms ( EPS ) , including akathisia , with quetiapine in patients with bipolar mania .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "extrapyramidal symptoms"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "bipolar mania"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "EPS"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "akathisia"
      ],
      [
        "T4",
        "Chemical",
        14,
        15,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1670,
    "text": "METHODS : Data were analyzed from four similarly designed , randomized , double - blind , 3 - to 12 - week studies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1671,
    "text": "Two studies evaluated quetiapine monotherapy ( up to 800 mg / day ) ( n = 209 ) versus placebo ( n = 198 ) , with lithium or haloperidol monotherapy as respective active controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "quetiapine"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "lithium"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1672,
    "text": "Two studies evaluated quetiapine ( up to 800 mg / day ) in combination with a mood stabilizer ( lithium or divalproex , QTP + Li / DVP ) ( n = 196 ) compared to placebo and mood stabilizer ( PBO + Li / DVP ) ( n = 203 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "quetiapine"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "lithium"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "divalproex"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "QTP"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "Li"
      ],
      [
        "T5",
        "Chemical",
        27,
        28,
        "DVP"
      ],
      [
        "T6",
        "Chemical",
        43,
        44,
        "Li"
      ],
      [
        "T7",
        "Chemical",
        45,
        46,
        "DVP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1673,
    "text": "Extrapyramidal symptoms were evaluated using the Simpson - Angus Scale ( SAS ) , the Barnes Akathisia Rating Scale ( BARS ) , adverse event reports and anticholinergic drug usage .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Extrapyramidal symptoms"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1674,
    "text": "RESULTS : The incidence of EPS - related adverse events , including akathisia , was no different with quetiapine monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "EPS"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "akathisia"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1675,
    "text": "Similarly , EPS - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "EPS"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "QTP"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "Li"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "DVP"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "Li"
      ],
      [
        "T5",
        "Chemical",
        28,
        29,
        "DVP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1676,
    "text": "Adverse events related to EPS occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to EPS .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "EPS"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "haloperidol"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "lithium"
      ],
      [
        "T3",
        "Disease",
        44,
        45,
        "EPS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1677,
    "text": "The incidence of akathisia was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "akathisia"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "quetiapine"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "QTP"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "Li"
      ],
      [
        "T4",
        "Chemical",
        32,
        33,
        "DVP"
      ],
      [
        "T5",
        "Chemical",
        42,
        43,
        "Li"
      ],
      [
        "T6",
        "Chemical",
        44,
        45,
        "DVP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1678,
    "text": "Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Lithium"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "tremor"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "quetiapine"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "tremor"
      ],
      [
        "T4",
        "Chemical",
        42,
        43,
        "lithium"
      ],
      [
        "T5",
        "Disease",
        52,
        53,
        "tremor"
      ],
      [
        "T6",
        "Chemical",
        56,
        57,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1679,
    "text": "Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than quetiapine .",
    "labels": [
      [
        "T0",
        "Disease",
        41,
        43,
        "extrapyramidal syndrome"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Haloperidol"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "akathisia"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "tremor"
      ],
      [
        "T4",
        "Chemical",
        55,
        56,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1680,
    "text": "No significant differences were observed between quetiapine and placebo on SAS and BARS scores .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1681,
    "text": "Anticholinergic use was low and similar with quetiapine or placebo .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1682,
    "text": "CONCLUSIONS : In bipolar mania , the incidence of EPS , including akathisia , with quetiapine therapy is similar to that with placebo .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "bipolar mania"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "EPS"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "akathisia"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1683,
    "text": "Is phenytoin administration safe in a hypothermic child ?",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "phenytoin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hypothermic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1684,
    "text": "A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "Chiari malformation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1685,
    "text": "During anaesthesia and surgery , he inadvertently became moderately hypothermic .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "hypothermic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1686,
    "text": "Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "phenytoin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1687,
    "text": "Following phenytoin administration , the patient developed acute severe bradycardia , refractory to atropine and adrenaline .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "phenytoin"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "bradycardia"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "atropine"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "adrenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1688,
    "text": "The cardiac depressant actions of phenytoin and hypothermia can be additive .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "phenytoin"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hypothermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1689,
    "text": "Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "phenytoin"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hypothermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1690,
    "text": "As phenytoin is a commonly used drug , clinicians need to be aware of this interaction .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "phenytoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1691,
    "text": "Valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "nonketotic hyperglycinemia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Valproate"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "chorea"
      ],
      [
        "T3",
        "Disease",
        5,
        6,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1692,
    "text": "Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Nonketotic hyperglycinemia"
      ],
      [
        "T1",
        "Disease",
        4,
        9,
        "disorder of amino acid metabolism"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "glycine"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "glycine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1693,
    "text": "In the classical form it presents as neonatal apnea , intractable seizures , and hypotonia , followed by significant psychomotor retardation .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "psychomotor retardation"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "apnea"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "seizures"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "hypotonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1694,
    "text": "An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "nonketotic hyperglycinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1695,
    "text": "This report describes a patient with mild language delay and mental retardation , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "language delay"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "mental retardation"
      ],
      [
        "T2",
        "Disease",
        18,
        20,
        "nonketotic hyperglycinemia"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "encephalopathy"
      ],
      [
        "T4",
        "Disease",
        27,
        28,
        "chorea"
      ],
      [
        "T5",
        "Chemical",
        32,
        33,
        "valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1696,
    "text": "Delayed institution of hypertension during focal cerebral ischemia : effect on brain edema .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "cerebral ischemia"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "brain edema"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1697,
    "text": "The effect of induced hypertension instituted after a 2 - h delay following middle cerebral artery occlusion ( MCAO ) on brain edema formation and histochemical injury was studied .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        17,
        "middle cerebral artery occlusion"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "brain edema"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "hypertension"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "MCAO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1698,
    "text": "Under isoflurane anesthesia , the MCA of 14 spontaneously hypertensive rats was occluded .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "isoflurane"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1699,
    "text": "In the control group ( n = 7 ) , the mean arterial pressure ( MAP ) was not manipulated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1700,
    "text": "In the hypertensive group ( n = 7 ) , the MAP was elevated by 25 - 30 mm Hg beginning 2 h after MCAO .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "hypertensive"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "MCAO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1701,
    "text": "Four hours after MCAO , the rats were killed and the brains harvested .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "MCAO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1702,
    "text": "The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "ischemia"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "MCAO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1703,
    "text": "Specific gravity ( SG ) was determined in the subcortex and in two sites in the cortex ( core and periphery of the ischemic territory ) .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1704,
    "text": "The extent of neuronal injury was determined by 2 , 3 , 5 - triphenyltetrazolium staining .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "neuronal injury"
      ],
      [
        "T1",
        "Chemical",
        8,
        15,
        "2 , 3 , 5 - triphenyltetrazolium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1705,
    "text": "In the ischemic core , there was no difference in SG in the subcortex and cortex in the two groups .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1706,
    "text": "In the periphery of the ischemic territory , SG in the cortex was greater ( less edema accumulation ) in the hypertensive group ( 1 . 041 + / - 0 . 001 vs 1 . 039 + / - 0 . 001 , P less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "ischemic"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "edema"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1707,
    "text": "The area of histochemical injury ( as a percent of the cross - sectional area of the hemisphere ) was less in the hypertensive group ( 33 + / - 3 % vs 21 + / - 2 % , P less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1708,
    "text": "The data indicate that phenylephrine - induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        42,
        44,
        "neuronal dysfunction"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "phenylephrine"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "hypertension"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "MCAO"
      ],
      [
        "T4",
        "Disease",
        16,
        17,
        "edema"
      ],
      [
        "T5",
        "Disease",
        19,
        20,
        "ischemic"
      ],
      [
        "T6",
        "Disease",
        25,
        26,
        "edema"
      ],
      [
        "T7",
        "Disease",
        31,
        32,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1709,
    "text": "Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "steroid"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1710,
    "text": "The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid ( AAS ) exposure and brain serotonin ( 5 - hydroxytryptamine , 5 - HT ) depletion on behavior of pubertal male rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        27,
        "5 - hydroxytryptamine"
      ],
      [
        "T1",
        "Chemical",
        28,
        31,
        "5 - HT"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "steroid"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1711,
    "text": "Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine ( PCPA 100 mg / kg , every other day ) ; controls received saline .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Serotonin"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "parachlorophenylalanine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "PCPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1712,
    "text": "At puberty ( P40 ) , half the PCPA - treated rats and half the saline - treated rats began treatment with testosterone ( T , 5 mg / kg , 5 days / week ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "PCPA"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "testosterone"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "T"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1713,
    "text": "Behavioral measures included locomotion , irritability , copulation , partner preference , and aggression .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "irritability"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "aggression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1714,
    "text": "Animals were tested for aggression in their home cage , both with and without physical provocation ( mild tail pinch ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "aggression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1715,
    "text": "Brain levels of 5 - HT and its metabolite , 5 - hydroxyindoleacetic acid ( 5 - HIAA ) , were determined using HPLC .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        10,
        14,
        "5 - hydroxyindoleacetic acid"
      ],
      [
        "T2",
        "Chemical",
        15,
        18,
        "5 - HIAA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1716,
    "text": "PCPA significantly and substantially depleted 5 - HT and 5 - HIAA in all brain regions examined .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        9,
        12,
        "5 - HIAA"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "PCPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1717,
    "text": "Chronic T treatment significantly decreased 5 - HT and 5 - HIAA in certain brain areas , but to a much lesser extent than PCPA .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        9,
        12,
        "5 - HIAA"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "T"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "PCPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1718,
    "text": "Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior , partner preference , or aggression .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "PCPA"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "irritability"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "aggression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1719,
    "text": "T alone had no effect on locomotion , irritability , or sexual behavior but increased partner preference and aggression .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "T"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "irritability"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "aggression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1720,
    "text": "The most striking effect of combining T + PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack , particularly following physical provocation .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "T"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "PCPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1721,
    "text": "Based on these data , it can be speculated that pubertal AAS users with low central 5 - HT may be especially prone to exhibit aggressive behavior .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "5 - HT"
      ],
      [
        "T1",
        "Disease",
        25,
        27,
        "aggressive behavior"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1722,
    "text": "Effects of UMB24 and ( + / - ) - SM 21 , putative sigma2 - preferring antagonists , on behavioral toxic and stimulant effects of cocaine in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "SM 21"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "UMB24"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1723,
    "text": "Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive , lethal , locomotor stimulatory and rewarding actions of cocaine in mice .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "convulsive"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1724,
    "text": "In contrast , the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1725,
    "text": "To begin addressing this need , we characterized UMB24 ( 1 - ( 2 - phenethyl ) - 4 - ( 2 - pyridyl ) - piperazine ) and ( + / - ) - SM 21 ( 3alpha - tropanyl - 2 - ( 4 - chorophenoxy ) butyrate ) in receptor binding and behavioral studies .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        27,
        "1 - ( 2 - phenethyl ) - 4 - ( 2 - pyridyl ) - piperazine"
      ],
      [
        "T1",
        "Chemical",
        35,
        37,
        "SM 21"
      ],
      [
        "T2",
        "Chemical",
        38,
        50,
        "3alpha - tropanyl - 2 - ( 4 - chorophenoxy ) butyrate"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "UMB24"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1726,
    "text": "Receptor binding studies confirmed that UMB24 and ( + / - ) - SM 21 display preferential affinity for sigma2 over sigma1 receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "SM 21"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "UMB24"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1727,
    "text": "In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - SM 21 significantly attenuated cocaine - induced convulsions and locomotor activity , but not lethality .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        20,
        "SM 21"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "UMB24"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1728,
    "text": "When administered alone , ( + / - ) - SM 21 produced no significant effects compared to control injections of saline , but UMB24 had locomotor depressant actions .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "SM 21"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "UMB24"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1729,
    "text": "Together , the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine , and further development of more selective , high affinity ligands are warranted .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1730,
    "text": "Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cardiac arrest"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "cerebral palsy"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "sevoflurane"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "clonidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1731,
    "text": "Clonidine is a frequently administered alpha2 - adrenergic agonist which can decrease heart rate and blood pressure .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Clonidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1732,
    "text": "We present a case of a 5 - year - old child with cerebral palsy and seizure disorder , receiving clonidine for restlessness , who presented for placement of a baclofen pump .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "cerebral palsy"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "seizure disorder"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "clonidine"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "restlessness"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "baclofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1733,
    "text": "Without the knowledge of the medical personnel , the patient ' s mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "clonidine"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1734,
    "text": "During induction of anesthesia , the patient developed bradycardia and hypotension requiring cardiac resuscitation .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "bradycardia"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1735,
    "text": "There are no previous reports of clonidine - associated cardiac arrest in a child undergoing induction of anesthesia .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "cardiac arrest"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "clonidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1736,
    "text": "Angiotensin - converting enzyme ( ACE ) inhibitor - associated angioedema of the stomach and small intestine : a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "angioedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1737,
    "text": "This is a case report on a 45 - year old African - American female with newly diagnosed hypertension , who was started on a combination pill of amlodipine / benazapril 10 / 5 mg .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "hypertension"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "amlodipine"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "benazapril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1738,
    "text": "The very next day , she presented at the emergency room ( ER ) with abdominal pain , nausea and vomiting .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "abdominal pain"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "nausea"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "vomiting"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1739,
    "text": "Physical exam , complete metabolic panel , and hemogram were in the normal range .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1740,
    "text": "She was discharged from the ER after a few hours of treatment with fluid and analgesics .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1741,
    "text": "However , she returned to the ER the next day with the same complaints .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1742,
    "text": "This time the physical exam was significant for a distended abdomen with dullness to percussion .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1743,
    "text": "CT scan of the abdomen revealed markedly thickened antrum of the stomach , duodenum and jejunum , along with fluid in the abdominal and pelvic cavity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1744,
    "text": "Angiotensin - converting enzyme inhibitor ( ACEI ) - induced angioedema was suspected , and anti - hypertensive medications were discontinued .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "angioedema"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1745,
    "text": "Her symptoms improved within the next 24 hours , and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        28,
        "ascites"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1746,
    "text": "The recognition of angiotensin - converting enzyme ( ACE ) and angiotensin receptor blocker ( ARB ) intestinal angioedema constitutes a challenge to primary care physicians , internists , emergency room personal and surgeons .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "intestinal angioedema"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "angiotensin"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "angiotensin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1747,
    "text": "Carbamazepine - induced cardiac dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1748,
    "text": "Characterization of two distinct clinical syndromes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1749,
    "text": "A patient with sinus bradycardia and atrioventricular block , induced by carbamazepine , prompted an extensive literature review of all previously reported cases .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "atrioventricular block"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "bradycardia"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1750,
    "text": "From the analysis of these cases , two distinct forms of carbamazepine - associated cardiac dysfunction emerged .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1751,
    "text": "One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "sinus tachycardias"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "carbamazepine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1752,
    "text": "The second group consisted almost exclusively of elderly women who developed potentially life - threatening bradyarrhythmias or atrioventricular conduction delay , associated with either therapeutic or modestly elevated carbamazepine serum levels .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "atrioventricular conduction delay"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "bradyarrhythmias"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1753,
    "text": "Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions , the recognition of the latter syndrome has important implications for the use of this drug in elderly patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "carbamazepine"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "psychiatric"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1754,
    "text": "Detection of abnormal cardiac adrenergic neuron activity in adriamycin - induced cardiomyopathy with iodine - 125 - metaiodobenzylguanidine .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        18,
        "iodine - 125 - metaiodobenzylguanidine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "adriamycin"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1755,
    "text": "Radiolabeled metaiodobenzylguanidine ( MIBG ) , an analog of norepinephrine ( NE ) , serves as an index of adrenergic neuron integrity and function .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Radiolabeled metaiodobenzylguanidine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "MIBG"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "norepinephrine"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "NE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1756,
    "text": "Using a rat model of adriamycin - induced cardiomyopathy , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "adriamycin"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "cardiomyopathy"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "adriamycin"
      ],
      [
        "T3",
        "Disease",
        30,
        31,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1757,
    "text": "The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment ( 2 mg / kg , once a week ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        8,
        "vacuolar degeneration of myocardial cells"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "adriamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1758,
    "text": "There were no abnormalities or only isolated degeneration in the 1 - or 2 - wk treatment groups , isolated or scattered degeneration in half of the 3 - wk group , frequent scattered degeneration in the 4 - wk group , scattered or focal degeneration in the 5 - wk group , and extensive degeneration in the 8 - wk group .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1759,
    "text": "Myocardial accumulation of [ 125I ] MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "MIBG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1760,
    "text": "However , the 4 - wk group had a slightly lower accumulation in the right ventricular wall ( 82 % of the control ) and significantly lower accumulation in the left ventricular wall ( about 66 % of the control : p less than 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1761,
    "text": "In the 5 - wk group , MIBG accumulation in the right and left ventricular wall was 35 % and 27 % of that in controls , respectively ( p less than 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "MIBG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1762,
    "text": "In the 8 - wk group , MIBG accumulation in the right and left ventricular wall was 18 % and 14 % of that in controls , respectively ( p less than 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "MIBG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1763,
    "text": "Thus , MIBG accumulation in the myocardium decreased in an adriamycin dose - dependent manner .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "MIBG"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "adriamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1764,
    "text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal vacuolar degeneration ) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin - induced cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "myocardial impairment"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "vacuolar degeneration"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "MIBG"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "adriamycin"
      ],
      [
        "T4",
        "Disease",
        37,
        38,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1765,
    "text": "Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "QT prolongation"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Syncope"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "methadone"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "heroin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1766,
    "text": "BACKGROUND : Methadone is prescribed to heroin addicts to decrease illicit opioid use .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Methadone"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "heroin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1767,
    "text": "Prolongation of the QT interval in the ECG of patients with torsade de pointes ( TdP ) has been reported in methadone users .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "torsade de pointes"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "TdP"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1768,
    "text": "As heroin addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of methadone .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "heroin"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "syncope"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "TdP"
      ],
      [
        "T3",
        "Chemical",
        53,
        54,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1769,
    "text": "METHODS : In this cross - sectional study interview , ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "heroin"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "methadone"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "buprenorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1770,
    "text": "Of the patients at the Drug Addiction Service in the municipal of Copenhagen , 450 ( approximately 52 % ) were included .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1771,
    "text": "The QT interval was estimated from 12 lead ECGs .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1772,
    "text": "All participants were interviewed about any experience of syncope .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "syncope"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1773,
    "text": "The association between opioid dose and QT , and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "methadone"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "syncope"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1774,
    "text": "RESULTS : Methadone dose was associated with longer QT interval of 0 . 140 ms / mg ( p = 0 . 002 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1775,
    "text": "No association between buprenorphine and QTc was found .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "buprenorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1776,
    "text": "Among the subjects treated with methadone , 28 % men and 32 % women had prolonged QTc interval .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "prolonged QTc interval"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1777,
    "text": "None of the subjects treated with buprenorphine had QTc interval > 0 . 440 s ( ( 1 / 2 ) ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "buprenorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1778,
    "text": "A 50 mg higher methadone dose was associated with a 1 . 2 ( 95 % CI 1 . 1 to 1 . 4 ) times higher odds for syncope .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "methadone"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "syncope"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1779,
    "text": "CONCLUSIONS : Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "QT prolongation"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Methadone"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "syncope"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "heroin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1780,
    "text": "Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "ziprasidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1781,
    "text": "Neuroleptic malignant syndrome ( NMS ) is the rarest and most serious of the neuroleptic - induced movement disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "movement disorders"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "NMS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1782,
    "text": "We describe a case of neuroleptic malignant syndrome ( NMS ) associated with the use of ziprasidone .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "NMS"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "ziprasidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1783,
    "text": "Although conventional neuroleptics are more frequently associated with NMS , atypical antipsychotic drugs like ziprasidone may also be a cause .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "NMS"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "ziprasidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1784,
    "text": "The patient is a 24 - year - old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80 - mg / day dose of orally administrated ziprasidone .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "schizophrenia"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "NMS"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "ziprasidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1785,
    "text": "This case is the earliest ( second day of treatment ) NMS due to ziprasidone reported in the literature .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "NMS"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "ziprasidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1786,
    "text": "Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "iron dextran"
      ],
      [
        "T1",
        "Disease",
        4,
        8,
        "degeneration of dopaminergic neurons"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1787,
    "text": "Iron accumulation is considered to be involved in the pathogenesis of Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        15,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Iron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1788,
    "text": "To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals .",
    "labels": [
      [
        "T0",
        "Disease",
        53,
        57,
        "degeneration of dopaminergic neurons"
      ],
      [
        "T1",
        "Chemical",
        65,
        67,
        "iron dextran"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "iron"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "tyrosine"
      ],
      [
        "T4",
        "Chemical",
        39,
        40,
        "iron"
      ],
      [
        "T5",
        "Chemical",
        59,
        60,
        "iron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1789,
    "text": "The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH - immunoreactive neurons in the SN .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "iron dextran"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "iron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1790,
    "text": "As a result , dopamine release and content , as well as its metabolites contents were decreased in caudate putamen .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1791,
    "text": "Even more dramatic changes were found in chronic overload group .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1792,
    "text": "These results suggest that peripheral iron dextran can increase the iron level in the SN , where excessive iron causes the degeneration of dopaminergic neurons .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "iron dextran"
      ],
      [
        "T1",
        "Disease",
        21,
        25,
        "degeneration of dopaminergic neurons"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "iron"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "iron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1793,
    "text": "The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "iron"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "iron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1794,
    "text": "Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "corticosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1795,
    "text": "The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events , in combination leading to overt disease .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1796,
    "text": "We investigated the effect of an early stress , in the form of maternal deprivation , combined with a later stress , simulated by chronic periadolescent corticosterone treatment , on behaviour in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "corticosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1797,
    "text": "Acute treatment with apomorphine caused disruption of prepulse inhibition ( PPI ) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment , but was surprisingly absent in rats that had undergone the combined early and late stress .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "apomorphine"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "corticosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1798,
    "text": "Amphetamine treatment significantly disrupted PPI in both non - deprived groups , but was absent in both maternally deprived groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1799,
    "text": "The serotonin - 1A receptor agonist , 8 - OH - DPAT , induced a significant disruption of PPI in all groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        12,
        "8 - OH - DPAT"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1800,
    "text": "Amphetamine - induced locomotor hyperactivity was similar in all groups .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "locomotor hyperactivity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1801,
    "text": "These results show an inhibitory interaction of early stress , caused by maternal deprivation , combined with ' adolescent ' stress , simulated by corticosterone treatment , on dopaminergic regulation of PPI .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "corticosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1802,
    "text": "The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation , or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "apomorphine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "amphetamine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1803,
    "text": "An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha - 2b and ribavirin treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "delusional parasitosis"
      ],
      [
        "T1",
        "Disease",
        9,
        12,
        "chronic hepatitis C"
      ],
      [
        "T2",
        "Chemical",
        14,
        19,
        "pegylated interferon alpha - 2b"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1804,
    "text": "During treatment of chronic hepatitis C patients with interferon and ribavirin , a lot of side effects are described .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "chronic hepatitis C"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1805,
    "text": "Twenty - three percent to 44 % of patients develop depression .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1806,
    "text": "A minority of patients evolve to psychosis .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1807,
    "text": "To the best of our knowledge , no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "psychogenic parasitosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1808,
    "text": "We present a 49 - year - old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha - 2b weekly and ribavirin .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "delusional parasitosis"
      ],
      [
        "T1",
        "Chemical",
        17,
        22,
        "pegylated interferon alpha - 2b"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1809,
    "text": "She complained of seeing parasites and the larvae of fleas in her stools .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1810,
    "text": "This could not be confirmed by any technical examination .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1811,
    "text": "All the complaints disappeared after stopping pegylated interferon alpha - 2b and reappeared after restarting it .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        11,
        "pegylated interferon alpha - 2b"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1812,
    "text": "She had a complete sustained viral response .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1813,
    "text": "Hepatonecrosis and cholangitis related to long - term phenobarbital therapy : an autopsy report of two patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hepatonecrosis"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "cholangitis"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "phenobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1814,
    "text": "Phenobarbital ( PB ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        36,
        "liver disease"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Phenobarbital"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "PB"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1815,
    "text": "Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly : one as consequence of cardiac arrest , the other of acute bronchopneumonia .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "cardiac arrest"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "epilepsy"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "PB"
      ],
      [
        "T3",
        "Disease",
        31,
        32,
        "bronchopneumonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1816,
    "text": "At autopsy , analysis of liver parenchyma revealed rich portal inflammatory infiltrate , which consisted of mixed eosinophil and monocyte cells , associated with several foci of necrosis surrounded by a hard ring of non - specific granulomatous tissue .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        28,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1817,
    "text": "Inflammatory reactions of internal and external hepatic biliary ducts were also seen .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1818,
    "text": "Our findings illustrate that PB may be associated with chronic liver damage , which may lead to more serious and deleterious consequences .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "liver damage"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1819,
    "text": "For this reason , each clinician should recognize this entity in the differential diagnosis of PB - related asymptomatic chronic hepatic enzyme dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        23,
        "chronic hepatic enzyme dysfunction"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1820,
    "text": "Delayed leukoencephalopathy with stroke - like presentation in chemotherapy recipients .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "leukoencephalopathy"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1821,
    "text": "BACKGROUND : A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy , most commonly in recipients of intrathecal methotrexate for childhood leukaemia .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "cerebrovascular accident"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "leukoencephalopathy"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "methotrexate"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "leukaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1822,
    "text": "Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1823,
    "text": "METHODS : We reviewed the medical literature for single reports and case series of patients presenting with stroke - like episodes while receiving systemic or intrathecal chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1824,
    "text": "We only included studies providing detailed neuroimaging data .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1825,
    "text": "Patients with cerebrovascular accidents were excluded .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "cerebrovascular accidents"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1826,
    "text": "RESULTS : We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and capecitabine .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        23,
        "5 - fluorouracil"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "leukoencephalopathy"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "methotrexate"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "carmofur"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "capecitabine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1827,
    "text": "Diffusion weighted imaging ( DWI ) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum , corresponding to areas of decreased proton diffusion on apparent diffusion coefficient ( ADC ) maps ( available in 21 / 27 patients ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        19,
        "lesions within the subcortical white matter"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1828,
    "text": "Lesions exceeded the confines of adjacent vascular territories .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1829,
    "text": "Complete resolution of symptoms within 1 - 4 days was accompanied by normalisation of ADC abnormalities .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1830,
    "text": "However , fluid attenuated inversion recovery ( FLAIR ) sequences frequently revealed persistent white matter abnormalities .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "white matter abnormalities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1831,
    "text": "CONCLUSIONS : Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "leukoencephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1832,
    "text": "DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        14,
        "cytotoxic oedema within cerebral white matter"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1833,
    "text": "Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "fetal pulmonary hypertension"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1834,
    "text": "RATIONALE : Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Fluoxetine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1835,
    "text": "Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "pulmonary hypertension syndrome"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1836,
    "text": "The mechanism responsible for this effect is unclear and paradoxical , considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "pulmonary hypertension"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1837,
    "text": "OBJECTIVES : To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1838,
    "text": "METHODS : Pregnant rats were treated with fluoxetine ( 10 mg / kg ) from Day 11 through Day 21 of gestation .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1839,
    "text": "MEASUREMENTS AND MAIN RESULTS : Fetuses were delivered by cesarean section .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1840,
    "text": "As compared with controls , fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum ( P = 0 . 02 ) and by an increase in pulmonary arterial medial thickness ( P < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "fetal pulmonary hypertension"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1841,
    "text": "Postnatal mortality was increased among experimental animals , and arterial oxygen saturation was 96 + / - 1 % in 1 - day - old control animals and significantly lower ( P < 0 . 01 ) in fluoxetine - exposed pups ( 79 + / - 2 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "oxygen"
      ],
      [
        "T1",
        "Chemical",
        38,
        39,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1842,
    "text": "In vitro , fluoxetine induced pulmonary arterial muscle contraction in fetal , but not adult , animals ( P < 0 . 01 ) and reduced serotonin - induced contraction at both ages ( P < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "fluoxetine"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1843,
    "text": "After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal , but not adult , cells ( P < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1844,
    "text": "CONCLUSIONS : In contrast to the adult , fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "pulmonary hypertension"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1845,
    "text": "Disulfiram - induced transient optic and peripheral neuropathy : a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        8,
        "optic and peripheral neuropathy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Disulfiram"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1846,
    "text": "AIM : To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "optic and peripheral neuropathy"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "alcohol dependence"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "disulfiram"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1847,
    "text": "MATERIALS AND METHODS : A case report .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1848,
    "text": "RESULTS : A 57 - year - old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "loss of vision"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "headaches"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1849,
    "text": "He also complained of paraesthesia with numbness in both feet .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "paraesthesia"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "numbness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1850,
    "text": "His vision was 6 / 15 and 2 / 60 in the right and left eyes , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1851,
    "text": "Fundoscopy revealed bilaterally swollen optic nerve heads .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1852,
    "text": "Visual field testing confirmed bilateral central - caecal scotomata .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "scotomata"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1853,
    "text": "He had been taking disulfiram for alcohol dependence for the preceding 3 years .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "alcohol dependence"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "disulfiram"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1854,
    "text": "Disulfiram discontinuation lead to an immediate symptomatic improvement .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Disulfiram"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1855,
    "text": "CONCLUSION : Physicians initiating long - term disulfiram therapy should be aware of these adverse effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "disulfiram"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1856,
    "text": "They should recommend annual ophthalmic reviews with visual field testing .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1857,
    "text": "Patients should be reassured with respect to the reversibility of these adverse effects .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1858,
    "text": "Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "fluocinolone acetonide"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "uveitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1859,
    "text": "OBJECTIVE : To report the incidence and management of elevated intraocular pressure ( IOP ) in patients with uveitis treated with the fluocinolone acetonide ( FA ) intravitreal implant .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "elevated intraocular pressure"
      ],
      [
        "T1",
        "Chemical",
        22,
        24,
        "fluocinolone acetonide"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "uveitis"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "FA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1860,
    "text": "DESIGN : Pooled data from 3 multicenter , double - masked , randomized , controlled , phase 2b / 3 clinical trials evaluating the safety and efficacy of the 0 . 59 - mg or 2 . 1 - mg FA intravitreal implant or standard therapy were analyzed .",
    "labels": [
      [
        "T0",
        "Chemical",
        40,
        41,
        "FA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1861,
    "text": "RESULTS : During the 3 - year follow - up , 71 . 0 % of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55 . 1 % , 24 . 7 % , and 6 . 2 % of eyes reached an IOP of 30 mm Hg or more , 40 mm Hg or more , and 50 mm Hg or more , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1862,
    "text": "Topical IOP - lowering medication was administered in 74 . 8 % of implanted eyes , and IOP - lowering surgeries , most of which were trabeculectomies ( 76 . 2 % ) , were performed on 36 . 6 % of implanted eyes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1863,
    "text": "Intraocular pressure - lowering surgeries were considered a success ( postoperative IOP of 6 - 21 mm Hg with or without additional IOP - lowering medication ) in 85 . 1 % of eyes at 1 year .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1864,
    "text": "The rate of hypotony ( IOP < / = 5 mm Hg ) following IOP - lowering surgery ( 42 . 5 % ) was not different from that of implanted eyes not subjected to surgery ( 35 . 4 % ) ( P = . 09 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypotony"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1865,
    "text": "CONCLUSION : Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1866,
    "text": "Myocardial Fas ligand expression increases susceptibility to AZT - induced cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "AZT"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1867,
    "text": "BACKGROUND : Dilated cardiomyopathy ( DCM ) and myocarditis occur in many HIV - infected individuals , resulting in symptomatic heart failure in up to 5 % of patients .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Dilated cardiomyopathy"
      ],
      [
        "T1",
        "Disease",
        12,
        15,
        "HIV - infected"
      ],
      [
        "T2",
        "Disease",
        20,
        22,
        "heart failure"
      ],
      [
        "T3",
        "Disease",
        5,
        6,
        "DCM"
      ],
      [
        "T4",
        "Disease",
        8,
        9,
        "myocarditis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1868,
    "text": "Highly active antiretroviral therapy ( HAART ) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ( AIDS ) , but has resulted in an increase in cardiac and skeletal myopathies .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        17,
        "acquired immunodeficiency syndrome"
      ],
      [
        "T1",
        "Disease",
        28,
        32,
        "cardiac and skeletal myopathies"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "AIDS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1869,
    "text": "METHODS AND RESULTS : In order to investigate whether the HAART component zidovudine ( 3 ' - azido - 2 ' , 3 ' - deoxythymidine ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of DCM , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        26,
        "3 ' - azido - 2 ' , 3 ' - deoxythymidine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "zidovudine"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "AZT"
      ],
      [
        "T3",
        "Disease",
        47,
        48,
        "DCM"
      ],
      [
        "T4",
        "Chemical",
        82,
        83,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1870,
    "text": "After 6 weeks , cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1871,
    "text": "NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1872,
    "text": "In contrast , AZT - treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose - dependent manner , with concomitant inflammatory infiltration of both ventricles .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "cardiac dilation"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1873,
    "text": "These changes were associated with an increased sarcolemmal expression of Fas and FasL , as well as increased activation of caspase 3 , translocation of calpain 1 to the sarcolemma and sarcomere , and increased numbers of cells undergoing apoptosis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1874,
    "text": "These were associated with changes in dystrophin and cardiac troponin I localization , as well as loss of sarcolemmal integrity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1875,
    "text": "CONCLUSIONS : The expression of Fas ligand in the myocardium , as identified in HIV - positive patients , might increase the susceptibility to HAART - induced cardiomyopathy due to activation of apoptotic pathways , resulting in cardiac dilation and dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        37,
        41,
        "cardiac dilation and dysfunction"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1876,
    "text": "Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients : results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        14,
        16,
        "diclofenac sodium"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "etoricoxib"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "etoricoxib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1877,
    "text": "OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis ( RA ) .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "etoricoxib"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "diclofenac"
      ],
      [
        "T3",
        "Disease",
        31,
        32,
        "RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1878,
    "text": "PATIENTS AND METHODS : A total of 4086 patients ( mean age 60 . 8 years ) diagnosed with RA were enrolled and received etoricoxib 90 mg daily ( n = 2032 ) or diclofenac 75 mg twice daily ( n = 2054 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "RA"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "etoricoxib"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "diclofenac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1879,
    "text": "Use of gastroprotective agents and low - dose aspirin was allowed .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1880,
    "text": "The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences ( AEs ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1881,
    "text": "General safety was also assessed , including adjudicated thrombotic cardiovascular event data .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "thrombotic cardiovascular"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1882,
    "text": "Efficacy was evaluated using the Patient Global Assessment of Disease Status ( PGADS ; 0 - 4 point scale ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1883,
    "text": "RESULTS : Mean ( SD ; maximum ) duration of treatment was 19 . 3 ( 10 . 3 ; 32 . 9 ) and 19 . 1 ( 10 . 4 ; 33 . 1 ) months in the etoricoxib and diclofenac groups , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        40,
        41,
        "etoricoxib"
      ],
      [
        "T1",
        "Chemical",
        42,
        43,
        "diclofenac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1884,
    "text": "The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac ( 5 . 2 vs 8 . 5 events per 100 patient - years , respectively ; hazard ratio 0 . 62 ( 95 % CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "GI AEs"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "etoricoxib"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "diclofenac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1885,
    "text": "The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hypertension"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "oedema"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "etoricoxib"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "diclofenac"
      ],
      [
        "T4",
        "Disease",
        51,
        52,
        "hypertension"
      ],
      [
        "T5",
        "Disease",
        59,
        60,
        "oedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1886,
    "text": "Etoricoxib and diclofenac treatment resulted in similar efficacy ( PGADS mean changes from baseline - 0 . 62 vs - 0 . 58 , respectively ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Etoricoxib"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "diclofenac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1887,
    "text": "CONCLUSIONS : Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "GI AEs"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Etoricoxib"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "diclofenac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1888,
    "text": "Discontinuations from renovascular AEs , although less common than discontinuations from GI AEs , were significantly higher with etoricoxib .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "GI AEs"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "etoricoxib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1889,
    "text": "Anxiogenic potential of ciprofloxacin and norfloxacin in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "ciprofloxacin"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "norfloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1890,
    "text": "INTRODUCTION : The possible anxiogenic effects of fluoroquinolones , namely ciprofloxacin and norfloxacin , were investigated in adult Charles Foster albino rats of either sex , weighing 150 - 200 g .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "fluoroquinolones"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "ciprofloxacin"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "norfloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1891,
    "text": "METHODS : The drugs were given orally , in doses of 50 mg / kg for five consecutive days and the experiments were performed on the fifth day .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1892,
    "text": "The tests included open - field exploratory behaviour , elevated plus maze and elevated zero maze , social interaction and novelty - suppressed feeding latency behaviour .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1893,
    "text": "RESULTS : The results indicate that ciprofloxacin - and norfloxacin - treated rats showed anxious behaviour in comparison to control rats in all the parameters studied .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "anxious behaviour"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ciprofloxacin"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "norfloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1894,
    "text": "However , ciprofloxacin - and norfloxacin - treated rats did not differ significantly from each other in various behavioural parameters .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "ciprofloxacin"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "norfloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1895,
    "text": "CONCLUSION : The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "ciprofloxacin"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "norfloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1896,
    "text": "Reduction of pain during induction with target - controlled propofol and remifentanil .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "pain"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "propofol"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "remifentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1897,
    "text": "BACKGROUND : Pain on injection of propofol is unpleasant .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Pain"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1898,
    "text": "We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "propofol"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "pain"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "remifentanil"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1899,
    "text": "A prospective , randomized , double - blind , placebo - controlled trial was performed to determine the effect - site concentration ( Ce ) of remifentanil to prevent the pain without producing complications .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "remifentanil"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1900,
    "text": "METHODS : A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline ( control ) or remifentanil to a target Ce of 2 ng ml ( - 1 ) ( R2 ) , 4 ng ml ( - 1 ) ( R4 ) , or 6 ng ml ( - 1 ) ( R6 ) administered via TCI .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "remifentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1901,
    "text": "After the target Ce was achieved , the infusion of propofol was started .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1902,
    "text": "Remifentanil - related complications were assessed during the remifentanil infusion , and pain caused by propofol was evaluated using a four - point scale during the propofol infusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Remifentanil"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "remifentanil"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "pain"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "propofol"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1903,
    "text": "RESULTS : The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups ( 12 / 32 and 6 / 31 vs 26 / 31 and 25 / 32 , respectively , P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1904,
    "text": "Pain was less severe in Groups R4 and R6 than in the control and R2 groups ( P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1905,
    "text": "However , both incidence and severity of pain were not different between Groups R4 and R6 .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1906,
    "text": "No significant complications were observed during the study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1907,
    "text": "CONCLUSIONS : During induction of anaesthesia with TCI of propofol and remifentanil , a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "propofol"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "remifentanil"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "propofol"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "pain"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "remifentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1908,
    "text": "Dexmedetomidine and cardiac protection for non - cardiac surgery : a meta - analysis of randomised controlled trials .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1909,
    "text": "We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non - cardiac surgery .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1910,
    "text": "We included prospective , randomised peri - operative studies of dexmedetomidine that reported mortality , cardiac morbidity or adverse drug events .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1911,
    "text": "A PubMed Central and EMBASE search was conducted up to July 2007 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1912,
    "text": "The reference lists of identified papers were examined for further trials .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1913,
    "text": "Of 425 studies identified , 20 were included in the meta - analysis ( 840 patients ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1914,
    "text": "Dexmedetomidine was associated with a trend towards improved cardiac outcomes ; all - cause mortality ( OR 0 . 27 , 95 % CI 0 . 01 - 7 . 13 , p = 0 . 44 ) , non - fatal myocardial infarction ( OR 0 . 26 , 95 % CI 0 . 04 - 1 . 60 , p = 0 . 14 ) , and myocardial ischaemia ( OR 0 . 65 , 95 % CI 0 . 26 - 1 . 63 , p = 0 . 36 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        42,
        44,
        "myocardial infarction"
      ],
      [
        "T1",
        "Disease",
        69,
        71,
        "myocardial ischaemia"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1915,
    "text": "Peri - operative hypotension ( 26 % , OR 3 . 80 , 95 % CI 1 . 91 - 7 . 54 , p = 0 . 0001 ) and bradycardia ( 17 % , OR 5 . 45 , 95 % CI 2 . 98 - 9 . 95 , p < 0 . 00001 ) were significantly increased .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        31,
        32,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1916,
    "text": "An anticholinergic did not reduce the incidence of bradycardia ( p = 0 . 43 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1917,
    "text": "A randomised placebo - controlled trial of dexmedetomidine is warranted .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1918,
    "text": "Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction : a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        6,
        8,
        "clomiphene citrate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1919,
    "text": "BACKGROUND : Clomiphene citrate ( CC ) is commonly prescribed for ovulation induction .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "Clomiphene citrate"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "CC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1920,
    "text": "It is considered safe , with minimal side effects .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1921,
    "text": "Thromboembolism is a rare but life - threatening complication that has been reported after ovulation induction with CC .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Thromboembolism"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "CC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1922,
    "text": "Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction ( MI ) during pregnancy , with a subsequently normal coronary angiogram .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "coronary thrombosis"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "myocardial infarction"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "thromboembolism"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1923,
    "text": "CASE : A 33 - year - old woman with a 5 - week gestation had recently received CC for ovulation induction and presented with chest pain .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "CC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1924,
    "text": "An electrocardiogram showed a lateral and anterior wall myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "myocardial infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1925,
    "text": "Cardiac enzymes showed a peak rise in troponin I to 9 . 10 ng / mL .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1926,
    "text": "An initial exercise stress test was normal .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1927,
    "text": "At the time of admission , the patient was at high risk of radiation injury to the fetus , so a coronary angiogram was postponed until the second trimester .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "radiation injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1928,
    "text": "It showed normal coronary vessels .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1929,
    "text": "CONCLUSION : This appears to be the first reported case documenting a possible association between CC and myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "CC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1930,
    "text": "Thrombosis might be a rare but hazardous complication of CC .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Thrombosis"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "CC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1931,
    "text": "Given this life - threatening complication , appropriate prophylactic measures should be used in high - risk woman undergoing ovarian stimulation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1932,
    "text": "Reverse or inverted left ventricular apical ballooning syndrome ( reverse Takotsubo cardiomyopathy ) in a young woman in the setting of amphetamine use .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        8,
        "left ventricular apical ballooning syndrome"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "Takotsubo cardiomyopathy"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1933,
    "text": "Transient left ventricular apical ballooning syndrome was first described in Japan as \" Takotsubo cardiomyopathy . \" This syndrome has been identified in many other countries .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        6,
        "left ventricular apical ballooning syndrome"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "Takotsubo cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1934,
    "text": "Many variations of this syndrome have been recently described in the literature .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1935,
    "text": "One of the rarest is the reverse type of this syndrome , with hyperdynamic apex and complete akinesia of the base ( as opposed to the classic apical ballooning ) .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "apical ballooning"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "akinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1936,
    "text": "In this article , we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "apical ballooning syndrome"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1937,
    "text": "This report is followed by review of the literature .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1938,
    "text": "Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        34,
        35,
        "telmisartan"
      ],
      [
        "T1",
        "Chemical",
        36,
        37,
        "amlodipine"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "amlodipine"
      ],
      [
        "T3",
        "Disease",
        46,
        47,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1939,
    "text": "OBJECTIVE : The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of telmisartan 40 mg + amlodipine 5 mg ( T + A ) compared with amlodipine 5 - mg monotherapy ( A ) in adult Indian patients with stage II hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        26,
        "telmisartan"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "amlodipine"
      ],
      [
        "T2",
        "Chemical",
        39,
        40,
        "amlodipine"
      ],
      [
        "T3",
        "Disease",
        54,
        55,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1940,
    "text": "METHODS : This comparative , Phase III , 12 - week , multicenter , prospective , randomized , double - blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension .",
    "labels": [
      [
        "T0",
        "Disease",
        36,
        37,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1941,
    "text": "Patients were treated with oral FDC of T + A or A QD before breakfast for 12 weeks ; blood pressure ( BP ) and heart rate were measured in the sitting position .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1942,
    "text": "Primary efficacy end points were reduction in clinical systolic BP ( SBP ) / diastolic BP ( DBP ) from baseline to study end and number of responders ( ie , patients who achieved target SBP / DBP < 130 / < 80 mm Hg ) at end of study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1943,
    "text": "Tolerability was assessed by treatment - emergent adverse events , identified using physical examination , laboratory analysis , and electrocardiography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1944,
    "text": "RESULTS : A total of 210 patients were enrolled in the study ; 203 patients ( 143 men , 60 women ) completed the study while 7 were lost to follow - up ( 4 patients in the T + A group and 3 in the A group ) and considered with - drawn .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1945,
    "text": "At study end , statistically significant percentage reductions from baseline within groups and between groups were observed in SBP ( T + A [ - 27 . 4 % ] ; A [ - 16 . 6 % ] ) and DBP ( T + A [ - 20 . 1 % ] ; A [ - 13 . 3 % ] ) ( all , P < 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1946,
    "text": "Response rates were 87 . 3 % ( 89 / 102 ) in the T + A group and 69 . 3 % ( 70 / 101 ) in the A group ( P < 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1947,
    "text": "The prevalences of adverse events were not significantly different between the 2 treatment groups ( T + A , 16 . 0 % [ 17 / 106 ] ; A , 15 . 4 % [ 16 / 104 ] ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1948,
    "text": "Peripheral edema was reported in 8 . 5 % patients ( 9 / 106 ) in the T + A group compared with 13 . 5 % ( 14 / 104 ) in the A group , and cough was reported in 3 . 8 % patients ( 4 / 106 ) in the T + A group and 1 . 0 % ( 1 / 104 ) patients in the A group ; these differences did not reach statistical significance .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "edema"
      ],
      [
        "T1",
        "Disease",
        38,
        39,
        "cough"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1949,
    "text": "The incidences of headache , dizziness , and diarrhea were similar between the 2 groups .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "headache"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "dizziness"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "diarrhea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1950,
    "text": "CONCLUSIONS : Among these Indian patients with stage II hypertension , the FDC of T + A was found to be significantly more effective , with regard to BP reductions , than A , and both treatments were well tolerated .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1951,
    "text": "Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "mental slowing"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "trihexyphenidyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1952,
    "text": "OBJECTIVES : The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl - induced subjective effects and objective memory performance .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "trihexyphenidyl"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "confusion"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "trihexyphenidyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1953,
    "text": "METHODS : This study comprised 24 cognitively intact , health elderly adults ( 12 APOE epsilon4 carriers ) at an outpatient geriatric psychiatry research clinic .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1954,
    "text": "This was a randomized , double blind , placebo - controlled , three - way , crossover experimental design .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1955,
    "text": "All participants received 1 . 0 mg or 2 . 0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "trihexyphenidyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1956,
    "text": "Bond and Lader ' s visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline , 1 , 2 . 5 , and 5 hours postdrug administration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1957,
    "text": "RESULTS : A 2 . 0 - mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "mental slowness"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "trihexyphenidyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1958,
    "text": "Drug effects as determined by difference scores between 2 . 0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "mental slowness"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "trihexyphenidyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1959,
    "text": "However , no significant effects were found with other visual analog scales reflecting subjective sedation and clear - headedness .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1960,
    "text": "CONCLUSION : The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "mental slowing"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "trihexyphenidyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1961,
    "text": "An evaluation of amikacin nephrotoxicity in the hematology / oncology population .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "amikacin"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1962,
    "text": "Amikacin is an aminoglycoside commonly used to provide empirical double gram - negative treatment for febrile neutropenia and other suspected infections .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "febrile neutropenia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Amikacin"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "aminoglycoside"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1963,
    "text": "Strategies of extended - interval and conventional dosing have been utilized extensively in the general medical population ; however , data are lacking to support a dosing strategy in the hematology / oncology population .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1964,
    "text": "To evaluate amikacin - associated nephrotoxicity in an adult hematology / oncology population , a prospective , randomized , open - label trial was conducted at a university - affiliated medical center .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "amikacin"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1965,
    "text": "Forty patients with a diagnosis consistent with a hematologic / oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended - interval amikacin .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "hematologic / oncologic disorder"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "aminoglycoside"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "amikacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1966,
    "text": "The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "nephrotoxicity"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "creatinine"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "amikacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1967,
    "text": "The occurrence of nephrotoxicity was similar between the conventional and extended - interval groups , at 10 % and 5 % , respectively ( P = 1 . 00 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1968,
    "text": "Six patients in the conventional group had a positive culture , compared with none in the extended - interval group ( P = 0 . 002 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1969,
    "text": "The occurrence of nephrotoxicity was similar between the two dosing regimens , but the distribution of risk factors was variable between the two groups .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1970,
    "text": "Efficacy could not be assessed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1971,
    "text": "High dose dexmedetomidine as the sole sedative for pediatric MRI .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1972,
    "text": "OBJECTIVE : This large - scale retrospective review evaluates the sedation profile of dexmedetomidine .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1973,
    "text": "AIM : To determine the hemodynamic responses , efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging ( MRI ) studies .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1974,
    "text": "BACKGROUND : Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1975,
    "text": "Over time , an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1976,
    "text": "METHODS / MATERIALS : As part of the ongoing Quality Assurance process , data on all sedations are reviewed monthly and protocols modified as needed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1977,
    "text": "Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007 .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1978,
    "text": "RESULTS : Since 2005 , the 10 - min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg . kg ( - 1 ) , and the infusion rate increased from 1 to 1 . 5 to 2 microg . kg ( - 1 ) . h ( - 1 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1979,
    "text": "The current sedation protocol progressively increased the rate of successful sedation ( able to complete the imaging study ) when using dexmedetomidine alone from 91 . 8 % to 97 . 6 % ( P = 0 . 009 ) , reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min ( P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "dexmedetomidine"
      ],
      [
        "T1",
        "Chemical",
        46,
        47,
        "pentobarbital"
      ],
      [
        "T2",
        "Chemical",
        54,
        55,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1980,
    "text": "Although dexmedetomidine sedation was associated with a 16 % incidence of bradycardia , all concomitant mean arterial blood pressures were within 20 % of age - adjusted normal range and oxygen saturations were 95 % or higher .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "dexmedetomidine"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "bradycardia"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1981,
    "text": "CONCLUSION : Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1982,
    "text": "While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established ' awake ' norms , this deviation is generally within 20 % of norms , and is not associated with adverse sequelae .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1983,
    "text": "Dexmedetomidine is useful as the sole sedative for pediatric MRI .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1984,
    "text": "Hepatotoxicity associated with sulfasalazine in inflammatory arthritis : A case series from a local surveillance of serious adverse events .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hepatotoxicity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "sulfasalazine"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "arthritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1985,
    "text": "BACKGROUND : Spontaneous reporting systems for adverse drug reactions ( ADRs ) are handicapped by under - reporting and limited detail on individual cases .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1986,
    "text": "We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti - rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1987,
    "text": "METHODS : Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1988,
    "text": "Patients ' , who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR , were identified .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hepatotoxicity"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "sulfasalazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1989,
    "text": "Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1990,
    "text": "The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hepatotoxicity"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "sulfasalazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1991,
    "text": "RESULTS : Ten cases were identified : eight occurred during surveillance .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1992,
    "text": "Eight patients were hospitalised , two in hepatic failure - one died after a liver transplant .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "hepatic failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1993,
    "text": "All but one event occurred within 6 weeks of treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1994,
    "text": "Seven patients had a skin rash , three eosinophilia and one interstitial nephritis .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "skin rash"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "interstitial nephritis"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "eosinophilia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1995,
    "text": "Five patients were of Black British of African or Caribbean descent .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1996,
    "text": "Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1997,
    "text": "Drug - related hepatotoxicity was judged probable or highly probable in 8 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1998,
    "text": "The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0 . 4 % of treated patients .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hepatotoxicity"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "sulfasalazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1999,
    "text": "CONCLUSION : Serious hepatotoxicity associated with sulfasalazine appears to be under - appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hepatotoxicity"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "sulfasalazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2000,
    "text": "Complete atrioventricular block secondary to lithium therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "atrioventricular block"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2001,
    "text": "Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Sinus node dysfunction"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2002,
    "text": "In the present case , complete atrioventricular ( AV ) block with syncopal attacks developed secondary to lithium therapy , necessitating permanent pacemaker implantation .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        11,
        "atrioventricular ( AV ) block"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "syncopal attacks"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2003,
    "text": "Serum lithium levels remained under or within the therapeutic range during the syncopal attacks .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "syncopal attacks"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2004,
    "text": "Lithium should be used with extreme caution , especially in patients with mild disturbance of AV conduction .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2005,
    "text": "Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout ( VIP - / - ) mice with cyclophosphamide ( CYP ) - induced cystitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "cyclophosphamide"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "CYP"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2006,
    "text": "Vasoactive intestinal polypeptide ( VIP ) is an immunomodulatory neuropeptide distributed in micturition pathways .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2007,
    "text": "VIP ( - / - ) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide ( CYP ) - induced cystitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "cyclophosphamide"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "CYP"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2008,
    "text": "Given VIP ' s role as an anti - inflammatory mediator , we hypothesized that VIP ( - / - ) mice would exhibit enhanced inflammatory mediator expression after cystitis .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        30,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2009,
    "text": "A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and VIP ( - / - ) mice with or without CYP - induced cystitis ( 150 mg / kg ; i . p . ; 48 h ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        36,
        37,
        "CYP"
      ],
      [
        "T1",
        "Disease",
        39,
        40,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2010,
    "text": "Four binary comparisons were made : WT control versus CYP treatment ( 48 h ) , VIP ( - / - ) control versus CYP treatment ( 48 h ) , WT control versus VIP ( - / - ) control , and WT with CYP treatment ( 48 h ) versus VIP ( - / - ) with CYP treatment ( 48 h ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "CYP"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "CYP"
      ],
      [
        "T2",
        "Chemical",
        45,
        46,
        "CYP"
      ],
      [
        "T3",
        "Chemical",
        59,
        60,
        "CYP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2011,
    "text": "The genes presented represent ( 1 ) greater than 1 . 5 - fold change in either direction and ( 2 ) the p value is less than 0 . 05 for the comparison being made .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2012,
    "text": "Several regulated genes were validated using enzyme - linked immunoassays including IL - 1beta and CXCL1 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2013,
    "text": "CYP treatment significantly ( p < or = 0 . 001 ) increased expression of CXCL1 and IL - 1beta in the urinary bladder of WT and VIP ( - / - ) mice , but expression in VIP ( - / - ) mice with CYP treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "CYP"
      ],
      [
        "T1",
        "Chemical",
        46,
        47,
        "CYP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2014,
    "text": "The data suggest that in VIP ( - / - ) mice with bladder inflammation , inflammatory mediators are increased above that observed in WT with CYP .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "bladder inflammation"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "CYP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2015,
    "text": "This shift in balance may contribute to increased bladder dysfunction in VIP ( - / - ) mice with bladder inflammation and altered neurochemical expression in micturition pathways .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "bladder dysfunction"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "bladder inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2016,
    "text": "Debrisoquine phenotype and the pharmacokinetics and beta - 2 receptor pharmacodynamics of metoprolol and its enantiomers .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Debrisoquine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2017,
    "text": "The metabolism of the cardioselective beta - blocker metoprolol is under genetic control of the debrisoquine / sparteine type .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "metoprolol"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "debrisoquine"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "sparteine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2018,
    "text": "The two metabolic phenotypes , extensive ( EM ) and poor metabolizers ( PM ) , show different stereoselective metabolism , resulting in apparently higher beta - 1 adrenoceptor antagonistic potency of racemic metoprolol in EMs .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        34,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2019,
    "text": "We investigated if the latter also applies to the beta - 2 adrenoceptor antagonism by metoprolol .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2020,
    "text": "The drug effect studied was the antagonism by metoprolol of terbutaline - induced hypokalemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "metoprolol"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "terbutaline"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hypokalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2021,
    "text": "By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S - isomer , were quantitated in EMs and PMs in terms of IC50 values , representing metoprolol plasma concentrations resulting in half - maximum receptor occupancy .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "metoprolol"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2022,
    "text": "Six EMs received 0 . 5 mg of terbutaline s . c . on two different occasions : 1 ) 1 hr after administration of a placebo and 2 ) 1 hr after 150 mg of metoprolol p . o .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "terbutaline"
      ],
      [
        "T1",
        "Chemical",
        36,
        37,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2023,
    "text": "Five PMs were studied according to the same protocol , except for a higher terbutaline dose ( 0 . 75 mg ) on day 2 .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "terbutaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2024,
    "text": "Blood samples for the analysis of plasma potassium , terbutaline , metoprolol ( racemic , R - and S - isomer ) , and alpha - hydroxymetoprolol concentrations were taken at regular time intervals , during 8 hr after metoprolol .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        27,
        "alpha - hydroxymetoprolol"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "potassium"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "terbutaline"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "metoprolol"
      ],
      [
        "T4",
        "Chemical",
        39,
        40,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2025,
    "text": "In PMs , metoprolol increased the terbutaline area under the plasma concentration vs . time curve ( + 67 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "metoprolol"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "terbutaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2026,
    "text": "Higher metoprolol / alpha - hydroxymetoprolol ratios in PMs were predictive for higher R - / S - isomer ratios of unchanged drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "alpha - hydroxymetoprolol"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2027,
    "text": "There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "metoprolol"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2028,
    "text": "The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery : findings in six cases .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "oxytocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2029,
    "text": "Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension , particularly when given as a bolus .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Oxytocin"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2030,
    "text": "The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2031,
    "text": "Parturients with normal volume status , heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2032,
    "text": "Oxytocin - induced hypotension at cesarean delivery may be incorrectly attributed to blood loss .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "blood loss"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Oxytocin"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2033,
    "text": "Pulse power analysis ( also called \" pulse contour analysis \" ) of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time , thereby elucidating the causative factors behind changes in blood pressure .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2034,
    "text": "Pulse power analysis was conducted in six cases of cesarean delivery performed under neuraxial anesthesia .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2035,
    "text": "Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume , heart rate and cardiac output .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypotension"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "oxytocin"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2036,
    "text": "Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2037,
    "text": "Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "nephrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2038,
    "text": "We investigated the effects of antithrombin , a plasma inhibitor of coagulation factors , in rats with puromycin aminonucleoside - induced nephrosis , which is an experimental model of human nephrotic syndrome .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        19,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        30,
        32,
        "nephrotic syndrome"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "nephrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2039,
    "text": "Antithrombin ( 50 or 500 IU / kg / i . v . ) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside ( 50 mg / kg / i . v . ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        29,
        31,
        "puromycin aminonucleoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2040,
    "text": "Treatment with antithrombin attenuated the puromycin aminonucleoside - induced hematological abnormalities .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "hematological abnormalities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2041,
    "text": "Puromycin aminonucleoside - induced renal dysfunction and hyperlipidemia were also suppressed .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        4,
        6,
        "renal dysfunction"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "hyperlipidemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2042,
    "text": "Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats , while an improvement of the damage was seen in antithrombin - treated rats .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "renal damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2043,
    "text": "In addition , antithrombin treatment markedly suppressed puromycin aminonucleoside - induced apoptosis of renal tubular epithelial cells .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "puromycin aminonucleoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2044,
    "text": "Furthermore , puromycin aminonucleoside - induced increases in renal cytokine content were also decreased .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "puromycin aminonucleoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2045,
    "text": "These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside - induced nephrotic syndrome .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "nephrotic syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2046,
    "text": "Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "nephrotic syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2047,
    "text": "Heparin - induced thrombocytopenia after liver transplantation .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Heparin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2048,
    "text": "BACKGROUND : Unfractionated heparin sodium ( UFH ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "Unfractionated heparin sodium"
      ],
      [
        "T1",
        "Chemical",
        9,
        14,
        "low - molecular weight heparin"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "UFH"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2049,
    "text": "Heparin - induced thrombocytopenia ( HIT ) is an adverse immune - mediated reaction to heparin , resulting in platelet count decreases of more than 50 % .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Heparin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "HIT"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2050,
    "text": "The frequencies of HIT after liver transplantation and platelet factor 4 / heparin - reactive antibody ( HIT antibody ) positivity in liver transplantation patients , however , are unknown .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "HIT"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "heparin"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2051,
    "text": "PATIENTS AND METHODS : The 32 men and 20 women underwent living donor liver transplantation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2052,
    "text": "We started LMWH ( 25 IU / kg / h ) on postoperative day ( POD ) 1 , switching to UFH ( 5000 U / d ) on POD 2 or 3 .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "UFH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2053,
    "text": "The dose of UFH was changed according to the activated clotting time level .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "UFH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2054,
    "text": "HIT antibody levels were measured the day before surgery and on POD 7 and 14 .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2055,
    "text": "Platelet count was measured daily for 3 weeks .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2056,
    "text": "RESULTS : The average platelet counts preoperatively , and on POD 7 , 14 , and 21 were 65 , 88 , 149 , and 169 x 10 ( 9 ) / L , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2057,
    "text": "Two patients developed hepatic artery thrombosis on POD 11 and 19 , respectively , although they were HIT antibody - negative and their platelet counts were stable .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "thrombosis"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2058,
    "text": "In 2 other patients , the platelet count decreased suddenly from 107 x 10 ( 9 ) / L on POD 4 to 65 x 10 ( 9 ) / L on POD 6 and from 76 x 10 ( 9 ) / L on POD 7 to 33 x 10 ( 9 ) / L on POD 9 , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2059,
    "text": "The heparin - induced platelet aggregation test was negative in these patients .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "platelet aggregation"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2060,
    "text": "The percentage of HIT antibody - positive patients was 0 . 5 % preoperatively , 5 . 6 % on POD 7 , and 5 . 6 % on POD 14 .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2061,
    "text": "None of the subjects / patients developed UFH - related HIT .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "UFH"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2062,
    "text": "CONCLUSIONS : In our series , the occurrence of HIT after liver transplantation was uncommon .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2063,
    "text": "Doxorubicin cardiomyopathy - induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Doxorubicin"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "cardiomyopathy"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2064,
    "text": "Clinical use of the anthracycline doxorubicin ( DOX ) is limited by its cardiotoxic effects , which are attributed to the induction of apoptosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "anthracycline"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "doxorubicin"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "DOX"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "cardiotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2065,
    "text": "To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of DOX - induced cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "DOX"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "cardiomyopathy"
      ],
      [
        "T2",
        "Disease",
        36,
        37,
        "inflammation"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "DOX"
      ],
      [
        "T4",
        "Disease",
        45,
        46,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2066,
    "text": "DOX control mice showed cardiac dysfunction measured by pressure - volume loops in vivo .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2067,
    "text": "This was associated with a reduced activation state of AKT , as well as an increased bax / bcl2 ratio in Western blots , indicating cardiac apoptosis .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "cardiac apoptosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2068,
    "text": "Furthermore , mRNA levels of the proinflammatory cytokine interleukin 6 were increased in the cardiac tissue .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2069,
    "text": "In DOX B1R ( - / - ) mice , cardiac dysfunction was improved compared to DOX control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "DOX"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2070,
    "text": "These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "DOX"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2071,
    "text": "These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "DOX"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2072,
    "text": "Detailed spectral profile analysis of penicillin - induced epileptiform activity in anesthetized rats .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "epileptiform activity"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "penicillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2073,
    "text": "Penicillin model is a widely used experimental model for epilepsy research .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Penicillin"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2074,
    "text": "In the present study we aimed to portray a detailed spectral analysis of penicillin - induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "epileptiform activity"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "penicillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2075,
    "text": "Male Wistar rats were anesthetized with i . p . urethane and connected to an electrocorticogram setup .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "urethane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2076,
    "text": "After a short period of basal activity recording , epileptic focus was induced by injecting 400IU / 2 microl penicillin - G potassium into the left lateral ventricle while the cortical activity was continuously recorded .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        23,
        "penicillin - G potassium"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2077,
    "text": "Basal activity , latent period and the penicillin - induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "epileptiform activity"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "penicillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2078,
    "text": "Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta , theta ( slow and fast ) , alpha - sigma , beta ( 1 and 2 ) and gamma ( 1 and 2 ) bands .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2079,
    "text": "Our results show that the most affected frequency bands were delta , theta , beta - 2 and gamma - 2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes ( basal activity , latent period and epileptiform activity ) .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "epileptiform activity"
      ],
      [
        "T1",
        "Disease",
        47,
        49,
        "epileptiform activity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2080,
    "text": "Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies .",
    "labels": [
      [
        "T0",
        "Disease",
        39,
        40,
        "epilepsies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2081,
    "text": "High fat diet - fed obese rats are highly sensitive to doxorubicin - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "fat"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "obese"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "doxorubicin"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2082,
    "text": "Often , chemotherapy by doxorubicin ( Adriamycin ) is limited due to life threatening cardiotoxicity in patients during and posttherapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "doxorubicin"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "Adriamycin"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2083,
    "text": "Recently , we have shown that moderate diet restriction remarkably protects against doxorubicin - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "doxorubicin"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2084,
    "text": "This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty - acid oxidation , ATP synthesis , and upregulated JAK / STAT3 pathway .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "triglycerides"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "ATP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2085,
    "text": "In the current study , we investigated whether a physiological intervention by feeding 40 % high fat diet ( HFD ) , which induces obesity in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to doxorubicin - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "fat"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "obesity"
      ],
      [
        "T2",
        "Chemical",
        40,
        41,
        "doxorubicin"
      ],
      [
        "T3",
        "Disease",
        43,
        44,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2086,
    "text": "A LD ( 10 ) dose ( 8 mg doxorubicin / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the obese ( OB ) rats in the absence of any significant renal or hepatic toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        31,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Disease",
        52,
        56,
        "renal or hepatic toxicity"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "doxorubicin"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "cardiotoxicity"
      ],
      [
        "T4",
        "Disease",
        41,
        42,
        "obese"
      ],
      [
        "T5",
        "Disease",
        43,
        44,
        "OB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2087,
    "text": "Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol ( toxic metabolite ) in the normal diet - fed ( ND ) and OB hearts .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Doxorubicin"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "doxorubicin"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "doxorubicinol"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "OB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2088,
    "text": "Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "OB"
      ],
      [
        "T1",
        "Disease",
        92,
        93,
        "OB"
      ],
      [
        "T2",
        "Chemical",
        100,
        101,
        "AMP"
      ],
      [
        "T3",
        "Chemical",
        115,
        116,
        "ATP"
      ],
      [
        "T4",
        "Chemical",
        120,
        121,
        "ATP"
      ],
      [
        "T5",
        "Chemical",
        122,
        123,
        "ADP"
      ],
      [
        "T6",
        "Chemical",
        125,
        126,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2089,
    "text": "Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK / STAT3 pathway .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2090,
    "text": "In conclusion , HFD - induced obese rats are highly sensitized to doxorubicin - induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "obese"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "doxorubicin"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "cardiotoxicity"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "ATP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2091,
    "text": "Isoproterenol induces primary loss of dystrophin in rat hearts : correlation with myocardial injury .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "myocardial injury"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2092,
    "text": "The mechanism of isoproterenol - induced myocardial damage is unknown , but a mismatch of oxygen supply vs . demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "myocardial damage"
      ],
      [
        "T1",
        "Disease",
        24,
        26,
        "myocardial hyperactivity"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "isoproterenol"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "oxygen"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2093,
    "text": "Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2094,
    "text": "Taking into account that the sarcolemmal integrity is stabilized by the dystrophin - glycoprotein complex ( DGC ) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins , this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins .",
    "labels": [
      [
        "T0",
        "Chemical",
        39,
        40,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2095,
    "text": "We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2096,
    "text": "Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2097,
    "text": "The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2098,
    "text": "Subsequently , after lysis of myofilaments , gamma - sarcoglycan , beta - dystroglycan , beta1 - integrin , and laminin alpha - 2 expressions were reduced followed by their breakdown , as epiphenomena of the myocytolytic process .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2099,
    "text": "In conclusion , administration of isoproterenol to rats results in primary loss of dystrophin , the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2100,
    "text": "These changes , related to ischaemic injury , explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "ischaemic injury"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2101,
    "text": "Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "liver tumors"
      ],
      [
        "T1",
        "Chemical",
        10,
        12,
        "oral contraceptives"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2102,
    "text": "Within the last several years , previously rare liver tumors have been seen in young women using oral contraceptive steroids .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "liver tumors"
      ],
      [
        "T1",
        "Chemical",
        17,
        19,
        "oral contraceptive"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2103,
    "text": "The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California , Irvine , has clearly identified 27 cases .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "Liver Tumors"
      ],
      [
        "T1",
        "Chemical",
        7,
        9,
        "Oral Contraceptives"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2104,
    "text": "The recent literature contains 44 case reports .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2105,
    "text": "Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia , adenoma , hamartoma , and hepatoma .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "focal nodular hyperplasia"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "adenoma"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "hamartoma"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "hepatoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2106,
    "text": "Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "oral contraceptive"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2107,
    "text": "Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "rupture"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2108,
    "text": "Ifosfamide continuous infusion without mesna .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ifosfamide"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2109,
    "text": "A phase I trial of a 14 - day cycle .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2110,
    "text": "Twenty patients received 27 courses of ifosfamide administered as a 24 - hour continuous infusion for 14 days without Mesna .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "ifosfamide"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "Mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2111,
    "text": "The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short - term infusions administered with Mesna .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "ifosfamide"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "Mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2112,
    "text": "Dose escalations proceeded from 200 to 300 , 400 , 450 , 500 , and 550 mg / m2 / d .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2113,
    "text": "Four patients developed transient microscopic hematuria at 400 , 450 , and 500 mg / m2 / d .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hematuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2114,
    "text": "There were no instances of macroscopic hematuria .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hematuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2115,
    "text": "At 550 mg / m2 / d , three patients experienced nonurologic toxicity ; confusion ( 1 ) , nausea ( 1 ) , and Grade 2 leukopenia ( 1 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "toxicity"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "confusion"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "nausea"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "leukopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2116,
    "text": "The recommended dose of 500 mg / m2 / d delivers a total dose of 7 g / m2 per cycle , which is comparable to that delivered in clinical practice for bolus or short - term infusion .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2117,
    "text": "Because few patients received multiple courses over time , the cumulative effects are indeterminate in the present trial .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2118,
    "text": "The frequency and predictability of hematuria are not precise , and at least daily monitoring by urine Hematest is essential , adding Mesna to the infusate in patients with persistent hematuria .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hematuria"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "Mesna"
      ],
      [
        "T2",
        "Disease",
        30,
        31,
        "hematuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2119,
    "text": "The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to 890 per cycle .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "ifosfamide"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "Mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2120,
    "text": "Clinical activity was demonstrated in a single patient , but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2121,
    "text": "A case of ventricular tachycardia related to caffeine pretreatment .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2122,
    "text": "Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice , especially in older patients with higher seizure thresholds .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "seizure"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2123,
    "text": "Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "ventricular ectopy"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "caffeine"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2124,
    "text": "We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "cardiac disease"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "ventricular tachycardia"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "arrhythmia"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2125,
    "text": "Although intravenous caffeine is generally well tolerated , the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "ventricular arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2126,
    "text": "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "gastrointestinal haemorrhage"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "haemopericardium"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2127,
    "text": "We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "haemorrhage"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2128,
    "text": "We propose that naturally occurring compounds such as flavonoids , which are present in fruit juices , may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "flavonoids"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "warfarin"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2129,
    "text": "While traditionally regarded as foodstuffs , consumption of fruit juices should be considered when patients develop adverse drug reactions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2130,
    "text": "Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride - induced seizures in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "bupropion hydrochloride"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2131,
    "text": "BACKGROUND : It is not known if there is a relationship between input rate and incidence of bupropion - induced seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "bupropion"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2132,
    "text": "This is important , since different controlled release formulations of bupropion release the active drug at different rates .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "bupropion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2133,
    "text": "METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known convulsive dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced convulsions in the Swiss albino mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "bupropion HCl"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "convulsive"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "bupropion"
      ],
      [
        "T3",
        "Disease",
        38,
        39,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2134,
    "text": "A total of 69 mice , approximately 7 weeks of age , and weighing 21 . 0 to 29 . 1 g were randomly assigned to bupropion HCl 120 mg / kg treatment by intraperitoneal ( IP ) administration in 7 groups ( 9 to 10 animals per group ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        28,
        "bupropion HCl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2135,
    "text": "Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min , 15 min , 30 min , 60 min , 90 min , 120 min , and 240 min .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Bupropion HCl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2136,
    "text": "The number , time of onset , duration and the intensity of the convulsions or absence of convulsions were recorded .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "convulsions"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2137,
    "text": "RESULTS : The results showed that IP administration of bupropion HCl 120 mg / kg by bolus injection induced convulsions in 6 out of 10 mice ( 60 % of convulsing mice ) in group 1 .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "bupropion HCl"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2138,
    "text": "Logistic regression analysis revealed that infusion time was significant ( p = 0 . 0004 ; odds ratio = 0 . 974 ) and increasing the IP infusion time of bupropion HCl 120 mg / kg was associated with a 91 % reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        32,
        "bupropion HCl"
      ],
      [
        "T1",
        "Disease",
        45,
        46,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2139,
    "text": "Further increase in infusion time resulted in further reduction in the odds of convulsions to 99 . 8 % reduction at 240 min .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2140,
    "text": "CONCLUSION : In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "convulsive"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "bupropion"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2141,
    "text": "Graft - versus - host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy : results of the EVTAC trial .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        6,
        "Graft - versus - host disease"
      ],
      [
        "T1",
        "Disease",
        18,
        21,
        "sinusoidal obstruction syndrome"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "everolimus"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "tacrolimus"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "microangiopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2142,
    "text": "A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft - versus - host disease ( GVHD ) after allogeneic hematopoietic stem cell transplantation ( HSCT ) .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        17,
        "graft - versus - host disease"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "methotrexate"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "GVHD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2143,
    "text": "Everolimus , a derivative of sirolimus , seems to mediate antileukemia effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Everolimus"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "sirolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2144,
    "text": "We report on a combination of everolimus and tacrolimus in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "myelodysplastic syndrome"
      ],
      [
        "T1",
        "Disease",
        31,
        34,
        "acute myeloid leukemia"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "everolimus"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "tacrolimus"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "MDS"
      ],
      [
        "T5",
        "Disease",
        35,
        36,
        "AML"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2145,
    "text": "All patients engrafted , and only 1 patient experienced grade IV mucositis .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "mucositis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2146,
    "text": "Nine patients ( 37 % ) developed acute grade II - IV GVHD , and 11 of 17 evaluable patients ( 64 % ) developed chronic extensive GVHD .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "GVHD"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "GVHD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2147,
    "text": "Transplantation - associated microangiopathy ( TMA ) occurred in 7 patients ( 29 % ) , with 2 cases of acute renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Transplantation - associated microangiopathy"
      ],
      [
        "T1",
        "Disease",
        20,
        23,
        "acute renal failure"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "TMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2148,
    "text": "The study was terminated prematurely because an additional 6 patients ( 25 % ) developed sinusoidal obstruction syndrome ( SOS ) , which was fatal in 2 cases .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "sinusoidal obstruction syndrome"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "SOS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2149,
    "text": "With a median follow - up of 26 months , the 2 - year overall survival rate was 47 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2150,
    "text": "Although this new combination appears to be effective as a prophylactic regimen for acute GVHD , the incidence of TMA and SOS is considerably higher than seen with other regimens .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "GVHD"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "TMA"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "SOS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2151,
    "text": "Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "colorectal adenomas"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "difluoromethylornithine"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "sulindac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2152,
    "text": "A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine ( DFMO ) plus sulindac or matched placebos .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "adenomatous polyps"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "difluoromethylornithine"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "DFMO"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "sulindac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2153,
    "text": "Temporary hearing loss is a known toxicity of treatment with DFMO , thus a comprehensive approach was developed to analyze serial air conduction audiograms .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "hearing loss"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "DFMO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2154,
    "text": "The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within - subject correlation due to repeated measurements at frequencies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2155,
    "text": "Based on 290 subjects , there was an average difference of 0 . 50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo ( 95 % confidence interval , - 0 . 64 to 1 . 63 dB ; P = 0 . 39 ) , adjusted for baseline values , age , and frequencies .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "DFMO"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "sulindac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2156,
    "text": "In the normal speech range of 500 to 3 , 000 Hz , an estimated difference of 0 . 99 dB ( - 0 . 17 to 2 . 14 dB ; P = 0 . 09 ) was detected .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2157,
    "text": "Dose intensity did not add information to models .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2158,
    "text": "There were 14 of 151 ( 9 . 3 % ) in the DFMO plus sulindac group and 4 of 139 ( 2 . 9 % ) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested ( P = 0 . 02 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "DFMO"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "sulindac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2159,
    "text": "Follow - up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1 . 08 dB ( - 0 . 81 to 2 . 96 dB ; P = 0 . 26 ) between treatment arms .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2160,
    "text": "There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "hearing loss"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "DFMO"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "sulindac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2161,
    "text": "The estimated attributable risk of ototoxicity from exposure to the drug is 8 . 4 % ( 95 % confidence interval , - 2 . 0 % to 18 . 8 % ; P = 0 . 12 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "ototoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2162,
    "text": "There is a < 2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "DFMO"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "sulindac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2163,
    "text": "Proteinase 3 - antineutrophil cytoplasmic antibody - ( PR3 - ANCA ) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "glomerulonephritis"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "sulphasalazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2164,
    "text": "A 59 - year - old woman with ulcerative colitis developed red eyes , pleural effusion , eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "ulcerative colitis"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "red eyes"
      ],
      [
        "T2",
        "Disease",
        14,
        16,
        "pleural effusion"
      ],
      [
        "T3",
        "Disease",
        19,
        21,
        "urinary abnormalities"
      ],
      [
        "T4",
        "Disease",
        17,
        18,
        "eosinophilia"
      ],
      [
        "T5",
        "Chemical",
        24,
        25,
        "sulphasalazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2165,
    "text": "Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "segmental necrotizing glomerulonephritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2166,
    "text": "Proteinase 3 - antineutrophil cytoplasmic antibody ( PR3 - ANCA ) titer was elevated at 183 ELISA units ( EU ) in sera ( normal range less than 10 EU ) , myeloperoxidase - ANCA was negative .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2167,
    "text": "PR3 - ANCA titer was 250 and 1 , 070 EU in pleural effusions on right and left side , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "pleural effusions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2168,
    "text": "Although cessation of sulphasalazine treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "red eyes"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "chest pain"
      ],
      [
        "T2",
        "Disease",
        27,
        29,
        "pleural effusions"
      ],
      [
        "T3",
        "Disease",
        58,
        60,
        "pleural effusion"
      ],
      [
        "T4",
        "Chemical",
        3,
        4,
        "sulphasalazine"
      ],
      [
        "T5",
        "Disease",
        9,
        10,
        "fever"
      ],
      [
        "T6",
        "Chemical",
        32,
        33,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2169,
    "text": "One month after steroid therapy , the pleural effusion disappeared , and PR3 - ANCA titer normalized 3 months later .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "pleural effusion"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2170,
    "text": "This case suggests that sulphasalazine can induce PR3 - ANCA - positive necrotizing glomerulonephritis .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "sulphasalazine"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "glomerulonephritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2171,
    "text": "Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        14,
        "idiopathic Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2172,
    "text": "A prospective , randomized , double - blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson ' s disease ( PD ) refractory to medical treatment was designed .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        27,
        "idiopathic Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2173,
    "text": "Ten consecutive patients ( mean age , 58 . 4 + / - 6 . 8 years ; 7 men , 3 women ) with similar characteristics at the duration of disease ( mean disease time , 8 . 4 + / - 3 . 5 years ) , disabling motor fluctuations ( Hoehn _ Yahr stage 3 - 5 in off - drug phases ) and levodopa - induced dyskinesias were selected .",
    "labels": [
      [
        "T0",
        "Chemical",
        67,
        68,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        70,
        71,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2174,
    "text": "All patients had bilateral symptoms and their levodopa equivalent dosing were analysed .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2175,
    "text": "Six patients were operated on in the globus pallidus interna ( GPi ) and four in the subthalamic nucleus ( STN ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2176,
    "text": "Clinical evaluation included the use of the Unified Parkinson ' s Disease Rating Scale ( UPDRS ) , Hoehn _ Yahr score and Schwab England activities of daily living ( ADL ) score in ' on ' - and ' off ' - drug conditions before surgery and 6 months after surgery .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "Parkinson ' s Disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2177,
    "text": "There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2178,
    "text": "Levodopa equivalent daily intake was significantly reduced in the STN group .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2179,
    "text": "Changes in UPDRS , Hoehn _ Yahr and Schwab England ADL scores were similar in both groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2180,
    "text": "Cognitive functions were unchanged in both groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2181,
    "text": "Complications were observed in two patients : one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg / day .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "homonymous hemianopsia"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "Valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2182,
    "text": "The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        23,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2183,
    "text": "DSMM XI study : dose definition for intravenous cyclophosphamide in combination with bortezomib / dexamethasone for remission induction in patients with newly diagnosed myeloma .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "cyclophosphamide"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "bortezomib"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "dexamethasone"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "myeloma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2184,
    "text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( MM ) .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        33,
        "multiple myeloma"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "cyclophosphamide"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "bortezomib"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "dexamethasone"
      ],
      [
        "T4",
        "Disease",
        34,
        35,
        "MM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2185,
    "text": "Thirty patients were treated with three 21 - day cycles of bortezomib 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900 , 1 , 200 , or 1 , 500 mg / m ( 2 ) on day 1 .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "bortezomib"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "dexamethasone"
      ],
      [
        "T2",
        "Chemical",
        39,
        40,
        "bortezomib"
      ],
      [
        "T3",
        "Chemical",
        46,
        47,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2186,
    "text": "The maximum tolerated dose of cyclophosphamide was defined as 900 mg / m ( 2 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2187,
    "text": "At this dose level , 92 % of patients achieved at least a partial response .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2188,
    "text": "The overall response rate [ complete response ( CR ) plus partial response ( PR ) ] across all dose levels was 77 % , with a 10 % CR rate .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2189,
    "text": "No patient experienced progressive disease .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2190,
    "text": "The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        10,
        "hematological and gastrointestinal toxicities"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2191,
    "text": "The results suggest that bortezomib in combination with cyclophosphamide at 900 mg / m ( 2 ) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "bortezomib"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "cyclophosphamide"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "dexamethasone"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "MM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2192,
    "text": "Naloxone reversal of hypotension due to captopril overdose .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Naloxone"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "captopril"
      ],
      [
        "T3",
        "Disease",
        7,
        8,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2193,
    "text": "The hemodynamic effects of captopril and other angiotensin - converting enzyme inhibitors may be mediated by the endogenous opioid system .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        12,
        "angiotensin - converting enzyme inhibitors"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "captopril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2194,
    "text": "The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "naloxone"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hypotensive"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "captopril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2195,
    "text": "We report a case of an intentional captopril overdose , manifested by marked hypotension , that resolved promptly with the administration of naloxone .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "captopril"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "overdose"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hypotension"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "naloxone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2196,
    "text": "To our knowledge , this is the first reported case of captopril - induced hypotension treated with naloxone .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "captopril"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "naloxone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2197,
    "text": "Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "naloxone"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "captopril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2198,
    "text": "Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "chondroitin sulfate"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2199,
    "text": "Heparin is a commonly implemented anticoagulant used to treat critically ill patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2200,
    "text": "Recently , a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate ( OSCS ) derivative that could elicit a hypotensive response in pigs following a single high - dose infusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        20,
        "chondroitin sulfate"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "heparin"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "hypotensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2201,
    "text": "Using both contaminated heparin products and the synthetically produced derivative , we showed that the OSCS produces dose - dependent hypotension in pigs .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2202,
    "text": "The no observed effect level ( NOEL ) for this contaminant appears to be approximately 1mg / kg , corresponding to a contamination level of approximately 3 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2203,
    "text": "We also demonstrated that OSCS can be identified in heparin products using a simple , inexpensive , commercially available heparin enzyme immunoassay ( EIA ) kit that has a limit of detection of approximately 0 . 1 % , well below the NOEL .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "heparin"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2204,
    "text": "This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2205,
    "text": "5 flourouracil - induced apical ballooning syndrome : a case report .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "5 flourouracil"
      ],
      [
        "T1",
        "Disease",
        4,
        7,
        "apical ballooning syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2206,
    "text": "The apical ballooning syndrome ( ABS ) is a recently described stress - mediated acute cardiac syndrome characterized by transient wall - motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular ( LV ) segments without obstructive epicardial coronary disease .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "apical ballooning syndrome"
      ],
      [
        "T1",
        "Disease",
        14,
        17,
        "acute cardiac syndrome"
      ],
      [
        "T2",
        "Disease",
        42,
        45,
        "epicardial coronary disease"
      ],
      [
        "T3",
        "Disease",
        5,
        6,
        "ABS"
      ],
      [
        "T4",
        "Disease",
        30,
        31,
        "hyperkinesis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2207,
    "text": "Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2208,
    "text": "However , there are no reports of ABS secondary to chemotherapeutic agents .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "ABS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2209,
    "text": "We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2210,
    "text": "A 79 - year - old woman presented with typical ischemic chest pain , elevated cardiac enzymes with significant ST - segment abnormalities on her electrocardiogram .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "chest pain"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2211,
    "text": "She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "colorectal cancer"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "fluorouracil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2212,
    "text": "Echocardiography revealed a wall - motion abnormality involving the apical and periapical segments which appeared akinetic .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "akinetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2213,
    "text": "Coronary angiography revealed no obstructive coronary lesions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2214,
    "text": "The patient was stabilized with medical therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2215,
    "text": "Four weeks later she remained completely asymptomatic .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2216,
    "text": "Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "akinesis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2217,
    "text": "Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm , endothelial damage and consequent thrombus formation .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiac complications"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "coronary vasospasm"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "cancer"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "thrombus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2218,
    "text": "In our patient , both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "catecholamines"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "cancer"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "ABS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2219,
    "text": "Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin - associated intracerebral hemorrhage .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "intracerebral hemorrhage"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hemorrhage"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2220,
    "text": "Warfarin - associated intracerebral hemorrhage ( W - ICH ) is a severe type of stroke .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "intracerebral hemorrhage"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Warfarin"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "ICH"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2221,
    "text": "There is no consensus on the optimal treatment for W - ICH .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "ICH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2222,
    "text": "Using a mouse model , we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate ( PCC ) can reduce hemorrhagic blood volume .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        18,
        "prothrombin complex concentrate"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "PCC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2223,
    "text": "Male CD - 1 mice were treated with warfarin ( 2 mg / kg over 24 h ) , resulting in a mean ( + / - s . d . ) International Normalized Ratio of 3 . 5 + / - 0 . 9 .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2224,
    "text": "First , we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "PCC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2225,
    "text": "Second , a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2226,
    "text": "Forty - five minutes later , the animals were randomly treated with PCC ( 100 U / kg ) or saline i . v . ( n = 12 per group ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "PCC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2227,
    "text": "Twenty - four hours after hemorrhage induction , hemorrhagic blood volume was quantified using a photometric hemoglobin assay .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2228,
    "text": "The mean hemorrhagic blood volume was reduced in PCC - treated animals ( 6 . 5 + / - 3 . 1 microL ) compared with saline controls ( 15 . 3 + / - 11 . 2 microL , P = 0 . 015 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "PCC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2229,
    "text": "In the saline group , 45 % of the mice developed large hematomas ( i . e . , > 15 microL ) .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "hematomas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2230,
    "text": "In contrast , such extensive lesions were never found in the PCC group .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "PCC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2231,
    "text": "We provide experimental data suggesting PCC to be an effective acute treatment for W - ICH in terms of reducing hemorrhagic blood volume .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "PCC"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "ICH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2232,
    "text": "Future studies are needed to assess the therapeutic potential emerging from our finding for human W - ICH .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "ICH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2233,
    "text": "Long term hormone therapy for perimenopausal and postmenopausal women .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2234,
    "text": "BACKGROUND : Hormone therapy ( HT ) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease , osteoporosis and dementia in older women .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "cardiovascular disease"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "osteoporosis"
      ],
      [
        "T2",
        "Disease",
        30,
        31,
        "dementia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2235,
    "text": "This is an updated version of the original Cochrane review first published in 2005 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2236,
    "text": "OBJECTIVES : To assess the effect of long - term HT on mortality , cardiovascular outcomes , cancer , gallbladder disease , cognition , fractures and quality of life .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "gallbladder disease"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "cancer"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "fractures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2237,
    "text": "SEARCH STRATEGY : We searched the following databases to November 2007 : Trials Register of the Cochrane Menstrual Disorders and Subfertility Group , Cochrane Central Register of Controlled Trials , MEDLINE , EMBASE , Biological Abstracts .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "Menstrual Disorders"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2238,
    "text": "Also relevant non - indexed journals and conference abstracts .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2239,
    "text": "SELECTION CRITERIA : Randomised double - blind trials of HT versus placebo , taken for at least one year by perimenopausal or postmenopausal women .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2240,
    "text": "HT included oestrogens , with or without progestogens , via oral , transdermal , subcutaneous or transnasal routes .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "oestrogens"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "progestogens"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2241,
    "text": "DATA COLLECTION AND ANALYSIS : Two authors independently assessed trial quality and extracted data .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2242,
    "text": "MAIN RESULTS : Nineteen trials involving 41 , 904 women were included .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2243,
    "text": "In relatively healthy women , combined continuous HT significantly increased the risk of venous thrombo - embolism or coronary event ( after one year ' s use ) , stroke ( after three years ) , breast cancer and gallbladder disease .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        17,
        "venous thrombo - embolism"
      ],
      [
        "T1",
        "Disease",
        36,
        38,
        "breast cancer"
      ],
      [
        "T2",
        "Disease",
        39,
        41,
        "gallbladder disease"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2244,
    "text": "Long - term oestrogen - only HT significantly increased the risk of venous thrombo - embolism , stroke and gallbladder disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "venous thrombo - embolism"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "gallbladder disease"
      ],
      [
        "T2",
        "Disease",
        46,
        48,
        "breast cancer"
      ],
      [
        "T3",
        "Chemical",
        3,
        4,
        "oestrogen"
      ],
      [
        "T4",
        "Disease",
        17,
        18,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2245,
    "text": "The only statistically significant benefits of HT were a decreased incidence of fractures and ( for combined HT ) colon cancer , with long - term use .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "colon cancer"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "fractures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2246,
    "text": "Among women aged over 65 who were relatively healthy ( i . e . generally fit , without overt disease ) and taking continuous combined HT , there was a statistically significant increase in the incidence of dementia .",
    "labels": [
      [
        "T0",
        "Disease",
        37,
        38,
        "dementia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2247,
    "text": "Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of venous thrombo - embolism . One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen - only HT , versus similar - sized placebo groups .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiovascular disease"
      ],
      [
        "T1",
        "Disease",
        19,
        23,
        "venous thrombo - embolism"
      ],
      [
        "T2",
        "Chemical",
        45,
        46,
        "oestrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2248,
    "text": "The only significantly increased risk reported was for venous thrombo - embolism in women taking combined continuous HT : their absolute risk remained low , at less than 1 / 500 .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "venous thrombo - embolism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2249,
    "text": "However , this study was not powered to detect differences between groups of younger women .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2250,
    "text": "AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2251,
    "text": "We need more evidence on the safety of HT for menopausal symptom control , though short - term use appears to be relatively safe for healthy younger women .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2252,
    "text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute renal failure"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "AIDS"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "tenofovir"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "vancomycin"
      ],
      [
        "T4",
        "Disease",
        15,
        16,
        "osteomyelitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2253,
    "text": "Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Renal failure"
      ],
      [
        "T1",
        "Chemical",
        16,
        19,
        "tenofovir disoproxil fumarate"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "vancomycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2254,
    "text": "Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "Fanconi syndrome"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "renal insufficiency"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Tenofovir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2255,
    "text": "Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Vancomycin"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "nephrotoxicity"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "nephrotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2256,
    "text": "Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "renal failure"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "tenofovir"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "vancomycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2257,
    "text": "Recurrent dysosmia induced by pyrazinamide .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "dysosmia"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "pyrazinamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2258,
    "text": "Pyrazinamide can have adverse effects such as hepatic toxicity , hyperuricemia or digestive disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "hepatic toxicity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Pyrazinamide"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "hyperuricemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2259,
    "text": "In rare cases , alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "pyrazinamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2260,
    "text": "We report a case of reversible olfactory disorder related to pyrazinamide in a woman , with a positive rechallenge .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "olfactory disorder"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "pyrazinamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2261,
    "text": "The patient presented every day a sensation of smelling something burning 15 min after drug intake .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2262,
    "text": "Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Dysosmia"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "pyrazinamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2263,
    "text": "The case was reported to the Tunisian Centre of Pharmacovigilance .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2264,
    "text": "Mice lacking mPGES - 1 are resistant to lithium - induced polyuria .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "lithium"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "polyuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2265,
    "text": "Cyclooxygenase - 2 activity is required for the development of lithium - induced polyuria .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "lithium"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "polyuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2266,
    "text": "However , the involvement of a specific , terminal prostaglandin ( PG ) isomerase has not been evaluated .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "prostaglandin"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "PG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2267,
    "text": "The present study was undertaken to assess lithium - induced polyuria in mice deficient in microsomal prostaglandin E synthase - 1 ( mPGES - 1 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        18,
        "prostaglandin E"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "lithium"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "polyuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2268,
    "text": "A 2 - wk administration of LiCl ( 4 mmol . kg ( - 1 ) . day ( - 1 ) ip ) in mPGES - 1 + / + mice led to a marked polyuria with hyposmotic urine .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "LiCl"
      ],
      [
        "T1",
        "Disease",
        36,
        37,
        "polyuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2269,
    "text": "This was associated with elevated renal mPGES - 1 protein expression and increased urine PGE ( 2 ) excretion .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        18,
        "PGE ( 2 )"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2270,
    "text": "In contrast , mPGES - 1 - / - mice were largely resistant to lithium - induced polyuria and a urine concentrating defect , accompanied by nearly complete blockade of high urine PGE ( 2 ) and cAMP output .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        36,
        "PGE ( 2 )"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "lithium"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "polyuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2271,
    "text": "Immunoblotting , immunohistochemistry , and quantitative ( q ) RT - PCR consistently detected a significant decrease in aquaporin - 2 ( AQP2 ) protein expression in both the renal cortex and medulla of lithium - treated + / + mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        34,
        35,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2272,
    "text": "This decrease was significantly attenuated in the - / - mice .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2273,
    "text": "qRT - PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2274,
    "text": "Similarly , the total protein abundance of the Na - K - 2Cl cotransporter ( NKCC2 ) in the medulla but not in the cortex of the + / + mice was significantly reduced by lithium treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "Na"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "K"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "2Cl"
      ],
      [
        "T3",
        "Chemical",
        35,
        36,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2275,
    "text": "In contrast , the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the - / - mice .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2276,
    "text": "We conclude that mPGES - 1 - derived PGE ( 2 ) mediates lithium - induced polyuria likely via inhibition of AQP2 and NKCC2 expression .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        12,
        "PGE ( 2 )"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "lithium"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "polyuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2277,
    "text": "Preservation of renal blood flow during hypotension induced with fenoldopam in dogs .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "fenoldopam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2278,
    "text": "The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2279,
    "text": "Specific dopamine - 1 , ( DA1 ) and dopamine - 2 ( DA2 ) receptor agonists are now under clinical investigation .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "dopamine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "DA1"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "dopamine"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "DA2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2280,
    "text": "Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Fenoldopam mesylate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2281,
    "text": "The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "fenoldopam"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2282,
    "text": "Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively , in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        34,
        35,
        "fenoldopam"
      ],
      [
        "T1",
        "Chemical",
        36,
        37,
        "sodium"
      ],
      [
        "T2",
        "Chemical",
        37,
        38,
        "nitroprusside"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "halothane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2283,
    "text": "Mean arterial pressure was decreased 30 + / - 8 per cent from control with infusion of fenoldopam ( 3 . 4 + / - 2 . 0 micrograms . kg - 1 . min - 1 ) and 34 + / - 4 per cent with infusion of sodium nitroprusside ( 5 . 9 micrograms . kg - 1 . min - 1 ) ( NS ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "fenoldopam"
      ],
      [
        "T1",
        "Chemical",
        49,
        50,
        "sodium"
      ],
      [
        "T2",
        "Chemical",
        50,
        51,
        "nitroprusside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2284,
    "text": "Renal blood flow ( RBF ) increased during fenoldopam - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced hypotension ( P less than 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "fenoldopam"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "sodium"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "nitroprusside"
      ],
      [
        "T4",
        "Disease",
        33,
        34,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2285,
    "text": "Sodium nitroprusside is a non - selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "nitroprusside"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2286,
    "text": "Fenoldopam is a selective dopamine - 1 ( DA1 ) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "dopamine"
      ],
      [
        "T1",
        "Disease",
        33,
        34,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2287,
    "text": "Seizures associated with levofloxacin : case presentation and literature review .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Seizures"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "levofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2288,
    "text": "PURPOSE : We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "seizures"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "levofloxacin"
      ],
      [
        "T2",
        "Chemical",
        50,
        51,
        "levofloxacin"
      ],
      [
        "T3",
        "Disease",
        53,
        54,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2289,
    "text": "METHODS : Several biomedical databases were searched including MEDLINE , Cochrane and Ovid .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2290,
    "text": "The main search terms utilized were case report and levofloxacin .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "levofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2291,
    "text": "The search was limited to studies published in English .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2292,
    "text": "RESULTS : Six cases of levofloxacin - induced seizures have been reported in the literature .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "levofloxacin"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2293,
    "text": "Drug - drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "levofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2294,
    "text": "CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "levofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2295,
    "text": "Dextran - etodolac conjugates : synthesis , in vitro and in vivo evaluation .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dextran"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "etodolac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2296,
    "text": "Etodolac ( E ) , is a non - narcotic analgesic and antiinflammatory drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Etodolac"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "E"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2297,
    "text": "A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac - dextran conjugates ( ED ) to improve its aqueous solubility and reduce gastrointestinal side effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "dextran"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "etodolac"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "dextran"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2298,
    "text": "An activated moiety , i . e . N - acylimidazole derivative of etodolac ( EAI ) , was condensed with the polysaccharide polymer dextran of different molecular weights ( 40000 , 60000 , 110000 and 200000 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "N - acylimidazole"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "etodolac"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "EAI"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "dextran"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2299,
    "text": "IR spectral data confirmed formation of ester bonding in the conjugates .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2300,
    "text": "Etodolac contents were evaluated by UV - spectrophotometric analysis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Etodolac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2301,
    "text": "The molecular weights were determined by measuring viscosity using the Mark - Howink - Sakurada equation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2302,
    "text": "In vitro hydrolysis of ED was done in aqueous buffers ( pH 1 . 2 , 7 . 4 , 9 ) and in 80 % ( v / v ) human plasma ( pH 7 . 4 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2303,
    "text": "At pH 9 , a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7 . 4 and 80 % human plasma ( pH 7 . 4 ) , following first - order kinetics .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "etodolac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2304,
    "text": "In vivo investigations were performed in animals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2305,
    "text": "Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model ( mice ) and carrageenan - induced rat paw edema model , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "acetic acid"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "writhing"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "carrageenan"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2306,
    "text": "In comparison to control , E and ED1 - ED4 showed highly significant analgesic and antiinflammatory activities ( p < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "E"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2307,
    "text": "Biological evaluation suggested that conjugates ( ED1 - ED4 ) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug - - etodolac .",
    "labels": [
      [
        "T0",
        "Chemical",
        28,
        29,
        "etodolac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2308,
    "text": "The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2309,
    "text": "This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both aconitine - induced rat and ouabain - induced guinea pig arrhythmia models .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "pilocarpine"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "aconitine"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "ouabain"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2310,
    "text": "Confocal microscopy was used to measure intracellular free - calcium concentrations ( [ Ca ( 2 + ) ] ( i ) ) in isolated myocytes .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "calcium"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "Ca"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2311,
    "text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias , decreased the time course of ventricular tachycardia and fibrillation , reduced arrhythmia score , and increased the survival time of arrhythmic rats and guinea pigs .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        21,
        "ventricular tachycardia and fibrillation"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "pilocarpine"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "arrhythmias"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "arrhythmia"
      ],
      [
        "T4",
        "Disease",
        32,
        33,
        "arrhythmic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2312,
    "text": "[ Ca ( 2 + ) ] ( i ) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "Ca"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "aconitine"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "ouabain"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2313,
    "text": "Moreover , M ( 3 ) - muscarinic acetylcholine receptor ( mAChR ) antagonist 4 - DAMP ( 4 - diphenylacetoxy - N - methylpiperidine - methiodide ) partially abolished the beneficial effects of pilocarpine .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        17,
        "4 - DAMP"
      ],
      [
        "T1",
        "Chemical",
        18,
        27,
        "4 - diphenylacetoxy - N - methylpiperidine - methiodide"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "acetylcholine"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2314,
    "text": "These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M ( 3 ) - mAChR .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "pilocarpine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "arrhythmic"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "aconitine"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2315,
    "text": "The mechanism may be related to the improvement of Ca ( 2 + ) handling .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "Ca"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2316,
    "text": "Effect of Hibiscus rosa sinensis on reserpine - induced neurobehavioral and biochemical alterations in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "Hibiscus rosa sinensis"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2317,
    "text": "Effect of methanolic extract of Hibiscus rosa sinensis ( 100 - 300 mg / kg ) was studied on reserpine - induced orofacial dyskinesia and neurochemical alterations .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "Hibiscus rosa sinensis"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "reserpine"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2318,
    "text": "The rats were treated with intraperitoneal reserpine ( 1 mg / kg , ip ) for 3 days every other day .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2319,
    "text": "On day 5 , vacuous chewing movements and tongue protrusions were counted for 5 min .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2320,
    "text": "Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however , coadministration of Hibiscus rosa sinensis roots extract ( 100 , 200 and 300 mg / kg , per orally ) attenuated the effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        18,
        "Hibiscus rosa sinensis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2321,
    "text": "Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase ( SOD ) , catalase ( CAT ) and glutathione reductase ( GSH ) , an index of oxidative stress process .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "reserpine"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "superoxide"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "glutathione"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2322,
    "text": "Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD , CAT and GSH levels .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2323,
    "text": "The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine - induced orofacial dyskinesia and oxidative stress .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "Hibiscus rosa sinensis"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "reserpine"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2324,
    "text": "Dynamic response of blood vessel in acute renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "acute renal failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2325,
    "text": "In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected , and that antioxidants can prevent the changes in dynamic responses of blood vessels .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2326,
    "text": "The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered , but also dynamics of this response , was used in this paper .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2327,
    "text": "Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2328,
    "text": "The beneficial effects of vitamin C administration to gentamicin - treated animals are also confirmed through : lower level of blood urea and creatinine and higher level of potassium .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "vitamin C"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "gentamicin"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "urea"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "creatinine"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2329,
    "text": "The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin - treated animals ( 8 . 07 + / - 1 . 7 s vs . 5 . 64 + / - 0 . 18 s ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2330,
    "text": "Vitamin C administration induced slowdown of pressure change back to the control values .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Vitamin C"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2331,
    "text": "The pressure dynamic properties , quantitatively defined by comparative pressure dynamic and total pressure dynamic , confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals and beneficial effects of vitamin C administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        39,
        41,
        "vitamin C"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2332,
    "text": "Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient : case report .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "myocardial hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2333,
    "text": "Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2334,
    "text": "However , adverse effects include cardiac toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "cardiac toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2335,
    "text": "Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "myocardial hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2336,
    "text": "The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2337,
    "text": "Initially , allograft rejection was feared ; however , myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy ; neither cellular nor humoral rejection was detected .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "myocardial hypertrophy"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2338,
    "text": "The blood tacrolimus concentration was higher than usual at that time ; thus , tacrolimus dosage was reduced .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "tacrolimus"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2339,
    "text": "Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur , as confirmed at echocardiography and myocardial biopsy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Myocardial hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2340,
    "text": "Thus , we conclude that tacrolimus induces reversible myocardial hypertrophy .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "myocardial hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2341,
    "text": "In patients receiving tacrolimus therapy , blood concentration should be carefully controlled and extreme attention paid to cardiac involvement .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2342,
    "text": "Nimodipine prevents memory impairment caused by nitroglycerin - induced hypotension in adult mice .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "memory impairment"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Nimodipine"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "nitroglycerin"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2343,
    "text": "BACKGROUND : Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "cognitive dysfunction"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "Hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2344,
    "text": "We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of nitroglycerin ( NTG ) - induced hypotension would preserve long - term associative memory .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "nimodipine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "NIMO"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "nitroglycerin"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "NTG"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2345,
    "text": "METHODS : The passive avoidance ( PA ) paradigm was used to assess memory retention .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2346,
    "text": "For PA training , latencies ( seconds ) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2347,
    "text": "Latencies were recorded 48 h later for a testing trial .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2348,
    "text": "Ninety - six Swiss - Webster mice ( 30 - 35 g , 6 - 8 wk ) , were randomized into 6 groups 1 ) saline ( control ) , 2 ) NTG immediately after learning , 3 ) NTG 3 h after learning , 4 ) NTG and NIMO , 5 ) vehicle , and 6 ) NIMO alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        34,
        "NTG"
      ],
      [
        "T1",
        "Chemical",
        40,
        41,
        "NTG"
      ],
      [
        "T2",
        "Chemical",
        48,
        49,
        "NTG"
      ],
      [
        "T3",
        "Chemical",
        50,
        51,
        "NIMO"
      ],
      [
        "T4",
        "Chemical",
        59,
        60,
        "NIMO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2349,
    "text": "The extent of hypotension and changes in brain tissue oxygenation ( PbtO ( 2 ) ) and in cerebral blood flow were studied in a separate group of animals .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2350,
    "text": "RESULTS : All groups exhibited similar training latencies ( 17 . 0 + / - 4 . 6 s ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2351,
    "text": "Mice subjected to hypotensive episodes showed a significant decrease in latency time ( 178 + / - 156 s ) compared with those injected with saline , NTG + NIMO , or delayed NTG ( 580 + / - 81 s , 557 + / - 67 s , and 493 + / - 146 s , respectively ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypotensive"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "NTG"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "NIMO"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "NTG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2352,
    "text": "A Kruskal - Wallis 1 - way analysis of variance indicated a significant difference among the 4 treatment groups ( H = 15 . 34 ; P < 0 . 001 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2353,
    "text": "In a separate group of mice not subjected to behavioral studies , the same dose of NTG ( n = 3 ) and NTG + NIMO ( n = 3 ) caused mean arterial blood pressure to decrease from 85 . 9 + / - 3 . 8 mm Hg sem to 31 . 6 + / - 0 . 8 mm Hg sem and from 86 . 2 + / - 3 . 7 mm Hg sem to 32 . 6 + / - 0 . 2 mm Hg sem , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "NTG"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "NTG"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "NIMO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2354,
    "text": "Mean arterial blood pressure in mice treated with NIMO alone decreased from 88 . 1 + / - 3 . 8 mm Hg to 80 . 0 + / - 2 . 9 mm Hg .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "NIMO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2355,
    "text": "The intergroup difference was statistically significant ( P < 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2356,
    "text": "PbtO ( 2 ) decreased from 51 . 7 + / - 4 . 5 mm Hg sem to 33 . 8 + / - 5 . 2 mm Hg sem in the NTG group and from 38 . 6 + / - 6 . 1 mm Hg sem to 25 . 4 + / - 2 . 0 mm Hg sem in the NTG + NIMO groups , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        34,
        "NTG"
      ],
      [
        "T1",
        "Chemical",
        64,
        65,
        "NTG"
      ],
      [
        "T2",
        "Chemical",
        66,
        67,
        "NIMO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2357,
    "text": "There were no significant differences among groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2358,
    "text": "CONCLUSION : In a PA retention paradigm , the injection of NTG immediately after learning produced a significant impairment of long - term associative memory in mice , whereas delayed induced hypotension had no effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "NTG"
      ],
      [
        "T1",
        "Disease",
        31,
        32,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2359,
    "text": "NIMO attenuated the disruption in consolidation of long - term memory caused by NTG but did not improve latency in the absence of hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "NIMO"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "NTG"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2360,
    "text": "The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension , because there were no differences in the PbtO ( 2 ) indices among groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "NIMO"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "calcium"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2361,
    "text": "Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2362,
    "text": "Metabotropic glutamate ( mGlu ) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson ' s disease ( PD ) .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        27,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "glutamate"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2363,
    "text": "Among the eight mGlu receptor subtypes , mGlu7 receptor is prominently expressed in the basal ganglia , but its role in restoring motor function in animal models of PD is not known .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        29,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2364,
    "text": "The effects of N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride ( AMN082 ) , the first selective allosteric activator of mGlu7 receptors , were thus tested in different rodent models of PD .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        16,
        "N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "AMN082"
      ],
      [
        "T2",
        "Disease",
        37,
        38,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2365,
    "text": "Here , we show that oral ( 5 mg / kg ) or intrastriatal administration ( 0 . 1 and 0 . 5 nmol ) of AMN082 reverses haloperidol - induced catalepsy in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "AMN082"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "haloperidol"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2366,
    "text": "AMN082 ( 2 . 5 and 5 mg / kg ) reduces apomorphine - induced rotations in unilateral 6 - hydroxydopamine ( 6 - OHDA ) - lesioned rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        21,
        "6 - hydroxydopamine"
      ],
      [
        "T1",
        "Chemical",
        22,
        25,
        "6 - OHDA"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "AMN082"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2367,
    "text": "In a more complex task commonly used to evaluate major akinetic symptoms of PD patients , 5 mg / kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6 - OHDA - lesioned rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        36,
        "6 - OHDA"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "akinetic"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "PD"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "AMN082"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2368,
    "text": "In addition , AMN082 reduces the duration of haloperidol - induced catalepsy in a mGlu7 receptor - dependent manner in wild - type but not mGlu7 receptor knockout mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "AMN082"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "haloperidol"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2369,
    "text": "Higher doses of AMN082 ( 10 and 20 mg / kg p . o . ) have no effect on the same models of PD .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "AMN082"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2370,
    "text": "Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2371,
    "text": "Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2372,
    "text": "Sorafenib - induced acute myocardial infarction due to coronary artery spasm .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "myocardial infarction"
      ],
      [
        "T1",
        "Disease",
        8,
        11,
        "coronary artery spasm"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Sorafenib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2373,
    "text": "A 65 - year - old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "renal cell carcinoma"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "chest pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2374,
    "text": "Two weeks before his admission , sorafenib had been started .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "sorafenib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2375,
    "text": "He was diagnosed with non - ST - elevation myocardial infarction by laboratory data and electrocardiogram .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "myocardial infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2376,
    "text": "Enhanced heart magnetic resonance imaging also showed subendocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "subendocardial infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2377,
    "text": "However , there was no stenosis in coronary arteries on angiography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2378,
    "text": "Coronary artery spasm was induced by a provocative test .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Coronary artery spasm"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2379,
    "text": "Cessation of sorafenib and administration of Ca - channel blocker and nitrates ameliorated his symptoms , but relapse occurred after resumption of sorafenib .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "sorafenib"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "Ca"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "nitrates"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "sorafenib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2380,
    "text": "Addition of oral nicorandil reduced his symptoms and maintained stable angina status .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "stable angina"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "nicorandil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2381,
    "text": "We report the first case of sorafenib - induced coronary artery spasm .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "coronary artery spasm"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "sorafenib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2382,
    "text": "Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Sorafenib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2383,
    "text": "On the other hand , the Rho / ROCK pathway has an important role in the pathogenesis of coronary artery spasm .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        21,
        "coronary artery spasm"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2384,
    "text": "Our report may show an adverse effect on the Rho / ROCK pathway by sorafenib use .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "sorafenib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2385,
    "text": "A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2386,
    "text": "The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood - brain barrier ( BBB ) and / or to improve the brain localization of a bioactive compound .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2387,
    "text": "A Tween 80 - coated poly - L - lactid acid nanoparticles was used as a model of colloidal drug delivery system , able to trespass the BBB .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        11,
        "poly - L - lactid acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2388,
    "text": "Tacrine , administered in LiCl pre - treated rats , induces electrocorticographic seizures and delayed hippocampal damage .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "hippocampal damage"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Tacrine"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "LiCl"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2389,
    "text": "The toxic effects of tacrine - loaded poly - L - lactid acid nanoparticles ( 5mg / kg ) , a saline solution of tacrine ( 5mg / kg ) and an empty colloidal nanoparticle suspension were compared following i . p . administration in LiCl - pre - treated Wistar rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        13,
        "poly - L - lactid acid"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "tacrine"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "tacrine"
      ],
      [
        "T3",
        "Chemical",
        45,
        46,
        "LiCl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2390,
    "text": "All the animals treated with tacrine - loaded nanoparticles showed an earlier outcome of CNS adverse symptoms , i . e . epileptic onset , with respect to those animals treated with the free compound ( 10 min vs . 22 min respectively ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "tacrine"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2391,
    "text": "In addition , tacrine - loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals , while the saline solution of tacrine only in 60 % of animals .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "damage of neuronal cells"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "tacrine"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "tacrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2392,
    "text": "Empty nanoparticles provided similar results to control ( saline - treated ) group of animals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2393,
    "text": "In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the tacrine - lithium model of epilepsy in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "tacrine"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "lithium"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2394,
    "text": "High - dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "tranexamic Acid"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2395,
    "text": "BACKGROUND : In 2 separate centers , we observed a notable increase in the incidence of postoperative convulsive seizures from 1 . 3 % to 3 . 8 % in patients having undergone major cardiac surgical procedures .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "convulsive"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2396,
    "text": "These events were temporally coincident with the initial use of high - dose tranexamic acid ( TXA ) therapy after withdrawal of aprotinin from general clinical usage .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "tranexamic acid"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "TXA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2397,
    "text": "The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "TXA"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2398,
    "text": "METHODS : An in - depth chart review was undertaken in all 24 patients who developed perioperative seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2399,
    "text": "Electroencephalographic activity was recorded in 11 of these patients , and all patients had a formal neurological evaluation and brain imaging studies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2400,
    "text": "RESULTS : Twenty - one of the 24 patients did not have evidence of new cerebral ischemic injury , but seizures were likely due to ischemic brain injury in 3 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "cerebral ischemic injury"
      ],
      [
        "T1",
        "Disease",
        25,
        28,
        "ischemic brain injury"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2401,
    "text": "All patients with seizures did not have permanent neurological abnormalities .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "neurological abnormalities"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2402,
    "text": "All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "seizures"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "TXA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2403,
    "text": "All but one patient were managed using cardiopulmonary bypass .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2404,
    "text": "No evidence of brain ischemic , metabolic , or hyperthermia - induced causes for their seizures was apparent .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "brain ischemic"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hyperthermia"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2405,
    "text": "CONCLUSION : Our results suggest that use of high - dose TXA in older patients in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical seizures in susceptible patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "TXA"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2406,
    "text": "Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiac arrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2407,
    "text": "Eight patients had cardiac manifestations that were life - threatening in five while taking psychotropic drugs , either phenothiazines or tricyclic antidepressants .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "phenothiazines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2408,
    "text": "Although most patients were receiving several drugs , Mellaril ( thioridazine ) appeared to be responsible for five cases of ventricular tachycardia , one of which was fatal in a 35 year old woman .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "Mellaril"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "thioridazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2409,
    "text": "Supraventricular tachycardia developed in one patient receiving Thorazine ( chlorpromazine ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Supraventricular tachycardia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "Thorazine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "chlorpromazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2410,
    "text": "Aventyl ( nortriptyline ) and Elavil ( amitriptyline ) each produced left bundle branch block in a 73 year old woman .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        15,
        "left bundle branch block"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Aventyl"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "nortriptyline"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "Elavil"
      ],
      [
        "T4",
        "Chemical",
        7,
        8,
        "amitriptyline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2411,
    "text": "Electrocardiographic T and U wave abnormalities were present in most patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2412,
    "text": "The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock ; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "ventricular arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2413,
    "text": "The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "tachyarrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2414,
    "text": "Five of the eight patients were 50 years of age or younger ; only one clearly had antecedent heart disease .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "heart disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2415,
    "text": "Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "cardiac arrhythmias"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "heart disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2416,
    "text": "A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "cardiac complications"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "phenothiazines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2417,
    "text": "Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "azidothymidine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "immunodeficient"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2418,
    "text": "The anaemia induced by 3 ' - azido - 3 ' dideoxythymidine ( AZT ) is poorly understood .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        12,
        "3 ' - azido - 3 ' dideoxythymidine"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "anaemia"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2419,
    "text": "We have used a murine model of AIDS , infection of female C57BL / 6 mice with LP - BM5 murine leukaemia ( MuLV ) virus , to determine if AZT - induced anaemia is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "AIDS"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "infection"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "leukaemia"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "AZT"
      ],
      [
        "T4",
        "Disease",
        33,
        34,
        "anaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2420,
    "text": "Mice in the early stage of LP - BM5 MuLV disease were given AZT in their drinking water at 1 . 0 and 2 . 5 mg / ml .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2421,
    "text": "AZT produced anaemia in both groups , in a dose - dependent fashion .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "AZT"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "anaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2422,
    "text": "Despite the anaemia , the number of splenic and bone marrow BFU - e in AZT treated mice increased up to five - fold over levels observed in infected untreated animals after 15 d of treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "anaemia"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2423,
    "text": "Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected , untreated mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2424,
    "text": "By day 30 , sensitivity of both splenic and bone marrow BFU - e of treated animals returned to that observed from cells of infected untreated animals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2425,
    "text": "The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine ( PHZ ) treated mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "AZT"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "anaemia"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "phenylhydrazine"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "PHZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2426,
    "text": "The numbers of BFU - e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "AZT"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "PHZ"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "anaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2427,
    "text": "However , reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "reticulocytosis"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "anaemia"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2428,
    "text": "AZT - induced peripheral anaemia in the face of increased numbers of BFU - e and increased levels of plasma EPO suggest a lesion in terminal differentiation .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "AZT"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "anaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2429,
    "text": "Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "postoperative delirium"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "hip fracture"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2430,
    "text": "OBJECTIVE : To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "hip fracture"
      ],
      [
        "T1",
        "Disease",
        24,
        26,
        "postoperative delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2431,
    "text": "PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation .",
    "labels": [
      [
        "T0",
        "Disease",
        37,
        39,
        "hip fracture"
      ],
      [
        "T1",
        "Disease",
        31,
        32,
        "delirium"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "dementia"
      ],
      [
        "T3",
        "Chemical",
        44,
        45,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2432,
    "text": "Sedation depth was titrated using processed electroencephalography with the bispectral index ( BIS ) , and patients were randomized to receive either deep ( BIS , approximately 50 ) or light ( BIS , > or = 80 ) sedation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2433,
    "text": "Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders ( Third Edition Revised ) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Postoperative delirium"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "Mental Disorders"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2434,
    "text": "RESULTS : From April 2 , 2005 , through October 30 , 2008 , a total of 114 patients were randomized .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2435,
    "text": "The prevalence of postoperative delirium was significantly lower in the light sedation group ( 11 / 57 [ 19 % ] vs 23 / 57 [ 40 % ] in the deep sedation group ; P = . 02 ) , indicating that 1 incident of delirium will be prevented for every 4 . 7 patients treated with light sedation .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "postoperative delirium"
      ],
      [
        "T1",
        "Disease",
        46,
        47,
        "delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2436,
    "text": "The mean + / - SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group ( 0 . 5 + / - 1 . 5 days vs 1 . 4 + / - 4 . 0 days ; P = . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2437,
    "text": "CONCLUSION : The use of light propofol sedation decreased the prevalence of postoperative delirium by 50 % compared with deep sedation .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "postoperative delirium"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2438,
    "text": "Limiting depth of sedation during spinal anesthesia is a simple , safe , and cost - effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "postoperative delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2439,
    "text": "The protective role of Nrf2 in streptozotocin - induced diabetic nephropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "diabetic nephropathy"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "streptozotocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2440,
    "text": "OBJECTIVE : Diabetic nephropathy is one of the major causes of renal failure , which is accompanied by the production of reactive oxygen species ( ROS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Diabetic nephropathy"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "renal failure"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2441,
    "text": "Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2442,
    "text": "Here , we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "diabetic nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2443,
    "text": "RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients , a streptozotocin - induced diabetic nephropathy model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "diabetic nephropathy"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "diabetic nephropathy"
      ],
      [
        "T2",
        "Disease",
        29,
        31,
        "diabetic nephropathy"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "streptozotocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2444,
    "text": "RESULTS : The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "diabetic nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2445,
    "text": "In the animal study , Nrf2 was demonstrated to be crucial in ameliorating streptozotocin - induced renal damage .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "renal damage"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "streptozotocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2446,
    "text": "This is evident by Nrf2 ( - / - ) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2 ( + / + ) mice .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "renal injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2447,
    "text": "Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2 - mediated protection against diabetic nephropathy is , at least , partially through inhibition of transforming growth factor - beta1 ( TGF - beta1 ) and reduction of extracellular matrix production .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "diabetic nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2448,
    "text": "In human renal mesangial cells , high glucose induced ROS production and activated expression of Nrf2 and its downstream genes .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2449,
    "text": "Furthermore , activation or overexpression of Nrf2 inhibited the promoter activity of TGF - beta1 in a dose - dependent manner , whereas knockdown of Nrf2 by siRNA enhanced TGF - beta1 transcription and fibronectin production .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2450,
    "text": "CONCLUSIONS : This work clearly indicates a protective role of Nrf2 in diabetic nephropathy , suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "diabetic nephropathy"
      ],
      [
        "T1",
        "Disease",
        37,
        39,
        "diabetic nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2451,
    "text": "Metformin prevents experimental gentamicin - induced nephropathy by a mitochondria - dependent pathway .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Metformin"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "gentamicin"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2452,
    "text": "The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "vascular dysfunction"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2453,
    "text": "Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "gentamicin"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2454,
    "text": "Mitochondrial analysis , respiration intensity , levels of reactive oxygen species , permeability transition , and cytochrome c release were assessed 3 and 6 days after gentamicin administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "oxygen"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2455,
    "text": "Metformin treatment fully blocked gentamicin - mediated acute renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Metformin"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2456,
    "text": "This was accompanied by a lower activity of N - acetyl - beta - D - glucosaminidase , together with a decrease of lipid peroxidation and increase of antioxidant systems .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2457,
    "text": "Metformin also protected the kidney from histological damage 6 days after gentamicin administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Metformin"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2458,
    "text": "These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "kidney dysfunction"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2459,
    "text": "We found that gentamicin treatment depleted respiratory components ( cytochrome c , NADH ) , probably due to the opening of mitochondrial transition pores .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2460,
    "text": "These injuries , partly mediated by a rise in reactive oxygen species from the electron transfer chain , were significantly decreased by metformin .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "oxygen"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2461,
    "text": "Thus , our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "metformin"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "gentamicin"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2462,
    "text": "Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography : a prospective study .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "contrast media"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2463,
    "text": "Despite increasing reports on nonionic contrast media - induced nephropathy ( CIN ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "contrast media"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "nephropathy"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "CIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2464,
    "text": "This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "contrast media"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "CIN"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "CM"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "iopromide"
      ],
      [
        "T4",
        "Chemical",
        19,
        20,
        "iohexol"
      ],
      [
        "T5",
        "Chemical",
        43,
        44,
        "CM"
      ],
      [
        "T6",
        "Disease",
        48,
        49,
        "cyanosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2465,
    "text": "The 80 patients in the study consecutively received either iopromide ( group A , n = 40 ) or iohexol ( group B , n = 40 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "iopromide"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "iohexol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2466,
    "text": "Serum sodium ( Na ) , potassium ( K ) , and creatinine ( Cr ) were measured 24 h before angiography as baseline values , then measured again at 12 - , 24 - , and 48 - h intervals after CM use .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "Na"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "potassium"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "K"
      ],
      [
        "T4",
        "Chemical",
        12,
        13,
        "creatinine"
      ],
      [
        "T5",
        "Chemical",
        14,
        15,
        "Cr"
      ],
      [
        "T6",
        "Chemical",
        42,
        43,
        "CM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2467,
    "text": "Urine samples for Na and Cr also were checked at the same intervals .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "Na"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "Cr"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2468,
    "text": "Risk of renal failure , Injury to the kidney , Failure of kidney function , Loss of kidney function , and End - stage renal damage ( RIFLE criteria ) were used to define CIN and its incidence in the study population .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "renal failure"
      ],
      [
        "T1",
        "Disease",
        5,
        9,
        "Injury to the kidney"
      ],
      [
        "T2",
        "Disease",
        10,
        14,
        "Failure of kidney function"
      ],
      [
        "T3",
        "Disease",
        15,
        19,
        "Loss of kidney function"
      ],
      [
        "T4",
        "Disease",
        24,
        26,
        "renal damage"
      ],
      [
        "T5",
        "Disease",
        34,
        35,
        "CIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2469,
    "text": "Accordingly , among the 15 CIN patients ( 18 . 75 % ) , 7 . 5 % of the patients in group A had increased risk and 3 . 75 % had renal injury , whereas 5 % of group B had increased risk and 2 . 5 % had renal injury .",
    "labels": [
      [
        "T0",
        "Disease",
        33,
        35,
        "renal injury"
      ],
      [
        "T1",
        "Disease",
        51,
        53,
        "renal injury"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "CIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2470,
    "text": "Whereas 33 . 3 % of the patients with CIN were among those who received the proper dosage of CM , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of CIN related to the different dosages of CM ( p = 0 . 014 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "CIN"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "CM"
      ],
      [
        "T2",
        "Disease",
        44,
        45,
        "CIN"
      ],
      [
        "T3",
        "Chemical",
        51,
        52,
        "CM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2471,
    "text": "Among the 15 patients with CIN , 6 had cyanotic congenital heart diseases , but the incidence did not differ significantly from that for the noncyanotic patients ( p = 0 . 243 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "congenital heart diseases"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "CIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2472,
    "text": "Although clinically silent , CIN is not rare in pediatrics .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "CIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2473,
    "text": "The incidence depends on dosage but not on the type of consumed nonionic CM , nor on the presence of cyanosis , and although CIN usually is reversible , more concern is needed for the prevention of such a complication in children .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "CM"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "cyanosis"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "CIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2474,
    "text": "Renal function and hemodynamics during prolonged isoflurane - induced hypotension in humans .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "isoflurane"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2475,
    "text": "The effect of isoflurane - induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "isoflurane"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2476,
    "text": "Glomerular filtration rate ( GFR ) and effective renal plasma flow ( ERPF ) were measured by inulin and para - aminohippurate ( PAH ) clearance , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        22,
        "para - aminohippurate"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "PAH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2477,
    "text": "Anesthesia was maintained with fentanyl , nitrous oxide , oxygen , and isoflurane .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "nitrous oxide"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "fentanyl"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "oxygen"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2478,
    "text": "Hypotension was induced for 236 . 9 + / - 15 . 1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59 . 8 + / - 0 . 4 mmHg .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypotension"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2479,
    "text": "GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2480,
    "text": "Postoperatively , ERPF returned to preoperative values , whereas GFR was higher than preoperative values .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2481,
    "text": "Renal vascular resistance increased during anesthesia but decreased when hypotension was induced , allowing the maintenance of renal blood flow .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2482,
    "text": "We conclude that renal compensatory mechanisms are preserved during isoflurane - induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "isoflurane"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2483,
    "text": "Brainstem dysgenesis in an infant prenatally exposed to cocaine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Brainstem dysgenesis"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2484,
    "text": "Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "cocaine abuse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2485,
    "text": "Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "fetal anomalies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2486,
    "text": "We report on an infant with multiple cranial - nerve involvement attributable to brainstem dysgenesis , born to a cocaine - addicted mother .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        11,
        "multiple cranial - nerve involvement"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "brainstem dysgenesis"
      ],
      [
        "T2",
        "Disease",
        19,
        22,
        "cocaine - addicted"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2487,
    "text": "A cross - sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "risperidone"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2488,
    "text": "OBJECTIVE : The aim of the present study was to investigate the effect of risperidone - induced hyperprolactinemia on trabecular bone mineral density ( BMD ) in children and adolescents .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "risperidone"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2489,
    "text": "METHOD : Medically healthy 7 - to 17 - year - old males chronically treated , in a naturalistic setting , with risperidone were recruited for this cross - sectional study through child psychiatry outpatient clinics between November 2005 and June 2007 .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2490,
    "text": "Anthropometric measurements and laboratory testing were conducted .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2491,
    "text": "The clinical diagnoses were based on chart review , and developmental and treatment history was obtained from the medical record .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2492,
    "text": "Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography , and areal BMD of the lumbar spine was estimated using dual - energy x - ray absorptiometry .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2493,
    "text": "RESULTS : Hyperprolactinemia was present in 49 % of 83 boys ( n = 41 ) treated with risperidone for a mean of 2 . 9 years .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Hyperprolactinemia"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2494,
    "text": "Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "testosterone"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2495,
    "text": "As expected , bone mineral content and BMD increased with sexual maturity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2496,
    "text": "After adjusting for the stage of sexual development and height and BMI z scores , serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius ( P < . 03 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2497,
    "text": "Controlling for relevant covariates , we also found treatment with selective serotonin reuptake inhibitors ( SSRIs ) to be associated with lower trabecular BMD at the radius ( P = . 03 ) and BMD z score at the lumbar spine ( P < . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2498,
    "text": "These findings became more marked when the analysis was restricted to non - Hispanic white patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2499,
    "text": "Of 13 documented fractures , 3 occurred after risperidone and SSRIs were started , and none occurred in patients with hyperprolactinemia .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "fractures"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "risperidone"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2500,
    "text": "CONCLUSIONS : This is the first study to link risperidone - induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "risperidone"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2501,
    "text": "Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2502,
    "text": "Fear - potentiated startle , but not light - enhanced startle , is enhanced by anxiogenic drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "startle"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "startle"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2503,
    "text": "RATIONALE AND OBJECTIVES : The light - enhanced startle paradigm ( LES ) is suggested to model anxiety , because of the non - specific cue and the long - term effect .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "startle"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2504,
    "text": "In contrast , the fear - potentiated startle ( FPS ) is suggested to model conditioned fear .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "startle"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2505,
    "text": "However , the pharmacological profiles of these two paradigms are very similar .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2506,
    "text": "The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2507,
    "text": "METHODS : Male Wistar rats received each dose of the alpha ( 2 ) - adrenoceptor antagonist yohimbine ( 0 . 25 - 1 . 0mg / kg ) , the 5 - HT ( 2C ) receptor agonist m - chlorophenylpiperazine ( mCPP , 0 . 5 - 2 . 0mg / kg ) or the GABA ( A ) inverse receptor agonist pentylenetetrazole ( PTZ , 3 - 30mg / kg ) and were subsequently tested in either LES or FPS .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        34,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        39,
        42,
        "m - chlorophenylpiperazine"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "yohimbine"
      ],
      [
        "T3",
        "Chemical",
        43,
        44,
        "mCPP"
      ],
      [
        "T4",
        "Chemical",
        57,
        58,
        "GABA"
      ],
      [
        "T5",
        "Chemical",
        64,
        65,
        "pentylenetetrazole"
      ],
      [
        "T6",
        "Chemical",
        66,
        67,
        "PTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2508,
    "text": "RESULTS : None of the drugs enhanced LES , whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "mCPP"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "yohimbine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2509,
    "text": "Furthermore , yohimbine increased baseline startle amplitude in the LES , while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "yohimbine"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "startle"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "mCPP"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "startle"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "PTZ"
      ],
      [
        "T5",
        "Disease",
        26,
        27,
        "startle"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2510,
    "text": "CONCLUSIONS : In contrast to findings in the FPS paradigm , none of the drugs were able to exacerbate the LES response .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2511,
    "text": "Thus , a clear pharmacological differentiation was found between LES and FPS .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2512,
    "text": "Rosaceiform dermatitis associated with topical tacrolimus treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "dermatitis"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2513,
    "text": "We describe herein 3 patients who developed rosacea - like dermatitis eruptions while using 0 . 03 % or 0 . 1 % tacrolimus ointment for facial dermatitis .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "facial dermatitis"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "rosacea"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "dermatitis"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "eruptions"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2514,
    "text": "Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "telangiectasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2515,
    "text": "Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis , although many cases have not been reported .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "tacrolimus"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "pimecrolimus"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "dermatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2516,
    "text": "Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Coenzyme Q10"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "cisplatin"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2517,
    "text": "The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i . p . injection of cisplatin ( 5 mg / kg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "coenzyme Q10"
      ],
      [
        "T1",
        "Disease",
        11,
        14,
        "acute renal injury"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2518,
    "text": "Coenzyme Q10 treatment ( 10 mg / kg / day , i . p . ) was applied for 6 consecutive days , starting 1 day before cisplatin administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Coenzyme Q10"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2519,
    "text": "Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Coenzyme Q10"
      ],
      [
        "T1",
        "Chemical",
        4,
        7,
        "blood urea nitrogen"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "creatinine"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2520,
    "text": "Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Coenzyme Q10"
      ],
      [
        "T1",
        "Chemical",
        11,
        13,
        "reduced glutathione"
      ],
      [
        "T2",
        "Chemical",
        34,
        36,
        "nitric oxide"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "superoxide"
      ],
      [
        "T4",
        "Disease",
        28,
        29,
        "tumor"
      ],
      [
        "T5",
        "Disease",
        29,
        30,
        "necrosis"
      ],
      [
        "T6",
        "Chemical",
        37,
        38,
        "platinum"
      ],
      [
        "T7",
        "Chemical",
        46,
        47,
        "selenium"
      ],
      [
        "T8",
        "Chemical",
        48,
        49,
        "zinc"
      ],
      [
        "T9",
        "Chemical",
        55,
        56,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2521,
    "text": "Also , histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "renal tissue damage"
      ],
      [
        "T1",
        "Chemical",
        12,
        14,
        "coenzyme Q10"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2522,
    "text": "Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin - induced overexpression of inducible nitric oxide synthase , nuclear factor - kappaB , caspase - 3 and p53 in renal tissue .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "coenzyme Q10"
      ],
      [
        "T1",
        "Chemical",
        15,
        17,
        "nitric oxide"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2523,
    "text": "It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "coenzyme Q10"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "cisplatin"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2524,
    "text": "Reversible cholestasis with bile duct injury following azathioprine therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "bile duct injury"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "cholestasis"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "azathioprine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2525,
    "text": "A case report .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2526,
    "text": "A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease , developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "liver disease"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "polymyositis"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "cholestasis"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "azathioprine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2527,
    "text": "Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "cholestasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2528,
    "text": "Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Azathioprine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2529,
    "text": "It is believed that this is the first reported case of reversible azathioprine - induced cholestasis associated with histological evidence of bile duct injury .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "bile duct injury"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "azathioprine"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "cholestasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2530,
    "text": "Dopamine is not essential for the development of methamphetamine - induced neurotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dopamine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "methamphetamine"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2531,
    "text": "It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "dopamine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "DA"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "methamphetamine"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "METH"
      ],
      [
        "T4",
        "Disease",
        16,
        17,
        "toxicity"
      ],
      [
        "T5",
        "Chemical",
        27,
        28,
        "DA"
      ],
      [
        "T6",
        "Disease",
        30,
        31,
        "toxicity"
      ],
      [
        "T7",
        "Chemical",
        36,
        37,
        "DA"
      ],
      [
        "T8",
        "Disease",
        39,
        40,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2532,
    "text": "However , temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2533,
    "text": "Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of alpha - methyl - para - tyrosine on METH - induced DA neurotoxicity is also confounded by drug effects on body temperature .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "L - dihydroxyphenylalanine"
      ],
      [
        "T1",
        "Chemical",
        18,
        25,
        "alpha - methyl - para - tyrosine"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "METH"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "DA"
      ],
      [
        "T4",
        "Disease",
        30,
        31,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2534,
    "text": "Further , we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity , as long as the thermic effects of METH are preserved .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "DA"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "METH"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "neurotoxicity"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2535,
    "text": "In addition , we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH - induced dopaminergic deficits that are of comparable magnitude on both sides of the brain .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "dopaminergic deficits"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "DA"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2536,
    "text": "Taken together , these findings demonstrate that DA is not essential for the development of METH - induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "DA"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "METH"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "neurotoxicity"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2537,
    "text": "Swallowing - induced atrial tachyarrhythmia triggered by salbutamol : case report and review of the literature .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "atrial tachyarrhythmia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "salbutamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2538,
    "text": "CASE : A 49 - year - old patient experienced chest discomfort while swallowing .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2539,
    "text": "On electrocardiogram , episodes of atrial tachyarrhythmia were recorded immediately after swallowing ; 24 - hour Holter monitoring recorded several events .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "atrial tachyarrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2540,
    "text": "The arrhythmia resolved after therapy with atenolol , but recurred a year later .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "arrhythmia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "atenolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2541,
    "text": "The patient noticed that before these episodes he had been using an inhalator of salbutamol .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "salbutamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2542,
    "text": "After stopping the beta - agonist , and after a week with the atenolol , the arrhythmia disappeared .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "atenolol"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2543,
    "text": "DISCUSSION : Swallowing - induced atrial tachyarrhythmia ( SIAT ) is a rare phenomenon .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "atrial tachyarrhythmia"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "SIAT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2544,
    "text": "Fewer than 50 cases of SIAT have been described in the literature .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "SIAT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2545,
    "text": "This article summarizes all the cases published , creating a comprehensive review of the current knowledge and approach to SIAT .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "SIAT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2546,
    "text": "It discusses demographics , clinical characteristics and types of arrhythmia , postulated mechanisms of SIAT , and different treatment possibilities such as medications , surgery , and radiofrequency catheter ablation ( RFCA ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "arrhythmia"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "SIAT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2547,
    "text": "CONCLUSION : Salbutamol is presented here as a possible trigger for SIAT .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Salbutamol"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "SIAT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2548,
    "text": "Although it is difficult to define causality in a case report , it is logical to think that a beta - agonist like salbutamol ( known to induce tachycardia ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta - blocker such as atenolol ( that blocks the adrenergic activity ) may relieve it .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "salbutamol"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "tachycardia"
      ],
      [
        "T2",
        "Chemical",
        51,
        52,
        "atenolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2549,
    "text": "The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin - induced diabetes mellitus .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "diabetes mellitus"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "streptozotocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2550,
    "text": "1 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2551,
    "text": "The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin - diabetic rats were investigated .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "streptozotocin"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "diabetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2552,
    "text": "2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2553,
    "text": "Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition ; effects which were prevented by insulin treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2554,
    "text": "3 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2555,
    "text": "Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "diabetic"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "ATP"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "bethanechol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2556,
    "text": "4 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2557,
    "text": "Diabetes of 4 months duration also resulted in decreases in body weight , and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition , effects which were reversed by insulin treatment for the final 2 months of the study .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2558,
    "text": "5 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2559,
    "text": "Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "diabetic"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "ATP"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "bethanechol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2560,
    "text": "6 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2561,
    "text": "The data indicate that the effects of streptozotocin - induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "streptozotocin"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2562,
    "text": "Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol - induced catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "NMDA"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "haloperidol"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2563,
    "text": "The inferior colliculus ( IC ) is primarily involved in the processing of auditory information , but it is distinguished from other auditory nuclei in the brainstem by its connections with structures of the motor system .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2564,
    "text": "Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing , escape - like behavior , and immobility .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        24,
        "amino acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2565,
    "text": "However , the nature of this immobility is still unclear .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2566,
    "text": "The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically ( 1 or 0 . 5 mg / kg ) in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "amino acid"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "dopamine"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2567,
    "text": "Haloperidol - induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        50,
        57,
        "N - methyl - d - aspartate"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Haloperidol"
      ],
      [
        "T3",
        "Disease",
        3,
        4,
        "catalepsy"
      ],
      [
        "T4",
        "Chemical",
        11,
        12,
        "glutamate"
      ],
      [
        "T5",
        "Chemical",
        12,
        13,
        "NMDA"
      ],
      [
        "T6",
        "Chemical",
        31,
        32,
        "AP7"
      ],
      [
        "T7",
        "Chemical",
        47,
        48,
        "NMDA"
      ],
      [
        "T8",
        "Chemical",
        58,
        59,
        "NMDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2568,
    "text": "The results showed that intracollicular microinjection of MK - 801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy , as indicated by a reduced latency to step down from a horizontal bar .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "AP7"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "haloperidol"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2569,
    "text": "Accordingly , intracollicular microinjection of NMDA increased the latency to step down the bar .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "NMDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2570,
    "text": "These findings suggest that glutamate - mediated mechanisms in the neural circuits at the IC level influence haloperidol - induced catalepsy and participate in the regulation of motor activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "glutamate"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "haloperidol"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2571,
    "text": "Severe congestive heart failure patient on amiodarone presenting with myxedemic coma : a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "congestive heart failure"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "myxedemic coma"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2572,
    "text": "This is a case report of myxedema coma secondary to amiodarone - induced hypothyroidism in a patient with severe congestive heart failure ( CHF ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "myxedema coma"
      ],
      [
        "T1",
        "Disease",
        19,
        22,
        "congestive heart failure"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "amiodarone"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "hypothyroidism"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "CHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2573,
    "text": "To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "myxedema coma"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2574,
    "text": "Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20 % with treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Myxedema coma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2575,
    "text": "The condition is treated with intravenous thyroxine ( T4 ) or intravenous tri - iodo - thyronine ( T3 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        17,
        "tri - iodo - thyronine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "thyroxine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "T4"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "T3"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2576,
    "text": "Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism , and thus may deserve closer follow up for thyroid stimulating hormone ( TSH ) levels .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "CHF"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "amiodarone"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "hypothyroidism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2577,
    "text": "This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "amiodarone"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "CHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2578,
    "text": "The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension , weakness or other unexplained symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "myxedema coma"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "CHF"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "hypotension"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "weakness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2579,
    "text": "Effects of active constituents of Crocus sativus L . , crocin on streptozocin - induced model of sporadic Alzheimer ' s disease in male rats .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        22,
        "Alzheimer ' s disease"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "crocin"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "streptozocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2580,
    "text": "BACKGROUND : The involvement of water - soluble carotenoids , crocins , as the main and active components of Crocus sativus L . extract in learning and memory processes has been proposed .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "carotenoids"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "crocins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2581,
    "text": "In the present study , the effect of crocins on sporadic Alzheimer ' s disease induced by intracerebroventricular ( icv ) streptozocin ( STZ ) in male rats was investigated .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        15,
        "Alzheimer ' s disease"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "crocins"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "streptozocin"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2582,
    "text": "METHODS : Male adult Wistar rats ( n = 90 and 260 - 290 g ) were divided into 1 , control ; 2 and 3 , crocins ( 15 and 30 mg / kg ) ; 4 , STZ ; 5 and 6 , STZ + crocins ( 15 and 30 mg / kg ) groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        28,
        "crocins"
      ],
      [
        "T1",
        "Chemical",
        39,
        40,
        "STZ"
      ],
      [
        "T2",
        "Chemical",
        45,
        46,
        "STZ"
      ],
      [
        "T3",
        "Chemical",
        47,
        48,
        "crocins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2583,
    "text": "In Alzheimer ' s disease groups , rats were injected with STZ - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar STZ - icv application was repeated .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        5,
        "Alzheimer ' s disease"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "STZ"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2584,
    "text": "In STZ + crocin animal groups , crocin was applied in doses of 15 and 30 mg / kg , i . p . , one day pre - surgery and continued for three weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "STZ"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "crocin"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "crocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2585,
    "text": "Prescription of crocin in each dose was repeated once for two days .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "crocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2586,
    "text": "However , the learning and memory performance was assessed using passive avoidance paradigm , and for spatial cognition evaluation , Y - maze task was used .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2587,
    "text": "RESULTS : It was found out that crocin ( 30 mg / kg ) - treated STZ - injected rats show higher correct choices and lower errors in Y - maze than vehicle - treated STZ - injected rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "crocin"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "STZ"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2588,
    "text": "In addition , crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ - injected group in passive avoidance test .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        15,
        "learning and memory impairment"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "crocin"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2589,
    "text": "CONCLUSION : Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the cognitive deficits caused by STZ - icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "cognitive deficits"
      ],
      [
        "T1",
        "Disease",
        36,
        38,
        "neurodegenerative diseases"
      ],
      [
        "T2",
        "Disease",
        40,
        44,
        "Alzheimer ' s disease"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "crocin"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2590,
    "text": "Serotonin 6 receptor gene is associated with methamphetamine - induced psychosis in a Japanese population .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Serotonin"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "methamphetamine"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2591,
    "text": "BACKGROUND : Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "psychotic disorders"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2592,
    "text": "The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced hyperactivity in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "5 - HT6"
      ],
      [
        "T1",
        "Chemical",
        25,
        28,
        "d - amphetamine"
      ],
      [
        "T2",
        "Chemical",
        41,
        44,
        "5 - HT6"
      ],
      [
        "T3",
        "Chemical",
        1,
        2,
        "serotonin"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "clozapine"
      ],
      [
        "T5",
        "Chemical",
        22,
        23,
        "olanzapine"
      ],
      [
        "T6",
        "Disease",
        30,
        31,
        "hyperactivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2593,
    "text": "In addition , the disrupted prepulse inhibition induced by d - amphetamine or phencyclidine was restored by 5 - HT6 receptor antagonist in an animal study using rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "d - amphetamine"
      ],
      [
        "T1",
        "Chemical",
        17,
        20,
        "5 - HT6"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "phencyclidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2594,
    "text": "These animal models were considered to reflect the positive symptoms of schizophrenia , and the above evidence suggests that altered 5 - HT6 receptors are involved in the pathophysiology of psychotic disorders .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        23,
        "5 - HT6"
      ],
      [
        "T1",
        "Disease",
        30,
        32,
        "psychotic disorders"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2595,
    "text": "The symptoms of methamphetamine ( METH ) - induced psychosis are similar to those of paranoid type schizophrenia .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "paranoid type schizophrenia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "methamphetamine"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "METH"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2596,
    "text": "Therefore , we conducted an analysis of the association of the 5 - HT6 gene ( HTR6 ) with METH - induced psychosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "5 - HT6"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "METH"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2597,
    "text": "METHOD : Using five tagging SNPs ( rs6693503 , rs1805054 , rs4912138 , rs3790757 and rs9659997 ) , we conducted a genetic association analysis of case - control samples ( 197 METH - induced psychosis patients and 337 controls ) in the Japanese population .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        32,
        "METH"
      ],
      [
        "T1",
        "Disease",
        34,
        35,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2598,
    "text": "The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "methamphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2599,
    "text": "RESULTS : rs6693503 was associated with METH - induced psychosis patients in the allele / genotype - wise analysis .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "METH"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2600,
    "text": "Moreover , this association remained significant after Bonferroni correction .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2601,
    "text": "In the haplotype - wise analysis , we detected an association between two markers ( rs6693503 and rs1805054 ) and three markers ( rs6693503 , rs1805054 and rs4912138 ) in HTR6 and METH - induced psychosis patients , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        33,
        "METH"
      ],
      [
        "T1",
        "Disease",
        35,
        36,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2602,
    "text": "CONCLUSION : HTR6 may play an important role in the pathophysiology of METH - induced psychosis in the Japanese population .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "METH"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2603,
    "text": "Neural correlates of S - ketamine induced psychosis during overt continuous verbal fluency .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "S - ketamine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2604,
    "text": "The glutamatergic N - methyl - D - aspartate ( NMDA ) receptor has been implicated in the pathophysiology of schizophrenia .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        9,
        "N - methyl - D - aspartate"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "NMDA"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2605,
    "text": "Administered to healthy volunteers , a subanesthetic dose of the non - competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "NMDA"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "ketamine"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2606,
    "text": "In patients with schizophrenia , ketamine exacerbates the core symptoms of illness , supporting the hypothesis of a glutamatergic dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "glutamatergic dysfunction"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "schizophrenia"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2607,
    "text": "In a counterbalanced , placebo - controlled , double - blind study design , healthy subjects were administered a continuous subanesthetic S - ketamine infusion while differences in BOLD responses measured with fMRI were detected .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        24,
        "S - ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2608,
    "text": "During the scanning period , subjects performed continuous overt verbal fluency tasks ( phonological , lexical and semantic ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2609,
    "text": "Ketamine - induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale ( PANSS ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2610,
    "text": "Ketamine elicited psychosis like psychopathology .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ketamine"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2611,
    "text": "Post - hoc t - tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency , while the phonological domain remained unaffected .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2612,
    "text": "Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency , but not for semantic verbal fluency .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2613,
    "text": "Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia , particularly in frontal and temporal brain regions .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ketamine"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2614,
    "text": "Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "NMDA"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2615,
    "text": "Long - term prognosis for transplant - free survivors of paracetamol - induced acute liver failure .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "acute liver failure"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2616,
    "text": "BACKGROUND : The prognosis for transplant - free survivors of paracetamol - induced acute liver failure remains unknown .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "acute liver failure"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2617,
    "text": "AIM : To examine whether paracetamol - induced acute liver failure increases long - term mortality .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "acute liver failure"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2618,
    "text": "METHODS : We followed up all transplant - free survivors of paracetamol - induced acute liver injury , hospitalized in a Danish national referral centre during 1984 - 2004 .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        17,
        "acute liver injury"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2619,
    "text": "We compared age - specific mortality rates from 1 year post - discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "liver injury"
      ],
      [
        "T1",
        "Disease",
        25,
        28,
        "acute liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2620,
    "text": "RESULTS : We included 641 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2621,
    "text": "On average , age - specific mortality rates were slightly higher for the 101 patients whose paracetamol - induced liver injury had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of liver disease , whereas suicides were frequent in both groups .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "liver injury"
      ],
      [
        "T1",
        "Disease",
        24,
        27,
        "acute liver failure"
      ],
      [
        "T2",
        "Disease",
        61,
        64,
        "acute liver failure"
      ],
      [
        "T3",
        "Disease",
        66,
        68,
        "liver disease"
      ],
      [
        "T4",
        "Chemical",
        16,
        17,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2622,
    "text": "These observations speak against long - term effects of acute liver failure .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "acute liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2623,
    "text": "More likely , the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "substance abuse"
      ],
      [
        "T1",
        "Disease",
        22,
        25,
        "acute liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2624,
    "text": "CONCLUSIONS : Paracetamol - induced acute liver failure did not affect long - term mortality .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "acute liver failure"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2625,
    "text": "Clinical follow - up may be justified by the cause of the liver failure , but not by the liver failure itself .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "liver failure"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2626,
    "text": "In vivo characterization of a dual adenosine A2A / A1 receptor antagonist in animal models of Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        12,
        "adenosine A2A / A1 receptor antagonist"
      ],
      [
        "T1",
        "Disease",
        16,
        20,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2627,
    "text": "The in vivo characterization of a dual adenosine A ( 2A ) / A ( 1 ) receptor antagonist in several animal models of Parkinson ' s disease is described .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        19,
        "adenosine A ( 2A ) / A ( 1 ) receptor antagonist"
      ],
      [
        "T1",
        "Disease",
        24,
        28,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2628,
    "text": "Discovery and scale - up syntheses of compound 1 are described in detail , highlighting optimization steps that increased the overall yield of 1 from 10 . 0 % to 30 . 5 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2629,
    "text": "Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .",
    "labels": [
      [
        "T0",
        "Disease",
        63,
        67,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        87,
        90,
        "6 - hydroxydopamine"
      ],
      [
        "T2",
        "Chemical",
        91,
        94,
        "6 - OHDA"
      ],
      [
        "T3",
        "Chemical",
        73,
        74,
        "haloperidol"
      ],
      [
        "T4",
        "Disease",
        76,
        77,
        "catalepsy"
      ],
      [
        "T5",
        "Chemical",
        81,
        82,
        "reserpine"
      ],
      [
        "T6",
        "Disease",
        84,
        85,
        "akinesia"
      ],
      [
        "T7",
        "Chemical",
        104,
        105,
        "MPTP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2630,
    "text": "Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "epileptic"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "penicillin"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2631,
    "text": "AIM : Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity , but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2632,
    "text": "The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin - induced epilepsy model .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "epileptic"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "penicillin"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2633,
    "text": "MATERIAL AND METHODS : Twenty - five Sprague - Dawley rats were implanted DBS electrodes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2634,
    "text": "In group - 1 ( n = 10 ) hippocampal DBS was off and in the group - 2 ( n = 10 ) hippocampal DBS was on ( 185 Hz , 0 . 5V , 1V , 2V , and 5V for 60 sec ) following penicillin G injection intracortically .",
    "labels": [
      [
        "T0",
        "Chemical",
        47,
        49,
        "penicillin G"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2635,
    "text": "In the control group hippocampal DBS was on following 8 l saline injection intracortically .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2636,
    "text": "EEG recordings were obtained before and 15 minutes following penicillin - G injection , and at 10th minutes following each stimulus for analysis in terms of frequency , amplitude , and power spectrum .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "penicillin - G"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2637,
    "text": "RESULTS : High frequency hippocampal DBS suppressed the acute penicillin - induced cortical epileptic activity independent from stimulus intensity .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "penicillin"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2638,
    "text": "In the control group , hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2639,
    "text": "CONCLUSION : Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "epileptic"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2640,
    "text": "These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2641,
    "text": "CCNU ( lomustine ) toxicity in dogs : a retrospective study ( 2002 - 07 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "CCNU"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "lomustine"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2642,
    "text": "OBJECTIVE : To describe the incidence of haematological , renal , hepatic and gastrointestinal toxicities in tumour - bearing dogs receiving 1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea ( CCNU ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        15,
        "haematological , renal , hepatic and gastrointestinal toxicities"
      ],
      [
        "T1",
        "Chemical",
        21,
        36,
        "1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea"
      ],
      [
        "T2",
        "Chemical",
        37,
        38,
        "CCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2643,
    "text": "DESIGN : The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "CCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2644,
    "text": "RESULTS : Of the 206 dogs treated with CCNU , 185 met the inclusion criteria for at least one class of toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "CCNU"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2645,
    "text": "CCNU was used most commonly in the treatment of lymphoma , mast cell tumour , brain tumour , histiocytic tumours and epitheliotropic lymphoma .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "mast cell tumour"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "brain tumour"
      ],
      [
        "T2",
        "Disease",
        18,
        20,
        "histiocytic tumours"
      ],
      [
        "T3",
        "Disease",
        21,
        23,
        "epitheliotropic lymphoma"
      ],
      [
        "T4",
        "Chemical",
        0,
        1,
        "CCNU"
      ],
      [
        "T5",
        "Disease",
        9,
        10,
        "lymphoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2646,
    "text": "Throughout treatment , 56 . 9 % of dogs experienced neutropenia , 34 . 2 % experienced anaemia and 14 . 2 % experienced thrombocytopenia .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "neutropenia"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "anaemia"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2647,
    "text": "Gastrointestinal toxicosis was detected in 37 . 8 % of dogs , the most common sign of which was vomiting ( 24 . 3 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Gastrointestinal toxicosis"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "vomiting"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2648,
    "text": "Potential renal toxicity and elevated alanine transaminase ( ALT ) concentration were reported in 12 . 2 % and 48 . 8 % of dogs , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "alanine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2649,
    "text": "The incidence of hepatic failure was 1 . 2 % .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hepatic failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2650,
    "text": "CONCLUSIONS : CCNU - associated toxicity in dogs is common , but is usually not life threatening .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "CCNU"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2651,
    "text": "Central vein thrombosis and topical dipivalyl epinephrine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "vein thrombosis"
      ],
      [
        "T1",
        "Chemical",
        5,
        7,
        "dipivalyl epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2652,
    "text": "A report is given on an 83 - year - old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "vein thrombosis"
      ],
      [
        "T1",
        "Chemical",
        29,
        31,
        "dipivalyl epinephrine"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2653,
    "text": "From present knowledge about the effects of adrenergic eye drops on ocular blood circulation , it is difficult to suggest an association between the two events , which may be coincidental only .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2654,
    "text": "Benzylacyclouridine reverses azidothymidine - induced marrow suppression without impairment of anti - human immunodeficiency virus activity .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "marrow suppression"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Benzylacyclouridine"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "azidothymidine"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "immunodeficiency"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2655,
    "text": "Increased extracellular concentrations of uridine ( Urd ) have been reported to reduce , in vitro , azidothymidine ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman immunodeficiency virus ( HIV ) activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "uridine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "Urd"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "azidothymidine"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "AZT"
      ],
      [
        "T4",
        "Disease",
        36,
        37,
        "immunodeficiency"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2656,
    "text": "Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced anemia and leukopenia was assessed .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "toxicities"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "Urd"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "benzylacyclouridine"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "BAU"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "AZT"
      ],
      [
        "T5",
        "Disease",
        27,
        28,
        "anemia"
      ],
      [
        "T6",
        "Disease",
        29,
        30,
        "leukopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2657,
    "text": "This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without Urd - related toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "Urd"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "Urd"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "Urd"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2658,
    "text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "anemic"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "leukopenic"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "AZT"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "AZT"
      ],
      [
        "T4",
        "Chemical",
        33,
        34,
        "BAU"
      ],
      [
        "T5",
        "Chemical",
        44,
        45,
        "AZT"
      ],
      [
        "T6",
        "Disease",
        47,
        48,
        "anemia"
      ],
      [
        "T7",
        "Disease",
        49,
        50,
        "leukopenia"
      ],
      [
        "T8",
        "Disease",
        83,
        84,
        "megaloblastosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2659,
    "text": "When coadministered with AZT from the onset of drug administration , BAU reduced AZT - induced marrow toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "marrow toxicity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "AZT"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "BAU"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2660,
    "text": "In vitro , at a concentration of 100 mumol / L , BAU possesses minimal anti - HIV activity and has no effect on the ability of AZT to reverse the HIV - induced cytopathic effect in MT4 cells .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "BAU"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2661,
    "text": "The clinical and biochemical implications of these findings are discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2662,
    "text": "Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "breast cancer"
      ],
      [
        "T1",
        "Disease",
        14,
        17,
        "impaired renal function"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "anuria"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "ifosfamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2663,
    "text": "A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal renal failure with anuria , the day after 5 g / m2 bolus ifosfamide .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "breast cancer"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "renal failure"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "cisplatin"
      ],
      [
        "T3",
        "Disease",
        24,
        25,
        "anuria"
      ],
      [
        "T4",
        "Chemical",
        34,
        35,
        "ifosfamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2664,
    "text": "Postrenal failure was excluded by echography .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Postrenal failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2665,
    "text": "A prerenal component could have contributed to renal failure because of a transient hypotension , due to an increasing ascitis , occurring just before anuria .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "renal failure"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "hypotension"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "anuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2666,
    "text": "However , correction of the hemodynamic parameters did not improve renal function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2667,
    "text": "Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ifosfamide"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "nephrotoxic"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "tubulopathies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2668,
    "text": "We strongly suspect that this lethal anuria was mainly due to ifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "anuria"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "ifosfamide"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "cisplatin"
      ],
      [
        "T3",
        "Disease",
        30,
        31,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2669,
    "text": "We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "ifosfamide"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "nephrotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2670,
    "text": "Nociceptive effects induced by intrathecal administration of prostaglandin D2 , E2 , or F2 alpha to conscious mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        15,
        "prostaglandin D2 , E2 , or F2 alpha"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2671,
    "text": "The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        22,
        "acetic acid"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "prostaglandins"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2672,
    "text": "Prostaglandin D2 ( 0 . 5 - 3 ng / mouse ) had a hyperalgesic action on the response to a hot plate during a 3 - 60 min period after injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Prostaglandin D2"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "hyperalgesic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2673,
    "text": "Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng / mouse , but the effect lasted shorter ( 3 - 30 min ) than that of prostaglandin D2 .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Prostaglandin E2"
      ],
      [
        "T1",
        "Chemical",
        31,
        33,
        "prostaglandin D2"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "hyperalgesic"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "pg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2674,
    "text": "Similar results were obtained by acetic acid writhing tests .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "acetic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2675,
    "text": "The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist ( greater than or equal to 100 ng ) but not by AH6809 , a prostanoid EP1 - receptor antagonist .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "prostaglandin D2"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "hyperalgesic"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "AH6809"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2676,
    "text": "Conversely , prostaglandin E2 - induced hyperalgesia was blocked by AH6809 ( greater than or equal to 500 ng ) but not by the substance P antagonist .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "prostaglandin E2"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hyperalgesia"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "AH6809"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2677,
    "text": "Prostaglandin F2 alpha had little effect on pain responses .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "Prostaglandin F2 alpha"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2678,
    "text": "These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord , but in different ways .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "prostaglandin D2"
      ],
      [
        "T1",
        "Chemical",
        8,
        10,
        "prostaglandin E2"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hyperalgesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2679,
    "text": "D - penicillamine in the treatment of localized scleroderma .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "D - penicillamine"
      ],
      [
        "T1",
        "Disease",
        7,
        9,
        "localized scleroderma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2680,
    "text": "Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Localized scleroderma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2681,
    "text": "There is no accepted or proven treatment for localized scleroderma .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "localized scleroderma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2682,
    "text": "Case reports of 11 patients with severe , extensive localized scleroderma who were treated with D - penicillamine are summarized in this article .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "localized scleroderma"
      ],
      [
        "T1",
        "Chemical",
        15,
        18,
        "D - penicillamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2683,
    "text": "This drug was judged to have a favorable effect on the disease course in 7 ( 64 % ) of 11 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2684,
    "text": "Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients , skin softening in 5 , and more normal growth of the affected limb in 2 of 3 children .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2685,
    "text": "Joint stiffness and contractures also improved .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "contractures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2686,
    "text": "The dose of D - penicillamine associated with a favorable response was as low as 2 to 5 mg / kg per day given over a period ranging from 15 to 53 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "D - penicillamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2687,
    "text": "D - Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients ; none developed renal insufficiency .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "D - Penicillamine"
      ],
      [
        "T1",
        "Disease",
        4,
        6,
        "nephrotic syndrome"
      ],
      [
        "T2",
        "Disease",
        20,
        22,
        "renal insufficiency"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2688,
    "text": "These data suggest that D - penicillamine may be effective in severe cases of localized scleroderma .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "D - penicillamine"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "localized scleroderma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2689,
    "text": "Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Cerebral sinus thrombosis"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "menorrhagia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2690,
    "text": "We describe a 42 - year - old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon - aminocaproic acid therapy for menorrhagia .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        18,
        "sagittal and left transverse sinus thrombosis"
      ],
      [
        "T1",
        "Chemical",
        21,
        25,
        "epsilon - aminocaproic acid"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "menorrhagia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2691,
    "text": "This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "blood loss"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "menorrhagia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2692,
    "text": "Although increased risk of thromboembolic disease has been reported during treatment with epsilon - aminocaproic acid , cerebral sinus thrombosis has not been previously described .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "thromboembolic disease"
      ],
      [
        "T1",
        "Chemical",
        12,
        16,
        "epsilon - aminocaproic acid"
      ],
      [
        "T2",
        "Disease",
        17,
        20,
        "cerebral sinus thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2693,
    "text": "Careful use of epsilon - aminocaproic acid therapy is recommended .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        7,
        "epsilon - aminocaproic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2694,
    "text": "Seizure activity with imipenem therapy : incidence and risk factors .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Seizure"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "imipenem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2695,
    "text": "Two elderly patients with a history of either cerebral vascular accident ( CVA ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem / cilastatin .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "cerebral vascular accident"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "head trauma"
      ],
      [
        "T2",
        "Disease",
        21,
        23,
        "renal disease"
      ],
      [
        "T3",
        "Chemical",
        30,
        33,
        "imipenem / cilastatin"
      ],
      [
        "T4",
        "Disease",
        12,
        13,
        "CVA"
      ],
      [
        "T5",
        "Disease",
        24,
        25,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2696,
    "text": "Neither patient had reported previous seizures or seizure - like activity nor was receiving anticonvulsant agents .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "seizures"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2697,
    "text": "All seizures were controlled with therapeutic doses of phenytoin .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "seizures"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "phenytoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2698,
    "text": "Both patients had received maximum doses of other beta - lactam antibiotics without evidence of seizure activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "beta - lactam"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2699,
    "text": "Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "serotonin"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypotensive"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "methyldopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2700,
    "text": "Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "methyldopa"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "serotonin"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "hypotensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2701,
    "text": "The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla , coinciding with the raphe magnus .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2702,
    "text": "In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .",
    "labels": [
      [
        "T0",
        "Chemical",
        53,
        58,
        "5 , 7 - dihydroxytryptamine"
      ],
      [
        "T1",
        "Chemical",
        59,
        64,
        "5 , 7 - DHT"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "hypertensive"
      ],
      [
        "T3",
        "Disease",
        4,
        5,
        "stroke"
      ],
      [
        "T4",
        "Chemical",
        11,
        12,
        "methyldopa"
      ],
      [
        "T5",
        "Chemical",
        19,
        20,
        "serotonin"
      ],
      [
        "T6",
        "Disease",
        29,
        30,
        "hypotension"
      ],
      [
        "T7",
        "Chemical",
        51,
        52,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2703,
    "text": "However , intraspinal injection of 5 , 7 - DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        10,
        "5 , 7 - DHT"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "serotonin"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2704,
    "text": "Further , 5 , 7 - DHT lesion of serotonin nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 serotonin cells , did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        7,
        "5 , 7 - DHT"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "serotonin"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "serotonin"
      ],
      [
        "T3",
        "Chemical",
        43,
        44,
        "serotonin"
      ],
      [
        "T4",
        "Chemical",
        44,
        45,
        "methyldopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2705,
    "text": "It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced hypotension via descending projections , the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "methyldopa"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "serotonin"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "hypotensive"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "methyldopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2706,
    "text": "Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "ventricular arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "cibenzoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2707,
    "text": "Using two - stage coronary ligation - , digitalis - , and adrenaline - induced canine ventricular arrhythmias , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "ventricular arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "digitalis"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "adrenaline"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "cibenzoline"
      ],
      [
        "T4",
        "Disease",
        33,
        34,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2708,
    "text": "Cibenzoline suppressed all the arrhythmias , and the minimum effective plasma concentrations for arrhythmias induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and adrenaline were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / - 1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cibenzoline"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "arrhythmias"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "arrhythmias"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "digitalis"
      ],
      [
        "T4",
        "Chemical",
        31,
        32,
        "adrenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2709,
    "text": "The concentration for adrenaline - induced arrhythmia was significantly higher than those for the other types of arrhythmias .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "adrenaline"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "arrhythmia"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "arrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2710,
    "text": "This pharmacological profile is similar to those of mexiletine and tocainide , and all three drugs have central nervous system ( CNS ) stimulant action .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "mexiletine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "tocainide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2711,
    "text": "Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs , its clinical usefulness is expected .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "cibenzoline"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hypotensive"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "depressive"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2712,
    "text": "Continuous ambulatory ECG monitoring during fluorouracil therapy : a prospective study .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "fluorouracil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2713,
    "text": "Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil ( 5 - FU ) therapy , this phenomenon has not been studied in a systematic fashion .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "cardiac toxicity"
      ],
      [
        "T1",
        "Chemical",
        13,
        16,
        "5 - FU"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "fluorouracil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2714,
    "text": "We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5 - FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "5 - FU"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "tumors"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2715,
    "text": "Patients were monitored for 23 + / - 4 hours before 5 - FU infusion , and 98 + / - 9 hours during 5 - FU infusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        24,
        27,
        "5 - FU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2716,
    "text": "Anginal episodes were rare : only one patient had angina ( during 5 - FU infusion ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        15,
        "5 - FU"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Anginal"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "angina"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2717,
    "text": "However , asymptomatic ST changes ( greater than or equal to 1 mm ST deviation ) were common : six of 25 patients ( 24 % ) had ST changes before 5 - FU infusion v 17 ( 68 % ) during 5 - FU infusion ( P less than . 002 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        34,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        42,
        45,
        "5 - FU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2718,
    "text": "The incidence of ischemic episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        24,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        36,
        39,
        "5 - FU"
      ],
      [
        "T2",
        "Chemical",
        69,
        72,
        "5 - FU"
      ],
      [
        "T3",
        "Chemical",
        88,
        91,
        "5 - FU"
      ],
      [
        "T4",
        "Disease",
        3,
        4,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2719,
    "text": "ECG changes were more common among patients with known coronary artery disease .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "coronary artery disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2720,
    "text": "There were two cases of sudden death , both of which occurred at the end of the chemotherapy course .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "sudden death"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2721,
    "text": "We conclude that 5 - FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia , particularly among patients with coronary artery disease .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "5 - FU"
      ],
      [
        "T1",
        "Disease",
        26,
        29,
        "coronary artery disease"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2722,
    "text": "The mechanism and clinical significance of these ECG changes remain to be determined .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2723,
    "text": "Nature , time course and dose dependence of zidovudine - related side effects : results from the Multicenter Canadian Azidothymidine Trial .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "zidovudine"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "Azidothymidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2724,
    "text": "To characterize the nature , time course and dose dependency of zidovudine - related side effects , we undertook a multicenter , prospective , dose - range finding study .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "zidovudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2725,
    "text": "Our study group consisted of 74 HIV - positive homosexual men belonging to groups II B , III and IV C2 from the Centers for Disease Control ( CDC ) classification of HIV disease .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        34,
        "HIV disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2726,
    "text": "Following a 3 - week observation period , volunteers were treated with zidovudine 600 mg / day for 18 weeks , 900 mg / day for 9 weeks and 1200 mg / day for 9 weeks , followed by a washout period of 6 weeks after which they were re - started on 1200 mg / day or the highest tolerated dose at 8 - hourly intervals .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "zidovudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2727,
    "text": "Subjects were randomly assigned to 4 - hourly or 8 - hourly regimens within CDC groups while taking 600 and 1200 mg / day .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2728,
    "text": "Clinical and laboratory evaluations were performed at 3 - week intervals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2729,
    "text": "Symptomatic adverse effects were present in 96 % of subjects , most commonly nausea ( 64 % ) , fatigue ( 55 % ) and headache ( 49 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "nausea"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "fatigue"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2730,
    "text": "These were generally self - limited , reappearing briefly at each dose increment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2731,
    "text": "A decrease in hemoglobin occurred shortly after initiation of therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2732,
    "text": "This was not dose dependent and reversed rapidly upon discontinuation of treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2733,
    "text": "A red blood cell count decrease , a mean cell volume increase and a granulocyte count decrease developed early in a dose - independent fashion , reverting at least partially during the washout phase .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2734,
    "text": "The decrease in reticulocyte count was dose related between 600 and 900 mg / day with no further change when the dose was escalated to 1200 mg / day .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2735,
    "text": "Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95 % of 65 specimens at week 18 . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "megaloblastosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2736,
    "text": "National project on the prevention of mother - to - infant infection by hepatitis B virus in Japan .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        16,
        "infection by hepatitis B virus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2737,
    "text": "In Japan , a nationwide prevention program against mother - to - infant infection by hepatitis B virus ( HBV ) started in 1985 .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        18,
        "infection by hepatitis B virus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2738,
    "text": "This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen ( HBsAg ) and hepatitis B e antigen ( HBeAg ) positive mothers .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        22,
        "hepatitis B surface antigen"
      ],
      [
        "T1",
        "Chemical",
        26,
        30,
        "hepatitis B e antigen"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "HBsAg"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "HBeAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2739,
    "text": "These infants are treated with two injections of hepatitis B immune globulin ( HBIG ) and at least three injections of plasma derived hepatitis B vaccine .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "hepatitis B"
      ],
      [
        "T1",
        "Chemical",
        23,
        26,
        "hepatitis B vaccine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2740,
    "text": "We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2741,
    "text": "93 . 4 % pregnant women had the chance to be examined for HBsAg , and the positive rate was 1 . 4 to 1 . 5 % .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "HBsAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2742,
    "text": "The HBeAg positive rate in HBsAg positive was 23 to 26 % .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "HBeAg"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "HBsAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2743,
    "text": "The HBsAg positive rate in neonates and in infants before two months were 3 % and 2 % respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "HBsAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2744,
    "text": "Some problems may arise , because 27 to 30 % of infants need the fourth vaccination in some restricted areas .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2745,
    "text": "Involvement of the mu - opiate receptor in peripheral analgesia .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "analgesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2746,
    "text": "The intradermal injection of mu ( morphine , Tyr - D - Ala - Gly - NMe - Phe - Gly - ol and morphiceptin ) , kappa ( trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide ) and delta ( [ D - Pen2 . 5 ] - enkephalin and [ D - Ser2 ] - [ Leu ] enkephalin - Thr ) selective opioid - agonists , by themselves , did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        23,
        "Tyr - D - Ala - Gly - NMe - Phe - Gly - ol"
      ],
      [
        "T1",
        "Chemical",
        29,
        53,
        "trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide"
      ],
      [
        "T2",
        "Chemical",
        57,
        66,
        "[ D - Pen2 . 5 ] - enkephalin"
      ],
      [
        "T3",
        "Chemical",
        67,
        79,
        "[ D - Ser2 ] - [ Leu ] enkephalin - Thr"
      ],
      [
        "T4",
        "Chemical",
        6,
        7,
        "morphine"
      ],
      [
        "T5",
        "Chemical",
        24,
        25,
        "morphiceptin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2747,
    "text": "Intradermal injection of mu , but not delta or kappa opioid - agonists , however , produced dose - dependent inhibition of prostaglandin E2 - induced hyperalgesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        24,
        "prostaglandin E2"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "hyperalgesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2748,
    "text": "The analgesic effect of the mu - agonist morphine was dose - dependently antagonized by naloxone and prevented by co - injection of pertussis toxin .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "naloxone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2749,
    "text": "Morphine did not , however , alter the hyperalgesia induced by 8 - bromo cyclic adenosine monophosphate .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        17,
        "8 - bromo cyclic adenosine monophosphate"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Morphine"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "hyperalgesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2750,
    "text": "We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu - opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system .",
    "labels": [
      [
        "T0",
        "Chemical",
        38,
        41,
        "cyclic adenosine monophosphate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2751,
    "text": "Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl - induced muscular rigidity in the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "muscular rigidity"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2752,
    "text": "Whereas muscular rigidity is a well - known side effect that is associated with high - dose fentanyl anesthesia , a paucity of information exists with regard to its underlying mechanism ( s ) .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "muscular rigidity"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2753,
    "text": "We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon , using male Sprague - Dawley rats anesthetized with ketamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2754,
    "text": "Under proper control of respiration , body temperature and end - tidal CO2 , intravenous administration of fentanyl ( 50 or 100 micrograms / kg ) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "CO2"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2755,
    "text": "Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha - adrenoceptor blocker , prazosin .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "muscular rigidity"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "prazosin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2756,
    "text": "Microinjection of fentanyl ( 2 . 5 micrograms / 50 nl ) directly into this pontine nucleus , on the other hand , elicited discernible electromyographic excitation .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2757,
    "text": "It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "muscular rigidity"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2758,
    "text": "Dexmedetomidine , acting through central alpha - 2 adrenoceptors , prevents opiate - induced muscle rigidity in the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "muscle rigidity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2759,
    "text": "The highly - selective alpha - 2 adrenergic agonist dexmedetomidine ( D - MED ) is capable of inducing muscle flaccidity and anesthesia in rats and dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "D - MED"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "muscle flaccidity"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2760,
    "text": "Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "muscle rigidity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2761,
    "text": "Although the neurochemistry of opiate - induced rigidity has yet to be fully elucidated , recent work suggests a role for a central adrenergic mechanism .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "rigidity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2762,
    "text": "In the present study , the authors determined if treatment with D - MED prevents the muscle rigidity caused by high - dose alfentanil anesthesia in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "D - MED"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "muscle rigidity"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "alfentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2763,
    "text": "Animals ( n = 42 ) were treated intraperitoneally with one of the following six regimens : 1 ) L - MED ( the inactive L - isomer of medetomidine ) , 30 micrograms / kg ; 2 ) D - MED , 10 micrograms / kg ; 3 ) D - MED , 30 micrograms / kg ; 4 ) D - MED [ 30 micrograms / kg ] and the central - acting alpha - 2 antagonist , idazoxan [ 10 mg / kg ] ; 5 ) D - MED [ 30 micrograms / kg ] and the peripheral - acting alpha - 2 antagonist DG - 5128 [ 10 mg / kg ] , or ; 6 ) saline .",
    "labels": [
      [
        "T0",
        "Chemical",
        39,
        42,
        "D - MED"
      ],
      [
        "T1",
        "Chemical",
        50,
        53,
        "D - MED"
      ],
      [
        "T2",
        "Chemical",
        61,
        64,
        "D - MED"
      ],
      [
        "T3",
        "Chemical",
        90,
        93,
        "D - MED"
      ],
      [
        "T4",
        "Chemical",
        108,
        111,
        "DG - 5128"
      ],
      [
        "T5",
        "Chemical",
        29,
        30,
        "medetomidine"
      ],
      [
        "T6",
        "Chemical",
        80,
        81,
        "idazoxan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2764,
    "text": "Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2765,
    "text": "Each rat was then injected with alfentanil ( ALF , 0 . 5 mg / kg sc ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "alfentanil"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "ALF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2766,
    "text": "ALF injection resulted in a marked increase in hindlimb EMG activity in the L - MED treatment group which was indistinguishable from that seen in animals treated with saline .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "ALF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2767,
    "text": "In contrast , D - MED prevented alfentanil - induced muscle rigidity in a dose - dependent fashion .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "D - MED"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "muscle rigidity"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "alfentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2768,
    "text": "The small EMG values obtained in the high - dose D - MED group were comparable with those recorded in earlier studies from control animals not given any opiate .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        13,
        "D - MED"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2769,
    "text": "The high - dose D - MED animals were flaccid , akinetic , and lacked a startle response during the entire experimental period . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "D - MED"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "akinetic"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "startle"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2770,
    "text": "Some central effects of repeated treatment with fluvoxamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "fluvoxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2771,
    "text": "We investigated the effect of repeated treatment with fluvoxamine , a selective serotonin uptake inhibitor , on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the \" behavioral despair \" test .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "fluvoxamine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "serotonin"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "methoxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2772,
    "text": "A repeated treatment with fluvoxamine ( twice daily for 14 days ) potentiated in mice and in rats ( weaker ) the amphetamine - induced hyperactivity .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "fluvoxamine"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "amphetamine"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "hyperactivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2773,
    "text": "The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hyperactivity"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "nomifensine"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "fluvoxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2774,
    "text": "The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "methoxamine"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "fluvoxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2775,
    "text": "Given three times fluvoxamine had no effect on the immobilization time in the \" behavioral despair \" test in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "fluvoxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2776,
    "text": "The results indicate that fluvoxamine given repeatedly acts differently than citalopram , another selective serotonin uptake inhibitor , and differs also from other antidepressant drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "fluvoxamine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "citalopram"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2777,
    "text": "Protective effect of a specific platelet - activating factor antagonist , BN 52021 , on bupivacaine - induced cardiovascular impairments in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "BN 52021"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "cardiovascular impairments"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2778,
    "text": "Administration of the local anaesthetic bupivacaine ( 1 . 5 or 2 mg / kg , i . v . ) to rats elicited a marked decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR ) leading to death ( in 67 % or 90 % of animals respectively ) .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        41,
        "decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR )"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2779,
    "text": "Intravenous injection of the specific platelet - activating factor ( PAF ) antagonist BN 52021 ( 10 mg / kg ) , 30 min before bupivacaine administration ( 2 mg / kg i . v . ) suppressed both the decrease of MBP and HR .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "BN 52021"
      ],
      [
        "T1",
        "Disease",
        40,
        45,
        "decrease of MBP and HR"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2780,
    "text": "In contrast , doses of 1 mg / kg BN 52021 given 30 min before or 10 mg / kg administered 5 min before i . v . injection of bupivacaine were ineffective .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "BN 52021"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2781,
    "text": "When BN 52021 ( 20 mg / kg i . v . ) was injected immediately after bupivacaine ( 2 mg / kg ) , a partial reversion of the decrease of MBP and HR was observed , whereas the dose of 10 mg / kg was ineffective .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "BN 52021"
      ],
      [
        "T1",
        "Disease",
        30,
        35,
        "decrease of MBP and HR"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2782,
    "text": "A partial recovery of bupivacaine - induced ECG alterations was observed after pretreatment of the rats with BN 52021 .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        19,
        "BN 52021"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2783,
    "text": "Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against bupivacaine - induced cardiovascular toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "BN 52021"
      ],
      [
        "T1",
        "Chemical",
        34,
        36,
        "BN 52021"
      ],
      [
        "T2",
        "Disease",
        47,
        49,
        "cardiovascular toxicity"
      ],
      [
        "T3",
        "Chemical",
        44,
        45,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2784,
    "text": "Thus , consistent with its direct effect on heart , PAF appears to be implicated in bupivacaine - induced cardiovascular alterations .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "cardiovascular alterations"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2785,
    "text": "The epidemiology of the acute flank pain syndrome from suprofen .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "flank pain"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "suprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2786,
    "text": "Suprofen , a new nonsteroidal anti - inflammatory drug , was marketed in early 1986 as an analgesic agent .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Suprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2787,
    "text": "Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system , 700 , 000 persons used the drug in the United States .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "flank pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2788,
    "text": "Through August 1986 , a total of 163 cases of this syndrome were reported .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2789,
    "text": "To elucidate the epidemiology of the syndrome , a case - control study was performed , comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen - exposed control subjects who did not have the syndrome .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        34,
        "suprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2790,
    "text": "Case patients were more likely to be men ( odds ratio , 3 . 8 ; 95 % confidence interval , 1 . 2 - 12 . 1 ) , suffer from hay fever and asthma ( odds ratio , 3 . 4 ; 95 % confidence interval , 1 . 0 - 11 . 9 ) ; to participate in regular exercise ( odds ratio , 5 . 9 ; 95 % confidence interval , 1 . 1 - 30 . 7 ) , especially in the use of Nautilus equipment ( p = 0 . 02 ) ; and to use alcohol ( odds ratio , 4 . 4 ; 95 % confidence interval , 1 . 1 - 17 . 5 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        34,
        "hay fever"
      ],
      [
        "T1",
        "Disease",
        35,
        36,
        "asthma"
      ],
      [
        "T2",
        "Chemical",
        103,
        104,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2791,
    "text": "Possible risk factors included young age , concurrent use of other analgesic agents ( especially ibuprofen ) , preexisting renal disease , a history of kidney stones , a history of gout , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "renal disease"
      ],
      [
        "T1",
        "Disease",
        25,
        27,
        "kidney stones"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "ibuprofen"
      ],
      [
        "T3",
        "Disease",
        31,
        32,
        "gout"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2792,
    "text": "These were findings that were suggestive but did not reach conventional statistical significance .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2793,
    "text": "These findings are consistent with the postulated mechanism for this unusual syndrome : acute diffuse crystallization of uric acid in renal tubules .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        19,
        "uric acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2794,
    "text": "Phlorizin - induced glycosuria does not prevent gentamicin nephrotoxicity in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Phlorizin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "glycosuria"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "gentamicin"
      ],
      [
        "T3",
        "Disease",
        8,
        9,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2795,
    "text": "Because rats with streptozotocin - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( ARF ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "diabetes mellitus"
      ],
      [
        "T1",
        "Disease",
        44,
        47,
        "acute renal failure"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "streptozotocin"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "DM"
      ],
      [
        "T4",
        "Disease",
        17,
        18,
        "glycosuria"
      ],
      [
        "T5",
        "Chemical",
        41,
        42,
        "gentamicin"
      ],
      [
        "T6",
        "Disease",
        48,
        49,
        "ARF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2796,
    "text": "The protection from gentamicin nephrotoxicity was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( P ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "gentamicin"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "nephrotoxicity"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "diabetic"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "glucose"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "phlorizin"
      ],
      [
        "T5",
        "Chemical",
        26,
        27,
        "P"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2797,
    "text": "DM rats with mild glycosuria ( similar in degree to that of the P treated animals ) were also studied .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "DM"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "glycosuria"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "P"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2798,
    "text": "Unanesthetized adult female , Sprague - Dawley rats were divided in four groups and studied for 15 days .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2799,
    "text": "Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild DM + gentamicin ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "P"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "P"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "P"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "gentamicin"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "gentamicin"
      ],
      [
        "T5",
        "Disease",
        37,
        38,
        "DM"
      ],
      [
        "T6",
        "Chemical",
        39,
        40,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2800,
    "text": "Nephrotoxic doses ( 40 mg / kg body wt / day ) of gentamicin were injected during the last nine days of study to the animals of groups II to IV .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Nephrotoxic"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2801,
    "text": "In Group I , P induced a moderate and stable glycosuria ( 3 . 9 + / - 0 . 1 g / day , SE ) , and no functional or morphologic evidence of renal dysfunction ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( tubular necrosis score [ maximum 4 ] , zero ) .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        37,
        "renal dysfunction"
      ],
      [
        "T1",
        "Disease",
        59,
        61,
        "tubular necrosis"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "P"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "glycosuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2802,
    "text": "In Group II , P did not prevent gentamicin - ARF ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and tubular necrosis score , 3 . 9 + / - 0 . 1 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        43,
        45,
        "tubular necrosis"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "P"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "gentamicin"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "ARF"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "P"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2803,
    "text": "These values were not different from those of Group III : maximal decrease in CCr 73 % ( P less than 0 . 001 ) ; lysozymuria , 2147 + / - 701 micrograms / day ; tubular necrosis score , 3 . 8 + / - 0 . 1 . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Disease",
        37,
        39,
        "tubular necrosis"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "P"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2804,
    "text": "Catalepsy induced by combinations of ketamine and morphine : potentiation , antagonism , tolerance and cross - tolerance in the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Catalepsy"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "ketamine"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2805,
    "text": "Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "ketamine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "morphine"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "analgesia"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2806,
    "text": "Pre - treatment with ketamine produced cross - tolerance to morphine , whereas pretreatment with morphine did not induce cross - tolerance to ketamine but rather augmented the cataleptic response ; this augmentation was attributed to residual morphine in the brain .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ketamine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "morphine"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "morphine"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "ketamine"
      ],
      [
        "T4",
        "Disease",
        28,
        29,
        "cataleptic"
      ],
      [
        "T5",
        "Chemical",
        37,
        38,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2807,
    "text": "The present studies explored the duration of the loss of righting reflex induced by sub - effective doses of ketamine and morphine , administered simultaneously .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "ketamine"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2808,
    "text": "There was mutual potentiation between sub - effective doses of ketamine and morphine , but sub - effective doses of ketamine partly antagonized fully - effective doses of morphine .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "ketamine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "morphine"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "ketamine"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2809,
    "text": "Latency to the loss of righting reflex , rigidity and behavior on recovery , reflected the relative predominance of ketamine or morphine in each combination .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "rigidity"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "ketamine"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2810,
    "text": "Naloxone inhibited the induced cataleptic effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Naloxone"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "cataleptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2811,
    "text": "The degree and time course of development of tolerance to daily administration of sub - effective dose combinations of ketamine and morphine were similar .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "ketamine"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2812,
    "text": "Rats , tolerant to ketamine - dominant combinations , were cross - tolerant to both drugs , while those tolerant to morphine - dominant combinations were cross - tolerant to morphine but showed either no cross - tolerance or an augmented response to ketamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ketamine"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "morphine"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "morphine"
      ],
      [
        "T3",
        "Chemical",
        43,
        44,
        "ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2813,
    "text": "While the mutual potentiation , antagonism and tolerance suggest common mechanisms for the induced catalepsy , differences in latency , rigidity and behavior , asymmetry of cross - tolerance and a widely - different ID50 for naloxone would argue against an action at a single opioid site .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "catalepsy"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "rigidity"
      ],
      [
        "T2",
        "Chemical",
        36,
        37,
        "naloxone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2814,
    "text": "Hydrocortisone - induced hypertension in humans : pressor responsiveness and sympathetic function .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Hydrocortisone"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2815,
    "text": "Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "hydrocortisone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2816,
    "text": "We studied the effects of 1 week of oral hydrocortisone ( 200 mg / day ) on blood pressure , cardiac output , total peripheral resistance , forearm vascular resistance , and norepinephrine spillover to plasma in eight healthy male volunteers .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "hydrocortisone"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2817,
    "text": "Although diastolic blood pressure remained unchanged , systolic blood pressure increased from 119 to 135 mm Hg ( SED + / - 3 . 4 , p less than 0 . 01 ) , associated with an increased cardiac output ( 5 . 85 - 7 . 73 l / min , SED + / - 0 . 46 , p less than 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        37,
        40,
        "increased cardiac output"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2818,
    "text": "Total peripheral vascular resistance fell from 15 . 1 to 12 . 2 mm Hg / l / min ( SED + / - 1 . 03 , p less than 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2819,
    "text": "Resting forearm vascular resistance remained unchanged , but the reflex response to the cold pressor test was accentuated , the rise in resistance increasing from 10 . 5 mm Hg / ml / 100 ml / min ( R units ) before treatment to 32 . 6 R units after treatment ( SED + / - 6 . 4 , p less than 0 . 025 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2820,
    "text": "The rise in forearm vascular resistance accompanying intra - arterial norepinephrine ( 25 , 50 , and 100 ng / min ) was also significantly greater after hydrocortisone , increasing from an average of 14 . 9 + / - 2 . 4 R units before treatment to 35 . 1 + / - 5 . 5 R units after hydrocortisone ( SED + / - 6 . 0 , p less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "norepinephrine"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "hydrocortisone"
      ],
      [
        "T2",
        "Chemical",
        60,
        61,
        "hydrocortisone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2821,
    "text": "A shift to the left in the dose - response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2822,
    "text": "Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "norepinephrine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2823,
    "text": "The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output ( presumably due to increased blood volume ) . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        6,
        "rise in resting blood pressure"
      ],
      [
        "T1",
        "Disease",
        12,
        15,
        "increased cardiac output"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "hydrocortisone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2824,
    "text": "Neuromuscular blockade with magnesium sulfate and nifedipine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Neuromuscular blockade"
      ],
      [
        "T1",
        "Chemical",
        3,
        5,
        "magnesium sulfate"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "nifedipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2825,
    "text": "A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "neuromuscular blockade"
      ],
      [
        "T1",
        "Chemical",
        14,
        16,
        "magnesium sulfate"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "nifedipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2826,
    "text": "This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "nifedipine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "magnesium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2827,
    "text": "Caution should be exercised when these two tocolytics are combined .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2828,
    "text": "Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "carbamazepine"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "cocaine"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2829,
    "text": "The effects of carbamazepine ( CBZ ) treatment on local anesthetic - kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "carbamazepine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "CBZ"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "seizures"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "CBZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2830,
    "text": "Chronic oral CBZ inhibited the development of both lidocaine - and cocaine - induced seizures , but had little effect on the fully developed local anesthetic seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "CBZ"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "seizures"
      ],
      [
        "T4",
        "Disease",
        26,
        27,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2831,
    "text": "Chronic CBZ also decreased the incidence of seizure - related mortality in the cocaine - injected rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "CBZ"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "seizure"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2832,
    "text": "Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute cocaine - induced seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "CBZ"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2833,
    "text": "Repeated i . p . injection of CBZ ( 15 mg / kg ) also was without effect on the development of lidocaine - or cocaine - kindled seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "CBZ"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2834,
    "text": "The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "CBZ"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "seizure"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2835,
    "text": "The effectiveness of chronic but not repeated , intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "CBZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2836,
    "text": "The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data , but remains to be directly evaluated .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "CBZ"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2837,
    "text": "Magnetic resonance imaging of cerebral venous thrombosis secondary to \" low - dose \" birth control pills .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "venous thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2838,
    "text": "The clinical and radiographic features of cerebral deep venous thrombosis in a 21 - year - old white woman are presented .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "deep venous thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2839,
    "text": "This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2840,
    "text": "The only known risk factor was \" low - dose \" oral contraceptive pills .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "oral contraceptive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2841,
    "text": "The magnetic resonance image ( MRI ) showed increased signal intensity from the internal cerebral veins , vein of Galen , and straight sinus .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2842,
    "text": "The diagnosis was confirmed by arterial angiography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2843,
    "text": "Beta - 2 - adrenoceptor - mediated hypokalemia and its abolishment by oxprenolol .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "hypokalemia"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "oxprenolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2844,
    "text": "The time course and concentration - effect relationship of terbutaline - induced hypokalemia was studied , using computer - aided pharmacokinetic - dynamic modeling .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "terbutaline"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hypokalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2845,
    "text": "Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia , together with the pharmacokinetic interaction between both drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "oxprenolol"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypokalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2846,
    "text": "Six healthy subjects were given a 0 . 5 mg subcutaneous dose of terbutaline on two occasions : 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "terbutaline"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "oxprenolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2847,
    "text": "In the 7 - hour period after terbutaline administration , plasma samples were taken for determination of plasma potassium levels and drug concentrations .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "terbutaline"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2848,
    "text": "The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "terbutaline"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2849,
    "text": "Oxprenolol caused decreases of 65 % and 56 % of terbutaline volume of distribution and clearance , respectively , and an increase of 130 % of its AUC .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Oxprenolol"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "terbutaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2850,
    "text": "In spite of higher terbutaline concentrations after oxprenolol pretreatment , the hypokalemia was almost completely antagonized by the beta 2 - blocking action .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "terbutaline"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "oxprenolol"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hypokalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2851,
    "text": "A dystonia - like syndrome after neuropeptide ( MSH / ACTH ) stimulation of the rat locus ceruleus .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "dystonia"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "MSH"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "ACTH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2852,
    "text": "The movement disorder investigated in these studies has some features in common with human idiopathic dystonia , and information obtained in these studies may be of potential clinical benefit .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "movement disorder"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "dystonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2853,
    "text": "The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE - mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo - cerebellar pathway .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2854,
    "text": "However , it is not certain as to the following : ( a ) what receptors were stimulated by the ACTH N - terminal fragments at the LC that resulted in this disorder ; ( b ) whether NE , released onto Purkinje cell synapses located at terminals of the ceruleo - cerebellar pathway , did indeed cause the long - term depression at Purkinje cell synapses ( previously described by others ) that resulted in the long duration of the movement disorder ; ( c ) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei , the output targets of the Purkinje cell axons , that may have been an important contributing factor to this disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        81,
        83,
        "movement disorder"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "ACTH"
      ],
      [
        "T2",
        "Disease",
        62,
        63,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2855,
    "text": "These questions are currently being investigated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2856,
    "text": "Enhanced stimulus - induced neurotransmitter overflow in epinephrine - induced hypertensive rats is not mediated by prejunctional beta - adrenoceptor activation .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "epinephrine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2857,
    "text": "The present study examines the effect of 6 - day epinephrine treatment ( 100 micrograms / kg per h , s . c . ) on stimulus - induced ( 1 Hz ) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle - and epinephrine - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "epinephrine"
      ],
      [
        "T1",
        "Chemical",
        45,
        46,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2858,
    "text": "Renal catecholamine stores and stimulus - induced overflow in the vehicle - treated group consisted of norepinephrine only .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "catecholamine"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2859,
    "text": "However , epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40 % of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "epinephrine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "epinephrine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "catecholamine"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "catecholamine"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "epinephrine"
      ],
      [
        "T5",
        "Chemical",
        27,
        28,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2860,
    "text": "Total tissue catecholamine content of the kidney on a molar basis was unchanged .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "catecholamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2861,
    "text": "Stimulus - induced fractional overflow of neurotransmitter from the epinephrine - treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "epinephrine"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "norepinephrine"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2862,
    "text": "This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2863,
    "text": "Propranolol had no effect on stimulus - induced overflow in either group .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2864,
    "text": "Phentolamine increased stimulus - induced overflow in both groups although the increment in overflow was greater in the epinephrine - treated group .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Phentolamine"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2865,
    "text": "In conclusion , chronic epinephrine treatment results in enhanced fractional neurotransmitter overflow .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2866,
    "text": "However , neither alterations in prejunctional beta - adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2867,
    "text": "Furthermore , data obtained with phentolamine alone do not suggest alpha - adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "phentolamine"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2868,
    "text": "GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "respiratory paralysis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "GABA"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "naloxone"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "thiopental"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2869,
    "text": "No agent is yet available to reverse respiratory paralysis produced by CNS depressants , such as general anesthetics .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "respiratory paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2870,
    "text": "In this study naloxone reversed respiratory paralysis induced by thiopental in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "respiratory paralysis"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "naloxone"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "thiopental"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2871,
    "text": "25 mg / kg , i . v . thiopental produced anesthesia without altering respiratory rate , increased GABA , decreased glutamate , and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "thiopental"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "GABA"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "glutamate"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "aspartate"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "glycine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2872,
    "text": "Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "thiosemicarbazide"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "thiopental"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2873,
    "text": "50 mg / kg , i . v . thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "respiratory arrest"
      ],
      [
        "T1",
        "Chemical",
        33,
        35,
        "amino acids"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "thiopental"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "GABA"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2874,
    "text": "Naloxone ( 2 . 5 mg / kg , i . v . ) reversed respiratory paralysis , glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "respiratory paralysis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Naloxone"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "glutamate"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2875,
    "text": "These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "respiratory paralysis"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "naloxone"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "thiopental"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2876,
    "text": "Diazepam facilitates reflex bradycardia in conscious rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Diazepam"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2877,
    "text": "The effects of diazepam on cardiovascular function were assessed in conscious rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2878,
    "text": "Intravenous administration of diazepam ( 1 - 30 mg kg - 1 ) produced a dose - dependent decrease in both the mean arterial pressure and the heart rate .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2879,
    "text": "Also , reflex bradycardia was produced in rats by intravenous infusion of adrenaline ( 1 . 25 - 2 . 5 micrograms kg - 1 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "bradycardia"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "adrenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2880,
    "text": "Intravenous pretreatment of the rats with diazepam , although causing no change in the adrenaline - induced pressor effect , did enhance the adrenaline - induced reflex bradycardia .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "diazepam"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "adrenaline"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "adrenaline"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2881,
    "text": "However , the diazepam enhancement of adrenaline - induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "diazepam"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "adrenaline"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "bradycardia"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "picrotoxin"
      ],
      [
        "T4",
        "Chemical",
        27,
        28,
        "chloride"
      ],
      [
        "T5",
        "Chemical",
        36,
        37,
        "benzodiazepine"
      ],
      [
        "T6",
        "Chemical",
        38,
        39,
        "GABA"
      ],
      [
        "T7",
        "Chemical",
        40,
        41,
        "chloride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2882,
    "text": "The data indicate that diazepam acts through the benzodiazepine - GABA - chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "diazepam"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "benzodiazepine"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "GABA"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "chloride"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2883,
    "text": "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension : the influence of dietary sodium restriction .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "potassium"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hypokalaemia"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "chlorthalidone"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "hypertension"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2884,
    "text": "To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "potassium"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypokalaemia"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "hypertension"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "hypokalaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2885,
    "text": "Chlorthalidone ( 50 mg daily ) was given for 14 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Chlorthalidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2886,
    "text": "Six patients received a normal - sodium diet and four a low - sodium ( 17 mmol / day ) diet .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2887,
    "text": "All patients had a normal initial total body potassium ( 40K ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2888,
    "text": "The electrolyte balances , weight , bromide space , plasma renin activity , and aldosterone secretion rate were measured .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "aldosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2889,
    "text": "In both groups a potassium deficit developed , with proportionally larger losses from the extracellular than from the intracellular compartment .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2890,
    "text": "In the normal - sodium group the highest mean potassium deficit was 176 mmol on day 9 , after which some potassium was regained ; in the low - sodium group the highest deficit was 276 mmol on day 13 .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "potassium"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "potassium"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2891,
    "text": "The normal - sodium group showed an immediate but temporary rise of the renin and aldosterone levels ; in the low - sodium group renin and aldosterone increased more slowly but remained elevated .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "aldosterone"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "sodium"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "aldosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2892,
    "text": "It is concluded that dietary sodium restriction increases diuretic - induced potassium loss , presumably by an increased activity of the renin - angiotensin - aldosterone system , while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "potassium"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "angiotensin"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "aldosterone"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "sodium"
      ],
      [
        "T5",
        "Chemical",
        42,
        43,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2893,
    "text": "Reversal of neuroleptic - induced catalepsy by novel aryl - piperazine anxiolytic drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "aryl - piperazine"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2894,
    "text": "The novel anxiolytic drug , buspirone , reverses catalepsy induced by haloperidol .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "buspirone"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2895,
    "text": "A series of aryl - piperazine analogues of buspirone and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "aryl - piperazine"
      ],
      [
        "T1",
        "Chemical",
        11,
        15,
        "5 - hydroxytryptaminergic agonists"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "buspirone"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "haloperidol"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2896,
    "text": "Those drugs with strong affinity for 5 - hydroxytryptamine1a receptors were able to reverse catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "5 - hydroxytryptamine1a"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2897,
    "text": "Drugs with affinity for other 5 - HT receptors or weak affinity were ineffective .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "5 - HT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2898,
    "text": "However , inhibition of postsynaptic 5 - HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "5 - HT"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2899,
    "text": "Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Glycopyrronium"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "edrophonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2900,
    "text": "We have compared , in 60 adult patients , the cardiovascular effects of glycopyrronium 5 micrograms kg - 1 and 10 micrograms kg - 1 given either simultaneously or 1 min before edrophonium 1 mg kg - 1 .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "glycopyrronium"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "edrophonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2901,
    "text": "Significant differences between the four groups were detected ( P less than 0 . 001 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2902,
    "text": "Both groups receiving 10 micrograms kg - 1 showed increases in heart rate of up to 30 beat min - 1 ( 95 % confidence limits 28 - 32 beat min - 1 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2903,
    "text": "Use of glycopyrronium 5 micrograms kg - 1 provided greater cardiovascular stability and , given 1 min before the edrophonium , was sufficient to minimize early , edrophonium - induced bradycardias .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "glycopyrronium"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "edrophonium"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "edrophonium"
      ],
      [
        "T3",
        "Disease",
        30,
        31,
        "bradycardias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2904,
    "text": "This low dose of glycopyrronium provided good control of oropharyngeal secretions .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "glycopyrronium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2905,
    "text": "Selective injection of iopentol , iohexol and metrizoate into the left coronary artery of the dog .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "iopentol"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "iohexol"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "metrizoate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2906,
    "text": "Induction of ventricular fibrillation and decrease of aortic pressure .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "ventricular fibrillation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2907,
    "text": "In twenty beagle dogs selective injections were made into the left coronary artery with iopentol , iohexol and metrizoate in doses of 4 ml , 8 ml and 16 ml .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "iopentol"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "iohexol"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "metrizoate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2908,
    "text": "Thirty - six iopentol injections , 35 iohexol injections and 37 metrizoate injections were made .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "iopentol"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "iohexol"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "metrizoate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2909,
    "text": "Frequencies of ventricular fibrillation were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and iohexol ( 3 % ) than after metrizoate ( 22 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "ventricular fibrillation"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "iopentol"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "iohexol"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "metrizoate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2910,
    "text": "Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Iopentol"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "iohexol"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "metrizoate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2911,
    "text": "Thyroid function and urine - concentrating ability during lithium treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2912,
    "text": "It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        19,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "hypothyroidism"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2913,
    "text": "We measured serum thyroxine and urine - concentrating ability ( Umax ) in response to desmopressin ( DDAVP ) in 85 patients receiving lithium .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "thyroxine"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2914,
    "text": "Hypothyroidism developed in eight patients while they were taking lithium .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypothyroidism"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2915,
    "text": "Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hypothyroid"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hypothyroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2916,
    "text": "It is concluded that the dominant mechanisms by which lithium exerts these two effects are different .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2917,
    "text": "Remodelling of nerve structure in experimental isoniazid neuropathy in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "isoniazid"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2918,
    "text": "The neuropathy caused by a single dose of isoniazid in rats was studied with a computer - assisted morphometric method .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "neuropathy"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "isoniazid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2919,
    "text": "Scatter diagrams of the g ratio ( quotient fibre diameter / axon diameter ) define regenerating fibres as a distinct population , distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2920,
    "text": "There was also evidence of a subtle direct toxic effect on the entire fibre population , causing axon shrinkage masked by readjustment of the myelin sheath .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2921,
    "text": "Multicenter , double - blind , multiple - dose , parallel - groups efficacy and safety trial of azelastine , chlorpheniramine , and placebo in the treatment of spring allergic rhinitis .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        31,
        "spring allergic rhinitis"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "azelastine"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "chlorpheniramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2922,
    "text": "Azelastine , a novel antiallergic medication , was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter , double - blind , multiple - dose , parallel - groups study .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "chlorpheniramine maleate"
      ],
      [
        "T1",
        "Disease",
        22,
        25,
        "spring allergic rhinitis"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Azelastine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2923,
    "text": "One hundred fifty - five subjects participated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2924,
    "text": "Subjects ranged in age from 18 to 60 years of age and had at least a 2 - year history of spring allergic rhinitis , confirmed by positive skin test to spring aeroallergens .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "spring allergic rhinitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2925,
    "text": "Medications were given four times daily ; the azelastine groups received 0 . 5 , 1 . 0 , or 2 . 0 mg in the morning and evening with placebo in the early and late afternoon ; the chlorpheniramine group received 4 . 0 mg four times daily .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "azelastine"
      ],
      [
        "T1",
        "Chemical",
        39,
        40,
        "chlorpheniramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2926,
    "text": "Daily subject symptom cards were completed during a screening period to assess pretreatment symptoms and during a 4 - week treatment period while subjects received study medications .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2927,
    "text": "Individual symptoms , total symptoms , and major symptoms were compared to determine efficacy of medication .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2928,
    "text": "Elicited , volunteered , and observed adverse experiences were recorded for each subject and compared among groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2929,
    "text": "Vital signs , body weights , serum chemistry values , complete blood cell counts , urine studies , and electrocardiograms were obtained for each subject and compared among groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2930,
    "text": "Symptoms relief in the group receiving the highest concentration of azelastine ( 2 . 0 mg twice daily ) was statistically greater than in the placebo group during all weeks of the study .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "azelastine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2931,
    "text": "Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "azelastine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2932,
    "text": "In contrast , although the chlorpheniramine group did have fewer symptoms than the placebo group during the study , the difference never reached statistical significance during any week of the study .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "chlorpheniramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2933,
    "text": "There were no serious side effects in any of the treatment groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2934,
    "text": "Drowsiness and altered taste perception were increased significantly over placebo only in the high - dose azelastine group .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "altered taste perception"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Drowsiness"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "azelastine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2935,
    "text": "Azelastine appears to be a safe , efficacious medication for seasonal allergic rhinitis .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "seasonal allergic rhinitis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Azelastine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2936,
    "text": "Toxicity due to remission inducing drugs in rheumatoid arthritis .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2937,
    "text": "Association with HLA - B35 and Cw4 antigens .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2938,
    "text": "Twenty - five patients with rheumatoid arthritis ( RA ) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "RA"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "toxicity"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2939,
    "text": "A strong association has been found between nephritis and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        18,
        "D - Penicillamine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "nephritis"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "dermatitis"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "Tiopronin"
      ],
      [
        "T4",
        "Disease",
        31,
        32,
        "dermatitis"
      ],
      [
        "T5",
        "Chemical",
        34,
        35,
        "gold"
      ],
      [
        "T6",
        "Chemical",
        35,
        36,
        "thiosulphate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2940,
    "text": "Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "RA"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "Tiopronin"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "nephritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2941,
    "text": "Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "contralateral rotation"
      ],
      [
        "T1",
        "Disease",
        5,
        8,
        "substantia nigra lesion"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2942,
    "text": "Following unilateral 6 - OHDA induced SN lesion , a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "6 - OHDA"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "SN lesion"
      ],
      [
        "T2",
        "Disease",
        13,
        15,
        "contralateral rotation"
      ],
      [
        "T3",
        "Disease",
        22,
        24,
        "ipsilateral circling"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2943,
    "text": "In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion , on amphetamine - induced rotational behavior .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "contralateral rotation"
      ],
      [
        "T1",
        "Disease",
        29,
        31,
        "rotational behavior"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2944,
    "text": "Three days post lesion , most rats circled predominantly contralaterally to the lesion .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2945,
    "text": "Such contralateral rotation may result from either degeneration - induced breakdown of the DA pool , or lesion - induced increase of DA turnover in the spared neurons .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "contralateral rotation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2946,
    "text": "A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning , indicating involvement of spared cells in the contralateral rotation .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        31,
        "contralateral rotation"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2947,
    "text": "However , regardless of the duration of recovery ( and irrespective of either lesion volume , amphetamine dose , or post - lesion motor exercise ) , amphetamine - induced rotation tended to become gradually more ipsilateral as the observation session progressed , and all rats circled ipsilaterally to the lesion in response to further amphetamine injections .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "amphetamine"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "amphetamine"
      ],
      [
        "T2",
        "Disease",
        30,
        31,
        "rotation"
      ],
      [
        "T3",
        "Chemical",
        55,
        56,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2948,
    "text": "These findings suggest that amphetamine has an irreversible effect on the post - lesion DA pool contributing to contralateral rotation .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "contralateral rotation"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2949,
    "text": "Mitomycin C associated hemolytic uremic syndrome .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Mitomycin C"
      ],
      [
        "T1",
        "Disease",
        3,
        6,
        "hemolytic uremic syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2950,
    "text": "Mitomycin C associated Hemolytic Uremic Syndrome ( HUS ) is a potentially fatal but uncommon condition that is not yet widely recognised .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Mitomycin C"
      ],
      [
        "T1",
        "Disease",
        3,
        6,
        "Hemolytic Uremic Syndrome"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "HUS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2951,
    "text": "It consists of microangiopathic hemolytic anemia , thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10 % of patients treated with this agent .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "renal failure"
      ],
      [
        "T2",
        "Chemical",
        14,
        16,
        "mitomycin C"
      ],
      [
        "T3",
        "Disease",
        7,
        8,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2952,
    "text": "The renal failure usually develops about 8 - 10 mth after start of mitomycin C treatment and the mortality is approximately 60 % from renal failure or pulmonary edema .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "renal failure"
      ],
      [
        "T1",
        "Chemical",
        13,
        15,
        "mitomycin C"
      ],
      [
        "T2",
        "Disease",
        24,
        26,
        "renal failure"
      ],
      [
        "T3",
        "Disease",
        27,
        29,
        "pulmonary edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2953,
    "text": "Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi , expanded subendothelial zones in glomerular capillary walls , ischemic wrinkling of glomerular basement membranes and mesangiolysis .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Renal lesions"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "HUS"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "thrombi"
      ],
      [
        "T3",
        "Disease",
        24,
        25,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2954,
    "text": "The mechanism of action is postulated as mitomycin C - induced endothelial cell damage .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "mitomycin C"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2955,
    "text": "We describe the clinical course and pathological findings in a 65 yr - old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "gastric adenocarcinoma"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "renal failure"
      ],
      [
        "T2",
        "Chemical",
        28,
        30,
        "mitomycin C"
      ],
      [
        "T3",
        "Disease",
        33,
        35,
        "pulmonary edema"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2956,
    "text": "Ketanserin pretreatment reverses alfentanil - induced muscle rigidity .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "muscle rigidity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Ketanserin"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "alfentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2957,
    "text": "Systemic pretreatment with ketanserin , a relatively specific type - 2 serotonin receptor antagonist , significantly attenuated the muscle rigidity produced in rats by the potent short - acting opiate agonist alfentanil .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "muscle rigidity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "ketanserin"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "serotonin"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "alfentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2958,
    "text": "Following placement of subcutaneous electrodes in each animal ' s left gastrocnemius muscle , rigidity was assessed by analyzing root - mean - square electromyographic activity .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "rigidity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2959,
    "text": "Intraperitoneal ketanserin administration at doses of 0 . 63 and 2 . 5 mg / kg prevented the alfentanil - induced increase in electromyographic activity compared with animals pretreated with saline .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "ketanserin"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "alfentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2960,
    "text": "Chlordiazepoxide at doses up to 10 mg / kg failed to significantly influence the rigidity produced by alfentanil .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Chlordiazepoxide"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "rigidity"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "alfentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2961,
    "text": "Despite the absence of rigidity , animals that received ketanserin ( greater than 0 . 31 mg / kg i . p . ) followed by alfentanil were motionless , flaccid , and less responsive to external stimuli than were animals receiving alfentanil alone .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "rigidity"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "ketanserin"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "alfentanil"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "alfentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2962,
    "text": "Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60 - min recording period than did animals that received ketanserin alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "ketanserin"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "alfentanil"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "ketanserin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2963,
    "text": "These results , in combination with previous work , suggest that muscle rigidity , a clinically relevant side - effect of parenteral narcotic administration , may be partly mediated via serotonergic pathways .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "muscle rigidity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2964,
    "text": "Pretreatment with type - 2 serotonin antagonists may be clinically useful in attenuating opiate - induced rigidity , although further studies will be necessary to assess the interaction of possibly enhanced CNS , cardiovascular , and respiratory depression .",
    "labels": [
      [
        "T0",
        "Disease",
        33,
        38,
        "cardiovascular , and respiratory depression"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "serotonin"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "rigidity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2965,
    "text": "Antagonism of diazepam - induced sedative effects by Ro15 - 1788 in patients after surgery under lumbar epidural block .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "Ro15 - 1788"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2966,
    "text": "A double - blind placebo - controlled investigation of efficacy and safety .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2967,
    "text": "The aim of this study was to assess the efficacy of Ro15 - 1788 and a placebo in reversing diazepam - induced effects after surgery under epidural block , and to evaluate the local tolerance and general safety of Ro15 - 1788 .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "Ro15 - 1788"
      ],
      [
        "T1",
        "Chemical",
        39,
        42,
        "Ro15 - 1788"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2968,
    "text": "Fifty - seven patients were sedated with diazepam for surgery under epidural anaesthesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2969,
    "text": "Antagonism of diazepam - induced effects by Ro15 - 1788 was investigated postoperatively in a double - blind placebo - controlled trial .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "Ro15 - 1788"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2970,
    "text": "The patient ' s subjective assessment of mood rating , an objective test of performance , a test for amnesia , and vital signs were recorded for up to 300 min after administration of the trial drug .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2971,
    "text": "No significant differences between the two groups were observed for mood rating , amnesia , or vital signs .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2972,
    "text": "The Ro15 - 1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        4,
        "Ro15 - 1788"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2973,
    "text": "There was no evidence of reaction at the injection site .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2974,
    "text": "Chorea associated with oral contraception .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "oral contraception"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Chorea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2975,
    "text": "Three patients developed chorea while receiving oral contraceptives .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "oral contraceptives"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "chorea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2976,
    "text": "Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "chorea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2977,
    "text": "The third patient had acute amphetamine - induced chorea after prolonged oral contraception .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "oral contraception"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "amphetamine"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "chorea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2978,
    "text": "Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "rheumatic fever"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "chorea"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "chorea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2979,
    "text": "Co - carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "retinyl acetate"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "forestomach carcinogenesis"
      ],
      [
        "T2",
        "Chemical",
        16,
        18,
        "butylated hydroxyanisole"
      ],
      [
        "T3",
        "Disease",
        2,
        3,
        "carcinogenic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2980,
    "text": "The potential modifying effect of retinyl acetate ( RA ) on butylated hydroxyanisole ( BHA ) - induced rat forestomach tumorigenesis was examined .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "retinyl acetate"
      ],
      [
        "T1",
        "Chemical",
        11,
        13,
        "butylated hydroxyanisole"
      ],
      [
        "T2",
        "Disease",
        19,
        21,
        "forestomach tumorigenesis"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "RA"
      ],
      [
        "T4",
        "Chemical",
        14,
        15,
        "BHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2981,
    "text": "Male F344 rats , 5 weeks of age , were maintained on diet containing 1 % or 2 % BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations ( w / v ) for 52 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "BHA"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2982,
    "text": "In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .",
    "labels": [
      [
        "T0",
        "Disease",
        43,
        45,
        "forestomach tumors"
      ],
      [
        "T1",
        "Disease",
        46,
        49,
        "squamous cell papilloma"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "BHA"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "RA"
      ],
      [
        "T4",
        "Disease",
        50,
        51,
        "carcinoma"
      ],
      [
        "T5",
        "Disease",
        63,
        64,
        "carcinoma"
      ],
      [
        "T6",
        "Disease",
        76,
        77,
        "carcinoma"
      ],
      [
        "T7",
        "Chemical",
        82,
        83,
        "RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2983,
    "text": "In rats given 1 % BHA , RA co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the BHA - induced epithelial hyperplasia .",
    "labels": [
      [
        "T0",
        "Disease",
        46,
        48,
        "epithelial hyperplasia"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "BHA"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "RA"
      ],
      [
        "T3",
        "Chemical",
        43,
        44,
        "BHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2984,
    "text": "Tumors , all papillomas , were induced in 3 rats ( 17 % ) with 0 . 25 % RA and in one rat ( 10 % ) with 0 . 05 % RA co - administration .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Tumors"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "papillomas"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "RA"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2985,
    "text": "RA alone did not induce hyperplastic changes in the forestomach .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2986,
    "text": "These findings indicate that RA acted as a co - carcinogen in the BHA forestomach carcinogenesis of the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "forestomach carcinogenesis"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "RA"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "BHA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2987,
    "text": "A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "mitomycin C"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2988,
    "text": "Since 1975 mitomycin C ( MMC ) has been suggested to be cardiotoxic , especially when combined with or given following doxorubicin .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "mitomycin C"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "MMC"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "cardiotoxic"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2989,
    "text": "Data on dose dependency or incidence concerning this side effect were not known .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2990,
    "text": "We have initiated a prospective study to obtain some more data on these subjects .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2991,
    "text": "Forty - four MMC - treated patients were studied , 37 of them could be evaluated .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "MMC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2992,
    "text": "All patients were studied by repeated physical examinations , chest X - rays , electro - and echocardiography and radionuclide left ventricular ejection fraction ( EF ) determinations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2993,
    "text": "The results were evaluated per cumulative dose level .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2994,
    "text": "One of the patients developed cardiac failure after 30 mg m - 2 MMC and only 150 mg m - 2 doxorubicin .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "cardiac failure"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "MMC"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2995,
    "text": "The cardiac failure was predicted by a drop in EF determined during a cold pressor test .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "cardiac failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2996,
    "text": "None of the other patients developed clinical cardiotoxicity , nor did the studied parameters change .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2997,
    "text": "The literature on this subject was also reviewed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2998,
    "text": "Based on the combined data from the present study and the literature , we suggest that MMC - related cardiotoxicity is dose dependent , occurring at cumulative dose levels of 30 mg m - 2 or more , mainly in patients also ( previously or simultaneously ) treated with doxorubicin .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "MMC"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "cardiotoxicity"
      ],
      [
        "T2",
        "Chemical",
        49,
        50,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2999,
    "text": "The incidence is likely to be less than 10 % even for this risk group .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3000,
    "text": "Reversible cerebral lesions associated with tiazofurin usage : MR demonstration .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "cerebral lesions"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "tiazofurin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3001,
    "text": "Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Tiazofurin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3002,
    "text": "We report our results with magnetic resonance ( MR ) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "cerebral abnormalities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3003,
    "text": "The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3004,
    "text": "The utility of MR in the evaluation of patients receiving this new agent is illustrated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3005,
    "text": "Receptor mechanisms of nicotine - induced locomotor hyperactivity in chronic nicotine - treated rats .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "locomotor hyperactivity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "nicotine"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "nicotine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3006,
    "text": "Rats were pretreated with saline or nicotine ( 1 . 5 mg / kg per day ) by subcutaneously implanting each animal with an Alzet osmotic mini - pump which continuously released saline or nicotine for 1 , 5 and 14 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "nicotine"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "nicotine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3007,
    "text": "At the end of each pretreatment period , animals were used for ( i ) determining their locomotor response to acutely injected nicotine ( 0 . 2 mg / kg , s . c . ) and ( ii ) measuring the density of L - [ 3H ] nicotine and [ 3H ] spiperone binding sites in the striatum .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "nicotine"
      ],
      [
        "T1",
        "Chemical",
        49,
        50,
        "nicotine"
      ],
      [
        "T2",
        "Chemical",
        54,
        55,
        "spiperone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3008,
    "text": "We observed no changes in nicotine - induced locomotor response , striatal L - [ 3H ] nicotine and [ 3H ] spiperone binding in the animals pretreated with nicotine for 1 day .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "nicotine"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "nicotine"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "spiperone"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "nicotine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3009,
    "text": "In rats which were pretreated with nicotine for 5 days , there was a significant increase in the nicotine - stimulated locomotor response which was associated with an increase in the number of L - [ 3H ] nicotine binding sites and also with an elevated dopamine ( DA ) level in the striatum .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "nicotine"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "nicotine"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "nicotine"
      ],
      [
        "T3",
        "Chemical",
        46,
        47,
        "dopamine"
      ],
      [
        "T4",
        "Chemical",
        48,
        49,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3010,
    "text": "The number of striatal [ 3H ] spiperone binding sites was not affected .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "spiperone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3011,
    "text": "In animals pretreated with nicotine for 14 days , the nicotine - induced locomotor response remained to be potentiated .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "nicotine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "nicotine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3012,
    "text": "However , this response was correlated with an elevated number of striatal [ 3H ] spiperone binding sites , whereas the number of striatal L - [ 3H ] nicotine binding sites and the striatal DA level were normal .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "spiperone"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "nicotine"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3013,
    "text": "These results suggest that chronic nicotine - treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing DA receptor supersensitivity in the striatum .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "locomotor hyperactivity"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "nicotine"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "nicotine"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "DA"
      ],
      [
        "T4",
        "Chemical",
        34,
        35,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3014,
    "text": "Amelioration of bendrofluazide - induced hypokalemia by timolol .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "bendrofluazide"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hypokalemia"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "timolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3015,
    "text": "The beta adrenergic blocking drug , timolol , tended to correct the hypokalemia of short - term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "timolol"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hypokalemia"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "bendrofluazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3016,
    "text": "Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium / potassium ratio .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Timolol"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "aldosterone"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "potassium"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "bendrofluazide"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "sodium"
      ],
      [
        "T5",
        "Chemical",
        20,
        21,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3017,
    "text": "There was no evidence of a shift of potassium from the intracellular to the extracellular space .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3018,
    "text": "St .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "St ."
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3019,
    "text": "Anthony ' s fire , then and now : a case report and historical review .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Anthony ' s fire"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3020,
    "text": "A rare case of morbid vasospasm , together with striking angiographic findings , is described secondary to the ingestion of methysergide by a 48 - year - old woman .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "vasospasm"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "methysergide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3021,
    "text": "A brief review of the literature on similar cases is presented .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3022,
    "text": "A discussion of the history of ergot includes its original discovery , the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache .",
    "labels": [
      [
        "T0",
        "Disease",
        33,
        35,
        "migraine headache"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ergot"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "gangrene"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3023,
    "text": "Despite the advent of calcium channel blockers and beta - adrenergic antagonists , ergot preparations continue to play a major role in migraine therapy , so that the danger of St .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        32,
        "St ."
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "calcium"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "ergot"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "migraine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3024,
    "text": "Anthony ' s fire persists .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Anthony ' s fire"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3025,
    "text": "Cardiac transplantation : improved quality of survival with a modified immunosuppressive protocol .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3026,
    "text": "The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3027,
    "text": "In group I , cyclosporine was given before the procedure at a loading dose of 17 . 5 mg / kg and then continued after the procedure to keep a whole blood level about 1000 ng / ml .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "cyclosporine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3028,
    "text": "In group II , cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine , which was used for the first postoperative week .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "cyclosporine"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "azathioprine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3029,
    "text": "Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "urea nitrogen"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3030,
    "text": "Group II also showed a significant decrease of chronic nephrotoxicity secondary to long - term therapy with cyclosporine .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "nephrotoxicity"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "cyclosporine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3031,
    "text": "Despite this improvement in late renal function , group II still shows a slow rise in serum creatinine .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3032,
    "text": "We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "cyclosporine"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3033,
    "text": "Ethopropazine and benztropine in neuroleptic - induced parkinsonism .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ethopropazine"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "benztropine"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "parkinsonism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3034,
    "text": "In a 12 - week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        21,
        "fluphenazine enanthate"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "ethopropazine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "benztropine"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "parkinsonism"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "schizophrenic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3035,
    "text": "Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine , their previous antiparkinsonian drug .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "parkinsonian symptoms"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Ethopropazine"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "benztropine"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "procyclidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3036,
    "text": "However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more anxiety and depression than ethopropazine treated patients .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "tardive dyskinesia"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "benztropine"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "procyclindine"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "anxiety"
      ],
      [
        "T4",
        "Disease",
        25,
        26,
        "depression"
      ],
      [
        "T5",
        "Chemical",
        27,
        28,
        "ethopropazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3037,
    "text": "This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic - induced parkinsonian symptoms , because of its more toxic central and peripheral atropinic effect .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "parkinsonian symptoms"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "benztropine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3038,
    "text": "Quinidine phenylethylbarbiturate - induced fulminant hepatitis in a pregnant woman .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Quinidine phenylethylbarbiturate"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3039,
    "text": "A case report .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3040,
    "text": "We report the case of a 19 - year - old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1 - month administration of quinidine phenylethylbarbiturate .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        33,
        "quinidine phenylethylbarbiturate"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3041,
    "text": "After delivery , the patient underwent orthotopic liver transplantation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3042,
    "text": "The patient was in good condition 16 months after liver transplantation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3043,
    "text": "Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Quinidine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "phenylethylbarbiturate"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3044,
    "text": "Mechanisms of myocardial ischemia induced by epinephrine : comparison with exercise - induced ischemia .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "epinephrine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3045,
    "text": "The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "coronary artery disease"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3046,
    "text": "Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "ischemia"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "oxygen"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3047,
    "text": "Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "epinephrine"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "depression"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "angina"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3048,
    "text": "However , the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3049,
    "text": "Exercise - induced myocardial ischemia was marked predominantly by increased heart rate and rate - pressure product with a minor contribution of end - diastolic volume , while epinephrine - induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate - pressure product .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "epinephrine"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3050,
    "text": "These findings indicate that ischemia produced by epinephrine , as may occur during states of emotional distress , has a mechanism distinct from that due to physical exertion .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "ischemia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3051,
    "text": "Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10 - propargyl - 5 , 8 - dideazafolic acid ( CB 3717 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        20,
        "N10 - propargyl - 5 , 8 - dideazafolic acid"
      ],
      [
        "T1",
        "Chemical",
        21,
        23,
        "CB 3717"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3052,
    "text": "CB 3717 , N10 - propargyl - 5 , 8 - dideazafolic acid , is a tight - binding inhibitor of thymidylate synthase ( TS ) whose cytotoxicity is mediated solely through the inhibition of this enzyme .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "CB 3717"
      ],
      [
        "T1",
        "Chemical",
        3,
        13,
        "N10 - propargyl - 5 , 8 - dideazafolic acid"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "cytotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3053,
    "text": "Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "CB 3717"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3054,
    "text": "Following a 12 - hour exposure of L1210 cells to 50 microM [ 3H ] CB 3717 , 30 % of the extractable radioactivity could be accounted for as CB 3717 tetra - and pentaglutamate , as determined by high - pressure liquid chromatography ( HPLC ) analyses .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "CB 3717"
      ],
      [
        "T1",
        "Chemical",
        29,
        31,
        "CB 3717"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3055,
    "text": "As inhibitors of isolated L1210 TS , CB 3717 di - , tri - , tetra - and pentaglutamate are 26 - , 87 - , 119 - and 114 - fold more potent than CB 3717 , respectively , and their formation may , therefore , be an important determinant of CB 3717 cytotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        35,
        37,
        "CB 3717"
      ],
      [
        "T1",
        "Chemical",
        52,
        54,
        "CB 3717"
      ],
      [
        "T2",
        "Disease",
        54,
        55,
        "cytotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3056,
    "text": "In early clinical studies with CB 3717 , activity has been seen in breast cancer , ovarian cancer , hepatoma , and mesothelioma .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "CB 3717"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "breast cancer"
      ],
      [
        "T2",
        "Disease",
        16,
        18,
        "ovarian cancer"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "hepatoma"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "mesothelioma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3057,
    "text": "Toxicities included hepatotoxicity , malaise , and dose - limiting nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Toxicities"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "hepatotoxicity"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "malaise"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3058,
    "text": "This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        25,
        "CB 3717"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3059,
    "text": "In an attempt to overcome this problem , a clinical trial of CB 3717 administered with alkaline diuresis is under way .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "CB 3717"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3060,
    "text": "Preliminary results at 400 and 500 mg / m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "renal toxicity"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3061,
    "text": "Hepatotoxicity and malaise are again the most frequent side effects .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hepatotoxicity"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "malaise"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3062,
    "text": "Evidence of antitumor activity has been seen in 3 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3063,
    "text": "Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "CB 3717"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3064,
    "text": "Type B hepatitis after needle - stick exposure : prevention with hepatitis B immune globulin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Type B hepatitis"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "hepatitis B"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3065,
    "text": "Final report of the Veterans Administration Cooperative Study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3066,
    "text": "Hepatitis B immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing type B hepatitis after needle - stick exposure to hepatitis B surface antigen ( HBsAG ) - positive donors .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hepatitis B"
      ],
      [
        "T1",
        "Disease",
        31,
        34,
        "type B hepatitis"
      ],
      [
        "T2",
        "Chemical",
        40,
        44,
        "hepatitis B surface antigen"
      ],
      [
        "T3",
        "Chemical",
        45,
        46,
        "HBsAG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3067,
    "text": "Clinical hepatitis developed in 1 . 4 % of HBIG and in 5 . 9 % of ISG recipients ( P = 0 . 016 ) , and seroconversion ( anti - HBs ) occurred in 5 . 6 % and 20 . 7 % of them respectively ( P less than 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3068,
    "text": "Mild and transient side - effects were noted in 3 . 0 % of ISG and in 3 . 2 % of HBIG recipients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3069,
    "text": "Available donor sera were examined for DNA polymerase ( DNAP ) and e antigen and antibody ( HBeAg ; anti - HBE ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "HBeAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3070,
    "text": "Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg - positive donors .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "HBeAg"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "HBsAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3071,
    "text": "Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high - risk subgroups .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hepatitis B"
      ],
      [
        "T1",
        "Disease",
        11,
        14,
        "type B hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3072,
    "text": "The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "type B hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3073,
    "text": "Production of autochthonous prostate cancer in Lobund - Wistar rats by treatments with N - nitroso - N - methylurea and testosterone .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "prostate cancer"
      ],
      [
        "T1",
        "Chemical",
        13,
        20,
        "N - nitroso - N - methylurea"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "testosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3074,
    "text": "More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "prostate adenocarcinomas"
      ],
      [
        "T1",
        "Chemical",
        27,
        34,
        "N - nitroso - N - methylurea"
      ],
      [
        "T2",
        "Chemical",
        44,
        46,
        "testosterone propionate"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "PAs"
      ],
      [
        "T4",
        "Chemical",
        48,
        49,
        "TP"
      ],
      [
        "T5",
        "Disease",
        63,
        64,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3075,
    "text": "The incubation periods averaged 10 . 6 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3076,
    "text": "Within the same timeframe , no L - W rat developed a similar palpable PA when treated only with TP .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "PA"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "TP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3077,
    "text": "In L - W rats , TP acted as a tumor enhancement agent , with primary emphasis on the development of prostate cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "prostate cancer"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "TP"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3078,
    "text": "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "netilmicin"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "tobramycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3079,
    "text": "We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "netilmicin sulfate"
      ],
      [
        "T1",
        "Chemical",
        11,
        13,
        "tobramycin sulfate"
      ],
      [
        "T2",
        "Chemical",
        16,
        18,
        "piperacillin sodium"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3080,
    "text": "The two treatment regimens were equally efficacious .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3081,
    "text": "Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin ( 17 % vs 11 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Nephrotoxicity"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "netilmicin"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "tobramycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3082,
    "text": "Ototoxicity occurred in four ( 9 . 5 % ) of 42 netilmicin and piperacillin and in 12 ( 22 % ) of 54 tobramycin and piperacillin - treated patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Ototoxicity"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "netilmicin"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "piperacillin"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "tobramycin"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "piperacillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3083,
    "text": "Of those evaluated with posttherapy audiograms , three of four netilmicin and piperacillin - treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin - treated patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "netilmicin"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "piperacillin"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "tobramycin"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "piperacillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3084,
    "text": "The number of greater than or equal to 15 - dB increases in auditory threshold as a proportion of total greater than or equal to 15 - dB changes ( increases and decreases ) was significantly lower in netilmicin and piperacillin - vs tobramycin and piperacillin - treated patients ( 18 of 78 vs 67 of 115 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        38,
        39,
        "netilmicin"
      ],
      [
        "T1",
        "Chemical",
        40,
        41,
        "piperacillin"
      ],
      [
        "T2",
        "Chemical",
        43,
        44,
        "tobramycin"
      ],
      [
        "T3",
        "Chemical",
        45,
        46,
        "piperacillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3085,
    "text": "We conclude that aminoglycoside - associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "aminoglycoside"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "ototoxicity"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "netilmicin"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "tobramycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3086,
    "text": "Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        15,
        "injury to different regions of the kidney"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3087,
    "text": "Acute experimental models of renal damage to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        6,
        "Acute experimental models of renal damage"
      ],
      [
        "T1",
        "Chemical",
        24,
        31,
        "hexachloro - 1 : 3 - butadiene"
      ],
      [
        "T2",
        "Chemical",
        35,
        37,
        "puromycin aminonucleoside"
      ],
      [
        "T3",
        "Chemical",
        42,
        45,
        "2 - bromoethylamine"
      ],
      [
        "T4",
        "Chemical",
        32,
        33,
        "HCBD"
      ],
      [
        "T5",
        "Chemical",
        38,
        39,
        "PAN"
      ],
      [
        "T6",
        "Chemical",
        46,
        47,
        "BEA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3088,
    "text": "Several routine indicators of nephrotoxicity , the enzymes alkaline phosphatase and N - acetyl - beta - glucosaminidase , and the molecular weight of protein excretion were determined on urine samples .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "protein excretion"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3089,
    "text": "Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "glomerular damage"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "HCBD"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "BEA"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3090,
    "text": "The latter was characterized by a pronounced increase in protein excretion , especially proteins with molecular weight greater than 40 , 000 Da .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "protein excretion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3091,
    "text": "In contrast , protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "protein excretion"
      ],
      [
        "T1",
        "Disease",
        15,
        18,
        "excretion of proteins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3092,
    "text": "Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis ( volume and specific gravity ) and by measurement of the two urinary enzymes .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "HCBD"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "BEA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3093,
    "text": "Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N - acetyl - beta - glucosaminidase showed a sustained elevation in papillary damage .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3094,
    "text": "It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "renal damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3095,
    "text": "A catch in the Reye .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "Reye"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3096,
    "text": "Twenty - six cases of Reye syndrome from The Children ' s Hospital , Camperdown , Australia , occurring between 1973 and 1982 were reviewed .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "Reye syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3097,
    "text": "Of these , 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "Reye syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3098,
    "text": "Aspirin or salicylate ingestion had occurred in only one of the 20 cases ( 5 % ) , and paracetamol ( acetaminophen ) had been administered in only six of the cases ( 30 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Aspirin"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "salicylate"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "paracetamol"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3099,
    "text": "Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90 % of the cases .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "Reye syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3100,
    "text": "The incidence of Reye syndrome in New South Wales , Australia , is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "Reye syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3101,
    "text": "The mortality for these Reye syndrome cases in Australia was 45 % as compared with a 32 % case - fatality rate in the United States .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "Reye syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3102,
    "text": "In Australia , the pediatric usage of aspirin has been extremely low for the past 25 years ( less than 1 % of total dosage units sold ) , with paracetamol ( acetaminophen ) dominating the pediatric analgesic and antipyretic market .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "aspirin"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "paracetamol"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3103,
    "text": "Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion , since there were no cases found at The Children ' s Hospital in 1983 , 1984 , or 1985 .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Reye syndrome"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "salicylates"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3104,
    "text": "Postpartum psychosis induced by bromocriptine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "psychosis"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "bromocriptine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3105,
    "text": "Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis , having received bromocriptine for inhibition of lactation .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        21,
        "inhibition of lactation"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "psychiatric"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "psychosis"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "bromocriptine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3106,
    "text": "Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        20,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Bromocriptine"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3107,
    "text": "These cases demonstrate that bromocriptine may cause psychosis even when given in low doses .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "bromocriptine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3108,
    "text": "Hyperglycemic acidotic coma and death in Kearns - Sayre syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Hyperglycemic acidotic coma"
      ],
      [
        "T1",
        "Disease",
        6,
        10,
        "Kearns - Sayre syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3109,
    "text": "This paper presents the clinical and metabolic findings in two young boys with long - standing Kearns - Sayre syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        20,
        "Kearns - Sayre syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3110,
    "text": "Following short exposure to oral prednisone , both boys developed lethargy , increasing somnolence , polydipsia , polyphagia , and polyuria .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "prednisone"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "lethargy"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "somnolence"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "polydipsia"
      ],
      [
        "T4",
        "Disease",
        17,
        18,
        "polyphagia"
      ],
      [
        "T5",
        "Disease",
        20,
        21,
        "polyuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3111,
    "text": "Both presented in the emergency room with profound coma , hypotension , severe hyperglycemia , and acidosis .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "coma"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypotension"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hyperglycemia"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "acidosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3112,
    "text": "Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "lactic acidosis"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "ketosis"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "lactate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3113,
    "text": "Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Respiratory failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3114,
    "text": "We believe these two cases represent a newly described and catastrophic metabolic - endocrine failure in the Kearns - Sayre syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        15,
        "metabolic - endocrine failure"
      ],
      [
        "T1",
        "Disease",
        17,
        21,
        "Kearns - Sayre syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3115,
    "text": "Experimental cyclosporine nephrotoxicity : risk of concomitant chemotherapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "cyclosporine"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3116,
    "text": "The role of cyclosporine ( CSA ) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "renal toxicity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "cyclosporine"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "CSA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3117,
    "text": "Administration of 20 mg / kg / day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "CSA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3118,
    "text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        25,
        "amphothericin B"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "CSA"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "nephrotoxic"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "gentamicin"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "ketoconazole"
      ],
      [
        "T5",
        "Chemical",
        40,
        41,
        "CSA"
      ],
      [
        "T6",
        "Disease",
        42,
        43,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3119,
    "text": "Gentamicin at toxic doses , however , increased CSA nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Gentamicin"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "CSA"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3120,
    "text": "Thus , the nephrotoxicity induced by CSA has a different pathogenetic mechanism .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "nephrotoxicity"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "CSA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3121,
    "text": "Diuretics , potassium and arrhythmias in hypertensive coronary disease .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "coronary disease"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "potassium"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "arrhythmias"
      ],
      [
        "T3",
        "Disease",
        6,
        7,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3122,
    "text": "It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "cardiac arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3123,
    "text": "If this were so , patients with coronary artery disease might be especially susceptible .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "coronary artery disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3124,
    "text": "Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hypertension"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "potassium"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "amiloride"
      ],
      [
        "T4",
        "Chemical",
        38,
        39,
        "potassium"
      ],
      [
        "T5",
        "Chemical",
        43,
        44,
        "chlorthalidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3125,
    "text": "Plasma potassium concentrations were on average 1 mmol / L lower during the chlorthalidone phase compared to amiloride therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "potassium"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "chlorthalidone"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "amiloride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3126,
    "text": "Blood pressure and volume states as assessed by bodyweight , plasma renin and noradrenaline ( norepinephrine ) concentrations were similar on the 2 regimens .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "noradrenaline"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3127,
    "text": "Compared to amiloride treatment , the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats ( 24 - hour Holter monitoring ) and a higher Lown grading , increased upslope and duration of the monophasic action potential , prolonged ventricular effective refractory period , and increased electrical instability during programmed ventricular stimulation .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "ventricular ectopic beats"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "amiloride"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "chlorthalidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3128,
    "text": "The above results indicate that because potassium - losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease , even minor falls in plasma potassium concentrations are probably best avoided in such patients .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "ischaemic heart disease"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "potassium"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3129,
    "text": "Transketolase abnormality in tolazamide - induced Wernicke ' s encephalopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        10,
        "Wernicke ' s encephalopathy"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "tolazamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3130,
    "text": "We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke ' s encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        22,
        "Wernicke ' s encephalopathy"
      ],
      [
        "T1",
        "Chemical",
        42,
        44,
        "thiamine pyrophosphate"
      ],
      [
        "T2",
        "Disease",
        54,
        58,
        "Wernicke - Korsakoff syndrome"
      ],
      [
        "T3",
        "Chemical",
        3,
        4,
        "thiamine"
      ],
      [
        "T4",
        "Disease",
        14,
        15,
        "diabetic"
      ],
      [
        "T5",
        "Chemical",
        25,
        26,
        "tolazamide"
      ],
      [
        "T6",
        "Chemical",
        45,
        46,
        "TPP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3131,
    "text": "In addition to this patient , we also studied this enzyme from three diabetic kindreds without any history of Wernicke ' s encephalopathy and from four normal controls .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        23,
        "Wernicke ' s encephalopathy"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "diabetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3132,
    "text": "We found that the above - mentioned patient and one of the diabetic kindreds with no history of Wernicke ' s encephalopathy had abnormal transketolase as determined by its Km for TPP .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        22,
        "Wernicke ' s encephalopathy"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "diabetic"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "TPP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3133,
    "text": "These data suggest a similarity between postalcoholic Wernicke - Korsakoff syndrome and the patient with tolazamide - induced Wernicke ' s encephalopathy from the standpoint of transketolase abnormality .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "Wernicke - Korsakoff syndrome"
      ],
      [
        "T1",
        "Disease",
        18,
        22,
        "Wernicke ' s encephalopathy"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "tolazamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3134,
    "text": "Bradycardia due to trihexyphenidyl hydrochloride .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "trihexyphenidyl hydrochloride"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3135,
    "text": "A chronic schizophrenic patient was treated with an anticholinergic drug , trihexyphenidyl hydrochloride .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "trihexyphenidyl hydrochloride"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "schizophrenic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3136,
    "text": "The patient developed , paradoxically , sinus bradycardia .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3137,
    "text": "The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "trihexyphenidyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3138,
    "text": "This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "psychiatric"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3139,
    "text": "Post - operative rigidity after fentanyl administration .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "rigidity"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3140,
    "text": "A case of thoraco - abdominal rigidity leading to respiratory failure is described in the post - operative period in an elderly patient who received a moderate dose of fentanyl .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "respiratory failure"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "rigidity"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3141,
    "text": "This was successfully reversed by naloxone .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "naloxone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3142,
    "text": "The mechanisms possibly implicated in this accident are discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3143,
    "text": "Anti - carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "carcinogenic"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "phenobarbital"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "diethylnitrosamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3144,
    "text": "The present work has been planned in order to elucidate the effect of phenobarbital ( PB : 15 mg per rat of ingested dose ) on carcinogenesis when it is administered simultaneously with diethylnitrosamine ( DEN : 10 mg / kg / day ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "phenobarbital"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "PB"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "carcinogenesis"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "diethylnitrosamine"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "DEN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3145,
    "text": "Wistar rats ( 180 g ) were treated by DEN alone or by DEN + PB during 2 , 4 and 6 weeks according to our schedule for hepatocarcinogenesis .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "DEN"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "DEN"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "PB"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "hepatocarcinogenesis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3146,
    "text": "After the end of the treatment , the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "preneoplastic foci"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "PB"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "DEN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3147,
    "text": "The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "DEN"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "DEN"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3148,
    "text": "When the treatment last only 2 weeks , the presence of PB did not change significantly the last parameters .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3149,
    "text": "In DEN + PB treated rats , the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "DEN"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "PB"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "tumor"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "DEN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3150,
    "text": "It is concluded that PB , which promotes carcinogenesis when administered after the DEN treatment , reduces the carcinogen effect when given simultaneously with DEN .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "PB"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "carcinogenesis"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "DEN"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "DEN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3151,
    "text": "This ' anti - carcinogen ' effect acts on the initiation as well as on the promotion of the precancerous lesions .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "precancerous lesions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3152,
    "text": "Biochemical investigations are in progress to obtain more information about this ' paradoxical ' PB effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3153,
    "text": "Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Bilateral optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ethambutol"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "isoniazid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3154,
    "text": "The case of a 40 - year - old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "ethambutol"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "isoniazid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3155,
    "text": "A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "bilateral retrobulbar neuropathy"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "scotoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3156,
    "text": "Ethambutol was stopped and only small improvement of the visual acuity followed .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3157,
    "text": "Isoniazid was discontinued later , followed by a dramatic improvement in the visual acuity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Isoniazid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3158,
    "text": "The hazards of optic nerve toxicity due to ethambutol are known .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3159,
    "text": "We emphasize the potential danger in the use of ethambutol and isoniazid .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "ethambutol"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "isoniazid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3160,
    "text": "A prospective study of adverse reactions associated with vancomycin therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "vancomycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3161,
    "text": "A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16 - month period .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "vancomycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3162,
    "text": "Vancomycin was curative in 95 % of 43 patients with proven infection .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Vancomycin"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3163,
    "text": "Drugs were ceased in six patients because of adverse reactions ; in three of these vancomycin was considered the likely cause .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "vancomycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3164,
    "text": "Reactions included thrombophlebitis ( 20 of 54 patients ) , rash ( 4 of 54 ) , nephrotoxicity ( 4 of 50 ) , proteinuria ( 1 of 50 ) and ototoxicity ( 1 of 11 patients tested by audiometry ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "thrombophlebitis"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "rash"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "nephrotoxicity"
      ],
      [
        "T3",
        "Disease",
        24,
        25,
        "proteinuria"
      ],
      [
        "T4",
        "Disease",
        31,
        32,
        "ototoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3165,
    "text": "Thrombophlebitis occurred only with infusion through peripheral cannulae ; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Thrombophlebitis"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "nephrotoxicity"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "ototoxicity"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "aminoglycoside"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "vancomycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3166,
    "text": "We conclude that vancomycin , administered appropriately , constitutes safe , effective therapy for infections caused by susceptible bacteria .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "vancomycin"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3167,
    "text": "Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "nephrotoxicity"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "amikacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3168,
    "text": "Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "amikacin"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3169,
    "text": "In 42 of these patients , data were examined for factors associated with clinical outcome .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3170,
    "text": "Variables evaluated included patient weight , age , sex , serum creatinine level , creatinine clearance , duration of therapy , total dose , mean daily dose , organism minimum inhibitory concentration ( MIC ) , mean peak levels , mean trough levels , mean area under the serum concentration - time curve ( AUC ) , total AUC , mean AUC greater than MIC , total AUC greater than MIC , mean Schumacher ' s intensity factor ( IF ) , total IF , In ( mean maximum concentration [ Cmax ] / MIC ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "creatinine"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3171,
    "text": "Model - dependent pharmacokinetic parameters were calculated by computer based on a one - compartment model .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3172,
    "text": "When the parameters were examined individually , duration of therapy and total AUC correlated significantly ( P less than . 05 ) with nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3173,
    "text": "In contrast , a stepwise discriminant function analysis identified only duration of therapy ( P less than . 001 ) as an important factor .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3174,
    "text": "Based on this model and on Bayes ' theorem , the predictive accuracy of identifying \" nephrotoxic \" patients increased from 0 . 17 to 0 . 39 .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "nephrotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3175,
    "text": "When examined individually , mean IF , MIC , total dose , mean daily dose , and ln ( mean Cmax / MIC ) correlated significantly ( P less than . 05 ) with cure .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3176,
    "text": "In contrast , a simultaneous multivariable analysis identified IF , MIC , and total dose according to one model and ln ( mean Cmax / MIC ) according to a second statistical model of parameters selected to have the greatest prospective value .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3177,
    "text": "Based on Bayes ' theorem and the first model , the predictive accuracy of identifying patients not cured increased from 0 . 19 to 0 . 83 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3178,
    "text": "For the second model , the predictive accuracy increased from 0 . 19 to 0 . 50 . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3179,
    "text": "Cardiac toxicity of 5 - fluorouracil .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cardiac toxicity"
      ],
      [
        "T1",
        "Chemical",
        3,
        6,
        "5 - fluorouracil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3180,
    "text": "Report of a case of spontaneous angina .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "angina"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3181,
    "text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5 - fluorouracil ( 5 - FU ) administration .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "colon carcinoma"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "chest pain"
      ],
      [
        "T2",
        "Chemical",
        18,
        21,
        "5 - fluorouracil"
      ],
      [
        "T3",
        "Chemical",
        22,
        25,
        "5 - FU"
      ],
      [
        "T4",
        "Disease",
        12,
        13,
        "metastasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3182,
    "text": "Clinical electrocardiographic evolution was similar to that observed in Prinzmetal ' s angina , and chest pain promptly resolved with nifedipine .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "Prinzmetal ' s angina"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "chest pain"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "nifedipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3183,
    "text": "These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "coronary spasm"
      ],
      [
        "T1",
        "Chemical",
        14,
        17,
        "5 - FU"
      ],
      [
        "T2",
        "Chemical",
        32,
        35,
        "5 - FU"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "cardiotoxicity"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "calcium"
      ],
      [
        "T5",
        "Disease",
        35,
        36,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3184,
    "text": "Dose - related beneficial and adverse effects of dietary corticosterone on organophosphorus - induced delayed neuropathy in chickens .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "corticosterone"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "organophosphorus"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3185,
    "text": "Tri - ortho - tolyl phosphate ( TOTP ) , 360 mg / kg , po , and 0 , 0 ' - diisopropyl phosphorofluoridate ( DFP ) , 1 mg / kg sc , were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        6,
        "Tri - ortho - tolyl phosphate"
      ],
      [
        "T1",
        "Chemical",
        18,
        25,
        "0 , 0 ' - diisopropyl phosphorofluoridate"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "TOTP"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "DFP"
      ],
      [
        "T4",
        "Chemical",
        55,
        56,
        "corticosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3186,
    "text": "Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3187,
    "text": "Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced neuropathy , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "corticosterone"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "TOTP"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "neuropathy"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "TOTP"
      ],
      [
        "T4",
        "Chemical",
        39,
        40,
        "DFP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3188,
    "text": "Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20 % of values measured in chickens not given organophosphorous compounds .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Neurotoxic"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "TOTP"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "DFP"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "organophosphorous"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3189,
    "text": "Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "corticosterone"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "TOTP"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "DFP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3190,
    "text": "Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Degenerating myelinated fibers"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "TOTP"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "DFP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3191,
    "text": "Hepatotoxicity of amiodarone .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hepatotoxicity"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3192,
    "text": "Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "tachyarrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3193,
    "text": "The use of amiodarone has , however , been limited due to its serious side - effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3194,
    "text": "A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cholestatic hepatitis"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "amiodarone"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "hepatotoxicity"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3195,
    "text": "It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment , including steatosis , alterations resembling alcoholic hepatitis , cholestatic hepatitis and micronodular cirrhosis of the liver .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "hepatic injury"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "alcoholic hepatitis"
      ],
      [
        "T2",
        "Disease",
        23,
        25,
        "cholestatic hepatitis"
      ],
      [
        "T3",
        "Disease",
        27,
        31,
        "cirrhosis of the liver"
      ],
      [
        "T4",
        "Chemical",
        12,
        13,
        "amiodarone"
      ],
      [
        "T5",
        "Disease",
        16,
        17,
        "steatosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3196,
    "text": "Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3197,
    "text": "Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "cholestatic injury"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hepatomegaly"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3198,
    "text": "Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "testosterone"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "carcinogenesis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3199,
    "text": "Germfree ( GF ) Lobund strain Wistar ( LW ) rats , fed vegetable diet L - 485 , have developed prostate adenocarcinomas spontaneously ( 10 % incidence ) at average age 34 months .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "prostate adenocarcinomas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3200,
    "text": "Conventional LW rats , implanted with testosterone at age 4 months , developed a higher incidence of prostate cancer after an average interval of 14 months : 24 % had developed gross tumors , and 40 % when it included microscopic tumors .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "prostate cancer"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "testosterone"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "tumors"
      ],
      [
        "T3",
        "Disease",
        41,
        42,
        "tumors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3201,
    "text": "Preliminary results indicate that testosterone - treated LW rats that were fed the same diet , which was supplemented with corn oil up to 20 % fat , developed prostate cancer after intervals of 6 - 12 months .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        31,
        "prostate cancer"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "testosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3202,
    "text": "Aged GF Sprague - Dawley ( SD ) rats have not developed prostate cancer spontaneously .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "prostate cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3203,
    "text": "Conventional SD rats fed diet L - 485 and treated with testosterone developed only prostatitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "testosterone"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "prostatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3204,
    "text": "Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "prostate cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3205,
    "text": "Time course alterations of QTC interval due to hypaque 76 .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "hypaque 76"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3206,
    "text": "Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one , three , five and ten minutes after injection of hypaque 76 .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        27,
        "hypaque 76"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3207,
    "text": "The subjects were ten patients found to have normal left ventricles and coronary arteries .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3208,
    "text": "Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "QTC prolongation"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3209,
    "text": "Rat extraocular muscle regeneration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3210,
    "text": "Repair of local anesthetic - induced damage .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3211,
    "text": "Local anesthetics that are commonly used in ophthalmic surgery ( 0 . 75 % bupivacaine hydrochloride , 2 . 0 % mepivacaine hydrochloride , and 2 . 0 % lidocaine hydrochloride plus 1 : 100 , 000 epinephrine ) were injected into the retrobulbar area of rat eyes .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "bupivacaine hydrochloride"
      ],
      [
        "T1",
        "Chemical",
        21,
        23,
        "mepivacaine hydrochloride"
      ],
      [
        "T2",
        "Chemical",
        29,
        31,
        "lidocaine hydrochloride"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3212,
    "text": "Controls were injected with physiological saline .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3213,
    "text": "All three anesthetics produced massive degeneration of the extraocular muscles .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3214,
    "text": "Muscle degeneration is followed by regeneration of the damaged muscle fibers .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Muscle degeneration"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3215,
    "text": "In addition to muscle damage , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and lidocaine plus epinephrine .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "muscle damage"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "mepivacaine"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "lidocaine"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3216,
    "text": "With these findings in rats , it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic - induced damage to the extraocular muscles .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "diplopia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3217,
    "text": "Gentamicin nephropathy in a neonate .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Gentamicin"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3218,
    "text": "The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin ( 5 mg / kg / day ) and penicillin are presented .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "gentamicin"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "penicillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3219,
    "text": "The serum gentamicin concentration had reached toxic levels when anuria developed .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "gentamicin"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "anuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3220,
    "text": "Numerous periodic acid Schiff ( PAS ) positive , diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "periodic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3221,
    "text": "The pathological changes induced by gentamicin in the human neonatal kidneys have not been previously reported .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3222,
    "text": "Induction by paracetamol of bladder and liver tumours in the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        8,
        "bladder and liver tumours"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3223,
    "text": "Effects on hepatocyte fine structure .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3224,
    "text": "Groups of male and female inbred Leeds strain rats were fed diets containing either 0 . 5 % or 1 . 0 % paracetamol by weight for up to 18 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3225,
    "text": "At the 1 . 0 % dosage level , 20 % of rats of both sexes developed neoplastic nodules of the liver , a statistically significant incidence .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3226,
    "text": "These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration , the latter also being observed in the low dosage male rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3227,
    "text": "Papillomas of the transitional epithelium of the bladder developed in all paracetamol - treated groups , and three rats bore bladder carcinomas .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "bladder carcinomas"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Papillomas"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3228,
    "text": "However , significant yields of bladder tumours were only obtained from low dosage females and high dosage males .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "bladder tumours"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3229,
    "text": "Additionally , 20 to 25 % of paracetamol - treated rats developed hyperplasia of the bladder epithelium , which was not coincident with the presence of bladder calculi .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "bladder calculi"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "paracetamol"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "hyperplasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3230,
    "text": "A low yield of tumours at various other sites also arose following paracetamol feeding .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "tumours"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3231,
    "text": "An electron microscope study of the livers of paracetamol - treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "paracetamol"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "hepatocarcinogens"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3232,
    "text": "Transient hemiparesis : a rare manifestation of diphenylhydantoin toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hemiparesis"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "diphenylhydantoin"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3233,
    "text": "Report of two cases .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3234,
    "text": "Among the common side effects of diphenylhydantoin ( DPH ) overdose , the most frequently encountered neurological signs are those of cerebellar dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "cerebellar dysfunction"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "diphenylhydantoin"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "DPH"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3235,
    "text": "Very rarely , the toxic neurological manifestations of this drug are of cerebral origin .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3236,
    "text": "Two patients are presented who suffered progressive hemiparesis due to DPH overdose .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "hemiparesis"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "DPH"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3237,
    "text": "Both had brain surgery before DPH treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "DPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3238,
    "text": "It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "cerebral damage"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "DPH"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3239,
    "text": "Tiapride in levodopa - induced involuntary movements .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "involuntary movements"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Tiapride"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3240,
    "text": "Tiapride , a substituted benzamide derivative closely related to metoclopramide , reduced levodopa - induced peak dose involuntary movements in 16 patients with idiopathic Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "involuntary movements"
      ],
      [
        "T1",
        "Disease",
        23,
        28,
        "idiopathic Parkinson ' s disease"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Tiapride"
      ],
      [
        "T3",
        "Chemical",
        4,
        5,
        "benzamide"
      ],
      [
        "T4",
        "Chemical",
        9,
        10,
        "metoclopramide"
      ],
      [
        "T5",
        "Chemical",
        12,
        13,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3241,
    "text": "However , an unacceptable increase in disability from Parkinsonism with aggravation of end - of - dose akinesia led to its cessation in 14 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "Parkinsonism"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "akinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3242,
    "text": "Tiapride had no effect on levodopa - induced early morning of \" off - period \" segmental dystonia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Tiapride"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "dystonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3243,
    "text": "These results fail to support the notion that levodopa - induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "dyskinesias"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3244,
    "text": "Quinidine hepatitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Quinidine"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3245,
    "text": "Long - term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT , lactic acid dehydrogenase , and alkaline phosphatase .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        19,
        "lactic acid"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "quinidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3246,
    "text": "Liver biopsy showed active hepatitis .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3247,
    "text": "Discontinuance of quinidine therapy led to normalization of liver function tests .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "quinidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3248,
    "text": "A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT , alkaline phosphatase , and lactic acid dehydrogenase values .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        20,
        "lactic acid"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "quinidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3249,
    "text": "We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "quinidine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3250,
    "text": "This report also suggests that , even after long - term administration , the hepatic toxicity is reversible .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "hepatic toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3251,
    "text": "Arterial thromboembolism in patients receiving systemic heparin therapy : a complication associated with heparin - induced thrombocytopenia .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "thromboembolism"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "heparin"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "heparin"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3252,
    "text": "Arterial thromboembolism is a recognized complication of systemic heparin therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "thromboembolism"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3253,
    "text": "Characteristic of the entity is arterial occlusion by platelet - fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy , preceded by profound thrombocytopenia with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "arterial occlusion"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "thrombi"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "ischemia"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "heparin"
      ],
      [
        "T4",
        "Disease",
        30,
        31,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3254,
    "text": "The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin , and might serve to warn the clinician of these complications .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "gastrointestinal and musculoskeletal symptoms"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3255,
    "text": "Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3256,
    "text": "The common factor relating thromboembolism and thrombocytopenia is heparin - induced platelet aggregation .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "platelet aggregation"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "thromboembolism"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "thrombocytopenia"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3257,
    "text": "Appropriate treatment consists of discontinuation of heparin , and anticoagulation with sodium warfarin if necessary .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "sodium warfarin"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3258,
    "text": "Vascular procedures are performed as indicated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3259,
    "text": "Pharmacology of GYKI - 41 099 ( chlorpropanol , Tobanum ) a new potent beta - adrenergic antagonist .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        6,
        "GYKI - 41 099"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "chlorpropanol"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "Tobanum"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3260,
    "text": "The compound GYKI - 41 099 , as a beta - adrenergic antagonist , is 3 - 8 times more potent than propranolol in vitro and in vivo .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        6,
        "GYKI - 41 099"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3261,
    "text": "Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "propranolol"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "pindolol"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "ouabain"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3262,
    "text": "GYKI - 41 900 has a negligible cardiodepressant activity ; it is not cardioselective .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        4,
        "GYKI - 41 900"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3263,
    "text": "The compound shows a rapid and long lasting effect .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3264,
    "text": "There was a prolonged elimination of the radioactivity after the injection of 14C - 41 099 to rats and dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        16,
        "14C - 41 099"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3265,
    "text": "The half life of the unlabeled substance in humans was more than 10 hours .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3266,
    "text": "Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "bendrofluazide"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "propranolol"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3267,
    "text": "Report of Medical Research Council Working Party on Mild to Moderate Hypertension .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "Hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3268,
    "text": "Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups : bendrofluazide , propranolol , or a placebo for either of these drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "hypertension"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "bendrofluazide"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3269,
    "text": "The trial is single - blind .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3270,
    "text": "23 582 patient - years of observation have been completed so far , 10 684 on active drugs and 12 898 on placebos .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3271,
    "text": "The results show an association between bendrofluazide treatment and impotence , and impotence also occurred more frequently in patients taking propranolol than in those taking placebos .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "bendrofluazide"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "impotence"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "impotence"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3272,
    "text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with bendrofluazide treatment , and Raynaud ' s phenomenon and dyspnoea in men and women taking propranolol .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "impaired glucose tolerance"
      ],
      [
        "T1",
        "Disease",
        27,
        31,
        "Raynaud ' s phenomenon"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "gout"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "bendrofluazide"
      ],
      [
        "T4",
        "Disease",
        32,
        33,
        "dyspnoea"
      ],
      [
        "T5",
        "Chemical",
        38,
        39,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3273,
    "text": "No corneal disease is known to have occurred in the propranolol group .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "corneal disease"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3274,
    "text": "Mean serum potassium level fell , and urea and uric acid levels rose , in men and women taking bendrofluazide .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "uric acid"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "potassium"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "urea"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "bendrofluazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3275,
    "text": "In the propranolol group , serum potassium and uric acid levels rose in both sexes , but the urea level rose significantly in women only .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "uric acid"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "potassium"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "urea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3276,
    "text": "Serotonergic drugs , benzodiazepines and baclofen block muscimol - induced myoclonic jerks in a strain of mice .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "myoclonic jerks"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "benzodiazepines"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "baclofen"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "muscimol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3277,
    "text": "In male Swiss mice , muscimol produced myoclonic jerks .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "myoclonic jerks"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "muscimol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3278,
    "text": "A 3 mg / kg ( i . p . ) dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3279,
    "text": "Increasing the brain serotonin levels by the administration of 5 - hydroxytryptophan ( 80 - 160 mg / kg ) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "5 - hydroxytryptophan"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "serotonin"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "muscimol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3280,
    "text": "However , in a similar experiment l - dopa ( 80 - 160 mg / kg ) was without effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "l - dopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3281,
    "text": "In doses of 3 - 10 mg / kg , the serotonin receptor agonist MK - 212 caused a dose - dependent blockade of the response of muscimol .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        17,
        "MK - 212"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "serotonin"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "muscimol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3282,
    "text": "Of the benzodiazepines , clonazepam ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than diazepam ( 0 . 3 - 3 mg / kg ) in blocking the myoclonic jerks .",
    "labels": [
      [
        "T0",
        "Disease",
        40,
        42,
        "myoclonic jerks"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "benzodiazepines"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "clonazepam"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3283,
    "text": "While ( - ) - baclofen ( 1 - 3 mg / kg ) proved to be an effective antagonist of muscimol , its ( + ) - isomer ( 5 - 20 mg / kg ) lacked this property .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "baclofen"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "muscimol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3284,
    "text": "Considering the fact that 5 - HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus , the muscimol - induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "5 - HTP"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "benzodiazepines"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "myoclonus"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "muscimol"
      ],
      [
        "T4",
        "Disease",
        27,
        28,
        "myoclonus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3285,
    "text": "Our present study indicated the possible value of MK - 212 and ( - ) - baclofen in the management of clinical myoclonus .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "MK - 212"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "baclofen"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "myoclonus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3286,
    "text": "Adverse interaction between beta - adrenergic blocking drugs and verapamil - - report of three cases .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        8,
        "beta - adrenergic blocking drugs"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3287,
    "text": "Three patients with ischaemic heart disease developed profound cardiac failure , hypotension and bradycardia during combined therapy with verapamil and beta - adrenergic blocking drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "ischaemic heart disease"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "cardiac failure"
      ],
      [
        "T2",
        "Chemical",
        20,
        25,
        "beta - adrenergic blocking drugs"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "hypotension"
      ],
      [
        "T4",
        "Disease",
        13,
        14,
        "bradycardia"
      ],
      [
        "T5",
        "Chemical",
        18,
        19,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3288,
    "text": "This clinical picture resolved completely with cessation of the combined therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3289,
    "text": "Baseline left ventricular function , assessed by cardiac catheterisation or nuclear angiography , was normal in two patients and only mildly reduced in the other .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3290,
    "text": "Simultaneously administration of beta - adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        8,
        "beta - adrenergic blocking drugs"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3291,
    "text": "Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "ranitidine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cimetidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3292,
    "text": "The H2 - histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short - and long - term basis in 22 patients with gastric acid hypersecretory states .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "histamine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ranitidine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "cimetidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3293,
    "text": "Nineteen patients had Zollinger - Ellison syndrome , one patient had systemic mastocytosis , and two patients had idiopathic hypersecretion .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "Zollinger - Ellison syndrome"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "systemic mastocytosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3294,
    "text": "The rates of onset of the action of cimetidine and ranitidine were the same .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "cimetidine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "ranitidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3295,
    "text": "The actions of both drugs were increased by anticholinergic agents , and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3296,
    "text": "However , ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed ( 1 . 2 g per day for ranitidine and 3 . 6 g per day for cimetidine ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "ranitidine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "cimetidine"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "ranitidine"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "cimetidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3297,
    "text": "Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "impotence"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "cimetidine"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "cimetidine"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "ranitidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3298,
    "text": "Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        38,
        "hepatic or hematologic toxicity"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "cimetidine"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "ranitidine"
      ],
      [
        "T3",
        "Chemical",
        46,
        47,
        "ranitidine"
      ],
      [
        "T4",
        "Chemical",
        55,
        56,
        "creatinine"
      ],
      [
        "T5",
        "Chemical",
        60,
        61,
        "cimetidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3299,
    "text": "The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3300,
    "text": "Both are safe at high doses , but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "ranitidine"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "cimetidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3301,
    "text": "Epileptogenic properties of enflurane and their clinical interpretation .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "enflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3302,
    "text": "Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "enflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3303,
    "text": "In one patient , enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "enflurane"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3304,
    "text": "Until the cause of the seizures was correctly identified , the patient was inappropriately treated with anticonvulsants .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3305,
    "text": "Two other patients suffered from partial , complex and generalized seizures uncontrolled by medication .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3306,
    "text": "Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure - free .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Epileptic"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "enflurane"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3307,
    "text": "Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "enflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3308,
    "text": "On the other hand , enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "enflurane"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3309,
    "text": "Development of isoproterenol - induced cardiac hypertrophy .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "cardiac hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3310,
    "text": "The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol ( ISO ) ( 0 . 3 mg / kg body weight ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiac hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "isoproterenol"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "ISO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3311,
    "text": "A time course was established for the change in tissue mass , RNA and DNA content , as well as hydroxyproline content .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "hydroxyproline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3312,
    "text": "Heart weight increased 44 % after 8 days of treatment with a half time of 3 . 4 days .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3313,
    "text": "Ventricular RNA content was elevated 26 % after 24 h of a single injection and reached a maximal level following 8 days of therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3314,
    "text": "The half time for RNA accumulation was 2 . 0 days .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3315,
    "text": "The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46 % after 4 days of therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "hydroxyproline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3316,
    "text": "Ventricular DNA content was unchanged during the early stage ( 1 - 4 days ) of hypertrophic growth but increased to a new steady - state level 19 % above the controls after 8 days of treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "hypertrophic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3317,
    "text": "Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3318,
    "text": "However , dP / dt in the ISO - treated hearts was slightly but significantly ( P less than 0 . 05 ) elevated .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "ISO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3319,
    "text": "These data indicate that the adaptive response to ISO shows an early hypertrophic phase ( 1 - 4 days ) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "ISO"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hypertrophic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3320,
    "text": "However , prolonged stimulation ( 8 - 12 days ) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "hypertrophy"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "hyperplasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3321,
    "text": "Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "penicillamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3322,
    "text": "Skin rashes , proteinuria , systemic lupus erythematosus , polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Skin rashes"
      ],
      [
        "T1",
        "Disease",
        5,
        8,
        "systemic lupus erythematosus"
      ],
      [
        "T2",
        "Disease",
        11,
        13,
        "myasthenia gravis"
      ],
      [
        "T3",
        "Disease",
        25,
        27,
        "rheumatoid arthritis"
      ],
      [
        "T4",
        "Disease",
        3,
        4,
        "proteinuria"
      ],
      [
        "T5",
        "Disease",
        9,
        10,
        "polymyositis"
      ],
      [
        "T6",
        "Chemical",
        20,
        21,
        "penicillamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3323,
    "text": "A patient who had developed all 5 is now described .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3324,
    "text": "The skin lesion resembled elastosis perforans serpiginosa , which has been reported as a rare side effect in patients with Wilson ' s disease but not in patients with rheumatoid arthritis treated with penicillamine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "skin lesion"
      ],
      [
        "T1",
        "Disease",
        4,
        7,
        "elastosis perforans serpiginosa"
      ],
      [
        "T2",
        "Disease",
        20,
        24,
        "Wilson ' s disease"
      ],
      [
        "T3",
        "Disease",
        29,
        31,
        "rheumatoid arthritis"
      ],
      [
        "T4",
        "Chemical",
        33,
        34,
        "penicillamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3325,
    "text": "Obsolete but dangerous antacid preparations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3326,
    "text": "One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon - ate - sodium bicarbonate powders for more than 20 years .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        25,
        "calcium carbon - ate"
      ],
      [
        "T1",
        "Chemical",
        26,
        28,
        "sodium bicarbonate"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "hypercalcaemia"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "nephrolithiasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3327,
    "text": "The powders had been obtained from pharmacists unknown to the patients ' medical practitioners .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3328,
    "text": "It is suggested that these preparations were responsible for the patient ' s problems , and that such powders should no longer be freely obtainable .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3329,
    "text": "Doxorubicin cardiomyopathy in children with left - sided Wilms tumor .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "Wilms tumor"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Doxorubicin"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3330,
    "text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "Wilms tumor"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "anthracycline"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "cardiomyopathy"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "tumor"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3331,
    "text": "The cardiomyopathy is attributed 1 ) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2 ) to the interaction of doxorubicin and irradiation on cardiac muscle .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "Wilms tumor"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "cardiomyopathy"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3332,
    "text": "It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "Wilms tumor"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3333,
    "text": "Effects of calcitonin on rat extrapyramidal motor system : behavioral and biochemical data .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3334,
    "text": "The effects of i . v . c . injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system , were investigated in male rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3335,
    "text": "Calcitonin injection resulted in a potentiation of haloperidol - induced catalepsy and a partial prevention of apomorphine - induced hyperactivity .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "haloperidol"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "apomorphine"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "hyperactivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3336,
    "text": "Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "DA"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "DOPAC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3337,
    "text": "The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA - related behavioral messages of striatal origin .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3338,
    "text": "Naloxazone pretreatment modifies cardiorespiratory , temperature , and behavioral effects of morphine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Naloxazone"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3339,
    "text": "Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone , an antagonist of high - affinity mu 1 opioid receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "naloxazone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3340,
    "text": "Pretreatment with naloxazone significantly blocked morphine analgesia , catalepsy and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "naloxazone"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "morphine"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "analgesia"
      ],
      [
        "T3",
        "Disease",
        8,
        9,
        "catalepsy"
      ],
      [
        "T4",
        "Disease",
        10,
        11,
        "hypothermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3341,
    "text": "Moreover , naloxazone significantly attenuated the morphine - induced hypotension and respiratory depression , whereas morphine - induced bradycardia was less affected .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "respiratory depression"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "naloxazone"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "morphine"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "hypotension"
      ],
      [
        "T4",
        "Chemical",
        15,
        16,
        "morphine"
      ],
      [
        "T5",
        "Disease",
        18,
        19,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3342,
    "text": "Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3343,
    "text": "Modification of drug action by hyperammonemia .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hyperammonemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3344,
    "text": "Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam , but NH4Ac treatment alone had no effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "ammonium acetate"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "NH4Ac"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "morphine"
      ],
      [
        "T3",
        "Disease",
        34,
        35,
        "incoordination"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "diazepam"
      ],
      [
        "T5",
        "Chemical",
        39,
        40,
        "NH4Ac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3345,
    "text": "Thus , hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "liver disease"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "hyperammonemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3346,
    "text": "Experiments in vitro showed that acetylcholine - induced catecholamine release from bovine adrenal medulla is depressed as much as 50 % by 0 . 3 mM NH4Ac and KCl - induced contractions of guinea - pig ileum were inhibited 20 % by 5 mM NH4Ac .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "acetylcholine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "catecholamine"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "NH4Ac"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "KCl"
      ],
      [
        "T4",
        "Chemical",
        44,
        45,
        "NH4Ac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3347,
    "text": "Addition of excess calcium reversed the depression in both tissues , but calcium - independent catecholamine release by acetaldehyde was not blocked by NH4Ac .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "calcium"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "depression"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "calcium"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "catecholamine"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "acetaldehyde"
      ],
      [
        "T5",
        "Chemical",
        23,
        24,
        "NH4Ac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3348,
    "text": "These results suggested that ammonia blocks calcium channels .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ammonia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3349,
    "text": "Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "NH4Ac"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "calcium"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3350,
    "text": "Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "verapamil"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "NH4Ac"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "morphine"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "analgesia"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "diazepam"
      ],
      [
        "T5",
        "Disease",
        24,
        25,
        "incoordination"
      ],
      [
        "T6",
        "Chemical",
        27,
        28,
        "amphetamine"
      ],
      [
        "T7",
        "Chemical",
        35,
        36,
        "verapamil"
      ],
      [
        "T8",
        "Chemical",
        37,
        38,
        "NH4Ac"
      ],
      [
        "T9",
        "Chemical",
        43,
        44,
        "metrazol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3351,
    "text": "The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hyperammonemia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3352,
    "text": "Levodopa - induced dyskinesia and thalamotomy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Levodopa"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3353,
    "text": "Levodopa - induced dyskinesia of the limbs in thirteen cases of Parkinsonism , which was choreic , ballistic or dystonic in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Levodopa"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "dyskinesia"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "Parkinsonism"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "dystonic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3354,
    "text": "Control of levodopa - induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "thalamic lesions"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "dyskinesias"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "Parkinsonism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3355,
    "text": "Treatment of ifosfamide - induced urothelial toxicity by oral administration of sodium 2 - mercaptoethane sulphonate ( MESNA ) to patients with inoperable lung cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "urothelial toxicity"
      ],
      [
        "T1",
        "Chemical",
        11,
        16,
        "sodium 2 - mercaptoethane sulphonate"
      ],
      [
        "T2",
        "Disease",
        23,
        25,
        "lung cancer"
      ],
      [
        "T3",
        "Chemical",
        2,
        3,
        "ifosfamide"
      ],
      [
        "T4",
        "Chemical",
        17,
        18,
        "MESNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3356,
    "text": "The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        15,
        "sodium 2 - mercaptoethane sulphonate"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "urothelial toxicity"
      ],
      [
        "T2",
        "Disease",
        37,
        39,
        "lung cancer"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "thiol"
      ],
      [
        "T4",
        "Chemical",
        16,
        17,
        "MESNA"
      ],
      [
        "T5",
        "Chemical",
        23,
        24,
        "ifosfamide"
      ],
      [
        "T6",
        "Chemical",
        25,
        26,
        "IF"
      ],
      [
        "T7",
        "Chemical",
        42,
        43,
        "IF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3357,
    "text": "MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg / m2 , each administered at 0 hr ( = injection of IF ) , 4 hr and 8 hr p . i .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "MESNA"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "IF"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "IF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3358,
    "text": "Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "haematuria"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "haematuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3359,
    "text": "In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions ( total 31 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "MESNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3360,
    "text": "A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures ( raised fluid intake and forced diuresis ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "IF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3361,
    "text": "In this group there were 1 complete and 5 partial remissions ( total 24 % ) , but nearly all patients developed either gross haematuria and / or symptoms of bladder irritation ( cystitis and pollakisuria ) .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        32,
        "bladder irritation"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "haematuria"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "cystitis"
      ],
      [
        "T3",
        "Disease",
        35,
        36,
        "pollakisuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3362,
    "text": "There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "MESNA"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3363,
    "text": "Our results support the view that MESNA , given orally in conjunction with combined cytostatic regimens which include IF , simplifies the treatment and provides optimum protection for the urinary epithelium .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "MESNA"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "IF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3364,
    "text": "Protection with oral MESNA is particularly suitable for outpatients .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "MESNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3365,
    "text": "Myoclonic , atonic , and absence seizures following institution of carbamazepine therapy in children .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        7,
        "Myoclonic , atonic , and absence seizures"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3366,
    "text": "Five children , aged 3 to 11 years , treated with carbamazepine for epilepsy , had an acute aberrant reaction characterized by the onset of myoclonic , atypical absence and / or atonic ( minor motor ) seizures within a few days .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        38,
        "myoclonic , atypical absence and / or atonic ( minor motor ) seizures"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "carbamazepine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3367,
    "text": "When the carbamazepine was discontinued , two of the children returned to their former state very quickly , two had the minor motor seizures resolve in 3 and 6 months , and one had the seizures persist .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "carbamazepine"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "seizures"
      ],
      [
        "T2",
        "Disease",
        35,
        36,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3368,
    "text": "The child in whom the seizures persisted was later found to have ceroid lipofuscinosis .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "ceroid lipofuscinosis"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3369,
    "text": "The other children are doing well on other anticonvulsants .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3370,
    "text": "Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "prostaglandin"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3371,
    "text": "To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "prostaglandins"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "PGs"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "seizure"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "convulsions"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "flurothyl"
      ],
      [
        "T5",
        "Chemical",
        26,
        27,
        "picrotoxin"
      ],
      [
        "T6",
        "Chemical",
        28,
        29,
        "pentetrazol"
      ],
      [
        "T7",
        "Chemical",
        30,
        31,
        "PTZ"
      ],
      [
        "T8",
        "Chemical",
        35,
        36,
        "bicuculline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3372,
    "text": "Ibuprofen , sulindac , mefenamic acid , and low dose meclofenamic acid increased the latency - to - onset in the flurothyl and / or PTZ models ; the electroshock , picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "mefenamic acid"
      ],
      [
        "T1",
        "Chemical",
        10,
        12,
        "meclofenamic acid"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Ibuprofen"
      ],
      [
        "T3",
        "Chemical",
        2,
        3,
        "sulindac"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "flurothyl"
      ],
      [
        "T5",
        "Chemical",
        25,
        26,
        "PTZ"
      ],
      [
        "T6",
        "Chemical",
        31,
        32,
        "picrotoxin"
      ],
      [
        "T7",
        "Chemical",
        33,
        34,
        "bicuculline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3373,
    "text": "These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "PGs"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "fluorthyl"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "PTZ"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "convulsions"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "picrotoxin"
      ],
      [
        "T5",
        "Chemical",
        31,
        32,
        "bicuculline"
      ],
      [
        "T6",
        "Disease",
        34,
        35,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3374,
    "text": "Acute changes of blood ammonia may predict short - term adverse effects of valproic acid .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "valproic acid"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "ammonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3375,
    "text": "Valproic acid ( VPA ) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Valproic acid"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "VPA"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3376,
    "text": "A standardized loading dose of VPA was administered , and venous blood was sampled at 0 , 1 , 2 , 3 , and 4 hours .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3377,
    "text": "Ammonia ( NH3 ) was higher in patients who , during continuous therapy , complained of drowsiness ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although VPA plasma levels were similar in both groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ammonia"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "NH3"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "drowsiness"
      ],
      [
        "T3",
        "Chemical",
        35,
        36,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3378,
    "text": "By measuring VPA - induced changes of blood NH3 content , it may be possible to identify patients at higher risk of obtundation when VPA is given chronically .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "VPA"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "NH3"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3379,
    "text": "Effect of captopril on pre - existing and aminonucleoside - induced proteinuria in spontaneously hypertensive rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "captopril"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "aminonucleoside"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "proteinuria"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3380,
    "text": "Proteinuria is a side effect of captopril treatment in hypertensive patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Proteinuria"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "captopril"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3381,
    "text": "The possibility of reproducing the same renal abnormality with captopril was examined in SHR .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "renal abnormality"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "captopril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3382,
    "text": "Oral administration of captopril at 100 mg / kg for 14 days failed to aggravate proteinuria pre - existing in SHR .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "captopril"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3383,
    "text": "Also , captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "captopril"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3384,
    "text": "Captopril had little or no demonstrable effects on serum electrolyte concentrations , excretion of urine , sodium and potassium , endogenous creatinine clearance , body weight , and food and water consumption .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Captopril"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "sodium"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "potassium"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3385,
    "text": "However , ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "ketone"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "captopril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3386,
    "text": "Complete heart block following a single dose of trazodone .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "heart block"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "trazodone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3387,
    "text": "Forty minutes after receiving a single starting dose of trazodone , a patient developed complete heart block .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "heart block"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "trazodone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3388,
    "text": "The case illustrates that , despite the results of earlier studies , trazodone ' s effect on cardiac conduction may be severe in individuals at risk for conduction delay .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "trazodone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3389,
    "text": "Phenobarbital - induced dyskinesia in a neurologically - impaired child .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "neurologically - impaired"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Phenobarbital"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3390,
    "text": "A 2 - year - old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "neurologic impairment"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "dyskinesia"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "phenobarbital"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3391,
    "text": "Known causes of movement disorders were eliminated after evaluation .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "movement disorders"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3392,
    "text": "On repeat challenge with phenobarbital , the dyskinesia recurred .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "phenobarbital"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3393,
    "text": "Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "movement disorders"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Phenobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3394,
    "text": "Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "amine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "ketamine"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "catatonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3395,
    "text": "The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine - induced catatonia in the intact , pinealectomized or hypophysectomized chick and rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "catecholamines"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "ketamine"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "catatonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3396,
    "text": "In the pinealectomized chick , pretreatment with dopamine increased the duration of catatonia ( DOC ) after ketamine , but pretreatment with norepinephrine did not .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "dopamine"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "catatonia"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "ketamine"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3397,
    "text": "The pineal indolamines exhibited mixed actions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3398,
    "text": "Serotonin and N - acetyl serotonin which augmented ketamine DOC , did not do so in the absence of the pineal gland , whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        6,
        "N - acetyl serotonin"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Serotonin"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "ketamine"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "melatonin"
      ],
      [
        "T4",
        "Chemical",
        27,
        28,
        "ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3399,
    "text": "Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent ; furthermore , melatonin did not augment the ketamine DOC whereas dopamine continued to do so .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ketamine"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "melatonin"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "ketamine"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3400,
    "text": "This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood - brain barrier in the young chick and the intact barrier in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "amines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3401,
    "text": "In addition , these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "ketamine"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "melatonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3402,
    "text": "Furthermore , dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "dopamine"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "ketamine"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "catatonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3403,
    "text": "Heparin - induced thrombocytopenia , thrombosis , and hemorrhage .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Heparin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "thrombosis"
      ],
      [
        "T3",
        "Disease",
        8,
        9,
        "hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3404,
    "text": "Sixty - two patients with a heparin - induced thrombocytopenia are reported .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3405,
    "text": "Clinical manifestations of this disorder include hemorrhage or , more frequently , thromboembolic events in patients receiving heparin .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hemorrhage"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "thromboembolic"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3406,
    "text": "Laboratory testing has revealed a falling platelet count , increased resistance to heparin , and aggregation of platelets by the patient ' s plasma when heparin is added .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        8,
        "a falling platelet count"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "heparin"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3407,
    "text": "Immunologic testing has demonstrated the presence of a heparin - dependent platelet membrane antibody .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3408,
    "text": "The 20 deaths , 52 hemorrhagic and thromboembolic complications , and 21 surgical procedures to manage the complications confirm the seriousness of the disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "hemorrhagic and thromboembolic complications"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3409,
    "text": "Specific risk factors have not been identified ; therefore , all patients receiving heparin should be monitored .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3410,
    "text": "If the platelet count falls to less than 100 , 000 / mm3 , while the patient is receiving heparin , platelet aggregation testing , using the patient ' s plasma , is indicated .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "platelet aggregation"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3411,
    "text": "Management consists of cessation of heparin , platelet anti - aggregating agents , and alternate forms of anticoagulation when indicated .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3412,
    "text": "Ventricular fibrillation from diatrizoate with and without chelating agents .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Ventricular fibrillation"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "diatrizoate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3413,
    "text": "The toxicity of Renografin 76 % was compared with that of Hypaque 76 % by selective injection of each into the right coronary artery of dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "Renografin 76 %"
      ],
      [
        "T1",
        "Chemical",
        11,
        14,
        "Hypaque 76 %"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3414,
    "text": "Renografin contains the chelating agents sodium citrate and disodium edetate , while Hypaque contains calcium disodium edetate and no sodium citrate .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "sodium citrate"
      ],
      [
        "T1",
        "Chemical",
        8,
        10,
        "disodium edetate"
      ],
      [
        "T2",
        "Chemical",
        14,
        17,
        "calcium disodium edetate"
      ],
      [
        "T3",
        "Chemical",
        19,
        21,
        "sodium citrate"
      ],
      [
        "T4",
        "Chemical",
        0,
        1,
        "Renografin"
      ],
      [
        "T5",
        "Chemical",
        12,
        13,
        "Hypaque"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3415,
    "text": "Ventricular fibrillation occurred significantly more often with Renografin , suggesting that chelating agents contribute to toxicity in coronary angiography .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Ventricular fibrillation"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "Renografin"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3416,
    "text": "Long - term efficacy and toxicity of high - dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "ventricular fibrillation"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "toxicity"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3417,
    "text": "Amiodarone was administered to 154 patients who had sustained , symptomatic ventricular tachycardia ( VT ) ( n = 118 ) or a cardiac arrest ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Disease",
        23,
        25,
        "cardiac arrest"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "VT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3418,
    "text": "The loading dose was 800 mg / day for 6 weeks and the maintenance dose was 600 mg / day .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3419,
    "text": "Sixty - nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation ( VF ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "ventricular fibrillation"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "amiodarone"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "VT"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "VF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3420,
    "text": "Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "VT"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3421,
    "text": "One or more adverse drug reactions occurred in 51 % of patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3422,
    "text": "Adverse effects forced a reduction in the dose of amiodarone in 41 % and discontinuation of amiodarone in 10 % of patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "amiodarone"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3423,
    "text": "The most common symptomatic adverse reactions were tremor or ataxia ( 35 % ) , nausea and anorexia ( 8 % ) , visual halos or blurring ( 6 % ) , thyroid function abnormalities ( 6 % ) and pulmonary interstitial infiltrates ( 5 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        27,
        "visual halos or blurring"
      ],
      [
        "T1",
        "Disease",
        32,
        35,
        "thyroid function abnormalities"
      ],
      [
        "T2",
        "Disease",
        40,
        43,
        "pulmonary interstitial infiltrates"
      ],
      [
        "T3",
        "Disease",
        7,
        8,
        "tremor"
      ],
      [
        "T4",
        "Disease",
        9,
        10,
        "ataxia"
      ],
      [
        "T5",
        "Disease",
        15,
        16,
        "nausea"
      ],
      [
        "T6",
        "Disease",
        17,
        18,
        "anorexia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3424,
    "text": "Although large - dose amiodarone is highly effective in the long - term treatment of VT or VF refractory to conventional antiarrhythmic drugs , it causes significant toxicity in approximately 50 % of patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "amiodarone"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "VT"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "VF"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3425,
    "text": "However , when the dose is adjusted based on clinical response or the development of adverse effects , 75 % of patients with VT or VF can be successfully managed with amiodarone .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "VT"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "VF"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3426,
    "text": "Why may epsilon - aminocaproic acid ( EACA ) induce myopathy in man ?",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        6,
        "epsilon - aminocaproic acid"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "EACA"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3427,
    "text": "Report of a case and literature review .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3428,
    "text": "A case of necrotizing myopathy due to a short epsilon - aminocaproic acid ( EACA ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( SAH ) is described .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "necrotizing myopathy"
      ],
      [
        "T1",
        "Chemical",
        9,
        13,
        "epsilon - aminocaproic acid"
      ],
      [
        "T2",
        "Disease",
        25,
        27,
        "subarachnoid haemorrhage"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "EACA"
      ],
      [
        "T4",
        "Disease",
        28,
        29,
        "SAH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3429,
    "text": "Pathogenetic hypotheses are discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3430,
    "text": "Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cerebral hemorrhage"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "phenylpropanolamine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3431,
    "text": "Phenylpropanolamine ( PPA ) is a drug that has been associated with serious side effects including stroke .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Phenylpropanolamine"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "PPA"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3432,
    "text": "It is often combined with caffeine in diet preparations and \" look - alike \" pills .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3433,
    "text": "In order to determine if PPA / caffeine can lead to stroke in normotensive and / or hypertensive rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "PPA"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "caffeine"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "stroke"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3434,
    "text": "Subarachnoid and cerebral hemorrhage was noted in 18 % of the hypertensive rats .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Subarachnoid and cerebral hemorrhage"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3435,
    "text": "A single PPA / caffeine administration ( same dose ) lead to acute hypertension in both the normotensive and hypertensive animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "PPA"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "caffeine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hypertension"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3436,
    "text": "These results suggest that PPA / caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "cerebral hemorrhage"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "PPA"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "caffeine"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3437,
    "text": "An acute elevation in blood pressure may be a contributing factor .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3438,
    "text": "Renal papillary necrosis due to naproxen .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Renal papillary necrosis"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "naproxen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3439,
    "text": "A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        19,
        21,
        "fenoprofen calcium"
      ],
      [
        "T2",
        "Disease",
        30,
        33,
        "renal papillary necrosis"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "sulindac"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "salicylates"
      ],
      [
        "T5",
        "Chemical",
        26,
        27,
        "gold"
      ],
      [
        "T6",
        "Disease",
        34,
        35,
        "RPN"
      ],
      [
        "T7",
        "Chemical",
        41,
        42,
        "naproxen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3440,
    "text": "No other factor predisposing to RPN could be discovered .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "RPN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3441,
    "text": "Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Sulindac"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "naproxen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3442,
    "text": "We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "renal toxicity"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "RPN"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "sulindac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3443,
    "text": "Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Nephrotoxic"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "aminoglycoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3444,
    "text": "To quantify the effects of gentamicin , kanamycin and netilmicin on renal protein reabsorption and accumulation , these drugs were administered to rats intraperitoneally ( 30 mg / kg / day ) for 7 , 14 or 21 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "gentamicin"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "kanamycin"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "netilmicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3445,
    "text": "Scanning electron microscopy of the glomerular endothelia , urinary measurements of sodium , potassium , endogenous lysozyme , N - acetyl - beta - D - glucosaminidase ( NAG ) as well as clearance and accumulation experiments after i . v . administration of egg - white lysozyme and measurements of inulin clearance ( GFR ) were done in each treatment group .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3446,
    "text": "Gentamicin administration decreased diameter , density and shape of endothelial fenestrae .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3447,
    "text": "Kanamycin and netilmicin appeared to have no effect at the dose used .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Kanamycin"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "netilmicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3448,
    "text": "All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "aminoglycosides"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "sodium"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3449,
    "text": "While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i . v . administration of egg - white lysozyme netilmicin had no effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "gentamicin"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "kanamycin"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "netilmicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3450,
    "text": "Daily excretion of total protein , endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "kanamycin"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3451,
    "text": "Thus , aminoglycosides may act as nephrotoxicants at glomerular and / or tubular level inducing impairment of renal reabsorption and accumulation of proteins .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        19,
        "impairment of renal reabsorption"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "aminoglycosides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3452,
    "text": "Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "obstructive sleep apnea syndrome"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "androgen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3453,
    "text": "We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54 - yr - old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        34,
        "syndrome of obstructive sleep apnea"
      ],
      [
        "T1",
        "Chemical",
        38,
        39,
        "androgens"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3454,
    "text": "When the androgens were withdrawn , the patient ' s physical changes , symptoms , sleep study , and supraglottic resistance all returned to normal .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "androgens"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3455,
    "text": "A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "obstructive sleep apnea"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "androgen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3456,
    "text": "Previous reports have favored a role of androgens in the pathogenesis of sleep apnea .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "sleep apnea"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "androgens"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3457,
    "text": "Our report provides direct evidence for this role .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3458,
    "text": "Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "androgens"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3459,
    "text": "Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "obstructive sleep apnea syndrome"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "androgen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3460,
    "text": "Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Cardiotoxic"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "adriamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3461,
    "text": "10 monkeys ( macaques ) received adriamycin by monthly intravenous injections at 12 mg / m2 ( 1 mg / kg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "adriamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3462,
    "text": "8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose ( 310 mg / m2 ) well below that considered the safe upper limit ( 550 mg / m2 ) in man .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "congestive heart failure"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "adriamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3463,
    "text": "Histologically , the myocardial lesions resembled those found in human anthracycline - induced cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "myocardial lesions"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "anthracycline"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3464,
    "text": "1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg / m2 of adriamycin ; the 10th monkey is alive and well 26 months after the last dose of drug .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "acute myeloblastic leukemia"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "adriamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3465,
    "text": "Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man , and that leukemia may be a consequence of prolonged treatment with this drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "adriamycin"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "leukemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3466,
    "text": "Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Tricuspid valve regurgitation"
      ],
      [
        "T1",
        "Chemical",
        4,
        6,
        "lithium carbonate"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3467,
    "text": "A newborn with massive tricuspid regurgitation , atrial flutter , congestive heart failure , and a high serum lithium level is described .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "tricuspid regurgitation"
      ],
      [
        "T1",
        "Disease",
        7,
        9,
        "atrial flutter"
      ],
      [
        "T2",
        "Disease",
        10,
        13,
        "congestive heart failure"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3468,
    "text": "This is the first patient to initially manifest tricuspid regurgitation and atrial flutter , and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "tricuspid regurgitation"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "atrial flutter"
      ],
      [
        "T2",
        "Disease",
        20,
        22,
        "cardiac disease"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3469,
    "text": "Sixty - three percent of these infants had tricuspid valve involvement .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3470,
    "text": "Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Lithium carbonate"
      ],
      [
        "T1",
        "Disease",
        11,
        14,
        "congenital heart disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3471,
    "text": "It also causes neurologic depression , cyanosis , and cardiac arrhythmia when consumed prior to delivery .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "neurologic depression"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "cardiac arrhythmia"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "cyanosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3472,
    "text": "Effects of the novel compound aniracetam ( Ro 13 - 5057 ) upon impaired learning and memory in rodents .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        11,
        "Ro 13 - 5057"
      ],
      [
        "T1",
        "Disease",
        13,
        17,
        "impaired learning and memory"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "aniracetam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3473,
    "text": "The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        9,
        "Ro 13 - 5057"
      ],
      [
        "T1",
        "Chemical",
        10,
        17,
        "1 - anisoyl - 2 - pyrrolidinone"
      ],
      [
        "T2",
        "Disease",
        25,
        28,
        "impaired cognitive functions"
      ],
      [
        "T3",
        "Chemical",
        3,
        4,
        "aniracetam"
      ],
      [
        "T4",
        "Disease",
        61,
        62,
        "hypercapnia"
      ],
      [
        "T5",
        "Chemical",
        83,
        84,
        "scopolamine"
      ],
      [
        "T6",
        "Disease",
        89,
        90,
        "amnesia"
      ],
      [
        "T7",
        "Disease",
        102,
        103,
        "amnesia"
      ],
      [
        "T8",
        "Chemical",
        145,
        146,
        "chloramphenicol"
      ],
      [
        "T9",
        "Chemical",
        147,
        148,
        "cycloheximide"
      ],
      [
        "T10",
        "Chemical",
        184,
        185,
        "cycloheximide"
      ],
      [
        "T11",
        "Disease",
        212,
        213,
        "hypercapnia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3474,
    "text": "These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10 - 100 mg / kg .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "impaired cognitive functions"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "aniracetam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3475,
    "text": "Generally , the dose - response curves were bell - shaped .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3476,
    "text": "The mechanisms underlying the activity of aniracetam and its ' therapeutic window ' are unknown .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "aniracetam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3477,
    "text": "Piracetam , another pyrrolidinone derivative was used for comparison .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Piracetam"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "pyrrolidinone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3478,
    "text": "It was active only in six of nine tests and had about one - tenth the potency of aniracetam .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "aniracetam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3479,
    "text": "The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "aniracetam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3480,
    "text": "Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "calcium chloride"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "carbachol"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "eserine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3481,
    "text": "The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , tremor and clonic - tonic convulsions produced by carbachol and eserine injected similarly was investigated .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "calcium chloride"
      ],
      [
        "T1",
        "Disease",
        47,
        51,
        "clonic - tonic convulsions"
      ],
      [
        "T2",
        "Disease",
        43,
        44,
        "mydriasis"
      ],
      [
        "T3",
        "Disease",
        45,
        46,
        "tremor"
      ],
      [
        "T4",
        "Chemical",
        53,
        54,
        "carbachol"
      ],
      [
        "T5",
        "Chemical",
        55,
        56,
        "eserine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3482,
    "text": "Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Calcium chloride"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "carbachol"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "eserine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3483,
    "text": "On the other hand , mydriasis , tremor and clonic - tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "clonic - tonic convulsions"
      ],
      [
        "T1",
        "Chemical",
        23,
        25,
        "calcium chloride"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "mydriasis"
      ],
      [
        "T3",
        "Disease",
        7,
        8,
        "tremor"
      ],
      [
        "T4",
        "Chemical",
        15,
        16,
        "carbachol"
      ],
      [
        "T5",
        "Chemical",
        17,
        18,
        "eserine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3484,
    "text": "It is apparent that calcium chloride can \" dissociate \" vocalization and fighting from autonomic and motor phenomena such as mydriasis , tremor and clonic - tonic convulsions caused by carbachol and eserine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "calcium chloride"
      ],
      [
        "T1",
        "Disease",
        24,
        28,
        "clonic - tonic convulsions"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "mydriasis"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "tremor"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "carbachol"
      ],
      [
        "T5",
        "Chemical",
        32,
        33,
        "eserine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3485,
    "text": "Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Calcium chloride"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "carbachol"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "eserine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3486,
    "text": "These results further support the view that calcium ions in excess have an atropine - like action also in the central nervous system .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "calcium"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "atropine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3487,
    "text": "Thiazide diuretics , hypokalemia and cardiac arrhythmias .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "cardiac arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Thiazide"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "hypokalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3488,
    "text": "Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Thiazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3489,
    "text": "Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypokalemia"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "thiazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3490,
    "text": "We treated 38 patients ( 22 low renin , 16 normal renin ) with moderate diastolic hypertension with hydrochlorothiazide ( HCTC ) administered on a twice daily schedule .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "diastolic hypertension"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "hydrochlorothiazide"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "HCTC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3491,
    "text": "Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg , 150 mg and 200 mg daily until blood pressure normalized .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3492,
    "text": "The serum K during the control period was 4 . 5 + / - 0 . 2 mEq / l an on 50 , 100 , 150 and 200 mg HCTZ daily 3 . 9 + / - 0 . 3 , 3 . 4 + / - 0 . 2 , 2 . 9 + / - 0 . 2 , and 2 . 4 + / - 0 . 3 mEq / l , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "K"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3493,
    "text": "Corresponding figures for whole body K were 4107 + / - 208 , 3722 + / - 319 , 3628 + / - 257 , 3551 + / - 336 , and 3269 + / - 380 mEq , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "K"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3494,
    "text": "In 13 patients we observed the effects of HCTZ therapy ( 100 mg daily ) on the occurrence of PVC ' s during rest as well as during static and dynamic exercise .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3495,
    "text": "During rest we observed 0 . 6 + / - 0 . 08 PVC beats / min + / - SEM and during static and dynamic exercise 0 . 6 + / - 0 . 06 and 0 . 8 + / - 0 . 15 , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3496,
    "text": "Corresponding figures during HCTZ therapy 100 mg daily were 1 . 4 + / - 0 . 1 , 3 . 6 + / - 0 . 7 and 5 . 7 4 / - 0 . 8 , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3497,
    "text": "The occurrence of PVC ' s correlated significantly with the fall in serum K + observed r = 0 . 72 , p less than 0 . 001 .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "K"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3498,
    "text": "In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "thiazide"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hypokalemia"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3499,
    "text": "The more profound hypokalemia , the greater the propensity for the occurrence of PVC ' s .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypokalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3500,
    "text": "Circulating lysosomal enzymes and acute hepatic necrosis .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "acute hepatic necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3501,
    "text": "The activities of the lysosomal enzymes acid and neutral protease , N - acetylglucosaminidase , and acid phosphatase were measured in the serum of patients with fulminant hepatic failure .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        29,
        "fulminant hepatic failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3502,
    "text": "Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        25,
        "fulminant hepatic failure"
      ],
      [
        "T1",
        "Disease",
        37,
        40,
        "fulminant hepatic failure"
      ],
      [
        "T2",
        "Disease",
        42,
        44,
        "viral hepatitis"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "paracetamol"
      ],
      [
        "T4",
        "Disease",
        27,
        28,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3503,
    "text": "A correlation was found between serum acid protease activity and prothrombin time , and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase , which showed a sharp early peak and then a fall .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        28,
        "aspartate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3504,
    "text": "Circulating lysosomal proteases can damage other organs , and measurement of their activity may therefore be of added value in assessing prognosis in this condition .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3505,
    "text": "Hepatic veno - occlusive disease caused by 6 - thioguanine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        5,
        "Hepatic veno - occlusive disease"
      ],
      [
        "T1",
        "Chemical",
        7,
        10,
        "6 - thioguanine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3506,
    "text": "Clinically reversible veno - occlusive disease of the liver developed in a 23 - year - old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6 - thioguanine .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        9,
        "veno - occlusive disease of the liver"
      ],
      [
        "T1",
        "Disease",
        19,
        22,
        "acute lymphocytic leukemia"
      ],
      [
        "T2",
        "Chemical",
        29,
        32,
        "6 - thioguanine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3507,
    "text": "Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3508,
    "text": "Although this disease was clinically reversible , some subintimal fibrosis about the terminal hepatic veins persisted .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3509,
    "text": "This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno - occlusive disease over time , and may be the first case of veno - occlusive related solely to 6 - thioguanine .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        19,
        "hepatic veno - occlusive disease"
      ],
      [
        "T1",
        "Chemical",
        35,
        38,
        "6 - thioguanine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3510,
    "text": "Chlorpropamide - induced optic neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Chlorpropamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3511,
    "text": "A 65 - year - old woman with adult - onset diabetes treated with chlorpropamide ( Diabenese ) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "adult - onset diabetes"
      ],
      [
        "T1",
        "Disease",
        20,
        23,
        "toxic optic neuropathy"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "chlorpropamide"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "Diabenese"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "chlorpropamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3512,
    "text": "Visual loss occurs in diabetics for a variety of reasons , and accurate diagnosis is necessary to institute appropriate therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Visual loss"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "diabetics"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3513,
    "text": "The possibility of a drug - induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "optic neuropathy"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "visual loss"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "diabetics"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3514,
    "text": "Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "nephrotic syndrome"
      ],
      [
        "T1",
        "Chemical",
        17,
        19,
        "puromycin aminonucleoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3515,
    "text": "This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se , or , at least in part , to the aminonucleoside .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "nephrotic syndrome"
      ],
      [
        "T1",
        "Chemical",
        18,
        20,
        "puromycin aminonucleoside"
      ],
      [
        "T2",
        "Disease",
        23,
        25,
        "nephrotic syndrome"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "aminonucleoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3516,
    "text": "The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside ( 20 mg / kg for 7 days ) and the subsequent development of nephrotic syndrome .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        22,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        36,
        38,
        "nephrotic syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3517,
    "text": "Since massive albuminuria occurred after 6 days of treatment , the time - course study was divided into two stages : pre - nephrotic stage ( day 1 - 5 ) and nephrotic stage ( day 6 - 11 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "albuminuria"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "nephrotic"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "nephrotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3518,
    "text": "In pre - nephrotic stage the plasma level of fatty acids , triacylglycerol and VLDL decreased while that of phospholipid , cholesteryl esters and HDL remained constant .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "fatty acids"
      ],
      [
        "T1",
        "Chemical",
        21,
        23,
        "cholesteryl esters"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "nephrotic"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "triacylglycerol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3519,
    "text": "Plasma apolipoprotein A - I tended to increase ( 40 % increase at day 5 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3520,
    "text": "At the beginning of nephrotic stage ( day 6 ) the concentration of plasma albumin dropped to a very low level , while that of apolipoprotein A - I increased abruptly ( 4 - fold increase ) and continued to rise , although less steeply , in the following days .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "nephrotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3521,
    "text": "The plasma concentration of HDL followed the same pattern .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3522,
    "text": "Plasma VLDL and LDL increased at a later stage ( day 9 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3523,
    "text": "Plasma apolipoprotein A - I was found not only in HDL ( 1 . 063 - 1 . 210 g / ml ) but also in the LDL density class ( 1 . 025 - 1 . 050 g / ml ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3524,
    "text": "In the pre - nephrotic stage lipoproteinuria was negligible , while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "nephrotic"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "nephrotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3525,
    "text": "These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "puromycin aminonucleoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3526,
    "text": "It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "nephrotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3527,
    "text": "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "chloramphenicol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3528,
    "text": "A 73 - year - old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "aplastic anemia"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "cataract"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "chloramphenicol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3529,
    "text": "The first signs of pancytopenia began within one month of the surgery .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "pancytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3530,
    "text": "The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "chloramphenicol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3531,
    "text": "This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions , although two cases of reversible bone marrow hypoplasia have also been reported .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "aplastic anemia"
      ],
      [
        "T1",
        "Disease",
        23,
        26,
        "bone marrow hypoplasia"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "chloramphenicol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3532,
    "text": "Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug - Induced Ocular Side Effects , Oregon Health Sciences University , Portland , OR 97201 .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "ocular toxicity"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "chloramphenicol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3533,
    "text": "Midazolam compared with thiopentone as an induction agent .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Midazolam"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "thiopentone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3534,
    "text": "In patients premedicated with scopolamine + morphine ( + 5 mg nitrazepam the evening before surgery ) , the sleep - inducing effect of midazolam 0 . 15 mg / kg i . v . was clearly slower in onset than that of thiopentone 4 . 67 mg / kg i . v . Somewhat fewer cardiovascular and local sequelae were found in the midazolam group , but , although apnoea occurred less often in the midazolam group it lasted longer .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "scopolamine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "morphine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "nitrazepam"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "midazolam"
      ],
      [
        "T4",
        "Chemical",
        43,
        44,
        "thiopentone"
      ],
      [
        "T5",
        "Chemical",
        64,
        65,
        "midazolam"
      ],
      [
        "T6",
        "Disease",
        70,
        71,
        "apnoea"
      ],
      [
        "T7",
        "Chemical",
        76,
        77,
        "midazolam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3535,
    "text": "On the whole , the differences between midazolam and thiopentone had no apparent clinical consequences .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "midazolam"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "thiopentone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3536,
    "text": "Midazolam is a new alternative agent for induction in combination anaesthesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Midazolam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3537,
    "text": "Extrapyramidal side effects and oral haloperidol : an analysis of explanatory patient and treatment characteristics .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3538,
    "text": "The incidence of extrapyramidal side effects ( EPS ) was evaluated in 98 patients treated with haloperidol .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3539,
    "text": "The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "parkinsonism"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3540,
    "text": "Prophylactic antiparkinsonian medication was effective in younger but not in older patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3541,
    "text": "However , these medications were more effective in both young and old patients when given after parkinsonism developed .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "parkinsonism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3542,
    "text": "Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients , while prophylactic antiparkinsonians were ineffective .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Akathisia"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "benzodiazepine"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "lorazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3543,
    "text": "The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3544,
    "text": "Deaths from local anesthetic - induced convulsions in mice .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3545,
    "text": "Median convulsant ( CD50 ) and median lethal ( LD50 ) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic - induced convulsions .",
    "labels": [
      [
        "T0",
        "Disease",
        33,
        34,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3546,
    "text": "The CD50 and LD50 , respectively , were 57 . 7 and 58 . 7 mg / kg for bupivacaine , 111 . 0 and 133 . 1 mg / kg for lidocaine , and 243 . 4 and 266 . 5 mg / kg for chloroprocaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        46,
        47,
        "chloroprocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3547,
    "text": "When given intraperitoneally , bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "chloroprocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3548,
    "text": "Convulsions always preceded death , except after precipitous cardiopulmonary arrest from extreme doses .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "cardiopulmonary arrest"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3549,
    "text": "A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of bupivacaine - induced seizures , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "convulsions"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "bupivacaine"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "seizures"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "chloroprocaine"
      ],
      [
        "T4",
        "Chemical",
        40,
        41,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3550,
    "text": "The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3551,
    "text": "REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "REM sleep deprivation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3552,
    "text": "The effects of REM sleep deprivation ( REMD ) on apomorphine - induced aggressiveness and quipazine - induced head twitches in rats were determined .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "REM sleep deprivation"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "head twitches"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "REMD"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "apomorphine"
      ],
      [
        "T4",
        "Disease",
        13,
        14,
        "aggressiveness"
      ],
      [
        "T5",
        "Chemical",
        15,
        16,
        "quipazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3553,
    "text": "Forty - eight hr of REMD increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) quipazine - induced head twitches .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        36,
        "head twitches"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "REMD"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "apomorphine"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "aggressiveness"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "REMD"
      ],
      [
        "T5",
        "Disease",
        29,
        30,
        "REMD"
      ],
      [
        "T6",
        "Chemical",
        31,
        32,
        "quipazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3554,
    "text": "Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3555,
    "text": "Fatal aplastic anemia due to indomethacin - - lymphocyte transformation tests in vitro .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3556,
    "text": "Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations , its role has not been definitely established .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3557,
    "text": "A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "allopurinol"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3558,
    "text": "Indomethacin was first given four weeks prior to the onset of symptoms .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3559,
    "text": "A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3560,
    "text": "Fortunately , this seems to be a very rare complication .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3561,
    "text": "Dose - effect and structure - function relationships in doxorubicin cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "doxorubicin"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3562,
    "text": "The cardiomyopathy ( CM ) produced by the anticancer drug doxorubicin ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        36,
        "myocardial disease"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "cardiomyopathy"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "CM"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "doxorubicin"
      ],
      [
        "T4",
        "Chemical",
        12,
        13,
        "DXR"
      ],
      [
        "T5",
        "Chemical",
        15,
        16,
        "Adriamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3563,
    "text": "We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "DXR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3564,
    "text": "Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg / m2 .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "DXR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3565,
    "text": "Performance abnormalities correlated weakly with dose , exhibited a curvilinear relationship , and had a \" threshold \" for expression .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3566,
    "text": "Catheterization abnormalities correlated well with morphologic damage ( r = 0 . 57 to 0 . 78 ) in a subgroup of patients in whom exercise hemodynamics were measured , and this relationship also exhibited a curvilinear , threshold configuration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3567,
    "text": "In DXR - CM myocardial damage is proportional to the degree of cytotoxic insult ( DXR dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "myocardial damage"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "DXR"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "CM"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "DXR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3568,
    "text": "Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose : possible role of cranial decompression .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "cerebral edema"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "hepatic failure"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "acetaminophen"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3569,
    "text": "Cerebral edema may complicate the course of fulminant hepatic failure .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cerebral edema"
      ],
      [
        "T1",
        "Disease",
        7,
        10,
        "fulminant hepatic failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3570,
    "text": "Response to conventional therapy has been disappointing .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3571,
    "text": "We present a patient with fatal acetaminophen - induced fulminant hepatic failure , with signs and symptoms of cerebral edema , unresponsive to conventional medical therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "fulminant hepatic failure"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "cerebral edema"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3572,
    "text": "Cranial decompression was carried out .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3573,
    "text": "A justification of the need for further evaluation of cranial decompression in such patients is presented .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3574,
    "text": "Subjective assessment of sexual dysfunction of patients on long - term administration of digoxin .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "sexual dysfunction"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3575,
    "text": "Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone ( LH ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "digoxin"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "estrogen"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "testosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3576,
    "text": "This study was undertaken to investigate the links between the long - term administration of digoxin therapy and sexual behavior , and the effect of digoxin on plasma levels of estradiol , testosterone , and LH .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "digoxin"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "digoxin"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "estradiol"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "testosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3577,
    "text": "The patients of the study and control group ( without digoxin ) were of similar cardiac functional capacity and age ( 25 - 40 years ) and were randomly selected from the rheumatic heart disease patients .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        35,
        "rheumatic heart disease"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3578,
    "text": "A subjective assessment of sexual behavior in the study and control groups was carried out , using parameters such as sexual desire , sexual excitement , and frequency of sexual relations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3579,
    "text": "Personal interviews and a questionnaire were also used for the evaluation of sexual behavior .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3580,
    "text": "The findings support the reports concerning digoxin effect on plasma estradiol , testosterone , and LH .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "digoxin"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "estradiol"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "testosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3581,
    "text": "The differences in the means were significant .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3582,
    "text": "Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire , sexual excitement phase ( erection ) , and frequency of sexual relations in the study group .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "decrease in sexual desire"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3583,
    "text": "Endometrial carcinoma after Hodgkin disease in childhood .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Endometrial carcinoma"
      ],
      [
        "T1",
        "Disease",
        3,
        5,
        "Hodgkin disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3584,
    "text": "A 34 - year - old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "endometrial carcinoma"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "Hodgkin disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3585,
    "text": "She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease , and received exogenous estrogens , a treatment implicated in the development of endometrial cancer in menopausal women .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "ovarian failure"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "Hodgkin disease"
      ],
      [
        "T2",
        "Disease",
        25,
        27,
        "endometrial cancer"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "estrogens"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3586,
    "text": "Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "ovarian failure"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "endometrial carcinoma"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "estrogens"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3587,
    "text": "Long - term lithium treatment and the kidney .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3588,
    "text": "Interim report on fifty patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3589,
    "text": "This is a report on the first part of our study of the effects of long - term lithium treatment on the kidney .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3590,
    "text": "Creatinine clearance , maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long - term lithium for more than one year .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Creatinine"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3591,
    "text": "These findings have been compared with norms and with values of the same tests from screening prior to lithium , available for most of our patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3592,
    "text": "No evidence was found for any reduction of glomerular filtration during lithium treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3593,
    "text": "Low clearance values found in several patients could be accounted for by their age and their pre - lithium values .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3594,
    "text": "Urinary concentration defect appeared frequent but the extent of the impairment is difficult to assess because of the uncertainty about the norms applicable to this group of patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3595,
    "text": "The concentration defect appeared reversible , at least in part .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3596,
    "text": "Polyuria above 3 litres / 24 hours was found in 10 % of patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Polyuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3597,
    "text": "An attempt is made to draw practical conclusions from the preliminary findings .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3598,
    "text": "Nephrotoxicity of cyclosporin A and FK506 : inhibition of calcineurin phosphatase .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "cyclosporin A"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Nephrotoxicity"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "FK506"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3599,
    "text": "Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Cyclosporin A"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "CsA"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "Fujimycine"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "FK506"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "macrolide"
      ],
      [
        "T5",
        "Chemical",
        27,
        28,
        "rapamycin"
      ],
      [
        "T6",
        "Disease",
        51,
        52,
        "hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3600,
    "text": "The molecular mechanisms of CsA and FK506 toxicity were investigated .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "CsA"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "FK506"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3601,
    "text": "Cyclophilin A and FK506 - binding protein , the main intracytoplasmic receptors for CsA and FK506 , respectively , were each detected in renal tissue extract .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "FK506"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "CsA"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "FK506"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3602,
    "text": "In the kidney , high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506 , but not by rapamycin .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "CsA"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "FK506"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "rapamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3603,
    "text": "Finally , specific immunophilin - drug - calcineurin complexes formed only in the presence of CsA and FK506 , but not rapamycin .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "CsA"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "FK506"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "rapamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3604,
    "text": "These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "nephrotoxic"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "CsA"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "FK506"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3605,
    "text": "Acute renal failure in high dose carboplatin chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3606,
    "text": "Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3607,
    "text": "We report a 4 1 / 2 - year - old girl who was treated with high - dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "embryonal rhabdomyosarcoma"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3608,
    "text": "Acute renal failure developed followed by a slow partial recovery of renal function .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute renal failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3609,
    "text": "Possible contributing factors are discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3610,
    "text": "Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "prostacyclin"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "beraprost"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "cilostazol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3611,
    "text": "Among various oral antiplatelets , a combination of a novel prostacyclin analogue beraprost ( BPT ) and a potent phosphodiesterase inhibitor cilostazol ( CLZ ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP ( cyclic adenosine 3 ' , 5 ' - monophosphate ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        40,
        49,
        "cyclic adenosine 3 ' , 5 ' - monophosphate"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "prostacyclin"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "beraprost"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "BPT"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "cilostazol"
      ],
      [
        "T5",
        "Chemical",
        23,
        24,
        "CLZ"
      ],
      [
        "T6",
        "Chemical",
        38,
        39,
        "cAMP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3612,
    "text": "Thereby , a clinical study of the combined administration of the two agents was attempted .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3613,
    "text": "Twelve healthy volunteers were assigned to take BPT / CLZ in the following schedule ; BPT : 40 micrograms at day 1 and 120 micrograms t . i . d . from day 7 to 14 , CLZ : 200 mg t . i . d . from day 3 to 14 .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "BPT"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "CLZ"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "BPT"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "CLZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3614,
    "text": "At various time intervals , physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "platelet aggregation"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "cAMP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3615,
    "text": "Throughout the observation period , no significant alteration in vital signs was observed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3616,
    "text": "Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one , especially after ingestion of CLZ .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "facial flush"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "headache"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "nausea"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "CLZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3617,
    "text": "All of these symptoms , probably caused by the vasodilating effect of the two agents , were of mild degree and no special treatment was required .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3618,
    "text": "Intraplatelet cAMP content was gradually but significantly increased to 9 . 84 + / - 4 . 59 pmol per 10 ( 9 ) platelets at day 14 in comparison with the initial value ( 6 . 87 + / - 2 . 25 pmol ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "cAMP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3619,
    "text": "The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3620,
    "text": "In conclusion , the combined administration of BPT / CLZ is safe at doses used in the study , though the beneficial clinical effect of the combined administration has yet to be elucidated .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "BPT"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "CLZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3621,
    "text": "Pravastatin - associated myopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Pravastatin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3622,
    "text": "Report of a case .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3623,
    "text": "A case of acute inflammatory myopathy associated with the use of pravastatin , a new hydrophilic 3 - hydroxy - 3 methylglutaril coenzyme A reductase inhibitor , is reported .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "inflammatory myopathy"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "pravastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3624,
    "text": "The patient , a 69 - year - old man was affected by non - insulin - dependent diabetes mellitus and hypertension .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        20,
        "non - insulin - dependent diabetes mellitus"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3625,
    "text": "He assumed pravastatin ( 20 mg / day ) because of hypercholesterolemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "pravastatin"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hypercholesterolemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3626,
    "text": "He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "myopathy"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "pravastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3627,
    "text": "A previously unknown hypothyroidism , probably due to chronic autoimmune thyroiditis , was evidenced .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "autoimmune thyroiditis"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hypothyroidism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3628,
    "text": "Muscle biopsy ( left gastrocnemius ) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4 + lymphocytes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3629,
    "text": "While lovastatin and simvastatin have been associated with toxic myopathy , pravastatin - associated myopathy could represent a distinct , inflammatory entity .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "lovastatin"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "simvastatin"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "myopathy"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "pravastatin"
      ],
      [
        "T4",
        "Disease",
        14,
        15,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3630,
    "text": "Reversal of ammonia coma in rats by L - dopa : a peripheral effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "L - dopa"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "ammonia"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "coma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3631,
    "text": "Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1 . 7 mmol NH4CL .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ammonia"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "coma"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "NH4CL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3632,
    "text": "This coma was prevented with 1 . 68 mmol L - dopa given by gastric intubation 15 minutes before the ammonium salt injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "L - dopa"
      ],
      [
        "T1",
        "Chemical",
        20,
        22,
        "ammonium salt"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "coma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3633,
    "text": "The effect of L - dopa was correlated with a decrease in blood and brain ammonia , an increase in brain dopamine , and an increase in renal excretion of ammonia and urea .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "L - dopa"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "ammonia"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "dopamine"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "ammonia"
      ],
      [
        "T4",
        "Chemical",
        32,
        33,
        "urea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3634,
    "text": "Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "dopamine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "dopamine"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "ammonia"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "coma"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "ammonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3635,
    "text": "Bilateral nephrectomy eliminated the beneficial effect of L - dopa on blood and brain ammonia and the ammonia coma was not prevented .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "L - dopa"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "ammonia"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "ammonia"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "coma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3636,
    "text": "Thus , the reduction in blood and brain ammonia and the prevention of ammonia coma after L - dopa , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "L - dopa"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "ammonia"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "ammonia"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "coma"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3637,
    "text": "These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L - dopa .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "L - dopa"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "encephalopathic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3638,
    "text": "Etoposide - related myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Etoposide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3639,
    "text": "The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide , in a man with no risk factors for coronary heart disease .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "myocardial infarction"
      ],
      [
        "T1",
        "Disease",
        21,
        24,
        "coronary heart disease"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "etoposide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3640,
    "text": "Possible causal mechanisms are discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3641,
    "text": "Halogenated anesthetics form liver adducts and antigens that cross - react with halothane - induced antibodies .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "halothane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3642,
    "text": "Two halogenated anesthetics , enflurane and isoflurane , have been associated with an allergic - type hepatic injury both alone and following previous exposure to halothane .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "hepatic injury"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "enflurane"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "isoflurane"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "halothane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3643,
    "text": "Halothane hepatitis appears to involve an aberrant immune response .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Halothane"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3644,
    "text": "An antibody response to a protein - bound biotransformation product ( trifluoroacetyl adduct ) has been detected on halothane hepatitis patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "trifluoroacetyl"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "halothane"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3645,
    "text": "This study was performed to determine cross - reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "enflurane"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "isoflurane"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "hypersensitivity"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "halothane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3646,
    "text": "The subcellular and lobular production of hepatic neoantigens recognized by halothane - induced antibodies following enflurane and isoflurane , and the biochemical nature of these neoantigens was investigated in two animal models .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "halothane"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "enflurane"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3647,
    "text": "Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Enflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3648,
    "text": "In the same liver , biochemical analysis detected fluorinated liver adducts that were up to 20 - fold greater in guinea pigs than in rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3649,
    "text": "This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "enflurane"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "isoflurane"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "hypersensitivity"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "halothane"
      ],
      [
        "T4",
        "Disease",
        26,
        27,
        "hepatitis"
      ],
      [
        "T5",
        "Chemical",
        32,
        33,
        "halothane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3650,
    "text": "The guinea pig would appear to be a useful model for further investigations of the immunological response to these antigens .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3651,
    "text": "Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "echothiophate iodide"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3652,
    "text": "A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops , presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "echothiophate iodide"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "muscle weakness"
      ],
      [
        "T2",
        "Disease",
        28,
        30,
        "myasthenia gravis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3653,
    "text": "Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3654,
    "text": "Seizure after flumazenil administration in a pediatric patient .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Seizure"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3655,
    "text": "Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "respiratory depression"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Flumazenil"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "benzodiazepine"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "benzodiazepines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3656,
    "text": "Seizures and cardiac arrhythmias have complicated its use in adult patients .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "cardiac arrhythmias"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3657,
    "text": "Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3658,
    "text": "Little information exists concerning adverse effects of flumazenil in children .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3659,
    "text": "We report the occurrence of a generalized tonic - clonic seizure in a pediatric patient following the administration of flumazenil .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "tonic - clonic seizure"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3660,
    "text": "Phase I trial of 13 - cis - retinoic acid in children with neuroblastoma following bone marrow transplantation .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        10,
        "13 - cis - retinoic acid"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "neuroblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3661,
    "text": "PURPOSE : Treatment of neuroblastoma cell lines with 13 - cis - retinoic acid ( cis - RA ) can cause sustained inhibition of proliferation .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        14,
        "13 - cis - retinoic acid"
      ],
      [
        "T1",
        "Chemical",
        15,
        18,
        "cis - RA"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "neuroblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3662,
    "text": "Since cis - RA has demonstrated clinical responses in neuroblastoma patients , it may be effective in preventing relapse after cytotoxic therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        4,
        "cis - RA"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "neuroblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3663,
    "text": "This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ) , toxicities , and pharmacokinetics of cis - RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation ( BMT ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        25,
        "cis - RA"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "toxicities"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "neuroblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3664,
    "text": "PATIENTS AND METHODS : Fifty - one assessable patients , 2 to 12 years of age , were treated with oral cis - RA administered in two equally divided doses daily for 2 weeks , followed by a 2 - week rest period , for up to 12 courses .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        24,
        "cis - RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3665,
    "text": "The dose was escalated from 100 to 200 mg / m2 / d until dose - limiting toxicity ( DLT ) was observed .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3666,
    "text": "A single intrapatient dose escalation was permitted .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3667,
    "text": "RESULTS : The MTD of cis - RA was 160 mg / m2 / d .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "cis - RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3668,
    "text": "Dose - limiting toxicities in six of nine patients at 200 mg / m2 / d included hypercalcemia ( n = 3 ) , rash ( n = 2 ) , and anemia / thrombocytopenia / emesis / rash ( n = 1 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "toxicities"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "hypercalcemia"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "rash"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "anemia"
      ],
      [
        "T4",
        "Disease",
        34,
        35,
        "thrombocytopenia"
      ],
      [
        "T5",
        "Disease",
        36,
        37,
        "emesis"
      ],
      [
        "T6",
        "Disease",
        38,
        39,
        "rash"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3669,
    "text": "All toxicities resolved after cis - RA was discontinued .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "cis - RA"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "toxicities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3670,
    "text": "Three complete responses were observed in marrow metastases .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "metastases"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3671,
    "text": "Serum levels of 7 . 4 + / - 3 . 0 mumol / L ( peak ) and 4 . 0 + / - 2 . 8 mumol / L ( trough ) at the MTD were maintained during 14 days of therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3672,
    "text": "The DLT correlated with serum levels > or = 10 mumol / L .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3673,
    "text": "CONCLUSION : The MTD of cis - RA given on this intermittent schedule was 160 mg / m2 / d .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "cis - RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3674,
    "text": "Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "neuroblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3675,
    "text": "The DLT included hypercalcemia , and may be predicted by serum cis - RA levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "cis - RA"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3676,
    "text": "Monitoring of serum calcium and cis - RA levels is indicated in future trials .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "cis - RA"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3677,
    "text": "Time dependence of plasma malondialdehyde , oxypurines , and nucleosides during incomplete cerebral ischemia in the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "cerebral ischemia"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "malondialdehyde"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "oxypurines"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "nucleosides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3678,
    "text": "Incomplete cerebral ischemia ( 30 min ) was induced in the rat by bilaterally clamping the common carotid arteries .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "cerebral ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3679,
    "text": "Peripheral venous blood samples were withdrawn from the femoral vein four times ( once every 5 min ) before ischemia ( 0 time ) and 5 , 15 , and 30 min after ischemia .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "ischemia"
      ],
      [
        "T1",
        "Disease",
        33,
        34,
        "ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3680,
    "text": "Plasma extracts were analyzed by a highly sensitive high - performance liquid chromatographic method for the direct determination of malondialdehyde , oxypurines , and nucleosides .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "malondialdehyde"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "oxypurines"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "nucleosides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3681,
    "text": "During ischemia , a time - dependent increase of plasma oxypurines and nucleosides was observed .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "ischemia"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "oxypurines"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "nucleosides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3682,
    "text": "Plasma malondialdehyde , which was present in minimal amount at zero time ( 0 . 058 mumol / liter plasma ; SD 0 . 015 ) , increased after 5 min of ischemia , resulting in a fivefold increase after 30 min of carotid occlusion ( 0 . 298 mumol / liter plasma ; SD 0 . 078 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "malondialdehyde"
      ],
      [
        "T1",
        "Disease",
        32,
        33,
        "ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3683,
    "text": "Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model , one receiving 20 mg / kg b . w . of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia , the other receiving 650 micrograms / kg b . w . of the hypotensive drug nitroprusside at a flow rate of 103 microliters / min intravenously during ischemia , although in this latter group malondialdehyde was significantly higher .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "malondialdehyde"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "acetylsalicylate"
      ],
      [
        "T2",
        "Disease",
        37,
        38,
        "ischemia"
      ],
      [
        "T3",
        "Disease",
        52,
        53,
        "hypotensive"
      ],
      [
        "T4",
        "Chemical",
        54,
        55,
        "nitroprusside"
      ],
      [
        "T5",
        "Disease",
        66,
        67,
        "ischemia"
      ],
      [
        "T6",
        "Chemical",
        73,
        74,
        "malondialdehyde"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3684,
    "text": "The present data indicate that the determination of malondialdehyde , oxypurines , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "malondialdehyde"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "oxypurines"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "nucleosides"
      ],
      [
        "T3",
        "Disease",
        30,
        31,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3685,
    "text": "Acute renal toxicity of doxorubicin ( adriamycin ) - loaded cyanoacrylate nanoparticles .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "renal toxicity"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "doxorubicin"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "adriamycin"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "cyanoacrylate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3686,
    "text": "Acute doxorubicin - loaded nanoparticle ( DXNP ) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "renal toxicity"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "doxorubicin"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "glomerulonephritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3687,
    "text": "In normal rats , 2 / 6 rats given free doxorubicin ( DX ) ( 5 mg / kg ) died within one week , whereas all control animals and all rats having received free NP or DXNP survived .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "doxorubicin"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "DX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3688,
    "text": "A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "proteinuria"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "DX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3689,
    "text": "Free NP did not provoke any proteinuria .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3690,
    "text": "Two hr post - injection , DXNP was 2 . 7 times more concentrated in kidneys than free DX ( p < 0 . 025 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "DX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3691,
    "text": "In rats with immune experimental glomerulonephritis , 5 / 6 rats given DX died within 7 days , in contrast to animals treated by DXNP , NP , or untreated , which all survived .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "glomerulonephritis"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "DX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3692,
    "text": "Proteinuria appeared in all series , but was 2 - 5 times more intense ( p > 0 . 001 ) and prolonged after doxorubicin treatment ( 400 - 700 mg / day ) , without significant difference between DXNP and DX .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Proteinuria"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "doxorubicin"
      ],
      [
        "T2",
        "Chemical",
        41,
        42,
        "DX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3693,
    "text": "Rats treated by unloaded NP behaved as controls .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3694,
    "text": "These results demonstrate that , in these experimental conditions , DXNP killed less animals than free DX , despite of an enhanced renal toxicity of the former .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "renal toxicity"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "DX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3695,
    "text": "Both effects ( better survival and nephrosis ) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system , including mesangial cells .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "nephrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3696,
    "text": "Prostaglandin E2 - induced bladder hyperactivity in normal , conscious rats : involvement of tachykinins ?",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Prostaglandin E2"
      ],
      [
        "T1",
        "Disease",
        4,
        6,
        "bladder hyperactivity"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "tachykinins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3697,
    "text": "In normal conscious rats investigated by continuous cystometry , intravesically instilled prostaglandin ( PG ) E2 facilitated micturition and increased basal intravesical pressure .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        16,
        "prostaglandin ( PG ) E2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3698,
    "text": "The effect was attenuated by both the NK1 receptor selective antagonist RP 67 , 580 and the NK2 receptor selective antagonist SR 48 , 968 , given intra - arterially , suggesting that it was mediated by stimulation of both NK1 and NK2 receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        15,
        "RP 67 , 580"
      ],
      [
        "T1",
        "Chemical",
        21,
        25,
        "SR 48 , 968"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3699,
    "text": "Intra - arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex , indicating that the PG had a direct contractant effect on the detrusor smooth muscle .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "PGE2"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "PG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3700,
    "text": "The effect of intra - arterial PGE2 could not be blocked by intra - arterial RP 67 , 580 or SR 48 , 968 , which opens the possibility that the micturition reflex elicited by intra - arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        19,
        "RP 67 , 580"
      ],
      [
        "T1",
        "Chemical",
        20,
        24,
        "SR 48 , 968"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "PGE2"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "PGE2"
      ],
      [
        "T4",
        "Chemical",
        50,
        51,
        "PG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3701,
    "text": "The present results thus suggest that intra - arterial PGE2 , given near the bladder , may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "PGE2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3702,
    "text": "However , when given intravesically , PGE2 may stimulate micturition by releasing tachykinins from nerves in and / or immediately below the urothelium .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "PGE2"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "tachykinins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3703,
    "text": "These tachykinins , in turn , initiate a micturition reflex by stimulating NK1 and NK2 receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "tachykinins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3704,
    "text": "Prostanoids may , via release of tachykinins , contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "bladder hyperactivity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Prostanoids"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "tachykinins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3705,
    "text": "Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "cardiogenic shock"
      ],
      [
        "T1",
        "Disease",
        5,
        7,
        "heart block"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "verapamil"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3706,
    "text": "A case report .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3707,
    "text": "A seventy - eight - year - old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained - release verapamil with concomitant use of metoprolol .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "heart block"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "verapamil"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3708,
    "text": "The patient continued to remain hypotensive with complete heart block , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "heart block"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hypotensive"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "atropine"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "dopamine"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3709,
    "text": "However , shortly after the use of intravenous calcium chloride , the refractory hypotension and complete heart block resolved .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "calcium chloride"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "heart block"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3710,
    "text": "Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "renal dysfunction"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "misoprostol"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3711,
    "text": "OBJECTIVE : To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "misoprostol"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3712,
    "text": "METHODS : Forty - five hospitalized elderly patients ( > 65 years old ) who required therapy with nonsteroidal antiinflammatory drugs ( NSAID ) were randomly assigned to receive either indomethacin , 150 mg / day ( Group A ) , or indomethacin 150 mg / day plus misoprostol at 0 . 6 mg / day ( Group B ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        31,
        "indomethacin"
      ],
      [
        "T1",
        "Chemical",
        42,
        43,
        "indomethacin"
      ],
      [
        "T2",
        "Chemical",
        48,
        49,
        "misoprostol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3713,
    "text": "Laboratory variables of renal function [ serum creatinine , blood urea nitrogen ( BUN ) and electrolytes ] were evaluated before initiation of therapy and every 2 days , until termination of the study ( a period of at least 6 days ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "blood urea nitrogen"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "creatinine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "BUN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3714,
    "text": "Response to treatment was estimated by the visual analog scale for severity of pain .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3715,
    "text": "RESULTS : Forty - two patients completed the study , 22 in Group A and 20 in Group B .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3716,
    "text": "BUN and creatinine increased by > 50 % of baseline levels in 54 and 45 % of Group A patients , respectively , compared to only 20 and 10 % of Group B patients ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "BUN"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3717,
    "text": "Potassium ( K ) increment of 0 . 6 mEq / l or more was observed in 50 % of Group A , but in only 15 % of Group B patients ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Potassium"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "K"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3718,
    "text": "The mean increments in BUN , creatinine , and K were reduced by 63 , 80 , and 42 % , respectively , in Group B patients compared to Group A . Response to treatment did not differ significantly between the 2 groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "BUN"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "creatinine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "K"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3719,
    "text": "CONCLUSION : Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "renal dysfunction"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3720,
    "text": "Addition of misoprostol can minimize this renal impairment without affecting pain control .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "renal impairment"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "misoprostol"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3721,
    "text": "Cognitive deterioration from long - term abuse of dextromethorphan : a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cognitive deterioration"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "dextromethorphan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3722,
    "text": "Dextromethorphan ( DM ) , the dextrorotatory isomer of 3 - hydroxy - N - methylmorphinan , is the main ingredient in a number of widely available , over - the - counter antitussives .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        16,
        "3 - hydroxy - N - methylmorphinan"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Dextromethorphan"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "DM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3723,
    "text": "Initial studies ( Bornstein 1968 ) showed that it possessed no respiratory suppressant effects and no addiction liability .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3724,
    "text": "Subsequently , however , several articles reporting abuse of this drug have appeared in the literature .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3725,
    "text": "The drug is known to cause a variety of acute toxic effects , ranging from nausea , restlessness , insomnia , ataxia , slurred speech and nystagmus to mood changes , perceptual alterations , inattention , disorientation and aggressive behavior ( Rammer et al 1988 ; Katona and Watson 1986 ; Isbell and Fraser 1953 ; Devlin et al 1985 ; McCarthy 1971 ; Dodds and Revai 1967 ; Degkwitz 1964 ; Hildebrand et al 1989 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        38,
        40,
        "aggressive behavior"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "nausea"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "restlessness"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "insomnia"
      ],
      [
        "T4",
        "Disease",
        21,
        22,
        "ataxia"
      ],
      [
        "T5",
        "Disease",
        26,
        27,
        "nystagmus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3726,
    "text": "There have also been two reported fatalities from DM overdoses ( Fleming 1986 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "DM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3727,
    "text": "However , there are no reports describing the effects of chronic abuse .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3728,
    "text": "This report describes a case of cognitive deterioration resulting from prolonged use of DM .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "cognitive deterioration"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "DM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3729,
    "text": "Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "coronary artery disease"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "ouabain"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3730,
    "text": "A hemodynamic , volumetric , and metabolic study in patients without heart failure .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3731,
    "text": "The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease , but have not been measured previously in man .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "digitalis glycosides"
      ],
      [
        "T1",
        "Disease",
        20,
        23,
        "coronary artery disease"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3732,
    "text": "We assessed the effects of ouabain ( 0 . 015 mg / kg body weight ) on hemodynamic , volumetric , and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        33,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        35,
        38,
        "congestive heart failure"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3733,
    "text": "Because the protocol was long and involved interventions which might affect the determinations , we also studied in nine patients using an identical protocol except that ouabain administration was omitted .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3734,
    "text": "Left ventricular end - diastolic pressure and left ventricular end - diastolic volume fell in each patient given ouabain , even though they were initially elevated in only two patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3735,
    "text": "Left ventricular end - diastolic pressure fell from 11 . 5 + / - 1 . 4 ( mean + / - SE ) to 5 . 6 + / - 0 . 9 mm Hg ( P less than 0 . 001 ) and left ventricular end - diastolic volume fell from 100 + / - 17 to 82 + / - 12 ml / m2 ( P less than 0 . 01 ) 1 h after ouabain infusion was completed .",
    "labels": [
      [
        "T0",
        "Chemical",
        78,
        79,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3736,
    "text": "The maximum velocity of contractile element shortening increased from 1 . 68 + / - 0 . 11 ml / s to 2 . 18 + / - 0 . 21 muscle - lengths / s ( P less than 0 . 05 ) and is consistent with an increase in contractility .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3737,
    "text": "No significant change in these parameters occurred in the control patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3738,
    "text": "No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "oxygen"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "ouabain"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3739,
    "text": "We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end - diastolic volume falls after ouabain administration even when it is initially normal .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        15,
        18,
        "congestive heart failure"
      ],
      [
        "T2",
        "Disease",
        18,
        25,
        "left ventricular end - diastolic volume falls"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3740,
    "text": "Though this fall would be associated with a decrease in wall tension , and , therefore , of myocardial oxygen consumption , it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "oxygen"
      ],
      [
        "T1",
        "Chemical",
        36,
        37,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3741,
    "text": "Nevertheless , compensatory mechanisms prevent a deterioration of resting myocardial metabolism .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3742,
    "text": "Dexamethasone - induced ocular hypertension in perfusion - cultured human eyes .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "ocular hypertension"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3743,
    "text": "PURPOSE : Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "ocular hypertension"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "corticosteroid glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3744,
    "text": "The purpose of this study was to determine whether glucocorticoid treatment can directly affect the outflow facility of isolated , perfusion - cultured human eyes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3745,
    "text": "METHODS : The anterior segments of human donor eyes from regional eye banks were placed in a constant flow , variable pressure perfusion culture system .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3746,
    "text": "Paired eyes were perfused in serum - free media with or without 10 ( - 7 ) M dexamethasone for 12 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3747,
    "text": "Intraocular pressure was monitored daily .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3748,
    "text": "After incubation , the eyes were morphologically characterized by light microscopy , transmission and scanning electron microscopy , and scanning laser confocal microscopy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3749,
    "text": "RESULTS : A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17 . 5 + / - 3 . 8 mm Hg after 12 days of dexamethasone exposure .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "dexamethasone"
      ],
      [
        "T1",
        "Chemical",
        41,
        42,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3750,
    "text": "The contralateral control eyes , which did not receive dexamethasone , maintained a stable intraocular pressure during the same period .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3751,
    "text": "The outflow pathway of the untreated eyes appeared morphologically normal .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3752,
    "text": "In contrast , the dexamethasone - treated hypertensive eyes had thickened trabecular beams , decreased intertrabecular spaces , thickened juxtacanalicular tissue , activated trabecular meshwork cells , and increased amounts of amorphogranular extracellular material , especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "hypertensive eyes"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3753,
    "text": "The dexamethasone - treated nonresponder eyes appeared to be morphologically similar to the untreated eyes , although several subtle dexamethasone - induced morphologic changes were evident .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "dexamethasone"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3754,
    "text": "CONCLUSION : Dexamethasone treatment of isolated , perfusion - cultured human eyes led to the generation of ocular hypertension in approximately 30 % of the dexamethasone - treated eyes .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "ocular hypertension"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Dexamethasone"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3755,
    "text": "Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "corticosteroid glaucoma"
      ],
      [
        "T1",
        "Disease",
        18,
        21,
        "open angle glaucoma"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3756,
    "text": "This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "steroid glaucoma"
      ],
      [
        "T1",
        "Disease",
        19,
        23,
        "primary open angle glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3757,
    "text": "Auditory disturbance associated with interscalene brachial plexus block .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3758,
    "text": "We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block ( IBPB ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3759,
    "text": "Bupivacaine 0 . 75 % with adrenaline was given followed by a 24 - hr continuous infusion of 0 . 25 % bupivacaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "adrenaline"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3760,
    "text": "Three audiometric threshold measurements ( 0 . 25 - 18 kHz ) were made : the first before IBPB , the second 2 - 6 h after surgery and the third on the first day after operation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3761,
    "text": "In four patients hearing impairment on the side of the block was demonstrated after operation , in three measurements on the day of surgery and in one on the following day .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hearing impairment"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3762,
    "text": "The frequencies at which the impairment occurred varied between patients ; in one only low frequencies ( 0 . 25 - 0 . 5 kHz ) were involved .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3763,
    "text": "The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3764,
    "text": "This patient had hearing threshold changes ( 15 - 20 dB ) at 6 - 10 kHz on the opposite side also .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3765,
    "text": "IBPB may cause transient auditory dysfunction in the ipsilateral ear , possibly via an effect on sympathetic innervation .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "auditory dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3766,
    "text": "The safety and efficacy of combination N - butyl - deoxynojirimycin ( SC - 48334 ) and zidovudine in patients with HIV - 1 infection and 200 - 500 CD4 cells / mm3 .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        11,
        "N - butyl - deoxynojirimycin"
      ],
      [
        "T1",
        "Chemical",
        12,
        15,
        "SC - 48334"
      ],
      [
        "T2",
        "Disease",
        21,
        25,
        "HIV - 1 infection"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "zidovudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3767,
    "text": "We conducted a double - blind , randomized phase II study to evaluate the safety and activity of combination therapy with N - butyl - deoxynojirimycin ( SC - 48334 ) ( an alpha - glucosidase I inhibitor ) and zidovudine versus zidovudine alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        26,
        "N - butyl - deoxynojirimycin"
      ],
      [
        "T1",
        "Chemical",
        27,
        30,
        "SC - 48334"
      ],
      [
        "T2",
        "Chemical",
        40,
        41,
        "zidovudine"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "zidovudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3768,
    "text": "Patients with 200 to 500 CD4 cells / mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC - 48334 ( 1000 mg every 8 h ) and zidovudine ( 100 mg every 8 h ) or zidovudine and placebo .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        24,
        "SC - 48334"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "zidovudine"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "zidovudine"
      ],
      [
        "T3",
        "Chemical",
        41,
        42,
        "zidovudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3769,
    "text": "Sixty patients received combination therapy and 58 , zidovudine and placebo .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "zidovudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3770,
    "text": "Twenty - three patients ( 38 % ) and 15 ( 26 % ) , in the combination and zidovudine groups , respectively , discontinued therapy ( p = 0 . 15 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "zidovudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3771,
    "text": "The mean SC - 48334 steady - state trough level ( 4 . 04 + / - 0 . 99 micrograms / ml ) was below the in vitro inhibitory concentration for human immunodeficiency virus ( HIV ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "SC - 48334"
      ],
      [
        "T1",
        "Disease",
        33,
        34,
        "immunodeficiency"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3772,
    "text": "The mean increase in CD4 cells at week 4 was 73 . 8 cells / mm3 and 52 . 4 cells / mm3 for the combination and zidovudine groups , respectively ( p > 0 . 36 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        28,
        "zidovudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3773,
    "text": "For patients with prior zidovudine therapy , the mean change in CD4 cells in the combination and zidovudine groups was 63 . 7 cells / mm3 and 4 . 9 cells / mm3 at week 8 and 6 . 8 cells / mm3 and - 45 . 1 cells / mm3 at week 16 , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "zidovudine"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "zidovudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3774,
    "text": "The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six ( 40 % ) and two ( 11 % ) at week 4 ( p = 0 . 10 ) and five ( 45 % ) and two ( 14 % ) at week 24 ( p = 0 . 08 ) , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "zidovudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3775,
    "text": "Diarrhea , flatulence , abdominal pain , and weight loss were common for combination recipients . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "abdominal pain"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "weight loss"
      ],
      [
        "T2",
        "Disease",
        0,
        1,
        "Diarrhea"
      ],
      [
        "T3",
        "Disease",
        2,
        3,
        "flatulence"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3776,
    "text": "Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        8,
        "nondepolarizing neuromuscular blocking agents"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "paralysis"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "corticosteroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3777,
    "text": "The long - term use of nondepolarizing neuromuscular blocking agents ( ND - NMBA ) has recently been implicated as a cause of prolonged muscle weakness , although the site of the lesion and the predisposing factors have been unclear .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        10,
        "nondepolarizing neuromuscular blocking agents"
      ],
      [
        "T1",
        "Chemical",
        11,
        14,
        "ND - NMBA"
      ],
      [
        "T2",
        "Disease",
        24,
        26,
        "muscle weakness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3778,
    "text": "We report 3 patients ( age 37 - 52 years ) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND - NMBAs .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "respiratory insufficiency"
      ],
      [
        "T1",
        "Chemical",
        23,
        26,
        "ND - NMBAs"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "weakness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3779,
    "text": "Two patients also received intravenous corticosteroids .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "corticosteroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3780,
    "text": "Renal function was normal but hepatic function was impaired in all patients , and all had acidosis .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "acidosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3781,
    "text": "Electrophysiologic studies revealed low amplitude compound motor action potentials , normal sensory studies , and fibrillations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3782,
    "text": "Repetitive stimulation at 2 Hz showed a decremental response in 2 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3783,
    "text": "The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng / mL .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "vecuronium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3784,
    "text": "A muscle biopsy in this patient showed loss of thick , myosin filaments .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        13,
        "loss of thick , myosin filaments"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3785,
    "text": "The weakness in these patients is due to pathology at both the neuromuscular junction ( most likely due to ND - NMBA ) and muscle ( most likely due to corticosteroids ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        14,
        "pathology at both the neuromuscular junction"
      ],
      [
        "T1",
        "Chemical",
        19,
        22,
        "ND - NMBA"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "weakness"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "corticosteroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3786,
    "text": "Hepatic dysfunction and acidosis are contributing risk factors .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hepatic dysfunction"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "acidosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3787,
    "text": "Failure of ancrod in the treatment of heparin - induced arterial thrombosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3788,
    "text": "The morbidity and mortality associated with heparin - induced thrombosis remain high despite numerous empirical therapies .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3789,
    "text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin , but its success in patients who have developed the thrombosis syndrome is not well defined .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "platelet aggregation"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "thrombosis"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "heparin"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "heparin"
      ],
      [
        "T4",
        "Disease",
        34,
        35,
        "thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3790,
    "text": "The authors present a case of failure of ancrod treatment in a patient with heparin - induced thrombosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3791,
    "text": "Water intoxication associated with oxytocin administration during saline - induced abortion .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Water intoxication"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "oxytocin"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "abortion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3792,
    "text": "Four cases of water intoxication in connection with oxytocin administration during saline - induced abortions are described .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "water intoxication"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "oxytocin"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "abortions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3793,
    "text": "The mechanism of water intoxication is discussed in regard to these cases .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "water intoxication"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3794,
    "text": "Oxytocin administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular irritability , or headaches .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        32,
        "water intoxication"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Oxytocin"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "abortions"
      ],
      [
        "T3",
        "Disease",
        47,
        48,
        "asthenia"
      ],
      [
        "T4",
        "Disease",
        50,
        51,
        "irritability"
      ],
      [
        "T5",
        "Disease",
        53,
        54,
        "headaches"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3795,
    "text": "The oxytocin should be given only in Ringers lactate or , alternately , in Ringers lactate and a 5 per cent dextrose and water solutions .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "oxytocin"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "lactate"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "lactate"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "dextrose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3796,
    "text": "The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "oxytocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3797,
    "text": "The oxytocin should not be administered in excess of 36 hours .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "oxytocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3798,
    "text": "If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "oxytocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3799,
    "text": "Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "proteinuria"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "rifampin"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "tuberculosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3800,
    "text": "Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "proteinuria"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "tuberculosis"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "rifampin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3801,
    "text": "Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3802,
    "text": "Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested , but there occurred a hyper - responsiveness of the lymphocytes of these eight patients to phytomitogen ( PHA - P ) . as well as of those of seven other tuberculous patients .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "tuberculosis"
      ],
      [
        "T1",
        "Disease",
        45,
        46,
        "tuberculous"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3803,
    "text": "This last finding may be related to time of testing and / or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "rifampin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3804,
    "text": "KF17837 : a novel selective adenosine A2A receptor antagonist with anticataleptic activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "KF17837"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3805,
    "text": "KF17837 is a novel selective adenosine A2A receptor antagonist .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "KF17837"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3806,
    "text": "Oral administration of KF17837 ( 2 . 5 , 10 . 0 and 30 . 0 mg / kg ) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist , CGS 21680 ( 10 micrograms ) , in a dose - dependent manner .",
    "labels": [
      [
        "T0",
        "Chemical",
        36,
        38,
        "CGS 21680"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "KF17837"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "cataleptic"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3807,
    "text": "KF17837 also reduced the catalepsy induced by haloperidol ( 1 mg / kg i . p . ) and by reserpine ( 5 mg / kg i . p . ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "KF17837"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "haloperidol"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "reserpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3808,
    "text": "These anticataleptic effects were exhibited dose dependently at doses from 0 . 625 and 2 . 5 mg / kg p . o . , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3809,
    "text": "Moreover , KF17837 ( 0 . 625 mg / kg p . o . ) potentiated the anticataleptic effects of a subthreshold dose of L - 3 , 4 - dihydroxyphenylalanine ( L - DOPA ; 25 mg / kg i . p . ) plus benserazide ( 6 . 25 mg / kg i . p . ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        31,
        "L - 3 , 4 - dihydroxyphenylalanine"
      ],
      [
        "T1",
        "Chemical",
        32,
        35,
        "L - DOPA"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "KF17837"
      ],
      [
        "T3",
        "Chemical",
        46,
        47,
        "benserazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3810,
    "text": "These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "KF17837"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "adenosine"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3811,
    "text": "Furthermore , KF17837 may be a useful drug in the treatment of parkinsonism .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "KF17837"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "parkinsonism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3812,
    "text": "Effect of nondopaminergic drugs on L - dopa - induced dyskinesias in MPTP - treated monkeys .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "L - dopa"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "dyskinesias"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "MPTP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3813,
    "text": "A group of four monkeys was rendered parkinsonian with the toxin MPTP .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "parkinsonian"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "MPTP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3814,
    "text": "They were then treated chronically with L - DOPA / benserazide 50 / 12 . 5 mg / kg given orally daily for 2 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        11,
        "L - DOPA / benserazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3815,
    "text": "This dose produced a striking antiparkinsonian effect , but all animals manifested dyskinesia .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3816,
    "text": "A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L - DOPA to see if the dyskinetic movements would be modified .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        20,
        "L - DOPA"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "dopamine"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "dyskinetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3817,
    "text": "Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        13,
        "5 - MDOT"
      ],
      [
        "T1",
        "Chemical",
        17,
        20,
        "MK - 801"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "clonidine"
      ],
      [
        "T3",
        "Chemical",
        6,
        7,
        "physostigmine"
      ],
      [
        "T4",
        "Chemical",
        8,
        9,
        "methysergide"
      ],
      [
        "T5",
        "Chemical",
        14,
        15,
        "propranolol"
      ],
      [
        "T6",
        "Disease",
        24,
        25,
        "dyskinetic"
      ],
      [
        "T7",
        "Disease",
        34,
        35,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3818,
    "text": "However , yohimbine and meperidine reduced predominantly the dyskinetic movements .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "yohimbine"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "meperidine"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "dyskinetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3819,
    "text": "Baclofen was also useful in one monkey against a more dystonic form of dyskinesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Baclofen"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "dystonic"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3820,
    "text": "Atropine converted the dystonic movements into chorea .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Atropine"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "dystonic"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "chorea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3821,
    "text": "Hallucinations and ifosfamide - induced neurotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hallucinations"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "ifosfamide"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3822,
    "text": "BACKGROUND : Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Hallucinations"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "neurotoxicity"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "ifosfamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3823,
    "text": "Most cases of ifosfamide - induced hallucinations have been reported with other mental status changes .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "ifosfamide"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hallucinations"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3824,
    "text": "METHODS : The authors interviewed six persons with ifosfamide - induced hallucinations in the presence of a clear sensorium .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "ifosfamide"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hallucinations"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3825,
    "text": "All patients were receiving high - dose ifosfamide as part of their bone marrow transplant procedure .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "ifosfamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3826,
    "text": "RESULTS : Hallucinations occurred only when the patient ' s eyes were closed and , in all but one case , were reported as disturbing or frightening .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Hallucinations"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3827,
    "text": "Underreporting of these hallucinations by patients is likely .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hallucinations"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3828,
    "text": "CONCLUSIONS : Hallucinations may be the sole or first manifestation of neurotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Hallucinations"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3829,
    "text": "The incidence may be dose and infusion - time related .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3830,
    "text": "The clinician should be alerted for possible ifosfamide - induced hallucinations , which may occur without other signs of neurotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "ifosfamide"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hallucinations"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3831,
    "text": "\" Eyes - closed \" hallucinatory experiences appear to be an unusual feature of this presentation .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hallucinatory"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3832,
    "text": "Patients anxious about this experience respond well to support and education about this occurrence .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3833,
    "text": "Optimal pharmacologic management of disturbed patients is unclear .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3834,
    "text": "If agitation becomes marked , high - potency neuroleptics ( i . e . , haloperidol ) may be effective .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "agitation"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3835,
    "text": "Photodistributed nifedipine - induced facial telangiectasia .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "nifedipine"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "telangiectasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3836,
    "text": "Five months after starting nifedipine ( Adalat ) , two patients developed photodistributed facial telangiectasia , which became more noticeable with time .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "nifedipine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "Adalat"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "telangiectasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3837,
    "text": "Neither patient complained of photosensitivity or flushing .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "flushing"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3838,
    "text": "Both patients reported a significant cosmetic improvement after discontinuing the drug .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3839,
    "text": "One commenced the closely related drug amlodipine 3 years later , with recurrence of telangiectasia .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "amlodipine"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "telangiectasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3840,
    "text": "The photodistribution of the telangiectasia suggests a significant drug / light interaction .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "telangiectasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3841,
    "text": "Penicillamine - induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Penicillamine"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "glomerulonephritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3842,
    "text": "A 67 - year - old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis ( RPGN ) after 5 months of D - penicillamine ( 250 mg / day ) treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        21,
        24,
        "D - penicillamine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "glomerulonephritis"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "RPGN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3843,
    "text": "Light microscopy study showed severe glomerulonephritis with crescent formation in 60 % of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "glomerulonephritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3844,
    "text": "Immunofluorescence revealed scanty granular IgG , IgA and C3 deposits along the capillary walls and mesangium .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3845,
    "text": "The patient was treated with steroid pulse , plasmapheresis , cyclophosphamide and antiplatelet agents .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "antiplatelet agents"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "steroid"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3846,
    "text": "A complete recovery of renal function was achieved in a few weeks .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3847,
    "text": "This new case of RPGN in the course of D - penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "D - penicillamine"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "RPGN"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3848,
    "text": "The prompt discontinuation of D - penicillamine and vigorous treatment measures could allow for a good prognosis as in this case .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "D - penicillamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3849,
    "text": "A case of polymyositis in a patient with primary biliary cirrhosis treated with D - penicillamine .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "primary biliary cirrhosis"
      ],
      [
        "T1",
        "Chemical",
        13,
        16,
        "D - penicillamine"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "polymyositis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3850,
    "text": "Although D - penicillamine has been used for many rheumatologic diseases , toxicity limits its usefulness in many patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        4,
        "D - penicillamine"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "rheumatologic diseases"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3851,
    "text": "Polymyositis / dermatomyositis can develop as one of the autoimmune complications of D - penicillamine treatment , but its exact pathogenesis remains unclear .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        15,
        "D - penicillamine"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Polymyositis"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "dermatomyositis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3852,
    "text": "We report a patient with primary biliary cirrhosis , who developed polymyositis while receiving D - penicillamine therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "primary biliary cirrhosis"
      ],
      [
        "T1",
        "Chemical",
        14,
        17,
        "D - penicillamine"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "polymyositis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3853,
    "text": "We described the special clinical course of the patient .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3854,
    "text": "Patients receiving D - penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis / dermatomyositis .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "D - penicillamine"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "polymyositis"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "dermatomyositis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3855,
    "text": "Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hyperalgesia"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "myoclonus"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "cancer"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3856,
    "text": "Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "cancer"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "morphine"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "hyperalgesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3857,
    "text": "All cases were retrospectively sampled from three different hospitals in Copenhagen .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3858,
    "text": "Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hyperalgesia"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hyperesthesia"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "myoclonus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3859,
    "text": "In 3 patients a pre - existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "neuralgia"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "myoclonus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3860,
    "text": "Although only few clinical descriptions of the relationship between hyperalgesia / myoclonus and high doses of morphine are available , experimental support from animal studies indicates that morphine , or its metabolites , plays a causative role for the observed behavioural syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "hyperalgesia"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "myoclonus"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "morphine"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3861,
    "text": "The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3862,
    "text": "Liposomal daunorubicin in advanced Kaposi ' s sarcoma : a phase II study .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        8,
        "Kaposi ' s sarcoma"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "daunorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3863,
    "text": "We report a non - randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin ( DaunoXome ) in the treatment of AIDS related Kaposi ' s sarcoma .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        32,
        "Kaposi ' s sarcoma"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "daunorubicin"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "AIDS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3864,
    "text": "Eleven homosexual men with advanced Kaposi ' s sarcoma were entered in the trial .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "Kaposi ' s sarcoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3865,
    "text": "Changes in size , colour and associated oedema of selected ' target ' lesions were measured .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "oedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3866,
    "text": "Clinical , biochemical and haematological toxicities were assessed .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "toxicities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3867,
    "text": "Ten subjects were evaluated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3868,
    "text": "A partial response was achieved in four , of whom two subsequently relapsed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3869,
    "text": "Stabilization of Kaposi ' s sarcoma occurred in the remaining six , maintained until the end of the trial period in four .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        6,
        "Kaposi ' s sarcoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3870,
    "text": "The drug was generally well tolerated , with few mild symptoms of toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3871,
    "text": "The main problem encountered was haematological toxicity , with three subjects experiencing severe neutropenia ( neutrophil count < 0 . 5 x 10 ( 9 ) / l ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "toxicity"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3872,
    "text": "There was no evidence of cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3873,
    "text": "In this small patient sample , liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi ' s sarcoma .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        23,
        "Kaposi ' s sarcoma"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "daunorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3874,
    "text": "Long - term effects of vincristine on the peripheral nervous system .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3875,
    "text": "Forty patients with Non - Hodgkin ' s Lymphoma treated with vincristine between 1984 and 1990 ( cumulative dose 12 mg in 18 - 24 weeks ) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        9,
        "Non - Hodgkin ' s Lymphoma"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "vincristine"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3876,
    "text": "The patients were interviewed with emphasis on neuropathic symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "neuropathic symptoms"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3877,
    "text": "Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed , four to 77 months ( median 34 months ) after vincristine treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        28,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3878,
    "text": "Twenty - seven patients reported neuropathic symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "neuropathic symptoms"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3879,
    "text": "In 13 of these 27 patients symptoms were still present at the time of examination .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3880,
    "text": "In these patients sensory signs and symptoms predominated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3881,
    "text": "In the other 14 patients symptoms had been present in the past .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3882,
    "text": "Symptoms persisted maximally 40 months since cessation of therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3883,
    "text": "There was no age difference between patients with and without complaints at the time of examination .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3884,
    "text": "Normal reflexes were found in two third of patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3885,
    "text": "Neuropathic complaints were not very troublesome on the long term .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3886,
    "text": "It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "vincristine"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "vincristine"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3887,
    "text": "Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives : case reports .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "focal nodular hyperplasia"
      ],
      [
        "T1",
        "Chemical",
        13,
        15,
        "oral contraceptives"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "adenomas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3888,
    "text": "Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives , are reported .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "focal nodular hyperplasia"
      ],
      [
        "T1",
        "Chemical",
        17,
        19,
        "oral contraceptives"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "adenoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3889,
    "text": "Special reference is made to their clinical presentation , which may be totally asymptomatic .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3890,
    "text": "Liver - function tests are of little diagnostic value , but valuable information may be obtained from both liver scanning and hepatic angiography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3891,
    "text": "Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "focal nodular hyperplasia"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "adenoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3892,
    "text": "Loss of glutamate decarboxylase mRNA - containing neurons in the rat dentate gyrus following pilocarpine - induced seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "glutamate"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "pilocarpine"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3893,
    "text": "In situ hybridization methods were used to determine if glutamic acid decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to seizure - induced damage in a model of chronic seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "glutamic acid"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "seizure"
      ],
      [
        "T2",
        "Disease",
        38,
        39,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3894,
    "text": "Sprague - Dawley rats were injected intraperitoneally with pilocarpine , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after pilocarpine - induced seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "pilocarpine"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "pilocarpine"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3895,
    "text": "In situ hybridization histochemistry , using a digoxigenin - labeled GAD cRNA probe , demonstrated a substantial decrease in the number of GAD mRNA - containing neurons in the hilus of the dentate gyrus in the pilocarpine - treated rats as compared to controls at all time intervals .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "digoxigenin"
      ],
      [
        "T1",
        "Chemical",
        36,
        37,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3896,
    "text": "Additional neuronanatomical studies , including cresyl violet staining , neuronal degeneration methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "cresyl violet"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "neuronal degeneration"
      ],
      [
        "T2",
        "Disease",
        38,
        40,
        "neuronal loss"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3897,
    "text": "The loss of GAD mRNA - containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3898,
    "text": "Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA - containing neurons in the hilus of both groups of experimental animals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3899,
    "text": "No significant differences were found in the molecular layer or the granule cell layer , which included labeled neurons along the lower margin of the granule cell layer .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3900,
    "text": "The results indicate that , in this model , a subpopulation of GAD mRNA - containing neurons within the dentate gyrus is selectively vulnerable to seizure - induced damage .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        26,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3901,
    "text": "Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3902,
    "text": "Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "labetalol"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3903,
    "text": "The effect of deliberate hypotension on brain function measured by neuropsychological tests was studied in 41 adult patients .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3904,
    "text": "Twenty - four patients were anaesthetized for middle - ear surgery with deliberate hypotension induced by labetalol with isoflurane ( hypotensive group ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "labetalol"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "isoflurane"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "hypotensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3905,
    "text": "Seventeen patients without hypotension served as a control group .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3906,
    "text": "The mean arterial pressure was 77 + / - 2 mmHg ( 10 . 3 + / - 0 . 3 kPa ) before hypotension and 50 + / - 0 mmHg ( 6 . 7 + / - 0 . 0 kPa ) during hypotension in the hypotensive group , and 86 + / - 2 mmHg ( 11 . 5 + / - 0 . 3 kPa ) during anaesthesia in the control group .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        25,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        45,
        46,
        "hypotension"
      ],
      [
        "T2",
        "Disease",
        48,
        49,
        "hypotensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3907,
    "text": "The following psychological tests were performed : four subtests of the Wechsler Adult Intelligence Scale ( similarities , digit span , vocabulary and digit symbol ) , Trail - Making tests A and B , Zung tests ( self - rating anxiety scale and self - rating depression scale ) and two - part memory test battery with immediate and delayed recall .",
    "labels": [
      [
        "T0",
        "Disease",
        41,
        42,
        "anxiety"
      ],
      [
        "T1",
        "Disease",
        47,
        48,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3908,
    "text": "The tests were performed preoperatively and 2 days postoperatively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3909,
    "text": "There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3910,
    "text": "The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "labetalol"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3911,
    "text": "Apparent cure of rheumatoid arthritis by bone marrow transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "rheumatoid arthritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3912,
    "text": "We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis ( RA ) by bone marrow transplantation ( BMT ) in 2 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3913,
    "text": "BMT was used to treat severe aplastic anemia which was caused by gold in one case and D - penicillamine in the other .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        17,
        20,
        "D - penicillamine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "gold"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3914,
    "text": "In the 8 and 6 years since the transplants ( representing 8 and 4 years since cessation of all immunosuppressive therapy , respectively ) , the RA in each case has been completely quiescent .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        27,
        "RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3915,
    "text": "Although short term remission of severe RA following BMT has been reported , these are the first cases for which prolonged followup has been available .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "RA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3916,
    "text": "This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "synovitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3917,
    "text": "Seizures induced by combined levomepromazine - fluvoxamine treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Seizures"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "levomepromazine"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "fluvoxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3918,
    "text": "We report a case of combined levomepromazine - fluvoxamine treatment - induced seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "levomepromazine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "fluvoxamine"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3919,
    "text": "It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "fluvoxamine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "phenothiazines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3920,
    "text": "Case report : pentamidine and polymorphic ventricular tachycardia revisited .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "pentamidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3921,
    "text": "Pentamidine isethionate has been associated with ventricular tachyarrhythmias , including torsade de pointes .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Pentamidine isethionate"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "ventricular tachyarrhythmias"
      ],
      [
        "T2",
        "Disease",
        10,
        13,
        "torsade de pointes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3922,
    "text": "This article reports two cases of this complication and reviews all reported cases to date .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3923,
    "text": "Pentamidine - induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "torsade de pointes"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Pentamidine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "magnesium"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "hypomagnesemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3924,
    "text": "Torsade de pointes occurred after an average of 10 days of treatment with pentamidine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Torsade de pointes"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "pentamidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3925,
    "text": "In these patients , no other acute side effects of pentamidine were observed .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "pentamidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3926,
    "text": "Torsade de pointes can be treated when recognized early , possibly without discontinuation of pentamidine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Torsade de pointes"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "pentamidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3927,
    "text": "When QTc interval prolongation is observed , early magnesium supplementation is advocated .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "QTc interval prolongation"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "magnesium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3928,
    "text": "Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "lovastatin"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypercholesterolemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3929,
    "text": "OBJECTIVE : To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "lovastatin"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "hypercholesterolemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3930,
    "text": "DESIGN : The Expanded Clinical Evaluation of Lovastatin ( EXCEL ) Study , a multicenter , double - blind , diet - and placebo - controlled trial , in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily , or 20 or 40 mg twice daily for 48 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "Lovastatin"
      ],
      [
        "T1",
        "Chemical",
        38,
        39,
        "lovastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3931,
    "text": "SETTING : Ambulatory patients recruited by 362 participating centers throughout the United States .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3932,
    "text": "PATIENTS : Women ( n = 3390 ) from the total cohort of 8245 volunteers .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3933,
    "text": "MEASUREMENTS : Plasma total , low - density lipoprotein ( LDL ) , and high - density lipoprotein ( HDL ) cholesterol , and triglycerides ; and laboratory and clinical evidence of adverse events monitored periodically throughout the study .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "cholesterol"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "triglycerides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3934,
    "text": "RESULTS : Among women , lovastatin ( 20 to 80 mg / d ) produced sustained ( 12 - to 48 - week ) , dose - related changes ( P < 0 . 001 ) : decreases in LDL cholesterol ( 24 % to 40 % ) and triglycerides ( 9 % to 18 % ) , and increases in HDL cholesterol ( 6 . 7 % to 8 . 6 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "lovastatin"
      ],
      [
        "T1",
        "Chemical",
        40,
        41,
        "cholesterol"
      ],
      [
        "T2",
        "Chemical",
        49,
        50,
        "triglycerides"
      ],
      [
        "T3",
        "Chemical",
        62,
        63,
        "cholesterol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3935,
    "text": "Depending on the dose , from 82 % to 95 % of lovastatin - treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4 . 14 mmol / L ( 160 mg / dL ) , and 40 % to 87 % achieved the goal of 3 . 36 mmol / L ( 130 mg / dL ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "lovastatin"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "Cholesterol"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "cholesterol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3936,
    "text": "Successive transaminase elevations greater than three times the upper limit of normal occurred in 0 . 1 % of women and were dose dependent above the 20 - mg dose .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3937,
    "text": "Myopathy , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal , was rare and associated with the highest recommended daily dose of lovastatin ( 80 mg ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Myopathy"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "creatine"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "lovastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3938,
    "text": "Estrogen - replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "lovastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3939,
    "text": "CONCLUSION : Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Lovastatin"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "hypercholesterolemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3940,
    "text": "Tetany and rhabdomyolysis due to surreptitious furosemide - - importance of magnesium supplementation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Tetany"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "rhabdomyolysis"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "furosemide"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "magnesium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3941,
    "text": "Diuretics may induce hypokalemia , hypocalcemia and hypomagnesemia .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypokalemia"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hypocalcemia"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "hypomagnesemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3942,
    "text": "While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone ( 1 , 2 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "muscle weakness"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "muscle spasms"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "hypokalemia"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "hypomagnesemia"
      ],
      [
        "T4",
        "Disease",
        16,
        17,
        "tetany"
      ],
      [
        "T5",
        "Chemical",
        22,
        23,
        "potassium"
      ],
      [
        "T6",
        "Chemical",
        24,
        25,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3943,
    "text": "Surreptitious diuretic ingestion has been described , mainly in women who are concerned that they are obese or edematous .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "obese"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "edematous"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3944,
    "text": "Symptomatic hypokalemia has been reported in such patients ( 3 - 7 ) and in one case hypocalcemia was observed ( 8 ) , but the effects of magnesium depletion were not noted in these patients .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypokalemia"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "hypocalcemia"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "magnesium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3945,
    "text": "Ciprofloxacin - induced nephrotoxicity in patients with cancer .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ciprofloxacin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "nephrotoxicity"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3946,
    "text": "Nephrotoxicity associated with ciprofloxacin is uncommon .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Nephrotoxicity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "ciprofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3947,
    "text": "Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "cancer"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "ciprofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3948,
    "text": "Other than elevation of serum creatinine levels , characteristic clinical manifestations and abnormal laboratory findings are not frequently present .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3949,
    "text": "Allergic interstitial nephritis is believed to be the underlying pathological - process .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "interstitial nephritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3950,
    "text": "Definitive diagnosis requires performance of renal biopsy , although this is not always feasible .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3951,
    "text": "An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin - induced acute renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "ciprofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3952,
    "text": "Venous complications of midazolam versus diazepam .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Venous complications"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "midazolam"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3953,
    "text": "Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures , this variable has not been well documented .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "venous complications"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "midazolam"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3954,
    "text": "We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "venous complications"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "diazepam"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "midazolam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3955,
    "text": "Overall , venous complications were more frequent with diazepam ( 22 of 62 patients ) than with midazolam ( 4 of 60 patients ) ( p < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "venous complications"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "diazepam"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "midazolam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3956,
    "text": "A palpable venous cord was present in 23 % ( 14 of 62 ) of patients in the diazepam group , compared with 2 % ( 1 of 60 patients ) in the midazolam group ( p < 0 . 002 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "diazepam"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "midazolam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3957,
    "text": "Pain at the injection site occurred in 35 % ( 22 of 62 ) of patients in the diazepam group compared with 7 % ( 4 of 60 patients ) in the midazolam group ( p < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Pain"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "diazepam"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "midazolam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3958,
    "text": "Swelling and warmth at the injection site were not significantly different between the two groups .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Swelling"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3959,
    "text": "Smoking , nonsteroidal anti - inflammatory drug use , intravenous catheter site , dwell time of the needle , alcohol use , and pain during the injection had no effect on the incidence of venous complications .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        36,
        "venous complications"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "alcohol"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3960,
    "text": "Clarithromycin - associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "visual hallucinations"
      ],
      [
        "T1",
        "Disease",
        9,
        12,
        "chronic renal failure"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Clarithromycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3961,
    "text": "Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Visual hallucinations"
      ],
      [
        "T1",
        "Disease",
        7,
        10,
        "chronic renal failure"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "uremia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3962,
    "text": "Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic , clarithromycin .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "visual hallucinations"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "macrolide"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "clarithromycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3963,
    "text": "We describe such a case in a patient with end - stage renal disease ( ESRD ) maintained on continuous ambulatory peritoneal dialysis ( CAPD ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        14,
        "end - stage renal disease"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "ESRD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3964,
    "text": "The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient , with underlying aluminum intoxication , may have facilitated the appearance of this neurotoxic side effect .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "chronic renal failure"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "clarithromycin"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "aluminum"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "neurotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3965,
    "text": "It is important to understand the pharmacokinetics of medications in face of chronic renal failure , the possibility of drug interactions , and how these factors should help guide medication therapy in the ESRD patient .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "chronic renal failure"
      ],
      [
        "T1",
        "Disease",
        33,
        34,
        "ESRD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3966,
    "text": "Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha - benzene hexachloride .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        16,
        "alpha - benzene hexachloride"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hepatoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3967,
    "text": "Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha - benzene hexachloride were examined histochemically and electron microscopically .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "liver lesions"
      ],
      [
        "T1",
        "Chemical",
        14,
        18,
        "alpha - benzene hexachloride"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "hepatomas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3968,
    "text": "Although most of the hepatomas were well - differentiated tumors and contained a considerable number of peroxisomes , the tumor cells did not respond to ethyl - alpha - p - chlorophenoxyisobutyrate with proliferation of peroxisomes .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        32,
        "ethyl - alpha - p - chlorophenoxyisobutyrate"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hepatomas"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "tumors"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3969,
    "text": "At the 16th week of carcinogen feeding , hyperplastic nodules appeared and advanced to further stages .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3970,
    "text": "A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3971,
    "text": "Within the nodules , foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3972,
    "text": "These cells proliferated further , replacing the most part of the nodules , and with this process hepatomas appeared to have been formed .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "hepatomas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3973,
    "text": "No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by ethyl - alpha - p - chlorophenoxyisobutyrate unlike in the case of rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        22,
        "ethyl - alpha - p - chlorophenoxyisobutyrate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3974,
    "text": "Contribution of the sympathetic nervous system to salt - sensitivity in lifetime captopril - treated spontaneously hypertensive rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "captopril"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3975,
    "text": "OBJECTIVE : To test the hypothesis that , in lifetime captopril - treated spontaneously hypertensive rats ( SHR ) , the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        34,
        "dietary sodium chloride"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "captopril"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "hypertensive"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3976,
    "text": "METHODS : Male SHR ( aged 6 weeks ) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        27,
        "sodium chloride"
      ],
      [
        "T1",
        "Chemical",
        33,
        35,
        "sodium chloride"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "captopril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3977,
    "text": "After 2 weeks , the rats were subjected to ganglionic blockade and 2 days later , an infusion of clonidine .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "clonidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3978,
    "text": "RESULTS : Lifetime captopril treatment significantly lowered mean arterial pressure in both groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "captopril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3979,
    "text": "Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride - induced increase in MAP in both groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        20,
        "dietary sodium chloride"
      ],
      [
        "T1",
        "Disease",
        22,
        25,
        "increase in MAP"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "hexamethonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3980,
    "text": "Infusion of the central nervous system alpha2 - adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high ( compared with the basal ) sodium chloride diet .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        11,
        "alpha2 - adrenergic receptor agonist"
      ],
      [
        "T1",
        "Chemical",
        36,
        38,
        "sodium chloride"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "clonidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3981,
    "text": "CONCLUSIONS : In both lifetime captopril - treated and control SHR , the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        26,
        "sodium chloride"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "captopril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3982,
    "text": "Angioedema associated with droperidol administration .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Angioedema"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "droperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3983,
    "text": "Angioedema , also known as angioneurotic edema or Quincke ' s disease , is a well - demarcated , localized edema involving the subcutaneous tissues that may cause upper - airway obstruction .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "angioneurotic edema"
      ],
      [
        "T1",
        "Disease",
        8,
        12,
        "Quincke ' s disease"
      ],
      [
        "T2",
        "Disease",
        28,
        32,
        "upper - airway obstruction"
      ],
      [
        "T3",
        "Disease",
        0,
        1,
        "Angioedema"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3984,
    "text": "We report the case of a previously healthy 19 - year - old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "drug allergies"
      ],
      [
        "T1",
        "Disease",
        24,
        26,
        "tongue swelling"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "angioedema"
      ],
      [
        "T3",
        "Chemical",
        41,
        42,
        "droperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3985,
    "text": "Late cardiotoxicity after treatment for a malignant bone tumor .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "bone tumor"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3986,
    "text": "Cardiac function was assessed in long - term survivors of malignant bone tumors who were treated according to Rosen ' s T5 or T10 protocol , both including doxorubicin .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "bone tumors"
      ],
      [
        "T1",
        "Chemical",
        18,
        25,
        "Rosen ' s T5 or T10 protocol"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3987,
    "text": "Thirty - one patients , age 10 - 45 years ( median age 17 . 8 years ) were evaluated 2 . 3 - 14 . 1 years ( median 8 . 9 years ) following completion of treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3988,
    "text": "Cumulative doses of doxorubicin were 225 - 550 mg / m2 ( median dose 360 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3989,
    "text": "The evaluation consisted of a history , physical examination , electrocardiogram ( ECG ) , signal averaged ECG , 24 - hour ambulatory ECG , echocardiography and radionuclide angiography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3990,
    "text": "Eighteen of 31 ( 58 % ) patients showed cardiac toxicity , defined as having one or more of the following abnormalities : late potentials , complex ventricular arrhythmias , left ventricular dilation , decreased shortening fraction , or decreased ejection fraction .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "cardiac toxicity"
      ],
      [
        "T1",
        "Disease",
        27,
        29,
        "ventricular arrhythmias"
      ],
      [
        "T2",
        "Disease",
        31,
        33,
        "ventricular dilation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3991,
    "text": "The incidence of cardiac abnormalities increased with length of follow - up ( P < or = . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiac abnormalities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3992,
    "text": "No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status , except for heart rate variability .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3993,
    "text": "When adjusted to body surface area , the left ventricular posterior wall thickness ( LVPW index ) was decreased in all patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3994,
    "text": "The incidence of doxorubicin - induced cardiotoxicity is high and increases with follow - up , irrespective of cumulative dose .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "doxorubicin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3995,
    "text": "Life - long cardiac follow - up in these patients is warranted .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3996,
    "text": "The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3997,
    "text": "Acute blood pressure elevations with caffeine in men with borderline systemic hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "caffeine"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3998,
    "text": "Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "caffeine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3999,
    "text": "Thus , caffeine ( 3 . 3 mg / kg ) versus placebo was tested in 48 healthy men ( aged 20 to 35 years ) selected after screening on 2 separate occasions .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4000,
    "text": "Borderline hypertensive men ( n = 24 ) were selected with screening systolic blood pressure ( BP ) of 140 to 160 mm Hg and / or diastolic BP 90 to 99 mm Hg .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4001,
    "text": "Low - risk controls ( n = 24 ) reported no parental history of hypertension and had screening BP < 130 / 85 mm Hg .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4002,
    "text": "Participants were then tested on 2 occasions after 12 - hour abstinence from caffeine in each of 2 protocols ; this required a total of 4 laboratory visits .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4003,
    "text": "Caffeine - induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls ( + 8 . 4 vs + 3 . 8 mm Hg , p < 0 . 0001 ) , and were attributable to larger changes in impedance - derived measures of systemic vascular resistance ( + 135 vs + 45 dynes . s . cm - 5 , p < 0 . 004 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4004,
    "text": "These findings were consistent and reached significance in both protocols .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4005,
    "text": "The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4006,
    "text": "Consequently , whereas all participants exhibited normotensive levels during the resting predrug baseline , 33 % of borderline subjects achieved hypertensive BP levels after caffeine ingestion .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "hypertensive"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4007,
    "text": "Thus , in borderline hypertensive men , exaggerated responses to caffeine were : selective for diastolic BP , consistent with greater vasoconstriction , replicated in 2 protocols , and representative of nearly all borderline hypertensives .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypertensive"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "caffeine"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "hypertensives"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4008,
    "text": "We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression , as well as hinder accurate diagnosis and treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4009,
    "text": "Absence of effect of sertraline on time - based sensitization of cognitive impairment with haloperidol .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "cognitive impairment"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "sertraline"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4010,
    "text": "This double - blind , randomized , placebo - controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "haloperidol"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "haloperidol"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "sertraline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4011,
    "text": "METHOD : All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25 .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4012,
    "text": "From Days 9 to 25 , subjects were randomly assigned to either sertraline ( 12 subjects ) or placebo ( 12 subjects ) ; the sertraline dose was titrated from 50 to 200 mg / day from Days 9 to 16 , and remained at 200 mg / day for the final 10 days of the drug administration period .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "sertraline"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "sertraline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4013,
    "text": "Cognitive function testing was performed before dosing and over a 24 - hour period after dosing on Days 1 , 2 , and 25 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4014,
    "text": "RESULTS : Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        6,
        "Impairment of cognitive function"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4015,
    "text": "When single - dose haloperidol was given again 25 days later , greater impairment with earlier onset was noted in several tests in both treatment groups , suggesting enhancement of this effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4016,
    "text": "There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "sertraline"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4017,
    "text": "Three subjects ( 2 on sertraline and 1 on placebo ) withdrew from the study because of side effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "sertraline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4018,
    "text": "Ten subjects in each group reported side effects related to treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4019,
    "text": "The side effect profiles of sertraline and of placebo were similar .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "sertraline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4020,
    "text": "CONCLUSION : Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "cognitive impairment"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Haloperidol"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "sertraline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4021,
    "text": "Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        10,
        "cerebral venous sinus and internal carotid artery thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4022,
    "text": "A case report .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4023,
    "text": "A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left hemiparesis and seizure two days after parenteral use of progesterone and estradiol .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "headache"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "nausea"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "vomiting"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "hemiparesis"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "seizure"
      ],
      [
        "T5",
        "Chemical",
        26,
        27,
        "progesterone"
      ],
      [
        "T6",
        "Chemical",
        28,
        29,
        "estradiol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4024,
    "text": "Diabetes mellitus ( DM ) was found during admission .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Diabetes mellitus"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "DM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4025,
    "text": "Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus ( SSS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "hemorrhagic infarct"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4026,
    "text": "Left carotid angiography found occlusion of the left internal carotid artery ( ICA ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        11,
        "occlusion of the left internal carotid artery"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4027,
    "text": "Right carotid angiograms failed to show the SSS and inferior sagittal sinus , suggestive of venous sinus thrombosis .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "venous sinus thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4028,
    "text": "Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        10,
        "cerebral artery and the venous sinus occlusion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4029,
    "text": "In this case , the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity , which provided a common denominator for thrombosis of both the ICA and the venous sinus .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        37,
        "thrombosis of both the ICA and the venous sinus"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "estradiol"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "progesterone"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "DM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4030,
    "text": "Chemotherapy of advanced inoperable non - small cell lung cancer with paclitaxel : a phase II trial .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        10,
        "non - small cell lung cancer"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4031,
    "text": "Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different tumor types , notably ovarian and breast carcinoma .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        29,
        "ovarian and breast carcinoma"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Paclitaxel"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "Taxol"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4032,
    "text": "Two phase II trials of 24 - hour paclitaxel infusions in chemotherapy - naive patients with stage IIIB or IV non - small cell lung cancer ( NSCLC ) reported response rates of 21 % and 24 % .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        26,
        "non - small cell lung cancer"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "paclitaxel"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "NSCLC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4033,
    "text": "Leukopenia was dose limiting : as many as 62 . 5 % of patients experienced grade 4 leukopenia .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Leukopenia"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "leukopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4034,
    "text": "We investigated the efficacy and toxicity of a 3 - hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "paclitaxel"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "NSCLC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4035,
    "text": "The 58 patients treated ( 41 men and 17 women ) had a median age of 59 years ( age range , 25 to 75 ) and a performance status of 0 through 2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4036,
    "text": "Most patients ( 72 . 4 % ) had stage IV NSCLC .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "NSCLC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4037,
    "text": "Paclitaxel 225 mg / m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4038,
    "text": "Of 50 patients evaluable for response , 12 ( 24 % ) had partial remission , 26 ( 52 % ) had no change , and 12 had disease progression ( 24 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4039,
    "text": "Hematologic toxicities were mild : only one patient ( 2 % ) developed grade 3 or 4 neutropenia , while 29 % had grade 1 or 2 .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "toxicities"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4040,
    "text": "Grade 1 or 2 polyneuropathy affected 56 % of patients while only one ( 2 % ) experienced severe polyneuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "polyneuropathy"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "polyneuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4041,
    "text": "Similarly , grade 1 or 2 myalgia / arthralgia was observed in 63 . 2 % of patients , but only 14 . 3 % experienced grade 3 or 4 .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "myalgia"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "arthralgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4042,
    "text": "Nausea and vomiting were infrequent , with 14 % of patients experiencing grade 1 or 2 and only 2 % experiencing grade 3 or 4 .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Nausea"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "vomiting"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4043,
    "text": "Paclitaxel is thus an active single agent in this patient population , with a 3 - hour infusion proving comparably effective to a 24 - hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Paclitaxel"
      ],
      [
        "T1",
        "Disease",
        38,
        39,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4044,
    "text": "Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated , and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "paclitaxel"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "NSCLC"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4045,
    "text": "Paclitaxel combined with carboplatin in the first - line treatment of advanced ovarian cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "ovarian cancer"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Paclitaxel"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4046,
    "text": "In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .",
    "labels": [
      [
        "T0",
        "Disease",
        45,
        47,
        "ovarian cancer"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "paclitaxel"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "Taxol"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "carboplatin"
      ],
      [
        "T4",
        "Chemical",
        48,
        49,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4047,
    "text": "The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration - time curve ( AUC ) of 5 using the Calvert formula .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4048,
    "text": "In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7 . 5 , respectively , combined with a fixed paclitaxel dose of 185 mg / m2 .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "carboplatin"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4049,
    "text": "To date , 30 previously untreated patients , all with a good performance status ( Eastern Cooperative Oncology Group 0 to 2 ) have been entered into this ongoing study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4050,
    "text": "The dose - limiting toxicity of the combination was myelosuppression ( leukopenia , granulocytopenia , and thrombocytopenia ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "toxicity"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "myelosuppression"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "leukopenia"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "granulocytopenia"
      ],
      [
        "T4",
        "Disease",
        16,
        17,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4051,
    "text": "Neurotoxicity was largely moderate .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4052,
    "text": "So far , 14 patients are evaluable for response ; of these , eight ( 57 % ) showed objective ( complete or partial ) response and disease stabilized in six patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4053,
    "text": "No patient had disease progression .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4054,
    "text": "We conclude that the combination of paclitaxel 185 mg / m2 administered as a 3 - hour infusion followed immediately by a 1 - hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21 - day schedule in the outpatient setting .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "paclitaxel"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4055,
    "text": "The recommended dose for phase III studies is paclitaxel 185 mg / m2 and carboplatin AUC 6 .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "paclitaxel"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4056,
    "text": "Effects of acute steroid administration on ventilatory and peripheral muscles in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4057,
    "text": "Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "myopathy"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "corticosteroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4058,
    "text": "The mechanism of this myopathy is poorly understood .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4059,
    "text": "Therefore , 60 male rats were randomly assigned to receive daily injection of saline ( C ) , methylprednisolone ( M ) , or triamcinolone ( T ) 80 mg / kg / d for 5 d .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "methylprednisolone"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "M"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "triamcinolone"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "T"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4060,
    "text": "Nutritional intake , measured daily in 15 animals , showed a significant reduction of food intake in the steroid - treated groups ( - 50 and - 79 % in M and T , respectively ) .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "reduction of food intake"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "steroid"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "M"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "T"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4061,
    "text": "This was associated with a similar loss in body weight .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        10,
        "loss in body weight"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4062,
    "text": "In the 45 remaining animals , diaphragm contractility and histopathologic features of several muscles were studied .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4063,
    "text": "Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4064,
    "text": "Maximal twitches of the diaphragm were lower in the C group ( 653 + / - 174 g / cm ( 2 ) ) than in the M group ( 837 + / - 171 g / cm ( 2 ) ; p < 0 . 05 ) and the T group ( 765 + / - 145 g / cm ( 2 ) , NS ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        28,
        "M"
      ],
      [
        "T1",
        "Chemical",
        50,
        51,
        "T"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4065,
    "text": "Half - relaxation time was prolonged in both steroid groups , and time to peak tension was longer with M , whereas tetanic tensions were similar .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "steroid"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "M"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "tetanic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4066,
    "text": "Steroid treatment also induced a leftward shift of the force - frequency curve at 25 and 50 Hz when compared with saline treatment ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4067,
    "text": "ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "atrophy"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "steroid"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "atrophy"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "T"
      ],
      [
        "T4",
        "Disease",
        40,
        41,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4068,
    "text": "Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , T , and PF ) , showed that muscle atrophy was considerably less pronounced in PF animals than in T - treated animals .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "muscle atrophy"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "T"
      ],
      [
        "T2",
        "Chemical",
        37,
        38,
        "T"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4069,
    "text": "We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "steroids"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "steroids"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "atrophy"
      ],
      [
        "T3",
        "Chemical",
        50,
        51,
        "steroid"
      ],
      [
        "T4",
        "Disease",
        53,
        54,
        "necrosis"
      ],
      [
        "T5",
        "Disease",
        60,
        61,
        "atrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4070,
    "text": "Continuous subcutaneous administration of mesna to prevent ifosfamide - induced hemorrhagic cystitis .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "hemorrhagic cystitis"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "mesna"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "ifosfamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4071,
    "text": "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hemorrhagic cystitis"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "ifosfamide"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4072,
    "text": "Mesna is generally administered by the intravenous route , although experience with oral delivery of the drug has increased .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4073,
    "text": "The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4074,
    "text": "In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations , such as in a patient taking oral mesna who experiences severe ifosfamide - induced emesis and is unable to absorb the drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "mesna"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "mesna"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "ifosfamide"
      ],
      [
        "T3",
        "Disease",
        36,
        37,
        "emesis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4075,
    "text": "Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe , practical , and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "mesna"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "ifosfamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4076,
    "text": "Leg and back pain after spinal anaesthesia involving hyperbaric 5 % lignocaine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Leg and back pain"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "lignocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4077,
    "text": "Fifty - four patients , aged 27 - 90 years , who were given lignocaine 5 % in 6 . 8 % glucose solution for spinal anaesthesia were studied .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "lignocaine"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4078,
    "text": "Thirteen of these patients experienced pain in the legs and / or back after recovery from anaesthesia .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        13,
        "pain in the legs and / or back"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4079,
    "text": "The patients affected were younger ( p < 0 . 05 ) and the site of the dural puncture was higher ( p < 0 . 01 ) than those individuals without pain .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        33,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4080,
    "text": "Five of the 13 patients ( 38 % ) with pain and seven of the 41 patients ( 17 % ) without pain admitted to a high alcohol intake , which might be a contributing factor .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "pain"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "pain"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4081,
    "text": "Leg and / or back pain is associated with the intrathecal use of hyperbaric 5 % lignocaine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        6,
        "Leg and / or back pain"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "lignocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4082,
    "text": "The use of serum cholinesterase in succinylcholine apnoea .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "succinylcholine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "apnoea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4083,
    "text": "Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "apnoea"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4084,
    "text": "Adequate spontaneous respiration was re - established in an average period of ten minutes after the injection .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4085,
    "text": "In 12 patients biochemical genetic examinations confirmed the presence of an atypical serum cholinesterase .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4086,
    "text": "In three patients none of the usual variants were found .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4087,
    "text": "It is therefore supposed that other unknown variants of serum cholinesterase exist which cannot hydrolyze succinylcholine .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4088,
    "text": "The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "succinylcholine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "apnoea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4089,
    "text": "Increased sulfation and decreased 7alpha - hydroxylation of deoxycholic acid in ethinyl estradiol - induced cholestasis in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "deoxycholic acid"
      ],
      [
        "T1",
        "Chemical",
        11,
        13,
        "ethinyl estradiol"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "cholestasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4090,
    "text": "Deoxycholic acid conjugation , transport capacity , and metabolism were compared in control and ethinyl estradiol - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Deoxycholic acid"
      ],
      [
        "T1",
        "Chemical",
        14,
        16,
        "ethinyl estradiol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4091,
    "text": "Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid , and both were decreased by ethinyl estradiol treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "deoxycholic acid"
      ],
      [
        "T1",
        "Chemical",
        14,
        16,
        "taurodeoxycholic acid"
      ],
      [
        "T2",
        "Chemical",
        22,
        24,
        "ethinyl estradiol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4092,
    "text": "During [ 24 - 14C ] sodium deoxycholate infusion , [ 14C ] biliary bile acid secretion increased , but bile flow did not change significantly in either control or ethinyl estradiol - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "sodium deoxycholate"
      ],
      [
        "T1",
        "Chemical",
        14,
        16,
        "bile acid"
      ],
      [
        "T2",
        "Chemical",
        30,
        32,
        "ethinyl estradiol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4093,
    "text": "Ethinyl estradiol - treated animals excreted significantly less 14C as taurocholic acid than did control animals , consistent with an impairment of 7alpha - hydroxylation of taurodeoxycholic acid .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Ethinyl estradiol"
      ],
      [
        "T1",
        "Chemical",
        10,
        12,
        "taurocholic acid"
      ],
      [
        "T2",
        "Chemical",
        26,
        28,
        "taurodeoxycholic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4094,
    "text": "Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid , but did result in an increase in sulfation of taurodeoxycholic acid from 1 . 5 % in controls to nearly 4 . 0 % ( P less than 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Ethinyl estradiol"
      ],
      [
        "T1",
        "Chemical",
        8,
        10,
        "deoxycholic acid"
      ],
      [
        "T2",
        "Chemical",
        20,
        22,
        "taurodeoxycholic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4095,
    "text": "These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "deoxycholic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4096,
    "text": "Furthermore , the rat converts deoxycholic acid , a poor choleretic , to taurocholic acid , a good choleretic .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "deoxycholic acid"
      ],
      [
        "T1",
        "Chemical",
        13,
        15,
        "taurocholic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4097,
    "text": "When this conversion is impaired with ethinyl estradiol treatment , sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "ethinyl estradiol"
      ],
      [
        "T1",
        "Chemical",
        23,
        25,
        "bile acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4098,
    "text": "Influence of diet free of NAD - precursors on acetaminophen hepatotoxicity in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "NAD"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "acetaminophen"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4099,
    "text": "Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "nicotinic acid amide"
      ],
      [
        "T1",
        "Chemical",
        16,
        22,
        "poly ( ADP - ribose )"
      ],
      [
        "T2",
        "Disease",
        52,
        54,
        "liver injury"
      ],
      [
        "T3",
        "Chemical",
        39,
        40,
        "acetaminophen"
      ],
      [
        "T4",
        "Chemical",
        41,
        42,
        "AAP"
      ],
      [
        "T5",
        "Disease",
        44,
        45,
        "hepatitis"
      ],
      [
        "T6",
        "Chemical",
        49,
        50,
        "AAP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4100,
    "text": "The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "NAD"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "AAP"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "hepatitis"
      ],
      [
        "T3",
        "Chemical",
        35,
        36,
        "ethanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4101,
    "text": "Liver injuries were quantified as serum activities of glutamate - oxaloacetate transaminase ( GOT ) and glutamate - pyruvate transaminase ( GPT ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Liver injuries"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "glutamate"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "oxaloacetate"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "glutamate"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "pyruvate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4102,
    "text": "While AAP caused a 117 - fold elevation of serum transaminase activities in mice kept on a standard laboratory diet , which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide ( NAA ) , adverse effects were noted in animals fed a diet free of precursors of NAD .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        33,
        "nicotinic acid amide"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "AAP"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "ethanol"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "NAA"
      ],
      [
        "T4",
        "Chemical",
        50,
        51,
        "NAD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4103,
    "text": "In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by ethanol in mice on a standard diet , the liver damage was inhibited by 50 % by ethanol .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        36,
        "liver damage"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "AAP"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "ethanol"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "ethanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4104,
    "text": "A further 64 % reduction of hepatitis was observed , when NAA was given to ethanol / AAP - mice .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hepatitis"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "NAA"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "ethanol"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "AAP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4105,
    "text": "Our results provide evidence that the AAP - induced hepatitis and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme ' s substrate NAD .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "AAP"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hepatitis"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "ethanol"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "NAA"
      ],
      [
        "T4",
        "Chemical",
        38,
        39,
        "NAD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4106,
    "text": "We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "hepatic damage"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "NAA"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4107,
    "text": "Nightmares and hallucinations after long - term intake of tramadol combined with antidepressants .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "hallucinations"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "tramadol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4108,
    "text": "Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Tramadol"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "cancer"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "pain"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4109,
    "text": "This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "dosulepine hydrochloride"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "chronic pain"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "paroxetine"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "tetraparetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4110,
    "text": "Fifty - six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho - active drugs and tramadol .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "hallucinations"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "tramadol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4111,
    "text": "The case report questions the long term use of pain killers combined with psycho - active drugs in chronic non malignant pain , especially if pain is under control .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "pain"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "pain"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4112,
    "text": "Effect of calcium chloride and 4 - aminopyridine therapy on desipramine toxicity in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "calcium chloride"
      ],
      [
        "T1",
        "Chemical",
        5,
        8,
        "4 - aminopyridine"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "desipramine"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4113,
    "text": "BACKGROUND : Hypotension is a major contributor to mortality in tricyclic antidepressant overdose .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Hypotension"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4114,
    "text": "Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4115,
    "text": "This study addressed the potential role of calcium channel blockade in tricyclic antidepressant - induced hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "calcium"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4116,
    "text": "METHODS : Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "calcium"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4117,
    "text": "CaCl2 and 4 - aminopyridine .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "4 - aminopyridine"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "CaCl2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4118,
    "text": "Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension , QRS prolongation , and bradycardia .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "desipramine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypotension"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4119,
    "text": "Fifteen min later , animals received CaCl2 , NaHCO3 , or saline .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "CaCl2"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "NaHCO3"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4120,
    "text": "In a second experiment , rats received tricyclic antidepressant desipramine IP followed in 15 min by 4 - aminopyridine or saline .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "4 - aminopyridine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "desipramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4121,
    "text": "RESULTS : NaHCO3 briefly ( 5 min ) reversed hypotension and QRS prolongation .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "NaHCO3"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4122,
    "text": "CaCl2 and 4 - aminopyridine failed to improve blood pressure .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "4 - aminopyridine"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "CaCl2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4123,
    "text": "The incidence of ventricular arrhythmias ( p = 0 . 004 ) and seizures ( p = 0 . 03 ) in the CaCl2 group was higher than the other groups .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "ventricular arrhythmias"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "CaCl2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4124,
    "text": "CONCLUSION : The administration of CaCl2 or 4 - aminopyridine did not reverse tricyclic antidepressant - induced hypotension in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "4 - aminopyridine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "CaCl2"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4125,
    "text": "CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        12,
        "cardiovascular and central nervous system toxicity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "CaCl2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4126,
    "text": "These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant - induced hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "calcium"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4127,
    "text": "Valsartan , a new angiotensin II antagonist for the treatment of essential hypertension : a comparative study of the efficacy and safety against amlodipine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "angiotensin II"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Valsartan"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "hypertension"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "amlodipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4128,
    "text": "OBJECTIVE : To compare the antihypertensive efficacy of a new angiotensin II antagonist , valsartan , with a reference therapy , amlodipine .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "angiotensin II"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "valsartan"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "amlodipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4129,
    "text": "METHODS : One hundred sixty - eight adult outpatients with mild to moderate hypertension were randomly allocated in double - blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "hypertension"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "valsartan"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "amlodipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4130,
    "text": "After 8 weeks of therapy , in patients whose blood pressure remained uncontrolled , 5 mg amlodipine was added to the initial therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "amlodipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4131,
    "text": "Patients were assessed at 4 , 8 , and 12 weeks .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4132,
    "text": "The primary efficacy variable was change from baseline in mean sitting diastolic blood pressure at 8 weeks .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4133,
    "text": "Secondary variables included change in sitting systolic blood pressure and responder rates .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4134,
    "text": "RESULTS : Both valsartan and amlodipine were effective at lowering blood pressure at 4 , 8 , and 12 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "valsartan"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "amlodipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4135,
    "text": "Similar decreases were observed in both groups , with no statistically significant differences between the groups for any variable analyzed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4136,
    "text": "For the primary variable the difference was 0 . 5 mm Hg in favor of valsartan ( p = 0 . 68 ; 95 % confidence interval , - 2 . 7 to 1 . 7 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "valsartan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4137,
    "text": "Responder rates at 8 weeks were 66 . 7 % for valsartan and 60 . 2 % for amlodipine ( p = 0 . 39 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "valsartan"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "amlodipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4138,
    "text": "Both treatments were well tolerated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4139,
    "text": "The incidence of drug - related dependent edema was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "edema"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "amlodipine"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "valsartan"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "amlodipine"
      ],
      [
        "T4",
        "Chemical",
        47,
        48,
        "valsartan"
      ],
      [
        "T5",
        "Chemical",
        51,
        52,
        "amlodipine"
      ],
      [
        "T6",
        "Chemical",
        60,
        61,
        "amlodipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4140,
    "text": "CONCLUSIONS : The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "valsartan"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "amlodipine"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4141,
    "text": "The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class , dihydropyridine calcium antagonists .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "valsartan"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "dihydropyridine"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4142,
    "text": "A measure of pupillary oscillation as a marker of cocaine - induced paranoia .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "pupillary oscillation"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cocaine"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "paranoia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4143,
    "text": "Cocaine - induced paranoia ( CIP ) remains an important drug - induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cocaine"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "paranoia"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "CIP"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "paranoia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4144,
    "text": "Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP ( n = 32 ) from another group of crack addicts who denied past CIP ( n = 29 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "pupillary oscillation"
      ],
      [
        "T1",
        "Chemical",
        13,
        15,
        "crack cocaine"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "CIP"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "crack"
      ],
      [
        "T4",
        "Disease",
        33,
        34,
        "CIP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4145,
    "text": "Serotonin syndrome from venlafaxine - tranylcypromine interaction .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Serotonin syndrome"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "venlafaxine"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "tranylcypromine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4146,
    "text": "Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , salivation , confusion , agitation and hyperthermia .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "muscle rigidity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "serotonin"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "serotonin"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "salivation"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "confusion"
      ],
      [
        "T5",
        "Disease",
        24,
        25,
        "agitation"
      ],
      [
        "T6",
        "Disease",
        26,
        27,
        "hyperthermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4147,
    "text": "The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor ( MAOI ) and a specific serotonin reuptake inhibitor .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4148,
    "text": "Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Venlafaxine"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "serotonin"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4149,
    "text": "We report a venlafaxine - MAOI interaction that resulted in the serotonin syndrome in a 23 - y - old male who was taking tranylcypromine for depression .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "serotonin syndrome"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "venlafaxine"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "tranylcypromine"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4150,
    "text": "He had been well until the morning of presentation when he took 1 / 2 tab of venlafaxine .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "venlafaxine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4151,
    "text": "Within 2 h he became confused with jerking movements of his extremities , tremors and rigidity .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "tremors"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "rigidity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4152,
    "text": "He was brought directly to a hospital where he was found to be agitated and confused with shivering , myoclonic jerks , rigidity , salivation and diaphoresis .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "myoclonic jerks"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "rigidity"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "salivation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4153,
    "text": "His pupils were 7 mm and sluggishly reactive to light .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4154,
    "text": "Vital signs were : blood pressure 120 / 67 mm Hg , heart rate 127 / min , respiratory rate 28 / min , and temperature 97 F .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4155,
    "text": "After 180 mg of diazepam i . v . he remained tremulous with muscle rigidity and clenched jaws .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "muscle rigidity"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4156,
    "text": "He was intubated for airway protection and because of hypoventilation , and was paralyzed to control muscle rigidity .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "muscle rigidity"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypoventilation"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "paralyzed"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4157,
    "text": "His subsequent course was remarkable for non - immune thrombocytopenia which resolved .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4158,
    "text": "The patient ' s maximal temperature was 101 . 2 F and his CPK remained < 500 units / L with no other evidence of rhabdomyolysis .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        26,
        "rhabdomyolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4159,
    "text": "His mental status normalized and he was transferred to a psychiatry ward .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4160,
    "text": "This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4161,
    "text": "Cyclophosphamide associated bladder cancer - - a highly aggressive disease : analysis of 12 cases .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "bladder cancer"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4162,
    "text": "PURPOSE : We gained knowledge of the etiology , treatment and prevention of cyclophosphamide associated urothelial cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "urothelial cancer"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4163,
    "text": "MATERIALS AND METHODS : The medical records of 6 men and 6 women ( mean age 55 years ) with cyclophosphamide associated bladder cancer were reviewed .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "bladder cancer"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4164,
    "text": "RESULTS : All tumors were grade 3 or 4 transitional cell carcinoma .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "tumors"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "carcinoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4165,
    "text": "Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4166,
    "text": "Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4167,
    "text": "The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4168,
    "text": "CONCLUSIONS : Cyclophosphamide associated bladder tumor is an aggressive disease .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "bladder tumor"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4169,
    "text": "However , long - term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease , even when noninvasive .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "bladder tumors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4170,
    "text": "A phase I clinical study of the antipurine antifolate lometrexol ( DDATHF ) given with oral folic acid .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        18,
        "folic acid"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "antipurine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "lometrexol"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "DDATHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4171,
    "text": "Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase ( GARFT ) , an enzyme essential for de novo purine synthesis .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "glycinamide ribonucleotide"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Lometrexol"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "purine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4172,
    "text": "Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs , notably methotrexate .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "lometrexol"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "tumours"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "methotrexate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4173,
    "text": "However , the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "lometrexol"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "toxicities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4174,
    "text": "Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration , i . e . for 7 days prior to and 7 days following a single bolus dose .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "folic acid"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "lometrexol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4175,
    "text": "This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "folic acid"
      ],
      [
        "T1",
        "Chemical",
        28,
        30,
        "folic acid"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "lometrexol"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "toxicity"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "lometrexol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4176,
    "text": "Thrombocytopenia and mucositis were the major toxicities .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Thrombocytopenia"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "mucositis"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "toxicities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4177,
    "text": "There was no clear relationship between clinical toxicity and the extent of plasma folate elevation .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "folate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4178,
    "text": "Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "folic acid"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "lometrexol"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "toxicity"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "lometrexol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4179,
    "text": "The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4180,
    "text": "This information will facilitate the future evaluation of this class of compounds in cancer therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4181,
    "text": "Fatal excited delirium following cocaine use : epidemiologic findings provide new evidence for mechanisms of cocaine toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "delirium"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4182,
    "text": "We describe an outbreak of deaths from cocaine - induced excited delirium ( EDDs ) in Dade County , Florida between 1979 and 1990 .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "cocaine"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "delirium"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "EDDs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4183,
    "text": "From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "cocaine"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "EDDs"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        30,
        31,
        "overdose"
      ],
      [
        "T4",
        "Disease",
        33,
        34,
        "delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4184,
    "text": "Compared with controls , EDDs were more frequently black , male , and younger .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "EDDs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4185,
    "text": "They were less likely to have a low body mass index , and more likely to have died in police custody , to have received medical treatment immediately before death , to have survived for a longer period , to have developed hyperthermia , and to have died in summer months .",
    "labels": [
      [
        "T0",
        "Disease",
        42,
        43,
        "hyperthermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4186,
    "text": "EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "EDDs"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "benzoylecgonine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4187,
    "text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate agitation , delirium , aberrant thermoregulation , rhabdomyolysis , and sudden death .",
    "labels": [
      [
        "T0",
        "Disease",
        37,
        39,
        "sudden death"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "agitation"
      ],
      [
        "T4",
        "Disease",
        29,
        30,
        "delirium"
      ],
      [
        "T5",
        "Disease",
        34,
        35,
        "rhabdomyolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4188,
    "text": "Pemoline induced acute choreoathetosis : case report and review of the literature .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Pemoline"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "choreoathetosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4189,
    "text": "BACKGROUND : Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "attention deficit disorder"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Pemoline"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "oxazolidine"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "amphetamines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4190,
    "text": "Pemoline has not been commonly associated in the literature as a cause of acute movement disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "movement disorders"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Pemoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4191,
    "text": "The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "pemoline"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "choreoathetosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4192,
    "text": "CASE REPORT : Two , 3 - year - old male , identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets .",
    "labels": [
      [
        "T0",
        "Chemical",
        29,
        30,
        "pemoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4193,
    "text": "The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "attention deficit disorder"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "methylphenidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4194,
    "text": "This was their first day of pemoline therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "pemoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4195,
    "text": "The choreoathetoid movements began 45 min to 1 h after ingestion .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "choreoathetoid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4196,
    "text": "The children gave no history of prior movement disorders and there was no family history of movement disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "movement disorders"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "movement disorders"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4197,
    "text": "The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "benzodiazepines"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "choreoathetoid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4198,
    "text": "Despite treatment , the children continued to have choreoathetosis for approximately 24 hours .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "choreoathetosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4199,
    "text": "Forty - eight hours after admission , the children appeared to be at their baseline and were discharged home .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4200,
    "text": "CONCLUSION : Pemoline associated movement disorder has been rarely reported in the acute toxicology literature .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "movement disorder"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Pemoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4201,
    "text": "The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "choreoathetoid"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "pemoline"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4202,
    "text": "Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4203,
    "text": "PURPOSE : To assess by electrophysiologic testing the effect of photorefractive keratectomy ( PRK ) on the retina and optic nerve .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4204,
    "text": "SETTING : Eye Clinic , S .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4205,
    "text": "Salvatore Hospital , L ' Aquila University , Italy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4206,
    "text": "METHODS : Standard pattern electroretinograms ( P - ERGs ) and standard pattern visual evoked potentials ( P - VEPs ) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5 . 00 and 15 . 00 diopters ( D ) ( mean 8 . 00 D ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4207,
    "text": "Testing was done preoperatively and 3 , 6 , 12 , and 18 months postoperatively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4208,
    "text": "The contralateral eyes served as controls .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4209,
    "text": "During the follow - up , 3 patients ( 12 % ) developed steroid - induced elevated intraocular pressure ( IOP ) that resolved after corticosteroid therapy was discontinued .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        19,
        "elevated intraocular pressure"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "steroid"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "corticosteroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4210,
    "text": "RESULTS : No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4211,
    "text": "CONCLUSION : Myopic excimer laser PRK did not seem to affect the posterior segment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4212,
    "text": "The transient steroid - induced IOP rise did not seem to cause functional impairment .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "IOP rise"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4213,
    "text": "Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "hydrogen peroxide"
      ],
      [
        "T1",
        "Disease",
        9,
        12,
        "acute liver failure"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "superoxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4214,
    "text": "Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure ( ALF ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "hydrogen peroxide"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "bacterial infections"
      ],
      [
        "T2",
        "Disease",
        20,
        23,
        "acute liver failure"
      ],
      [
        "T3",
        "Chemical",
        2,
        3,
        "superoxide"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "ALF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4215,
    "text": "In the present study , oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "oxygen"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "ALF"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "paracetamol"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4216,
    "text": "Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "ALF"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "ALF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4217,
    "text": "Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "hydrogen peroxide"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Superoxide"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "ALF"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "ALF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4218,
    "text": "This defect persisted when zymosan opsonized by control serum was used ( P < 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4219,
    "text": "Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( fMLP ) from a further 18 ALF patients was unaffected compared with control neutrophils .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "hydrogen peroxide"
      ],
      [
        "T1",
        "Chemical",
        9,
        16,
        "formyl - methionyl - leucyl - phenylalanine"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Superoxide"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "fMLP"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "ALF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4220,
    "text": "Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects ( P < 0 . 0005 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "ALF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4221,
    "text": "These results demonstrate a neutrophil defect in ALF due to paracetamol overdose , that is complement dependent but independent of serum complement , possibly connected to the complement receptor .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "ALF"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "paracetamol"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4222,
    "text": "Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen , adriamycin , carbon tetrachloride , chloroform and galactosamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Cholesteryl hemisuccinate"
      ],
      [
        "T1",
        "Chemical",
        14,
        16,
        "carbon tetrachloride"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "acetaminophen"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "adriamycin"
      ],
      [
        "T4",
        "Chemical",
        17,
        18,
        "chloroform"
      ],
      [
        "T5",
        "Chemical",
        19,
        20,
        "galactosamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4223,
    "text": "In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( CS ) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride ( CCl4 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "cholesteryl hemisuccinate"
      ],
      [
        "T1",
        "Chemical",
        16,
        18,
        "tris salt"
      ],
      [
        "T2",
        "Chemical",
        34,
        36,
        "carbon tetrachloride"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "CS"
      ],
      [
        "T4",
        "Disease",
        31,
        32,
        "hepatotoxic"
      ],
      [
        "T5",
        "Chemical",
        37,
        38,
        "CCl4"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4224,
    "text": "To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        36,
        "gamma - cholesteryloxybutyric acid"
      ],
      [
        "T1",
        "Chemical",
        37,
        39,
        "tris salt"
      ],
      [
        "T2",
        "Chemical",
        49,
        51,
        "carbon tetrachloride"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "CS"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "CS"
      ],
      [
        "T5",
        "Chemical",
        30,
        31,
        "CS"
      ],
      [
        "T6",
        "Chemical",
        40,
        41,
        "CSE"
      ],
      [
        "T7",
        "Chemical",
        43,
        44,
        "acetaminophen"
      ],
      [
        "T8",
        "Chemical",
        46,
        47,
        "adriamycin"
      ],
      [
        "T9",
        "Chemical",
        53,
        54,
        "chloroform"
      ],
      [
        "T10",
        "Chemical",
        56,
        57,
        "galactosamine"
      ],
      [
        "T11",
        "Disease",
        59,
        60,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4225,
    "text": "The results of these studies demonstrated that CS - mediated protection is not selective for a particular species , organ system or toxic chemical .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "CS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4226,
    "text": "A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "CS"
      ],
      [
        "T1",
        "Disease",
        33,
        34,
        "hepatotoxic"
      ],
      [
        "T2",
        "Chemical",
        36,
        37,
        "CCl4"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "CHCl3"
      ],
      [
        "T4",
        "Chemical",
        40,
        41,
        "acetaminophen"
      ],
      [
        "T5",
        "Chemical",
        42,
        43,
        "galactosamine"
      ],
      [
        "T6",
        "Disease",
        50,
        51,
        "cardiotoxic"
      ],
      [
        "T7",
        "Chemical",
        54,
        55,
        "adriamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4227,
    "text": "Maximal CS - mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "CS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4228,
    "text": "These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "CS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4229,
    "text": "The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate ( in light of the protection observed against galactosamine hepatotoxicity ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "CS"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "galactosamine"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4230,
    "text": "However , based on the data presented , we can not exclude the possibility that CS administration inhibits chemical bioactivation .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "CS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4231,
    "text": "Our findings do suggest that CS - mediated protection is dependent on the action of the intact anionic CS molecule ( non - hydrolyzable CSE was as protective as CS ) , whose mechanism has yet to be defined .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "CS"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "CS"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "CSE"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "CS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4232,
    "text": "A murine model of adenomyosis : the effects of hyperprolactinemia induced by fluoxetine hydrochloride , a selective serotonin reuptake inhibitor , on adenomyosis induction in Wistar albino rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "fluoxetine hydrochloride"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "adenomyosis"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "hyperprolactinemia"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "serotonin"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "adenomyosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4233,
    "text": "OBJECTIVE : The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "fluoxetine"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "hyperprolactinemia"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "adenomyosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4234,
    "text": "DESIGN : Fluoxetine , a serotonin reuptake inhibitor , was given to Wistar Albino rats for 98 days to produce hyperprolactinemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Fluoxetine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "serotonin"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4235,
    "text": "The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4236,
    "text": "Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4237,
    "text": "SETTING : Marmara University School of Medicine , Department of Histology and Embryology , Zeynep Kamil Women and Children ' s Hospital .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4238,
    "text": "MAIN OUTCOME MEASURES : Serum prolactin levels , uterine histopathology .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4239,
    "text": "RESULTS : The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4240,
    "text": "Histological studies revealed 11 cases of adenomyosis , all within the noncastrated group receiving fluoxetine .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "adenomyosis"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4241,
    "text": "CONCLUSION : It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4242,
    "text": "This invasion eventually progresses to adenomyosis .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "adenomyosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4243,
    "text": "Postinfarction ventricular septal defect associated with long - term steroid therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "ventricular septal defect"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4244,
    "text": "Two cases of postinfarction ventricular septal rupture in patients on long - term steroid therapy are presented and the favourable outcome in both cases described .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "ventricular septal rupture"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4245,
    "text": "A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "septal rupture"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4246,
    "text": "Neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "kainic acid"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "status epilepticus"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "steroids"
      ],
      [
        "T3",
        "Chemical",
        4,
        5,
        "pilocarpine"
      ],
      [
        "T4",
        "Disease",
        12,
        13,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4247,
    "text": "Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced seizures in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        16,
        "3 alpha - hydroxy pregnane - 20 - ones"
      ],
      [
        "T1",
        "Chemical",
        20,
        33,
        "3 alpha - hydroxy pregnane - 21 - diol - 20 - ones"
      ],
      [
        "T2",
        "Chemical",
        49,
        51,
        "kainic acid"
      ],
      [
        "T3",
        "Chemical",
        53,
        60,
        "N - methyl - D - aspartate"
      ],
      [
        "T4",
        "Chemical",
        5,
        6,
        "progesterone"
      ],
      [
        "T5",
        "Chemical",
        18,
        19,
        "deoxycorticosterone"
      ],
      [
        "T6",
        "Chemical",
        46,
        47,
        "pilocarpine"
      ],
      [
        "T7",
        "Chemical",
        61,
        62,
        "NMDA"
      ],
      [
        "T8",
        "Disease",
        65,
        66,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4248,
    "text": "Steroids with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against pilocarpine ( 416 mg / kg , s . c . ) - induced limbic motor seizures and status epilepticus ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .",
    "labels": [
      [
        "T0",
        "Disease",
        48,
        50,
        "status epilepticus"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Steroids"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "pilocarpine"
      ],
      [
        "T3",
        "Disease",
        46,
        47,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4249,
    "text": "The corresponding epimers with the 3 - hydroxy group in the beta - position were also effective but less potent ( ED50 values , 33 . 8 - 63 . 5 , i . p . ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4250,
    "text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "steroids"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "benzodiazepine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "clonazepam"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "pilocarpine"
      ],
      [
        "T4",
        "Disease",
        16,
        17,
        "seizures"
      ],
      [
        "T5",
        "Chemical",
        18,
        19,
        "steroids"
      ],
      [
        "T6",
        "Disease",
        44,
        45,
        "seizure"
      ],
      [
        "T7",
        "Chemical",
        48,
        49,
        "clonazepam"
      ],
      [
        "T8",
        "Chemical",
        54,
        55,
        "steroids"
      ],
      [
        "T9",
        "Disease",
        59,
        60,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4251,
    "text": "Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic seizures induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        34,
        "kainic acid"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Steroids"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "seizures"
      ],
      [
        "T3",
        "Disease",
        53,
        54,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4252,
    "text": "However , when a second dose of the steroid was administered 1 hr after the first dose , complete protection from the kainic acid - induced limbic seizures and status epilepticus was obtained .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        24,
        "kainic acid"
      ],
      [
        "T1",
        "Disease",
        29,
        31,
        "status epilepticus"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "steroid"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4253,
    "text": "The steroids also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA seizures or lethality .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "steroids"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "NMDA"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "NMDA"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4254,
    "text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "kainic acid"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "status epilepticus"
      ],
      [
        "T2",
        "Disease",
        37,
        39,
        "status epilepticus"
      ],
      [
        "T3",
        "Chemical",
        4,
        5,
        "steroids"
      ],
      [
        "T4",
        "Chemical",
        11,
        12,
        "pilocarpine"
      ],
      [
        "T5",
        "Disease",
        18,
        19,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4255,
    "text": "Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "nephrotic syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4256,
    "text": "Plasma concentration and urine excretion of the renin - angiotensin system proteins are altered in rats with nephrotic syndrome ( NS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "nephrotic syndrome"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "angiotensin"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "NS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4257,
    "text": "In this work the messenger ribonucleic acid ( mRNA ) levels of angiotensinogen ( Ao ) were analyzed with the slot - blot hybridization technique in liver and other extrahepatic tissues : kidney , heart , brain , and adrenal gland from control , nephrotic , and pair - fed ( PF ) rats .",
    "labels": [
      [
        "T0",
        "Disease",
        44,
        45,
        "nephrotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4258,
    "text": "NS was induced by a single injection of puromycin amino - nucleoside ( PAN ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        12,
        "puromycin amino - nucleoside"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "NS"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4259,
    "text": "Although a great urinary excretion and half - normal plasma levels of Ao were observed on day 6 after PAN injection , when NS was clearly established , hepatic Ao mRNA levels did not change .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "PAN"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "NS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4260,
    "text": "Furthermore , the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6 , nor did its hepatic levels at days 1 , 3 , 5 , or 7 after PAN injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        36,
        37,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4261,
    "text": "These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "NS"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4262,
    "text": "Neuroleptic malignant syndrome with risperidone .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4263,
    "text": "Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4264,
    "text": "Risperidone , a benzisoxazole derivative antipsychotic , has high serotonin 5 - HT2 receptor blockade and dose - related D2 receptor blockade .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Risperidone"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "benzisoxazole"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4265,
    "text": "The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "extrapyramidal symptoms"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4266,
    "text": "With this low frequency of extrapyramidal symptoms , it was thought the frequency of neuroleptic malignant syndrome might also be lowered .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "extrapyramidal symptoms"
      ],
      [
        "T1",
        "Disease",
        14,
        17,
        "neuroleptic malignant syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4267,
    "text": "A 73 - year - old woman developed neuroleptic malignant syndrome after monotherapy with risperidone .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4268,
    "text": "The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "risperidone"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "dantrolene"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "bromocriptine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4269,
    "text": "It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4270,
    "text": "The attenuating effect of carteolol hydrochloride , a beta - adrenoceptor antagonist , on neuroleptic - induced catalepsy in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "carteolol hydrochloride"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4271,
    "text": "It is known that beta - adrenoceptor antagonists are effective in the treatment of akathisia , one of the extrapyramidal side effects that occur during neuroleptic treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "akathisia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4272,
    "text": "Neuroleptic - induced catalepsy , a model of neuroleptic - induced extrapyramidal side effects , was considered suitable as a model for predicting neuroleptic - induced akathisia in humans , although neuroleptic - induced catalepsy was not considered a specific test for neuroleptic - induced akathisia .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "catalepsy"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "akathisia"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "catalepsy"
      ],
      [
        "T3",
        "Disease",
        45,
        46,
        "akathisia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4273,
    "text": "Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on haloperidol - induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden , a muscarinic receptor antagonist .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "carteolol"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "haloperidol"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "catalepsy"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "propranolol"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "biperiden"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4274,
    "text": "Carteolol , as well as propranolol and biperiden , inhibited the haloperidol - induced catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Carteolol"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "biperiden"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "haloperidol"
      ],
      [
        "T4",
        "Disease",
        14,
        15,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4275,
    "text": "The inhibitory effect of carteolol was almost comparable to that of propranolol , but was weaker than that of biperiden .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "carteolol"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "biperiden"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4276,
    "text": "Carteolol did not evoke postsynaptic dopamine receptor - stimulating behavioral signs such as stereotypy and hyperlocomotion in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Carteolol"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "dopamine"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "hyperlocomotion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4277,
    "text": "Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine - induced stereotypy and locomotor activity in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Carteolol"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "haloperidol"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4278,
    "text": "In addition , carteolol did not evoke 5 - HT1A receptor - stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5 - hydroxytryptophan - induced head twitch in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        30,
        "5 - hydroxytryptophan"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "carteolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4279,
    "text": "Finally , carteolol did not inhibit physostigmine - induced lethality in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "carteolol"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "physostigmine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4280,
    "text": "These results strongly suggest that carteolol improves haloperidol - induced catalepsy via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "carteolol"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "haloperidol"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "catalepsy"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "akathisia"
      ],
      [
        "T4",
        "Chemical",
        40,
        41,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4281,
    "text": "Granulosa cell tumor of the ovary associated with antecedent tamoxifen use .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        6,
        "Granulosa cell tumor of the ovary"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4282,
    "text": "BACKGROUND : Increased attention has been focused recently on the estrogenic effects of tamoxifen .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4283,
    "text": "Review of the literature reveals an association between tamoxifen use and gynecologic tumors .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "tamoxifen"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "tumors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4284,
    "text": "CASE : A 52 - year - old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor - positive breast carcinoma .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "breast carcinoma"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "tamoxifen"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "estrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4285,
    "text": "Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "aspartate"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "alanine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4286,
    "text": "After an additional 17 months of elevated serum transaminases , the patient was found to have a stage Ic granulosa cell tumor of the ovary .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        25,
        "granulosa cell tumor of the ovary"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4287,
    "text": "CONCLUSION : Patients with tamoxifen - induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "liver dysfunction"
      ],
      [
        "T1",
        "Disease",
        15,
        18,
        "granulosa cell tumors"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "tamoxifen"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4288,
    "text": "Lifetime treatment of mice with azidothymidine ( AZT ) produces myelodysplasia .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "azidothymidine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "AZT"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "myelodysplasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4289,
    "text": "AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "macrocytic anemia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "AZT"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "AIDS"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4290,
    "text": "It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "AZT"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "thymidine"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "phosphate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4291,
    "text": "CBA / Ca male mice started on AZT 0 . 75 mg / ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0 . 5 mg / ml H2O for a group , another group removed from AZT to see recovery , and third group remained on 0 . 75 mg .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "AZT"
      ],
      [
        "T1",
        "Chemical",
        46,
        47,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4292,
    "text": "At 687 days mice that had been on 0 . 75 mg had average platelet counts of 2 . 5 x 10 ( 6 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4293,
    "text": "Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome ( MDS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "myelodysplastic syndrome"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "MDS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4294,
    "text": "A variety of histological patterns was observed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4295,
    "text": "There were two cases of hypocellular myelodysplasia , two cases of hypersegmented myelodysplastic granulocytosis , two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei , one case of megakaryocytic myelosis associated with a hyperplastic marrow , dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis , hemosiderosis and a hypocellular marrow .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        37,
        "hyperplastic marrow"
      ],
      [
        "T1",
        "Disease",
        41,
        43,
        "hypocellular marrow"
      ],
      [
        "T2",
        "Disease",
        54,
        56,
        "hypocellular marrow"
      ],
      [
        "T3",
        "Disease",
        6,
        7,
        "myelodysplasia"
      ],
      [
        "T4",
        "Disease",
        12,
        13,
        "myelodysplastic"
      ],
      [
        "T5",
        "Disease",
        38,
        39,
        "dysmyelopoiesis"
      ],
      [
        "T6",
        "Disease",
        47,
        48,
        "myelodysplasia"
      ],
      [
        "T7",
        "Disease",
        49,
        50,
        "dyserythropoiesis"
      ],
      [
        "T8",
        "Disease",
        51,
        52,
        "hemosiderosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4296,
    "text": "Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells , which is known to be seen commonly in the myelodysplastic syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "myelodysplastic syndrome"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "AZT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4297,
    "text": "Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4298,
    "text": "Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4299,
    "text": "Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "ketamine"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4300,
    "text": "This depression was followed by the sudden appearance of a stimulatory phase .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4301,
    "text": "Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine - induced tachycardia , while it was completely abolished in the reserpinized dogs or by a prior injection of a beta - blocking agent into the SA node artery .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "ketamine"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "tachycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4302,
    "text": "This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of ketamine injected in the SA node artery .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "ketamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4303,
    "text": "Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat pituitary tumors may mediate estrogen - initiated tumor angiogenesis .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "pituitary tumors"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "estrogen"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "estrogen"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4304,
    "text": "Estrogens , which have been associated with several types of human and animal cancers , can induce tumor angiogenesis in the pituitary of Fischer 344 rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Estrogens"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "cancers"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4305,
    "text": "The mechanistic details of tumor angiogenesis induction , during estrogen carcinogenesis , are still unknown .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "tumor"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "estrogen"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "carcinogenesis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4306,
    "text": "To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats , the density of blood vessels was analysed using factor VIII related antigen ( FVIIIRAg ) immunohistochemistry and the expression of vascular endothelial growth factor / vascular permeability factor ( VEGF / VPF ) was examined by Western blot and immunohistochemical analysis .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "estrogen"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4307,
    "text": "The expression of VEGF receptor ( VEGFR - 2 / Flk - 1 / KDR ) was also examined by immunohistochemistry .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4308,
    "text": "The results demonstrated that 17beta - estradiol ( E2 ) induces neovascularization , as well as the growth and enlargement of blood vessels after 7 days of exposure .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "17beta - estradiol"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "E2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4309,
    "text": "The high tumor angiogenic potential was associated with an elevated VEGF / VPF protein expression in the E2 exposed pituitary of ovariectomized ( OVEX ) rats .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "tumor"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "E2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4310,
    "text": "VEGF / VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin ( UEA1 ) binding studies , indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non - endothelial cells .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4311,
    "text": "After 15 days of E2 exposure , VEGF / VPF protein expression , in the non - endothelial cell population , sharply declined and was restricted to the blood vessels .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "E2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4312,
    "text": "The function of non - endothelial - derived VEGF is not clear .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4313,
    "text": "Furthermore , immunohistochemical studies demonstrated that VEGFR - 2 ( flk - 1 / KDR ) , expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        33,
        "E2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4314,
    "text": "These findings suggest that over expression of VEGF and its receptor ( VEGFR - 2 ) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary .",
    "labels": [
      [
        "T0",
        "Chemical",
        29,
        30,
        "estrogen"
      ],
      [
        "T1",
        "Disease",
        31,
        32,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4315,
    "text": "Persistent nephrogenic diabetes insipidus following lithium therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4316,
    "text": "We report the case of a patient who developed severe hypernatraemic dehydration following a head injury .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "head injury"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "dehydration"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4317,
    "text": "Ten years previously he had been diagnosed to have lithium - induced nephrogenic diabetes insipidus , and lithium therapy had been discontinued .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "lithium"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4318,
    "text": "He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion , with clear evidence of nephrogenic diabetes insipidus .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        31,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "polyuric"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "lithium"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "vasopressin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4319,
    "text": "Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Lithium"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "polyuria"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4320,
    "text": "We discuss the possible renal mechanisms and the implications for management of patients with lithium - induced nephrogenic diabetes insipidus .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4321,
    "text": "Effects of NIK - 247 on cholinesterase and scopolamine - induced amnesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "NIK - 247"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "scopolamine"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4322,
    "text": "The effects of NIK - 247 on cholinesterase , scopolamine - induced amnesia and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and E - 2020 .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "NIK - 247"
      ],
      [
        "T1",
        "Chemical",
        31,
        34,
        "E - 2020"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "scopolamine"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "amnesia"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "tacrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4323,
    "text": "NIK - 247 , tacrine and E - 2020 all strongly inhibited acetylcholinesterase ( AChE ) in human red blood cells ( IC50s = 1 . 0 x 10 ( - 6 ) , 2 . 9 x 10 ( - 7 ) and 3 . 7 x 10 ( - 8 ) M , respectively ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "NIK - 247"
      ],
      [
        "T1",
        "Chemical",
        6,
        9,
        "E - 2020"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "tacrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4324,
    "text": "In addition , NIK - 247 and tacrine , but not E - 2020 , strongly inhibited butyrylcholinestrase ( BuChE ) in human serum .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "NIK - 247"
      ],
      [
        "T1",
        "Chemical",
        11,
        14,
        "E - 2020"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "tacrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4325,
    "text": "All three drugs produced mixed inhibition of AChE activity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4326,
    "text": "Moreover , the inhibitory effect of NIK - 247 on AChE was reversible .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "NIK - 247"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4327,
    "text": "All compounds at 0 . 1 - 1 mg / kg p . o . significantly improved the amnesia induced by scopolamine ( 0 . 5 mg / kg s . c . ) in rats performing a passive avoidance task .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "amnesia"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4328,
    "text": "The three compounds at 1 and 3 mg / kg p . o . did not significantly decrease spontaneous movement by rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4329,
    "text": "These findings suggest that NIK - 247 at a low dose ( 0 . 1 - 1 mg / kg p . o . ) improves scopolamine - induced amnesia but does not affect spontaneous movement .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "NIK - 247"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "scopolamine"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4330,
    "text": "The findings suggest that NIK - 247 may be a useful drug for the treatment of Alzheimer ' s disease .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "NIK - 247"
      ],
      [
        "T1",
        "Disease",
        16,
        20,
        "Alzheimer ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4331,
    "text": "Potential therapeutic use of the selective dopamine D1 receptor agonist , A - 86929 : an acute study in parkinsonian levodopa - primed monkeys .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "A - 86929"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "dopamine"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "parkinsonian"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4332,
    "text": "The clinical utility of dopamine ( DA ) D1 receptor agonists in the treatment of Parkinson ' s disease ( PD ) is still unclear .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        19,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "dopamine"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "DA"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4333,
    "text": "The therapeutic use of selective DA D1 receptor agonists such as SKF - 82958 ( 6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide ) and A - 77636 ( [ 1R , 3S ] 3 - [ 1 ' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride ) seems limited because of their duration of action , which is too short for SKF - 82958 ( < 1 hr ) and too long for A - 77636 ( > 20 hr , leading to behavioral tolerance ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "SKF - 82958"
      ],
      [
        "T1",
        "Chemical",
        15,
        50,
        "6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide"
      ],
      [
        "T2",
        "Chemical",
        52,
        55,
        "A - 77636"
      ],
      [
        "T3",
        "Chemical",
        56,
        93,
        "[ 1R , 3S ] 3 - [ 1 ' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride"
      ],
      [
        "T4",
        "Chemical",
        108,
        111,
        "SKF - 82958"
      ],
      [
        "T5",
        "Chemical",
        120,
        123,
        "A - 77636"
      ],
      [
        "T6",
        "Chemical",
        5,
        6,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4334,
    "text": "We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        29,
        "1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine"
      ],
      [
        "T1",
        "Chemical",
        69,
        72,
        "A - 86929"
      ],
      [
        "T2",
        "Chemical",
        73,
        125,
        "[ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "MPTP"
      ],
      [
        "T4",
        "Chemical",
        39,
        40,
        "levodopa"
      ],
      [
        "T5",
        "Disease",
        42,
        43,
        "dyskinesias"
      ],
      [
        "T6",
        "Disease",
        48,
        49,
        "dyskinetic"
      ],
      [
        "T7",
        "Chemical",
        131,
        132,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4335,
    "text": "Levodopa and the DA D2 - like receptor agonist , LY - 171555 ( [ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride ) were also used for comparison .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        13,
        "LY - 171555"
      ],
      [
        "T1",
        "Chemical",
        14,
        55,
        "[ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Levodopa"
      ],
      [
        "T3",
        "Chemical",
        3,
        4,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4336,
    "text": "Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "A - 86929"
      ],
      [
        "T1",
        "Chemical",
        18,
        21,
        "LY - 171555"
      ],
      [
        "T2",
        "Chemical",
        39,
        42,
        "LY - 171555"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "MPTP"
      ],
      [
        "T4",
        "Disease",
        14,
        15,
        "parkinsonism"
      ],
      [
        "T5",
        "Chemical",
        16,
        17,
        "levodopa"
      ],
      [
        "T6",
        "Chemical",
        29,
        30,
        "levodopa"
      ],
      [
        "T7",
        "Disease",
        32,
        33,
        "dyskinesias"
      ],
      [
        "T8",
        "Chemical",
        46,
        47,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4337,
    "text": "Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus ( referred to as the basal ganglia output ) compared with levodopa and selective DA D2 receptor agonist .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "DA"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "levodopa"
      ],
      [
        "T2",
        "Chemical",
        37,
        38,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4338,
    "text": "Potent DA D1 receptor agents with an intermediate duration of efficacy such as A - 86929 ( approximately 4 hr at higher doses tested ) are potential therapeutic tools in PD and merit further attention .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        16,
        "A - 86929"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "DA"
      ],
      [
        "T2",
        "Disease",
        30,
        31,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4339,
    "text": "Neuropeptide - Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "temporal lobe epilepsy"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4340,
    "text": "Neuropeptide - Y ( NPY ) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy ( TLE ) .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "temporal lobe epilepsy"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "TLE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4341,
    "text": "This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure - like events following high - frequency stimulation in hippocampal slices .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4342,
    "text": "The pilocarpine ( PILO ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        24,
        26,
        "brain damage"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "pilocarpine"
      ],
      [
        "T3",
        "Chemical",
        3,
        4,
        "PILO"
      ],
      [
        "T4",
        "Disease",
        7,
        8,
        "epilepsy"
      ],
      [
        "T5",
        "Disease",
        21,
        22,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4343,
    "text": "We report peroxidase - antiperoxidase immunostaining for NPY in several brain regions in this model .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4344,
    "text": "PILO - injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals , in the dentate gyrus inner molecular layer and , in a few cases , within presumed granule cells .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "PILO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4345,
    "text": "NPY immunoreactivity was also dramatically changed in the entorhinal cortex , amygdala and sensorimotor areas .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4346,
    "text": "In addition , PILO injected animals exhibited a reduction in the number of NPY - immunoreactive interneurons compared with controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "PILO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4347,
    "text": "The results demonstrate that changes in NPY expression , including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons , are present in the PILO model of TLE .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        31,
        "PILO"
      ],
      [
        "T1",
        "Disease",
        33,
        34,
        "TLE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4348,
    "text": "However , the significance of this changed synthesis of NPY remains to be determined .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4349,
    "text": "Posteroventral medial pallidotomy in advanced Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4350,
    "text": "BACKGROUND : Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson ' s disease , but the studies to date have involved small numbers of patients and short - term follow - up .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        17,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4351,
    "text": "METHODS : Forty patients with Parkinson ' s disease underwent serial , detailed assessments both after drug withdrawal ( \" off \" period ) and while taking their optimal medical regimens ( \" on \" period ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4352,
    "text": "All patients were examined preoperatively and 39 were examined at six months ; 27 of the patients were also examined at one year , and 11 at two years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4353,
    "text": "RESULTS : The percent improvements at six months were as follows : off - period score for overall motor function , 28 percent ( 95 percent confidence interval , 19 to 38 percent ) , with most of the improvement in the contralateral limbs ; off - period score for activities of daily living , 29 percent ( 95 percent confidence interval , 19 to 39 percent ) ; on - period score for contralateral dyskinesias , 82 percent ( 95 percent confidence interval , 72 to 91 percent ) ; and on - period score for ipsilateral dyskinesias , 44 percent ( 95 percent confidence interval , 29 to 59 percent ) .",
    "labels": [
      [
        "T0",
        "Disease",
        75,
        76,
        "dyskinesias"
      ],
      [
        "T1",
        "Disease",
        98,
        99,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4354,
    "text": "The improvements in dyskinesias and the total scores for off - period parkinsonism , contralateral bradykinesia , and rigidity were sustained in the 11 patients examined at two years .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "dyskinesias"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "parkinsonism"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "bradykinesia"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "rigidity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4355,
    "text": "The improvement in ipsilateral dyskinesias was lost after one year , and the improvements in postural stability and gait lasted only three to six months .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4356,
    "text": "Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4357,
    "text": "The complications of surgery were generally well tolerated , and there were no significant changes in the use of medication .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4358,
    "text": "CONCLUSIONS : In late - stage Parkinson ' s disease , pallidotomy significantly reduces levodopa - induced dyskinesias and off - period disability .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        10,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4359,
    "text": "Much of the benefit is sustained at two years , although some improvements , such as those on the ipsilateral side and in axial symptoms , wane within the first year .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4360,
    "text": "The on - period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4361,
    "text": "Clarithromycin - induced ventricular tachycardia .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Clarithromycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4362,
    "text": "Clarithromycin is a relatively new macrolide antibiotic that offers twice - daily dosing .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Clarithromycin"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "macrolide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4363,
    "text": "It differs from erythromycin only in the methylation of the hydroxyl group at position 6 .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "erythromycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4364,
    "text": "Although the side - effect profile of erythromycin is established , including gastroenteritis and interactions with other drugs subject to hepatic mixed - function oxidase metabolism , experience with the newer macrolides is still being recorded .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "erythromycin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "gastroenteritis"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "macrolides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4365,
    "text": "Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Cardiotoxicity"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "erythromycin"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "macrolides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4366,
    "text": "We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "ventricular dysrhythmias"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "clarithromycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4367,
    "text": "The dysrhythmias resolved after discontinuation of the drug .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "dysrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4368,
    "text": "Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine - morphine administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "glyceryl trinitrate"
      ],
      [
        "T1",
        "Disease",
        6,
        10,
        "sphincter of Oddi spasm"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "prostigmine"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4369,
    "text": "OBJECTIVE : In this study the effect of glyceryl trinitrate on the prostigmine - morphine - induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "glyceryl trinitrate"
      ],
      [
        "T1",
        "Disease",
        17,
        21,
        "sphincter of Oddi spasm"
      ],
      [
        "T2",
        "Disease",
        28,
        32,
        "sphincter of Oddi dyskinesia"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "prostigmine"
      ],
      [
        "T4",
        "Chemical",
        14,
        15,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4370,
    "text": "METHOD : Sphincter of Oddi spasm was induced by prostigmine - morphine administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        6,
        "Sphincter of Oddi spasm"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "prostigmine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "morphine"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "prostigmine"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4371,
    "text": "The entire procedure was repeated during glyceryl trinitrate infusion ( Nitrolingual 1 microg / kg / min for 120 min ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "glyceryl trinitrate"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "Nitrolingual"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4372,
    "text": "RESULTS : Prostigmine - morphine provocation caused significant increases in the time to peak activity ( Tmax ) over the hepatic hilum ( HH : 34 . 33 + / - 5 . 05 vs . 22 . 77 + / - 3 . 26 ) and the common bile duct ( CBD : 60 . 44 + / - 5 . 99 vs . 40 . 0 + / - 2 . 88 ) and in the half - time of excretion ( T1 / 2 ) over the liver parenchyma ( LP : 120 . 04 + / - 16 . 01 vs . 27 . 37 + / - 2 . 19 ) , HH ( 117 . 61 + / - 14 . 71 vs . 31 . 85 + / - 3 . 99 ) and CBD ( 158 . 11 + / - 9 . 18 vs . 40 . 1 + / - 6 . 24 ) , indicating a complete spasm at the level of the sphincter of Oddi .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Prostigmine"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "morphine"
      ],
      [
        "T2",
        "Disease",
        168,
        169,
        "spasm"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4373,
    "text": "Glyceryl trinitrate infusion completely normalized the prostigmine - morphine - induced alterations in these quantitative parameters ( TmaX over the LP : 11 . 33 + / - 1 . 13 ; over the HH : 18 . 88 + / - 1 . 48 ; and over the CBD : 36 . 22 + / - 1 . 92 ; and T1 / 2 over the LP : 28 . 21 + / - 1 . 83 ; over the HH : 33 . 42 + / - 3 . 10 ; and over the CBD : 41 . 66 + / - 6 . 33 ) , suggesting an effective sphincter - relaxing effect of glyceryl trinitrate .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Glyceryl trinitrate"
      ],
      [
        "T1",
        "Chemical",
        117,
        119,
        "glyceryl trinitrate"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "prostigmine"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4374,
    "text": "CONCLUSION : These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine - induced sphincter of Oddi spasm in humans .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "glyceryl trinitrate"
      ],
      [
        "T1",
        "Disease",
        19,
        23,
        "sphincter of Oddi spasm"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4375,
    "text": "Since glyceryl trinitrate is able to overcome even the drastic effect of morphine , it might be of relevance in the treatment of sphincter of Oddi dyskinesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "glyceryl trinitrate"
      ],
      [
        "T1",
        "Disease",
        23,
        27,
        "sphincter of Oddi dyskinesia"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4376,
    "text": "Immunopathology of penicillamine - induced glomerular disease .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "glomerular disease"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "penicillamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4377,
    "text": "Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D - penicillamine .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        16,
        19,
        "D - penicillamine"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4378,
    "text": "Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase , or no departure from normal .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4379,
    "text": "Electron microscopy , however , revealed subepithelial electron - dense deposits , fusion of epithelial cell foot processes , and evidence of mesangial cell hyperactivity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4380,
    "text": "Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4381,
    "text": "The findings were similar to those in early membranous glomerulonephritis , differences being observed however in the results of staining for the early - acting complement components C1q and C4 .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "membranous glomerulonephritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4382,
    "text": "It is tentatively concluded that complement was activated by the classical pathway .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4383,
    "text": "Experimental cranial pain elicited by capsaicin : a PET study .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "pain"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "capsaicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4384,
    "text": "Using a positron emission tomography ( PET ) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state , but not in the headache free interval .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "migraine"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "headache"
      ],
      [
        "T2",
        "Disease",
        35,
        36,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4385,
    "text": "It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called ' migraine generator ' .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "migraine"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "migraine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4386,
    "text": "To test this hypothesis we performed an experimental pain study in seven healthy volunteers , using the same positioning in the PET scanner as in the migraine patients .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "pain"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "migraine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4387,
    "text": "A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "capsaicin"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "painful"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4388,
    "text": "Increases of regional cerebral blood flow ( rCBF ) were found bilaterally in the insula , in the anterior cingulate cortex , the cavernous sinus and the cerebellum .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4389,
    "text": "Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "migraine"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "pain"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4390,
    "text": "The increase of activation in the region of the cavernous sinus however , suggests that this structure is more likely to be involved in trigeminal transmitted pain as such , rather than in a specific type of headache as was suggested for cluster headache .",
    "labels": [
      [
        "T0",
        "Disease",
        42,
        44,
        "cluster headache"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "pain"
      ],
      [
        "T2",
        "Disease",
        37,
        38,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4391,
    "text": "Value of methylprednisolone in prevention of the arthralgia - myalgia syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        20,
        "iron dextran"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "methylprednisolone"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "arthralgia"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4392,
    "text": "The safety and efficacy of total dose infusion ( TDI ) of iron dextran has been well documented .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "iron dextran"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4393,
    "text": "In 40 % of treated patients , an arthralgia - myalgia syndrome develops .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "arthralgia"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4394,
    "text": "The purpose of this randomized , double - blind , prospective study was to investigate whether intravenous ( i . v . ) administration of methylprednisolone ( MP ) prevents this complication .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        26,
        "methylprednisolone"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "MP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4395,
    "text": "Sixty - five patients , 34 women and 31 men , ages 36 to 80 years , received either normal saline before and after TDI ( group 1 ) , 125 mg i . v . MP before and saline after TDI ( group 2 ) , or 125 mg i . v . MP before and after TDI ( group 3 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        36,
        37,
        "MP"
      ],
      [
        "T1",
        "Chemical",
        54,
        55,
        "MP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4396,
    "text": "Patients were observed for 72 hours and reactions were recorded and graded according to severity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4397,
    "text": "Fifty - eight percent of group 1 patients , 33 % of group 2 , and 26 % of group 3 had reactions to TDI .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4398,
    "text": "The severity of reactions ( minimal , mild , and moderate , respectively ) was as follows : group 1 - - 6 , 6 , and 2 ; group 2 - - 1 , 5 , and 0 ; group 3 - - 5 , 1 , and 0 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4399,
    "text": "Data were analyzed by the two - sided Fisher ' s exact test using 95 % confidence intervals with the approximation of Woolf .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4400,
    "text": "These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia - myalgia syndrome .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "MP"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "arthralgia"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4401,
    "text": "We conclude that 125 mg i . v . MP should be given routinely before and after TDI of iron dextran .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        21,
        "iron dextran"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "MP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4402,
    "text": "Prolongation of the QT interval related to cisapride - diltiazem interaction .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        5,
        "Prolongation of the QT interval"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cisapride"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "diltiazem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4403,
    "text": "Cisapride , a cytochrome P450 3A4 ( CYP3A4 ) substrate , is widely prescribed for the treatment of gastrointestinal motility disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        21,
        "gastrointestinal motility disorders"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Cisapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4404,
    "text": "Prolongation of QT interval , torsades de pointes , and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents , but not with other CYP3A4 inhibitors .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Prolongation of QT interval"
      ],
      [
        "T1",
        "Disease",
        5,
        8,
        "torsades de pointes"
      ],
      [
        "T2",
        "Disease",
        10,
        13,
        "sudden cardiac death"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "erythromycin"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "azole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4405,
    "text": "A possible drug interaction occurred in a 45 - year - old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem , an agent that has inhibitory effect on CYP3A4 , for hypertension .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        21,
        "gastroesophageal reflux disorder"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "cisapride"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "diltiazem"
      ],
      [
        "T3",
        "Disease",
        34,
        35,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4406,
    "text": "The patient was in near syncope and had QT - interval prolongation .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "QT - interval prolongation"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "syncope"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4407,
    "text": "After discontinuing cisapride , the QT interval returned to normal and symptoms did not recur .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "cisapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4408,
    "text": "We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4 , including diltiazem .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "cisapride"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "diltiazem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4409,
    "text": "Cortical motor overactivation in parkinsonian patients with L - dopa - induced peak - dose dyskinesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "L - dopa"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "parkinsonian"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4410,
    "text": "We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L - dopa medication , the first one without L - dopa induced dyskinesia ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        40,
        43,
        "L - dopa"
      ],
      [
        "T1",
        "Chemical",
        49,
        52,
        "L - dopa"
      ],
      [
        "T2",
        "Disease",
        37,
        38,
        "parkinsonian"
      ],
      [
        "T3",
        "Disease",
        53,
        54,
        "dyskinesia"
      ],
      [
        "T4",
        "Disease",
        67,
        68,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4411,
    "text": "Single photon emission tomography with i . v . 133Xe was used to measure the rCBF changes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4412,
    "text": "The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non - dyskinetic parkinsonian patients , with a significant overactivation in the supplementary motor area and the ipsi - and contralateral primary motor areas .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "dyskinetic"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "parkinsonian"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "dyskinetic"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4413,
    "text": "These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement , like L - dopa - induced peak dose dyskinesia , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "abnormal involuntary movement"
      ],
      [
        "T1",
        "Chemical",
        15,
        18,
        "L - dopa"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "hyperkinetic"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4414,
    "text": "Open - label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "levofloxacin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "sinusitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4415,
    "text": "PURPOSE : To evaluate the efficacy and safety of levofloxacin ( 500 mg orally once daily for 10 to 14 days ) in treating adult outpatients with acute bacterial sinusitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "levofloxacin"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "sinusitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4416,
    "text": "PATIENTS AND METHODS : A total of 329 patients enrolled in the study at 24 centers .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4417,
    "text": "All patients had a pre - therapy Gram ' s stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4418,
    "text": "Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4419,
    "text": "Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre - therapy pathogen ( s ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4420,
    "text": "RESULTS : The most common pathogens were Haemophilus influenzae , Streptococcus pneumoniae , Staphylococcus aureus , and Moraxella catarrhalis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4421,
    "text": "Of 300 clinically evaluable patients , 175 ( 58 % ) were cured and 90 ( 30 % ) were improved at the post - therapy evaluation , resulting in a clinical success rate of 88 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4422,
    "text": "Thirty - five patients ( 12 % ) clinically failed treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4423,
    "text": "The microbiologic eradication rate ( presumed plus documented ) among 138 microbiologically evaluable patients was 92 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4424,
    "text": "Microbiologic eradication rates ( presumed plus documented ) of the most common pathogens ranged from 93 % ( M . catarrhalis ) to 100 % ( S . pneumoniae ) at the post - therapy visit .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4425,
    "text": "All but one of the 265 patients who were cured or improved at post - therapy returned for a long - term follow - up visit ; 243 ( 92 % ) remained well 4 to 6 weeks after therapy ; and 21 ( 8 % ) had a relapse of symptoms .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4426,
    "text": "Adverse events considered to be related to levofloxacin administration were reported by 29 patients ( 9 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "levofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4427,
    "text": "The most common drug - related adverse events were diarrhea , flatulence , and nausea ; most adverse events were mild to moderate in severity .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "diarrhea"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "flatulence"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "nausea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4428,
    "text": "CONCLUSION : The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "levofloxacin"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "sinusitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4429,
    "text": "Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case - control study .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "endometrial carcinoma"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4430,
    "text": "F d ration Nationale des Centres de Lutte Contre le Cancer ( FNCLCC ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4431,
    "text": "Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer , its endometrial iatrogenic effects must be carefully examined .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "breast cancer"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "breast cancer"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4432,
    "text": "We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case - control study .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "endometrial cancer"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "breast cancer"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4433,
    "text": "Cases of endometrial cancer diagnosed after breast cancer ( n = 135 ) and 467 controls matched for age , year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "endometrial cancer"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "breast cancer"
      ],
      [
        "T2",
        "Disease",
        24,
        26,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4434,
    "text": "Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not ( crude relative risk = 4 . 9 , p = 0 . 0001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "endometrial cancer"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4435,
    "text": "Univariate and adjusted analyses showed that the risk increased with the length of treatment ( p = 0 . 0001 ) or the cumulative dose of tamoxifen received ( p = 0 . 0001 ) , irrespective of the daily dose .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4436,
    "text": "Women who had undergone pelvic radiotherapy also had a higher risk ( crude relative risk = 7 . 8 , p = 0 . 0001 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4437,
    "text": "After adjusting for confounding factors , the risk was higher for tamoxifen users ( p = 0 . 0012 ) , treatment for more than 3 years ( all p < 0 . 03 ) and pelvic radiotherapy ( p = 0 . 012 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4438,
    "text": "Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "endometrial cancer"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "advanced disease"
      ],
      [
        "T2",
        "Disease",
        19,
        21,
        "endometrial cancer"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4439,
    "text": "Our results suggest a causal role of tamoxifen in endometrial cancer , particularly when used as currently proposed for breast cancer prevention .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "endometrial cancer"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "breast cancer"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4440,
    "text": "Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4441,
    "text": "Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Endometrial cancers"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4442,
    "text": "Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "breast cancer"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4443,
    "text": "A long - term evaluation of the risk - benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "breast cancer"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4444,
    "text": "Contribution of the glycine site of NMDA receptors in rostral and intermediate - caudal parts of the striatum to the regulation of muscle tone in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "glycine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "NMDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4445,
    "text": "The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "glycine"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "NMDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4446,
    "text": "Muscle tone was examined using a combined mechanoand electromyographic method , which measured simultaneously the muscle resistance ( MMG ) of the rat ' s hind foot to passive extension and flexion in the ankle joint and the electromyographic activity ( EMG ) of the antagonistic muscles of that joint : gastrocnemius and tibialis anterior .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4447,
    "text": "Muscle rigidity was induced by haloperidol ( 2 . 5 mg / kg i . p . ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Muscle rigidity"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4448,
    "text": "5 , 7 - dichlorokynurenic acid ( 5 , 7 - DCKA ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced muscle rigidity ( MMG ) and the enhanced electromyographic activity ( EMG ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        6,
        "5 , 7 - dichlorokynurenic acid"
      ],
      [
        "T1",
        "Chemical",
        7,
        12,
        "5 , 7 - DCKA"
      ],
      [
        "T2",
        "Disease",
        53,
        55,
        "muscle rigidity"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "glycine"
      ],
      [
        "T4",
        "Chemical",
        50,
        51,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4449,
    "text": "5 , 7 - DCKA injected bilaterally in a dose of 4 . 5 microg / 0 . 5 microl into the intermediate - caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        5,
        "5 , 7 - DCKA"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4450,
    "text": "The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "glycine"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "NMDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4451,
    "text": "Carboplatin toxic effects on the peripheral nervous system of the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4452,
    "text": "BACKGROUND : The most striking of carboplatin ' s advantages ( CBDCA ) over cisplatin ( CDDP ) is its markedly reduced rate of neurotoxic effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "carboplatin"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "CBDCA"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "cisplatin"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "CDDP"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "neurotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4453,
    "text": "However , the use of CBDCA higher - intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        33,
        "peripheral nervous system damage"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "CBDCA"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "neurotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4454,
    "text": "MATERIALS AND METHODS : Two different schedules of CBDCA administration ( 10 mg / kg and 15 mg / kg i . p . twice a week for nine times ) were evaluated in Wistar rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "CBDCA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4455,
    "text": "Neurotoxicity was assessed for behavioral ( tail - flick test ) , neurophysiological ( nerve conduction velocity in the tail nerve ) , morphological , morphometrical and analytical effects .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4456,
    "text": "RESULTS : CBDCA administration induced dose - dependent peripheral neurotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "peripheral neurotoxicity"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "CBDCA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4457,
    "text": "Pain perception and nerve conduction velocity in the tail were significantly impaired , particularly after the high - dose treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4458,
    "text": "The dorsal root ganglia sensory neurons and , to a lesser extent , satellite cells showed the same changes as those induced by CDDP , mainly affecting the nucleus and nucleolus of ganglionic sensory neurons .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "CDDP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4459,
    "text": "Moreover , significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "platinum"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "CBDCA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4460,
    "text": "CONCLUSIONS : CBDCA is neurotoxic in our model , and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "CBDCA"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "neurotoxic"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "CDDP"
      ],
      [
        "T3",
        "Disease",
        31,
        32,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4461,
    "text": "This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "CBDCA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4462,
    "text": "Effects of cisapride on symptoms and postcibal small - bowel motor function in patients with irritable bowel syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "irritable bowel syndrome"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "cisapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4463,
    "text": "BACKGROUND : Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "Irritable bowel syndrome"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "abdominal pain"
      ],
      [
        "T2",
        "Disease",
        19,
        22,
        "disordered gastrointestinal motility"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4464,
    "text": "Our aim was to assess the effects of long - term treatment with a prokinetic agent , cisapride , on postprandial jejunal motility and symptoms in the irritable bowel syndrome ( IBS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        30,
        "irritable bowel syndrome"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "cisapride"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "IBS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4465,
    "text": "METHODS : Thirty - eight patients with IBS ( constipation - predominant , n = 17 ; diarrhoea - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week ' s treatment [ cisapride , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "IBS"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "constipation"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "diarrhoea"
      ],
      [
        "T3",
        "Chemical",
        41,
        42,
        "cisapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4466,
    "text": "RESULTS : In diarrhoea - predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "diarrhoea"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "cisapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4467,
    "text": "In cisapride - treated diarrhoea - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / - 2 . 6 mm Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "cisapride"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "diarrhoea"
      ],
      [
        "T2",
        "Chemical",
        37,
        38,
        "cisapride"
      ],
      [
        "T3",
        "Chemical",
        90,
        91,
        "cisapride"
      ],
      [
        "T4",
        "Chemical",
        146,
        147,
        "cisapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4468,
    "text": "No significant differences in jejunal motility were found in the constipation - predominant IBS group .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "constipation"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "IBS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4469,
    "text": "Symptoms were assessed by using a visual analogue scale before and after treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4470,
    "text": "Symptom scores relating to the severity of constipation were lower in cisapride - treated constipation - predominant IBS patients [ score , 54 + / - 5 versus 67 + / - 14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "constipation"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "cisapride"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "constipation"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "IBS"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "cisapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4471,
    "text": "Diarrhoea - predominant IBS patients had a higher pain score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Diarrhoea"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "IBS"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "pain"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "cisapride"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "cisapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4472,
    "text": "CONCLUSION : Cisapride affects jejunal contraction characteristics and some symptoms in IBS .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Cisapride"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "IBS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4473,
    "text": "Prevention of breast cancer with tamoxifen : preliminary findings from the Italian randomised trial among hysterectomised women .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "breast cancer"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4474,
    "text": "Italian Tamoxifen Prevention Study .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "Tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4475,
    "text": "BACKGROUND : Tamoxifen is a candidate chemopreventive agent in breast cancer , although the drug may be associated with the development of endometrial cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "breast cancer"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "endometrial cancer"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "Tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4476,
    "text": "Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4477,
    "text": "METHODS : In October , 1992 , we started a double - blind placebo - controlled , randomised trial of tamoxifen in women ( mainly in Italy ) who did not have breast cancer and who had had a hysterectomy .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        34,
        "breast cancer"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4478,
    "text": "Women were randomised to receive tamoxifen 20 mg per day or placebo , both orally for 5 years .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4479,
    "text": "The original plan was to follow the intervention phase by 5 years ' follow - up .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4480,
    "text": "In June , 1997 , the trialists and the data - monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4481,
    "text": "Recruitment ended on July 11 , 1997 , and the study will continue as planned .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4482,
    "text": "The primary endpoints are the occurrence of and deaths from breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4483,
    "text": "This preliminary interim analysis is based on intention - to - treat .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4484,
    "text": "FINDINGS : 5408 women were randomised ; participating women have a median follow - up of 46 months for major endpoints .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4485,
    "text": "41 cases of breast cancer occurred so far ; there have been no deaths from breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "breast cancer"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4486,
    "text": "There is no difference in breast - cancer frequency between the placebo ( 22 cases ) and tamoxifen ( 19 ) arms .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "breast - cancer"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4487,
    "text": "There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "breast cancer"
      ],
      [
        "T1",
        "Disease",
        40,
        42,
        "breast cancer"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "tamoxifen"
      ],
      [
        "T3",
        "Chemical",
        51,
        52,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4488,
    "text": "Compared with the placebo group , there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "vascular events"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "hypertriglyceridaemia"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4489,
    "text": "INTERPRETATION : Although this preliminary analysis has low power , in this cohort of women at low - to - normal risk of breast cancer , the postulated protective effects of tamoxifen are not yet apparent .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "breast cancer"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4490,
    "text": "Women using hormone - replacement therapy appear to have benefited from use of tamoxifen .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4491,
    "text": "There were no deaths from breast cancer recorded in women in the study .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4492,
    "text": "It is essential to continue follow - up to quantify the long - term risks and benefits of tamoxifen therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "tamoxifen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4493,
    "text": "Epileptogenic activity of folic acid after drug induces SLE ( folic acid and epilepsy )",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "folic acid"
      ],
      [
        "T1",
        "Chemical",
        10,
        12,
        "folic acid"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "SLE"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4494,
    "text": "OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "folic acid"
      ],
      [
        "T1",
        "Disease",
        28,
        30,
        "birth defects"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "epileptic"
      ],
      [
        "T3",
        "Disease",
        31,
        32,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4495,
    "text": "STUDY DESIGN : First a randomised trial , later periconception care including in total 12225 females .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4496,
    "text": "RESULTS : Of 60 epileptic women with periconceptional folic acid ( 0 . 8 mg ) - containing multivitamin supplementation , no one developed epilepsy - related side effects during the periconception period .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "folic acid"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "epileptic"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4497,
    "text": "One epileptic woman delivered a newborn with cleft lip and palate .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "cleft lip and palate"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4498,
    "text": "Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4499,
    "text": "This 22 - year - old epileptic woman was treated continuously by carbamazepine and a folic acid ( 1 mg ) - containing multivitamin from the 20th week of gestation .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "folic acid"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "epileptic"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4500,
    "text": "She developed status epilepticus and later symptoms of systemic lupus erythematodes .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        8,
        11,
        "systemic lupus erythematodes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4501,
    "text": "Her pregnancy ended with stillbirth .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "stillbirth"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4502,
    "text": "CONCLUSIONS : The epileptic pregnant patient ' s autoimmune disease ( probably drug - induced lupus ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of folic acid triggered a cluster of seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "autoimmune disease"
      ],
      [
        "T1",
        "Chemical",
        37,
        39,
        "folic acid"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "epileptic"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "lupus"
      ],
      [
        "T4",
        "Disease",
        43,
        44,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4503,
    "text": "Physiological dose ( < 1 mg ) of folic acid both in healthy and 60 epileptic women , all without any autoimmune disease , did not increase the risk for epileptic seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "folic acid"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "autoimmune disease"
      ],
      [
        "T2",
        "Disease",
        30,
        32,
        "epileptic seizures"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4504,
    "text": "Stroke and cocaine or amphetamine use .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Stroke"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4505,
    "text": "The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "amphetamine"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "ischemic"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4506,
    "text": "The limited number of epidemiologic studies of stroke and use of cocaine and / or amphetamine have been done in settings that serve mostly the poor and / or minorities .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "stroke"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4507,
    "text": "This case - control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4508,
    "text": "We attempted to identify all incident strokes in women ages 15 - 44 years during a 3 - year period using hospital admission and discharge records , emergency department logs , and payment requests for out - of - plan hospitalizations .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "strokes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4509,
    "text": "We selected controls , matched on age and facility of usual care , at random from healthy members of the health plan .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4510,
    "text": "We obtained information in face - to - face interviews .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4511,
    "text": "There were 347 confirmed stroke cases and 1 , 021 controls .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4512,
    "text": "The univariate matched odds ratio for stroke in women who admitted to using cocaine and / or amphetamine was 8 . 5 ( 95 % confidence interval = 3 . 6 - 20 . 0 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "stroke"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4513,
    "text": "After further adjustment for potential confounders , the odds ratio in women who reported using cocaine and / or amphetamine was 7 . 0 ( 95 % confidence interval = 2 . 8 - 17 . 9 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4514,
    "text": "The use of cocaine and / or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous , insured urban population .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "amphetamine"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4515,
    "text": "Acute renal failure subsequent to the administration of rifampicin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "rifampicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4516,
    "text": "A follow - up study of cases reported earlier .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4517,
    "text": "A clinical presentation is made of a 2 - 3 year follow - up of six cases of acute renal failure that have been reported earlier .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        21,
        "acute renal failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4518,
    "text": "The patients had developed transient renal failure after the intermittent administration of rifampicin .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "renal failure"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "rifampicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4519,
    "text": "The stage of olig - anuria lasted for 1 - 3 weeks , and five of the patients were treated by hemodialysis .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "anuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4520,
    "text": "Two of the patients died due to unrelated causes during the follow - up period .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4521,
    "text": "The four patients re - examined were clinically cured .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4522,
    "text": "Pathologic findings by light microscopy and immunofluorescence at biopsy were scarce .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4523,
    "text": "Nothing abnormal was seen by electron microscopy in two of the cases studied .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4524,
    "text": "Renal function was normal .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4525,
    "text": "In three cases the excretion at 131I - hippuran renography was slightly slowed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4526,
    "text": "Although in the acute stage the renal lesions histologically appeared toxic , evidence suggestive of an immunological mechanism cannot be excluded .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "renal lesions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4527,
    "text": "Chronic effects of a novel synthetic anthracycline derivative ( SM - 5887 ) on normal heart and doxorubicin - induced cardiomyopathy in beagle dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "SM - 5887"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "anthracycline"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "doxorubicin"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4528,
    "text": "This study was designed to investigate the chronic cardiotoxic potential of SM - 5887 and a possible deteriorating effect of SM - 5887 on low - grade cardiotoxicity pre - induced by doxorubicin in beagle dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "SM - 5887"
      ],
      [
        "T1",
        "Chemical",
        20,
        23,
        "SM - 5887"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "cardiotoxic"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "cardiotoxicity"
      ],
      [
        "T4",
        "Chemical",
        32,
        33,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4529,
    "text": "In the chronic treatment , beagle dogs of each sex were given intravenously once every 3 weeks , either a sublethal dose of doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        36,
        "SM - 5887"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4530,
    "text": "The experiment was terminated 3 weeks after the ninth dosing .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4531,
    "text": "Animals which received over six courses of doxorubicin demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological cardiomyopathy , while animals which were terminally sacrificed after the SM - 5887 administration did not show any changes in ECG , blood pressure and histopathological examinations .",
    "labels": [
      [
        "T0",
        "Chemical",
        35,
        38,
        "SM - 5887"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "doxorubicin"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4532,
    "text": "To examine a possibly deteriorating cardiotoxic effect of SM - 5887 , low - grade cardiomyopathy was induced in dogs by four courses of doxorubicin ( 1 . 5 mg / kg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "SM - 5887"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "cardiotoxic"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "cardiomyopathy"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4533,
    "text": "Nine weeks after pre - treatment , dogs were given four courses of either doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) once every 3 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        27,
        "SM - 5887"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4534,
    "text": "The low - grade cardiotoxic changes were enhanced by the additional doxorubicin treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "cardiotoxic"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4535,
    "text": "On the contrary , the SM - 5887 treatment did not progress the grade of cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "SM - 5887"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4536,
    "text": "In conclusion , SM - 5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin - induced cardiotoxicity in dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "SM - 5887"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "cardiotoxicity"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "doxorubicin"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4537,
    "text": "Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "valvular heart disease"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "fenfluramine"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "dexfenfluramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4538,
    "text": "BACKGROUND : Because uncontrolled echocardiographic surveys suggested that up to 30 % to 38 % of users of fenfluramine and dexfenfluramine had valvular disease , these drugs were withdrawn from the market .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "valvular disease"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "fenfluramine"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "dexfenfluramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4539,
    "text": "OBJECTIVE : To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "valvular abnormalities"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "fenfluramine"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "dexfenfluramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4540,
    "text": "DESIGN : Cohort study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4541,
    "text": "SETTING : Academic primary care practices .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4542,
    "text": "PATIENTS : 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "fenfluramine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "dexfenfluramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4543,
    "text": "MEASUREMENTS : Follow - up echocardiography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4544,
    "text": "The primary outcome was new or worsening valvulopathy , defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U . S .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        18,
        "aortic or mitral regurgitation"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "valvulopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4545,
    "text": "Food and Drug Administration criteria ( at least mild aortic regurgitation or moderate mitral regurgitation ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "aortic regurgitation"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "mitral regurgitation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4546,
    "text": "RESULTS : Two patients ( 4 . 3 % [ 95 % CI , 0 . 6 % to 14 . 8 % ] ) receiving fenfluramine - phentermine developed valvular heart disease .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        33,
        "valvular heart disease"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "fenfluramine"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "phentermine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4547,
    "text": "One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "bicuspid aortic valve"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "aortic regurgitation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4548,
    "text": "The second patient developed new moderate aortic insufficiency .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "aortic insufficiency"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4549,
    "text": "CONCLUSION : Users of diet medications are at risk for valvular heart disease .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "valvular heart disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4550,
    "text": "However , the incidence may be lower than that reported previously .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4551,
    "text": "Therapeutic drug monitoring of tobramycin : once - daily versus twice - daily dosage schedules .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "tobramycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4552,
    "text": "OBJECTIVE : To evaluate the effect of dosage regimen ( once - daily vs . twice - daily ) of tobramicyn on steady - state serum concentrations and toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "tobramicyn"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4553,
    "text": "MATERIALS AND METHODS : Patients undergoing treatment with i . v . tobramycin ( 4 mg / kg / day ) were randomised to two groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "tobramycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4554,
    "text": "Group OD ( n = 22 ) received a once - daily dose of tobramycin and group TD ( n = 21 ) received the same dose divided into two doses daily .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "tobramycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4555,
    "text": "Tobramycin serum concentrations ( peak and trough ) were measured by enzyme multiplied immunoassay .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Tobramycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4556,
    "text": "The renal and auditory functions of the patients were monitored before , during and immediately after treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4557,
    "text": "RESULTS : The two groups were comparable with respect to sex , age , body weight and renal function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4558,
    "text": "No statistically significant differences were found in mean daily dose , duration of treatment , or cumulative dose .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4559,
    "text": "Trough concentrations were < 2 g / ml in the two groups ( 100 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4560,
    "text": "Peak concentrations were > 6 microg / ml in 100 % of the OD group and in 67 % of the TD group ( P < 0 . 01 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4561,
    "text": "Mean peak concentrations were markedly different : 11 . 00 + / - 2 . 89 microg / ml in OD vs . 6 . 53 + / - 1 . 45 microg / ml in TD ( P < 0 . 01 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4562,
    "text": "The pharmacokinetics parameters were : Ke , ( 0 . 15 + / - 0 . 03 / h in OD vs . 0 . 24 + / - 0 . 06 / h in TD ) , t1 / 2 , ( 4 . 95 + / - 1 . 41 h in OD vs . 3 . 07 + / - 0 . 71 h in TD ) , Vd ( 0 . 35 + / - 0 . 11 l / kg in OD vs . 0 . 33 + / - 0 . 09 l / kg in TD ) , Cl ( 0 . 86 + / - 0 . 29 ml / min / kg in OD vs . 1 . 28 + / - 0 . 33 ml / min / kg in TD ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4563,
    "text": "Increased serum creatinine was observed in 73 % of patients in OD versus 57 % of patients in TD , without evidence of nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "creatinine"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4564,
    "text": "In TD group , three patients developed decreased auditory function , of which one presented with an auditory loss of - 30 dB , whereas in the OD group only one patient presented decreased auditory function .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "decreased auditory function"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "auditory loss"
      ],
      [
        "T2",
        "Disease",
        33,
        36,
        "decreased auditory function"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4565,
    "text": "CONCLUSION : This small study suggests that a once - daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice - daily regimen .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "tobramycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4566,
    "text": "Using a single - dose therapy , peak concentration determination is not necessary , only trough samples should be monitored to ensure levels below 2 microg / ml .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4567,
    "text": "Enhanced bradycardia induced by beta - adrenoceptor antagonists in rats pretreated with isoniazid .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "bradycardia"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "isoniazid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4568,
    "text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        30,
        "gamma - aminobutyric acid"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "isoniazid"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "hypotension"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "tachycardia"
      ],
      [
        "T4",
        "Disease",
        16,
        17,
        "bradycardia"
      ],
      [
        "T5",
        "Chemical",
        31,
        32,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4569,
    "text": "In the present study , the possible enhancement by isoniazid of bradycardia induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with chloralose - urethane .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "isoniazid"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "bradycardia"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "chloralose"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "urethane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4570,
    "text": "Isoniazid significantly increased bradycardia after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Isoniazid"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "bradycardia"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "propranolol"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "pindolol"
      ],
      [
        "T4",
        "Chemical",
        9,
        10,
        "labetalol"
      ],
      [
        "T5",
        "Chemical",
        11,
        12,
        "atenolol"
      ],
      [
        "T6",
        "Chemical",
        17,
        18,
        "clonidine"
      ],
      [
        "T7",
        "Chemical",
        22,
        23,
        "hexamethonium"
      ],
      [
        "T8",
        "Chemical",
        24,
        25,
        "carbachol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4571,
    "text": "Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "methylatropine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4572,
    "text": "These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "isoniazid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4573,
    "text": "Such interference could be exerted centrally , possibly at the nucleus ambiguus , or peripherally at the sinus node .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4574,
    "text": "Structural and functional impairment of mitochondria in adriamycin - induced cardiomyopathy in mice : suppression of cytochrome c oxidase II gene expression .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        6,
        "Structural and functional impairment of mitochondria"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "adriamycin"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4575,
    "text": "The use of adriamycin ( ADR ) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "cardiovascular toxicity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "adriamycin"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "ADR"
      ],
      [
        "T3",
        "Disease",
        8,
        9,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4576,
    "text": "Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase ( COX ) and suppresses its enzyme activity led us to investigate ADR ' s action on the cardiovascular functions and heart mitochondrial morphology in Balb - c mice i . p . treated with ADR for several weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "ADR"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "ADR"
      ],
      [
        "T2",
        "Chemical",
        45,
        46,
        "ADR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4577,
    "text": "At various times during treatment , the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4578,
    "text": "In parallel , total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady - state level of three RNA transcripts encoded by the COXII , COXIII , and COXIV genes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4579,
    "text": "Similarly , samples obtained from the liver of the same animals were analyzed for comparative studies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4580,
    "text": "Our results indicated that 1 ) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent swelling , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "cardiovascular arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "ADR"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "bradycardia"
      ],
      [
        "T3",
        "Disease",
        53,
        54,
        "swelling"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4581,
    "text": "Such abnormalities were not observed in the mitochondria of liver tissue ; and 3 ) among the three genes of COX enzyme examined , only COXII gene expression was suppressed by ADR treatment , mainly after 8 weeks in both heart and liver .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        32,
        "ADR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4582,
    "text": "Knowing that heart mitochondria represent almost 40 % of heart muscle by weight , we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        31,
        "mitochondrial structural and functional impairment"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "ADR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 0,
    "text": "Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Torsade de pointes"
      ],
      [
        "T1",
        "Disease",
        3,
        5,
        "ventricular tachycardia"
      ],
      [
        "T2",
        "Disease",
        15,
        17,
        "dilated cardiomyopathy"
      ],
      [
        "T3",
        "Disease",
        18,
        21,
        "congestive heart failure"
      ],
      [
        "T4",
        "Chemical",
        9,
        10,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1,
    "text": "The authors describe the case of a 56 - year - old woman with chronic , severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose ( 2 . 5 mcg / kg per min ) dobutamine .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "heart failure"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "dilated cardiomyopathy"
      ],
      [
        "T2",
        "Disease",
        27,
        29,
        "ventricular arrhythmias"
      ],
      [
        "T3",
        "Disease",
        31,
        33,
        "QT prolongation"
      ],
      [
        "T4",
        "Disease",
        34,
        37,
        "torsade de pointes"
      ],
      [
        "T5",
        "Disease",
        37,
        39,
        "ventricular tachycardia"
      ],
      [
        "T6",
        "Chemical",
        56,
        57,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2,
    "text": "This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "torsade de pointes"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "ventricular tachycardia"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "dobutamine"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "arrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3,
    "text": "The mechanisms of proarrhythmic effects of Dubutamine are discussed .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "Dubutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4,
    "text": "Positive skin tests in late reactions to radiographic contrast media .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "contrast media"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 5,
    "text": "In the last few years delayed reactions several hours after the injection of radiographic and contrast materials ( PRC ) have been described with increasing frequency .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "contrast materials"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "PRC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 6,
    "text": "The authors report two observations on patients with delayed reactions in whom intradermoreactions ( IDR ) and patch tests to a series of ionic and non ionic PRC were studied .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        28,
        "PRC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 7,
    "text": "After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction ( dyspnea , loss of consciousness ) and delayed macro - papular rash appeared , whilst patient n degree 2 developed a generalised sensation of heat , persistent pain at the site of injection immediately and a generalised macro - papular reaction after 24 hours .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "loss of consciousness"
      ],
      [
        "T1",
        "Disease",
        27,
        31,
        "macro - papular rash"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "dyspnea"
      ],
      [
        "T3",
        "Disease",
        46,
        47,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 8,
    "text": "The skin tests revealed positive delayed reactions of 24 hours and 48 hours by IDR and patch tests to only some PRC with common chains in their structures .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "PRC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 9,
    "text": "The positive skin tests are in favour of immunological reactions and may help in diagnosis of allergy in the patients .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "allergy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 10,
    "text": "Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5 - fluorouracil with the complication of dehydration and infection .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hyperammonemic encephalopathy"
      ],
      [
        "T1",
        "Chemical",
        13,
        16,
        "5 - fluorouracil"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "cancer"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "dehydration"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 11,
    "text": "From 1986 to 1998 , 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5 - fluorouracil ( 5 - FU ) were identified .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "hyperammonemic encephalopathy"
      ],
      [
        "T1",
        "Chemical",
        21,
        24,
        "5 - fluorouracil"
      ],
      [
        "T2",
        "Chemical",
        25,
        28,
        "5 - FU"
      ],
      [
        "T3",
        "Disease",
        6,
        7,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 12,
    "text": "None of the patients had decompensated liver disease .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "liver disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 13,
    "text": "Onset of hyperammonemic encephalopathy varied from 0 . 5 to 5 days ( mean : 2 . 6 + / - 1 . 3 days ) after the initiation of chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "hyperammonemic encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 14,
    "text": "Plasma ammonium level ranged from 248 to 2387 microg % ( mean : 626 + / - 431 microg % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "ammonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 15,
    "text": "Among the 32 episodes , 26 ( 81 % ) had various degrees of azotemia , 18 ( 56 % ) occurred during bacterial infections and 14 ( 44 % ) without infection occurred during periods of dehydration .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "bacterial infections"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "azotemia"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "infection"
      ],
      [
        "T3",
        "Disease",
        37,
        38,
        "dehydration"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 16,
    "text": "Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections ( p = 0 . 003 and 0 . 0006 , respectively ) and in nine patients receiving high daily doses ( 2600 or 1800 mg / m2 ) of 5 - FU ( p = 0 . 0001 and < 0 . 0001 , respectively ) .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "bacterial infections"
      ],
      [
        "T1",
        "Chemical",
        48,
        51,
        "5 - FU"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "ammonium"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "hyperammonemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 17,
    "text": "In 25 out of 32 episodes ( 78 % ) , plasma ammonium levels and mental status returned to normal within 2 days after adequate management .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "ammonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 18,
    "text": "In conclusion , hyperammonemic encephalopathy can occur in patients receiving continuous infusion of 5 - FU .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hyperammonemic encephalopathy"
      ],
      [
        "T1",
        "Chemical",
        13,
        16,
        "5 - FU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 19,
    "text": "Azotemia , body fluid insufficiency and bacterial infections were frequently found in these patients .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "bacterial infections"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Azotemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 20,
    "text": "It is therefore important to recognize this condition in patients receiving continuous infusion of 5 - FU .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        17,
        "5 - FU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 21,
    "text": "The effects of quinine and 4 - aminopyridine on conditioned place preference and changes in motor activity induced by morphine in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "4 - aminopyridine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "quinine"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 22,
    "text": "1 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 23,
    "text": "The effects of two unselective potassium ( K ( + ) - ) channel blockers , quinine ( 12 . 5 , 25 and 50 mg / kg ) and 4 - aminopyridine ( 1 and 2 mg / kg ) , on conditioned place preference and biphasic changes in motor activity induced by morphine ( 10 mg / kg ) were tested in Wistar rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        33,
        "4 - aminopyridine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "potassium"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "K"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "quinine"
      ],
      [
        "T4",
        "Chemical",
        54,
        55,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 24,
    "text": "Quinine is known to block voltage - , calcium - and ATP - sensitive K ( + ) - channels while 4 - aminopyridine is known to block voltage - sensitive K ( + ) - channels .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        24,
        "4 - aminopyridine"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Quinine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "calcium"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "ATP"
      ],
      [
        "T4",
        "Chemical",
        14,
        15,
        "K"
      ],
      [
        "T5",
        "Chemical",
        31,
        32,
        "K"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 25,
    "text": "2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 26,
    "text": "In the counterbalanced method , quinine attenuated morphine - induced place preference , whereas 4 - aminopyridine was ineffective .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        17,
        "4 - aminopyridine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "quinine"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 27,
    "text": "In the motor activity test measured with an Animex - activity meter neither of the K ( + ) - channel blockers affected morphine - induced hypoactivity , but both K ( + ) - channel blockers prevented morphine - induced secondary hyperactivity .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "K"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "morphine"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "hypoactivity"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "K"
      ],
      [
        "T4",
        "Chemical",
        38,
        39,
        "morphine"
      ],
      [
        "T5",
        "Disease",
        42,
        43,
        "hyperactivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 28,
    "text": "3 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 29,
    "text": "These results suggest the involvement of quinine - sensitive but not 4 - aminopyridine - sensitive K ( + ) - channels in morphine reward .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "4 - aminopyridine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "quinine"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "K"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 30,
    "text": "It is also suggested that the blockade of K ( + ) - channels sensitive to these blockers is not sufficient to prevent morphine - induced hypoactivity whereas morphine - induced hyperactivity seems to be connected to both quinine - and 4 - aminopyridine - sensitive K ( + ) - channels .",
    "labels": [
      [
        "T0",
        "Chemical",
        41,
        44,
        "4 - aminopyridine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "K"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "morphine"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "hypoactivity"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "morphine"
      ],
      [
        "T5",
        "Disease",
        31,
        32,
        "hyperactivity"
      ],
      [
        "T6",
        "Chemical",
        38,
        39,
        "quinine"
      ],
      [
        "T7",
        "Chemical",
        46,
        47,
        "K"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 31,
    "text": "Nociceptin / orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "orphanin FQ"
      ],
      [
        "T1",
        "Disease",
        7,
        11,
        "learning and memory impairment"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Nociceptin"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "nocistatin"
      ],
      [
        "T4",
        "Chemical",
        13,
        14,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 32,
    "text": "1 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 33,
    "text": "Nociceptin , also known as orphanin FQ , is an endogenous ligand for the orphan opioid receptor - like receptor 1 ( ORL1 ) and involves in various functions in the central nervous system ( CNS ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "orphanin FQ"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Nociceptin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 34,
    "text": "On the other hand , nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin - induced allodynia and hyperalgesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "nocistatin"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "nociceptin"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "nociceptin"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "allodynia"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "hyperalgesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 35,
    "text": "2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 36,
    "text": "Although ORL1 receptors which display a high degree of sequence homology with classical opioid receptors are abundant in the hippocampus , little is known regarding their role in learning and memory .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 37,
    "text": "3 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 38,
    "text": "The present study was designed to investigate whether nociceptin / orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine , a muscarinic cholinergic receptor antagonist , using spontaneous alternation of Y - maze and step - down type passive avoidance tasks in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "orphanin FQ"
      ],
      [
        "T1",
        "Disease",
        16,
        21,
        "impairment of learning and memory"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "nociceptin"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "nocistatin"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 39,
    "text": "4 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 40,
    "text": "While nocistatin ( 0 . 5 - 5 . 0 nmol mouse - 1 , i . c . v . ) administered 30 min before spontaneous alternation performance or the training session of the passive avoidance task , had no effect on spontaneous alternation or passive avoidance behaviours , a lower per cent alternation and shorter median step - down latency in the retention test were obtained in nociceptin ( 1 . 5 and / or 5 . 0 nmol mouse - 1 , i . c . v . ) - treated normal mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "nocistatin"
      ],
      [
        "T1",
        "Chemical",
        69,
        70,
        "nociceptin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 41,
    "text": "5 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 42,
    "text": "Administration of nocistatin ( 1 . 5 and / or 5 . 0 nmol mouse - 1 , i . c . v . ) 30 min before spontaneous alternation performance or the training session of the passive avoidance task , attenuated the scopolamine - induced impairment of spontaneous alternation and passive avoidance behaviours .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "nocistatin"
      ],
      [
        "T1",
        "Chemical",
        43,
        44,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 43,
    "text": "6 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 44,
    "text": "These results indicated that nocistatin , a new biologically active peptide , ameliorates impairments of spontaneous alternation and passive avoidance induced by scopolamine , and suggested that these peptides play opposite roles in learning and memory .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "nocistatin"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 45,
    "text": "Meloxicam - induced liver toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "liver toxicity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Meloxicam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 46,
    "text": "We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to meloxicam .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hepatitis"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "meloxicam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 47,
    "text": "Recently introduced in Belgium , meloxicam is the first nonsteroidal antiinflammatory drug with selective action on the inducible form of cyclooxygenase 2 .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "meloxicam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 48,
    "text": "The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hepatitis"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "meloxicam"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "hypersensitivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 49,
    "text": "This first case of meloxicam related liver toxicity demonstrates the potential of this drug to induce hepatic damage .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "liver toxicity"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "hepatic damage"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "meloxicam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 50,
    "text": "Induction of apoptosis by remoxipride metabolites in HL60 and CD34 + / CD19 - human bone marrow progenitor cells : potential relevance to remoxipride - induced aplastic anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "remoxipride"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "remoxipride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 51,
    "text": "The antipsychotic agent , remoxipride [ ( S ) - ( - ) - 3 - bromo - N - [ ( 1 - ethyl - 2 - pyrrolidinyl ) methyl ] - 2 , 6 - dimethoxybenz amide ] has been associated with acquired aplastic anemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        39,
        "( S ) - ( - ) - 3 - bromo - N - [ ( 1 - ethyl - 2 - pyrrolidinyl ) methyl ] - 2 , 6 - dimethoxybenz amide"
      ],
      [
        "T1",
        "Disease",
        45,
        47,
        "aplastic anemia"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "remoxipride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 52,
    "text": "We have examined the ability of remoxipride , three pyrrolidine ring metabolites and five aromatic ring metabolites of the parent compound to induce apoptosis in HL60 cells and human bone marrow progenitor ( HBMP ) cells .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "remoxipride"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "pyrrolidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 53,
    "text": "Cells were treated for 0 - 24 h with each compound ( 0 - 200 microM ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 54,
    "text": "Apoptosis was assessed by fluorescence microscopy in Hoechst 33342 - and propidium iodide stained cell samples .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "Hoechst 33342"
      ],
      [
        "T1",
        "Chemical",
        11,
        13,
        "propidium iodide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 55,
    "text": "Results were confirmed by determination of internucleosomal DNA fragmentation using gel electrophoresis for HL60 cell samples and terminal deoxynucleotidyl transferase assay in HBMP cells .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 56,
    "text": "The catechol and hydroquinone metabolites , NCQ436 and NCQ344 , induced apoptosis in HL60 and HBMP cells in a time - and concentration dependent manner , while the phenols , NCR181 , FLA873 , and FLA797 , and the derivatives formed by oxidation of the pyrrolidine ring , FLA838 , NCM001 , and NCL118 , had no effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "catechol"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "hydroquinone"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "NCQ436"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "NCQ344"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "phenols"
      ],
      [
        "T5",
        "Chemical",
        35,
        36,
        "FLA797"
      ],
      [
        "T6",
        "Chemical",
        45,
        46,
        "pyrrolidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 57,
    "text": "No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types , inducing apoptosis at lower concentrations and necrosis at higher concentrations .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "necrosis"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "NCQ436"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "NCQ344"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 58,
    "text": "These data show that the catechol and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells , leading to apoptosis , while the phenol metabolites were inactive .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "catechol"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "hydroquinone"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "remoxipride"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "phenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 59,
    "text": "Similarly , benzene - derived catechol and hydroquinone , but not phenol , induce apoptosis in HBMP cells [ Moran et al . , Mol . Pharmacol . , 50 ( 1996 ) 610 - 615 ] .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "benzene"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "catechol"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "hydroquinone"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "phenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 60,
    "text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "aplastic anemia"
      ],
      [
        "T1",
        "Disease",
        37,
        39,
        "aplastic anemia"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "remoxipride"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "benzene"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "NCQ436"
      ],
      [
        "T5",
        "Chemical",
        23,
        24,
        "NCQ344"
      ],
      [
        "T6",
        "Chemical",
        44,
        45,
        "remoxipride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 61,
    "text": "Synthesis and preliminary pharmacological investigations of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine derivatives as potential atypical antipsychotic agents in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        20,
        "1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 62,
    "text": "In research towards the development of new atypical antipsychotic agents , one strategy is that the dopaminergic system can be modulated through manipulation of the serotonergic system .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 63,
    "text": "The synthesis and preliminary pharmacological evaluation of a series of potential atypical antipsychotic agents based on the structure of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine ( 7 ) is described .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        33,
        "1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 64,
    "text": "Compound 7e , 5 - { 2 - [ 4 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazinyl ] ethyl } - 2 , 3 - dihy dro - 1H - indol - 2 - one , from this series showed significant affinities at the 5 - HT1A and 5 - HT2A receptors and moderate affinity at the D2 receptor .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        41,
        "5 - { 2 - [ 4 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazinyl ] ethyl } - 2 , 3 - dihy dro - 1H - indol - 2 - one"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 65,
    "text": "7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "catalepsy"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 66,
    "text": "Sub - chronic inhibition of nitric - oxide synthesis modifies haloperidol - induced catalepsy and the number of NADPH - diaphorase neurons in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "nitric - oxide"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "haloperidol"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "catalepsy"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "NADPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 67,
    "text": "RATIONALE : NG - nitro - L - arginine ( L - NOARG ) , an inhibitor of nitric - oxide synthase ( NOS ) , induces catalepsy in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        9,
        "NG - nitro - L - arginine"
      ],
      [
        "T1",
        "Chemical",
        10,
        13,
        "L - NOARG"
      ],
      [
        "T2",
        "Chemical",
        18,
        21,
        "nitric - oxide"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 68,
    "text": "This effect undergoes rapid tolerance , showing a significant decrease after 2 days of sub - chronic L - NOARG treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        20,
        "L - NOARG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 69,
    "text": "Nitric oxide ( NO ) has been shown to influence dopaminergic neurotransmission in the striatum .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Nitric oxide"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "NO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 70,
    "text": "Neuroleptic drugs such as haloperidol , which block dopamine receptors , also cause catalepsy in rodents .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "haloperidol"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "dopamine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 71,
    "text": "OBJECTIVES : To investigate the effects of subchronic L - NOARG treatment in haloperidol - induced catalepsy and the number of NOS neurons in areas related to motor control .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "L - NOARG"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "haloperidol"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 72,
    "text": "METHODS : Male albino Swiss mice were treated sub - chronically ( twice a day for 4 days ) with L - NOARG ( 40 mg / kg i . p . ) or haloperidol ( 1 mg / kg i . p . ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        23,
        "L - NOARG"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 73,
    "text": "Catalepsy was evaluated at the beginning and the end of the treatments .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 74,
    "text": "Reduced nicotinamide adenine dinucleotide phosphate - diaphorase ( NADPH - d ) histochemistry was also employed to visualize NOS as an index of enzyme expression in mice brain regions related to motor control .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        5,
        "nicotinamide adenine dinucleotide phosphate"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "NADPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 75,
    "text": "RESULTS : L - NOARG sub - chronic administration produced tolerance of L - NOARG and of haloperidol - induced catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "L - NOARG"
      ],
      [
        "T1",
        "Chemical",
        12,
        15,
        "L - NOARG"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "haloperidol"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 76,
    "text": "It also induced an increase in the number of NADPH - d - positive cells in the dorsal part of the caudate and accumbens nuclei compared with haloperidol and in the pedunculopontine tegmental nucleus compared with saline .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "NADPH"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 77,
    "text": "In contrast , there was a decrease in NADPH - d neuron number in the substantia nigra , pars compacta in both haloperidol - treated and L - NOARG - treated animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        29,
        "L - NOARG"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "NADPH"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 78,
    "text": "CONCLUSIONS : The results give further support to the hypothesis that NO plays a role in motor behavior control and suggest that it may take part in the synaptic changes produced by antipsychotic treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "NO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 79,
    "text": "Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "left ventricular dysfunction"
      ],
      [
        "T1",
        "Disease",
        8,
        11,
        "coronary artery disease"
      ],
      [
        "T2",
        "Disease",
        17,
        19,
        "myocardial ischaemia"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 80,
    "text": "OBJECTIVE : To determine whether pharmacological stress leads to prolonged but reversible left ventricular dysfunction in patients with coronary artery disease , similar to that seen after exercise .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "left ventricular dysfunction"
      ],
      [
        "T1",
        "Disease",
        18,
        21,
        "coronary artery disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 81,
    "text": "DESIGN : A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and dobutamine induced ischaemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "dobutamine"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "ischaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 82,
    "text": "SUBJECTS : 10 patients with stable angina , angiographically proven coronary artery disease , and normal left ventricular function .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "stable angina"
      ],
      [
        "T1",
        "Disease",
        10,
        13,
        "coronary artery disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 83,
    "text": "INTERVENTIONS : Treadmill exercise and dobutamine stress were performed on different days .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 84,
    "text": "Quantitative assessment of systolic and diastolic left ventricular function was performed using transthoracic echocardiography at baseline and at regular intervals after each test .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 85,
    "text": "RESULTS : Both forms of stress led to prolonged but reversible systolic and diastolic dysfunction .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 86,
    "text": "There was no difference in the maximum double product ( p = 0 . 53 ) or ST depression ( p = 0 . 63 ) with either form of stress .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 87,
    "text": "After exercise , ejection fraction was reduced at 15 and 30 minutes compared with baseline ( mean ( SEM ) , - 5 . 6 ( 1 . 5 ) % , p < 0 . 05 ; and - 6 . 1 ( 2 . 2 ) % , p < 0 . 01 ) , and at 30 and 45 minutes after dobutamine ( - 10 . 8 ( 1 . 8 ) % and - 5 . 5 ( 1 . 8 ) % , both p < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        64,
        65,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 88,
    "text": "Regional analysis showed a reduction in the worst affected segment 15 and 30 minutes after exercise ( - 27 . 9 ( 7 . 2 ) % and - 28 . 6 ( 5 . 7 ) % , both p < 0 . 01 ) , and at 30 minutes after dobutamine ( - 32 ( 5 . 3 ) % , p < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        52,
        53,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 89,
    "text": "The isovolumic relaxation period was prolonged 45 minutes after each form of stress ( p < 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 90,
    "text": "CONCLUSIONS : In patients with coronary artery disease , dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction , presumed to be myocardial stunning , similar to that seen after exercise .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        16,
        19,
        "left ventricular dysfunction"
      ],
      [
        "T2",
        "Disease",
        23,
        25,
        "myocardial stunning"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "dobutamine"
      ],
      [
        "T4",
        "Disease",
        11,
        12,
        "ischaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 91,
    "text": "Dobutamine induced ischaemia could therefore be used to study the pathophysiology of this phenomenon further in patients with coronary artery disease .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        21,
        "coronary artery disease"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Dobutamine"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "ischaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 92,
    "text": "Anorexigens and pulmonary hypertension in the United States : results from the surveillance of North American pulmonary hypertension .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "pulmonary hypertension"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "pulmonary hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 93,
    "text": "BACKGROUND : The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension ( PPH ) .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        19,
        "primary pulmonary hypertension"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "PPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 94,
    "text": "Recently , fenfluramine appetite suppressants became widely used in the United States but were withdrawn in September 1997 because of concerns over adverse effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "fenfluramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 95,
    "text": "MATERIALS AND METHODS : We conducted a prospective surveillance study on patients diagnosed with pulmonary hypertension at 12 large referral centers in North America .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "pulmonary hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 96,
    "text": "Data collected on patients seen from September 1 , 1996 , to December 31 , 1997 , included the cause of the pulmonary hypertension and its severity .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "pulmonary hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 97,
    "text": "Patients with no identifiable cause of pulmonary hypertension were classed as PPH .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "pulmonary hypertension"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "PPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 98,
    "text": "A history of drug exposure also was taken with special attention on the use of antidepressants , anorexigens , and amphetamines .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "amphetamines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 99,
    "text": "RESULTS : Five hundred seventy - nine patients were studied , 205 with PPH and 374 with pulmonary hypertension from other causes ( secondary pulmonary hypertension [ SPH ] ) .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "pulmonary hypertension"
      ],
      [
        "T1",
        "Disease",
        24,
        26,
        "pulmonary hypertension"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "PPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 100,
    "text": "The use of anorexigens was common in both groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 101,
    "text": "However , of the medications surveyed , only the fenfluramines had a significant preferential association with PPH as compared with SPH ( adjusted odds ratio for use > 6 months , 7 . 5 ; 95 % confidence interval , 1 . 7 to 32 . 4 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "fenfluramines"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "PPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 102,
    "text": "The association was stronger with longer duration of use when compared to shorter duration of use and was more pronounced in recent users than in remote users .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 103,
    "text": "An unexpectedly high ( 11 . 4 % ) number of patients with SPH had used anorexigens .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 104,
    "text": "CONCLUSION : The magnitude of the association with PPH , the increase of association with increasing duration of use , and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "PPH"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "fenfluramines"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "fenfluramines"
      ],
      [
        "T3",
        "Disease",
        37,
        38,
        "PPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 105,
    "text": "The high prevalence of anorexigen use in patients with SPH also raises the possibility that these drugs precipitate pulmonary hypertension in patients with underlying conditions associated with SPH .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "pulmonary hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 106,
    "text": "Clinical aspects of heparin - induced thrombocytopenia and thrombosis and other side effects of heparin therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "thrombosis"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 107,
    "text": "Heparin , first used to prevent the clotting of blood in vitro , has been clinically used to treat thrombosis for more than 50 years .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Heparin"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 108,
    "text": "Although several new anticoagulant drugs are in development , heparin remains the anticoagulant of choice to treat acute thrombotic episodes .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "thrombotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 109,
    "text": "The clinical effects of heparin are meritorious , but side effects do exist .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 110,
    "text": "Bleeding is the primary untoward effect of heparin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Bleeding"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 111,
    "text": "Major bleeding is of primary concern in patients receiving heparin therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "bleeding"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 112,
    "text": "However , additional important untoward effects of heparin therapy include heparin - induced thrombocytopenia , heparin - associated osteoporosis , eosinophilia , skin reactions , allergic reactions other than thrombocytopenia , alopecia , transaminasemia , hyperkalemia , hypoaldosteronism , and priapism .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "skin reactions"
      ],
      [
        "T1",
        "Disease",
        25,
        27,
        "allergic reactions"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "heparin"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "heparin"
      ],
      [
        "T4",
        "Disease",
        13,
        14,
        "thrombocytopenia"
      ],
      [
        "T5",
        "Chemical",
        15,
        16,
        "heparin"
      ],
      [
        "T6",
        "Disease",
        18,
        19,
        "osteoporosis"
      ],
      [
        "T7",
        "Disease",
        20,
        21,
        "eosinophilia"
      ],
      [
        "T8",
        "Disease",
        29,
        30,
        "thrombocytopenia"
      ],
      [
        "T9",
        "Disease",
        31,
        32,
        "alopecia"
      ],
      [
        "T10",
        "Disease",
        35,
        36,
        "hyperkalemia"
      ],
      [
        "T11",
        "Disease",
        37,
        38,
        "hypoaldosteronism"
      ],
      [
        "T12",
        "Disease",
        40,
        41,
        "priapism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 113,
    "text": "These side effects are relatively rare in a given individual , but given the extremely widespread use of heparin , some are quite common , particularly HITT and osteoporosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "HITT"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "osteoporosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 114,
    "text": "Although reasonable incidences of many of these side effects can be \" softly \" deduced from current reports dealing with unfractionated heparin , at present the incidences of these side effects with newer low molecular weight heparins appear to be much less common .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "heparin"
      ],
      [
        "T1",
        "Chemical",
        36,
        37,
        "heparins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 115,
    "text": "However , only longer experience will more clearly define the incidence of each side effect with low molecular weight preparations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 116,
    "text": "A case of bilateral optic neuropathy in a patient on tacrolimus ( FK506 ) therapy after liver transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "tacrolimus"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "FK506"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 117,
    "text": "PURPOSE : To report a case of bilateral optic neuropathy in a patient receiving tacrolimus ( FK 506 , Prograf ; Fujisawa USA , Inc , Deerfield , Illinois ) for immunosuppression after orthotropic liver transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        16,
        18,
        "FK 506"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 118,
    "text": "METHOD : Case report .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 119,
    "text": "In a 58 - year - old man receiving tacrolimus after orthotropic liver transplantation , serial neuro - ophthalmologic examinations and laboratory studies were performed .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 120,
    "text": "RESULTS : The patient had episodic deterioration of vision in both eyes , with clinical features resembling ischemic optic neuropathies .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "ischemic optic neuropathies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 121,
    "text": "Deterioration of vision occurred despite discontinuation of the tacrolimus .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Deterioration of vision"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 122,
    "text": "CONCLUSION : Tacrolimus and other immunosuppressive agents may be associated with optic nerve toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "optic nerve toxicity"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 123,
    "text": "Hypercalcemia , arrhythmia , and mood stabilizers .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypercalcemia"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 124,
    "text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium - associated hypercalcemia .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "bipolar"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "lithium"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "hypercalcemia"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "bradyarrhythmia"
      ],
      [
        "T4",
        "Disease",
        25,
        26,
        "bipolar"
      ],
      [
        "T5",
        "Chemical",
        28,
        29,
        "lithium"
      ],
      [
        "T6",
        "Disease",
        31,
        32,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 125,
    "text": "A printout of all cases of hypercalcemia that presented during a 1 - year period was generated .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 126,
    "text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids , the authors identified 18 non - lithium - treated patients with hypercalcemias related to malignancies and other medical conditions ( group A ) and 12 patients with lithium - associated hypercalcemia ( group B ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypercalcemias"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "lithium"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "hypercalcemias"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "malignancies"
      ],
      [
        "T4",
        "Chemical",
        38,
        39,
        "lithium"
      ],
      [
        "T5",
        "Disease",
        41,
        42,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 127,
    "text": "Patients in group B were not comparable to those in group A , as the latter were medically compromised and were receiving multiple pharmacotherapies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 128,
    "text": "Thus , two control groups were generated : group C1 , which included age - and sex - comparable lithium - treated bipolar normocalcemic patients , and group C2 , which included bipolar normocalcemic patients treated with anticonvulsant mood stabilizers .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "lithium"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "bipolar"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "bipolar"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 129,
    "text": "The electrocardiographic ( ECG ) findings for patients in group B were compared with those of patients in groups C1 and C2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 130,
    "text": "It was found that these groups did not differ in their overall frequency of ECG abnormalities ; however , there were significant differences in the frequency of conduction defects .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 131,
    "text": "Patients with hypercalcemia resulting from medical diseases and bipolar patients with lithium - associated hypercalcemia had significantly higher frequencies of conduction defects .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "hypercalcemia"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "bipolar"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "lithium"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 132,
    "text": "Patients in group A had significant mortality at 2 - year follow - up ( 28 % ) , in contrast to zero mortality in the other three groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 133,
    "text": "The clinical implications of these findings are discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 134,
    "text": "Attenuation of nephrotoxicity by a novel lipid nanosphere ( NS - 718 ) incorporating amphotericin B .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "amphotericin B"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 135,
    "text": "NS - 718 , a lipid nanosphere incorporating amphotericin B , is effective against pathogenic fungi and has low toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "amphotericin B"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 136,
    "text": "We compared the toxicity of NS - 718 with that of Fungizone ( amphotericin B - sodium deoxycholate ; D - AmB ) in vitro using renal cell cultures and in vivo by biochemical analysis , histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        18,
        "amphotericin B - sodium deoxycholate"
      ],
      [
        "T1",
        "Chemical",
        19,
        22,
        "D - AmB"
      ],
      [
        "T2",
        "Chemical",
        45,
        47,
        "amphotericin B"
      ],
      [
        "T3",
        "Disease",
        3,
        4,
        "toxicity"
      ],
      [
        "T4",
        "Chemical",
        11,
        12,
        "Fungizone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 137,
    "text": "Incubation with NS - 718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D - AmB .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        23,
        "D - AmB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 138,
    "text": "Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D - AmB 3 mg / kg but not in those given the same dose of NS - 718 .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        18,
        "D - AmB"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "urea"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 139,
    "text": "Histopathological examination of the kidney showed tubular necrosis in D - AmB - treated rats but no change in NS - 718 - treated rats .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "tubular necrosis"
      ],
      [
        "T1",
        "Chemical",
        9,
        12,
        "D - AmB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 140,
    "text": "Amphotericin B concentrations in the kidney in NS - 718 - treated rats were higher than those in D - AmB - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Amphotericin B"
      ],
      [
        "T1",
        "Chemical",
        18,
        21,
        "D - AmB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 141,
    "text": "Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS - 718 attenuates the nephrotoxicity of amphotericin B .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "amphotericin B"
      ],
      [
        "T1",
        "Chemical",
        24,
        26,
        "amphotericin B"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 142,
    "text": "Patterns of sulfadiazine acute nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "acute nephrotoxicity"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "sulfadiazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 143,
    "text": "Sulfadiazine acute nephrotoxicity is reviving specially because of its use in toxoplasmosis in HIV - positive patients .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "acute nephrotoxicity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Sulfadiazine"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "toxoplasmosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 144,
    "text": "We report 4 cases , one of them in a previously healthy person .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 145,
    "text": "Under treatment with sulfadiazine they developed oliguria , abdominal pain , renal failure and showed multiple radiolucent renal calculi in echography .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "abdominal pain"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "renal failure"
      ],
      [
        "T2",
        "Disease",
        17,
        19,
        "renal calculi"
      ],
      [
        "T3",
        "Chemical",
        3,
        4,
        "sulfadiazine"
      ],
      [
        "T4",
        "Disease",
        6,
        7,
        "oliguria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 146,
    "text": "All patients recovered their previous normal renal function after adequate hydration and alcalinization .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 147,
    "text": "A nephrostomy tube had to be placed in one of the patients for ureteral lithiasis in a single functional kidney .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "ureteral lithiasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 148,
    "text": "None of them needed dialysis or a renal biopsy because of a typical benign course .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 149,
    "text": "Treatment with sulfadiazine requires exquisite control of renal function , an increase in water ingestion and possibly the alcalinization of the urine .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "sulfadiazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 150,
    "text": "We communicate a case in a previously healthy person , a fact not found in the recent literature .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 151,
    "text": "Probably many more cases are not detected .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 152,
    "text": "We think that a prospective study would be useful .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 153,
    "text": "Downbeat nystagmus associated with intravenous patient - controlled administration of morphine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Downbeat nystagmus"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 154,
    "text": "IMPLICATIONS : This case documents a patient who developed dizziness with downbeating nystagmus while receiving a relatively large dose of IV patient - controlled analgesia morphine .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "downbeating nystagmus"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "dizziness"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 155,
    "text": "Although there have been case reports of epidural morphine with these symptoms and signs , this has not been previously documented with IV or patient - controlled analgesia morphine .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 156,
    "text": "Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "dronedarone"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 157,
    "text": "The hemodynamic and antiadrenergic effects of dronedarone , a noniodinated compound structurally related to amiodarone , were compared with those of amiodarone after prolonged oral administration , both at rest and during sympathetic stimulation in conscious dogs with a healed myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        40,
        42,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "dronedarone"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "amiodarone"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 158,
    "text": "All dogs ( n = 6 ) randomly received orally dronedarone ( 10 and 30 mg / kg ) , amiodarone ( 10 and 30 mg / kg ) , and placebo twice daily for 7 days , with a 3 - week washout between consecutive treatments .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "dronedarone"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 159,
    "text": "Heart rate ( HR ) , mean arterial pressure ( MBP ) , positive rate of increase of left ventricular pressure ( + LVdP / dt ) , echocardiographically assessed left ventricular ejection fraction ( LVEF ) , and fractional shortening ( FS ) , as well as chronotropic response to isoproterenol and exercise - induced sympathetic stimulation were evaluated under baseline and posttreatment conditions .",
    "labels": [
      [
        "T0",
        "Chemical",
        51,
        52,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 160,
    "text": "Resting values of LVEF , FS , + LVdP / dt , and MBP remained unchanged whatever the drug and the dosing regimen , whereas resting HR was significantly and dose - dependently lowered after dronedarone and to a lesser extent after amiodarone .",
    "labels": [
      [
        "T0",
        "Chemical",
        35,
        36,
        "dronedarone"
      ],
      [
        "T1",
        "Chemical",
        42,
        43,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 161,
    "text": "Both dronedarone and amiodarone significantly reduced the exercise - induced tachycardia and , at the highest dose , decreased the isoproterenol - induced tachycardia .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "dronedarone"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "amiodarone"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "tachycardia"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "isoproterenol"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "tachycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 162,
    "text": "Thus , dronedarone and amiodarone displayed a similar level of antiadrenergic effect and did not impair the resting left ventricular function .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "dronedarone"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 163,
    "text": "Consequently , dronedarone might be particularly suitable for the treatment and prevention of various clinical arrhythmias , without compromising the left ventricular function .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "dronedarone"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "arrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 164,
    "text": "Phase 2 trial of liposomal doxorubicin ( 40 mg / m ( 2 ) ) in platinum / paclitaxel - refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        26,
        "ovarian and fallopian tube cancers"
      ],
      [
        "T1",
        "Disease",
        28,
        32,
        "carcinoma of the peritoneum"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "doxorubicin"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "platinum"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 165,
    "text": "BACKGROUND : Several studies have demonstrated liposomal doxorubicin ( Doxil ) to be an active antineoplastic agent in platinum - resistant ovarian cancer , with dose limiting toxicity of the standard dosing regimen ( 50 mg / m ( 2 ) q 4 weeks ) being severe erythrodysesthesia ( \" hand - foot syndrome \" ) and stomatitis .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "ovarian cancer"
      ],
      [
        "T1",
        "Disease",
        50,
        54,
        "hand - foot syndrome"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "doxorubicin"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "Doxil"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "platinum"
      ],
      [
        "T5",
        "Disease",
        27,
        28,
        "toxicity"
      ],
      [
        "T6",
        "Disease",
        47,
        48,
        "erythrodysesthesia"
      ],
      [
        "T7",
        "Disease",
        57,
        58,
        "stomatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 166,
    "text": "We wished to develop a more tolerable liposomal doxorubicin treatment regimen and document its level of activity in a well - defined patient population with platinum / paclitaxel - refractory disease .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "doxorubicin"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "platinum"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 167,
    "text": "METHODS AND MATERIALS : Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum / paclitaxel - refractory disease ( stable or progressive disease following treatment with these agents or previous objective response < 3 months in duration ) were treated with liposomal doxorubicin at a dose of 40 mg / m ( 2 ) q 4 weeks .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        11,
        "ovarian or fallopian tube cancers"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "peritoneal carcinoma"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "platinum"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "paclitaxel"
      ],
      [
        "T4",
        "Chemical",
        46,
        47,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 168,
    "text": "RESULTS : A total of 49 patients ( median age : 60 ; range 41 - 81 ) entered this phase 2 trial .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 169,
    "text": "The median number of prior regimens was 2 ( range : 1 - 6 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 170,
    "text": "Six ( 12 % ) and 4 ( 8 % ) patients experienced grade 2 hand - foot syndrome and stomatitis , respectively ( no episodes of grade 3 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        19,
        "hand - foot syndrome"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "stomatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 171,
    "text": "One patient developed grade 3 diarrhea requiring hospitalization for hydration .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "diarrhea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 172,
    "text": "Six ( 12 % ) individuals required dose reductions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 173,
    "text": "The median number of courses of liposomal doxorubicin administered on this protocol was 2 ( range : 1 - 12 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 174,
    "text": "Four of 44 patients ( 9 % ) evaluable for response exhibited objective and subjective evidence of an antineoplastic effect of therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 175,
    "text": "CONCLUSION : This modified liposomal doxorubicin regimen results in less toxicity ( stomatitis , hand - foot syndrome ) than the standard FDA - approved dose schedule .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        18,
        "hand - foot syndrome"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "doxorubicin"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "toxicity"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "stomatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 176,
    "text": "Definite , although limited , antineoplastic activity is observed in patients with well - defined platinum - and paclitaxel - refractory ovarian cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "ovarian cancer"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "platinum"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 177,
    "text": "Efficacy of olanzapine in acute bipolar mania : a double - blind , placebo - controlled study .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "bipolar mania"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 178,
    "text": "The Olanzipine HGGW Study Group .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "Olanzipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 179,
    "text": "BACKGROUND : We compared the efficacy and safety of olanzapine vs placebo for the treatment of acute bipolar mania .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "bipolar mania"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 180,
    "text": "METHODS : Four - week , randomized , double - blind , parallel study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 181,
    "text": "A total of 115 patients with a DSM - IV diagnosis of bipolar disorder , manic or mixed , were randomized to olanzapine , 5 to 20 mg / d ( n = 55 ) , or placebo ( n = 60 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "bipolar disorder"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "manic"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 182,
    "text": "The primary efficacy measure was the Young - Mania Rating Scale ( Y - MRS ) total score .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "Mania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 183,
    "text": "Response and euthymia were defined , a priori , as at least a 50 % improvement from baseline to end point and as a score of no less than 12 at end point in the Y - MRS total score , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 184,
    "text": "Safety was assessed using adverse events , Extrapyramidal Symptom ( EPS ) rating scales , laboratory values , electrocardiograms , vital signs , and weight change .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "Extrapyramidal Symptom"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "EPS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 185,
    "text": "RESULTS : Olanzapine - treated patients demonstrated a statistically significant greater mean ( + / - SD ) improvement in Y - MRS total score than placebo - treated patients ( - 14 . 8 + / - 12 . 5 and - 8 . 1 + / - 12 . 7 , respectively ; P < . 001 ) , which was evident at the first postbaseline observation 1 week after randomization and was maintained throughout the study ( last observation carried forward ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 186,
    "text": "Olanzapine - treated patients demonstrated a higher rate of response ( 65 % vs 43 % , respectively ; P = . 02 ) and euthymia ( 61 % vs 36 % , respectively ; P = . 01 ) than placebo - treated patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 187,
    "text": "There were no statistically significant differences in EPSs between groups .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "EPSs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 188,
    "text": "However , olanzapine - treated patients had a statistically significant greater mean ( + / - SD ) weight gain than placebo - treated patients ( 2 . 1 + / - 2 . 8 vs 0 . 45 + / - 2 . 3 kg , respectively ) and also experienced more treatment - emergent somnolence ( 21 patients [ 38 . 2 % ] vs 5 [ 8 . 3 % ] , respectively ) .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "weight gain"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "olanzapine"
      ],
      [
        "T2",
        "Disease",
        56,
        57,
        "somnolence"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 189,
    "text": "CONCLUSION : Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "bipolar mania"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 190,
    "text": "The effect of pupil dilation with tropicamide on vision and driving simulator performance .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "pupil dilation"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "tropicamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 191,
    "text": "PURPOSE : To assess the effect of pupil dilation on vision and driving ability .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "pupil dilation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 192,
    "text": "METHODS : A series of tests on various parameters of visual function and driving simulator performance were performed on 12 healthy drivers , before and after pupil dilation using guttae tropicamide 1 % .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "pupil dilation"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "tropicamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 193,
    "text": "A driving simulator ( Transport Research Laboratory ) was used to measure reaction time ( RT ) , speed maintenance and steering accuracy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 194,
    "text": "Tests of basic visual function included high - and low - contrast visual acuity ( HCVA and LCVA ) , Pelli - Robson contrast threshold ( CT ) and Goldmann perimetry ( FIELDS ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 195,
    "text": "Useful Field of View ( UFOV - - a test of visual attention ) was also undertaken .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 196,
    "text": "The mean differences in the pre - and post - dilatation measurements were tested for statistical significance at the 95 % level using one - tail paired t - tests .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 197,
    "text": "RESULTS : Pupillary dilation resulted in a statistically significant deterioration in CT and HCVA only .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Pupillary dilation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 198,
    "text": "Five of 12 drivers also exhibited deterioration in LCVA , CT and RT .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 199,
    "text": "Little evidence emerged for deterioration in FIELDS and UFOV .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 200,
    "text": "Also , 7 of 12 drivers appeared to adjust their driving behaviour by reducing their speed on the driving simulator , leading to improved steering accuracy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 201,
    "text": "CONCLUSIONS : Pupillary dilation may lead to a decrease in vision and daylight driving performance in young people .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Pupillary dilation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 202,
    "text": "A larger study , including a broader spectrum of subjects , is warranted before guidelines can be recommended .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 203,
    "text": "A case of isotretinoin embryopathy with bilateral anotia and Taussig - Bing malformation .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "isotretinoin embryopathy"
      ],
      [
        "T1",
        "Disease",
        9,
        13,
        "Taussig - Bing malformation"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "anotia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 204,
    "text": "We report a newborn infant with multiple congenital anomalies ( anotia and Taussig - Bing malformation ) due to exposure to isotretinoin within the first trimester .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "Taussig - Bing malformation"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "anotia"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "isotretinoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 205,
    "text": "In this paper we aim to draw to the fact that caution is needed when prescribing vitamin A - containing drugs to women of childbearing years .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        18,
        "vitamin A"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 206,
    "text": "Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence : a placebo - controlled , double - blind crossover study .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "stress incontinence"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "methoxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 207,
    "text": "The aim of the study was to evaluate the potential role for a selective alpha1 - adrenoceptor agonist in the treatment of urinary stress incontinence .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        25,
        "urinary stress incontinence"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 208,
    "text": "A randomised , double - blind , placebo - controlled , crossover study design was employed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 209,
    "text": "Half log incremental doses of intravenous methoxamine or placebo ( saline ) were administered to a group of women with genuine stress incontinence while measuring maximum urethral pressure ( MUP ) , blood pressure , heart rate , and symptomatic side effects .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "stress incontinence"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "methoxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 210,
    "text": "Methoxamine evoked non - significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        21,
        "a significant rise in systolic blood pressure"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Methoxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 211,
    "text": "Systemic side effects including piloerection , headache , and cold extremities were experienced in all subjects .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 212,
    "text": "The results indicate that the clinical usefulness of direct , peripherally acting sub - type - selective alpha1 - adrenoceptor agonists in the medical treatment of stress incontinence may be limited by associated piloerection and cardiovascular side effects .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "stress incontinence"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 213,
    "text": "Hyperglycemic effect of amino compounds structurally related to caproate in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hyperglycemic"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "amino"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "caproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 214,
    "text": "The chronic feeding of small amounts ( 0 . 3 - 3 % of diet weight ) of certain amino derivatives of caproate resulted in hyperglycemia , an elevated glucose tolerance curve and , occasionally , glucosuria .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "amino"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "caproate"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "hyperglycemia"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "glucose"
      ],
      [
        "T4",
        "Disease",
        36,
        37,
        "glucosuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 215,
    "text": "Effective compounds included norleucine , norvaline , glutamate , epsilon - aminocaproate , methionine , and leucine .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "epsilon - aminocaproate"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "norleucine"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "norvaline"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "glutamate"
      ],
      [
        "T4",
        "Chemical",
        13,
        14,
        "methionine"
      ],
      [
        "T5",
        "Chemical",
        16,
        17,
        "leucine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 216,
    "text": "Toleration of high doses of angiotensin - converting enzyme inhibitors in patients with chronic heart failure : results from the ATLAS trial .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        10,
        "angiotensin - converting enzyme inhibitors"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 217,
    "text": "The Assessment of Treatment with Lisinopril and Survival .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "Lisinopril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 218,
    "text": "BACKGROUND : Treatment with angiotensin - converting enzyme ( ACE ) inhibitors reduces mortality and morbidity in patients with chronic heart failure ( CHF ) , but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials , primarily because of concerns about the safety and tolerability of these agents , especially at the recommended doses .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        12,
        "angiotensin - converting enzyme ( ACE ) inhibitors"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "heart failure"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "CHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 219,
    "text": "The present study examines the safety and tolerability of high - compared with low - dose lisinopril in CHF .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "lisinopril"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "CHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 220,
    "text": "METHODS : The Assessment of Lisinopril and Survival study was a multicenter , randomized , double - blind trial in which patients with or without previous ACE inhibitor treatment were stabilized receiving medium - dose lisinopril ( 12 . 5 or 15 . 0 mg once daily [ OD ] ) for 2 to 4 weeks and then randomized to high - ( 35 . 0 or 32 . 5 mg OD ) or low - dose ( 5 . 0 or 2 . 5 mg OD ) groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        28,
        "ACE inhibitor"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "Lisinopril"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "lisinopril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 221,
    "text": "Patients with New York Heart Association classes II to IV CHF and left ventricular ejection fractions of no greater than 0 . 30 ( n = 3164 ) were randomized and followed up for a median of 46 months .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "CHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 222,
    "text": "We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment , with a focus on hypotension and renal dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "renal dysfunction"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 223,
    "text": "RESULTS : Of 405 patients not previously receiving an ACE inhibitor , doses in only 4 . 2 % could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension ( 2 . 0 % ) or because of renal dysfunction or hyperkalemia ( 2 . 3 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "ACE inhibitor"
      ],
      [
        "T1",
        "Disease",
        46,
        48,
        "renal dysfunction"
      ],
      [
        "T2",
        "Disease",
        36,
        37,
        "hypotension"
      ],
      [
        "T3",
        "Disease",
        49,
        50,
        "hyperkalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 224,
    "text": "Doses in more than 90 % of randomized patients in the high - and low - dose groups were titrated to their assigned target , and the mean doses of blinded medication in both groups remained similar throughout the study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 225,
    "text": "Withdrawals occurred in 27 . 1 % of the high - and 30 . 7 % of the low - dose groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 226,
    "text": "Subgroups presumed to be at higher risk for ACE inhibitor intolerance ( blood pressure , < 120 mm Hg ; creatinine , > or = 132 . 6 micromol / L [ > or = 1 . 5 mg / dL ] ; age , > or = 70 years ; and patients with diabetes ) generally tolerated the high - dose strategy .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "ACE inhibitor"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "creatinine"
      ],
      [
        "T2",
        "Disease",
        54,
        55,
        "diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 227,
    "text": "CONCLUSIONS : These findings demonstrate that ACE inhibitor therapy in most patients with CHF can be successfully titrated to and maintained at high doses , and that more aggressive use of these agents is warranted .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "ACE inhibitor"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "CHF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 228,
    "text": "Cocaine , ethanol , and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "cocaine and ethanol abuse"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Cocaine"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "ethanol"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "cocaethylene"
      ],
      [
        "T4",
        "Disease",
        6,
        7,
        "cardiotoxity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 229,
    "text": "OBJECTIVES : Simultaneous abuse of cocaine and ethanol affects 12 million Americans annually .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        8,
        "abuse of cocaine and ethanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 230,
    "text": "In combination , these substances are substantially more toxic than either drug alone .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 231,
    "text": "Their combined cardiac toxicity may be due to independent effects of each drug ; however , they may also be due to cocaethylene ( CE ) , a cocaine metabolite formed only in the presence of ethanol .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "cardiac toxicity"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "cocaethylene"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "CE"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "cocaine"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "ethanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 232,
    "text": "The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "CE"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "cardiotoxicity"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "cocaine"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "ethanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 233,
    "text": "METHODS : Twenty - three dogs were randomized to receive either 1 ) three intravenous ( IV ) boluses of cocaine 7 . 5 mg / kg with ethanol ( 1 g / kg ) as an IV infusion ( C + E , n = 8 ) , 2 ) three cocaine boluses only ( C , n = 6 ) , 3 ) ethanol infusion only ( E , n = 5 ) , or 4 ) placebo boluses and infusion ( n = 4 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "ethanol"
      ],
      [
        "T2",
        "Chemical",
        52,
        53,
        "cocaine"
      ],
      [
        "T3",
        "Chemical",
        65,
        66,
        "ethanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 234,
    "text": "Hemodynamic measurements , electrocardiograms , and serum drug concentrations were obtained at baseline , and then at fixed time intervals after each drug was administered .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 235,
    "text": "RESULTS : Two of eight dogs in the C + E group experienced cardiovascular collapse .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "cardiovascular collapse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 236,
    "text": "The most dramatic hemodynamic changes occurred after each cocaine bolus in the C + E and C only groups ; however , persistent hemodynamic changes occurred in the C + E group .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 237,
    "text": "Peak CE levels were associated with a 45 % ( SD + / - 22 % , 95 % CI = 22 % to 69 % ) decrease in cardiac output ( p < 0 . 05 ) , a 56 % ( SD + / - 23 % , 95 % CI = 32 % to 80 % ) decrease in dP / dt ( max ) ( p < . 006 ) , and a 23 % ( SD + / - 15 % , 95 % CI = 7 % to 49 % ) decrease in SVO ( 2 ) ( p < 0 . 025 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        31,
        "decrease in cardiac output"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "CE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 238,
    "text": "Ventricular arrhythmias were primarily observed in the C + E group , in which four of eight dogs experienced ventricular tachycardia .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Ventricular arrhythmias"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "ventricular tachycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 239,
    "text": "CONCLUSIONS : Cocaine and ethanol in combination were more toxic than either substance alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Cocaine"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "ethanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 240,
    "text": "Co - administration resulted in prolonged cardiac toxicity and was dysrhythmogenic .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "cardiac toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 241,
    "text": "Peak serum cocaethylene concentrations were associated with prolonged myocardial depression .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "myocardial depression"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "cocaethylene"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 242,
    "text": "Worsening of Parkinsonism after the use of veralipride for treatment of menopause : case report .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Parkinsonism"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "veralipride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 243,
    "text": "We describe a female patient with stable Parkinson ' s disease who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with veralipride , as well as the improvement of her symptoms back to baseline after discontinuation of the drug .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "veralipride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 244,
    "text": "We emphasize the anti - dopaminergic effect of veralipride .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "veralipride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 245,
    "text": "Viracept and irregular heartbeat warning .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "irregular heartbeat"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Viracept"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 246,
    "text": "A group of doctors in Boston warn that the protease inhibitor Viracept may cause an irregular heart beat , known as bradycardia , in people with HIV .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "irregular heart beat"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "Viracept"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 247,
    "text": "Bradycardia occurred in a 45 - year - old male patient who was Viracept in combination with other anti - HIV drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Bradycardia"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "Viracept"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 248,
    "text": "The symptoms ceased after switching to another drug combination .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 249,
    "text": "Frequency of appearance of myeloperoxidase - antineutrophil cytoplasmic antibody ( MPO - ANCA ) in Graves ' disease patients treated with propylthiouracil and the relationship between MPO - ANCA and clinical manifestations .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "Graves ' disease"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "propylthiouracil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 250,
    "text": "OBJECTIVE : Myeloperoxidase antineutrophil cytoplasmic antibody ( MPO - ANCA ) - positive vasculitis has been reported in patients with Graves ' disease who were treated with propylthiouracil ( PTU ) .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        23,
        "Graves ' disease"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "vasculitis"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "propylthiouracil"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "PTU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 251,
    "text": "The appearance of MPO - ANCA in these cases was suspected of being related to PTU because the titres of MPO - ANCA decreased when PTU was stopped .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "PTU"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "PTU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 252,
    "text": "Nevertheless , there have been no studies on the temporal relationship between the appearance of MPO - ANCA and vasculitis during PTU therapy , or on the incidence of MPO - ANCA in untreated Graves ' disease patients .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        37,
        "Graves ' disease"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "vasculitis"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "PTU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 253,
    "text": "Therefore , we sought to address these parameters in patients with Graves ' disease .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "Graves ' disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 254,
    "text": "PATIENTS : We investigated 102 untreated patients with hyperthyroidism due to Graves ' disease for the presence of MPO - ANCA , and for the development vasculitis after starting PTU therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "Graves ' disease"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hyperthyroidism"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "vasculitis"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "PTU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 255,
    "text": "Twenty - nine of them were later excluded because of adverse effects of PTU or because the observation period was less than 3 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "PTU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 256,
    "text": "The remaining 73 patients ( 55 women and 18 men ) , all of whom were examined for more than 3 months , were adopted as the subjects of the investigation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 257,
    "text": "The median observation period was 23 . 6 months ( range : 3 - 37 months ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 258,
    "text": "MEASUREMENTS : MPO - ANCA was measured at intervals of 2 - 6 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 259,
    "text": "RESULTS : Before treatment , the MPO - ANCA titres of all 102 untreated Graves ' disease patients were within the reference range ( below 10 U / ml ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        17,
        "Graves ' disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 260,
    "text": "Three ( 4 . 1 % ) of the 73 patients were positive for MPO - ANCA at 13 , 16 and 17 months , respectively , after the start of PTU therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        32,
        "PTU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 261,
    "text": "In two of them , the MPO - ANCA titres transiently increased to 12 . 8 and 15 . 0 U / ml , respectively , despite continued PTU therapy , but no vasculitic disorders developed .",
    "labels": [
      [
        "T0",
        "Disease",
        33,
        35,
        "vasculitic disorders"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "PTU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 262,
    "text": "In the third patient , the MPO - ANCA titre increased to 204 U / ml and she developed a higher fever , oral ulcers and polyarthralgia , but the symptoms resolved 2 weeks after stopping PTU therapy , and the MPO - ANCA titre decreased to 20 . 7 U / ml by 4 months after discontinuing PTU .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "oral ulcers"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "fever"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "polyarthralgia"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "PTU"
      ],
      [
        "T4",
        "Chemical",
        58,
        59,
        "PTU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 263,
    "text": "CONCLUSIONS : PTU therapy may be related to the appearance of MPO - ANCA , but MPO - ANCA does not appear to be closely related to vasculitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "PTU"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 264,
    "text": "Prevalence of heart disease in asymptomatic chronic cocaine users .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "heart disease"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 265,
    "text": "To determine the prevalence of heart disease in outpatient young asymptomatic chronic cocaine users , 35 cocaine users and 32 age - matched controls underwent resting and exercise electrocardiography ( ECG ) and Doppler echocardiography .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "heart disease"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 266,
    "text": "Findings consistent with coronary artery disease were detected in 12 ( 34 % ) patients and 3 ( 9 % ) controls ( p = 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "coronary artery disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 267,
    "text": "Decreased left ventricular systolic function was demonstrated in 5 ( 14 % ) patients , but in none of the controls ( p = 0 . 055 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 268,
    "text": "Finally , resting and peak exercise abnormal left ventricular filling was detected in 38 and 35 % of patients as compared to 19 and 9 % of controls , respectively ( p = 0 . 11 and 0 . 02 , respectively ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        10,
        "abnormal left ventricular filling"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 269,
    "text": "We conclude that coronary artery or myocardial disease is common ( 38 % ) in young asymptomatic chronic cocaine users .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        8,
        "coronary artery or myocardial disease"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 270,
    "text": "Therefore , screening ECG and echocardiography may be warranted in these patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 271,
    "text": "Cardioprotective effects of Picrorrhiza kurroa against isoproterenol - induced myocardial stress in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 272,
    "text": "The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots ( PK ) on isoproterenol - induced myocardial infarction in rats with respect to lipid metabolism in serum and heart tissue has been investigated .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "ethanol"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 273,
    "text": "Oral pre - treatment with PK ( 80 mg kg ( - 1 ) day ( - 1 ) for 15 days ) significantly prevented the isoproterenol - induced myocardial infarction and maintained the rats at near normal status .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        31,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 274,
    "text": "Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long - QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Disease",
        13,
        17,
        "long - QT syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 275,
    "text": "BACKGROUND : This study examined the role of phase 2 early afterdepolarization ( EAD ) in producing a trigger to initiate torsade de pointes ( TdP ) with QT prolongation induced by dl - sotalol and azimilide .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "torsade de pointes"
      ],
      [
        "T1",
        "Disease",
        28,
        30,
        "QT prolongation"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "TdP"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "sotalol"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "azimilide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 276,
    "text": "The contribution of transmural dispersion of repolarization ( TDR ) to transmural propagation of EAD and the maintenance of TdP was also evaluated .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "TdP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 277,
    "text": "METHODS AND RESULTS : Transmembrane action potentials from epicardium , midmyocardium , and endocardium were recorded simultaneously , together with a transmural ECG , in arterially perfused canine and rabbit left ventricular preparations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 278,
    "text": "dl - Sotalol preferentially prolonged action potential duration ( APD ) in M cells dose - dependently ( 1 to 100 micromol / L ) , leading to QT prolongation and an increase in TDR .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "QT prolongation"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 279,
    "text": "Azimilide , however , significantly prolonged APD and QT interval at concentrations from 0 . 1 to 10 micromol / L but shortened them at 30 micromol / L .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Azimilide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 280,
    "text": "Unlike dl - sotalol , azimilide ( > 3 micromol / L ) increased epicardial APD markedly , causing a diminished TDR .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "sotalol"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "azimilide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 281,
    "text": "Although both dl - sotalol and azimilide rarely induced EADs in canine left ventricles , they produced frequent EADs in rabbits , in which more pronounced QT prolongation was seen .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "QT prolongation"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "sotalol"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "azimilide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 282,
    "text": "An increase in TDR by dl - sotalol facilitated transmural propagation of EADs that initiated multiple episodes of spontaneous TdP in 3 of 6 rabbit left ventricles .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "sotalol"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "TdP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 283,
    "text": "Of note , although azimilide ( 3 to 10 micromol / L ) increased APD more than dl - sotalol , its EADs often failed to propagate transmurally , probably because of a diminished TDR .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "azimilide"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 284,
    "text": "CONCLUSIONS : This study provides the first direct evidence from intracellular action potential recordings that phase 2 EAD can be generated from intact ventricular wall and produce a trigger to initiate the onset of TdP under QT prolongation .",
    "labels": [
      [
        "T0",
        "Disease",
        36,
        38,
        "QT prolongation"
      ],
      [
        "T1",
        "Disease",
        34,
        35,
        "TdP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 285,
    "text": "A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine - associated chest pain .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "dobutamine"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 286,
    "text": "STUDY OBJECTIVE : Chest pain in the setting of cocaine use poses a diagnostic dilemma .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "Chest pain"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 287,
    "text": "Dobutamine stress echocardiography ( DSE ) is a widely available and sensitive test for evaluating cardiac ischemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dobutamine"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 288,
    "text": "Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use , we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine - associated chest pain .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        37,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "dobutamine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "cocaine"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 289,
    "text": "METHODS : A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary - care teaching hospital .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 290,
    "text": "Patients were eligible for DSE if they had used cocaine within 24 hours preceding the onset of chest pain and had a normal ECG and tropinin I level .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 291,
    "text": "Patients exhibiting signs of continuing cocaine toxicity were excluded from the study .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "cocaine"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 292,
    "text": "All patients were admitted to the hospital for serial testing after the DSE testing in the intensive diagnostic and treatment unit .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 293,
    "text": "RESULTS : Twenty - four patients were enrolled .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 294,
    "text": "Two patients had inadequate resting images , one DSE was terminated because of inferior hypokinesis , another DSE was terminated because of a rate - related atrial conduction deficit , and 1 patient did not reach the target heart rate .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "hypokinesis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 295,
    "text": "Thus , 19 patients completed a DSE and reached their target heart rates .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 296,
    "text": "None of the patients experienced signs of exaggerated adrenergic response , which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias ( excluding sinus tachycardia ) .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        34,
        "sinus tachycardia"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "tachydysrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 297,
    "text": "Further suggesting lack of exaggerated adrenergic response , 13 ( 65 % ) of 20 patients required supplemental atropine to reach their target heart rates .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "atropine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 298,
    "text": "CONCLUSION : No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine - related chest pain .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "dobutamine"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 299,
    "text": "Prenatal cocaine exposure and cranial sonographic findings in preterm infants .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "preterm infants"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 300,
    "text": "PURPOSE : Prenatal cocaine exposure has been linked with subependymal hemorrhage and the formation of cysts that are detectable on cranial sonography in neonates born at term .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cocaine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hemorrhage"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "cysts"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 301,
    "text": "We sought to determine if prenatal cocaine exposure increases the incidence of subependymal cysts in preterm infants .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "subependymal cysts"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "preterm infants"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 302,
    "text": "METHODS : We retrospectively reviewed the medical records and cranial sonograms obtained during a 1 - year period on 122 premature ( < 36 weeks of gestation ) infants .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        29,
        "premature ( < 36 weeks of gestation ) infants"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 303,
    "text": "Infants were categorized into 1 of 2 groups : those exposed to cocaine and those not exposed to cocaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 304,
    "text": "Infants were assigned to the cocaine - exposed group if there was a maternal history of cocaine abuse during pregnancy or if maternal or neonatal urine toxicology results were positive at the time of delivery .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "cocaine abuse"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 305,
    "text": "RESULTS : Five of the 122 infants were excluded from the study because of insufficient medical and drug histories .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 306,
    "text": "The incidence of subependymal cysts in the 117 remaining infants was 14 % ( 16 of 117 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "subependymal cysts"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 307,
    "text": "The incidence of subependymal cysts in infants exposed to cocaine prenatally was 44 % ( 8 of 18 ) compared with 8 % ( 8 of 99 ) in the unexposed group ( p < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "subependymal cysts"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 308,
    "text": "CONCLUSIONS : We found an increased incidence of subependymal cyst formation in preterm infants who were exposed to cocaine prenatally .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "subependymal cyst"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "preterm infants"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 309,
    "text": "This result is consistent with results of similar studies in term infants .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 310,
    "text": "Thalidomide neuropathy in patients treated for metastatic prostate cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "prostate cancer"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Thalidomide"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 311,
    "text": "We prospectively evaluated thalidomide - induced neuropathy using electrodiagnostic studies .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "thalidomide"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 312,
    "text": "Sixty - seven men with metastatic androgen - independent prostate cancer in an open - label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies ( NCS ) prior to and at 3 - month intervals during treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "prostate cancer"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "androgen"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 313,
    "text": "NCS included recording of sensory nerve action potentials ( SNAPs ) from median , radial , ulnar , and sural nerves .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 314,
    "text": "SNAP amplitudes for each nerve were expressed as the percentage of its baseline , and the mean of the four was termed the SNAP index .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 315,
    "text": "A 40 % decline in the SNAP index was considered clinically significant .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 316,
    "text": "Thalidomide was discontinued in 55 patients for lack of therapeutic response .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 317,
    "text": "Of 67 patients initially enrolled , 24 remained on thalidomide for 3 months , 8 remained at 6 months , and 3 remained at 9 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 318,
    "text": "Six patients developed neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 319,
    "text": "Clinical symptoms and a decline in the SNAP index occurred concurrently .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 320,
    "text": "Older age and cumulative dose were possible contributing factors .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 321,
    "text": "Neuropathy may thus be a common complication of thalidomide in older patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Neuropathy"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 322,
    "text": "The SNAP index can be used to monitor peripheral neuropathy , but not for early detection .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "peripheral neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 323,
    "text": "Overexpression of copper / zinc - superoxide dismutase protects from kanamycin - induced hearing loss .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "hearing loss"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "copper"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "zinc"
      ],
      [
        "T3",
        "Chemical",
        6,
        7,
        "superoxide"
      ],
      [
        "T4",
        "Chemical",
        10,
        11,
        "kanamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 324,
    "text": "The participation of reactive oxygen species in aminoglycoside - induced ototoxicity has been deduced from observations that aminoglycoside - iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "oxygen"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "aminoglycoside"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "ototoxicity"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "aminoglycoside"
      ],
      [
        "T4",
        "Chemical",
        19,
        20,
        "iron"
      ],
      [
        "T5",
        "Chemical",
        25,
        26,
        "superoxide"
      ],
      [
        "T6",
        "Disease",
        33,
        34,
        "ototoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 325,
    "text": "We therefore hypothesized that overexpression of Cu / Zn - superoxide dismutase ( h - SOD1 ) should protect transgenic mice from ototoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "Cu"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "Zn"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "superoxide"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "ototoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 326,
    "text": "Immunocytochemistry confirmed expression of h - SOD1 in inner ear tissues of transgenic C57BL / 6 - TgN [ SOD1 ] 3Cje mice .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 327,
    "text": "Transgenic and nontransgenic littermates received kanamycin ( 400 mg / kg body weight / day ) for 10 days beginning on day 10 after birth .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "kanamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 328,
    "text": "Auditory thresholds were tested by evoked auditory brain stem responses at 1 month after birth .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 329,
    "text": "In nontransgenic animals , the threshold in the kanamycin - treated group was 45 - 50 dB higher than in saline - injected controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "kanamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 330,
    "text": "In the transgenic group , kanamycin increased the threshold by only 15 dB over the respective controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "kanamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 331,
    "text": "The effects were similar at 12 and 24 kHz .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 332,
    "text": "The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside - induced ototoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "superoxide"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "aminoglycoside"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "ototoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 333,
    "text": "The results also suggest transgenic animals as suitable models to investigate the underlying mechanisms and possible strategies for prevention .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 334,
    "text": "Fatty liver induced by tetracycline in the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Fatty liver"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "tetracycline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 335,
    "text": "Dose - response relationships and effect of sex .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 336,
    "text": "Dose - response relationships , biochemical mechanisms , and sex differences in the experimental fatty liver induced by tetracycline were studied in the intact rat and with the isolated perfused rat liver in vitro .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "fatty liver"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "tetracycline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 337,
    "text": "In the intact male and female rat , no direct relationship was observed between dose of tetracycline and hepatic accumulation of triglyceride .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "tetracycline"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "triglyceride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 338,
    "text": "With provision of adequate oleic acid as a substrate for the isolated perfused liver , a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of triglyceride by livers from male and female rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "oleic acid"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "tetracycline"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "triglyceride"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "depression"
      ],
      [
        "T4",
        "Chemical",
        37,
        38,
        "triglyceride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 339,
    "text": "Marked differences were observed between female and male rats with regard to base line ( control ) hepatic concentration of triglyceride and output of triglyceride .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "triglyceride"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "triglyceride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 340,
    "text": "Accumulation of hepatic triglyceride , as a per cent of control values , in response to graded doses of tetracycline , did not differ significantly between male , female and pregnant rat livers .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "triglyceride"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "tetracycline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 341,
    "text": "However , livers from female , and especially pregnant female rats , were strikingly resistant to the effects of tetracycline on depression of output of triglyceride under these experimental conditions .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "tetracycline"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "depression"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "triglyceride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 342,
    "text": "These differences between the sexes could not be related to altered disposition of tetracycline or altered uptake of oleic acid .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        20,
        "oleic acid"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "tetracycline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 343,
    "text": "Depressed hepatic secretion of triglyceride accounted only for 30 to 50 % of accumulated hepatic triglyceride , indicating that additional mechanisms must be involved in the production of the triglyceride - rich fatty liver in response to tetracycline .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        34,
        "fatty liver"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "triglyceride"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "triglyceride"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "triglyceride"
      ],
      [
        "T4",
        "Chemical",
        37,
        38,
        "tetracycline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 344,
    "text": "Prednisone induces anxiety and glial cerebral changes in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Prednisone"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 345,
    "text": "OBJECTIVE : To assess whether prednisone ( PDN ) produces anxiety and / or cerebral glial changes in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "prednisone"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "PDN"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 346,
    "text": "METHODS : Male Wistar rats were studied and 3 groups were formed ( 8 rats per group ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 347,
    "text": "The moderate - dose group received 5 mg / kg / day PDN released from a subcutaneous implant .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "PDN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 348,
    "text": "In the high - dose group , implants containing PDN equivalent to 60 mg / kg / day were applied .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "PDN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 349,
    "text": "In the control group implants contained no PDN .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "PDN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 350,
    "text": "Anxiety was assessed using an open field and elevated plus - maze devices .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 351,
    "text": "The number of cells and cytoplasmic transformation of astrocytes and microglia cells were assessed by immunohistochemical analyses .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 352,
    "text": "RESULTS : Anxiety was documented in both groups of PDN treated rats compared with controls .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Anxiety"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "PDN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 353,
    "text": "The magnitude of transformation of the microglia assessed by the number of intersections was significantly higher in the PDN groups than in controls in the prefrontal cortex ( moderate - dose , 24 . 1 ; high - dose , 23 . 6 ; controls 18 . 7 ; p < 0 . 01 ) and striatum ( moderate - dose 25 . 6 ; high - dose 26 . 3 ; controls 18 . 9 ; p < 0 . 01 ) , but not in hippocampus .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "PDN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 354,
    "text": "The number of stained microglia cells was significantly higher in the PDN treated groups in the prefrontal cortex than in controls ( moderate - dose , 29 . 1 ; high - dose , 28 . 4 ; control , 17 . 7 cells per field ; p < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "PDN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 355,
    "text": "Stained microglia cells were significantly more numerous striatum and hippocampus in the high - dose group compared to controls .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 356,
    "text": "CONCLUSION : Subacute exposure to PDN induced anxiety and reactivity of microglia .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "PDN"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 357,
    "text": "The relevance of these features for patients using PDN remains to be elucidated .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "PDN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 358,
    "text": "Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        18,
        "squamous cell carcinoma of the cervix"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "carboplatin"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 359,
    "text": "BACKGROUND : The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "cervical carcinoma"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "carboplatin"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 360,
    "text": "METHODS : The combination of carboplatin ( area under the concentration curve [ AUC ] , 5 ) and liposomal doxorubicin ( Doxil ; starting dose , 40 mg / m ( 2 ) ) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile .",
    "labels": [
      [
        "T0",
        "Disease",
        46,
        50,
        "squamous cell cervical carcinoma"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "carboplatin"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "doxorubicin"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "Doxil"
      ],
      [
        "T4",
        "Disease",
        55,
        56,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 361,
    "text": "RESULTS : Twenty - nine patients were assessable for response , and 35 patients were assessable for toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 362,
    "text": "The overall response rate was 38 % , the median time to response was 10 weeks , the median duration of response was 26 weeks , and the median survival was 37 weeks .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 363,
    "text": "The main toxic effect was myelosuppression , with Grade 3 and 4 neutropenia in 16 patients , anemia in 12 patients , thrombocytopenia in 11 patients , and neutropenic fever in 3 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "neutropenic fever"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "myelosuppression"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "neutropenia"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "anemia"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 364,
    "text": "Four patients had five infusion - related reactions during the infusion of liposomal doxorubicin , leading to treatment discontinuation in three patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 365,
    "text": "Grade > or = 2 nonhematologic toxicity included nausea in 17 patients , emesis in 14 patients , fatigue in 9 patients , mucositis and / or stomatitis in 8 patients , constipation in 6 patients , weight loss in 5 patients , hand - foot syndrome in 2 patients , and skin reactions in 3 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        37,
        39,
        "weight loss"
      ],
      [
        "T1",
        "Disease",
        43,
        47,
        "hand - foot syndrome"
      ],
      [
        "T2",
        "Disease",
        52,
        54,
        "skin reactions"
      ],
      [
        "T3",
        "Disease",
        6,
        7,
        "toxicity"
      ],
      [
        "T4",
        "Disease",
        8,
        9,
        "nausea"
      ],
      [
        "T5",
        "Disease",
        13,
        14,
        "emesis"
      ],
      [
        "T6",
        "Disease",
        18,
        19,
        "fatigue"
      ],
      [
        "T7",
        "Disease",
        23,
        24,
        "mucositis"
      ],
      [
        "T8",
        "Disease",
        27,
        28,
        "stomatitis"
      ],
      [
        "T9",
        "Disease",
        32,
        33,
        "constipation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 366,
    "text": "CONCLUSIONS : The combination of carboplatin and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "cervical carcinoma"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "carboplatin"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 367,
    "text": "Antimicrobial - induced mania ( antibiomania ) : a review of spontaneous reports .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "mania"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "antibiomania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 368,
    "text": "The authors reviewed reported cases of antibiotic - induced manic episodes by means of a MEDLINE and PsychLit search for reports of antibiotic - induced mania .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "manic"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "mania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 369,
    "text": "Unpublished reports were requested from the World Health Organization ( WHO ) and the Food and Drug Administration ( FDA ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 370,
    "text": "Twenty - one reports of antimicrobial - induced mania were found in the literature .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "mania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 371,
    "text": "There were 6 cases implicating clarithromycin , 13 implicating isoniazid , and 1 case each implicating erythromycin and amoxicillin .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "clarithromycin"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "isoniazid"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "erythromycin"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "amoxicillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 372,
    "text": "The WHO reported 82 cases .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 373,
    "text": "Of these , clarithromycin was implicated in 23 ( 27 . 6 % ) cases , ciprofloxacin in 12 ( 14 . 4 % ) cases , and ofloxacin in 10 ( 12 % ) cases .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "clarithromycin"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "ciprofloxacin"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "ofloxacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 374,
    "text": "Cotrimoxazole , metronidazole , and erythromycin were involved in 15 reported manic episodes .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cotrimoxazole"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "metronidazole"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "erythromycin"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "manic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 375,
    "text": "Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "clarithromycin"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "ciprofloxacin"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "mania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 376,
    "text": "Statistical analysis of the data would not have demonstrated a significant statistical correlative risk and was therefore not undertaken .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 377,
    "text": "Patients have an increased risk of developing mania while being treated with antimicrobials .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "mania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 378,
    "text": "Although this is not a statistically significant risk , physicians must be aware of the effect and reversibility .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 379,
    "text": "Further research clearly is required to determine the incidence of antimicrobial - induced mania , the relative risk factors of developing an antimicrobial - induced manic episode among various demographic populations , and the incidence of patients who continue to have persistent affective disorders once the initial episode , which occurs while the patient is taking antibiotics , subsides .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "mania"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "manic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 380,
    "text": "The authors elected to name this syndrome \" antibiomania . \"",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "antibiomania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 381,
    "text": "Levodopa - induced ocular dyskinesias in Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "ocular dyskinesias"
      ],
      [
        "T1",
        "Disease",
        6,
        10,
        "Parkinson ' s disease"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 382,
    "text": "Levodopa - induced ocular dyskinesias are very uncommon .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "ocular dyskinesias"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 383,
    "text": "Usually they occur simultaneously with limb peak - dose choreatic dyskinesias .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "choreatic dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 384,
    "text": "We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa , and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa - induce ocular dyskinesias .",
    "labels": [
      [
        "T0",
        "Disease",
        40,
        42,
        "ocular dyskinesias"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "levodopa"
      ],
      [
        "T2",
        "Chemical",
        37,
        38,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 385,
    "text": "A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea : an open , randomized , cross - over trial .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "glyceryl trinitrate"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "diclofenac"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "dysmenorrhea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 386,
    "text": "Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial prostaglandins ; non - steroidal anti - inflammatory drugs are the first choice for its treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "dysmenorrhea"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "prostaglandins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 387,
    "text": "However , in vivo and in vitro studies have demonstrated that myometrial cells are also targets of the relaxant effects of nitric oxide ( NO ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        23,
        "nitric oxide"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "NO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 388,
    "text": "The aim of the present study was to determine the efficacy of glyceryl trinitrate ( GTN ) , an NO donor , in the resolution of primary dysmenorrhea in comparison with diclofenac ( DCF ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "glyceryl trinitrate"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "GTN"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "NO"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "dysmenorrhea"
      ],
      [
        "T4",
        "Chemical",
        31,
        32,
        "diclofenac"
      ],
      [
        "T5",
        "Chemical",
        33,
        34,
        "DCF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 389,
    "text": "A total of 24 patients with the diagnosis of severe primary dysmenorrhea were studied during two consecutive menstrual cycles .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "dysmenorrhea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 390,
    "text": "In an open , cross - over , controlled design , patients were randomized to receive either DCF per os or GTN patches the first days of menses , when menstrual cramps became unendurable .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "DCF"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 391,
    "text": "In the subsequent cycle the other treatment was used .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 392,
    "text": "Patients received up to 3 doses / day of 50 mg DCF or 2 . 5 mg / 24 h transdermal GTN for the first 3 days of the cycle , according to their needs .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "DCF"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 393,
    "text": "The participants recorded menstrual symptoms and possible side - effects at different times ( 0 , 30 , 60 , 120 minutes ) after the first dose of medication on the first day of the cycle , with both drugs .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 394,
    "text": "The difference in pain intensity score ( DPI ) was the main outcome variable .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 395,
    "text": "Both treatments significantly reduced DPI by the 30th minute ( GTN , - 12 . 8 + / - 17 . 9 ; DCF , - 18 . 9 + / - 16 . 6 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "GTN"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "DCF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 396,
    "text": "However , DCF continued to be effective in reducing pelvic pain for two hours , whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC ( after one hour : GTN , - 12 . 8 + / - 17 . 9 ; DFC , - 18 . 9 + / - 16 . 6 and after two hours : GTN , - 23 . 7 + / - 20 . 5 ; DFC , - 59 . 7 + / - 17 . 9 , p = 0 . 0001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "pelvic pain"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "DCF"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "GTN"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "GTN"
      ],
      [
        "T4",
        "Chemical",
        68,
        69,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 397,
    "text": "Low back pain was also relieved by both drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Low back pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 398,
    "text": "Headache was significantly increased by GTN but not by DCF .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Headache"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "GTN"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "DCF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 399,
    "text": "Eight patients stopped using GTN because headache - - attributed to its use - - became intolerable .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "GTN"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 400,
    "text": "These findings indicate that GTN has a reduced efficacy and tolerability by comparison with DCF in the treatment of primary dysmenorrhea .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "GTN"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "DCF"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "dysmenorrhea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 401,
    "text": "Temocapril , a long - acting non - SH group angiotensin converting enzyme inhibitor , modulates glomerular injury in chronic puromycin aminonucleoside nephrosis .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "glomerular injury"
      ],
      [
        "T1",
        "Chemical",
        20,
        22,
        "puromycin aminonucleoside"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Temocapril"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "angiotensin"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "nephrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 402,
    "text": "The purpose of the present study was to determine whether chronic administration of temocapril , a long - acting non - SH group angiotensin converting enzyme ( ACE ) inhibitor , reduced proteinuria , inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside ( PAN ) - induced nephrotic rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        42,
        44,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "temocapril"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "angiotensin"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "proteinuria"
      ],
      [
        "T4",
        "Disease",
        36,
        37,
        "hypertrophy"
      ],
      [
        "T5",
        "Disease",
        39,
        40,
        "glomerulosclerosis"
      ],
      [
        "T6",
        "Chemical",
        45,
        46,
        "PAN"
      ],
      [
        "T7",
        "Disease",
        49,
        50,
        "nephrotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 403,
    "text": "Nephrosis was induced by injection of PAN ( 15mg / 100g body weight ) in male Sprague - Dawley ( SD ) rats .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Nephrosis"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 404,
    "text": "Four groups were used , i ) the PAN group ( 14 ) , ii ) PAN / temocapril ( 13 ) , iii ) temocapril ( 14 ) and iv ) untreated controls ( 15 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "PAN"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "PAN"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "temocapril"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "temocapril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 405,
    "text": "Temocapril ( 8 mg / kg / day ) was administered to the rats which were killed at weeks 4 , 14 or 20 .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Temocapril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 406,
    "text": "At each time point , systolic blood pressure ( BP ) , urinary protein excretion and renal histopathological findings were evaluated , and morphometric image analysis was done .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 407,
    "text": "Systolic BP in the PAN group was significantly high at 4 , 14 and 20 weeks , but was normal in the PAN / temocapril group .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "PAN"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "PAN"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "temocapril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 408,
    "text": "Urinary protein excretion in the PAN group increased significantly , peaking at 8 days , then decreased at 4 weeks , but rose again significantly at 14 and 20 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 409,
    "text": "Temocapril did not attenuate proteinuria at 8 days , but it did markedly lower it from weeks 4 to 20 .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Temocapril"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 410,
    "text": "The glomerulosclerosis index ( GSI ) was 6 . 21 % at 4 weeks and respectively 25 . 35 % and 30 . 49 % at 14 and 20 weeks in the PAN group .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "glomerulosclerosis"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 411,
    "text": "There was a significant correlation between urinary protein excretion and GSI ( r = 0 . 808 , p < 0 . 0001 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 412,
    "text": "The ratio of glomerular tuft area to the area of Bowman ' s capsules ( GT / BC ) in the PAN group was significantly increased , but it was significantly lower in the PAN / temocapril group .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "PAN"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "PAN"
      ],
      [
        "T2",
        "Chemical",
        36,
        37,
        "temocapril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 413,
    "text": "It appears that temocapril was effective in retarding renal progression and protected renal function in PAN neprotic rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "temocapril"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "PAN"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "neprotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 414,
    "text": "Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Pulmonary hypertension"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "ibuprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 415,
    "text": "We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "patent ductus arteriosus"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hypoxaemia"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "ibuprofen"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "ibuprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 416,
    "text": "Echocardiography showed severely decreased pulmonary blood flow .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 417,
    "text": "Hypoxaemia resolved quickly on inhaled nitric oxide therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Hypoxaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 418,
    "text": "We suggest that investigators involved in similar trials pay close attention to pulmonary pressure if hypoxaemia occurs after prophylactic administration of ibuprofen .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "hypoxaemia"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "ibuprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 419,
    "text": "Hyponatremia and syndrome of inappropriate anti - diuretic hormone reported with the use of Vincristine : an over - representation of Asians ?",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        9,
        "syndrome of inappropriate anti - diuretic hormone"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Hyponatremia"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "Vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 420,
    "text": "PURPOSE : This retrospective study used a pharmaceutical company ' s global safety database to determine the reporting rate of hyponatremia and / or syndrome of inappropriate secretion of anti - diuretic hormone ( SIADH ) among vincristine - treated patients and to explore the possibility of at - risk population subgroups .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        33,
        "syndrome of inappropriate secretion of anti - diuretic hormone"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "hyponatremia"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "SIADH"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 421,
    "text": "METHOD : We searched the Eli Lilly and Company ' s computerized adverse event database for all reported cases of hyponatremia and / or SIADH as of 1 November 1999 that had been reported during the use of vincristine .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "hyponatremia"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "SIADH"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 422,
    "text": "RESULTS : A total of 76 cases of hyponatremia and / or SIADH associated with vincristine use were identified .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hyponatremia"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "SIADH"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 423,
    "text": "The overall reporting rate was estimated to be 1 . 3 / 100 , 000 treated patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 424,
    "text": "The average age of patients was 35 . 6 + / - 28 . 3 years , and 62 % were males .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 425,
    "text": "Approximately 75 % of the patients were receiving treatment for leukemia or lymphoma .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "leukemia"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "lymphoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 426,
    "text": "Among the 39 reports that included information on race , the racial distribution was : 1 Black , 3 Caucasian , and 35 Asian .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 427,
    "text": "CONCLUSION : Our data suggest that Asian patients may be at increased risk of hyponatremia and / or SIADH associated with vincristine use .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "hyponatremia"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "SIADH"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 428,
    "text": "Although the overall reported rate of SIADH associated with vincristine is very low , physicians caring for Asian oncology patients should be aware of this potential serious but reversible adverse event .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "SIADH"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 429,
    "text": "Delayed toxicity of cyclophosphamide on the bladder of DBA / 2 and C57BL / 6 female mouse .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 430,
    "text": "The present study describes the delayed development of a severe bladder pathology in a susceptible strain of mice ( DBA / 2 ) but not in a resistant strain ( C57BL / 6 ) when both were treated with a single 300 mg / kg dose of cyclophosphamide ( CY ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        47,
        48,
        "cyclophosphamide"
      ],
      [
        "T1",
        "Chemical",
        49,
        50,
        "CY"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 431,
    "text": "Inbred DBA / 2 and C57BL / 6 female mice were injected with CY , and the effect of the drug on the bladder was assessed during 100 days by light microscopy using different staining procedures , and after 30 days by conventional electron microscopy .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "CY"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 432,
    "text": "Early CY toxicity caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7 - 10 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "CY"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "toxicity"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "haemorrhagic"
      ],
      [
        "T3",
        "Disease",
        7,
        8,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 433,
    "text": "After 30 days of CY injection ulcerous and non - ulcerous forms of chronic cystitis appeared in 86 % of DBA / 2 mice but only in 4 % of C57BL / 6 mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "CY"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 434,
    "text": "Delayed cystitis was characterized by infiltration and transepithelial passage into the lumen of inflammatory cells and by frequent exfoliation of the urothelium .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 435,
    "text": "Mast cells appeared in the connective and muscular layers of the bladder at a much higher number in DBA / 2 mice than in C57BL / 6 mice or untreated controls .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 436,
    "text": "Electron microscopy disclosed the absence of the typical discoidal vesicles normally present in the cytoplasm of surface cells .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 437,
    "text": "Instead , numerous abnormal vesicles containing one or several dark granules were observed in the cytoplasm of cells from all the epithelial layers .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 438,
    "text": "Delayed cystitis still persisted in DBA / 2 mice 100 days after treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 439,
    "text": "These results indicate that delayed toxicity of CY in female DBA / 2 mice causes a bladder pathology that is not observed in C57BL / 6 mice .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "CY"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 440,
    "text": "This pathology resembles interstitial cystitis in humans and could perhaps be used as an animal model for studies on the disease .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "interstitial cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 441,
    "text": "High - dose 5 - fluorouracil / folinic acid in combination with three - weekly mitomycin C in the treatment of advanced gastric cancer .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "5 - fluorouracil"
      ],
      [
        "T1",
        "Chemical",
        7,
        9,
        "folinic acid"
      ],
      [
        "T2",
        "Chemical",
        15,
        17,
        "mitomycin C"
      ],
      [
        "T3",
        "Disease",
        22,
        24,
        "gastric cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 442,
    "text": "A phase II study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 443,
    "text": "BACKGROUND : The 24 - hour continuous infusion of 5 - fluorouracil ( 5 - FU ) and folinic acid ( FA ) as part of several new multidrug chemotherapy regimens in advanced gastric cancer ( AGC ) has shown to be effective , with low toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "5 - fluorouracil"
      ],
      [
        "T1",
        "Chemical",
        13,
        16,
        "5 - FU"
      ],
      [
        "T2",
        "Chemical",
        18,
        20,
        "folinic acid"
      ],
      [
        "T3",
        "Disease",
        33,
        35,
        "gastric cancer"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "FA"
      ],
      [
        "T5",
        "Disease",
        36,
        37,
        "AGC"
      ],
      [
        "T6",
        "Disease",
        46,
        47,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 444,
    "text": "In a previous phase II study with 3 - weekly bolus 5 - FU , FA and mitomycin C ( MMC ) we found a low toxicity rate and response rates comparable to those of regimens such as ELF , FAM or FAMTX , and a promising median overall survival .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        17,
        19,
        "mitomycin C"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "FA"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "MMC"
      ],
      [
        "T4",
        "Disease",
        26,
        27,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 445,
    "text": "In order to improve this MMC - dependent schedule we initiated a phase II study with high - dose 5 - FU / FA and 3 - weekly bolus MMC .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        22,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "MMC"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "FA"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "MMC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 446,
    "text": "PATIENTS AND METHODS : From February , 1998 to September , 2000 we recruited 33 patients with AGC to receive weekly 24 - hour 5 - FU 2 , 600 mg / m ( 2 ) preceded by 2 - hour FA 500 mg / m ( 2 ) for 6 weeks , followed by a 2 - week rest period .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        27,
        "5 - FU"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "AGC"
      ],
      [
        "T2",
        "Chemical",
        41,
        42,
        "FA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 447,
    "text": "Bolus MMC 10 mg / m ( 2 ) was added in 3 - weekly intervals .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "MMC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 448,
    "text": "Treatment given on an outpatient basis , using portable pump systems , was repeated on day 57 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 449,
    "text": "Patients ' characteristics were : male / female ratio 20 / 13 ; median age 57 ( 27 - 75 ) years ; median WHO status 1 ( 0 - 2 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 450,
    "text": "18 patients had a primary AGC , and 15 showed a relapsed AGC .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "AGC"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "AGC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 451,
    "text": "Median follow - up was 11 . 8 months ( range of those surviving : 2 . 7 - 11 . 8 months ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 452,
    "text": "RESULTS : 32 patients were evaluable for response - complete remission 9 . 1 % ( n = 3 ) , partial remission 45 . 5 % ( n = 15 ) , no change 27 . 3 % ( n = 9 ) , progressive disease 15 . 1 % ( n = 5 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 453,
    "text": "Median overall survival time was 10 . 2 months [ 95 % confidence interval ( CI ) : 8 . 7 - 11 . 6 ] , and median progression - free survival time was 7 . 6 months ( 95 % CI : 4 . 4 - 10 . 9 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 454,
    "text": "The worst toxicities ( % ) observed were ( CTC - NCI 1 / 2 / 3 ) : leukopenia 45 . 5 / 18 . 2 / 6 . 1 , thrombocytopenia 33 . 3 / 9 . 1 / 6 . 1 , vomitus 24 . 2 / 9 . 1 / 0 , diarrhea 36 . 4 / 6 . 1 / 3 . 0 , stomatitis 18 . 2 / 9 . 1 / 0 , hand - foot syndrome 12 . 1 / 0 / 0 .",
    "labels": [
      [
        "T0",
        "Disease",
        80,
        84,
        "hand - foot syndrome"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "toxicities"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "leukopenia"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "thrombocytopenia"
      ],
      [
        "T4",
        "Disease",
        45,
        46,
        "vomitus"
      ],
      [
        "T5",
        "Disease",
        56,
        57,
        "diarrhea"
      ],
      [
        "T6",
        "Disease",
        69,
        70,
        "stomatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 455,
    "text": "Two patients developed hemolytic - uremic syndrome ( HUS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "hemolytic - uremic syndrome"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "HUS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 456,
    "text": "CONCLUSIONS : High - dose 5 - FU / FA / MMC is an effective and well - tolerated outpatient regimen for AGC ( objective response rate 54 . 6 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "FA"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "MMC"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "AGC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 457,
    "text": "It may serve as an alternative to cisplatin - containing regimens ; however , it has to be considered that possibly HUS may occur .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "cisplatin"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "HUS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 458,
    "text": "Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1 - infected children treated with indinavir .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "impaired renal function"
      ],
      [
        "T1",
        "Disease",
        10,
        17,
        "human immunodeficiency virus type 1 - infected"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "leukocyturia"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "indinavir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 459,
    "text": "BACKGROUND : Prolonged administration of indinavir is associated with the occurrence of a variety of renal complications in adults .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "indinavir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 460,
    "text": "These well - documented side effects have restricted the use of this potent protease inhibitor in children .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 461,
    "text": "DESIGN : A prospective study to monitor indinavir - related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1 - infected children treated with indinavir .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        23,
        "human immunodeficiency virus type 1 - infected"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "indinavir"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "nephrotoxicity"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "indinavir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 462,
    "text": "METHODS : Urinary pH , albumin , creatinine , the presence of erythrocytes , leukocytes , bacteria and crystals , and culture were analyzed every 3 months for 96 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 463,
    "text": "Serum creatinine levels were routinely determined at the same time points .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 464,
    "text": "Steady - state pharmacokinetics of indinavir were done at week 4 after the initiation of indinavir .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "indinavir"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "indinavir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 465,
    "text": "RESULTS : The cumulative incidence of persistent sterile leukocyturia ( > or = 75 cells / micro L in at least 2 consecutive visits ) after 96 weeks was 53 % .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "leukocyturia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 466,
    "text": "Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin / creatinine ratio and by microscopic hematuria .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "leukocyturia"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "creatinine"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "hematuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 467,
    "text": "The cumulative incidence of serum creatinine levels > 50 % above normal was 33 % after 96 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 468,
    "text": "Children with persistent sterile leukocyturia more frequently had serum creatinine levels of 50 % above normal than those children without persistent sterile leukocyturia .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "leukocyturia"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "creatinine"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "leukocyturia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 469,
    "text": "In children younger than 5 . 6 years , persistent sterile leukocyturia was significantly more frequent than in older children .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "leukocyturia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 470,
    "text": "A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve > 19 mg / L x h or a peak serum level of indinavir > 12 mg / L .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "leukocyturia"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "indinavir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 471,
    "text": "In 4 children , indinavir was discontinued because of nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "indinavir"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 472,
    "text": "Subsequently , the serum creatinine levels decreased , the urine albumin / creatinine ratios returned to zero , and the leukocyturia disappeared within 3 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "creatinine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "creatinine"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "leukocyturia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 473,
    "text": "CONCLUSIONS : Children treated with indinavir have a high cumulative incidence of persistent sterile leukocyturia .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "indinavir"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "leukocyturia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 474,
    "text": "Children with persistent sterile leukocyturia more frequently had an increase in serum creatinine levels of > 50 % above normal .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "leukocyturia"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 475,
    "text": "Younger children have an additional risk for renal complications .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 476,
    "text": "The impairment of the renal function in these children occurred in the absence of clinical symptoms of nephrolithiasis .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        6,
        "impairment of the renal function"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "nephrolithiasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 477,
    "text": "Indinavir - associated nephrotoxicity must be monitored closely , especially in children with risk factors such as persistent sterile leukocyturia , age < 5 . 6 years , an area under the curve of indinavir > 19 mg / L x h , and a C ( max ) > 12 mg / L .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Indinavir"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "nephrotoxicity"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "leukocyturia"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "indinavir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 478,
    "text": "Utility of troponin I in patients with cocaine - associated chest pain .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 479,
    "text": "Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction ( MI ) difficult in patients with cocaine - associated chest pain .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "myocardial necrosis"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "myocardial infarction"
      ],
      [
        "T2",
        "Disease",
        27,
        29,
        "chest pain"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "MI"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 480,
    "text": "Troponin sampling may offer greater diagnostic utility in these patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 481,
    "text": "OBJECTIVE : To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "cocaine"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 482,
    "text": "METHODS : Outcomes were examined in patients admitted for possible MI after cocaine use .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "MI"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 483,
    "text": "All patients underwent a rapid rule - in protocol that included serial sampling of creatine kinase ( CK ) , CK - MB , and cardiac troponin I ( cTnI ) over eight hours .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "creatine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 484,
    "text": "Outcomes included CK - MB MI ( CK - MB > or = 8 ng / mL with a relative index [ ( CK - MB x 100 ) / total CK ] > or = 4 , cardiac death , and significant coronary disease ( > or = 50 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        38,
        40,
        "cardiac death"
      ],
      [
        "T1",
        "Disease",
        43,
        45,
        "coronary disease"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 485,
    "text": "RESULTS : Of the 246 admitted patients , 34 ( 14 % ) met CK - MB criteria for MI and 38 ( 16 % ) had cTnI elevations .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 486,
    "text": "Angiography was performed in 29 of 38 patients who were cTnI - positive , with significant disease present in 25 ( 86 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 487,
    "text": "Three of the four patients without significant disease who had cTnI elevations met CK - MB criteria for MI , and the other had a peak CK - MB level of 13 ng / mL .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 488,
    "text": "Sensitivities , specificities , and positive and negative likelihood ratios for predicting cardiac death or significant disease were high for both CK - MB MI and cTnI and were not significantly different .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "cardiac death"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 489,
    "text": "CONCLUSIONS : Most patients with cTnI elevations meet CK - MB criteria for MI , as well as have a high incidence of underlying significant disease .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 490,
    "text": "Troponin appears to have an equivalent diagnostic accuracy compared with CK - MB for diagnosing necrosis in patients with cocaine - associated chest pain and suspected MI .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "chest pain"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "necrosis"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 491,
    "text": "Acute interstitial nephritis due to nicergoline ( Sermion ) .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "interstitial nephritis"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "nicergoline"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "Sermion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 492,
    "text": "We report a case of acute interstitial nephritis ( AIN ) due to nicergoline ( Sermion ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "interstitial nephritis"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "AIN"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "nicergoline"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "Sermion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 493,
    "text": "A 50 - year - old patient admitted to our hospital for fever and acute renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        17,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "fever"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 494,
    "text": "Before admission , he had been taking nicergoline and bendazac lysine due to retinal vein occlusion at ophthalmologic department .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "bendazac lysine"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "retinal vein occlusion"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "nicergoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 495,
    "text": "Thereafter , he experienced intermittent fever and skin rash .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "skin rash"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "fever"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 496,
    "text": "On admission , clinical symptoms ( i . e . arthralgia and fever ) and laboratory findings ( i . e . eosinophilia and renal failure ) suggested AIN , and which was confirmed by pathologic findings on renal biopsy .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "renal failure"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "arthralgia"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "fever"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "eosinophilia"
      ],
      [
        "T4",
        "Disease",
        28,
        29,
        "AIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 497,
    "text": "A lymphocyte transformation test demonstrated a positive result against nicergoline .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "nicergoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 498,
    "text": "Treatment was consisted of withdrawal of nicergoline and intravenous methylprednisolone , and his renal function was completely recovered .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "nicergoline"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "methylprednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 499,
    "text": "To our knowledge , this is the first report of nicergoline - associated AIN .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "nicergoline"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "AIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 500,
    "text": "Neuroleptic malignant syndrome complicated by massive intestinal bleeding in a patient with chronic renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Disease",
        12,
        15,
        "chronic renal failure"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 501,
    "text": "A patient with chronic renal failure ( CRF ) developed neuroleptic malignant syndrome ( NMS ) after administration of risperidone and levomepromazine .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "chronic renal failure"
      ],
      [
        "T1",
        "Disease",
        10,
        13,
        "neuroleptic malignant syndrome"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "CRF"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "NMS"
      ],
      [
        "T4",
        "Chemical",
        19,
        20,
        "risperidone"
      ],
      [
        "T5",
        "Chemical",
        21,
        22,
        "levomepromazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 502,
    "text": "In addition to the typical symptoms of NMS , massive intestinal bleeding was observed during the episode .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "NMS"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 503,
    "text": "This report suggests that NMS in a patient with CRF may be complicated by intestinal bleeding and needs special caution for this complication .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "NMS"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "CRF"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 504,
    "text": "Blood brain barrier in right - and left - pawed female rats assessed by a new staining method .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 505,
    "text": "The asymmetrical breakdown of the blood - brain barrier ( BBB ) was studied in female rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 506,
    "text": "Paw preference was assessed by a food reaching test .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 507,
    "text": "Adrenaline - induced hypertension was used to destroy the BBB , which was evaluated using triphenyltetrazolium ( TTC ) staining of the brain slices just after giving adrenaline for 30 s .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Adrenaline"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hypertension"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "triphenyltetrazolium"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "TTC"
      ],
      [
        "T4",
        "Chemical",
        27,
        28,
        "adrenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 508,
    "text": "In normal rats , the whole brain sections exhibited complete staining with TTC .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "TTC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 509,
    "text": "After adrenaline infusion for 30 s , there were large unstained areas in the left brain in right - pawed animals , and vice versa in left - pawed animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "adrenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 510,
    "text": "Similar results were obtained in seizure - induced breakdown of BBB .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 511,
    "text": "These results were explained by an asymmetric cerebral blood flow depending upon the paw preference in rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 512,
    "text": "It was suggested that this new method and the results are consistent with contralateral motor control that may be important in determining the dominant cerebral hemisphere in animals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 513,
    "text": "Carvedilol protects against doxorubicin - induced mitochondrial cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Carvedilol"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "doxorubicin"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 514,
    "text": "Several cytopathic mechanisms have been suggested to mediate the dose - limiting cumulative and irreversible cardiomyopathy caused by doxorubicin .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "cardiomyopathy"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 515,
    "text": "Recent evidence indicates that oxidative stress and mitochondrial dysfunction are key factors in the pathogenic process .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "mitochondrial dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 516,
    "text": "The objective of this investigation was to test the hypothesis that carvedilol , a nonselective beta - adrenergic receptor antagonist with potent antioxidant properties , protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "carvedilol"
      ],
      [
        "T1",
        "Chemical",
        37,
        38,
        "doxorubicin"
      ],
      [
        "T2",
        "Disease",
        38,
        39,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 517,
    "text": "Heart and liver mitochondria were isolated from rats treated for 7 weeks with doxorubicin ( 2 mg / kg sc / week ) , carvedilol ( 1 mg / kg ip / week ) , or the combination of the two drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "doxorubicin"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "carvedilol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 518,
    "text": "Heart mitochondria isolated from doxorubicin - treated rats exhibited depressed rates for state 3 respiration ( 336 + / - 26 versus 425 + / - 53 natom O / min / mg protein ) and a lower respiratory control ratio ( RCR ) ( 4 . 3 + / - 0 . 6 versus 5 . 8 + / - 0 . 4 ) compared with cardiac mitochondria isolated from saline - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 519,
    "text": "Mitochondrial calcium - loading capacity and the activity of NADH - dehydrogenase were also suppressed in cardiac mitochondria from doxorubicin - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "calcium"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 520,
    "text": "Doxorubicin treatment also caused a decrease in RCR for liver mitochondria ( 3 . 9 + / - 0 . 9 versus 5 . 6 + / - 0 . 7 for control rats ) and inhibition of hepatic cytochrome oxidase activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 521,
    "text": "Coadministration of carvedilol decreased the extent of cellular vacuolization in cardiac myocytes and prevented the inhibitory effect of doxorubicin on mitochondrial respiration in both heart and liver .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "carvedilol"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 522,
    "text": "Carvedilol also prevented the decrease in mitochondrial Ca ( 2 + ) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Carvedilol"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "Ca"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 523,
    "text": "Carvedilol by itself did not affect any of the parameters measured for heart or liver mitochondria .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Carvedilol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 524,
    "text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose - limiting mitochondrial dysfunction and cardiomyopathy that accompanies long - term doxorubicin therapy in cancer patients .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "mitochondrial dysfunction"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "carvedilol"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "cardiomyopathy"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "doxorubicin"
      ],
      [
        "T4",
        "Disease",
        40,
        41,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 525,
    "text": "Cocaine - induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine - induced hyperactivity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cocaine"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hyperactivity"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "adenosine"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "amphetamine"
      ],
      [
        "T4",
        "Disease",
        15,
        16,
        "hyperactivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 526,
    "text": "The influence of adenosine receptor agonists and antagonists on cocaine - and amphetamine - induced hyperactivity was examined in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "adenosine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "amphetamine"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "hyperactivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 527,
    "text": "All adenosine receptor agonists significantly decreased the locomotor activity in mice , and the effects were dose - dependent .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "decreased the locomotor activity"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 528,
    "text": "It seems that adenosine A1 and A2 receptors might be involved in this reaction .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 529,
    "text": "Moreover , all adenosine receptor agonists : 2 - p - ( 2 - carboxyethyl ) phenethylamino - 5 ' - N - ethylcarboxamidoadenosine ( CGS 21680 ) , A2A receptor agonist , N6 - cyclopentyladenosine ( CPA ) , A1 receptor agonist , and 5 ' - N - ethylcarboxamidoadenosine ( NECA ) , A2 / A1 receptor agonist significantly and dose - dependently decreased cocaine - induced locomotor activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        24,
        "2 - p - ( 2 - carboxyethyl ) phenethylamino - 5 ' - N - ethylcarboxamidoadenosine"
      ],
      [
        "T1",
        "Chemical",
        25,
        27,
        "CGS 21680"
      ],
      [
        "T2",
        "Chemical",
        33,
        36,
        "N6 - cyclopentyladenosine"
      ],
      [
        "T3",
        "Chemical",
        45,
        51,
        "5 ' - N - ethylcarboxamidoadenosine"
      ],
      [
        "T4",
        "Chemical",
        3,
        4,
        "adenosine"
      ],
      [
        "T5",
        "Chemical",
        37,
        38,
        "CPA"
      ],
      [
        "T6",
        "Chemical",
        52,
        53,
        "NECA"
      ],
      [
        "T7",
        "Chemical",
        66,
        67,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 530,
    "text": "CPA reduced cocaine action at the doses which , given alone , did not influence motility , while CGS 21680 and NECA decreased the action of cocaine at the doses which , given alone , decreased locomotor activity in animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        20,
        "CGS 21680"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "CPA"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "cocaine"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "NECA"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 531,
    "text": "These results suggest the involvement of both adenosine receptors in the action of cocaine although agonists of A1 receptors seem to have stronger influence on it .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "adenosine"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 532,
    "text": "The selective blockade of A2 adenosine receptor by DMPX ( 3 , 7 - dimethyl - 1 - propargylxanthine ) significantly enhanced cocaine - induced locomotor activity of animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        19,
        "3 , 7 - dimethyl - 1 - propargylxanthine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "adenosine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "DMPX"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 533,
    "text": "Caffeine had similar action but the effect was not significant .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 534,
    "text": "CPT ( 8 - cyclopentyltheophylline ) - - A1 receptor antagonist , did not show any influence in this test .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "8 - cyclopentyltheophylline"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "CPT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 535,
    "text": "Similarly , all adenosine receptor agonists decreased amphetamine - induced hyperactivity , but at the higher doses than those which were active in cocaine - induced hyperactivity .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "adenosine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "amphetamine"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "hyperactivity"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "cocaine"
      ],
      [
        "T4",
        "Disease",
        26,
        27,
        "hyperactivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 536,
    "text": "The selective blockade of A2 adenosine receptors ( DMPX ) and non - selective blockade of adenosine receptors ( caffeine ) significantly increased the action of amphetamine in the locomotor activity test .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "adenosine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "DMPX"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "adenosine"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "caffeine"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 537,
    "text": "Our results have shown that all adenosine receptor agonists ( A1 and A2 ) reduce cocaine - and amphetamine - induced locomotor activity and indicate that cocaine - induced hyperactivity is more influenced by adenosine receptor agonists ( particularly A1 receptors ) than amphetamine - induced hyperactivity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "adenosine"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "amphetamine"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "cocaine"
      ],
      [
        "T4",
        "Disease",
        29,
        30,
        "hyperactivity"
      ],
      [
        "T5",
        "Chemical",
        34,
        35,
        "adenosine"
      ],
      [
        "T6",
        "Chemical",
        43,
        44,
        "amphetamine"
      ],
      [
        "T7",
        "Disease",
        46,
        47,
        "hyperactivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 538,
    "text": "Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "myocardial infarction"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ],
      [
        "T3",
        "Disease",
        5,
        6,
        "bradyarrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 539,
    "text": "OBJECTIVES : The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation ( AF ) increases the risk of bradyarrhythmia requiring a permanent pacemaker .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "amiodarone"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "AF"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "bradyarrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 540,
    "text": "BACKGROUND : Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy ' s use in the management of patients with ventricular arrhythmias .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "ventricular arrhythmias"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "bradyarrhythmia"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 541,
    "text": "METHODS : A study cohort of 8 , 770 patients age > or = 65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction ( MI ) between 1991 and 1999 .",
    "labels": [
      [
        "T0",
        "Disease",
        33,
        35,
        "myocardial infarction"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "AF"
      ],
      [
        "T2",
        "Disease",
        36,
        37,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 542,
    "text": "Using a nested case - control design , 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched ( 1 : 4 ) to 1 , 908 controls .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "bradyarrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 543,
    "text": "Multivariable logistic regression was used to estimate the odds ratio ( OR ) of pacemaker insertion associated with amiodarone use , controlling for baseline risk factors and exposure to sotalol , Class I antiarrhythmic agents , beta - blockers , calcium channel blockers , and digoxin .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "amiodarone"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "sotalol"
      ],
      [
        "T2",
        "Chemical",
        40,
        41,
        "calcium"
      ],
      [
        "T3",
        "Chemical",
        45,
        46,
        "digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 544,
    "text": "RESULTS : amiodarone use was associated with an increased risk of pacemaker insertion ( OR : 2 . 14 , 95 % confidence interval [ CI ] : 1 . 30 to 3 . 54 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 545,
    "text": "This effect was modified by gender , with a greater risk in women versus men ( OR : 3 . 86 , 95 % CI : 1 . 70 to 8 . 75 vs . OR : 1 . 52 , 95 % CI : 0 . 80 to 2 . 89 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 546,
    "text": "Digoxin was the only other medication associated with an increased risk of pacemaker insertion ( OR : 1 . 78 , 95 % CI : 1 . 37 to 2 . 31 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 547,
    "text": "CONCLUSIONS : This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "amiodarone"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "AF"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "MI"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "bradyarrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 548,
    "text": "The finding of an augmented risk of pacemaker insertion in elderly women receiving amiodarone requires further investigation .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 549,
    "text": "Indomethacin - induced morphologic changes in the rat urinary bladder epithelium .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 550,
    "text": "OBJECTIVES : To evaluate the morphologic changes in rat urothelium induced by indomethacin .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 551,
    "text": "Nonsteroidal anti - inflammatory drug - induced cystitis is a poorly recognized and under - reported condition .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 552,
    "text": "In addition to tiaprofenic acid , indomethacin has been reported to be associated with this condition .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "tiaprofenic acid"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 553,
    "text": "METHODS : Three groups were established : a control group ( n = 10 ) , a high - dose group ( n = 10 ) , treated with one intraperitoneal injection of indomethacin 20 mg / kg , and a therapeutic dose group ( n = 10 ) in which oral indomethacin was administered 3 . 25 mg / kg body weight daily for 3 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        34,
        "indomethacin"
      ],
      [
        "T1",
        "Chemical",
        52,
        53,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 554,
    "text": "The animals were then killed and the bladders removed for light and electron microscopic studies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 555,
    "text": "RESULTS : The light microscopic findings showed some focal epithelial degeneration that was more prominent in the high - dose group .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 556,
    "text": "When compared with the control group , both indomethacin groups revealed statistically increased numbers of mast cells in the mucosa ( P < 0 . 0001 ) and penetration of lanthanum nitrate through intercellular areas of the epithelium .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        32,
        "lanthanum nitrate"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 557,
    "text": "Furthermore , the difference in mast cell counts between the high and therapeutic dose groups was also statistically significant ( P < 0 . 0001 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 558,
    "text": "CONCLUSIONS : Indomethacin resulted in histopathologic findings typical of interstitial cystitis , such as leaky bladder epithelium and mucosal mastocytosis .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "interstitial cystitis"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Indomethacin"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "mastocytosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 559,
    "text": "The true incidence of nonsteroidal anti - inflammatory drug - induced cystitis in humans must be clarified by prospective clinical trials .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 560,
    "text": "An open - label phase II study of low - dose thalidomide in androgen - independent prostate cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "prostate cancer"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "thalidomide"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "androgen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 561,
    "text": "The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological malignancies .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "haematological malignancies"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 562,
    "text": "Thalidomide blocks the activity of angiogenic agents including bFGF , VEGF and IL - 6 .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 563,
    "text": "We undertook an open - label study using thalidomide 100 mg once daily for up to 6 months in 20 men with androgen - independent prostate cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "prostate cancer"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "thalidomide"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "androgen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 564,
    "text": "The mean time of study was 109 days ( median 107 , range 4 - 184 days ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 565,
    "text": "Patients underwent regular measurement of prostate - specific antigen ( PSA ) , urea and electrolytes , serum bFGF and VEGF .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "urea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 566,
    "text": "Three men ( 15 % ) showed a decline in serum PSA of at least 50 % , sustained throughout treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 567,
    "text": "Of 16 men treated for at least 2 months , six ( 37 . 5 % ) showed a fall in absolute PSA by a median of 48 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 568,
    "text": "Increasing levels of serum bFGF and VEGF were associated with progressive disease ; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels , and three of four men with a rising PSA showed an increase in both growth factors .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 569,
    "text": "Adverse effects included constipation , morning drowsiness , dizziness and rash , and resulted in withdrawal from the study by three men .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "constipation"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "drowsiness"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "dizziness"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "rash"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 570,
    "text": "Evidence of peripheral sensory neuropathy was found in nine of 13 men before treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "peripheral sensory neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 571,
    "text": "In the seven men who completed six months on thalidomide , subclinical evidence of peripheral neuropathy was found in four before treatment , but in all seven at repeat testing .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "peripheral neuropathy"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 572,
    "text": "The findings indicate that thalidomide may be an option for patients who have failed other forms of therapy , provided close follow - up is maintained for development of peripheral neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        31,
        "peripheral neuropathy"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 573,
    "text": "Central nervous system toxicity following the administration of levobupivacaine for lumbar plexus block : A report of two cases .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Central nervous system toxicity"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "levobupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 574,
    "text": "BACKGROUND AND OBJECTIVES : Central nervous system and cardiac toxicity following the administration of local anesthetics is a recognized complication of regional anesthesia .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        10,
        "Central nervous system and cardiac toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 575,
    "text": "Levobupivacaine , the pure S ( - ) enantiomer of bupivacaine , was developed to improve the cardiac safety profile of bupivacaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Levobupivacaine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 576,
    "text": "We describe 2 cases of grand mal seizures following accidental intravascular injection of levobupivacaine .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "grand mal seizures"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "levobupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 577,
    "text": "CASE REPORT : Two patients presenting for elective orthopedic surgery of the lower limb underwent blockade of the lumbar plexus via the posterior approach .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 578,
    "text": "Immediately after the administration of levobupivacaine 0 . 5 % with epinephrine 2 . 5 microgram / mL , the patients developed grand mal seizures , despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        25,
        "grand mal seizures"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "levobupivacaine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "epinephrine"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 579,
    "text": "The seizures were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "sodium thiopental"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 580,
    "text": "Neither patient developed signs of cardiovascular toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "cardiovascular toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 581,
    "text": "Both patients were treated preoperatively with beta - adrenergic antagonist medications , which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        26,
        "levobupivacaine"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 582,
    "text": "CONCLUSIONS : Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine , if adequate amounts of levobupivacaine reach the circulation , it will result in convulsions .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "cardiac toxicity"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "levobupivacaine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "bupivacaine"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "levobupivacaine"
      ],
      [
        "T4",
        "Disease",
        28,
        29,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 583,
    "text": "Plasma concentrations sufficient to result in central nervous system toxicity did not produce manifestations of cardiac toxicity in these 2 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        10,
        "central nervous system toxicity"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "cardiac toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 584,
    "text": "Amiodarone - induced torsade de pointes during bladder irrigation : an unusual presentation - - a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "torsade de pointes"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 585,
    "text": "The authors present a case of early ( within 4 days ) development of torsade de pointes ( TdP ) associated with oral amiodarone therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        17,
        "torsade de pointes"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "TdP"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 586,
    "text": "Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and digoxin excess .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "TdP"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "hypokalemia"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 587,
    "text": "Transient prolongation of the QT during bladder irrigation prompted the episode of TdP .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "TdP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 588,
    "text": "It is well known that bradycardia exacerbates acquired TdP .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "bradycardia"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "TdP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 589,
    "text": "The authors speculate that the increased vagal tone during bladder irrigation , a vagal maneuver , in the context of amiodarone therapy resulted in amiodarone - induced proarrhythmia .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "amiodarone"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "amiodarone"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "proarrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 590,
    "text": "In the absence of amiodarone therapy , a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "amiodarone"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "TdP"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "hypokalemia"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "hypomagnesemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 591,
    "text": "Anaesthetic complications associated with myotonia congenita : case study and comparison with other myotonic disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "myotonia congenita"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "myotonic disorders"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 592,
    "text": "Myotonia congenita ( MC ) is caused by a defect in the skeletal muscle chloride channel function , which may cause sustained membrane depolarisation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Myotonia congenita"
      ],
      [
        "T1",
        "Disease",
        21,
        24,
        "sustained membrane depolarisation"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "MC"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "chloride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 593,
    "text": "We describe a previously healthy 32 - year - old woman who developed a life - threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of suxamethonium .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "muscle spasm"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "suxamethonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 594,
    "text": "The muscle spasms disappeared spontaneously and the surgery proceeded without further problems .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "muscle spasms"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 595,
    "text": "When subsequently questioned , she reported minor symptoms suggesting a myotonic condition .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "myotonic condition"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 596,
    "text": "Myotonia was found on clinical examination and EMG .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Myotonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 597,
    "text": "The diagnosis MC was confirmed genetically .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "MC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 598,
    "text": "Neither the patient nor the anaesthetist were aware of the diagnosis before this potentially lethal complication occurred .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 599,
    "text": "We give a brief overview of ion channel disorders including malignant hyperthermia and their anaesthetic considerations .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "ion channel disorders"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "malignant hyperthermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 600,
    "text": "Respiratory pattern in a rat model of epilepsy .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 601,
    "text": "PURPOSE : Apnea is known to occur during seizures , but systematic studies of ictal respiratory changes in adults are few .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Apnea"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 602,
    "text": "Data regarding respiratory pattern defects during interictal periods also are scarce .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 603,
    "text": "Here we sought to generate information with regard to the interictal period in animals with pilocarpine - induced epilepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "pilocarpine"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 604,
    "text": "METHODS : Twelve rats ( six chronically epileptic animals and six controls ) were anesthetized , given tracheotomies , and subjected to hyperventilation or hypoventilation conditions .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "epileptic"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "hyperventilation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 605,
    "text": "Breathing movements caused changes in thoracic volume and forced air to flow tidally through a pneumotachograph .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 606,
    "text": "This flow was measured by using a differential pressure transducer , passed through a polygraph , and from this to a computer with custom software that derived ventilation ( VE ) , tidal volume ( VT ) , inspiratory time ( TI ) , expiratory time ( TE ) , breathing frequency ( f ) , and mean inspiratory flow ( VT / TI ) on a breath - by - breath basis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 607,
    "text": "RESULTS : The hyperventilation maneuver caused a decrease in spontaneous ventilation in pilocarpine - treated and control rats .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hyperventilation"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 608,
    "text": "Although VE had a similar decrease in both groups , in the epileptic group , the decrease in VE was due to a significant ( p < 0 . 05 ) increase in TE peak in relation to that of the control animals .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 609,
    "text": "The hypoventilation maneuver led to an increase in the arterial Paco2 , followed by an increase in VE .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 610,
    "text": "In the epileptic group , the increase in VE was mediated by a significant ( p < 0 . 05 ) decrease in TE peak compared with the control group .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 611,
    "text": "Systemic application of KCN , to evaluate the effects of peripheral chemoreception activation on ventilation , led to a similar increase in VE for both groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 612,
    "text": "CONCLUSIONS : The data indicate that pilocarpine - treated animals have an altered ability to react to ( or compensate for ) blood gas changes with changes in ventilation and suggest that it is centrally determined .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 613,
    "text": "We speculate on the possible relation of the current findings on treating different epilepsy - associated conditions .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 614,
    "text": "Fatal myeloencephalopathy due to intrathecal vincristine administration .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "myeloencephalopathy"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 615,
    "text": "Vincristine was accidentally given intrathecally to a child with leukaemia , producing sensory and motor dysfunction followed by encephalopathy and death .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "sensory and motor dysfunction"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Vincristine"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "leukaemia"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 616,
    "text": "Separate times for administering vincristine and intrathecal therapy is recommended .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 617,
    "text": "Progesterone potentiation of bupivacaine arrhythmogenicity in pentobarbital - anesthetized rats and beating rat heart cell cultures .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Progesterone"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "pentobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 618,
    "text": "The effects of progesterone treatment on bupivacaine arrhythmogenicity in beating rat heart myocyte cultures and on anesthetized rats were determined .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "progesterone"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 619,
    "text": "After determining the bupivacaine AD50 ( the concentration of bupivacaine that caused 50 % of all beating rat heart myocyte cultures to become arrhythmic ) , we determined the effect of 1 - hour progesterone HCl exposure on myocyte contractile rhythm .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "bupivacaine"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "arrhythmic"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "progesterone"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "HCl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 620,
    "text": "Each concentration of progesterone ( 6 . 25 , 12 . 5 , 25 , and 50 micrograms / ml ) caused a significant and concentration - dependent reduction in the AD50 for bupivacaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "progesterone"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 621,
    "text": "Estradiol treatment also increased the arrhythmogenicity of bupivacaine in myocyte cultures , but was only one fourth as potent as progesterone .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Estradiol"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "progesterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 622,
    "text": "Neither progesterone nor estradiol effects on bupivacaine arrhythmogenicity were potentiated by epinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "progesterone"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "estradiol"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "bupivacaine"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 623,
    "text": "Chronic progesterone pretreatment ( 5 mg / kg / day for 21 days ) caused a significant increase in bupivacaine arrhythmogenicity in intact pentobarbital - anesthetized rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "progesterone"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "pentobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 624,
    "text": "There was a significant decrease in the time to onset of arrhythmia as compared with control nonprogesterone - treated rats ( 6 . 2 + / - 1 . 3 vs . 30 . 8 + / - 2 . 5 min , mean + / - SE ) .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 625,
    "text": "The results of this study indicate that progesterone can potentiate bupivacaine arrhythmogenicity both in vivo and in vitro .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "progesterone"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 626,
    "text": "Potentiation of bupivacaine arrhythmia in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "bupivacaine"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 627,
    "text": "Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "acute liver failure"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "paracetamol"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 628,
    "text": "BACKGROUND / AIMS : Experimental studies have suggested that apoptosis via the Fas / Fas Ligand signaling system may play an important role in the development of acute liver failure .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        30,
        "acute liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 629,
    "text": "The aim of the study was to investigate the soluble form of Fas in patients with acute liver failure .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        19,
        "acute liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 630,
    "text": "METHODOLOGY : Serum levels of sFas ( soluble Fas ) were measured by ELISA in 24 patients with acute liver failure and 10 normal control subjects .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        21,
        "acute liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 631,
    "text": "Serum levels of tumor necrosis factor - alpha and interferon - gamma were also determined by ELISA .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "tumor"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 632,
    "text": "RESULTS : Serum sFas was significantly increased in patients with acute liver failure ( median , 26 . 8 U / mL ; range , 6 . 9 - 52 . 7 U / mL ) compared to the normal controls ( median , 8 . 6 U / mL ; range , 6 . 5 - 12 . 0 U / mL , P < 0 . 0001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "acute liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 633,
    "text": "Levels were significantly greater in patients with acute liver failure due to paracetamol overdose ( median , 28 . 7 U / mL ; range , 12 . 8 - 52 . 7 U / mL , n = 17 ) than those due to non - A to E hepatitis ( median , 12 . 5 U / mL ; range , 6 . 9 - 46 . 0 U / mL , n = 7 , P < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "acute liver failure"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "paracetamol"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "overdose"
      ],
      [
        "T3",
        "Disease",
        50,
        51,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 634,
    "text": "There was no relationship of sFas to eventual outcome in the patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 635,
    "text": "A significant correlation was observed between serum sFas levels and aspartate aminotransferase ( r = 0 . 613 , P < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "aspartate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 636,
    "text": "CONCLUSIONS : The increased concentration of sFas in serum of patients with acute liver failure may reflect activation of Fas - mediated apoptosis in the liver and this together with increased tumor necrosis factor - alpha may be an important factor in liver cell loss .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "acute liver failure"
      ],
      [
        "T1",
        "Disease",
        31,
        32,
        "tumor"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 637,
    "text": "Bilateral subthalamic nucleus stimulation for Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 638,
    "text": "High frequency stimulation of the subthalamic nucleus ( STN ) is known to ameliorate the signs and symptoms of advanced Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        24,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 639,
    "text": "AIM : We studied the effect of high frequency STN stimulation in 23 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 640,
    "text": "METHOD : Twenty - three patients suffering from severe Parkinson ' s disease ( Stages III - V on Hoehn and Yahr scale ) and , particularly bradykinesia , rigidity , and levodopa - induced dyskinesias underwent bilateral implantation of electrodes in the STN .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "bradykinesia"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "rigidity"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "levodopa"
      ],
      [
        "T4",
        "Disease",
        35,
        36,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 641,
    "text": "Preoperative and postoperative assessments of these patients at 1 , 3 , 6 and 12 months follow - up , in \" on \" and \" off \" drug conditions , was carried out using Unified Parkinson ' s Disease Rating Scale , Hoehn and Yahr staging , England activities of daily living score and video recordings .",
    "labels": [
      [
        "T0",
        "Disease",
        36,
        40,
        "Parkinson ' s Disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 642,
    "text": "RESULTS : After one year of electrical stimulation of the STN , the patients ' scores for activities of daily living and motor examination scores ( Unified Parkinson ' s Disease Rating Scale parts II and III ) off medication improved by 62 % and 61 % respectively ( p < 0 . 0005 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        31,
        "Parkinson ' s Disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 643,
    "text": "The subscores for the akinesia , rigidity , tremor and gait also improved .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "akinesia"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "rigidity"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "tremor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 644,
    "text": "( p < 0 . 0005 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 645,
    "text": "The average levodopa dose decreased from 813 mg to 359 mg .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 646,
    "text": "The cognitive functions remained unchanged .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 647,
    "text": "Two patients developed device - related complications and two patients experienced abnormal weight gain .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 648,
    "text": "CONCLUSION : Bilateral subthalamic nucleus stimulation is an effective treatment for advanced Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 649,
    "text": "It reduces the severity of \" off \" phase symptoms , improves the axial symptoms and reduces levodopa requirements .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 650,
    "text": "The reduction in the levodopa dose is useful in controlling drug - induced dyskinesias .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        14,
        "drug - induced dyskinesias"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 651,
    "text": "Acute renal failure occurring during intravenous desferrioxamine therapy : recovery after haemodialysis .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "desferrioxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 652,
    "text": "A patient with transfusion - dependent thalassemia was undergoing home intravenous desferrioxamine ( DFX ) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "thalassemia"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "desferrioxamine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "DFX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 653,
    "text": "Due to an accidental malfunctioning of the infusion pump , the patient was inadvertently administered a toxic dosage of the drug which caused renal insufficiency .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "renal insufficiency"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 654,
    "text": "Given the progressive deterioration of the symptoms and of the laboratory values , despite adequate medical treatment , a decision was made to introduce haemodialytical therapy in order to remove the drug and therapy reduce the nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        36,
        37,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 655,
    "text": "From the results obtained , haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive acute renal failure caused by desferrioxamine .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "desferrioxamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 656,
    "text": "Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "carboplatin"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "retinoblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 657,
    "text": "BACKGROUND : Focal subtenon carboplatin injections have recently been used as a presumably toxicity - free adjunct to systemic chemotherapy for intraocular retinoblastoma .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "carboplatin"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "toxicity"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "retinoblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 658,
    "text": "OBJECTIVE : To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "abnormal ocular motility"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 659,
    "text": "METHODS : We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "abnormal ocular motility"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "retinoblastoma"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 660,
    "text": "During ocular manipulation under general anesthesia , we assessed their eyes by forced duction testing , comparing ocular motility after tumor control with ocular motility at diagnosis .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 661,
    "text": "Eyes subsequently enucleated because of treatment failure ( n = 4 ) were examined histologically .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 662,
    "text": "RESULTS : Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "retinoblastoma"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 663,
    "text": "Histopathological examination revealed many lipophages in the periorbital fat surrounding the optic nerve in 1 eye , indicative of phagocytosis of previously existing fat cells and suggesting prior fat necrosis .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        30,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 664,
    "text": "The enucleations were technically difficult and hazardous for globe rupture because of extensive orbital soft tissue adhesions .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "rupture"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 665,
    "text": "CONCLUSIONS : Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues , leading to mechanical restriction of eye movements and making subsequent enucleation difficult .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "carboplatin"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 666,
    "text": "Subtenon carboplatin is not free of toxicity , and its use is best restricted to specific indications .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "carboplatin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 667,
    "text": "Ethambutol and optic neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 668,
    "text": "PURPOSE : To demonstrate the association between ethambutol and optic neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 669,
    "text": "METHOD : Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "optic neuropathy"
      ],
      [
        "T1",
        "Disease",
        14,
        21,
        "tuberculosis of the lung or lymph node"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 670,
    "text": "The clinical characteristics and initial and final visual acuity were analyzed to determine visual outcome .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 671,
    "text": "RESULTS : All patients had optic neuropathy between 1 to 6 months ( mean = 2 . 9 months ) after starting ethambutol therapy at a dosage ranging from 13 to 20 mg / kg / day ( mean = 17 mg / kg / day ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 672,
    "text": "Seven ( 54 % ) of the 13 patients experienced visual recovery after stopping the drug .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 673,
    "text": "Of 6 patients with irreversible visual impairment , 4 patients had diabetes mellitus , glaucoma and a history of heavy smoking .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "visual impairment"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "diabetes mellitus"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 674,
    "text": "CONCLUSION : Early recognition of optic neuropathy should be considered in patients with ethambutol therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 675,
    "text": "A low dose and prompt discontinuation of the drug is recommended particularly in individuals with diabetes mellitus , glaucoma or who are heavy smokers .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "diabetes mellitus"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 676,
    "text": "Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "gustatory hyperhidrosis"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "glycopyrrolate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 677,
    "text": "Gustatory hyperhidrosis is facial sweating usually associated with the eating of hot spicy food or even smelling this food .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Gustatory hyperhidrosis"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "sweating"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 678,
    "text": "Current options of treatment include oral anticholinergic drugs , the topical application of anticholinergics or aluminum chloride , and the injection of botulinum toxin .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "aluminum chloride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 679,
    "text": "Thirteen patients have been treated to date with 1 . 5 % or 2 % topical glycopyrrolate .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "glycopyrrolate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 680,
    "text": "All patients had gustatory hyperhidrosis , which interfered with their social activities , after transthroacic endoscopic sympathectomy , and which was associated with compensatory focal hyperhidrosis .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "gustatory hyperhidrosis"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "hyperhidrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 681,
    "text": "After applying topical glycopyrrolate , the subjective effect was excellent ( no sweating after eating hot spicy food ) in 10 patients ( 77 % ) , and fair ( clearly reduced sweating ) in 3 patients ( 23 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "glycopyrrolate"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "sweating"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "sweating"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 682,
    "text": "All had reported incidents of being very embarrassed whilst eating hot spicy foods .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 683,
    "text": "Adverse effects included a mildly dry mouth and a sore throat in 2 patients ( 2 % glycopyrrolate ) , a light headache in 1 patient ( 1 . 5 % glycopyrrolate ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "dry mouth"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "sore throat"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "glycopyrrolate"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "headache"
      ],
      [
        "T4",
        "Chemical",
        31,
        32,
        "glycopyrrolate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 684,
    "text": "The topical application of a glycopyrrolate pad appeared to be safe , efficacious , well tolerated , and a convenient method of treatment for moderate to severe symptoms of gustatory hyperhidrosis in post transthoracic endoscopic sympathectomy or sympathicotomy patients , with few side effects .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        31,
        "gustatory hyperhidrosis"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "glycopyrrolate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 685,
    "text": "Neuroleptic - associated hyperprolactinemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Neuroleptic"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 686,
    "text": "Can it be treated with bromocriptine ?",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "bromocriptine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 687,
    "text": "Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea / oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "neuroleptic medications"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hyperprolactinemia"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "amenorrhea"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "oligomenorrhea"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "bromocriptine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 688,
    "text": "Daily dosages of 5 - 10 mg corrected the hyperprolactinemia and restored menstruation in four of the six patients .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 689,
    "text": "One woman , however , developed worsened psychiatric symptoms while taking bromocriptine , and it was discontinued .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "psychiatric symptoms"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "bromocriptine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 690,
    "text": "Thus , three of six patients had their menstrual irregularity successfully corrected with bromocriptine .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "bromocriptine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 691,
    "text": "This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic - associated hyperprolactinemia and amenorrhea / galactorrhea .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "bromocriptine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "neuroleptic"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "hyperprolactinemia"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "amenorrhea"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "galactorrhea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 692,
    "text": "Ethacrynic acid - induced convulsions and brain neurotransmitters in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Ethacrynic acid"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 693,
    "text": "Intracerebroventricular injection of ethacrynic acid ( 50 % convulsive dose ; 50 micrograms / mouse ) accelerated the synthesis / turnover of 5 - hydroxytryptamine ( 5 - HT ) but suppressed the synthesis of gamma - aminobutyric acid and acetylcholine in mouse brain .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "ethacrynic acid"
      ],
      [
        "T1",
        "Chemical",
        22,
        25,
        "5 - hydroxytryptamine"
      ],
      [
        "T2",
        "Chemical",
        26,
        29,
        "5 - HT"
      ],
      [
        "T3",
        "Chemical",
        35,
        39,
        "gamma - aminobutyric acid"
      ],
      [
        "T4",
        "Disease",
        8,
        9,
        "convulsive"
      ],
      [
        "T5",
        "Chemical",
        40,
        41,
        "acetylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 694,
    "text": "These effects were completely antagonized by pretreatment with a glutamate / N - methyl - D - aspartate antagonist , aminophosphonovaleric acid .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        18,
        "N - methyl - D - aspartate"
      ],
      [
        "T1",
        "Chemical",
        20,
        22,
        "aminophosphonovaleric acid"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 695,
    "text": "In ethacrynic acid - induced convulsions , these neurotransmitter systems may be differentially modulated , probably through activation of glutaminergic neurons in the brain .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "ethacrynic acid"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 696,
    "text": "Pharmacology of gamma - aminobutyric acidA receptor complex after the in vivo administration of the anxioselective and anticonvulsant beta - carboline derivative abecarnil .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        6,
        "gamma - aminobutyric acidA"
      ],
      [
        "T1",
        "Chemical",
        18,
        21,
        "beta - carboline"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "abecarnil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 697,
    "text": "In rodents , the effect of the beta - carboline derivative isopropyl - 6 - benzyloxy - 4 - methoxymethyl - beta - carboline - 3 - carboxylate ( abecarrnil ) , a new ligand for benzodiazepine receptors possessing anxiolytic and anticonvulsant properties , was evaluated on the function of central gamma - aminobutyric acid ( GABA ) A receptor complex , both in vitro and in vivo .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "beta - carboline"
      ],
      [
        "T1",
        "Chemical",
        11,
        28,
        "isopropyl - 6 - benzyloxy - 4 - methoxymethyl - beta - carboline - 3 - carboxylate"
      ],
      [
        "T2",
        "Chemical",
        51,
        55,
        "gamma - aminobutyric acid"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "abecarrnil"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "benzodiazepine"
      ],
      [
        "T5",
        "Chemical",
        56,
        57,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 698,
    "text": "Added in vitro to rat cortical membrane preparation , abecarnil increased [ 3H ] GABA binding , enhanced muscimol - stimulated 36Cl - uptake and reduced the binding of t - [ 35S ] butylbicyclophosphorothionate ( [ 35S ] TBPS ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        29,
        35,
        "t - [ 35S ] butylbicyclophosphorothionate"
      ],
      [
        "T1",
        "Chemical",
        36,
        40,
        "[ 35S ] TBPS"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "abecarnil"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "GABA"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "muscimol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 699,
    "text": "These effects were similar to those induced by diazepam , whereas the partial agonist Ro 16 - 6028 ( tert - butyl - ( S ) - 8 - bromo - 11 , 12 , 13 , 13a - tetrahydro - 9 - oxo - 9H - imidazo [ 1 , 5 - a ] - pyrrolo - [ 2 , 1 - c ] [ 1 , 4 ] benzodiazepine - 1 - carboxylate ) showed very weak efficacy in these biochemical tests .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        18,
        "Ro 16 - 6028"
      ],
      [
        "T1",
        "Chemical",
        19,
        75,
        "tert - butyl - ( S ) - 8 - bromo - 11 , 12 , 13 , 13a - tetrahydro - 9 - oxo - 9H - imidazo [ 1 , 5 - a ] - pyrrolo - [ 2 , 1 - c ] [ 1 , 4 ] benzodiazepine - 1 - carboxylate"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 700,
    "text": "After i . p . injection to rats , abecarnil and diazepam decreased in a time - dependent and dose - related ( 0 . 25 - 20 mg / kg i . p . ) manner [ 35S ] TBPS binding measured ex vivo in the cerebral cortex .",
    "labels": [
      [
        "T0",
        "Chemical",
        37,
        41,
        "[ 35S ] TBPS"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "abecarnil"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 701,
    "text": "Moreover , both drugs at the dose of 0 . 5 mg / kg antagonized completely the convulsant activity and the increase of [ 35S ] TBPS binding induced by isoniazide ( 350 mg / kg s . c . ) as well as the increase of [ 35S ] TBPS binding induced by foot - shock stress .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        27,
        "[ 35S ] TBPS"
      ],
      [
        "T1",
        "Chemical",
        47,
        51,
        "[ 35S ] TBPS"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "isoniazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 702,
    "text": "To better correlate the biochemical and the pharmacological effects , we studied the action of abecarnil on [ 35S ] TBPS binding , exploratory motility and on isoniazid - induced biochemical and pharmacological effects in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        21,
        "[ 35S ] TBPS"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "abecarnil"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "isoniazid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 703,
    "text": "In these animals , abecarnil produced a paralleled dose - dependent ( 0 . 05 - 1 mg / kg i . p . ) reduction of both motor behavior and cortical [ 35S ] TBPS binding .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "abecarnil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 704,
    "text": "Moreover , 0 . 05 mg / kg of this beta - carboline reduced markedly the increase of [ 35S ] TBPS binding and the convulsions induced by isoniazid ( 200 mg / kg s . c . ) . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        13,
        "beta - carboline"
      ],
      [
        "T1",
        "Chemical",
        18,
        22,
        "[ 35S ] TBPS"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "convulsions"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "isoniazid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 705,
    "text": "Recurrent myocardial infarction in a postpartum patient receiving bromocriptine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "bromocriptine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 706,
    "text": "Myocardial infarction in puerperium is infrequently reported .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Myocardial infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 707,
    "text": "Spasm , coronary dissection , or atheromatous etiology has been described .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Spasm"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 708,
    "text": "Bromocriptine has been implicated in several previous case reports of myocardial infarction in the puerperium .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Bromocriptine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 709,
    "text": "Our case ( including an inadvertent rechallenge ) suggests such a relationship .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 710,
    "text": "Although generally regarded as \" safe , \" possible serious cardiac effects of bromocriptine should be acknowledged .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "bromocriptine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 711,
    "text": "Asterixis induced by carbamazepine therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Asterixis"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 712,
    "text": "There are very few reports about asterixis as a side effect of treatment with psychopharmacologic agents .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "asterixis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 713,
    "text": "In this report we present four patients treated with a combination of different psychotropic drugs , in whom asterixis was triggered either by adding carbamazepine ( CBZ ) to a treatment regimen , or by increasing its dosage .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "asterixis"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "carbamazepine"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "CBZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 714,
    "text": "Neither dosage nor serum levels of CBZ were in a higher range .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "CBZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 715,
    "text": "We consider asterixis to be an easily overlooked sign of neurotoxicity , which may occur even at low or moderate dosage levels , if certain drugs as lithium or clozapine are used in combination with CBZ .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "asterixis"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "neurotoxicity"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "lithium"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "clozapine"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "CBZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 716,
    "text": "Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypotensive"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 717,
    "text": "Blood pressure effects of i . v . levodopa were examined in parkinsonian patients with stable and fluctuating responses to levodopa .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "parkinsonian"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 718,
    "text": "The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypotensive"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 719,
    "text": "Stable responders demonstrated a small hypotensive response .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hypotensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 720,
    "text": "Baseline blood pressures were higher in fluctuating patients ; a higher baseline blood pressure correlated with greater hypotensive effects .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "hypotensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 721,
    "text": "Antiparkinsonian effects of levodopa temporally correlated with blood pressure changes .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 722,
    "text": "Phenylalanine , a large neutral amino acid ( LNAA ) competing with levodopa for transport across the blood - brain barrier , reduced the hypotensive and antiparkinsonian effects of levodopa .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "amino acid"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Phenylalanine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "levodopa"
      ],
      [
        "T3",
        "Disease",
        24,
        25,
        "hypotensive"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 723,
    "text": "We conclude that levodopa has a central hypotensive action that parallels the motor effects in fluctuating patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hypotensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 724,
    "text": "The hypotensive effect appears to be related to the higher baseline blood pressure we observed in fluctuating patients relative to stable patients .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypotensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 725,
    "text": "Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        7,
        "Syndrome of inappropriate secretion of antidiuretic hormone"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 726,
    "text": "A 77 - year - old woman with refractory multiple myeloma was treated with a 4 - day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "multiple myeloma"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "vincristine"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "doxorubicin"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 727,
    "text": "Nine days after her second cycle she presented with lethargy and weakness associated with hyponatremia .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "lethargy"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "weakness"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "hyponatremia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 728,
    "text": "Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone , which was attributed to the vincristine infusion .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        10,
        "syndrome of inappropriate secretion of antidiuretic hormone"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 729,
    "text": "After normal serum sodium levels returned , further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "doxorubicin"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "dexamethasone"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "vincristine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 730,
    "text": "Heart failure : to digitalise or not ?",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 731,
    "text": "The view against .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 732,
    "text": "Despite extensive clinical experience the role of digoxin is still not well defined .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 733,
    "text": "In patients with atrial fibrillation digoxin is beneficial for ventricular rate control .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 734,
    "text": "For patients in sinus rhythm and heart failure the situation is less clear .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 735,
    "text": "Digoxin has a narrow therapeutic : toxic ratio and concentrations are affected by a number of drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 736,
    "text": "Also , digoxin has undesirable effects such as increasing peripheral resistance and myocardial demands , and causing arrhythmias .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "digoxin"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "arrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 737,
    "text": "There is a paucity of data from well - designed trials .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 738,
    "text": "The trials that are available are generally small with limitations in design and these show variation in patient benefit .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 739,
    "text": "More convincing evidence is required showing that digoxin improves symptoms or exercise capacity .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 740,
    "text": "Furthermore , no trial has had sufficient power to evaluate mortality .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 741,
    "text": "Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction ( MI ) .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "digoxin"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 742,
    "text": "Angiotensin - converting enzyme ( ACE ) inhibitors should be used first as they are safer , do not require blood level monitoring , modify progression of disease , relieve symptoms , improve exercise tolerance and reduce mortality .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Angiotensin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 743,
    "text": "Caution should be exercised in using digoxin until large mortality trials are completed showing either benefit or harm .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 744,
    "text": "Until then digoxin should be considered a third - line therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "digoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 745,
    "text": "Isradipine treatment for hypertension in general practice in Hong Kong .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Isradipine"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 746,
    "text": "A 6 - week open study of the introduction of isradipine treatment was conducted in general practice in Hong Kong .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "isradipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 747,
    "text": "303 Chinese patients with mild to moderate hypertension entered the study .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 748,
    "text": "Side effects were reported in 21 % of patients and caused withdrawal from the study in 3 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 749,
    "text": "The main side - effects were headache , dizziness , palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "headache"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "dizziness"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "palpitation"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "flushing"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "isradipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 750,
    "text": "Supine blood pressure was reduced ( P less than 0 . 01 ) from 170 + / - 20 / 102 + / - 6 mmHg to 153 + / - 19 / 92 + / - 8 , 147 + / - 18 / 88 + / - 7 and 144 + / - 14 / 87 + / - 6 mmHg at 2 , 4 and 6 weeks respectively in evaluable patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 751,
    "text": "Similar reductions occurred in standing blood pressure and there was no evidence of postural hypotension .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "postural hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 752,
    "text": "Normalization and responder rates at 6 weeks were 86 % and 69 % respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 753,
    "text": "Dosage was increased from 2 . 5 mg b . d . to 5 mg b . d . at 4 weeks in patients with diastolic blood pressure greater than 90 mmHg and their further response was greater than those remaining on 2 . 5 mg b . d .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 754,
    "text": "Pharmacological characteristics and side effects of a new galenic formulation of propofol without soyabean oil .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 755,
    "text": "We compared the pharmacokinetics , pharmacodynamics and safety profile of a new galenic formulation of propofol ( AM149 1 % ) , which does not contain soyabean oil , with a standard formulation of propofol ( Disoprivan 1 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "propofol"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "propofol"
      ],
      [
        "T2",
        "Chemical",
        36,
        37,
        "Disoprivan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 756,
    "text": "In a randomised , double - blind , cross - over study , 30 healthy volunteers received a single intravenous bolus injection of 2 . 5 mg . kg - 1 propofol .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        32,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 757,
    "text": "Plasma propofol levels were measured for 48 h following drug administration and evaluated according to a three - compartment model .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 758,
    "text": "The pharmacodynamic parameters assessed included induction and emergence times , respiratory and cardiovascular effects , and pain on injection .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 759,
    "text": "Patients were monitored for side effects over 48 h .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 760,
    "text": "Owing to a high incidence of thrombophlebitis , the study was terminated prematurely and only the data of the two parallel treatment groups ( 15 patients in each group ) were analysed .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "thrombophlebitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 761,
    "text": "Plasma concentrations did not differ significantly between the two formulations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 762,
    "text": "Anaesthesia induction and emergence times , respiratory and cardiovascular variables showed no significant differences between the two treatment groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 763,
    "text": "Pain on injection ( 80 vs . 20 % , p < 0 . 01 ) and thrombophlebitis ( 93 . 3 vs . 6 . 6 % , p < 0 . 001 ) occurred more frequently with AM149 than with Disoprivan .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Pain"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "thrombophlebitis"
      ],
      [
        "T2",
        "Chemical",
        42,
        43,
        "Disoprivan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 764,
    "text": "Although both formulations had similar pharmacokinetic and pharmacodynamic profiles the new formulation is not suitable for clinical use due to the high incidence of thrombophlebitis produced .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        25,
        "thrombophlebitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 765,
    "text": "Pure red cell aplasia , toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Pure red cell aplasia"
      ],
      [
        "T1",
        "Disease",
        5,
        7,
        "toxic dermatitis"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "lymphadenopathy"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "diphenylhydantoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 766,
    "text": "A patient taking diphenylhydantoin for 3 weeks developed a generalized skin rash , lymphadenopathy and pure red cell aplasia .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "skin rash"
      ],
      [
        "T1",
        "Disease",
        15,
        19,
        "pure red cell aplasia"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "diphenylhydantoin"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "lymphadenopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 767,
    "text": "After withdrawal of the pharmacon all symptoms disappeared spontaneously .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 768,
    "text": "Skin rash is a well - known complication of diphenylhydantoin treatment as is benign and malignant lymphadenopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Skin rash"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "diphenylhydantoin"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "lymphadenopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 769,
    "text": "Pure red cell aplasia associated with diphenylhydantoin medication has been reported in 3 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Pure red cell aplasia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "diphenylhydantoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 770,
    "text": "The exact mechanism by which diphenylhydantoin exerts its toxic effects is not known .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "diphenylhydantoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 771,
    "text": "In this patient the time relation between the ingestion of diphenylhydantoin and the occurrence of the skin rash , lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "skin rash"
      ],
      [
        "T1",
        "Disease",
        21,
        25,
        "pure red cell aplasia"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "diphenylhydantoin"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "lymphadenopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 772,
    "text": "Vinorelbine - related cardiac events : a meta - analysis of randomized clinical trials .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Vinorelbine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 773,
    "text": "Several cases of cardiac adverse reactions related to vinorelbine ( VNR ) have been reported in the literature .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "vinorelbine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "VNR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 774,
    "text": "In order to quantify the incidence of these cardiac events , we performed a meta - analysis of clinical trials comparing VNR with other chemotherapeutic agents in the treatment of various malignancies .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "VNR"
      ],
      [
        "T1",
        "Disease",
        31,
        32,
        "malignancies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 775,
    "text": "Randomized clinical trials comparing VNR with other drugs in the treatment of cancer were searched in Medline , Embase , Evidence - based Medicine Reviews databases and the Cochrane library from 1987 to 2002 .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "VNR"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 776,
    "text": "Outcomes of interest were severe cardiac events , toxic deaths and cardiac event - related deaths reported in each publication .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 777,
    "text": "We found 19 trials , involving 2441 patients treated by VNR and 2050 control patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "VNR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 778,
    "text": "The incidence of cardiac events with VNR was 1 . 19 % [ 95 % confidence interval ( CI ) ( 0 . 75 ; 1 . 67 ) ] .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "VNR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 779,
    "text": "There was no difference in the risk of cardiac events between VNR and other drugs [ odds ratio : 0 . 92 , 95 % CI ( 0 . 54 ; 1 . 55 ) ] .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "VNR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 780,
    "text": "The risk of VNR cardiac events was similar to vindesine ( VDS ) and other cardiotoxic drugs [ fluorouracil , anthracyclines , gemcitabine ( GEM ) em leader ] .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "VNR"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "vindesine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "VDS"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "cardiotoxic"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "fluorouracil"
      ],
      [
        "T5",
        "Chemical",
        20,
        21,
        "anthracyclines"
      ],
      [
        "T6",
        "Chemical",
        22,
        23,
        "gemcitabine"
      ],
      [
        "T7",
        "Chemical",
        24,
        25,
        "GEM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 781,
    "text": "Even if it did not reach statistical significance because of a few number of cases , the risk was lower in trials excluding patients with cardiac history , and seemed to be higher in trials including patients with pre - existing cardiac diseases .",
    "labels": [
      [
        "T0",
        "Disease",
        41,
        43,
        "cardiac diseases"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 782,
    "text": "Vinorelbine - related cardiac events concern about 1 % of treated patients in clinical trials .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Vinorelbine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 783,
    "text": "However , the risk associated with VNR seems to be similar to that of other chemotherapeutic agents in the same indications .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "VNR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 784,
    "text": "MRI findings of hypoxic cortical laminar necrosis in a child with hemolytic anemia crisis .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 785,
    "text": "We present magnetic resonance imaging findings of a 5 - year - old girl who had a rapidly installing hemolytic anemia crisis induced by trimethoprim - sulfomethoxazole , resulting in cerebral anoxia leading to permanent damage .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        24,
        27,
        "trimethoprim - sulfomethoxazole"
      ],
      [
        "T2",
        "Disease",
        30,
        32,
        "cerebral anoxia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 786,
    "text": "Magnetic Resonance imaging revealed cortical laminar necrosis in arterial border zones in both cerebral hemispheres , ischemic changes in subcortical white matter of left cerebral hemisphere , and in the left putamen .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 787,
    "text": "Although cortical laminar necrosis is a classic entity in adulthood related to conditions of energy depletions , there are few reports available in children .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 788,
    "text": "A wide review of the literature is also presented .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 789,
    "text": "The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "visual field defects"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "Vigabatrin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 790,
    "text": "PURPOSE : To determine the natural history of visual field defects in a group of patients known to have Vigabatrin - associated changes who elected to continue the medication because of good seizure control .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "visual field defects"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "Vigabatrin"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 791,
    "text": "METHODS : All patients taking Vigabatrin alone or in combination with other antiepileptic drugs for at least 5 years ( range 5 - 12 years ) were entered into a visual surveillance programme .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "Vigabatrin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 792,
    "text": "Patients were followed up at 6 - monthly intervals for not less than 18 months ( range 18 - 43 months ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 793,
    "text": "In all , 16 patients with unequivocal defects continued the medication .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 794,
    "text": "Following already published methodology ( Eye 2002 ; 16 ; 567 - 571 ) monocular mean radial degrees ( MRDs ) to the I / 4e isopter on Goldmann perimetry was calculated for the right eye at the time of discovery of a visual field defect and again after not less than 18 months follow - up .",
    "labels": [
      [
        "T0",
        "Disease",
        43,
        46,
        "visual field defect"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 795,
    "text": "RESULTS : Mean right eye MRD at presentation was 36 . 98 degrees ( range 22 . 25 - 51 . 0 ) , compared to 38 . 40 degrees ( range 22 . 5 - 49 . 75 ) after follow - up ; P = 0 . 338 unpaired t - test .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 796,
    "text": "Only one patient demonstrated a deterioration in visual field during the study period and discontinued treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "deterioration in visual field"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 797,
    "text": "CONCLUSION : Established visual field defects presumed to be due to Vigabatrin therapy did not usually progress in spite of continuing use of the medication .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "visual field defects"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "Vigabatrin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 798,
    "text": "These data give support to the hypothesis that the pathogenesis of Vigabatrin - associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose - dependent toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        17,
        "visual field defects"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "Vigabatrin"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 799,
    "text": "Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "facial inflammatory dermatoses"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "dermatitis"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 800,
    "text": "BACKGROUND : Tacrolimus ointment is increasingly used for anti - inflammatory treatment of sensitive areas such as the face , and recent observations indicate that the treatment is effective in steroid - aggravated rosacea and perioral dermatitis .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        37,
        "perioral dermatitis"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Tacrolimus"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "steroid"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "rosacea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 801,
    "text": "We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "dermatitis"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 802,
    "text": "OBSERVATIONS : Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "inflammatory facial dermatoses"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 803,
    "text": "Within 2 to 3 weeks of initially effective and well - tolerated treatment , 3 patients with a history of rosacea and 1 with a history of acne experienced sudden worsening with pustular rosaceiform lesions .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "rosacea"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "acne"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 804,
    "text": "Biopsy revealed an abundance of Demodex mites in 2 of these patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 805,
    "text": "In 1 patient with eyelid eczema , rosaceiform periocular dermatitis gradually appeared after 3 weeks of treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "periocular dermatitis"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "eczema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 806,
    "text": "In 1 patient with atopic dermatitis , telangiectatic and papular rosacea insidiously appeared after 5 months of treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "atopic dermatitis"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "papular rosacea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 807,
    "text": "CONCLUSIONS : Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with tacrolimus ointment is heterogeneous .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "dermatitis"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 808,
    "text": "A variety of factors , such as vasoactive properties of tacrolimus , proliferation of Demodex due to local immunosuppression , and the occlusive properties of the ointment , may be involved in the observed phenomena .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "tacrolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 809,
    "text": "Future studies are needed to identify individual risk factors .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 810,
    "text": "Intravascular hemolysis and acute renal failure following intermittent rifampin therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "hemolysis"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "rifampin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 811,
    "text": "Renal failure is a rare complication associated with the use of rifampin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Renal failure"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "rifampin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 812,
    "text": "Intravascular hemolysis leading to acute renal failure following rifampin therapy is extremely rare .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "hemolysis"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "rifampin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 813,
    "text": "Two patients with leprosy who developed hemolysis and acute renal failure following rifampin are reported .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "leprosy"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "hemolysis"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "rifampin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 814,
    "text": "Structural abnormalities in the brains of human subjects who use methamphetamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "methamphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 815,
    "text": "We visualize , for the first time , the profile of structural deficits in the human brain associated with chronic methamphetamine ( MA ) abuse .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        17,
        "structural deficits in the human brain"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "methamphetamine"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 816,
    "text": "Studies of human subjects who have used MA chronically have revealed deficits in dopaminergic and serotonergic systems and cerebral metabolic abnormalities .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "metabolic abnormalities"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 817,
    "text": "Using magnetic resonance imaging ( MRI ) and new computational brain - mapping techniques , we determined the pattern of structural brain alterations associated with chronic MA abuse in human subjects and related these deficits to cognitive impairment .",
    "labels": [
      [
        "T0",
        "Disease",
        36,
        38,
        "cognitive impairment"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 818,
    "text": "We used high - resolution MRI and surface - based computational image analyses to map regional abnormalities in the cortex , hippocampus , white matter , and ventricles in 22 human subjects who used MA and 21 age - matched , healthy controls .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        28,
        "abnormalities in the cortex , hippocampus , white matter , and ventricles"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 819,
    "text": "Cortical maps revealed severe gray - matter deficits in the cingulate , limbic , and paralimbic cortices of MA abusers ( averaging 11 . 3 % below control ; p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 820,
    "text": "On average , MA abusers had 7 . 8 % smaller hippocampal volumes than control subjects ( p < 0 . 01 ; left , p = 0 . 01 ; right , p < 0 . 05 ) and significant white - matter hypertrophy ( 7 . 0 % ; p < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "MA"
      ],
      [
        "T1",
        "Disease",
        44,
        45,
        "hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 821,
    "text": "Hippocampal deficits were mapped and correlated with memory performance on a word - recall test ( p < 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 822,
    "text": "MRI - based maps suggest that chronic methamphetamine abuse causes a selective pattern of cerebral deterioration that contributes to impaired memory performance .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "impaired memory performance"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "methamphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 823,
    "text": "MA may selectively damage the medial temporal lobe and , consistent with metabolic studies , the cingulate - limbic cortex , inducing neuroadaptation , neuropil reduction , or cell death .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 824,
    "text": "Prominent white - matter hypertrophy may result from altered myelination and adaptive glial changes , including gliosis secondary to neuronal damage .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "neuronal damage"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hypertrophy"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "gliosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 825,
    "text": "These brain substrates may help account for the symptoms of MA abuse , providing therapeutic targets for drug - induced brain injury .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "brain injury"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "MA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 826,
    "text": "Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator - activated receptor - alpha target gene activation .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 827,
    "text": "Amiodarone , an efficacious and widely used antiarrhythmic agent , has been reported to cause hepatotoxicity in some patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 828,
    "text": "To gain insight into the mechanism of this unwanted effect , mice were administered various doses of amiodarone and examined for changes in hepatic histology and gene regulation .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 829,
    "text": "Amiodarone induced hepatomegaly , hepatocyte microvesicular lipid accumulation , and a significant decrease in serum triglycerides and glucose .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "hepatomegaly"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "triglycerides"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 830,
    "text": "Northern blot analysis of hepatic RNA revealed a dose - dependent increase in the expression of a number of genes critical for fatty acid oxidation , lipoprotein assembly , and lipid transport .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        24,
        "fatty acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 831,
    "text": "Many of these genes are regulated by the peroxisome proliferator - activated receptor - alpha ( PPARalpha ) , a ligand - activated nuclear hormone receptor transcription factor .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 832,
    "text": "The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [ PPARalpha - / - ] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "hepatomegaly"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 833,
    "text": "Compared to wild - type mice , treatment of PPARalpha - / - mice with amiodarone resulted in an increased rate and extent of total body weight loss .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "weight loss"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 834,
    "text": "The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of amiodarone on the function of this receptor were indirect .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "amiodarone"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "hepatoma"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 835,
    "text": "Based upon these results , we conclude that amiodarone disrupts hepatic lipid homeostasis and that the increased expression of PPARalpha target genes is secondary to this toxic effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 836,
    "text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone - induced hepatotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "hepatotoxic"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "amiodarone"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "amiodarone"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 837,
    "text": "Safety and compliance with once - daily niacin extended - release / lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment ( IMPACT ) study .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        13,
        "niacin extended - release / lovastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 838,
    "text": "Niacin extended - release / lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        6,
        "Niacin extended - release / lovastatin"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "hypercholesterolemia"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "dyslipidemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 839,
    "text": "This open - labeled , multicenter study evaluated the safety of bedtime niacin extended - release / lovastatin when dosed as initial therapy and patient compliance to treatment in various clinical practice settings .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        18,
        "niacin extended - release / lovastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 840,
    "text": "A total of 4 , 499 patients with dyslipidemia requiring drug intervention was enrolled at 1 , 081 sites .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "dyslipidemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 841,
    "text": "Patients were treated with 1 tablet ( 500 mg of niacin extended - release / 20 mg of lovastatin ) once nightly for 4 weeks and then 2 tablets for 8 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "niacin"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "lovastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 842,
    "text": "Patients also received dietary counseling , educational materials , and reminders to call a toll - free number that provided further education about dyslipidemia and niacin extended - release / lovastatin .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        31,
        "niacin extended - release / lovastatin"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "dyslipidemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 843,
    "text": "Primary end points were study compliance , increases in liver transaminases to > 3 times the upper limit of normal , and clinical myopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 844,
    "text": "Final study status was available for 4 , 217 patients ( 94 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 845,
    "text": "Compliance to niacin extended - release / lovastatin was 77 % , with 3 , 245 patients completing the study .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        8,
        "niacin extended - release / lovastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 846,
    "text": "Patients in the southeast and those enrolled by endocrinologists had the lowest compliance and highest adverse event rates .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 847,
    "text": "Flushing was the most common adverse event , reported by 18 % of patients and leading to discontinuation by 6 % .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Flushing"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 848,
    "text": "Incidence of increased aspartate aminotransferase and / or alanine aminotransferase > 3 times the upper limit of normal was < 0 . 3 % .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "aspartate"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "alanine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 849,
    "text": "An increase of creatine phosphokinase to > 5 times the upper limit of normal occurred in 0 . 24 % of patients , and no cases of drug - induced myopathy were observed .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "creatine"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 850,
    "text": "Niacin extended - release / lovastatin 1 , 000 / 40 mg , dosed as initial therapy , was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        6,
        "Niacin extended - release / lovastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 851,
    "text": "Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "Terminalia chebula"
      ],
      [
        "T1",
        "Disease",
        7,
        9,
        "myocardial injury"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 852,
    "text": "Cardioprotective effect of ethanolic extract of Terminalia chebula fruits ( 500 mg / kg body wt ) was examined in isoproterenol ( 200 mg / kg body wt ) induced myocardial damage in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        9,
        "ethanolic extract of Terminalia chebula fruits"
      ],
      [
        "T1",
        "Disease",
        30,
        32,
        "myocardial damage"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 853,
    "text": "In isoproterenol administered rats , the level of lipid peroxides increased significantly in the serum and heart .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "isoproterenol"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "peroxides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 854,
    "text": "A significant decrease was observed in the activity of the myocardial marker enzymes with a concomitant increase in their activity in serum .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 855,
    "text": "Histopathological examination was carried out to confirm the myocardial necrosis .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 856,
    "text": "T . chebula extract pretreatment was found to ameliorate the effect of isoproterenol on lipid peroxide formation and retained the activities of the diagnostic marker enzymes .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        4,
        "T . chebula extract"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "isoproterenol"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "peroxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 857,
    "text": "A case of postoperative anxiety due to low dose droperidol used with patient - controlled analgesia .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "anxiety"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "droperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 858,
    "text": "A multiparous woman in good psychological health underwent urgent caesarean section in labour .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 859,
    "text": "Postoperatively , she was given a patient - controlled analgesia device delivering boluses of diamorphine 0 . 5 mg and droperidol 0 . 025 mg .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "diamorphine"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "droperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 860,
    "text": "Whilst using the device she gradually became anxious , the feeling worsening after each bolus .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 861,
    "text": "The diagnosis of droperidol - induced psychological disturbance was not made straight away although on subsequent close questioning the patient gave a very clear history .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "psychological disturbance"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "droperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 862,
    "text": "After she had received a total of only 0 . 9 mg droperidol , a syringe containing diamorphine only was substituted and her unease resolved completely .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "droperidol"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "diamorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 863,
    "text": "We feel that , although the dramatic extrapyramidal side effects of dopaminergic antiemetics are well known , more subtle manifestations may easily be overlooked .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 864,
    "text": "Accurate patient history contributes to differentiating diabetes insipidus : a case study .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "diabetes insipidus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 865,
    "text": "This case study highlights the important contribution of nursing in obtaining an accurate health history .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 866,
    "text": "The case discussed herein initially appeared to be neurogenic diabetes insipidus ( DI ) secondary to a traumatic brain injury .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "neurogenic diabetes insipidus"
      ],
      [
        "T1",
        "Disease",
        17,
        20,
        "traumatic brain injury"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "DI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 867,
    "text": "The nursing staff , by reviewing the patient ' s health history with his family , discovered a history of polydipsia and long - standing lithium use .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "polydipsia"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 868,
    "text": "Lithium is implicated in drug - induced nephrogenic DI , and because the patient had not received lithium since being admitted to the hospital , his treatment changed to focus on nephrogenic DI .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "nephrogenic DI"
      ],
      [
        "T1",
        "Disease",
        31,
        33,
        "nephrogenic DI"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Lithium"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 869,
    "text": "By combining information from the patient history , the physical examination , and radiologic and laboratory studies , the critical care team demonstrated that the patient had been self - treating his lithium - induced nephrogenic DI and developed neurogenic DI secondary to brain trauma .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        37,
        "nephrogenic DI"
      ],
      [
        "T1",
        "Disease",
        39,
        41,
        "neurogenic DI"
      ],
      [
        "T2",
        "Disease",
        43,
        45,
        "brain trauma"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 870,
    "text": "Thus successful treatment required that nephrogenic and neurogenic DI be treated concomitantly .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "neurogenic DI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 871,
    "text": "Factors contributing to ribavirin - induced anemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "ribavirin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 872,
    "text": "BACKGROUND AND AIM : Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "chronic hepatitis C"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "hemolytic anemia"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "Interferon"
      ],
      [
        "T3",
        "Chemical",
        6,
        7,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 873,
    "text": "This study was conducted to identify the factors contributing to ribavirin - induced anemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "ribavirin"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 874,
    "text": "METHODS : Eighty - eight patients with chronic hepatitis C who received interferon - alpha - 2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "chronic hepatitis C"
      ],
      [
        "T1",
        "Chemical",
        12,
        17,
        "interferon - alpha - 2b"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 875,
    "text": "A hemoglobin concentration of < 10 g / dL was defined as ribavirin - induced anemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "ribavirin"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 876,
    "text": "RESULTS : Ribavirin - induced anemia occurred in 18 ( 20 . 5 % ) patients during treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Ribavirin"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 877,
    "text": "A 2 g / dL decrease in hemoglobin concentrations in patients with anemia was observed at week 2 after the start of treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 878,
    "text": "The hemoglobin concentration in patients with > or = 2 g / dL decrease at week 2 was observed to be significantly lower even after week 2 than in patients with < 2 g / dL decrease ( P < 0 . 01 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 879,
    "text": "A significant relationship was observed between the rate of reduction of hemoglobin concentrations at week 2 and the severity of anemia ( P < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 880,
    "text": "Such factors as sex ( female ) , age ( > or = 60 years old ) , and the ribavirin dose by body weight ( 12 mg / kg or more ) were significant by univariate analysis .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 881,
    "text": "CONCLUSIONS : Careful administration is necessary in patients > or = 60 years old , in female patients , and in patients receiving a ribavirin dose of 12 mg / kg or more .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "ribavirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 882,
    "text": "Patients who experience a fall in hemoglobin concentrations of 2 g / dL or more at week 2 after the start of treatment should be monitored with particular care .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 883,
    "text": "Zidovudine - induced hepatitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Zidovudine"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 884,
    "text": "A case of acute hepatitis induced by zidovudine in a 38 - year - old patient with AIDS is presented .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hepatitis"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "zidovudine"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "AIDS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 885,
    "text": "The mechanism whereby the hepatitis was induced is not known .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 886,
    "text": "However , the patient tolerated well an alternative reverse transcriptase inhibitor , 2 ' 3 ' dideoxyinosine .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        17,
        "2 ' 3 ' dideoxyinosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 887,
    "text": "Physicians caring for patients with AIDS should be aware of this hitherto rarely reported complication .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "AIDS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 888,
    "text": "Oxidative damage precedes nitrative damage in adriamycin - induced cardiac mitochondrial injury .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "mitochondrial injury"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "adriamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 889,
    "text": "The purpose of the present study was to determine if elevated reactive oxygen ( ROS ) / nitrogen species ( RNS ) reported to be present in adriamycin ( ADR ) - induced cardiotoxicity actually resulted in cardiomyocyte oxidative / nitrative damage , and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "oxygen"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "nitrogen"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "adriamycin"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "ADR"
      ],
      [
        "T4",
        "Disease",
        33,
        34,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 890,
    "text": "B6C3 mice were treated with a single dose of 20 mg / kg ADR .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "ADR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 891,
    "text": "Ultrastructural damage and levels of 4 - hydroxy - 2 - nonenal ( 4HNE ) - protein adducts and 3 - nitrotyrosine ( 3NT ) were analyzed .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        12,
        "4 - hydroxy - 2 - nonenal"
      ],
      [
        "T1",
        "Chemical",
        19,
        22,
        "3 - nitrotyrosine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "4HNE"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "3NT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 892,
    "text": "Quantitative ultrastructural damage using computerized image techniques showed cardiomyocyte injury as early as 3 hours , with mitochondria being the most extensively and progressively injured subcellular organelle .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 893,
    "text": "Analysis of 4HNE protein adducts by immunogold electron microscopy showed appearance of 4HNE protein adducts in mitochondria as early as 3 hours , with a peak at 6 hours and subsequent decline at 24 hours .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "4HNE"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "4HNE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 894,
    "text": "3NT levels were significantly increased in all subcellular compartments at 6 hours and subsequently declined at 24 hours .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "3NT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 895,
    "text": "Our data showed ADR induced 4HNE - protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "mitochondrial injury"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "ADR"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "4HNE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 896,
    "text": "These results document for the first time in vivo that mitochondrial oxidative damage precedes nitrative damage .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "mitochondrial oxidative damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 897,
    "text": "The progressive nature of mitochondrial injury suggests that mitochondria , not other subcellular organelles , are the major site of intracellular injury .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "mitochondrial injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 898,
    "text": "Sotalol - induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "coronary spasm"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "dilated cardiomyopathy"
      ],
      [
        "T2",
        "Disease",
        14,
        16,
        "ventricular tachycardia"
      ],
      [
        "T3",
        "Chemical",
        0,
        1,
        "Sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 899,
    "text": "A 54 - year - old man with severe left ventricular dysfunction due to dilated cardiomyopathy was referred to our hospital for symptomatic incessant sustained ventricular tachycardia ( VT ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "ventricular dysfunction"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "dilated cardiomyopathy"
      ],
      [
        "T2",
        "Disease",
        25,
        27,
        "ventricular tachycardia"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "VT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 900,
    "text": "After the administration of nifekalant hydrochloride , sustained VT was terminated .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "nifekalant hydrochloride"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "VT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 901,
    "text": "An alternate class III agent , sotalol , was also effective for the prevention of VT .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "sotalol"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "VT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 902,
    "text": "However , one month after switching over nifekalant to sotalol , a short duration of ST elevation was documented in ECG monitoring at almost the same time for three consecutive days .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "nifekalant"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 903,
    "text": "ST elevation with chest discomfort disappeared since he began taking long - acting diltiazem .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "diltiazem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 904,
    "text": "Coronary vasospasm may be induced by the non - selective beta - blocking properties of sotalol .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Coronary vasospasm"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 905,
    "text": "Effects of the antidepressant trazodone , a 5 - HT 2A / 2C receptor antagonist , on dopamine - dependent behaviors in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "trazodone"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 906,
    "text": "RATIONALE : 5 - Hydroxytryptamine , via stimulation of 5 - HT 2C receptors , exerts a tonic inhibitory influence on dopaminergic neurotransmission , whereas activation of 5 - HT 2A receptors enhances stimulated DAergic neurotransmission .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "5 - Hydroxytryptamine"
      ],
      [
        "T1",
        "Chemical",
        9,
        12,
        "5 - HT"
      ],
      [
        "T2",
        "Chemical",
        27,
        30,
        "5 - HT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 907,
    "text": "The antidepressant trazodone is a 5 - HT 2A / 2C receptor antagonist .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "trazodone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 908,
    "text": "OBJECTIVES : To evaluate the effect of trazodone treatment on behaviors dependent on the functional status of the nigrostriatal DAergic system .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "trazodone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 909,
    "text": "METHODS : The effect of pretreatment with trazodone on dexamphetamine - and apomorphine - induced oral stereotypies , on catalepsy induced by haloperidol and apomorphine ( 0 . 05 mg / kg , i . p . ) , on ergometrine - induced wet dog shake ( WDS ) behavior and fluoxetine - induced penile erections was studied in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "oral stereotypies"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "trazodone"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "dexamphetamine"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "apomorphine"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "catalepsy"
      ],
      [
        "T5",
        "Chemical",
        22,
        23,
        "haloperidol"
      ],
      [
        "T6",
        "Chemical",
        24,
        25,
        "apomorphine"
      ],
      [
        "T7",
        "Chemical",
        40,
        41,
        "ergometrine"
      ],
      [
        "T8",
        "Chemical",
        51,
        52,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 910,
    "text": "We also investigated whether trazodone induces catalepsy in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "trazodone"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 911,
    "text": "RESULTS : Trazodone at 2 . 5 - 20 mg / kg i . p . did not induce catalepsy , and did not antagonize apomorphine ( 1 . 5 and 3 mg / kg ) stereotypy and apomorphine ( 0 . 05 mg / kg ) - induced catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Trazodone"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "apomorphine"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "apomorphine"
      ],
      [
        "T4",
        "Disease",
        49,
        50,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 912,
    "text": "However , pretreatment with 5 , 10 and 20 mg / kg i . p . trazodone enhanced dexamphetamine stereotypy , and antagonized haloperidol catalepsy , ergometrine - induced WDS behavior and fluoxetine - induced penile erections .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "trazodone"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "dexamphetamine"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "haloperidol"
      ],
      [
        "T3",
        "Disease",
        24,
        25,
        "catalepsy"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "ergometrine"
      ],
      [
        "T5",
        "Chemical",
        32,
        33,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 913,
    "text": "Trazodone at 30 , 40 and 50 mg / kg i . p . induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Trazodone"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "apomorphine"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "dexamphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 914,
    "text": "CONCLUSIONS : Our results indicate that trazodone at 2 . 5 - 20 mg / kg does not block pre - and postsynaptic striatal D2 DA receptors , while at 30 , 40 and 50 mg / kg it blocks postsynaptic striatal D2 DA receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "trazodone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 915,
    "text": "Furthermore , at 5 , 10 and 20 mg / kg , trazodone blocks 5 - HT 2A and 5 - HT 2C receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        17,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        19,
        22,
        "5 - HT"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "trazodone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 916,
    "text": "We suggest that trazodone ( 5 , 10 and 20 mg / kg ) , by blocking the 5 - HT 2C receptors , releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5 - HT , and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        21,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        34,
        37,
        "5 - HT"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "trazodone"
      ],
      [
        "T3",
        "Chemical",
        41,
        42,
        "dexamphetamine"
      ],
      [
        "T4",
        "Chemical",
        45,
        46,
        "haloperidol"
      ],
      [
        "T5",
        "Disease",
        46,
        47,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 917,
    "text": "Swallowing abnormalities and dyskinesia in Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Swallowing abnormalities"
      ],
      [
        "T1",
        "Disease",
        5,
        9,
        "Parkinson ' s disease"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 918,
    "text": "Gastrointestinal abnormalities in Parkinson ' s disease ( PD ) have been known for almost two centuries , but many aspects concerning their pathophysiology have not been completely clarified .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Gastrointestinal abnormalities"
      ],
      [
        "T1",
        "Disease",
        3,
        7,
        "Parkinson ' s disease"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 919,
    "text": "The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa - induced dyskinesia .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "PD"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 920,
    "text": "Fifteen dyskinetic , 12 nondyskinetic patients , and a control group were included .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "dyskinetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 921,
    "text": "Patients were asked about dysphagia and evaluated with the Unified Parkinson ' s Disease Rating Scale Parts II and III and the Hoehn and Yahr scale .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        14,
        "Parkinson ' s Disease"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "dysphagia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 922,
    "text": "Deglutition was assessed using modified barium swallow with videofluoroscopy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 923,
    "text": "Nondyskinetic patients , but not the dyskinetic ones , showed less oropharyngeal swallowing efficiency ( OPSE ) for liquid food than controls ( Dunnett , P = 0 . 02 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "dyskinetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 924,
    "text": "Dyskinetic patients tended to have a greater OPSE than nondyskinetic ( Dunnett , P = 0 . 06 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Dyskinetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 925,
    "text": "Patients who were using a higher dose of levodopa had a greater OPSE and a trend toward a smaller oral transit time ( Pearson ' s correlation , P = 0 . 01 and 0 . 08 , respectively ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 926,
    "text": "Neither the report of dysphagia nor any of the PD severity parameters correlated to the videofluoroscopic variables .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "dysphagia"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 927,
    "text": "In the current study , dyskinetic patients performed better in swallowing function , which could be explained on the basis of a greater levodopa dose .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "dyskinetic"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 928,
    "text": "Our results suggest a role for levodopa in the oral phase of deglutition and confirm that dysphagia is not a good predictor of deglutition alterations in PD .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "dysphagia"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 929,
    "text": "Inhibition of nuclear factor - kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "tubulointerstitial nephritis"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 930,
    "text": "BACKGROUND : Animals treated with gentamicin can show residual areas of interstitial fibrosis in the renal cortex .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "gentamicin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 931,
    "text": "This study investigated the expression of nuclear factor - kappaB ( NF - kappaB ) , mitogen - activated protein ( MAP ) kinases and macrophages in the renal cortex and structural and functional renal changes of rats treated with gentamicin or gentamicin + pyrrolidine dithiocarbamate ( PDTC ) , an NF - kappaB inhibitor .",
    "labels": [
      [
        "T0",
        "Chemical",
        44,
        46,
        "pyrrolidine dithiocarbamate"
      ],
      [
        "T1",
        "Chemical",
        40,
        41,
        "gentamicin"
      ],
      [
        "T2",
        "Chemical",
        42,
        43,
        "gentamicin"
      ],
      [
        "T3",
        "Chemical",
        47,
        48,
        "PDTC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 932,
    "text": "METHODS : 38 female Wistar rats were injected with gentamicin , 40 mg / kg , twice a day for 9 days , 38 with gentamicin + PDTC , and 28 with 0 . 15 M NaCl solution .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "gentamicin"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "gentamicin"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "PDTC"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "NaCl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 933,
    "text": "The animals were killed 5 and 30 days after these injections and the kidneys were removed for histological and immunohistochemical studies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 934,
    "text": "The results of the immunohistochemical studies were scored according to the extent of staining .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 935,
    "text": "The fractional interstitial area was determined by morphometry .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 936,
    "text": "RESULTS : Gentamicin - treated rats presented a transitory increase in plasma creatinine levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Gentamicin"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 937,
    "text": "Increased ED - 1 , MAP kinases and NF - kappaB staining were also observed in the renal cortex from all gentamicin - treated rats compared to control ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 938,
    "text": "The animals killed on day 30 also presented fibrosis in the renal cortex despite the recovery of renal function .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 939,
    "text": "Treatment with PDTC reduced the functional and structural changes induced by gentamicin .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "PDTC"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 940,
    "text": "CONCLUSIONS : These data show that inhibition of NF - kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "tubulointerstitial nephritis"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 941,
    "text": "Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents : a frequently sampled intravenous glucose tolerance test and minimal model analysis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Glucose"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "schizophrenia"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 942,
    "text": "BACKGROUND : While the incidence of new - onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents , it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "diabetes mellitus"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "schizophrenia"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "glucose"
      ],
      [
        "T3",
        "Disease",
        43,
        44,
        "diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 943,
    "text": "OBJECTIVE : To study the 2 drugs most clearly implicated ( clozapine and olanzapine ) and risperidone using a frequently sampled intravenous glucose tolerance test .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "clozapine"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "olanzapine"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "risperidone"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 944,
    "text": "DESIGN : A cross - sectional design in stable , treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "schizophrenia"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 945,
    "text": "SETTING : Subjects were recruited from an urban community mental health clinic and were studied at a general clinical research center .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 946,
    "text": "Patients Fifty subjects signed informed consent and 41 underwent the frequently sampled intravenous glucose tolerance test .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 947,
    "text": "Thirty - six nonobese subjects with schizophrenia or schizoaffective disorder , matched by body mass index and treated with either clozapine , olanzapine , or risperidone , were included in the analysis .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "schizoaffective disorder"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "schizophrenia"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "clozapine"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "olanzapine"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 948,
    "text": "MAIN OUTCOME MEASURES : Fasting plasma glucose and fasting serum insulin levels , insulin sensitivity index , homeostasis model assessment of insulin resistance , and glucose effectiveness .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "insulin sensitivity"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "insulin resistance"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "glucose"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 949,
    "text": "RESULTS : The mean + / - SD duration of treatment with the identified atypical antipsychotic agent was 68 . 3 + / - 28 . 9 months ( clozapine ) , 29 . 5 + / - 17 . 5 months ( olanzapine ) , and 40 . 9 + / - 33 . 7 ( risperidone ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        29,
        30,
        "clozapine"
      ],
      [
        "T1",
        "Chemical",
        43,
        44,
        "olanzapine"
      ],
      [
        "T2",
        "Chemical",
        57,
        58,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 950,
    "text": "Fasting serum insulin concentrations differed among groups ( F ( 33 ) = 3 . 35 ; P = . 047 ) ( clozapine > olanzapine > risperidone ) with significant differences between clozapine and risperidone ( t ( 33 ) = 2 . 32 ; P = . 03 ) and olanzapine and risperidone ( t ( 33 ) = 2 . 15 ; P = . 04 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "clozapine"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "olanzapine"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "risperidone"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "clozapine"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "risperidone"
      ],
      [
        "T5",
        "Chemical",
        52,
        53,
        "olanzapine"
      ],
      [
        "T6",
        "Chemical",
        54,
        55,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 951,
    "text": "There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( clozapine < olanzapine < risperidone ) , with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone ( clozapine vs risperidone , t ( 33 ) = - 4 . 29 ; P < . 001 ; olanzapine vs risperidone , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "insulin sensitivity"
      ],
      [
        "T1",
        "Disease",
        43,
        45,
        "insulin resistance"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "clozapine"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "olanzapine"
      ],
      [
        "T4",
        "Chemical",
        31,
        32,
        "risperidone"
      ],
      [
        "T5",
        "Chemical",
        38,
        39,
        "clozapine"
      ],
      [
        "T6",
        "Chemical",
        40,
        41,
        "olanzapine"
      ],
      [
        "T7",
        "Chemical",
        52,
        53,
        "risperidone"
      ],
      [
        "T8",
        "Chemical",
        54,
        55,
        "clozapine"
      ],
      [
        "T9",
        "Chemical",
        56,
        57,
        "risperidone"
      ],
      [
        "T10",
        "Chemical",
        73,
        74,
        "olanzapine"
      ],
      [
        "T11",
        "Chemical",
        75,
        76,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 952,
    "text": "The homeostasis model assessment of insulin resistance also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( clozapine > olanzapine > risperidone ) ( clozapine vs risperidone , t ( 33 ) = 2 . 94 ; P = . 006 ; olanzapine vs risperidone , t ( 33 ) = 2 . 42 ; P = . 02 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "insulin resistance"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "clozapine"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "olanzapine"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "risperidone"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "clozapine"
      ],
      [
        "T5",
        "Chemical",
        37,
        38,
        "risperidone"
      ],
      [
        "T6",
        "Chemical",
        53,
        54,
        "olanzapine"
      ],
      [
        "T7",
        "Chemical",
        55,
        56,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 953,
    "text": "There was a significant difference among groups in glucose effectiveness ( F ( 30 ) = 4 . 18 ; P = . 02 ) ( clozapine < olanzapine < risperidone ) with significant differences between clozapine and risperidone ( t ( 30 ) = - 2 . 59 ; P = . 02 ) and olanzapine and risperidone ( t ( 30 ) = - 2 . 34 , P = . 03 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "glucose"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "clozapine"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "olanzapine"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "risperidone"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "clozapine"
      ],
      [
        "T5",
        "Chemical",
        38,
        39,
        "risperidone"
      ],
      [
        "T6",
        "Chemical",
        56,
        57,
        "olanzapine"
      ],
      [
        "T7",
        "Chemical",
        58,
        59,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 954,
    "text": "CONCLUSIONS : Both nonobese clozapine - and olanzapine - treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone - treated subjects .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "insulin resistance"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "clozapine"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "olanzapine"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "glucose"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 955,
    "text": "Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "insulin resistance"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "clozapine"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 956,
    "text": "Thoracic hematomyelia secondary to coumadin anticoagulant therapy : a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Thoracic hematomyelia"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "coumadin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 957,
    "text": "A case of thoracic hematomyelia secondary to anticoagulant therapy is presented .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "thoracic hematomyelia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 958,
    "text": "Clinical features , similar to 2 other previously reported cases , are discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 959,
    "text": "A high index of suspicion may lead to a quick diagnostic procedure and successful decompressive surgery .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 960,
    "text": "Mania associated with fluoxetine treatment in adolescents .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Mania"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 961,
    "text": "Fluoxetine , a selective serotonin reuptake inhibitor , is gaining increased acceptance in the treatment of adolescent depression .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Fluoxetine"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "serotonin"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 962,
    "text": "Generally safe and well tolerated by adults , fluoxetine has been reported to induce mania .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "fluoxetine"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "mania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 963,
    "text": "The cases of five depressed adolescents , 14 - 16 years of age , who developed mania during pharmacotherapy with fluoxetine , are reported here .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "depressed"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "mania"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 964,
    "text": "Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention - deficit hyperactivity disorder and affective instability ; major depression with psychotic features ; a family history of affective disorder , especially bipolar disorder ; and a diagnosis of bipolar disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        25,
        "attention - deficit hyperactivity disorder"
      ],
      [
        "T1",
        "Disease",
        39,
        41,
        "affective disorder"
      ],
      [
        "T2",
        "Disease",
        43,
        45,
        "bipolar disorder"
      ],
      [
        "T3",
        "Disease",
        50,
        52,
        "bipolar disorder"
      ],
      [
        "T4",
        "Disease",
        7,
        8,
        "mania"
      ],
      [
        "T5",
        "Disease",
        9,
        10,
        "hypomania"
      ],
      [
        "T6",
        "Chemical",
        11,
        12,
        "fluoxetine"
      ],
      [
        "T7",
        "Disease",
        30,
        31,
        "depression"
      ],
      [
        "T8",
        "Disease",
        32,
        33,
        "psychotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 965,
    "text": "Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "fluoxetine"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "mania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 966,
    "text": "Acute renal insufficiency after high - dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute renal insufficiency"
      ],
      [
        "T1",
        "Disease",
        11,
        14,
        "primary systemic amyloidosis"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "melphalan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 967,
    "text": "BACKGROUND : Patients with primary systemic amyloidosis ( AL ) have a poor prognosis .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "primary systemic amyloidosis"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "AL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 968,
    "text": "Median survival time from standard treatments is only 17 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 969,
    "text": "High - dose intravenous melphalan followed by peripheral blood stem cell transplant ( PBSCT ) appears to be the most promising therapy , but treatment mortality can be high .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "melphalan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 970,
    "text": "The authors have noted the development of acute renal insufficiency immediately after melphalan conditioning .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "acute renal insufficiency"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "melphalan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 971,
    "text": "This study was undertaken to further examine its risk factors and impact on posttransplant mortality .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 972,
    "text": "METHODS : Consecutive AL patients who underwent PBSCT were studied retrospectively .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "AL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 973,
    "text": "Acute renal insufficiency ( ARI ) after high - dose melphalan was defined by a minimum increase of 0 . 5 mg / dL ( 44 micromol / L ) in the serum creatinine level that is greater than 50 % of baseline immediately after conditioning .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute renal insufficiency"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "ARI"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "melphalan"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 974,
    "text": "Urine sediment score was the sum of the individual types of sediment identified on urine microscopy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 975,
    "text": "RESULTS : Of the 80 patients studied , ARI developed in 18 . 8 % of the patients after high - dose melphalan .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "ARI"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "melphalan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 976,
    "text": "Univariate analysis identified age , hypoalbuminemia , heavy proteinuria , diuretic use , and urine sediment score ( > 3 ) as risk factors .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hypoalbuminemia"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 977,
    "text": "Age and urine sediment score remained independently significant risk factors in the multivariate analysis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 978,
    "text": "Patients who had ARI after high - dose melphalan underwent dialysis more often ( P = 0 . 007 ) , and had a worse 1 - year survival ( P = 0 . 03 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "ARI"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "melphalan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 979,
    "text": "CONCLUSION : The timing of renal injury strongly suggests melphalan as the causative agent .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "renal injury"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "melphalan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 980,
    "text": "Ongoing tubular injury may be a prerequisite for renal injury by melphalan as evidenced by the active urinary sediment .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "tubular injury"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "renal injury"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "melphalan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 981,
    "text": "Development of ARI adversely affected the outcome after PBSCT .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "ARI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 982,
    "text": "Effective preventive measures may help decrease the treatment mortality of PBSCT in AL patients .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "AL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 983,
    "text": "Focal cerebral ischemia in rats : effect of phenylephrine - induced hypertension during reperfusion .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "cerebral ischemia"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "phenylephrine"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 984,
    "text": "After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats , the effect of phenylephrine - induced hypertension on ischemic brain injury and blood - brain barrier permeability was determined .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "middle cerebral artery occlusion"
      ],
      [
        "T1",
        "Disease",
        22,
        25,
        "ischemic brain injury"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hypertensive"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "phenylephrine"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 985,
    "text": "Blood pressure was manipulated by one of the following schedules during 120 min of reperfusion : Control , normotensive reperfusion ; 90 / hypertension ( 90 / HTN ) , blood pressure was increased by 35 mm Hg during the initial 90 min of reperfusion only ; 15 / hypertension ( 15 / HTN ) , normotensive reperfusion for 30 min followed by 15 min of hypertension and 75 min of normotension .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "hypertension"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "HTN"
      ],
      [
        "T2",
        "Disease",
        49,
        50,
        "hypertension"
      ],
      [
        "T3",
        "Disease",
        53,
        54,
        "HTN"
      ],
      [
        "T4",
        "Disease",
        66,
        67,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 986,
    "text": "Part A , for eight rats in each group brain injury was evaluated by staining tissue using 2 , 3 , 5 - triphenyltetrazolium chloride and edema was evaluated by microgravimetry .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "brain injury"
      ],
      [
        "T1",
        "Chemical",
        17,
        25,
        "2 , 3 , 5 - triphenyltetrazolium chloride"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 987,
    "text": "Part B , for eight different rats in each group blood - brain barrier permeability was evaluated by measuring the amount and extent of extravasation of Evans Blue dye .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 988,
    "text": "Brain injury ( percentage of the ischemic hemisphere ) was less in the 15 / HTN group ( 16 + / - 6 , mean + / - SD ) versus the 90 / HTN group ( 30 + / - 6 ) , which was in turn less than the control group ( 42 + / - 5 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Brain injury"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "ischemic hemisphere"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "HTN"
      ],
      [
        "T3",
        "Disease",
        34,
        35,
        "HTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 989,
    "text": "Specific gravity was greater in the 15 / HTN group ( 1 . 043 + / - 0 . 002 ) versus the 90 / HTN ( 1 . 036 + / - 0 . 003 ) and control ( 1 . 037 + / - 0 . 003 ) groups .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "HTN"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "HTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 990,
    "text": "Evans Blue ( mug g - 1 of brain tissue ) was greater in the 90 / HTN group ( 24 . 4 + / - 6 . 0 ) versus the control group ( 12 . 3 + / - 4 . 1 ) , which was in turn greater than the 15 / HTN group ( 7 . 3 + / - 3 . 2 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Evans Blue"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "HTN"
      ],
      [
        "T2",
        "Disease",
        55,
        56,
        "HTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 991,
    "text": "This study supports a hypothesis that during reperfusion , a short interval of hypertension decreases brain injury and edema ; and that sustained hypertension increases the risk of vasogenic edema .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "brain injury"
      ],
      [
        "T1",
        "Disease",
        28,
        30,
        "vasogenic edema"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hypertension"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "edema"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 992,
    "text": "People aged over 75 in atrial fibrillation on warfarin : the rate of major hemorrhage and stroke in more than 500 patient - years of follow - up .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "warfarin"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "hemorrhage"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 993,
    "text": "OBJECTIVES : To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted - dose warfarin who had been recently been admitted to hospital .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hemorrhage"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "stroke"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 994,
    "text": "DESIGN : A retrospective observational cohort study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 995,
    "text": "SETTING : A major healthcare network involving four tertiary hospitals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 996,
    "text": "PARTICIPANTS : Two hundred thirty - five patients aged 76 and older admitted to a major healthcare network between July 1 , 2001 , and June 30 , 2002 , with atrial fibrillation on warfarin were enrolled .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        33,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 997,
    "text": "MEASUREMENTS : Information regarding major bleeding episodes , strokes , and warfarin use was obtained from patients , relatives , primary physicians , and medical records .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "bleeding"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "strokes"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 998,
    "text": "RESULTS : Two hundred twenty - eight patients ( 42 % men ) with a mean age of 81 . 1 ( range 76 - 94 ) were included in the analysis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 999,
    "text": "Total follow - up on warfarin was 530 years ( mean 28 months ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1000,
    "text": "There were 53 major hemorrhages , for an annual rate of 10 . 0 % , including 24 ( 45 . 3 % ) life - threatening and five ( 9 . 4 % ) fatal bleeds .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hemorrhages"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1001,
    "text": "The annual stroke rate after initiation of warfarin was 2 . 6 % .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "stroke"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1002,
    "text": "CONCLUSION : The rate of major hemorrhage was high in this old , frail group , but excluding fatalities , resulted in no long - term sequelae , and the stroke rate on warfarin was low , demonstrating how effective warfarin treatment is .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hemorrhage"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "stroke"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "warfarin"
      ],
      [
        "T3",
        "Chemical",
        40,
        41,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1003,
    "text": "Safety of celecoxib in patients with adverse skin reactions to acetaminophen ( paracetamol ) and nimesulide associated or not with common non - steroidal anti - inflammatory drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "skin reactions"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "celecoxib"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "acetaminophen"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "paracetamol"
      ],
      [
        "T4",
        "Chemical",
        15,
        16,
        "nimesulide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1004,
    "text": "BACKGROUND : Acetaminophen ( paracetamol - - P ) and Nimesulide ( N ) are widely used analgesic - antipyretic / anti - inflammatory drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Acetaminophen"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "paracetamol"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "P"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "Nimesulide"
      ],
      [
        "T4",
        "Chemical",
        12,
        13,
        "N"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1005,
    "text": "The rate of adverse hypersensitivity reactions to these agents is generally low .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypersensitivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1006,
    "text": "On the contrary non - steroidal anti - inflammatory drugs ( NSAIDs ) are commonly involved in such reactions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1007,
    "text": "Celecoxib ( CE ) is a novel drug , with high selectivity and affinity for COX - 2 enzyme .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Celecoxib"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "CE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1008,
    "text": "OBJECTIVE : We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "cutaneous reactions"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "CE"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "P"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "N"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1009,
    "text": "METHODS : We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "hypersensitivity"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "P"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "N"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1010,
    "text": "The diagnosis of P and N - induced skin reactions was based in vivo challenge .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "skin reactions"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "P"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "N"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1011,
    "text": "The placebo was blindly administered at the beginning of each challenge .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1012,
    "text": "After three days , a cumulative dosage of 200 mg of CE in refracted doses were given .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "CE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1013,
    "text": "After 2 - 3 days , a single dose of 200 mg was administered .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1014,
    "text": "All patients were observed for 6 hours after each challenge , and controlled again after 24 hours to exclude delayed reactions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1015,
    "text": "The challenge was considered positive if one or more of the following appeared : erythema , rush or urticaria - angioedema .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "erythema"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "urticaria"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "angioedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1016,
    "text": "RESULTS : No reaction was observed with placebo and eight patients ( 88 . 8 % ) tolerated CE .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "CE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1017,
    "text": "Only one patient developed a moderate angioedema of the lips .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "angioedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1018,
    "text": "CONCLUSION : Only one hypersensitivity reaction to CE was documented among 9 P and N - highly NSAIDs intolerant patients .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypersensitivity"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "CE"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "P"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "N"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1019,
    "text": "Thus , we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "CE"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "P"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "N"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1020,
    "text": "Case - control study of regular analgesic and nonsteroidal anti - inflammatory use and end - stage renal disease .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        19,
        "end - stage renal disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1021,
    "text": "BACKGROUND : Studies on the association between the long - term use of aspirin and other analgesic and nonsteroidal anti - inflammatory drugs ( NSAIDs ) and end - stage renal disease ( ESRD ) have given conflicting results .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        32,
        "end - stage renal disease"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "aspirin"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "ESRD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1022,
    "text": "In order to examine this association , a case - control study with incident cases of ESRD was carried out .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "ESRD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1023,
    "text": "METHODS : The cases were all patients entering the local dialysis program because of ESRD in the study area between June 1 , 1995 and November 30 , 1997 .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "ESRD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1024,
    "text": "They were classified according to the underlying disease , which had presumably led them to ESRD .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "ESRD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1025,
    "text": "Controls were patients admitted to the same hospitals from where the cases arose , also matched by age and sex .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1026,
    "text": "Odds ratios were calculated using a conditional logistic model , including potential confounding factors , both for the whole study population and for the various underlying diseases .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1027,
    "text": "RESULTS : Five hundred and eighty - three cases and 1190 controls were included in the analysis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1028,
    "text": "Long - term use of any analgesic was associated with an overall odds ratio of 1 . 22 ( 95 % CI , 0 . 89 - 1 . 66 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1029,
    "text": "For specific groups of drugs , the risks were 1 . 56 ( 1 . 05 - 2 . 30 ) for aspirin , 1 . 03 ( 0 . 60 - 1 . 76 ) for pyrazolones , 0 . 80 ( 0 . 39 - 1 . 63 ) for paracetamol , and 0 . 94 ( 0 . 57 - 1 . 56 ) for nonaspirin NSAIDs .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "aspirin"
      ],
      [
        "T1",
        "Chemical",
        37,
        38,
        "pyrazolones"
      ],
      [
        "T2",
        "Chemical",
        52,
        53,
        "paracetamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1030,
    "text": "The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use , and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [ 2 . 35 ( 1 . 17 - 4 . 72 ) ] .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "ESRD"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "aspirin"
      ],
      [
        "T2",
        "Disease",
        30,
        31,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1031,
    "text": "CONCLUSION : Our data indicate that long - term use of nonaspirin analgesic drugs and NSAIDs is not associated with an increased risk of ESRD .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        25,
        "ESRD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1032,
    "text": "However , the chronic use of aspirin may increase the risk of ESRD .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "aspirin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "ESRD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1033,
    "text": "Two cases of amisulpride overdose : a cause for prolonged QT syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "prolonged QT syndrome"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "amisulpride"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "overdose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1034,
    "text": "Two cases of deliberate self - poisoning with 5 g and 3 . 6 g of amisulpride , respectively , are reported .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "poisoning"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "amisulpride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1035,
    "text": "In both cases , QT prolongation and hypocalcaemia were noted .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "QT prolongation"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hypocalcaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1036,
    "text": "The QT prolongation appeared to respond to administration of i . v . calcium gluconate .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "QT prolongation"
      ],
      [
        "T1",
        "Chemical",
        13,
        15,
        "calcium gluconate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1037,
    "text": "Growth - associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with cycloheximide .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "epileptic"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "cycloheximide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1038,
    "text": "PURPOSE : GAP43 has been thought to be linked with mossy fiber sprouting ( MFS ) in various experimental models of epilepsy .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        22,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1039,
    "text": "To investigate how GAP43 expression ( GAP43 - ir ) correlates with MFS , we assessed the intensity ( densitometry ) and extension ( width ) of GAP43 - ir in the inner molecular layer of the dentate gyrus ( IML ) of rats subject to status epilepticus induced by pilocarpine ( Pilo ) , previously injected or not with cycloheximide ( CHX ) , which has been shown to inhibit MFS .",
    "labels": [
      [
        "T0",
        "Disease",
        46,
        48,
        "status epilepticus"
      ],
      [
        "T1",
        "Chemical",
        50,
        51,
        "pilocarpine"
      ],
      [
        "T2",
        "Chemical",
        52,
        53,
        "Pilo"
      ],
      [
        "T3",
        "Chemical",
        60,
        61,
        "cycloheximide"
      ],
      [
        "T4",
        "Chemical",
        62,
        63,
        "CHX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1040,
    "text": "METHODS : CHX was injected before the Pilo injection in adult Wistar rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "CHX"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "Pilo"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1041,
    "text": "The Pilo group was injected with the same drugs , except for CHX .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "Pilo"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "CHX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1042,
    "text": "Animals were killed between 30 and 60 days later , and brain sections were processed for GAP43 immunohistochemistry .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1043,
    "text": "RESULTS : Densitometry showed no significant difference regarding GAP43 - ir in the IML between Pilo , CHX + Pilo , and control groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "Pilo"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "CHX"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "Pilo"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1044,
    "text": "However , the results of the width of the GAP43 - ir band in the IML showed that CHX + Pilo and control animals had a significantly larger band ( p = 0 . 03 ) as compared with that in the Pilo group .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "CHX"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "Pilo"
      ],
      [
        "T2",
        "Chemical",
        42,
        43,
        "Pilo"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1045,
    "text": "CONCLUSIONS : Our current finding that animals in the CHX + Pilo group have a GAP43 - ir band in the IML , similar to that of controls , reinforces prior data on the blockade of MFS in these animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "CHX"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "Pilo"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1046,
    "text": "The change in GAP43 - ir present in Pilo - treated animals was a thinning of the band to a very narrow layer just above the granule cell layer that is likely to be associated with the loss of hilar cell projections that express GAP - 43 .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "Pilo"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1047,
    "text": "Nicotine antagonizes caffeine - but not pentylenetetrazole - induced anxiogenic effect in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Nicotine"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "caffeine"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "pentylenetetrazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1048,
    "text": "RATIONALE : Nicotine and caffeine are widely consumed licit psychoactive drugs worldwide .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Nicotine"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1049,
    "text": "Epidemiological studies showed that they were generally used concurrently .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1050,
    "text": "Although some studies in experimental animals indicate clear pharmacological interactions between them , no studies have shown a specific interaction on anxiety responses .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        22,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1051,
    "text": "OBJECTIVES : The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug , pentylenetetrazole , in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "nicotine"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "anxiety"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "caffeine"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "pentylenetetrazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1052,
    "text": "The elevated plus - maze ( EPM ) test was used to evaluate the effects of drugs on anxiety .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1053,
    "text": "METHODS : Adult male Swiss Webster mice ( 25 - 32 g ) were given nicotine ( 0 . 05 - 0 . 25 mg / kg s . c . ) or saline 10 min before caffeine ( 70 mg / kg i . p . ) or pentylenetetrazole ( 15 and 30 mg / kg i . p . ) injections .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "nicotine"
      ],
      [
        "T1",
        "Chemical",
        37,
        38,
        "caffeine"
      ],
      [
        "T2",
        "Chemical",
        49,
        50,
        "pentylenetetrazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1054,
    "text": "After 15 min , mice were evaluated for their open - and closed - arm time and entries on the EPM for a 10 - min session .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1055,
    "text": "Locomotor activity was recorded for individual groups by using the same treatment protocol with the EPM test .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1056,
    "text": "RESULTS : Nicotine ( 0 . 05 - 0 . 25 mg / kg ) itself did not produce any significant effect in the EPM test , whereas caffeine ( 70 mg / kg ) and pentylenetetrazole ( 30 mg / kg ) produced an anxiogenic effect , apparent with decreases in open - arm time and entry .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Nicotine"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "caffeine"
      ],
      [
        "T2",
        "Chemical",
        36,
        37,
        "pentylenetetrazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1057,
    "text": "Nicotine ( 0 . 25 mg / kg ) pretreatment blocked the caffeine - but not pentylenetetrazole - induced anxiety .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Nicotine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "caffeine"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "pentylenetetrazole"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1058,
    "text": "Administration of each drug and their combinations did not produce any effect on locomotor activity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1059,
    "text": "CONCLUSIONS : Our results suggest that the antagonistic effect of nicotine on caffeine - induced anxiety is specific to caffeine , instead of a non - specific anxiolytic effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "nicotine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "caffeine"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "anxiety"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1060,
    "text": "Thus , it may extend the current findings on the interaction between nicotine and caffeine .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "nicotine"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1061,
    "text": "Long term hormone therapy for perimenopausal and postmenopausal women .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1062,
    "text": "BACKGROUND : Hormone therapy ( HT ) is widely used for controlling menopausal symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "menopausal symptoms"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1063,
    "text": "It has also been used for the management and prevention of cardiovascular disease , osteoporosis and dementia in older women but the evidence supporting its use for these indications is largely observational .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "cardiovascular disease"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "osteoporosis"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "dementia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1064,
    "text": "OBJECTIVES : To assess the effect of long - term HT on mortality , heart disease , venous thromboembolism , stroke , transient ischaemic attacks , breast cancer , colorectal cancer , ovarian cancer , endometrial cancer , gallbladder disease , cognitive function , dementia , fractures and quality of life .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "heart disease"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "venous thromboembolism"
      ],
      [
        "T2",
        "Disease",
        22,
        25,
        "transient ischaemic attacks"
      ],
      [
        "T3",
        "Disease",
        26,
        28,
        "breast cancer"
      ],
      [
        "T4",
        "Disease",
        29,
        31,
        "colorectal cancer"
      ],
      [
        "T5",
        "Disease",
        32,
        34,
        "ovarian cancer"
      ],
      [
        "T6",
        "Disease",
        35,
        37,
        "endometrial cancer"
      ],
      [
        "T7",
        "Disease",
        38,
        40,
        "gallbladder disease"
      ],
      [
        "T8",
        "Disease",
        20,
        21,
        "stroke"
      ],
      [
        "T9",
        "Disease",
        44,
        45,
        "dementia"
      ],
      [
        "T10",
        "Disease",
        46,
        47,
        "fractures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1065,
    "text": "SEARCH STRATEGY : We searched the following databases up to November 2004 : the Cochrane Menstrual Disorders and Subfertility Group Trials Register , Cochrane Central Register of Controlled Trials ( CENTRAL ) , MEDLINE , EMBASE , Biological Abstracts .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1066,
    "text": "Relevant non - indexed journals and conference abstracts were also searched .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1067,
    "text": "SELECTION CRITERIA : Randomised double - blind trials of HT ( oestrogens with or without progestogens ) versus placebo , taken for at least one year by perimenopausal or postmenopausal women .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "oestrogens"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "progestogens"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1068,
    "text": "DATA COLLECTION AND ANALYSIS : Fifteen RCTs were included .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1069,
    "text": "Trials were assessed for quality and two review authors extracted data independently .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1070,
    "text": "They calculated risk ratios for dichotomous outcomes and weighted mean differences for continuous outcomes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1071,
    "text": "Clinical heterogeneity precluded meta - analysis for most outcomes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1072,
    "text": "MAIN RESULTS : All the statistically significant results were derived from the two biggest trials .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1073,
    "text": "In relatively healthy women , combined continuous HT significantly increased the risk of venous thromboembolism or coronary event ( after one year ' s use ) , stroke ( after 3 years ) , breast cancer ( after 5 years ) and gallbladder disease .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "venous thromboembolism"
      ],
      [
        "T1",
        "Disease",
        34,
        36,
        "breast cancer"
      ],
      [
        "T2",
        "Disease",
        42,
        44,
        "gallbladder disease"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1074,
    "text": "Long - term oestrogen - only HT also significantly increased the risk of stroke and gallbladder disease .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "gallbladder disease"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "oestrogen"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1075,
    "text": "Overall , the only statistically significant benefits of HT were a decreased incidence of fractures and colon cancer with long - term use .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "colon cancer"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "fractures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1076,
    "text": "Among relatively healthy women over 65 years taking continuous combined HT , there was a statistically significant increase in the incidence of dementia .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        23,
        "dementia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1077,
    "text": "Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of venous thromboembolism .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiovascular disease"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "venous thromboembolism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1078,
    "text": "No trials focussed specifically on younger women .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1079,
    "text": "However , one trial analysed subgroups of 2839 relatively healthy 50 to 59 year - old women taking combined continuous HT and 1637 taking oestrogen - only HT , versus similar - sized placebo groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "oestrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1080,
    "text": "The only significantly increased risk reported was for venous thromboembolism in women taking combined continuous HT ; their absolute risk remained very low .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "venous thromboembolism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1081,
    "text": "AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "chronic disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1082,
    "text": "We need more evidence on the safety of HT for menopausal symptom control , though short - term use appears to be relatively safe for healthy younger women .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1083,
    "text": "Drug - induced liver injury : an analysis of 461 incidences submitted to the Spanish registry over a 10 - year period .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        5,
        "Drug - induced liver injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1084,
    "text": "BACKGROUND & AIMS : Progress in the understanding of susceptibility factors to drug - induced liver injury ( DILI ) and outcome predictability are hampered by the lack of systematic programs to detect bona fide cases .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        17,
        "drug - induced liver injury"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "DILI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1085,
    "text": "METHODS : A cooperative network was created in 1994 in Spain to identify all suspicions of DILI following a prospective structured report form .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "DILI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1086,
    "text": "The liver damage was characterized according to hepatocellular , cholestatic , and mixed laboratory criteria and to histologic criteria when available .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "liver damage"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "cholestatic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1087,
    "text": "Further evaluation of causality assessment was centrally performed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1088,
    "text": "RESULTS : Since April 1994 to August 2004 , 461 out of 570 submitted cases , involving 505 drugs , were deemed to be related to DILI .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        27,
        "DILI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1089,
    "text": "The antiinfective group of drugs was the more frequently incriminated , amoxicillin - clavulanate accounting for the 12 . 8 % of the whole series .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "amoxicillin - clavulanate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1090,
    "text": "The hepatocellular pattern of damage was the most common ( 58 % ) , was inversely correlated with age ( P < . 0001 ) , and had the worst outcome ( Cox regression , P < . 034 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1091,
    "text": "Indeed , the incidence of liver transplantation and death in this group was 11 . 7 % if patients had jaundice at presentation , whereas the corresponding figure was 3 . 8 % in nonjaundiced patients ( P < . 04 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "jaundice"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1092,
    "text": "Factors associated with the development of fulminant hepatic failure were female sex ( OR = 25 ; 95 % CI : 4 . 1 - 151 ; P < . 0001 ) , hepatocellular damage ( OR = 7 . 9 ; 95 % CI : 1 . 6 - 37 ; P < . 009 ) , and higher baseline plasma bilirubin value ( OR = 1 . 15 ; 95 % CI : 1 . 09 - 1 . 22 ; P < . 0001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "fulminant hepatic failure"
      ],
      [
        "T1",
        "Chemical",
        62,
        63,
        "bilirubin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1093,
    "text": "CONCLUSIONS : Patients with drug - induced hepatocellular jaundice have 11 . 7 % chance of progressing to death or transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "jaundice"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1094,
    "text": "Amoxicillin - clavulanate stands out as the most common drug related to DILI .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "Amoxicillin - clavulanate"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "DILI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1095,
    "text": "Morphological evaluation of the effect of d - ribose on adriamycin - evoked cardiotoxicity in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "d - ribose"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "adriamycin"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1096,
    "text": "The influence of d - ribose on adriamycin - induced myocardiopathy in rats was studied .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "d - ribose"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "adriamycin"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "myocardiopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1097,
    "text": "Adriamycin in the cumulative dose of 25 mg / kg evoked fully developed cardiac toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "cardiac toxicity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Adriamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1098,
    "text": "D - ribose in the multiple doses of 200 mg / kg did not influence ADR cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "D - ribose"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "ADR"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1099,
    "text": "In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin - induced nephrotoxicity : protection by erdosteine .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "vancomycin"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "nephrotoxicity"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "erdosteine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1100,
    "text": "The aims of this study were to examine vancomycin ( VCM ) - induced oxidative stress that promotes production of reactive oxygen species ( ROS ) and to investigate the role of erdosteine , an expectorant agent , which has also antioxidant properties , on kidney tissue against the possible VCM - induced renal impairment in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        53,
        55,
        "renal impairment"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "vancomycin"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "VCM"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "oxygen"
      ],
      [
        "T4",
        "Chemical",
        32,
        33,
        "erdosteine"
      ],
      [
        "T5",
        "Chemical",
        50,
        51,
        "VCM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1101,
    "text": "Rats were divided into three groups : sham , VCM and VCM plus erdosteine .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "VCM"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "VCM"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "erdosteine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1102,
    "text": "VCM was administrated intraperitoneally ( i . p . ) with 200mgkg ( - 1 ) twice daily for 7 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "VCM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1103,
    "text": "Erdosteine was administered orally .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Erdosteine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1104,
    "text": "VCM administration to control rats significantly increased renal malondialdehyde ( MDA ) and urinary N - acetyl - beta - d - glucosaminidase ( NAG , a marker of renal tubular injury ) excretion but decreased superoxide dismutase ( SOD ) and catalase ( CAT ) activities .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        32,
        "renal tubular injury"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "VCM"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "malondialdehyde"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "MDA"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "superoxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1105,
    "text": "Erdosteine administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion , and increased SOD activity , but not CAT activity in renal tissue when compared with VCM alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Erdosteine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "VCM"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "MDA"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "VCM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1106,
    "text": "Erdosteine showed histopathological protection against VCM - induced nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Erdosteine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "VCM"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1107,
    "text": "There were a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , atrophy , desquamation , and necrosis in VCM - treated rats more than those of the control and the erdosteine groups .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "atrophy"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "desquamation"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "necrosis"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "VCM"
      ],
      [
        "T4",
        "Chemical",
        33,
        34,
        "erdosteine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1108,
    "text": "Erdosteine caused a marked reduction in the extent of tubular damage .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Erdosteine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1109,
    "text": "It is concluded that oxidative tubular damage plays an important role in the VCM - induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM - induced kidney damage both at the biochemical and histological levels .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        32,
        "kidney damage"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "VCM"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "nephrotoxicity"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "erdosteine"
      ],
      [
        "T4",
        "Chemical",
        27,
        28,
        "VCM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1110,
    "text": "Gemfibrozil - lovastatin therapy for primary hyperlipoproteinemias .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Gemfibrozil"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "lovastatin"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "hyperlipoproteinemias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1111,
    "text": "The specific aim of this retrospective , observational study was to assess safety and efficacy of long - term ( 21 months / patient ) , open - label , gemfibrozil - lovastatin treatment in 80 patients with primary mixed hyperlipidemia ( 68 % of whom had atherosclerotic vascular disease ) .",
    "labels": [
      [
        "T0",
        "Disease",
        47,
        50,
        "atherosclerotic vascular disease"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "gemfibrozil"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "lovastatin"
      ],
      [
        "T3",
        "Disease",
        40,
        41,
        "hyperlipidemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1112,
    "text": "Because ideal lipid targets were not reached ( low - density lipoprotein ( LDL ) cholesterol less than 130 mg / dl , high - density lipoprotein ( HDL ) cholesterol greater than 35 mg / dl , or total cholesterol / HDL cholesterol less than 4 . 5 mg / dl ) with diet plus a single drug , gemfibrozil ( 1 . 2 g / day ) - lovastatin ( primarily 20 or 40 mg ) treatment was given .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "cholesterol"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "cholesterol"
      ],
      [
        "T2",
        "Chemical",
        40,
        41,
        "cholesterol"
      ],
      [
        "T3",
        "Chemical",
        43,
        44,
        "cholesterol"
      ],
      [
        "T4",
        "Chemical",
        60,
        61,
        "gemfibrozil"
      ],
      [
        "T5",
        "Chemical",
        70,
        71,
        "lovastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1113,
    "text": "Follow - up visits were scheduled with 2 - drug therapy every 6 to 8 weeks , an average of 10 . 3 visits per patient , with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured .",
    "labels": [
      [
        "T0",
        "Chemical",
        37,
        38,
        "creatine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1114,
    "text": "Only 1 of the 4 , 446 liver function tests ( 0 . 02 % ) , a gamma glutamyl transferase , was greater than or equal to 3 times the upper normal limit .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1115,
    "text": "Of the 714 creatine phosphokinase levels , 9 % were high ; only 1 ( 0 . 1 % ) was greater than or equal to 3 times the upper normal limit .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "creatine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1116,
    "text": "With 2 - drug therapy , mean total cholesterol decreased 22 % from 255 to 200 mg / dl , triglyceride levels decreased 35 % from 236 to 154 mg / dl , LDL cholesterol decreased 26 % from 176 to 131 mg / dl , and the total cholesterol / HDL cholesterol ratio decreased 24 % from 7 . 1 to 5 . 4 , all p less than or equal to 0 . 0001 .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "cholesterol"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "triglyceride"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "cholesterol"
      ],
      [
        "T3",
        "Chemical",
        49,
        50,
        "cholesterol"
      ],
      [
        "T4",
        "Chemical",
        52,
        53,
        "cholesterol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1117,
    "text": "Myositis , attributable to the drug combination and symptomatic enough to discontinue it , occurred in 3 % of patients , and in 1 % with concurrent high creatine phosphokinase ( 769 U / liter ) ; no patients had rhabdomyolysis or myoglobinuria . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Myositis"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "creatine"
      ],
      [
        "T2",
        "Disease",
        40,
        41,
        "rhabdomyolysis"
      ],
      [
        "T3",
        "Disease",
        42,
        43,
        "myoglobinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1118,
    "text": "Does domperidone potentiate mirtazapine - associated restless legs syndrome ?",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "restless legs syndrome"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "domperidone"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "mirtazapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1119,
    "text": "There is now evidence to suggest a central role for the dopaminergic system in restless legs syndrome ( RLS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        17,
        "restless legs syndrome"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "RLS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1120,
    "text": "For example , the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists , whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "RLS"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "levodopa"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "dopamine"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "dopamine"
      ],
      [
        "T4",
        "Disease",
        27,
        28,
        "RLS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1121,
    "text": "To our knowledge , there is no previous report regarding whether domperidone , a peripheral dopamine D2 receptor antagonist , can also induce or aggravate symptoms of RLS .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "domperidone"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "dopamine"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "RLS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1122,
    "text": "Mirtazapine , the first noradrenergic and specific serotonergic antidepressant ( NaSSA ) , has been associated with RLS in several recent publications .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Mirtazapine"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "RLS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1123,
    "text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "postprandial dyspepsia"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "RLS"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "mirtazapine"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "domperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1124,
    "text": "Our patient started to have symptoms of RLS only after he had been treated with mirtazapine , and his RLS symptoms resolved completely upon discontinuation of his mirtazapine .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "RLS"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "mirtazapine"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "RLS"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "mirtazapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1125,
    "text": "Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine - associated RLS .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "mirtazapine"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "RLS"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "domperione"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "mirtazapine"
      ],
      [
        "T4",
        "Disease",
        29,
        30,
        "RLS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1126,
    "text": "However , physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals , especially those receiving concomitant dopamine D2 receptor antagonists .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "mirtazapine"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "RLS"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1127,
    "text": "Antiandrogenic therapy can cause coronary arterial disease .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "coronary arterial disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1128,
    "text": "AIM : To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "prostate cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1129,
    "text": "MATERIALS AND METHODS : We studied with a 2 . 5 years follow - up the changes in plasma cholesterols ( C ) , triglycerides ( TG ) , lipoproteins ( LP ) , and apolipoproteins ( Apo ) B - 100 , A - I , and A - II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer ( stage : T1cN0M0 , Gleason score : 2 - 5 ) during treatment with cyproterone acetate ( CPA ) without surgical management or radiation therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        65,
        67,
        "prostate cancer"
      ],
      [
        "T1",
        "Chemical",
        82,
        84,
        "cyproterone acetate"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "cholesterols"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "C"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "triglycerides"
      ],
      [
        "T5",
        "Chemical",
        26,
        27,
        "TG"
      ],
      [
        "T6",
        "Chemical",
        85,
        86,
        "CPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1130,
    "text": "RESULTS : Significant decreases of HDL - C , Apo A - I and Apo A - II and an increase of triglyceride levels in VLDL were induced by CPA .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "triglyceride"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "CPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1131,
    "text": "After a period of 2 . 5 years on CPA treatment , four patients out of twenty - four were found to be affected by coronary heart disease .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        28,
        "coronary heart disease"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "CPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1132,
    "text": "CONCLUSIONS : Ischaemic coronary arteriosclerosis with an incidence rate of 16 . 6 % as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol , Apo A - I and Apo A - II pro fi les , other than the well - known hyperglyceridemic effect caused by estrogen .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "coronary arteriosclerosis"
      ],
      [
        "T1",
        "Disease",
        47,
        49,
        "hyperglyceridemic effect"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "CPA"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "cholesterol"
      ],
      [
        "T4",
        "Chemical",
        51,
        52,
        "estrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1133,
    "text": "5 - Fluorouracil cardiotoxicity induced by alpha - fluoro - beta - alanine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "5 - Fluorouracil"
      ],
      [
        "T1",
        "Chemical",
        6,
        13,
        "alpha - fluoro - beta - alanine"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1134,
    "text": "Cardiotoxicity is a rare complication occurring during 5 - fluorouracil ( 5 - FU ) treatment for malignancies .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "5 - fluorouracil"
      ],
      [
        "T1",
        "Chemical",
        11,
        14,
        "5 - FU"
      ],
      [
        "T2",
        "Disease",
        0,
        1,
        "Cardiotoxicity"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "malignancies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1135,
    "text": "We herein report the case of a 70 - year - old man with 5 - FU - induced cardiotoxicity , in whom a high serum level of alpha - fluoro - beta - alanine ( FBAL ) was observed .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        17,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        28,
        35,
        "alpha - fluoro - beta - alanine"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "cardiotoxicity"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "FBAL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1136,
    "text": "The patient , who had unresectable colon cancer metastases to the liver and lung , was referred to us for chemotherapy from an affiliated hospital ; he had no cardiac history .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "colon cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1137,
    "text": "After admission , the patient received a continuous intravenous infusion of 5 - FU ( 1000 mg / day ) , during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng / ml .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "5 - FU"
      ],
      [
        "T1",
        "Disease",
        23,
        25,
        "precordial pain"
      ],
      [
        "T2",
        "Disease",
        26,
        30,
        "right bundle branch block"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "FBAL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1138,
    "text": "Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5 - FU .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "precordial pain"
      ],
      [
        "T1",
        "Chemical",
        14,
        17,
        "5 - FU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1139,
    "text": "As the precordial pain in this patient was considered to have been due to 5 - FU - induced cardiotoxicity , the administration of 5 - FU was abandoned .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "precordial pain"
      ],
      [
        "T1",
        "Chemical",
        14,
        17,
        "5 - FU"
      ],
      [
        "T2",
        "Chemical",
        24,
        27,
        "5 - FU"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1140,
    "text": "Instead , oral administration of S - 1 ( a derivative of 5 - FU ) , at 200 mg / day twice a week , was instituted , because S - 1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase , which catalyzes the degradative of 5 - FU into FBAL .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        15,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        47,
        50,
        "5 - FU"
      ],
      [
        "T2",
        "Chemical",
        39,
        40,
        "dihydropyrimidine"
      ],
      [
        "T3",
        "Chemical",
        51,
        52,
        "FBAL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1141,
    "text": "The serum FBAL concentration subsequently decreased to 352 ng / ml , the same as the value measured on the first day of S - 1 administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "FBAL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1142,
    "text": "Thereafter , no cardiac symptoms were observed .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiac symptoms"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1143,
    "text": "The patient achieved a partial response 6 months after the initiation of the S - 1 treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1144,
    "text": "The experience of this case , together with a review of the literature , suggests that FBAL is related to 5 - FU - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        23,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "FBAL"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1145,
    "text": "S - 1 may be administered safely to patients with 5 - FU - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        13,
        "5 - FU"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1146,
    "text": "Hepatocellular carcinoma in Fanconi ' s anemia treated with androgen and corticosteroid .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hepatocellular carcinoma"
      ],
      [
        "T1",
        "Disease",
        3,
        7,
        "Fanconi ' s anemia"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "androgen"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "corticosteroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1147,
    "text": "The case of an 11 - year - old boy is reported who was known to have Fanconi ' s anemia for 3 years and was treated with androgens , corticosteroids and transfusions .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        21,
        "Fanconi ' s anemia"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "androgens"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "corticosteroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1148,
    "text": "Two weeks before his death he was readmitted because of aplastic crisis with septicemia and marked abnormalities in liver function and died of hemorrhagic bronchopneumonia .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "hemorrhagic bronchopneumonia"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "septicemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1149,
    "text": "At autopsy peliosis and multiple hepatic tumors were found which histologically proved to be well - differentiated hepatocellular carcinoma .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "hepatic tumors"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "hepatocellular carcinoma"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "peliosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1150,
    "text": "This case contributes to the previous observations that non - metastasizing hepatic neoplasms and peliosis can develop in patients with androgen - and corticosteroid - treated Fanconi ' s anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "hepatic neoplasms"
      ],
      [
        "T1",
        "Disease",
        26,
        30,
        "Fanconi ' s anemia"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "peliosis"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "androgen"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "corticosteroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1151,
    "text": "The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin - induced cardiotoxicity in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "monoHER"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "doxorubicin"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "doxorubicin"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1152,
    "text": "PURPOSE : Despite its well - known cardiotoxicity , the anthracyclin doxorubicin ( DOX ) continues to be an effective and widely used chemotherapeutic agent .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "doxorubicin"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1153,
    "text": "DOX - induced cardiac damage presumably results from the formation of free radicals by DOX .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiac damage"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "DOX"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1154,
    "text": "Reactive oxygen species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1155,
    "text": "The semisynthetic flavonoid monohydroxyethylrutoside ( monoHER ) showed cardioprotection against DOX - induced cardiotoxicity through its radical scavenging and iron chelating properties .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "flavonoid"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "monohydroxyethylrutoside"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "monoHER"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "DOX"
      ],
      [
        "T4",
        "Disease",
        13,
        14,
        "cardiotoxicity"
      ],
      [
        "T5",
        "Chemical",
        19,
        20,
        "iron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1156,
    "text": "Because of the relatively short final half - life of monoHER ( about 30 min ) , it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "monoHER"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "monoHER"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "DOX"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "monoHER"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1157,
    "text": "Therefore , the aim of the present study was to investigate this possible effect .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1158,
    "text": "METHODS : Six groups of 6 BALB / c mice were treated with saline , DOX alone or DOX ( 4 mg / kg i . v . ) preceded by monoHER ( 500 mg / kg i . p . ) with an interval of 10 , 30 , 60 or 120 min .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "DOX"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "DOX"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "monoHER"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1159,
    "text": "After a 6 - week treatment period and additional observation for 2 weeks , the mice were sacrificed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1160,
    "text": "Their cardiac tissues were processed for light microscopy , after which cardiomyocyte damage was evaluated according to Billingham ( in Cancer Treat Rep 62 ( 6 ) : 865 - 872 , 1978 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "cardiomyocyte damage"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "Cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1161,
    "text": "Microscopic evaluation revealed that treatment with DOX alone induced significant cardiac damage in comparison to the saline control group ( P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "cardiac damage"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1162,
    "text": "RESULTS : The number of damaged cardiomyocytes was 9 . 6 - fold ( 95 % CI 4 . 4 - 21 . 0 ) higher in mice treated with DOX alone than that in animals of the control group .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        31,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1163,
    "text": "The ratio of aberrant cardiomyocytes in mice treated with DOX preceded by monoHER and those in mice treated with saline ranged from 1 . 6 to 2 . 8 ( mean 2 . 2 , 95 % CI 1 . 2 - 4 . 1 , P = 0 . 019 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "DOX"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "monoHER"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1164,
    "text": "The mean protective effect by adding monoHER before DOX led to a significant 4 . 4 - fold reduction ( P < 0 . 001 , 95 % CI 2 . 3 - 8 . 2 ) of abnormal cardiomyocytes .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "monoHER"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1165,
    "text": "This protective effect did not depend on the time interval between monoHER and DOX administration ( P = 0 . 345 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "monoHER"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1166,
    "text": "CONCLUSION : The results indicate that in an outpatient clinical setting monoHER may be administered shortly before DOX .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "monoHER"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1167,
    "text": "Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "atrial fibrillation and flutter"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "bepridil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1168,
    "text": "BACKGROUND : Bepridil hydrochloride ( Bpd ) has attracted attention as an effective drug for atrial fibrillation ( AF ) and atrial flutter ( AFL ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "Bepridil hydrochloride"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "atrial fibrillation"
      ],
      [
        "T2",
        "Disease",
        21,
        23,
        "atrial flutter"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "Bpd"
      ],
      [
        "T4",
        "Disease",
        18,
        19,
        "AF"
      ],
      [
        "T5",
        "Disease",
        24,
        25,
        "AFL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1169,
    "text": "However , serious adverse effects , including torsade de pointes ( Tdp ) , have been reported .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "torsade de pointes"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "Tdp"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1170,
    "text": "METHODS AND RESULTS : Adverse effects of Bpd requiring discontinuation of treatment were evaluated .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "Bpd"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1171,
    "text": "Bpd was administered to 459 patients ( 361 males , 63 + / - 12 years old ) comprising 378 AF and 81 AFL cases .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Bpd"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "AF"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "AFL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1172,
    "text": "Mean left ventricular ejection fraction and atrial dimension ( LAD ) were 66 + / - 11 % and 40 + / - 6 mm , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1173,
    "text": "Adverse effects were observed in 19 patients ( 4 % ) during an average follow - up of 20 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1174,
    "text": "There was marked QT prolongation greater than 0 . 55 s in 13 patients , bradycardia less than 40 beats / min in 6 patients , dizziness and general fatigue in 1 patient each .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "QT prolongation"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "bradycardia"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "dizziness"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "fatigue"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1175,
    "text": "In 4 of 13 patients with QT prolongation , Tdp occurred .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "QT prolongation"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "Tdp"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1176,
    "text": "The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "Tdp"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hypokalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1177,
    "text": "There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age , which were larger and older in the patients with Tdp .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "Tdp"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "Tdp"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1178,
    "text": "CONCLUSION : Careful observation of serum potassium concentration and the ECG should always be done during Bpd administration , particularly in elderly patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "potassium"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "Bpd"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1179,
    "text": "Enhanced isoproterenol - induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "cardiac hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1180,
    "text": "We have previously shown that a permanent deficiency in the brain renin - angiotensin system ( RAS ) may increase the sensitivity of the baroreflex control of heart rate .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "angiotensin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1181,
    "text": "In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta - adrenoceptor ( beta - AR ) agonist isoproterenol ( Iso ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        28,
        29,
        "isoproterenol"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "Iso"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1182,
    "text": "Transgenic rats with low brain angiotensinogen ( TGR ) were used .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1183,
    "text": "In isolated hearts , Iso induced a significantly greater increase in left ventricular ( LV ) pressure and maximal contraction ( + dP / dt ( max ) ) in the TGR than in the Sprague - Dawley ( SD ) rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "Iso"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1184,
    "text": "LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats ( in g LV wt / 100 g body wt , 0 . 28 + / - 0 . 004 vs . 0 . 24 + / - 0 . 004 , respectively ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "LV hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "Iso"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1185,
    "text": "The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta - AR and upregulation of LV beta - AR kinase - 1 mRNA levels compared with those in SD rats .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "LV hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1186,
    "text": "The decrease in the heart rate ( HR ) induced by the beta - AR antagonist metoprolol in conscious rats was significantly attenuated in TGR compared with SD rats ( - 9 . 9 + / - 1 . 7 % vs . - 18 . 1 + / - 1 . 5 % ) , whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "metoprolol"
      ],
      [
        "T1",
        "Chemical",
        63,
        64,
        "atropine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1187,
    "text": "These results indicate that TGR are more sensitive to beta - AR agonist - induced cardiac inotropic response and hypertrophy , possibly due to chronically low sympathetic outflow directed to the heart .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "cardiac inotropic"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1188,
    "text": "Drug - induced long QT syndrome in injection drug users receiving methadone : high frequency in hospitalized patients and risk factors .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "long QT syndrome"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1189,
    "text": "BACKGROUND : Drug - induced long QT syndrome is a serious adverse drug reaction .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "long QT syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1190,
    "text": "Methadone prolongs the QT interval in vitro in a dose - dependent manner .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1191,
    "text": "In the inpatient setting , the frequency of QT interval prolongation with methadone treatment , its dose dependence , and the importance of cofactors such as drug - drug interactions remain unknown .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "QT interval prolongation"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1192,
    "text": "METHODS : We performed a systematic , retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5 - year period in a tertiary care hospital .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "methadone"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1193,
    "text": "A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "methadone"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1194,
    "text": "In addition to methadone dose , 15 demographic , biological , and pharmacological variables were considered as potential risk factors for QT prolongation .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "QT prolongation"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1195,
    "text": "RESULTS : Among 167 methadone maintenance patients , the prevalence of QTc prolongation to 0 . 50 second ( ( 1 / 2 ) ) or longer was 16 . 2 % compared with 0 % in 80 control subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1196,
    "text": "Six patients ( 3 . 6 % ) in the methadone group presented torsades de pointes .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "torsades de pointes"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1197,
    "text": "QTc length was weakly but significantly associated with methadone daily dose ( Spearman rank correlation coefficient , 0 . 20 ; P < . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1198,
    "text": "Multivariate regression analysis allowed attribution of 31 . 8 % of QTc variability to methadone dose , cytochrome P - 450 3A4 drug - drug interactions , hypokalemia , and altered liver function .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "methadone"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "hypokalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1199,
    "text": "CONCLUSIONS : QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "QT interval prolongation"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1200,
    "text": "Methadone dose , presence of cytochrome P - 450 3A4 inhibitors , potassium level , and liver function contribute to QT prolongation .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "QT prolongation"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Methadone"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1201,
    "text": "Long QT syndrome can occur with low doses of methadone .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Long QT syndrome"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1202,
    "text": "Mechanisms of hypertension induced by nitric oxide ( NO ) deficiency : focus on venous function .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "hypertension"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "NO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1203,
    "text": "Loss of endothelial cell - derived nitric oxide ( NO ) in hypertension is a hallmark of arterial dysfunction .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "arterial dysfunction"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "NO"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1204,
    "text": "Experimental hypertension created by the removal of NO , however , involves mechanisms in addition to decreased arterial vasodilator activity .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypertension"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "NO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1205,
    "text": "These include augmented endothelin - 1 ( ET - 1 ) release , increased sympathetic nervous system activity , and elevated tissue oxidative stress .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1206,
    "text": "We hypothesized that increased venous smooth muscle ( venomotor ) tone plays a role in Nomega - nitro - L - arginine ( LNNA ) hypertension through these mechanisms .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        22,
        "Nomega - nitro - L - arginine"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "LNNA"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1207,
    "text": "Rats were treated with the NO synthase inhibitor LNNA ( 0 . 5 g / L in drinking water ) for 2 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "NO"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "LNNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1208,
    "text": "Mean arterial pressure of conscious rats was 119 + / - 2 mm Hg in control and 194 + / - 5 mm Hg in LNNA rats ( P < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        26,
        "LNNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1209,
    "text": "Carotid arteries and vena cava were removed for measurement of isometric contraction .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1210,
    "text": "Maximal contraction to norepinephrine was modestly reduced in arteries from LNNA compared with control rats whereas the maximum contraction to ET - 1 was significantly reduced ( 54 % control ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "norepinephrine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "LNNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1211,
    "text": "Maximum contraction of vena cava to norepinephrine ( 37 % control ) also was reduced but no change in response to ET - 1 was observed .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1212,
    "text": "Mean circulatory filling pressure , an in vivo measure of venomotor tone , was not elevated in LNNA hypertension at 1 or 2 weeks after LNNA .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "LNNA"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "hypertension"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "LNNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1213,
    "text": "The superoxide scavenger tempol ( 30 , 100 , and 300 micromol kg ( - 1 ) , IV ) did not change arterial pressure in control rats but caused a dose - dependent decrease in LNNA rats ( - 18 + / - 8 , - 26 + / - 15 , and - 54 + / - 11 mm Hg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "superoxide"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "tempol"
      ],
      [
        "T2",
        "Chemical",
        36,
        37,
        "LNNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1214,
    "text": "Similarly , ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats ( 76 + / - 9 mm Hg ) compared with control rats ( 35 + / - 10 mm Hg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "hexamethonium"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "LNNA"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1215,
    "text": "Carotid arteries , vena cava , and sympathetic ganglia from LNNA rats had higher basal levels of superoxide compared with those from control rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "LNNA"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "superoxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1216,
    "text": "These data suggest that while NO deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels , the impact on veins does not make a major contribution to this form of hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "NO"
      ],
      [
        "T1",
        "Disease",
        34,
        35,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1217,
    "text": "Association of DRD2 polymorphisms and chlorpromazine - induced extrapyramidal syndrome in Chinese schizophrenic patients .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "extrapyramidal syndrome"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "chlorpromazine"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "schizophrenic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1218,
    "text": "AIM : Extrapyramidal syndrome ( EPS ) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Extrapyramidal syndrome"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "EPS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1219,
    "text": "Recently , many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        25,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1220,
    "text": "In this study , we evaluate the role DRD2 plays in chlorpromazine - induced EPS in schizophrenic patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "chlorpromazine"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "EPS"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "schizophrenic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1221,
    "text": "METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , Ser311Cys , rs6275 , rs6277 and TaqIA ) in the DRD2 gene in 146 schizophrenic inpatients ( 59 with EPS and 87 without EPS according to the Simpson - Angus Scale ) treated with chlorpromazine after 8 weeks .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        36,
        "schizophrenic"
      ],
      [
        "T1",
        "Disease",
        40,
        41,
        "EPS"
      ],
      [
        "T2",
        "Disease",
        44,
        45,
        "EPS"
      ],
      [
        "T3",
        "Chemical",
        55,
        56,
        "chlorpromazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1222,
    "text": "The alleles of all loci were determined by PCR ( polymerase chain reaction ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1223,
    "text": "RESULTS : Polymorphisms TaqID , Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1224,
    "text": "No statistical significance was found in the allele distribution of - 141Cins > del , TaqIB , rs6275 and TaqIA or in the estimated haplotypes ( constituted by TaqIB , rs6275 and TaqIA ) in linkage disequilibrium between the two groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1225,
    "text": "CONCLUSION : Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine , at least in Chinese patients with schizophrenia .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        33,
        "chlorpromazine"
      ],
      [
        "T1",
        "Disease",
        40,
        41,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1226,
    "text": "Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "EPS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1227,
    "text": "Physical training decreases susceptibility to subsequent pilocarpine - induced seizures in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "pilocarpine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1228,
    "text": "Regular motor activity has many benefits for mental and physical condition but its implications for epilepsy are still controversial .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1229,
    "text": "In order to elucidate this problem , we have studied the effect of long - term physical activity on susceptibility to subsequent seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        23,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1230,
    "text": "Male Wistar rats were subjected to repeated training sessions in a treadmill and swimming pool .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1231,
    "text": "Thereafter , seizures were induced by pilocarpine injections in trained and non - trained control groups .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "seizures"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1232,
    "text": "During the acute period of status epilepticus , we measured : ( 1 ) the latency of the first motor sign , ( 2 ) the intensity of seizures , ( 3 ) the time when it occurred within the 6 - h observation period , and ( 4 ) the time when the acute period ended .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1233,
    "text": "All these behavioral parameters showed statistically significant changes suggesting that regular physical exercises decrease susceptibility to subsequently induced seizures and ameliorate the course of experimentally induced status epilepticus .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1234,
    "text": "Tonic dopaminergic stimulation impairs associative learning in healthy subjects .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "impairs associative learning"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1235,
    "text": "Endogenous dopamine plays a central role in salience coding during associative learning .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1236,
    "text": "Administration of the dopamine precursor levodopa enhances learning in healthy subjects and stroke patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "dopamine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1237,
    "text": "Because levodopa increases both phasic and tonic dopaminergic neurotransmission , the critical mechanism mediating the enhancement of learning is unresolved .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1238,
    "text": "We here probed how selective tonic dopaminergic stimulation affects associative learning .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1239,
    "text": "Forty healthy subjects were trained in a novel vocabulary of 45 concrete nouns over the course of 5 consecutive training days in a prospective , randomized , double - blind , placebo - controlled design .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1240,
    "text": "Subjects received the tonically stimulating dopamine - receptor agonist pergolide ( 0 . 1 mg ) vs placebo 120 min before training on each training day .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "dopamine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "pergolide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1241,
    "text": "The dopamine agonist significantly impaired novel word learning compared to placebo .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        8,
        "impaired novel word learning"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1242,
    "text": "This learning decrement persisted up to the last follow - up 4 weeks post - training .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1243,
    "text": "Subjects treated with pergolide also showed restricted emotional responses compared to the PLACEBO group .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "pergolide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1244,
    "text": "The extent of ' flattened ' affect with pergolide was related to the degree of learning inhibition .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "pergolide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1245,
    "text": "These findings suggest that tonic occupation of dopamine receptors impairs learning by competition with phasic dopamine signals .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "dopamine"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1246,
    "text": "Thus , phasic signaling seems to be the critical mechanism by which dopamine enhances associative learning in healthy subjects and stroke patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "dopamine"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1247,
    "text": "Minocycline - induced vasculitis fulfilling the criteria of polyarteritis nodosa .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "polyarteritis nodosa"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Minocycline"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1248,
    "text": "A 47 - year - old man who had been taking minocycline for palmoplantar pustulosis developed fever , myalgias , polyneuropathy , and testicular pain , with elevated C - reactive protein ( CRP ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "palmoplantar pustulosis"
      ],
      [
        "T1",
        "Disease",
        23,
        25,
        "testicular pain"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "minocycline"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "fever"
      ],
      [
        "T4",
        "Disease",
        18,
        19,
        "myalgias"
      ],
      [
        "T5",
        "Disease",
        20,
        21,
        "polyneuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1249,
    "text": "Neither myeloperoxidase - nor proteinase - 3 - antineutrophil cytoplasmic antibody was positive .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1250,
    "text": "These manifestations met the American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "polyarteritis nodosa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1251,
    "text": "Stopping minocycline led to amelioration of symptoms and normalization of CRP level .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "minocycline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1252,
    "text": "To our knowledge , this is the second case of minocycline - induced vasculitis satisfying the criteria .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "minocycline"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1253,
    "text": "Differential diagnosis for drug - induced disease is invaluable even for patients with classical polyarteritis nodosa .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "polyarteritis nodosa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1254,
    "text": "Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "hepatitis B"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "hepatitis B"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1255,
    "text": "BACKGROUND : Combined hepatitis B immune globulin ( HBIg ) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hepatitis B"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "hepatitis B"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "lamivudine"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "HBsAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1256,
    "text": "This study was undertaken to evaluate the outcomes of liver transplantation for patients with hepatitis B virus ( HBV ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "hepatitis B"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1257,
    "text": "METHODS : A retrospective chart analysis and a review of the organ transplant database identified 51 patients ( 43 men and 8 women ) transplanted for benign HBV - related cirrhotic diseases between June 2002 and December 2004 who had survived more than 3 months .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        32,
        "cirrhotic diseases"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1258,
    "text": "HBIg was administered intravenously during the first week and intramuscularly thereafter .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1259,
    "text": "RESULTS : At a median follow - up of 14 . 1 months , the overall recurrence rate in the 51 patients was 3 . 9 % ( 2 / 51 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1260,
    "text": "The overall patient survival was 88 . 3 % , and 82 . 4 % after 1 and 2 years , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1261,
    "text": "A daily oral dose of 100 mg lamivudine for 2 weeks before transplantation for 10 patients enabled 57 . 1 % ( 4 / 7 ) and 62 . 5 % ( 5 / 8 ) of HBV - DNA and HBeAg positive patients respectively to convert to be negative .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "lamivudine"
      ],
      [
        "T1",
        "Chemical",
        41,
        42,
        "HBeAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1262,
    "text": "Intramuscular HBIg was well tolerated in all patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1263,
    "text": "CONCLUSION : Lamivudine combined with intramuscular HBIg can effectively prevent allograft from the recurrence of HBV after liver transplantation .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1264,
    "text": "Anticonvulsant effect of eslicarbazepine acetate ( BIA 2 - 093 ) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "eslicarbazepine acetate"
      ],
      [
        "T1",
        "Chemical",
        6,
        10,
        "BIA 2 - 093"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "seizures"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "picrotoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1265,
    "text": "Eslicarbazepine acetate ( BIA 2 - 093 , S - ( - ) - 10 - acetoxy - 10 , 11 - dihydro - 5H - dibenzo / b , f / azepine - 5 - carboxamide ) is a novel antiepileptic drug , now in Phase III clinical trials , designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine ( CBZ ) and oxcarbazepine ( OXC ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Eslicarbazepine acetate"
      ],
      [
        "T1",
        "Chemical",
        3,
        7,
        "BIA 2 - 093"
      ],
      [
        "T2",
        "Chemical",
        8,
        37,
        "S - ( - ) - 10 - acetoxy - 10 , 11 - dihydro - 5H - dibenzo / b , f / azepine - 5 - carboxamide"
      ],
      [
        "T3",
        "Chemical",
        67,
        68,
        "carbamazepine"
      ],
      [
        "T4",
        "Chemical",
        69,
        70,
        "CBZ"
      ],
      [
        "T5",
        "Chemical",
        72,
        73,
        "oxcarbazepine"
      ],
      [
        "T6",
        "Chemical",
        74,
        75,
        "OXC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1266,
    "text": "We have studied the effects of oral treatment with eslicarbazepine acetate on a whole - animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or seizure patterns .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "eslicarbazepine acetate"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "seizures"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1267,
    "text": "In the animals treated with threshold doses of picrotoxin , the average number of seizures was 2 . 3 + / - 1 . 2 , and average seizure duration was 39 . 5 + / - 8 . 4s .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "picrotoxin"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "seizures"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1268,
    "text": "Pre - treatment with a dose of 30 mg / kg 2h before picrotoxin microperfusion prevented seizures in the 75 % of the rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "picrotoxin"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1269,
    "text": "Lower doses ( 3 and 10mg / kg ) did not suppress seizures , however , after administration of 10mg / kg , significant reductions in seizures duration ( 24 . 3 + / - 6 . 8s ) and seizure number ( 1 . 6 + / - 0 . 34 ) were found .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "seizures"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "seizures"
      ],
      [
        "T2",
        "Disease",
        40,
        41,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1270,
    "text": "No adverse effects of eslicarbazepine acetate were observed in the behavioral / EEG patterns studied , including sleep / wakefulness cycle , at the doses studied .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "eslicarbazepine acetate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1271,
    "text": "Acute renal failure associated with prolonged intake of slimming pills containing anthraquinones .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "anthraquinones"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1272,
    "text": "Chinese herbal medicine preparations are widely available and often regarded by the public as natural and safe remedies for a variety of medical conditions .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Chinese herbal"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1273,
    "text": "Nephropathy caused by Chinese herbs has previously been reported , usually involving the use of aristolochic acids .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "Chinese herbs"
      ],
      [
        "T1",
        "Chemical",
        15,
        17,
        "aristolochic acids"
      ],
      [
        "T2",
        "Disease",
        0,
        1,
        "Nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1274,
    "text": "We report a 23 - year - old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives , extracted from Rhizoma Rhei ( rhubarb ) .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        20,
        22,
        "Chinese herbal"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "anthraquinone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1275,
    "text": "The renal injury was probably aggravated by the concomitant intake of a non - steroidal anti - inflammatory drug , diclofenac .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "renal injury"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "diclofenac"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1276,
    "text": "Renal pathology was that of hypocellular interstitial fibrosis .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1277,
    "text": "Spontaneous renal recovery occurred upon cessation of the slimming pills , but mild interstitial fibrosis and tubular atrophy was still evident histologically 4 months later .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "fibrosis"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "atrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1278,
    "text": "Although a causal relationship between the use of an anthraquinone - containing herbal agent and renal injury remains to be proven , phytotherapy - associated interstitial nephropathy should be considered in patients who present with unexplained renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "renal injury"
      ],
      [
        "T1",
        "Disease",
        36,
        38,
        "renal failure"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "anthraquinone"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1279,
    "text": "Chloroacetaldehyde as a sulfhydryl reagent : the role of critical thiol groups in ifosfamide nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Chloroacetaldehyde"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "sulfhydryl"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "thiol"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "ifosfamide"
      ],
      [
        "T4",
        "Disease",
        14,
        15,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1280,
    "text": "Chloroacetaldehyde ( CAA ) is a metabolite of the alkylating agent ifosfamide ( IFO ) and putatively responsible for renal damage following anti - tumor therapy with IFO .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "renal damage"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Chloroacetaldehyde"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "CAA"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "ifosfamide"
      ],
      [
        "T4",
        "Chemical",
        13,
        14,
        "IFO"
      ],
      [
        "T5",
        "Disease",
        24,
        25,
        "tumor"
      ],
      [
        "T6",
        "Chemical",
        27,
        28,
        "IFO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1281,
    "text": "Depletion of sulfhydryl ( SH ) groups has been reported from cell culture , animal and clinical studies .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "sulfhydryl"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "SH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1282,
    "text": "In this work the effect of CAA on human proximal tubule cells in primary culture ( hRPTEC ) was investigated .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "CAA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1283,
    "text": "Toxicity of CAA was determined by protein content , cell number , LDH release , trypan blue exclusion assay and caspase - 3 activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "trypan blue"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Toxicity"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "CAA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1284,
    "text": "Free thiols were measured by the method of Ellman .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "thiols"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1285,
    "text": "CAA reduced hRPTEC cell number and protein , induced a loss in free intracellular thiols and an increase in necrosis markers .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "CAA"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "thiols"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1286,
    "text": "CAA but not acrolein inhibited the cysteine proteases caspase - 3 , caspase - 8 and cathepsin B .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "CAA"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "acrolein"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "cysteine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1287,
    "text": "Caspase activation by cisplatin was inhibited by CAA .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cisplatin"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "CAA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1288,
    "text": "In cells stained with fluorescent dyes targeting lysosomes , CAA induced an increase in lysosomal size and lysosomal leakage .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "CAA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1289,
    "text": "The effects of CAA on cysteine protease activities and thiols could be reproduced in cell lysate .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "CAA"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "cysteine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "thiols"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1290,
    "text": "Acidification , which slowed the reaction of CAA with thiol donors , could also attenuate effects of CAA on necrosis markers , thiol depletion and cysteine protease inhibition in living cells .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "CAA"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "thiol"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "CAA"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "necrosis"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "thiol"
      ],
      [
        "T5",
        "Chemical",
        25,
        26,
        "cysteine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1291,
    "text": "Thus , CAA directly reacts with cellular protein and non - protein thiols , mediating its toxicity on hRPTEC .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "CAA"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "thiols"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1292,
    "text": "This effect can be reduced by acidification .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1293,
    "text": "Therefore , urinary acidification could be an option to prevent IFO nephropathy in patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "IFO"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1294,
    "text": "Stereological methods reveal the robust size and stability of ectopic hilar granule cells after pilocarpine - induced status epilepticus in the adult rat .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "status epilepticus"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1295,
    "text": "Following status epilepticus in the rat , dentate granule cell neurogenesis increases greatly , and many of the new neurons appear to develop ectopically , in the hilar region of the hippocampal formation .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "status epilepticus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1296,
    "text": "It has been suggested that the ectopic hilar granule cells could contribute to the spontaneous seizures that ultimately develop after status epilepticus .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1297,
    "text": "However , the population has never been quantified , so it is unclear whether it is substantial enough to have a strong influence on epileptogenesis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1298,
    "text": "To quantify this population , the total number of ectopic hilar granule cells was estimated using unbiased stereology at different times after pilocarpine - induced status epilepticus .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "status epilepticus"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1299,
    "text": "The number of hilar neurons immunoreactive for Prox - 1 , a granule - cell - specific marker , was estimated using the optical fractionator method .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1300,
    "text": "The results indicate that the size of the hilar ectopic granule cell population after status epilepticus is substantial , and stable over time .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "status epilepticus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1301,
    "text": "Interestingly , the size of the population appears to be correlated with the frequency of behavioral seizures , because animals with more ectopic granule cells in the hilus have more frequent behavioral seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "seizures"
      ],
      [
        "T1",
        "Disease",
        32,
        33,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1302,
    "text": "The hilar ectopic granule cell population does not appear to vary systematically across the septotemporal axis , although it is associated with an increase in volume of the hilus .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1303,
    "text": "The results provide new insight into the potential role of ectopic hilar granule cells in the pilocarpine model of temporal lobe epilepsy .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "temporal lobe epilepsy"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1304,
    "text": "A prospective , open - label trial of galantamine in autistic disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "autistic disorder"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "galantamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1305,
    "text": "OBJECTIVE : Post - mortem studies have reported abnormalities of the cholinergic system in autism .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "autism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1306,
    "text": "The purpose of this study was to assess the use of galantamine , an acetylcholinesterase inhibitor and nicotinic receptor modulator , in the treatment of interfering behaviors in children with autism .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "galantamine"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "autism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1307,
    "text": "METHODS : Thirteen medication - free children with autism ( mean age , 8 . 8 + / - 3 . 5 years ) participated in a 12 - week , open - label trial of galantamine .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "autism"
      ],
      [
        "T1",
        "Chemical",
        36,
        37,
        "galantamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1308,
    "text": "Patients were rated monthly by parents on the Aberrant Behavior Checklist ( ABC ) and the Conners ' Parent Rating Scale - Revised , and by a physician using the Children ' s Psychiatric Rating Scale and the Clinical Global Impressions scale .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1309,
    "text": "RESULTS : Patients showed a significant reduction in parent - rated irritability and social withdrawal on the ABC as well as significant improvements in emotional lability and inattention on the Conners ' Parent Rating Scale - - Revised .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "irritability"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1310,
    "text": "Similarly , clinician ratings showed reductions in the anger subscale of the Children ' s Psychiatric Rating Scale .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1311,
    "text": "Eight of 13 participants were rated as responders on the basis of their improvement scores on the Clinical Global Impressions scale .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1312,
    "text": "Overall , galantamine was well - tolerated , with no significant adverse effects apart from headaches in one patient .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "galantamine"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "headaches"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1313,
    "text": "CONCLUSION : In this open trial , galantamine was well - tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism , particularly aggression , behavioral dyscontrol , and inattention .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        33,
        "behavioral dyscontrol"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "galantamine"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "autism"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "aggression"
      ],
      [
        "T4",
        "Disease",
        35,
        36,
        "inattention"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1314,
    "text": "Further controlled trials are warranted .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1315,
    "text": "Randomized comparison of olanzapine versus risperidone for the treatment of first - episode schizophrenia : 4 - month outcomes .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "olanzapine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "risperidone"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1316,
    "text": "OBJECTIVE : The authors compared 4 - month treatment outcomes for olanzapine versus risperidone in patients with first - episode schizophrenia spectrum disorders .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "olanzapine"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "risperidone"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1317,
    "text": "METHOD : One hundred twelve subjects ( 70 % male ; mean age = 23 . 3 years [ SD = 5 . 1 ] ) with first - episode schizophrenia ( 75 % ) , schizophreniform disorder ( 17 % ) , or schizoaffective disorder ( 8 % ) were randomly assigned to treatment with olanzapine ( 2 . 5 - 20 mg / day ) or risperidone ( 1 - 6 mg / day ) .",
    "labels": [
      [
        "T0",
        "Disease",
        36,
        38,
        "schizophreniform disorder"
      ],
      [
        "T1",
        "Disease",
        44,
        46,
        "schizoaffective disorder"
      ],
      [
        "T2",
        "Disease",
        30,
        31,
        "schizophrenia"
      ],
      [
        "T3",
        "Chemical",
        56,
        57,
        "olanzapine"
      ],
      [
        "T4",
        "Chemical",
        68,
        69,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1318,
    "text": "RESULTS : Response rates did not significantly differ between olanzapine ( 43 . 7 % , 95 % CI = 28 . 8 % - 58 . 6 % ) and risperidone ( 54 . 3 % , 95 % CI = 39 . 9 % - 68 . 7 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "olanzapine"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1319,
    "text": "Among those responding to treatment , more subjects in the olanzapine group ( 40 . 9 % , 95 % CI = 16 . 8 % - 65 . 0 % ) than in the risperidone group ( 18 . 9 % , 95 % CI = 0 % - 39 . 2 % ) had subsequent ratings not meeting response criteria .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "olanzapine"
      ],
      [
        "T1",
        "Chemical",
        35,
        36,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1320,
    "text": "Negative symptom outcomes and measures of parkinsonism and akathisia did not differ between medications .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "parkinsonism"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "akathisia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1321,
    "text": "Extrapyramidal symptom severity scores were 1 . 4 ( 95 % CI = 1 . 2 - 1 . 6 ) with risperidone and 1 . 2 ( 95 % CI = 1 . 0 - 1 . 4 ) with olanzapine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Extrapyramidal symptom"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "risperidone"
      ],
      [
        "T2",
        "Chemical",
        41,
        42,
        "olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1322,
    "text": "Significantly more weight gain occurred with olanzapine than with risperidone : the increase in weight at 4 months relative to baseline weight was 17 . 3 % ( 95 % CI = 14 . 2 % - 20 . 5 % ) with olanzapine and 11 . 3 % ( 95 % CI = 8 . 4 % - 14 . 3 % ) with risperidone .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "weight gain"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "olanzapine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "risperidone"
      ],
      [
        "T3",
        "Chemical",
        43,
        44,
        "olanzapine"
      ],
      [
        "T4",
        "Chemical",
        65,
        66,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1323,
    "text": "Body mass index at baseline and at 4 months was 24 . 3 ( 95 % CI = 22 . 8 - 25 . 7 ) versus 28 . 2 ( 95 % CI = 26 . 7 - 29 . 7 ) with olanzapine and 23 . 9 ( 95 % CI = 22 . 5 - 25 . 3 ) versus 26 . 7 ( 95 % CI = 25 . 2 - 28 . 2 ) with risperidone .",
    "labels": [
      [
        "T0",
        "Chemical",
        44,
        45,
        "olanzapine"
      ],
      [
        "T1",
        "Chemical",
        80,
        81,
        "risperidone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1324,
    "text": "CONCLUSIONS : Clinical outcomes with risperidone were equal to those with olanzapine , and response may be more stable .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "risperidone"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1325,
    "text": "Olanzapine may have an advantage for motor side effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1326,
    "text": "Both medications caused substantial rapid weight gain , but weight gain was greater with olanzapine .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "weight gain"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "weight gain"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "olanzapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1327,
    "text": "Early paracentral visual field loss in patients taking hydroxychloroquine .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "visual field loss"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "hydroxychloroquine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1328,
    "text": "OBJECTIVE : To review the natural history and ocular and systemic adverse effects of patients taking hydroxychloroquine sulfate who attended an ophthalmic screening program .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        18,
        "hydroxychloroquine sulfate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1329,
    "text": "DESIGN : Retrospective study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1330,
    "text": "RESULTS : Records of 262 patients who were taking hydroxychloroquine and screened in the Department of Ophthalmology were reviewed .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "hydroxychloroquine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1331,
    "text": "Of the 262 patients , 14 ( 18 % ) of 76 who had stopped treatment at the time of the study experienced documented adverse effects .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1332,
    "text": "Systemic adverse effects occurred in 8 patients ( 10 . 5 % ) and ocular adverse effects , in 5 ( 6 . 5 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1333,
    "text": "Thirty - five patients ( 13 . 4 % ) had visual field abnormalities , which were attributed to hydroxychloroquine treatment in 4 patients ( 1 . 5 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "visual field abnormalities"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "hydroxychloroquine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1334,
    "text": "Three of the 4 patients were taking less than 6 . 5 mg / kg per day and all patients had normal renal and liver function test results .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1335,
    "text": "CONCLUSIONS : The current study used a protocol of visual acuity and color vision assessment , funduscopy , and Humphrey 10 - 2 visual field testing and shows that visual field defects appeared before any corresponding changes in any other tested clinical parameters ; the defects were reproducible and the test parameters were reliable .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        32,
        "visual field defects"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1336,
    "text": "Patients taking hydroxychloroquine can demonstrate a toxic reaction in the retina despite the absence of known risk factors .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "hydroxychloroquine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1337,
    "text": "Screening , including Humphrey 10 - 2 visual field assessment , is recommended 2 years after the initial baseline and yearly thereafter .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1338,
    "text": "Peri - operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "atrioventricular block"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "epirubicin"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1339,
    "text": "A 47 - year - old woman presented for mastectomy and immediate latissimus dorsi flap reconstruction having been diagnosed with carcinoma of the breast 6 months previously .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        24,
        "carcinoma of the breast"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1340,
    "text": "In the preceding months she had received neo - adjuvant chemotherapy with epirubicin , paclitaxel ( Taxol ) and cyclophosphamide .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "epirubicin"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "paclitaxel"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "Taxol"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1341,
    "text": "This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1342,
    "text": "She was found to be bradycardic at pre - operative assessment but had no cardiac symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "bradycardic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1343,
    "text": "Second degree Mobitz type II atrioventricular block was diagnosed on electrocardiogram , and temporary transvenous ventricular pacing instituted in the peri - operative period .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "atrioventricular block"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1344,
    "text": "We discuss how evidence - based guidelines would not have been helpful in this case , and how chemotherapy can exhibit substantial cardiotoxicity that may develop over many years .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        23,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1345,
    "text": "We suggest that patients who have received chemotherapy at any time should have a pre - operative electrocardiogram even if they are asymptomatic .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1346,
    "text": "Risks and benefits of COX - 2 inhibitors vs non - selective NSAIDs : does their cardiovascular risk exceed their gastrointestinal benefit ?",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        8,
        "COX - 2 inhibitors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1347,
    "text": "A retrospective cohort study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1348,
    "text": "OBJECTIVES : The risk of acute myocardial infarction ( AMI ) with COX - 2 inhibitors may offset their gastrointestinal ( GI ) benefit compared with non - selective ( NS ) non - steroidal anti - inflammatory drugs ( NSAIDs ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "acute myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        12,
        16,
        "COX - 2 inhibitors"
      ],
      [
        "T2",
        "Chemical",
        32,
        39,
        "non - steroidal anti - inflammatory drugs"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "AMI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1349,
    "text": "We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX - 2 inhibitors , NS - NSAIDs and acetaminophen .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "GI bleeding"
      ],
      [
        "T1",
        "Chemical",
        17,
        21,
        "COX - 2 inhibitors"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "AMI"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1350,
    "text": "METHODS : We conducted a retrospective cohort study using administrative data of patients > or = 65 years of age who filled a prescription for NSAID or acetaminophen during 1999 - 2002 .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        28,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1351,
    "text": "Outcomes were compared using Cox regression models with time - dependent exposures .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1352,
    "text": "RESULTS : Person - years of exposure among non - users of aspirin were : 75 , 761 to acetaminophen , 42 , 671 to rofecoxib 65 , 860 to celecoxib , and 37 , 495 to NS - NSAIDs .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "aspirin"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "acetaminophen"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "rofecoxib"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "celecoxib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1353,
    "text": "Among users of aspirin , they were : 14 , 671 to rofecoxib , 22 , 875 to celecoxib , 9 , 832 to NS - NSAIDs and 38 , 048 to acetaminophen .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "aspirin"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "rofecoxib"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "celecoxib"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1354,
    "text": "Among non - users of aspirin , the adjusted hazard ratios ( 95 % confidence interval ) of hospitalization for AMI / GI vs the acetaminophen ( with no aspirin ) group were : rofecoxib 1 . 27 ( 1 . 13 , 1 . 42 ) , celecoxib 0 . 93 ( 0 . 83 , 1 . 03 ) , naproxen 1 . 59 ( 1 . 31 , 1 . 93 ) , diclofenac 1 . 17 ( 0 . 99 , 1 . 38 ) and ibuprofen 1 . 05 ( 0 . 74 , 1 . 51 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "aspirin"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "AMI"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "acetaminophen"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "aspirin"
      ],
      [
        "T4",
        "Chemical",
        34,
        35,
        "rofecoxib"
      ],
      [
        "T5",
        "Chemical",
        48,
        49,
        "celecoxib"
      ],
      [
        "T6",
        "Chemical",
        62,
        63,
        "naproxen"
      ],
      [
        "T7",
        "Chemical",
        76,
        77,
        "diclofenac"
      ],
      [
        "T8",
        "Chemical",
        90,
        91,
        "ibuprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1355,
    "text": "Among users of aspirin , they were : rofecoxib 1 . 73 ( 1 . 52 , 1 . 98 ) , celecoxib 1 . 34 ( 1 . 19 , 1 . 52 ) , ibuprofen 1 . 51 ( 0 . 95 , 2 . 41 ) , diclofenac 1 . 69 ( 1 . 35 , 2 . 10 ) , naproxen 1 . 35 ( 0 . 97 , 1 . 88 ) and acetaminophen 1 . 29 ( 1 . 17 , 1 . 42 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "aspirin"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "rofecoxib"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "celecoxib"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "ibuprofen"
      ],
      [
        "T4",
        "Chemical",
        50,
        51,
        "diclofenac"
      ],
      [
        "T5",
        "Chemical",
        64,
        65,
        "naproxen"
      ],
      [
        "T6",
        "Chemical",
        78,
        79,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1356,
    "text": "CONCLUSION : Among non - users of aspirin , naproxen seemed to carry the highest risk for AMI / GI bleeding .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "GI bleeding"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "aspirin"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "naproxen"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "AMI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1357,
    "text": "The AMI / GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS - NSAIDs .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "AMI"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "celecoxib"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "acetaminophen"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "rofecoxib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1358,
    "text": "Among users of aspirin , both celecoxib and naproxen seemed to be the least toxic .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "aspirin"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "celecoxib"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "naproxen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1359,
    "text": "Quinine - induced arrhythmia in a patient with severe malaria .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "severe malaria"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Quinine"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1360,
    "text": "It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( premature ventricular contraction ) while getting quinine infusion was reported .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "severe malaria"
      ],
      [
        "T1",
        "Disease",
        19,
        22,
        "premature ventricular contraction"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "jaundice"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "arrhythmia"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "quinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1361,
    "text": "A man , 25 years old , was admitted to hospital with high fever , chill , vomiting , jaundice .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "fever"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "chill"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "vomiting"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "jaundice"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1362,
    "text": "The patient was fully conscious , blood pressure 120 / 80 mmHg , pulse rate 100 x / minute , regular .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1363,
    "text": "On admission , laboratory examination showed Plasmodium falciparum ( + + + + ) , total bilirubin 8 . 25 mg / dL , conjugated bilirubin 4 . 36 mg / dL , unconjugated bilirubin 3 . 89 mg / dL , potassium 3 . 52 meq / L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5 % 500 mg / 8 hour .",
    "labels": [
      [
        "T0",
        "Disease",
        53,
        55,
        "severe malaria"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "bilirubin"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "bilirubin"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "bilirubin"
      ],
      [
        "T4",
        "Chemical",
        42,
        43,
        "potassium"
      ],
      [
        "T5",
        "Disease",
        56,
        57,
        "jaundice"
      ],
      [
        "T6",
        "Chemical",
        59,
        60,
        "quinine"
      ],
      [
        "T7",
        "Chemical",
        62,
        63,
        "dextrose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1364,
    "text": "On the second day the patient had vomitus , diarrhea , tinnitus , loss of hearing .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "loss of hearing"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "vomitus"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "diarrhea"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "tinnitus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1365,
    "text": "After 30 hours of quinine infusion the patient felt palpitation and electrocardiography ( ECG ) recording showed premature ventricular contraction ( PVC ) > 5 x / minute , trigemini , constant type - - sinoatrial block , positive U wave .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "premature ventricular contraction"
      ],
      [
        "T1",
        "Disease",
        35,
        37,
        "sinoatrial block"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "quinine"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "palpitation"
      ],
      [
        "T4",
        "Disease",
        21,
        22,
        "PVC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1366,
    "text": "He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5 % / 24 hour and potassium aspartate tablet .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        23,
        "potassium aspartate"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "dextrose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1367,
    "text": "Quinine infusion was discontinued and changed with sulfate quinine tablets .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Quinine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "quinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1368,
    "text": "Three hours later the patient felt better , the frequency of PVC reduced to 4 - 5 x / minute and on the third day ECG was normal , potassium level was 3 . 34 meq / L .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "PVC"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1369,
    "text": "He was discharged on 7th day in good condition .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1370,
    "text": "Quinine , like quinidine , is a chincona alkaloid that has anti - arrhythmic property , although it also pro - arrhythmic that can cause various arrhythmias , including severe arrhythmia such as multiple PVC .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Quinine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "quinidine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "arrhythmic"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "arrhythmic"
      ],
      [
        "T4",
        "Disease",
        26,
        27,
        "arrhythmias"
      ],
      [
        "T5",
        "Disease",
        30,
        31,
        "arrhythmia"
      ],
      [
        "T6",
        "Disease",
        34,
        35,
        "PVC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1371,
    "text": "Administration of parenteral quinine must be done carefully and with good observation because of its pro - arrhythmic effect , especially in older patients who have heart diseases or patients with electrolyte disorder ( hypokalemia ) which frequently occurs due to vomiting and or diarrhea in malaria cases .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "heart diseases"
      ],
      [
        "T1",
        "Disease",
        31,
        33,
        "electrolyte disorder"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "quinine"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "arrhythmic"
      ],
      [
        "T4",
        "Disease",
        34,
        35,
        "hypokalemia"
      ],
      [
        "T5",
        "Disease",
        41,
        42,
        "vomiting"
      ],
      [
        "T6",
        "Disease",
        44,
        45,
        "diarrhea"
      ],
      [
        "T7",
        "Disease",
        46,
        47,
        "malaria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1372,
    "text": "Penicillamine - related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation , anxiety and SPECT abnormalities .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "lichenoid dermatitis"
      ],
      [
        "T1",
        "Chemical",
        8,
        10,
        "zinc acetate"
      ],
      [
        "T2",
        "Disease",
        12,
        14,
        "Wilson disease"
      ],
      [
        "T3",
        "Chemical",
        0,
        1,
        "Penicillamine"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1373,
    "text": "Wilson ' s disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic , neurologic and psychiatric disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Wilson ' s disease"
      ],
      [
        "T1",
        "Disease",
        24,
        30,
        "hepatic , neurologic and psychiatric disorders"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "copper"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "copper"
      ],
      [
        "T4",
        "Disease",
        18,
        19,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1374,
    "text": "We report a case of Wilson ' s disease with chronic liver disease ; moreover , in our patient , presenting also with high levels of state anxiety without depression , 99mTc - ECD - SPECT showed cortical hypoperfusion in frontal lobes , more marked on the left frontal lobe .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "Wilson ' s disease"
      ],
      [
        "T1",
        "Disease",
        10,
        13,
        "chronic liver disease"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "anxiety"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1375,
    "text": "During the follow - up of our patient , penicillamine was interrupted after the appearance of a lichenoid dermatitis , and zinc acetate permitted to continue the successful treatment of the patient without side - effects .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "lichenoid dermatitis"
      ],
      [
        "T1",
        "Chemical",
        21,
        23,
        "zinc acetate"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "penicillamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1376,
    "text": "In our case the therapy with zinc acetate represented an effective treatment for a Wilson ' s disease patient in which penicillamine - related side effects appeared .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "zinc acetate"
      ],
      [
        "T1",
        "Disease",
        14,
        18,
        "Wilson ' s disease"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "penicillamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1377,
    "text": "The safety of the zinc acetate allowed us to avoid other potentially toxic chelating drugs ; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of Wilson ' s disease .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "zinc acetate"
      ],
      [
        "T1",
        "Disease",
        35,
        39,
        "Wilson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1378,
    "text": "Since most of Wilson ' s disease penicillamine - treated patients do not seem to develop this skin lesion , it could be conceivable that a specific genetic factor is involved in drug response .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "Wilson ' s disease"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "skin lesion"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "penicillamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1379,
    "text": "Further studies are needed for a better clarification of Wilson ' s disease therapy , and in particular to differentiate specific therapies for different Wilson ' s disease phenotypes .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "Wilson ' s disease"
      ],
      [
        "T1",
        "Disease",
        24,
        28,
        "Wilson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1380,
    "text": "A dramatic drop in blood pressure following prehospital GTN administration .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        6,
        "drop in blood pressure"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1381,
    "text": "A male in his sixties with no history of cardiac chest pain awoke with chest pain following an afternoon sleep .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "chest pain"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "chest pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1382,
    "text": "The patient did not self medicate .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1383,
    "text": "The patient ' s observations were within normal limits , he was administered oxygen via a face mask and glyceryl trinitrate ( GTN ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        21,
        "glyceryl trinitrate"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "oxygen"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1384,
    "text": "Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate , this was rectified by atropine sulphate and a fluid challenge .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        14,
        "drop in blood pressure"
      ],
      [
        "T1",
        "Chemical",
        22,
        24,
        "atropine sulphate"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "GTN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1385,
    "text": "There was no further deterioration in the patient ' s condition during transport to hospital .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1386,
    "text": "There are very few documented case like this in the prehospital scientific literature .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1387,
    "text": "The cause appears to be the Bezold - Jarish reflex , stimulation of the ventricular walls which in turn decreases sympathetic outflow from the vasomotor centre .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1388,
    "text": "Prehospital care providers who are managing any patient with a syncopal episode that fails to recover within a reasonable time frame should consider the Bezold - Jarisch reflex as the cause and manage the patient accordingly .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "syncopal episode"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1389,
    "text": "Chronic lesion of rostral ventrolateral medulla in spontaneously hypertensive rats .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1390,
    "text": "We studied the effects of chronic selective neuronal lesion of rostral ventrolateral medulla on mean arterial pressure , heart rate , and neurogenic tone in conscious , unrestrained spontaneously hypertensive rats .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        30,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1391,
    "text": "The lesions were placed via bilateral microinjections of 30 nmol / 200 nl N - methyl - D - aspartic acid .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        21,
        "N - methyl - D - aspartic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1392,
    "text": "The restimulation of this area with N - methyl - D - aspartic acid 15 days postlesion failed to produce a pressor response .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        14,
        "N - methyl - D - aspartic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1393,
    "text": "One day postlesion , the resting mean arterial pressure was significantly decreased in lesioned rats when compared with sham rats ( 100 + / - 7 versus 173 + / - 4 mm Hg , p less than 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1394,
    "text": "Fifteen days later , the lesioned group still showed values significantly lower than the sham group ( 150 + / - 6 versus 167 + / - 5 mm Hg , p less than 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1395,
    "text": "No significant heart rate differences were observed between the sham and lesioned groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1396,
    "text": "The ganglionic blocker trimethaphan ( 5 mg / kg i . v . ) caused similar reductions in mean arterial pressure in both lesioned and sham groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "trimethaphan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1397,
    "text": "The trimethaphan - induced hypotension was accompanied by a significant bradycardia in lesioned rats ( - 32 + / - 13 beats per minute ) but a tachycardia in sham rats ( + 33 + / - 12 beats per minute ) 1 day postlesion .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "trimethaphan"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hypotension"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "bradycardia"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "tachycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1398,
    "text": "Therefore , rostral ventrolateral medulla neurons appear to play a significant role in maintaining hypertension in conscious spontaneously hypertensive rats .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "hypertension"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1399,
    "text": "Spinal or suprabulbar structures could be responsible for the gradual recovery of the hypertension in the lesioned rats .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1400,
    "text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG - asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Acute encephalopathy"
      ],
      [
        "T1",
        "Disease",
        3,
        5,
        "cerebral vasospasm"
      ],
      [
        "T2",
        "Chemical",
        9,
        12,
        "PEG - asparaginase"
      ],
      [
        "T3",
        "Disease",
        19,
        22,
        "acute lymphoblastic leukemia"
      ],
      [
        "T4",
        "Chemical",
        14,
        15,
        "cytarabine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1401,
    "text": "A 7 - year - old girl with an unusual reaction to induction chemotherapy for precursor B - cell acute lymphoblastic leukemia ( ALL ) is described .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "acute lymphoblastic leukemia"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "ALL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1402,
    "text": "The patient developed acute encephalopathy evidenced by behavioral changes , aphasia , incontinence , visual hallucinations , and right - sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "acute encephalopathy"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "visual hallucinations"
      ],
      [
        "T2",
        "Disease",
        24,
        26,
        "cerebral vasospasm"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "aphasia"
      ],
      [
        "T4",
        "Disease",
        12,
        13,
        "incontinence"
      ],
      [
        "T5",
        "Disease",
        21,
        22,
        "weakness"
      ],
      [
        "T6",
        "Chemical",
        35,
        36,
        "cytarabine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1403,
    "text": "Vincristine , dexamethasone , and polyethylene glycol - asparaginase were also administered before the episode as part of induction therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        9,
        "polyethylene glycol - asparaginase"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Vincristine"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1404,
    "text": "Neurologic status returned to baseline within 10 days of the acute event , and magnetic resonance angiography findings returned to normal 4 months later .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1405,
    "text": "Comparison of valsartan / hydrochlorothiazide combination therapy at doses up to 320 / 25 mg versus monotherapy : a double - blind , placebo - controlled study followed by long - term combination therapy in hypertensive adults .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "valsartan"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "hydrochlorothiazide"
      ],
      [
        "T2",
        "Disease",
        35,
        36,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1406,
    "text": "BACKGROUND : One third of patients treated for hypertension attain adequate blood pressure ( BP ) control , and multidrug regimens are often required .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1407,
    "text": "Given the lifelong nature of hypertension , there is a need to evaluate the long - term efficacy and tolerability of higher doses of combination anti - hypertensive therapies .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hypertension"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1408,
    "text": "OBJECTIVE : This study investigated the efficacy and tolerability of valsartan ( VAL ) or hydrochlorothiazide ( HCTZ ) - monotherapy and higher - dose combinations in patients with essential hypertension .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        31,
        "essential hypertension"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "valsartan"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "VAL"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "hydrochlorothiazide"
      ],
      [
        "T4",
        "Chemical",
        17,
        18,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1409,
    "text": "METHODS : The first part of this study was an 8 - week , multicenter , randomized , double - blind , placebo controlled , parallel - group trial .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1410,
    "text": "Patients with essential hypertension ( mean sitting diastolic BP [ MSDBP ] , > or = 95 mm Hg and < 110 mm Hg ) were randomized to 1 of 8 treatment groups : VAL 160 or 320 mg ; HCTZ 12 . 5 or 25 mg ; VAL / HCTZ 160 / 12 . 5 , 320 / 12 . 5 , or 320 / 25 mg ; or placebo .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "essential hypertension"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "VAL"
      ],
      [
        "T2",
        "Chemical",
        40,
        41,
        "HCTZ"
      ],
      [
        "T3",
        "Chemical",
        48,
        49,
        "VAL"
      ],
      [
        "T4",
        "Chemical",
        50,
        51,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1411,
    "text": "Mean changes in MSDBP and mean sitting systolic BP ( MSSBP ) were analyzed at the 8 - week core study end point .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1412,
    "text": "VAL / HCTZ 320 / 12 . 5 and 320 / 25 mg were further investigated in a 54 - week , open - label extension .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "VAL"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1413,
    "text": "Response was defined as MSDBP < 90 mm Hg or a > or = 10 mm Hg decrease compared to baseline .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1414,
    "text": "Control was defined as MSDBP < 90 mm Hg compared with baseline .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1415,
    "text": "Tolerability was assessed by monitoring adverse events at randomization and all subsequent study visits and regular evaluation of hematology and blood chemistry .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1416,
    "text": "RESULTS : A total of 1346 patients were randomized into the 8 - week core study ( 734 men , 612 women ; 924 white , 291 black , 23 Asian , 108 other ; mean age , 52 . 7 years ; mean weight , 92 . 6 kg ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1417,
    "text": "All active treatments were associated with significantly reduced MSSBP and MSDBP during the core 8 - week study , with each monotherapy significantly contributing to the overall effect of combination therapy ( VAL and HCTZ , P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        33,
        "VAL"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1418,
    "text": "Each combination was associated with significantly greater reductions in MSSBP and MSDBP compared with the monotherapies and placebo ( all , P < 0 . 001 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1419,
    "text": "The mean reduction in MSSBP / MSDBP with VAL / HCTZ 320 / 25 mg was 24 . 7 / 16 . 6 mm Hg , compared with 5 . 9 / 7 . 0 mm Hg with placebo .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "VAL"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1420,
    "text": "The reduction in MSSBP was significantly greater with VAL / HCTZ 320 / 25 mg compared with VAL / HCTZ 160 / 12 . 5 mg ( P < 0 . 002 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "VAL"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "HCTZ"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "VAL"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1421,
    "text": "Rates of response and BP control were significantly higher in the groups that received combination treatment compared with those that received monotherapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1422,
    "text": "The incidence of hypokalemia was lower with VAL / HCTZ combinations ( 1 . 8 % - 6 . 1 % ) than with HCTZ monotherapies ( 7 . 1 % - 13 . 3 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypokalemia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "VAL"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "HCTZ"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1423,
    "text": "The majority of adverse events in the core study were of mild to moderate severity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1424,
    "text": "The efficacy and tolerability of VAL / HCTZ combinations were maintained during the extension ( 797 patients ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "VAL"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1425,
    "text": "CONCLUSIONS : In this study population , combination therapies with VAL / HCTZ were associated with significantly greater BP reductions compared with either monotherapy , were well tolerated , and were associated with less hypokalemia than HCTZ alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "VAL"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "HCTZ"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "hypokalemia"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "HCTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1426,
    "text": "Succimer chelation improves learning , attention , and arousal regulation in lead - exposed rats but produces lasting cognitive impairment in the absence of lead exposure .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "cognitive impairment"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Succimer"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "lead"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "lead"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1427,
    "text": "BACKGROUND : There is growing pressure for clinicians to prescribe chelation therapy at only slightly elevated blood lead levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "lead"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1428,
    "text": "However , very few studies have evaluated whether chelation improves cognitive outcomes in Pb - exposed children , or whether these agents have adverse effects that may affect brain development in the absence of Pb exposure .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "Pb"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "Pb"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1429,
    "text": "OBJECTIVES : The present study was designed to answer these questions , using a rodent model of early childhood Pb exposure and treatment with succimer , a widely used chelating agent for the treatment of Pb poisoning .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        37,
        "Pb poisoning"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "Pb"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "succimer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1430,
    "text": "RESULTS : Pb exposure produced lasting impairments in learning , attention , inhibitory control , and arousal regulation , paralleling the areas of dysfunction seen in Pb - exposed children .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        18,
        "impairments in learning , attention , inhibitory control , and arousal regulation"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Pb"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "Pb"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1431,
    "text": "Succimer treatment of the Pb - exposed rats significantly improved learning , attention , and arousal regulation , although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Succimer"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "Pb"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "Pb"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1432,
    "text": "In contrast , succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        20,
        "cognitive and affective dysfunction"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "succimer"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "Pb"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "Pb"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1433,
    "text": "CONCLUSIONS : These are the first data , to our knowledge , to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "cognitive deficits"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "Pb"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1434,
    "text": "These findings suggest that it may be possible to identify a succimer treatment protocol that improves cognitive outcomes in Pb - exposed children .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "succimer"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "Pb"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1435,
    "text": "However , they also suggest that succimer treatment should be strongly discouraged for children who do not have elevated tissue levels of Pb or other heavy metals .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "succimer"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "Pb"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1436,
    "text": "Caffeine challenge test in panic disorder and depression with panic attacks .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "panic disorder"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "panic attacks"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Caffeine"
      ],
      [
        "T3",
        "Disease",
        7,
        8,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1437,
    "text": "Our aim was to observe if patients with panic disorder ( PD ) and patients with major depression with panic attacks ( MDP ) ( Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition criteria ) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "panic disorder"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "major depression"
      ],
      [
        "T2",
        "Disease",
        19,
        21,
        "panic attacks"
      ],
      [
        "T3",
        "Disease",
        30,
        32,
        "Mental Disorders"
      ],
      [
        "T4",
        "Disease",
        46,
        48,
        "panic attacks"
      ],
      [
        "T5",
        "Disease",
        11,
        12,
        "PD"
      ],
      [
        "T6",
        "Disease",
        22,
        23,
        "MDP"
      ],
      [
        "T7",
        "Chemical",
        51,
        52,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1438,
    "text": "We randomly selected 29 patients with PD , 27 with MDP , 25 with major depression without panic attacks ( MD ) , and 28 healthy volunteers .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "major depression"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "panic attacks"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "PD"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "MDP"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "MD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1439,
    "text": "The patients had no psychotropic drug for at least a 4 - week period .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1440,
    "text": "In a randomized double - blind experiment performed in 2 occasions 7 days apart , 480 mg caffeine and a caffeine - free ( placebo ) solution were administered in a coffee form and anxiety scales were applied before and after each test .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "caffeine"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "caffeine"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1441,
    "text": "A total of 58 . 6 % ( n = 17 ) of patients with PD , 44 . 4 % ( n = 12 ) of patients with MDP , 12 . 0 % ( n = 3 ) of patients with MD , and 7 . 1 % ( n = 2 ) of control subjects had a panic attack after the 480 - mg caffeine challenge test ( chi ( 2 ) ( 3 ) = 16 . 22 , P = . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        60,
        62,
        "panic attack"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "PD"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "MDP"
      ],
      [
        "T3",
        "Disease",
        43,
        44,
        "MD"
      ],
      [
        "T4",
        "Chemical",
        67,
        68,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1442,
    "text": "The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "PD"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "MDP"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "caffeine"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "MD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1443,
    "text": "No panic attack was observed after the caffeine - free solution intake .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "panic attack"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1444,
    "text": "The patients with MD had a lower heart rate response to the test than all the other groups ( 2 - way analysis of variance , group by time interaction with Greenhouse - Geisser correction : F ( 3 , 762 ) = 2 . 85 , P = . 026 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "MD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1445,
    "text": "Our data suggest that there is an association between panic attacks , no matter if associated with PD or MDP , and hyperreactivity to an oral caffeine challenge test .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "panic attacks"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "PD"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "MDP"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1446,
    "text": "Mitral annuloplasty as a ventricular restoration method for the failing left ventricle : a pilot study .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "failing left ventricle"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1447,
    "text": "BACKGROUND AND AIM OF THE STUDY : Undersized mitral annuloplasty ( MAP ) is effective in patients with dilated cardiomyopathy and functional mitral regurgitation ( MR ) since , as well as addressing the MR , the MAP may also reshape the dilated left ventricular ( LV ) base .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "dilated cardiomyopathy"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "mitral regurgitation"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "MR"
      ],
      [
        "T3",
        "Disease",
        34,
        35,
        "MR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1448,
    "text": "However , the direct benefits of this possible reshaping on LV function in the absence of underlying MR remain incompletely understood .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "MR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1449,
    "text": "The study aim was to identify these benefits in a canine model of acute heart failure .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1450,
    "text": "METHODS : Six dogs underwent MAP with a prosthetic band on the posterior mitral annulus , using four mattress sutures .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1451,
    "text": "The sutures were passed individually through four tourniquets and exteriorized untied via the left atriotomy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1452,
    "text": "Sonomicrometry crystals were implanted around the mitral annulus and left ventricle to measure geometry and regional function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1453,
    "text": "Acute heart failure was induced by propranolol and volume loading after weaning from cardiopulmonary bypass ; an absence of MR was confirmed by echocardiography .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "heart failure"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "propranolol"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "MR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1454,
    "text": "MAP was accomplished by cinching the tourniquets .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1455,
    "text": "Data were acquired at baseline , after induction of acute heart failure , and after MAP .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1456,
    "text": "RESULTS : MAP decreased mitral annular dimensions in both commissure - commissure and septal - lateral directions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1457,
    "text": "Concomitantly , the diastolic diameter of the LV base and LV sphericity decreased ( i . e . , improved ) from 37 . 4 + / - 9 . 3 to 35 . 9 + / - 10 mm ( p = 0 . 063 ) , and from 67 . 9 + / - 18 . 6 % to 65 . 3 + / - 18 . 9 % ( p = 0 . 016 ) , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1458,
    "text": "Decreases were evident in both LV end - diastolic pressure ( from 17 + / - 7 to 15 + / - 6 mmHg , p = 0 . 0480 and Tau ( from 48 + / - 8 to 45 + / - 8 ms , p < 0 . 01 ) , while fractional shortening at the LV base increased from 7 . 7 + / - 4 . 5 % to 9 . 4 + / - 4 . 5 % ( p = 0 . 045 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1459,
    "text": "After MAP , increases were identified in both cardiac output ( from 1 . 54 + / - 0 . 57 to 1 . 65 + / - 0 . 57 1 / min ) and Emax ( from 1 . 86 + / - 0 . 9 to 2 . 41 + / - 1 . 31 mmHg / ml ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1460,
    "text": "CONCLUSION : The data acquired suggest that isolated MAP may have certain benefits on LV dimension / function in acute heart failure , even in the absence of MR .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "heart failure"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "MR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1461,
    "text": "However , further investigations are warranted in a model of chronic heart failure .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1462,
    "text": "Piperacillin / tazobactam - induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "Piperacillin / tazobactam"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1463,
    "text": "Despite popular use of piperacillin , the dire neurotoxicity associated with piperacillin still goes unrecognized , leading to a delay in appropriate management .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "piperacillin"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "neurotoxicity"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "piperacillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1464,
    "text": "We report a 57 - year - old woman with end - stage renal disease receiving continuous ambulatory peritoneal dialysis ( CAPD ) , who developed slurred speech , tremor , bizarre behavior , progressive mental confusion , and 2 episodes of generalized tonic - clonic seizure ( GTCS ) after 5 doses of piperacillin / tazobactam ( 2 g / 250 mg ) were given for bronchiectasis with secondary infection .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        15,
        "end - stage renal disease"
      ],
      [
        "T1",
        "Disease",
        43,
        47,
        "tonic - clonic seizure"
      ],
      [
        "T2",
        "Chemical",
        54,
        57,
        "piperacillin / tazobactam"
      ],
      [
        "T3",
        "Disease",
        69,
        71,
        "secondary infection"
      ],
      [
        "T4",
        "Disease",
        29,
        30,
        "tremor"
      ],
      [
        "T5",
        "Disease",
        36,
        37,
        "confusion"
      ],
      [
        "T6",
        "Disease",
        48,
        49,
        "GTCS"
      ],
      [
        "T7",
        "Disease",
        67,
        68,
        "bronchiectasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1465,
    "text": "The laboratory data revealed normal plasma electrolyte and ammonia levels but leukocytosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "ammonia"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "leukocytosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1466,
    "text": "Neurologic examinations showed dysarthria and bilateral Babinski sign .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "dysarthria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1467,
    "text": "Computed tomography of brain and electroencephalogram were unremarkable .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1468,
    "text": "Despite the use of antiepileptic agents , another GTCS episode recurred after the sixth dose of piperacillin / tazobactam .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "piperacillin / tazobactam"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "GTCS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1469,
    "text": "Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "organic brain lesions"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1470,
    "text": "Initiation of high - flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1471,
    "text": "Piperacillin - induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Piperacillin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "encephalopathy"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "uremic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1472,
    "text": "CAPD is inefficient in removing piperacillin , whereas hemodialysis can rapidly terminate the piperacillin - induced encephalopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "piperacillin"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "piperacillin"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1473,
    "text": "Frequency of transient ipsilateral vocal cord paralysis in patients undergoing carotid endarterectomy under local anesthesia .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "vocal cord paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1474,
    "text": "BACKGROUND : Especially because of improvements in clinical neurologic monitoring , carotid endarterectomy done under local anesthesia has become the technique of choice in several centers .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1475,
    "text": "Temporary ipsilateral vocal nerve palsies due to local anesthetics have been described , however .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "vocal nerve palsies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1476,
    "text": "Such complications are most important in situations where there is a pre - existing contralateral paralysis .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1477,
    "text": "We therefore examined the effect of local anesthesia on vocal cord function to better understand its possible consequences .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1478,
    "text": "METHODS : This prospective study included 28 patients undergoing carotid endarterectomy under local anesthesia .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1479,
    "text": "Vocal cord function was evaluated before , during , and after surgery ( postoperative day 1 ) using flexible laryngoscopy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1480,
    "text": "Anesthesia was performed by injecting 20 to 40 mL of a mixture of long - acting ( ropivacaine ) and short - acting ( prilocaine ) anesthetic .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "ropivacaine"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "prilocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1481,
    "text": "RESULTS : All patients had normal vocal cord function preoperatively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1482,
    "text": "Twelve patients ( 43 % ) were found to have intraoperative ipsilateral vocal cord paralysis .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "vocal cord paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1483,
    "text": "It resolved in all cases < or = 24 hours .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1484,
    "text": "There were no significant differences in operating time or volume or frequency of anesthetic administration in patients with temporary vocal cord paralysis compared with those without .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "vocal cord paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1485,
    "text": "CONCLUSION : Local anesthesia led to temporary ipsilateral vocal cord paralysis in almost half of these patients .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "vocal cord paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1486,
    "text": "Because pre - existing paralysis is of a relevant frequency ( up to 3 % ) , a preoperative evaluation of vocal cord function before carotid endarterectomy under local anesthesia is recommended to avoid intraoperative bilateral paralysis .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "paralysis"
      ],
      [
        "T1",
        "Disease",
        36,
        37,
        "paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1487,
    "text": "In patients with preoperative contralateral vocal cord paralysis , surgery under general anesthesia should be considered .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "vocal cord paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1488,
    "text": "Impaired fear recognition in regular recreational cocaine users .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Impaired fear recognition"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1489,
    "text": "INTRODUCTION : The ability to read facial expressions is essential for normal human social interaction .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1490,
    "text": "The aim of the present study was to conduct the first investigation of facial expression recognition performance in recreational cocaine users .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1491,
    "text": "MATERIALS AND METHODS : Three groups , comprised of 21 cocaine naive participants ( CN ) , 30 occasional cocaine ( OC ) , and 48 regular recreational cocaine ( RC ) users , were compared .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1492,
    "text": "An emotional facial expression ( EFE ) task consisting of a male and female face expressing six basic emotions ( happiness , surprise , sadness , anger , fear , and disgust ) was administered .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1493,
    "text": "Mean percent accuracy and latencies for correct responses across eight presentations of each basic emotion were derived .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1494,
    "text": "Participants were also assessed with the \" Eyes task \" to investigate their ability to recognize more complex emotional states and the Symptom CheckList - 90 - Revised to measure psychopathology .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1495,
    "text": "RESULTS : There were no group differences in psychopathology or \" eyes task \" performance , but the RC group , who otherwise had similar illicit substance use histories to the OC group , exhibited impaired fear recognition accuracy compared to the OC and CN groups .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        38,
        "impaired fear recognition"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1496,
    "text": "The RC group also correctly identified anger , fear , happiness , and surprise , more slowly than CN , but not OC participants .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1497,
    "text": "The OC group was slower than CN when correctly identifying disgust .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1498,
    "text": "The selective deficit in fear recognition accuracy manifested by the RC group cannot be explained by the subacute effects of cocaine , or ecstasy , because recent and less recent users of these drugs within this group were similarly impaired .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        6,
        "deficit in fear recognition"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1499,
    "text": "Possible parallels between RC users and psychopaths with respect to impaired fear recognition , amygdala dysfunction , and etiology are discussed .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "impaired fear recognition"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "amygdala dysfunction"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "psychopaths"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1500,
    "text": "Damage of substantia nigra pars reticulata during pilocarpine - induced status epilepticus in the rat : immunohistochemical study of neurons , astrocytes and serum - protein extravasation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        6,
        "Damage of substantia nigra pars reticulata"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "status epilepticus"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1501,
    "text": "The substantia nigra has a gating function controlling the spread of epileptic seizure activity .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "epileptic seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1502,
    "text": "Additionally , in models of prolonged status epilepticus the pars reticulata of substantia nigra ( SNR ) suffers from a massive lesion which may arise from a massive metabolic derangement and hyperexcitation developing in the activated SNR .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "prolonged status epilepticus"
      ],
      [
        "T1",
        "Disease",
        28,
        30,
        "metabolic derangement"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1503,
    "text": "In this study , status epilepticus was induced by systemic injection of pilocarpine in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "status epilepticus"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1504,
    "text": "The neuropathology of SNR was investigated using immunohistochemical techniques with the major emphasis on the time - course of changes in neurons and astrocytes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1505,
    "text": "Animals surviving 20 , 30 , 40 , 60 min , 2 , 3 , 6 hours , 1 , 2 , and 3 days after induction of status epilepticus were perfusion - fixed , and brains processed for immunohistochemical staining of SNR .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "status epilepticus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1506,
    "text": "Nissl - staining and antibodies against the neuron - specific calcium - binding protein , parvalbumin , served to detect neuronal damage in SNR .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "neuronal damage"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1507,
    "text": "Antibodies against the astroglia - specific cytoskeletal protein , glial fibrillary acidic protein ( GFAP ) , and against the glial calcium - binding protein , S - 100 protein , were used to assess the status of astrocytes .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1508,
    "text": "Immunohistochemical staining for serum - albumin and immunoglobulins in brain tissue was taken as indicator of blood - brain barrier disturbances and vasogenic edema formation .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "vasogenic edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1509,
    "text": "Immunohistochemical staining indicated loss of GFAP - staining already at 30 min after induction of seizures in an oval focus situated in the center of SNR while sparing medial and lateral aspects .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1510,
    "text": "At 1 h there was additional vacuolation in S - 100 protein staining .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1511,
    "text": "By 2 hours , parvalbumin - staining changed in the central SNR indicating neuronal damage , and Nissl - staining visualized some neuronal distortion .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "neuronal damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1512,
    "text": "Staining for serum - proteins occurred in a patchy manner throughout the forebrain during the first hours .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1513,
    "text": "By 6 h , vasogenic edema covered the lesioned SNR .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "vasogenic edema"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "lesioned SNR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1514,
    "text": "By 24 h , glial and neuronal markers indicated a massive lesion in the center of SNR .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1515,
    "text": "By 48 - 72 h , astrocytes surrounding the lesion increased in size , and polymorphic phagocytotic cells invaded the damaged area .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1516,
    "text": "In a further group of animals surviving 1 to 5 days , conventional paraffin - sections confirmed the neuronal and glial damage of SNR .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "damage of SNR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1517,
    "text": "Additional pathology of similar quality was found in the globus pallidus .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1518,
    "text": "Since astrocytes were always damaged in parallel with neurons in SNR it is proposed that the anatomical and functional interrelationship between neurons and astrocytes is particularly tight in SNR .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1519,
    "text": "Both cell elements may suffer in common from metabolic disturbance and neurotransmitter dysfunction as occur during massive status epilepticus .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "neurotransmitter dysfunction"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "status epilepticus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1520,
    "text": "Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU - induced cortical dysplasia .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "cortical dysplasia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "melatonin"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "BCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1521,
    "text": "Cortical dysplasia is a malformation characterized by defects in proliferation , migration and maturation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cortical dysplasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1522,
    "text": "This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine - [ 1 , 3 - bis ( 2 - chloroethyl ) - 1 - nitrosoure ] ( BCNU ) and to investigate the effects of exogenous melatonin upon cerebellar BCNU - induced cortical dysplasia , using histological and biochemical analyses .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        34,
        "1 , 3 - bis ( 2 - chloroethyl ) - 1 - nitrosoure"
      ],
      [
        "T1",
        "Disease",
        51,
        53,
        "cortical dysplasia"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "carmustine"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "BCNU"
      ],
      [
        "T4",
        "Chemical",
        45,
        46,
        "melatonin"
      ],
      [
        "T5",
        "Chemical",
        48,
        49,
        "BCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1523,
    "text": "Pregnant Wistar rats were assigned to five groups : intact - control , saline - control , melatonin - treated , BCNU - exposed and BCNU - exposed plus melatonin .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "melatonin"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "BCNU"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "BCNU"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "melatonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1524,
    "text": "Rats were exposed to BCNU on embryonic day 15 and melatonin was given until delivery .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "BCNU"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "melatonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1525,
    "text": "Immuno / histochemistry and electron microscopy were carried out on the offspring cerebellum , and levels of malondialdehyde and superoxide dismutase were determined .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "malondialdehyde"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "superoxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1526,
    "text": "Histopathologically , typical findings were observed in the cerebella from the control groups , but the findings consistent with early embryonic development were noted in BCNU - exposed cortical dysplasia group .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "cortical dysplasia"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "BCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1527,
    "text": "There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU - exposed group , but a decreased immunoreactivity to glial fibrillary acidic protein , synaptophysin and transforming growth factor beta1 was observed , indicating a delayed maturation , and melatonin significantly reversed these changes .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "BCNU"
      ],
      [
        "T1",
        "Chemical",
        47,
        48,
        "melatonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1528,
    "text": "Malondialdehyde level in BCNU - exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group ( P < 0 . 01 ) , while there were no significant differences in the superoxide dismutase levels between these groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Malondialdehyde"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "BCNU"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "melatonin"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "malondialdehyde"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "BCNU"
      ],
      [
        "T5",
        "Chemical",
        38,
        39,
        "superoxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1529,
    "text": "These data suggest that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum and melatonin protects the cerebellum against the effects of BCNU .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "BCNU"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "melatonin"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "BCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1530,
    "text": "Reduced cardiotoxicity of doxorubicin given in the form of N - ( 2 - hydroxypropyl ) methacrylamide conjugates : and experimental study in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        17,
        "N - ( 2 - hydroxypropyl ) methacrylamide"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "cardiotoxicity"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1531,
    "text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg / kg doxorubicin ( DOX ) given either as free drug or in the form of three N - ( 2 - hydroxypropyl ) methacrylamide ( HPMA ) copolymer conjugates .",
    "labels": [
      [
        "T0",
        "Chemical",
        35,
        43,
        "N - ( 2 - hydroxypropyl ) methacrylamide"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "toxicity"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "cardiotoxicity"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "doxorubicin"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "DOX"
      ],
      [
        "T5",
        "Chemical",
        44,
        45,
        "HPMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1532,
    "text": "In these HPMA copolymers , DOX was covalently bound via peptide linkages that were either non - biodegradable ( Gly - Gly ) or degradable by lysosomal proteinases ( Gly - Phe - Leu - Gly ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        29,
        36,
        "Gly - Phe - Leu - Gly"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "HPMA"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1533,
    "text": "In addition , one biodegradable conjugate containing galactosamine was used ; this residue was targeted to the liver .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "galactosamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1534,
    "text": "Over the first 3 weeks after the i . v . administration of free and polymer - bound DOX , all animals showed a transient reduction in body weight .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1535,
    "text": "However , the maximal reduction in body weight seen in animals that received polymer - bound DOX ( 4 mg / kg ) was significantly lower than that observed in those that received free DOX ( 4 mg / kg ) or a mixture of the unmodified parent HPMA copolymer and free DOX ( 4 mg / kg ; P less than 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "DOX"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "DOX"
      ],
      [
        "T2",
        "Chemical",
        48,
        49,
        "HPMA"
      ],
      [
        "T3",
        "Chemical",
        52,
        53,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1536,
    "text": "Throughout the study ( 20 weeks ) , deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX ; in these cases , histological investigations revealed marked changes in the heart that were consistent with DOX - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "DOX"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "HPMA"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "DOX"
      ],
      [
        "T4",
        "Chemical",
        48,
        49,
        "DOX"
      ],
      [
        "T5",
        "Disease",
        51,
        52,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1537,
    "text": "Sequential measurements of cardiac output in surviving animals that received either free DOX or the mixture of HPMA copolymer and free DOX showed a reduction of approximately 30 % in function beginning at the 4th week after drug administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "DOX"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "HPMA"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1538,
    "text": "The heart rate in these animals was approximately 12 % lower than that measured in age - matched control rats ( P less than 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1539,
    "text": "Animals that were given the HPMA copolymer conjugates containing DOX exhibited no significant change in cardiac output throughout the study ( P less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "HPMA"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1540,
    "text": "In addition , no significant histological change was observed in the heart of animals that received DOX in the form of HPMA copolymer conjugates and were killed at the end of the study .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "DOX"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "HPMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1541,
    "text": "However , these animals had shown a significant increase in heart rate beginning at 8 weeks after drug administration ( P less than 0 . 01 ) . ( ABSTRACT TRUNCATED AT 400 WORDS )",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1542,
    "text": "Corneal ulcers associated with aerosolized crack cocaine use .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Corneal ulcers"
      ],
      [
        "T1",
        "Chemical",
        5,
        7,
        "crack cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1543,
    "text": "PURPOSE : We report 4 cases of corneal ulcers associated with drug abuse .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "corneal ulcers"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "drug abuse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1544,
    "text": "The pathogenesis of these ulcers and management of these patients are also reviewed .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "ulcers"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1545,
    "text": "METHODS : Review of all cases of corneal ulcers associated with drug abuse seen at our institution from July 2006 to December 2006 .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "corneal ulcers"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "drug abuse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1546,
    "text": "RESULTS : Four patients with corneal ulcers associated with crack cocaine use were reviewed .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "corneal ulcers"
      ],
      [
        "T1",
        "Chemical",
        9,
        11,
        "crack cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1547,
    "text": "All corneal ulcers were cultured , and the patients were admitted to the hospital for intensive topical antibiotic treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "corneal ulcers"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1548,
    "text": "Each patient received comprehensive health care , including medical and substance abuse consultations .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "substance abuse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1549,
    "text": "Streptococcal organisms were found in 3 cases and Capnocytophaga and Brevibacterium casei in 1 patient .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1550,
    "text": "The infections responded to antibiotic treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1551,
    "text": "Two patients needed a lateral tarsorrhaphy for persistent epithelial defects .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "epithelial defects"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1552,
    "text": "CONCLUSIONS : Aerosolized crack cocaine use can be associated with the development of corneal ulcers .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "crack cocaine"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "corneal ulcers"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1553,
    "text": "Drug abuse provides additional challenges for management .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Drug abuse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1554,
    "text": "Not only treatment of their infections but also the overall poor health of the patients and increased risk of noncompliance need to be addressed .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1555,
    "text": "Comprehensive care may provide the patient the opportunity to discontinue their substance abuse , improve their overall health , and prevent future corneal complications .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "substance abuse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1556,
    "text": "Topical 0 . 025 % capsaicin in chronic post - herpetic neuralgia : efficacy , predictors of response and long - term course .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "post - herpetic neuralgia"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "capsaicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1557,
    "text": "In order to evaluate the efficacy , time - course of action and predictors of response to topical capsaicin , 39 patients with chronic post - herpetic neuralgia ( PHN ) , median duration 24 months , were treated with 0 . 025 % capsaicin cream for 8 weeks .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        28,
        "post - herpetic neuralgia"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "capsaicin"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "PHN"
      ],
      [
        "T3",
        "Chemical",
        44,
        45,
        "capsaicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1558,
    "text": "During therapy the patients rated their pain on a visual analogue scale ( VAS ) and a verbal outcome scale .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1559,
    "text": "A follow - up investigation was performed 10 - 12 months after study onset on the patients who had improved .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1560,
    "text": "Nineteen patients ( 48 . 7 % ) substantially improved after the 8 - week trial ; 5 ( 12 . 8 % ) discontinued therapy due to side - effects such as intolerable capsaicin - induced burning sensations ( 4 ) or mastitis ( 1 ) ; 15 ( 38 . 5 % ) reported no benefit .",
    "labels": [
      [
        "T0",
        "Chemical",
        34,
        35,
        "capsaicin"
      ],
      [
        "T1",
        "Disease",
        43,
        44,
        "mastitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1561,
    "text": "The decrease in VAS ratings was significant after 2 weeks of continuous application .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1562,
    "text": "Of the responders 72 . 2 % were still improved at the follow - up ; only one - third of them had continued application irregularly .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1563,
    "text": "Treatment effect was not dependent on patient ' s age , duration or localization of PHN ( trigeminal involvement was excluded ) , sensory disturbance or pain character .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "sensory disturbance"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "PHN"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1564,
    "text": "Treatment response was not correlated with the incidence , time - course or severity of capsaicin - induced burning .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "capsaicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1565,
    "text": "If confirmed in controlled trials , the long - term results of this open , non - randomized study might indicate that the analgesic effect of capsaicin in PHN is mediated by both interference with neuropeptide metabolism and morphological changes ( perhaps degeneration ) of nociceptive afferents .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "capsaicin"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "PHN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1566,
    "text": "Myo - inositol - 1 - phosphate ( MIP ) synthase inhibition : in - vivo study in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        7,
        "Myo - inositol - 1 - phosphate"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "MIP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1567,
    "text": "Lithium and valproate are the prototypic mood stabilizers and have diverse structures and targets .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Lithium"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1568,
    "text": "Both drugs influence inositol metabolism .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "inositol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1569,
    "text": "Lithium inhibits IMPase and valproate inhibits MIP synthase .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Lithium"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "valproate"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "MIP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1570,
    "text": "This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine - induced seizures model .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "MIP"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "lithium"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "inositol"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "pilocarpine"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1571,
    "text": "This lack of effects may stem from the low contribution of de - novo synthesis to cellular inositol supply or to the inhibition of the de - novo synthesis by lithium itself .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "inositol"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1572,
    "text": "Non - steroidal anti - inflammatory drugs - associated acute interstitial nephritis with granular tubular basement membrane deposits .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "interstitial nephritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1573,
    "text": "Acute tubulo - interstitial nephritis ( ATIN ) is an important cause of acute renal failure resulting from a variety of insults , including immune complex - mediated tubulo - interstitial injury , but drugs such as non - steroidal anti - inflammatory drugs ( NSAIDs ) are a far more frequent cause .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        5,
        "Acute tubulo - interstitial nephritis"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "acute renal failure"
      ],
      [
        "T2",
        "Disease",
        28,
        32,
        "tubulo - interstitial injury"
      ],
      [
        "T3",
        "Disease",
        6,
        7,
        "ATIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1574,
    "text": "Overall , as an entity , ATIN remains under - diagnosed , as symptoms resolve spontaneously if the medication is stopped .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "ATIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1575,
    "text": "We report on a 14 - year - old boy who developed acute renal failure 2 weeks after aortic valve surgery .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "acute renal failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1576,
    "text": "He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "aspirin"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "ibuprofen"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "fever"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1577,
    "text": "He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen ( BUN ) concentration of of 147 mg / dl , creatinine of 15 . 3 mg / dl and serum potassium of 8 . 7 mEq / l .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "blood urea nitrogen"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "BUN"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "creatinine"
      ],
      [
        "T3",
        "Chemical",
        40,
        41,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1578,
    "text": "Dialysis was immediately initiated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1579,
    "text": "A kidney biopsy showed inflammatory infiltrate consistent with ATIN .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "ATIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1580,
    "text": "However , in the tubular basement membrane ( TBM ) , very intense granular deposits of polyclonal IgG and C3 were noted .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1581,
    "text": "He needed dialysis for 2 weeks and was treated successfully with steroids for 6 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1582,
    "text": "His renal recovery and disappearance of proteinuria took a year .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1583,
    "text": "In conclusion , this is a first report of NSAIDs - associated ATIN , showing deposits of granular immune complex present only in the TBM and not in the glomeruli .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "ATIN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1584,
    "text": "Rifampicin - associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "staphylococcal endocarditis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Rifampicin"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "glomerulonephritis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1585,
    "text": "Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "glomerulonephritis"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "rifampicin"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "tuberculosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1586,
    "text": "Changing epidemiology of infections such as infective endocarditis ( IE ) has led to an increase in the use of rifampicin for Staphylococcal infections .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "infective endocarditis"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "Staphylococcal infections"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "infections"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "IE"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "rifampicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1587,
    "text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin , and review the literature regarding this complication of rifampicin therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "Staphylococcal IE"
      ],
      [
        "T1",
        "Disease",
        12,
        15,
        "acute renal failure"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "glomerulonephritis"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "rifampicin"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "rifampicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1588,
    "text": "Rate of YMDD motif mutants in lamivudine - untreated Iranian patients with chronic hepatitis B virus infection .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        17,
        "chronic hepatitis B virus infection"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1589,
    "text": "BACKGROUND : Lamivudine is used for the treatment of chronic hepatitis B patients .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "chronic hepatitis B"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1590,
    "text": "Recent studies show that the YMDD motif mutants ( resistant hepatitis B virus ) occur as natural genome variability in lamivudine - untreated chronic hepatitis B patients .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "hepatitis B"
      ],
      [
        "T1",
        "Disease",
        23,
        26,
        "chronic hepatitis B"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1591,
    "text": "In this study we aimed to determine the rate of YMDD motif mutants in lamivudine - untreated chronic hepatitis B patients in Iran .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "chronic hepatitis B"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1592,
    "text": "PATIENTS AND METHODS : A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "chronic hepatitis B"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1593,
    "text": "Serum samples from patients were tested by polymerase chain reaction - restriction fragment length polymorphism ( PCR - RFLP ) for detection of YMDD motif mutants .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1594,
    "text": "All patients were also tested for liver enzymes , anti - HCV , HBeAg , and anti - HBe .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "HBeAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1595,
    "text": "RESULTS : Of the 77 patients enrolled in the study , 73 % were male and 27 % were female .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1596,
    "text": "Mean ALT and AST levels were 124 . 4 + / - 73 . 4 and 103 . 1 + / - 81 IU / l , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1597,
    "text": "HBeAg was positive in 40 % and anti - HBe in 60 % of the patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "HBeAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1598,
    "text": "Anti - HCV was negative in all of them .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1599,
    "text": "YMDD motif mutants were not detected in any of the patients despite the liver enzyme levels and the presence of HBeAg or anti - HBe .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "HBeAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1600,
    "text": "CONCLUSION : Although the natural occurrence of YMDD motif mutants in lamivudine - untreated patients with chronic hepatitis B has been reported , these mutants were not detected in Iranian lamivudine - untreated chronic hepatitis B patients .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        19,
        "chronic hepatitis B"
      ],
      [
        "T1",
        "Disease",
        33,
        36,
        "chronic hepatitis B"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "lamivudine"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1601,
    "text": "Branch retinal vein occlusion and fluoxetine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "retinal vein occlusion"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1602,
    "text": "A case of branch retinal vein occlusion associated with fluoxetine - induced secondary hypertension is described .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "retinal vein occlusion"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "fluoxetine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1603,
    "text": "Although an infrequent complication of selective serotonin reuptake inhibitor therapy , it is important that ophthalmologists are aware that these agents can cause hypertension because this class of drugs is widely prescribed .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "serotonin"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1604,
    "text": "The differential effects of bupivacaine and lidocaine on prostaglandin E2 release , cyclooxygenase gene expression and pain in a clinical pain model .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "prostaglandin E2"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "lidocaine"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "pain"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1605,
    "text": "BACKGROUND : In addition to blocking nociceptive input from surgical sites , long - acting local anesthetics might directly modulate inflammation .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1606,
    "text": "In the present study , we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 ( PGE2 ) production and cyclooxygenase ( COX ) gene expression that increases postoperative pain in human subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "prostaglandin E2"
      ],
      [
        "T1",
        "Disease",
        29,
        31,
        "postoperative pain"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "bupivacaine"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "PGE2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1607,
    "text": "METHODS : Subjects ( n = 114 ) undergoing extraction of impacted third molars received either 2 % lidocaine or 0 . 5 % bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "lidocaine"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "rofecoxib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1608,
    "text": "Oral mucosal biopsies were taken before surgery and 48 h after surgery .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1609,
    "text": "After extraction , a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 ( TXB2 ) measurements .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "thromboxane B2"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "PGE2"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "TXB2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1610,
    "text": "RESULTS : The bupivacaine / rofecoxib group reported significantly less pain , as assessed by a visual analog scale , compared with the other three treatment groups over the first 4 h .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "rofecoxib"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1611,
    "text": "However , the bupivacaine / placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "bupivacaine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "pain"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "PGE2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1612,
    "text": "Moreover , bupivacaine significantly increased COX - 2 gene expression at 48 h as compared with the lidocaine / placebo group .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1613,
    "text": "Thromboxane levels were not significantly affected by any of the treatments , indicating that the effects seen were attributable to inhibition of COX - 2 , but not COX - 1 .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Thromboxane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1614,
    "text": "CONCLUSIONS : These results suggest that bupivacaine stimulates COX - 2 gene expression after tissue injury , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "tissue injury"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "PGE2"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1615,
    "text": "p75NTR expression in rat urinary bladder sensory neurons and spinal cord with cyclophosphamide - induced cystitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "cyclophosphamide"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1616,
    "text": "A role for nerve growth factor ( NGF ) in contributing to increased voiding frequency and altered sensation from the urinary bladder has been suggested .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1617,
    "text": "Previous studies have examined the expression and regulation of tyrosine kinase receptors ( Trks ) in micturition reflexes with urinary bladder inflammation .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "urinary bladder inflammation"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "tyrosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1618,
    "text": "The present studies examine the expression and regulation of another receptor known to bind NGF , p75 ( NTR ) , after various durations of bladder inflammation induced by cyclophosphamide ( CYP ) .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "bladder inflammation"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "cyclophosphamide"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "CYP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1619,
    "text": "CYP - induced cystitis increased ( P < or = 0 . 001 ) p75 ( NTR ) expression in the superficial lateral and medial dorsal horn in L1 - L2 and L6 - S1 spinal segments .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "CYP"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1620,
    "text": "The number of p75 ( NTR ) - immunoreactive ( - IR ) cells in the lumbosacral dorsal root ganglia ( DRG ) also increased ( P < or = 0 . 05 ) with CYP - induced cystitis ( acute , intermediate , and chronic ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        35,
        36,
        "CYP"
      ],
      [
        "T1",
        "Disease",
        38,
        39,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1621,
    "text": "Quantitative , real - time polymerase chain reaction also demonstrated significant increases ( P < or = 0 . 01 ) in p75 ( NTR ) mRNA in DRG with intermediate and chronic CYP - induced cystitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        34,
        "CYP"
      ],
      [
        "T1",
        "Disease",
        36,
        37,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1622,
    "text": "Retrograde dye - tracing techniques with Fastblue were used to identify presumptive bladder afferent cells in the lumbosacral DRG .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1623,
    "text": "In bladder afferent cells in DRG , p75 ( NTR ) - IR was also increased ( P < or = 0 . 01 ) with cystitis .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        27,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1624,
    "text": "In addition to increases in p75 ( NTR ) - IR in DRG cell bodies , increases ( P < or = 0 . 001 ) in pericellular ( encircling DRG cells ) p75 ( NTR ) - IR in DRG also increased .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1625,
    "text": "Confocal analyses demonstrated that pericellular p75 ( NTR ) - IR was not colocalized with the glial marker , glial fibrillary acidic protein ( GFAP ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1626,
    "text": "These studies demonstrate that p75 ( NTR ) expression in micturition reflexes is present constitutively and modified by bladder inflammation .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "bladder inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1627,
    "text": "The functional significance of p75 ( NTR ) expression in micturition reflexes remains to be determined .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1628,
    "text": "Azathioprine - induced suicidal erythrocyte death .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Azathioprine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1629,
    "text": "BACKGROUND : Azathioprine is widely used as an immunosuppressive drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Azathioprine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1630,
    "text": "The side effects of azathioprine include anemia , which has been attributed to bone marrow suppression .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "azathioprine"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1631,
    "text": "Alternatively , anemia could result from accelerated suicidal erythrocyte death or eryptosis , which is characterized by exposure of phosphatidylserine ( PS ) at the erythrocyte surface and by cell shrinkage .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "anemia"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "phosphatidylserine"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "PS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1632,
    "text": "METHODS : The present experiments explored whether azathioprine influences eryptosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "azathioprine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1633,
    "text": "According to annexin V binding , erythrocytes from patients indeed showed a significant increase of PS exposure within 1 week of treatment with azathioprine .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "PS"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "azathioprine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1634,
    "text": "In a second series , cytosolic Ca2 + activity ( Fluo3 fluorescence ) , cell volume ( forward scatter ) , and PS - exposure ( annexin V binding ) were determined by FACS analysis in erythrocytes from healthy volunteers .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "Ca2"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "Fluo3"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "PS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1635,
    "text": "RESULTS : Exposure to azathioprine ( > or = 2 microg / mL ) for 48 hours increased cytosolic Ca2 + activity and annexin V binding and decreased forward scatter .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "azathioprine"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "Ca2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1636,
    "text": "The effect of azathioprine on both annexin V binding and forward scatter was significantly blunted in the nominal absence of extracellular Ca2 + .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "azathioprine"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "Ca2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1637,
    "text": "CONCLUSIONS : Azathioprine triggers suicidal erythrocyte death , an effect presumably contributing to azathioprine - induced anemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Azathioprine"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "azathioprine"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1638,
    "text": "Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "idiopathic epilepsy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Levetiracetam"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "phenobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1639,
    "text": "OBJECTIVE : To assess pharmacokinetics , efficacy , and tolerability of oral levetiracetam administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected idiopathic epilepsy .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "idiopathic epilepsy"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "levetiracetam"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "phenobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1640,
    "text": "DESIGN - Open - label , noncomparative clinical trial .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1641,
    "text": "ANIMALS : 12 cats suspected to have idiopathic epilepsy that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "idiopathic epilepsy"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "phenobarbital"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "phenobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1642,
    "text": "PROCEDURES : Cats were treated with levetiracetam ( 20 mg / kg [ 9 . 1 mg / lb ] , PO , q 8 h ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "levetiracetam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1643,
    "text": "After a minimum of 1 week of treatment , serum levetiracetam concentrations were measured before and 2 , 4 , and 6 hours after drug administration , and maximum and minimum serum concentrations and elimination half - life were calculated .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "levetiracetam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1644,
    "text": "Seizure frequencies before and after initiation of levetiracetam treatment were compared , and adverse effects were recorded .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Seizure"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "levetiracetam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1645,
    "text": "RESULTS : Median maximum serum levetiracetam concentration was 25 . 5 microg / mL , median minimum serum levetiracetam concentration was 8 . 3 microg / mL , and median elimination half - life was 2 . 9 hours .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "levetiracetam"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "levetiracetam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1646,
    "text": "Median seizure frequency prior to treatment with levetiracetam ( 2 . 1 seizures / mo ) was significantly higher than median seizure frequency after initiation of levetiracetam treatment ( 0 . 42 seizures / mo ) , and 7 of 10 cats were classified as having responded to levetiracetam treatment ( ie , reduction in seizure frequency of > or = 50 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "seizure"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "levetiracetam"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "seizures"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "seizure"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "levetiracetam"
      ],
      [
        "T5",
        "Disease",
        32,
        33,
        "seizures"
      ],
      [
        "T6",
        "Chemical",
        48,
        49,
        "levetiracetam"
      ],
      [
        "T7",
        "Disease",
        55,
        56,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1647,
    "text": "Two cats had transient lethargy and inappetence .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "lethargy"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "inappetence"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1648,
    "text": "CONCLUSIONS AND CLINICAL RELEVANCE : Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with idiopathic epilepsy .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "idiopathic epilepsy"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "levetiracetam"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "phenobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1649,
    "text": "Serotonin reuptake inhibitors , paranoia , and the ventral basal ganglia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Serotonin"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "paranoia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1650,
    "text": "Antidepressants have previously been associated with paranoid reactions in psychiatric patients .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "paranoid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1651,
    "text": "Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "paranoid"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "serotonin"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "fluoxetine"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "amitriptyline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1652,
    "text": "Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of depressive and psychotic symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        20,
        "depressive and psychotic symptoms"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "paranoid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1653,
    "text": "Complicated depressive disorders ( including atypicality of course and symptomatology , chronicity , psychosis , bipolarity , and secondary onset in the course of a primary psychosis ) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "depressive disorders"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "psychosis"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "psychosis"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "paranoid"
      ],
      [
        "T4",
        "Chemical",
        37,
        38,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1654,
    "text": "Although the pharmacology and neurobiology of paranoia remain cryptic , several mechanisms , including 5HT3 receptor - mediated dopamine release , beta - noradrenergic receptor downregulation , or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia ( possibly in lateral orbitofrontal or anterior cingulate circuits ) , might apply to this phenomenon .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "paranoia"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1655,
    "text": "These cases call attention to possible paranoid exacerbations with serotonin reuptake blockers in select patients and raise neurobiological considerations regarding paranoia .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "paranoid"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "serotonin"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "paranoia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1656,
    "text": "Clinical comparison of cardiorespiratory effects during unilateral and conventional spinal anaesthesia .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1657,
    "text": "BACKGROUND : Spinal anaesthesia is widely employed in clinical practice but has the main drawback of post - spinal block hypotension .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1658,
    "text": "Efforts must therefore continue to be made to obviate this setback OBJECTIVE : To evaluate the cardiovascular and respiratory changes during unilateral and conventional spinal anaesthesia .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1659,
    "text": "METHODS : With ethical approval , we studied 74 American Society of Anesthesiologists ( ASA ) , physical status class 1 and 2 patients scheduled for elective unilateral lower limb surgery .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1660,
    "text": "Patients were randomly allocated into one of two groups : lateral and conventional spinal anaesthesia groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1661,
    "text": "In the lateral position with operative side down , patients recived 10 mg ( 2mls ) of 0 . 5 % hyperbaric bupivacaine through a 25 - gauge spinal needle .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1662,
    "text": "Patients in the unilateral group were maintained in the lateral position for 15 minutes following spinal injection while those in the conventional group were turned supine immediately after injection .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1663,
    "text": "Blood pressure , heart rate , respiratory rate and oxygen saturation were monitored over 1 hour .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1664,
    "text": "RESULTS : Three patients ( 8 . 1 % ) in the unilateral group and 5 ( 13 . 5 % ) in the conventional group developed hypotension , P = 0 . 71 .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        28,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1665,
    "text": "Four ( 10 . 8 % ) patients in the conventional group and 1 ( 2 . 7 % ) in the unilateral group , P = 0 . 17 required epinephrine infusion to treat hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        32,
        "epinephrine"
      ],
      [
        "T1",
        "Disease",
        35,
        36,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1666,
    "text": "Patients in the conventional group had statistically significant greater fall in the systolic blood pressures at 15 , 30 and 45 minutes when compared to the baseline ( P = 0 . 003 , 0 . 001 and 0 . 004 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1667,
    "text": "The mean respiratory rate and oxygen saturations in the two groups were similar .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1668,
    "text": "CONCLUSION : Compared to conventional spinal anaesthesia , unilateral spinal anaesthesia was associated with fewer cardiovascular perturbations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1669,
    "text": "Also , the type of spinal block instituted affected neither the respiratory rate nor the arterial oxygen saturation .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1670,
    "text": "Spectrum of adverse events after generic HAART in southern Indian HIV - infected patients .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "HIV - infected"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1671,
    "text": "To determine the incidence of clinically significant adverse events after long - term , fixed - dose , generic highly active antiretroviral therapy ( HAART ) use among HIV - infected individuals in South India , we examined the experiences of 3154 HIV - infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        31,
        "HIV - infected"
      ],
      [
        "T1",
        "Disease",
        42,
        45,
        "HIV - infected"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1672,
    "text": "The most common regimens were 3TC + d4T + nevirapine ( NVP ) ( 54 . 8 % ) , zidovudine ( AZT ) + 3TC + NVP ( 14 . 5 % ) , 3TC + d4T + efavirenz ( EFV ) ( 20 . 1 % ) , and AZT + 3TC + EFV ( 5 . 4 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "3TC"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "d4T"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "nevirapine"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "NVP"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "zidovudine"
      ],
      [
        "T5",
        "Chemical",
        22,
        23,
        "AZT"
      ],
      [
        "T6",
        "Chemical",
        25,
        26,
        "3TC"
      ],
      [
        "T7",
        "Chemical",
        27,
        28,
        "NVP"
      ],
      [
        "T8",
        "Chemical",
        35,
        36,
        "3TC"
      ],
      [
        "T9",
        "Chemical",
        37,
        38,
        "d4T"
      ],
      [
        "T10",
        "Chemical",
        39,
        40,
        "efavirenz"
      ],
      [
        "T11",
        "Chemical",
        41,
        42,
        "EFV"
      ],
      [
        "T12",
        "Chemical",
        51,
        52,
        "AZT"
      ],
      [
        "T13",
        "Chemical",
        53,
        54,
        "3TC"
      ],
      [
        "T14",
        "Chemical",
        55,
        56,
        "EFV"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1673,
    "text": "The most common adverse events and median CD4 at time of event were rash ( 15 . 2 % ; CD4 , 285 cells / microL ) and peripheral neuropathy ( 9 . 0 % and 348 cells / microL ) .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "peripheral neuropathy"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "rash"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1674,
    "text": "Clinically significant anemia ( hemoglobin < 7 g / dL ) was observed in 5 . 4 % of patients ( CD4 , 165 cells / microL ) and hepatitis ( clinical jaundice with alanine aminotransferase > 5 times upper limits of normal ) in 3 . 5 % of patients ( CD4 , 260 cells / microL ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "anemia"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "hepatitis"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "jaundice"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "alanine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1675,
    "text": "Women were significantly more likely to experience lactic acidosis , while men were significantly more likely to experience immune reconstitution syndrome ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "lactic acidosis"
      ],
      [
        "T1",
        "Disease",
        18,
        21,
        "immune reconstitution syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1676,
    "text": "Among the patients with 1 year of follow - up , NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "peripheral neuropathy"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "NVP"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "rash"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "d4T"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1677,
    "text": "Anemia and hepatitis often occur within 12 weeks of initiating generic HAART .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Anemia"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1678,
    "text": "Frequent and early monitoring for these toxicities is warranted in developing countries where generic HAART is increasingly available .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "toxicities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1679,
    "text": "Thalidomide and sensory neurotoxicity : a neurophysiological study .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "sensory neurotoxicity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1680,
    "text": "BACKGROUND : Recent studies confirmed a high incidence of sensory axonal neuropathy in patients treated with different doses of thalidomide .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "sensory axonal neuropathy"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1681,
    "text": "The study ' s aims were to measure variations in sural nerve sensory action potential ( SAP ) amplitude in patients with refractory cutaneous lupus erythematosus ( CLE ) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        26,
        "cutaneous lupus erythematosus"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "CLE"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "thalidomide"
      ],
      [
        "T3",
        "Disease",
        39,
        40,
        "neurotoxic"
      ],
      [
        "T4",
        "Chemical",
        42,
        43,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1682,
    "text": "PATIENTS AND METHODS : Clinical and electrophysiological data in 12 female patients with CLE during treatment with thalidomide and up to 47 months after discontinuation of treatment were analysed .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "CLE"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1683,
    "text": "Sural nerve SAP amplitude reduction > or = 40 % was the criteria for discontinuing therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1684,
    "text": "RESULTS : During treatment , 11 patients showed a reduction in sural nerve SAP amplitude compared to baseline values ( 9 with a reduction > or = 50 % and 2 < 50 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1685,
    "text": "One patient showed no changes in SAP amplitude .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1686,
    "text": "Five patients complained of paresthesias and leg cramps .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "paresthesias"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "cramps"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1687,
    "text": "After thalidomide treatment , sural SAP amplitude recovered in 3 patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1688,
    "text": "At detection of reduction in sural nerve SAP amplitude , the median thalidomide cumulative dose was 21 . 4 g .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1689,
    "text": "The threshold neurotoxic dosage is lower than previously reported .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "neurotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1690,
    "text": "CONCLUSIONS : Sural nerve SAP amplitude reduction is a reliable and sensitive marker of degeneration and recovery of sensory fibres .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1691,
    "text": "This electrophysiological parameter provides information about subclinical neurotoxic potential of thalidomide but is not helpful in predicting the appearance of sensory symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "neurotoxic"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1692,
    "text": "Five cases of encephalitis during treatment of loiasis with diethylcarbamazine .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "encephalitis"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "loiasis"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "diethylcarbamazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1693,
    "text": "Five cases of encephalitis following treatment with diethylcarbamazine ( DEC ) were observed in Congolese patients with Loa loa filariasis .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "encephalitis"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "diethylcarbamazine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "DEC"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "filariasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1694,
    "text": "Two cases had a fatal outcome and one resulted in severe sequelae .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1695,
    "text": "The notable fact was that this complication occurred in three patients hospitalized before treatment began , with whom particularly strict therapeutic precautions were taken , i . e . , initial dose less than 10 mg of DEC , very gradual dose increases , and associated anti - allergic treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        37,
        38,
        "DEC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1696,
    "text": "This type of drug - induced complication may not be that uncommon in highly endemic regions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1697,
    "text": "It occurs primarily , but not exclusively , in subjects presenting with a high microfilarial load .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1698,
    "text": "The relationship between the occurrence of encephalitis and the decrease in microfilaremia is evident .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "encephalitis"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "microfilaremia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1699,
    "text": "The pathophysiological mechanisms are discussed in the light of these observations and the few other comments on this subject published in the literature .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1700,
    "text": "Amiodarone - related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease : Diagnostic pitfall and new findings .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "pulmonary mass"
      ],
      [
        "T1",
        "Disease",
        7,
        9,
        "membranous glomerulonephritis"
      ],
      [
        "T2",
        "Disease",
        13,
        16,
        "valvular heart disease"
      ],
      [
        "T3",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1701,
    "text": "Amiodarone is an anti - arrhythmic drug for life - threatening tachycardia , but various adverse effects have been reported .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "arrhythmic"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "tachycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1702,
    "text": "Reported herein is an autopsy case of valvular heart disease , in a patient who developed a lung mass ( 1 . 5 cm in diameter ) and proteinuria ( 2 . 76 g / day ) after treatment with amiodarone for a long time .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "valvular heart disease"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "lung mass"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "proteinuria"
      ],
      [
        "T3",
        "Chemical",
        40,
        41,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1703,
    "text": "The lung mass was highly suspected to be lung cancer on CT and positron emission tomography , but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra - alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies , indicating that it was an amiodarone - related lesion .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "lung mass"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "lung cancer"
      ],
      [
        "T2",
        "Chemical",
        47,
        48,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1704,
    "text": "In addition , the lung tissue had unevenly distributed hemosiderin deposition , and abnormally tortuous capillaries were seen in the mass and in heavily hemosiderotic lung portions outside the mass .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "hemosiderin"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "hemosiderotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1705,
    "text": "In the kidneys , glomeruli had membrane spikes , prominent swelling of podocytes and subepithelial deposits , which were sometimes large and hump - like .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1706,
    "text": "Autoimmune diseases , viral hepatitis , malignant neoplasms or other diseases with a known relationship to membranous glomerulonephritis were not found .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Autoimmune diseases"
      ],
      [
        "T1",
        "Disease",
        3,
        5,
        "viral hepatitis"
      ],
      [
        "T2",
        "Disease",
        16,
        18,
        "membranous glomerulonephritis"
      ],
      [
        "T3",
        "Disease",
        7,
        8,
        "neoplasms"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1707,
    "text": "The present case highlights the possibility that differential diagnosis between an amiodarone - related pulmonary lesion and a neoplasm can be very difficult radiologically , and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "pulmonary lesion"
      ],
      [
        "T1",
        "Disease",
        28,
        30,
        "membranous glomerulonephritis"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "amiodarone"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "neoplasm"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1708,
    "text": "Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes : a matched case - control study .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "type 2 diabetes"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "sulphonylurea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1709,
    "text": "AIMS : This study sought to assess the risk of developing coronary artery disease ( CAD ) associated with initial treatment of type 2 diabetes with different sulphonylureas .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        22,
        25,
        "type 2 diabetes"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "CAD"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "sulphonylureas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1710,
    "text": "METHODS : In type 2 diabetic patients , cases who developed CAD were compared retrospectively with controls that did not .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "type 2 diabetic"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "CAD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1711,
    "text": "The 20 - year risk of CAD at diagnosis of diabetes , using the UKPDS risk engine , was used to match cases with controls .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "CAD"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1712,
    "text": "RESULTS : The 76 cases of CAD were compared with 152 controls .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "CAD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1713,
    "text": "The hazard of developing CAD ( 95 % CI ) associated with initial treatment increased by 2 . 4 - fold ( 1 . 3 - 4 . 3 , P = 0 . 004 ) with glibenclamide ; 2 - fold ( 0 . 9 - 4 . 6 , P = 0 . 099 ) with glipizide ; 2 . 9 - fold ( 1 . 6 - 5 . 1 , P = 0 . 000 ) with either , and was unchanged with metformin .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "CAD"
      ],
      [
        "T1",
        "Chemical",
        37,
        38,
        "glibenclamide"
      ],
      [
        "T2",
        "Chemical",
        58,
        59,
        "glipizide"
      ],
      [
        "T3",
        "Chemical",
        87,
        88,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1714,
    "text": "The hazard decreased 0 . 3 - fold ( 0 . 7 - 1 . 7 , P = 0 . 385 ) with glimepiride , 0 . 4 - fold ( 0 . 7 - 1 . 3 , P = 0 . 192 ) with gliclazide , and 0 . 4 - fold ( 0 . 7 - 1 . 1 , P = 0 . 09 ) with either .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "glimepiride"
      ],
      [
        "T1",
        "Chemical",
        47,
        48,
        "gliclazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1715,
    "text": "CONCLUSIONS : Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "type 2 diabetes"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "glibenclamide"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "glipizide"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "CAD"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "gliclazide"
      ],
      [
        "T5",
        "Chemical",
        24,
        25,
        "glimepiride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1716,
    "text": "If confirmed , this may be important because most Indian patients receive the cheaper older sulphonylureas , and present guidelines do not distinguish between individual agents .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "sulphonylureas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1717,
    "text": "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "adriamycin"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "nephropathy"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "hypertensive"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "losartan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1718,
    "text": "BACKGROUND : The aim of the study was to investigate the antihypertensive effects of angiotensin II type - 1 receptor blocker , losartan , and its potential in slowing down renal disease progression in spontaneously hypertensive rats ( SHR ) with adriamycin ( ADR ) nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "angiotensin II"
      ],
      [
        "T1",
        "Disease",
        30,
        32,
        "renal disease"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "losartan"
      ],
      [
        "T3",
        "Disease",
        35,
        36,
        "hypertensive"
      ],
      [
        "T4",
        "Chemical",
        41,
        42,
        "adriamycin"
      ],
      [
        "T5",
        "Chemical",
        43,
        44,
        "ADR"
      ],
      [
        "T6",
        "Disease",
        45,
        46,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1719,
    "text": "METHODS : Six - month - old female SHR were randomly selected in six groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1720,
    "text": "Two control groups ( SH ( 6 ) , SH ( 12 ) ) received vehicle .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1721,
    "text": "Groups ADR ( 6 ) , ADR + LOS ( 6 ) and ADR ( 12 ) , and ADR + LOS ( 12 ) received ADR ( 2 mg / kg / b . w . i . v . ) twice in a 3 - week interval .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "ADR"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ADR"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "LOS"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "ADR"
      ],
      [
        "T4",
        "Chemical",
        19,
        20,
        "ADR"
      ],
      [
        "T5",
        "Chemical",
        21,
        22,
        "LOS"
      ],
      [
        "T6",
        "Chemical",
        26,
        27,
        "ADR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1722,
    "text": "Group ADR + LOS ( 6 ) received losartan ( 10 mg / kg / b . w . / day by gavages ) for 6 weeks and group ADR + LOS ( 12 ) for 12 weeks after second injection of ADR .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "ADR"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "LOS"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "losartan"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "ADR"
      ],
      [
        "T4",
        "Chemical",
        31,
        32,
        "LOS"
      ],
      [
        "T5",
        "Chemical",
        42,
        43,
        "ADR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1723,
    "text": "Animals were killed after 6 or 12 weeks , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1724,
    "text": "Haemodynamic measurements were performed on anaesthetized animals , blood and urine samples were taken for biochemical analysis and the left kidney was processed for morphological studies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1725,
    "text": "RESULTS : Short - term losartan treatment , besides antihypertensive effect , improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "losartan"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "glomerulosclerosis"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1726,
    "text": "Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis , thus preventing heavy proteinuria and chronic renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "interstitial fibrosis"
      ],
      [
        "T1",
        "Disease",
        25,
        28,
        "chronic renal failure"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "losartan"
      ],
      [
        "T3",
        "Disease",
        8,
        9,
        "glomerulosclerosis"
      ],
      [
        "T4",
        "Disease",
        15,
        16,
        "atrophy"
      ],
      [
        "T5",
        "Disease",
        23,
        24,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1727,
    "text": "Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Losartan"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "uraemia"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "urea"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "ADR"
      ],
      [
        "T4",
        "Disease",
        10,
        11,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1728,
    "text": "Histological examination showed that losartan could prevent tubular atrophy , interstitial infiltration and fibrosis in ADR nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "losartan"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "atrophy"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "fibrosis"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "ADR"
      ],
      [
        "T4",
        "Disease",
        16,
        17,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1729,
    "text": "CONCLUSION : Losartan reduces the rate of progression of ADR - induced focal segmental glomerulosclerosis to end - stage renal disease in SHR .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "focal segmental glomerulosclerosis"
      ],
      [
        "T1",
        "Disease",
        16,
        21,
        "end - stage renal disease"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "Losartan"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "ADR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1730,
    "text": "The risks of aprotinin and tranexamic acid in cardiac surgery : a one - year follow - up of 1188 consecutive patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "tranexamic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1731,
    "text": "BACKGROUND : Our aim was to investigate postoperative complications and mortality after administration of aprotinin compared to tranexamic acid in an unselected , consecutive cohort .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        19,
        "tranexamic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1732,
    "text": "METHODS : Perioperative data from consecutive cardiac surgery patients were prospectively collected between September 2005 and June 2006 in a university - affiliated clinic ( n = 1188 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1733,
    "text": "During the first 5 mo , 596 patients received aprotinin ( Group A ) ; in the next 5 mo , 592 patients were treated with tranexamic acid ( Group T ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        28,
        "tranexamic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1734,
    "text": "Except for antifibrinolytic therapy , the anesthetic and surgical protocols remained unchanged .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1735,
    "text": "RESULTS : The pre - and intraoperative variables were comparable between the treatment groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1736,
    "text": "Postoperatively , a significantly higher incidence of seizures was found in Group T ( 4 . 6 % vs 1 . 2 % , P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1737,
    "text": "This difference was also significant in the primary valve surgery and the high risk surgery subgroups ( 7 . 9 % vs 1 . 2 % , P = 0 . 003 ; 7 . 3 % vs 2 . 4 % , P = 0 . 035 , respectively ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1738,
    "text": "Persistent atrial fibrillation ( 7 . 9 % vs 2 . 3 % , P = 0 . 020 ) and renal failure ( 9 . 7 % vs 1 . 7 % , P = 0 . 002 ) were also more common in Group T , in the primary valve surgery subgroup .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "renal failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1739,
    "text": "On the contrary , among primary coronary artery bypass surgery patients , there were more acute myocardial infarctions and renal dysfunction in Group A ( 5 . 8 % vs 2 . 0 % , P = 0 . 027 ; 22 . 5 % vs 15 . 2 % , P = 0 . 036 , respectively ) .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "myocardial infarctions"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "renal dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1740,
    "text": "The 1 - yr mortality was significantly higher after aprotinin treatment in the high risk surgery group ( 17 . 7 % vs 9 . 8 % , P = 0 . 034 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1741,
    "text": "CONCLUSION : Both antifibrinolytic drugs bear the risk of adverse outcome depending on the type of cardiac surgery .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1742,
    "text": "Administration of aprotinin should be avoided in coronary artery bypass graft and high risk patients , whereas administration of tranexamic acid is not recommended in valve surgery .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        21,
        "tranexamic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1743,
    "text": "Delirium in an elderly woman possibly associated with administration of misoprostol .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Delirium"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "misoprostol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1744,
    "text": "Misoprostol has been associated with adverse reactions , including gastrointestinal symptoms , gynecologic problems , and headache .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Misoprostol"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1745,
    "text": "Changes in mental status , however , have not been reported .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1746,
    "text": "We present a case in which an 89 - year - old woman in a long - term care facility became confused after the initiation of misoprostol therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "misoprostol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1747,
    "text": "The patient ' s change in mental status was first reported nine days after the initiation of therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1748,
    "text": "Her delirium significantly improved after misoprostol was discontinued and her mental status returned to normal within a week .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "delirium"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "misoprostol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1749,
    "text": "Because no other factors related to this patient changed significantly , the delirium experienced by this patient possibly resulted from misoprostol therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "delirium"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "misoprostol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1750,
    "text": "The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "cardiac arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1751,
    "text": "1 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1752,
    "text": "The optical isomers of propranolol have been compared for their beta - blocking and antiarrhythmic activities . 2 .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1753,
    "text": "In blocking the positive inotropic and chronotropic responses to isoprenaline , ( + ) - propranolol had less than one hundredth the potency of ( - ) - propranolol .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "isoprenaline"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1754,
    "text": "At dose levels of ( + ) - propranolol which attenuated the responses to isoprenaline , there was a significant prolongation of the PR interval of the electrocardiogram . 3 .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "propranolol"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "isoprenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1755,
    "text": "The metabolic responses to isoprenaline in dogs ( an increase in circulating glucose , lactate and free fatty acids ) were all blocked by ( - ) - propranolol .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        19,
        "fatty acids"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "isoprenaline"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "glucose"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "lactate"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1756,
    "text": "( + ) - Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both lactate and glucose . 4 .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "fatty acid"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "Propranolol"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "lactate"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1757,
    "text": "Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea - pigs . 5 .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1758,
    "text": "The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "propranolol"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "procaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1759,
    "text": "The racemic compound was significantly less potent than either isomer . 6 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1760,
    "text": "Both isomers of propranolol were capable of preventing adrenaline - induced cardiac arrhythmias in cats anaesthetized with halothane , but the mean dose of ( - ) - propranolol was 0 . 09 + / - 0 . 02 mg / kg whereas that of ( + ) - propranolol was 4 . 2 + / - 1 . 2 mg / kg .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "cardiac arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "adrenaline"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "halothane"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "propranolol"
      ],
      [
        "T5",
        "Chemical",
        49,
        50,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1761,
    "text": "At the effective dose level of ( + ) - propranolol there was a significant prolongation of the PR interval of the electrocardiogram .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1762,
    "text": "Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline . 7 .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "adrenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1763,
    "text": "Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1764,
    "text": "The dose of ( - ) - propranolol was significantly smaller than that of ( + ) - propranolol in both species but much higher than that required to produce evidence of beta - blockade . 8 .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "propranolol"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1765,
    "text": "The implications of these results are discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1766,
    "text": "Topotecan in combination with radiotherapy in unresectable glioblastoma : a phase 2 study .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Topotecan"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "glioblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1767,
    "text": "Improving glioblastoma multiforme ( GBM ) treatment with radio - chemotherapy remains a challenge .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "glioblastoma multiforme"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "GBM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1768,
    "text": "Topotecan is an attractive option as it exhibits growth inhibition of human glioma as well as brain penetration .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Topotecan"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "glioma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1769,
    "text": "The present study assessed the combination of radiotherapy ( 60 Gy / 30 fractions / 40 days ) and topotecan ( 0 . 9 mg / m ( 2 ) / day on days 1 - 5 on weeks 1 , 3 and 5 ) in 50 adults with histologically proven and untreated GBM .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "topotecan"
      ],
      [
        "T1",
        "Disease",
        53,
        54,
        "GBM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1770,
    "text": "The incidence of non - hematological toxicities was low and grade 3 - 4 hematological toxicities were reported in 20 patients ( mainly lymphopenia and neutropenia ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "toxicities"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "toxicities"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "lymphopenia"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1771,
    "text": "Partial response and stabilization rates were 2 % and 32 % , respectively , with an overall time to progression of 12 weeks .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1772,
    "text": "One - year overall survival ( OS ) rate was 42 % , with a median OS of 40 weeks .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1773,
    "text": "Topotecan in combination with radiotherapy was well tolerated .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Topotecan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1774,
    "text": "However , while response and stabilization concerned one - third of the patients , the study did not show increased benefits in terms of survival in patients with unresectable GBM .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        30,
        "GBM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1775,
    "text": "Long - term lithium therapy leading to hyperparathyroidism : a case report .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "lithium"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hyperparathyroidism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1776,
    "text": "PURPOSE : This paper reviews the effect of chronic lithium therapy on serum calcium level and parathyroid glands , its pathogenesis , and treatment options .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "lithium"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1777,
    "text": "We examined the case of a lithium - treated patient who had recurrent hypercalcemia to better understand the disease process .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "lithium"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1778,
    "text": "CONCLUSION : Primary hyperparathyroidism is a rare but potentially life - threatening side effect of long - term lithium therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Primary hyperparathyroidism"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1779,
    "text": "Careful patient selection and long - term follow - up can reduce morbidity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1780,
    "text": "PRACTICAL IMPLICATIONS : As much as 15 % of lithium - treated patients become hypercalcemic .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "lithium"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "hypercalcemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1781,
    "text": "By routinely monitoring serum calcium levels , healthcare providers can improve the quality of life of this patient group .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1782,
    "text": "Comparison of laryngeal mask with endotracheal tube for anesthesia in endoscopic sinus surgery .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1783,
    "text": "BACKGROUND : The purpose of this study was to compare surgical conditions , including the amount of intraoperative bleeding as well as intraoperative blood pressure , during functional endoscopic sinus surgery ( FESS ) using flexible reinforced laryngeal mask airway ( FRLMA ) versus endotracheal tube ( ETT ) in maintaining controlled hypotension anesthesia induced by propofol - remifentanil total i . v . anesthesia ( TIVA ) .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "bleeding"
      ],
      [
        "T1",
        "Disease",
        52,
        53,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        56,
        57,
        "propofol"
      ],
      [
        "T3",
        "Chemical",
        58,
        59,
        "remifentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1784,
    "text": "METHODS : Sixty normotensive American Society of Anesthesiologists I - II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol - remifentanil - TIVA were randomly assigned into two groups : group I , FRLMA ; group II , ETT .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "propofol"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "remifentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1785,
    "text": "Hemorrhage was measured and the visibility of the operative field was evaluated according to a six - point scale .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1786,
    "text": "RESULTS : Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "remifentanil"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "remifentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1787,
    "text": "CONCLUSION : In summary , our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        36,
        37,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        41,
        42,
        "remifentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1788,
    "text": "Nonalcoholic fatty liver disease during valproate therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Nonalcoholic fatty liver disease"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1789,
    "text": "Valproic acid ( VPA ) is effective for the treatment of many types of epilepsy , but its use can be associated with an increase in body weight .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Valproic acid"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "VPA"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1790,
    "text": "We report a case of nonalcoholic fatty liver disease ( NAFLD ) arising in a child who developed obesity during VPA treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "nonalcoholic fatty liver disease"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "NAFLD"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "obesity"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1791,
    "text": "Laboratory data revealed hyperinsulinemia with insulin resistance .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "insulin resistance"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hyperinsulinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1792,
    "text": "After the withdrawal of VPA therapy , our patient showed a significant weight loss , a decrease of body mass index , and normalization of metabolic and endocrine parameters ; moreover , ultrasound measurements showed a complete normalization .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "weight loss"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1793,
    "text": "The present case suggests that obesity , hyperinsulinemia , insulin resistance , and long - term treatment with VPA may be all associated with the development of NAFLD ; this side effect is reversible after VPA withdrawal .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "insulin resistance"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "obesity"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "hyperinsulinemia"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "VPA"
      ],
      [
        "T4",
        "Disease",
        27,
        28,
        "NAFLD"
      ],
      [
        "T5",
        "Chemical",
        35,
        36,
        "VPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1794,
    "text": "Carbimazole induced ANCA positive vasculitis .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "ANCA positive vasculitis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Carbimazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1795,
    "text": "Anti - thyroid drugs , like carbimazole and propylthiouracil ( PTU ) are commonly prescribed for the treatment of hyperthyroidism .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        4,
        "Anti - thyroid drugs"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "carbimazole"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "propylthiouracil"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "PTU"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "hyperthyroidism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1796,
    "text": "One should be aware of the side effects of antithyroid medications .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "antithyroid medications"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1797,
    "text": "Antineutrophil cytoplasmic antibody ( ANCA ) - - associated vasculitis is a potentially life - threatening adverse effect of antithyroidmedications .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        10,
        "Antineutrophil cytoplasmic antibody ( ANCA ) - - associated vasculitis"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "antithyroidmedications"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1798,
    "text": "We report a patient with Graves ' disease who developed ANCA positive carbimazole induced vasculitis .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "Graves ' disease"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "carbimazole"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1799,
    "text": "The episode was characterized by a vasculitic skin rash associated with large joint arthritis , pyrexia and parotiditis but no renal or pulmonary involvement .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "skin rash"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "vasculitic"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "arthritis"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "pyrexia"
      ],
      [
        "T4",
        "Disease",
        17,
        18,
        "parotiditis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1800,
    "text": "He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "myositis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1801,
    "text": "Carbimazole and methimazole have a lower incidence of reported ANCA positive side effects than PUT .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Carbimazole"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "methimazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1802,
    "text": "To the best of our knowledge this is the first ANCA positive carbimazole induced vasculitis case reported from India .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "carbimazole"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1803,
    "text": "Aspirin for the primary prevention of cardiovascular events : an update of the evidence for the U . S .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1804,
    "text": "Preventive Services Task Force .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1805,
    "text": "BACKGROUND : Coronary heart disease and cerebrovascular disease are leading causes of death in the United States .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "Coronary heart disease"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "cerebrovascular disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1806,
    "text": "In 2002 , the U . S .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1807,
    "text": "Preventive Services Task Force ( USPSTF ) strongly recommended that clinicians discuss aspirin with adults who are at increased risk for coronary heart disease .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "coronary heart disease"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1808,
    "text": "PURPOSE : To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions , strokes , and death .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "myocardial infarctions"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "aspirin"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "strokes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1809,
    "text": "DATA SOURCES : MEDLINE and Cochrane Library ( search dates , 1 January 2001 to 28 August 2008 ) , recent systematic reviews , reference lists of retrieved articles , and suggestions from experts .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1810,
    "text": "STUDY SELECTION : English - language randomized , controlled trials ( RCTs ) ; case - control studies ; meta - analyses ; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease ( CVD ) were selected to answer the following questions : Does aspirin decrease coronary heart events , strokes , death from coronary heart events or stroke , or all - cause mortality in adults without known CVD ?",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        37,
        "cardiovascular disease"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "aspirin"
      ],
      [
        "T2",
        "Disease",
        38,
        39,
        "CVD"
      ],
      [
        "T3",
        "Chemical",
        49,
        50,
        "aspirin"
      ],
      [
        "T4",
        "Disease",
        55,
        56,
        "strokes"
      ],
      [
        "T5",
        "Disease",
        63,
        64,
        "stroke"
      ],
      [
        "T6",
        "Disease",
        74,
        75,
        "CVD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1811,
    "text": "Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes ?",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "gastrointestinal bleeding"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "hemorrhagic strokes"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1812,
    "text": "DATA EXTRACTION : All studies were reviewed , abstracted , and rated for quality by using predefined USPSTF criteria .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1813,
    "text": "DATA SYNTHESIS : New evidence from 1 good - quality RCT , 1 good - quality meta - analysis , and 2 fair - quality subanalyses of RCTs demonstrates that aspirin use reduces the number of CVD events in patients without known CVD .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        31,
        "aspirin"
      ],
      [
        "T1",
        "Disease",
        36,
        37,
        "CVD"
      ],
      [
        "T2",
        "Disease",
        42,
        43,
        "CVD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1814,
    "text": "Men in these studies experienced fewer myocardial infarctions and women experienced fewer ischemic strokes .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "myocardial infarctions"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "strokes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1815,
    "text": "Aspirin does not seem to affect CVD mortality or all - cause mortality in either men or women .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Aspirin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "CVD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1816,
    "text": "The use of aspirin for primary prevention increases the risk for major bleeding events , primarily gastrointestinal bleeding events , in both men and women .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "gastrointestinal bleeding"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "aspirin"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1817,
    "text": "Men have an increased risk for hemorrhagic strokes with aspirin use .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "hemorrhagic strokes"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1818,
    "text": "A new RCT and meta - analysis suggest that the risk for hemorrhagic strokes in women is not statistically significantly increased .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "hemorrhagic strokes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1819,
    "text": "LIMITATIONS : New evidence on aspirin for the primary prevention of CVD is limited .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "aspirin"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "CVD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1820,
    "text": "The dose of aspirin used in the RCTs varied , which prevented the estimation of the most appropriate dose for primary prevention .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1821,
    "text": "Several of the RCTs were conducted within populations of health professionals , which potentially limits generalizability .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1822,
    "text": "CONCLUSION : Aspirin reduces the risk for myocardial infarction in men and strokes in women .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Aspirin"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "strokes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1823,
    "text": "Aspirin use increases the risk for serious bleeding events .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Aspirin"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1824,
    "text": "Reducing harm associated with anticoagulation : practical considerations of argatroban therapy in heparin - induced thrombocytopenia .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "argatroban"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "heparin"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1825,
    "text": "Argatroban is a hepatically metabolized , direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin - induced thrombocytopenia ( HIT ) and for patients with or at risk of HIT undergoing percutaneous coronary intervention ( PCI ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Argatroban"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "thrombosis"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "heparin"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "thrombocytopenia"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "HIT"
      ],
      [
        "T5",
        "Disease",
        32,
        33,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1826,
    "text": "The objective of this review is to summarize practical considerations of argatroban therapy in HIT .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "argatroban"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1827,
    "text": "The US FDA - recommended argatroban dose in HIT is 2 microg / kg / min ( reduced in patients with hepatic impairment and in paediatric patients ) , adjusted to achieve activated partial thromboplastin times ( aPTTs ) 1 . 5 - 3 times baseline ( not > 100 seconds ) .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "hepatic impairment"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "argatroban"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1828,
    "text": "Contemporary experiences indicate that reduced doses are also needed in patients with conditions associated with hepatic hypoperfusion , e . g . heart failure , yet are unnecessary for renal dysfunction , adult age , sex , race / ethnicity or obesity .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "heart failure"
      ],
      [
        "T1",
        "Disease",
        29,
        31,
        "renal dysfunction"
      ],
      [
        "T2",
        "Disease",
        41,
        42,
        "obesity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1829,
    "text": "Argatroban 0 . 5 - 1 . 2 microg / kg / min typically supports therapeutic aPTTs .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Argatroban"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1830,
    "text": "The FDA - recommended dose during PCI is 25 microg / kg / min ( 350 microg / kg initial bolus ) , adjusted to achieve activated clotting times ( ACTs ) of 300 - 450 sec .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1831,
    "text": "For PCI , argatroban has not been investigated in hepatically impaired patients ; dose adjustment is unnecessary for adult age , sex , race / ethnicity or obesity , and lesser doses may be adequate with concurrent glycoprotein IIb / IIIa inhibition .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "argatroban"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "obesity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1832,
    "text": "Argatroban prolongs the International Normalized Ratio , and published approaches for monitoring the argatroban - to - warfarin transition should be followed .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Argatroban"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "argatroban"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1833,
    "text": "Major bleeding with argatroban is 0 - 10 % in the non - interventional setting and 0 - 5 . 8 % periprocedurally .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "bleeding"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "argatroban"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1834,
    "text": "Argatroban has no specific antidote , and if excessive anticoagulation occurs , argatroban infusion should be stopped or reduced .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Argatroban"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "argatroban"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1835,
    "text": "Improved familiarity of healthcare professionals with argatroban therapy in HIT , including in special populations and during PCI , may facilitate reduction of harm associated with HIT ( e . g . fewer thromboses ) or its treatment ( e . g . fewer argatroban medication errors ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "argatroban"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "HIT"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "HIT"
      ],
      [
        "T3",
        "Chemical",
        44,
        45,
        "argatroban"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1836,
    "text": "Rhabdomyolysis and brain ischemic stroke in a heroin - dependent male under methadone maintenance therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "ischemic stroke"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Rhabdomyolysis"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "heroin"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1837,
    "text": "OBJECTIVE : There are several complications associated with heroin abuse , some of which are life - threatening .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "heroin abuse"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1838,
    "text": "Methadone may aggravate this problem .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1839,
    "text": "METHOD : A clinical case description .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1840,
    "text": "RESULTS : A 33 - year - old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "ischemic stroke"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "rhabdomyolysis"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "heroin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1841,
    "text": "He had used heroin since age 20 , and had used 150 mg methadone daily for 6 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "heroin"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1842,
    "text": "He was found unconsciousness at home and was sent to our hospital .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "unconsciousness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1843,
    "text": "In the ER , his opiate level was 4497 ng / ml .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1844,
    "text": "In the ICU , we found rhabdomyolysis , acute renal failure and acute respiratory failure .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "respiratory failure"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "rhabdomyolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1845,
    "text": "After transfer to an internal ward , we noted aphasia and weakness of his left limbs .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "aphasia"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "weakness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1846,
    "text": "After MRI , we found cerebral ischemic infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "cerebral ischemic infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1847,
    "text": "CONCLUSION : Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "ischemic stroke"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "methadone"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "heroin"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "rhabdomyolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1848,
    "text": "Patients under methadone maintenance therapy should be warned regarding these serious adverse events .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "methadone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1849,
    "text": "Hypotheses of heroin - related rhabdomyolysis and stroke in heroin abusers are discussed .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "heroin"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "rhabdomyolysis"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "stroke"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "heroin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1850,
    "text": "Increased vulnerability to 6 - hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "6 - hydroxydopamine"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1851,
    "text": "Motor impairment , dopamine ( DA ) neuronal activity and proenkephalin ( PENK ) gene expression in the caudate - putamen ( CPu ) were measured in 6 - OHDA - lesioned and treated ( L - DOPA + benserazide ) CB1 KO and WT mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        30,
        "6 - OHDA"
      ],
      [
        "T1",
        "Chemical",
        35,
        40,
        "L - DOPA + benserazide"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "dopamine"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "DA"
      ],
      [
        "T4",
        "Chemical",
        10,
        11,
        "proenkephalin"
      ],
      [
        "T5",
        "Chemical",
        12,
        13,
        "PENK"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1852,
    "text": "A lesion induced by 6 - OHDA produced more severe motor deterioration in CB1 KO mice accompanied by more loss of DA neurons and increased PENK gene expression in the CPu .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "6 - OHDA"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "DA"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "PENK"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1853,
    "text": "Oxidative / nitrosative and neuroinflammatory parameters were estimated in the CPu and cingulate cortex ( Cg ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1854,
    "text": "CB1 KO mice exhibited higher MDA levels and iNOS protein expression in the CPu and Cg compared to WT mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "MDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1855,
    "text": "Treatment with L - DOPA + benserazide ( 12 weeks ) resulted in less severe dyskinesias in CB1 KO than in WT mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        7,
        "L - DOPA + benserazide"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1856,
    "text": "The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion , and reduced L - DOPA - induced dyskinesias .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        25,
        "L - DOPA"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "DA"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1857,
    "text": "These results suggest that activation of CB1 receptors offers neuroprotection against dopaminergic lesion and the development of L - DOPA - induced dyskinesias .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        20,
        "L - DOPA"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1858,
    "text": "Hepatocellular oxidant stress following intestinal ischemia - reperfusion injury .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "reperfusion injury"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1859,
    "text": "Reperfusion of ischemic intestine results in acute liver dysfunction characterized by hepatocellular enzyme release into plasma , reduction in bile flow rate , and neutrophil sequestration within the liver .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "liver dysfunction"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1860,
    "text": "The pathophysiology underlying this acute hepatic injury is unknown .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "hepatic injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1861,
    "text": "This study was undertaken to determine whether oxidants are associated with the hepatic injury and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "hepatic injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1862,
    "text": "Rats were subjected to a standardized intestinal ischemia - reperfusion injury .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "reperfusion injury"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1863,
    "text": "Hepatic tissue was assayed for lipid peroxidation products and oxidized and reduced glutathione .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        13,
        "oxidized and reduced glutathione"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1864,
    "text": "There was no change in hepatic tissue total glutathione following intestinal ischemia - reperfusion injury .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "reperfusion injury"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "glutathione"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1865,
    "text": "Oxidized glutathione ( GSSG ) increased significantly following 30 and 60 min of reperfusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Oxidized glutathione"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "GSSG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1866,
    "text": "There was no increase in any of the products of lipid peroxidation associated with this injury .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1867,
    "text": "An increase in GSSG within hepatic tissue during intestinal reperfusion suggests exposure of hepatocytes to an oxidant stress .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "GSSG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1868,
    "text": "The lack of a significant increase in products of lipid peroxidation suggests that the oxidant stress is of insufficient magnitude to result in irreversible injury to hepatocyte cell membranes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1869,
    "text": "These data also suggest that the measurement of tissue GSSG may be a more sensitive indicator of oxidant stress than measurement of products of lipid peroxidation .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "GSSG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1870,
    "text": "Animal model of mania induced by ouabain : Evidence of oxidative stress in submitochondrial particles of the rat brain .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "mania"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1871,
    "text": "The intracerebroventricular ( ICV ) administration of ouabain ( a Na ( + ) / K ( + ) - ATPase inhibitor ) in rats has been suggested to mimic some symptoms of human bipolar mania .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        36,
        "bipolar mania"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "ouabain"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "Na"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "K"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1872,
    "text": "Clinical studies have shown that bipolar disorder may be related to mitochondrial dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "bipolar disorder"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "mitochondrial dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1873,
    "text": "Herein , we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1874,
    "text": "To achieve this aim , the effects of ouabain injection immediately after and 7 days following a single ICV administration ( at concentrations of 10 ( - 2 ) and 10 ( - 3 ) M ) on locomotion was measured using the open - field test .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1875,
    "text": "Additionally , thiobarbituric acid reactive substances ( TBARSs ) and superoxide production were measured in submitochondrial particles of the prefrontal cortex , hippocampus , striatum and amygdala .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "thiobarbituric acid"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "superoxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1876,
    "text": "Our findings demonstrated that ouabain at 10 ( - 2 ) and 10 ( - 3 ) M induced hyperlocomotion in rats , and this response remained up to 7 days following a single ICV injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ouabain"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "hyperlocomotion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1877,
    "text": "In addition , we observed that the persistent increase in the rat spontaneous locomotion is associated with increased TBARS levels and superoxide generation in submitochondrial particles in the prefrontal cortex , striatum and amygdala .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "superoxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1878,
    "text": "In conclusion , ouabain - induced mania - like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "bipolar disorder"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "ouabain"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "mania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1879,
    "text": "Intraoperative dialysis during liver transplantation with citrate dialysate .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "citrate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1880,
    "text": "Liver transplantation for acutely ill patients with fulminant liver failure carries high intraoperative and immediate postoperative risks .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "fulminant liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1881,
    "text": "These are increased with the presence of concomitant acute kidney injury ( AKI ) and intraoperative dialysis is sometimes required to allow the transplant to proceed .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "acute kidney injury"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "AKI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1882,
    "text": "The derangements in the procoagulant and anticoagulant pathways during fulminant liver failure can lead to difficulties with anticoagulation during dialysis , especially when continued in the operating room .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "fulminant liver failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1883,
    "text": "Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of citrate toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "citrate"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "citrate"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1884,
    "text": "Citrate dialysate , a new dialysate with citric acid can be used for anticoagulation in patients who cannot tolerate heparin or regional citrate .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "citric acid"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Citrate"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "heparin"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "citrate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1885,
    "text": "We report a case of a 40 - year - old female with acetaminophen - induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        19,
        "fulminant liver failure"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "acetaminophen"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "AKI"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "citrate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1886,
    "text": "The patient tolerated the procedure well without any signs of citrate toxicity and maintained adequate anticoagulation for patency of the dialysis circuit .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "citrate"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1887,
    "text": "Citrate dialysate is a safe alternative for intradialytic support of liver transplantation in fulminant liver failure .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "fulminant liver failure"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Citrate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1888,
    "text": "Delirium in a patient with toxic flecainide plasma concentrations : the role of a pharmacokinetic drug interaction with paroxetine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Delirium"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "flecainide"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "paroxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1889,
    "text": "OBJECTIVE : To describe a case of flecainide - induced delirium associated with a pharmacokinetic drug interaction with paroxetine .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "flecainide"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "delirium"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "paroxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1890,
    "text": "CASE SUMMARY : A 69 - year - old white female presented to the emergency department with a history of confusion and paranoia over the past several days .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "confusion"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "paranoia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1891,
    "text": "On admission the patient was taking carvedilol 12 mg twice daily , warfarin 2 mg / day , folic acid 1 mg / day , levothyroxine 100 microg / day , pantoprazole 40 mg / day , paroxetine 40 mg / day , and flecainide 100 mg twice daily .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        20,
        "folic acid"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "carvedilol"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "warfarin"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "levothyroxine"
      ],
      [
        "T4",
        "Chemical",
        31,
        32,
        "pantoprazole"
      ],
      [
        "T5",
        "Chemical",
        37,
        38,
        "paroxetine"
      ],
      [
        "T6",
        "Chemical",
        44,
        45,
        "flecainide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1892,
    "text": "Flecainide had been started 2 weeks prior for atrial fibrillation .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Flecainide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1893,
    "text": "Laboratory test findings on admission were notable only for a flecainide plasma concentration of 1360 microg / L ( reference range 200 - 1000 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "flecainide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1894,
    "text": "A metabolic drug interaction between flecainide and paroxetine , which the patient had been taking for more than 5 years , was considered .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "flecainide"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "paroxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1895,
    "text": "Paroxetine was discontinued and the dose of flecainide was reduced to 50 mg twice daily .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Paroxetine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "flecainide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1896,
    "text": "Her delirium resolved 3 days later .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1897,
    "text": "DISCUSSION : Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Flecainide"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "sodium"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1898,
    "text": "A MEDLINE search ( 1966 - January 2009 ) revealed one in vivo pharmacokinetic study on the interaction between flecainide , a CYP2D6 substrate , and paroxetine , a CYP2D6 inhibitor , as well as 3 case reports of flecainide - induced delirium .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "flecainide"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "paroxetine"
      ],
      [
        "T2",
        "Chemical",
        39,
        40,
        "flecainide"
      ],
      [
        "T3",
        "Disease",
        42,
        43,
        "delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1899,
    "text": "According to the Naranjo probability scale , flecainide was the probable cause of the patient ' s delirium ; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "flecainide"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "delirium"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "flecainide"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "paroxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1900,
    "text": "CONCLUSIONS : Supratherapeutic flecainide plasma concentrations may cause delirium .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "flecainide"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1901,
    "text": "Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors , flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "flecainide"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "paroxetine"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "flecainide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1902,
    "text": "Efficacy of everolimus ( RAD001 ) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "everolimus"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "RAD001"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "NSCLC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1903,
    "text": "BACKGROUND : Treatment options are scarce in pretreated advanced non - small - cell lung cancer ( NSCLC ) patients .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        16,
        "non - small - cell lung cancer"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "NSCLC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1904,
    "text": "RAD001 , an oral inhibitor of the mammalian target of rapamycin ( mTOR ) , has shown phase I efficacy in NSCLC .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "RAD001"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "rapamycin"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "NSCLC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1905,
    "text": "METHODS : Stage IIIb or IV NSCLC patients , with two or fewer prior chemotherapy regimens , one platinum based ( stratum 1 ) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors ( stratum 2 ) , received RAD001 10 mg / day until progression or unacceptable toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "NSCLC"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "platinum"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "tyrosine"
      ],
      [
        "T3",
        "Chemical",
        41,
        42,
        "RAD001"
      ],
      [
        "T4",
        "Disease",
        50,
        51,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1906,
    "text": "Primary objective was overall response rate ( ORR ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1907,
    "text": "Analyses of markers associated with the mTOR pathway were carried out on archival tumor from a subgroup using immunohistochemistry ( IHC ) and direct mutation sequencing .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1908,
    "text": "RESULTS : Eighty - five patients were enrolled , 42 in stratum 1 and 43 in stratum .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1909,
    "text": "ORR was 4 . 7 % ( 7 . 1 % stratum 1 ; 2 . 3 % stratum 2 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1910,
    "text": "Overall disease control rate was 47 . 1 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1911,
    "text": "Median progression - free survivals ( PFSs ) were 2 . 6 ( stratum 1 ) and 2 . 7 months ( stratum 2 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1912,
    "text": "Common > or = grade 3 events were fatigue , dyspnea , stomatitis , anemia , and thrombocytopenia .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "fatigue"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "dyspnea"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "stomatitis"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "anemia"
      ],
      [
        "T4",
        "Disease",
        17,
        18,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1913,
    "text": "Pneumonitis , probably or possibly related , mainly grade 1 / 2 , occurred in 25 % .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Pneumonitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1914,
    "text": "Cox regression analysis of IHC scores found that only phospho AKT ( pAKT ) was a significant independent predictor of worse PFS .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1915,
    "text": "CONCLUSIONS : RAD001 10 mg / day was well tolerated , showing modest clinical activity in pretreated NSCLC .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "RAD001"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "NSCLC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1916,
    "text": "Evaluation of RAD001 plus standard therapy for metastatic NSCLC continues .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "RAD001"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "NSCLC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1917,
    "text": "Posttransplant anemia : the role of sirolimus .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "anemia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "sirolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1918,
    "text": "Posttransplant anemia is a common problem that may hinder patients ' quality of life .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1919,
    "text": "It occurs in 12 to 76 % of patients , and is most common in the immediate posttransplant period .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1920,
    "text": "A variety of factors have been identified that increase the risk of posttransplant anemia , of which the level of renal function is most important .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1921,
    "text": "Sirolimus , a mammalian target of rapamycin inhibitor , has been implicated as playing a special role in posttransplant anemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Sirolimus"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "rapamycin"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1922,
    "text": "This review considers anemia associated with sirolimus , including its presentation , mechanisms , and management .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "anemia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "sirolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1923,
    "text": "Coronary computerized tomography angiography for rapid discharge of low - risk patients with cocaine - associated chest pain .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1924,
    "text": "BACKGROUND : Most patients presenting to emergency departments ( EDs ) with cocaine - associated chest pain are admitted for at least 12 hours and receive a \" rule out acute coronary syndrome \" protocol , often with noninvasive testing prior to discharge .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "chest pain"
      ],
      [
        "T1",
        "Disease",
        30,
        33,
        "acute coronary syndrome"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1925,
    "text": "In patients without cocaine use , coronary computerized tomography angiography ( CTA ) has been shown to be useful for identifying a group of patients at low risk for cardiac events who can be safely discharged .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1926,
    "text": "It is unclear whether a coronary CTA strategy would be efficacious in cocaine - associated chest pain , as coronary vasospasm may account for some of the ischemia .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "chest pain"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "coronary vasospasm"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "ischemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1927,
    "text": "We studied whether a negative coronary CTA in patients with cocaine - associated chest pain could identify a subset safe for discharge .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1928,
    "text": "METHODS : We prospectively evaluated the safety of coronary CTA for low - risk patients who presented to the ED with cocaineassociated chest pain ( self - reported or positive urine test ) .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "chest pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1929,
    "text": "Consecutive patients received either immediate coronary CTA in the ED ( without serial markers ) or underwent coronary CTA after a brief observation period with serial cardiac marker measurements .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1930,
    "text": "Patients with negative coronary CTA ( maximal stenosis less than 50 % ) were discharged .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "stenosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1931,
    "text": "The main outcome was 30 - day cardiovascular death or myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "myocardial infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1932,
    "text": "RESULTS : A total of 59 patients with cocaine - associated chest pain were evaluated .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1933,
    "text": "Patients had a mean age of 45 . 6 + / - 6 . 6 yrs and were 86 % black , 66 % male .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1934,
    "text": "Seventy - nine percent had a normal or nonspecific ECG and 85 % had a TIMI score < 2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1935,
    "text": "Twenty patients received coronary CTA immediately in the ED , 18 of whom were discharged following CTA ( 90 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1936,
    "text": "Thirty - nine received coronary CTA after a brief observation period , with 37 discharged home following CTA ( 95 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1937,
    "text": "Six patients had coronary stenosis > or = 50 % .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "coronary stenosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1938,
    "text": "During the 30 - day follow - up period , no patients died of a cardiovascular event ( 0 % ; 95 % CI , 0 - 6 . 1 % ) and no patient sustained a nonfatal myocardial infarction ( 0 % ; 95 % CI , 0 - 6 . 1 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        38,
        40,
        "myocardial infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1939,
    "text": "CONCLUSIONS : Although cocaine - associated myocardial ischemia can result from coronary vasoconstriction , patients with cocaine associated chest pain , a non - ischemic ECG , and a TIMI risk score < 2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30 - day adverse events .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "chest pain"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "cocaine"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "cocaine"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1940,
    "text": "Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        7,
        "haemorrhagic infarction of the globus pallidus"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1941,
    "text": "Cocaine is a risk factor for both ischemic and haemorrhagic stroke .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "ischemic and haemorrhagic stroke"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1942,
    "text": "We present the case of a 31 - year - old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        19,
        "ischemia of the globus pallidus"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "alcohol"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1943,
    "text": "Drug - related globus pallidus infarctions are most often associated with heroin .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "globus pallidus infarctions"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "heroin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1944,
    "text": "Bilateral basal ganglia infarcts after the use of cocaine , without concurrent heroin use , have never been reported .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "basal ganglia infarcts"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "heroin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1945,
    "text": "In our patient , transient cardiac arrhythmia or respiratory dysfunction related to cocaine and / or ethanol use were the most likely causes of cerebral hypoperfusion .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "cardiac arrhythmia"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "respiratory dysfunction"
      ],
      [
        "T2",
        "Disease",
        24,
        26,
        "cerebral hypoperfusion"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "cocaine"
      ],
      [
        "T4",
        "Chemical",
        16,
        17,
        "ethanol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1946,
    "text": "Late fulminant posterior reversible encephalopathy syndrome after liver transplant .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        6,
        "posterior reversible encephalopathy syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1947,
    "text": "OBJECTIVES : Posterior leukoencephalopathy due to calcineurin - inhibitor - related neurotoxicity is a rare but severe complication that results from treatment with immunosuppressive agents ( primarily those administered after a liver or kidney transplant ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Posterior leukoencephalopathy"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1948,
    "text": "The pathophysiologic mechanisms of that disorder remain unknown .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1949,
    "text": "CASE : We report the case of a 46 - year - old woman who received a liver transplant in our center as treatment for alcoholic cirrhosis and in whom either a fulminant course of posterior leukoencephalopathy or posterior reversible encephalopathy syndrome developed 110 days after transplant .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "alcoholic cirrhosis"
      ],
      [
        "T1",
        "Disease",
        35,
        37,
        "posterior leukoencephalopathy"
      ],
      [
        "T2",
        "Disease",
        38,
        42,
        "posterior reversible encephalopathy syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1950,
    "text": "After an initially uneventful course after the transplant , the patient rapidly fell into deep coma .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1951,
    "text": "RESULTS : Cerebral MRI scan showed typical signs of enhancement in the pontine and posterior regions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1952,
    "text": "Switching the immunosuppressive regimen from tacrolimus to cyclosporine did not improve the clinical situation .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "tacrolimus"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cyclosporine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1953,
    "text": "The termination of treatment with any calcineurin inhibitor resulted in a complete resolution of that complication .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1954,
    "text": "CONCLUSIONS : Posterior reversible encephalopathy syndrome after liver transplant is rare .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        6,
        "Posterior reversible encephalopathy syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1955,
    "text": "We recommend a complete cessation of any calcineurin inhibitor rather than a dose reduction .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1956,
    "text": "Prolonged hypothermia as a bridge to recovery for cerebral edema and intracranial hypertension associated with fulminant hepatic failure .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "cerebral edema"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "intracranial hypertension"
      ],
      [
        "T2",
        "Disease",
        15,
        18,
        "fulminant hepatic failure"
      ],
      [
        "T3",
        "Disease",
        1,
        2,
        "hypothermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1957,
    "text": "BACKGROUND : To review evidence - based treatment options in patients with cerebral edema complicating fulminant hepatic failure ( FHF ) and discuss the potential applications of hypothermia .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "cerebral edema"
      ],
      [
        "T1",
        "Disease",
        15,
        18,
        "fulminant hepatic failure"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "FHF"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "hypothermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1958,
    "text": "METHOD : Case - based observations from a medical intensive care unit ( MICU ) in a tertiary care facility in a 27 - year - old female with FHF from acetaminophen and resultant cerebral edema .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        36,
        "cerebral edema"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "FHF"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1959,
    "text": "RESULTS : Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from acetaminophen which was ingested over a 2 - day period .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1960,
    "text": "The patient had depressed of mental status lasting at least 24 h prior to admission .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1961,
    "text": "Initial evaluation confirmed FHF from acetaminophen and cerebral edema .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "cerebral edema"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "FHF"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1962,
    "text": "The patient was treated with hyperosmolar therapy , hyperventilation , sedation , and chemical paralysis .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hyperventilation"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1963,
    "text": "Her intracranial pressure remained elevated despite maximal medical therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1964,
    "text": "We then initiated therapeutic hypothermia which was continued for 5 days .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypothermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1965,
    "text": "At re - warming , patient had resolution of her cerebral edema and intracranial hypertension .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "cerebral edema"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "intracranial hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1966,
    "text": "At discharge , she had complete recovery of neurological and hepatic functions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1967,
    "text": "CONCLUSION : In patients with FHF and cerebral edema from acetaminophen overdose , prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "cerebral edema"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "FHF"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "acetaminophen"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "overdose"
      ],
      [
        "T4",
        "Disease",
        15,
        16,
        "hypothermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1968,
    "text": "A clinical trial of hypothermia in patients with this condition is warranted .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypothermia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1969,
    "text": "Binasal visual field defects are not specific to vigabatrin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Binasal visual field defects"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "vigabatrin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1970,
    "text": "This study investigated the visual defects associated with the antiepileptic drug vigabatrin ( VGB ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "visual defects"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "vigabatrin"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "VGB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1971,
    "text": "Two hundred four people with epilepsy were grouped on the basis of antiepileptic drug therapy ( current , previous , or no exposure to VGB ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "epilepsy"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "VGB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1972,
    "text": "Groups were matched with respect to age , gender , and seizure frequency .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1973,
    "text": "All patients underwent objective assessment of electrophysiological function ( wide - field multifocal electroretinography ) and conventional visual field testing ( static perimetry ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1974,
    "text": "Bilateral visual field constriction was observed in 59 % of patients currently taking VGB , 43 % of patients who previously took VGB , and 24 % of patients with no exposure to VGB .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "VGB"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "VGB"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "VGB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1975,
    "text": "Assessment of retinal function revealed abnormal responses in 48 % of current VGB users and 22 % of prior VGB users , but in none of the patients without previous exposure to VGB .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "VGB"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "VGB"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "VGB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1976,
    "text": "Bilateral visual field abnormalities are common in the treated epilepsy population , irrespective of drug history .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Bilateral visual field abnormalities"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1977,
    "text": "Assessment by conventional static perimetry may neither be sufficiently sensitive nor specific to reliably identify retinal toxicity associated with VGB .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "retinal toxicity"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "VGB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1978,
    "text": "Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "crack cocaine"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "HIV infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1979,
    "text": "BACKGROUND : Little is known about the possible role that smoking crack cocaine has on the incidence of HIV infection .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "crack cocaine"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "HIV infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1980,
    "text": "Given the increasing use of crack cocaine , we sought to examine whether use of this illicit drug has become a risk factor for HIV infection .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "crack cocaine"
      ],
      [
        "T1",
        "Disease",
        24,
        26,
        "HIV infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1981,
    "text": "METHODS : We included data from people participating in the Vancouver Injection Drug Users Study who reported injecting illicit drugs at least once in the month before enrolment , lived in the greater Vancouver area , were HIV - negative at enrolment and completed at least 1 follow - up study visit .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1982,
    "text": "To determine whether the risk of HIV seroconversion among daily smokers of crack cocaine changed over time , we used Cox proportional hazards regression and divided the study into 3 periods : May 1 , 1996 - Nov .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "HIV seroconversion"
      ],
      [
        "T1",
        "Chemical",
        12,
        14,
        "crack cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1983,
    "text": "30 , 1999 ( period 1 ) , Dec .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1984,
    "text": "1 , 1999 - Nov .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1985,
    "text": "30 , 2002 ( period 2 ) , and Dec .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1986,
    "text": "1 , 2002 - Dec .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1987,
    "text": "30 , 2005 ( period 3 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1988,
    "text": "RESULTS : Overall , 1048 eligible injection drug users were included in our study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1989,
    "text": "Of these , 137 acquired HIV infection during follow - up .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "HIV infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1990,
    "text": "The mean proportion of participants who reported daily smoking of crack cocaine increased from 11 . 6 % in period 1 to 39 . 7 % in period 3 .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "crack cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1991,
    "text": "After adjusting for potential confounders , we found that the risk of HIV seroconversion among participants who were daily smokers of crack cocaine increased over time ( period 1 : hazard ratio [ HR ] 1 . 03 , 95 % confidence interval [ CI ] 0 . 57 - 1 . 85 ; period 2 : HR 1 . 68 , 95 % CI 1 . 01 - 2 . 80 ; and period 3 : HR 2 . 74 , 95 % CI 1 . 06 - 7 . 11 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "HIV seroconversion"
      ],
      [
        "T1",
        "Chemical",
        21,
        23,
        "crack cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1992,
    "text": "INTERPRETATION : Smoking of crack cocaine was found to be an independent risk factor for HIV seroconversion among people who were injection drug users .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "crack cocaine"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "HIV seroconversion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1993,
    "text": "This finding points to the urgent need for evidence - based public health initiatives targeted at people who smoke crack cocaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        21,
        "crack cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1994,
    "text": "Fluoxetine improves the memory deficits caused by the chemotherapy agent 5 - fluorouracil .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "memory deficits"
      ],
      [
        "T1",
        "Chemical",
        10,
        13,
        "5 - fluorouracil"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1995,
    "text": "Cancer patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1996,
    "text": "A widely used chemotherapeutic agent , 5 - fluorouracil ( 5 - FU ) , readily crosses the blood - brain barrier and so could have a direct effect on brain function .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "5 - fluorouracil"
      ],
      [
        "T1",
        "Chemical",
        10,
        13,
        "5 - FU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1997,
    "text": "In particular this anti mitotic drug could reduce cell proliferation in the neurogenic regions of the adult brain .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 1998,
    "text": "In contrast reports indicate that hippocampal dependent neurogenesis and cognition are enhanced by the SSRI antidepressant Fluoxetine .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "SSRI"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "Fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 1999,
    "text": "In this investigation the behavioural effects of chronic ( two week ) treatment with 5 - FU and ( three weeks ) with Fluoxetine either separately or in combination with 5 - FU were tested on adult Lister hooded rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        17,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        30,
        33,
        "5 - FU"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "Fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2000,
    "text": "Behavioural effects were tested using a context dependent conditioned emotional response test ( CER ) which showed that animals treated with 5 - FU had a significant reduction in freezing time compared to controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        24,
        "5 - FU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2001,
    "text": "A separate group of animals was tested using a hippocampal dependent spatial working memory test , the object location recognition test ( OLR ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2002,
    "text": "Animals treated only with 5 - FU showed significant deficits in their ability to carry out the OLR task but co administration of Fluoxetine improved their performance .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "Fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2003,
    "text": "5 - FU chemotherapy caused a significant reduction in the number of proliferating cells in the sub granular zone of the dentate gyrus compared to controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "5 - FU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2004,
    "text": "This reduction was eliminated when Fluoxetine was co administered with 5 - FU .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        13,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "Fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2005,
    "text": "Fluoxetine on its own had no effect on proliferating cell number or behaviour .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2006,
    "text": "These findings suggest that 5 - FU can negatively affect both cell proliferation and hippocampal dependent working memory and that these deficits can be reversed by the simultaneous administration of the antidepressant Fluoxetine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "5 - FU"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "Fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2007,
    "text": "Liver - specific ablation of integrin - linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "hepatomegaly"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "phenobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2008,
    "text": "We have recently demonstrated that disruption of extracellular matrix ( ECM ) / integrin signaling via elimination of integrin - linked kinase ( ILK ) in hepatocytes interferes with signals leading to termination of liver regeneration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2009,
    "text": "This study investigates the role of ILK in liver enlargement induced by phenobarbital ( PB ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "phenobarbital"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2010,
    "text": "Wild - type ( WT ) and ILK : liver - / - mice were given PB ( 0 . 1 % in drinking water ) for 10 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2011,
    "text": "Livers were harvested on 2 , 5 , and 10 days during PB administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2012,
    "text": "In the hepatocyte - specific ILK / liver - / - mice , the liver : body weight ratio was more than double as compared to 0 h at day 2 ( 2 . 5 times ) , while at days 5 and 10 , it was enlarged three times .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2013,
    "text": "In the WT mice , the increase was as expected from previous literature ( 1 . 8 times ) and seems to have leveled off after day 2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2014,
    "text": "There were slightly increased proliferating cell nuclear antigen - positive cells in the ILK / liver - / - animals at day 2 as compared to WT after PB administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        28,
        29,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2015,
    "text": "In the WT animals , the proliferative response had come back to normal by days 5 and 10 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2016,
    "text": "Hepatocytes of the ILK / liver - / - mice continued to proliferate up until day 10 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2017,
    "text": "ILK / liver - / - mice also showed increased expression of key genes involved in hepatocyte proliferation at different time points during PB administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2018,
    "text": "In summary , ECM proteins communicate with the signaling machinery of dividing cells via ILK to regulate hepatocyte proliferation and termination of the proliferative response .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2019,
    "text": "Lack of ILK in the hepatocytes imparts prolonged proliferative response not only to stimuli related to liver regeneration but also to xenobiotic chemical mitogens , such as PB .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        28,
        "PB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2020,
    "text": "Decreased Expression of Na / K - ATPase , NHE3 , NBC1 , AQP1 and OAT in Gentamicin - induced Nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "Na"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "K"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "Gentamicin"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "Nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2021,
    "text": "The present study was aimed to determine whether there is an altered regulation of tubular transporters in gentamicin - induced nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "gentamicin"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2022,
    "text": "Sprague - Dawley male rats ( 200 ~ 250 g ) were subcutaneously injected with gentamicin ( 100 mg / kg per day ) for 7 days , and the expression of tubular transporters was determined by immunoblotting and immunohistochemistry .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2023,
    "text": "The mRNA and protein expression of OAT was also determined .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2024,
    "text": "Gentamicin - treated rats exhibited significantly decreased creatinine clearance along with increased plasma creatinine levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Gentamicin"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "creatinine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2025,
    "text": "Accordingly , the fractional excretion of sodium increased .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2026,
    "text": "Urine volume was increased , while urine osmolality and free water reabsorption were decreased .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2027,
    "text": "Immunoblotting and immunohistochemistry revealed decreased expression of Na ( + ) / K ( + ) - ATPase , NHE3 , NBC1 , and AQP1 in the kidney of gentamicin - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "Na"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "K"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2028,
    "text": "The expression of OAT1 and OAT3 was also decreased .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2029,
    "text": "Gentamicin - induced nephropathy may at least in part be causally related with a decreased expression of Na ( + ) / K ( + ) - ATPase , NHE3 , NBC1 , AQP1 and OAT .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Gentamicin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "nephropathy"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "Na"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "K"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2030,
    "text": "Acute renal failure after high - dose methotrexate therapy in a patient with ileostomy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "methotrexate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2031,
    "text": "High - dose methotrexate ( HD - MTX ) is an important treatment for Burkitt lymphoma , but can cause hepatic and renal toxicity when its clearance is delayed .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "Burkitt lymphoma"
      ],
      [
        "T1",
        "Disease",
        20,
        24,
        "hepatic and renal toxicity"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "methotrexate"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "MTX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2032,
    "text": "We report a case of acute renal failure after HD - MTX therapy in a patient with ileostomy , The patient was a 3 - year - old boy who had received a living - related liver transplantation for congenital biliary atresia .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        40,
        42,
        "biliary atresia"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "MTX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2033,
    "text": "At day 833 after the transplantation , he was diagnosed with PTLD ( post - transplantation lymphoproliferative disorder , Burkitt - type malignant lymphoma ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        18,
        "post - transplantation lymphoproliferative disorder"
      ],
      [
        "T1",
        "Disease",
        19,
        24,
        "Burkitt - type malignant lymphoma"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "PTLD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2034,
    "text": "During induction therapy , he suffered ileal perforation and ileostomy was performed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2035,
    "text": "Subsequent HD - MTX therapy caused acute renal failure that required continuous hemodialysis .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "MTX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2036,
    "text": "We supposed that intravascular hypovolemia due to substantial drainage from the ileostoma caused acute prerenal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "acute prerenal failure"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hypovolemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2037,
    "text": "After recovery of his renal function , we could safely treat the patient with HD - MTX therapy by controlling drainage from ileostoma with total parenteral nutrition .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "MTX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2038,
    "text": "Longitudinal association of alcohol use with HIV disease progression and psychological health of women with HIV .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "HIV disease"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2039,
    "text": "We evaluated the association of alcohol consumption and depression , and their effects on HIV disease progression among women with HIV .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "HIV disease"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "alcohol"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2040,
    "text": "The study included 871 women with HIV who were recruited from 1993 - 1995 in four US cities .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2041,
    "text": "The participants had physical examination , medical record extraction , and venipuncture , CD4 + T - cell counts determination , measurement of depression symptoms ( using the self - report Center for Epidemiological Studies - Depression Scale ) , and alcohol use assessment at enrollment , and semiannually until March 2000 .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "depression"
      ],
      [
        "T1",
        "Disease",
        36,
        37,
        "Depression"
      ],
      [
        "T2",
        "Chemical",
        41,
        42,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2042,
    "text": "Multilevel random coefficient ordinal models as well as multilevel models with joint responses were used in the analysis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2043,
    "text": "There was no significant association between level of alcohol use and CD4 + T - cell counts .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2044,
    "text": "When participants were stratified by antiretroviral therapy ( ART ) use , the association between alcohol and CD4 + T - cell did not reach statistical significance .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2045,
    "text": "The association between alcohol consumption and depression was significant ( p < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "alcohol"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2046,
    "text": "Depression had a significant negative effect on CD4 + T - cell counts over time regardless of ART use .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2047,
    "text": "Our findings suggest that alcohol consumption has a direct association with depression .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "alcohol"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2048,
    "text": "Moreover , depression is associated with HIV disease progression .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "HIV disease"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2049,
    "text": "Our findings have implications for the provision of alcohol use interventions and psychological resources to improve the health of women with HIV .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "alcohol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2050,
    "text": "Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine - induced status epilepticus .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "status epilepticus"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2051,
    "text": "BACKGROUND : Neuroinflammation occurs after seizures and is implicated in epileptogenesis .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Neuroinflammation"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2052,
    "text": "CCR2 is a chemokine receptor for CCL2 and their interaction mediates monocyte infiltration in the neuroinflammatory cascade triggered in different brain pathologies .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "neuroinflammatory"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2053,
    "text": "In this work CCR2 and CCL2 expression were examined following status epilepticus ( SE ) induced by pilocarpine injection .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "SE"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2054,
    "text": "METHODS : SE was induced by pilocarpine injection .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "SE"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2055,
    "text": "Control rats were injected with saline instead of pilocarpine .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2056,
    "text": "Five days after SE , CCR2 staining in neurons and glial cells was examined using imunohistochemical analyses .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "SE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2057,
    "text": "The number of CCR2 positive cells was determined using stereology probes in the hippocampus .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2058,
    "text": "CCL2 expression in the hippocampus was examined by molecular assay .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2059,
    "text": "RESULTS : Increased CCR2 was observed in the hippocampus after SE .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "SE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2060,
    "text": "Seizures also resulted in alterations to the cell types expressing CCR2 .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2061,
    "text": "Increased numbers of neurons that expressed CCR2 was observed following SE .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "SE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2062,
    "text": "Microglial cells were more closely apposed to the CCR2 - labeled cells in SE rats .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "SE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2063,
    "text": "In addition , rats that experienced SE exhibited CCR2 - labeling in populations of hypertrophied astrocytes , especially in CA1 and dentate gyrus .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "SE"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "hypertrophied"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2064,
    "text": "These CCR2 + astroctytes were not observed in control rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2065,
    "text": "Examination of CCL2 expression showed that it was elevated in the hippocampus following SE .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "SE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2066,
    "text": "CONCLUSION : The data show that CCR2 and CCL2 are up - regulated in the hippocampus after pilocarpine - induced SE .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "pilocarpine"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "SE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2067,
    "text": "Seizures also result in changes to CCR2 receptor expression in neurons and astrocytes .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2068,
    "text": "These changes might be involved in detrimental neuroplasticity and neuroinflammatory changes that occur following seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "neuroinflammatory"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2069,
    "text": "Metallothionein induction reduces caspase - 3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Metallothionein"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "carmustine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2070,
    "text": "Hippocampal integrity is essential for cognitive functions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2071,
    "text": "On the other hand , induction of metallothionein ( MT ) by ZnSO ( 4 ) and its role in neuroprotection has been documented .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        16,
        "ZnSO ( 4 )"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "metallothionein"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "MT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2072,
    "text": "The present study aimed to explore the effect of MT induction on carmustine ( BCNU ) - induced hippocampal cognitive dysfunction in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "cognitive dysfunction"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "MT"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "carmustine"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "BCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2073,
    "text": "A total of 60 male Wistar albino rats were randomly divided into four groups ( 15 / group ) : The control group injected with single doses of normal saline ( i . c . v ) followed 24 h later by BCNU solvent ( i . v ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        42,
        43,
        "BCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2074,
    "text": "The second group administered ZnSO ( 4 ) ( 0 . 1 micromol / 10 microl normal saline , i . c . v , once ) then BCNU solvent ( i . v ) after 24 h .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        8,
        "ZnSO ( 4 )"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "BCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2075,
    "text": "Third group received BCNU ( 20 mg / kg , i . v , once ) 24 h after injection with normal saline ( i . c . v ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "BCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2076,
    "text": "Fourth group received a single dose of ZnSO ( 4 ) ( 0 . 1 micromol / 10 microl normal saline , i . c . v ) then BCNU ( 20 mg / kg , i . v , once ) after 24 h .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        11,
        "ZnSO ( 4 )"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "BCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2077,
    "text": "The obtained data revealed that BCNU administration resulted in deterioration of learning and short - term memory ( STM ) , as measured by using radial arm water maze , accompanied with decreased hippocampal glutathione reductase ( GR ) activity and reduced glutathione ( GSH ) content .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        17,
        "deterioration of learning and short - term memory"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "BCNU"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "glutathione"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "glutathione"
      ],
      [
        "T4",
        "Chemical",
        44,
        45,
        "GSH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2078,
    "text": "Also , BCNU administration increased serum tumor necrosis factor - alpha ( TNFalpha ) , hippocampal MT and malondialdehyde ( MDA ) contents as well as caspase - 3 activity in addition to histological alterations .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "BCNU"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "tumor"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "necrosis"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "MT"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "malondialdehyde"
      ],
      [
        "T5",
        "Chemical",
        20,
        21,
        "MDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2079,
    "text": "ZnSO ( 4 ) pretreatment counteracted BCNU - induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase - 3 .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        4,
        "ZnSO ( 4 )"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "BCNU"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "GSH"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "MDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2080,
    "text": "The histological features were improved in hippocampus of rats treated with ZnSO ( 4 ) + BCNU compared to only BCNU - treated animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        15,
        "ZnSO ( 4 )"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "BCNU"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "BCNU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2081,
    "text": "In conclusion , MT induction halts BCNU - induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha , MDA and caspase - 3 activity with subsequent preservation of cognition .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "MT"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "BCNU"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "toxicity"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "GSH"
      ],
      [
        "T4",
        "Chemical",
        27,
        28,
        "MDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2082,
    "text": "Fatal carbamazepine induced fulminant eosinophilic ( hypersensitivity ) myocarditis : emphasis on anatomical and histological characteristics , mechanisms and genetics of drug hypersensitivity and differential diagnosis .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "fulminant eosinophilic"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "drug hypersensitivity"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "carbamazepine"
      ],
      [
        "T3",
        "Disease",
        6,
        7,
        "hypersensitivity"
      ],
      [
        "T4",
        "Disease",
        8,
        9,
        "myocarditis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2083,
    "text": "The most severe adverse reactions to carbamazepine have been observed in the haemopoietic system , the liver and the cardiovascular system .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2084,
    "text": "A frequently fatal , although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic ( hypersensitivity ) myocarditis .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "carbamazepine"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hypersensitivity"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "myocarditis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2085,
    "text": "We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hypersensitivity"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "myocarditis"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2086,
    "text": "Acute hypersensitivity myocarditis was not suspected clinically , and the diagnosis was made post - mortem .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypersensitivity"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "myocarditis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2087,
    "text": "Histology revealed diffuse infiltration of the myocardium by eosinophils and lymphocytes with myocyte damage .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2088,
    "text": "Clinically , death was due to cardiogenic shock .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "cardiogenic shock"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2089,
    "text": "To best of our knowledge this is the second case of fatal carbamazepine induced myocarditis reported in English literature .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "carbamazepine"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "myocarditis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2090,
    "text": "Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "MPTP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2091,
    "text": "OBJECTIVES : Neuropsychiatric symptoms are increasingly recognised as a significant problem in patients with Parkinson ' s disease ( PD ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        18,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2092,
    "text": "These symptoms may be due to ' sensitisation ' following repeated levodopa treatment or a direct effect of dopamine on the disease state .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "levodopa"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2093,
    "text": "The levodopa - treated MPTP - lesioned marmoset was used as a model of neuropsychiatric symptoms in PD patients .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "neuropsychiatric symptoms"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "levodopa"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "MPTP"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2094,
    "text": "Here we compare the time course of levodopa - induced motor fluctuations and neuropsychiatric - like behaviors to determine the relationship between duration of treatment and onset of symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        17,
        "neuropsychiatric - like behaviors"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2095,
    "text": "METHODS : Marmosets were administered 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( 2 . 0 mg / kg s . c . ) for five days , resulting in stable parkinsonism .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        22,
        "1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine"
      ],
      [
        "T1",
        "Disease",
        41,
        42,
        "parkinsonism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2096,
    "text": "Levodopa ( 15 mg / kg and benserazide , 3 . 75 mg / kg ) p . o .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Levodopa"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "benserazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2097,
    "text": "b . i . d , was administered for 30 days .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2098,
    "text": "Animals were evaluated for parkinsonian disability , dyskinesia and on - time ( motor fluctuations ) and neuropsychiatric - like behaviors on Day 0 ( prior to levodopa ) and on Days 1 , 7 , 13 , 27 and 30 of treatment using post hoc DVD analysis by a trained rater , blind to the treatment day .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "parkinsonian disability"
      ],
      [
        "T1",
        "Disease",
        17,
        21,
        "neuropsychiatric - like behaviors"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "dyskinesia"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2099,
    "text": "RESULTS : The neuropsychiatric - like behavior rating scale demonstrated high interrater reliability between three trained raters of differing professional backgrounds .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "neuropsychiatric - like behavior"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2100,
    "text": "As anticipated , animals exhibited a progressive increase in levodopa - induced motor fluctuations , dyskinesia and wearing - off , that correlated with the duration of levodopa therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "dyskinesia"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2101,
    "text": "In contrast , levodopa - induced neuropsychiatric - like behaviors were present on Day 1 of levodopa treatment and their severity did not correlate with duration of treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        10,
        "neuropsychiatric - like behaviors"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "levodopa"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2102,
    "text": "CONCLUSIONS : The data suggest that neuropsychiatric disorders in PD are more likely an interaction between levodopa and the disease state than a consequence of sensitisation to repeated dopaminergic therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "neuropsychiatric disorders"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "PD"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2103,
    "text": "Contrast medium nephrotoxicity after renal artery and coronary angioplasty .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Contrast medium"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2104,
    "text": "BACKGROUND : Renal dysfunction induced by iodinated contrast medium ( CM ) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty ( PTRA ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Renal dysfunction"
      ],
      [
        "T1",
        "Chemical",
        7,
        9,
        "contrast medium"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "CM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2105,
    "text": "PURPOSE : To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention ( PCI ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "nephrotoxic"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "CM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2106,
    "text": "MATERIAL AND METHODS : A total of 33 patients successfully treated with PTRA ( PTRA group , mean age 70 + / - 12 years , 23 female , basal creatinine 1 . 46 + / - 0 . 79 , range 0 . 7 - 4 . 9 mg / dl ) were compared with 33 patients undergoing successful PCI ( PCI group ) , matched for basal creatinine ( 1 . 44 + / - 0 . 6 , range 0 . 7 - 3 . 4 mg / dl ) , gender , and age .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        31,
        "creatinine"
      ],
      [
        "T1",
        "Chemical",
        69,
        70,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2107,
    "text": "In both groups postprocedural ( 48 h ) serum creatinine was measured .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2108,
    "text": "RESULTS : Postprocedural creatinine level decreased nonsignificantly in the PTRA group ( 1 . 46 + / - 0 . 8 vs . 1 . 34 + / - 0 . 5 mg / dl , P = NS ) and increased significantly in the PCI group ( 1 . 44 + / - 0 . 6 vs . 1 . 57 + / - 0 . 7 mg / dl , P < 0 . 02 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2109,
    "text": "Changes in serum creatinine after intervention ( after - before ) were significantly different between the PTRA and PCI groups ( - 0 . 12 + / - 0 . 5 vs . 0 . 13 + / - 0 . 3 , P = 0 . 014 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2110,
    "text": "This difference was not related to either a different clinical risk profile or to the volume of CM administered .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "CM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2111,
    "text": "CONCLUSION : In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "renal damage"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "CM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2112,
    "text": "The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "CM"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2113,
    "text": "Diphenhydramine prevents the haemodynamic changes of cimetidine in ICU patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Diphenhydramine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "cimetidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2114,
    "text": "Cimetidine , a histamine 2 ( H2 ) antagonist , produces a decrease in arterial pressure due to vasodilatation , especially in critically ill patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cimetidine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "histamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2115,
    "text": "This may be because cimetidine acts as a histamine agonist .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "cimetidine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "histamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2116,
    "text": "We , therefore , investigated the effects of the histamine 1 ( H1 ) receptor antagonist , diphenhydramine , on the haemodynamic changes observed after cimetidine in ICU patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "histamine"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "diphenhydramine"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "cimetidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2117,
    "text": "Each patient was studied on two separate days .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2118,
    "text": "In a random fashion , they received cimetidine 200 mg iv on one day , and on the other , a pretreatment of diphenhydramine 40 mg iv with cimetidine 200 mg iv .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "cimetidine"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "diphenhydramine"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "cimetidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2119,
    "text": "In the non - pretreatment group , mean arterial pressure ( MAP ) decreased from 107 . 4 + / - 8 . 4 mmHg to 86 . 7 + / - 11 . 4 mmHg ( P less than 0 . 01 ) two minutes after cimetidine .",
    "labels": [
      [
        "T0",
        "Chemical",
        47,
        48,
        "cimetidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2120,
    "text": "Also , systemic vascular resistance ( SVR ) decreased during the eight - minute observation period ( P less than 0 . 01 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2121,
    "text": "In contrast , in the pretreatment group , little haemodynamic change was seen .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2122,
    "text": "We conclude that an H1 antagonist may be useful in preventing hypotension caused by iv cimetidine , since the vasodilating activity of cimetidine is mediated , in part , through the H1 receptor .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "cimetidine"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "cimetidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2123,
    "text": "Medical and psychiatric outcomes for patients transplanted for acetaminophen - induced acute liver failure : a case - control study .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "acute liver failure"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "acetaminophen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2124,
    "text": "BACKGROUND : Acetaminophen - induced hepatotoxicity is the most common cause of acute liver failure ( ALF ) in the UK .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "acute liver failure"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Acetaminophen"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "hepatotoxicity"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "ALF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2125,
    "text": "Patients often consume the drug with suicidal intent or with a background of substance dependence .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2126,
    "text": "AIMS AND METHODS : We compared the severity of pretransplant illness , psychiatric co - morbidity , medical and psychosocial outcomes of all patients who had undergone liver transplantation ( LT ) emergently between 1999 - 2004 for acetaminophen - induced ALF ( n = 36 ) with age - and sex - matched patients undergoing emergent LT for non - acetaminophen - induced ALF ( n = 35 ) and elective LT for chronic liver disease ( CLD , n = 34 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        74,
        77,
        "chronic liver disease"
      ],
      [
        "T1",
        "Chemical",
        38,
        39,
        "acetaminophen"
      ],
      [
        "T2",
        "Disease",
        41,
        42,
        "ALF"
      ],
      [
        "T3",
        "Chemical",
        61,
        62,
        "acetaminophen"
      ],
      [
        "T4",
        "Disease",
        64,
        65,
        "ALF"
      ],
      [
        "T5",
        "Disease",
        78,
        79,
        "CLD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2127,
    "text": "RESULTS : Acetaminophen - induced ALF patients undergoing LT had a greater severity of pre - LT illness reflected by higher Acute Physiology and Chronic Health Evaluation II scores and requirement for organ support compared with the other two groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Acetaminophen"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "ALF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2128,
    "text": "Twenty ( 56 % ) acetaminophen - induced ALF patients had a formal psychiatric diagnosis before LT ( non - acetaminophen - induced ALF = 0 / 35 , CLD = 2 / 34 ; P < 0 . 01 for all ) and nine ( 25 % ) had a previous suicide attempt .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "acetaminophen"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "ALF"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "acetaminophen"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "ALF"
      ],
      [
        "T4",
        "Disease",
        29,
        30,
        "CLD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2129,
    "text": "During follow - up ( median 5 years ) , there were no significant differences in rejection ( acute and chronic ) , graft failure or survival between the groups ( acetaminophen - induced ALF 1 year 87 % , 5 years 75 % ; non - acetaminophen - induced ALF 88 % , 78 % ; CLD 93 % , 82 % : P > 0 . 6 log rank ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        32,
        "acetaminophen"
      ],
      [
        "T1",
        "Disease",
        34,
        35,
        "ALF"
      ],
      [
        "T2",
        "Chemical",
        47,
        48,
        "acetaminophen"
      ],
      [
        "T3",
        "Disease",
        50,
        51,
        "ALF"
      ],
      [
        "T4",
        "Disease",
        57,
        58,
        "CLD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2130,
    "text": "Two acetaminophen - induced ALF patients reattempted suicide post - LT ( one died 8 years post - LT ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "acetaminophen"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "ALF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2131,
    "text": "CONCLUSIONS : Despite a high prevalence of psychiatric disturbance , outcomes for patients transplanted emergently for acetaminophen - induced ALF were comparable to those transplanted for non - acetaminophen - induced ALF and electively for CLD .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "acetaminophen"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "ALF"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "acetaminophen"
      ],
      [
        "T3",
        "Disease",
        31,
        32,
        "ALF"
      ],
      [
        "T4",
        "Disease",
        35,
        36,
        "CLD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2132,
    "text": "Multidisciplinary approaches with long - term psychiatric follow - up may contribute to low post - transplant suicide rates seen and low rates of graft loss because of non - compliance .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2133,
    "text": "Antithrombotic drug use , cerebral microbleeds , and intracerebral hemorrhage : a systematic review of published and unpublished studies .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "cerebral microbleeds"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "intracerebral hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2134,
    "text": "BACKGROUND AND PURPOSE : Cerebral microbleeds ( MB ) are potential risk factors for intracerebral hemorrhage ( ICH ) , but it is unclear if they are a contraindication to using antithrombotic drugs .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "Cerebral microbleeds"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "intracerebral hemorrhage"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "MB"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "ICH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2135,
    "text": "Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke ( IS ) / transient ischemic attack ( TIA ) .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "ischemic stroke"
      ],
      [
        "T1",
        "Disease",
        25,
        28,
        "transient ischemic attack"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "MB"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "ICH"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "IS"
      ],
      [
        "T5",
        "Disease",
        29,
        30,
        "TIA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2136,
    "text": "METHODS : We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in : ( 1 ) antithrombotic users vs nonantithrombotic users with ICH ; ( 2 ) antithrombotic users vs nonusers with IS / TIA ; and ( 3 ) ICH vs ischemic events stratified by antithrombotic use .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "stroke"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "TIA"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "MB"
      ],
      [
        "T3",
        "Disease",
        35,
        36,
        "ICH"
      ],
      [
        "T4",
        "Disease",
        45,
        46,
        "IS"
      ],
      [
        "T5",
        "Disease",
        47,
        48,
        "TIA"
      ],
      [
        "T6",
        "Disease",
        53,
        54,
        "ICH"
      ],
      [
        "T7",
        "Disease",
        55,
        56,
        "ischemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2137,
    "text": "We also analyzed published and unpublished follow - up data to determine the risk of ICH in antithrombotic users with MB .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "ICH"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "MB"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2138,
    "text": "RESULTS : In a pooled analysis of 1460 ICH and 3817 IS / TIA , MB were more frequent in ICH vs IS / TIA in all treatment groups , but the excess increased from 2 . 8 ( odds ratio ; range , 2 . 3 - 3 . 5 ) in nonantithrombotic users to 5 . 7 ( range , 3 . 4 - 9 . 7 ) in antiplatelet users and 8 . 0 ( range , 3 . 5 - 17 . 8 ) in warfarin users ( P difference = 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "ICH"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "IS"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "TIA"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "MB"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "ICH"
      ],
      [
        "T5",
        "Disease",
        22,
        23,
        "IS"
      ],
      [
        "T6",
        "Disease",
        24,
        25,
        "TIA"
      ],
      [
        "T7",
        "Chemical",
        89,
        90,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2139,
    "text": "There was also an excess of MB in warfarin users vs nonusers with ICH ( OR , 2 . 7 ; 95 % CI , 1 . 6 - 4 . 4 ; P < 0 . 001 ) but none in warfarin users with IS / TIA ( OR , 1 . 3 ; 95 % CI , 0 . 9 - 1 . 7 ; P = 0 . 33 ; P difference = 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "MB"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "warfarin"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "ICH"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "warfarin"
      ],
      [
        "T4",
        "Disease",
        45,
        46,
        "IS"
      ],
      [
        "T5",
        "Disease",
        47,
        48,
        "TIA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2140,
    "text": "There was a smaller excess of MB in antiplatelet users vs nonusers with ICH ( OR , 1 . 7 ; 95 % CI , 1 . 3 - 2 . 3 ; P < 0 . 001 ) , but findings were similar for antiplatelet users with IS / TIA ( OR , 1 . 4 ; 95 % CI , 1 . 2 - 1 . 7 ; P < 0 . 001 ; P difference = 0 . 25 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "MB"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "ICH"
      ],
      [
        "T2",
        "Disease",
        48,
        49,
        "IS"
      ],
      [
        "T3",
        "Disease",
        50,
        51,
        "TIA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2141,
    "text": "In pooled follow - up data for 768 antithrombotic users , presence of MB at baseline was associated with a substantially increased risk of subsequent ICH ( OR , 12 . 1 ; 95 % CI , 3 . 4 - 42 . 5 ; P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "MB"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "ICH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2142,
    "text": "CONCLUSIONS : The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin - associated ICH .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "MB"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "warfarin"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "ICH"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "MB"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "warfarin"
      ],
      [
        "T5",
        "Disease",
        25,
        26,
        "ICH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2143,
    "text": "Limited prospective data corroborate these findings , but larger prospective studies are urgently required .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2144,
    "text": "Studies of synergy between morphine and a novel sodium channel blocker , CNSB002 , in rat models of inflammatory and neuropathic pain .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "neuropathic pain"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "morphine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "sodium"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "CNSB002"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2145,
    "text": "OBJECTIVE : This study determined the antihyperalgesic effect of CNSB002 , a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        33,
        "neuropathic pain"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "CNSB002"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "sodium"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2146,
    "text": "DESIGN : Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models : carrageenan - induced paw inflammation and streptozotocin ( STZ ) - induced diabetic neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        48,
        50,
        "diabetic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "morphine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "CNSB002"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "pain"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "carrageenan"
      ],
      [
        "T5",
        "Disease",
        40,
        41,
        "inflammation"
      ],
      [
        "T6",
        "Chemical",
        42,
        43,
        "streptozotocin"
      ],
      [
        "T7",
        "Chemical",
        44,
        45,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2147,
    "text": "RESULTS : The maximum nonsedating doses were : morphine , 3 . 2 mg / kg ; CNSB002 10 . 0 mg / kg ; 5 . 0 mg / kg CNSB002 with morphine 3 . 2 mg / kg in combination .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "CNSB002"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "CNSB002"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2148,
    "text": "The doses calculated to cause 50 % reversal of hyperalgesia ( ED50 ) were 7 . 54 ( 1 . 81 ) and 4 . 83 ( 1 . 54 ) in the carrageenan model and 44 . 18 ( 1 . 37 ) and 9 . 14 ( 1 . 24 ) in the STZ - induced neuropathy model for CNSB002 and morphine , respectively ( mg / kg ; mean , SEM ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "hyperalgesia"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "carrageenan"
      ],
      [
        "T2",
        "Chemical",
        55,
        56,
        "STZ"
      ],
      [
        "T3",
        "Disease",
        58,
        59,
        "neuropathy"
      ],
      [
        "T4",
        "Chemical",
        61,
        62,
        "CNSB002"
      ],
      [
        "T5",
        "Chemical",
        63,
        64,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2149,
    "text": "These values were greater than the maximum nonsedating doses .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2150,
    "text": "The ED50 values for morphine when given in combination with CNSB002 ( 5 mg / kg ) were less than the maximum nonsedating dose : 0 . 56 ( 1 . 55 ) in the carrageenan model and 1 . 37 ( 1 . 23 ) in the neuropathy model ( mg / kg ; mean , SEM ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "CNSB002"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "carrageenan"
      ],
      [
        "T3",
        "Disease",
        48,
        49,
        "neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2151,
    "text": "The antinociception after morphine ( 3 . 2 mg / kg ) was increased by co - administration with CNSB002 from 28 . 0 and 31 . 7 % to 114 . 6 and 56 . 9 % reversal of hyperalgesia in the inflammatory and neuropathic models , respectively ( P < 0 . 01 ; one - way analysis of variance - significantly greater than either drug given alone ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "CNSB002"
      ],
      [
        "T2",
        "Disease",
        40,
        41,
        "hyperalgesia"
      ],
      [
        "T3",
        "Disease",
        45,
        46,
        "neuropathic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2152,
    "text": "CONCLUSIONS : The maximum antihyperalgesic effect achievable with nonsedating doses of morphine may be increased significantly when the drug is used in combination with CNSB002 .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "morphine"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "CNSB002"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2153,
    "text": "Heparin - induced thrombocytopenia : a practical review .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Heparin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2154,
    "text": "Heparin - induced thrombocytopenia ( HIT ) remains under - recognized despite its potentially devastating outcomes .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Heparin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2155,
    "text": "It begins when heparin exposure stimulates the formation of heparin - platelet factor 4 antibodies , which in turn triggers the release of procoagulant platelet particles .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "heparin"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2156,
    "text": "Thrombosis and thrombocytopenia that follow comprise the 2 hallmark traits of HIT , with the former largely responsible for significant vascular complications .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Thrombosis"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2157,
    "text": "The prevalence of HIT varies among several subgroups , with greater incidence in surgical as compared with medical populations .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2158,
    "text": "HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after heparin exposure .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "HIT"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "thrombosis"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "thrombosis"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2159,
    "text": "Early recognition that incorporates the clinical and serologic clues is paramount to timely institution of treatment , as its delay may result in catastrophic outcomes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2160,
    "text": "The treatment of HIT mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy , most commonly using a direct thrombin inhibitor .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        27,
        "direct thrombin inhibitor"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "HIT"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2161,
    "text": "Current \" diagnostic \" tests , which primarily include functional and antigenic assays , have more of a confirmatory than diagnostic role in the management of HIT .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        27,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2162,
    "text": "Special attention must be paid to cardiac patients who are often exposed to heparin multiple times during their course of treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2163,
    "text": "Direct thrombin inhibitors are appropriate , evidence - based alternatives to heparin in patients with a history of HIT , who need to undergo percutaneous coronary intervention .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "Direct thrombin inhibitors"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "heparin"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2164,
    "text": "As heparin remains one of the most frequently used medications today with potential for HIT with every heparin exposure , a close vigilance of platelet counts must be practiced whenever heparin is initiated .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "HIT"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "heparin"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2165,
    "text": "Abductor paralysis after botox injection for adductor spasmodic dysphonia .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "adductor spasmodic dysphonia"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "paralysis"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "botox"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2166,
    "text": "OBJECTIVES / HYPOTHESIS : Botulinum toxin ( Botox ) injections into the thyroarytenoid muscles are the current standard of care for adductor spasmodic dysphonia ( ADSD ) .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "adductor spasmodic dysphonia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "Botox"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "ADSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2167,
    "text": "Reported adverse effects include a period of breathiness , throat pain , and difficulty with swallowing liquids .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "throat pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2168,
    "text": "Here we report multiple cases of bilateral abductor paralysis following Botox injections for ADSD , a complication previously unreported .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "paralysis"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "Botox"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "ADSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2169,
    "text": "STUDY DESIGN : Retrospective case series .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2170,
    "text": "METHODS : Patients that received Botox injections for spasmodic dysphonia between January 2000 and October 2009 were evaluated .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "spasmodic dysphonia"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "Botox"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2171,
    "text": "Patients with ADSD were identified .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "ADSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2172,
    "text": "The number of treatments received and adverse effects were noted .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2173,
    "text": "For patients with bilateral abductor paralysis , age , sex , paralytic Botox dose , prior Botox dose , and course following paralysis were noted .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "paralysis"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "Botox"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "Botox"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2174,
    "text": "RESULTS : From a database of 452 patients receiving Botox , 352 patients had been diagnosed with ADSD .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "Botox"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "ADSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2175,
    "text": "Of these 352 patients , eight patients suffered bilateral abductor paralysis , and two suffered this complication twice .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2176,
    "text": "All affected patients were females over the age of 50 years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2177,
    "text": "Most patients had received treatments prior to abductor paralysis and continued receiving after paralysis .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "paralysis"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2178,
    "text": "Seven patients recovered after a brief period of activity restrictions , and one underwent a tracheotomy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2179,
    "text": "The incidence of abductor paralysis after Botox injection for ADSD was 0 . 34 % .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "paralysis"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "Botox"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "ADSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2180,
    "text": "CONCLUSIONS : Bilateral abductor paralysis is a rare complication of Botox injections for ADSD , causing difficulty with breathing upon exertion .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "paralysis"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "Botox"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "ADSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2181,
    "text": "The likely mechanism of paralysis is diffusion of Botox around the muscular process of the arytenoid to the posterior cricoarytenoid muscles .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "paralysis"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "Botox"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2182,
    "text": "The paralysis is temporary , and watchful waiting with restriction of activity is the recommended management .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "paralysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2183,
    "text": "Mitochondrial impairment contributes to cocaine - induced cardiac dysfunction : Prevention by the targeted antioxidant MitoQ .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Mitochondrial impairment"
      ],
      [
        "T1",
        "Disease",
        7,
        9,
        "cardiac dysfunction"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "cocaine"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "MitoQ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2184,
    "text": "The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine - induced cardiac dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2185,
    "text": "We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cocaine abuse"
      ],
      [
        "T1",
        "Disease",
        16,
        19,
        "left ventricular dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2186,
    "text": "Seven days of cocaine administration to rats led to an increased oxygen consumption detected in cardiac fibers , specifically through complex I and complex III .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2187,
    "text": "ROS levels were increased , specifically in interfibrillar mitochondria .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2188,
    "text": "In parallel there was a decrease in ATP synthesis , whereas no difference was observed in subsarcolemmal mitochondria .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "ATP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2189,
    "text": "This uncoupling effect on oxidative phosphorylation was not detectable after short - term exposure to cocaine , suggesting that these mitochondrial abnormalities were a late rather than a primary event in the pathological response to cocaine .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "mitochondrial abnormalities"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2190,
    "text": "MitoQ , a mitochondrial - targeted antioxidant , was shown to completely prevent these mitochondrial abnormalities as well as cardiac dysfunction characterized here by a diastolic dysfunction studied with a conductance catheter to obtain pressure - volume data .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "mitochondrial abnormalities"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "cardiac dysfunction"
      ],
      [
        "T2",
        "Disease",
        25,
        27,
        "diastolic dysfunction"
      ],
      [
        "T3",
        "Chemical",
        0,
        1,
        "MitoQ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2191,
    "text": "Taken together , these results extend previous studies and demonstrate that cocaine - induced cardiac dysfunction may be due to a mitochondrial defect .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "mitochondrial defect"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2192,
    "text": "Trimethoprim - induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Trimethoprim"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2193,
    "text": "A 10 - year - old male with acute leukemia presented with post - chemotherapy anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "acute leukemia"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2194,
    "text": "During red cell transfusion , he developed hemoglobinuria .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "hemoglobinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2195,
    "text": "Transfusion reaction workup was negative .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2196,
    "text": "Drug - induced immune hemolytic anemia was suspected because of positive direct antiglobulin test , negative eluate , and microspherocytes on smear pre - and post - transfusion .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "hemolytic anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2197,
    "text": "Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim - sulfamethoxazole but negative with sulfamethoxazole .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        16,
        "trimethoprim - sulfamethoxazole"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "trimethoprim"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "sulfamethoxazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2198,
    "text": "The patient recovered after discontinuing the drug , with no recurrence in 2 years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2199,
    "text": "Other causes of anemia should be considered in patients with worse - than - expected anemia after chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "anemia"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2200,
    "text": "Furthermore , hemolysis during transfusion is not always a transfusion reaction .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "hemolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2201,
    "text": "Verapamil stimulation test in hyperprolactinemia : loss of prolactin response in anatomic or functional stalk effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Verapamil"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2202,
    "text": "AIM : Verapamil stimulation test was previously investigated as a tool for differential diagnosis of hyperprolactinemia , but with conflicting results .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Verapamil"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2203,
    "text": "Macroprolactinemia was never considered in those previous studies .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Macroprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2204,
    "text": "Here , we aimed to re - investigate the diagnostic value of verapamil in a population who were all screened for macroprolactinemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "verapamil"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "macroprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2205,
    "text": "Prolactin responses to verapamil in 65 female patients ( age : 29 . 9 + / - 8 . 1 years ) with hyperprolactinemia were tested in a descriptive , matched case - control study .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "verapamil"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2206,
    "text": "METHODS : Verapamil 80 mg , p . o . was administered , and then PRL levels were measured at 8th and 16th hours , by immunometric chemiluminescence .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2207,
    "text": "Verapamil responsiveness was determined by peak percent change in basal prolactin levels ( PRL ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2208,
    "text": "RESULTS : Verapamil significantly increased PRL levels in healthy controls ( N . 8 , PRL : 183 % ) , macroprolactinoma ( N . 8 , PRL : 7 % ) , microprolactinoma ( N . 19 , PRL : 21 % ) , macroprolactinemia ( N . 23 , PRL : 126 % ) , but not in pseudoprolactinoma ( N . 8 , PRL : 0 . 8 % ) , and risperidone - induced hyperprolactinemia ( N . 7 , PRL : 3 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Verapamil"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "macroprolactinoma"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "microprolactinoma"
      ],
      [
        "T3",
        "Disease",
        45,
        46,
        "macroprolactinemia"
      ],
      [
        "T4",
        "Disease",
        60,
        61,
        "pseudoprolactinoma"
      ],
      [
        "T5",
        "Chemical",
        75,
        76,
        "risperidone"
      ],
      [
        "T6",
        "Disease",
        78,
        79,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2209,
    "text": "ROC curve analysis revealed that unresponsiveness to verapamil defined as PRL < 7 % , discriminated anatomical or functional stalk effect ( sensitivity : 74 % , specificity : 73 % , AUC : 0 . 855 + / - 0 . 04 , P < 0 . 001 , CI : 0 . 768 - 0 . 942 ) associated with pseudoprolactinoma or risperidone - induced hyperprolactinemia , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "verapamil"
      ],
      [
        "T1",
        "Disease",
        62,
        63,
        "pseudoprolactinoma"
      ],
      [
        "T2",
        "Chemical",
        64,
        65,
        "risperidone"
      ],
      [
        "T3",
        "Disease",
        67,
        68,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2210,
    "text": "CONCLUSION : Verapamil responsiveness is not a reliable finding for the differential diagnosis of hyperprolactinemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Verapamil"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2211,
    "text": "However , verapamil unresponsiveness discriminates stalk effect ( i . e . , anatomically or functionally inhibited dopaminergic tonus ) from other causes of hyperprolactinemia with varying degrees of responsiveness .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "verapamil"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2212,
    "text": "Blockade of endothelial - mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin - induced diabetic nephropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "diabetic nephropathy"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "streptozotocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2213,
    "text": "OBJECTIVE : A multicenter , controlled trial showed that early blockade of the renin - angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy , suggesting that other mechanism ( s ) are involved in the pathogenesis of early diabetic nephropathy ( diabetic nephropathy ) .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        23,
        "type 1 diabetes"
      ],
      [
        "T1",
        "Disease",
        47,
        49,
        "diabetic nephropathy"
      ],
      [
        "T2",
        "Disease",
        50,
        52,
        "diabetic nephropathy"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "angiotensin"
      ],
      [
        "T4",
        "Disease",
        31,
        32,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2214,
    "text": "We have previously demonstrated that endothelial - mesenchymal - transition ( EndoMT ) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin ( STZ ) - induced diabetes .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        22,
        "fibrosis"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "streptozotocin"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "STZ"
      ],
      [
        "T3",
        "Disease",
        34,
        35,
        "diabetes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2215,
    "text": "In the present study , we hypothesized that blocking EndoMT reduces the early development of diabetic nephropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "diabetic nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2216,
    "text": "RESEARCH DESIGN AND METHODS : EndoMT was induced in a mouse pancreatic microvascular endothelial cell line ( MMEC ) in the presence of advanced glycation end products ( AGEs ) and in the endothelial lineage - traceble mouse line Tie2 - Cre ; Loxp - EGFP by administration of AGEs , with nonglycated mouse albumin serving as a control .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2217,
    "text": "Phosphorylated Smad3 was detected by immunoprecipitation / Western blotting and confocal microscopy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2218,
    "text": "Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 ( SIS3 ) were performed in MMECs and in STZ - induced diabetic nephropathy in Tie2 - Cre ; Loxp - EGFP mice .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "diabetic nephropathy"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2219,
    "text": "RESULTS : Confocal microscopy and real - time PCR demonstrated that AGEs induced EndoMT in MMECs and in Tie2 - Cre ; Loxp - EGFP mice .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2220,
    "text": "Immunoprecipitation / Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ - induced diabetic nephropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "diabetic nephropathy"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2221,
    "text": "Confocal microscopy and real - time PCR further demonstrated that SIS3 abrogated EndoMT , reduced renal fibrosis , and retarded progression of nephropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "fibrosis"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2222,
    "text": "CONCLUSIONS : EndoMT is a novel pathway leading to early development of diabetic nephropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "diabetic nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2223,
    "text": "Blockade of EndoMT by SIS3 may provide a new strategy to retard the progression of diabetic nephropathy and other diabetes complications .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "diabetic nephropathy"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "diabetes complications"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2224,
    "text": "Cytostatic and anti - angiogenic effects of temsirolimus in refractory mantle cell lymphoma .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "mantle cell lymphoma"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "temsirolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2225,
    "text": "Mantle cell lymphoma ( MCL ) is a rare and aggressive type of B - cell non - Hodgkin ' s lymphoma .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Mantle cell lymphoma"
      ],
      [
        "T1",
        "Disease",
        13,
        22,
        "B - cell non - Hodgkin ' s lymphoma"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "MCL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2226,
    "text": "Patients become progressively refractory to conventional chemotherapy , and their prognosis is poor .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2227,
    "text": "However , a 38 % remission rate has been recently reported in refractory MCL treated with temsirolimus , a mTOR inhibitor . Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment , and a progression - free survival of 10 months .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "MCL"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "temsirolimus"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "MCL"
      ],
      [
        "T3",
        "Disease",
        36,
        37,
        "tumor"
      ],
      [
        "T4",
        "Chemical",
        41,
        42,
        "temsirolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2228,
    "text": "In this case , lymph node biopsies were performed before and six months after temsirolimus therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "temsirolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2229,
    "text": "Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest , but did not induce any change in the number of apoptotic tumor cells .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "temsirolimus"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "tumor"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2230,
    "text": "Apart from this cytostatic effect , temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "temsirolimus"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2231,
    "text": "Moreover , numerous patchy , well - limited fibrotic areas , compatible with post - necrotic tissue repair , were found after 6 - month temsirolimus therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "necrotic"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "temsirolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2232,
    "text": "Thus , temsirolimus reduced tumor burden through associated cytostatic and anti - angiogenic effects . This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "temsirolimus"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "tumor"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "temsirolimus"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "tumor"
      ],
      [
        "T4",
        "Disease",
        32,
        33,
        "MCL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2233,
    "text": "Acute renal failure due to rifampicin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "rifampicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2234,
    "text": "A 23 - year - old male patient with bacteriologically proven pulmonary tuberculosis was treated with the various regimens of antituberculosis drugs for nearly 15 months .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "pulmonary tuberculosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2235,
    "text": "Rifampicin was administered thrice as one of the 3 - 4 drug regimen and each time he developed untoward side effects like nausea , vomiting and fever with chills and rigors .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Rifampicin"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "nausea"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "vomiting"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "fever"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2236,
    "text": "The last such episode was of acute renal failure at which stage the patient was seen by the authors of this report .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2237,
    "text": "The patient , however , made a full recovery .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2238,
    "text": "Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin - converting enzyme inhibitor and spironolactone .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Syncope"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hyperkalemia"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "angiotensin"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "spironolactone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2239,
    "text": "A 76 year - old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "myocardial infarction"
      ],
      [
        "T1",
        "Disease",
        25,
        28,
        "loss of consciousness"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "bradycardia"
      ],
      [
        "T3",
        "Disease",
        34,
        35,
        "hyperkalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2240,
    "text": "The concentration of serum potassium was high , and normal sinus rhythm was restored after correction of the serum potassium level .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "potassium"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2241,
    "text": "The cause of hyperkalemia was considered to be several doses of spiranolactone , an aldosterone antagonist , in addition to the long - term intake of ramipril , an ACE inhibitor .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hyperkalemia"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "spiranolactone"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "aldosterone"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "ramipril"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2242,
    "text": "This case is a good example of electrolyte imbalance causing acute life - threatening cardiac events .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2243,
    "text": "Clinicians should be alert to the possibility of hyperkalemia , especially in elderly patients using ACE / ARB in combination with potassium sparing agents and who have mild renal disturbance .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "renal disturbance"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hyperkalemia"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2244,
    "text": "Diffuse skeletal pain after administration of alendronate .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "pain"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "alendronate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2245,
    "text": "BACKGROUND : Osteoporosis is caused by bone resorption in excess of bone formation , and bisphosphonates , are used to inhibit bone resorption .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "Osteoporosis"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "bisphosphonates"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2246,
    "text": "Alendronate , a biphosphonate , is effective for both the treatment and prevention of osteoporosis in postmenopausal women .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Alendronate"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "biphosphonate"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "osteoporosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2247,
    "text": "Side effects are relatively few and prominently gastrointestinal .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2248,
    "text": "Musculoskeletal pain may be an important side effect in these patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Musculoskeletal pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2249,
    "text": "We presented a patient admitted to our out - patient clinic with diffuse skeletal pain after three consecutive administration of alendronate .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "pain"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "alendronate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2250,
    "text": "CONCLUSION : We conclude that patients with osteoporosis can report pain , and bisphosphonate - related pain should also be considered before ascribing this complaint to osteoporosis .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "osteoporosis"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "pain"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "bisphosphonate"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "pain"
      ],
      [
        "T4",
        "Disease",
        26,
        27,
        "osteoporosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2251,
    "text": "Cerebrospinal fluid penetration of high - dose daptomycin in suspected Staphylococcus aureus meningitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "daptomycin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "meningitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2252,
    "text": "OBJECTIVE : To report a case of methicillin - sensitive Staphylococcus aureus ( MSSA ) bacteremia with suspected MSSA meningitis treated with high - dose daptomycin assessed with concurrent serum and cerebrospinal fluid ( CSF ) concentrations .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "methicillin"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "bacteremia"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "meningitis"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "daptomycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2253,
    "text": "CASE SUMMARY : A 54 - year - old male presented to the emergency department with generalized weakness and presumed health - care - associated pneumonia shown on chest radiograph .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "weakness"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "pneumonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2254,
    "text": "Treatment was empirically initiated with vancomycin , levofloxacin , and piperacillin / tazobactam .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "vancomycin"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "levofloxacin"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "piperacillin"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "tazobactam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2255,
    "text": "Blood cultures revealed S . aureus susceptible to oxacillin .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "oxacillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2256,
    "text": "Empiric antibiotic treatment was narrowed to nafcillin on day 4 .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "nafcillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2257,
    "text": "On day 8 , the patient developed acute renal failure ( serum creatinine 1 . 9 mg / dL , increased from 1 . 2 mg / dL the previous day and 0 . 8 mg / dL on admission ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2258,
    "text": "The patient ' s Glasgow Coma Score was 3 , with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10 .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "cardiac arrest"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2259,
    "text": "The patient experienced relapsing MSSA bacteremia on day 9 , increasing the suspicion for a central nervous system ( CNS ) infection .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "bacteremia"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2260,
    "text": "Nafcillin was discontinued and daptomycin 9 mg / kg daily was initiated for suspected meningitis and was continued until the patient ' s death on day 16 .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Nafcillin"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "daptomycin"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "meningitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2261,
    "text": "Daptomycin serum and CSF trough concentrations were 11 . 21 ug / mL and 0 . 52 ug / mL , respectively , prior to the third dose .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Daptomycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2262,
    "text": "Lumbar puncture results were inconclusive and no further blood cultures were positive for MSSA .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2263,
    "text": "Creatine kinase levels were normal prior to daptomycin therapy and were not reassessed .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Creatine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "daptomycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2264,
    "text": "DISCUSSION : Daptomycin was initiated in our patient secondary to possible nafcillin - induced acute interstitial nephritis and relapsing bacteremia .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "interstitial nephritis"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Daptomycin"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "nafcillin"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "bacteremia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2265,
    "text": "At a dose of 9 mg / kg , resultant penetration of 5 % was higher than in previous reports , more consistent with inflamed meninges .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2266,
    "text": "CONCLUSIONS : High - dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "daptomycin"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "bacteremia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2267,
    "text": "Further clinical evaluation in patients with confirmed meningitis is warranted .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "meningitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2268,
    "text": "The role of nitric oxide in convulsions induced by lindane in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "convulsions"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "lindane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2269,
    "text": "Lindane is an organochloride pesticide and scabicide .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Lindane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2270,
    "text": "It evokes convulsions mainly trough the blockage of GABA ( A ) receptors .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "convulsions"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2271,
    "text": "Nitric oxide ( NO ) , gaseous neurotransmitter , has contradictor role in epileptogenesis due to opposite effects of L - arginine , precursor of NO syntheses ( NOS ) , and L - NAME ( NOS inhibitor ) observed in different epilepsy models .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Nitric oxide"
      ],
      [
        "T1",
        "Chemical",
        19,
        22,
        "L - arginine"
      ],
      [
        "T2",
        "Chemical",
        32,
        35,
        "L - NAME"
      ],
      [
        "T3",
        "Chemical",
        3,
        4,
        "NO"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "NO"
      ],
      [
        "T5",
        "Disease",
        42,
        43,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2272,
    "text": "The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane - induced epilepsy in male Wistar albino rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "NO"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "lindane"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2273,
    "text": "The administration of L - arginine ( 600 , 800 and 1000 mg / kg , i . p . ) in dose - dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose ( 4 mg / kg , i . p . ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "L - arginine"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "convulsion"
      ],
      [
        "T2",
        "Disease",
        38,
        39,
        "convulsion"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "lindane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2274,
    "text": "On the contrary , pretreatment with L - NAME ( 500 , 700 and 900 mg / kg , i . p . ) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane ( 8 mg / kg , i . p . ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "L - NAME"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "convulsion"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "convulsion"
      ],
      [
        "T3",
        "Disease",
        39,
        40,
        "convulsive"
      ],
      [
        "T4",
        "Chemical",
        42,
        43,
        "lindane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2275,
    "text": "EEG analyses showed increase of number and duration of ictal periods in EEG of rats receiving l - arginine prior to lindane and decrease of this number in rats pretreated with L - NAME .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "l - arginine"
      ],
      [
        "T1",
        "Chemical",
        31,
        34,
        "L - NAME"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "lindane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2276,
    "text": "These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "NO"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "lindane"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2277,
    "text": "Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy : description of two cases .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "polyneuropathy"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "thiotepa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2278,
    "text": "Two cases of severe delayed neurologic toxicity related to the administration of intrathecal ( IT ) combination chemotherapy including thiotepa ( TSPA ) are presented .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "neurologic toxicity"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "thiotepa"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "TSPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2279,
    "text": "Both cases developed axonal neuropathy with motor predominance in the lower extremities 1 and 6 months after IT chemotherapy was administered .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "axonal neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2280,
    "text": "Neurologic toxicities have been described with IT - methotrexate , IT - cytosine arabinoside and IT - TSPA .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Neurologic toxicities"
      ],
      [
        "T1",
        "Chemical",
        12,
        14,
        "cytosine arabinoside"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "methotrexate"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "TSPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2281,
    "text": "To our knowledge , however , axonal neuropathy following administration of these three agents has not been previously described .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "axonal neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2282,
    "text": "In spite of the fact that TSPA is a useful IT agent , its combination with MTX , ara - C and radiotherapy could cause severe neurotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        21,
        "ara - C"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "TSPA"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "MTX"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2283,
    "text": "This unexpected complication indicates the need for further toxicology research on IT - TSPA .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "TSPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2284,
    "text": "Effects of cromakalim and pinacidil on large epicardial and small coronary arteries in conscious dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "cromakalim"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "pinacidil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2285,
    "text": "The effects of i . v . bolus administration of cromakalim ( 1 - 10 micrograms / kg ) and pinacidil ( 3 - 100 micrograms / kg ) on large ( circumflex artery ) and small coronary arteries and on systemic hemodynamics were investigated in chronically instrumented conscious dogs and compared to those of nitroglycerin ( 0 . 03 - 10 micrograms / kg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "cromakalim"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "pinacidil"
      ],
      [
        "T2",
        "Chemical",
        55,
        56,
        "nitroglycerin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2286,
    "text": "Nitroglycerin , up to 0 . 3 micrograms / kg , selectively increased circumflex artery diameter ( CxAD ) without simultaneously affecting any other cardiac or systemic hemodynamic parameter .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Nitroglycerin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2287,
    "text": "In contrast , cromakalim and pinacidil at all doses and nitroglycerin at doses higher than 0 . 3 micrograms / kg simultaneously and dose - dependently increased CxAD , coronary blood flow and heart rate and decreased coronary vascular resistance and aortic pressure .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cromakalim"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "pinacidil"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "nitroglycerin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2288,
    "text": "Cromakalim was approximately 8 - to 9 . 5 - fold more potent than pinacidil in increasing CxAD .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cromakalim"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "pinacidil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2289,
    "text": "Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug - induced tachycardia was abolished .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        26,
        "beta adrenergic and muscarinic receptors blockade"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "cromakalim"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "pinacidil"
      ],
      [
        "T4",
        "Disease",
        30,
        31,
        "tachycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2290,
    "text": "When circumflex artery blood flow was maintained constant , the increases in CxAD induced by cromakalim ( 10 micrograms / kg ) , pinacidil ( 30 micrograms / kg ) and nitroglycerin ( 10 micrograms / kg ) were reduced by 68 + / - 7 , 54 + / - 9 and 1 + / - 1 % , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "cromakalim"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "pinacidil"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "nitroglycerin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2291,
    "text": "Thus , whereas nitroglycerin preferentially and flow - independently dilates large coronary arteries , cromakalim and pinacidil dilate both large and small coronary arteries and this effect is not dependent upon the simultaneous beta adrenoceptors - mediated rise in myocardial metabolic demand .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "nitroglycerin"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "cromakalim"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "pinacidil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2292,
    "text": "Finally , two mechanisms at least , direct vasodilation and flow dependency , are involved in the cromakalim - and pinacidil - induced increase in CxAD .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "cromakalim"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "pinacidil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2293,
    "text": "Mefenamic acid - induced neutropenia and renal failure in elderly females with hypothyroidism .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Mefenamic acid"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "renal failure"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "neutropenia"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "hypothyroidism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2294,
    "text": "We report mefenamic acid - induced non - oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "mefenamic acid"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "renal failure"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2295,
    "text": "The neutropenia was due to maturation arrest of the myeloid series in one patient .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2296,
    "text": "Both patients were also hypothyroid , but it is not clear whether this was a predisposing factor to the development of these adverse reactions .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypothyroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2297,
    "text": "However , it would seem prudent not to use mefenamic acid in hypothyroid patients until the hypothyroidism has been corrected .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "mefenamic acid"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hypothyroid"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "hypothyroidism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2298,
    "text": "Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "calcium carbonate"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "hypercalcemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2299,
    "text": "Fourteen of 39 dialysis patients ( 36 % ) became hypercalcemic after switching to calcium carbonate as their principal phosphate binder .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "calcium carbonate"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypercalcemic"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "phosphate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2300,
    "text": "In order to identify risk factors associated with the development of hypercalcemia , indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age , sex , length of time on dialysis , and etiology of renal disease .",
    "labels": [
      [
        "T0",
        "Disease",
        50,
        52,
        "renal disease"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hypercalcemia"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2301,
    "text": "In addition to experiencing hypercalcemic episodes with peak calcium values of 2 . 7 to 3 . 8 mmol / L ( 10 . 7 to 15 . 0 mg / dL ) , patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch , compared with the mean value obtained during the 7 months of observation after the switch ( 2 . 4 + / - 0 . 03 to 2 . 5 + / - 0 . 03 mmol / L [ 9 . 7 + / - 0 . 2 to 10 . 2 + / - 0 . 1 mg / dL ] , P = 0 . 006 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypercalcemic"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "calcium"
      ],
      [
        "T2",
        "Disease",
        37,
        38,
        "hypercalcemic"
      ],
      [
        "T3",
        "Chemical",
        46,
        47,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2302,
    "text": "In contrast , eucalcemic patients exhibited no change in mean calcium values over the same time period ( 2 . 3 + / - 0 . 05 to 2 . 3 + / - 0 . 05 mmol / L [ 9 . 2 + / - 0 . 2 to 9 . 2 + / - 0 . 2 mg / dL ] ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2303,
    "text": "CaCO3 dosage , calculated dietary calcium intake , and circulating levels of vitamin D metabolites were similar in both groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "vitamin D"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "CaCO3"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2304,
    "text": "Physical activity index and predialysis serum bicarbonate levels also were similar in both groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "bicarbonate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2305,
    "text": "However , there was a significant difference in parameters reflecting bone turnover rates between groups . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2306,
    "text": "Late - onset scleroderma renal crisis induced by tacrolimus and prednisolone : a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "scleroderma renal crisis"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "tacrolimus"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "prednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2307,
    "text": "Scleroderma renal crisis ( SRC ) is a rare complication of systemic sclerosis ( SSc ) but can be severe enough to require temporary or permanent renal replacement therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Scleroderma renal crisis"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "systemic sclerosis"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "SRC"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "SSc"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2308,
    "text": "Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "corticosteroid"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "SRC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2309,
    "text": "Furthermore , there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "thrombotic microangiopathy"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "cyclosporine"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "SSc"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2310,
    "text": "In this article , we report a patient with SRC induced by tacrolimus and corticosteroids .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "SRC"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "tacrolimus"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "corticosteroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2311,
    "text": "The aim of this work is to call attention to the risk of tacrolimus use in patients with SSc .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "tacrolimus"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "SSc"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2312,
    "text": "Methyldopa - induced hemolytic anemia in a 15 year old presenting as near - syncope .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Methyldopa"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "syncope"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2313,
    "text": "Methyldopa is an antihypertensive medication which is available generically and under the trade name Aldomet that is widely prescribed in the adult population and infrequently used in children .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Methyldopa"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "Aldomet"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2314,
    "text": "Methyldopa causes an autoimmune hemolytic anemia in a small percentage of patients who take the drug .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "autoimmune hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Methyldopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2315,
    "text": "We report a case of methyldopa - induced hemolytic anemia in a 15 - year - old boy who presented to the emergency department with near - syncope .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "emergency department"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "methyldopa"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "syncope"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2316,
    "text": "The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "methyldopa"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "trauma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2317,
    "text": "Evaluation revealed a hemoglobin of three grams , 3 + Coombs ' test with polyspecific anti - human globulin and monospecific IgG reagents , and a warm reacting autoantibody .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2318,
    "text": "Transfusion and corticosteroid therapy resulted in a complete recovery of the patient .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "corticosteroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2319,
    "text": "Emergency physicians treating children must be aware of this syndrome in order to diagnose and treat it correctly .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2320,
    "text": "A brief review of autoimmune and drug - induced hemolytic anemias is provided .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "hemolytic anemias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2321,
    "text": "The risk and associated factors of methamphetamine psychosis in methamphetamine - dependent patients in Malaysia .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "methamphetamine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "psychosis"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "methamphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2322,
    "text": "OBJECTIVE : The objective of this study was to determine the risk of lifetime and current methamphetamine - induced psychosis in patients with methamphetamine dependence .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "methamphetamine"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "psychosis"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "methamphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2323,
    "text": "The association between psychiatric co - morbidity and methamphetamine - induced psychosis was also studied .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "methamphetamine"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2324,
    "text": "METHODS : This was a cross - sectional study conducted concurrently at a teaching hospital and a drug rehabilitation center in Malaysia .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2325,
    "text": "Patients with the diagnosis of methamphetamine based on DSM - IV were interviewed using the Mini International Neuropsychiatric Interview ( M . I . N . I . ) for methamphetamine - induced psychosis and other Axis I psychiatric disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        38,
        40,
        "psychiatric disorders"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "methamphetamine"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "methamphetamine"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2326,
    "text": "The information on sociodemographic background and drug use history was obtained from interview or medical records .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2327,
    "text": "RESULTS : Of 292 subjects , 47 . 9 % of the subjects had a past history of psychotic symptoms and 13 . 0 % of the patients were having current psychotic symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "psychotic symptoms"
      ],
      [
        "T1",
        "Disease",
        31,
        33,
        "psychotic symptoms"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2328,
    "text": "Co - morbid major depressive disorder ( OR = 7 . 18 , 95 CI = 2 . 612 - 19 . 708 ) , bipolar disorder ( OR = 13 . 807 , 95 CI = 5 . 194 - 36 . 706 ) , antisocial personality disorder ( OR = 12 . 619 , 95 CI = 6 . 702 - 23 . 759 ) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine - induced psychosis after adjusted for other factors .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "depressive disorder"
      ],
      [
        "T1",
        "Disease",
        25,
        27,
        "bipolar disorder"
      ],
      [
        "T2",
        "Disease",
        46,
        49,
        "antisocial personality disorder"
      ],
      [
        "T3",
        "Chemical",
        69,
        70,
        "methamphetamine"
      ],
      [
        "T4",
        "Chemical",
        76,
        77,
        "methamphetamine"
      ],
      [
        "T5",
        "Disease",
        79,
        80,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2329,
    "text": "Major depressive disorder ( OR = 2 . 870 , CI = 1 . 154 - 7 . 142 ) and antisocial personality disorder ( OR = 3 . 299 , 95 CI = 1 . 375 - 7 . 914 ) were the only factors associated with current psychosis .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Major depressive disorder"
      ],
      [
        "T1",
        "Disease",
        21,
        24,
        "antisocial personality disorder"
      ],
      [
        "T2",
        "Disease",
        49,
        50,
        "psychosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2330,
    "text": "CONCLUSION : There was a high risk of psychosis in patients with methamphetamine dependence .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "psychosis"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "methamphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2331,
    "text": "It was associated with co - morbid affective disorder , antisocial personality , and heavy methamphetamine use .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "affective disorder"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "antisocial personality"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "methamphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2332,
    "text": "It is recommended that all cases of methamphetamine dependence should be screened for psychotic symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "psychotic symptoms"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "methamphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2333,
    "text": "Cerebellar sensory processing alterations impact motor cortical plasticity in Parkinson ' s disease : clues from dyskinetic patients .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "dyskinetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2334,
    "text": "The plasticity of primary motor cortex ( M1 ) in patients with Parkinson ' s disease ( PD ) and levodopa - induced dyskinesias ( LIDs ) is severely impaired .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "PD"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "levodopa"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "dyskinesias"
      ],
      [
        "T4",
        "Disease",
        25,
        26,
        "LIDs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2335,
    "text": "We recently reported in young healthy subjects that inhibitory cerebellar stimulation enhanced the sensorimotor plasticity of M1 that was induced by paired associative stimulation ( PAS ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2336,
    "text": "This study demonstrates that the deficient sensorimotor M1 plasticity in 16 patients with LIDs could be reinstated by a single session of real inhibitory cerebellar stimulation but not sham stimulation .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "LIDs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2337,
    "text": "This was evident only when a sensory component was involved in the induction of plasticity , indicating that cerebellar sensory processing function is involved in the resurgence of M1 plasticity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2338,
    "text": "The benefit of inhibitory cerebellar stimulation on LIDs is known .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "LIDs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2339,
    "text": "To explore whether this benefit is linked to the restoration of sensorimotor plasticity of M1 , we conducted an additional study looking at changes in LIDs and PAS - induced plasticity after 10 sessions of either bilateral , real inhibitory cerebellar stimulation or sham stimulation .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        26,
        "LIDs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2340,
    "text": "Only real and not sham stimulation had an antidyskinetic effect and it was paralleled by a resurgence in the sensorimotor plasticity of M1 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2341,
    "text": "These results suggest that alterations in cerebellar sensory processing function , occurring secondary to abnormal basal ganglia signals reaching it , may be an important element contributing to the maladaptive sensorimotor plasticity of M1 and the emergence of abnormal involuntary movements .",
    "labels": [
      [
        "T0",
        "Disease",
        38,
        41,
        "abnormal involuntary movements"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2342,
    "text": "The long - term safety of danazol in women with hereditary angioedema .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "hereditary angioedema"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "danazol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2343,
    "text": "Although the short - term safety ( less than or equal to 6 months ) of danazol has been established in a variety of settings , no information exists as to its long - term safety .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "danazol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2344,
    "text": "We therefore investigated the long - term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with danazol for a continuous period of 6 months or longer .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "hereditary angioedema"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "danazol"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "danazol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2345,
    "text": "The mean age of the patients was 35 . 2 years and the mean duration of therapy was 59 . 7 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2346,
    "text": "Virtually all patients experienced one or more adverse reactions .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2347,
    "text": "Menstrual abnormalities ( 79 % ) , weight gain ( 60 % ) , muscle cramps / myalgias ( 40 % ) , and transaminase elevations ( 40 % ) were the most common adverse reactions .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Menstrual abnormalities"
      ],
      [
        "T1",
        "Disease",
        7,
        9,
        "weight gain"
      ],
      [
        "T2",
        "Disease",
        14,
        16,
        "muscle cramps"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "myalgias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2348,
    "text": "The drug was discontinued due to adverse reactions in 8 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2349,
    "text": "No patient has died or suffered any apparent long - term sequelae that were directly attributable to the drug .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2350,
    "text": "We conclude that , despite a relatively high incidence of adverse reactions , danazol has proven to be remarkably safe over the long - term in this group of patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "danazol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2351,
    "text": "The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide - induced cystitis in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "cyclophosphamide"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2352,
    "text": "PURPOSE : The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide ( CYP ) - induced cystitis in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "cyclophosphamide"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "CYP"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2353,
    "text": "METHODS : Sixty female Sprague - Dawley ( SD ) rats were randomly divided into three groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2354,
    "text": "The rats in the control group were intraperitoneally ( i . p . ) injected with 0 . 9 % saline ( 4 ml / kg ) ; the rats in the model group were i . p . injected with CYP ( 150 mg / kg ) ; and the rats in the intervention group were i . p . injected with CYP with subsequently perfusion of bladder with P2X3 and NK1 receptors ' antagonists , Suramin and GR 82334 .",
    "labels": [
      [
        "T0",
        "Chemical",
        79,
        81,
        "GR 82334"
      ],
      [
        "T1",
        "Chemical",
        41,
        42,
        "CYP"
      ],
      [
        "T2",
        "Chemical",
        63,
        64,
        "CYP"
      ],
      [
        "T3",
        "Chemical",
        77,
        78,
        "Suramin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2355,
    "text": "Spontaneous pain behaviors following the administration of CYP were observed .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "pain"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "CYP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2356,
    "text": "Urodynamic parameters , bladder pressure - volume curve , maximum voiding pressure ( MVP ) , and maximum cystometric capacity ( MCC ) , were recorded .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2357,
    "text": "Pathological changes in bladder tissue were observed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2358,
    "text": "Immunofluorescence was used to detect the expression of P2X3 and NK1 receptors in bladder .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2359,
    "text": "RESULTS : Cyclophosphamide treatment increased the spontaneous pain behaviors scores .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Cyclophosphamide"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2360,
    "text": "The incidence of bladder instability during urine storage period of model group was significantly higher than intervention group ( X ( 2 ) = 7 . 619 , P = 0 . 007 ) and control group ( X ( 2 ) = 13 . 755 , P = 0 . 000 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2361,
    "text": "MCC in the model group was lower than the control and intervention groups ( P < 0 . 01 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2362,
    "text": "Histological changes evident in model and intervention groups rats ' bladder included edema , vasodilation , and infiltration of inflammatory cells .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2363,
    "text": "In model group , the expression of P2X3 receptor increased in urothelium and suburothelium , and NK1 receptor increased in suburothelium , while the expression of them in intervention group was lower .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2364,
    "text": "CONCLUSIONS : In CYP - induced cystitis , the expression of P2X3 and NK1 receptors increased in urothelium and / or suburothelium .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "CYP"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2365,
    "text": "Perfusion of bladder with P2X3 and NK1 receptors antagonists ameliorated the bladder function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2366,
    "text": "Patient tolerance study of topical chlorhexidine diphosphanilate : a new topical agent for burns .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "chlorhexidine diphosphanilate"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "burns"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2367,
    "text": "Effective topical antimicrobial agents decrease infection and mortality in burn patients .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "infection"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "burn"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2368,
    "text": "Chlorhexidine phosphanilate ( CHP ) , a new broad - spectrum antimicrobial agent , has been evaluated as a topical burn wound dressing in cream form , but preliminary clinical trials reported that it was painful upon application .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Chlorhexidine phosphanilate"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "CHP"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "burn"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2369,
    "text": "This study compared various concentrations of CHP to determine if a tolerable concentration could be identified with retention of antimicrobial efficacy .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "CHP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2370,
    "text": "Twenty - nine burn patients , each with two similar burns which could be separately treated , were given pairs of treatments at successive 12 - h intervals over a 3 - day period .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "burn"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "burns"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2371,
    "text": "One burn site was treated with each of four different CHP concentrations , from 0 . 25 per cent to 2 per cent , their vehicle , and 1 per cent silver sulphadiazine ( AgSD ) cream , an antimicrobial agent frequently used for topical treatment of burn wounds .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        33,
        "silver sulphadiazine"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "burn"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "CHP"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "AgSD"
      ],
      [
        "T4",
        "Disease",
        47,
        48,
        "burn"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2372,
    "text": "The other site was always treated with AgSD cream .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "AgSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2373,
    "text": "There was a direct relationship between CHP concentration and patients ' ratings of pain on an analogue scale .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "CHP"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2374,
    "text": "The 0 . 25 per cent CHP cream was closest to AgSD in pain tolerance ; however , none of the treatments differed statistically from AgSD or from each other .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "CHP"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "AgSD"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "pain"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "AgSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2375,
    "text": "In addition , ease of application of CHP creams was less satisfactory than that of AgSD .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "CHP"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "AgSD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2376,
    "text": "It was concluded that formulations at or below 0 . 5 per cent CHP may prove acceptable for wound care , but the vehicle system needs pharmaceutical improvement to render it more tolerable and easier to use .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "CHP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2377,
    "text": "Acute hepatitis associated with clopidogrel : a case report and review of the literature .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hepatitis"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "clopidogrel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2378,
    "text": "Drug - induced hepatotoxicity is a common cause of acute hepatitis , and the recognition of the responsible drug may be difficult .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hepatotoxicity"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2379,
    "text": "We describe a case of clopidogrel - related acute hepatitis .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "clopidogrel"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2380,
    "text": "The diagnosis is strongly suggested by an accurate medical history and liver biopsy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2381,
    "text": "Reports about cases of hepatotoxicity due to clopidogrel are increasing in the last few years , after the increased use of this drug .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hepatotoxicity"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "clopidogrel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2382,
    "text": "In conclusion , we believe that physicians should carefully consider the risk of drug - induced hepatic injury when clopidogrel is prescribed .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "hepatic injury"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "clopidogrel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2383,
    "text": "Bortezomib and dexamethasone as salvage therapy in patients with relapsed / refractory multiple myeloma : analysis of long - term clinical outcomes .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "multiple myeloma"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Bortezomib"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2384,
    "text": "Bortezomib ( bort ) - dexamethasone ( dex ) is an effective therapy for relapsed / refractory ( R / R ) multiple myeloma ( MM ) .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "multiple myeloma"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Bortezomib"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "bort"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "dexamethasone"
      ],
      [
        "T4",
        "Chemical",
        7,
        8,
        "dex"
      ],
      [
        "T5",
        "Disease",
        25,
        26,
        "MM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2385,
    "text": "This retrospective study investigated the combination of bort ( 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 every 3 weeks ) and dex ( 20 mg on the day of and the day after bort ) as salvage treatment in 85 patients with R / R MM after prior autologous stem cell transplantation or conventional chemotherapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "bort"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "dex"
      ],
      [
        "T2",
        "Chemical",
        45,
        46,
        "bort"
      ],
      [
        "T3",
        "Disease",
        57,
        58,
        "MM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2386,
    "text": "The median number of prior lines of therapy was 2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2387,
    "text": "Eighty - seven percent of the patients had received immunomodulatory drugs included in some line of therapy before bort - dex .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "bort"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "dex"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2388,
    "text": "The median number of bort - dex cycles was 6 , up to a maximum of 12 cycles .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "bort"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "dex"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2389,
    "text": "On an intention - to - treat basis , 55 % of the patients achieved at least partial response , including 19 % CR and 35 % achieved at least very good partial response .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2390,
    "text": "Median durations of response , time to next therapy and treatment - free interval were 8 , 11 . 2 , and 5 . 1 months , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2391,
    "text": "The most relevant adverse event was peripheral neuropathy , which occurred in 78 % of the patients ( grade II , 38 % ; grade III , 21 % ) and led to treatment discontinuation in 6 % .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "peripheral neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2392,
    "text": "With a median follow up of 22 months , median time to progression , progression - free survival ( PFS ) and overall survival ( OS ) were 8 . 9 , 8 . 7 , and 22 months , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2393,
    "text": "Prolonged PFS and OS were observed in patients achieving CR and receiving bort - dex a single line of prior therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "bort"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "dex"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2394,
    "text": "Bort - dex was an effective salvage treatment for MM patients , particularly for those in first relapse .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Bort"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "dex"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "MM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2395,
    "text": "Pubertal exposure to Bisphenol A increases anxiety - like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "Bisphenol A"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2396,
    "text": "The negative effects of Bisphenol A ( BPA ) on neurodevelopment and behaviors have been well established .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "Bisphenol A"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "BPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2397,
    "text": "Acetylcholinesterase ( AChE ) is a regulatory enzyme which is involved in anxiety - like behavior .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2398,
    "text": "This study investigated behavioral phenotypes and AChE activity in male mice following BPA exposure during puberty .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "BPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2399,
    "text": "On postnatal day ( PND ) 35 , male mice were exposed to 50mg BPA / kg diet per day for a period of 35 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "BPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2400,
    "text": "On PND71 , a behavioral assay was performed using the elevated plus maze ( EPM ) and the light / dark test .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2401,
    "text": "In addition , AChE activity was measured in the prefrontal cortex , hypothalamus , cerebellum and hippocampus .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2402,
    "text": "Results from our behavioral phenotyping indicated that anxiety - like behavior was increased in mice exposed to BPA .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "anxiety"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "BPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2403,
    "text": "AChE activity was significantly decreased in the hippocampus of mice with BPA compared to control mice , whereas no difference was found in the prefrontal cortex , hypothalamus and cerebellum .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "BPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2404,
    "text": "Our findings showed that pubertal BPA exposure increased anxiety - like behavior , which may be associated with decreased AChE activity of the hippocampus in adult male mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "BPA"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2405,
    "text": "Further studies are necessary to investigate the cholinergic signaling of the hippocampus in PBE induced anxiety - like behaviors .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "anxiety"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2406,
    "text": "Biochemical effects of Solidago virgaurea extract on experimental cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2407,
    "text": "Cardiovascular diseases ( CVDs ) are the major health problem of advanced as well as developing countries of the world .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cardiovascular diseases"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "CVDs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2408,
    "text": "The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol - induced cardiotoxicity in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "isoproterenol"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2409,
    "text": "The subcutaneous injection of isoproterenol ( 30 mg / kg ) into rats twice at an interval of 24 h , for two consecutive days , led to a significant increase in serum lactate dehydrogenase , creatine phosphokinase , alanine transaminase , aspartate transaminase , and angiotensin - converting enzyme activities , total cholesterol , triglycerides , free serum fatty acid , cardiac tissue malondialdehyde ( MDA ) , and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group ( P < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        59,
        61,
        "fatty acid"
      ],
      [
        "T1",
        "Chemical",
        70,
        72,
        "nitric oxide"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "isoproterenol"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "lactate"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "creatine"
      ],
      [
        "T5",
        "Chemical",
        39,
        40,
        "alanine"
      ],
      [
        "T6",
        "Chemical",
        42,
        43,
        "aspartate"
      ],
      [
        "T7",
        "Chemical",
        46,
        47,
        "angiotensin"
      ],
      [
        "T8",
        "Chemical",
        53,
        54,
        "cholesterol"
      ],
      [
        "T9",
        "Chemical",
        55,
        56,
        "triglycerides"
      ],
      [
        "T10",
        "Chemical",
        64,
        65,
        "malondialdehyde"
      ],
      [
        "T11",
        "Chemical",
        66,
        67,
        "MDA"
      ],
      [
        "T12",
        "Chemical",
        80,
        81,
        "glutathione"
      ],
      [
        "T13",
        "Chemical",
        82,
        83,
        "superoxide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2410,
    "text": "Pretreatment with S . virgaurea extract for 5 weeks at a dose of 250 mg / kg followed by isoproterenol injection significantly prevented the observed alterations .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2411,
    "text": "Captopril ( 50 mg / kg / day , given orally ) , an inhibitor of angiotensin - converting enzyme used as a standard cardioprotective drug , was used as a positive control in this study .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Captopril"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "angiotensin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2412,
    "text": "The data of the present study suggest that S . virgaurea extract exerts its protective effect by decreasing MDA level and increasing the antioxidant status in isoproterenol - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "MDA"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2413,
    "text": "The study emphasizes the beneficial action of S . virgaurea extract as a cardioprotective agent .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2414,
    "text": "\" Real - world \" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed / refractory multiple myeloma who were treated according to the standard clinical practice : a study of the Greek Myeloma Study Group .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "multiple myeloma"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "lenalidomide"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "dexamethasone"
      ],
      [
        "T3",
        "Disease",
        38,
        39,
        "Myeloma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2415,
    "text": "Lenalidomide and dexamethasone ( RD ) is a standard of care for relapsed / refractory multiple myeloma ( RRMM ) , but there is limited published data on its efficacy and safety in the \" real world \" ( RW ) , according to the International Society of Pharmacoeconomics and Outcomes Research definition .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "multiple myeloma"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Lenalidomide"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "dexamethasone"
      ],
      [
        "T3",
        "Chemical",
        4,
        5,
        "RD"
      ],
      [
        "T4",
        "Disease",
        18,
        19,
        "RRMM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2416,
    "text": "We studied 212 RRMM patients who received RD in RW .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "RRMM"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "RD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2417,
    "text": "Objective response ( > PR ( partial response ) ) rate was 77 . 4 % ( complete response ( CR ) , 20 . 2 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2418,
    "text": "Median time to first and best response was 2 and 5 months , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2419,
    "text": "Median time to CR when RD was given as 2nd or > 2 ( nd ) - line treatment at 4 and 11 months , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "RD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2420,
    "text": "Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or bortezomib .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "thalidomide"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "bortezomib"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2421,
    "text": "Median duration of response was 34 . 4 months , and it was higher in patients who received RD until progression ( not reached versus 19 months , p < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "RD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2422,
    "text": "Improvement of humoral immunity occurred in 60 % of responders ( p < 0 . 001 ) and in the majority of patients who achieved stable disease .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2423,
    "text": "Adverse events were reported in 68 . 9 % of patients ( myelosuppression in 49 . 4 % ) and 12 . 7 % of patients needed hospitalization .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "myelosuppression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2424,
    "text": "Peripheral neuropathy was observed only in 2 . 5 % of patients and deep vein thrombosis in 5 . 7 % .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Peripheral neuropathy"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "deep vein thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2425,
    "text": "Dose reductions were needed in 31 % of patients and permanent discontinuation in 38 . 9 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2426,
    "text": "Median time to treatment discontinuation was 16 . 8 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2427,
    "text": "Performance status ( PS ) and initial lenalidomide dose predicted for treatment discontinuation .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "lenalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2428,
    "text": "Extra - medullary relapses occurred in 3 . 8 % of patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2429,
    "text": "Our study confirms that RD is effective and safe in RRMM in the RW ; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "RD"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "RRMM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2430,
    "text": "The cytogenetic action of ifosfamide , mesna , and their combination on peripheral rabbit lymphocytes : an in vivo / in vitro cytogenetic study .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ifosfamide"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2431,
    "text": "Ifosfamide ( IFO ) is an alkylating nitrogen mustard , administrated as an antineoplasmic agent .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ifosfamide"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "IFO"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "nitrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2432,
    "text": "It is characterized by its intense urotoxic action , leading to hemorrhagic cystitis .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "hemorrhagic cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2433,
    "text": "This side effect of IFO raises the requirement for the co - administration with sodium 2 - sulfanylethanesulfonate ( Mesna ) aiming to avoid or minimize this effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        18,
        "sodium 2 - sulfanylethanesulfonate"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "IFO"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "Mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2434,
    "text": "IFO and Mesna were administrated separately on rabbit ' s lymphocytes in vivo , which were later developed in vitro .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "IFO"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2435,
    "text": "Cytogenetic markers for sister chromatid exchanges ( SCEs ) , proliferation rate index ( PRI ) and Mitotic Index were recorded .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2436,
    "text": "Mesna ' s action , in conjunction with IFO reduces the frequency of SCEs , in comparison with the SCEs recordings obtained when IFO is administered alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Mesna"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "IFO"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "IFO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2437,
    "text": "In addition to this , when high concentrations of Mesna were administered alone significant reductions of the PRI were noted , than with IFO acting at the same concentration on the lymphocytes .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "Mesna"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "IFO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2438,
    "text": "Mesna significantly reduces IFO ' s genotoxicity , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Mesna"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "IFO"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "genotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2439,
    "text": "Risk factors and predictors of levodopa - induced dyskinesia among multiethnic Malaysians with Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        17,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2440,
    "text": "Chronic pulsatile levodopa therapy for Parkinson ' s disease ( PD ) leads to the development of motor fluctuations and dyskinesia .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "levodopa"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "PD"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2441,
    "text": "We studied the prevalence and predictors of levodopa - induced dyskinesia among multiethnic Malaysian patients with PD .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "dyskinesia"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "PD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2442,
    "text": "METHODS : This is a cross - sectional study involving 95 patients with PD on uninterrupted levodopa therapy for at least 6 months .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "PD"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2443,
    "text": "The instrument used was the UPDRS questionnaires .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2444,
    "text": "The predictors of dyskinesia were determined using multivariate logistic regression analysis .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2445,
    "text": "RESULTS : The mean age was 65 . 6 + 8 . 5 years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2446,
    "text": "The mean onset age was 58 . 5 + 9 . 8 years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2447,
    "text": "The median disease duration was 6 ( 7 ) years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2448,
    "text": "Dyskinesia was present in 44 % ( n = 42 ) with median levodopa therapy of 3 years .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Dyskinesia"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2449,
    "text": "There were 64 . 3 % Chinese , 31 % Malays , and 3 . 7 % Indians and other ethnic groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2450,
    "text": "Eighty - one percent of patients with dyskinesia had clinical fluctuations .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2451,
    "text": "Patients with dyskinesia had lower onset age ( p < 0 . 001 ) , longer duration of levodopa therapy ( p < 0 . 001 ) , longer disease duration ( p < 0 . 001 ) , higher total daily levodopa dose ( p < 0 . 001 ) , and higher total UPDRS scores ( p = 0 . 005 ) than patients without dyskinesia .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "dyskinesia"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "levodopa"
      ],
      [
        "T2",
        "Chemical",
        42,
        43,
        "levodopa"
      ],
      [
        "T3",
        "Disease",
        67,
        68,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2452,
    "text": "The three significant predictors of dyskinesia were duration of levodopa therapy , onset age , and total daily levodopa dose .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "dyskinesia"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "levodopa"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2453,
    "text": "CONCLUSIONS : The prevalence of levodopa - induced dyskinesia in our patients was 44 % .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "levodopa"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2454,
    "text": "The most significant predictors were duration of levodopa therapy , total daily levodopa dose , and onset age .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "levodopa"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2455,
    "text": "Dose - dependent neurotoxicity of high - dose busulfan in children : a clinical and pharmacological study .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "neurotoxicity"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "busulfan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2456,
    "text": "Busulfan is known to be neurotoxic in animals and humans , but its acute neurotoxicity remains poorly characterized in children .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Busulfan"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "neurotoxic"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2457,
    "text": "We report here a retrospective study of 123 children ( median age , 6 . 5 years ) receiving high - dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors , brain tumors excluded .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        37,
        "brain tumors"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "busulfan"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "tumors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2458,
    "text": "Busulfan was given p . o . , every 6 hours for 16 doses over 4 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Busulfan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2459,
    "text": "Two total doses were consecutively used : 16 mg / kg , then 600 mg / m2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2460,
    "text": "The dose calculation on the basis of body surface area results in higher doses in young children than in older patients ( 16 to 28 mg / kg ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2461,
    "text": "Ninety - six patients were not given anticonvulsive prophylaxis ; 7 ( 7 . 5 % ) developed seizures during the 4 days of the busulfan course or within 24 h after the last dosing .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "seizures"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "busulfan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2462,
    "text": "When the total busulfan dose was taken into account , there was a significant difference in terms of neurotoxicity incidence among patients under 16 mg / kg ( 1 of 57 , 1 . 7 % ) and patients under 600 mg / m2 ( 6 of 39 , 15 . 4 % ) ( P less than 0 . 02 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "busulfan"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2463,
    "text": "Twenty - seven patients were given a 600 - mg / m2 busulfan total dose with continuous i . v . infusion of clonazepam ; none had any neurological symptoms .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "neurological symptoms"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "busulfan"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "clonazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2464,
    "text": "Busulfan levels were measured by a gas chromatographic - mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg / m2 busulfan with clonazepam : busulfan cerebrospinal fluid : plasma ratio was 1 . 39 .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        26,
        "central nervous system disease"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Busulfan"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "busulfan"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "clonazepam"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "busulfan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2465,
    "text": "This was significantly different ( P less than 0 . 02 ) from the cerebrospinal fluid : plasma ratio previously defined in children receiving a 16 - mg / kg total dose of busulfan .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        34,
        "busulfan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2466,
    "text": "This study shows that busulfan neurotoxicity is dose - dependent in children and efficiently prevented by clonazepam .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "busulfan"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "neurotoxicity"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "clonazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2467,
    "text": "A busulfan dose calculated on the basis of body surface area , resulting in higher doses in young children , was followed by increased neurotoxicity , close to neurotoxicity incidence observed in adults .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "busulfan"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "neurotoxicity"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2468,
    "text": "Since plasma pharmacokinetic studies showed a faster busulfan clearance in children than in adults , this new dose may approximate more closely the adult systemic exposure obtained after the usual 16 - mg / kg total dose , with potential inferences in terms of anticancer or myeloablative effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "busulfan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2469,
    "text": "The busulfan dose in children and infants undergoing bone marrow transplantation should be reconsidered on the basis of pharmacokinetic studies .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "busulfan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2470,
    "text": "An unexpected diagnosis in a renal - transplant patient with proteinuria treated with everolimus : AL amyloidosis .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "proteinuria"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "everolimus"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "AL"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "amyloidosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2471,
    "text": "Proteinuria is an expected complication in transplant patients treated with mammalian target of rapamycin inhibitors ( mTOR - i ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Proteinuria"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "rapamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2472,
    "text": "However , clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection , interstitial fibrosis and tubular atrophy , or recurrent or de novo glomerulopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        27,
        "fibrosis"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "atrophy"
      ],
      [
        "T2",
        "Disease",
        36,
        37,
        "glomerulopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2473,
    "text": "In this case we report the unexpected diagnosis of amyloidosis in a renal - transplant patient with pre - transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "amyloidosis"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "proteinuria"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "tacrolimus"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "everolimus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2474,
    "text": "Long - term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "cognitive deficits"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "galactose"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "streptozotocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2475,
    "text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer ' s disease ( sAD ) type is associated with dysfunction of the insulin - receptor ( IR ) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        14,
        "Alzheimer ' s disease"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "dementia"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "glucose"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "glucose"
      ],
      [
        "T4",
        "Chemical",
        42,
        43,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2476,
    "text": "An alternative source of energy is d - galactose ( the C - 4 - epimer of d - glucose ) which is transported into the brain by insulin - independent GLUT3 transporter where it might be metabolized to glucose via the Leloir pathway .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "d - galactose"
      ],
      [
        "T1",
        "Chemical",
        17,
        20,
        "d - glucose"
      ],
      [
        "T2",
        "Chemical",
        39,
        40,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2477,
    "text": "Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model , but the effects of oral galactose treatment on cognitive functions have never been tested .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "memory deterioration"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "galactose"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "galactose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2478,
    "text": "We have investigated the effects of continuous daily oral galactose ( 200 mg / kg / day ) treatment on cognitive deficits in streptozotocin - induced ( STZ - icv ) rat model of sAD , tested by Morris Water Maze and Passive Avoidance test , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "cognitive deficits"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "galactose"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "streptozotocin"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2479,
    "text": "One month of oral galactose treatment initiated immediately after the STZ - icv administration , successfully prevented development of the STZ - icv - induced cognitive deficits .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "cognitive deficits"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "galactose"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "STZ"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2480,
    "text": "Beneficial effect of oral galactose was independent of the rat age and of the galactose dose ranging from 100 to 300 mg / kg / day .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "galactose"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "galactose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2481,
    "text": "Additionally , oral galactose administration led to the appearance of galactose in the blood .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "galactose"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "galactose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2482,
    "text": "The increase of galactose concentration in the cerebrospinal fluid was several times lower after oral than after parenteral administration of the same galactose dose .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "galactose"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "galactose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2483,
    "text": "Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "cognitive deficits"
      ],
      [
        "T1",
        "Disease",
        24,
        26,
        "glucose hypometabolism"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "galactose"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "AD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2484,
    "text": "An investigation of the pattern of kidney injury in HIV - positive persons exposed to tenofovir disoproxil fumarate : an examination of a large population database ( MHRA database ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "kidney injury"
      ],
      [
        "T1",
        "Chemical",
        15,
        18,
        "tenofovir disoproxil fumarate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2485,
    "text": "The potential for tenofovir to cause a range of kidney syndromes has been established from mechanistic and randomised clinical trials .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "tenofovir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2486,
    "text": "However , the exact pattern of kidney involvement is still uncertain .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2487,
    "text": "We undertook a descriptive analysis of Yellow Card records of 407 HIV - positive persons taking tenofovir disoproxil fumarate ( TDF ) as part of their antiretroviral therapy regimen and submitted to the Medicines and Healthcare Products Regulatory Agency ( MHRA ) with suspected kidney adverse effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "tenofovir disoproxil fumarate"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "TDF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2488,
    "text": "Reports that satisfy defined criteria were classified as acute kidney injury , kidney tubular dysfunction and Fanconi syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "acute kidney injury"
      ],
      [
        "T1",
        "Disease",
        12,
        15,
        "kidney tubular dysfunction"
      ],
      [
        "T2",
        "Disease",
        16,
        18,
        "Fanconi syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2489,
    "text": "Of the 407 Yellow Card records analysed , 106 satisfied criteria for TDF - related kidney disease , of which 53 ( 50 % ) had features of kidney tubular dysfunction , 35 ( 33 % ) were found to have features of glomerular dysfunction and 18 ( 17 % ) had Fanconi syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "kidney disease"
      ],
      [
        "T1",
        "Disease",
        28,
        31,
        "kidney tubular dysfunction"
      ],
      [
        "T2",
        "Disease",
        43,
        45,
        "glomerular dysfunction"
      ],
      [
        "T3",
        "Disease",
        52,
        54,
        "Fanconi syndrome"
      ],
      [
        "T4",
        "Chemical",
        12,
        13,
        "TDF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2490,
    "text": "The median TDF exposure was 316 days ( interquartile range 120 - 740 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "TDF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2491,
    "text": "The incidence of hospitalisation for TDF kidney adverse effects was high , particularly amongst patients with features of Fanconi syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "Fanconi syndrome"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "TDF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2492,
    "text": "The pattern of kidney syndromes in this population series mirrors that reported in randomised clinical trials .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2493,
    "text": "Cessation of TDF was associated with complete restoration of kidney function in up half of the patients in this report .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "TDF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2494,
    "text": "Incidence of postoperative delirium is high even in a population without known risk factors .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "postoperative delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2495,
    "text": "PURPOSE : Postoperative delirium is a recognized complication in populations at risk .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Postoperative delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2496,
    "text": "The aim of this study is to assess the prevalence of early postoperative delirium in a population without known risk factors admitted to the ICU for postoperative monitoring after elective major surgery .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "postoperative delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2497,
    "text": "The secondary outcome investigated is to identify eventual independent risk factors among demographic data and anesthetic drugs used .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2498,
    "text": "METHODS : An observational , prospective study was conducted on a consecutive cohort of patients admitted to our ICU within and for at least 24 h after major surgical procedures .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2499,
    "text": "Exclusion criteria were any preexisting predisposing factor for delirium or other potentially confounding neurological dysfunctions .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "neurological dysfunctions"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2500,
    "text": "Patients were assessed daily using the confusion assessment method for the ICU scale for 3 days after the surgical procedure .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "confusion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2501,
    "text": "Early postoperative delirium incidence risk factors were then assessed through three different multiple regression models .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "postoperative delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2502,
    "text": "RESULTS : According to the confusion assessment method for the ICU scale , 28 % of patients were diagnosed with early postoperative delirium .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "postoperative delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2503,
    "text": "The use of thiopentone was significantly associated with an eight - fold - higher risk for delirium compared to propofol ( 57 . 1 % vs . 7 . 1 % , RR = 8 . 0 , X2 = 4 . 256 ; df = 1 ; 0 . 05 < p < 0 . 02 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "thiopentone"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "delirium"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2504,
    "text": "CONCLUSION : In this study early postoperative delirium was found to be a very common complication after major surgery , even in a population without known risk factors .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "postoperative delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2505,
    "text": "Thiopentone was independently associated with an increase in its relative risk .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Thiopentone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2506,
    "text": "A single neurotoxic dose of methamphetamine induces a long - lasting depressive - like behaviour in mice .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "neurotoxic"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "methamphetamine"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "depressive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2507,
    "text": "Methamphetamine ( METH ) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "depressive symptoms"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Methamphetamine"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "METH"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2508,
    "text": "However , it is currently unknown if the acute toxic dosage of METH also causes a long - lasting depressive phenotype and persistent monoaminergic deficits .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "METH"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "depressive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2509,
    "text": "Thus , we now assessed the depressive - like behaviour in mice at early and long - term periods following a single high METH dose ( 30 mg / kg , i . p . ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "depressive"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2510,
    "text": "METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2511,
    "text": "However , METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post - administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "METH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2512,
    "text": "This depressive - like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission , indicated by a reduction in the levels of dopamine , DOPAC and HVA , tyrosine hydroxylase and serotonin , observed at both 3 and 49 days post - administration .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "depressive"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "METH"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "dopamine"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "DOPAC"
      ],
      [
        "T4",
        "Chemical",
        33,
        34,
        "HVA"
      ],
      [
        "T5",
        "Chemical",
        35,
        36,
        "tyrosine"
      ],
      [
        "T6",
        "Chemical",
        38,
        39,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2513,
    "text": "In parallel , another neurochemical feature of depression - - astroglial dysfunction - - was unaffected in the cortex and the striatal levels of the astrocytic protein marker , glial fibrillary acidic protein , were only transiently increased at 3 days .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2514,
    "text": "These findings demonstrate for the first time that a single high dose of METH induces long - lasting depressive - like behaviour in mice associated with a persistent disruption of frontostriatal dopaminergic and serotonergic homoeostasis .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "METH"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "depressive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2515,
    "text": "Linezolid - induced optic neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Linezolid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2516,
    "text": "Many systemic antimicrobials have been implicated to cause ocular adverse effects .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2517,
    "text": "This is especially relevant in multidrug therapy where more than one drug can cause a similar ocular adverse effect .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2518,
    "text": "We describe a case of progressive loss of vision associated with linezolid therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "loss of vision"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "linezolid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2519,
    "text": "A 45 - year - old male patient who was on treatment with multiple second - line anti - tuberculous drugs including linezolid and ethambutol for extensively drug - resistant tuberculosis ( XDR - TB ) presented to us with painless progressive loss of vision in both eyes .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        31,
        "extensively drug - resistant tuberculosis"
      ],
      [
        "T1",
        "Disease",
        32,
        35,
        "XDR - TB"
      ],
      [
        "T2",
        "Disease",
        42,
        45,
        "loss of vision"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "linezolid"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2520,
    "text": "Color vision was defective and fundus examination revealed optic disc edema in both eyes .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "optic disc edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2521,
    "text": "Ethambutol - induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "toxic optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Ethambutol"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2522,
    "text": "Deterioration of vision occurred despite withdrawal of ethambutol .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Deterioration of vision"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2523,
    "text": "Discontinuation of linezolid resulted in marked improvement of vision .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "linezolid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2524,
    "text": "Our report emphasizes the need for monitoring of visual function in patients on long - term linezolid treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "linezolid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2525,
    "text": "Resuscitation with lipid , epinephrine , or both in levobupivacaine - induced cardiac toxicity in newborn piglets .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "cardiac toxicity"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "epinephrine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "levobupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2526,
    "text": "BACKGROUND : The optimal dosing regimens of lipid emulsion , epinephrine , or both are not yet determined in neonates in cases of local anaesthetic systemic toxicity ( LAST ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "epinephrine"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2527,
    "text": "METHODS : Newborn piglets received levobupivacaine until cardiovascular collapse occurred .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "cardiovascular collapse"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "levobupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2528,
    "text": "Standard cardiopulmonary resuscitation was started and electrocardiogram ( ECG ) was monitored for ventricular tachycardia , fibrillation , or QRS prolongation .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "fibrillation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2529,
    "text": "Piglets were then randomly allocated to four groups : control ( saline ) , Intralipid ( ) alone , epinephrine alone , or a combination of Intralipd plus epinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "epinephrine"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2530,
    "text": "Resuscitation continued for 30 min or until there was a return of spontaneous circulation ( ROSC ) accompanied by a mean arterial pressure at or superior to the baseline pressure and normal sinus rhythm for a period of 30 min .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2531,
    "text": "RESULTS : ROSC was achieved in only one of the control piglets compared with most of the treated piglets .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2532,
    "text": "Mortality was not significantly different between the three treatment groups , but was significantly lower in all the treatment groups compared with control .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2533,
    "text": "The number of ECG abnormalities was zero in the Intralipid only group , but 14 and 17 , respectively , in the epinephrine and epinephrine plus lipid groups ( P < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "epinephrine"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2534,
    "text": "CONCLUSIONS : Lipid emulsion with or without epinephrine , or epinephrine alone were equally effective in achieving a return to spontaneous circulation in this model of LAST .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "epinephrine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2535,
    "text": "Epinephrine alone or in combination with lipid was associated with an increased number of ECG abnormalities compared with lipid emulsion alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2536,
    "text": "Incidence of heparin - induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients : a retrospective cohort analysis .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "thrombocytopenia type II"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2537,
    "text": "BACKGROUND : Thrombocytopenia in patients with end - stage liver disease is a common disorder caused mainly by portal hypertension , low levels of thrombopoetin , and endotoxemia .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        11,
        "end - stage liver disease"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "portal hypertension"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "Thrombocytopenia"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "endotoxemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2538,
    "text": "The impact of immune - mediated heparin - induced thrombocytopenia type II ( HIT type II ) as a cause of thrombocytopenia after liver transplantation is not yet understood , with few literature citations reporting contradictory results .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "thrombocytopenia type II"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "HIT type II"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "heparin"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2539,
    "text": "The aim of our study was to demonstrate the perioperative course of thrombocytopenia after liver transplantation and determine the occurrence of clinical HIT type II .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        25,
        "HIT type II"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2540,
    "text": "METHOD : We retrospectively evaluated the medical records of 205 consecutive adult patients who underwent full - size liver transplantation between January 2006 and December 2010 due to end - stage or malignant liver disease .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        35,
        "end - stage or malignant liver disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2541,
    "text": "Preoperative platelet count , postoperative course of platelets , and clinical signs of HIT type II were analyzed .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "HIT type II"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2542,
    "text": "RESULTS : A total of 155 ( 75 . 6 % ) of 205 patients had thrombocytopenia before transplantation , significantly influenced by Model of End - Stage Liver Disease score and liver cirrhosis .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        30,
        "End - Stage Liver Disease"
      ],
      [
        "T1",
        "Disease",
        32,
        34,
        "liver cirrhosis"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2543,
    "text": "The platelet count exceeded 100 , 000 / uL in most of the patients ( n = 193 ) at a medium of 7 d .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2544,
    "text": "Regarding HIT II , there were four ( 1 . 95 % ) patients with a background of HIT type II .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "HIT II"
      ],
      [
        "T1",
        "Disease",
        18,
        21,
        "HIT type II"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2545,
    "text": "CONCLUSIONS : The incidence of HIT in patients with end - stage hepatic failure is , with about 1 . 95 % , rare .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        14,
        "end - stage hepatic failure"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "HIT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2546,
    "text": "For further reduction of HIT type II , the use of intravenous heparin should be avoided and the prophylactic anticoagulation should be performed with low - molecular - weight heparin after normalization of platelet count .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "HIT type II"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "heparin"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2547,
    "text": "Takotsubo syndrome ( or apical ballooning syndrome ) secondary to Zolmitriptan .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Takotsubo syndrome"
      ],
      [
        "T1",
        "Disease",
        4,
        7,
        "apical ballooning syndrome"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "Zolmitriptan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2548,
    "text": "Takotsubo syndrome ( TS ) , also known as broken heart syndrome , is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an acute coronary syndrome ( ie , ST - segment elevation , T wave inversions , and pathologic Q waves ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Takotsubo syndrome"
      ],
      [
        "T1",
        "Disease",
        9,
        12,
        "broken heart syndrome"
      ],
      [
        "T2",
        "Disease",
        30,
        33,
        "acute coronary syndrome"
      ],
      [
        "T3",
        "Disease",
        3,
        4,
        "TS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2549,
    "text": "We report a case of 54 - year - old woman with medical history of mitral valve prolapse and migraines , who was admitted to the hospital for substernal chest pain and electrocardiogram demonstrated 1 / 2 mm ST - segment elevation in leads II , III , aVF , V5 , and V6 and positive troponin I .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "mitral valve prolapse"
      ],
      [
        "T1",
        "Disease",
        29,
        31,
        "chest pain"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "migraines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2550,
    "text": "Emergent coronary angiogram revealed normal coronary arteries with moderately reduced left ventricular ejection fraction with wall motion abnormalities consistent with TS .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "TS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2551,
    "text": "Detailed history obtained retrospectively revealed that the patient took zolmitriptan sparingly only when she had migraines .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "zolmitriptan"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "migraines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2552,
    "text": "But before this event , she was taking zolmitriptan 2 - 3 times daily for several days because of a persistent migraine headache .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "migraine headache"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "zolmitriptan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2553,
    "text": "She otherwise reported that she is quite active , rides horses , and does show jumping without any limitations in her physical activity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2554,
    "text": "There was no evidence of any recent stress or status migrainosus .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "status migrainosus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2555,
    "text": "Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to zolmitriptan , but none of the cases were associated with TS .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "coronary artery vasospasm"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "zolmitriptan"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "TS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2556,
    "text": "Depression , impulsiveness , sleep , and memory in past and present polydrug users of 3 , 4 - methylenedioxymethamphetamine ( MDMA , ecstasy ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        20,
        "3 , 4 - methylenedioxymethamphetamine"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Depression"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "impulsiveness"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "MDMA"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2557,
    "text": "RATIONALE : Ecstasy ( 3 , 4 - methylenedioxymethamphetamine , MDMA ) is a worldwide recreational drug of abuse .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        9,
        "3 , 4 - methylenedioxymethamphetamine"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Ecstasy"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2558,
    "text": "Unfortunately , the results from human research investigating its psychological effects have been inconsistent .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2559,
    "text": "OBJECTIVES : The present study aimed to be the largest to date in sample size and 5HT - related behaviors ; the first to compare present ecstasy users with past users after an abstinence of 4 or more years , and the first to include robust controls for other recreational substances .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2560,
    "text": "METHODS : A sample of 997 participants ( 52 % male ) was recruited to four control groups ( non - drug ( ND ) , alcohol / nicotine ( AN ) , cannabis / alcohol / nicotine ( CAN ) , non - ecstasy polydrug ( PD ) ) , and two ecstasy polydrug groups ( present ( MDMA ) and past users ( EX - MDMA ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "alcohol"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "nicotine"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "AN"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "cannabis"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "alcohol"
      ],
      [
        "T5",
        "Chemical",
        37,
        38,
        "nicotine"
      ],
      [
        "T6",
        "Chemical",
        39,
        40,
        "CAN"
      ],
      [
        "T7",
        "Chemical",
        44,
        45,
        "ecstasy"
      ],
      [
        "T8",
        "Chemical",
        53,
        54,
        "ecstasy"
      ],
      [
        "T9",
        "Chemical",
        59,
        60,
        "MDMA"
      ],
      [
        "T10",
        "Chemical",
        67,
        68,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2561,
    "text": "Participants completed a drug history questionnaire , Beck Depression Inventory , Barratt Impulsiveness Scale , Pittsburgh Sleep Quality Index , and Wechsler Memory Scale - Revised which , in total , provided 13 psychometric measures .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "Depression"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "Impulsiveness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2562,
    "text": "RESULTS : While the CAN and PD groups tended to record greater deficits than the non - drug controls , the MDMA and EX - MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "CAN"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "MDMA"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2563,
    "text": "Strikingly , despite prolonged abstinence ( mean , 4 . 98 ; range , 4 - 9 years ) , past ecstasy users showed few signs of recovery .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2564,
    "text": "Compared with present ecstasy users , the past users showed no change for ten measures , increased impairment for two measures , and improvement on just one measure .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2565,
    "text": "CONCLUSIONS : Given this record of impaired memory and clinically significant levels of depression , impulsiveness , and sleep disturbance , the prognosis for the current generation of ecstasy users is a major cause for concern .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "impaired memory"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "sleep disturbance"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "depression"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "impulsiveness"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2566,
    "text": "Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson ' s disease patients .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        17,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2567,
    "text": "Levodopa is the most effective symptomatic therapy for Parkinson ' s disease , but its chronic use could lead to chronic adverse outcomes , such as motor fluctuations , dyskinesia and visual hallucinations .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Disease",
        31,
        33,
        "visual hallucinations"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Levodopa"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2568,
    "text": "HOMER1 is a protein with pivotal function in glutamate transmission , which has been related to the pathogenesis of these complications .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2569,
    "text": "This study investigates whether polymorphisms in the HOMER1 gene promoter region are associated with the occurrence of the chronic complications of levodopa therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2570,
    "text": "A total of 205 patients with idiopathic Parkinson ' s disease were investigated .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        11,
        "idiopathic Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2571,
    "text": "Patients were genotyped for rs4704559 , rs10942891 and rs4704560 by allelic discrimination with Taqman assays .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2572,
    "text": "The rs4704559 G allele was associated with a lower prevalence of dyskinesia ( prevalence ratio ( PR ) = 0 . 615 , 95 % confidence interval ( CI ) 0 . 426 - 0 . 887 , P = 0 . 009 ) and visual hallucinations ( PR = 0 . 515 , 95 % CI 0 . 295 - 0 . 899 , P = 0 . 020 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        45,
        47,
        "visual hallucinations"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "dyskinesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2573,
    "text": "Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "levodopa"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2574,
    "text": "Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1 / 2 pathway in rat liver .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Crocin"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "diazinon"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2575,
    "text": "INTRODUCTION : Diazinon Yis one of the most broadly used organophosphorus insecticides in agriculture .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Diazinon"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "organophosphorus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2576,
    "text": "It has been shown that exposure to diazinon may interfere with lipid metabolism .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "diazinon"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2577,
    "text": "Moreover , the hypolipidemic effect of crocin has been established .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "crocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2578,
    "text": "Earlier studies revealed the major role of Extracellular signal - regulated kinase ( ERK ) pathways in low - density lipoprotein receptor ( LDLr ) expression .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2579,
    "text": "The aim of this study was to evaluate changes in the regulation of lipid metabolism , ERK and LDLr expression in the liver of rats exposed to subacute diazinon .",
    "labels": [
      [
        "T0",
        "Chemical",
        28,
        29,
        "diazinon"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2580,
    "text": "Furthermore ameliorating effect of crocin on diazinon induced disturbed cholesterol homeostasis was studied .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "crocin"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "diazinon"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "cholesterol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2581,
    "text": "METHODS : 24 Rats were divided into 4 groups and received following treatments for 4 weeks ; Corn oil ( control ) , diazinon ( 15mg / kg per day , orally ) and crocin ( 12 . 5 and 25mg / kg per day , intraperitoneally ) in combination with diazinon ( 15 mg / kg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "diazinon"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "crocin"
      ],
      [
        "T2",
        "Chemical",
        51,
        52,
        "diazinon"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2582,
    "text": "The levels of cholesterol , triglyceride and LDL in blood of rats were analyzed .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cholesterol"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "triglyceride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2583,
    "text": "Moreover mRNA levels of LDLr and ERK1 / 2 as well as protein levels of total and activated forms of ERK1 / 2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2584,
    "text": "RESULTS : Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol , triglyceride and LDL .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "diazinon"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "cholesterol"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "triglyceride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2585,
    "text": "Moreover diazinon decreased ERK1 / 2 protein phosphorylation and LDLr transcript .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "diazinon"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2586,
    "text": "Crocin reduced inhibition of ERK activation and diazinon - induced hyperlipemia and increased levels of LDLr transcript .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Crocin"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "diazinon"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "hyperlipemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2587,
    "text": "CONCLUSIONS : Crocin may be considered as a novel protective agent in diazinon - induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Crocin"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "diazinon"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "hyperlipemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2588,
    "text": "GEM - P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "Hodgkin lymphoma"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "GEM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2589,
    "text": "Hodgkin lymphoma ( HL ) is a relatively chemosensitive malignancy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hodgkin lymphoma"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "HL"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "malignancy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2590,
    "text": "However , for those who relapse , high - dose chemotherapy with autologous stem cell transplant is the treatment of choice which relies on adequate disease control with salvage chemotherapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2591,
    "text": "Regimens commonly used often require inpatient administration and can be difficult to deliver due to toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2592,
    "text": "Gemcitabine and cisplatin have activity in HL , non - overlapping toxicity with first - line chemotherapeutics , and may be delivered in an outpatient setting .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Gemcitabine"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "cisplatin"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "HL"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2593,
    "text": "In this retrospective single - centre analysis , patients with relapsed or refractory HL treated with gemcitabine 1 , 000 mg / m ( 2 ) day ( D ) 1 , D8 and D15 ; methylprednisolone 1 , 000 mg D1 - 5 ; and cisplatin 100 mg / m ( 2 ) D15 , every 28 days ( GEM - P ) were included .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "HL"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "gemcitabine"
      ],
      [
        "T2",
        "Chemical",
        36,
        37,
        "methylprednisolone"
      ],
      [
        "T3",
        "Chemical",
        46,
        47,
        "cisplatin"
      ],
      [
        "T4",
        "Chemical",
        60,
        61,
        "GEM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2594,
    "text": "Demographic , survival , response and toxicity data were recorded .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2595,
    "text": "Forty - one eligible patients were identified : median age 27 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2596,
    "text": "One hundred and twenty - two cycles of GEM - P were administered in total ( median 3 cycles ; range 1 - 6 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "GEM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2597,
    "text": "Twenty of 41 ( 48 % ) patients received GEM - P as second - line treatment and 11 / 41 ( 27 % ) as third - line therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "GEM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2598,
    "text": "Overall response rate ( ORR ) to GEM - P in the entire cohort was 80 % ( complete response ( CR ) 37 % , partial response 44 % ) with 14 / 15 CR confirmed as a metabolic CR on PET and ORR of 85 % in the 20 second - line patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "GEM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2599,
    "text": "The most common grade 3 / 4 toxicities were haematological : neutropenia 54 % and thrombocytopenia 51 % .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "toxicities"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "neutropenia"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2600,
    "text": "Median follow - up from the start of GEM - P was 4 . 5 years .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "GEM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2601,
    "text": "Following GEM - P , 5 - year progression - free survival was 46 % ( 95 % confidence interval ( CI ) , 30 - 62 % ) and 5 - year overall survival was 59 % ( 95 % CI , 43 - 74 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "GEM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2602,
    "text": "Fourteen of 41 patients proceeded directly to autologous transplant .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2603,
    "text": "GEM - P is a salvage chemotherapy with relatively high response rates , leading to successful transplantation in appropriate patients , in the treatment of relapsed or refractory HL .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "GEM"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "HL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2604,
    "text": "Basal functioning of the hypothalamic - pituitary - adrenal ( HPA ) axis and psychological distress in recreational ecstasy polydrug users .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2605,
    "text": "RATIONALE : Ecstasy ( MDMA ) is a psychostimulant drug which is increasingly associated with psychobiological dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "psychobiological dysfunction"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Ecstasy"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "MDMA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2606,
    "text": "While some recent studies suggest acute changes in neuroendocrine function , less is known about long - term changes in HPA functionality in recreational users .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2607,
    "text": "OBJECTIVES : The current study is the first to explore the effects of ecstasy - polydrug use on psychological distress and basal functioning of the HPA axis through assessing the secretion of cortisol across the diurnal period .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "ecstasy"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "cortisol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2608,
    "text": "METHOD : Seventy - six participants ( 21 nonusers , 29 light ecstasy - polydrug users , 26 heavy ecstasy - polydrug users ) completed a substance use inventory and measures of psychological distress at baseline , then two consecutive days of cortisol sampling ( on awakening , 30 min post awakening , between 1400 and 1600 hours and pre bedtime ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "ecstasy"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "ecstasy"
      ],
      [
        "T2",
        "Chemical",
        42,
        43,
        "cortisol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2609,
    "text": "On day 2 , participants also attended the laboratory to complete a 20 - min multitasking stressor .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2610,
    "text": "RESULTS : Both user groups exhibited significantly greater levels of anxiety and depression than nonusers .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "anxiety"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2611,
    "text": "On day 1 , all participants exhibited a typical cortisol profile , though light users had significantly elevated levels pre - bed .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "cortisol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2612,
    "text": "On day 2 , heavy users demonstrated elevated levels upon awakening and all ecstasy - polydrug users demonstrated elevated pre - bed levels compared to non - users .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2613,
    "text": "Significant between group differences were also observed in afternoon cortisol levels and in overall cortisol secretion across the day .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "cortisol"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "cortisol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2614,
    "text": "CONCLUSIONS : The increases in anxiety and depression are in line with previous observations in recreational ecstasy - polydrug users .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "anxiety"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "depression"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2615,
    "text": "Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "cortisol"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2616,
    "text": "Ifosfamide related encephalopathy : the need for a timely EEG evaluation .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Ifosfamide"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2617,
    "text": "BACKGROUND : Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas , lymphoma , gynecologic and testicular cancers .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        26,
        "gynecologic and testicular cancers"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Ifosfamide"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "cancers"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "sarcomas"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "lymphoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2618,
    "text": "Encephalopathy has been reported in 10 - 40 % of patients receiving high - dose IV ifosfamide .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Encephalopathy"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "ifosfamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2619,
    "text": "OBJECTIVE : To highlight the role of electroencephalogram ( EEG ) in the early detection and management of ifosfamide related encephalopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "ifosfamide"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2620,
    "text": "METHODS : Retrospective chart review including clinical data and EEG recordings was done on five patients , admitted to MD Anderson Cancer Center between years 2009 and 2012 , who developed ifosfamide related acute encephalopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        22,
        "Cancer"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "ifosfamide"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2621,
    "text": "RESULTS : All five patients experienced symptoms of encephalopathy soon after ( within 12 h - 2 days ) receiving ifosfamide .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "encephalopathy"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "ifosfamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2622,
    "text": "Two patients developed generalized convulsions while one patient developed continuous non - convulsive status epilepticus ( NCSE ) that required ICU admission and intubation .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        15,
        "non - convulsive status epilepticus"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "convulsions"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "NCSE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2623,
    "text": "Initial EEG showed epileptiform discharges in three patients ; run of triphasic waves in one patient and moderate degree diffuse generalized slowing .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2624,
    "text": "Mixed pattern with the presence of both sharps and triphasic waves were also noted .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2625,
    "text": "Repeat EEGs within 24 _ h of symptom onset showed marked improvement that was correlated with clinical improvement .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2626,
    "text": "CONCLUSIONS : Severity of ifosfamide related encephalopathy correlates with EEG changes .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "ifosfamide"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2627,
    "text": "We suggest a timely EEG evaluation for patients receiving ifosfamide who develop features of encephalopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "ifosfamide"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2628,
    "text": "Incidence of contrast - induced nephropathy in hospitalised patients with cancer .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "contrast"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "nephropathy"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2629,
    "text": "OBJECTIVES : To determine the frequency of and possible factors related to contrast - induced nephropathy ( CIN ) in hospitalised patients with cancer .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "contrast"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "nephropathy"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2630,
    "text": "METHODS : Ninety adult patients were enrolled .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2631,
    "text": "Patients with risk factors for acute renal failure were excluded .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "acute renal failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2632,
    "text": "Blood samples were examined the day before contrast - enhanced computed tomography ( CT ) and serially for 3 days thereafter .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "contrast"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2633,
    "text": "CIN was defined as an increase in serum creatinine ( Cr ) of 0 . 5 mg / dl or more , or elevation of Cr to 25 % over baseline .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "creatinine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "Cr"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "Cr"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2634,
    "text": "Relationships between CIN and possible risk factors were investigated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2635,
    "text": "RESULTS : CIN was detected in 18 / 90 ( 20 % ) patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2636,
    "text": "CIN developed in 25 . 5 % patients who underwent chemotherapy and in 11 % patients who did not ( P = 0 . 1 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2637,
    "text": "CIN more frequently developed in patients who had undergone CT within 45 days after the last chemotherapy ( P = 0 . 005 ) ; it was also an independent risk factor ( P = 0 . 017 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2638,
    "text": "CIN was significantly more after treatment with bevacizumab / irinotecan ( P = 0 . 021 ) and in patients with hypertension ( P = 0 . 044 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "bevacizumab"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "irinotecan"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2639,
    "text": "CONCLUSIONS : The incidence of CIN after CT in hospitalised oncological patients was 20 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2640,
    "text": "CIN developed 4 . 5 - times more frequently in patients with cancer who had undergone recent chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2641,
    "text": "Hypertension and the combination of bevacizumab / irinotecan may be additional risk factors for CIN development .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypertension"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "bevacizumab"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "irinotecan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2642,
    "text": "KEY POINTS : .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2643,
    "text": "Contrast - induced nephropathy ( CIN ) is a concern for oncological patients undergoing CT .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Contrast"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2644,
    "text": ". CIN occurs more often when CT is performed < 45 days after chemotherapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2645,
    "text": ". Hypertension and treatment with bevacizumab appear to be additional risk factors .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "Hypertension"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "bevacizumab"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2646,
    "text": "Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        5,
        "Syndrome of inappropriate antidiuretic hormone"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "desvenlafaxine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2647,
    "text": "OBJECTIVE : To report a case of syndrome of inappropriate anti - diuretic hormone ( SIADH ) secretion associated with desvenlafaxine .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        14,
        "syndrome of inappropriate anti - diuretic hormone"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "SIADH"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "desvenlafaxine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2648,
    "text": "CASE SUMMARY : A 57 - year old female with hyponatraemia .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "hyponatraemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2649,
    "text": "Her medications included desvenlafaxine , and symptoms included nausea , anxiety and confusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "desvenlafaxine"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "nausea"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "anxiety"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "confusion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2650,
    "text": "The serum sodium at this time was 120 mmol / L , serum osmolality was 263 mosmol / kg , urine osmolality 410 mosmol / kg and urine sodium 63 mmol / L , consistent with a diagnosis of SIADH .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "sodium"
      ],
      [
        "T2",
        "Disease",
        39,
        40,
        "SIADH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2651,
    "text": "Desvenlafaxine was ceased and fluid restriction implemented .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Desvenlafaxine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2652,
    "text": "After 4 days the sodium increased to 128 mmol / L and fluid restriction was relaxed .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2653,
    "text": "During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol / L during treatment with mirtazapine .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "mirtazapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2654,
    "text": "DISCUSSION : SIADH has been widely reported with a range of antidepressants .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "SIADH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2655,
    "text": "This case report suggests that desvenlafaxine might cause clinically significant hyponatremia .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "desvenlafaxine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hyponatremia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2656,
    "text": "CONCLUSIONS : Clinicians should be aware of the potential for antidepressants to cause hyponatremia , and take appropriate corrective action where necessary .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "hyponatremia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2657,
    "text": "Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2658,
    "text": "The mechanism of doxorubicin ( DOX ) - induced cardiotoxicity remains controversial .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "doxorubicin"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "DOX"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2659,
    "text": "Wistar rats ( n = 66 ) received DOX injections intraperitoneally and were randomly assigned to 2 experimental protocols : ( 1 ) rats were killed before ( - 24 h , n = 8 ) and 24 h after ( + 24 h , n = 8 ) a single dose of DOX ( 4 mg / kg body weight ) to determine the DOX acute effect and ( 2 ) rats ( n = 58 ) received 4 injections of DOX ( 4 mg / kg body weight / week ) and were killed before the first injection ( M0 ) and 1 week after each injection ( M1 , M2 , M3 , and M4 ) to determine the chronological effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "DOX"
      ],
      [
        "T1",
        "Chemical",
        53,
        54,
        "DOX"
      ],
      [
        "T2",
        "Chemical",
        65,
        66,
        "DOX"
      ],
      [
        "T3",
        "Chemical",
        82,
        83,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2660,
    "text": "Animals used at M0 ( n = 8 ) were also used at moment - 24 h of acute study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2661,
    "text": "Cardiac total antioxidant performance ( TAP ) , DNA damage , and morphology analyses were carried out at each time point .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2662,
    "text": "Single dose of DOX was associated with increased cardiac disarrangement , necrosis , and DNA damage ( strand breaks ( SBs ) and oxidized pyrimidines ) and decreased TAP .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "cardiac disarrangement"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "DOX"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2663,
    "text": "The chronological study showed an effect of a cumulative dose on body weight ( R = - 0 . 99 , p = 0 . 011 ) , necrosis ( R = 1 . 00 , p = 0 . 004 ) , TAP ( R = 0 . 95 , p = 0 . 049 ) , and DNA SBs ( R = - 0 . 95 , p = 0 . 049 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        29,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2664,
    "text": "DNA SBs damage was negatively associated with TAP ( R = - 0 . 98 , p = 0 . 018 ) , and necrosis ( R = - 0 . 97 , p = 0 . 027 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        25,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2665,
    "text": "Our results suggest that oxidative damage is associated with acute cardiotoxicity induced by a single dose of DOX only .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2666,
    "text": "Increased resistance to the oxidative stress is plausible for the multiple dose of DOX .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2667,
    "text": "Thus , different mechanisms may be involved in acute toxicity versus chronic toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "toxicity"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2668,
    "text": "Tacrolimus - related seizure after pediatric liver transplantation - - a single - center experience .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Tacrolimus"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2669,
    "text": "To identify the risk factors for new - onset seizures after pediatric LT and to assess their clinical implications and long - term prognosis .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2670,
    "text": "The clinical and laboratory data of 27 consecutive children who underwent LT from January 2007 to December 2010 in our center were analyzed retrospectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2671,
    "text": "Patients were divided into seizures group and a non - seizures group .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "seizures"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2672,
    "text": "Pre - operative , intra - operative , and post - operative data were collected .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2673,
    "text": "Seizures occurred in four children , an incidence of 14 . 8 % .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2674,
    "text": "All exhibited generalized tonic - clonic seizures within the first two wk after LT .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "tonic - clonic seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2675,
    "text": "Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender , pediatric end - stage liver disease score before surgery , Child - Pugh score before surgery , serum total bilirubin after surgery , and trough TAC level .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        22,
        "end - stage liver disease"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "bilirubin"
      ],
      [
        "T3",
        "Chemical",
        41,
        42,
        "TAC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2676,
    "text": "Multivariate analysis showed that trough TAC level was the only independent risk factor associated with the seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "TAC"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2677,
    "text": "All children who experienced seizures survived with good graft function and remained seizure - free without anti - epileptic drugs over a mean follow - up period of 33 . 7 + 14 . 6 months .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "seizures"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "seizure"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2678,
    "text": "High trough TAC level was the predominant factor that contributed to seizures in the early post - operative period after pediatric LT .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "TAC"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2679,
    "text": "High PELD and Child - Pugh scores before LT and high post - operative serum Tbil may be contributory risk factors for TAC - related seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "TAC"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2680,
    "text": "The flavonoid apigenin delays forgetting of passive avoidance conditioning in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "flavonoid"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "apigenin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2681,
    "text": "The present experiments were performed to study the effect of the flavonoid apigenin ( 20 mg / kg intraperitoneally ( i . p . ) , 1 h before acquisition ) , on 24 h retention performance and forgetting of a step - through passive avoidance task , in young male Wistar rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "flavonoid"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "apigenin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2682,
    "text": "There were no differences between saline - and apigenin - treated groups in the 24 h retention trial .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "apigenin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2683,
    "text": "Furthermore , apigenin did not prevent the amnesia induced by scopolamine ( 1mg / kg , i . p . , 30 min before the acquisition ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "apigenin"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "amnesia"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2684,
    "text": "The saline - and apigenin - treated rats that did not step through into the dark compartment during the cut - off time ( 540 s ) were retested weekly for up to eight weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "apigenin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2685,
    "text": "In the saline treated group , the first significant decline in passive avoidance response was observed at four weeks , and complete memory loss was found five weeks after the acquisition of the passive avoidance task .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "memory loss"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2686,
    "text": "At the end of the experimental period , 60 % of the animals treated with apigenin still did not step through .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "apigenin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2687,
    "text": "These data suggest that 1 ) apigenin delays the long - term forgetting but did not modulate the 24 h retention of fear memory and 2 ) the obtained beneficial effect of apigenin on the passive avoidance conditioning is mediated by mechanisms that do not implicate its action on the muscarinic cholinergic system .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "apigenin"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "apigenin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2688,
    "text": "Histamine antagonists and d - tubocurarine - induced hypotension in cardiac surgical patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "d - tubocurarine"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Histamine"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2689,
    "text": "Hemodynamic effects and histamine release by bolus injection of 0 . 35 mg / kg of d - tubocurarine were studied in 24 patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "d - tubocurarine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "histamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2690,
    "text": "H1 - and H2 - histamine antagonists or placebo were given before dosing with d - tubocurarine in a randomized double - blind fashion to four groups : group 1 - - placebo ; group 2 - - cimetidine , 4 mg / kg , plus placebo ; group 3 - - chlorpheniramine , 0 . 1 mg / kg , plus placebo ; and group 4 - - cimetidine plus chlorpheniramine .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        17,
        "d - tubocurarine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "histamine"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "cimetidine"
      ],
      [
        "T3",
        "Chemical",
        52,
        53,
        "chlorpheniramine"
      ],
      [
        "T4",
        "Chemical",
        69,
        70,
        "cimetidine"
      ],
      [
        "T5",
        "Chemical",
        71,
        72,
        "chlorpheniramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2691,
    "text": "Histamine release occurred in most patients , the highest level 2 minutes after d - tubocurarine dosing .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        16,
        "d - tubocurarine"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Histamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2692,
    "text": "Group 1 had a moderate negative correlation between plasma histamine change and systemic vascular resistance ( r = 0 . 58 ; P less than 0 . 05 ) not present in group 4 .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "histamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2693,
    "text": "Prior dosing with antagonists partially prevented the fall in systemic vascular resistance .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2694,
    "text": "These data demonstrate that the hemodynamic changes associated with d - tubocurarine dosing are only partially explained by histamine release .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "d - tubocurarine"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "histamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2695,
    "text": "Thus prior dosing with H1 - and H2 - antagonists provides only partial protection .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2696,
    "text": "Cholecystokinin - octapeptide restored morphine - induced hippocampal long - term potentiation impairment in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "Cholecystokinin - octapeptide"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2697,
    "text": "Cholecystokinin - octapeptide ( CCK - 8 ) , which is a typical brain - gut peptide , exerts a wide range of biological activities on the central nervous system .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "Cholecystokinin - octapeptide"
      ],
      [
        "T1",
        "Chemical",
        4,
        7,
        "CCK - 8"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2698,
    "text": "We have previously reported that CCK - 8 significantly alleviated morphine - induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine - treated animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "CCK - 8"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "morphine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "amnesia"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2699,
    "text": "Here , we investigated the effects of CCK - 8 on long - term potentiation ( LTP ) in the lateral perforant path ( LPP ) - granule cell synapse of rat dentate gyrus ( DG ) in acute saline or morphine - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "CCK - 8"
      ],
      [
        "T1",
        "Chemical",
        41,
        42,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2700,
    "text": "Population spikes ( PS ) , which were evoked by stimulation of the LPP , were recorded in the DG region .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2701,
    "text": "Acute morphine ( 30mg / kg , s . c . ) treatment significantly attenuated hippocampal LTP and CCK - 8 ( 1ug , i . c . v . ) restored the amplitude of PS that was attenuated by morphine injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        21,
        "CCK - 8"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "morphine"
      ],
      [
        "T2",
        "Chemical",
        40,
        41,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2702,
    "text": "Furthermore , microinjection of CCK - 8 ( 0 . 1 and 1ug , i . c . v . ) also significantly augmented hippocampal LTP in saline - treated ( 1ml / kg , s . c . ) rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "CCK - 8"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2703,
    "text": "Pre - treatment of the CCK2 receptor antagonist L - 365 , 260 ( 10ug , i . c . v ) reversed the effects of CCK - 8 , but the CCK1 receptor antagonist L - 364 , 718 ( 10ug , i . c . v ) did not .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        29,
        "CCK - 8"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2704,
    "text": "The present results demonstrate that CCK - 8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK - 8 on morphine - induced memory impairment .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "CCK - 8"
      ],
      [
        "T1",
        "Chemical",
        25,
        28,
        "CCK - 8"
      ],
      [
        "T2",
        "Disease",
        32,
        34,
        "memory impairment"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "morphine"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2705,
    "text": "Glial activation and post - synaptic neurotoxicity : the key events in Streptozotocin ( ICV ) induced memory impairment in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "memory impairment"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "neurotoxicity"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "Streptozotocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2706,
    "text": "In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin ( STZ ) induced memory impaired rats was explored .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "memory impaired"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "Streptozotocin"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2707,
    "text": "In experiment set up 1 : Memory deficit was found in Morris water maze test on 14 - 16 days after STZ ( ICV ; 3mg / Kg ) administration .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "Memory deficit"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2708,
    "text": "STZ causes increased expression of GFAP , CD11b and TNF - a indicating glial activation and neuroinflammation .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "STZ"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "neuroinflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2709,
    "text": "STZ also significantly increased the level of ROS , nitrite , Ca ( 2 + ) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "STZ"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "nitrite"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "Ca"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "excitotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2710,
    "text": "Increased expression and activity of Caspase - 3 was also observed in STZ treated rat which specify apoptotic cell death in hippocampus and cortex .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2711,
    "text": "STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD - 95 , while , expression of pre synaptic markers ( synaptophysin and SNAP - 25 ) remains unaltered indicating selective post synaptic neurotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "STZ"
      ],
      [
        "T1",
        "Disease",
        35,
        36,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2712,
    "text": "Oral treatment with Memantine ( 10mg / kg ) and Ibuprofen ( 50 mg / kg ) daily for 13 days attenuated STZ induced glial activation , apoptotic cell death and post synaptic neurotoxicity in rat brain .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "Memantine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "Ibuprofen"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "STZ"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2713,
    "text": "Further , in experiment set up 2 : where memory function was not affected i . e . 7 - 9 days after STZ treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2714,
    "text": "The level of GFAP , CD11b , TNF - a , ROS and nitrite levels were increased .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "nitrite"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2715,
    "text": "On the other hand , apoptotic marker , synaptic markers , mitochondrial activity and Ca ( 2 + ) levels remained unaffected .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "Ca"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2716,
    "text": "Collective data indicates that neuroinflammatory process and oxidative stress occurs earlier to apoptosis and does not affect memory function .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "neuroinflammatory"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2717,
    "text": "Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "memory impairment"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "neurotoxicity"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2718,
    "text": "Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast - induced nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "sodium chloride"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "diltiazem"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "contrast"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2719,
    "text": "INTRODUCTION AND OBJECTIVE : Contrast - induced nephropathy ( CIN ) significantly increases the morbidity and mortality of patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "Contrast"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2720,
    "text": "The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem , a calcium channel blocker , in preventing CIN .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        17,
        "sodium chloride"
      ],
      [
        "T1",
        "Chemical",
        18,
        20,
        "sodium bicarbonate"
      ],
      [
        "T2",
        "Chemical",
        23,
        25,
        "sodium chloride"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "diltiazem"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2721,
    "text": "MATERIALS AND METHODS : Our study included patients who were administered 30 - 60 mL of iodinated contrast agent for percutaneous coronary angiography ( PCAG ) , all with creatinine values between 1 . 1 and 3 . 1 mg / dL .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "contrast"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2722,
    "text": "Patients were divided into three groups and each group had 20 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2723,
    "text": "The first group of patients was administered isotonic sodium chloride ; the second group was administered a solution that of 5 % dextrose and sodium bicarbonate , while the third group was administered isotonic sodium chloride before and after the contrast injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "sodium chloride"
      ],
      [
        "T1",
        "Chemical",
        24,
        26,
        "sodium bicarbonate"
      ],
      [
        "T2",
        "Chemical",
        34,
        36,
        "sodium chloride"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "dextrose"
      ],
      [
        "T4",
        "Chemical",
        40,
        41,
        "contrast"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2724,
    "text": "The third group received an additional injection of diltiazem the day before and first 2 days after the contrast injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "diltiazem"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "contrast"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2725,
    "text": "All of the patients ' plasma blood urea nitrogen ( BUN ) and creatinine levels were measured on the second and seventh day after the administration of intravenous contrast material .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "blood urea nitrogen"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "BUN"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "creatinine"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "contrast"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2726,
    "text": "RESULTS : The basal creatinine levels were similar for all three groups ( p > 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2727,
    "text": "Among a total of 60 patients included in the study , 16 patients developed acute renal failure ( ARF ) on the second day after contrast material was injected ( 26 . 6 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        17,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "ARF"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "contrast"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2728,
    "text": "The number of patients who developed ARF on the second day after the injection in the first group was five ( 25 % ) , in the second group was six ( 30 % ) and the third group was five ( 25 % ) ( p > 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "ARF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2729,
    "text": "CONCLUSION : There was no significant difference between isotonic sodium chloride , sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "sodium chloride"
      ],
      [
        "T1",
        "Chemical",
        12,
        14,
        "sodium bicarbonate"
      ],
      [
        "T2",
        "Chemical",
        16,
        18,
        "sodium chloride"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "diltiazem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2730,
    "text": "Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group ( POG ) P9605 ( standard risk ) and P9201 ( lesser risk ) acute lymphoblastic leukemia protocols ( ACCL0131 ) : a methotrexate consequence ?",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        32,
        "acute lymphoblastic leukemia"
      ],
      [
        "T1",
        "Chemical",
        38,
        39,
        "methotrexate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2731,
    "text": "A report from the Children ' s Oncology Group .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2732,
    "text": "Concerns about long - term methotrexate ( MTX ) neurotoxicity in the 1990s led to modifications in intrathecal ( IT ) therapy , leucovorin rescue , and frequency of systemic MTX administration in children with acute lymphoblastic leukemia .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        38,
        "acute lymphoblastic leukemia"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "methotrexate"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "MTX"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "neurotoxicity"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "MTX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2733,
    "text": "In this study , neurocognitive outcomes and neuroradiologic evidence of leukoencephalopathy were compared in children treated with intense central nervous system ( CNS ) - directed therapy ( P9605 ) versus those receiving fewer CNS - directed treatment days during intensive consolidation ( P9201 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "leukoencephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2734,
    "text": "A total of 66 children from 16 Pediatric Oncology Group institutions with \" standard - risk \" acute lymphoblastic leukemia , 1 . 00 to 9 . 99 years at diagnosis , without evidence of CNS leukemia at diagnosis were enrolled on ACCL0131 : 28 from P9201 and 38 from P9605 .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "acute lymphoblastic leukemia"
      ],
      [
        "T1",
        "Disease",
        36,
        37,
        "leukemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2735,
    "text": "Magnetic resonance imaging scans and standard neuropsychological tests were performed > 2 . 6 years after the end of treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2736,
    "text": "Significantly more P9605 patients developed leukoencephalopathy compared with P9201 patients ( 68 % , 95 % confidence interval 49 % - 83 % vs . 22 % , 95 % confidence interval 5 % - 44 % ; P = 0 . 001 ) identified as late as 7 . 7 years after the end of treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "leukoencephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2737,
    "text": "Overall , 40 % of patients scored < 85 on either Verbal or Performance IQ .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2738,
    "text": "Children on both studies had significant attention problems , but P9605 children scored below average on more neurocognitive measures than those treated on P9201 ( 82 % , 14 / 17 measures vs . 24 % , 4 / 17 measures ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "attention problems"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2739,
    "text": "This supports ongoing concerns about intensive MTX exposure as a major contributor to CNS late effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "MTX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2740,
    "text": "Tranexamic acid overdosage - induced generalized seizure in renal failure .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Tranexamic acid"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "renal failure"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2741,
    "text": "We report a 45 - year - old lady with chronic kidney disease stage 4 due to chronic tubulointerstial disease .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "chronic kidney disease"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "tubulointerstial disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2742,
    "text": "She was admitted to our center for severe anemia due to menorrhagia and deterioration of renal function .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        17,
        "deterioration of renal function"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "anemia"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "menorrhagia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2743,
    "text": "She was infused three units of packed cells during a session of hemodialysis .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2744,
    "text": "Tranexamic acid ( TNA ) 1 g 8 - hourly was administered to her to control bleeding per vaginum .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Tranexamic acid"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "TNA"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2745,
    "text": "Two hours after the sixth dose of TNA , she had an episode of generalized tonic clonic convulsions .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "tonic clonic convulsions"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "TNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2746,
    "text": "TNA was discontinued .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "TNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2747,
    "text": "Investigations of the patient revealed no biochemical or structural central nervous system abnormalities that could have provoked the convulsions .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "nervous system abnormalities"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2748,
    "text": "She did not require any further dialytic support .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2749,
    "text": "She had no further episodes of convulsion till dis - charge and during the two months of follow - up .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "convulsion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2750,
    "text": "Thus , the precipitating cause of convulsions was believed to be an overdose of TNA .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "convulsions"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "overdose"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "TNA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2751,
    "text": "Pre - treatment of bupivacaine - induced cardiovascular depression using different lipid formulations of propofol .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "cardiovascular depression"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2752,
    "text": "BACKGROUND : Pre - treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine , and the lipid content of propofol may alleviate bupivacaine - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "propofol"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "bupivacaine"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2753,
    "text": "The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "propofol"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "bupivacaine"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2754,
    "text": "METHODS : Rats were anaesthetised with ketamine and were given 0 . 5 mg / kg / min propofol in intralipid ( Group P ) , propofol in medialipid ( Group L ) , or saline ( Group C ) over 20 min .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "ketamine"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "propofol"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2755,
    "text": "Thereafter , 2 mg / kg / min bupivacaine 0 . 5 % was infused .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2756,
    "text": "We recorded time to first dysrhythmia occurrence , respective times to 25 % and 50 % reduction of the heart rate ( HR ) and mean arterial pressure , and time to asystole and total amount of bupivacaine consumption .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "dysrhythmia"
      ],
      [
        "T1",
        "Disease",
        32,
        33,
        "asystole"
      ],
      [
        "T2",
        "Chemical",
        37,
        38,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2757,
    "text": "Blood and tissue samples were collected following asystole .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "asystole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2758,
    "text": "RESULTS : The time to first dysrhythmia occurrence , time to 25 % and 50 % reductions in HR , and time to asystole were longer in Group P than the other groups .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "dysrhythmia"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "asystole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2759,
    "text": "The cumulative bupivacaine dose given at those time points was higher in Group P . Plasma bupivacaine levels were significantly lower in Group P than in Group C . Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "Bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2760,
    "text": "CONCLUSION : We conclude that pre - treatment with propofol in intralipid , compared with propofol in medialipid or saline , delayed the onset of bupivacaine - induced cardiotoxic effects as well as reduced plasma bupivacaine levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "propofol"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "propofol"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "bupivacaine"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "cardiotoxic"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2761,
    "text": "Further studies are needed to explore tissue bupivacaine levels of propofol in medialipid and adapt these results to clinical practice .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2762,
    "text": "Drug - Induced Acute Liver Injury Within 12 Hours After Fluvastatin Therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        6,
        "Drug - Induced Acute Liver Injury"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "Fluvastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2763,
    "text": "Although statins are generally well - tolerated drugs , recent cases of drug - induced liver injury associated with their use have been reported .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        17,
        "drug - induced liver injury"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "statins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2764,
    "text": "A 52 - year - old Chinese man reported with liver damage , which appeared 12 hours after beginning treatment with fluvastatin .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "liver damage"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "fluvastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2765,
    "text": "Patient presented with complaints of increasing nausea , anorexia , and upper abdominal pain .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "abdominal pain"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "nausea"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "anorexia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2766,
    "text": "His laboratory values showed elevated creatine kinase and transaminases .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "creatine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2767,
    "text": "Testing for autoantibodies was also negative .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2768,
    "text": "The liver biochemistries eventually normalized within 3 weeks of stopping the fluvastatin .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "fluvastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2769,
    "text": "Therefore , when prescribing statins , the possibility of hepatic damage should be taken into account .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "hepatic damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2770,
    "text": "Fluconazole associated agranulocytosis and thrombocytopenia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Fluconazole"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "agranulocytosis"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2771,
    "text": "CASE : We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "fluconazole"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "agranulocytosis"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2772,
    "text": "The patient began to have changes in white blood cells and platelets within 48 h of administration of fluconazole and began to recover with 48 h of discontinuation .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "fluconazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2773,
    "text": "This case highlights that drug - induced blood dyscrasias can occur unexpectedly as a result of treatment with a commonly used drug thought to be \" safe \" .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "blood dyscrasias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2774,
    "text": "CONCLUSION : According to Naranjo ' s algorithm the likelihood that our patient ' s agranulocytosis and thrombocytopenia occurred as a result of therapy with fluconazole is probable , with a total of six points .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "agranulocytosis"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "fluconazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2775,
    "text": "We feel that the weight of the overall evidence of this evidence is strong .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2776,
    "text": "In particular the temporal relationship of bone marrow suppression to the initiation of fluconazole and the abatement of symptoms that rapidly reversed immediately following discontinuation .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "bone marrow suppression"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "fluconazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2777,
    "text": "Two - dimensional speckle tracking echocardiography combined with high - sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine - based chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "epirubicine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2778,
    "text": "AIMS : To investigate whether alterations of myocardial strain and high - sensitive cardiac troponin T ( cTnT ) could predict future cardiac dysfunction in patients after epirubicin exposure .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "myocardial strain"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "cardiac dysfunction"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "epirubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2779,
    "text": "METHODS : Seventy - five patients with non - Hodgkin lymphoma treated with epirubicin were studied .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "non - Hodgkin lymphoma"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "epirubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2780,
    "text": "Blood collection and echocardiography were performed at baseline , 1 day after the third cycle , and 1 day after completion of chemotherapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2781,
    "text": "Patients were studied using echocardiography during follow - up .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2782,
    "text": "Global longitudinal ( GLS ) , circumferential ( GCS ) , and radial strain ( GRS ) were calculated using speckle tracking echocardiography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2783,
    "text": "Left ventricular ejection fraction was analysed by real - time 3D echocardiography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2784,
    "text": "Cardiotoxicity was defined as a reduction of the LVEF of > 5 % to < 55 % with symptoms of heart failure or an asymptomatic reduction of the LVEF of > 10 % to < 55 % .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "heart failure"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2785,
    "text": "RESULTS : Fourteen patients ( 18 . 67 % ) developed cardiotoxicity after treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2786,
    "text": "GLS ( - 18 . 48 + 1 . 72 % vs . - 15 . 96 + 1 . 6 % ) , GCS ( - 20 . 93 + 2 . 86 % vs . - 19 . 20 + 3 . 21 % ) , and GRS ( 39 . 23 + 6 . 44 % vs . 34 . 98 + 6 . 2 % ) were markedly reduced and cTnT was elevated from 0 . 0010 + 0 . 0020 to 0 . 0073 + 0 . 0038 ng / mL ( P all < 0 . 01 ) at the completion of chemotherapy compared with baseline values .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2787,
    "text": "A > 15 . 9 % decrease in GLS [ sensitivity , 86 % ; specificity , 75 % ; area under the curve ( AUC ) = 0 . 815 ; P = 0 . 001 ] and a > 0 . 004 ng / mL elevation in cTnT ( sensitivity , 79 % ; specificity , 64 % ; AUC = 0 . 757 ; P = 0 . 005 ) from baseline to the third cycle of chemotherapy predicted later cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        83,
        84,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2788,
    "text": "The decrease in GLS remained the only independent predictor of cardiotoxicity ( P = 0 . 000 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2789,
    "text": "CONCLUSIONS : GLS combined with cTnT may provide a reliable and non - invasive method to predict cardiac dysfunction in patients receiving anthracycline - based chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "anthracycline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2790,
    "text": "Prevention of etomidate - induced myoclonus : which is superior : Fentanyl , midazolam , or a combination ?",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "etomidate"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "myoclonus"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "Fentanyl"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "midazolam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2791,
    "text": "A Retrospective comparative study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2792,
    "text": "BACKGROUND : In this retrospective comparative study , we aimed to compare the effectiveness of fentanyl , midazolam , and a combination of fentanyl and midazolam to prevent etomidate - induced myoclonus .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "fentanyl"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "midazolam"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "fentanyl"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "midazolam"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "etomidate"
      ],
      [
        "T5",
        "Disease",
        31,
        32,
        "myoclonus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2793,
    "text": "MATERIAL AND METHODS : This study was performed based on anesthesia records .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2794,
    "text": "Depending on the drugs that would be given before the induction of anesthesia with etomidate , the patients were separated into 4 groups : no pretreatment ( Group NP ) , fentanyl 1 ug . kg - 1 ( Group F ) , midazolam 0 . 03 mg . kg - 1 ( Group M ) , and midazolam 0 . 015 mg . kg - 1 + fentanyl 0 . 5 ug . kg - 1 ( Group FM ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "etomidate"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "fentanyl"
      ],
      [
        "T2",
        "Chemical",
        43,
        44,
        "midazolam"
      ],
      [
        "T3",
        "Chemical",
        58,
        59,
        "midazolam"
      ],
      [
        "T4",
        "Chemical",
        68,
        69,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2795,
    "text": "Patients who received the same anesthetic procedure were selected : 2 minutes after intravenous injections of the pretreatment drugs , anesthesia is induced with 0 . 3 mg . kg - 1 etomidate injected intravenously over a period of 20 - 30 seconds .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        33,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2796,
    "text": "Myoclonic movements are evaluated , which were observed and graded according to clinical severity during the 2 minutes after etomidate injection .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Myoclonic movements"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2797,
    "text": "The severity of pain due to etomidate injection , mean arterial pressure , heart rate , and adverse effects were also evaluated .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "pain"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2798,
    "text": "RESULTS : Study results showed that myoclonus incidence was 85 % , 40 % , 70 % , and 25 % in Group NP , Group F , Group M , and Group FM , respectively , and were significantly lower in Group F and Group FM .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "myoclonus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2799,
    "text": "CONCLUSIONS : We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate - induced myoclonus .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "fentanyl"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "fentanyl"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "midazolam"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "etomidate"
      ],
      [
        "T4",
        "Disease",
        21,
        22,
        "myoclonus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2800,
    "text": "Convulsant effect of lindane and regional brain concentration of GABA and dopamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "lindane"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "GABA"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2801,
    "text": "Lindane ( gamma - hexachlorocyclohexane ) is an organochlorine insecticide with known neurotoxic effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "gamma - hexachlorocyclohexane"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Lindane"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "neurotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2802,
    "text": "Its mechanism of action is not well understood although it has been proposed that lindane acts as a non - competitive antagonist at the gamma - aminobutyric acid ( GABA ) - A receptor .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        28,
        "gamma - aminobutyric acid"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "lindane"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2803,
    "text": "We studied the effect of lindane ( 150 mg / kg ) on the GABAergic and dopaminergic systems by measuring the concentration of GABA , dopamine and its metabolites in 7 brain areas at the onset of seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "lindane"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "GABA"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "dopamine"
      ],
      [
        "T3",
        "Disease",
        37,
        38,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2804,
    "text": "All animals suffered tonic convulsions at 18 . 3 + / - 1 . 4 min after lindane administration .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "convulsions"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "lindane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2805,
    "text": "The concentration of GABA was only slightly but significantly decreased in the colliculi without modifications in the other areas .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2806,
    "text": "The concentration of dopamine was increased in the mesencephalon and that of its metabolite DOPAC was also increased in the mesencephalon and the striatum .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "dopamine"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "DOPAC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2807,
    "text": "Cholestatic presentation of yellow phosphorus poisoning .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Cholestatic"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "phosphorus"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "poisoning"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2808,
    "text": "Yellow phosphorus , a component of certain pesticide pastes and fireworks , is well known to cause hepatotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "phosphorus"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2809,
    "text": "Poisoning with yellow phosphorus classically manifests with acute hepatitis leading to acute liver failure which may need liver transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "acute hepatitis"
      ],
      [
        "T1",
        "Disease",
        11,
        14,
        "acute liver failure"
      ],
      [
        "T2",
        "Disease",
        0,
        1,
        "Poisoning"
      ],
      [
        "T3",
        "Chemical",
        3,
        4,
        "phosphorus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2810,
    "text": "We present a case of yellow phosphorus poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow phosphorus hepatotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "phosphorus"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "poisoning"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "cholestasis"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "cholestasis"
      ],
      [
        "T4",
        "Chemical",
        32,
        33,
        "phosphorus"
      ],
      [
        "T5",
        "Disease",
        33,
        34,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2811,
    "text": "Vasovagal syncope and severe bradycardia following intranasal dexmedetomidine for pediatric procedural sedation .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Vasovagal syncope"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "bradycardia"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2812,
    "text": "We report syncope and bradycardia in an 11 - year - old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "syncope"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "bradycardia"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "dexmedetomidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2813,
    "text": "Following successful completion of VCUG and a 60 - min recovery period , the patient ' s level of consciousness and vital signs returned to presedation levels .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2814,
    "text": "Upon leaving the sedation area , the patient collapsed , with no apparent inciting event .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2815,
    "text": "The patient quickly regained consciousness and no injury occurred .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2816,
    "text": "The primary abnormality found was persistent bradycardia , and she was admitted to the hospital for telemetric observation .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2817,
    "text": "The bradycardia lasted ~ 2 h , and further cardiac workup revealed no underlying abnormality .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2818,
    "text": "Unanticipated and previously unreported outcomes may be witnessed as we expand the use of certain sedatives to alternative routes of administration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2819,
    "text": "Paradoxical severe agitation induced by add - on high - doses quetiapine in schizo - affective disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        17,
        "schizo - affective disorder"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "agitation"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2820,
    "text": "We report the case of a 35 - year - old patient suffering from schizo - affective disorder since the age of 19 years , treated by a combination of first - generation antipsychotics , zuclopenthixol ( 100 mg / day ) and lithium ( 1200 mg / day ) ( serum lithium = 0 . 85 mEq / l ) .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        18,
        "schizo - affective disorder"
      ],
      [
        "T1",
        "Chemical",
        35,
        36,
        "zuclopenthixol"
      ],
      [
        "T2",
        "Chemical",
        43,
        44,
        "lithium"
      ],
      [
        "T3",
        "Chemical",
        52,
        53,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2821,
    "text": "This patient had no associated personality disorder ( particularly no antisocial disorder ) and no substance abuse disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "personality disorder"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "antisocial disorder"
      ],
      [
        "T2",
        "Disease",
        15,
        18,
        "substance abuse disorder"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2822,
    "text": "Within the 48 h following the gradual introduction of quetiapine ( up to 600 mg / day ) , the patient presented severe agitation without an environmental explanation , contrasting with the absence of a history of aggressiveness or personality disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        39,
        41,
        "personality disorder"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "quetiapine"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "agitation"
      ],
      [
        "T3",
        "Disease",
        37,
        38,
        "aggressiveness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2823,
    "text": "The diagnoses of manic shift and akathisia were dismissed .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "manic"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "akathisia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2824,
    "text": "The withdrawal and the gradual reintroduction of quetiapine 2 weeks later , which led to another severe agitation , enabled us to attribute the agitation specifically to quetiapine .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "quetiapine"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "agitation"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "agitation"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2825,
    "text": "Antioxidant effects of bovine lactoferrin on dexamethasone - induced hypertension in rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "dexamethasone"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2826,
    "text": "Dexamethasone - ( Dex - ) induced hypertension is associated with enhanced oxidative stress .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dexamethasone"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "Dex"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2827,
    "text": "Lactoferrin ( LF ) is an iron - binding glycoprotein with antihypertensive properties .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "iron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2828,
    "text": "In this study , we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "hypertension"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "Dex"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2829,
    "text": "Male Wistar rats were treated by Dex ( 30 u g / kg / day subcutaneously ) or saline for 14 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "Dex"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2830,
    "text": "Oral bovine LF ( 30 , 100 , 300 mg / kg ) was given from day 8 to 14 in a reversal study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2831,
    "text": "In a prevention study , rats received 4 days of LF treatment followed by Dex and continued during the test period .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "Dex"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2832,
    "text": "Systolic blood pressure ( SBP ) was measured using tail - cuff method .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2833,
    "text": "Thymus weight was used as a marker of glucocorticoid activity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2834,
    "text": "Plasma hydrogen peroxide ( H2O2 ) concentration and ferric reducing antioxidant power ( FRAP ) value were determined .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "hydrogen peroxide"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "H2O2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2835,
    "text": "Dexamethasone significantly increased SBP and plasma H2O2 level and decreased thymus and body weights .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Dexamethasone"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "H2O2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2836,
    "text": "LF lowered ( P < 0 . 01 ) and dose dependently prevented ( P < 0 . 001 ) Dex - induced hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "Dex"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2837,
    "text": "LF prevented body weight loss and significantly reduced the elevated plasma H2O2 and increased FRAP values .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "weight loss"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "H2O2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2838,
    "text": "Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex - induced hypertension , suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "Dex"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2839,
    "text": "The association between tranexamic acid and convulsive seizures after cardiac surgery : a multivariate analysis in 11 529 patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "tranexamic acid"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "convulsive"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2840,
    "text": "Because of a lack of contemporary data regarding seizures after cardiac surgery , we undertook a retrospective analysis of prospectively collected data from 11 529 patients in whom cardiopulmonary bypass was used from January 2004 to December 2010 .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2841,
    "text": "A convulsive seizure was defined as a transient episode of disturbed brain function characterised by abnormal involuntary motor movements .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        19,
        "abnormal involuntary motor movements"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "convulsive"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2842,
    "text": "Multivariate regression analysis was performed to identify independent predictors of postoperative seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2843,
    "text": "A total of 100 ( 0 . 9 % ) patients developed postoperative convulsive seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "convulsive"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2844,
    "text": "Generalised and focal seizures were identified in 68 and 32 patients , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Generalised and focal seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2845,
    "text": "The median ( IQR [ range ] ) time after surgery when the seizure occurred was 7 ( 6 - 12 [ 1 - 216 ] ) h and 8 ( 6 - 11 [ 4 - 18 ] ) h , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2846,
    "text": "Epileptiform findings on electroencephalography were seen in 19 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2847,
    "text": "Independent predictors of postoperative seizures included age , female sex , redo cardiac surgery , calcification of ascending aorta , congestive heart failure , deep hypothermic circulatory arrest , duration of aortic cross - clamp and tranexamic acid .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        23,
        "congestive heart failure"
      ],
      [
        "T1",
        "Chemical",
        36,
        38,
        "tranexamic acid"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "seizures"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "hypothermic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2848,
    "text": "When tested in a multivariate regression analysis , tranexamic acid was a strong independent predictor of seizures ( OR 14 . 3 , 95 % CI 5 . 5 - 36 . 7 ; p < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "tranexamic acid"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2849,
    "text": "Patients with convulsive seizures had 2 . 5 times higher in - hospital mortality rates and twice the length of hospital stay compared with patients without convulsive seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "convulsive"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "seizures"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "convulsive"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2850,
    "text": "Mean ( IQR [ range ] ) length of stay in the intensive care unit was 115 ( 49 - 228 [ 32 - 481 ] ) h in patients with convulsive seizures compared with 26 ( 22 - 69 [ 14 - 1080 ] ) h in patients without seizures ( p < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        32,
        "convulsive"
      ],
      [
        "T1",
        "Disease",
        32,
        33,
        "seizures"
      ],
      [
        "T2",
        "Disease",
        50,
        51,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2851,
    "text": "Convulsive seizures are a serious postoperative complication after cardiac surgery .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "postoperative complication"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Convulsive"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2852,
    "text": "As tranexamic acid is the only modifiable factor , its administration , particularly in doses exceeding 80 mg . kg ( - 1 ) , should be weighed against the risk of postoperative seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "tranexamic acid"
      ],
      [
        "T1",
        "Disease",
        33,
        34,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2853,
    "text": "Dysfunctional overnight memory consolidation in ecstasy users .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Dysfunctional overnight memory"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2854,
    "text": "Sleep plays an important role in the consolidation and integration of memory in a process called overnight memory consolidation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2855,
    "text": "Previous studies indicate that ecstasy users have marked and persistent neurocognitive and sleep - related impairments .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "sleep - related impairments"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2856,
    "text": "We extend past research by examining overnight memory consolidation among regular ecstasy users ( n = 12 ) and drug naive healthy controls ( n = 26 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2857,
    "text": "Memory recall of word pairs was evaluated before and after a period of sleep , with and without interference prior to testing .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2858,
    "text": "In addition , we assessed neurocognitive performances across tasks of learning , memory and executive functioning .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2859,
    "text": "Ecstasy users demonstrated impaired overnight memory consolidation , a finding that was more pronounced following associative interference .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "impaired overnight memory"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2860,
    "text": "Additionally , ecstasy users demonstrated impairments on tasks recruiting frontostriatal and hippocampal neural circuitry , in the domains of proactive interference memory , long - term memory , encoding , working memory and complex planning .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2861,
    "text": "We suggest that ecstasy - associated dysfunction in fronto - temporal circuitry may underlie overnight consolidation memory impairments in regular ecstasy users .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "memory impairments"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "ecstasy"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "ecstasy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2862,
    "text": "Normoammonemic encephalopathy : solely valproate induced or multiple mechanisms ?",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "encephalopathy"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2863,
    "text": "A 77 - year - old woman presented with subacute onset progressive confusion , aggression , auditory hallucinations and delusions .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "auditory hallucinations"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "confusion"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "aggression"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "delusions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2864,
    "text": "In the preceding months , the patient had a number of admissions with transient unilateral hemiparesis with facial droop , and had been started on valproate for presumed hemiplegic migraine .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "hemiplegic migraine"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hemiparesis"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2865,
    "text": "Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow - up .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2866,
    "text": "Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2867,
    "text": "EEG undertaken during inpatient stay showed changes consistent with encephalopathy , and low titre N - methyl - D - aspartate ( NMDA ) receptor antibodies were present in this patient .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        21,
        "N - methyl - D - aspartate"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "encephalopathy"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "NMDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2868,
    "text": "The possible aetiologies of valproate - induced encephalopathy and NMDA receptor - associated encephalitis present a diagnostic dilemma .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "valproate"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "encephalopathy"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "NMDA"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "encephalitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2869,
    "text": "We present a putative combinatorial hypothesis to explain this patient ' s symptoms .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2870,
    "text": "Cerebellar and oculomotor dysfunction induced by rapid infusion of pethidine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Cerebellar and oculomotor dysfunction"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "pethidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2871,
    "text": "Pethidine is an opioid that gains its popularity for the effective pain control through acting on the opioid - receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Pethidine"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2872,
    "text": "However , rapid pain relief sometimes brings about unfavourable side effects that largely limit its clinical utility .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2873,
    "text": "Common side effects include nausea , vomiting and hypotension .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "nausea"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "vomiting"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2874,
    "text": "In patients with impaired renal and liver function , and those who need long - term pain control , pethidine may cause excitatory central nervous system ( CNS ) effects through its neurotoxic metabolite , norpethidine , resulting in irritability and seizure attack .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        8,
        "impaired renal and liver function"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "pain"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "pethidine"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "neurotoxic"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "norpethidine"
      ],
      [
        "T5",
        "Disease",
        39,
        40,
        "irritability"
      ],
      [
        "T6",
        "Disease",
        41,
        42,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2875,
    "text": "On the contrary , though not clinically apparent , pethidine potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "pethidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2876,
    "text": "In this case report , we highlight opioid ' s inhibitory side effects on the cerebellar structure that causes dysmetria , dysarthria , reduced smooth pursuit gain and decreased saccadic velocity .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "dysmetria"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "dysarthria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2877,
    "text": "Baboon syndrome induced by ketoconazole .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Baboon syndrome"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "ketoconazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2878,
    "text": "A 27 - year - old male patient presented with a maculopapular eruption on the flexural areas and buttocks after using oral ketoconazole .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "maculopapular eruption"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "ketoconazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2879,
    "text": "The patient was diagnosed with drug - induced baboon syndrome based on his history , which included prior sensitivity to topical ketoconazole , a physical examination , and histopathological findings .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "baboon syndrome"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "ketoconazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2880,
    "text": "Baboon syndrome is a drug - or contact allergen - related maculopapular eruption that typically involves the flexural and gluteal areas .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Baboon syndrome"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "maculopapular eruption"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2881,
    "text": "To the best of our knowledge , this is the first reported case of ketoconazole - induced baboon syndrome in the English literature .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "baboon syndrome"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "ketoconazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2882,
    "text": "A Case of Sudden Cardiac Death due to Pilsicainide - Induced Torsades de Pointes .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "Sudden Cardiac Death"
      ],
      [
        "T1",
        "Disease",
        11,
        14,
        "Torsades de Pointes"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "Pilsicainide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2883,
    "text": "An 84 - year - old male received oral pilsicainide , a pure sodium channel blocker with slow recovery kinetics , to convert his paroxysmal atrial fibrillation to a sinus rhythm ; the patient developed sudden cardiac death two days later .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Disease",
        35,
        38,
        "sudden cardiac death"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "pilsicainide"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2884,
    "text": "The Holter electrocardiogram , which was worn by chance , revealed torsade de pointes with gradually prolonged QT intervals .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "torsade de pointes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2885,
    "text": "This drug is rapidly absorbed from the gastrointestinal tract , and most of it is excreted from the kidney .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2886,
    "text": "Although the patient ' s renal function was not highly impaired and the dose of pilsicainide was low , the plasma concentration of pilsicainide may have been high , which can produce torsades de pointes in the octogenarian .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        35,
        "torsades de pointes"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "pilsicainide"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "pilsicainide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2887,
    "text": "Although the oral administration of class IC drugs , including pilsicainide , is effective to terminate atrial fibrillation , careful consideration must be taken before giving these drugs to octogenarians .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "atrial fibrillation"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "pilsicainide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2888,
    "text": "All - trans retinoic acid - induced inflammatory myositis in a patient with acute promyelocytic leukemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        5,
        "All - trans retinoic acid"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "acute promyelocytic leukemia"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "myositis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2889,
    "text": "All - trans retinoic acid ( ATRA ) , a component of standard therapy for acute promyelocytic leukemia ( APL ) , is associated with potentially serious but treatable adverse effects involving numerous organ systems , including rare skeletal muscle involvement .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        5,
        "All - trans retinoic acid"
      ],
      [
        "T1",
        "Disease",
        15,
        18,
        "acute promyelocytic leukemia"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "ATRA"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "APL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2890,
    "text": "Only a handful of cases of ATRA - induced myositis in children have been reported , and none in the radiology literature .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "ATRA"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "myositis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2891,
    "text": "We present such a case in a 15 - year - old boy with APL , where recognition of imaging findings played a crucial role in making the diagnosis and facilitated prompt , effective treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "APL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2892,
    "text": "Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "lomustine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "cyclophosphamide"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "lymphoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2893,
    "text": "This retrospective study describes toxicity associated with a protocol of lomustine ( CCNU ) and cyclophosphamide ( CTX ) in dogs with lymphoma .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "lomustine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "CCNU"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "cyclophosphamide"
      ],
      [
        "T4",
        "Chemical",
        17,
        18,
        "CTX"
      ],
      [
        "T5",
        "Disease",
        22,
        23,
        "lymphoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2894,
    "text": "CCNU was administered per os ( PO ) at a targeted dosage of 60 mg / m ( 2 ) body surface area on day 0 , CTX was administered PO at a targeted dosage of 250 mg / m ( 2 ) divided over days 0 through 4 , and all dogs received prophylactic antibiotics .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "CCNU"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "CTX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2895,
    "text": "Ninety treatments were given to the 57 dogs included in the study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2896,
    "text": "Neutropenia was the principal toxic effect , and the overall frequency of grade 4 neutropenia after the first treatment of CCNU / CTX was 30 % ( 95 % confidence interval , 19 - 43 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Neutropenia"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "neutropenia"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "CCNU"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "CTX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2897,
    "text": "The mean body weight of dogs with grade 4 neutropenia ( 19 . 7 kg + 13 . 4 kg ) was significantly less than the mean body weight of dogs that did not develop grade 4 neutropenia ( 31 . 7 kg + 12 . 4 kg ; P = . 005 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "neutropenia"
      ],
      [
        "T1",
        "Disease",
        37,
        38,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2898,
    "text": "One dog ( 3 % ) developed hematologic changes suggestive of hepatotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "hepatotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2899,
    "text": "No dogs had evidence of either renal toxicity or hemorrhagic cystitis .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "renal toxicity"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "hemorrhagic cystitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2900,
    "text": "Adverse gastrointestinal effects were uncommon .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2901,
    "text": "On the basis of the findings reported herein , a dose of 60 mg / m ( 2 ) of CCNU combined with 250 mg / m ( 2 ) of CTX ( divided over 5 days ) q 4 wk is tolerable in tumor - bearing dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "CCNU"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "CTX"
      ],
      [
        "T2",
        "Disease",
        44,
        45,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2902,
    "text": "Nelarabine neurotoxicity with concurrent intrathecal chemotherapy : Case report and review of literature .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Nelarabine"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2903,
    "text": "Severe nelarabine neurotoxicity in a patient who received concurrent intrathecal ( IT ) chemotherapy is reported .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "nelarabine"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2904,
    "text": "A 37 - year - old Caucasian woman with a history of T - cell lymphoblastic lymphoma was admitted for relapsed disease .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        17,
        "T - cell lymphoblastic lymphoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2905,
    "text": "She was originally treated with induction chemotherapy followed by an autologous transplant .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2906,
    "text": "She developed relapsed disease 10 months later with leukemic involvement .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "leukemic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2907,
    "text": "She was re - induced with nelarabine 1500 mg / m ( 2 ) on days 1 , 3 , and 5 with 1 dose of IT cytarabine 100 mg on day 2 as central nervous system ( CNS ) prophylaxis .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "nelarabine"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "cytarabine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2908,
    "text": "At the time of treatment , she was on continuous renal replacement therapy due to sequelae of tumor lysis syndrome ( TLS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "tumor lysis syndrome"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "TLS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2909,
    "text": "She tolerated therapy well , entered a complete remission , and recovered her renal function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2910,
    "text": "She received a second cycle of nelarabine without additional IT prophylaxis one month later .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "nelarabine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2911,
    "text": "A week after this second cycle , she noted numbness in her lower extremities .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2912,
    "text": "Predominantly sensory , though also motor and autonomic , peripheral neuropathy started in her feet , ascended proximally to the mid - thoracic region , and eventually included her distal upper extremities .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "peripheral neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2913,
    "text": "A magnetic resonance imaging ( MRI ) of her spine demonstrated changes from C2 to C6 consistent with subacute combined degeneration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2914,
    "text": "Nelarabine was felt to be the cause of her symptoms .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Nelarabine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2915,
    "text": "Her neuropathy stabilized and showed slight improvement and ultimately received an unrelated , reduced - intensity allogeneic transplant while in complete remission , but relapsed disease 10 weeks later .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2916,
    "text": "She is currently being treated with best supportive care .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2917,
    "text": "To our knowledge , this is the first published case report of severe neurotoxicity caused by nelarabine in a patient who received concurrent IT chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "neurotoxicity"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "nelarabine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2918,
    "text": "Valproate - induced hyperammonemic encephalopathy in a renal transplanted patient .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Valproate"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hyperammonemic"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2919,
    "text": "Neurological complications after renal transplantation constitute an important cause of morbidity and mortality .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Neurological complications"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2920,
    "text": "Their differential diagnosis is difficult and essential for subsequent patient ' s management .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2921,
    "text": "Valproate - induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Valproate"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hyperammonemic"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "encephalopathy"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2922,
    "text": "Here , we describe the case of a 15 - year - old girl who was on a long - term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        31,
        "impaired consciousness"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "valproate"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "epilepsy"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "hyperammonemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2923,
    "text": "After withdraw of valproate , patients ' symptoms resolved within 24 h .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2924,
    "text": "Clinicians should increase their awareness for potential complication of valproate , especially in transplanted patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "valproate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2925,
    "text": "Necrotising fasciitis after bortezomib and dexamethasone - containing regimen in an elderly patient of Waldenstrom macroglobulinaemia .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Necrotising fasciitis"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "Waldenstrom macroglobulinaemia"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "bortezomib"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2926,
    "text": "Bortezomib and high - dose dexamethasone - containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B - cell malignancies .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "bacterial infections"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Bortezomib"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "dexamethasone"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "malignancies"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2927,
    "text": "However , information is limited concerning the safety of the regimen in elderly patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2928,
    "text": "We report a case of a 76 - year - old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib , high - dose dexamethasone and rituximab .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "Waldenstrom macroglobulinaemia"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "necrotising fasciitis"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "neutropenia"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "bortezomib"
      ],
      [
        "T4",
        "Chemical",
        31,
        32,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2929,
    "text": "Despite immediate intravenous antimicrobial therapy , he succumbed 23 h after the onset .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2930,
    "text": "Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high - dose dexamethasone in elderly patients , and we believe this case warrants further investigation .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "bacterial infections"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "bortezomib"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2931,
    "text": "An integrated characterization of serological , pathological , and functional events in doxorubicin - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "doxorubicin"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2932,
    "text": "Many efficacious cancer treatments cause significant cardiac morbidity , yet biomarkers or functional indices of early damage , which would allow monitoring and intervention , are lacking .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2933,
    "text": "In this study , we have utilized a rat model of progressive doxorubicin ( DOX ) - induced cardiomyopathy , applying multiple approaches , including cardiac magnetic resonance imaging ( MRI ) , to provide the most comprehensive characterization to date of the timecourse of serological , pathological , and functional events underlying this toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "doxorubicin"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "DOX"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "cardiomyopathy"
      ],
      [
        "T3",
        "Disease",
        54,
        55,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2934,
    "text": "Hannover Wistar rats were dosed with 1 . 25 mg / kg DOX weekly for 8 weeks followed by a 4 week off - dosing \" recovery \" period .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2935,
    "text": "Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "subcellular degeneration"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2936,
    "text": "Histopathological analysis revealed progressive cardiomyocyte degeneration , hypertrophy / cytomegaly , and extensive vacuolation after two doses .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "cardiomyocyte degeneration"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2937,
    "text": "Extensive replacement fibrosis ( quantified by Sirius red staining ) developed during the off - dosing period .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2938,
    "text": "Functional indices assessed by cardiac MRI ( including left ventricular ejection fraction ( LVEF ) , cardiac output , and E / A ratio ) declined progressively , reaching statistical significance after two doses and culminating in \" clinical \" LV dysfunction by 12 weeks .",
    "labels": [
      [
        "T0",
        "Disease",
        40,
        42,
        "LV dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2939,
    "text": "Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I ( cTnI ) emerged after eight doses , importantly preceding the LVEF decline to < 50 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2940,
    "text": "Troponin I levels positively correlated with delayed and peak gadolinium contrast enhancement , histopathological grading , and diastolic dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "diastolic dysfunction"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "gadolinium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2941,
    "text": "In summary , subcellular cardiomyocyte degeneration was the earliest marker , followed by progressive functional decline and histopathological manifestations .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "cardiomyocyte degeneration"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2942,
    "text": "Myocardial contrast enhancement and elevations in cTnI occurred later .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2943,
    "text": "However , all indices predated \" clinical \" LV dysfunction and thus warrant further evaluation as predictive biomarkers .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "LV dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2944,
    "text": "Intradermal glutamate and capsaicin injections : intra - and interindividual variability of provoked hyperalgesia and allodynia .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "glutamate"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "capsaicin"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "hyperalgesia"
      ],
      [
        "T3",
        "Disease",
        15,
        16,
        "allodynia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2945,
    "text": "Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "pain disorders"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "glutamate"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "capsaicin"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "pain"
      ],
      [
        "T4",
        "Disease",
        16,
        17,
        "hyperalgesia"
      ],
      [
        "T5",
        "Disease",
        18,
        19,
        "allodynia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2946,
    "text": "The aim of the present study was to investigate the reproducibility of these models .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2947,
    "text": "Twenty healthy male volunteers ( mean age 24 years ; range 18 - 38 years ) received intradermal injections of glutamate and capsaicin in the volar forearm .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "glutamate"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "capsaicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2948,
    "text": "Magnitudes of secondary pinprick hyperalgesia and brush - evoked allodynia were investigated using von Frey filaments ( gauges 10 , 15 , 60 and 100 g ) and brush strokes .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hyperalgesia"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "allodynia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2949,
    "text": "Areas of secondary hyperalgesia and allodynia were quantified immediately after injection and after 15 , 30 and 60 min .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "secondary hyperalgesia"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "allodynia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2950,
    "text": "Two identical experiments separated by at least 7 days were performed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2951,
    "text": "Reproducibility across and within volunteers ( inter - and intra - individual variation , respectively ) was assessed using intraclass correlation coefficient ( ICC ) and coefficient of variation ( CV ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2952,
    "text": "Secondary pinprick hyperalgesia was observed as a marked increase in the visual analogue scale ( VAS ) response to von Frey gauges 60 and 100 g ( P < 0 . 001 ) after glutamate injection .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "hyperalgesia"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2953,
    "text": "For capsaicin , secondary pinprick hyperalgesia was detected with all von Frey gauges ( P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "capsaicin"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hyperalgesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2954,
    "text": "Glutamate evoked reproducible VAS response to all von Frey gauges ( ICC > 0 . 60 ) and brush strokes ( ICC > 0 . 83 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2955,
    "text": "Capsaicin injection was reproducible for secondary hyperalgesia ( ICC > 0 . 70 ) and allodynia ( ICC > 0 . 71 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "secondary hyperalgesia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Capsaicin"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "allodynia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2956,
    "text": "Intra - individual variability was generally lower for the VAS response to von Frey and brush compared with areas of secondary hyperalgesia and allodynia .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "secondary hyperalgesia"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "allodynia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2957,
    "text": "In conclusion , glutamate and capsaicin yield reproducible hyperalgesic and allodynic responses , and the present model is well suited for basic research , as well as for assessing the modulation of central phenomena .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "glutamate"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "capsaicin"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "hyperalgesic"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "allodynic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2958,
    "text": "Ocular - specific ER stress reduction rescues glaucoma in murine glucocorticoid - induced glaucoma .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "glaucoma"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2959,
    "text": "Administration of glucocorticoids induces ocular hypertension in some patients .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "ocular hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2960,
    "text": "If untreated , these patients can develop a secondary glaucoma that resembles primary open - angle glaucoma ( POAG ) .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        17,
        "primary open - angle glaucoma"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "glaucoma"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "POAG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2961,
    "text": "The underlying pathology of glucocorticoid - induced glaucoma is not fully understood , due in part to lack of an appropriate animal model .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2962,
    "text": "Here , we developed a murine model of glucocorticoid - induced glaucoma that exhibits glaucoma features that are observed in patients .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "glaucoma"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2963,
    "text": "Treatment of WT mice with topical ocular 0 . 1 % dexamethasone led to elevation of intraocular pressure ( IOP ) , functional and structural loss of retinal ganglion cells , and axonal degeneration , resembling glucocorticoid - induced glaucoma in human patients .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "retinal ganglion"
      ],
      [
        "T1",
        "Disease",
        32,
        34,
        "axonal degeneration"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "dexamethasone"
      ],
      [
        "T3",
        "Disease",
        39,
        40,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2964,
    "text": "Furthermore , dexamethasone - induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork ( TM ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "ocular hypertension"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2965,
    "text": "Similar to patients , withdrawal of dexamethasone treatment reduced elevated IOP and ER stress in this animal model .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2966,
    "text": "Dexamethasone induced the transcriptional factor CHOP , a marker for chronic ER stress , in the anterior segment tissues , and Chop deletion reduced ER stress in these tissues and prevented dexamethasone - induced ocular hypertension .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        36,
        "ocular hypertension"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Dexamethasone"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2967,
    "text": "Furthermore , reduction of ER stress in the TM with sodium 4 - phenylbutyrate prevented dexamethasone - induced ocular hypertension in WT mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        14,
        "sodium 4 - phenylbutyrate"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "ocular hypertension"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2968,
    "text": "Our data indicate that ER stress contributes to glucocorticoid - induced ocular hypertension and suggest that reducing ER stress has potential as a therapeutic strategy for treating glucocorticoid - induced glaucoma .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "ocular hypertension"
      ],
      [
        "T1",
        "Disease",
        30,
        31,
        "glaucoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2969,
    "text": "Effects of ginsenosides on opioid - induced hyperalgesia in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "ginsenosides"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hyperalgesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2970,
    "text": "Opioid - induced hyperalgesia ( OIH ) is characterized by nociceptive sensitization caused by the cessation of chronic opioid use .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hyperalgesia"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "OIH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2971,
    "text": "OIH can limit the clinical use of opioid analgesics and complicate withdrawal from opioid addiction .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "opioid addiction"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "OIH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2972,
    "text": "In this study , we investigated the effects of Re , Rg1 , and Rb1 ginsenosides , the bioactive components of ginseng , on OIH .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        16,
        "Re , Rg1 , and Rb1 ginsenosides"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "OIH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2973,
    "text": "OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "OIH"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2974,
    "text": "During withdrawal ( days 8 and 9 ) , these mice were administered Re , Rg1 , or Rb1 intragastrically two times per day .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "Re"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "Rg1"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "Rb1"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2975,
    "text": "On the test day ( day 10 ) , mice were subjected to the thermal sensitivity test and the acetic acid - induced writhing test .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        21,
        "acetic acid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2976,
    "text": "Re ( 300 mg / kg ) inhibited OIH in both the thermal sensitivity test and the acetic acid - induced writhing test .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        19,
        "acetic acid"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Re"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "OIH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2977,
    "text": "However , the Rg1 and Rb1 ginsenosides failed to prevent OIH in either test .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        7,
        "Rg1 and Rb1 ginsenosides"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "OIH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2978,
    "text": "Furthermore , Rg1 showed a tendency to aggravate OIH in the acetic acid - induced writhing test .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "acetic acid"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Rg1"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "OIH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2979,
    "text": "Our data suggested that the ginsenoside Re , but not Rg1 or Rb1 , may contribute toward reversal of OIH .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "ginsenoside Re"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "Rg1"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "Rb1"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "OIH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2980,
    "text": "A comparison of severe hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "dexmedetomidine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2981,
    "text": "OBJECTIVE : Dexmedetomidine and propofol are commonly used sedatives in neurocritical care as they allow for frequent neurologic examinations .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Dexmedetomidine"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2982,
    "text": "However , both agents are associated with significant hemodynamic side effects .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2983,
    "text": "The primary objective of this study is to compare the prevalence of severe hemodynamic effects in neurocritical care patients receiving dexmedetomidine and propofol .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "dexmedetomidine"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2984,
    "text": "DESIGN : Multicenter , retrospective , propensity - matched cohort study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2985,
    "text": "SETTING : Neurocritical care units at two academic medical centers with dedicated neurocritical care teams and board - certified neurointensivists .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2986,
    "text": "PATIENTS : Neurocritical care patients admitted between July 2009 and September 2012 were evaluated and then matched 1 : 1 based on propensity scoring of baseline characteristics .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2987,
    "text": "INTERVENTIONS : Continuous sedation with dexmedetomidine or propofol .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "dexmedetomidine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2988,
    "text": "MEASUREMENTS AND MAIN RESULTS : A total of 342 patients ( 105 dexmedetomidine and 237 propofol ) were included in the analysis , with 190 matched ( 95 in each group ) by propensity score .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "dexmedetomidine"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2989,
    "text": "The primary outcome of this study was a composite of severe hypotension ( mean arterial pressure < 60 mm Hg ) and bradycardia ( heart rate < 50 beats / min ) during sedative infusion .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2990,
    "text": "No difference in the primary composite outcome in both the unmatched ( 30 % vs 30 % , p = 0 . 94 ) or matched cohorts ( 28 % vs 34 % , p = 0 . 35 ) could be found .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 2991,
    "text": "When analyzed separately , no differences could be found in the prevalence of severe hypotension or bradycardia in either the unmatched or matched cohorts .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2992,
    "text": "CONCLUSIONS : Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "bradycardia"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "dexmedetomidine"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "propofol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2993,
    "text": "Providers should similarly consider the likelihood of hypotension or bradycardia before starting either sedative .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2994,
    "text": "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin - induced cardiotoxicity in rats with breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "mitochondrial dysfunction"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "breast cancer"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Hydroxytyrosol"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "doxorubicin"
      ],
      [
        "T4",
        "Disease",
        11,
        12,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2995,
    "text": "Oxidative stress is involved in several processes including cancer , aging and cardiovascular disease , and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "cardiovascular disease"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "cancer"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2996,
    "text": "Doxorubicin causes significant cardiotoxicity characterized by marked increases in oxidative stress and mitochondrial dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "mitochondrial dysfunction"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Doxorubicin"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2997,
    "text": "Herein , we investigate whether doxorubicin - associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "cardiac toxicity"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "breast cancer"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "doxorubicin"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "hydroxytyrosol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2998,
    "text": "Thirty - six rats bearing breast tumors induced chemically were divided into 4 groups : control , hydroxytyrosol ( 0 . 5mg / kg , 5days / week ) , doxorubicin ( 1mg / kg / week ) , and doxorubicin plus hydroxytyrosol .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "breast tumors"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "hydroxytyrosol"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "doxorubicin"
      ],
      [
        "T3",
        "Chemical",
        40,
        41,
        "doxorubicin"
      ],
      [
        "T4",
        "Chemical",
        42,
        43,
        "hydroxytyrosol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 2999,
    "text": "Cardiac disturbances at the cellular and mitochondrial level , mitochondrial electron transport chain complexes I - IV and apoptosis - inducing factor , and oxidative stress markers have been analyzed .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cardiac disturbances"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3000,
    "text": "Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiac disturbances"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Hydroxytyrosol"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3001,
    "text": "These results suggest that hydroxytyrosol improve the mitochondrial electron transport chain .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "hydroxytyrosol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3002,
    "text": "This study demonstrates that hydroxytyrosol protect rat heart damage provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "heart damage"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "hydroxytyrosol"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3003,
    "text": "Amiodarone - induced myxoedema coma .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "myxoedema coma"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3004,
    "text": "A 62 - year - old man was found to have bradycardia , hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "respiratory failure"
      ],
      [
        "T1",
        "Disease",
        25,
        27,
        "atrial fibrillation"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "bradycardia"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "hypothermia"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3005,
    "text": "Thyroid - stimulating hormone was found to be 168 uIU / mL ( nl . 0 . 3 - 5 uIU / mL ) and free thyroxine ( FT4 ) was < 0 . 2 ng / dL ( nl . 0 . 8 - 1 . 8 ng / dL ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "thyroxine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3006,
    "text": "He received intravenous fluids , vasopressor therapy and stress dose steroids ; he was intubated and admitted to the intensive care unit .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3007,
    "text": "He received 500 ug of intravenous levothyroxine in the first 18 h of therapy , and 150 ug intravenous daily thereafter .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "levothyroxine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3008,
    "text": "Haemodynamic improvement , along with complete recovery of mental status , occurred after 48 h .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3009,
    "text": "Twelve hours after the initiation of therapy , FT4 was 0 . 96 ng / dL .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3010,
    "text": "The patient was maintained on levothyroxine 175 ( g POorally daily .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "levothyroxine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3011,
    "text": "A thyroid ultrasound showed diffuse heterogeneity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3012,
    "text": "The 24 hour excretion of iodine was 3657 ( mcg ( 25 - 756 ( mcg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "iodine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3013,
    "text": "The only two cases of amiodarone - induced myxoedema coma in the literature report patient death despite supportive therapy and thyroid hormone replacement .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "myxoedema coma"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3014,
    "text": "This case represents the most thoroughly investigated case of amiodarone - induced myxoedema coma with a history significant for subclinical thyroid disease .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "myxoedema coma"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "thyroid disease"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "amiodarone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3015,
    "text": "Use of argatroban and catheter - directed thrombolysis with alteplase in an oncology patient with heparin - induced thrombocytopenia with thrombosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "argatroban"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "thrombolysis"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "heparin"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "thrombocytopenia"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3016,
    "text": "PURPOSE : The case of an oncology patient who developed heparin - induced thrombocytopenia with thrombosis ( HITT ) and was treated with argatroban plus catheter - directed thrombolysis ( CDT ) with alteplase is presented .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "heparin"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "thrombosis"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "HITT"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "argatroban"
      ],
      [
        "T5",
        "Disease",
        28,
        29,
        "thrombolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3017,
    "text": "SUMMARY : A 63 - year - old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper - extremity deep venous thrombosis ( DVT ) and pulmonary embolism secondary to heparin - induced thrombocytopenia .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        34,
        "upper - extremity deep venous thrombosis"
      ],
      [
        "T1",
        "Disease",
        38,
        40,
        "pulmonary embolism"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "amyloidosis"
      ],
      [
        "T3",
        "Disease",
        35,
        36,
        "DVT"
      ],
      [
        "T4",
        "Chemical",
        42,
        43,
        "heparin"
      ],
      [
        "T5",
        "Disease",
        45,
        46,
        "thrombocytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3018,
    "text": "A continuous i . v . infusion of argatroban was initiated , and the patient was managed on the general medical floor .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "argatroban"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3019,
    "text": "After one week of therapy , he was transferred to the intensive care unit with cardiopulmonary compromise related to superior vena cava ( SVC ) syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        26,
        "superior vena cava ( SVC ) syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3020,
    "text": "A percutaneous mechanical thrombectomy and CDT with alteplase were attempted , but the procedure was aborted due to epistaxis .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "epistaxis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3021,
    "text": "The epistaxis resolved the next day , and the patient was restarted on argatroban .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "epistaxis"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "argatroban"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3022,
    "text": "A second percutaneous mechanical thrombectomy was performed six days later and resulted in partial revascularization of the SVC and central veins .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3023,
    "text": "Postthrombectomy continuous CDT with alteplase was commenced while argatroban was withheld , and complete patency of the SVC and central veins was achieved after three days of therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "argatroban"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3024,
    "text": "Alteplase was discontinued , and the patient was reinitiated on argatroban ; ultimately , he was transitioned to warfarin for long - term anticoagulation .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "argatroban"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3025,
    "text": "Although the patient recovered , he experienced permanent vision and hearing loss , as well as end - stage renal disease .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "vision and hearing loss"
      ],
      [
        "T1",
        "Disease",
        16,
        21,
        "end - stage renal disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3026,
    "text": "CONCLUSION : A 63 - year - old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "SVC syndrome"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "amyloidosis"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "HITT"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "argatroban"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3027,
    "text": "Effects of dehydroepiandrosterone in amphetamine - induced schizophrenia models in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "dehydroepiandrosterone"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "amphetamine"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3028,
    "text": "OBJECTIVE : To examine the effects of dehydroepiandrosterone ( DHEA ) on animal models of schizophrenia .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "dehydroepiandrosterone"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "DHEA"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3029,
    "text": "METHODS : Seventy Swiss albino female mice ( 25 - 35 g ) were divided into 4 groups : amphetamine - free ( control ) , amphetamine , 50 , and 100 mg / kg DHEA .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "amphetamine"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "amphetamine"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "DHEA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3030,
    "text": "The DHEA was administered intraperitoneally ( ip ) for 5 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "DHEA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3031,
    "text": "Amphetamine ( 3 mg / kg ip ) induced hyper locomotion , apomorphine ( 1 . 5 mg / kg subcutaneously [ sc ] ) induced climbing , and haloperidol ( 1 . 5 mg / kg sc ) induced catalepsy tests were used as animal models of schizophrenia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Amphetamine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hyper"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "apomorphine"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "haloperidol"
      ],
      [
        "T4",
        "Disease",
        40,
        41,
        "catalepsy"
      ],
      [
        "T5",
        "Disease",
        48,
        49,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3032,
    "text": "The study was conducted at the Animal Experiment Laboratories , Department of Pharmacology , Medical School , Eskisehir Osmangazi University , Eskisehir , Turkey between March and May 2012 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3033,
    "text": "Statistical analysis was carried out using Kruskal - Wallis test for hyper locomotion , and one - way ANOVA for climbing and catalepsy tests .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "hyper"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3034,
    "text": "RESULTS : In the amphetamine - induced locomotion test , there were significant increases in all movements compared with the amphetamine - free group .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "amphetamine"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3035,
    "text": "Both DHEA 50 mg / kg ( p < 0 . 05 ) , and 100 mg / kg ( p < 0 . 01 ) significantly decreased all movements compared with the amphetamine - induced locomotion group .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "DHEA"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3036,
    "text": "There was a significant difference between groups in the haloperidol - induced catalepsy test ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "haloperidol"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3037,
    "text": "There was no significant difference between groups in terms of total climbing time in the apomorphine - induced climbing test ( p > 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3038,
    "text": "CONCLUSION : We observed that DHEA reduced locomotor activity and increased catalepsy at both doses , while it had no effect on climbing behavior .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "DHEA"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3039,
    "text": "We suggest that DHEA displays typical neuroleptic - like effects , and may be used in the treatment of schizophrenia .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "DHEA"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "schizophrenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3040,
    "text": "Availability of human induced pluripotent stem cell - derived cardiomyocytes in assessment of drug potential for QT prolongation .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "QT prolongation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3041,
    "text": "Field potential duration ( FPD ) in human - induced pluripotent stem cell - derived cardiomyocytes ( hiPS - CMs ) , which can express QT interval in an electrocardiogram , is reported to be a useful tool to predict K ( + ) channel and Ca ( 2 + ) channel blocker effects on QT interval .",
    "labels": [
      [
        "T0",
        "Chemical",
        40,
        41,
        "K"
      ],
      [
        "T1",
        "Chemical",
        46,
        47,
        "Ca"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3042,
    "text": "However , there is no report showing that this technique can be used to predict multichannel blocker potential for QT prolongation .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "QT prolongation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3043,
    "text": "The aim of this study is to show that FPD from MEA ( Multielectrode array ) of hiPS - CMs can detect QT prolongation induced by multichannel blockers .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "QT prolongation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3044,
    "text": "hiPS - CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3045,
    "text": "IKr and IKs blockers concentration - dependently prolonged corrected FPD ( FPDc ) , whereas Ca ( 2 + ) channel blockers concentration - dependently shortened FPDc .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "Ca"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3046,
    "text": "Also , the multichannel blockers Amiodarone , Paroxetine , Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "Amiodarone"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "Paroxetine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "Terfenadine"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "Citalopram"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3047,
    "text": "Finally , the IKr blockers , Terfenadine and Citalopram , which are reported to cause Torsade de Pointes ( TdP ) in clinical practice , produced early afterdepolarization ( EAD ) .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "Torsade de Pointes"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "Terfenadine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "Citalopram"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "TdP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3048,
    "text": "hiPS - CMs using MEA system and FPDc can predict the effects of drug candidates on QT interval .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3049,
    "text": "This study also shows that this assay can help detect EAD for drugs with TdP potential .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "TdP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3050,
    "text": "Dermal developmental toxicity of N - phenylimide herbicides in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3051,
    "text": "BACKGROUND : S - 53482 and S - 23121 are N - phenylimide herbicides and produced embryolethality , teratogenicity ( mainly ventricular septal defects and wavy ribs ) , and growth retardation in rats in conventional oral developmental toxicity studies .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "S - 53482"
      ],
      [
        "T1",
        "Chemical",
        6,
        9,
        "S - 23121"
      ],
      [
        "T2",
        "Disease",
        21,
        24,
        "ventricular septal defects"
      ],
      [
        "T3",
        "Disease",
        30,
        32,
        "growth retardation"
      ],
      [
        "T4",
        "Disease",
        16,
        17,
        "embryolethality"
      ],
      [
        "T5",
        "Disease",
        18,
        19,
        "teratogenicity"
      ],
      [
        "T6",
        "Disease",
        38,
        39,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3052,
    "text": "Our objective in this study was to investigate whether the compounds induce developmental toxicity via the dermal route , which is more relevant to occupational exposure , hence better addressing human health risks .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3053,
    "text": "METHODS : S - 53482 was administered dermally to rats at 30 , 100 , and 300 mg / kg during organogenesis , and S - 23121 was administered at 200 , 400 , and 800 mg / kg ( the maximum applicable dose level ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "S - 53482"
      ],
      [
        "T1",
        "Chemical",
        24,
        27,
        "S - 23121"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3054,
    "text": "Fetuses were obtained by a Cesarean section and examined for external , visceral , and skeletal alterations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3055,
    "text": "RESULTS : Dermal exposure of rats to S - 53482 at 300 mg / kg produced patterns of developmental toxicity similar to those resulting from oral exposure .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "S - 53482"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3056,
    "text": "Toxicity included embryolethality , teratogenicity , and growth retardation .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "growth retardation"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Toxicity"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "embryolethality"
      ],
      [
        "T3",
        "Disease",
        4,
        5,
        "teratogenicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3057,
    "text": "Dermal administration of S - 23121 at 800 mg / kg resulted in an increased incidence of embryonic death and ventricular septal defect , but retarded fetal growth was not observed as it was following oral exposure to S - 23121 .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "S - 23121"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "embryonic death"
      ],
      [
        "T2",
        "Disease",
        20,
        23,
        "ventricular septal defect"
      ],
      [
        "T3",
        "Chemical",
        38,
        41,
        "S - 23121"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3058,
    "text": "CONCLUSIONS : Based on the results , S - 53482 and S - 23121 were teratogenic when administered dermally to pregnant rats as were the compounds administered orally .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "S - 53482"
      ],
      [
        "T1",
        "Chemical",
        11,
        14,
        "S - 23121"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "teratogenic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3059,
    "text": "Thus , investigation of the mechanism and its human relevancy become more important .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3060,
    "text": "Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Renal Toxicity"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "Cancer"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "Cisplatin"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "Mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3061,
    "text": "BACKGROUND : Cisplatin is a widely used antineoplastic .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3062,
    "text": "One of the major complications of cisplatin use is dose - limiting nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "cisplatin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3063,
    "text": "There are many strategies to prevent this toxicity , including the use of mannitol as a nephroprotectant in combination with hydration .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3064,
    "text": "OBJECTIVE : We aimed to evaluate the rates of cisplatin - induced nephrotoxicity in cancer patients receiving single - agent cisplatin with and without mannitol .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "cisplatin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "nephrotoxicity"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "cancer"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "cisplatin"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3065,
    "text": "METHODS : This single - center retrospective analysis was a quasi experiment created by the national mannitol shortage .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3066,
    "text": "Data were collected on adult cancer patients receiving single - agent cisplatin as an outpatient from January 2011 to September 2012 .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "cancer"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3067,
    "text": "The primary outcome was acute kidney injury ( AKI ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "acute kidney injury"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "AKI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3068,
    "text": "RESULTS : We evaluated 143 patients who received single - agent cisplatin ; 97 . 2 % of patients had head and neck cancer as their primary malignancy .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        24,
        "head and neck cancer"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "cisplatin"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "malignancy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3069,
    "text": "Patients who did not receive mannitol were more likely to develop nephrotoxicity : odds ratio [ OR ] = 2 . 646 ( 95 % CI = 1 . 008 , 6 . 944 ; P = 0 . 048 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "mannitol"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3070,
    "text": "Patients who received the 100 mg / m ( 2 ) dosing and patients who had a history of hypertension also had a higher likelihood of developing nephrotoxicity : OR = 11 . 494 ( 95 % CI = 4 . 149 , 32 . 258 ; P < 0 . 0001 ) and OR = 3 . 219 ( 95 % CI = 1 . 228 , 8 . 439 ; P = 0 . 017 ) , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "hypertension"
      ],
      [
        "T1",
        "Disease",
        27,
        28,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3071,
    "text": "CONCLUSIONS : When limited quantities of mannitol are available , it should preferentially be given to patients at particularly high risk of nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "mannitol"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3072,
    "text": "Our analysis suggests that those patients receiving the dosing schedule of 100 mg / m ( 2 ) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "cisplatin"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "hypertension"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "nephrotoxicity"
      ],
      [
        "T3",
        "Chemical",
        40,
        41,
        "mannitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3073,
    "text": "Metformin protects against seizures , learning and memory impairments and oxidative damage induced by pentylenetetrazole - induced kindling in mice .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "learning and memory impairments"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Metformin"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "seizures"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "pentylenetetrazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3074,
    "text": "Cognitive impairment , the most common and severe comorbidity of epilepsy , greatly diminishes the quality of life .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cognitive impairment"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3075,
    "text": "However , current therapeutic interventions for epilepsy can also cause untoward cognitive effects .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3076,
    "text": "Thus , there is an urgent need for new kinds of agents targeting both seizures and cognition deficits .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "cognition deficits"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3077,
    "text": "Oxidative stress is considered to play an important role in epileptogenesis and cognitive deficits , and antioxidants have a putative antiepileptic potential .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "cognitive deficits"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3078,
    "text": "Metformin , the most commonly prescribed antidiabetic oral drug , has antioxidant properties .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3079,
    "text": "This study was designed to evaluate the ameliorative effects of metformin on seizures , cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole - induced kindling animals .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "cognitive impairment"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "metformin"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "seizures"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "pentylenetetrazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3080,
    "text": "Male C57BL / 6 mice were administered with subconvulsive dose of pentylenetetrazole ( 37 mg / kg , i . p . ) every other day for 14 injections .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "pentylenetetrazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3081,
    "text": "Metformin was injected intraperitoneally in dose of 200mg / kg along with alternate - day PTZ .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Metformin"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "PTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3082,
    "text": "We found that metformin suppressed the progression of kindling , ameliorated the cognitive impairment and decreased brain oxidative stress .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "cognitive impairment"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3083,
    "text": "Thus the present study concluded that metformin may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "cognitive impairment"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "metformin"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "epilepsy"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3084,
    "text": "P53 inhibition exacerbates late - stage anthracycline cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "anthracycline"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3085,
    "text": "AIMS : Doxorubicin ( DOX ) is an effective anti - cancer therapeutic , but is associated with both acute and late - stage cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Doxorubicin"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "DOX"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "cancer"
      ],
      [
        "T3",
        "Disease",
        24,
        25,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3086,
    "text": "Children are particularly sensitive to DOX - induced heart failure .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "heart failure"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3087,
    "text": "Here , the impact of p53 inhibition on acute vs . late - stage DOX cardiotoxicity was examined in a juvenile model .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "DOX"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3088,
    "text": "METHODS AND RESULTS : Two - week - old MHC - CB7 mice ( which express dominant - interfering p53 in cardiomyocytes ) and their non - transgenic ( NON - TXG ) littermates received weekly DOX injections for 5 weeks ( 25 mg / kg cumulative dose ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        36,
        37,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3089,
    "text": "One week after the last DOX treatment ( acute stage ) , MHC - CB7 mice exhibited improved cardiac function and lower levels of cardiomyocyte apoptosis when compared with the NON - TXG mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3090,
    "text": "Surprisingly , by 13 weeks following the last DOX treatment ( late stage ) , MHC - CB7 exhibited a progressive decrease in cardiac function and higher rates of cardiomyocyte apoptosis when compared with NON - TXG mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3091,
    "text": "p53 inhibition blocked transient DOX - induced STAT3 activation in MHC - CB7 mice , which was associated with enhanced induction of the DNA repair proteins Ku70 and Ku80 .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3092,
    "text": "Mice with cardiomyocyte - restricted deletion of STAT3 exhibited worse cardiac function , higher levels of cardiomyocyte apoptosis , and a greater induction of Ku70 and Ku80 in response to DOX treatment during the acute stage when compared with control animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        31,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3093,
    "text": "CONCLUSION : These data support a model wherein a p53 - dependent cardioprotective pathway , mediated via STAT3 activation , mitigates DOX - induced myocardial stress during drug delivery .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "DOX"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3094,
    "text": "Furthermore , these data suggest an explanation as to how p53 inhibition can result in cardioprotection during drug treatment and , paradoxically , enhanced cardiotoxicity long after the cessation of drug treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        25,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3095,
    "text": "Metronidazole - induced encephalopathy : an uncommon scenario .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Metronidazole"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3096,
    "text": "Metronidazole can produce neurological complications although it is not a common scenario .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Metronidazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3097,
    "text": "We present a case where a patient developed features of encephalopathy following prolonged metronidazole intake .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "encephalopathy"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "metronidazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3098,
    "text": "Magnetic resonance imaging ( MRI ) brain showed abnormal signal intensity involving both dentate nuclei of cerebellum and splenium of corpus callosum .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3099,
    "text": "The diagnosis of metronidazole toxicity was made by the MRI findings and supported clinically .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "metronidazole"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3100,
    "text": "Aconitine - induced Ca2 + overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Aconitine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "Ca2"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3101,
    "text": "Aconitine is a major bioactive diterpenoid alkaloid with high content derived from herbal aconitum plants .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Aconitine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3102,
    "text": "Emerging evidence indicates that voltage - dependent Na ( + ) channels have pivotal roles in the cardiotoxicity of aconitine .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "Na"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "cardiotoxicity"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "aconitine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3103,
    "text": "However , no reports are available on the role of Ca ( 2 + ) in aconitine poisoning .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "Ca"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "aconitine"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "poisoning"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3104,
    "text": "In this study , we explored the importance of pathological Ca ( 2 + ) signaling in aconitine poisoning in vitro and in vivo .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "Ca"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "aconitine"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "poisoning"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3105,
    "text": "We found that Ca ( 2 + ) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "Ca"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3106,
    "text": "To investigate effects of aconitine on myocardial injury , we performed cytotoxicity assay in neonatal rat ventricular myocytes ( NRVMs ) , as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "myocardial injury"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "aconitine"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "cytotoxicity"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "lactate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3107,
    "text": "The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose - dependently .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "myocardial injury"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "aconitine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3108,
    "text": "To confirm the pro - apoptotic effects , we performed flow cytometric detection , cardiac histology , transmission electron microscopy and terminal deoxynucleotidyl transferase - mediated dUTP - biotin nick end labeling assay .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        27,
        "dUTP"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "biotin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3109,
    "text": "The results showed that aconitine stimulated apoptosis time - dependently .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "aconitine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3110,
    "text": "The expression analysis of Ca ( 2 + ) handling proteins demonstrated that aconitine promoted Ca ( 2 + ) overload through the expression regulation of Ca ( 2 + ) handling proteins .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "Ca"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "aconitine"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "Ca"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "Ca"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3111,
    "text": "The expression analysis of apoptosis - related proteins revealed that pro - apoptotic protein expression was upregulated , and anti - apoptotic protein BCL - 2 expression was downregulated .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3112,
    "text": "Furthermore , increased phosphorylation of MAPK family members , especially the P - P38 / P38 ratio was found in cardiac tissues .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3113,
    "text": "Hence , our results suggest that aconitine significantly aggravates Ca ( 2 + ) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of P38 mitogen - activated protein kinase .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "aconitine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "Ca"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3114,
    "text": "Chronic treatment with metformin suppresses toll - like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "left ventricular dysfunction"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "myocardial infarction"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3115,
    "text": "Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP - activated protein kinase ( AMPK ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "metformin"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "AMP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3116,
    "text": "In the present study , the effect of chronic pre - treatment with metformin on cardiac dysfunction and toll - like receptor 4 ( TLR4 ) activities following myocardial infarction and their relation with AMPK were assessed .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "cardiac dysfunction"
      ],
      [
        "T1",
        "Disease",
        28,
        30,
        "myocardial infarction"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3117,
    "text": "Male Wistar rats were randomly assigned to one of 5 groups ( n = 6 ) : normal control and groups were injected isoproterenol after chronic pre - treatment with 0 , 25 , 50 , or 100mg / kg of metformin twice daily for 14 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "isoproterenol"
      ],
      [
        "T1",
        "Chemical",
        41,
        42,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3118,
    "text": "Isoproterenol ( 100mg / kg ) was injected subcutaneously on the 13th and 14th days to induce acute myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "acute myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3119,
    "text": "Isoproterenol alone decreased left ventricular systolic pressure and myocardial contractility indexed as LVdp / dtmax and LVdp / dtmin .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3120,
    "text": "The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg / kg of metformin .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "left ventricular dysfunction"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3121,
    "text": "Metfromin markedly lowered isoproterenol - induced elevation in the levels of TLR4 mRNA , myeloid differentiation protein 88 ( MyD88 ) , tumor necrosis factor - alpha ( TNF - a ) , and interleukin 6 ( IL - 6 ) in the heart tissues .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "isoproterenol"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "tumor"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3122,
    "text": "Similar changes were also seen in the serum levels of TNF - a and IL - 6 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3123,
    "text": "However , the lower doses of 25 and 50mg / kg were more effective than 100mg / kg .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3124,
    "text": "Phosphorylated AMPKa ( p - AMPK ) in the myocardium was significantly elevated by 25mg / kg of metformin , slightly by 50mg / kg , but not by 100mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3125,
    "text": "Chronic pre - treatment with metformin reduces post - myocardial infarction cardiac dysfunction and suppresses inflammatory responses , possibly through inhibition of TLR4 activities .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "metformin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3126,
    "text": "This mechanism can be considered as a target to protect infarcted myocardium .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3127,
    "text": "Unusual complications of antithyroid drug therapy : four case reports and review of literature .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3128,
    "text": "Two cases of propylthiouracil - associated acute hepatitis , one case of fatal methimazole - associated hepatocellular necrosis and one case of propylthiouracil - associated lupus - like syndrome are described .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "hepatocellular necrosis"
      ],
      [
        "T1",
        "Disease",
        25,
        29,
        "lupus - like syndrome"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "propylthiouracil"
      ],
      [
        "T3",
        "Disease",
        7,
        8,
        "hepatitis"
      ],
      [
        "T4",
        "Chemical",
        13,
        14,
        "methimazole"
      ],
      [
        "T5",
        "Chemical",
        22,
        23,
        "propylthiouracil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3129,
    "text": "The literature related to antithyroid drug side effects and the mechanisms for their occurrence are reviewed and the efficacy and complications of thyroidectomy and radioiodine compared to those of antithyroid drugs .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3130,
    "text": "It is concluded that in most circumstances 131I is the therapy of choice for hyperthyroidism .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "hyperthyroidism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3131,
    "text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington ' s disease at the terminal stage of recurrent breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Disease",
        16,
        20,
        "Huntington ' s disease"
      ],
      [
        "T2",
        "Disease",
        26,
        28,
        "breast cancer"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "tetrabenazine"
      ],
      [
        "T4",
        "Chemical",
        10,
        11,
        "tiapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3132,
    "text": "We herein describe the case of an 81 - year - old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride ( 75 mg / day ) and tetrabenazine ( 12 . 5 mg / day ) for Huntington ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Disease",
        47,
        51,
        "Huntington ' s disease"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "tiapride"
      ],
      [
        "T3",
        "Chemical",
        37,
        38,
        "tetrabenazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3133,
    "text": "The patient had been treated with tiapride or tetrabenazine alone without any adverse effects before the administration of the combination therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "tiapride"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "tetrabenazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3134,
    "text": "She also had advanced breast cancer when the combination therapy was initiated .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3135,
    "text": "To the best of our knowledge , the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "tetrabenazine"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "tiapride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3136,
    "text": "Tetrabenazine should be administered very carefully in combination with other neuroleptic drugs , particularly in patients with a worsening general condition .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "neuroleptic drugs"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Tetrabenazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3137,
    "text": "A metoprolol - terbinafine combination induced bradycardia .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "metoprolol"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "terbinafine"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3138,
    "text": "To report a sinus bradycardia induced by metoprolol and terbinafine drug - drug interaction and its management .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "sinus bradycardia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "metoprolol"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "terbinafine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3139,
    "text": "A 63 year - old Caucasian man on metoprolol 200 mg / day for stable coronary artery disease was prescribed a 90 - day course of oral terbinafine 250 mg / day for onychomycosis .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "coronary artery disease"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "metoprolol"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "terbinafine"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "onychomycosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3140,
    "text": "On the 49th day of terbinafine therapy , he was brought to the emergency room for a decrease of his global health status , confusion and falls .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "terbinafine"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "confusion"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3141,
    "text": "The electrocardiogram revealed a 37 beats / min sinus bradycardia .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "sinus bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3142,
    "text": "A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient ' s sinus bradycardia and the drug interaction between metoprolol and terbinafine .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "adverse drug reaction"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "sinus bradycardia"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "metoprolol"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "terbinafine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3143,
    "text": "The heart rate ameliorated first with a decrease in the dose of metoprolol .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3144,
    "text": "It was subsequently changed to bisoprolol and the heart rate remained normal .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "bisoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3145,
    "text": "By inhibiting the cytochrome P450 2D6 , terbinafine had decreased metoprolol ' s clearance , leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "sinus bradycardia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "terbinafine"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "metoprolol"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "metoprolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3146,
    "text": "Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "peripheral neuropathy"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3147,
    "text": "Ethambutol is known to cause optic neuropathy and , more rarely , axonal polyneuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "optic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Ethambutol"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "polyneuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3148,
    "text": "We characterize the clinical , neurophysiological , and neuroimaging findings in a 72 - year - old man who developed visual loss and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ethambutol .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "visual loss"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "paresthesias"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "ethambutol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3149,
    "text": "This case demonstrates the selective vulnerability of the anterior visual pathways and peripheral nerves to ethambutol toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "ethambutol"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3150,
    "text": "Testosterone ameliorates streptozotocin - induced memory impairment in male rats .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "memory impairment"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Testosterone"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "streptozotocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3151,
    "text": "AIM : To study the effects of testosterone on streptozotocin ( STZ ) - induced memory impairment in male rats .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "memory impairment"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "testosterone"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "streptozotocin"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3152,
    "text": "METHODS : Adult male Wistar rats were intracerebroventricularly ( icv ) infused with STZ ( 750 ug ) on d 1 and d 3 , and a passive avoidance task was assessed 2 weeks after the first injection of STZ .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "STZ"
      ],
      [
        "T1",
        "Chemical",
        39,
        40,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3153,
    "text": "Castration surgery was performed in another group of rats , and the passive avoidance task was assessed 4 weeks after the operation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3154,
    "text": "Testosterone ( 1 mg . kg ( - 1 ) . d ( - 1 ) , sc ) , the androgen receptor antagonist flutamide ( 10 mg . kg ( - 1 ) . d ( - 1 ) , ip ) , the estrogen receptor antagonist tamoxifen ( 1 mg . kg ( - 1 ) . d ( - 1 ) , ip ) or the aromatase inhibitor letrozole ( 4 mg . kg ( - 1 ) . d ( - 1 ) , ip ) were administered for 6 d after the first injection of STZ .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Testosterone"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "androgen"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "flutamide"
      ],
      [
        "T3",
        "Chemical",
        45,
        46,
        "estrogen"
      ],
      [
        "T4",
        "Chemical",
        48,
        49,
        "tamoxifen"
      ],
      [
        "T5",
        "Chemical",
        71,
        72,
        "letrozole"
      ],
      [
        "T6",
        "Chemical",
        100,
        101,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3155,
    "text": "RESULTS : STZ administration and castration markedly decreased both STL1 ( the short memory ) and STL2 ( the long memory ) in passive avoidance tests .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3156,
    "text": "Testosterone replacement almost restored the STL1 and STL2 in castrated rats , and significantly prolonged the STL1 and STL2 in STZ - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Testosterone"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3157,
    "text": "Administration of flutamide , letrozole or tamoxifen significantly impaired the memory in intact rats , and significantly attenuated the testosterone replacement in improving STZ - and castration - induced memory impairment .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "impaired the memory"
      ],
      [
        "T1",
        "Disease",
        29,
        31,
        "memory impairment"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "flutamide"
      ],
      [
        "T3",
        "Chemical",
        4,
        5,
        "letrozole"
      ],
      [
        "T4",
        "Chemical",
        6,
        7,
        "tamoxifen"
      ],
      [
        "T5",
        "Chemical",
        19,
        20,
        "testosterone"
      ],
      [
        "T6",
        "Chemical",
        23,
        24,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3158,
    "text": "CONCLUSION : Testosterone administration ameliorates STZ - and castration - induced memory impairment in male Wistar rats .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "memory impairment"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Testosterone"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "STZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3159,
    "text": "Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine - induced seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "garcinielliptone FC"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "pilocarpine"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3160,
    "text": "Garcinielliptone FC ( GFC ) isolated from hexanic fraction seed extract of species Platonia insignis Mart .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Garcinielliptone FC"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "GFC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3161,
    "text": "It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "skin diseases"
      ],
      [
        "T1",
        "Disease",
        29,
        31,
        "inflammatory diseases"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "diarrheas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3162,
    "text": "However , there is no research on GFC effects in the central nervous system of rodents .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "GFC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3163,
    "text": "The present study aimed to evaluate the GFC effects at doses of 25 , 50 or 75 mg / kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid ( r - aminobutyric acid ( GABA ) , glutamine , aspartate and glutathione ) levels as well as on acetylcholinesterase ( AChE ) activity in mice hippocampus after seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        34,
        "amino acid"
      ],
      [
        "T1",
        "Chemical",
        35,
        39,
        "r - aminobutyric acid"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "GFC"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "seizure"
      ],
      [
        "T4",
        "Chemical",
        40,
        41,
        "GABA"
      ],
      [
        "T5",
        "Chemical",
        43,
        44,
        "glutamine"
      ],
      [
        "T6",
        "Chemical",
        45,
        46,
        "aspartate"
      ],
      [
        "T7",
        "Chemical",
        47,
        48,
        "glutathione"
      ],
      [
        "T8",
        "Disease",
        63,
        64,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3164,
    "text": "GFC produced an increased latency to first seizure , at doses 25mg / kg ( 20 . 12 + 2 . 20 min ) , 50mg / kg ( 20 . 95 + 2 . 21 min ) or 75 mg / kg ( 23 . 43 + 1 . 99 min ) when compared with seized mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "GFC"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3165,
    "text": "In addition , GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46 . 90 % when compared with seized mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3166,
    "text": "In aspartate , glutamine and glutamate levels detected a decrease of 5 . 21 % , 13 . 55 % and 21 . 80 % , respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "aspartate"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "glutamine"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3167,
    "text": "Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity ( 63 . 30 % ) when compared with seized mice .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3168,
    "text": "The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine - induced status epilepticus , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "status epilepticus"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "GFC"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "pilocarpine"
      ],
      [
        "T3",
        "Disease",
        30,
        31,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3169,
    "text": "In conclusion , our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and glutamate contents and of AChE activity in seized mice hippocampus .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "GFC"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "pilocarpine"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "GABA"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3170,
    "text": "This compound may be useful to produce neuronal protection and it can be considered as an anticonvulsant agent .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3171,
    "text": "Standard operating procedures for antibiotic therapy and the occurrence of acute kidney injury : a prospective , clinical , non - interventional , observational study .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "acute kidney injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3172,
    "text": "INTRODUCTION : Acute kidney injury ( AKI ) occurs in 7 % of hospitalized and 66 % of Intensive Care Unit ( ICU ) patients .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "Acute kidney injury"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "AKI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3173,
    "text": "It increases mortality , hospital length of stay , and costs .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3174,
    "text": "The aim of this study was to investigate , whether there is an association between adherence to guidelines ( standard operating procedures ( SOP ) ) for potentially nephrotoxic antibiotics and the occurrence of AKI .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        29,
        "nephrotoxic"
      ],
      [
        "T1",
        "Disease",
        34,
        35,
        "AKI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3175,
    "text": "METHODS : This study was carried out as a prospective , clinical , non - interventional , observational study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3176,
    "text": "Data collection was performed over a total of 170 days in three ICUs at Charite - Universitaetsmedizin Berlin .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3177,
    "text": "A total of 675 patients were included ; 163 of these had therapy with vancomycin , gentamicin , or tobramycin ; were > 18 years ; and treated in the ICU for > 24 hours .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "vancomycin"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "gentamicin"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "tobramycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3178,
    "text": "Patients with an adherence to SOP > 70 % were classified into the high adherence group ( HAG ) and patients with an adherence of < 70 % into the low adherence group ( LAG ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3179,
    "text": "AKI was defined according to RIFLE criteria .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "AKI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3180,
    "text": "Adherence to SOPs was evaluated by retrospective expert audit .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3181,
    "text": "Development of AKI was compared between groups with exact Chi2 - test and multivariate logistic regression analysis ( two - sided P < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "AKI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3182,
    "text": "RESULTS : LAG consisted of 75 patients ( 46 % ) versus 88 HAG patients ( 54 % ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3183,
    "text": "AKI occurred significantly more often in LAG with 36 % versus 21 % in HAG ( P = 0 . 035 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "AKI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3184,
    "text": "Basic characteristics were comparable , except an increased rate of soft tissue infections in LAG .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3185,
    "text": "Multivariate analysis revealed an odds ratio of 2 . 5 - fold for LAG to develop AKI compared with HAG ( 95 % confidence interval 1 . 195 to 5 . 124 , P = 0 . 039 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "AKI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3186,
    "text": "CONCLUSION : Low adherence to SOPs for potentially nephrotoxic antibiotics was associated with a higher occurrence of AKI .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "nephrotoxic"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "AKI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3187,
    "text": "TRIAL REGISTRATION : Current Controlled Trials ISRCTN54598675 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3188,
    "text": "Registered 17 August 2007 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3189,
    "text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "hepatitis C virus infected"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Rhabdomyolysis"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "telaprevir"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "simvastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3190,
    "text": "A 46 - year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin , pegylated interferon and telaprevir .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "hepatitis C virus infection"
      ],
      [
        "T1",
        "Chemical",
        19,
        21,
        "pegylated interferon"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "ribavirin"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "telaprevir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3191,
    "text": "The patient also received simvastatin .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "simvastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3192,
    "text": "One month after starting the antiviral therapy , the patient was admitted to the hospital because he developed rhabdomyolysis .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "rhabdomyolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3193,
    "text": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug - drug interaction was suspected .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "simvastatin"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3194,
    "text": "The creatine kinase peaked at 62 , 246 IU / L and the patient was treated with intravenous normal saline .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "creatine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3195,
    "text": "The patient ' s renal function remained unaffected .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3196,
    "text": "Fourteen days after hospitalization , creatine kinase level had returned to 230 IU / L and the patient was discharged .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "creatine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3197,
    "text": "Telaprevir was considered the probable causative agent of an interaction with simvastatin according to the Drug Interaction Probability Scale .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Telaprevir"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "simvastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3198,
    "text": "The interaction is due to inhibition of CYP3A4 - mediated simvastatin clearance .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "simvastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3199,
    "text": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "muscle toxicity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Simvastatin"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "statin"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "statin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3200,
    "text": "In conclusion , with this case we illustrate that telaprevir as well as statins are susceptible to clinical relevant drug - drug interactions .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "telaprevir"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "statins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3201,
    "text": "Combination of bortezomib , thalidomide , and dexamethasone ( VTD ) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "multiple myeloma"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "bortezomib"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "thalidomide"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3202,
    "text": "Consolidation therapy for patients with multiple myeloma ( MM ) has been widely adopted to improve treatment response following autologous stem cell transplantation .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "multiple myeloma"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "MM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3203,
    "text": "In this study , we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib , thalidomide , and dexamethasone ( VTD ) as consolidation therapy in 24 Japanese patients with newly diagnosed MM .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "bortezomib"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "thalidomide"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "dexamethasone"
      ],
      [
        "T3",
        "Disease",
        34,
        35,
        "MM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3204,
    "text": "VTD consisted of bortezomib at a dose of 1 . 3 mg / m ( 2 ) and dexamethasone at a dose of 40 mg / day on days 1 , 8 , 15 , and 22 of a 35 - day cycle , with daily oral thalidomide at a dose of 100 mg / day .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "bortezomib"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "dexamethasone"
      ],
      [
        "T2",
        "Chemical",
        47,
        48,
        "thalidomide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3205,
    "text": "Grade 3 - 4 neutropenia and thrombocytopenia were documented in four and three patients ( 17 and 13 % ) , respectively , but drug dose reduction due to cytopenia was not required in any case .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "neutropenia"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "cytopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3206,
    "text": "Peripheral neuropathy was common ( 63 % ) , but severe grade 3 - 4 peripheral neuropathy was not observed .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Peripheral neuropathy"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "peripheral neuropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3207,
    "text": "Very good partial response or better response ( > VGPR ) rates before and after consolidation therapy were 54 and 79 % , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3208,
    "text": "Patients had a significant probability of improving from < VGPR before consolidation therapy to > VGPR after consolidation therapy ( p = 0 . 041 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3209,
    "text": "The VTD regimen may be safe and effective as a consolidation therapy in the treatment of MM in Japanese population .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3210,
    "text": "Conversion to sirolimus ameliorates cyclosporine - induced nephropathy in the rat : focus on serum , urine , gene , and protein renal expression biomarkers .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "sirolimus"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "cyclosporine"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3211,
    "text": "Protocols of conversion from cyclosporin A ( CsA ) to sirolimus ( SRL ) have been widely used in immunotherapy after transplantation to prevent CsA - induced nephropathy , but the molecular mechanisms underlying these protocols remain nuclear .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "cyclosporin A"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "CsA"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "sirolimus"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "SRL"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "CsA"
      ],
      [
        "T5",
        "Disease",
        27,
        28,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3212,
    "text": "This study aimed to identify the molecular pathways and putative biomarkers of CsA - to - SRL conversion in a rat model .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "CsA"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "SRL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3213,
    "text": "Four animal groups ( n = 6 ) were tested during 9 weeks : control , CsA , SRL , and conversion ( CsA for 3 weeks followed by SRL for 6 weeks ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "CsA"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "SRL"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "CsA"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "SRL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3214,
    "text": "Classical and emergent serum , urinary , and kidney tissue ( gene and protein expression ) markers were assessed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3215,
    "text": "Renal lesions were analyzed in hematoxylin and eosin , periodic acid - Schiff , and Masson ' s trichrome stains .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Renal lesions"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "hematoxylin"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "eosin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3216,
    "text": "SRL - treated rats presented proteinuria and NGAL ( serum and urinary ) as the best markers of renal impairment .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "renal impairment"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "SRL"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "proteinuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3217,
    "text": "Short CsA treatment presented slight or even absent kidney lesions and TGF - b , NF - kb , mTOR , PCNA , TP53 , KIM - 1 , and CTGF as relevant gene and protein changes .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "kidney lesions"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "CsA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3218,
    "text": "Prolonged CsA exposure aggravated renal damage , without clear changes on the traditional markers , but with changes in serums TGF - b and IL - 7 , TBARs clearance , and kidney TGF - b and mTOR .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "renal damage"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "CsA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3219,
    "text": "Conversion to SRL prevented CsA - induced renal damage evolution ( absent / mild grade lesions ) , while NGAL ( serum versus urine ) seems to be a feasible biomarker of CsA replacement to SRL .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "renal damage"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "SRL"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "CsA"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "CsA"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "SRL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3220,
    "text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin - induced acute renal injury .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        13,
        "acute renal injury"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3221,
    "text": "Cisplatin treatment has been adopted in some chemotherapies ; however , this drug can induce acute kidney injury due its ability to negatively affect renal function , augment serum levels of creatinine and urea , increase the acute tubular necrosis score and up - regulate cytokines ( e . g . , IL - 1b and TNF - a ) .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "acute kidney injury"
      ],
      [
        "T1",
        "Disease",
        37,
        40,
        "acute tubular necrosis"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Cisplatin"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "creatinine"
      ],
      [
        "T4",
        "Chemical",
        33,
        34,
        "urea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3222,
    "text": "The kinin B2 receptor has been associated with the inflammation process , as well as the regulation of cytokine expression , and its deletion resulted in an improvement in the diabetic nephropathy status .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        32,
        "diabetic nephropathy"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3223,
    "text": "To examine the role of the kinin B2 receptor in cisplatin - induced acute kidney injury , kinin B2 receptor knockout mice were challenged with cisplatin .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        16,
        "acute kidney injury"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "cisplatin"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3224,
    "text": "Additionally , WT mice were treated with a B2 receptor antagonist after cisplatin administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3225,
    "text": "B2 receptor - deficient mice were less sensitive to this drug than the WT mice , as shown by reduced weight loss , better preservation of kidney function , down regulation of inflammatory cytokines and less acute tubular necrosis .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "weight loss"
      ],
      [
        "T1",
        "Disease",
        36,
        39,
        "acute tubular necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3226,
    "text": "Moreover , treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum creatinine and blood urea after cisplatin administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "creatinine"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "urea"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3227,
    "text": "Thus , our data suggest that the kinin B2 receptor is involved in cisplatin - induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines , thus resulting in declined renal function .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        19,
        "acute kidney injury"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "cisplatin"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "necrotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3228,
    "text": "These results highlight the kinin B2 receptor antagonist treatment in amelioration of nephrotoxicity induced by cisplatin therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "nephrotoxicity"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3229,
    "text": "Safety and efficacy of fluocinolone acetonide intravitreal implant ( 0 . 59 mg ) in birdshot retinochoroidopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "fluocinolone acetonide"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "birdshot retinochoroidopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3230,
    "text": "PURPOSE : To report the treatment outcomes of the fluocinolone acetonide intravitreal implant ( 0 . 59 mg ) in patients with birdshot retinochoroidopathy whose disease is refractory or intolerant to conventional immunomodulatory therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "fluocinolone acetonide"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "birdshot retinochoroidopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3231,
    "text": "METHODS : A retrospective case series involving 11 birdshot retinochoroidopathy patients ( 11 eyes ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "birdshot retinochoroidopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3232,
    "text": "Eleven patients ( 11 eyes ) underwent surgery for fluocinolone acetonide implant ( 0 . 59 mg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "fluocinolone acetonide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3233,
    "text": "Treatment outcomes of interest were noted at baseline , before fluocinolone acetonide implant , and then at 6 months , 1 year , 2 years , 3 years , and beyond 3 years .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "fluocinolone acetonide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3234,
    "text": "Disease activity markers , including signs of ocular inflammation , evidence of retinal vasculitis , Swedish interactive threshold algorithm - short wavelength automated perimetry Humphrey visual field analysis , electroretinographic parameters , and optical coherence tomography were recorded .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "retinal vasculitis"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3235,
    "text": "Data on occurrence of cataract and raised intraocular pressure were collected in all eyes .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "raised intraocular pressure"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "cataract"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3236,
    "text": "RESULTS : Intraocular inflammation was present in 54 . 5 , 9 . 9 , 11 . 1 , and 0 % of patients at baseline , 6 months , 1 year , 2 years , 3 years , and beyond 3 years after receiving the implant , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3237,
    "text": "Active vasculitis was noted in 36 . 3 % patients at baseline and 0 % at 3 years of follow - up .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "vasculitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3238,
    "text": "More than 20 % ( 47 . 61 - 67 . 2 % ) reduction in central retinal thickness was noted in all patients with cystoid macular edema at 6 months , 1 year , 2 years , and 3 years postimplant .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        28,
        "cystoid macular edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3239,
    "text": "At baseline , 54 . 5 % patients were on immunomodulatory agents .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3240,
    "text": "This percentage decreased to 45 . 45 , 44 . 4 , and 14 . 28 % at 1 year , 2 years , and 3 years postimplant , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3241,
    "text": "Adverse events included increased intraocular pressure ( 54 . 5 % ) and cataract formation ( 100 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "increased intraocular pressure"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "cataract"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3242,
    "text": "CONCLUSION : The data suggest that fluocinolone acetonide implant ( 0 . 59 mg ) helps to control inflammation in otherwise treatment - refractory cases of birdshot retinochoroidopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "fluocinolone acetonide"
      ],
      [
        "T1",
        "Disease",
        26,
        28,
        "birdshot retinochoroidopathy"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "inflammation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3243,
    "text": "It is associated with significant side effects of cataract and ocular hypertension requiring treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "ocular hypertension"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "cataract"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3244,
    "text": "Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "rocuronium"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "fasciculation"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "myalgia"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3245,
    "text": "BACKGROUND : Succinylcholine commonly produces frequent adverse effects , including muscle fasciculation and myalgia .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "muscle fasciculation"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Succinylcholine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3246,
    "text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine - induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "rocuronium"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "succinylcholine"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "fasciculation"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "myalgia"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "rocuronium"
      ],
      [
        "T5",
        "Chemical",
        30,
        31,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3247,
    "text": "METHODS : This randomized , double - blinded study was conducted in 100 patients randomly allocated into five groups of 20 patients each .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3248,
    "text": "Patients were randomized to receive 0 . 02 , 0 . 03 , 0 . 04 , 0 . 05 and 0 . 06 mg / kg rocuronium as a precurarizing dose .",
    "labels": [
      [
        "T0",
        "Chemical",
        27,
        28,
        "rocuronium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3249,
    "text": "Neuromuscular monitoring after each precurarizing dose was recorded from the adductor pollicis muscle using acceleromyography with train - of - four stimulation of the ulnar nerve .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3250,
    "text": "All patients received succinylcholine 1 . 5 mg / kg at 2 minutes after the precurarization , and were assessed the incidence and severity of fasciculations , while myalgia was assessed at 24 hours after surgery .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "succinylcholine"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "fasciculations"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3251,
    "text": "RESULTS : The incidence and severity of visible muscle fasciculation was significantly less with increasing the amount of precurarizing dose of rocuronium ( P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "muscle fasciculation"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "rocuronium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3252,
    "text": "Those of myalgia tend to decrease according to increasing the amount of precurarizing dose of rocuronium , but there was no significance ( P = 0 . 072 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "myalgia"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "rocuronium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3253,
    "text": "The onset time of succinylcholine was significantly longer with increasing the amount of precurarizing dose of rocuronium ( P < 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "succinylcholine"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "rocuronium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3254,
    "text": "CONCLUSIONS : Precurarization with 0 . 04 mg / kg rocuronium was the optimal dose considering the reduction in the incidence and severity of fasciculation and myalgia with acceptable onset time , and the safe and effective precurarization .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "rocuronium"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "fasciculation"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3255,
    "text": "Absence of PKC - alpha attenuates lithium - induced nephrogenic diabetes insipidus .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3256,
    "text": "Lithium , an effective antipsychotic , induces nephrogenic diabetes insipidus ( NDI ) in 40 % of patients .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Lithium"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "NDI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3257,
    "text": "The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the cAMP pathway and chronically reducing urea transporter ( UT - A1 ) and water channel ( AQP2 ) expression in the inner medulla .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "lithium"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "cAMP"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "urea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3258,
    "text": "Targeting an alternative signaling pathway , such as PKC - mediated signaling , may be an effective method of treating lithium - induced polyuria .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "lithium"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "polyuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3259,
    "text": "PKC - alpha null mice ( PKCa KO ) and strain - matched wild type ( WT ) controls were treated with lithium for 0 , 3 or 5 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3260,
    "text": "WT mice had increased urine output and lowered urine osmolality after 3 and 5 days of treatment whereas PKCa KO mice had no change in urine output or concentration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3261,
    "text": "Western blot analysis revealed that AQP2 expression in medullary tissues was lowered after 3 and 5 days in WT mice ; however , AQP2 was unchanged in PKCa KO .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3262,
    "text": "Similar results were observed with UT - A1 expression .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3263,
    "text": "Animals were also treated with lithium for 6 weeks .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3264,
    "text": "Lithium - treated WT mice had 19 - fold increased urine output whereas treated PKCa KO animals had a 4 - fold increase in output .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3265,
    "text": "AQP2 and UT - A1 expression was lowered in 6 week lithium - treated WT animals whereas in treated PKCa KO mice , AQP2 was only reduced by 2 - fold and UT - A1 expression was unaffected .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3266,
    "text": "Urinary sodium , potassium and calcium were elevated in lithium - fed WT but not in lithium - fed PKCa KO mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "potassium"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "calcium"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "lithium"
      ],
      [
        "T4",
        "Chemical",
        16,
        17,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3267,
    "text": "Our data show that ablation of PKCa preserves AQP2 and UT - A1 protein expression and localization in lithium - induced NDI , and prevents the development of the severe polyuria associated with lithium therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "lithium"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "NDI"
      ],
      [
        "T2",
        "Disease",
        30,
        31,
        "polyuria"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3268,
    "text": "Is Dysguesia Going to be a Rare or a Common Side - effect of Amlodipine ?",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "Dysguesia"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "Amlodipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3269,
    "text": "A very rare side - effect of amlodipine is dysguesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "amlodipine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "dysguesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3270,
    "text": "A review of the literature produced only one case .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3271,
    "text": "We report a case about a female with essential hypertension on drug treatment with amlodipine developed loss of taste sensation .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        20,
        "loss of taste sensation"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypertension"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "amlodipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3272,
    "text": "Condition moderately improved on stoppage of the drug for 25 days .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3273,
    "text": "We conclude that amlodipine can cause dysguesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "amlodipine"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "dysguesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3274,
    "text": "Here , we describe the clinical presentation and review the relevant literature on amlodipine and dysguesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "amlodipine"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "dysguesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3275,
    "text": "Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Rhabdomyolysis"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "simvastatin"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "clarithromycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3276,
    "text": "Clarithromycin is the most documented cytochrome P450 3A4 ( CYP3A4 ) inhibitor to cause an adverse interaction with simvastatin .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Clarithromycin"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "simvastatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3277,
    "text": "This particular case is of interest as rhabdomyolysis only occurred after an increase in the dose of clarithromycin .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "rhabdomyolysis"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "clarithromycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3278,
    "text": "The patient developed raised cardiac biomarkers without any obvious cardiac issues , a phenomenon that has been linked to rhabdomyolysis previously .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "rhabdomyolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3279,
    "text": "To date , there has been no reported effect of rhabdomyolysis on the structure and function of cardiac muscle .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "rhabdomyolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3280,
    "text": "Clinicians need to be aware of prescribing concomitant medications that increase the risk of myopathy or inhibit the CYP3A4 enzyme .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3281,
    "text": "Our case suggests that troponin elevation could be associated with statin induced rhabdomyolysis , which may warrant further studies .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "statin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "rhabdomyolysis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3282,
    "text": "Characterization of a novel BCHE \" silent \" allele : point mutation ( p . Val204Asp ) causes loss of activity and prolonged apnea with suxamethonium .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        24,
        "apnea"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "suxamethonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3283,
    "text": "Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants ( suxamethonium or mivacurium ) in patients who have mutations in the BCHE gene .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Butyrylcholinesterase deficiency"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "apnea"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "suxamethonium"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "mivacurium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3284,
    "text": "Here , we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant ( c . 695T > A , p . Val204Asp ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "suxamethonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3285,
    "text": "Inhibition studies , kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a \" silent \" phenotype .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3286,
    "text": "Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine ( BTC ) and benzoylcholine , and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "butyrylthiocholine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "BTC"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "benzoylcholine"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "dibucaine"
      ],
      [
        "T4",
        "Chemical",
        19,
        20,
        "fluoride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3287,
    "text": "Electrophoretic analysis of plasma BChE of the proband and his mother showed that patient has a reduced amount of tetrameric enzyme in plasma and that minor fast - moving BChE components : monomer , dimer , and monomer - albumin conjugate are missing .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3288,
    "text": "Kinetic analysis showed that the p . Val204Asp / p . Asp70Gly - p . Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "BTC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3289,
    "text": "Both catalytic parameters Km = 265 uM for BTC , two times higher than that of the atypical enzyme , and a low Vmax are consistent with the absence of activity against suxamethonium .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "BTC"
      ],
      [
        "T1",
        "Chemical",
        32,
        33,
        "suxamethonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3290,
    "text": "Molecular dynamic ( MD ) simulations showed that the overall effect of the mutation p . Val204Asp is disruption of hydrogen bonding between Gln223 and Glu441 , leading Ser198 and His438 to move away from each other with subsequent disruption of the catalytic triad functionality regardless of the type of substrate .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "hydrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3291,
    "text": "MD also showed that the enzyme volume is increased , suggesting a pre - denaturation state .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3292,
    "text": "This fits with the reduced concentration of p . Ala204Asp / p . Asp70Gly - p . Ala539Thr tetrameric enzyme in the plasma and non - detectable fast moving - bands on electrophoresis gels .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3293,
    "text": "Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo : a manageable issue .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "anemia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "artesunate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3294,
    "text": "Cases of delayed hemolytic anemia have been described after treatment with injectable artesunate , the current World Health Organization ( WHO ) - recommended first - line drug for the treatment of severe malaria .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "artesunate"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "malaria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3295,
    "text": "A total of 350 patients ( 215 [ 61 . 4 % ] < 5 years of age and 135 [ 38 . 6 % ] > 5 years of age ) were followed - up after treatment with injectable artesunate for severe malaria in hospitals and health centers of the Democratic Republic of the Congo .",
    "labels": [
      [
        "T0",
        "Chemical",
        40,
        41,
        "artesunate"
      ],
      [
        "T1",
        "Disease",
        43,
        44,
        "malaria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3296,
    "text": "Complete series of hemoglobin ( Hb ) measurements were available for 201 patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3297,
    "text": "A decrease in Hb levels between 2 and 5 g / dL was detected in 23 ( 11 . 4 % ) patients during the follow - up period .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3298,
    "text": "For five patients , Hb levels decreased below 5 g / dL during at least one follow - up visit .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3299,
    "text": "All cases of delayed anemia were clinically manageable and resolved within one month .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3300,
    "text": "Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol - induced acute myocardial injury in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "myocardial injury"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "betaine"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3301,
    "text": "The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 ( STAT3 ) and apoptotic pathways as the potential mechanism underlying the drug effect .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "betaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3302,
    "text": "Male Sprague Dawley rats were treated with betaine ( 100 , 200 , and 400 mg / kg ) orally for 40 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "betaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3303,
    "text": "Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol ( 85 mg / kg ) , for two consecutive days .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "myocardial ischemic injury"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3304,
    "text": "Serum cardiac marker enzyme , histopathological variables and expression of protein levels were analyzed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3305,
    "text": "Oral administration of betaine ( 200 and 400 mg / kg ) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "ventricular remodeling"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "betaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3306,
    "text": "Western blot analysis showed that isoproterenol - induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "isoproterenol"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "betaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3307,
    "text": "Furthermore , betaine ( 200 and 400 mg / kg ) treatment increased the ventricular expression of Bcl - 2 and reduced the level of Bax , therefore causing a significant increase in the ratio of Bcl - 2 / Bax .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "betaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3308,
    "text": "The protective role of betaine on myocardial damage was further confirmed by histopathological examination .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "myocardial damage"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "betaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3309,
    "text": "In summary , our results showed that betaine pretreatment attenuated isoproterenol - induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "betaine"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3310,
    "text": "Quetiapine - induced neutropenia in a bipolar patient with hepatocellular carcinoma .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "hepatocellular carcinoma"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Quetiapine"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "neutropenia"
      ],
      [
        "T3",
        "Disease",
        6,
        7,
        "bipolar"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3311,
    "text": "OBJECTIVE : Quetiapine is a dibenzothiazepine derivative , similar to clozapine , which has the highest risk of causing blood dyscrasias , especially neutropenia .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "blood dyscrasias"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Quetiapine"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "clozapine"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3312,
    "text": "There are some case reports about this side effect of quetiapine , but possible risk factors are seldom discussed and identified .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3313,
    "text": "A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "hepatocellular carcinoma"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "neutropenia"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3314,
    "text": "CASE REPORT : A 62 - year - old Taiwanese widow with bipolar disorder was diagnosed with hepatocellular carcinoma at age 60 .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "bipolar disorder"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "hepatocellular carcinoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3315,
    "text": "She developed leucopenia after being treated with quetiapine .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "leucopenia"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3316,
    "text": "After quetiapine was discontinued , her white blood cell count returned to normal .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3317,
    "text": "CONCLUSIONS : Although neutropenia is not a common side effect of quetiapine , physicians should be cautious about its presentation and associated risk factors .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "neutropenia"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3318,
    "text": "Hepatic dysfunction may be one of the possible risk factors , and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hepatic dysfunction"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "fever"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "quetiapine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3319,
    "text": "Lateral antebrachial cutaneous neuropathy after steroid injection at lateral epicondyle .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "neuropathy"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3320,
    "text": "BACKGROUND AND OBJECTIVES : This report aimed to present a case of lateral antebrachial cutaneous neuropathy ( LACNP ) that occurred after a steroid injection in the lateral epicondyle to treat lateral epicondylitis in a 40 - year - old woman .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        33,
        "lateral epicondylitis"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "neuropathy"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3321,
    "text": "MATERIAL AND METHOD : A 40 - year - old woman presented with decreased sensation and paresthesia over her right lateral forearm ; the paresthesia had occurred after a steroid injection in the right lateral epicondyle 3 months before .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "paresthesia"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "paresthesia"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3322,
    "text": "Her sensation of light touch and pain was diminished over the lateral side of the right forearm and wrist area .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3323,
    "text": "RESULTS : The sensory action potential amplitude of the right lateral antebrachial cutaneous nerve ( LACN ) ( 6 . 2 uV ) was lower than that of the left ( 13 . 1 uV ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3324,
    "text": "The difference of amplitude between both sides was significant because there was more than a 50 % reduction .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3325,
    "text": "She was diagnosed with right LACNP ( mainly axonal involvement ) on the basis of the clinical manifestation and the electrodiagnostic findings .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3326,
    "text": "Her symptoms improved through physical therapy but persisted to some degree .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3327,
    "text": "CONCLUSION : This report describes the case of a woman with LACNP that developed after a steroid injection for the treatment of lateral epicondylitis .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "lateral epicondylitis"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "steroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3328,
    "text": "An electrodiagnostic study , including a nerve conduction study of the LACN , was helpful to diagnose right LACNP and to find the passage of the LACN on the lateral epicondyle .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3329,
    "text": "Curcumin prevents maleate - induced nephrotoxicity : relation to hemodynamic alterations , oxidative stress , mitochondrial oxygen consumption and activity of respiratory complex I .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Curcumin"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "maleate"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "nephrotoxicity"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3330,
    "text": "The potential protective effect of the dietary antioxidant curcumin ( 120 mg / Kg / day for 6 days ) against the renal injury induced by maleate was evaluated .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "renal injury"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "curcumin"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "maleate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3331,
    "text": "Tubular proteinuria and oxidative stress were induced by a single injection of maleate ( 400 mg / kg ) in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "proteinuria"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "maleate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3332,
    "text": "Maleate - induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein , glucose , sodium , neutrophil gelatinase - associated lipocalin ( NGAL ) and N - acetyl b - D - glucosaminidase ( NAG ) , upregulation of kidney injury molecule ( KIM ) - 1 , decrease in renal blood flow and claudin - 2 expression besides of necrosis and apoptosis of tubular cells on 24 h .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "renal injury"
      ],
      [
        "T1",
        "Disease",
        47,
        49,
        "kidney injury"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Maleate"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "glucose"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "sodium"
      ],
      [
        "T5",
        "Disease",
        68,
        69,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3333,
    "text": "Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3334,
    "text": "Studies were also conducted in renal epithelial LLC - PK1 cells and in mitochondria isolated from kidneys of all the experimental groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3335,
    "text": "Maleate induced cell damage and reactive oxygen species ( ROS ) production in LLC - PK1 cells in culture .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Maleate"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3336,
    "text": "In addition , maleate treatment reduced oxygen consumption in ADP - stimulated mitochondria and diminished respiratory control index when using malate / glutamate as substrate .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "maleate"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "oxygen"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "ADP"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "malate"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "glutamate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3337,
    "text": "The activities of both complex I and aconitase were also diminished .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3338,
    "text": "All the above - described alterations were prevented by curcumin .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "curcumin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3339,
    "text": "It is concluded that curcumin is able to attenuate in vivo maleate - induced nephropathy and in vitro cell damage .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "curcumin"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "maleate"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3340,
    "text": "The in vivo protection was associated to the prevention of oxidative stress and preservation of mitochondrial oxygen consumption and activity of respiratory complex I , and the in vitro protection was associated to the prevention of ROS production .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3341,
    "text": "Anticonvulsant actions of MK - 801 on the lithium - pilocarpine model of status epilepticus in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "MK - 801"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "status epilepticus"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "lithium"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3342,
    "text": "MK - 801 , a noncompetitive N - methyl - D - aspartate ( NMDA ) receptor antagonist , was tested for anticonvulsant effects in rats using two seizure models , coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        6,
        13,
        "N - methyl - D - aspartate"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "NMDA"
      ],
      [
        "T3",
        "Disease",
        28,
        29,
        "seizure"
      ],
      [
        "T4",
        "Chemical",
        33,
        34,
        "lithium"
      ],
      [
        "T5",
        "Chemical",
        35,
        36,
        "pilocarpine"
      ],
      [
        "T6",
        "Chemical",
        43,
        44,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3343,
    "text": "Three major results are reported .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3344,
    "text": "First , pretreatment with MK - 801 produced an effective and dose - dependent anticonvulsant action with the lithium - pilocarpine model but not with rats treated with pilocarpine alone , suggesting that different biochemical mechanisms control seizures in these two models .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "lithium"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "pilocarpine"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "pilocarpine"
      ],
      [
        "T4",
        "Disease",
        37,
        38,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3345,
    "text": "Second , the anticonvulsant effect of MK - 801 in the lithium - pilocarpine model only occurred after initial periods of seizure activity .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "lithium"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "pilocarpine"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3346,
    "text": "This observation is suggested to be an in vivo demonstration of the conclusion derived from in vitro experiments that MK - 801 binding requires agonist - induced opening of the channel sites of the NMDA receptor .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        22,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "NMDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3347,
    "text": "Third , although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine , it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        32,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "lithium"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "pilocarpine"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "pilocarpine"
      ],
      [
        "T5",
        "Disease",
        38,
        39,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3348,
    "text": "Administration of MK - 801 30 or 60 min after pilocarpine , i . e . , during status epilepticus , gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "MK - 801"
      ],
      [
        "T1",
        "Disease",
        18,
        20,
        "status epilepticus"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "pilocarpine"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3349,
    "text": "These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium - pilocarpine model .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "brain damage"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "NMDA"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "lithium"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3350,
    "text": "This was further supported by results showing that nonconvulsive doses of NMDA and pilocarpine were synergistic , resulting in status epilepticus and subsequent mortality .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "status epilepticus"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "NMDA"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3351,
    "text": "Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "tobramycin"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "carbenicillin"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "infections"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3352,
    "text": "The cure rate of infections in cancer patients is adversely affected by neutropenia ( less than 1 , 000 / mm3 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "infections"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "cancer"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3353,
    "text": "In particular , patients with severe neutropenia ( less than 100 / mm3 ) have shown a poor response to antibiotics .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3354,
    "text": "To overcome the adverse effects of neutropenia , tobramycin was given by continuous infusion and combined with intermittent carbenicillin .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "neutropenia"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "tobramycin"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "carbenicillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3355,
    "text": "Tobramycin was given to a total daily dose of 300 mg / m2 and carbenicillin was given at a dose of 5 gm every four hours .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Tobramycin"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "carbenicillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3356,
    "text": "There were 125 infectious episodes in 116 cancer patients receiving myelosuppressive chemotherapy .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3357,
    "text": "The overall cure rate was 70 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3358,
    "text": "Pneumonia was the most common infection and 61 % of 59 episodes were cured .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Pneumonia"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3359,
    "text": "Gram - negative bacilli were the most common causative organisms and 69 % of these infections were cured .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3360,
    "text": "The most common pathogen was Klebsiella pneumoniae and this , together with Escherichia coli and Pseudomonas aeruginosa , accounted for 74 % of all gram - negative bacillary infections .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        29,
        "gram - negative bacillary infections"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "pneumoniae"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3361,
    "text": "Response was not influenced by the initial neutrophil count , with a 62 % cure rate for 39 episodes associated with severe neutropenia .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        23,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3362,
    "text": "However , failure of the neutrophil count to increase during therapy adversely affected response .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3363,
    "text": "Azotemia was the major side effect recognized , and it occurred in 11 % of episodes .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Azotemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3364,
    "text": "Major azotemia ( serum creatinine greater than 2 . 5 mg / dl or BUN greater than 50 mg / dl ) occurred in only 2 % .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "azotemia"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3365,
    "text": "Azotemia was not related to duration of therapy or serum tobramycin concentration .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Azotemia"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "tobramycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3366,
    "text": "This antibiotic regimen showed both therapeutic efficacy and acceptable renal toxicity for these patients .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "renal toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3367,
    "text": "Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study : an updated analysis .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "tumours"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "organophosphate"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "diazinon"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3368,
    "text": "OBJECTIVE : Diazinon , a common organophosphate insecticide with genotoxic properties , was previously associated with lung cancer in the Agricultural Health Study ( AHS ) cohort , but few other epidemiological studies have examined diazinon - associated cancer risk .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "lung cancer"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Diazinon"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "organophosphate"
      ],
      [
        "T3",
        "Chemical",
        35,
        36,
        "diazinon"
      ],
      [
        "T4",
        "Disease",
        38,
        39,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3369,
    "text": "We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "diazinon"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "cancer"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "tumour"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3370,
    "text": "METHODS : Male pesticide applicators in Iowa and North Carolina reported lifetime diazinon use at enrolment ( 1993 - 1997 ) and follow - up ( 1998 - 2005 ) ; cancer incidence was assessed through 2010 ( North Carolina ) / 2011 ( Iowa ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "diazinon"
      ],
      [
        "T1",
        "Disease",
        31,
        32,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3371,
    "text": "Among applicators with usage information sufficient to evaluate exposure - response patterns , we used Poisson regression to estimate adjusted rate ratios ( RRs ) and 95 % CI for cancer sites with > 10 exposed cases for both lifetime ( LT ) exposure days and intensity - weighted ( IW ) lifetime exposure days ( accounting for factors impacting exposure ) .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        31,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3372,
    "text": "RESULTS : We observed elevated lung cancer risks ( N = 283 ) among applicators with the greatest number of LT ( RR = 1 . 60 ; 95 % CI 1 . 11 to 2 . 31 ; Ptrend = 0 . 02 ) and IW days of diazinon use ( RR = 1 . 41 ; 95 % CI 0 . 98 to 2 . 04 ; Ptrend = 0 . 08 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "lung cancer"
      ],
      [
        "T1",
        "Chemical",
        49,
        50,
        "diazinon"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3373,
    "text": "Kidney cancer ( N = 94 ) risks were non - significantly elevated ( RRLT days = 1 . 77 ; 95 % CI 0 . 90 to 3 . 51 ; Ptrend = 0 . 09 ; RRIW days 1 . 37 ; 95 % CI 0 . 64 to 2 . 92 ; Ptrend = 0 . 50 ) , as were risks for aggressive prostate cancer ( N = 656 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Kidney cancer"
      ],
      [
        "T1",
        "Disease",
        67,
        69,
        "prostate cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3374,
    "text": "CONCLUSIONS : Our updated evaluation of diazinon provides additional evidence of an association with lung cancer risk .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "lung cancer"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "diazinon"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3375,
    "text": "Newly identified links to kidney cancer and associations with aggressive prostate cancer require further evaluation .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "kidney cancer"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "prostate cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3376,
    "text": "Associations of Ozone and PM2 . 5 Concentrations With Parkinson ' s Disease Among Participants in the Agricultural Health Study .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "Parkinson ' s Disease"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "Ozone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3377,
    "text": "OBJECTIVE : This study describes associations of ozone and fine particulate matter with Parkinson ' s disease observed among farmers in North Carolina and Iowa .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        12,
        "particulate matter"
      ],
      [
        "T1",
        "Disease",
        13,
        17,
        "Parkinson ' s disease"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "ozone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3378,
    "text": "METHODS : We used logistic regression to determine the associations of these pollutants with self - reported , doctor - diagnosed Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        25,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3379,
    "text": "Daily predicted pollutant concentrations were used to derive surrogates of long - term exposure and link them to study participants ' geocoded addresses .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3380,
    "text": "RESULTS : We observed positive associations of Parkinson ' s disease with ozone ( odds ratio = 1 . 39 ; 95 % CI : 0 . 98 to 1 . 98 ) and fine particulate matter ( odds ratio = 1 . 34 ; 95 % CI : 0 . 93 to 1 . 93 ) in North Carolina but not in Iowa .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        35,
        37,
        "particulate matter"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "ozone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3381,
    "text": "CONCLUSIONS : The plausibility of an effect of ambient concentrations of these pollutants on Parkinson ' s disease risk is supported by experimental data demonstrating damage to dopaminergic neurons at relevant concentrations .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        18,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3382,
    "text": "Additional studies are needed to address uncertainties related to confounding and to examine temporal aspects of the associations we observed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3383,
    "text": "Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "glomerulosclerosis"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3384,
    "text": "UNASSIGNED : Our previous study has indicated that prenatal caffeine exposure ( PCE ) could induce intrauterine growth retardation ( IUGR ) of offspring .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        19,
        "intrauterine growth retardation"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "caffeine"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "IUGR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3385,
    "text": "Recent research suggested that IUGR is a risk factor for glomerulosclerosis .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "IUGR"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "glomerulosclerosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3386,
    "text": "However , whether PCE could induce glomerulosclerosis and its underlying mechanisms remain unknown .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "glomerulosclerosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3387,
    "text": "This study aimed to demonstrate the induction to glomerulosclerosis in adult offspring by PCE and its intrauterine programming mechanisms .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "glomerulosclerosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3388,
    "text": "A rat model of IUGR was established by PCE , male fetuses and adult offspring at the age of postnatal week 24 were euthanized .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "IUGR"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3389,
    "text": "The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis , accompanied by elevated levels of serum creatinine and urine protein .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "interstitial fibrosis"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "glomerulosclerosis"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "creatinine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3390,
    "text": "Renal angiotensin II receptor type 2 ( AT2R ) gene expression in adult offspring was reduced by PCE , whereas the renal angiotensin II receptor type 1a ( AT1aR ) / AT2R expression ratio was increased .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "angiotensin II"
      ],
      [
        "T1",
        "Chemical",
        22,
        24,
        "angiotensin II"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3391,
    "text": "The fetal kidneys in the PCE group displayed an enlarged Bowman ' s space and a shrunken glomerular tuft , accompanied by a reduced cortex width and an increase in the nephrogenic zone / cortical zone ratio .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3392,
    "text": "Observation by electronic microscope revealed structural damage of podocytes ; the reduced expression level of podocyte marker genes , nephrin and podocin , was also detected by q - PCR .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3393,
    "text": "Moreover , AT2R gene and protein expressions in fetal kidneys were inhibited by PCE , associated with the repression of the gene expression of glial - cell - line - derived neurotrophic factor ( GDNF ) / tyrosine kinase receptor ( c - Ret ) signaling pathway .",
    "labels": [
      [
        "T0",
        "Chemical",
        37,
        38,
        "tyrosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3394,
    "text": "These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring , and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        11,
        "dysplasia of fetal kidneys"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "glomerulosclerosis"
      ],
      [
        "T2",
        "Disease",
        34,
        35,
        "glomerulosclerosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3395,
    "text": "1 , 3 - Butadiene , CML and the t ( 9 : 22 ) translocation : A reality check .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        5,
        "1 , 3 - Butadiene"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "CML"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3396,
    "text": "UNASSIGNED : Epidemiological studies of 1 , 3 - butadiene have suggest that exposures to humans are associated with chronic myeloid leukemia ( CML ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        10,
        "1 , 3 - butadiene"
      ],
      [
        "T1",
        "Disease",
        19,
        22,
        "chronic myeloid leukemia"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "CML"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3397,
    "text": "CML has a well - documented association with ionizing radiation , but reports of associations with chemical exposures have been questioned .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "CML"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3398,
    "text": "Ionizing radiation is capable of inducing the requisite CML - associated t ( 9 : 22 ) translocation ( Philadelphia chromosome ) in appropriate cells in vitro but , thus far , chemicals have not shown this capacity .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "Philadelphia chromosome"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "CML"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3399,
    "text": "We have proposed that 1 , 3 - butadiene metabolites be so tested as a reality check on the epidemiological reports .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        9,
        "1 , 3 - butadiene"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3400,
    "text": "In order to conduct reliable testing in this regard , it is essential that a positive control for induction be available .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3401,
    "text": "We have used ionizing radiation to develop such a control .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3402,
    "text": "Results described here demonstrate that this agent does in fact induce pathogenic t ( 9 : 22 ) translocations in a human myeloid cell line in vitro , but does so at low frequencies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3403,
    "text": "Conditions that will be required for studies of 1 , 3 - butadiene are discussed .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        13,
        "1 , 3 - butadiene"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3404,
    "text": "Cancer incidence and metolachlor use in the Agricultural Health Study : An update .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Cancer"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "metolachlor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3405,
    "text": "UNASSIGNED : Metolachlor , a widely used herbicide , is classified as a Group C carcinogen by the U . S .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Metolachlor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3406,
    "text": "Environmental Protection Agency based on increased liver neoplasms in female rats .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "liver neoplasms"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3407,
    "text": "Epidemiologic studies of the health effects of metolachlor have been limited .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "metolachlor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3408,
    "text": "The Agricultural Health Study ( AHS ) is a prospective cohort study including licensed private and commercial pesticide applicators in Iowa and North Carolina enrolled 1993 - 1997 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3409,
    "text": "We evaluated cancer incidence through 2010 / 2011 ( NC / IA ) for 49 , 616 applicators , 53 % of whom reported ever using metolachlor .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "cancer"
      ],
      [
        "T1",
        "Chemical",
        26,
        27,
        "metolachlor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3410,
    "text": "We used Poisson regression to evaluate relations between two metrics of metolachlor use ( lifetime days , intensity - weighted lifetime days ) and cancer incidence .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "metolachlor"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3411,
    "text": "We saw no association between metolachlor use and incidence of all cancers combined ( n = 5 , 701 with a 5 - year lag ) or most site - specific cancers .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "metolachlor"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "cancers"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "cancers"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3412,
    "text": "For liver cancer , in analyses restricted to exposed workers , elevations observed at higher categories of use were not statistically significant .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "liver cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3413,
    "text": "However , trends for both lifetime and intensity - weighted lifetime days of metolachor use were positive and statistically significant with an unexposed reference group .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "metolachor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3414,
    "text": "A similar pattern was observed for follicular cell lymphoma , but no other lymphoma subtypes .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "follicular cell lymphoma"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "lymphoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3415,
    "text": "An earlier suggestion of increased lung cancer risk at high levels of metolachlor use in this cohort was not confirmed in this update .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "lung cancer"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "metolachlor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3416,
    "text": "This suggestion of an association between metolachlor and liver cancer among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "liver cancer"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "liver neoplasms"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "metolachlor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3417,
    "text": "However , our findings for both liver cancer and follicular cell lymphoma warrant follow - up to better differentiate effects of metolachlor use from other factors .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "liver cancer"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "lymphoma"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "metolachlor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3418,
    "text": "Mechanisms Underlying Latent Disease Risk Associated with Early - Life Arsenic Exposure : Current Research Trends and Scientific Gaps .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "Arsenic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3419,
    "text": "BACKGROUND : Millions of individuals worldwide , particularly those living in rural and developing areas , are exposed to harmful levels of inorganic arsenic ( iAs ) in their drinking water .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        24,
        "inorganic arsenic"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "iAs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3420,
    "text": "Inorganic As exposure during key developmental periods is associated with a variety of adverse health effects including those that are evident in adulthood .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Inorganic As"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3421,
    "text": "There is considerable interest in identifying the molecular mechanisms that relate early - life iAs exposure to the development of these latent diseases , particularly in relationship to cancer .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "iAs"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3422,
    "text": "OBJECTIVES : This work summarizes research on the molecular mechanisms that underlie the increased risk of cancer development in adulthood that is associated with early - life iAs exposure .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "cancer"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "iAs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3423,
    "text": "DISCUSSION : Epigenetic reprogramming that imparts functional changes in gene expression , the development of cancer stem cells , and immunomodulation are plausible underlying mechanisms by which early - life iAs exposure elicits latent carcinogenic effects .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "cancer"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "iAs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3424,
    "text": "CONCLUSIONS : Evidence is mounting that relates early - life iAs exposure and cancer development later in life .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "iAs"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3425,
    "text": "Future research should include animal studies that address mechanistic hypotheses and studies of human populations that integrate early - life exposure , molecular alterations , and latent disease outcomes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3426,
    "text": "Nifedipine induced bradycardia in a patient with autonomic neuropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "autonomic neuropathy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Nifedipine"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3427,
    "text": "An 80 year old diabetic male with evidence of peripheral and autonomic neuropathy was admitted with chest pain .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "peripheral and autonomic neuropathy"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "chest pain"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "diabetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3428,
    "text": "He was found to have atrial flutter at a ventricular rate of 70 / min which slowed down to 30 - 40 / min when nifedipine ( 60 mg ) in 3 divided doses , during which he was paced at a rate of 70 / min .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "atrial flutter"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "nifedipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3429,
    "text": "This is inconsistent with the well - established finding that nifedipine induces tachycardia in normally innervated hearts .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "nifedipine"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "tachycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3430,
    "text": "However , in hearts deprived of compensatory sympathetic drive , it may lead to bradycardia .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3431,
    "text": "The effect of haloperidol in cocaine and amphetamine intoxication .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "haloperidol"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3432,
    "text": "The effectiveness of haloperidol pretreatment in preventing the toxic effects of high doses of amphetamine and cocaine was studied in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "haloperidol"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "amphetamine"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3433,
    "text": "In this model , toxic effects were induced by intraperitoneal ( i . p . ) injection of amphetamine 75 mg / kg ( 100 % death rate ) or cocaine 70 mg / kg ( 82 % death rate ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "amphetamine"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3434,
    "text": "Haloperidol failed to prevent amphetamine - induced seizures , but did lower the mortality rate at most doses tested .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Haloperidol"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "amphetamine"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3435,
    "text": "Haloperidol decreased the incidence of cocaine - induced seizures at the two highest doses , but the lowering of the mortality rate did not reach statistical significance at any dose .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Haloperidol"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "cocaine"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3436,
    "text": "These data suggest a protective role for the central dopamine blocker haloperidol against death from high - dose amphetamine exposure without reducing the incidence of seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "dopamine"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "haloperidol"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "amphetamine"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3437,
    "text": "In contrast , haloperidol demonstrated an ability to reduce cocaine - induced seizures without significantly reducing mortality .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "haloperidol"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cocaine"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3438,
    "text": "Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "renal carcinomas"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "estrogen"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "diethylstilbesterol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3439,
    "text": "Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "renal carcinomas"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Estrogen"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "diethylstilbesterol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3440,
    "text": "Radiolabelling , following the in vivo injection of 3H - 17 beta estradiol , was increased only over the nuclei of tumor cells ; stereologic analysis revealed a 4 . 5 - to 6 . 7 - times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "estradiol"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "tumor"
      ],
      [
        "T2",
        "Chemical",
        42,
        43,
        "silver"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3441,
    "text": "Despite rapid tubular excretion of estradiol which peaked in less than 1 h , the normal cells did not appear to bind the ligand .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "estradiol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3442,
    "text": "This is the first published report documenting the preferential in vivo binding of estrogen to nuclei of cells in estrogen induced hamster renal carcinomas .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "renal carcinomas"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "estrogen"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "estrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3443,
    "text": "Bradycardia due to biperiden .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Bradycardia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "biperiden"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3444,
    "text": "In a 38 - year - old male patient suffering from a severe postzosteric trigeminal neuralgia , intravenous application of 10 mg biperiden lactate led to a long - lasting paradoxical reaction characterized by considerable bradycardia , dysarthria , and dysphagia .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "trigeminal neuralgia"
      ],
      [
        "T1",
        "Chemical",
        22,
        24,
        "biperiden lactate"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "postzosteric"
      ],
      [
        "T3",
        "Disease",
        35,
        36,
        "bradycardia"
      ],
      [
        "T4",
        "Disease",
        37,
        38,
        "dysarthria"
      ],
      [
        "T5",
        "Disease",
        40,
        41,
        "dysphagia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3445,
    "text": "The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "orciprenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3446,
    "text": "Bradycardia induced by biperiden is attributed to the speed of injection and to a dose - related dual effect of atropine - like drugs on muscarine receptors .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Bradycardia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "biperiden"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "atropine"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "muscarine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3447,
    "text": "Deliberate hypotension induced by labetalol with halothane , enflurane or isoflurane for middle - ear surgery .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "labetalol"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "halothane"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "enflurane"
      ],
      [
        "T4",
        "Chemical",
        10,
        11,
        "isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3448,
    "text": "The feasibility of using labetalol , an alpha - and beta - adrenergic blocking agent , as a hypotensive agent in combination with inhalation anaesthetics ( halothane , enflurane or isoflurane ) was studied in 23 adult patients undergoing middle - ear surgery .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "labetalol"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "hypotensive"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "halothane"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "enflurane"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3449,
    "text": "The mean arterial pressure was decreased from 86 + / - 5 ( s . e . mean ) mmHg to 52 + / - 1 mmHg ( 11 . 5 + / - 0 . 7 to 6 . 9 + / - 0 . 1 kPa ) for 98 + / - 10 min in the halothane ( H ) group , from 79 + / - 5 to 53 + / - 1 mmHg ( 10 . 5 + / - 0 . 7 to 7 . 1 + / - 0 . 1 kPa ) for 129 + / - 11 min in the enflurane ( E ) group , and from 80 + / - 4 to 49 + / - 1 mmHg ( 10 . 7 + / - 0 . 5 to 6 . 5 + / - 0 . 1 kPa ) for 135 + / - 15 min in the isoflurane ( I ) group .",
    "labels": [
      [
        "T0",
        "Chemical",
        58,
        59,
        "halothane"
      ],
      [
        "T1",
        "Chemical",
        60,
        61,
        "H"
      ],
      [
        "T2",
        "Chemical",
        108,
        109,
        "enflurane"
      ],
      [
        "T3",
        "Chemical",
        110,
        111,
        "E"
      ],
      [
        "T4",
        "Chemical",
        159,
        160,
        "isoflurane"
      ],
      [
        "T5",
        "Chemical",
        161,
        162,
        "I"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3450,
    "text": "The mean H concentration during hypotension in the inspiratory gas was 0 . 7 + / - 0 . 1 vol % , the mean E concentration 1 . 6 + / - 0 . 2 vol % , and the mean I concentration 1 . 0 + / - 0 . 1 vol % .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "H"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "E"
      ],
      [
        "T3",
        "Chemical",
        42,
        43,
        "I"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3451,
    "text": "In addition , the patients received fentanyl and d - tubocurarine .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "d - tubocurarine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3452,
    "text": "The initial dose of labetalol for lowering blood pressure was similar , 0 . 52 - 0 . 59 mg / kg , in all the groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "labetalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3453,
    "text": "During hypotension , the heart rate was stable without tachy - or bradycardia .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "tachy - or bradycardia"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3454,
    "text": "The operating conditions regarding bleeding were estimated in a double - blind manner , and did not differ significantly between the groups .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3455,
    "text": "During hypotension , the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups , except the isoflurane group .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "creatinine"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "hypotension"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "isoflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3456,
    "text": "After hypotension there was no rebound phenomenon in either blood pressure or heart rate .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3457,
    "text": "These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "labetalol"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hypotension"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "tachycardia"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3458,
    "text": "Convulsion following intravenous fluorescein angiography .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Convulsion"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "fluorescein"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3459,
    "text": "Tonic - clonic seizures followed intravenous fluorescein injection for fundus angiography in a 47 - year - old male .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Tonic - clonic seizures"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "fluorescein"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3460,
    "text": "Despite precautions this adverse reaction recurred on re - exposure to intravenous fluorescein .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "fluorescein"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3461,
    "text": "Pharmacology of ACC - 9653 ( phenytoin prodrug ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "phenytoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3462,
    "text": "ACC - 9653 , the disodium phosphate ester of 3 - hydroxymethyl - 5 , 5 - diphenylhydantoin , is a prodrug of phenytoin with advantageous physicochemical properties .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        5,
        8,
        "disodium phosphate ester"
      ],
      [
        "T2",
        "Chemical",
        9,
        18,
        "3 - hydroxymethyl - 5 , 5 - diphenylhydantoin"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "phenytoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3463,
    "text": "ACC - 9653 is rapidly converted enzymatically to phenytoin in vivo .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "phenytoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3464,
    "text": "ACC - 9653 and phenytoin sodium have equivalent anticonvulsant activity against seizures induced by maximal electroshock ( MES ) in mice following i . p . , oral , or i . v . administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        4,
        6,
        "phenytoin sodium"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3465,
    "text": "The ED50 doses were 16 mg / kg for i . v . ACC - 9653 and 8 mg / kg for i . v . phenytoin sodium .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        16,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        26,
        28,
        "phenytoin sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3466,
    "text": "ACC - 9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain - induced ventricular tachycardia in anesthetized dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        4,
        6,
        "phenytoin sodium"
      ],
      [
        "T2",
        "Disease",
        14,
        16,
        "ventricular tachycardia"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "ouabain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3467,
    "text": "The total doses of ACC - 9653 or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 + / - 6 and 14 + / - 3 mg / kg , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        8,
        10,
        "phenytoin sodium"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3468,
    "text": "Only phenytoin sodium displayed in vitro antiarrhythmic activity against strophanthidin - induced arrhythmias in guinea pig right atria .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "phenytoin sodium"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "strophanthidin"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "arrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3469,
    "text": "In anesthetized dogs , a high dose of ACC - 9653 ( 31 mg / kg ) was infused over 15 , 20 , and 30 min and the responses were compared to an equimolar dose of phenytoin sodium ( 21 mg / kg ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        37,
        39,
        "phenytoin sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3470,
    "text": "The ACC - 9653 and phenytoin sodium treatments produced similar marked reductions in diastolic blood pressure and contractile force ( LVdP / dt ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        4,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        5,
        7,
        "phenytoin sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3471,
    "text": "The maximum effects of each treatment occurred at the time of maximum phenytoin sodium levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "phenytoin sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3472,
    "text": "Acute toxicity studies of ACC - 9653 and phenytoin sodium were carried out in mice , rats , rabbits , and dogs by i . v . , i . m . , and i . p . routes of administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        8,
        10,
        "phenytoin sodium"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3473,
    "text": "The systemic toxic signs of both agents were similar and occurred at approximately equivalent doses .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3474,
    "text": "Importantly , the local irritation of ACC - 9653 was markedly less than phenytoin sodium following i . m . administration . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "ACC - 9653"
      ],
      [
        "T1",
        "Chemical",
        13,
        15,
        "phenytoin sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3475,
    "text": "Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "salbutamol"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "asthmatics"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3476,
    "text": "High doses of inhaled salbutamol produce substantial improvements in airway response in patients with asthma , and are associated with dose - dependent systemic beta - adrenoceptor responses .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "salbutamol"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "asthma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3477,
    "text": "The purpose of the present study was to investigate whether tachyphylaxis occurs during prolonged treatment with high dose inhaled salbutamol .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "salbutamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3478,
    "text": "Twelve asthmatic patients ( FEV1 , 81 + / - 4 % predicted ) , requiring only occasional inhaled beta - agonists as their sole therapy , were given a 14 - day treatment with high dose inhaled salbutamol ( HDS ) , 4 , 000 micrograms daily , low dose inhaled salbutamol ( LDS ) , 800 micrograms daily , or placebo ( PI ) by metered - dose inhaler in a double - blind , randomized crossover design .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "asthmatic"
      ],
      [
        "T1",
        "Chemical",
        38,
        39,
        "salbutamol"
      ],
      [
        "T2",
        "Chemical",
        52,
        53,
        "salbutamol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3479,
    "text": "During the 14 - day run - in and during washout periods , inhaled beta - agonists were withheld and ipratropium bromide was substituted for rescue purposes .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        22,
        "ipratropium bromide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3480,
    "text": "At the end of each 14 - day treatment , a dose - response curve ( DRC ) was performed , and airway ( FEV1 , FEF25 - 75 ) chronotropic ( HR ) , tremor , and metabolic ( K , Glu ) responses were measured at each step ( from 100 to 4 , 000 micrograms ) .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        36,
        "tremor"
      ],
      [
        "T1",
        "Chemical",
        40,
        41,
        "K"
      ],
      [
        "T2",
        "Chemical",
        42,
        43,
        "Glu"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3481,
    "text": "Treatment had no significant effect on baseline values .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3482,
    "text": "There were dose - dependent increases in FEV1 and FEF25 - 75 ( p less than 0 . 001 ) , and pretreatment with HDS did not displace the DRC to the right .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3483,
    "text": "DRC for HR ( p less than 0 . 001 ) , K ( p less than 0 . 001 ) , and Glu ( p less than 0 . 005 ) were attenuated after treatment with HDS compared with PI .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "K"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "Glu"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3484,
    "text": "There were also differences between HDS and LDS for HR ( p less than 0 . 001 ) and Glu ( p less than 0 . 05 ) responses .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "Glu"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3485,
    "text": "Frequency and severity of subjective adverse effects were also reduced after HDS : tremor ( p less than 0 . 001 ) , palpitations ( p less than 0 . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "tremor"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "palpitations"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3486,
    "text": "Phenytoin induced fatal hepatic injury .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hepatic injury"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Phenytoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3487,
    "text": "A 61 year old female developed fatal hepatic failure after phenytoin administration .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "hepatic failure"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "phenytoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3488,
    "text": "A typical multisystem clinical pattern precedes the manifestations of hepatic injury .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "hepatic injury"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3489,
    "text": "The hematologic , biochemical and pathologic features indicate a mixed hepatocellular damage due to drug hypersensitivity .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "hepatocellular damage"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "drug hypersensitivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3490,
    "text": "In a patient receiving phenytoin who presents a viral - like illness , early recognition and discontinuation of the drug are mandatory .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "phenytoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3491,
    "text": "Treatment of lethal pertussis vaccine reaction with histamine H1 antagonists .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "pertussis vaccine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "histamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3492,
    "text": "We studied mortality after pertussis immunization in the mouse .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "pertussis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3493,
    "text": "Without treatment , 73 of 92 animals ( 80 % ) died after injection of bovine serum albumin ( BSA ) on day + 7 of pertussis immunization .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        27,
        "pertussis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3494,
    "text": "After pretreatment with 3 mg of cyproheptadine , 2 mg mianserin , or 2 mg chlorpheniramine , only 5 of 105 animals ( 5 % ) died after receiving BSA on day + 7 ( p less than 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "cyproheptadine"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "mianserin"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "chlorpheniramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3495,
    "text": "Blockade of histamine H1 receptors may reduce mortality in pertussis immunization - induced encephalopathy in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "histamine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "pertussis"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3496,
    "text": "Support for adrenaline - hypertension hypothesis : 18 hour pressor effect after 6 hours adrenaline infusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "adrenaline"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hypertension"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "adrenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3497,
    "text": "In a double blind , crossover study 6 h infusions of adrenaline ( 15 ng / kg / min ; 1 ng = 5 . 458 pmol ) , noradrenaline ( 30 ng / kg / min ; 1 ng = 5 . 911 pmol ) , and a 5 % dextrose solution ( 5 . 4 ml / h ) , were given to ten healthy volunteers in random order 2 weeks apart .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "adrenaline"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "noradrenaline"
      ],
      [
        "T2",
        "Chemical",
        51,
        52,
        "dextrose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3498,
    "text": "By means of intra - arterial ambulatory monitoring the haemodynamic effects were followed for 18 h after the infusions were stopped .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3499,
    "text": "Adrenaline , but not noradrenaline , caused a delayed and protracted pressor effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Adrenaline"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "noradrenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3500,
    "text": "Over the total postinfusion period systolic and diastolic arterial pressure were 6 ( SEM 2 ) % and 7 ( 2 ) % , respectively , higher than after dextrose infusion ( ANOVA , p less than 0 . 001 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        29,
        30,
        "dextrose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3501,
    "text": "Thus , \" stress \" levels of adrenaline ( 230 pg / ml ) for 6 h cause a delayed and protracted pressor effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "adrenaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3502,
    "text": "These findings are strong support for the adrenaline - hypertension hypothesis in man .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "adrenaline"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3503,
    "text": "Effect of alkylxanthines on gentamicin - induced acute renal failure in the rat .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "alkylxanthines"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3504,
    "text": "Adenosine antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure ( ARF ) .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Adenosine"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "ischaemic"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "nephrotoxic"
      ],
      [
        "T4",
        "Disease",
        21,
        22,
        "ARF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3505,
    "text": "In the present study , the effects of three alkylxanthines with different potencies as adenosine antagonists 8 - phenyltheophylline , theophylline and enprofylline , were examined in rats developing acute renal failure after 4 daily injections of gentamicin ( 200 mg kg - 1 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "8 - phenyltheophylline"
      ],
      [
        "T1",
        "Disease",
        29,
        32,
        "acute renal failure"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "alkylxanthines"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "adenosine"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "theophylline"
      ],
      [
        "T5",
        "Chemical",
        22,
        23,
        "enprofylline"
      ],
      [
        "T6",
        "Chemical",
        37,
        38,
        "gentamicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3506,
    "text": "Renal function was assessed by biochemical ( plasma urea and creatinine ) , functional ( urine analysis and [ 3H ] inulin and [ 14C ] p - aminohippuric acid clearances ) and morphological ( degree of necrosis ) indices .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        30,
        "p - aminohippuric acid"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "urea"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "creatinine"
      ],
      [
        "T3",
        "Disease",
        37,
        38,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3507,
    "text": "The various drug treatments produced improvements in some , but not all , measurements of renal function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3508,
    "text": "However , any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle ( polyethylene glycol and NaOH ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        23,
        "polyethylene glycol"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "NaOH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3509,
    "text": "The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little , if any , pathophysiological role in gentamicin - induced ARF .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "alkylxanthines"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "adenosine"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "gentamicin"
      ],
      [
        "T3",
        "Disease",
        31,
        32,
        "ARF"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3510,
    "text": "Adverse ocular reactions possibly associated with isotretinoin .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "isotretinoin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3511,
    "text": "A total of 261 adverse ocular reactions occurred in 237 patients who received isotretinoin , a commonly used drug in the treatment of severe cystic acne .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "isotretinoin"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "acne"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3512,
    "text": "Blepharoconjunctivitis , subjective complaints of dry eyes , blurred vision , contact lens intolerance , and photodermatitis are reversible side effects .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "dry eyes"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "blurred vision"
      ],
      [
        "T2",
        "Disease",
        0,
        1,
        "Blepharoconjunctivitis"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "photodermatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3513,
    "text": "More serious ocular adverse reactions include papilledema , pseudotumor cerebri , and white or gray subepithelial corneal opacities ; all of these are reversible if the drug is discontinued .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "pseudotumor cerebri"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "corneal opacities"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "papilledema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3514,
    "text": "Reported cases of decreased dark adaptation are under investigation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3515,
    "text": "Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use ( including microphthalmos , orbital hypertelorism , and optic nerve hypoplasia ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "congenital abnormalities"
      ],
      [
        "T1",
        "Disease",
        23,
        26,
        "optic nerve hypoplasia"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Isotretinoin"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "microphthalmos"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "hypertelorism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3516,
    "text": "Procaterol and terbutaline in bronchial asthma .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "bronchial asthma"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Procaterol"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "terbutaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3517,
    "text": "A double - blind , placebo - controlled , cross - over study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3518,
    "text": "Procaterol , a new beta - 2 adrenoceptor stimulant , was studied in a double - blind , placebo - controlled , cross - over trial in patients with bronchial asthma .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        31,
        "bronchial asthma"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Procaterol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3519,
    "text": "Oral procaterol 50 micrograms b . d . , procaterol 100 micrograms b . d . , and terbutaline 5 mg t . i . d . , were compared when given randomly in 1 - week treatment periods .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "procaterol"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "procaterol"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "terbutaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3520,
    "text": "The best clinical effect was found with terbutaline .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "terbutaline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3521,
    "text": "Both anti - asthmatic and tremorgenic effects of procaterol were dose - related .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "asthmatic"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "tremorgenic"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "procaterol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3522,
    "text": "Procaterol appeared effective in the doses tested , and a twice daily regimen would appear to be suitable with this drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Procaterol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3523,
    "text": "Subacute effects of propranolol and B 24 / 76 on isoproterenol - induced rat heart hypertrophy in correlation with blood pressure .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "heart hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3524,
    "text": "We compared the potential beta - receptor blocker , B 24 / 76 i . e . 1 - ( 2 , 4 - dichlorophenoxy ) - 3 [ 2 - 3 , 4 - dimethoxyphenyl ) ethanolamino ] - prop an - 2 - ol , which is characterized by beta 1 - adrenoceptor blocking and beta 2 - adrenoceptor stimulating properties with propranolol .",
    "labels": [
      [
        "T0",
        "Chemical",
        64,
        65,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3525,
    "text": "The studies were performed using an experimental model of isoproterenol - induced heart hypertrophy in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "heart hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3526,
    "text": "A correlation of the blood pressure was neither found in the development nor in the attempt to suppress the development of heart hypertrophy with the two beta - receptor blockers .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "heart hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3527,
    "text": "Both beta - blockers influenced the development of hypertrophy to a different , but not reproducible extent .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3528,
    "text": "It was possible to suppress the increased ornithine decarboxylase activity with both beta - blockers in hypertrophied hearts , but there was no effect on the heart mass .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "hypertrophied hearts"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "ornithine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3529,
    "text": "Neither propranolol nor B 24 / 76 could stop the changes in the characteristic myosin isoenzyme pattern of the hypertrophied rat heart .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "propranolol"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "hypertrophied"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3530,
    "text": "Thus , the investigations did not provide any evidence that the beta - receptor blockers propranolol and B 24 / 76 have the potency to prevent isoproterenol from producing heart hypertrophy .",
    "labels": [
      [
        "T0",
        "Disease",
        29,
        31,
        "heart hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3531,
    "text": "Increased anxiogenic effects of caffeine in panic disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "panic disorders"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3532,
    "text": "The effects of oral administration of caffeine ( 10 mg / kg ) on behavioral ratings , somatic symptoms , blood pressure and plasma levels of 3 - methoxy - 4 - hydroxyphenethyleneglycol ( MHPG ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM - III criteria for agoraphobia with panic attacks or panic disorder .",
    "labels": [
      [
        "T0",
        "Chemical",
        26,
        33,
        "3 - methoxy - 4 - hydroxyphenethyleneglycol"
      ],
      [
        "T1",
        "Disease",
        55,
        57,
        "panic attacks"
      ],
      [
        "T2",
        "Disease",
        58,
        60,
        "panic disorder"
      ],
      [
        "T3",
        "Chemical",
        6,
        7,
        "caffeine"
      ],
      [
        "T4",
        "Chemical",
        34,
        35,
        "MHPG"
      ],
      [
        "T5",
        "Chemical",
        37,
        38,
        "cortisol"
      ],
      [
        "T6",
        "Disease",
        53,
        54,
        "agoraphobia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3533,
    "text": "Caffeine produced significantly greater increases in subject - rated anxiety , nervousness , fear , nausea , palpitations , restlessness , and tremors in the patients compared with healthy subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Caffeine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "anxiety"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "nausea"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "palpitations"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "restlessness"
      ],
      [
        "T5",
        "Disease",
        22,
        23,
        "tremors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3534,
    "text": "In the patients , but not the healthy subjects , these symptoms were significantly correlated with plasma caffeine levels .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3535,
    "text": "Seventy - one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "panic attacks"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3536,
    "text": "Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Caffeine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "MHPG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3537,
    "text": "Caffeine increased plasma cortisol levels equally in the patient and healthy groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Caffeine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "cortisol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3538,
    "text": "Because caffeine is an adenosine receptor antagonist , these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "panic disorder"
      ],
      [
        "T1",
        "Disease",
        18,
        22,
        "abnormalities in neuronal systems"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "caffeine"
      ],
      [
        "T3",
        "Chemical",
        4,
        5,
        "adenosine"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "adenosine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3539,
    "text": "Patients with anxiety disorders may benefit by avoiding caffeine - containing foods and beverages .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "anxiety disorders"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3540,
    "text": "Comparison of the effect of oxitropium bromide and of slow - release theophylline on nocturnal asthma .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "oxitropium bromide"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "theophylline"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "asthma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3541,
    "text": "The effects of a new inhaled antimuscarinic drug , oxitropium bromide , and of a slow - release theophylline preparation upon nocturnal asthma were compared in a placebo - controlled double - blind study .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "oxitropium bromide"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "theophylline"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "asthma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3542,
    "text": "Two samples were studied : 12 patients received oxitropium at 600 micrograms ( 6 subjects ) or at 400 micrograms t . i . d .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "oxitropium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3543,
    "text": "( 6 subjects ) whereas 11 received theophylline at 300 mg b . i . d .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "theophylline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3544,
    "text": "Morning dipping , assessed by the fall in peak flow overnight , was significantly reduced in the periods when either active drug was taken , whereas no difference was noticed during the placebo administration .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3545,
    "text": "No significant difference was noticed between results obtained with either active drug , as well as with either dosage of oxitropium .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "oxitropium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3546,
    "text": "No subject reported side effects of oxitropium , as compared to three subjects reporting nausea , vomiting and tremors after theophylline .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "oxitropium"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "nausea"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "vomiting"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "tremors"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "theophylline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3547,
    "text": "Oxitropium proves to be a valuable alternative to theophylline in nocturnal asthma , since it is equally potent , safer and does not require the titration of dosage .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Oxitropium"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "theophylline"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "asthma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3548,
    "text": "Penicillin anaphylaxis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Penicillin"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "anaphylaxis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3549,
    "text": "A case of oral penicillin anaphylaxis is described , and the terminology , occurrence , clinical manifestations , pathogenesis , prevention , and treatment of anaphylaxis are reviewed .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "penicillin"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "anaphylaxis"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "anaphylaxis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3550,
    "text": "Emergency physicians should be aware of oral penicillin anaphylaxis in order to prevent its occurrence by prescribing the antibiotic judiciously and knowledgeably and to offer optimal medical therapy once this life - threatening reaction has begun .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "penicillin"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "anaphylaxis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3551,
    "text": "Reversible valproic acid - induced dementia : a case report .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "valproic acid"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "dementia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3552,
    "text": "Reversible valproic acid - induced dementia was documented in a 21 - year - old man with epilepsy who had a 3 - year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        3,
        "valproic acid"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "dementia"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3553,
    "text": "Repeat neuropsychological testing 7 weeks after discontinuation of the drug revealed dramatic improvement in IQ , memory , naming , and other tasks commensurate with clinical recovery in his intellectual capacity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3554,
    "text": "Possible pathophysiological mechanisms which may have been operative in this case include : a direct central nervous system ( CNS ) toxic effect of valproic acid ; a paradoxical epileptogenic effect secondary to the drug ; and an indirect CNS toxic effect mediated through valproic acid - induced hyperammonemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        26,
        "valproic acid"
      ],
      [
        "T1",
        "Chemical",
        44,
        46,
        "valproic acid"
      ],
      [
        "T2",
        "Disease",
        48,
        49,
        "hyperammonemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3555,
    "text": "Reversal of scopolamine - induced amnesia of passive avoidance by pre - and post - training naloxone .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "scopolamine"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "amnesia"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "naloxone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3556,
    "text": "In a series of five experiments , the modulating role of naloxone on a scopolamine - induced retention deficit in a passive avoidance paradigm was investigated in mice .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        19,
        "retention deficit"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "naloxone"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3557,
    "text": "Scopolamine , but not methyl scopolamine ( 1 and 3 mg / kg ) , induced an amnesia as measured by latency and duration parameters .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "methyl scopolamine"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Scopolamine"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3558,
    "text": "Naloxone ( 0 . 3 , 1 , 3 , and 10 mg / kg ) injected prior to training attenuated the retention deficit with a peak of activity at 3 mg / kg .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "retention deficit"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Naloxone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3559,
    "text": "The effect of naloxone could be antagonized with morphine ( 1 , 3 , and 10 mg / kg ) , demonstrating the opioid specificity of the naloxone effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "naloxone"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "morphine"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "naloxone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3560,
    "text": "Post - training administration of naloxone ( 3 mg / kg ) as a single or as a split dose also attenuated the scopolamine - induced amnesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "naloxone"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "scopolamine"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3561,
    "text": "Control experiments indicated that neither an increase in pain sensitivity ( pre - training naloxone ) nor an induced aversive state ( post - training naloxone ) appear to be responsible for the influence of naloxone on the scopolamine - induced retention deficit .",
    "labels": [
      [
        "T0",
        "Disease",
        41,
        43,
        "retention deficit"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "pain"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "naloxone"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "naloxone"
      ],
      [
        "T4",
        "Chemical",
        35,
        36,
        "naloxone"
      ],
      [
        "T5",
        "Chemical",
        38,
        39,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3562,
    "text": "These results extend previous findings implicating a cholinergic - opioid interaction in memory processes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3563,
    "text": "A possible mechanism for this interaction involving the septo - hippocampal cholinergic pathway is discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3564,
    "text": "Electron microscopic investigations of the cyclophosphamide - induced lesions of the urinary bladder of the rat and their prevention by mesna .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        13,
        "lesions of the urinary bladder"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "cyclophosphamide"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3565,
    "text": "Fully developed cyclophosphamide - induced cystitis is characterized by nearly complete detachment of the urothelium , severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "cyclophosphamide"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "cystitis"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "edema"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "necroses"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3566,
    "text": "The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the luminal membrane .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "cyclophosphamide"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "luminal"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3567,
    "text": "This damages the cellular barrier against the hypertonic urine .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3568,
    "text": "Subsequent breaks in the lateral cell membranes of the superficial cells and in all the plasma membranes of the intermediate and basal cells , intercellular and intracellular edema and disintegration of the desmosomes and hemidesmosomes lead to progressive degeneration and detachment of the epithelial cells with exposure and splitting of the basal membrane .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        28,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3569,
    "text": "The morphological changes of the endothelial cells , which become more pronounced in the later stages of the experiment , the involvement of blood vessels regardless of their diameter and the location - dependent extent of the damage indicate a direct type of damage which is preceded by a mediator - induced increase in permeability , the morphological correlate of which is the formation of gaps in the interendothelial cell connections on the venules .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3570,
    "text": "These changes can be effectively prevented by mesna .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "mesna"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3571,
    "text": "The only sign of a possible involvement is the increase in the number of specific granules with a presumed lysosomal function in the superficial cells .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3572,
    "text": "Increase in intragastric pressure during suxamethonium - induced muscle fasciculations in children : inhibition by alfentanil .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "muscle fasciculations"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "suxamethonium"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "alfentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3573,
    "text": "Changes in intragastric pressure after the administration of suxamethonium 1 . 5 mg kg - 1 i . v . were studied in 32 children ( mean age 6 . 9 yr ) pretreated with either physiological saline or alfentanil 50 micrograms kg - 1 .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "suxamethonium"
      ],
      [
        "T1",
        "Chemical",
        39,
        40,
        "alfentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3574,
    "text": "Anaesthesia was induced with thiopentone 5 mg kg - 1 .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "thiopentone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3575,
    "text": "The incidence and intensity of muscle fasciculations caused by suxamethonium were significantly greater in the control than in the alfentanil group .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "muscle fasciculations"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "suxamethonium"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "alfentanil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3576,
    "text": "The intragastric pressure during muscle fasciculations was significantly higher in the control group ( 16 + / - 0 . 7 ( SEM ) cm H2O ) than in the alfentanil group ( 7 . 7 + / - 1 . 5 ( SEM ) cm H2O ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "muscle fasciculations"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "H2O"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "alfentanil"
      ],
      [
        "T3",
        "Chemical",
        46,
        47,
        "H2O"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3577,
    "text": "The increase in intragastric pressure was directly related to the intensity of muscle fasciculations ( regression line : y = 0 . 5 + 4 . 78x with r of 0 . 78 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "muscle fasciculations"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3578,
    "text": "It is concluded that intragastric pressure increases significantly during muscle fasciculations caused by suxamethonium in healthy children .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "muscle fasciculations"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "suxamethonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3579,
    "text": "Alfentanil 50 micrograms kg - 1 effectively inhibits the incidence and intensity of suxamethonium - induced muscle fasciculations ; moreover , intragastric pressure remains at its control value .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "muscle fasciculations"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Alfentanil"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "suxamethonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3580,
    "text": "Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "cardiotoxic"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "isoproterenol"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "streptozotocin"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "diabetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3581,
    "text": "A morphometric study of isoproterenol induced myocardial fibrosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "isoproterenol"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3582,
    "text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol ( ISO ) was investigated in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "streptozotocin"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "diabetes"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "cardiotoxic"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "isoproterenol"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "ISO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3583,
    "text": "Thirty to 135 min after the injection of crystalline insulin , ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later , a highly significant correlation ( r = 0 . 83 , 2 p = 0 . 006 ) to the slope of the fall in blood glucose after insulin treatment appeared .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "ISO"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "ISO"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "fibrosis"
      ],
      [
        "T3",
        "Chemical",
        56,
        57,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3584,
    "text": "The myocardial content of catecholamines was estimated in these 8 day diabetic rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "catecholamines"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "diabetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3585,
    "text": "The norepinephrine content was significantly increased while epinephrine remained unchanged .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "norepinephrine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3586,
    "text": "An enhanced sympathetic nervous system activity with a consequent down regulation of the myocardial beta - adrenergic receptors could , therefore , explain this catecholamine resistance .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "catecholamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3587,
    "text": "The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in diabetic rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "streptozotocin"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "ISO"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "catecholamine"
      ],
      [
        "T3",
        "Disease",
        29,
        30,
        "diabetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3588,
    "text": "The phenomenon described might elucidate pathogenetic mechanisms behind toxic myocardial cell degeneration and may possibly have relevance for acute cardiovascular complications in diabetic patients .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        23,
        "diabetic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3589,
    "text": "Differential effects of non - steroidal anti - inflammatory drugs on seizures produced by pilocarpine in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "seizures"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3590,
    "text": "The muscarinic cholinergic agonist pilocarpine induces in rats seizures and status epilepticus followed by widespread damage to the forebrain .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "status epilepticus"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "pilocarpine"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3591,
    "text": "The present study was designed to investigate the effect of 5 non - steroidal anti - inflammatory drugs , sodium salicylate , phenylbutazone , indomethacin , ibuprofen and mefenamic acid , on seizures produced by pilocarpine .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        21,
        "sodium salicylate"
      ],
      [
        "T1",
        "Chemical",
        28,
        30,
        "mefenamic acid"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "phenylbutazone"
      ],
      [
        "T3",
        "Chemical",
        24,
        25,
        "indomethacin"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "ibuprofen"
      ],
      [
        "T5",
        "Disease",
        32,
        33,
        "seizures"
      ],
      [
        "T6",
        "Chemical",
        35,
        36,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3592,
    "text": "Pretreatment of rats with sodium salicylate , ED50 103 mg / kg ( 60 - 174 ) , and phenylbutazone , 59 mg / kg ( 50 - 70 ) converted the non - convulsant dose of pilocarpine , 200 mg / kg , to a convulsant one .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "sodium salicylate"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "phenylbutazone"
      ],
      [
        "T2",
        "Chemical",
        37,
        38,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3593,
    "text": "Indomethacin , 1 - 10 mg / kg , and ibuprofen , 10 - 100 mg / kg , failed to modulate seizures produced by pilocarpine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Indomethacin"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "ibuprofen"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "seizures"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3594,
    "text": "Mefenamic acid , 26 ( 22 - 30 ) mg / kg , prevented seizures and protected rats from seizure - related brain damage induced by pilocarpine , 380 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Mefenamic acid"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "brain damage"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "seizures"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "seizure"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3595,
    "text": "These results indicate that non - steroidal anti - inflammatory drugs differentially modulate the threshold for pilocarpine - induced seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "pilocarpine"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3596,
    "text": "Acute neurologic dysfunction after high - dose etoposide therapy for malignant glioma .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Acute neurologic dysfunction"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "malignant glioma"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "etoposide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3597,
    "text": "Etoposide ( VP - 16 - 213 ) has been used in the treatment of many solid tumors and hematologic malignancies .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        7,
        "VP - 16 - 213"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "hematologic malignancies"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Etoposide"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "tumors"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3598,
    "text": "When used in high doses and in conjunction with autologous bone marrow transplantation , this agent has activity against several treatment - resistant cancers including malignant glioma .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "malignant glioma"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "cancers"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3599,
    "text": "In six of eight patients ( 75 % ) who we treated for recurrent or resistant glioma , sudden severe neurologic deterioration occurred .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "neurologic deterioration"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "glioma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3600,
    "text": "This developed a median of 9 days after initiation of high - dose etoposide therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "etoposide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3601,
    "text": "Significant clinical manifestations have included confusion , papilledema , somnolence , exacerbation of motor deficits , and sharp increase in seizure activity .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "motor deficits"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "confusion"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "papilledema"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "somnolence"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3602,
    "text": "These abnormalities resolved rapidly after initiation of high - dose intravenous dexamethasone therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "dexamethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3603,
    "text": "In all patients , computerized tomographic ( CT ) brain scans demonstrated stability in tumor size and peritumor edema when compared with pretransplant scans .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "tumor"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3604,
    "text": "This complication appears to represent a significant new toxicity of high - dose etoposide therapy for malignant glioma .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "malignant glioma"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "toxicity"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "etoposide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3605,
    "text": "Progressive bile duct injury after thiabendazole administration .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        4,
        "bile duct injury"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "thiabendazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3606,
    "text": "A 27 - yr - old man developed jaundice 2 wk after exposure to thiabendazole .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "jaundice"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "thiabendazole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3607,
    "text": "Cholestasis persisted for 3 yr , at which time a liver transplant was performed .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Cholestasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3608,
    "text": "Two liver biopsy specimens and the hepatectomy specimen were remarkable for almost complete disappearance of interlobular bile ducts .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3609,
    "text": "Prominent fibrosis and hepatocellular regeneration were also present ; however , the lobular architecture was preserved .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3610,
    "text": "This case represents an example of \" idiosyncratic \" drug - induced liver damage in which the primary target of injury is the bile duct .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        14,
        "drug - induced liver damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3611,
    "text": "An autoimmune pathogenesis of the bile duct destruction is suggested .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "bile duct destruction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3612,
    "text": "Differential effects of 1 , 4 - dihydropyridine calcium channel blockers : therapeutic implications .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        8,
        "1 , 4 - dihydropyridine"
      ],
      [
        "T1",
        "Chemical",
        8,
        11,
        "calcium channel blockers"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3613,
    "text": "Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "cardiovascular disease"
      ],
      [
        "T1",
        "Chemical",
        20,
        24,
        "calcium channel blocking agents"
      ],
      [
        "T2",
        "Disease",
        30,
        32,
        "cardiovascular diseases"
      ],
      [
        "T3",
        "Chemical",
        6,
        7,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3614,
    "text": "The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3615,
    "text": "Clinical applications of calcium channel blockers parallel their tissue selectivity .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "calcium channel blockers"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3616,
    "text": "In contrast to verapamil and diltiazem , which are roughly equipotent in their actions on the heart and vascular smooth muscle , the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        27,
        "calcium channel blockers"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "verapamil"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "diltiazem"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "dihydropyridine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3617,
    "text": "As the first dihydropyridine available for use in the United States , nifedipine controls angina and hypertension with minimal depression of cardiac function .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "dihydropyridine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "nifedipine"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "angina"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3618,
    "text": "Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "calcium channel blockers"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3619,
    "text": "Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule , which encourages patient compliance in long - term therapy of hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "nitrendipine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "nisoldipine"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3620,
    "text": "The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "nisoldipine"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "angina"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3621,
    "text": "Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage , migraine headache , dementia , and stroke .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "subarachnoid hemorrhage"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "migraine headache"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "nimodipine"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "dementia"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3622,
    "text": "In general , the dihydropyridine calcium channel blockers are usually well tolerated , with headache , facial flushing , palpitations , edema , nausea , anorexia , and dizziness being the more common adverse effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "calcium channel blockers"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "dihydropyridine"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "headache"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "flushing"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "palpitations"
      ],
      [
        "T5",
        "Disease",
        21,
        22,
        "edema"
      ],
      [
        "T6",
        "Disease",
        23,
        24,
        "nausea"
      ],
      [
        "T7",
        "Disease",
        25,
        26,
        "anorexia"
      ],
      [
        "T8",
        "Disease",
        28,
        29,
        "dizziness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3623,
    "text": "The enhancement of aminonucleoside nephrosis by the co - administration of protamine .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "nephrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3624,
    "text": "An experimental model of focal segmental glomerular sclerosis ( FSGS ) was developed in rats by the combined administration of puromycin - aminonucleoside ( AMNS ) and protamine sulfate ( PS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        8,
        "focal segmental glomerular sclerosis"
      ],
      [
        "T1",
        "Chemical",
        20,
        23,
        "puromycin - aminonucleoside"
      ],
      [
        "T2",
        "Chemical",
        27,
        29,
        "protamine sulfate"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "FSGS"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "AMNS"
      ],
      [
        "T5",
        "Chemical",
        30,
        31,
        "PS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3625,
    "text": "Male Sprague - Dawley rats , uninephrectomized three weeks before , received daily injections of subcutaneous AMNS ( 1 mg / 100 g body wt ) and intravenous PS ( 2 separated doses of 2 . 5 mg / 100 g body wt ) for four days .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "AMNS"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "PS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3626,
    "text": "The series of injections were repeated another three times at 10 day intervals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3627,
    "text": "The animals were sacrificed on days 24 , 52 , and 80 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3628,
    "text": "They developed nephrotic syndrome and finally renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "nephrotic syndrome"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "renal failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3629,
    "text": "The time - course curve of creatinine clearance dropped and showed significant difference ( P less than 0 . 01 ) from that of each control group , such as , AMNS alone , PS alone or saline injected .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "creatinine"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "AMNS"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "PS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3630,
    "text": "Their glomeruli showed changes of progressive FSGS .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "FSGS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3631,
    "text": "The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ruthenium red on the lamina rara externa and marked changes in epithelial cell cytoplasm .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "ruthenium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3632,
    "text": "Therefore , it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end - stage renal disease .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        33,
        "end - stage renal disease"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "PS"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "toxicity"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "AMNS"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "FSGS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3633,
    "text": "Theophylline neurotoxicity in pregnant rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Theophylline"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3634,
    "text": "The purpose of this investigation was to determine whether the neurotoxicity of theophylline is altered in advanced pregnancy .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "neurotoxicity"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "theophylline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3635,
    "text": "Sprague - Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal seizures which occurred after 28 and 30 minutes respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "aminophylline"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3636,
    "text": "Theophylline concentrations at this endpoint in serum ( total ) and CSF were similar but serum ( free ) and brain concentrations were slightly different in pregnant rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Theophylline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3637,
    "text": "Theophylline serum protein binding determined by equilibrium dialysis was lower in pregnant rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Theophylline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3638,
    "text": "Fetal serum concentrations at onset of seizures in the mother were similar to maternal brain and CSF concentrations and correlated significantly with the former .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3639,
    "text": "It is concluded that advanced pregnancy has a negligible effect on the neurotoxic response to theophylline in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "neurotoxic"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "theophylline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3640,
    "text": "Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hyperkalemia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "indomethacin"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "naproxen"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "fludrocortisone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3641,
    "text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen , without major decline in renal function .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        13,
        15,
        "mefenamic acid"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "nephropathy"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "hyperkalemia"
      ],
      [
        "T4",
        "Disease",
        21,
        22,
        "hypoaldosteronism"
      ],
      [
        "T5",
        "Chemical",
        26,
        27,
        "indomethacin"
      ],
      [
        "T6",
        "Chemical",
        28,
        29,
        "naproxen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3642,
    "text": "It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "renal disease"
      ],
      [
        "T1",
        "Disease",
        11,
        16,
        "type IV renal tubular acidosis"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "prostaglandin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3643,
    "text": "Because he was unable to discontinue nonsteroidal anti - inflammatory drug therapy , fludrocortisone was added , correcting the hyperkalemia and allowing indomethacin therapy to be continued safely .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "fludrocortisone"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "hyperkalemia"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3644,
    "text": "Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5 - fluorouracil .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        15,
        "5 - fluorouracil"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Hypotension"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "cardiotoxicity"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3645,
    "text": "Cardiac symptoms , including hypotension , developed in three patients with advanced colorectal carcinoma while being treated with cisplatin ( CDDP ) and 5 - fluorouracil ( 5 - FU ) .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "colorectal carcinoma"
      ],
      [
        "T1",
        "Chemical",
        23,
        26,
        "5 - fluorouracil"
      ],
      [
        "T2",
        "Chemical",
        27,
        30,
        "5 - FU"
      ],
      [
        "T3",
        "Disease",
        4,
        5,
        "hypotension"
      ],
      [
        "T4",
        "Chemical",
        18,
        19,
        "cisplatin"
      ],
      [
        "T5",
        "Chemical",
        20,
        21,
        "CDDP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3646,
    "text": "In two patients , hypotension was associated with severe left ventricular dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "left ventricular dysfunction"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3647,
    "text": "All three patients required therapy discontinuation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3648,
    "text": "Cardiac enzymes remained normal despite transient electrocardiographic ( EKG ) changes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3649,
    "text": "The presentation and cardiac evaluation ( hemodynamic , echocardiographic , and scintigraphic ) of these patients suggest new manifestations of 5 - FU cardiotoxicity that may be influenced by CDDP .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        23,
        "5 - FU"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "cardiotoxicity"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "CDDP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3650,
    "text": "The possible pathophysiologic mechanisms are discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3651,
    "text": "Fatal aplastic anemia in a patient treated with carbamazepine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3652,
    "text": "A case of fatal aplastic anemia due to carbamazepine treatment in an epileptic woman is reported .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "carbamazepine"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "epileptic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3653,
    "text": "Despite concerns of fatal bone marrow toxicity due to carbamazepine , this is only the fourth documented and published report .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "bone marrow toxicity"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3654,
    "text": "Carbamazepine is a safe drug , but physicians and patients should be aware of the exceedingly rare but potentially fatal side effects , better prevented by clinical than by laboratory monitoring .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3655,
    "text": "Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine - induced hypotension and bradycardia .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "clonidine"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "hypotension"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3656,
    "text": "The effects of microinjection of clonidine ( 1 - 10 micrograms in 1 microliter ) into a region adjacent to the ventrolateral surface of the medulla oblongata on cardiovascular function were assessed in urethane - anesthetized rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "clonidine"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "urethane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3657,
    "text": "Intramedullary administration of clonidine , but not saline vehicle , caused a dose - dependent decrease in both the mean arterial pressure and the heart rate .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "clonidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3658,
    "text": "The clonidine - induced hypotension was antagonized by prior spinal transection , but not bilateral vagotomy .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "clonidine"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3659,
    "text": "On the other hand , the clonidine - induced bradycardia was antagonized by prior bilateral vagotomy , but not spinal transection .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "clonidine"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3660,
    "text": "Furthermore , selective destruction of the spinal 5 - HT nerves , produced by bilateral spinal injection of 5 , 7 - dihydroxytryptamine , reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        18,
        23,
        "5 , 7 - dihydroxytryptamine"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "bradycardiac"
      ],
      [
        "T3",
        "Chemical",
        35,
        36,
        "clonidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3661,
    "text": "The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine - induced hypotension and bradycardia .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "clonidine"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "hypotension"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3662,
    "text": "The induced hypotension is brought about by a decrease in sympathetic efferent activity , whereas the induced bradycardia was due to an increase in vagal efferent activity .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3663,
    "text": "Hypertension in neuroblastoma induced by imipramine .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypertension"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "neuroblastoma"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "imipramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3664,
    "text": "Hypertension is a well - known finding in some patients with neuroblastoma .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypertension"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "neuroblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3665,
    "text": "However , it has not previously been described in association with the use of Imipramine .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "Imipramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3666,
    "text": "We report the occurrence of severe hypertension ( blood pressure 190 / 160 ) in a 4 - year - old girl with neuroblastoma who was given Imipramine to control a behavior disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        31,
        33,
        "behavior disorder"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hypertension"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "neuroblastoma"
      ],
      [
        "T3",
        "Chemical",
        27,
        28,
        "Imipramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3667,
    "text": "It was determined later that this patient ' s tumor was recurring at the time of her hypertensive episode .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "tumor"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3668,
    "text": "Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine ( when she was in florid relapse ) , we believe that this drug rather than her underlying disease alone caused her hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "Imipramine"
      ],
      [
        "T1",
        "Disease",
        39,
        40,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3669,
    "text": "The mechanism for this reaction is believed to be increased levels of vasoactive catecholamines due to interference of their physiologic inactivation by Imipramine .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "catecholamines"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "Imipramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3670,
    "text": "From this experience , we urge extreme caution in the use of tricyclic antidepressants in children with active neuroblastoma .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "neuroblastoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3671,
    "text": "Rechallenge of patients who developed oral candidiasis or hoarseness with beclomethasone dipropionate .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "oral candidiasis"
      ],
      [
        "T1",
        "Chemical",
        10,
        12,
        "beclomethasone dipropionate"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "hoarseness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3672,
    "text": "Of 158 asthmatic patients who were placed on inhaled beclomethasone , 15 ( 9 . 5 % ) developed either hoarseness ( 8 ) , oral thrush ( 6 ) , or both ( 1 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "asthmatic"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "beclomethasone"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "hoarseness"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "thrush"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3673,
    "text": "When their adverse reactions subsided , seven of these 15 patients were rechallenged with inhaled beclomethasone .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "beclomethasone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3674,
    "text": "These included five cases who developed hoarseness and three who developed Candidiasis .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hoarseness"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "Candidiasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3675,
    "text": "One patient had both .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3676,
    "text": "Oral thrush did not recur , but 60 % ( 3 / 5 ) of patients with hoarseness had recurrence .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "thrush"
      ],
      [
        "T1",
        "Disease",
        17,
        18,
        "hoarseness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3677,
    "text": "We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated ; however , because of the high recurrence rate , patients who develop hoarseness should not be re - challenged .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "beclomethasone"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "hoarseness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3678,
    "text": "Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "prednisone"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "beclomethasone"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "hoarseness"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "candidiasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3679,
    "text": "Cyclophosphamide cardiotoxicity : an analysis of dosing as a risk factor .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cyclophosphamide"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3680,
    "text": "Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide ( CYA ) which is usually calculated based on the patient ' s weight .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "cyclophosphamide"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "CYA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3681,
    "text": "At these high doses of CYA , serious cardiotoxicity may occur , but definitive risk factors for the development of such cardiotoxicity have not been described .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "CYA"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "cardiotoxicity"
      ],
      [
        "T2",
        "Disease",
        21,
        22,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3682,
    "text": "Since chemotherapeutic agent toxicity generally correlates with dose per body surface area , we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "CYA"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "CYA"
      ],
      [
        "T3",
        "Disease",
        33,
        34,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3683,
    "text": "Eighty patients who were to receive CYA 50 mg / kg / d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia , Wiskott - Aldrich syndrome , or severe combined immunodeficiency syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        30,
        "aplastic anemia"
      ],
      [
        "T1",
        "Disease",
        31,
        35,
        "Wiskott - Aldrich syndrome"
      ],
      [
        "T2",
        "Disease",
        37,
        41,
        "severe combined immunodeficiency syndrome"
      ],
      [
        "T3",
        "Chemical",
        6,
        7,
        "CYA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3684,
    "text": "Fourteen of 84 ( 17 % ) patients had symptoms and signs consistent with CYA cardiotoxicity within ten days of receiving 1 to 4 doses of CYA .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "CYA"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "cardiotoxicity"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "CYA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3685,
    "text": "Six of the 14 patients died with congestive heart failure .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "congestive heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3686,
    "text": "The dose of CYA per body surface area was calculated for all patients and the patients were divided into two groups based on daily CYA dose : Group 1 , CYA less than or equal to 1 . 55 g / m2 / d ; Group 2 , CYA greater than 1 . 55 g / m2 / d .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "CYA"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "CYA"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "CYA"
      ],
      [
        "T3",
        "Chemical",
        48,
        49,
        "CYA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3687,
    "text": "Cardiotoxicity that was thought to be related to CYA occurred in 1 / 32 ( 3 % ) of patients in Group 1 and in 13 / 52 ( 25 % ) patients in Group 2 ( P less than 0 . 025 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Cardiotoxicity"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "CYA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3688,
    "text": "Congestive heart failure caused or contributed to death in 0 / 32 patients in Group 1 v 6 / 52 ( 12 % ) of patients in Group 2 ( P less than 0 . 25 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Congestive heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3689,
    "text": "There was no difference in the rate of engraftment of evaluable patients in the two groups ( P greater than 0 . 5 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3690,
    "text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area , and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1 . 55 g / m2 / d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "aplastic anemia"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "CYA"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "cardiotoxicity"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "CYA"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "immunodeficiencies"
      ],
      [
        "T5",
        "Chemical",
        35,
        36,
        "CYA"
      ],
      [
        "T6",
        "Disease",
        54,
        55,
        "cardiotoxicity"
      ],
      [
        "T7",
        "Chemical",
        58,
        59,
        "CYA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3691,
    "text": "This study reaffirms the principle that drug toxicity correlates with dose per body surface area .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3692,
    "text": "Studies of risk factors for aminoglycoside nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "aminoglycoside"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3693,
    "text": "The epidemiology of aminoglycoside - induced nephrotoxicity is not fully understood .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "aminoglycoside"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3694,
    "text": "Experimental studies in healthy human volunteers indicate aminoglycosides cause proximal tubular damage in most patients , but rarely , if ever , cause glomerular or tubular dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        27,
        "glomerular or tubular dysfunction"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "aminoglycosides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3695,
    "text": "Clinical trials of aminoglycosides in seriously ill patients indicate that the relative risk for developing acute renal failure during therapy ranges from 8 to 10 and that the attributable risk is 70 % to 80 % .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        18,
        "acute renal failure"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "aminoglycosides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3696,
    "text": "Further analysis of these data suggests that the duration of therapy , plasma aminoglycoside levels , liver disease , advanced age , high initial estimated creatinine clearance and , possibly , female gender all increase the risk for nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "liver disease"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "aminoglycoside"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "creatinine"
      ],
      [
        "T3",
        "Disease",
        38,
        39,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3697,
    "text": "Other causes of acute renal failure , such as shock , appear to have an additive effect .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "shock"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3698,
    "text": "Predictive models have been developed from these analyses that should be useful for identifying patients at high risk .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3699,
    "text": "These models may also be useful in developing insights into the pathophysiology of aminoglycoside - induced nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "aminoglycoside"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3700,
    "text": "Central action of narcotic analgesics .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3701,
    "text": "Part IV .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3702,
    "text": "Noradrenergic influences on the activity of analgesics in rats .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3703,
    "text": "The effect of clonidine , naphazoline and xylometazoline on analgesia induced by morphine , codeine , fentanyl and pentazocine , and on cataleptic effect of morphine , codine and fentanyl was studied in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "clonidine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "naphazoline"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "xylometazoline"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "morphine"
      ],
      [
        "T4",
        "Chemical",
        14,
        15,
        "codeine"
      ],
      [
        "T5",
        "Chemical",
        16,
        17,
        "fentanyl"
      ],
      [
        "T6",
        "Chemical",
        18,
        19,
        "pentazocine"
      ],
      [
        "T7",
        "Disease",
        22,
        23,
        "cataleptic"
      ],
      [
        "T8",
        "Chemical",
        25,
        26,
        "morphine"
      ],
      [
        "T9",
        "Chemical",
        27,
        28,
        "codine"
      ],
      [
        "T10",
        "Chemical",
        29,
        30,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3704,
    "text": "The biochemical assays on the influence of four analgesics on the brain concentration and turnover of noradrenaline ( NA ) were also performed .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "noradrenaline"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "NA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3705,
    "text": "It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "NA"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "morphine"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "fentanyl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3706,
    "text": "Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Codeine"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "clonidine"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "naphazoline"
      ],
      [
        "T4",
        "Chemical",
        11,
        12,
        "xylometazoline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3707,
    "text": "The brain concentration of NA was not changed by morphine and fentanyl , but one of the doses of codeine ( 45 mg / kg ) slightly enhanced it .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "NA"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "morphine"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "fentanyl"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "codeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3708,
    "text": "Pentazocine dose - dependently decreased the brain level of NA .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Pentazocine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "NA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3709,
    "text": "The rate of NA turnover was not altered by analgesics except for the higher dose of fentanyl ( 0 . 2 mg / kg ) following which the disappearance of NA from the brain was diminished .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "NA"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "fentanyl"
      ],
      [
        "T2",
        "Chemical",
        30,
        31,
        "NA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3710,
    "text": "The results are discussed in the light of various and non - uniform data from the literature .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3711,
    "text": "It is suggested that in rats the brain NA plays a less important function than the other monoamines in the behavioural activity of potent analgesics .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "NA"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "monoamines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3712,
    "text": "Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate ( MSG ) : evaluation of experimental parameters in flurothyl seizure testing .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "monosodium glutamate"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Flurothyl"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "seizure"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "MSG"
      ],
      [
        "T4",
        "Chemical",
        23,
        24,
        "flurothyl"
      ],
      [
        "T5",
        "Disease",
        24,
        25,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3713,
    "text": "Monosodium glutamate ( MSG ) administration to neonatal rodents produces convulsions and results in numerous biochemical and behavioral deficits .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Monosodium glutamate"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "MSG"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3714,
    "text": "These studies were undertaken to determine if neonatal administration of MSG produced permanent alterations in seizure susceptibility , since previous investigations were inconclusive .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "MSG"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3715,
    "text": "A flurothyl ether seizure screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG ( 4 mg / g and 1 mg / g ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "flurothyl"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "ether"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "seizure"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "seizure"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "MSG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3716,
    "text": "MSG treatment resulted in significant reductions in whole brain weight but did not alter seizure threshold .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "MSG"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3717,
    "text": "A naloxone ( 5 mg / kg ) challenge was also ineffective in altering the seizure thresholds of either control of MSG - treated mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "naloxone"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "seizure"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "MSG"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3718,
    "text": "Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure ; however , the relationship of hypothermia to seizure induction was unclear .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Flurothyl"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "ether"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "hypothermia"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "flurothyl"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "hypothermia"
      ],
      [
        "T5",
        "Disease",
        21,
        22,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3719,
    "text": "Flurothyl seizure testing proved to be a rapid and reliable technique with which to evaluate seizure susceptibility .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Flurothyl"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "seizure"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3720,
    "text": "Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma - vinyl - GABA into the substantia nigra .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        18,
        "gamma - vinyl - GABA"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "pilocarpine"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "isoniazid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3721,
    "text": "Pilocarpine , given intraperitoneally to rats , reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "temporal lobe epilepsy"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Pilocarpine"
      ],
      [
        "T2",
        "Disease",
        27,
        28,
        "convulsive"
      ],
      [
        "T3",
        "Disease",
        38,
        39,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3722,
    "text": "In the present study , the effects of manipulating the activity of the gamma - aminobutyric acid ( GABA ) - mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats , were investigated .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        17,
        "gamma - aminobutyric acid"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "GABA"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "seizures"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3723,
    "text": "In animals pretreated with microinjections of isoniazid , 150 micrograms , an inhibitor of activity of the GABA - synthesizing enzyme , L - glutamic acid decarboxylase , into the substantia nigra pars reticulata ( SNR ) , bilaterally , non - convulsant doses of pilocarpine , 100 and 200 mg / kg , resulted in severe motor limbic seizures and status epilepticus .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        26,
        "L - glutamic acid"
      ],
      [
        "T1",
        "Disease",
        61,
        63,
        "status epilepticus"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "isoniazid"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "GABA"
      ],
      [
        "T4",
        "Chemical",
        45,
        46,
        "pilocarpine"
      ],
      [
        "T5",
        "Disease",
        59,
        60,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3724,
    "text": "Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine - induced convulsions .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "pilocarpine"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3725,
    "text": "Morphological analysis of frontal forebrain sections with light microscopy revealed seizure - related damage to the hippocampal formation , thalamus , amygdala , olfactory cortex , substantia nigra and neocortex , which is typically observed with pilocarpine in doses exceeding 350 mg / kg .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "seizure"
      ],
      [
        "T1",
        "Chemical",
        36,
        37,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3726,
    "text": "Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine , 200 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "isoniazid"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3727,
    "text": "Application of an irreversible inhibitor of GABA transaminase , gamma - vinyl - GABA ( D , L - 4 - amino - hex - 5 - enoic acid ) , 5 micrograms , into the SNR , bilaterally , suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine , 380 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        14,
        "gamma - vinyl - GABA"
      ],
      [
        "T1",
        "Chemical",
        15,
        29,
        "D , L - 4 - amino - hex - 5 - enoic acid"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "GABA"
      ],
      [
        "T3",
        "Disease",
        47,
        48,
        "seizures"
      ],
      [
        "T4",
        "Chemical",
        50,
        51,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3728,
    "text": "This treatment was also sufficient to protect animals from the occurrence of brain damage .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "brain damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3729,
    "text": "Microinjections of gamma - vinyl - GABA , 5 micrograms , into the dorsal striatum , bilaterally , failed to prevent the development of convulsions produced by pilocarpine , 380 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        7,
        "gamma - vinyl - GABA"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "convulsions"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3730,
    "text": "The results demonstrate that the threshold for pilocarpine - induced seizures in rats is subjected to the regulation of the GABA - mediated synaptic inhibition within the substantia nigra .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "pilocarpine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "GABA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3731,
    "text": "Human and canine ventricular vasoactive intestinal polypeptide : decrease with heart failure .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3732,
    "text": "Vasoactive intestinal polypeptide ( VIP ) is a systemic and coronary vasodilator that may have positive inotropic properties .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3733,
    "text": "Myocardial levels of VIP were assayed before and after the development of heart failure in two canine models .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "heart failure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3734,
    "text": "In the first , cobalt cardiomyopathy was induced in eight dogs ; VIP ( by radioimmunoassay ) decreased from 35 + / - 11 pg / mg protein ( mean + / - SD ) to 5 + / - 4 pg / mg protein ( P less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "cobalt"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3735,
    "text": "In six dogs with doxorubicin - induced heart failure , VIP decreased from 31 + / - 7 to 11 + / - 4 pg / mg protein ( P less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "heart failure"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3736,
    "text": "In addition , VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients ( five with rheumatic disease , nine with myxomatous degeneration ) receiving mitral valve prostheses .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        34,
        "rheumatic disease"
      ],
      [
        "T1",
        "Disease",
        37,
        39,
        "myxomatous degeneration"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3737,
    "text": "The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease ( one patient receiving a transplant and three receiving mitral prostheses ) ( 6 . 3 + / - 1 . 9 pg / mg protein ) .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "coronary disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3738,
    "text": "The other patients undergoing transplantation had an average ejection fraction of 17 % + / - 6 % and a VIP level of 8 . 8 + / - 3 . 9 pg / mg protein .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3739,
    "text": "The hearts without coronary artery disease ( average ejection fraction of this group 62 % + / - 10 % ) had a VIP concentration of 14 . 1 + / - 7 . 9 pg / mg protein , and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant ( P less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        51,
        53,
        "coronary disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3740,
    "text": "Myocardial catecholamines were also determined in 14 subjects ; a weak correlation ( r = 0 . 57 , P less than 0 . 05 ) between the tissue concentrations of VIP and norepinephrine was noted . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "catecholamines"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3741,
    "text": "Non - invasive detection of coronary artery disease by body surface electrocardiographic mapping after dipyridamole infusion .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "coronary artery disease"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "dipyridamole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3742,
    "text": "Electrocardiographic changes after dipyridamole infusion ( 0 . 568 mg / kg / 4 min ) were studied in 41 patients with coronary artery disease and compared with those after submaximal treadmill exercise by use of the body surface mapping technique .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        25,
        "coronary artery disease"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "dipyridamole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3743,
    "text": "Patients were divided into three groups ; 19 patients without myocardial infarction ( non - MI group ) , 14 with anterior infarction ( ANT - MI ) and eight with inferior infarction ( INF - MI ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "myocardial infarction"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "anterior infarction"
      ],
      [
        "T2",
        "Disease",
        24,
        27,
        "ANT - MI"
      ],
      [
        "T3",
        "Disease",
        31,
        33,
        "inferior infarction"
      ],
      [
        "T4",
        "Disease",
        34,
        37,
        "INF - MI"
      ],
      [
        "T5",
        "Disease",
        15,
        16,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3744,
    "text": "Eighty - seven unipolar electrocardiograms ( ECGs ) distributed over the entire thoracic surface were simultaneously recorded .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3745,
    "text": "After dipyridamole , ischemic ST - segment depression ( 0 . 05 mV or more ) was observed in 84 % of the non - MI group , 29 % of the ANT - MI group , 63 % of the INF - MI group and 61 % of the total population .",
    "labels": [
      [
        "T0",
        "Disease",
        32,
        35,
        "ANT - MI"
      ],
      [
        "T1",
        "Disease",
        41,
        44,
        "INF - MI"
      ],
      [
        "T2",
        "Chemical",
        1,
        2,
        "dipyridamole"
      ],
      [
        "T3",
        "Disease",
        3,
        4,
        "ischemic"
      ],
      [
        "T4",
        "Disease",
        7,
        8,
        "depression"
      ],
      [
        "T5",
        "Disease",
        25,
        26,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3746,
    "text": "Exercise - induced ST depression was observed in 84 % of the non - MI group , 43 % of the ANT - MI group , 38 % of the INF - MI group and 61 % of the total .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "ANT - MI"
      ],
      [
        "T1",
        "Disease",
        30,
        33,
        "INF - MI"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "depression"
      ],
      [
        "T3",
        "Disease",
        14,
        15,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3747,
    "text": "For individual patients , there were no obvious differences between the body surface distribution of ST depression in both tests .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3748,
    "text": "The increase in pressure rate product after dipyridamole was significantly less than that during the treadmill exercise .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "dipyridamole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3749,
    "text": "The data suggest that the dipyridamole - induced myocardial ischemia is caused by the inhomogenous distribution of myocardial blood flow .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "dipyridamole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3750,
    "text": "We conclude that the dipyridamole ECG test is as useful as the exercise ECG test for the assessment of coronary artery disease .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        22,
        "coronary artery disease"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "dipyridamole"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3751,
    "text": "Bradycardia after high - dose intravenous methylprednisolone therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Bradycardia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "methylprednisolone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3752,
    "text": "In 5 consecutive patients with rheumatoid arthritis who received intravenous high - dose methylprednisolone ( MP ) therapy ( 1 g daily for 2 or 3 consecutive days ) , a decline in pulse rate was observed , most pronounced on day 4 .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "rheumatoid arthritis"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "methylprednisolone"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "MP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3753,
    "text": "In one of the 5 patients the bradycardia was associated with complaints of substernal pressure .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3754,
    "text": "Reversal to normal heart rate was found on day 7 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3755,
    "text": "Electrocardiographic registrations showed sinus bradycardia in all cases .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "sinus bradycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3756,
    "text": "No significant changes in plasma concentrations of electrolytes were found .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3757,
    "text": "Careful observation of patients receiving high - dose MP is recommended .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "MP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3758,
    "text": "High - dose MP may be contraindicated in patients with known heart disease .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "heart disease"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "MP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3759,
    "text": "Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "downbeat nystagmus"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "oscillopsia"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3760,
    "text": "Downbeat nystagmus is often associated with structural lesions at the craniocervical junction , but has occasionally been reported as a manifestation of metabolic imbalance or drug intoxication .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Downbeat nystagmus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3761,
    "text": "We recorded the eye movements of two patients with reversible downbeat nystagmus related to carbamazepine therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "downbeat nystagmus"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3762,
    "text": "The nystagmus of both patients resolved after reduction of the serum carbamazepine levels .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "nystagmus"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3763,
    "text": "Neuroradiologic investigations including magnetic resonance imaging scans in both patients showed no evidence of intracranial abnormality .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3764,
    "text": "In patients with downbeat nystagmus who are taking anticonvulsant medications , consideration should be given to reduction in dose before further investigation is undertaken .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "downbeat nystagmus"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3765,
    "text": "Improvement by denopamine ( TA - 064 ) of pentobarbital - induced cardiac failure in the dog heart - lung preparation .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "TA - 064"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "cardiac failure"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "denopamine"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "pentobarbital"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3766,
    "text": "The efficacy of denopamine , an orally active beta 1 - adrenoceptor agonist , in improving cardiac failure was assessed in dog heart - lung preparations .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "cardiac failure"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "denopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3767,
    "text": "Cardiac functions depressed by pentobarbital ( 118 + / - 28 mg ; mean value + / - SD ) such that cardiac output and maximum rate of rise of left ventricular pressure ( LV dP / dt max ) had been reduced by about 35 % and 26 % of the respective controls were improved by denopamine ( 10 - 300 micrograms ) in a dose - dependent manner .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "pentobarbital"
      ],
      [
        "T1",
        "Chemical",
        57,
        58,
        "denopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3768,
    "text": "With 100 micrograms denopamine , almost complete restoration of cardiac performance was attained , associated with a slight increase in heart rate .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "denopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3769,
    "text": "No arrhythmias were induced by these doses of denopamine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "arrhythmias"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "denopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3770,
    "text": "The results warrant clinical trials of denopamine in the treatment of cardiac failure .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "cardiac failure"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "denopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3771,
    "text": "Clonazepam monotherapy for epilepsy in childhood .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Clonazepam"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3772,
    "text": "Sixty patients ( age - range one month to 14 years ) with other types of epilepsy than infantile spasms were treated with clonazepam .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "infantile spasms"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "epilepsy"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "clonazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3773,
    "text": "Disappearance of seizures and normalization of abnormal EEG with disappearance of seizures were recognized in 77 % and 50 % , respectively .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "seizures"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3774,
    "text": "Seizures disappeared in 71 % of the patients with generalized seizures and 89 % of partial seizures .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Seizures"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "seizures"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3775,
    "text": "Improvement of abnormal EEG was noticed in 76 % of diffuse paroxysms and in 67 % of focal paroxysms .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3776,
    "text": "In excellent cases , mean effective dosages were 0 . 086 + / - 0 . 021 mg / kg / day in infants and 0 . 057 + / - 0 . 022 mg / kg / day in schoolchildren , this difference was statistically significant ( p less than 0 . 005 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3777,
    "text": "The incidence of side effects such as drowsiness and ataxia was only 5 % .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "drowsiness"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "ataxia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3778,
    "text": "Postmarketing study of timolol - hydrochlorothiazide antihypertensive therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "timolol"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "hydrochlorothiazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3779,
    "text": "A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed - ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide , administered twice daily for one month to hypertensive patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        24,
        "timolol maleate"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "hydrochlorothiazide"
      ],
      [
        "T2",
        "Disease",
        37,
        38,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3780,
    "text": "Data on 9 , 037 patients were collected by 1 , 455 participating physicians .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3781,
    "text": "Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of timolol - hydrochlorothiazide therapy ( P less than 0 . 01 , both comparisons ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "timolol"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "hydrochlorothiazide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3782,
    "text": "Age , race , and sex appeared to have no influence on the decrease in blood pressure .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3783,
    "text": "The antihypertensive effect of the drug was greater in patients with more severe hypertension .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3784,
    "text": "Overall , 1 , 453 patients experienced a total of 2 , 658 adverse events , the most common being fatigue , dizziness , and weakness .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "fatigue"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "dizziness"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "weakness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3785,
    "text": "Treatment in 590 patients was discontinued because of adverse events .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3786,
    "text": "Salicylate nephropathy in the Gunn rat : potential role of prostaglandins .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Salicylate"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "nephropathy"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "prostaglandins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3787,
    "text": "We examined the potential role of prostaglandins in the development of analgesic nephropathy in the Gunn strain of rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "prostaglandins"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3788,
    "text": "The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase , leading to marked bilirubin deposition in renal medulla and papilla .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hyperbilirubinemia"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "glucuronyl"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "bilirubin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3789,
    "text": "These rats are also highly susceptible to develop papillary necrosis with analgesic administration .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "papillary necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3790,
    "text": "We used homozygous ( jj ) and phenotypically normal heterozygous ( jJ ) animals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3791,
    "text": "Four groups of rats ( n = 7 ) were studied : jj and jJ rats treated either with aspirin 300 mg / kg every other day or sham - treated .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3792,
    "text": "After one week , slices of cortex , outer and inner medulla from one kidney were incubated in buffer and prostaglandin synthesis was determined by radioimmunoassay .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "prostaglandin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3793,
    "text": "The other kidney was examined histologically .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3794,
    "text": "A marked corticomedullary gradient of prostaglandin synthesis was observed in all groups .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "prostaglandin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3795,
    "text": "PGE2 synthesis was significantly higher in outer medulla , but not cortex or inner medulla , of jj ( 38 + / - 6 ng / mg prot ) than jJ rats ( 15 + / - 3 ) ( p less than 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "PGE2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3796,
    "text": "Aspirin treatment reduced PGE2 synthesis in all regions , but outer medullary PGE2 remained higher in jj ( 18 + / - 3 ) than jJ rats ( 9 + / - 2 ) ( p less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Aspirin"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "PGE2"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "PGE2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3797,
    "text": "PGF2 alpha was also significantly higher in the outer medulla of jj rats with and without aspirin administration ( p less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "PGF2 alpha"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3798,
    "text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin - treated jj but not jJ rats as evidenced by : increased incidence and severity of hematuria ( p less than 0 . 01 ) ; increased serum creatinine ( p less than 0 . 05 ) ; and increase in outer medullary histopathologic lesions ( p less than 0 . 005 compared to either sham - treated jj or aspirin - treated jJ ) .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "renal damage"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "prostaglandin"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "aspirin"
      ],
      [
        "T3",
        "Disease",
        31,
        32,
        "hematuria"
      ],
      [
        "T4",
        "Chemical",
        43,
        44,
        "creatinine"
      ],
      [
        "T5",
        "Chemical",
        75,
        76,
        "aspirin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3799,
    "text": "These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity , and that inhibition of prostaglandin synthesis may lead to pathological renal medullary lesions and deterioration of renal function .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        30,
        "pathological renal medullary lesions"
      ],
      [
        "T1",
        "Disease",
        31,
        35,
        "deterioration of renal function"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "prostaglandin"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "prostaglandin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3800,
    "text": "Prophylactic lidocaine in the early phase of suspected myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3801,
    "text": "Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double - blind randomized trial of lidocaine vs placebo .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3802,
    "text": "During the 1 hour after administration of the drug the incidence of ventricular fibrillation or sustained ventricular tachycardia among the 204 patients with acute myocardial infarction was low , 1 . 5 % .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "ventricular fibrillation"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "ventricular tachycardia"
      ],
      [
        "T2",
        "Disease",
        24,
        26,
        "myocardial infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3803,
    "text": "Lidocaine , given in a 300 mg dose intramuscularly followed by 100 mg intravenously , did not prevent sustained ventricular tachycardia , although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine ( p less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Lidocaine"
      ],
      [
        "T2",
        "Disease",
        35,
        36,
        "arrhythmias"
      ],
      [
        "T3",
        "Chemical",
        45,
        46,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3804,
    "text": "The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "lidocaine"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3805,
    "text": "The mean plasma lidocaine level of patients on beta - blocking agents was no different from that in patients not on beta blocking agents .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3806,
    "text": "During the 1 - hour study period , the incidence of central nervous system side effects was significantly greater in the lidocaine group , hypotension occurred in 11 patients , nine of whom had received lidocaine , and four patients died from asystole , three of whom had had lidocaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "lidocaine"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "lidocaine"
      ],
      [
        "T3",
        "Disease",
        42,
        43,
        "asystole"
      ],
      [
        "T4",
        "Chemical",
        49,
        50,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3807,
    "text": "We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3808,
    "text": "Evidence for a cholinergic role in haloperidol - induced catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "haloperidol"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3809,
    "text": "Experiments in mice tested previous evidence that activation of cholinergic systems promotes catalepsy and that cholinergic mechanisms need to be intact for full expression of neuroleptic - induced catalepsy .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "catalepsy"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "neuroleptic"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3810,
    "text": "Large doses of the cholinomimetic , pilocarpine , could induce catalepsy when peripheral cholinergic receptors were blocked .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "pilocarpine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3811,
    "text": "Low doses of pilocarpine caused a pronounced enhancement of the catalepsy that was induced by the dopaminergic blocker , haloperidol .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "pilocarpine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "catalepsy"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3812,
    "text": "A muscarinic receptor blocker , atropine , disrupted haloperidol - induced catalepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "atropine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "haloperidol"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3813,
    "text": "Intracranial injection of an acetylcholine - synthesis inhibitor , hemicholinium , prevented the catalepsy that is usually induced by haloperidol .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "acetylcholine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "hemicholinium"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "catalepsy"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3814,
    "text": "These findings suggest the hypothesis that the catalepsy that is produced by neuroleptics such as haloperidol is actually mediated by intrinsic central cholinergic systems .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "catalepsy"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "neuroleptics"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3815,
    "text": "Alternatively , activation of central cholinergic systems could promote catalepsy by suppression of dopaminergic systems .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "catalepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3816,
    "text": "Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cardiovascular dysfunction"
      ],
      [
        "T1",
        "Chemical",
        5,
        7,
        "sodium pentobarbital"
      ],
      [
        "T2",
        "Chemical",
        10,
        12,
        "barium chloride"
      ],
      [
        "T3",
        "Disease",
        3,
        4,
        "hypersensitivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3817,
    "text": "Barium - supplemented Long - Evans hooded rats were characterized by a persistent hypertension that was evident after 1 month of barium ( 100 micrograms / ml mineral fortified water ) treatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Barium"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "hypertension"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3818,
    "text": "Analysis of in vivo myocardial excitability , contractility , and metabolic characteristics at 16 months revealed other significant barium - induced disturbances within the cardiovascular system .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        26,
        "disturbances within the cardiovascular system"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3819,
    "text": "The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        19,
        "sodium pentobarbital"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "barium"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hypersensitivity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3820,
    "text": "Under barbiturate anesthesia , virtually all of the myocardial contractile indices were depressed significantly in barium - exposed rats relative to the corresponding control - fed rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "barbiturate"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3821,
    "text": "The lack of a similar response to ketamine and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium - treated rats were linked specifically to this anesthetic , and were not representative of a generalized anesthetic response .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        19,
        "sodium pentobarbital"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "ketamine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "xylazine"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3822,
    "text": "Other myocardial pathophysiologic and metabolic changes induced by barium were manifest , irrespective of the anesthetic employed .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3823,
    "text": "The contractile element shortening velocity of the cardiac muscle fibers was significantly slower in both groups of barium - treated rats relative to the control groups , irrespective of the anesthetic regimen .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3824,
    "text": "Similarly , significant disturbances in myocardial energy metabolism were detected in the barium - exposed rats which were consistent with the reduced contractile element shortening velocity .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3825,
    "text": "In addition , the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from barium - exposed rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3826,
    "text": "Overall , the altered cardiac contractility and excitability characteristics , the myocardial metabolic disturbances , and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "metabolic disturbances"
      ],
      [
        "T1",
        "Chemical",
        23,
        25,
        "sodium pentobarbital"
      ],
      [
        "T2",
        "Disease",
        32,
        34,
        "cardiomyopathic disorder"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "hypersensitivity"
      ],
      [
        "T4",
        "Chemical",
        37,
        38,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3827,
    "text": "These experimental findings represent the first indication that life - long barium ingestion may have significant adverse effects on the mammalian cardiovascular system .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "barium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3828,
    "text": "Propranolol antagonism of phenylpropanolamine - induced hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Propranolol"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "phenylpropanolamine"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3829,
    "text": "Phenylpropanolamine ( PPA ) overdose can cause severe hypertension , intracerebral hemorrhage , and death .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "intracerebral hemorrhage"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Phenylpropanolamine"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "PPA"
      ],
      [
        "T3",
        "Disease",
        4,
        5,
        "overdose"
      ],
      [
        "T4",
        "Disease",
        8,
        9,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3830,
    "text": "We studied the efficacy and safety of propranolol in the treatment of PPA - induced hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "propranolol"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "PPA"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3831,
    "text": "Subjects received propranolol either by mouth for 48 hours before PPA or as a rapid intravenous infusion after PPA .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "propranolol"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "PPA"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "PPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3832,
    "text": "PPA , 75 mg alone , increased blood pressure ( 31 + / - 14 mm Hg systolic , 20 + / - 5 mm Hg diastolic ) , and propranolol pretreatment antagonized this increase ( 12 + / - 10 mm Hg systolic , 10 + / - 7 mm Hg diastolic ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "PPA"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3833,
    "text": "Intravenous propranolol after PPA also decreased blood pressure .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "propranolol"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "PPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3834,
    "text": "Left ventricular function ( assessed by echocardiography ) showed that PPA increased the stroke volume 30 % ( from 62 . 5 + / - 20 . 9 to 80 . 8 + / - 22 . 4 ml ) , the ejection fraction 9 % ( from 64 % + / - 10 % to 70 % + / - 7 % ) , and cardiac output 14 % ( from 3 . 6 + / - 0 . 6 to 4 . 1 + / - 1 . 0 L / min ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "PPA"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "stroke"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3835,
    "text": "Intravenous propranolol reversed these effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3836,
    "text": "Systemic vascular resistance was increased by PPA 28 % ( from 1710 + / - 200 to 2190 + / - 700 dyne X sec / cm5 ) and was further increased by propranolol 22 % ( to 2660 + / - 1200 dyne X sec / cm5 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "PPA"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3837,
    "text": "We conclude that PPA increases blood pressure by increasing systemic vascular resistance and cardiac output , and that propranolol antagonizes this increase by reversing the effect of PPA on cardiac output .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "PPA"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "PPA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3838,
    "text": "That propranolol antagonizes the pressor effect of PPA is in contrast to the interaction in which propranolol enhances the pressor effect of norepinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "propranolol"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "PPA"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "propranolol"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3839,
    "text": "This is probably because PPA has less beta 2 activity than does norepinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "PPA"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3840,
    "text": "Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "glomerular sclerosis"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "aminonucleoside"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "nephrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3841,
    "text": "The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside ( PAN ) model .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "mesangial dysfunction"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "glomerular sclerosis"
      ],
      [
        "T2",
        "Chemical",
        15,
        17,
        "puromycin aminonucleoside"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3842,
    "text": "Five male Wistar rats received repeated subcutaneous PAN injections ; five controls received saline only .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3843,
    "text": "After 4 weeks the PAN rats were severely proteinuric ( 190 + / - 80 mg / 24 hr ) , and all rats were given colloidal carbon ( CC ) intravenously .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "PAN"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "proteinuric"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "carbon"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3844,
    "text": "At 5 months glomerular sclerosis was found in 7 . 6 + / - 3 . 4 % of the glomeruli of PAN rats ; glomeruli of the controls were normal .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "glomerular sclerosis"
      ],
      [
        "T1",
        "Chemical",
        22,
        23,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3845,
    "text": "Glomeruli of PAN rats contained significantly more CC than glomeruli of controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3846,
    "text": "Glomeruli with sclerosis contained significantly more CC than non - sclerotic glomeruli in the same kidneys .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "sclerosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3847,
    "text": "CC was preferentially localized within the sclerotic areas of the affected glomeruli .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3848,
    "text": "Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment , we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where sclerosis will develop subsequently .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "PAN"
      ],
      [
        "T1",
        "Disease",
        40,
        41,
        "sclerosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3849,
    "text": "Cluster analysis showed a random distribution of lesions in the PAN glomeruli in concordance with the random localization of mesangial areas with dysfunction in this model .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3850,
    "text": "Similar to the remnant kidney model in PAN nephrosis the development of glomerular sclerosis may be related to \" mesangial overloading . \"",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "glomerular sclerosis"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "PAN"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "nephrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3851,
    "text": "Relationship between nicotine - induced seizures and hippocampal nicotinic receptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "nicotine"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3852,
    "text": "A controversy has existed for several years concerning the physiological relevance of the nicotinic receptor measured by alpha - bungarotoxin binding .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3853,
    "text": "Using mice derived from a classical F2 and backcross genetic design , a relationship between nicotine - induced seizures and alpha - bungarotoxin nicotinic receptor concentration was found .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "nicotine"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3854,
    "text": "Mice sensitive to the convulsant effects of nicotine had greater alpha - bungarotoxin binding in the hippocampus than seizure insensitive mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "nicotine"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3855,
    "text": "The binding sites from seizure sensitive and resistant mice were equally affected by treatment with dithiothreitol , trypsin or heat .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "seizure"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "dithiothreitol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3856,
    "text": "Thus it appears that the difference between seizure sensitive and insensitive animals may be due to a difference in hippocampal nicotinic receptor concentration as measured with alpha - bungarotoxin binding .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3857,
    "text": "The role of p - aminophenol in acetaminophen - induced nephrotoxicity : effect of bis ( p - nitrophenyl ) phosphate on acetaminophen and p - aminophenol nephrotoxicity and metabolism in Fischer 344 rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "p - aminophenol"
      ],
      [
        "T1",
        "Chemical",
        14,
        21,
        "bis ( p - nitrophenyl ) phosphate"
      ],
      [
        "T2",
        "Chemical",
        24,
        27,
        "p - aminophenol"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "acetaminophen"
      ],
      [
        "T4",
        "Disease",
        10,
        11,
        "nephrotoxicity"
      ],
      [
        "T5",
        "Chemical",
        22,
        23,
        "acetaminophen"
      ],
      [
        "T6",
        "Disease",
        27,
        28,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3858,
    "text": "Acetaminophen ( APAP ) produces proximal tubular necrosis in Fischer 344 ( F344 ) rats .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "tubular necrosis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Acetaminophen"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "APAP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3859,
    "text": "Recently , p - aminophenol ( PAP ) , a known potent nephrotoxicant , was identified as a metabolite of APAP in F344 rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "p - aminophenol"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "PAP"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "APAP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3860,
    "text": "The purpose of this study was to determine if PAP formation is a requisite step in APAP - induced nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "PAP"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "APAP"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3861,
    "text": "Therefore , the effect of bis ( p - nitrophenyl ) phosphate ( BNPP ) , an acylamidase inhibitor , on APAP and PAP nephrotoxicity and metabolism was determined .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        12,
        "bis ( p - nitrophenyl ) phosphate"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "BNPP"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "APAP"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "PAP"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3862,
    "text": "BNPP ( 1 to 8 mM ) reduced APAP deacetylation and covalent binding in F344 renal cortical homogenates in a concentration - dependent manner .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "BNPP"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "APAP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3863,
    "text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP ( 900 mg / kg ) nephrotoxicity but not PAP nephrotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "BNPP"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "APAP"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "PAP"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "APAP"
      ],
      [
        "T4",
        "Disease",
        23,
        24,
        "nephrotoxicity"
      ],
      [
        "T5",
        "Chemical",
        26,
        27,
        "PAP"
      ],
      [
        "T6",
        "Disease",
        27,
        28,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3864,
    "text": "This result was not due to altered disposition of either APAP or acetylated metabolites in plasma or renal cortical and hepatic tissue .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "APAP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3865,
    "text": "Rather , BNPP pretreatment reduced the fraction of APAP excreted as PAP by 64 and 75 % after APAP doses of 750 and 900 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "BNPP"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "APAP"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "PAP"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "APAP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3866,
    "text": "BNPP did not alter the excretion of APAP or any of its non - deacetylated metabolites nor did BNPP alter excretion of PAP or its metabolites after PAP doses of 150 and 300 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "BNPP"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "APAP"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "BNPP"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "PAP"
      ],
      [
        "T4",
        "Chemical",
        27,
        28,
        "PAP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3867,
    "text": "Therefore , the BNPP - induced reduction in APAP - induced nephrotoxicity appears to be due to inhibition of APAP deacetylation .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "BNPP"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "APAP"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "nephrotoxicity"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "APAP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3868,
    "text": "It is concluded that PAP formation , in vivo , accounts , at least in part , for APAP - induced renal tubular necrosis .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        24,
        "renal tubular necrosis"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "PAP"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "APAP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3869,
    "text": "Morphine - induced seizures in newborn infants .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Morphine"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3870,
    "text": "Two neonates suffered from generalized seizures during the course of intravenous morphine sulfate for post - operative analgesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "morphine sulfate"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3871,
    "text": "They received morphine in doses of 32 micrograms / kg / hr and 40 micrograms / kg / hr larger than a group of 10 neonates who received 6 - 24 micrograms / kg / hr and had no seizures .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "morphine"
      ],
      [
        "T1",
        "Disease",
        39,
        40,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3872,
    "text": "Plasma concentrations of morphine in these neonates was excessive ( 60 and 90 mg / ml ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3873,
    "text": "Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "seizures"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "convulsions"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3874,
    "text": "It is suggested that post - operative intravenous morphine should not exceed 20 micrograms / kg / ml in neonates .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "morphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3875,
    "text": "Indomethacin induced hypotension in sodium and volume depleted rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Indomethacin"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3876,
    "text": "After a single oral dose of 4 mg / kg indomethacin ( IDM ) to sodium and volume depleted rats plasma renin activity ( PRA ) and systolic blood pressure fell significantly within four hours .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "indomethacin"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "IDM"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3877,
    "text": "In sodium repleted animals indomethacin did not change systolic blood pressure ( BP ) although plasma renin activity was decreased .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "sodium"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3878,
    "text": "Thus , indomethacin by inhibition of prostaglandin synthesis may diminish the blood pressure maintaining effect of the stimulated renin - angiotensin system in sodium and volume depletion .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "indomethacin"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "prostaglandin"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "angiotensin"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3879,
    "text": "On the antiarrhythmic activity of one N - substituted piperazine derivative of trans - 2 - amino - 3 - hydroxy - 1 , 2 , 3 , 4 - tetrahydroanaphthalene .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        31,
        "trans - 2 - amino - 3 - hydroxy - 1 , 2 , 3 , 4 - tetrahydroanaphthalene"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "piperazine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3880,
    "text": "The antiarrhythmic activity of the compound N - ( trans - 3 - hydroxy - 1 , 2 , 3 , 4 - tetrahydro - 2 - naphthyl ) - N - ( 3 - oxo - 3 - phenyl - 2 - methylpropyl ) - piperazine hydrochloride , referred to as P11 , is studied on anaesthesized cats and Wistar albino rats , as well as on non - anaesthesized rabbits .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        48,
        "N - ( trans - 3 - hydroxy - 1 , 2 , 3 , 4 - tetrahydro - 2 - naphthyl ) - N - ( 3 - oxo - 3 - phenyl - 2 - methylpropyl ) - piperazine hydrochloride"
      ],
      [
        "T1",
        "Chemical",
        52,
        53,
        "P11"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3881,
    "text": "Four types of experimental arrhythmia are used - - with BaCl2 , with chloroform - adrenaline , with strophantine G and with aconitine .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        20,
        "strophantine G"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "arrhythmia"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "BaCl2"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "chloroform"
      ],
      [
        "T4",
        "Chemical",
        15,
        16,
        "adrenaline"
      ],
      [
        "T5",
        "Chemical",
        22,
        23,
        "aconitine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3882,
    "text": "The compound P11 is introduced in doses of 0 . 25 and 0 . 50 mg / kg intravenously and 10 mg / kg orally .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "P11"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3883,
    "text": "The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used , causing greatest inhibition on the arrhythmia induced by chloroform - adrenaline ( in 90 per cent ) and with BaCl2 ( in 84 per cent ) .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "arrhythmia"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "arrhythmia"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "chloroform"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "adrenaline"
      ],
      [
        "T4",
        "Chemical",
        32,
        33,
        "BaCl2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3884,
    "text": "The results obtained are associated with the beta - adrenoblocking and with the membrane - stabilizing action of the compound .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3885,
    "text": "Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "subarachnoid hemorrhage"
      ],
      [
        "T1",
        "Chemical",
        5,
        7,
        "aminocaproic acid"
      ],
      [
        "T2",
        "Disease",
        9,
        13,
        "acute renal artery thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3886,
    "text": "Case report .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3887,
    "text": "Epsilon aminocaproic acid ( EACA ) has been used to prevent rebleeding in patients with subarachnoid hemorrhage ( SAH ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "Epsilon aminocaproic acid"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "subarachnoid hemorrhage"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "EACA"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "SAH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3888,
    "text": "Although this agent does decrease the frequency of rebleeding , several reports have described thrombotic complications of EACA therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        15,
        "thrombotic"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "EACA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3889,
    "text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH , arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA , or other thromboembolic phenomena .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "intracranial vascular thrombosis"
      ],
      [
        "T1",
        "Disease",
        31,
        33,
        "thromboembolic phenomena"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "SAH"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "thrombi"
      ],
      [
        "T4",
        "Chemical",
        27,
        28,
        "EACA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3890,
    "text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders , EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \" consumption coagulopathies . \" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        30,
        "disseminated intravascular coagulation"
      ],
      [
        "T1",
        "Disease",
        33,
        35,
        "consumption coagulopathies"
      ],
      [
        "T2",
        "Disease",
        47,
        53,
        "thrombosis of a normal renal artery"
      ],
      [
        "T3",
        "Disease",
        3,
        4,
        "thrombi"
      ],
      [
        "T4",
        "Chemical",
        13,
        14,
        "EACA"
      ],
      [
        "T5",
        "Disease",
        23,
        24,
        "thrombi"
      ],
      [
        "T6",
        "Disease",
        41,
        42,
        "infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3891,
    "text": "This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "EACA"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "SAH"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "SAH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3892,
    "text": "The corresponding clinical event was characterized by marked hypertension and abrupt neurological deterioration .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3893,
    "text": "Effect of vincristine sulfate on Pseudomonas infections in monkeys .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "vincristine sulfate"
      ],
      [
        "T1",
        "Disease",
        5,
        7,
        "Pseudomonas infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3894,
    "text": "In rhesus monkeys , intravenous challenge with 0 . 6 x 10 ( 10 ) to 2 . 2 x 10 ( 10 ) Pseudomonas aeruginosa organisms caused acute illness of 4 to 5 days ' duration with spontaneous recovery in 13 of 15 monkeys ; blood cultures became negative 3 to 17 days after challenge .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3895,
    "text": "Leukocytosis was observed in all monkeys .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Leukocytosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3896,
    "text": "Intravenous or intratracheal inoculation of 2 . 0 to 2 . 5 mg of vincristine sulfate was followed by leukopenia in 4 to 5 days .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "vincristine sulfate"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "leukopenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3897,
    "text": "Intravenous inoculation of 4 . 2 x 10 ( 10 ) to 7 . 8 x 10 ( 10 ) pyocin type 6 Pseudomonas organisms in monkeys given vincristine sulfate 4 days previously resulted in fatal infection in 11 of 14 monkeys , whereas none of four receiving Pseudomonas alone died .",
    "labels": [
      [
        "T0",
        "Chemical",
        28,
        30,
        "vincristine sulfate"
      ],
      [
        "T1",
        "Disease",
        36,
        37,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3898,
    "text": "These studies suggest that an antimetabolite - induced leukopenia predisposes to severe Pseudomonas sepsis and that such monkeys may serve as a biological model for study of comparative efficacy of antimicrobial agents .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "leukopenia"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "sepsis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3899,
    "text": "Modification by propranolol of cardiovascular effects of induced hypoglycaemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "propranolol"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hypoglycaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3900,
    "text": "The cardiovascular effects of hypoglycaemia , with and without beta - blockade , were compared in fourteen healthy men .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hypoglycaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3901,
    "text": "Eight received insulin alone , and eight , including two of the original insulin - only group , were given propranolol and insulin .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        21,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3902,
    "text": "In the insulin - group the period of hypoglycaemia was associated with an increase in heart - rate and a fall in diastolic blood - pressure .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hypoglycaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3903,
    "text": "In the propranolol - insulin group there was a significant fall in heart - rate in most subjects and an increase in diastolic pressure .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3904,
    "text": "Typical S - T / T changes occurred in the insulin - group but in none of the propranolol - insulin group .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3905,
    "text": "Hypertension in diabetics prone to hypoglycaemia attacks should not be treated with beta - blockers because these drugs may cause a sharp rise in blood - pressure in such patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypertension"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "diabetics"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "hypoglycaemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3906,
    "text": "Long - term propranolol therapy in pregnancy : maternal and fetal outcome .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3907,
    "text": "Propranolol , a beta - adrenergic blocking agent , has found an important position in the practice of medicine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3908,
    "text": "Its use in pregnancy , however , is an open question as a number of detrimental side effects have been reported in the fetus and neonate .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3909,
    "text": "Ten patients and 12 pregnancies are reported where chronic propranolol has been administered .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3910,
    "text": "Five patients with serial pregnancies with and without propranolol therapy are also examined .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3911,
    "text": "Maternal , fetal , and neonatal complications are examined .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3912,
    "text": "An attempt is made to differentiate drug - related complications from maternal disease - - related complications .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3913,
    "text": "We conclude that previously reported hypoglycemia , hyperbilirubinemia , polycythemia , neonatal apnea , and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "neonatal apnea"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "hypoglycemia"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "hyperbilirubinemia"
      ],
      [
        "T3",
        "Disease",
        9,
        10,
        "polycythemia"
      ],
      [
        "T4",
        "Disease",
        15,
        16,
        "bradycardia"
      ],
      [
        "T5",
        "Chemical",
        26,
        27,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3914,
    "text": "Growth retardation , however , appears to be significant in both of our series .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Growth retardation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3915,
    "text": "Central excitatory actions of flurazepam .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "flurazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3916,
    "text": "Toxic actions of flurazepam ( FZP ) were studied in cats , mice and rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "flurazepam"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "FZP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3917,
    "text": "High doses caused an apparent central excitation , most clearly seen as clonic convulsions , superimposed on general depression .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        14,
        "convulsions"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "depression"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3918,
    "text": "Following a lethal dose , death was always associated with convulsions .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3919,
    "text": "Comparing the relative sensitivity to central depression and excitation revealed that rats were least likely to have convulsions at doses that did not first cause loss of consciousness , while cats most clearly showed marked central excitatory actions .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        28,
        "loss of consciousness"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "depression"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3920,
    "text": "Signs of FZP toxocity in cats included excessive salivation , extreme apprehensive behavior , retching , muscle tremors and convulsions .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "muscle tremors"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "FZP"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "toxocity"
      ],
      [
        "T3",
        "Disease",
        8,
        9,
        "salivation"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3921,
    "text": "An interaction between FZP and pentylenetetrazol ( PTZ ) was shown by pretreating mice with FZP before PTZ challenge .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "FZP"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "pentylenetetrazol"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "PTZ"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "FZP"
      ],
      [
        "T4",
        "Chemical",
        17,
        18,
        "PTZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3922,
    "text": "As a function of dose , FZP first protected against convulsions and death .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "FZP"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3923,
    "text": "At higher doses , however , convulsions again emerged .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3924,
    "text": "These doses of FZP were lower than those that would alone cause convulsions .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "FZP"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "convulsions"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3925,
    "text": "These results may be relevant to the use of FZP in clinical situations in which there is increased neural excitability , such as epilepsy or sedative - hypnotic drug withdrawal .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "FZP"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3926,
    "text": "Use of propranolol in the treatment of idiopathic orthostatic hypotension .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "idiopathic orthostatic hypotension"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3927,
    "text": "Five patients with idiopathic orthostatic hypotension who had physiologic and biochemical evidence of severe autonomic dysfunction were included in the study .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "idiopathic orthostatic hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3928,
    "text": "They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "catecholamines"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "hypersensitivity"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "norepinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3929,
    "text": "Treatment with propanolol administered intravenously ( 1 - 5 mg ) produced increases in supine and upright blood pressure in 4 of the 5 individuals with rises ranging from 11 / 6 to 22 / 11 mmHg .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "propanolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3930,
    "text": "Chronic oral administration of propranolol ( 40 - 160 mg / day ) also elevated the blood pressures of these individuals with increases in the order of 20 - 35 / 15 - 25 mmg being observed .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3931,
    "text": "In 1 patient , marked hypertension was induced by propranolol and the drug had to be withdrawn .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "hypertension"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3932,
    "text": "It otherwise was well tolerated and no important side effects were observed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3933,
    "text": "Treatment has been continued in 3 individuals for 6 - 13 months with persistence of the pressor effect , although there appears to have been some decrease in the degree of response with time .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3934,
    "text": "Hemodynamic measurements in 1 of the patients demonstrated an increase in total peripheral resistance and essentially no change in cardiac output following propranolol therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3935,
    "text": "The studies suggest that propranolol is a useful drug in selected patients with severe idiopathic orthostatic hypotension .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        17,
        "idiopathic orthostatic hypotension"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3936,
    "text": "Total intravenous anesthesia with etomidate .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3937,
    "text": "III .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3938,
    "text": "Some observations in adults .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3939,
    "text": "An investigation was undertaken to determine the dosage of etomidate required to maintain sleep in adults undergoing surgery under regional local anesthesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3940,
    "text": "Premedication of diazepam 10 mg and atropine 0 . 5 mg was given , and sleep was induced and maintained by intermittent intravenous injections of etomidate 0 . 1 / mg / kg , given whenever the patient would open his eyes on request .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "diazepam"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "atropine"
      ],
      [
        "T2",
        "Chemical",
        25,
        26,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3941,
    "text": "A mean overall dose of etomidate 17 . 4 microgram / kg / min . was required to maintain sleep , but great individual variation occurred , with older patients requiring less drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3942,
    "text": "The investigation was discontinued after 18 patients because of the frequency and intensity of side - effects , particularly pain and myoclonia , which caused the technique to be abandoned in two cases .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        20,
        "pain"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "myoclonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3943,
    "text": "It is considered unlikely that etomidate will prove to be the hypnotic of choice for a totally intravenous anesthetic technique in adults because of the high incidence of myoclonia after prolonged administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "etomidate"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "myoclonia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3944,
    "text": "In several patients uncontrollable muscle movements persisted for many minutes after complete recovery of consciousness .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3945,
    "text": "Evidence for cardiac beta 2 - adrenoceptors in man .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3946,
    "text": "We compared the effects of single doses of 50 mg atenolol ( cardioselective ) , 40 mg propranolol ( nonselective ) , and placebo on both exercise - and isoproterenol - induced tachycardia in two experiments involving nine normal subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "atenolol"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "isoproterenol"
      ],
      [
        "T3",
        "Disease",
        32,
        33,
        "tachycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3947,
    "text": "Maximal exercise heart rate was reduced from 187 + / - 4 ( SEM ) after placebo to 146 + / - 7 bpm after atenolol and 138 + / - 6 bpm after propranolol , but there were no differences between the drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        26,
        "atenolol"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3948,
    "text": "The effects on isoproterenol tachycardia were determined before and after atropine ( 0 . 04 mg / kg IV ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "isoproterenol"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "tachycardia"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "atropine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3949,
    "text": "Isoproterenol sensitivity was determined as the intravenous dose that increased heart rate by 25 bpm ( CD25 ) and this was increased from 1 . 8 + / - 0 . 3 micrograms after placebo to 38 . 9 + / - 8 . 3 micrograms after propranolol and 8 . 3 + / - 1 . 7 micrograms after atenolol .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Isoproterenol"
      ],
      [
        "T1",
        "Chemical",
        47,
        48,
        "propranolol"
      ],
      [
        "T2",
        "Chemical",
        60,
        61,
        "atenolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3950,
    "text": "The difference in the effects of the two was significant .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3951,
    "text": "After atropine the CD25 was unchanged after placebo ( 2 . 3 + / - 0 . 3 micrograms ) and atenolol ( 7 . 7 + / - 1 . 3 micrograms ) ; it was reduced after propranolol ( 24 . 8 + / - 5 . 0 micrograms ) , but remained different from atenolol .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "atropine"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "atenolol"
      ],
      [
        "T2",
        "Chemical",
        39,
        40,
        "propranolol"
      ],
      [
        "T3",
        "Chemical",
        57,
        58,
        "atenolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3952,
    "text": "This change with propranolol sensitivity was calculated as the apparent Ka , this was unchanged by atropine ( 11 . 7 + / - 2 . 1 and 10 . 1 + / - 2 . 5 ml / ng ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "propranolol"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "atropine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3953,
    "text": "These data are consistent with the hypothesis that exercise - induced tachycardia results largely from beta 1 - receptor activation that is blocked by both cardioselective and nonselective drugs , whereas isoproterenol activates both beta 1 - and beta 2 - receptors so that after cardioselective blockade there remains a beta 2 - component that can be blocked with a nonselective drug .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "tachycardia"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3954,
    "text": "While there appear to be beta 2 - receptors in the human heart , their physiologic or pathologic roles remain to be defined .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3955,
    "text": "Hormones and risk of breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3956,
    "text": "This paper reports the results of a study of 50 menopausal women receiving hormonal replacement therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3957,
    "text": "The majority ( 29 ) had surgical menopause ; their mean age was 45 . 7 years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3958,
    "text": "It was hypothesized that progestins could equilibrate the effects of the estrogenic stimulation on the mammary and endometrial target tissues of women on hormonal replacement therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "progestins"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3959,
    "text": "The treatment schedule consisted of conjugated estrogens ( Premarin ) 1 . 25 mg / day for 21 days and Medroxyprogesterone acetate 10 mg / day for 10 days in each month .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "conjugated estrogens"
      ],
      [
        "T1",
        "Chemical",
        20,
        22,
        "Medroxyprogesterone acetate"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "Premarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3960,
    "text": "The mean treatment period was 18 months .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3961,
    "text": "During the follow - up period , attention was paid to breast modifications as evidenced by symptomatology , physical examination , and plate thermography .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3962,
    "text": "Mastodynia was reported by 21 patients , and physical examination revealed a light increase in breast firmness in 12 women and a moderate increase in breast nodularity in 2 women .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Mastodynia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3963,
    "text": "Themography confirmed the existence of an excessive breast stimulation in 1 women who complained of moderate mastodynia and in 5 of the 7 women who complained of severe mastodynia .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "mastodynia"
      ],
      [
        "T1",
        "Disease",
        28,
        29,
        "mastodynia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3964,
    "text": "Normalization was obtained by halving the estrogen dose .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "estrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3965,
    "text": "These results suggest that hormonal replacement therapy can be safely prescribed if the following criteria are satisfied : 1 ) preliminary evaluation of patients from a clinical , metabolic , cytologic , and mammographic perspective ; 2 ) cyclic treatment schedule , with a progestative phase of 10 days ; and 3 ) periodic complete follow - up , with accurate thermographic evaluation of the breast target tissues .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3966,
    "text": "Early infections in kidney , heart , and liver transplant recipients on cyclosporine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "infections"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "cyclosporine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3967,
    "text": "Eighty - one renal , seventeen heart , and twenty - four liver transplant patients were followed for infection .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3968,
    "text": "Seventeen renal patients received azathioprine ( Aza ) and prednisone as part of a randomized trial of immunosuppression with 21 cyclosporine - and - prednisone - treated renal transplant patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "azathioprine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "Aza"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "prednisone"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "cyclosporine"
      ],
      [
        "T4",
        "Chemical",
        24,
        25,
        "prednisone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3969,
    "text": "All others received cyclosporine and prednisone .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cyclosporine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "prednisone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3970,
    "text": "The randomized Aza patients had more overall infections ( P less than 0 . 05 ) and more nonviral infections ( P less than 0 . 02 ) than the randomized cyclosporine patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Aza"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "infections"
      ],
      [
        "T2",
        "Disease",
        19,
        20,
        "infections"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "cyclosporine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3971,
    "text": "Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "infections"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "cyclosporine"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "infections"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "Aza"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3972,
    "text": "There were no infectious deaths in renal transplant patients on cyclosporine or Aza , but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "cyclosporine"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "Aza"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3973,
    "text": "Renal patients on cyclosporine had the fewest bacteremias .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cyclosporine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "bacteremias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3974,
    "text": "Analysis of site of infection showed a preponderance of abdominal infections in liver patients , intrathoracic infections in heart patients , and urinary tract infections in renal patients .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "abdominal infections"
      ],
      [
        "T1",
        "Disease",
        22,
        25,
        "urinary tract infections"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "infection"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3975,
    "text": "Pulmonary infections were less common in cyclosporine - treated renal patients than in Aza - treated patients ( P less than 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "infections"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "cyclosporine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "Aza"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3976,
    "text": "Aza patients had significantly more staphylococcal infections than all other transplant groups ( P less than 0 . 005 ) , and systemic fungal infections occurred only in the liver transplant group .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "staphylococcal infections"
      ],
      [
        "T1",
        "Disease",
        23,
        25,
        "fungal infections"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Aza"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3977,
    "text": "Cytomegalovirus ( CMV ) shedding or serological rises in antibody titer , or both occurred in 78 % of cyclosporine patients and 76 % of Aza patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "cyclosporine"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "Aza"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3978,
    "text": "Of the cyclosporine patients , 15 % had symptoms related to CMV infection .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "CMV infection"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "cyclosporine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3979,
    "text": "Serological evidence for Epstein Barr Virus infection was found in 20 % of 65 cyclosporine patients studied .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        7,
        "Epstein Barr Virus infection"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "cyclosporine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3980,
    "text": "Three had associated symptoms , and one developed a lymphoma .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "lymphoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3981,
    "text": "Structure - activity and dose - effect relationships of the antagonism of picrotoxin - induced seizures by cholecystokinin , fragments and analogues of cholecystokinin in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "picrotoxin"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "cholecystokinin"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "cholecystokinin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3982,
    "text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester ( CCK - 8 - SE ) and nonsulphated cholecystokinin octapeptide ( CCK - 8 - NS ) enhanced the latency of seizures induced by picrotoxin in mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        5,
        "cholecystokinin octapeptide"
      ],
      [
        "T1",
        "Chemical",
        8,
        11,
        "CCK - 8"
      ],
      [
        "T2",
        "Chemical",
        16,
        18,
        "cholecystokinin octapeptide"
      ],
      [
        "T3",
        "Chemical",
        19,
        22,
        "CCK - 8"
      ],
      [
        "T4",
        "Disease",
        29,
        30,
        "seizures"
      ],
      [
        "T5",
        "Chemical",
        32,
        33,
        "picrotoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3983,
    "text": "Experiments with N - and C - terminal fragments revealed that the C - terminal tetrapeptide ( CCK - 5 - 8 ) was the active centre of the CCK octapeptide molecule .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 3984,
    "text": "The analogues CCK - 8 - SE and CCK - 8 - NS ( dose range 0 . 2 - 6 . 4 mumol / kg ) and caerulein dose range 0 . 1 - 0 . 8 mumol / kg ) showed bell - shaped dose - effect curves , with the greatest maximum inhibition for CCK - 8 - NS .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "CCK - 8"
      ],
      [
        "T1",
        "Chemical",
        8,
        11,
        "CCK - 8"
      ],
      [
        "T2",
        "Chemical",
        57,
        60,
        "CCK - 8"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "caerulein"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3985,
    "text": "The peptide CCK - 5 - 8 had weak anticonvulsant activity in comparison to the octapeptides , 3 . 2 mumol / kg and larger doses of the reference drug , diazepam , totally prevented picrotoxin - induced seizures and mortality .",
    "labels": [
      [
        "T0",
        "Chemical",
        31,
        32,
        "diazepam"
      ],
      [
        "T1",
        "Chemical",
        35,
        36,
        "picrotoxin"
      ],
      [
        "T2",
        "Disease",
        38,
        39,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3986,
    "text": "The maximum effect of the peptides tested was less than that of diazepam .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3987,
    "text": "Experiments with analogues and derivatives of CCK - 5 - 8 demonstrated that the effectiveness of the beta - alanyl derivatives of CCK - 5 - 8 were enhanced and that they were equipotent with CCK - 8 - SE .",
    "labels": [
      [
        "T0",
        "Chemical",
        35,
        38,
        "CCK - 8"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3988,
    "text": "Of the CCK - 2 - 8 analogues , Ser ( SO3H ) 7 - Ac - CCK - 2 - 8 - SE and Thr ( SO3H ) 7 - Ac - CCK - 2 - 8 - SE and Hyp ( SO3H ) - Ac - CCK - 2 - 8 - SE were slightly more active than CCK - 8 - SE .",
    "labels": [
      [
        "T0",
        "Chemical",
        60,
        63,
        "CCK - 8"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3989,
    "text": "Vasopressin as a possible contributor to hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Vasopressin"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3990,
    "text": "The role of vasopressin as a pressor agent to the hypertensive process was examined .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "vasopressin"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3991,
    "text": "Vasopressin plays a major role in the pathogenesis of DOCA - salt hypertension , since the elevation of blood pressure was not substantial in the rats with lithium - treated diabetes insipidus after DOCA - salt treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        30,
        32,
        "diabetes insipidus"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Vasopressin"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "DOCA"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "hypertension"
      ],
      [
        "T4",
        "Chemical",
        27,
        28,
        "lithium"
      ],
      [
        "T5",
        "Chemical",
        33,
        34,
        "DOCA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3992,
    "text": "Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "DDAVP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3993,
    "text": "Furthermore , the pressor action of vasopressin appears to be important in the development of this model of hypertension , since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "vasopressin"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "hypertension"
      ],
      [
        "T2",
        "Disease",
        35,
        36,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3994,
    "text": "Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "vasopressin"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3995,
    "text": "An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for sodium balance in the brain .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "vasopressin"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "angiotensin"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3996,
    "text": "However , the role of vasopressin remains to be determined in human essential hypertension .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "vasopressin"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3997,
    "text": "Toxic hepatitis induced by disulfiram in a non - alcoholic .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Toxic hepatitis"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "disulfiram"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3998,
    "text": "A reversible toxic liver damage was observed in a non - alcoholic woman treated with disulfiram .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "toxic liver damage"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "disulfiram"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 3999,
    "text": "The causative relationship was proven by challenge .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4000,
    "text": "Atrial thrombosis involving the heart of F - 344 rats ingesting quinacrine hydrochloride .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Atrial thrombosis"
      ],
      [
        "T1",
        "Chemical",
        11,
        13,
        "quinacrine hydrochloride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4001,
    "text": "Quinacrine hydrochloride is toxic for the heart of F - 344 rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Quinacrine hydrochloride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4002,
    "text": "Rats treated with 500 ppm quinacrine hydrochloride in the diet all developed a high incidence of left atrial thrombosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "quinacrine hydrochloride"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "atrial thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4003,
    "text": "The lesion was associated with cardiac hypertrophy and dilatation and focal myocardial degeneration .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "cardiac hypertrophy"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "myocardial degeneration"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4004,
    "text": "Rats died from cardiac hypertrophy with severe acute and chronic congestion of the lungs , liver , and other organs .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiac hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4005,
    "text": "Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1 , 000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart , while untreated control rats in this laboratory did not have atrial thrombosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "quinacrine hydrochloride"
      ],
      [
        "T1",
        "Chemical",
        14,
        16,
        "sodium nitrite"
      ],
      [
        "T2",
        "Disease",
        39,
        41,
        "atrial thrombosis"
      ],
      [
        "T3",
        "Disease",
        21,
        22,
        "thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4006,
    "text": "Sodium nitrite in combination with quinacrine hydrochloride appeared to have no additional effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Sodium nitrite"
      ],
      [
        "T1",
        "Chemical",
        5,
        7,
        "quinacrine hydrochloride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4007,
    "text": "Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Alternating sinus rhythm"
      ],
      [
        "T1",
        "Disease",
        5,
        7,
        "sinoatrial block"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4008,
    "text": "Alternating sinus rhythm and intermittent sinoatrial ( S - A ) block was observed in a 57 - year - old woman , under treatment for angina with 80 mg propranolol daily .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Alternating sinus rhythm"
      ],
      [
        "T1",
        "Disease",
        5,
        12,
        "sinoatrial ( S - A ) block"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "angina"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4009,
    "text": "The electrocardiogram showed alternation of long and short P - P intervals and occasional pauses .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4010,
    "text": "These pauses were always preceded by the short P - P intervals and were usually followed by one or two P - P intervals of 0 . 92 - 0 . 95 s representing the basic sinus cycle .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4011,
    "text": "Following these basic sinus cycles , alternating rhythm started with the longer P - P interval .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "alternating rhythm"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4012,
    "text": "The long P - P intervals ranged between 1 . 04 - 1 . 12 s and the short P - P intervals between 0 . 80 - 0 . 84 s , respectively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4013,
    "text": "The duration of the pauses were equal or almost equal to one short plus one long P - P interval or to twice the basic sinus cycle .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4014,
    "text": "In one recording a short period of regular sinus rhythm with intermittent 2 / 1 S - A block was observed .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        19,
        "S - A block"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4015,
    "text": "This short period of sinus rhythm was interrupted by sudden prolongation of the P - P interval starting the alternative rhythm .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4016,
    "text": "There were small changes in the shape of the P waves and P - R intervals .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4017,
    "text": "S - A conduction through two pathways , the first with 2 / 1 block the second having 0 . 12 - 0 . 14 s longer conduction time and with occasional 2 / 1 block was proposed for the explanation of the alternating P - P interval and other electrocardiographic features seen .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4018,
    "text": "Atropine 1 mg given intravenously resulted in shortening of all P - P intervals without changing the rhythm .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Atropine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4019,
    "text": "The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2 / 1 S - A block was seen .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        23,
        "S - A block"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4020,
    "text": "This was accepted as evidence for propranolol being the cause of this conduction disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "conduction disorder"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "propranolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4021,
    "text": "Antitumor effect , cardiotoxicity , and nephrotoxicity of doxorubicin in the IgM solid immunocytoma - bearing LOU / M / WSL rat .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "nephrotoxicity"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "doxorubicin"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "immunocytoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4022,
    "text": "Antitumor activity , cardiotoxicity , and nephrotoxicity induced by doxorubicin were studied in LOU / M / WSL inbred rats each bearing a transplantable solid IgM immunocytoma .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "nephrotoxicity"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "doxorubicin"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "immunocytoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4023,
    "text": "Animals with a tumor ( diameter , 15 . 8 + / - 3 . 3 mm ) were treated with iv injections of doxorubicin on 5 consecutive days , followed by 1 weekly injection for 7 weeks ( dose range , 0 . 015 - 4 . 0 mg / kg body wt ) .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "tumor"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4024,
    "text": "Tumor regression was observed with 0 . 5 mg doxorubicin / kg .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Tumor"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4025,
    "text": "Complete disappearance of the tumor was induced with 1 . 0 mg doxorubicin / kg .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "tumor"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4026,
    "text": "Histologic evidence of cardiotoxicity scored as grade III was only observed at a dose of 1 . 0 mg doxorubicin / kg .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Chemical",
        19,
        20,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4027,
    "text": "Light microscopic evidence of renal damage was seen above a dose of 0 . 5 mg doxorubicin / kg , which resulted in albuminuria and very low serum albumin levels .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "renal damage"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "doxorubicin"
      ],
      [
        "T2",
        "Disease",
        23,
        24,
        "albuminuria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4028,
    "text": "In the group that received 1 . 0 mg doxorubicin / kg , the serum albumin level decreased from 33 . 6 + / - 4 . 1 to 1 . 5 + / - 0 . 5 g / liter .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4029,
    "text": "Ascites and hydrothorax were observed simultaneously .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Ascites"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "hydrothorax"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4030,
    "text": "The same experiments were performed with non - tumor - bearing rats , in which no major differences were observed .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4031,
    "text": "In conclusion , antitumor activity , cardiotoxicity , and nephrotoxicity were studied simultaneously in the same LOU / M / WSL rat .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "cardiotoxicity"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4032,
    "text": "Albuminuria due to renal damage led to extremely low serum albumin levels , so ascites and hydrothorax were not necessarily a consequence of the observed cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "renal damage"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Albuminuria"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "ascites"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "hydrothorax"
      ],
      [
        "T4",
        "Disease",
        25,
        26,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4033,
    "text": "Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "bradycardia"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "timolol"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4034,
    "text": "A 69 - yr - old man , who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops , developed a bradycardia and became hypotensive during halothane anaesthesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "pilocarpine nitrate"
      ],
      [
        "T1",
        "Chemical",
        17,
        19,
        "timolol maleate"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "bradycardia"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "hypotensive"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "halothane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4035,
    "text": "Both timolol and pilocarpine were subsequently identified in a 24 - h collection of urine .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "timolol"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4036,
    "text": "Timolol ( but not pilocarpine ) was detected in a sample of plasma removed during surgery ; the plasma concentration of timolol ( 2 . 6 ng ml - 1 ) was consistent with partial beta - adrenoceptor blockade .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Timolol"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "pilocarpine"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "timolol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4037,
    "text": "It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "halothane"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "bradycardia"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4038,
    "text": "Pilocarpine may have had a contributory effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4039,
    "text": "Succinylcholine apnoea : attempted reversal with anticholinesterases .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Succinylcholine"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "apnoea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4040,
    "text": "Anticholinesterases were administered in an attempt to antagonize prolonged neuromuscular blockade following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "neuromuscular blockade"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4041,
    "text": "Edrophonium 10 mg , given 74 min after succinylcholine , when train - of - four stimulation was characteristic of phase II block , produced partial antagonism which was not sustained .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Edrophonium"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4042,
    "text": "Repeated doses of edrophonium to 70 mg and neostigmine to 2 . 5 mg did not antagonize or augment the block .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "edrophonium"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "neostigmine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4043,
    "text": "Spontaneous respiration recommenced 200 min after succinylcholine administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "succinylcholine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4044,
    "text": "It is concluded that anticholinesterases are only partially effective in restoring neuromuscular function in succinylcholine apnoea despite muscle twitch activity typical of phase II block .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "succinylcholine"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "apnoea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4045,
    "text": "Effect of doxorubicin on [ omega - I - 131 ] heptadecanoic acid myocardial scintigraphy and echocardiography in dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        13,
        "[ omega - I - 131 ] heptadecanoic acid"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4046,
    "text": "The effects of serial treatment with doxorubicin on dynamic myocardial scintigraphy with [ omega - I - 131 ] heptadecanoic acid ( I - 131 HA ) , and on global left - ventricular function determined echocardiographically , were studied in a group of nine mongrel dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        21,
        "[ omega - I - 131 ] heptadecanoic acid"
      ],
      [
        "T1",
        "Chemical",
        22,
        26,
        "I - 131 HA"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4047,
    "text": "Total extractable myocardial lipid was compared postmortem between a group of control dogs and doxorubicin - treated dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4048,
    "text": "A significant and then progressive fall in global LV function was observed at a cumulative doxorubicin dose of 4 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4049,
    "text": "A significant increase in the myocardial t1 / 2 of the I - 131 HA was observed only at a higher cumulative dose , 10 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        15,
        "I - 131 HA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4050,
    "text": "No significant alteration in total extractable myocardial lipids was observed between control dogs and those treated with doxorubicin .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4051,
    "text": "Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I - 131 HA are not the initiating factor in doxorubicin cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        19,
        "I - 131 HA"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "doxorubicin"
      ],
      [
        "T2",
        "Disease",
        26,
        27,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4052,
    "text": "Hemodynamics and myocardial metabolism under deliberate hypotension .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4053,
    "text": "An experimental study in dogs .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4054,
    "text": "Coronary blood flow , cardiac work and metabolism were studied in dogs under sodium nitroprusside ( SNP ) and trimetaphan ( TMP ) deliberate hypotension ( 20 % and 40 % mean pressure decrease from baseline ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        15,
        "sodium nitroprusside"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "SNP"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "trimetaphan"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "TMP"
      ],
      [
        "T4",
        "Disease",
        24,
        25,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4055,
    "text": "Regarding the effects of drug - induced hypotension on coronary blood flow , aortic and coronary sinus metabolic data ( pH , pO2 , pCO2 ) we could confirm that nitroprusside hypotension could be safely used to 30 % mean blood pressure decrease from control , trimetaphan hypotension to 20 % mean blood pressure decrease .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "nitroprusside"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "hypotension"
      ],
      [
        "T3",
        "Chemical",
        46,
        47,
        "trimetaphan"
      ],
      [
        "T4",
        "Disease",
        47,
        48,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4056,
    "text": "Cardiac work was significantly reduced during SNP hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "SNP"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4057,
    "text": "Myocardial O2 consumption and O2 availability were directly dependent on the coronary perfusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "O2"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "O2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4058,
    "text": "Careful invasive monitoring of the blood pressure , blood gases and of the ECG ST - T segment is mandatory .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4059,
    "text": "Evidence for a selective brain noradrenergic involvement in the locomotor stimulant effects of amphetamine in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4060,
    "text": "Male rats received the noradrenaline neurotoxin DSP4 ( 50 mg / kg ) 7 days prior to injection of D - amphetamine ( 10 or 40 mumol / kg i . p . ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        22,
        "D - amphetamine"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "noradrenaline"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "DSP4"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4061,
    "text": "The hyperactivity induced by D - amphetamine ( 10 mumol / kg ) was significantly reduced by DSP4 pretreatment .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "D - amphetamine"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "hyperactivity"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "DSP4"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4062,
    "text": "However , the increased rearings and the amphetamine - induced stereotypies were not blocked by pretreatment with DSP4 .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "amphetamine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "stereotypies"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "DSP4"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4063,
    "text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline - uptake blocking agent , desipramine , which prevents the neurotoxic action of DSP4 .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "amphetamine"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "hyperactivity"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "DSP4"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "noradrenaline"
      ],
      [
        "T4",
        "Chemical",
        20,
        21,
        "desipramine"
      ],
      [
        "T5",
        "Disease",
        25,
        26,
        "neurotoxic"
      ],
      [
        "T6",
        "Chemical",
        28,
        29,
        "DSP4"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4064,
    "text": "The present results suggest a selective involvement of central noradrenergic neurones in the locomotor stimulant effect of amphetamine in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "amphetamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4065,
    "text": "Accelerated junctional rhythms during oral verapamil therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Accelerated junctional rhythms"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4066,
    "text": "This study examined the frequency of atrioventricular ( AV ) dissociation and accelerated junctional rhythms in 59 patients receiving oral verapamil .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        15,
        "accelerated junctional rhythms"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4067,
    "text": "Accelerated junctional rhythms and AV dissociation were frequent in patients with supraventricular tachyarrhythmias , particularly AV nodal reentry .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Accelerated junctional rhythms"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "supraventricular tachyarrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4068,
    "text": "Verapamil administration to these patients led to an asymptomatic increase in activity of these junctional pacemakers .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4069,
    "text": "In patients with various chest pain syndromes , verapamil neither increased the frequency of junctional rhythms nor suppressed their role as escape rhythms under physiologically appropriate circumstances .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4070,
    "text": "Interstrain variation in acute toxic response to caffeine among inbred mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4071,
    "text": "Acute toxic dosage - dependent behavioral effects of caffeine were compared in adult males from seven inbred mouse strains ( A / J , BALB / cJ , CBA / J , C3H / HeJ , C57BL / 6J , DBA / 2J , SWR / J ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4072,
    "text": "C57BL / 6J , chosen as a \" prototypic \" mouse strain , was used to determine behavioral responses to a broad range ( 5 - 500 mg / kg ) of caffeine doses .",
    "labels": [
      [
        "T0",
        "Chemical",
        32,
        33,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4073,
    "text": "Five phenotypic characteristics - - locomotor activity , righting ability , clonic seizure induction , stress - induced lethality , death without external stress - - were scored at various caffeine doses in drug - naive animals under empirically optimized , rigidly constant experimental conditions .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "clonic seizure"
      ],
      [
        "T1",
        "Chemical",
        30,
        31,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4074,
    "text": "Mice ( n = 12 for each point ) received single IP injections of a fixed volume / g body weight of physiological saline carrier with or without caffeine in doses ranging from 125 - 500 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        28,
        29,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4075,
    "text": "Loss of righting ability was scored at 1 , 3 , 5 min post dosing and at 5 min intervals thereafter for 20 min .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4076,
    "text": "In the same animals the occurrence of clonic seizures was scored as to time of onset and severity for 20 min after drug administration .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "clonic seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4077,
    "text": "When these proceeded to tonic seizures , death occurred in less than 20 min .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "tonic seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4078,
    "text": "Animals surviving for 20 min were immediately stressed by a swim test in 25 degrees C water , and death - producing tonic seizures were scored for 2 min .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "tonic seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4079,
    "text": "In other animals locomotor activity was measured 15 or 60 min after caffeine administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4080,
    "text": "By any single behavioral criterion or a combination of these criteria , marked differences in response to toxic caffeine doses were observed between strains .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "caffeine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4081,
    "text": "These results indicate that behavioral toxicity testing of alkylxanthines in a single mouse strain may be misleading and suggest that toxic responses of the central nervous system to this class of compounds are genetically influenced in mammals .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "toxicity"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "alkylxanthines"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4082,
    "text": "Treatment of ovarian cancer with a combination of cis - platinum , adriamycin , cyclophosphamide and hexamethylmelamine .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "ovarian cancer"
      ],
      [
        "T1",
        "Chemical",
        8,
        11,
        "cis - platinum"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "adriamycin"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "cyclophosphamide"
      ],
      [
        "T4",
        "Chemical",
        16,
        17,
        "hexamethylmelamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4083,
    "text": "During the last 2 1 / 2 years , 38 patients with ovarian cancer were treated with a combination of cisplatinum ( CPDD ) , 50 mg / m2 , adriamycin , 30 mg / m2 , cyclophosphamide , 300 mg / m2 , on day 1 ; and hexamethylmelamine ( HMM ) , 6 mg / kg daily , for 14 days .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "ovarian cancer"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "cisplatinum"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "CPDD"
      ],
      [
        "T3",
        "Chemical",
        30,
        31,
        "adriamycin"
      ],
      [
        "T4",
        "Chemical",
        37,
        38,
        "cyclophosphamide"
      ],
      [
        "T5",
        "Chemical",
        49,
        50,
        "hexamethylmelamine"
      ],
      [
        "T6",
        "Chemical",
        51,
        52,
        "HMM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4084,
    "text": "Each course was repeated monthly .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4085,
    "text": "2 patients had stage II , 14 stage III and 22 stage IV disease .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4086,
    "text": "14 of the 38 patients were previously treated with chemotherapy , 1 with radiation , 6 with both chemotherapy and radiation , and 17 did not have any treatment before CPDD combination .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        31,
        "CPDD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4087,
    "text": "31 of the 38 cases ( 81 . 5 % ) demonstrated objective responses lasting for 2 months or more .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4088,
    "text": "These responses were partial in 19 and complete in 12 cases .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4089,
    "text": "Hematologic toxicity was moderate and with reversible anemia developing in 71 % of patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Hematologic toxicity"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "anemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4090,
    "text": "Gastrointestinal side effects from CPDD were universal .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "CPDD"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4091,
    "text": "HMM gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "gastrointestinal toxicity"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "HMM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4092,
    "text": "Severe nephrotoxicity was observed in 2 patients but was reversible .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4093,
    "text": "There were no drug - related deaths .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4094,
    "text": "Nontraumatic dissecting aneurysm of the basilar artery .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "dissecting aneurysm"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4095,
    "text": "A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension , smoke , and oral contraceptives is reported in a young female patient with a locked - in syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "dissecting aneurysm"
      ],
      [
        "T1",
        "Chemical",
        18,
        20,
        "oral contraceptives"
      ],
      [
        "T2",
        "Disease",
        29,
        33,
        "locked - in syndrome"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4096,
    "text": "A method for the measurement of tremor , and a comparison of the effects of tocolytic beta - mimetics .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "tremor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4097,
    "text": "A method permitting measurement of finger tremor as a displacement - time curve is described , using a test system with simple amplitude calibration .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "tremor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4098,
    "text": "The coordinates of the inversion points of the displacement - time curves were transferred through graphical input equipment to punched tape .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4099,
    "text": "By means of a computer program , periods and amplitudes of tremor oscillations were calculated and classified .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "tremor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4100,
    "text": "The event frequency for each class of periods and amplitudes was determined .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4101,
    "text": "The actions of fenoterol - hydrobromide , ritodrin - HCl and placebo given to 10 healthy subjects by intravenous infusion in a double - blind crossover study were tested by this method .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "fenoterol - hydrobromide"
      ],
      [
        "T1",
        "Chemical",
        7,
        10,
        "ritodrin - HCl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4102,
    "text": "At therapeutic doses both substances raised the mean tremor amplitude to about three times the control level .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "tremor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4103,
    "text": "At the same time , the mean period within each class of amplitudes shortened by 10 - - 20 ms , whereas the mean periods calculated from all oscillations together did not change significantly .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4104,
    "text": "After the end of fenoterol - hydrobromide infusion , tremor amplitudes decreased significantly faster than those following ritodrin - HCl infusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "fenoterol - hydrobromide"
      ],
      [
        "T1",
        "Chemical",
        17,
        20,
        "ritodrin - HCl"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "tremor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4105,
    "text": "Propylthiouracil - induced hepatic damage .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "hepatic damage"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Propylthiouracil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4106,
    "text": "Two cases of propylthiouracil - induced liver damage have been observed .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "liver damage"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "propylthiouracil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4107,
    "text": "The first case is of an acute type of damage , proven by rechallenge ; the second presents a clinical and histologic picture resembling chronic active hepatitis , with spontaneous remission .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        27,
        "chronic active hepatitis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4108,
    "text": "Studies on the bradycardia induced by bepridil .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "bradycardia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "bepridil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4109,
    "text": "Bepridil , a novel active compound for prophylactic treatment of anginal attacks , induced persistent bradycardia and a non - specific anti - tachycardial effect , the mechanisms of which were investigated in vitro and in vivo .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "anginal attacks"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Bepridil"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "bradycardia"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "tachycardial"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4110,
    "text": "In vitro perfusion of bepridil in the life - support medium for isolated sino - atrial tissue from rabbit heart , caused a reduction in action potential ( AP ) spike frequency ( recorded by KCl microelectrodes ) starting at doses of 5 X 10 ( - 6 ) M .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "bepridil"
      ],
      [
        "T1",
        "Chemical",
        35,
        36,
        "KCl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4111,
    "text": "This effect was dose - dependent up to concentrations of 5 X 10 ( - 5 ) M , whereupon blockade of sinus activity set in .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4112,
    "text": "Bepridil at a dose of 5 X 10 ( - 6 ) M , induced a concomitant reduction in AP amplitude ( falling from 71 + / - 8 mV to 47 + / - 6 mV ) , maximum systolic depolarization velocity ( phase 0 ) which fell from 1 . 85 + / - 0 . 35 V / s to 0 . 84 + / - 0 . 28 V / s , together with maximum diastolic depolarization velocity ( phase 4 ) which fell from 38 + / - 3 mV / s to 24 + / - 5 mV / s .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Bepridil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4113,
    "text": "In vivo injection of bepridil at a dose of 5 mg / kg ( i . v . ) into 6 anaesthetized dogs which had undergone ablation of all the extrinsic cardiac afferent nerve supply , together with a bilateral medullo - adrenalectomy , caused a marked reduction in heart rate which fell from 98 . 7 + / - 4 . 2 beats / min to 76 + / - 5 . 3 beats / min sustained for more than 45 min .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "bepridil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4114,
    "text": "It is concluded that bepridil reduces heart rate by acting directly on the sinus node .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "bepridil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4115,
    "text": "This effect , which results in a flattening of the phase 0 and phase 4 slope , together with a longer AP duration , may be due to an increase in the time constants of slow inward ionic currents ( already demonstrated elsewhere ) , but also to an increased time constant for deactivation of the outward potassium current ( Ip ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        57,
        58,
        "potassium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4116,
    "text": "Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        5,
        "renal tubular acidosis"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Hepatitis"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "methoxyflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4117,
    "text": "A 69 - year - old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "acute cholecystitis"
      ],
      [
        "T1",
        "Disease",
        17,
        20,
        "hepatic insufficiency syndrome"
      ],
      [
        "T2",
        "Disease",
        21,
        24,
        "renal tubular acidosis"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "methoxyflurane"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4118,
    "text": "Massive bleeding appeared during surgery which lasted for six hours .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4119,
    "text": "Postoperative evolution under supportive therapy was favourable .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4120,
    "text": "Complete recovery was confirmed by repeated controls performed over a period of one year after surgery .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4121,
    "text": "Pituitary response to luteinizing hormone - releasing hormone during haloperidol - induced hyperprolactinemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "haloperidol"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4122,
    "text": "The effects of a 6 - hour infusion with haloperidol on serum prolactin and luteinizing hormone ( LH ) levels was studied in a group of male subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "haloperidol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4123,
    "text": "Five hours after starting the infusions , a study of the pituitary responses to LH - releasing hormone ( LH - RH ) was carried out .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4124,
    "text": "Control patients received infusions of 0 . 9 % NaCl solution .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "NaCl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4125,
    "text": "During the course of haloperidol infusions , significant hyperprolactinemia was found , together with an abolished pituitary response to LH - RH , as compared with responses of control subjects .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "haloperidol"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4126,
    "text": "Antirifampicin antibodies in acute rifampicin - associated renal failure .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "renal failure"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "rifampicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4127,
    "text": "5 patients with acute renal failure ( 3 with thrombopenia and hemolysis ) induced by the reintroduction of rifampicin are described .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "thrombopenia"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hemolysis"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "rifampicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4128,
    "text": "No correlation was found between the severity of clinical manifestations and the total dose taken by the patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4129,
    "text": "In all but 1 patient , antirifampicin antibodies were detected .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4130,
    "text": "Antibodies suggested to be of the IgM class were detected in all 3 patients with hematological disorders .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "hematological disorders"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4131,
    "text": "The pattern of non - specific acute tubular necrosis found in the 2 biopsied patients , indistinguishable from that of ischemic origin , raised the possibility of a vascular - mediated damage .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "acute tubular necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4132,
    "text": "In 3 patients , the possibility of a triggering immunoallergic mechanism is discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4133,
    "text": "Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        8,
        "adenosine triphosphate"
      ],
      [
        "T1",
        "Chemical",
        9,
        11,
        "sodium nitroprusside"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4134,
    "text": "Adenosine triphosphate ( ATP ) and sodium nitroprusside ( SNP ) are administered to patients to induce and control hypotension during anesthesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Adenosine triphosphate"
      ],
      [
        "T1",
        "Chemical",
        6,
        8,
        "sodium nitroprusside"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "ATP"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "SNP"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4135,
    "text": "SNP is authorized for clinical use in USA and UK , and ATP is clinically used in other countries such as Japan .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "SNP"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "ATP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4136,
    "text": "We investigated how these two drugs act on the cardiovascular systems of 20 dogs whose hearts had been denervated by a procedure we had devised .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4137,
    "text": "ATP ( 10 dogs ) or SNP ( 10 dogs ) was administered to reduce mean arterial pressure by 30 % to 70 % of control .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "ATP"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "SNP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4138,
    "text": "Before , during and after induced hypotension , we measured major cardiovascular parameters .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4139,
    "text": "Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure ( p less than 0 . 001 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 001 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , total body oxygen consumption ( p less than 0 . 05 ) , and heart rate ( p less than 0 . 001 ) ; all these variables returned normal within 30 min after ATP was stopped .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypotension"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "ATP"
      ],
      [
        "T2",
        "Chemical",
        76,
        77,
        "oxygen"
      ],
      [
        "T3",
        "Chemical",
        108,
        109,
        "ATP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4140,
    "text": "Cardiac output did not change .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4141,
    "text": "During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure ( p less than 0 . 01 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 01 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , and oxygen content difference between arterial and mixed venous blood ( p less than 0 . 05 ) , while heart rate ( p less than 0 . 001 ) and cardiac output ( p less than 0 . 05 ) were increased .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypotension"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "SNP"
      ],
      [
        "T2",
        "Chemical",
        75,
        76,
        "oxygen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4142,
    "text": "Recoveries of heart rate and left ventricular end - diastolic pressure were not shown within 60 min after SNP had been stopped .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "SNP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4143,
    "text": "Both ATP and SNP should act on the pacemaker tissue of the heart .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "ATP"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "SNP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4144,
    "text": "Comparative study : Endografine ( diatrizoate ) , Vasurix polyvidone ( acetrizoate ) , Dimer - X ( iocarmate ) and Hexabrix ( ioxaglate ) in hysterosalpingography .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        10,
        "Vasurix polyvidone"
      ],
      [
        "T1",
        "Chemical",
        14,
        17,
        "Dimer - X"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "Endografine"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "diatrizoate"
      ],
      [
        "T4",
        "Chemical",
        11,
        12,
        "acetrizoate"
      ],
      [
        "T5",
        "Chemical",
        18,
        19,
        "iocarmate"
      ],
      [
        "T6",
        "Chemical",
        21,
        22,
        "Hexabrix"
      ],
      [
        "T7",
        "Chemical",
        23,
        24,
        "ioxaglate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4145,
    "text": "Side effects of hysterosalpingography with Dimer - X , Hexabrix , Vasurix polyvidone and Endografine in 142 consecutive patients , receiving one of the four tested media were evaluated from replies to postal questionnaires .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "Dimer - X"
      ],
      [
        "T1",
        "Chemical",
        11,
        13,
        "Vasurix polyvidone"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "Hexabrix"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "Endografine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4146,
    "text": "The Dimer - X group had a higher incidence of nausea and dizziness .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        4,
        "Dimer - X"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "nausea"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "dizziness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4147,
    "text": "The Endografine group had a higher incidence of abdominal pain .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "abdominal pain"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "Endografine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4148,
    "text": "These differences occur especially in the age groups under 30 years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4149,
    "text": "Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        4,
        "Vasurix polyvidone"
      ],
      [
        "T1",
        "Chemical",
        8,
        10,
        "contrast media"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Hexabrix"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "toxicity"
      ],
      [
        "T4",
        "Chemical",
        19,
        20,
        "Hexabrix"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4150,
    "text": "Post - suxamethonium pains in Nigerian surgical patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "suxamethonium"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "pains"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4151,
    "text": "Contrary to an earlier report by Coxon , scoline pain occurs in African negroes .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "scoline"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4152,
    "text": "Its incidence was determined in a prospective study involving a total of 100 Nigerian patients ( 50 out - patients and 50 in - patients ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4153,
    "text": "About 62 % of the out - patients developed scoline pain as compared with about 26 % among the in - patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "scoline"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4154,
    "text": "The abolition of muscle fasciculations ( by 0 . 075mg / kg dose of Fazadinium ) did not influence the occurrence of scoline pain .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "fasciculations"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "Fazadinium"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "scoline"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4155,
    "text": "Neither the type of induction agent ( Althesin or Thiopentone ) nor the salt preparation of suxamethonium used ( chloride or bromide ) , affected the incidence of scoline pain .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "Althesin"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "Thiopentone"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "suxamethonium"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "chloride"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "bromide"
      ],
      [
        "T5",
        "Chemical",
        28,
        29,
        "scoline"
      ],
      [
        "T6",
        "Disease",
        29,
        30,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4156,
    "text": "Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        6,
        "carcinoma of the renal pelvis"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4157,
    "text": "A 47 - year - old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "cerebral vasculitis"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hydroureteronephrosis"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "hematuria"
      ],
      [
        "T3",
        "Chemical",
        25,
        26,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4158,
    "text": "A right nephroureterectomy was required for control of bleeding .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4159,
    "text": "The pathology specimen contained clinically occult invasive carcinoma of the renal pelvis .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        12,
        "carcinoma of the renal pelvis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4160,
    "text": "Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known , it is less widely appreciated that it is also associated with carcinoma of the urinary tract .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "hemorrhagic cystitis"
      ],
      [
        "T1",
        "Disease",
        33,
        38,
        "carcinoma of the urinary tract"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "cyclophosphamide"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "carcinoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4161,
    "text": "Twenty carcinomas of the urinary bladder and one carcinoma of the prostate have been reported in association with its use .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        6,
        "carcinomas of the urinary bladder"
      ],
      [
        "T1",
        "Disease",
        8,
        12,
        "carcinoma of the prostate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4162,
    "text": "The present case is the first carcinoma of the renal pelvis reported in association with cyclophosphamide treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        11,
        "carcinoma of the renal pelvis"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4163,
    "text": "It is the third urinary tract cancer reported in association with cyclophosphamide treatment for nonmalignant disease .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "urinary tract cancer"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4164,
    "text": "The association of the tumor with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to cyclophosphamide .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "tumor"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hydroureteronephrosis"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4165,
    "text": "Patients who are candidates for long - term cyclophosphamide treatment should be routinely evaluated for obstructive uropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "obstructive uropathy"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "cyclophosphamide"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4166,
    "text": "Medial changes in arterial spasm induced by L - norepinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "L - norepinephrine"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "spasm"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4167,
    "text": "In normal rats , the media of small arteries ( 0 . 4 - - 0 . 2 mm in diameter ) previously was shown to contain intracellular vacuoles , identified ultrastructurally as herniations of one smooth muscle cell into another .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4168,
    "text": "The hypothesis that intense vasoconstriction would increase the number of such vacuoles has been tested .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4169,
    "text": "In the media of the saphenous artery and its distal branch , vasoconstriction induced by L - norepinephrine produced many cell - to - cell hernias within 15 minutes .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        18,
        "L - norepinephrine"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "hernias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4170,
    "text": "At 1 day their number was reduced to about 1 / 10 of the original number .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4171,
    "text": "By 7 days the vessel was almost restored to normal .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4172,
    "text": "Triple stimulation over 1 day induced more severe changes in the media .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4173,
    "text": "These findings suggest that smooth muscle cells are susceptible to damage in the course of their specific function .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4174,
    "text": "The experimental data are discussed in relation to medial changes observed in other instances of arterial spasm .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "spasm"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4175,
    "text": "Endothelial changes that developed in the same experimental model were described in a previous paper .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4176,
    "text": "Bilateral retinal artery and choriocapillaris occlusion following the injection of long - acting corticosteroid suspensions in combination with other drugs : I .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        6,
        "retinal artery and choriocapillaris occlusion"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "corticosteroid"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4177,
    "text": "Clinical studies .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4178,
    "text": "Two well - documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft - tissue injection with methylprednisolone acetate in combination with lidocaine , epinephrine , or penicillin are reported .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        12,
        "retinal artery and choriocapillaris occlusions"
      ],
      [
        "T1",
        "Chemical",
        23,
        25,
        "methylprednisolone acetate"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "blindness"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "lidocaine"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "epinephrine"
      ],
      [
        "T5",
        "Chemical",
        33,
        34,
        "penicillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4179,
    "text": "One case had only a unilateral injection .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4180,
    "text": "The acute observations included hazy sensorium , superior gaze palsy , pupillary abnormalities , and conjunctival hemorrhages with edema .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "pupillary abnormalities"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "palsy"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "hemorrhages"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "edema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4181,
    "text": "Follow - up changes showed marked visual loss , constricted visual fields , optic nerve pallor , vascular attenuation , and chorioretinal atrophy .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "visual loss"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "chorioretinal atrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4182,
    "text": "The literature is reviewed , and possible causes are discussed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4183,
    "text": "Abnormalities of the pupil and visual - evoked potential in quinine amblyopia .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "quinine"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "amblyopia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4184,
    "text": "Total blindness with a transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of quinine sulfate for leg cramps .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "tonic pupillary"
      ],
      [
        "T1",
        "Chemical",
        31,
        33,
        "quinine sulfate"
      ],
      [
        "T2",
        "Disease",
        34,
        36,
        "leg cramps"
      ],
      [
        "T3",
        "Disease",
        1,
        2,
        "blindness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4185,
    "text": "He later recovered normal visual acuity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4186,
    "text": "A transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials in quinine toxicity , to our knowledge , have not been previously reported .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "tonic pupillary"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "quinine"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4187,
    "text": "Suxamethonium - induced jaw stiffness and myalgia associated with atypical cholinesterase : case report .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "jaw stiffness"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Suxamethonium"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4188,
    "text": "An 11 - year - old boy was given halothane , nitrous oxide and oxygen , pancuronium 0 . 4 mg and suxamethonium 100 mg for induction of anaesthesia .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "nitrous oxide"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "halothane"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "oxygen"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "pancuronium"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "suxamethonium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4189,
    "text": "In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "jaw stiffness"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4190,
    "text": "Four hours of apnoea ensued and he suffered generalized severe myalgia lasting for one week .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "apnoea"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "myalgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4191,
    "text": "He was found to have atypical plasma cholinesterase with a dibucaine number of 12 , indicating homozygocity .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "dibucaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4192,
    "text": "This was verified by study of the family .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4193,
    "text": "The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "prolonged jaw rigidity"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "myalgia"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "suxamethonium"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "pancuronium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4194,
    "text": "Indomethacin - induced hyperkalemia in three patients with gouty arthritis .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "gouty arthritis"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Indomethacin"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "hyperkalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4195,
    "text": "We describe three patients in whom severe , life - threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "renal insufficiency"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "gouty arthritis"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "hyperkalemia"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4196,
    "text": "This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "hyporeninemic hypoaidosteronism"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "prostaglandin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4197,
    "text": "Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti - inflammatory agents , particularly in those patients with diabetes mellitus or preexisting renal disease , will help prevent this potentially serious complication .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        27,
        "diabetes mellitus"
      ],
      [
        "T1",
        "Disease",
        29,
        31,
        "renal disease"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "potassium"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "indomethacin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4198,
    "text": "Etomidate : a foreshortened clinical trial .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4199,
    "text": "A clinical evaluation of etomidate for outpatient cystoscopy was embarked upon .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4200,
    "text": "Unpremedicated patients were given fentanyl 1 microgram / kg followed by etomidate 0 . 3 mg / kg .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "fentanyl"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4201,
    "text": "Anaesthesia was maintained with intermittent etomidate in 2 - 4 mg doses .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "etomidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4202,
    "text": "Patients were interviewed personally later the same day , and by questionnaire three to four weeks later .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4203,
    "text": "The trial was discontinued after 20 cases because of an unacceptable incidence of side effects .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4204,
    "text": "Venous pain occurred in 68 % of patients and 50 % had redness , pain or swelling related to the injection site , in some cases lasting up to three weeks after anaesthesia .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "pain"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "pain"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "swelling"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4205,
    "text": "Skeletal movements occurred in 50 % of patients ; 30 % experienced respiratory upset , one sufficiently severe to necessitate abandoning the technique .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "respiratory upset"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4206,
    "text": "Nausea and vomiting occurred in 40 % and 25 % had disturbing emergence psychoses .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Nausea"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "vomiting"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "psychoses"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4207,
    "text": "Levodopa - induced dyskinesias are improved by fluoxetine .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Levodopa"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "dyskinesias"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4208,
    "text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa - responsive patients with Parkinson ' s disease after an acute challenge with the mixed dopamine agonist , apomorphine , before and after the administration of fluoxetine ( 20 mg twice per day ) for 11 + / - 1 days .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "motor disability"
      ],
      [
        "T1",
        "Disease",
        16,
        20,
        "Parkinson ' s disease"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "dyskinesias"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "levodopa"
      ],
      [
        "T4",
        "Chemical",
        27,
        28,
        "dopamine"
      ],
      [
        "T5",
        "Chemical",
        30,
        31,
        "apomorphine"
      ],
      [
        "T6",
        "Chemical",
        38,
        39,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4209,
    "text": "After fluoxetine treatment , there was a significant 47 % improvement ( p < 0 . 05 ) of apomorphine - induced dyskinesias without modification of parkinsonian motor disability .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "motor disability"
      ],
      [
        "T1",
        "Chemical",
        1,
        2,
        "fluoxetine"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "apomorphine"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "dyskinesias"
      ],
      [
        "T4",
        "Disease",
        26,
        27,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4210,
    "text": "The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias ( onset - and end - of - dose dyskinesias ) and in the upper limbs during choreic mid - dose dyskinesias .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "dystonic dyskinesias"
      ],
      [
        "T1",
        "Disease",
        34,
        39,
        "choreic mid - dose dyskinesias"
      ],
      [
        "T2",
        "Disease",
        1,
        2,
        "dyskinesias"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4211,
    "text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa - or dopamine agonist - induced dyskinesias without aggravating parkinsonian motor disability .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "motor disability"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "fluoxetine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "levodopa"
      ],
      [
        "T3",
        "Chemical",
        15,
        16,
        "dopamine"
      ],
      [
        "T4",
        "Disease",
        19,
        20,
        "dyskinesias"
      ],
      [
        "T5",
        "Disease",
        22,
        23,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4212,
    "text": "A large population - based follow - up study of trimethoprim - sulfamethoxazole , trimethoprim , and cephalexin for uncommon serious drug toxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        13,
        "trimethoprim - sulfamethoxazole"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "drug toxicity"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "trimethoprim"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "cephalexin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4213,
    "text": "We conducted a population - based 45 - day follow - up study of 232 , 390 people who were prescribed trimethoprim - sulfamethoxazole ( TMP - SMZ ) , 266 , 951 prescribed trimethoprim alone , and 196 , 397 prescribed cephalexin , to estimate the risk of serious liver , blood , skin , and renal disorders resulting in referral or hospitalization associated with these drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        24,
        "trimethoprim - sulfamethoxazole"
      ],
      [
        "T1",
        "Chemical",
        25,
        28,
        "TMP - SMZ"
      ],
      [
        "T2",
        "Disease",
        50,
        59,
        "liver , blood , skin , and renal disorders"
      ],
      [
        "T3",
        "Chemical",
        34,
        35,
        "trimethoprim"
      ],
      [
        "T4",
        "Chemical",
        42,
        43,
        "cephalexin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4214,
    "text": "The results were based on information recorded on office computers by selected general practitioners in the United Kingdom , together with a review of clinical records .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4215,
    "text": "The risk of clinically important idiopathic liver disease was similar for persons prescribed TMP - SMZ ( 5 . 2 / 100 , 000 ) and those prescribed trimethoprim alone ( 3 . 8 / 100 , 000 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "liver disease"
      ],
      [
        "T1",
        "Chemical",
        13,
        16,
        "TMP - SMZ"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "trimethoprim"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4216,
    "text": "The risk for those prescribed cephalexin was somewhat lower ( 2 . 0 / 100 , 000 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "cephalexin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4217,
    "text": "Only five patients experienced blood disorders , one of whom was exposed to TMP - SMZ ; of seven with erythema multiforme and Stevens - Johnson syndrome , four were exposed to TMP - SMZ .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        16,
        "TMP - SMZ"
      ],
      [
        "T1",
        "Disease",
        20,
        22,
        "erythema multiforme"
      ],
      [
        "T2",
        "Disease",
        23,
        27,
        "Stevens - Johnson syndrome"
      ],
      [
        "T3",
        "Chemical",
        32,
        35,
        "TMP - SMZ"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4218,
    "text": "The one case of toxic epidermal necrolysis occurred in a patient who took cephalexin .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "toxic epidermal necrolysis"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "cephalexin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4219,
    "text": "Finally , only five cases of acute parenchymal renal disease occurred , none likely to be caused by a study drug .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "renal disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4220,
    "text": "We conclude that the risk of the serious diseases studied is small for the three agents , and compares reasonably with the risk for many other antibiotics .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4221,
    "text": "Clinical safety of lidocaine in patients with cocaine - associated myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4222,
    "text": "STUDY OBJECTIVE : To evaluate the safety of lidocaine in the setting of cocaine - induced myocardial infarction ( MI ) .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4223,
    "text": "DESIGN : A retrospective , multicenter study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4224,
    "text": "SETTING : Twenty - nine university , university - affiliated , or community hospitals during a 6 - year period ( total of 117 cumulative hospital - years ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4225,
    "text": "PARTICIPANTS : Patients with cocaine - associated MI who received lidocaine in the emergency department .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "cocaine"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "MI"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4226,
    "text": "RESULTS : Of 29 patients who received lidocaine in the setting of cocaine - associated MI , no patient died ; exhibited bradydysrhythmias , ventricular tachycardia , or ventricular fibrillation ; or experienced seizures after administration of lidocaine ( 95 % confidence interval , 0 % to 11 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        24,
        26,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Disease",
        28,
        30,
        "ventricular fibrillation"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "lidocaine"
      ],
      [
        "T3",
        "Chemical",
        12,
        13,
        "cocaine"
      ],
      [
        "T4",
        "Disease",
        15,
        16,
        "MI"
      ],
      [
        "T5",
        "Disease",
        22,
        23,
        "bradydysrhythmias"
      ],
      [
        "T6",
        "Disease",
        33,
        34,
        "seizures"
      ],
      [
        "T7",
        "Chemical",
        37,
        38,
        "lidocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4227,
    "text": "CONCLUSION : Despite theoretical concerns that lidocaine may enhance cocaine toxicity , the use of lidocaine in patients with cocaine - associated MI was not associated with significant cardiovascular or central nervous system toxicity .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        34,
        "cardiovascular or central nervous system toxicity"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "lidocaine"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "cocaine"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "toxicity"
      ],
      [
        "T4",
        "Chemical",
        15,
        16,
        "lidocaine"
      ],
      [
        "T5",
        "Chemical",
        19,
        20,
        "cocaine"
      ],
      [
        "T6",
        "Disease",
        22,
        23,
        "MI"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4228,
    "text": "Experimental progressive muscular dystrophy and its treatment with high doses anabolizing agents .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "muscular dystrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4229,
    "text": "We are still a long way from discovering an unequivocal pathogenetic interpretation of progressive muscular dystrophy in man .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "muscular dystrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4230,
    "text": "Noteworthy efforts have been made in the experimental field ; a recessive autosomic form found in the mouse seems to bear the closest resemblance to the human form from the genetic point of view .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4231,
    "text": "Myopathy due to lack of vitamin E and myopathy induced by certain viruses have much in common anatomically and pathologically with the human form .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "vitamin E"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Myopathy"
      ],
      [
        "T2",
        "Disease",
        8,
        9,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4232,
    "text": "The authors induced myodystrophy in the rat by giving it a diet lacking in vitamin E .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "vitamin E"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "myodystrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4233,
    "text": "The pharmacological characteristics of vitamin E and the degenerative changes brought about by its deficiency , especially in the muscles , are illustrated .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "vitamin E"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4234,
    "text": "It is thus confirmed that the histological characteristics of myopathic rat muscle induced experimentally are extraordinarily similar to those of human myopathy as confirmed during biopsies performed at the Orthopaedic Traumatological Centre , Florence .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "myopathic"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "myopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4235,
    "text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent ( Dianabol , CIBA ) at high doses in rats rendered myopathic by a diet deficient in vitamin E .",
    "labels": [
      [
        "T0",
        "Chemical",
        45,
        47,
        "vitamin E"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "myopathic"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "steroids"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "Dianabol"
      ],
      [
        "T4",
        "Chemical",
        31,
        32,
        "CIBA"
      ],
      [
        "T5",
        "Disease",
        39,
        40,
        "myopathic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4236,
    "text": "In this way they obtained appreciable changes in body weight ( increased from 50 to 70 g after forty days at a dose of 5 mg per day of anabolizing agent ) , but most of all they found histological changes due to \" regenerative \" changes in the muscle tissue , which however maintained its myopathic characteristics in the control animals that were not treated with the anabolizing agent .",
    "labels": [
      [
        "T0",
        "Disease",
        56,
        57,
        "myopathic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4237,
    "text": "The authors conclude by affirming the undoubted efficacy of the anabolizing steroids in experimental myopathic disease , but they have reservations as to the transfer of the results into the human field , where high dosage cannot be carried out continuously because of the effects of the drug on virility ; because the tissue injury too often occurs at an irreversible stage vis - a - vis the \" regeneration \" of the muscle tissue ; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "myopathic disease"
      ],
      [
        "T1",
        "Chemical",
        89,
        91,
        "vitamin E"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4238,
    "text": "Paclitaxel 3 - hour infusion given alone and combined with carboplatin : preliminary results of dose - escalation trials .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Paclitaxel"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4239,
    "text": "Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) by 3 - hour infusion was combined with carboplatin in a phase I / II study directed to patients with non - small cell lung cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        34,
        40,
        "non - small cell lung cancer"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Paclitaxel"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "Taxol"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4240,
    "text": "Carboplatin was given at a fixed target area under the concentration - time curve of 6 . 0 by the Calvert formula , whereas paclitaxel was escalated in patient cohorts from 150 mg / m2 ( dose level I ) to 175 , 200 , 225 , and 250 mg / m2 .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Carboplatin"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4241,
    "text": "The 225 mg / m2 level was expanded for the phase II study since the highest level achieved ( 250 mg / m2 ) required modification because of nonhematologic toxicities ( arthralgia and sensory neuropathy ) .",
    "labels": [
      [
        "T0",
        "Disease",
        33,
        35,
        "sensory neuropathy"
      ],
      [
        "T1",
        "Disease",
        29,
        30,
        "toxicities"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "arthralgia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4242,
    "text": "Therapeutic effects were noted at all dose levels , with objective responses in 17 ( two complete and 15 partial regressions ) of 41 previously untreated patients .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4243,
    "text": "Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Toxicities"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4244,
    "text": "Carboplatin did not appear to add to the hematologic toxicities observed , and the paclitaxel / carboplatin combination could be dosed every 3 weeks .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "hematologic toxicities"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Carboplatin"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "paclitaxel"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "carboplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4245,
    "text": "The dose - dependent effect of misoprostol on indomethacin - induced renal dysfunction in well compensated cirrhosis .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "renal dysfunction"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "misoprostol"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "indomethacin"
      ],
      [
        "T3",
        "Disease",
        16,
        17,
        "cirrhosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4246,
    "text": "Misoprostol ( 200 micrograms ) has been shown to acutely counteract the indomethacin - induced renal dysfunction in well compensated cirrhotic patients .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "renal dysfunction"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Misoprostol"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "indomethacin"
      ],
      [
        "T3",
        "Disease",
        20,
        21,
        "cirrhotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4247,
    "text": "The aim of this study was to determine if the prophylactic value of misoprostol was dose - dependent .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "misoprostol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4248,
    "text": "Parameters of renal hemodynamics and tubular sodium and water handling were assessed by clearance techniques in 26 well compensated cirrhotic patients before and after an oral combination of 50 mg of indomethacin and various doses of misoprostol .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "sodium"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "cirrhotic"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "indomethacin"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "misoprostol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4249,
    "text": "The 200 - micrograms dose was able to totally abolish the deleterious renal effects of indomethacin , whereas the 800 - micrograms dose resulted in significant worsening of renal hemodynamics and sodium retention .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "indomethacin"
      ],
      [
        "T1",
        "Chemical",
        31,
        32,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4250,
    "text": "These changes were maximal in the hour immediately after medications and slowly returned toward base - line levels thereafter .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4251,
    "text": "These results suggest that the renal protective effects of misoprostol is dose - dependent .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "misoprostol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4252,
    "text": "However , until this apparent ability of 200 micrograms of misoprostol to prevent the adverse effects of indomethacin on renal function is confirmed with chronic frequent dosing , it would be prudent to avoid nonsteroidal anti - inflammatory therapy in patients with cirrhosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "misoprostol"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "indomethacin"
      ],
      [
        "T2",
        "Disease",
        42,
        43,
        "cirrhosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4253,
    "text": "Increased frequency and severity of angio - oedema related to long - term therapy with angiotensin - converting enzyme inhibitor in two patients .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "angio - oedema"
      ],
      [
        "T1",
        "Chemical",
        15,
        20,
        "angiotensin - converting enzyme inhibitor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4254,
    "text": "Adverse reactions to drugs are well recognized as a cause of acute or chronic urticaria , and angio - oedema .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        20,
        "angio - oedema"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "urticaria"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4255,
    "text": "Angiotensin - converting enzyme ( ACE ) inhibitors , used to treat hypertension and congestive heart failure , were introduced in Europe in the middle of the eighties , and the use of these drugs has increased progressively .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        8,
        "Angiotensin - converting enzyme ( ACE ) inhibitors"
      ],
      [
        "T1",
        "Disease",
        14,
        17,
        "congestive heart failure"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4256,
    "text": "Soon after the introduction of ACE inhibitors , acute bouts of angio - oedema were reported in association with the use of these drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "ACE inhibitors"
      ],
      [
        "T1",
        "Disease",
        11,
        14,
        "angio - oedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4257,
    "text": "We wish to draw attention to the possibility of adverse reactions to ACE inhibitors after long - term use and in patients with pre - existing angio - oedema .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "ACE inhibitors"
      ],
      [
        "T1",
        "Disease",
        26,
        29,
        "angio - oedema"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4258,
    "text": "Myoclonus associated with lorazepam therapy in very - low - birth - weight infants .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Myoclonus"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "lorazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4259,
    "text": "Lorazepam is being used with increasing frequency as a sedative in the newborn and the young infant .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Lorazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4260,
    "text": "Concern has been raised with regard to the safety of lorazepam in this age group , especially in very - low - birth - weight ( VLBW ; < 1 , 500 g ) infants .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "lorazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4261,
    "text": "Three young infants , all of birth weight < 1 , 500 g , experienced myoclonus following the intravenous administration of lorazepam .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "myoclonus"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "lorazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4262,
    "text": "The potential neurotoxic effects of the drug ( and its vehicle ) in this population are discussed .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "neurotoxic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4263,
    "text": "Injectable lorazepam should be used with caution in VLBW infants .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "lorazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4264,
    "text": "Transvenous right ventricular pacing during cardiopulmonary resuscitation of pediatric patients with acute cardiomyopathy .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4265,
    "text": "We describe the cardiopulmonary resuscitation efforts on five patients who presented in acute circulatory failure from myocardial dysfunction .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "circulatory failure"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "myocardial dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4266,
    "text": "Three patients had acute viral myocarditis , one had a carbamazepine - induced acute eosinophilic myocarditis , and one had cardiac hemosiderosis resulting in acute cardiogenic shock .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "eosinophilic myocarditis"
      ],
      [
        "T1",
        "Disease",
        25,
        27,
        "cardiogenic shock"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "myocarditis"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "carbamazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4267,
    "text": "All patients were continuously monitored with central venous and arterial catheters in addition to routine noninvasive monitoring .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4268,
    "text": "An introducer sheath , a pacemaker , and sterile pacing wires were made readily available for the patients , should the need arise to terminate resistant cardiac dysrhythmias .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        28,
        "dysrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4269,
    "text": "All patients developed cardiocirculatory arrest associated with extreme hypotension and dysrhythmias within the first 48 hours of their admission to the pediatric intensive care unit ( PICU ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hypotension"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "dysrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4270,
    "text": "Right ventricular pacemaker wires were inserted in all of them during cardiopulmonary resuscitation ( CPR ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4271,
    "text": "In four patients , cardiac pacing was used , resulting in a temporary captured rhythm and restoration of their cardiac output .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4272,
    "text": "These patients had a second event of cardiac arrest , resulting in death , within 10 to 60 minutes .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "cardiac arrest"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4273,
    "text": "In one patient , cardiac pacing was not used , because he converted to normal sinus rhythm by electrical defibrillation within three minutes of initiating CPR .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4274,
    "text": "We conclude that cardiac pacing during resuscitative efforts in pediatric patients suffering from acute myocardial dysfunction may not have long - term value in and of itself ; however , if temporary hemodynamic stability is achieved by this procedure , it may provide additional time needed to institute other therapeutic modalities .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "myocardial dysfunction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4275,
    "text": "Efficacy and safety of granisetron , a selective 5 - hydroxytryptamine - 3 receptor antagonist , in the prevention of nausea and vomiting induced by high - dose cisplatin .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        11,
        "5 - hydroxytryptamine"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "granisetron"
      ],
      [
        "T2",
        "Disease",
        20,
        21,
        "nausea"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "vomiting"
      ],
      [
        "T4",
        "Chemical",
        28,
        29,
        "cisplatin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4276,
    "text": "PURPOSE : To assess the antiemetic effects and safety profile of four different doses of granisetron ( Kytril ; SmithKline Beecham Pharmaceuticals , Philadelphia , PA ) when administered as a single intravenous ( IV ) dose for prophylaxis of cisplatin - induced nausea and vomiting .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "granisetron"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "Kytril"
      ],
      [
        "T2",
        "Chemical",
        40,
        41,
        "cisplatin"
      ],
      [
        "T3",
        "Disease",
        43,
        44,
        "nausea"
      ],
      [
        "T4",
        "Disease",
        45,
        46,
        "vomiting"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4277,
    "text": "PATIENTS AND METHODS : One hundred eighty - four chemotherapy - naive patients receiving high - dose cisplatin ( 81 to 120 mg / m2 ) were randomized to receive one of four granisetron doses ( 5 , 10 , 20 , or 40 micrograms / kg ) administered before chemotherapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "cisplatin"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "granisetron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4278,
    "text": "Patients were observed on an inpatient basis for 18 to 24 hours , and vital signs , nausea , vomiting , retching , and appetite were assessed .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "nausea"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "vomiting"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4279,
    "text": "Safety analyses included incidence of adverse experiences and laboratory parameter changes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4280,
    "text": "RESULTS : After granisetron doses of 5 , 10 , 20 , and 40 micrograms / kg , a major response ( < or = two vomiting or retching episodes , and no antiemetic rescue ) was recorded in 23 % , 57 % , 58 % , and 60 % of patients , respectively , and a complete response ( no vomiting or retching , and no antiemetic rescue ) in 18 % , 41 % , 40 % , and 47 % of patients , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "granisetron"
      ],
      [
        "T1",
        "Disease",
        26,
        27,
        "vomiting"
      ],
      [
        "T2",
        "Disease",
        62,
        63,
        "vomiting"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4281,
    "text": "There was a statistically longer time to first episode of nausea ( P = . 0015 ) and vomiting ( P = . 0001 ) , and fewer patients were administered additional antiemetic medication in the 10 - micrograms / kg dosing groups than in the 5 - micrograms / kg dosing group .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "nausea"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "vomiting"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4282,
    "text": "As granisetron dose increased , appetite return increased ( P = . 040 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "granisetron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4283,
    "text": "Headache was the most frequently reported adverse event ( 20 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Headache"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4284,
    "text": "CONCLUSION : A single 10 - , 20 - , or 40 - micrograms / kg dose of granisetron was effective in controlling vomiting in 57 % to 60 % of patients who received cisplatin at doses greater than 81 mg / m2 and totally prevented vomiting in 40 % to 47 % of patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        19,
        "granisetron"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "vomiting"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "cisplatin"
      ],
      [
        "T3",
        "Disease",
        46,
        47,
        "vomiting"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4285,
    "text": "There were no statistically significant differences in efficacy between the 10 - micrograms / kg dose and the 20 - and 40 - micrograms / kg doses .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4286,
    "text": "Granisetron was well tolerated at all doses .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Granisetron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4287,
    "text": "Adverse interaction between clonidine and verapamil .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "clonidine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4288,
    "text": "OBJECTIVE : To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular ( AV ) block in both patients and severe hypotension in one patient .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        22,
        "atrioventricular ( AV ) block"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "clonidine"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "verapamil"
      ],
      [
        "T3",
        "Disease",
        27,
        28,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4289,
    "text": "CASE SUMMARIES : A 54 - year - old woman with hyperaldosteronism was treated with verapamil 480 mg / d and spironolactone 100 mg / d .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "hyperaldosteronism"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "verapamil"
      ],
      [
        "T2",
        "Chemical",
        21,
        22,
        "spironolactone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4290,
    "text": "After the addition of a minimal dose of clonidine ( 0 . 15 mg bid ) , she developed complete AV block and severe hypotension , which resolved upon cessation of all medications .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "AV block"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "clonidine"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4291,
    "text": "A 65 - year - old woman was treated with extended - release verapamil 240 mg / d .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4292,
    "text": "After the addition of clonidine 0 . 15 mg bid she developed complete AV block , which resolved after all therapy was stopped .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "AV block"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "clonidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4293,
    "text": "DISCUSSION : An adverse interaction between clonidine and verapamil has not been reported previously .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "clonidine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4294,
    "text": "We describe two such cases and discuss the various mechanisms that might cause such an interaction .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4295,
    "text": "Clinicians should be acquainted with this possibly fatal interaction between two commonly used antihypertensive drugs .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4296,
    "text": "CONCLUSIONS : Caution is recommended in combining clonidine and verapamil therapy , even in patients who do not have sinus or AV node dysfunction .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "clonidine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "verapamil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4297,
    "text": "The two drugs may act synergistically on both the AV node and the peripheral circulation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4298,
    "text": "Pharmacological studies on a new dihydrothienopyridine calcium antagonist , S - 312 - d .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        7,
        "dihydrothienopyridine calcium"
      ],
      [
        "T1",
        "Chemical",
        9,
        14,
        "S - 312 - d"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4299,
    "text": "5th communication : anticonvulsant effects in mice .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4300,
    "text": "S - 312 , S - 312 - d , but not S - 312 - l , L - type calcium channel antagonists , showed anticonvulsant effects on the audiogenic tonic convulsions in DBA / 2 mice ; and their ED50 values were 18 . 4 ( 12 . 8 - 27 . 1 ) mg / kg , p . o . and 15 . 0 ( 10 . 2 - 23 . 7 ) mg / kg , p . o . , respectively , while that of flunarizine was 34 . 0 ( 26 . 0 - 44 . 8 ) mg / kg , p . o .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "S - 312"
      ],
      [
        "T1",
        "Chemical",
        4,
        9,
        "S - 312 - d"
      ],
      [
        "T2",
        "Chemical",
        12,
        17,
        "S - 312 - l"
      ],
      [
        "T3",
        "Disease",
        30,
        33,
        "audiogenic tonic convulsions"
      ],
      [
        "T4",
        "Chemical",
        21,
        22,
        "calcium"
      ],
      [
        "T5",
        "Chemical",
        91,
        92,
        "flunarizine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4301,
    "text": "Although moderate anticonvulsant effects of S - 312 - d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole ( 85 mg / kg , s . c . ) or bemegride ( 40 mg / kg , s . c . ) , no effects were observed in convulsions induced by N - methyl - D - aspartate , picrotoxin , or electroshock in Slc : ddY mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        10,
        "S - 312 - d"
      ],
      [
        "T1",
        "Chemical",
        55,
        62,
        "N - methyl - D - aspartate"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "convulsions"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "pentylenetetrazole"
      ],
      [
        "T4",
        "Chemical",
        34,
        35,
        "bemegride"
      ],
      [
        "T5",
        "Disease",
        52,
        53,
        "convulsions"
      ],
      [
        "T6",
        "Chemical",
        63,
        64,
        "picrotoxin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4302,
    "text": "S - 312 - d may be useful in the therapy of certain types of human epilepsy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        5,
        "S - 312 - d"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "epilepsy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4303,
    "text": "Transmural myocardial infarction with sumatriptan .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "sumatriptan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4304,
    "text": "For sumatriptan , tightness in the chest caused by an unknown mechanism has been reported in 3 - 5 % of users .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "sumatriptan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4305,
    "text": "We describe a 47 - year - old woman with an acute myocardial infarction after administration of sumatriptan 6 mg subcutaneously for cluster headache .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "myocardial infarction"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "cluster headache"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "sumatriptan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4306,
    "text": "The patient had no history of underlying ischaemic heart disease or Prinzmetal ' s angina .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "ischaemic heart disease"
      ],
      [
        "T1",
        "Disease",
        11,
        15,
        "Prinzmetal ' s angina"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4307,
    "text": "She recovered without complications .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4308,
    "text": "Flumazenil induces seizures and death in mixed cocaine - diazepam intoxications .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Flumazenil"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "cocaine"
      ],
      [
        "T3",
        "Chemical",
        9,
        10,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4309,
    "text": "STUDY HYPOTHESIS : Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine - benzodiazepine intoxication .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "benzodiazepine"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "flumazenil"
      ],
      [
        "T2",
        "Disease",
        11,
        12,
        "seizures"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "cocaine"
      ],
      [
        "T4",
        "Chemical",
        16,
        17,
        "benzodiazepine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4310,
    "text": "DESIGN : Male Sprague - Dawley rats received 100 mg / kg cocaine IP alone , 5 mg / kg diazepam alone , or a combination of diazepam and cocaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "diazepam"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "diazepam"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4311,
    "text": "Three minutes later , groups were challenged with vehicle or flumazenil 5 or 10 mg / kg IP .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4312,
    "text": "Animal behavior , seizures ( time to and incidence ) , death ( time to and incidence ) , and cortical EEG tracings were recorded .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4313,
    "text": "INTERVENTIONS : Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "flumazenil"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4314,
    "text": "RESULTS : In group 1 , animals received cocaine followed by vehicle .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4315,
    "text": "This resulted in 100 % developing seizures and death .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4316,
    "text": "Group 2 received diazepam alone followed by vehicle .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4317,
    "text": "Animals became somnolent and none died .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4318,
    "text": "Group 3 received diazepam followed by 5 mg / kg flumazenil .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "diazepam"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4319,
    "text": "Animals became somnolent after diazepam and then active after flumazenil administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "diazepam"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4320,
    "text": "In group 4 , a combination of cocaine and diazepam was administered simultaneously .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4321,
    "text": "This resulted in no overt or EEG - detectable seizures and a 50 % incidence of death .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4322,
    "text": "Group 5 received a similar combination of cocaine and diazepam , followed later by 5 mg / kg flumazenil .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "diazepam"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4323,
    "text": "This resulted in an increased incidence of seizures , 90 % ( P < . 01 ) , and death , 100 % ( P < or = . 01 ) , compared with group 4 .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4324,
    "text": "Group 6 received cocaine and diazepam followed by 10 mg / kg flumazenil .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "diazepam"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "flumazenil"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4325,
    "text": "This also resulted in an increased incidence of seizures , 90 % ( P < or = . 01 ) , and death , 90 % ( P < or = . 05 ) , compared with group 4 .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4326,
    "text": "CONCLUSION : Flumazenil can unmask seizures and increase the incidence of death in a model of combined cocaine - diazepam intoxications .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "Flumazenil"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "cocaine"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4327,
    "text": "Mechanisms for protective effects of free radical scavengers on gentamicin - mediated nephropathy in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "gentamicin"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4328,
    "text": "Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on gentamicin ( GM ) - mediated nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "gentamicin"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "GM"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4329,
    "text": "Administration of GM at 40 mg / kg sc for 13 days to rats induced a significant reduction in renal blood flow ( RBF ) and inulin clearance ( CIn ) as well as marked tubular damage .",
    "labels": [
      [
        "T0",
        "Disease",
        35,
        37,
        "tubular damage"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "GM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4330,
    "text": "A significant reduction in urinary guanosine 3 ' , 5 ' - cyclic monophosphate ( cGMP ) excretion and a significant increase in renal cortical renin and endothelin - 1 contents were also observed in GM - mediated nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        14,
        "guanosine 3 ' , 5 ' - cyclic monophosphate"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "cGMP"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "GM"
      ],
      [
        "T3",
        "Disease",
        38,
        39,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4331,
    "text": "Superoxide dismutase ( SOD ) or dimethylthiourea ( DMTU ) significantly lessened the GM - induced decrement in CIn .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Superoxide"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "dimethylthiourea"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "DMTU"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "GM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4332,
    "text": "The SOD - induced increase in glomerular filtration rate was associated with a marked improvement in RBF , an increase in urinary cGMP excretion , and a decrease in renal renin and endothelin - 1 content .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "cGMP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4333,
    "text": "SOD did not attenuate the tubular damage .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "tubular damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4334,
    "text": "In contrast , DMTU significantly reduced the tubular damage and lipid peroxidation , but it did not affect renal hemodynamics and vasoactive substances .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "tubular damage"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "DMTU"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4335,
    "text": "Neither SOD nor DMTU affected the renal cortical GM content in GM - treated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "DMTU"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "GM"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "GM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4336,
    "text": "These results suggest that 1 ) both SOD and DMTU have protective effects on GM - mediated nephropathy , 2 ) the mechanisms for the protective effects differ for SOD and DMTU , and 3 ) superoxide anions play a critical role in GM - induced renal vasoconstriction .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "DMTU"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "GM"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "nephropathy"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "DMTU"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "superoxide"
      ],
      [
        "T5",
        "Chemical",
        43,
        44,
        "GM"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4337,
    "text": "Cephalothin - induced immune hemolytic anemia .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "hemolytic anemia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Cephalothin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4338,
    "text": "A patient with renal disease developed Coombs - positive hemolytic anemia while receiving cephalothin therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "renal disease"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "hemolytic anemia"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "cephalothin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4339,
    "text": "An anti - cephalothin IgG antibody was detected in the patient ' s serum and in the eluates from her erythrocytes .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "cephalothin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4340,
    "text": "In addition , nonimmunologic binding of normal and patient ' s serum proteins to her own and cephalothin - coated normal red cells was demonstrated .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "cephalothin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4341,
    "text": "Skin tests and in vitro lymphocyte stimulation revealed that the patient was sensitized to cephalothin and also to ampicillin .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "cephalothin"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "ampicillin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4342,
    "text": "Careful investigation of drug - induced hemolytic anemias reveals the complexity of the immune mechanisms involved .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "hemolytic anemias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4343,
    "text": "Assessment of cardiomyocyte DNA synthesis during hypertrophy in adult mice .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4344,
    "text": "The ability of cardiomyocytes to synthesize DNA in response to experimentally induced cardiac hypertrophy was assessed in adult mice .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        14,
        "cardiac hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4345,
    "text": "Isoproterenol delivered by osmotic minipump implantation in adult C3Heb / FeJ mice resulted in a 46 % increase in heart weight and a 19 . 3 % increase in cardiomyocyte area .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4346,
    "text": "No DNA synthesis , as assessed by autoradiographic analysis of isolated cardiomyocytes , was observed in control or hypertrophic hearts .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "hypertrophic hearts"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4347,
    "text": "A survey of 15 independent inbred strains of mice revealed that ventricular cardiomyocyte nuclear number ranged from 3 to 13 % mononucleate , suggesting that cardiomyocyte terminal differentiation is influenced directly or indirectly by genetic background .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4348,
    "text": "To determine whether the capacity for reactive DNA synthesis was also subject to genetic regulation , cardiac hypertrophy was induced in the strains of mice comprising the extremes of the nuclear number survey .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        18,
        "cardiac hypertrophy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4349,
    "text": "These data indicate that adult mouse atrial and ventricular cardiomyocytes do not synthesize DNA in response to isoproterenol - induced cardiac hypertrophy .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        22,
        "cardiac hypertrophy"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4350,
    "text": "Central cardiovascular effects of AVP and ANP in normotensive and spontaneously hypertensive rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "AVP"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4351,
    "text": "The purpose of the present study was to compare influence of central arginine vasopressin ( AVP ) and of atrial natriuretic peptide ( ANP ) on control of arterial blood pressure ( MAP ) and heart rate ( HR ) in normotensive ( WKY ) and spontaneously hypertensive ( SHR ) rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "arginine vasopressin"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "AVP"
      ],
      [
        "T2",
        "Disease",
        47,
        48,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4352,
    "text": "Three series of experiments were performed on 30 WKY and 30 SHR , chronically instrumented with guide tubes in the lateral ventricle ( LV ) and arterial and venous catheters .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4353,
    "text": "MAP and HR were monitored before and after i . v . injections of either vehicle or 1 , 10 and 50 ng of AVP and 25 , 125 and 500 ng of ANP .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "AVP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4354,
    "text": "Sensitivity of cardiac component of baroreflex ( CCB ) , expressed as a slope of the regression line was determined from relationships between systolic arterial pressure ( SAP ) and HR period ( HRp ) during phenylephrine ( Phe ) - induced hypertension and sodium nitroprusside ( SN ) - induced hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        44,
        46,
        "sodium nitroprusside"
      ],
      [
        "T1",
        "Chemical",
        36,
        37,
        "phenylephrine"
      ],
      [
        "T2",
        "Chemical",
        38,
        39,
        "Phe"
      ],
      [
        "T3",
        "Disease",
        42,
        43,
        "hypertension"
      ],
      [
        "T4",
        "Chemical",
        47,
        48,
        "SN"
      ],
      [
        "T5",
        "Disease",
        51,
        52,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4355,
    "text": "CCB was measured before and after administration of either vehicle , AVP , ANP , or both peptides together .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "AVP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4356,
    "text": "Increases of MAP occurred after LV administration of 1 , 10 and 50 ng of AVP in WKY and of 10 and 50 ng in SHR .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "AVP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4357,
    "text": "ANP did not cause significant changes in MAP in both strains as compared to vehicle , but it abolished AVP - induced MAP increase in WKY and SHR .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "AVP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4358,
    "text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN - induced hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "AVP"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "SN"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4359,
    "text": "In SHR but not in WKY administration of ANP , AVP and ANP + AVP decreased CCB during Phe - induced MAP elevation .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "AVP"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "AVP"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "Phe"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4360,
    "text": "The results indicate that centrally applied AVP and ANP exert differential effects on blood pressure and baroreflex control of heart rate in WKY and SHR and suggest interaction of these two peptides in blood pressure regulation at the level of central nervous system .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "AVP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4361,
    "text": "Cutaneous exposure to warfarin - like anticoagulant causing an intracerebral hemorrhage : a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "intracerebral hemorrhage"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4362,
    "text": "A case of intercerebral hematoma due to warfarin - induced coagulopathy is presented .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hematoma"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "warfarin"
      ],
      [
        "T2",
        "Disease",
        10,
        11,
        "coagulopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4363,
    "text": "The 39 - year - old woman had spread a warfarin - type rat poison around her house weekly using her bare hands , with no washing post application .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4364,
    "text": "Percutaneous absorption of warfarin causing coagulopathy , reported three times in the past , is a significant risk if protective measures , such as gloves , are not used .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "warfarin"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "coagulopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4365,
    "text": "An adverse drug interaction with piroxicam , which she took occasionally , may have exacerbated the coagulopathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "piroxicam"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "coagulopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4366,
    "text": "Pediatric heart transplantation without chronic maintenance steroids .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4367,
    "text": "From 1986 to February 1993 , 40 children aged 2 months to 18 years ( average age 10 . 4 + / - 5 . 8 years ) underwent heart transplantation .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4368,
    "text": "Indications for transplantation were idiopathic cardiomyopathy ( 52 % ) , congenital heart disease ( 35 % ) with and without prior repair ( 71 % and 29 % , respectively ) , hypertrophic cardiomyopathy ( 5 % ) , valvular heart disease ( 3 % ) , and doxorubicin cardiomyopathy ( 5 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "idiopathic cardiomyopathy"
      ],
      [
        "T1",
        "Disease",
        11,
        14,
        "congenital heart disease"
      ],
      [
        "T2",
        "Disease",
        33,
        35,
        "hypertrophic cardiomyopathy"
      ],
      [
        "T3",
        "Disease",
        40,
        43,
        "valvular heart disease"
      ],
      [
        "T4",
        "Chemical",
        49,
        50,
        "doxorubicin"
      ],
      [
        "T5",
        "Disease",
        50,
        51,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4369,
    "text": "Patients were managed with cyclosporine and azathioprine .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "cyclosporine"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "azathioprine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4370,
    "text": "No prophylaxis with antilymphocyte globulin was used .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4371,
    "text": "Steroids were given to 39 % of patients for refractory rejection , but weaning was always attempted and generally successful ( 64 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4372,
    "text": "Five patients ( 14 % ) received maintenance steroids .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "steroids"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4373,
    "text": "Four patients died in the perioperative period and one died 4 months later .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4374,
    "text": "There have been no deaths related to rejection or infection .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4375,
    "text": "Average follow - up was 36 + / - 19 months ( range 1 to 65 months ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4376,
    "text": "Cumulative survival is 88 % at 5 years .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4377,
    "text": "In patients less than 7 years of age , rejection was monitored noninvasively .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4378,
    "text": "In the first postoperative month , 89 % of patients were treated for rejection .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4379,
    "text": "Freedom from serious infections was 83 % at 1 month and 65 % at 1 year .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "infections"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4380,
    "text": "Cytomegalovirus infections were treated successfully with ganciclovir in 11 patients .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Cytomegalovirus infections"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "ganciclovir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4381,
    "text": "No impairment of growth was observed in children who underwent transplantation compared with a control population .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4382,
    "text": "Twenty - one patients ( 60 % ) have undergone annual catheterizations and no sign of graft atherosclerosis has been observed .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "atherosclerosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4383,
    "text": "Seizures occurred in five patients ( 14 % ) and hypertension was treated in 10 patients ( 28 % ) .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Seizures"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypertension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4384,
    "text": "No patient was disabled and no lymphoproliferative disorder was observed . ( ABSTRACT TRUNCATED AT 250 WORDS )",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "lymphoproliferative disorder"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4385,
    "text": "Delirium during fluoxetine treatment .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Delirium"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "fluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4386,
    "text": "A case report .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4387,
    "text": "The correlation between high serum tricyclic antidepressant concentrations and central nervous system side effects has been well established .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4388,
    "text": "Only a few reports exist , however , on the relationship between the serum concentrations of selective serotonin reuptake inhibitors ( SSRIs ) and their toxic effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4389,
    "text": "In some cases , a high serum concentration of citalopram ( > 600 nmol / L ) in elderly patients has been associated with increased somnolence and movement difficulties .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "movement difficulties"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "citalopram"
      ],
      [
        "T2",
        "Disease",
        25,
        26,
        "somnolence"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4390,
    "text": "Widespread cognitive disorders , such as delirium , have not been previously linked with high blood levels of SSRIs .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "cognitive disorders"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4391,
    "text": "In this report , we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine ( fluoxetine plus desmethylfluoxetine ) concentration .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "hyperkinetic"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "delirium"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "fluoxetine"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "fluoxetine"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "desmethylfluoxetine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4392,
    "text": "Pulmonary edema and shock after high - dose aracytine - C for lymphoma ; possible role of TNF - alpha and PAF .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Pulmonary edema"
      ],
      [
        "T1",
        "Chemical",
        8,
        11,
        "aracytine - C"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "shock"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "lymphoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4393,
    "text": "Four out of 23 consecutive patients treated with high - dose Ara - C for lymphomas in our institution developed a strikingly similar syndrome during the perfusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "Ara - C"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "lymphomas"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4394,
    "text": "It was characterized by the onset of fever , diarrhea , shock , pulmonary edema , acute renal failure , metabolic acidosis , weight gain and leukocytosis .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "pulmonary edema"
      ],
      [
        "T1",
        "Disease",
        16,
        19,
        "acute renal failure"
      ],
      [
        "T2",
        "Disease",
        20,
        22,
        "metabolic acidosis"
      ],
      [
        "T3",
        "Disease",
        23,
        25,
        "weight gain"
      ],
      [
        "T4",
        "Disease",
        7,
        8,
        "fever"
      ],
      [
        "T5",
        "Disease",
        9,
        10,
        "diarrhea"
      ],
      [
        "T6",
        "Disease",
        11,
        12,
        "shock"
      ],
      [
        "T7",
        "Disease",
        26,
        27,
        "leukocytosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4395,
    "text": "Thorough bacteriological screening failed to provide evidence of infection .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "infection"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4396,
    "text": "Sequential biological assays of IL - 1 , IL - 2 , TNF and PAF were performed during Ara - C infusion to ten patients , including the four who developed the syndrome .",
    "labels": [
      [
        "T0",
        "Chemical",
        18,
        21,
        "Ara - C"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4397,
    "text": "TNF and PAF activity was found in the serum of respectively two and four of the cases , but not in the six controls .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4398,
    "text": "As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome , we hypothesize that high - dose Ara - C may be associated with cytokine release .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        20,
        "adult respiratory distress syndrome"
      ],
      [
        "T1",
        "Chemical",
        27,
        30,
        "Ara - C"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "shock"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4399,
    "text": "Protective effect of clentiazem against epinephrine - induced cardiac injury in rats .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "cardiac injury"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "clentiazem"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4400,
    "text": "We investigated the effects of clentiazem , a 1 , 5 - benzothiazepine calcium antagonist , on epinephrine - induced cardiomyopathy in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        13,
        "1 , 5 - benzothiazepine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "clentiazem"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "calcium"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "epinephrine"
      ],
      [
        "T4",
        "Disease",
        20,
        21,
        "cardiomyopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4401,
    "text": "With 2 - week chronic epinephrine infusion , 16 of 30 rats died within 4 days , and severe ischemic lesions and fibrosis of the left ventricles were observed .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "ischemic lesions"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "epinephrine"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4402,
    "text": "In epinephrine - treated rats , left atrial and left ventricular papillary muscle contractile responses to isoproterenol were reduced , but responses to calcium were normal or enhanced compared to controls .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "epinephrine"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "isoproterenol"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4403,
    "text": "Left ventricular alpha and beta adrenoceptor densities were also reduced compared to controls .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4404,
    "text": "Treatment with clentiazem prevented epinephrine - induced death ( P < . 05 ) , and attenuated the ventricular ischemic lesions and fibrosis , in a dose - dependent manner .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "ischemic lesions"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "clentiazem"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "epinephrine"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "fibrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4405,
    "text": "Left atrial and left ventricular papillary muscle contractile responses to isoproterenol were reduced compared to controls in groups treated with clentiazem alone , but combined with epinephrine , clentiazem restored left atrial responses and enhanced left ventricular papillary responses to isoproterenol .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "isoproterenol"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "clentiazem"
      ],
      [
        "T2",
        "Chemical",
        26,
        27,
        "epinephrine"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "clentiazem"
      ],
      [
        "T4",
        "Chemical",
        40,
        41,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4406,
    "text": "On the other hand clentiazem did not prevent epinephrine - induced down - regulation of alpha and beta adrenoceptors .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "clentiazem"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4407,
    "text": "Interestingly , clentiazem , infused alone , resulted in decreased adrenergic receptor densities in the left ventricle .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "clentiazem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4408,
    "text": "Clentiazem also did not prevent the enhanced responses to calcium seen in the epinephrine - treated animals , although the high dose of clentiazem partially attenuated the maximal response to calcium compared to epinephrine - treated animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Clentiazem"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "calcium"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "epinephrine"
      ],
      [
        "T3",
        "Chemical",
        23,
        24,
        "clentiazem"
      ],
      [
        "T4",
        "Chemical",
        30,
        31,
        "calcium"
      ],
      [
        "T5",
        "Chemical",
        33,
        34,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4409,
    "text": "In conclusion , clentiazem attenuated epinephrine - induced cardiac injury , possibly through its effect on the adrenergic pathway .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "cardiac injury"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "clentiazem"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4410,
    "text": "Kaliuretic effect of L - dopa treatment in parkinsonian patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "L - dopa"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4411,
    "text": "Hypokalemia , sometimes severe , was observed in some L - dopa - treated parkinsonian patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        12,
        "L - dopa"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Hypokalemia"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "parkinsonian"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4412,
    "text": "The influence of L - dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow , glomerular filtration rate , plasma concentration of potassium and sodium as well as urinary excretion of potassium , sodium and aldosterone .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "L - dopa"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "potassium"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "hypokalemia"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "potassium"
      ],
      [
        "T4",
        "Chemical",
        40,
        41,
        "sodium"
      ],
      [
        "T5",
        "Chemical",
        47,
        48,
        "potassium"
      ],
      [
        "T6",
        "Chemical",
        49,
        50,
        "sodium"
      ],
      [
        "T7",
        "Chemical",
        51,
        52,
        "aldosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4413,
    "text": "L - Dopa intake was found to cause an increased excretion of potassium , and sometimes also of sodium , in the hypokalemic but not in the normokalemic patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "L - Dopa"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "potassium"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "sodium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4414,
    "text": "This effect on the renal function could be prohibited by the administration of a peripheral dopa decarbodylase inhibitor .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4415,
    "text": "It is not known why this effect occurred in some individuals but not in others , but our results indicate a correlation between aldosterone production and this renal effect of L - dopa .",
    "labels": [
      [
        "T0",
        "Chemical",
        30,
        33,
        "L - dopa"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "aldosterone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4416,
    "text": "Cocaine induced myocardial ischemia .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4417,
    "text": "We report a case of myocardial ischemia induced by cocaine .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "myocardial ischemia"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4418,
    "text": "The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "coronary artery spasm"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "ischemia"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "nitroglycerin"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "calcium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4419,
    "text": "Doxorubicin - induced cardiotoxicity monitored by ECG in freely moving mice .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Doxorubicin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4420,
    "text": "A new model to test potential protectors .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4421,
    "text": "In laboratory animals , histology is most commonly used to study doxorubicin - induced cardiotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "doxorubicin"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4422,
    "text": "However , for monitoring during treatment , large numbers of animals are needed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4423,
    "text": "Recently we developed a new method to measure ECG values in freely moving mice by telemetry .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4424,
    "text": "With this model we investigated the effect of chronic doxorubicin administration on the ECG of freely moving BALB / c mice and the efficacy of ICRF - 187 as a protective agent .",
    "labels": [
      [
        "T0",
        "Chemical",
        25,
        28,
        "ICRF - 187"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4425,
    "text": "The ST interval significantly widened from 15 . 0 + / - 1 . 5 to 56 . 8 + / - 11 . 8 ms in week 10 ( 7 weekly doses of 4 mg / kg doxorubicin given i . v . plus 3 weeks of observation ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        38,
        39,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4426,
    "text": "The ECG of the control animals did not change during the entire study .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4427,
    "text": "After sacrifice the hearts of doxorubicin - treated animals were enlarged and the atria were hypertrophic .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "doxorubicin"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hypertrophic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4428,
    "text": "As this schedule exerted more toxicity than needed to investigate protective agents , the protection of ICRF - 187 was determined using a dose schedule with lower general toxicity ( 6 weekly doses of 4 mg / kg doxorubicin given i . v . plus 2 weeks of observation ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        19,
        "ICRF - 187"
      ],
      [
        "T1",
        "Disease",
        5,
        6,
        "toxicity"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "toxicity"
      ],
      [
        "T3",
        "Chemical",
        38,
        39,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4429,
    "text": "On this schedule , the animals ' hearts appeared normal after sacrifice and ICRF - 187 ( 50 mg / kg given i . p . 1 h before doxorubicin ) provided almost full protection .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        16,
        "ICRF - 187"
      ],
      [
        "T1",
        "Chemical",
        29,
        30,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4430,
    "text": "These data were confirmed by histology .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4431,
    "text": "The results indicate that this new model is very sensitive and enables monitoring of the development of cardiotoxicity with time .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4432,
    "text": "These findings result in a model that allows the testing of protectors against doxorubicin - induced cardiotoxicity as demonstrated by the protection provided by ICRF - 187 .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        27,
        "ICRF - 187"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "doxorubicin"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "cardiotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4433,
    "text": "Epinephrine dysrhythmogenicity is not enhanced by subtoxic bupivacaine in dogs .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Epinephrine"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4434,
    "text": "Since bupivacaine and epinephrine may both precipitate dysrhythmias , circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "epinephrine"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "dysrhythmias"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "bupivacaine"
      ],
      [
        "T4",
        "Chemical",
        19,
        20,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4435,
    "text": "We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of epinephrine in conscious , healthy dogs and in anesthetized dogs with myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        23,
        25,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "bupivacaine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4436,
    "text": "Forty - one conscious dogs received 10 micrograms . kg - 1 . min - 1 epinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4437,
    "text": "Seventeen animals responded with ventricular tachycardia ( VT ) within 3 min .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "ventricular tachycardia"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "VT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4438,
    "text": "After 3 h , these responders randomly received 1 or 2 mg / kg bupivacaine or saline over 5 min , followed by 10 micrograms . kg - 1 . min - 1 epinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        33,
        34,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4439,
    "text": "In the bupivacaine groups , epinephrine caused fewer prodysrhythmic effects than without bupivacaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "epinephrine"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4440,
    "text": "VT appeared in fewer dogs and at a later time , and there were more sinoatrial beats and less ectopies .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "VT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4441,
    "text": "Epinephrine shortened QT less after bupivacaine than in control animals .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Epinephrine"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4442,
    "text": "One day after experimental myocardial infarction , six additional halothane - anesthetized dogs received 4 micrograms . kg - 1 . min - 1 epinephrine until VT appeared .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "halothane"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "epinephrine"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "VT"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4443,
    "text": "After 45 min , 1 mg / kg bupivacaine was injected over 5 min , again followed by 4 micrograms . kg - 1 . min - 1 epinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4444,
    "text": "In these dogs , the prodysrhythmic response to epinephrine was also mitigated by preceding bupivacaine .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "epinephrine"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "bupivacaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4445,
    "text": "Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        2,
        3,
        "epinephrine"
      ],
      [
        "T2",
        "Disease",
        9,
        10,
        "VT"
      ],
      [
        "T3",
        "Disease",
        17,
        18,
        "dysrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4446,
    "text": "There is no evidence that systemic subtoxic bupivacaine administration enhances the dysrhythmogenicity of subsequent epinephrine .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "bupivacaine"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "epinephrine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4447,
    "text": "Milk - alkali syndrome induced by 1 , 25 ( OH ) 2D in a patient with hypoparathyroidism .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Milk - alkali syndrome"
      ],
      [
        "T1",
        "Chemical",
        6,
        13,
        "1 , 25 ( OH ) 2D"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "hypoparathyroidism"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4448,
    "text": "Milk - alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Milk - alkali syndrome"
      ],
      [
        "T1",
        "Disease",
        17,
        20,
        "peptic ulcer disease"
      ],
      [
        "T2",
        "Chemical",
        24,
        25,
        "calcium"
      ],
      [
        "T3",
        "Chemical",
        26,
        27,
        "alkali"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4449,
    "text": "Although with current ulcer therapy ( H - 2 blockers , omeprazole , and sucralfate ) , the frequency of milk - alkali syndrome has decreased significantly , the classic triad of hypercalcemia , alkalosis , and renal impairment remains the hallmark of the syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        24,
        "milk - alkali syndrome"
      ],
      [
        "T1",
        "Disease",
        37,
        39,
        "renal impairment"
      ],
      [
        "T2",
        "Disease",
        3,
        4,
        "ulcer"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "omeprazole"
      ],
      [
        "T4",
        "Chemical",
        14,
        15,
        "sucralfate"
      ],
      [
        "T5",
        "Disease",
        32,
        33,
        "hypercalcemia"
      ],
      [
        "T6",
        "Disease",
        34,
        35,
        "alkalosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4450,
    "text": "Milk - alkali syndrome can present serious and occasionally life - threatening illness unless diagnosed and treated appropriately .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        4,
        "Milk - alkali syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4451,
    "text": "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        13,
        "calcium carbonate"
      ],
      [
        "T1",
        "Disease",
        23,
        27,
        "milk - alkali syndrome"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "hypoparathyroidism"
      ],
      [
        "T3",
        "Chemical",
        14,
        15,
        "calcitriol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4452,
    "text": "The patient was successfully treated with intravenous pamidronate on his first admission and with hydrocortisone on the second .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "pamidronate"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "hydrocortisone"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4453,
    "text": "This illustrates intravenous pamidronate as a valuable therapeutic tool when milk - alkali syndrome presents as hypercalcemic emergency .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        14,
        "milk - alkali syndrome"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "hypercalcemic emergency"
      ],
      [
        "T2",
        "Chemical",
        3,
        4,
        "pamidronate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4454,
    "text": "Famotidine - associated delirium .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Famotidine"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "delirium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4455,
    "text": "A series of six cases .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4456,
    "text": "Famotidine is a histamine H2 - receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Famotidine"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "ulcers"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4457,
    "text": "Although all of the currently available H2 - receptor antagonists have shown the propensity to cause delirium , only two previously reported cases have been associated with famotidine .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        17,
        "delirium"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "famotidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4458,
    "text": "The authors report on six cases of famotidine - associated delirium in hospitalized patients who cleared completely upon removal of famotidine .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "famotidine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "delirium"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "famotidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4459,
    "text": "The pharmacokinetics of famotidine are reviewed , with no change in its metabolism in the elderly population seen .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "famotidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4460,
    "text": "The implications of using famotidine in elderly persons are discussed .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "famotidine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4461,
    "text": "Encephalopathy during amitriptyline therapy : are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders ?",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "serotonin syndrome"
      ],
      [
        "T2",
        "Disease",
        0,
        1,
        "Encephalopathy"
      ],
      [
        "T3",
        "Chemical",
        2,
        3,
        "amitriptyline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4462,
    "text": "This report describes a case of encephalopathy developed in the course of amitriptyline therapy , during a remission of unipolar depression .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "unipolar depression"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "encephalopathy"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "amitriptyline"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4463,
    "text": "This patient could have been diagnosed as having either neuroleptic malignant syndrome ( NMS ) or serotonin syndrome ( SS ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "serotonin syndrome"
      ],
      [
        "T2",
        "Disease",
        13,
        14,
        "NMS"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "SS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4464,
    "text": "The major determinant of the symptoms may have been dopamine / serotonin imbalance in the central nervous system .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "dopamine"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4465,
    "text": "The NMS - like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "NMS"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "encephalopathy"
      ],
      [
        "T2",
        "Disease",
        16,
        17,
        "NMS"
      ],
      [
        "T3",
        "Disease",
        18,
        19,
        "SS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4466,
    "text": "Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen - induced tumor .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "tumor"
      ],
      [
        "T1",
        "Disease",
        6,
        7,
        "hemorrhagic"
      ],
      [
        "T2",
        "Chemical",
        10,
        11,
        "estrogen"
      ],
      [
        "T3",
        "Disease",
        13,
        14,
        "tumor"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4467,
    "text": "Chronic administration of estrogen to the Fischer 344 ( F344 ) rat induces growth of large , hemorrhagic pituitary tumors .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        20,
        "pituitary tumors"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "estrogen"
      ],
      [
        "T2",
        "Disease",
        17,
        18,
        "hemorrhagic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4468,
    "text": "Ten weeks of diethylstilbestrol ( DES ) treatment caused female F344 rat pituitaries to grow to an average of 109 . 2 + / - 6 . 3 mg ( mean + / - SE ) versus 11 . 3 + / - 1 . 4 mg for untreated rats , and to become highly hemorrhagic .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "diethylstilbestrol"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "DES"
      ],
      [
        "T2",
        "Disease",
        55,
        56,
        "hemorrhagic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4469,
    "text": "The same DES treatment produced no significant growth ( 8 . 9 + / - 0 . 5 mg for treated females versus 8 . 7 + / - 1 . 1 for untreated females ) or morphological changes in Brown Norway ( BN ) rat pituitaries .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "DES"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4470,
    "text": "An F1 hybrid of F344 and BN exhibited significant pituitary growth after 10 weeks of DES treatment with an average mass of 26 . 3 + / - 0 . 7 mg compared with 8 . 6 + / - 0 . 9 mg for untreated rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        15,
        16,
        "DES"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4471,
    "text": "Surprisingly , the F1 hybrid tumors were not hemorrhagic and had hemoglobin content and outward appearance identical to that of BN .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "tumors"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "hemorrhagic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4472,
    "text": "Expression of both growth and morphological changes is due to multiple genes .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4473,
    "text": "However , while DES - induced pituitary growth exhibited quantitative , additive inheritance , the hemorrhagic phenotype exhibited recessive , epistatic inheritance .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "DES"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "hemorrhagic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4474,
    "text": "Only 5 of the 160 F2 pituitaries exhibited the hemorrhagic phenotype ; 36 of the 160 F2 pituitaries were in the F344 range of mass , but 31 of these were not hemorrhagic , indicating that the hemorrhagic phenotype is not merely a consequence of extensive growth .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "hemorrhagic"
      ],
      [
        "T1",
        "Disease",
        32,
        33,
        "hemorrhagic"
      ],
      [
        "T2",
        "Disease",
        37,
        38,
        "hemorrhagic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4475,
    "text": "The hemorrhagic F2 pituitaries were all among the most massive , indicating that some of the genes regulate both phenotypes .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hemorrhagic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4476,
    "text": "Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic bladder irritation .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "bladder irritation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4477,
    "text": "Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase ( NOS ) in bladder pathways following acute and chronic irritation of the urinary tract of the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        25,
        30,
        "irritation of the urinary tract"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4478,
    "text": "Chemical cystitis was induced by cyclophosphamide ( CYP ) which is metabolized to acrolein , an irritant eliminated in the urine .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "cystitis"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "cyclophosphamide"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "CYP"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "acrolein"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4479,
    "text": "Injection of CYP ( n = 10 , 75 mg / kg , i . p . ) 2 hours prior to perfusion ( acute treatment ) of the animals increased Fos - immunoreactivity ( IR ) in neurons in the dorsal commissure , dorsal horn , and autonomic regions of spinal segments ( L1 - L2 and L6 - S1 ) which receive afferent inputs from the bladder , urethra , and ureter .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "CYP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4480,
    "text": "Fos - IR in the spinal cord was not changed in rats receiving chronic CYP treatment ( n = 15 , 75 mg / kg , i . p . , every 3rd day for 2 weeks ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "CYP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4481,
    "text": "In control animals and in animals treated acutely with CYP , only small numbers of NOS - IR cells ( 0 . 5 - 0 . 7 cell profiles / sections ) were detected in the L6 - S1 dorsal root ganglia ( DRG ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "CYP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4482,
    "text": "Chronic CYP administration significantly ( P < or = . 002 ) increased bladder weight by 60 % and increased ( 7 - to 11 - fold ) the numbers of NOS - immunoreactive ( IR ) afferent neurons in the L6 - S1 DRG .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "CYP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4483,
    "text": "A small increase ( 1 . 5 - fold ) also occurred in the L1 DRG , but no change was detected in the L2 and L5 DRG .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4484,
    "text": "Bladder afferent cells in the L6 - S1 DRG labeled by Fluorogold ( 40 microliters ) injected into the bladder wall did not exhibit NOS - IR in control animals ; however , following chronic CYP administration , a significant percentage of bladder afferent neurons were NOS - IR : L6 ( 19 . 8 + / - 4 . 6 % ) and S1 ( 25 . 3 + / - 2 . 9 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        35,
        36,
        "CYP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4485,
    "text": "These results indicate that neuronal gene expression in visceral sensory pathways can be upregulated by chemical irritation of afferent receptors in the urinary tract and / or that pathological changes in the urinary tract can initiate chemical signals that alter the chemical properties of visceral afferent neurons .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4486,
    "text": "Effects of a new calcium antagonist , CD - 832 , on isoproterenol - induced myocardial ischemia in dogs with partial coronary stenosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "CD - 832"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "myocardial ischemia"
      ],
      [
        "T2",
        "Disease",
        21,
        23,
        "coronary stenosis"
      ],
      [
        "T3",
        "Chemical",
        4,
        5,
        "calcium"
      ],
      [
        "T4",
        "Chemical",
        12,
        13,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4487,
    "text": "Effects of CD - 832 on isoproterenol ( ISO ) - induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "CD - 832"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "myocardial ischemia"
      ],
      [
        "T2",
        "Disease",
        20,
        22,
        "coronary stenosis"
      ],
      [
        "T3",
        "Chemical",
        6,
        7,
        "isoproterenol"
      ],
      [
        "T4",
        "Chemical",
        8,
        9,
        "ISO"
      ],
      [
        "T5",
        "Chemical",
        35,
        36,
        "nifedipine"
      ],
      [
        "T6",
        "Chemical",
        37,
        38,
        "diltiazem"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4488,
    "text": "In the presence of coronary artery stenosis , 3 - min periods of intracoronary ISO infusion ( 10 ng / kg / min ) increased heart rate and maximal rate of left ventricular pressure rise , which resulted in a decrease in percentage segmental shortening and ST - segment elevation of the epicardial electrocardiogram .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "coronary artery stenosis"
      ],
      [
        "T1",
        "Chemical",
        14,
        15,
        "ISO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4489,
    "text": "After the control ISO infusion with stenosis was performed , equihypotensive doses of CD - 832 ( 3 and 10 micrograms / kg / min , n = 7 ) , nifedipine ( 1 and 3 micrograms / kg / min , n = 9 ) or diltiazem ( 10 and 30 micrograms / kg / min , n = 7 ) were infused 5 min before and during the second and third ISO infusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        16,
        "CD - 832"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "ISO"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "stenosis"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "nifedipine"
      ],
      [
        "T4",
        "Chemical",
        47,
        48,
        "diltiazem"
      ],
      [
        "T5",
        "Chemical",
        73,
        74,
        "ISO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4490,
    "text": "Both CD - 832 and diltiazem , but not nifedipine , significantly reduced the increase in heart rate induced by ISO infusion .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        4,
        "CD - 832"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "diltiazem"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "nifedipine"
      ],
      [
        "T3",
        "Chemical",
        20,
        21,
        "ISO"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4491,
    "text": "In contrast to nifedipine , CD - 832 ( 10 micrograms / kg / min ) prevented the decrease in percentage segmental shortening from 32 + / - 12 % to 115 + / - 26 % of the control value ( P < . 01 ) and ST - segment elevation from 5 . 6 + / - 1 . 0 mV to 1 . 6 + / - 1 . 3 mV ( P < . 01 ) at 3 min after ISO infusion with stenosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        8,
        "CD - 832"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "nifedipine"
      ],
      [
        "T2",
        "Chemical",
        84,
        85,
        "ISO"
      ],
      [
        "T3",
        "Disease",
        87,
        88,
        "stenosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4492,
    "text": "Diltiazem ( 30 micrograms / kg / min ) also prevented the decrease in percentage segmental shortening from 34 + / - 14 % to 63 + / - 18 % of the control value ( P < . 05 ) and ST - segment elevation from 4 . 7 + / - 0 . 7 mV to 2 . 1 + / - 0 . 7 mV ( P < . 01 ) at 3 min after ISO infusion with stenosis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Diltiazem"
      ],
      [
        "T1",
        "Chemical",
        78,
        79,
        "ISO"
      ],
      [
        "T2",
        "Disease",
        81,
        82,
        "stenosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4493,
    "text": "These data show that CD - 832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD - 832 plays a major role in the beneficial effects of CD - 832 .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "CD - 832"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "myocardial ischemia"
      ],
      [
        "T2",
        "Chemical",
        23,
        26,
        "CD - 832"
      ],
      [
        "T3",
        "Chemical",
        35,
        38,
        "CD - 832"
      ],
      [
        "T4",
        "Chemical",
        11,
        12,
        "ISO"
      ],
      [
        "T5",
        "Disease",
        14,
        15,
        "stenosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4494,
    "text": "The effect of recombinant human insulin - like growth factor - I on chronic puromycin aminonucleoside nephropathy in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4495,
    "text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside ( PAN ) nephropathy , an experimental model of glomerular disease .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "puromycin aminonucleoside"
      ],
      [
        "T1",
        "Disease",
        25,
        27,
        "glomerular disease"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "PAN"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4496,
    "text": "Therefore , we examined whether recombinant human ( rh ) IGF - I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "growth failure"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "PAN"
      ],
      [
        "T2",
        "Disease",
        28,
        29,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4497,
    "text": "The glomerulopathy was induced by seven serial injections of PAN over 12 wk .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "glomerulopathy"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "PAN"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4498,
    "text": "Experimental animals ( n = 6 ) received rhIGF - I , 400 micrograms / d , whereas control rats ( n = 6 ) received the vehicle .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4499,
    "text": "rhIGF - I improved weight gain by 14 % ( p < 0 . 05 ) , without altering hematocrit or blood pressure in rats with renal disease .",
    "labels": [
      [
        "T0",
        "Disease",
        26,
        28,
        "renal disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4500,
    "text": "Urinary protein excretion was unaltered by rhIGF - I treatment in rats with chronic PAN nephropathy .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "PAN"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4501,
    "text": "After 12 wk , the inulin clearance was higher in rhIGF - I - treated rats , 0 . 48 + / - 0 . 08 versus 0 . 24 + / - 0 . 06 mL / min / 100 g of body weight in untreated PAN nephropathy animals , p < 0 . 05 .",
    "labels": [
      [
        "T0",
        "Chemical",
        47,
        48,
        "PAN"
      ],
      [
        "T1",
        "Disease",
        48,
        49,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4502,
    "text": "The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis , tubulointerstitial injury , or renal cortical malondialdehyde content .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "glomerular hypertrophy"
      ],
      [
        "T1",
        "Disease",
        16,
        18,
        "tubulointerstitial injury"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "glomerulosclerosis"
      ],
      [
        "T3",
        "Chemical",
        22,
        23,
        "malondialdehyde"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4503,
    "text": "In rats with PAN nephropathy , administration of rhIGF - I increased IGF - I and GH receptor gene expression , without altering the steady state level of IGF - I receptor mRNA .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "PAN"
      ],
      [
        "T1",
        "Disease",
        4,
        5,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4504,
    "text": "In normal rats with intact kidneys , rhIGF - I administration ( n = 4 ) did not alter weight gain , blood pressure , proteinuria , GFR , glomerular planar area , renal cortical malondialdehyde content , or glomerular or tubulointerstitial damage , compared with untreated animals ( n = 4 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        41,
        43,
        "tubulointerstitial damage"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "proteinuria"
      ],
      [
        "T2",
        "Chemical",
        35,
        36,
        "malondialdehyde"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4505,
    "text": "rhIGF - I treatment reduced the steady state renal IGF - I mRNA level but did not modify gene expression of the IGF - I or GH receptors .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4506,
    "text": "We conclude that : 1 ) administration of rhIGF - I improves growth and GFR in rats with chronic PAN nephropathy and 2 ) unlike rhGH , long - term use of rhIGF - I does not worsen renal functional and structural injury in this disease model .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        20,
        "PAN"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "nephropathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4507,
    "text": "Nefiracetam ( DM - 9384 ) reverses apomorphine - induced amnesia of a passive avoidance response : delayed emergence of the memory retention effects .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "DM - 9384"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Nefiracetam"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "apomorphine"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4508,
    "text": "Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine - induced learning and post - training consolidation deficits .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        18,
        "learning and post - training consolidation deficits"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Nefiracetam"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "pyrrolidone"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "scopolamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4509,
    "text": "Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10 - 12h post - training period , we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "apomorphine"
      ],
      [
        "T1",
        "Chemical",
        28,
        29,
        "nefiracetam"
      ],
      [
        "T2",
        "Disease",
        31,
        32,
        "amnesia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4510,
    "text": "A step - down passive avoidance paradigm was employed and nefiracetam ( 3 mg / kg ) and apomorphine ( 0 . 5 mg / kg ) were given alone or in combination during training and at the 10 - 12h post - training period of consolidation .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "nefiracetam"
      ],
      [
        "T1",
        "Chemical",
        18,
        19,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4511,
    "text": "Co - administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti - amnesic effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "nefiracetam"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4512,
    "text": "However , administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post - training time and the converse was also true .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "nefiracetam"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "amnesia"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "apomorphine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4513,
    "text": "These effects were not mediated by a dopaminergic mechanism as nefiracetam , at millimolar concentrations , failed to displace either [ 3H ] SCH 23390 or [ 3H ] spiperone binding from D1 or D2 dopamine receptor subtypes , respectively .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        25,
        "SCH 23390"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "nefiracetam"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "spiperone"
      ],
      [
        "T3",
        "Chemical",
        35,
        36,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4514,
    "text": "It is suggested that nefiracetam augments molecular processes in the early stages of events which ultimately lead to consolidation of memory .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "nefiracetam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4515,
    "text": "Phenytoin encephalopathy as probable idiosyncratic reaction : case report .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Phenytoin"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4516,
    "text": "A case of phenytoin ( DPH ) encephalopathy with increasing seizures and EEG and mental changes is described .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "phenytoin"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "DPH"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "encephalopathy"
      ],
      [
        "T3",
        "Disease",
        10,
        11,
        "seizures"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4517,
    "text": "Despite adequate oral dosage of DPH ( 5 mg / kg / daily ) the plasma level was very low ( 2 . 8 microgramg / ml ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "DPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4518,
    "text": "The encephalopathy was probably an idiosyncratic and not toxic or allergic reaction .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "encephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4519,
    "text": "In fact the concentration of free DPH was normal , the patient presented a retarded morbilliform rash during DPH treatment , the protidogram was normal , and an intradermic DPH injection had no local effect .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "DPH"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "rash"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "DPH"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "DPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4520,
    "text": "The authors conclude that in a patient starting DPH treatment an unexpected increase in seizures , with EEG and mental changes occurring simultaneously , should alert the physician to the possible need for eliminating DPH from the therapeutic regimen , even if plasma concentrations are low .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "DPH"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "seizures"
      ],
      [
        "T2",
        "Chemical",
        34,
        35,
        "DPH"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4521,
    "text": "Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "endometrial disease"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "oestrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4522,
    "text": "The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving oestrogen therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "endometrial disease"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "oestrogen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4523,
    "text": "Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hyperplasia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "oestrogen"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "progestagen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4524,
    "text": "Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "norethisterone"
      ],
      [
        "T1",
        "Disease",
        20,
        21,
        "hyperplasia"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "hyperplasia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4525,
    "text": "4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "endometrial carcinoma"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "oestrogen"
      ],
      [
        "T2",
        "Disease",
        24,
        25,
        "hyperplasia"
      ],
      [
        "T3",
        "Disease",
        26,
        27,
        "malignancy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4526,
    "text": "Cyclical low - dose oestrogen therapy with 7 - - 13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        24,
        "endometrial hyperplasia"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "oestrogen"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "progestagen"
      ],
      [
        "T3",
        "Disease",
        25,
        26,
        "carcinoma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4527,
    "text": "Effects of exercise on the severity of isoproterenol - induced myocardial infarction .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4528,
    "text": "The effect of exercise on the severity of isoproterenol - induced myocardial infarction was studied in male rats .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "myocardial infarction"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4529,
    "text": "Ninety - three rats were randomly divided into three groups .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4530,
    "text": "The exercise - isoproterenol ( E - 1 ) and exercise control ( EC ) groups exercised daily for thirty days on a treadmill at 1 mph , 2 % grade while animals of the sedentary - isoproterenol ( S - I ) group remained sedentary .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "isoproterenol"
      ],
      [
        "T1",
        "Chemical",
        37,
        38,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4531,
    "text": "Eight animals were assigned to the sedentary control ( SC ) group which remained sedentary throughout the experimental period .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4532,
    "text": "Forty - eight hours after the final exercise period , S - I and E - I animals received a single subcutaneous injection of isoproterenol ( 250 mg / kg body weight ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4533,
    "text": "Animals of the S - I group exhibited significantly ( Pp less than 0 . 05 ) greater mortality from the effects of isoproterenol than animals of the E - I group .",
    "labels": [
      [
        "T0",
        "Chemical",
        23,
        24,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4534,
    "text": "Serum CPK activity for E - I animals was significantly ( p less than 0 . 05 ) greater than for animals in the S - I and EC groups twenty hours following isoproterenol injection .",
    "labels": [
      [
        "T0",
        "Chemical",
        33,
        34,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4535,
    "text": "No statistically significant differences were observed between the two isoproterenol treated groups for severity of the induced lesions , changes in heart weight , or heart weight to body weight ratios .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "isoproterenol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4536,
    "text": "The results indicated that exercise reduced the mortality associated with the effects of large dosages of isoproterenol but had little on the severity of the infarction .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "isoproterenol"
      ],
      [
        "T1",
        "Disease",
        25,
        26,
        "infarction"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4537,
    "text": "Human corticotropin - releasing hormone and thyrotropin - releasing hormone modulate the hypercapnic ventilatory response in humans .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "corticotropin"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "thyrotropin"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "hypercapnic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4538,
    "text": "Human corticotropin - releasing hormone ( hCRH ) and thyrotropin - releasing hormone ( TRH ) are known to stimulate ventilation after i . v . administration in humans .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "corticotropin"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "thyrotropin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4539,
    "text": "In a placebo - controlled , single - blind study we aimed to clarify if both peptides act by altering central chemosensitivity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4540,
    "text": "Two subsequent CO2 - rebreathing tests were performed in healthy young volunteers .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "CO2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4541,
    "text": "During the first test 0 . 9 % NaCl was given i . v . ; during the second test 200 micrograms of hCRH ( n = 12 ) or 400 micrograms of TRH ( n = 6 ) was administered i . v . Nine subjects received 0 . 9 % NaCl i . v . during both rebreathing manoeuvres .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "NaCl"
      ],
      [
        "T1",
        "Chemical",
        52,
        53,
        "NaCl"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4542,
    "text": "The CO2 - response curves for the two tests were compared within the same subject .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "CO2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4543,
    "text": "In the hCRH group a marked parallel shift of the CO2 - response curve to the left was observed after hCRH ( P < 0 . 01 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "CO2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4544,
    "text": "The same effect occurred following TRH but was less striking ( P = 0 . 05 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4545,
    "text": "hCRH and TRH caused a reduction in the CO2 threshold .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "CO2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4546,
    "text": "The CO2 - response curves in the control group were nearly identical .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "CO2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4547,
    "text": "The results indicate an additive effect of both releasing hormones on the hypercapnic ventilatory response in humans , presumably independent of central chemosensitivity .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "hypercapnic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4548,
    "text": "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers : a placebo - controlled trial .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "hepatitis B"
      ],
      [
        "T1",
        "Chemical",
        11,
        15,
        "hepatitis B surface antigen"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4549,
    "text": "Lamivudine is a novel 2 ' , 3 ' - dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        12,
        "2 ' , 3 ' - dideoxy cytosine"
      ],
      [
        "T1",
        "Disease",
        19,
        21,
        "hepatitis B"
      ],
      [
        "T2",
        "Chemical",
        0,
        1,
        "Lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4550,
    "text": "We performed a single - blind , placebo - controlled study to assess its effectiveness and safety in Chinese hepatitis B surface antigen ( HBsAg ) carriers .",
    "labels": [
      [
        "T0",
        "Chemical",
        19,
        23,
        "hepatitis B surface antigen"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "HBsAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4551,
    "text": "Forty - two Chinese HBsAg carriers were randomized to receive placebo ( 6 patients ) or lamivudine orally in dosages of 25 mg , 100 mg , or 300 mg daily ( 12 patients for each dosage ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "HBsAg"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4552,
    "text": "The drug was given for 4 weeks .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4553,
    "text": "The patients were closely monitored clinically , biochemically , and serologically up to 4 weeks after drug treatment .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4554,
    "text": "All 36 patients receiving lamivudine had a decrease in hepatitis B virus ( HBV ) DNA values of > 90 % ( P < . 001 compared with placebo ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "hepatitis B"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4555,
    "text": "Although 25 mg of lamivudine was slightly less effective than 100 mg ( P = . 011 ) and 300 mg ( P = . 005 ) , it still induced 94 % suppression of HBV DNA after the fourth week of therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4556,
    "text": "HBV DNA values returned to pretreatment levels within 4 weeks of cessation of therapy .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4557,
    "text": "There was no change in the hepatitis B e antigen status or in aminotransferase levels .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "hepatitis B"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4558,
    "text": "No serious adverse events were observed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4559,
    "text": "In conclusion , a 4 - week course of lamivudine was safe and effective in suppression of HBV DNA in Chinese HBsAg carriers .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "lamivudine"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "HBsAg"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4560,
    "text": "The suppression was > 90 % but reversible .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4561,
    "text": "Studies with long - term lamivudine administration should be performed to determine if prolonged suppression of HBV DNA can be achieved .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "lamivudine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4562,
    "text": "Population - based study of risk of venous thromboembolism associated with various oral contraceptives .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "venous thromboembolism"
      ],
      [
        "T1",
        "Chemical",
        12,
        14,
        "oral contraceptives"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4563,
    "text": "BACKGROUND : Four studies published since December , 1995 , reported that the incidence of venous thromboembolism ( VTE ) was higher in women who used oral contraceptives ( OCs ) containing the third - generation progestagens gestodene or desogestrel than in users of OCs containing second - generation progestagens .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "venous thromboembolism"
      ],
      [
        "T1",
        "Chemical",
        26,
        28,
        "oral contraceptives"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "VTE"
      ],
      [
        "T3",
        "Chemical",
        29,
        30,
        "OCs"
      ],
      [
        "T4",
        "Chemical",
        36,
        37,
        "progestagens"
      ],
      [
        "T5",
        "Chemical",
        37,
        38,
        "gestodene"
      ],
      [
        "T6",
        "Chemical",
        39,
        40,
        "desogestrel"
      ],
      [
        "T7",
        "Chemical",
        44,
        45,
        "OCs"
      ],
      [
        "T8",
        "Chemical",
        49,
        50,
        "progestagens"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4564,
    "text": "However , confounding and bias in the design of these studies may have affected the findings .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4565,
    "text": "The aim of our study was to re - examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        16,
        "VTE"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "OC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4566,
    "text": "METHODS : We used computer records of patients from 143 general practices in the UK .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4567,
    "text": "The study was based on the medical records of about 540 , 000 women born between 1941 and 1981 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4568,
    "text": "All women who had a recorded diagnosis of deep - vein thrombosis , venous thrombosis not otherwise specified , or pulmonary embolus during the study period , and who had been treated with an anticoagulant were identified as potential cases of VTE .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "deep - vein thrombosis"
      ],
      [
        "T1",
        "Disease",
        13,
        15,
        "venous thrombosis"
      ],
      [
        "T2",
        "Disease",
        41,
        42,
        "VTE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4569,
    "text": "We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations , and a nested case - control study to calculate the odds ratios of VTE associated with use of different types of OC , after adjustment for potential confounding factors .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        12,
        "VTE"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "OC"
      ],
      [
        "T2",
        "Disease",
        33,
        34,
        "VTE"
      ],
      [
        "T3",
        "Chemical",
        41,
        42,
        "OC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4570,
    "text": "In the case - control study , we matched cases to controls by exact year of birth , practice , and current use of OCs .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        25,
        "OCs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4571,
    "text": "We used a multiple logistic regression model that included body - mass index , number of cycles , change in type of OC prescribed within 3 months of the event , previous pregnancy , and concurrent disease .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        23,
        "OC"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4572,
    "text": "FINDINGS : 85 women met the inclusion criteria for VTE , two of whom were users of progestagen - only OCs .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "VTE"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "progestagen"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "OCs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4573,
    "text": "Of the 83 cases of VTE associated with use of combined OCs , 43 were recorded as deep - vein thrombosis , 35 as pulmonary thrombosis , and five as venous thrombosis not otherwise specified .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        21,
        "deep - vein thrombosis"
      ],
      [
        "T1",
        "Disease",
        30,
        32,
        "venous thrombosis"
      ],
      [
        "T2",
        "Disease",
        5,
        6,
        "VTE"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "OCs"
      ],
      [
        "T4",
        "Disease",
        25,
        26,
        "thrombosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4574,
    "text": "The crude rate of VTE per 10 , 000 woman - years was 4 . 10 in current users of any OC , 3 . 10 in users of second - generation OCs , and 4 . 96 in users of third - generation preparations .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "VTE"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "OC"
      ],
      [
        "T2",
        "Chemical",
        32,
        33,
        "OCs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4575,
    "text": "After adjustment for age , the rate ratio of VTE in users of third - generation relative to second - generation OCs was 1 . 68 ( 95 % CI 1 . 04 - 2 . 75 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        10,
        "VTE"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "OCs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4576,
    "text": "Logistic regression showed no significant difference in the risk of VTE between users of third - generation and second - generation OCs .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "VTE"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "OCs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4577,
    "text": "Among users of third - generation progestagens , the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "progestagens"
      ],
      [
        "T1",
        "Disease",
        11,
        12,
        "VTE"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "desogestrel"
      ],
      [
        "T3",
        "Chemical",
        21,
        22,
        "ethinyloestradiol"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "gestodene"
      ],
      [
        "T5",
        "Chemical",
        28,
        29,
        "desogestrel"
      ],
      [
        "T6",
        "Chemical",
        32,
        33,
        "ethinyloestradiol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4578,
    "text": "With all second - generation OCs as the reference , the odds ratios for VTE were 3 . 49 ( 1 . 21 - 10 . 12 ) for desogestrel plus 20 g ethinyloestradiol and 1 . 18 ( 0 . 66 - 2 . 17 ) for the other third - generation progestagens .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "OCs"
      ],
      [
        "T1",
        "Disease",
        14,
        15,
        "VTE"
      ],
      [
        "T2",
        "Chemical",
        29,
        30,
        "desogestrel"
      ],
      [
        "T3",
        "Chemical",
        33,
        34,
        "ethinyloestradiol"
      ],
      [
        "T4",
        "Chemical",
        53,
        54,
        "progestagens"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4579,
    "text": "INTERPRETATION : The previously reported increase in odds ratio associated with third - generation OCs when compared with second - generation products is likely to have been the result of residual confounding by age .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "OCs"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4580,
    "text": "The increased odds ratio associated with products containing 20 micrograms ethinyloestradiol and desogestrel compared with the 30 micrograms product is biologically implausible , and is likely to be the result of preferential prescribing and , thus , confounding .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        11,
        "ethinyloestradiol"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "desogestrel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4581,
    "text": "MK - 801 augments pilocarpine - induced electrographic seizure but protects against brain damage in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "MK - 801"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "brain damage"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "pilocarpine"
      ],
      [
        "T3",
        "Disease",
        8,
        9,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4582,
    "text": "1 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4583,
    "text": "The authors examined the anticonvulsant effects of MK - 801 on the pilocarpine - induced seizure model .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        10,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "pilocarpine"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4584,
    "text": "Intraperitoneal injection of pilocarpine ( 400 mg / kg ) induced tonic and clonic seizure .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        15,
        "tonic and clonic seizure"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4585,
    "text": "Scopolamine ( 10 mg / kg ) and pentobarbital ( 5 mg / kg ) prevented development of pilocarpine - induced behavioral seizure but MK - 801 ( 0 . 5 mg / kg ) did not .",
    "labels": [
      [
        "T0",
        "Chemical",
        24,
        27,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Scopolamine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "pentobarbital"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "pilocarpine"
      ],
      [
        "T4",
        "Disease",
        22,
        23,
        "seizure"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4586,
    "text": "2 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4587,
    "text": "An electrical seizure measured with hippocampal EEG appeared in the pilocarpine - treated group .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "seizure"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4588,
    "text": "Scopolamine and pentobarbital blocked the pilocarpine - induced electrographic seizure , MK - 801 treatment augmented the electrographic seizure induced by pilocarpine .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        14,
        "MK - 801"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Scopolamine"
      ],
      [
        "T2",
        "Chemical",
        2,
        3,
        "pentobarbital"
      ],
      [
        "T3",
        "Chemical",
        5,
        6,
        "pilocarpine"
      ],
      [
        "T4",
        "Disease",
        9,
        10,
        "seizure"
      ],
      [
        "T5",
        "Disease",
        18,
        19,
        "seizure"
      ],
      [
        "T6",
        "Chemical",
        21,
        22,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4589,
    "text": "3 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4590,
    "text": "Brain damage was assessed by examining the hippocampus microscopically .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Brain damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4591,
    "text": "Pilocarpine produced neuronal death in the hippocampus , which showed pyknotic changes .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "neuronal death"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4592,
    "text": "Pentobarbital , scopolamine and MK - 801 protected the brain damage by pilocarpine , though in the MK - 801 - treated group , the pyramidal cells of hippocampus appeared darker than normal .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "MK - 801"
      ],
      [
        "T1",
        "Disease",
        9,
        11,
        "brain damage"
      ],
      [
        "T2",
        "Chemical",
        17,
        20,
        "MK - 801"
      ],
      [
        "T3",
        "Chemical",
        0,
        1,
        "Pentobarbital"
      ],
      [
        "T4",
        "Chemical",
        2,
        3,
        "scopolamine"
      ],
      [
        "T5",
        "Chemical",
        12,
        13,
        "pilocarpine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4593,
    "text": "In all treatments , granule cells of the dentate gyrus were not affected .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4594,
    "text": "4 .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4595,
    "text": "These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission , the elevation of which may cause brain damage through an excitatory NMDA receptor - mediated mechanism .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "status epilepticus"
      ],
      [
        "T1",
        "Disease",
        26,
        28,
        "brain damage"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "pilocarpine"
      ],
      [
        "T3",
        "Chemical",
        31,
        32,
        "NMDA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4596,
    "text": "Paclitaxel , 5 - fluorouracil , and folinic acid in metastatic breast cancer : BRE - 26 , a phase II trial .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "5 - fluorouracil"
      ],
      [
        "T1",
        "Chemical",
        7,
        9,
        "folinic acid"
      ],
      [
        "T2",
        "Disease",
        11,
        13,
        "breast cancer"
      ],
      [
        "T3",
        "Chemical",
        0,
        1,
        "Paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4597,
    "text": "5 - Fluorouracil plus folinic acid and paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) are effective salvage therapies for metastatic breast cancer patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "5 - Fluorouracil"
      ],
      [
        "T1",
        "Chemical",
        4,
        6,
        "folinic acid"
      ],
      [
        "T2",
        "Disease",
        27,
        29,
        "breast cancer"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "paclitaxel"
      ],
      [
        "T4",
        "Chemical",
        9,
        10,
        "Taxol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4598,
    "text": "Paclitaxel and 5 - fluorouracil have additive cytotoxicity in MCF - 7 cell lines .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "5 - fluorouracil"
      ],
      [
        "T1",
        "Chemical",
        0,
        1,
        "Paclitaxel"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "cytotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4599,
    "text": "We performed a phase II trial of paclitaxel 175 mg / m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5 - fluorouracil 350 mg / m2 on days 1 to 3 every 28 days ( TFL ) in women with metastatic breast cancer .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        22,
        "folinic acid"
      ],
      [
        "T1",
        "Chemical",
        28,
        31,
        "5 - fluorouracil"
      ],
      [
        "T2",
        "Disease",
        50,
        52,
        "breast cancer"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4600,
    "text": "Analysis is reported on 37 patients with a minimum of 6 months follow - up who received a total of 192 cycles of TFL : nine cycles ( 5 % ) were associated with grade 3 / 4 neutropenia requiring hospitalization ; seven ( 4 % ) cycles in two patients required granulocyte colony - stimulating factor due to neutropenia ; no patient required platelet transfusions .",
    "labels": [
      [
        "T0",
        "Chemical",
        52,
        57,
        "granulocyte colony - stimulating factor"
      ],
      [
        "T1",
        "Disease",
        38,
        39,
        "neutropenia"
      ],
      [
        "T2",
        "Disease",
        59,
        60,
        "neutropenia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4601,
    "text": "Grade 3 / 4 nonhematologic toxicities were uncommon .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "toxicities"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4602,
    "text": "Among the 34 patients evaluable for response , there were three complete responses ( 9 % ) and 18 partial responses ( 53 % ) for an overall response rate of 62 % .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4603,
    "text": "Of the 19 evaluable patients with prior doxorubicin exposure , 11 ( 58 % ) responded compared with nine of 15 ( 60 % ) without prior doxorubicin .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "doxorubicin"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "doxorubicin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4604,
    "text": "Plasma paclitaxel concentrations were measured at the completion of paclitaxel infusion and at 24 hours in 19 patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "paclitaxel"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "paclitaxel"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4605,
    "text": "TFL is an active , well - tolerated regimen in metastatic breast cancer .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "breast cancer"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4606,
    "text": "Efficacy and proarrhythmia with the use of d , l - sotalol for sustained ventricular tachyarrhythmias .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        12,
        "d , l - sotalol"
      ],
      [
        "T1",
        "Disease",
        14,
        16,
        "ventricular tachyarrhythmias"
      ],
      [
        "T2",
        "Disease",
        2,
        3,
        "proarrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4607,
    "text": "This study prospectively evaluated the clinical efficacy , the incidence of torsades de pointes , and the presumable risk factors for torsades de pointes in patients treated with d , l - sotalol for sustained ventricular tachyarrhythmias .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        14,
        "torsades de pointes"
      ],
      [
        "T1",
        "Disease",
        21,
        24,
        "torsades de pointes"
      ],
      [
        "T2",
        "Chemical",
        28,
        33,
        "d , l - sotalol"
      ],
      [
        "T3",
        "Disease",
        35,
        37,
        "ventricular tachyarrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4608,
    "text": "Eighty - one consecutive patients ( 54 with coronary artery disease , and 20 with dilated cardiomyopathy ) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d , l - sotalol to prevent induction of the ventricular tachyarrhythmia .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "coronary artery disease"
      ],
      [
        "T1",
        "Disease",
        15,
        17,
        "dilated cardiomyopathy"
      ],
      [
        "T2",
        "Disease",
        21,
        23,
        "ventricular tachycardia"
      ],
      [
        "T3",
        "Disease",
        24,
        26,
        "ventricular fibrillation"
      ],
      [
        "T4",
        "Chemical",
        28,
        33,
        "d , l - sotalol"
      ],
      [
        "T5",
        "Disease",
        38,
        40,
        "ventricular tachyarrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4609,
    "text": "During oral loading with d , l - sotalol , continuous electrocardiographic ( ECG ) monitoring was performed .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        9,
        "d , l - sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4610,
    "text": "Those patients in whom d , l - sotalol prevented induction of ventricular tachycardia or ventricular fibrillation were discharged with the drug and followed up on an outpatient basis for 21 + / - 18 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        9,
        "d , l - sotalol"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "ventricular tachycardia"
      ],
      [
        "T2",
        "Disease",
        15,
        17,
        "ventricular fibrillation"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4611,
    "text": "Induction of the ventricular tachyarrhythmia was prevented by oral d , l - sotalol in 35 ( 43 % ) patients ; the ventricular tachyarrhythmia remained inducible in 40 ( 49 % ) patients ; and two ( 2 . 5 % ) patients did not tolerate even 40 mg of d , l - sotalol once daily .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "ventricular tachyarrhythmia"
      ],
      [
        "T1",
        "Chemical",
        9,
        14,
        "d , l - sotalol"
      ],
      [
        "T2",
        "Disease",
        23,
        25,
        "ventricular tachyarrhythmia"
      ],
      [
        "T3",
        "Chemical",
        51,
        56,
        "d , l - sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4612,
    "text": "Four ( 5 % ) patients had from torsades de pointes during the initial oral treatment with d , l - sotalol .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "torsades de pointes"
      ],
      [
        "T1",
        "Chemical",
        17,
        22,
        "d , l - sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4613,
    "text": "Neither ECG [ sinus - cycle length ( SCL ) , QT or QTc interval , or U wave ] nor clinical parameters identified patients at risk for torsades de pointes .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        31,
        "torsades de pointes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4614,
    "text": "However , the oral dose of d , l - sotalol was significantly lower in patients with torsades de pointes ( 200 + / - 46 vs . 328 + / - 53 mg / day ; p = 0 . 0017 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        11,
        "d , l - sotalol"
      ],
      [
        "T1",
        "Disease",
        17,
        20,
        "torsades de pointes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4615,
    "text": "Risk factors associated with the development of torsades de pointes were the appearance of an U wave ( p = 0 . 049 ) , female gender ( p = 0 . 015 ) , and significant dose - corrected changes of SCL , QT interval , and QTc interval ( p < 0 . 05 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "torsades de pointes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4616,
    "text": "During follow - up , seven ( 20 % ) patients had a nonfatal ventricular tachycardia recurrence , and two ( 6 % ) patients died suddenly .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        16,
        "ventricular tachycardia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4617,
    "text": "One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d , l - sotalol .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "cardiac disease"
      ],
      [
        "T1",
        "Disease",
        9,
        12,
        "torsades de pointes"
      ],
      [
        "T2",
        "Chemical",
        19,
        24,
        "d , l - sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4618,
    "text": "Torsades de pointes occurred early during treatment even with low doses of oral d , l - sotalol .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Torsades de pointes"
      ],
      [
        "T1",
        "Chemical",
        13,
        18,
        "d , l - sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4619,
    "text": "Pronounced changes in the surface ECG ( cycle length , QT , and QTc ) in relation to the dose of oral d , l - sotalol might identify a subgroup of patients with an increased risk for torsades de pointes .",
    "labels": [
      [
        "T0",
        "Chemical",
        22,
        27,
        "d , l - sotalol"
      ],
      [
        "T1",
        "Disease",
        38,
        41,
        "torsades de pointes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4620,
    "text": "Other ECG parameters before the application of d , l - sotalol did not identify patients at increased risk for torsades de pointes .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        12,
        "d , l - sotalol"
      ],
      [
        "T1",
        "Disease",
        20,
        23,
        "torsades de pointes"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4621,
    "text": "Recurrence rates of ventricular tachyarrhythmias are high despite complete suppression of the arrhythmia during programmed stimulation .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "ventricular tachyarrhythmias"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "arrhythmia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4622,
    "text": "Therefore programmed electrical stimulation in the case of d , l - sotalol seems to be of limited prognostic value .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        13,
        "d , l - sotalol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4623,
    "text": "Chronic hyperprolactinemia and changes in dopamine neurons .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hyperprolactinemia"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4624,
    "text": "The tuberoinfundibular dopaminergic ( TIDA ) system is known to inhibit prolactin ( PRL ) secretion .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4625,
    "text": "In young animals this system responds to acute elevations in serum PRL by increasing its activity .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4626,
    "text": "However , this responsiveness is lost in aging rats with chronically high serum PRL levels .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4627,
    "text": "The purpose of this study was to induce hyperprolactinemia in rats for extended periods of time and examine its effects on dopaminergic systems in the brain .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4628,
    "text": "Hyperprolactinemia was induced by treatment with haloperidol , a dopamine receptor antagonist , and Palkovits ' microdissection technique in combination with high - performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hyperprolactinemia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "haloperidol"
      ],
      [
        "T2",
        "Chemical",
        9,
        10,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4629,
    "text": "After 6 months of hyperprolactinemia , dopamine ( DA ) concentrations in the median eminence ( ME ) increased by 84 % over the control group .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hyperprolactinemia"
      ],
      [
        "T1",
        "Chemical",
        6,
        7,
        "dopamine"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4630,
    "text": "Nine months of hyperprolactinemia produced a 50 % increase in DA concentrations in the ME over the control group .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        4,
        "hyperprolactinemia"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "DA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4631,
    "text": "However , DA response was lost if a 9 - month long haloperidol - induced hyperprolactinemia was followed by a 1 1 / 2 month - long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "DA"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "haloperidol"
      ],
      [
        "T2",
        "Disease",
        15,
        16,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4632,
    "text": "There was no change in the levels of DA , norepinephrine ( NE ) , serotonin ( 5 - HT ) , or their metabolites in the arcuate nucleus ( AN ) , medial preoptic area ( MPA ) , caudate putamen ( CP ) , substantia nigra ( SN ) , and zona incerta ( ZI ) , except for a decrease in 5 - hydroxyindoleacetic acid ( 5 - HIAA ) in the AN after 6 - months of hyperprolactinemia and an increase in DA concentrations in the AN after 9 - months of hyperprolactinemia .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        20,
        "5 - HT"
      ],
      [
        "T1",
        "Chemical",
        64,
        68,
        "5 - hydroxyindoleacetic acid"
      ],
      [
        "T2",
        "Chemical",
        69,
        72,
        "5 - HIAA"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "DA"
      ],
      [
        "T4",
        "Chemical",
        10,
        11,
        "norepinephrine"
      ],
      [
        "T5",
        "Chemical",
        12,
        13,
        "NE"
      ],
      [
        "T6",
        "Chemical",
        15,
        16,
        "serotonin"
      ],
      [
        "T7",
        "Disease",
        81,
        82,
        "hyperprolactinemia"
      ],
      [
        "T8",
        "Chemical",
        86,
        87,
        "DA"
      ],
      [
        "T9",
        "Disease",
        96,
        97,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4633,
    "text": "These results demonstrate that hyperprolactinemia specifically affects TIDA neurons and these effects vary , depending on the duration and intensity of hyperprolactinemia .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "hyperprolactinemia"
      ],
      [
        "T1",
        "Disease",
        21,
        22,
        "hyperprolactinemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4634,
    "text": "The age - related decrease in hypothalamic dopamine function may be associated with increases in PRL secretion .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4635,
    "text": "Treatment - related disseminated necrotizing leukoencephalopathy with characteristic contrast enhancement of the white matter .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "leukoencephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4636,
    "text": "This report describes unique contrast enhancement of the white matter on T1 - weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy , which developed from acute lymphoblastic leukemia treated with high - dose methotrexate .",
    "labels": [
      [
        "T0",
        "Disease",
        28,
        31,
        "acute lymphoblastic leukemia"
      ],
      [
        "T1",
        "Disease",
        23,
        24,
        "leukoencephalopathy"
      ],
      [
        "T2",
        "Chemical",
        36,
        37,
        "methotrexate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4637,
    "text": "In both patients , the enhancement was more pronounced near the base of the brain than at the vertex .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4638,
    "text": "Necropsy of the first case revealed loss of myelination and necrosis of the white matter .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "loss of myelination"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "necrosis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4639,
    "text": "Possible mechanisms causing such a leukoencephalopathy are discussed .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "leukoencephalopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4640,
    "text": "Thrombotic complications in acute promyelocytic leukemia during all - trans - retinoic acid therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "acute promyelocytic leukemia"
      ],
      [
        "T1",
        "Chemical",
        7,
        13,
        "all - trans - retinoic acid"
      ],
      [
        "T2",
        "Disease",
        0,
        1,
        "Thrombotic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4641,
    "text": "A case of acute renal failure , due to occlusion of renal vessels in a patient with acute promyelocytic leukemia ( APL ) treated with all - trans - retinoic acid ( ATRA ) and tranexamic acid has been described recently .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        6,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        9,
        13,
        "occlusion of renal vessels"
      ],
      [
        "T2",
        "Disease",
        17,
        20,
        "acute promyelocytic leukemia"
      ],
      [
        "T3",
        "Chemical",
        25,
        31,
        "all - trans - retinoic acid"
      ],
      [
        "T4",
        "Chemical",
        35,
        37,
        "tranexamic acid"
      ],
      [
        "T5",
        "Disease",
        21,
        22,
        "APL"
      ],
      [
        "T6",
        "Chemical",
        32,
        33,
        "ATRA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4642,
    "text": "We report a case of acute renal failure in an APL patient treated with ATRA alone .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        8,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "APL"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "ATRA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4643,
    "text": "This case further supports the concern about thromboembolic complications associated with ATRA therapy in APL patients .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        8,
        "thromboembolic"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "ATRA"
      ],
      [
        "T2",
        "Disease",
        14,
        15,
        "APL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4644,
    "text": "The patients , a 43 - year - old man , presented all the signs and symptoms of APL and was included in a treatment protocol with ATRA .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        19,
        "APL"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "ATRA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4645,
    "text": "After 10 days of treatment , he developed acute renal failure that was completely reversible after complete remission of APL was achieved and therapy discontinued .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        11,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "APL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4646,
    "text": "We conclude that ATRA is a valid therapeutic choice for patients with APL , although the procoagulant tendency is not completely corrected .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        4,
        "ATRA"
      ],
      [
        "T1",
        "Disease",
        12,
        13,
        "APL"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4647,
    "text": "Thrombotic events , however , could be avoided by using low - dose heparin .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Thrombotic"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4648,
    "text": "Pupillary changes associated with the development of stimulant - induced mania : a case report .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "mania"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4649,
    "text": "A 30 - year - old cocaine - dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion ( DEP ) became manic during his second week on the study drug .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "diethylpropion"
      ],
      [
        "T2",
        "Chemical",
        27,
        28,
        "DEP"
      ],
      [
        "T3",
        "Disease",
        30,
        31,
        "manic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4650,
    "text": "Pupillometric changes while on DEP , especially changes in the total power of pupillary oscillation , were dramatically different than those observed in the eight other study subjects who did not become manic .",
    "labels": [
      [
        "T0",
        "Disease",
        13,
        15,
        "pupillary oscillation"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "DEP"
      ],
      [
        "T2",
        "Disease",
        32,
        33,
        "manic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4651,
    "text": "The large changes in total power of pupillary oscillation occurred a few days before the patient became fully manic .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "pupillary oscillation"
      ],
      [
        "T1",
        "Disease",
        18,
        19,
        "manic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4652,
    "text": "Such medication - associated changes in the total power of pupillary oscillation might be of utility in identifying persons at risk for manic - like adverse effects during the medical use of psychomotor stimulants or sympathomimetic agents .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "pupillary oscillation"
      ],
      [
        "T1",
        "Disease",
        22,
        23,
        "manic"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4653,
    "text": "Fetal risks due to warfarin therapy during pregnancy .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4654,
    "text": "Two mothers with heart valve prosthesis were treated with warfarin during pregnancy .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4655,
    "text": "In the first case a caesarean section was done one week after replacement of warfarin with heparin .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "warfarin"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4656,
    "text": "The baby died of cerebral and pulmonary hemorrhage .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        8,
        "cerebral and pulmonary hemorrhage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4657,
    "text": "The second mother had a male infant by caesarean section .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4658,
    "text": "The baby showed warfarin - induced embryopathy with nasal hypoplasia and stippled epiphyses ( chondrodysplasia punctata ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        10,
        "nasal hypoplasia"
      ],
      [
        "T1",
        "Disease",
        11,
        13,
        "stippled epiphyses"
      ],
      [
        "T2",
        "Disease",
        14,
        16,
        "chondrodysplasia punctata"
      ],
      [
        "T3",
        "Chemical",
        3,
        4,
        "warfarin"
      ],
      [
        "T4",
        "Disease",
        6,
        7,
        "embryopathy"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4659,
    "text": "Nasal hypoplasia with or without stippled epiphyses has now been reported in 11 infants born to mothers treated with warfarin during the first trimester , and a causal association is probable .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Nasal hypoplasia"
      ],
      [
        "T1",
        "Disease",
        5,
        7,
        "stippled epiphyses"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "warfarin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4660,
    "text": "In view of the risks to both mother and fetus in women with prosthetic cardiac valves it is recommended that therapeutic abortion be advised as the first alternative .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4661,
    "text": "The negative mucosal potential : separating central and peripheral effects of NSAIDs in man .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4662,
    "text": "OBJECTIVE : We wanted to test whether assessment of both a central pain - related signal ( chemo - somatosensory evoked potential , CSSEP ) and a concomitantly recorded peripheral signal ( negative mucosal potential , NMP ) allows for separation of central and peripheral effects of NSAIDs .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4663,
    "text": "For this purpose , experimental conditions were created in which NSAIDs had previously been observed to produce effects on phasic and tonic pain by either central or peripheral mechanisms .",
    "labels": [
      [
        "T0",
        "Disease",
        22,
        23,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4664,
    "text": "METHODS : According to a double - blind , randomised , controlled , threefold cross - over design , 18 healthy subjects ( 11 males , 7 females ; mean age 26 years ) received either placebo , 400 mg ibuprofen , or 800 mg ibuprofen .",
    "labels": [
      [
        "T0",
        "Chemical",
        40,
        41,
        "ibuprofen"
      ],
      [
        "T1",
        "Chemical",
        45,
        46,
        "ibuprofen"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4665,
    "text": "Phasic pain was applied by means of short pulses of CO2 to the nasal mucosa ( stimulus duration 500 ms , interval approximately 60 s ) , and tonic pain was induced in the nasal cavity by means of dry air of controlled temperature , humidity and flow rate ( 22 degrees C , 0 % relative humidity , 145 ml . s - 1 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "pain"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "CO2"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4666,
    "text": "Both CSSEPs as central and NMPs as peripheral correlates of pain were obtained in response to the CO2 stimuli .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "pain"
      ],
      [
        "T1",
        "Chemical",
        17,
        18,
        "CO2"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4667,
    "text": "Additionally , the subjects rated the intensity of both phasic and tonic pain by means of visual analogue scales .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        13,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4668,
    "text": "RESULTS : As described earlier , administration of ibuprofen was followed by a decrease in tonic pain but - relative to placebo - an increase in correlates of phasic pain , indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "ibuprofen"
      ],
      [
        "T1",
        "Disease",
        16,
        17,
        "pain"
      ],
      [
        "T2",
        "Disease",
        29,
        30,
        "pain"
      ],
      [
        "T3",
        "Chemical",
        36,
        37,
        "ibuprofen"
      ],
      [
        "T4",
        "Disease",
        42,
        43,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4669,
    "text": "Based on the similar behaviour of CSSEP and NMP , it was concluded that the pharmacological process underlying this phenomenon was localised in the periphery .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4670,
    "text": "By means of the simultaneous recording of interrelated peripheral and central electrophysiologic correlates of nociception , it was possible to separate central and peripheral effects of an NSAID .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4671,
    "text": "The major advantage of this pain model is the possibility of obtaining peripheral pain - related activity directly using a non - invasive technique in humans .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "pain"
      ],
      [
        "T1",
        "Disease",
        13,
        14,
        "pain"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4672,
    "text": "Effect of D - Glucarates on basic antibiotic - induced renal damage in rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "D - Glucarates"
      ],
      [
        "T1",
        "Disease",
        10,
        12,
        "renal damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4673,
    "text": "Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        7,
        "acute renal failure"
      ],
      [
        "T1",
        "Disease",
        0,
        1,
        "Dehydrated"
      ],
      [
        "T2",
        "Chemical",
        11,
        12,
        "aminoglycoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4674,
    "text": "Oral administration of 2 , 5 - di - O - acetyl - D - glucaro - 1 , 4 - 6 , 3 - dilactone protected rats against renal failure induced by kanamycin - dextran .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        26,
        "2 , 5 - di - O - acetyl - D - glucaro - 1 , 4 - 6 , 3 - dilactone"
      ],
      [
        "T1",
        "Disease",
        29,
        31,
        "renal failure"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "kanamycin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4675,
    "text": "The protective effect was prevalent among D - glucarates , and also to other saccharic acid , hexauronic acids and hexaaldonic acids , although to a lesser degree , but not to a hexaaldose , sugar alcohols , substances inthe TCA cycle and other acidic compounds .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        9,
        "D - glucarates"
      ],
      [
        "T1",
        "Chemical",
        14,
        16,
        "saccharic acid"
      ],
      [
        "T2",
        "Chemical",
        17,
        19,
        "hexauronic acids"
      ],
      [
        "T3",
        "Chemical",
        20,
        22,
        "hexaaldonic acids"
      ],
      [
        "T4",
        "Chemical",
        35,
        37,
        "sugar alcohols"
      ],
      [
        "T5",
        "Chemical",
        40,
        41,
        "TCA"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4676,
    "text": "D - Glucarates were effective against renal damage induced by peptide antibiotics as well as various aminoglycoside antibitocis .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "D - Glucarates"
      ],
      [
        "T1",
        "Disease",
        6,
        8,
        "renal damage"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "aminoglycoside"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4677,
    "text": "Dose - responses were observed in the protective effect of D - Glucarates .",
    "labels": [
      [
        "T0",
        "Chemical",
        10,
        13,
        "D - Glucarates"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4678,
    "text": "With a D - glucarate of a fixed size of dose , approximately the same degree of protection was obtained against renal damages induced by different basic antibiotics despite large disparities in administration doses of different antibiotics .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "D - glucarate"
      ],
      [
        "T1",
        "Disease",
        21,
        23,
        "renal damages"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4679,
    "text": "D - Glucarates had the ability to prevent renal damage but not to cure it .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        3,
        "D - Glucarates"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "renal damage"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4680,
    "text": "Rats excreted acidic urine when they were spared from renal lesions by monosaccharides .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "renal lesions"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "monosaccharides"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4681,
    "text": "The reduction effect of D - glucarates against nephrotoxicity of basic antibiotics was discussed .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "D - glucarates"
      ],
      [
        "T1",
        "Disease",
        8,
        9,
        "nephrotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4682,
    "text": "Acute severe depression following peri - operative ondansetron .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        3,
        "depression"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "ondansetron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4683,
    "text": "A 41 - year - old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used .",
    "labels": [
      [
        "T0",
        "Disease",
        12,
        16,
        "postoperative nausea and vomiting"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "ondansetron"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4684,
    "text": "She had developed a severe acute major depression disorder almost immediately thereafter , possibly related to the use of a serotonin antagonist .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        9,
        "major depression disorder"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4685,
    "text": "Nine years before she had experienced a self - limited puerperal depressive episode .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "depressive episode"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4686,
    "text": "Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea - free postoperative course without exacerbation of the depression disorder .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        23,
        "depression disorder"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "propofol"
      ],
      [
        "T2",
        "Chemical",
        8,
        9,
        "serotonin"
      ],
      [
        "T3",
        "Disease",
        12,
        13,
        "nausea"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4687,
    "text": "Hypertensive response during dobutamine stress echocardiography .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypertensive"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4688,
    "text": "Among 3 , 129 dobutamine stress echocardiographic studies , a hypertensive response , defined as systolic blood pressure ( BP ) > or = 220 mm Hg and / or diastolic BP > or = 110 mm Hg , occurred in 30 patients ( 1 % ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "dobutamine"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4689,
    "text": "Patients with this response more often had a history of hypertension and had higher resting systolic and diastolic BP before dobutamine infusion .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        11,
        "hypertension"
      ],
      [
        "T1",
        "Chemical",
        20,
        21,
        "dobutamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4690,
    "text": "Continuously nebulized albuterol in severe exacerbations of asthma in adults : a case - controlled study .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "albuterol"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "asthma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4691,
    "text": "A retrospective , case - controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol ( CNA ) versus intermittent albuterol ( INA ) treatments is reported .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "asthma"
      ],
      [
        "T1",
        "Chemical",
        25,
        26,
        "albuterol"
      ],
      [
        "T2",
        "Chemical",
        31,
        32,
        "albuterol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4692,
    "text": "Forty matched pairs of patients with asthma are compared .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        7,
        "asthma"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4693,
    "text": "CNA was administered for a mean of 11 + / - 10 hr .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4694,
    "text": "The incidence of cardiac dysrhythmias was similar between groups .",
    "labels": [
      [
        "T0",
        "Disease",
        3,
        5,
        "cardiac dysrhythmias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4695,
    "text": "Symptomatic hypokalemia did not occur .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        2,
        "hypokalemia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4696,
    "text": "CNA patients had higher heart rates during treatment , which may reflect severity of illness .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4697,
    "text": "The incidence of intubation was similar .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4698,
    "text": "We conclude that CNA and INA demonstrated similar profiles with regard to safety , morbidity , and mortality .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4699,
    "text": "Paraplegia following intrathecal methotrexate : report of a case and review of the literature .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Paraplegia"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "methotrexate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4700,
    "text": "A patient who developed paraplegia following the intrathecal instillation of methotrexate is discribed .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        5,
        "paraplegia"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "methotrexate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4701,
    "text": "The ten previously reported cases of this unusual complication are reviewed .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4702,
    "text": "The following factors appear to predispose to the development of this complication : abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia , and epidural cerebrospinal leakage ; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults ; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents ; and the use of methotrexate diluents of unphysiologic pH , ionic content and osmolarity .",
    "labels": [
      [
        "T0",
        "Disease",
        21,
        25,
        "central nervous system leukemia"
      ],
      [
        "T1",
        "Chemical",
        34,
        35,
        "methothexate"
      ],
      [
        "T2",
        "Chemical",
        46,
        47,
        "methotrexate"
      ],
      [
        "T3",
        "Disease",
        63,
        64,
        "neurotoxic"
      ],
      [
        "T4",
        "Chemical",
        68,
        69,
        "methotrexate"
      ],
      [
        "T5",
        "Chemical",
        77,
        78,
        "methotrexate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4703,
    "text": "The role of methotrexate contaminants , local folate deficiency , and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        9,
        "folate deficiency"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "methotrexate"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "methotrexate"
      ],
      [
        "T3",
        "Disease",
        19,
        20,
        "toxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4704,
    "text": "The incidence of neurotoxicity may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia , in older children and adults , and in the presence of epidural leakage .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        21,
        "central nervous system leukemia"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "neurotoxicity"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "methotrexate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4705,
    "text": "Only preservative - free methotrexate in Elliott ' s B Solution at a concentration of not more than 1 mg / ml should be used for intrathecal administration .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "methotrexate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4706,
    "text": "Periodic monitoring of cerebruspinal fluid methotrexate levels may be predictive of the development of serious neurotoxicity .",
    "labels": [
      [
        "T0",
        "Chemical",
        5,
        6,
        "methotrexate"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "neurotoxicity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4707,
    "text": "Hyperosmolar nonketotic coma precipitated by lithium - induced nephrogenic diabetes insipidus .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Hyperosmolar nonketotic coma"
      ],
      [
        "T1",
        "Disease",
        8,
        11,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T2",
        "Chemical",
        5,
        6,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4708,
    "text": "A 45 - year - old man , with a 10 - year history of manic depression treated with lithium , was admitted with hyperosmolar , nonketotic coma .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "manic depression"
      ],
      [
        "T1",
        "Disease",
        24,
        28,
        "hyperosmolar , nonketotic coma"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4709,
    "text": "He gave a five - year history of polyuria and polydipsia , during which time urinalysis had been negative for glucose .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        9,
        "polyuria"
      ],
      [
        "T1",
        "Disease",
        10,
        11,
        "polydipsia"
      ],
      [
        "T2",
        "Chemical",
        20,
        21,
        "glucose"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4710,
    "text": "After recovery from hyperglycaemia , he remained polyuric despite normal blood glucose concentrations ; water deprivation testing indicated nephrogenic diabetes insipidus , likely to be lithium - induced .",
    "labels": [
      [
        "T0",
        "Disease",
        18,
        21,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hyperglycaemia"
      ],
      [
        "T2",
        "Disease",
        7,
        8,
        "polyuric"
      ],
      [
        "T3",
        "Chemical",
        11,
        12,
        "glucose"
      ],
      [
        "T4",
        "Chemical",
        25,
        26,
        "lithium"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4711,
    "text": "We hypothesize that when this man developed type 2 diabetes , chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar dehydration .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "type 2 diabetes"
      ],
      [
        "T1",
        "Disease",
        15,
        18,
        "nephrogenic diabetes insipidus"
      ],
      [
        "T2",
        "Disease",
        12,
        13,
        "polyuria"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "dehydration"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4712,
    "text": "Effects of the intracoronary infusion of cocaine on left ventricular systolic and diastolic function in humans .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4713,
    "text": "BACKGROUND : In dogs , a large amount of intravenous cocaine causes a profound deterioration of left ventricular ( LV ) systolic function and an increase in LV end - diastolic pressure .",
    "labels": [
      [
        "T0",
        "Disease",
        14,
        23,
        "deterioration of left ventricular ( LV ) systolic function"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4714,
    "text": "This study was done to assess the influence of a high intracoronary cocaine concentration on LV systolic and diastolic function in humans .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4715,
    "text": "METHODS AND RESULTS : In 20 patients ( 14 men and 6 women aged 39 to 72 years ) referred for cardiac catheterization for the evaluation of chest pain , we measured heart rate , systemic arterial pressure , LV pressure and its first derivative ( dP / dt ) , and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15 - minute intracoronary infusion of saline ( n = 10 , control subjects ) or cocaine hydrochloride 1 mg / min ( n = 10 ) .",
    "labels": [
      [
        "T0",
        "Disease",
        27,
        29,
        "chest pain"
      ],
      [
        "T1",
        "Chemical",
        84,
        86,
        "cocaine hydrochloride"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4716,
    "text": "No variable changed with saline .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4717,
    "text": "With cocaine , the drug concentration in blood obtained from the coronary sinus was 3 . 0 + / - 0 . 4 ( mean + / - SD ) mg / L , similar in magnitude to the blood cocaine concentration reported in abusers dying of cocaine intoxication .",
    "labels": [
      [
        "T0",
        "Chemical",
        1,
        2,
        "cocaine"
      ],
      [
        "T1",
        "Chemical",
        40,
        41,
        "cocaine"
      ],
      [
        "T2",
        "Chemical",
        47,
        48,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4718,
    "text": "Cocaine induced no significant change in heart rate , LV dP / dt ( positive or negative ) , or LV end - diastolic volume , but it caused an increase in systolic and mean arterial pressures , LV end - diastolic pressure , and LV end - systolic volume , as well as a decrease in LV ejection fraction .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4719,
    "text": "CONCLUSIONS : In humans , the intracoronary infusion of cocaine sufficient in amount to achieve a high drug concentration in coronary sinus blood causes a deterioration of LV systolic and diastolic performance .",
    "labels": [
      [
        "T0",
        "Disease",
        25,
        32,
        "deterioration of LV systolic and diastolic performance"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "cocaine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4720,
    "text": "Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "carbetocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4721,
    "text": "OBJECTIVE : To determine the maximum tolerated dose ( MTD ) of carbetocin ( a long - acting synthetic analogue of oxytocin ) , when administered immediately after vaginal delivery at term .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        13,
        "carbetocin"
      ],
      [
        "T1",
        "Chemical",
        21,
        22,
        "oxytocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4722,
    "text": "MATERIALS AND METHODS : Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "Carbetocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4723,
    "text": "Dosage groups of 15 , 30 , 50 , 75 , 100 , 125 , 150 , 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method ( CRM ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        21,
        22,
        "carbetocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4724,
    "text": "RESULTS : All dosage groups consisted of three women , except those with 100 microg ( n = 6 ) and 200 microg ( n = 18 ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4725,
    "text": "Recorded were dose - limiting adverse events : hyper - or hypotension ( three ) , severe abdominal pain ( 0 ) , vomiting ( 0 ) and retained placenta ( four ) .",
    "labels": [
      [
        "T0",
        "Disease",
        8,
        12,
        "hyper - or hypotension"
      ],
      [
        "T1",
        "Disease",
        17,
        19,
        "abdominal pain"
      ],
      [
        "T2",
        "Disease",
        28,
        30,
        "retained placenta"
      ],
      [
        "T3",
        "Disease",
        23,
        24,
        "vomiting"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4726,
    "text": "Serious adverse events occurred in seven women : six cases with blood loss > or = 1000 ml , four cases of manual placenta removal , five cases of additional oxytocics administration and five cases of blood transfusion .",
    "labels": [
      [
        "T0",
        "Disease",
        11,
        13,
        "blood loss"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4727,
    "text": "Maximum blood loss was greatest at the upper and lower dose levels , and lowest in the 70 - 125 microg dose range .",
    "labels": [
      [
        "T0",
        "Disease",
        1,
        3,
        "blood loss"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4728,
    "text": "Four out of six cases with blood loss > or = 1000 ml occurred in the 200 microg group .",
    "labels": [
      [
        "T0",
        "Disease",
        6,
        8,
        "blood loss"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4729,
    "text": "The majority of additional administration of oxytocics ( 4 / 5 ) and blood transfusion ( 3 / 5 ) occurred in the dose groups of 200 microg .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4730,
    "text": "All retained placentae were found in the group of 200 microg .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4731,
    "text": "CONCLUSION : The MTD was calculated to be at 200 microg carbetocin .",
    "labels": [
      [
        "T0",
        "Chemical",
        11,
        12,
        "carbetocin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4732,
    "text": "Heparin - induced thrombocytopenia , paradoxical thromboembolism , and other side effects of heparin therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Heparin"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "thrombocytopenia"
      ],
      [
        "T2",
        "Disease",
        6,
        7,
        "thromboembolism"
      ],
      [
        "T3",
        "Chemical",
        13,
        14,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4733,
    "text": "Although several new anticoagulant drugs are in development , heparin remains the drug of choice for most anticoagulation needs .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4734,
    "text": "The clinical effects of heparin are meritorious , but side effects do exist .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "heparin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4735,
    "text": "Important untoward effects of heparin therapy including heparin - induced thrombocytopenia , heparin - associated osteoporosis , eosinophilia , skin reactions , allergic reactions other than thrombocytopenia and alopecia will be discussed in this article .",
    "labels": [
      [
        "T0",
        "Disease",
        19,
        21,
        "skin reactions"
      ],
      [
        "T1",
        "Disease",
        22,
        24,
        "allergic reactions"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "heparin"
      ],
      [
        "T3",
        "Chemical",
        7,
        8,
        "heparin"
      ],
      [
        "T4",
        "Disease",
        10,
        11,
        "thrombocytopenia"
      ],
      [
        "T5",
        "Chemical",
        12,
        13,
        "heparin"
      ],
      [
        "T6",
        "Disease",
        15,
        16,
        "osteoporosis"
      ],
      [
        "T7",
        "Disease",
        17,
        18,
        "eosinophilia"
      ],
      [
        "T8",
        "Disease",
        26,
        27,
        "thrombocytopenia"
      ],
      [
        "T9",
        "Disease",
        28,
        29,
        "alopecia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4736,
    "text": "Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        4,
        6,
        "ureteric obstruction"
      ],
      [
        "T1",
        "Chemical",
        11,
        12,
        "indinavir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4737,
    "text": "OBJECTIVE : We describe the unique CT features of ureteric calculi in six HIV - infected patients receiving indinavir , the most commonly used HIV protease inhibitor , which is associated with an increased incidence of urolithiasis .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        11,
        "ureteric calculi"
      ],
      [
        "T1",
        "Disease",
        13,
        16,
        "HIV - infected"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "indinavir"
      ],
      [
        "T3",
        "Disease",
        36,
        37,
        "urolithiasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4738,
    "text": "CONCLUSION : Ureteric obstruction caused by precipitated indinavir crystals may be difficult to diagnose with unenhanced CT .",
    "labels": [
      [
        "T0",
        "Disease",
        2,
        4,
        "Ureteric obstruction"
      ],
      [
        "T1",
        "Chemical",
        7,
        8,
        "indinavir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4739,
    "text": "The calculi are not opaque , and secondary signs of obstruction may be absent or minimal and should be sought carefully .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4740,
    "text": "Images may need to be obtained using i . v . contrast material to enable diagnosis of ureteric stones or obstruction in patients with HIV infection who receive indinavir therapy .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        21,
        "ureteric stones or obstruction"
      ],
      [
        "T1",
        "Disease",
        24,
        26,
        "HIV infection"
      ],
      [
        "T2",
        "Chemical",
        28,
        29,
        "indinavir"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4741,
    "text": "Ischemic colitis and sumatriptan use .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        2,
        "Ischemic colitis"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "sumatriptan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4742,
    "text": "Sumatriptan succinate , a serotonin - 1 ( 5 - hydroxytryptamine - 1 ) receptor agonist , is an antimigraine drug that is reported to act by selectively constricting intracranial arteries .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        2,
        "Sumatriptan succinate"
      ],
      [
        "T1",
        "Chemical",
        8,
        11,
        "5 - hydroxytryptamine"
      ],
      [
        "T2",
        "Chemical",
        4,
        5,
        "serotonin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4743,
    "text": "Recently , vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic , pulmonary , and coronary circulations .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4744,
    "text": "Cases have been published of coronary vasospasm , myocardial ischemia , and myocardial infarction occurring after sumatriptan use .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        7,
        "coronary vasospasm"
      ],
      [
        "T1",
        "Disease",
        8,
        10,
        "myocardial ischemia"
      ],
      [
        "T2",
        "Disease",
        12,
        14,
        "myocardial infarction"
      ],
      [
        "T3",
        "Chemical",
        16,
        17,
        "sumatriptan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4745,
    "text": "We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with sumatriptan .",
    "labels": [
      [
        "T0",
        "Disease",
        10,
        12,
        "ischemic colitis"
      ],
      [
        "T1",
        "Disease",
        15,
        16,
        "migraine"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "sumatriptan"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4746,
    "text": "Pallidotomy with the gamma knife : a positive experience .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4747,
    "text": "51 patients with medically refractory Parkinson ' s disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia , rigidity , and L - DOPA - induced dyskinesias .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        9,
        "Parkinson ' s disease"
      ],
      [
        "T1",
        "Chemical",
        27,
        30,
        "L - DOPA"
      ],
      [
        "T2",
        "Disease",
        22,
        23,
        "bradykinesia"
      ],
      [
        "T3",
        "Disease",
        24,
        25,
        "rigidity"
      ],
      [
        "T4",
        "Disease",
        32,
        33,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4748,
    "text": "In 29 patients , the pallidotomies were performed with the Leksell Gamma Knife and in 22 they were performed with the standard radiofrequency ( RF ) method .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4749,
    "text": "Clinical assessment as well as blinded ratings of Unified Parkinson ' s Disease Rating Scale ( UPDRS ) scores were carried out pre - and postoperatively .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        13,
        "Parkinson ' s Disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4750,
    "text": "Mean follow - up time is 20 . 6 months ( range 6 - 48 ) and all except 4 patients have been followed more than one year .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4751,
    "text": "85 percent of patients with dyskinesias were relieved of symptoms , regardless of whether the pallidotomies were performed with the Gamma Knife or radiofrequency methods .",
    "labels": [
      [
        "T0",
        "Disease",
        5,
        6,
        "dyskinesias"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4752,
    "text": "About 2 / 3 of the patients in both Gamma Knife and radiofrequency groups showed improvements in bradykinesia and rigidity , although when considered as a group neither the Gamma Knife nor the radiofrequency group showed statistically significant improvements in UPDRS scores .",
    "labels": [
      [
        "T0",
        "Disease",
        17,
        18,
        "bradykinesia"
      ],
      [
        "T1",
        "Disease",
        19,
        20,
        "rigidity"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4753,
    "text": "One patient in the Gamma Knife group ( 3 . 4 % ) developed a homonymous hemianopsia 9 months following treatment and 5 patients ( 27 . 7 % ) in the radiofrequency group became transiently confused postoperatively .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "homonymous hemianopsia"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4754,
    "text": "No other complications were seen .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4755,
    "text": "Gamma Knife pallidotomy is as effective as radiofrequency pallidotomy in controlling certain of the symptoms of Parkinson ' s disease .",
    "labels": [
      [
        "T0",
        "Disease",
        16,
        20,
        "Parkinson ' s disease"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4756,
    "text": "It may be the only practical technique available in certain patients , such as those who take anticoagulants , have bleeding diatheses or serious systemic medical illnesses .",
    "labels": [
      [
        "T0",
        "Disease",
        20,
        21,
        "bleeding"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4757,
    "text": "It is a viable option for other patients as well .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4758,
    "text": "Centrally mediated cardiovascular effects of intracisternal application of carbachol in anesthetized rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "carbachol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4759,
    "text": "The pressor response to the intracisternal ( i . c . ) injection of carbachol ( 1 mug ) in anesthetized rats was analyzed .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        15,
        "carbachol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4760,
    "text": "This response was significantly reduced by the intravenous ( i . v . ) injection of guanethidine ( 5 mg ) , hexamethonium ( 10 mg ) or phentolamine ( 5 mg ) , and conversely , potentiated by i . v . desmethylimipramine ( 0 . 3 mg ) , while propranolol ( 0 . 5 mg ) i . v . selectively inhibited the enlargement of pulse pressure and the tachycardia following i . c . carbachol ( 1 mug ) .",
    "labels": [
      [
        "T0",
        "Disease",
        66,
        70,
        "enlargement of pulse pressure"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "guanethidine"
      ],
      [
        "T2",
        "Chemical",
        22,
        23,
        "hexamethonium"
      ],
      [
        "T3",
        "Chemical",
        28,
        29,
        "phentolamine"
      ],
      [
        "T4",
        "Chemical",
        43,
        44,
        "desmethylimipramine"
      ],
      [
        "T5",
        "Chemical",
        52,
        53,
        "propranolol"
      ],
      [
        "T6",
        "Disease",
        72,
        73,
        "tachycardia"
      ],
      [
        "T7",
        "Chemical",
        78,
        79,
        "carbachol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4761,
    "text": "On the other hand , the pressor response to i . c . carbachol ( 1 mug ) was almost completely blocked by i . c . atropine ( 3 mug ) or hexamethonium ( 500 mug ) , and significantly reduced by i . c . chlorpromazine ( 50 mug ) but significantly potentiated by i . c . desmethylimipramine ( 30 mug ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        13,
        14,
        "carbachol"
      ],
      [
        "T1",
        "Chemical",
        27,
        28,
        "atropine"
      ],
      [
        "T2",
        "Chemical",
        33,
        34,
        "hexamethonium"
      ],
      [
        "T3",
        "Chemical",
        47,
        48,
        "chlorpromazine"
      ],
      [
        "T4",
        "Chemical",
        60,
        61,
        "desmethylimipramine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4762,
    "text": "The pressor response to i . c . carbachol ( 1 mug ) remained unchanged after sectioning of the bilateral cervical vagal nerves but disappeared after sectioning of the spinal cord ( C7 - C8 ) .",
    "labels": [
      [
        "T0",
        "Chemical",
        8,
        9,
        "carbachol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4763,
    "text": "From the above result it is suggested that the pressor response to i . c . carbachol ortral and peripheral adrenergic mechanisms , and that the sympathetic trunk is the main pathway .",
    "labels": [
      [
        "T0",
        "Chemical",
        16,
        17,
        "carbachol"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4764,
    "text": "Neuroleptic malignant syndrome and methylphenidate .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        3,
        "Neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Chemical",
        4,
        5,
        "methylphenidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4765,
    "text": "A 1 - year - old female presented with neuroleptic malignant syndrome probably caused by methylphenidate .",
    "labels": [
      [
        "T0",
        "Disease",
        9,
        12,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "methylphenidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4766,
    "text": "She had defects in the supratentorial brain including the basal ganglia and the striatum ( multicystic encephalomalacia ) due to severe perinatal hypoxic - ischemic encephalopathy , which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome .",
    "labels": [
      [
        "T0",
        "Disease",
        15,
        17,
        "multicystic encephalomalacia"
      ],
      [
        "T1",
        "Disease",
        22,
        26,
        "hypoxic - ischemic encephalopathy"
      ],
      [
        "T2",
        "Disease",
        37,
        40,
        "neuroleptic malignant syndrome"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4767,
    "text": "A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4768,
    "text": "However , methylphenidate is a dopamine agonist via the inhibition of uptake of dopamine , and therefore dopaminergic systems in the brainstem ( mainly the midbrain ) and the spinal cord were unlikely to participate in the onset of this syndrome .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "methylphenidate"
      ],
      [
        "T1",
        "Chemical",
        5,
        6,
        "dopamine"
      ],
      [
        "T2",
        "Chemical",
        13,
        14,
        "dopamine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4769,
    "text": "A relative gamma - aminobutyric acid - ergic deficiency might occur because diazepam , a gamma - aminobutyric acid - mimetic agent , was strikingly effective .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        6,
        "gamma - aminobutyric acid"
      ],
      [
        "T1",
        "Chemical",
        15,
        19,
        "gamma - aminobutyric acid"
      ],
      [
        "T2",
        "Chemical",
        12,
        13,
        "diazepam"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4770,
    "text": "This is the first reported patient with neuroleptic malignant syndrome probably caused by methylphenidate .",
    "labels": [
      [
        "T0",
        "Disease",
        7,
        10,
        "neuroleptic malignant syndrome"
      ],
      [
        "T1",
        "Chemical",
        13,
        14,
        "methylphenidate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4771,
    "text": "Differential effects of 17alpha - ethinylestradiol on the neutral and acidic pathways of bile salt synthesis in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        3,
        6,
        "17alpha - ethinylestradiol"
      ],
      [
        "T1",
        "Chemical",
        13,
        15,
        "bile salt"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4772,
    "text": "Effects of 17alpha - ethinylestradiol ( EE ) on the neutral and acidic biosynthetic pathways of bile salt ( BS ) synthesis were evaluated in rats with an intact enterohepatic circulation and in rats with long - term bile diversion to induce BS synthesis .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        5,
        "17alpha - ethinylestradiol"
      ],
      [
        "T1",
        "Chemical",
        16,
        18,
        "bile salt"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "EE"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "BS"
      ],
      [
        "T4",
        "Chemical",
        42,
        43,
        "BS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4773,
    "text": "For this purpose , bile salt pool composition , synthesis of individual BS in vivo , hepatic activities , and expression levels of cholesterol 7alpha - hydroxylase ( CYP7A ) , and sterol 27 - hydroxylase ( CYP27 ) , as well as of other enzymes involved in BS synthesis , were analyzed in rats treated with EE ( 5 mg / kg , 3 days ) or its vehicle .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        6,
        "bile salt"
      ],
      [
        "T1",
        "Chemical",
        12,
        13,
        "BS"
      ],
      [
        "T2",
        "Chemical",
        23,
        24,
        "cholesterol"
      ],
      [
        "T3",
        "Chemical",
        32,
        33,
        "sterol"
      ],
      [
        "T4",
        "Chemical",
        48,
        49,
        "BS"
      ],
      [
        "T5",
        "Chemical",
        57,
        58,
        "EE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4774,
    "text": "BS pool size was decreased by 27 % but total BS synthesis was not affected by EE in intact rats .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "BS"
      ],
      [
        "T1",
        "Chemical",
        10,
        11,
        "BS"
      ],
      [
        "T2",
        "Chemical",
        16,
        17,
        "EE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4775,
    "text": "Synthesis of cholate was reduced by 68 % in EE - treated rats , while that of chenodeoxycholate was increased by 60 % .",
    "labels": [
      [
        "T0",
        "Chemical",
        2,
        3,
        "cholate"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "EE"
      ],
      [
        "T2",
        "Chemical",
        17,
        18,
        "chenodeoxycholate"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4776,
    "text": "The recently identified Delta22 - isomer of beta - muricholate contributed for 5 . 4 % and 18 . 3 % ( P < 0 . 01 ) to the pool in control and EE - treated rats , respectively , but could not be detected in bile after exhaustion of the pool .",
    "labels": [
      [
        "T0",
        "Chemical",
        34,
        35,
        "EE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4777,
    "text": "A clear reduction of BS synthesis was found in bile - diverted rats treated with EE , yet biliary BS composition was only minimally affected .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "BS"
      ],
      [
        "T1",
        "Chemical",
        15,
        16,
        "EE"
      ],
      [
        "T2",
        "Chemical",
        19,
        20,
        "BS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4778,
    "text": "Activity of CYP7A was decreased by EE in both intact and bile - diverted rats , whereas the activity of the CYP27 was not affected .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "EE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4779,
    "text": "Hepatic mRNA levels of CYP7A were significantly reduced by EE in bile - diverted rats only ; CYP27 mRNA levels were not affected by EE .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        10,
        "EE"
      ],
      [
        "T1",
        "Chemical",
        24,
        25,
        "EE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4780,
    "text": "In addition , mRNA levels of sterol 12alpha - hydroxylase and lithocholate 6beta - hydroxylase were increased by bile diversion and suppressed by EE .",
    "labels": [
      [
        "T0",
        "Chemical",
        6,
        7,
        "sterol"
      ],
      [
        "T1",
        "Chemical",
        23,
        24,
        "EE"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4781,
    "text": "This study shows that 17alpha - ethinylestradiol ( EE ) - induced intrahepatic cholestasis in rats is associated with selective inhibition of the neutral pathway of bile salt ( BS ) synthesis .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        7,
        "17alpha - ethinylestradiol"
      ],
      [
        "T1",
        "Disease",
        12,
        14,
        "intrahepatic cholestasis"
      ],
      [
        "T2",
        "Chemical",
        26,
        28,
        "bile salt"
      ],
      [
        "T3",
        "Chemical",
        8,
        9,
        "EE"
      ],
      [
        "T4",
        "Chemical",
        29,
        30,
        "BS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4782,
    "text": "Simultaneous impairment of other enzymes in the BS biosynthetic pathways may contribute to overall effects of EE on BS synthesis .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        8,
        "BS"
      ],
      [
        "T1",
        "Chemical",
        16,
        17,
        "EE"
      ],
      [
        "T2",
        "Chemical",
        18,
        19,
        "BS"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4783,
    "text": "Glibenclamide - sensitive hypotension produced by helodermin assessed in the rat .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Glibenclamide"
      ],
      [
        "T1",
        "Disease",
        3,
        4,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        6,
        7,
        "helodermin"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4784,
    "text": "The effects of helodermin , a basic 35 - amino acid peptide isolated from the venom of a lizard salivary gland , on arterial blood pressure and heart rate were examined in the rat , focusing on the possibility that activation of ATP sensitive K + ( K ( ATP ) ) channels is involved in the responses .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "amino acid"
      ],
      [
        "T1",
        "Chemical",
        3,
        4,
        "helodermin"
      ],
      [
        "T2",
        "Chemical",
        42,
        43,
        "ATP"
      ],
      [
        "T3",
        "Chemical",
        44,
        45,
        "K"
      ],
      [
        "T4",
        "Chemical",
        47,
        48,
        "K"
      ],
      [
        "T5",
        "Chemical",
        49,
        50,
        "ATP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4785,
    "text": "The results were also compared with those of vasoactive intestinal polypeptide ( VIP ) .",
    "labels": [],
    "pseudo": 0
  },
  {
    "id": 4786,
    "text": "Helodermin produced hypotension in a dose - dependent manner with approximately similar potency and duration to VIP .",
    "labels": [
      [
        "T0",
        "Chemical",
        0,
        1,
        "Helodermin"
      ],
      [
        "T1",
        "Disease",
        2,
        3,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4787,
    "text": "Hypotension induced by both peptides was significantly attenuated by glibenclamide , which abolished a levcromakalim - produced decrease in arterial blood pressure .",
    "labels": [
      [
        "T0",
        "Disease",
        0,
        1,
        "Hypotension"
      ],
      [
        "T1",
        "Chemical",
        9,
        10,
        "glibenclamide"
      ],
      [
        "T2",
        "Chemical",
        14,
        15,
        "levcromakalim"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4788,
    "text": "Oxyhemoglobin did not affect helodermin - induced hypotension , whereas it shortened the duration of acetylcholine ( ACh ) - produced hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "helodermin"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "acetylcholine"
      ],
      [
        "T3",
        "Chemical",
        17,
        18,
        "ACh"
      ],
      [
        "T4",
        "Disease",
        21,
        22,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4789,
    "text": "These findings suggest that helodermin - produced hypotension is partly attributable to the activation of glibenclamide - sensitive K + channels ( K ( ATP ) channels ) , which presumably exist on arterial smooth muscle cells .",
    "labels": [
      [
        "T0",
        "Chemical",
        4,
        5,
        "helodermin"
      ],
      [
        "T1",
        "Disease",
        7,
        8,
        "hypotension"
      ],
      [
        "T2",
        "Chemical",
        15,
        16,
        "glibenclamide"
      ],
      [
        "T3",
        "Chemical",
        18,
        19,
        "K"
      ],
      [
        "T4",
        "Chemical",
        22,
        23,
        "K"
      ],
      [
        "T5",
        "Chemical",
        24,
        25,
        "ATP"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4790,
    "text": "EDRF ( endothelium - derived relaxing factor ) / nitric oxide does not seem to play an important role in the peptide - produced hypotension .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "nitric oxide"
      ],
      [
        "T1",
        "Disease",
        24,
        25,
        "hypotension"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4791,
    "text": "Long - term efficacy and adverse event of nifedipine sustained - release tablets for cyclosporin A - induced hypertension in patients with psoriasis .",
    "labels": [
      [
        "T0",
        "Chemical",
        14,
        16,
        "cyclosporin A"
      ],
      [
        "T1",
        "Chemical",
        8,
        9,
        "nifedipine"
      ],
      [
        "T2",
        "Disease",
        18,
        19,
        "hypertension"
      ],
      [
        "T3",
        "Disease",
        22,
        23,
        "psoriasis"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4792,
    "text": "Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker , sustained - release nifedipine , to study the clinical antihypertensive effects and adverse events during treatment with both drugs .",
    "labels": [
      [
        "T0",
        "Chemical",
        9,
        11,
        "cyclosporin A"
      ],
      [
        "T1",
        "Disease",
        1,
        2,
        "psoriatic"
      ],
      [
        "T2",
        "Disease",
        4,
        5,
        "hypertension"
      ],
      [
        "T3",
        "Chemical",
        19,
        20,
        "calcium"
      ],
      [
        "T4",
        "Chemical",
        26,
        27,
        "nifedipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4793,
    "text": "Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy .",
    "labels": [
      [
        "T0",
        "Chemical",
        12,
        14,
        "cyclosporin A"
      ],
      [
        "T1",
        "Disease",
        9,
        10,
        "hypertensive"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4794,
    "text": "Both systolic and diastolic blood pressures of these 13 patients were decreased significantly after 4 weeks of nifedipine therapy , and blood pressure was maintained within the normal range thereafter for 25 months .",
    "labels": [
      [
        "T0",
        "Chemical",
        17,
        18,
        "nifedipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4795,
    "text": "The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients .",
    "labels": [
      [
        "T0",
        "Chemical",
        7,
        9,
        "cyclosporin A"
      ],
      [
        "T1",
        "Chemical",
        15,
        18,
        "blood urea nitrogen"
      ],
      [
        "T2",
        "Disease",
        28,
        30,
        "gingival hyperplasia"
      ],
      [
        "T3",
        "Chemical",
        10,
        11,
        "nifedipine"
      ]
    ],
    "pseudo": 0
  },
  {
    "id": 4796,
    "text": "Our findings indicate that sustained - release nifedipine is useful for hypertensive psoriatic patients under long - term treatment with cyclosporin A , but that these patients should be monitored for gingival hyperplasia .",
    "labels": [
      [
        "T0",
        "Chemical",
        20,
        22,
        "cyclosporin A"
      ],
      [
        "T1",
        "Disease",
        31,
        33,
        "gingival hyperplasia"
      ],
      [
        "T2",
        "Chemical",
        7,
        8,
        "nifedipine"
      ],
      [
        "T3",
        "Disease",
        11,
        12,
        "hypertensive"
      ],
      [
        "T4",
        "Disease",
        12,
        13,
        "psoriatic"
      ]
    ],
    "pseudo": 0
  }
]